PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Ivanov, AI; Christodoulou, J; Parkinson, JA; Barnham, KJ; Tucker, A; Woodrow, J; Sadler, PJ				Ivanov, AI; Christodoulou, J; Parkinson, JA; Barnham, KJ; Tucker, A; Woodrow, J; Sadler, PJ			Cisplatin binding sites on human albumin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SERUM-ALBUMIN; NUCLEAR MAGNETIC-RESONANCE; HUMAN-BLOOD-PLASMA; METHIONINE COMPLEXES; SECONDARY STRUCTURE; PLATINUM COMPLEXES; NMR-SPECTROSCOPY; PROTEIN-BINDING; DRUG-BINDING; IN-VITRO	Reactions of cisplatin (cis-[PtCl2(NH3)(2)]) with albumin are thought to play an important role in the metabolism of this anticancer drug. They are investigated here via (i) labeling of cisplatin with N-15 and use of two-dimensional H-1,N-15 NMR spectroscopy, (ii) comparison of natural human serum albumin with recombinant human albumin (higher homogeneity and SH content), (iii) chemical modification of Cys, Met, and His residues, (iv) reactions of bound platinum with thiourea, and (v) gel filtration chromatography, In contrast to previous reports, it is shown that the major sulfur-containing binding site involves Met and not Cys-34, and also a N ligand, in the form of an S,N macrochelate. Additional monofunctional adducts involving other Met residues and Cys-34 are also observed. During the later stages of reactions of cisplatin with albumin, release of NH3 occurs due to the strong trans influence of Met sulfur, which weakens the Pt-NH3 bonds, and protein cross-linking is observed. The consequences of these findings for the biological activity of cisplatin-albumin complexes are discussed.	Univ Edinburgh, Dept Chem, Edinburgh EH9 3JJ, Midlothian, Scotland; Univ London Birkbeck Coll, Dept Chem, London WC1H 0PP, England; Delta Biotechnol Ltd, Nottingham NG7 1FD, England	University of Edinburgh; University of London; Birkbeck University London	Sadler, PJ (corresponding author), Univ Edinburgh, Dept Chem, W Mains Rd, Edinburgh EH9 3JJ, Midlothian, Scotland.	pjs01@holyrood.ed.ac.uk		Parkinson, John Andrew/0000-0003-4270-6135; Christodoulou, John/0000-0002-6710-3843				Aull J.L., 1980, METAL IONS BIOL SYST, V11, P337; AULL JL, 1979, BIOCHIM BIOPHYS ACTA, V571, P352, DOI 10.1016/0005-2744(79)90105-0; Barnham KJ, 1996, J CHEM SOC DALTON, P2867, DOI 10.1039/dt9960002867; Barnham KJ, 1996, INORG CHEM, V35, P1065, DOI 10.1021/ic950973d; BERNERSPRICE SJ, 1992, J CHEM SOC CHEM COMM, P789, DOI 10.1039/c39920000789; BernersPrice SJ, 1996, COORDIN CHEM REV, V151, P1; BERNERSPRICE SJ, 1990, J INORG BIOCHEM, V38, P305, DOI 10.1016/0162-0134(90)80005-I; BORCH RF, 1979, P NATL ACAD SCI USA, V76, P6611, DOI 10.1073/pnas.76.12.6611; CANAL P, 1995, PLATINUM OTHER MET 2, P53; CARZER DC, 1994, ADV PROTEIN CHEM, V45, P153; CHEN RF, 1967, J BIOL CHEM, V242, P173; CHRISTODOULOU J, 1995, FEBS LETT, V376, P1, DOI 10.1016/0014-5793(95)01231-2; COLE WC, 1980, CHEM-BIOL INTERACT, V30, P223, DOI 10.1016/0009-2797(80)90128-3; CURLING JM, 1977, PROCESS BIOCHEM, V12, P22; DECONTI RC, 1973, CANCER RES, V33, P1310; DeJonge ETM, 1997, INT J GYNECOL CANCER, V7, P158, DOI 10.1046/j.1525-1438.1997.00438.x; DeSimone PA, 1987, P AM SOC CLIN ONCOL, V6, P33; DICKERSON RE, 1969, J MOL BIOL, V45, P77, DOI 10.1016/0022-2836(69)90210-1; Dodsworth N, 1996, BIOTECHNOL APPL BIOC, V24, P171; Eastman A, 1996, PLATINUM AND OTHER METAL COORDINATION COMPOUNDS IN CANCER CHEMOTHERAPY 2, P283; EASTMAN A, 1986, BIOCHEMISTRY-US, V25, P3912, DOI 10.1021/bi00361a026; ELFERINK F, 1986, CLIN CHEM, V32, P641; ESPINOSA E, 1995, LUNG CANCER, V12, P67, DOI 10.1016/0169-5002(95)00407-R; FOUNTZILAS G, 1992, ANN ONCOL, V7, P553; FREEMAN R, 1988, HDB NUCL MAGNETIC RE, P250; GONIAS SL, 1981, J BIOL CHEM, V256, P2478; GONIAS SL, 1983, J BIOL CHEM, V258, P5764; GROSS KH, 1988, J MAGN RESON, V76, P87, DOI 10.1016/0022-2364(88)90203-X; GULLO JJ, 1980, CANCER CHEMOTH PHARM, V5, P21, DOI 10.1007/BF00578558; Guo ZJ, 1997, J CHEM SOC DALTON, P469, DOI 10.1039/a604210d; Gurd F R, 1972, Methods Enzymol, V25, P424, DOI 10.1016/S0076-6879(72)25038-8; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; HADJILIADIS N, 1994, INORG CHEM, V33, P5057, DOI 10.1021/ic00100a034; HE XM, 1992, NATURE, V358, P209, DOI 10.1038/358209a0; HEGEDUS L, 1987, CANCER CHEMOTH PHARM, V20, P211, DOI 10.1007/BF00570487; HERVE F, 1994, CLIN PHARMACOKINET, V26, P44, DOI 10.2165/00003088-199426010-00004; HOLDING JD, 1992, BRIT J CLIN PHARMACO, V33, P75, DOI 10.1111/j.1365-2125.1992.tb04003.x; HOLDING JD, 1991, BRIT J CLIN PHARMACO, V32, P173, DOI 10.1111/j.1365-2125.1991.tb03878.x; HOSHINO T, 1995, J PHARM SCI, V84, P216, DOI 10.1002/jps.2600840219; HWANG TL, 1995, J MAGN RESON SER A, V112, P275, DOI 10.1006/jmra.1995.1047; ISMAIL IM, 1982, POLYHEDRON, V1, P57, DOI 10.1016/S0277-5387(00)81069-4; Jarve RK, 1997, CANCER CHEMOTH PHARM, V39, P341, DOI 10.1007/s002800050581; JOCELYN PC, 1987, METHOD ENZYMOL, V143, P44; JONES WC, 1976, J BIOL CHEM, V251, P7452; Kamal MA, 1996, ANTICANCER RES, V16, P3725; Kane SA, 1996, BIOCHEMISTRY-US, V35, P2180, DOI 10.1021/bi952240a; KELLAND LR, 1994, METAL COMPOUNDS CANC, P32; KERRISON JS, 1977, J CHEM SOC CHEM COMM, P861; Kratz F., 1993, METAL COMPLEXES CANC, P391; LAUTERMANN J, 1995, HEARING RES, V88, P47, DOI 10.1016/0378-5955(95)00097-N; Litterst C., 1976, J CLIN HEMATOL ONCOL, V7, P169; MA J, 1994, BRIT J CANCER, V69, P858, DOI 10.1038/bjc.1994.166; Miles E W, 1977, Methods Enzymol, V47, P431; MOMBURG R, 1987, J PHARM PHARMACOL, V39, P691, DOI 10.1111/j.2042-7158.1987.tb06971.x; Nagai N, 1996, J PHARM PHARMACOL, V48, P918, DOI 10.1111/j.2042-7158.1996.tb06002.x; NANJI AA, 1986, CANCER CHEMOTH PHARM, V17, P274; NORMAN RE, 1992, INORG CHEM, V31, P877, DOI 10.1021/ic00031a033; NORMAN RE, 1988, INORG CHEM, V27, P3583, DOI 10.1021/ic00293a028; OHTA N, 1993, BIOL PHARM BULL, V16, P631; OHTA N, 1992, INT J PHARM, V85, P39, DOI 10.1016/0378-5173(92)90131-K; Parnis FX, 1997, AM J CLIN ONCOL-CANC, V20, P319, DOI 10.1097/00000421-199706000-00024; PEEREY LM, 1987, INORG CHEM, V26, P2079, DOI 10.1021/ic00260a014; PETERS T, 1985, ADV PROTEIN CHEM, V37, P161, DOI 10.1016/S0065-3233(08)60065-0; PIZZO SV, 1988, J INORG BIOCHEM, V33, P67, DOI 10.1016/0162-0134(88)80035-7; Polyzos A, 1997, J CHEMOTHERAPY, V9, P102, DOI 10.1179/joc.1997.9.2.102; Reeder F, 1997, EUR J BIOCHEM, V249, P370, DOI 10.1111/j.1432-1033.1997.00370.x; Reedijk J, 1995, HDB METAL LIGAND INT, V2, P967; Repta A.J., 1980, CISPLATIN, P285, DOI [10.1016/b978-0-12-565050-2.50022-x, DOI 10.1016/B978-0-12-565050-2.50022-X]; RIORDAN JF, 1972, METHOD ENZYMOL, V25, P424; SADLER PJ, 1994, EUR J BIOCHEM, V220, P193, DOI 10.1111/j.1432-1033.1994.tb18614.x; SADLER PJ, 1992, EUR J BIOCHEM, V205, P631, DOI 10.1111/j.1432-1033.1992.tb16821.x; STONEHOUSE J, 1994, J MAGN RESON SER A, V107, P178, DOI 10.1006/jmra.1994.1066; SUGII A, 1991, CHEM PHARM BULL, V39, P408; TAKAHASHI K, 1985, JPN J CANCER RES, V76, P68; TOSETTI F, 1988, ANTICANCER RES, V8, P381; TRYNDA L, 1994, J INORG BIOCHEM, V53, P249, DOI 10.1016/0162-0134(94)85112-3; WRIGHT TL, 1987, HEPATOLOGY, V7, P294, DOI 10.1002/hep.1840070214; WRIGHT TL, 1988, GASTROENTEROLOGY, V94, P443, DOI 10.1016/0016-5085(88)90435-0; YOTSUYANAGI T, 1991, CHEM PHARM BULL, V39, P3003; Zeng HH, 1997, INT J BIOL MACROMOL, V20, P107, DOI 10.1016/S0141-8130(96)01144-0; ZHANG JG, 1994, BIOCHEM PHARMACOL, V47, P1127, DOI 10.1016/0006-2952(94)90383-2	81	302	311	5	63	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14721	14730		10.1074/jbc.273.24.14721	http://dx.doi.org/10.1074/jbc.273.24.14721			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614070	hybrid			2022-12-27	WOS:000074160400012
J	Williamson, EA; Xu, HN; Gombart, AF; Verbeek, W; Chumakov, AM; Friedman, AD; Koeffler, HP				Williamson, EA; Xu, HN; Gombart, AF; Verbeek, W; Chumakov, AM; Friedman, AD; Koeffler, HP			Identification of transcriptional activation and repression domains in human CCAAT enhancer binding protein epsilon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER NUCLEAR-PROTEIN; DNA-BINDING; C/EBP FAMILY; SYNERGISTICALLY ACTIVATE; MYELOMONOCYTIC CELLS; NEGATIVE INHIBITOR; EXPRESSION NF-IL6; ALBUMIN GENE; PROMOTER; ELEMENTS	Human CCAAT/enhancer-bindimg protein epsilon (C/EBP epsilon), a new member of the C/EBP family, significantly upregulates both the mim-1 and human myeloperoxidase promoters, suggesting an important role for C/EBP epsilon in the transcriptional regulation of a subset of myeloid-specific genes. To elucidate the structure and function of C/EBP epsilon in transcriptional activation, amino acid residues 1-115, 147-249, or 1-249 of C/EBP epsilon were fused to the yeast GAL4 DNA binding domain. These expression vectors were cotransfected with a chloramphenicol acetyltransferase reporter gene and, in all cell lines tested, only the GAL-C/EBP epsilon-(1-115) fusion protein significantly tly activated expression from the chloramphenicol acetyltransferase reporter gene. Sixteen deletion mutants of C/EBP epsilon mapped the transactivation domain to amino acids 1-18 at the N terminus and revealed the presence of a transcription repression element between amino acid residues 116 and 162. Expression vectors containing the repression domain of C/EBP epsilon strongly inhibited gene transcription from TK, SV40, and adenoviral major late promoters bearing GAL4 binding sites. Fusion of this repression domain to the VP16 activation domain inhibited the transactivation function of VP16. Deletion of this repression domain increased gene transcription from a neutrophil elastase promoter-luciferase reporter. Taken together, these data suggest that C/EBP epsilon regulates transcription by utilizing both activation and repression functions.	Univ Calif Los Angeles, Sch Med, Cedars Sinai Res Inst, Dept Med,Div Hematol Oncol, Los Angeles, CA 90048 USA; Johns Hopkins Univ, Div Pediat Oncol, Baltimore, MD 21287 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Johns Hopkins University	Williamson, EA (corresponding author), Univ Calif Los Angeles, Sch Med, Cedars Sinai Res Inst, Dept Med,Div Hematol Oncol, 8700 Beverly Blvd,B121, Los Angeles, CA 90048 USA.		Chumakov, Alexey/N-1541-2014	Chumakov, Alexey/0000-0003-2733-3166				AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; Antonson P, 1996, GENOMICS, V35, P30, DOI 10.1006/geno.1996.0319; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Chih DY, 1997, BLOOD, V90, P2987, DOI 10.1182/blood.V90.8.2987; Chumakov AM, 1997, MOL CELL BIOL, V17, P1375, DOI 10.1128/MCB.17.3.1375; COOPER C, 1995, NUCLEIC ACIDS RES, V23, P4371, DOI 10.1093/nar/23.21.4371; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; KATZ S, 1993, EMBO J, V12, P1321, DOI 10.1002/j.1460-2075.1993.tb05777.x; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LUNDGREN M, 1994, J IMMUNOL, V153, P2983; Mink S, 1996, MOL CELL BIOL, V16, P1316; Moore DD, 1995, GLOB MOB SURV; Morosetti R, 1997, BLOOD, V90, P2591, DOI 10.1182/blood.V90.7.2591.2591_2591_2600; NERLOV C, 1994, GENE DEV, V8, P350, DOI 10.1101/gad.8.3.350; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; OLIVIERO S, 1989, EMBO J, V8, P1145, DOI 10.1002/j.1460-2075.1989.tb03485.x; PEI DQ, 1991, MOL CELL BIOL, V11, P1480, DOI 10.1128/MCB.11.3.1480; POLL V, 1990, CELL, V63, P643; RAY A, 1995, J BIOL CHEM, V270, P7365, DOI 10.1074/jbc.270.13.7365; ROMAN C, 1990, GENE DEV, V4, P1404, DOI 10.1101/gad.4.8.1404; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SADOWSKI I, 1988, NATURE, V335, P559; SCOTT LM, 1992, BLOOD, V80, P1725; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; SUTHERLAND JA, 1992, GENE DEV, V6, P1810, DOI 10.1101/gad.6.9.1810; TSUKADA J, 1994, MOL CELL BIOL, V14, P7285, DOI 10.1128/MCB.14.11.7285; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VALLEJO M, 1993, P NATL ACAD SCI USA, V90, P4679, DOI 10.1073/pnas.90.10.4679; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P6462, DOI 10.1073/pnas.94.12.6462; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; Zhang DE, 1996, MOL CELL BIOL, V16, P1231	47	46	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14796	14804		10.1074/jbc.273.24.14796	http://dx.doi.org/10.1074/jbc.273.24.14796			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614080	hybrid			2022-12-27	WOS:000074160400022
J	Barrientos, A; Kenyon, L; Moraes, CT				Barrientos, A; Kenyon, L; Moraes, CT			Human xenomitochondrial cybrids - Cellular models of mitochondrial complex I deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH DEHYDROGENASE; UBIQUINONE OXIDOREDUCTASE; SUBUNIT; REDUCTASE; SEQUENCE; PROTEIN; GENOME; MTDNA	The subunits forming the mitochondrial oxidative phosphorylation system are coded by both nuclear and mitochondrial genes. Recently, we attempted to introduce mtDNA from non-human apes into a human cell line lacking mtDNA (rho degrees), and succeeded in producing human-common chimpanzee, human-pigmy chimpanzee, and human-gorilla xenomitochondrial cybrids (HXC), Here, we present a comprehensive characterization of oxidative phosphorylation function in these cells. Mitochondrial complexes TC, III, IV, and V had activities indistinguishable from parental human or non-human primate cells. In contrast, a complex I deficiency was observed in all HXC. Kinetic studies of complex I using decylubiquinone or NADH as Limiting substrates showed that the V-max was decreased in HXC by approximately 40%, and the K-m for the NADH was significantly increased (3-fold, p < 0.001), Rotenone inhibition studies of intact cell respiration and pyruvate-malate oxidation in permeabilized cells showed that 3 nM rotenone produced a mild effect in control cells (0-10% inhibition) but produced a marked inhibition of HXC respiration (50-75%). Immunoblotting analyses of three subunits of complex I (ND1, 75 and 49 kDa) showed that their relative amounts were not significantly altered in HXC cells, These results establish EMC as cellular models of complex I deficiency in humans and underscore the importance of nuclear and mitochondrial genomes co-evolution in optimizing oxidative phosphorylation function.	Univ Miami, Sch Med, Dept Neurol, Miami, FL 33136 USA; Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33136 USA	University of Miami; University of Miami	Moraes, CT (corresponding author), Univ Miami, Sch Med, Dept Neurol, 1501 NW 9th Ave, Miami, FL 33136 USA.	cmoraes@mednet.med.miami.edu	Moraes, Carlos/AAT-3818-2021		NIGMS NIH HHS [GM55766] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BELOGRUDOV G, 1994, BIOCHEMISTRY-US, V33, P4571, DOI 10.1021/bi00181a018; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOMYN A, 1986, SCIENCE, V234, P614, DOI 10.1126/science.3764430; CHOMYN A, 1985, NATURE, V314, P592, DOI 10.1038/314592a0; CLAYTON DA, 1992, J INHERIT METAB DIS, V15, P439, DOI 10.1007/BF01799602; DARLEYUSMAR VM, 1983, P NATL ACAD SCI-BIOL, V80, P5103, DOI 10.1073/pnas.80.16.5103; Davis RE, 1997, P NATL ACAD SCI USA, V94, P4526, DOI 10.1073/pnas.94.9.4526; EARLEY FGP, 1987, FEBS LETT, V219, P108, DOI 10.1016/0014-5793(87)81200-0; GALANTE YM, 1979, ARCH BIOCHEM BIOPHYS, V192, P559, DOI 10.1016/0003-9861(79)90126-7; Hao HL, 1997, MOL CELL BIOL, V17, P6831, DOI 10.1128/MCB.17.12.6831; Hao HL, 1996, J BIOL CHEM, V271, P2347, DOI 10.1074/jbc.271.4.2347; HATEFI Y, 1967, BIOCHEM BIOPH RES CO, V26, P301, DOI 10.1016/0006-291X(67)90122-2; Hirano M, 1997, P NATL ACAD SCI USA, V94, P14894, DOI 10.1073/pnas.94.26.14894; HOFHAUS G, 1991, J MOL BIOL, V221, P1027, DOI 10.1016/0022-2836(91)80190-6; Hofhaus G, 1996, J BIOL CHEM, V271, P13155, DOI 10.1074/jbc.271.22.13155; HORAI S, 1995, P NATL ACAD SCI USA, V92, P532, DOI 10.1073/pnas.92.2.532; Jun AS, 1996, MOL CELL BIOL, V16, P771; KADENBACH B, 1987, CURR TOP BIOENERG, V15, P113; Kenyon L, 1997, P NATL ACAD SCI USA, V94, P9131, DOI 10.1073/pnas.94.17.9131; KIKUNO R, 1985, FEBS LETT, V189, P85, DOI 10.1016/0014-5793(85)80847-4; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; MAJANDER A, 1991, FEBS LETT, V292, P289, DOI 10.1016/0014-5793(91)80886-8; Malgat Monique, 1995, Journal of Biological Systems, V3, P165, DOI 10.1142/S0218339095000162; POYTON RO, 1988, ANN NY ACAD SCI, V550, P289, DOI 10.1111/j.1749-6632.1988.tb35344.x; RAGAN CI, 1987, CURR TOP BIOENERG, V15, P1; ROBINSON BH, 1993, BIOCHIM BIOPHYS ACTA, V1182, P231, DOI 10.1016/0925-4439(93)90064-8; ROBINSON BH, 1989, METABOLIC BASIS INHE, V1, P869; RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8; RUSTIN P, 1991, LANCET, V337, P338; SCHAPIRA AHV, 1989, LANCET, V1, P1269, DOI 10.1016/S0140-6736(89)92366-0; SCHAPIRA AHV, 1988, LANCET, V1, P500; SEN K, 1985, ARCH BIOCHEM BIOPHYS, V242, P393, DOI 10.1016/0003-9861(85)90223-1; SINGER TP, 1994, BBA-BIOENERGETICS, V1187, P198, DOI 10.1016/0005-2728(94)90110-4; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; Wallace DC, 1997, P NATL ACAD SCI USA, V94, P14900, DOI 10.1073/pnas.94.26.14900; WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231; WALLACE DC, 1995, HUMAN GENE MAPPING 1, P910	39	151	152	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14210	14217		10.1074/jbc.273.23.14210	http://dx.doi.org/10.1074/jbc.273.23.14210			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603924	hybrid			2022-12-27	WOS:000074021500026
J	Collet, JF; Stroobant, V; Pirard, M; Delpierre, G; Van Schaftingen, E				Collet, JF; Stroobant, V; Pirard, M; Delpierre, G; Van Schaftingen, E			A new class of phosphotransferases phosphorylated on an aspartate residue in an amino-terminal DXDX(T/V) motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBLE EPOXIDE HYDROLASE; L-2-HALOACID DEHALOGENASE; ADENOSINE-TRIPHOSPHATASE; REGULATORY PROTEIN; ACTIVE-SITE; RAT-LIVER; IDENTIFICATION; INTERMEDIATE; EXPRESSION; ENZYME	When incubated with their substrates, human phosphomannomutase and L-3-phosphoserine phosphatase are known to form phosphoenzymes with chemical characteristics of an acyl-phosphate, The phosphorylated residue in phosphomannomutase has now been identified by mass spectrometry after reduction of the phosphoenzyme with tritiated borohydride and trypsin digestion. It is the first aspartate in a conserved DVDGT motif. Replacement of either aspartate of this motif by asparagine or glutamate resulted in complete inactivation of the enzyme. The same mutations performed in the DXDST motif of L-3-phosphoserine phosphatase also resulted in complete inactivation of the enzyme, except for the replacement of the second aspartate by glutamate, which reduced the activity by only about 40%, This suggests that the first aspartate of the motif is also the phosphorylated residue in L-3-phosphoserine phosphatase. Data banks contained seven other phosphomutases or phosphatases sharing a similar, totally conserved DXDX(TN) motif at their amino terminus. One of these (beta-phosphoglucomutase) is shown to form a phosphoenzyme with the characteristics of an acyl-phosphate. In conclusion, phosphomannomutase and L-3-phosphoserine phosphatase belong to a new phosphotransferase family with an amino-terminal DXDX(TN) motif that serves as an intermediate phosphoryl acceptor.	Christian de Duve Inst Celular Pathol, Physiol Chem Lab, B-1200 Brussels, Belgium; Catholic Univ Louvain, B-1200 Brussels, Belgium; Ludwig Inst Canc Res, B-1200 Brussels, Belgium	Universite Catholique Louvain; Ludwig Institute for Cancer Research	Van Schaftingen, E (corresponding author), UCL 7539, Ave Hippocrate 75, B-1200 Brussels, Belgium.		Van+Schaftingen, Emile/AAF-5532-2020; Collet, Jean Francois/F-2105-2010	Van Schaftingen, Emile/0000-0002-6199-7647; Collet, Jean-Francois/0000-0001-8069-7036				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDERSON L, 1957, ARCH BIOCHEM BIOPHYS, V70, P121, DOI 10.1016/0003-9861(57)90085-1; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P17, DOI 10.1016/S0968-0004(97)01162-6; BAZAN JF, 1989, P NATL ACAD SCI USA, V86, P9642, DOI 10.1073/pnas.86.24.9642; BEETHAM JK, 1993, ARCH BIOCHEM BIOPHYS, V305, P197, DOI 10.1006/abbi.1993.1411; BIEMANN K, 1988, BIOMED ENVIRON MASS, V16, P99, DOI 10.1002/bms.1200160119; BORHAN B, 1995, J BIOL CHEM, V270, P26923, DOI 10.1074/jbc.270.45.26923; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Collet JF, 1997, FEBS LETT, V408, P281, DOI 10.1016/S0014-5793(97)00438-9; DEGANI C, 1973, J BIOL CHEM, V248, P8222; ENGSTROEM L, 1961, BIOCHIM BIOPHYS ACTA, V52, P49, DOI 10.1016/0006-3002(61)90902-7; Hisano T, 1996, J BIOL CHEM, V271, P20322, DOI 10.1074/jbc.271.34.20322; HOKIN LE, 1965, P NATL ACAD SCI USA, V54, P177, DOI 10.1073/pnas.54.1.177; Jaeken J, 1996, ARCH DIS CHILD, V74, P542, DOI 10.1136/adc.74.6.542; Jaeken J, 1997, J MED GENET, V34, P594, DOI 10.1136/jmg.34.7.594; KNEHR M, 1993, J BIOL CHEM, V268, P17623; KNOWLES JR, 1980, ANNU REV BIOCHEM, V49, P877, DOI 10.1146/annurev.bi.49.070180.004305; KOONIN EV, 1994, J MOL BIOL, V244, P125, DOI 10.1006/jmbi.1994.1711; LIU JQ, 1995, J BIOL CHEM, V270, P18309, DOI 10.1074/jbc.270.31.18309; Matthijs G, 1997, GENOMICS, V40, P41, DOI 10.1006/geno.1996.4536; MILSTEIN C, 1961, BIOCHEM J, V79, P456, DOI 10.1042/bj0790456; OTOOLE GA, 1994, J BIOL CHEM, V269, P26503; PILKIS SJ, 1983, J BIOL CHEM, V258, P6135; Pirard M, 1997, FEBS LETT, V411, P251, DOI 10.1016/S0014-5793(97)00704-7; PLAPP BV, 1995, METHOD ENZYMOL, V249, P91; POST RL, 1973, J BIOL CHEM, V248, P6993; ROSE ZB, 1970, ARCH BIOCHEM BIOPHYS, V140, P508, DOI 10.1016/0003-9861(70)90095-0; SANDERS DA, 1989, J BIOL CHEM, V264, P21770; SEAL SN, 1987, J BIOL CHEM, V262, P13496; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; VANDERCAMMEN A, 1992, BIOCHEM J, V286, P253, DOI 10.1042/bj2860253; VanSchaftingen E, 1995, FEBS LETT, V377, P318, DOI 10.1016/0014-5793(95)01357-1; VeigadaCunha M, 1996, J BIOL CHEM, V271, P6292, DOI 10.1074/jbc.271.11.6292; WO YYP, 1992, BIOCHEMISTRY-US, V31, P1712, DOI 10.1021/bi00121a019	34	218	223	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14107	14112		10.1074/jbc.273.23.14107	http://dx.doi.org/10.1074/jbc.273.23.14107			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603909	hybrid			2022-12-27	WOS:000074021500011
J	Taketani, Y; Segawa, H; Chikamori, M; Morita, K; Tanaka, K; Kido, S; Yamamoto, H; Iemori, Y; Tatsumi, S; Tsugawa, N; Okano, T; Kobayashi, T; Miyamoto, K; Takeda, E				Taketani, Y; Segawa, H; Chikamori, M; Morita, K; Tanaka, K; Kido, S; Yamamoto, H; Iemori, Y; Tatsumi, S; Tsugawa, N; Okano, T; Kobayashi, T; Miyamoto, K; Takeda, E			Regulation of type II renal Na+-dependent inorganic phosphate transporters by 1,25-dihydroxyvitamin D-3 - Identification of a vitamin D-responsive element in the human NAPI-3 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BORDER MEMBRANE-VESICLES; D-RECEPTOR; JUXTAMEDULLARY CORTEX; 24-HYDROXYLASE GENE; GLUCOSE-ABSORPTION; RAT; EXPRESSION; HORMONE; PROTEIN; KIDNEY	Vitamin D is an important regulator of phosphate homeostasis. The effects of vitamin D on the expression of renal Na+-dependent inorganic phosphate (P-i) transporters (types I and II) were investigated. In vitamin D-deficient rats, the amounts of type II Na+-dependent P-i transporter (NaPi-2) protein and mRNA were decreased in the juxtamedullary kidney cortex, but not in the superficial cortex, compared with control rats. The administration of 1,25-dihydroxyvitamin D-3 (1,25-(OH)(2)D-3) to vitamin D-deficient rats increased the initial rate of P-i uptake as well as the amounts of NaPi-2 mRNA and protein in the juxtamedullary cortex. The transcriptional activity of a luciferase reporter plasmid containing the promoter region of the human type II Na+-dependent P-i transporter NaPi-3 gene was increased markedly by 1,25-(OH)(2)D-3 in COS-7 cells expressing the human vitamin D receptor. A deletion and mutation analysis of the NaPi-3 gene promoter identified the vitamin D-responsive element as the sequence 5'-GGGGCAGCAAGGGCA-3' nucleotides -1977 to -1963 relative to the transcription start site. This element bound a heterodimer of the vitamin D receptor and retinoid X receptor, and it enhanced the basal transcriptional activity of the promoter of the herpes simplex virus thymidine kinase gene in an orientation-independent manner. Thus, one mechanism by which vitamin D regulates P-i homeostasis is through the modulation of the expression of type II Na+-dependent P-i transporter genes in the juxtamedullary kidney cortex.	Univ Tokushima, Sch Med, Dept Clin Nutr, Tokushima 770, Japan; Kobe Pharmaceut Univ, Dept Hyg Sci, Kobe, Hyogo 658, Japan	Tokushima University; Kobe Pharmaceutical University	Miyamoto, K (corresponding author), Univ Tokushima, Sch Med, Dept Clin Nutr, Kuramoto Cho 3, Tokushima 770, Japan.	miyamoto@nutr.med.tokusbima-u.ac.jp		Tatsumi, Sawako/0000-0002-4862-2955				Arai H, 1997, J BONE MINER RES, V12, P915, DOI 10.1359/jbmr.1997.12.6.915; ARAKAWA T, 1995, FEBS LETT, V363, P105, DOI 10.1016/0014-5793(95)00293-I; Berndt T. J., 1992, KIDNEY PHYSL PATHOPH, P2511; Biber J, 1996, KIDNEY INT, V49, P981, DOI 10.1038/ki.1996.139; Christakos S, 1996, BIOCHEM J, V316, P361, DOI 10.1042/bj3160361; CLARLBERG D, 1993, NAURE, V361, P657; DELORME AC, 1983, J BIOL CHEM, V258, P1878; DEMAY MB, 1992, P NATL ACAD SCI USA, V89, P8097, DOI 10.1073/pnas.89.17.8097; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DOUSA TP, 1986, KIDNEY INT, V29, P352; ELSTEIN D, 1986, PFLUG ARCH EUR J PHY, V407, P451, DOI 10.1007/BF00652633; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; Hartmann CM, 1996, P NATL ACAD SCI USA, V93, P7409, DOI 10.1073/pnas.93.14.7409; HAYASHI S, 1987, GENE DEV, V1, P818, DOI 10.1101/gad.1.8.818; HEINLE H, 1977, FEBS LETT, V73, P220, DOI 10.1016/0014-5793(77)80985-X; IIDA K, 1995, P NATL ACAD SCI USA, V92, P6112, DOI 10.1073/pnas.92.13.6112; KEMPSON SA, 1995, AM J PHYSIOL-RENAL, V268, pF784, DOI 10.1152/ajprenal.1995.268.4.F784; KERNER SA, 1989, P NATL ACAD SCI USA, V86, P4455, DOI 10.1073/pnas.86.12.4455; KIMURA T, 1994, J BONE MINER MET, V12, pS7; KOSEKI C, 1980, FOLIA PHARMACOL JPN, V76, P59, DOI 10.1254/fpj.76.59; LEVI M, 1994, PFLUG ARCH EUR J PHY, V426, P5, DOI 10.1007/BF00374664; LEVI M, 1990, AM J PHYSIOL, V258, pF1616, DOI 10.1152/ajprenal.1990.258.6.F1616; LI H, 1991, ENDOCRINOLOGY, V128, P2844, DOI 10.1210/endo-128-6-2844; Li H, 1996, AM J PHYSIOL-ENDOC M, V271, pE1021, DOI 10.1152/ajpendo.1996.271.6.E1021; LI H, 1995, CELL MOL BIOL RES, V41, P4561; LIAO J, 1990, P NATL ACAD SCI USA, V87, P9751, DOI 10.1073/pnas.87.24.9751; MACDONALD PN, 1991, J BIOL CHEM, V266, P18808; Mackey SL, 1996, MOL ENDOCRINOL, V10, P298, DOI 10.1210/me.10.3.298; MAGAGNIN S, 1993, P NATL ACAD SCI USA, V90, P5979, DOI 10.1073/pnas.90.13.5979; MAJESKA RJ, 1980, ENDOCRINOLOGY, V107, P1494, DOI 10.1210/endo-107-5-1494; MARUYAMA K, 1991, METHODS NUCL ACIDS R, P283; MCKEOWN JW, 1979, AM J PHYSIOL, V237, pF312, DOI 10.1152/ajprenal.1979.237.4.F312; MINAMI H, 1993, GASTROENTEROLOGY, V105, P692, DOI 10.1016/0016-5085(93)90884-F; Murer H, 1997, PFLUG ARCH EUR J PHY, V433, P379, DOI 10.1007/s004240050292; MURER H, 1992, KIDNEY PHYSL PATHOPH, P2481; NAKAGAWA N, 1991, J BIOL CHEM, V266, P13616; Ohyama Y, 1996, J BIOL CHEM, V271, P30381, DOI 10.1074/jbc.271.48.30381; PIKE JW, 1991, ANNU REV NUTR, V11, P189, DOI 10.1146/annurev.nu.11.070191.001201; PIKE JW, 1987, J BIOL CHEM, V262, P1305; QUAMME GA, 1990, AM J PHYSIOL, V258, pF356, DOI 10.1152/ajprenal.1990.258.2.F356; REEVE LE, 1982, AM J CLIN NUTR, V36, P122, DOI 10.1093/ajcn/36.1.122; SONE T, 1990, J BIOL CHEM, V265, P21997; SUZUKI M, 1989, KIDNEY INT, V34, P268; TAKAHASHI Y, 1994, BBA-LIPID LIPID MET, V1212, P217, DOI 10.1016/0005-2760(94)90256-9; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Taketani Y, 1997, BIOCHEM J, V324, P927, DOI 10.1042/bj3240927; Tenenhouse HS, 1997, J BONE MINER RES, V12, P159, DOI 10.1359/jbmr.1997.12.2.159; TURNER ST, 1985, KIDNEY INT, V27, P879, DOI 10.1038/ki.1985.95; ULLRICH KJ, 1977, PFLUG ARCH EUR J PHY, V372, P269, DOI 10.1007/BF01063862; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; YUSUFI ANK, 1994, BBA-BIOMEMBRANES, V1191, P117, DOI 10.1016/0005-2736(94)90239-9; ZIEROLD C, 1994, P NATL ACAD SCI USA, V91, P900, DOI 10.1073/pnas.91.3.900	52	115	117	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14575	14581		10.1074/jbc.273.23.14575	http://dx.doi.org/10.1074/jbc.273.23.14575			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603973	hybrid			2022-12-27	WOS:000074021500075
J	Amado, M; Almeida, R; Carneiro, F; Levery, SB; Holmes, EH; Nomoto, M; Hollingsworth, MA; Hassan, H; Schwientek, T; Nielsen, PA; Bennett, EP; Clausen, H				Amado, M; Almeida, R; Carneiro, F; Levery, SB; Holmes, EH; Nomoto, M; Hollingsworth, MA; Hassan, H; Schwientek, T; Nielsen, PA; Bennett, EP; Clausen, H			A family of human beta 3-galactosyltransferases - Characterization of four members of a UDP-galactose :beta-N-acetyl-glucosamine/beta N-acetyl-galactosamine beta-1,3-galactosyltransferase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; GANGLIOSIDES; EXPRESSION; LEWIS; ALPHA; NMR; BETA-1->3-GALACTOSYLTRANSFERASE; ORGANIZATION; CONFIRMATION; TRANSFERASES	BLAST analysis of expressed sequence tags (ESTs) using the coding sequence of a human UDP-galactose:beta-N-acetyl-glucosamine beta-1,3-galactosyltransferase, designated beta 3Gal-T1, revealed no ESTs with identical sequences but a large number with similarity. Three different sets of overlapping ESTs with sequence similarities to beta 3Gal-T1 were compiled, and complete coding regions of these genes were obtained Expression of two of these genes in the Baculo virus system showed that one represented a UDP-galactose:beta-N-acetylglucosamine beta-1,3-galactosyltransferase (beta 3Gal-T2) with similar kinetic properties as beta 3Gal-T1. Another gene represented a UDP-galactose:beta-N-acetyl-galactosamine beta-1,3-galactosyltransferase (beta 3Gal-T4) involved in G(M1)/G(D1) ganglioside synthesis, and this gene was highly similar to a recently reported rat G(D1) synthase (Miyazaki,H., Fukumoto, S., Okada, M., Hasegawa, T., and Furukawa, K. (1997) J. Biol. Chem. 272, 24794-24799), Northern analysis of mRNA from human organs with the four homologous cDNA revealed different expression patterns. beta 3Gal-T1 mRNA was expressed in brain, beta 3Gal-T2 was expressed in brain and heart, and beta 3Gal-T3 and -T4 were more widely expressed. The coding regions for each of the four genes were contained in single exons. beta 3Gal-T2, -T3, and -T4 were localized to 1q31, 3q25, and 6p21.3, respectively, by EST mapping. The results demonstrate the existence of a family of homologous beta 3-galactosyltransferase genes.	Univ Copenhagen, Sch Dent, Copenhagen 2200 N, Denmark; Univ Porto, IPATIMUP, Inst Mol Pathol & Immunol, P-4200 Oporto, Portugal; Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA; NW Hosp, Dept Cell Surface Biochem, Seattle, WA 98125 USA; Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA	University of Copenhagen; Universidade do Porto; University System of Georgia; University of Georgia; University of Nebraska System; University of Nebraska Medical Center	Clausen, H (corresponding author), Univ Copenhagen, Sch Dent, Norre Alle 20, Copenhagen 2200 N, Denmark.	henrik.clausen@odont.ku.dk	Bennett, Eric/AAG-6120-2020; Carneiro, Fatima/J-6432-2013; clausen, henrik/AAD-8016-2021; Carneiro, Fatima/AAV-8677-2021; Almeida, Raquel/B-9647-2012	Bennett, Eric/0000-0002-4976-0647; Carneiro, Fatima/0000-0002-1964-1006; Carneiro, Fatima/0000-0002-1964-1006; Almeida, Raquel/0000-0002-5622-1633; Clausen, Henrik/0000-0002-0915-5055	NCI NIH HHS [R01 CA41521, R01 CA70740, 1 RO1 CA66234] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070740, R01CA066234, R01CA041521] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACQUOTTI D, 1990, J AM CHEM SOC, V112, P7772, DOI 10.1021/ja00177a043; Almeida R, 1997, J BIOL CHEM, V272, P31979, DOI 10.1074/jbc.272.51.31979; Bennett EP, 1996, J BIOL CHEM, V271, P17006, DOI 10.1074/jbc.271.29.17006; BIERHUIZEN MFA, 1995, GLYCOBIOLOGY, V5, P417, DOI 10.1093/glycob/5.4.417; Chandrasekaran EV, 1996, BIOCHEMISTRY-US, V35, P8925, DOI 10.1021/bi952194e; Clausen H, 1996, GLYCOBIOLOGY, V6, P635, DOI 10.1093/glycob/6.6.635; CLAUSEN H, 1989, VOX SANG, V56, P1, DOI 10.1111/j.1423-0410.1989.tb03040.x; DABROWSKI J, 1980, BIOCHEMISTRY-US, V19, P5652, DOI 10.1021/bi00565a030; DABROWSKI J, 1980, CHEM PHYS LIPIDS, V26, P187, DOI 10.1016/0009-3084(80)90006-7; Gerhold D, 1996, BIOESSAYS, V18, P973, DOI 10.1002/bies.950181207; GOODE S, 1992, DEVELOPMENT, V116, P177; Goode S, 1996, DEV BIOL, V178, P35, DOI 10.1006/dbio.1996.0196; Hennet T, 1998, J BIOL CHEM, V273, P58, DOI 10.1074/jbc.273.1.58; HOLMES EH, 1989, ARCH BIOCHEM BIOPHYS, V274, P14, DOI 10.1016/0003-9861(89)90410-4; HOLMES EH, 1989, ARCH BIOCHEM BIOPHYS, V270, P630, DOI 10.1016/0003-9861(89)90546-8; Kimura H, 1997, BIOCHEM BIOPH RES CO, V237, P131, DOI 10.1006/bbrc.1997.7100; KOBATA A, 1992, EUR J BIOCHEM, V209, P483, DOI 10.1111/j.1432-1033.1992.tb17313.x; Kobata A., 1984, BIOL CARBOHYDRATES, V2, P87; KOERNER TAW, 1983, BIOCHEMISTRY-US, V22, P2676, DOI 10.1021/bi00280a014; Kolbinger F, 1998, J BIOL CHEM, V273, P433, DOI 10.1074/jbc.273.1.433; Kono M, 1997, GLYCOBIOLOGY, V7, P469, DOI 10.1093/glycob/7.4.469; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEGAULT DJ, 1995, J BIOL CHEM, V270, P20987, DOI 10.1074/jbc.270.36.20987; LEVERY SB, 1992, BIOCHEMISTRY-US, V31, P1069, DOI 10.1021/bi00119a016; LEVERY SB, 1988, CARBOHYD RES, V178, P121, DOI 10.1016/0008-6215(88)80106-X; LI YT, 1984, J BIOL CHEM, V259, P8980; Miyazaki H, 1997, J BIOL CHEM, V272, P24794, DOI 10.1074/jbc.272.40.24794; ORIOL R, 1986, VOX SANG, V51, P161, DOI 10.1111/j.1423-0410.1986.tb01946.x; REGUIGNEARNOULD I, 1995, CYTOGENET CELL GENET, V71, P158, DOI 10.1159/000134098; Sato T, 1998, P NATL ACAD SCI USA, V95, P472, DOI 10.1073/pnas.95.2.472; SCARSDALE JN, 1990, BIOCHEMISTRY-US, V29, P9843, DOI 10.1021/bi00494a014; SCHACHTER H, 1994, MOL GLYCOBIOLOGY, P88; SCHULTE S, 1993, P NATL ACAD SCI USA, V90, P10265, DOI 10.1073/pnas.90.21.10265; Shaper NL, 1997, J BIOL CHEM, V272, P31389, DOI 10.1074/jbc.272.50.31389; SHEARES BT, 1982, J BIOL CHEM, V257, P599; SHEARES BT, 1983, J BIOL CHEM, V258, P9893; STELLNER K, 1974, J BIOL CHEM, V249, P1022; TSUJI S, 1996, GLYCOBIOLOGY, V6, P5; VANDIE I, 1997, GLYCOBIOLOGY, V7, P5; Wandall HH, 1997, J BIOL CHEM, V272, P23503, DOI 10.1074/jbc.272.38.23503; Yuan YP, 1997, CELL, V88, P9, DOI 10.1016/S0092-8674(00)81852-8	43	140	160	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					12770	12778		10.1074/jbc.273.21.12770	http://dx.doi.org/10.1074/jbc.273.21.12770			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582303	hybrid			2022-12-27	WOS:000073768500014
J	Fensome, A; Whatmore, J; Morgan, C; Jones, D; Cockcroft, S				Fensome, A; Whatmore, J; Morgan, C; Jones, D; Cockcroft, S			ADP-ribosylation factor and Rho proteins mediate fMLP-dependent activation of phospholipase D in human neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED HUMAN-NEUTROPHILS; PLECKSTRIN-HOMOLOGY DOMAINS; BOTULINUM C3 EXOENZYME; GTP-BINDING PROTEIN; BETA-GAMMA-SUBUNITS; HL-60 CELLS; KINASE-C; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; SYNERGISTIC ACTIVATION	Activation of intact human neutrophils by fMLP stimulates phospholipase D (PLD) by an unknown signaling pathway. The small GTPase, ADP-ribosylation factor (ARF), and Rho proteins regulate the activity of PLD1 directly. Cell permeabilization with streptolysin O leads Do loss of cytosolic proteins including ARF but not Rho proteins from the human neutrophils, PLD activation by fMLP is refractory in these cytosol-depleted cells. Readdition of myr-ARF1 but not non-myr-ARF1 restores fMLP-stimulated PLD activity, C3 toxin, which inactivates Rho proteins, reduces the ARF-reconstituted PLD activity, illustrating that although Rho alone does not stimulate PLD activity, it synergizes with ARF, To identify the signaling pathway to ARF and Rho activation by fMLP, we used pertussis toxin and wortmannin to examine the requirement for heterotrimeric G proteins of the G(i) family and for phosphoinositide 3-kinase, respectively. PLD activity in both intact cells and the ARF-restored response in cytosol-depleted cells is inhibited by pertussis toxin, indicating a requirement for G(i2)/G(i3) protein. In contrast, wortmannin inhibited only fMLP-stimulated PLD activity in intact neutrophils, but it has no effect on myr-ARF1-reconstituted activity. fMLP-stimulated translocation of ARF and Rho proteins to membranes is not inhibited by wortmannin, It is concluded that activation of G(i) proteins is obligatory for ARF/Rho activation by fMLP, but activation of phosphoinositide 3-kinase is not required.	Univ London Univ Coll, Dept Physiol, London WC1E 6JJ, England	University of London; University College London	Cockcroft, S (corresponding author), Univ London Univ Coll, Dept Physiol, Univ St, London WC1E 6JJ, England.	ucgbsxc@ucl.ac.uk	Cockcroft, Shamshad/F-9480-2011	Cockcroft, Shamshad/0000-0002-5731-476X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Abousalham A, 1997, J BIOL CHEM, V272, P1069, DOI 10.1074/jbc.272.2.1069; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BENNETT JP, 1980, BIOCHIM BIOPHYS ACTA, V601, P584, DOI 10.1016/0005-2736(80)90560-X; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BONSER RW, 1991, BRIT J PHARMACOL, V103, P1237, DOI 10.1111/j.1476-5381.1991.tb12330.x; BOURGOIN S, 1995, J BIOL CHEM, V270, P3172, DOI 10.1074/jbc.270.7.3172; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; Cockcroft S, 1996, PROG LIPID RES, V35, P345, DOI 10.1016/S0163-7827(96)00009-4; COCKCROFT S, 1984, BIOCHIM BIOPHYS ACTA, V795, P37, DOI 10.1016/0005-2760(84)90102-4; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; COCKCROFT S, 1989, FEBS LETT, V245, P25, DOI 10.1016/0014-5793(89)80184-X; COLLEY WC, 1974, BIOCHEM J, V356, P326; DEMATTEIS MA, 1993, NATURE, V364, P818, DOI 10.1038/364818a0; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; Exton JH, 1997, PHYSIOL REV, V77, P303, DOI 10.1152/physrev.1997.77.2.303; FRANCO M, 1995, J BIOL CHEM, V270, P1337, DOI 10.1074/jbc.270.3.1337; GENY B, 1993, EUR J BIOCHEM, V215, P389, DOI 10.1111/j.1432-1033.1993.tb18045.x; GENY B, 1992, BIOCHEM J, V284, P531, DOI 10.1042/bj2840531; GIERSCHIK P, 1989, J BIOL CHEM, V264, P21470; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; HORN W, 1986, BIOCHEM BIOPH RES CO, V139, P1169, DOI 10.1016/S0006-291X(86)80300-X; KANAHO Y, 1992, J IMMUNOL, V149, P622; Karnam P, 1997, J BIOL CHEM, V272, P6136, DOI 10.1074/jbc.272.10.6136; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; Kular G, 1997, BIOCHEM J, V325, P299, DOI 10.1042/bj3250299; KURIBARA H, 1995, J BIOL CHEM, V270, P25667, DOI 10.1074/jbc.270.43.25667; KWAK JY, 1995, J BIOL CHEM, V270, P27093, DOI 10.1074/jbc.270.45.27093; LAMBETH JD, 1995, J BIOL CHEM, V270, P2431, DOI 10.1074/jbc.270.6.2431; LEE YH, 1994, J BIOL CHEM, V269, P26842; Malcolm KC, 1996, J BIOL CHEM, V271, P13135, DOI 10.1074/jbc.271.22.13135; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; Martin A, 1996, J BIOL CHEM, V271, P17397, DOI 10.1074/jbc.271.29.17397; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; Meacci E, 1997, P NATL ACAD SCI USA, V94, P1745, DOI 10.1073/pnas.94.5.1745; MEADE CJ, 1986, BIOCHEM J, V238, P425, DOI 10.1042/bj2380425; Morgan CP, 1997, BIOCHEM J, V325, P581, DOI 10.1042/bj3250581; Nakamura M, 1997, BIOCHEM PHARMACOL, V53, P1929, DOI 10.1016/S0006-2952(97)00169-X; OKADA T, 1994, J BIOL CHEM, V269, P3563; PAI JK, 1988, J BIOL CHEM, V263, P12472; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; RANDAZZO PA, 1995, J BIOL CHEM, V270, P14809, DOI 10.1074/jbc.270.24.14809; REGAZZI R, 1991, BIOCHEM J, V275, P639, DOI 10.1042/bj2750639; RIDER LG, 1987, J BIOL CHEM, V262, P5603; Schmidt M, 1996, J BIOL CHEM, V271, P2422, DOI 10.1074/jbc.271.5.2422; Shome K, 1997, CURR BIOL, V7, P387, DOI 10.1016/S0960-9822(06)00186-2; SIDDIQI AR, 1995, J BIOL CHEM, V270, P8466, DOI 10.1074/jbc.270.15.8466; SINGER WD, 1995, J BIOL CHEM, V270, P14944, DOI 10.1074/jbc.270.25.14944; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; STUTCHFIELD J, 1993, BIOCHEM J, V293, P649, DOI 10.1042/bj2930649; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; WALKER MW, 1992, J BIOL CHEM, V267, P3230; Whatmore J, 1996, BIOCHEM J, V320, P785, DOI 10.1042/bj3200785; XIE MS, 1991, J CLIN INVEST, V88, P45, DOI 10.1172/JCI115303; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980; YEO EJ, 1994, J BIOL CHEM, V269, P27823	61	85	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					13157	13164		10.1074/jbc.273.21.13157	http://dx.doi.org/10.1074/jbc.273.21.13157			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582356	hybrid			2022-12-27	WOS:000073768500067
J	Figueiredo-Pereira, ME; Yakushin, S; Cohen, G				Figueiredo-Pereira, ME; Yakushin, S; Cohen, G			Disruption of the intracellular sulfhydryl homeostasis by cadmium-induced oxidative stress leads to protein thiolation and ubiquitination in neuronal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-PEROXIDATION; EPITHELIAL-CELLS; PROTEOLYSIS; GLUTATHIONE; TOXICITY; DEGRADATION; PATHWAY; COMPLEX; CONSEQUENCES; MECHANISMS	Cadmium is a potent cell poison known to cause oxidative stress by increasing lipid peroxidation and/or by changing intracellular glutathione levels and to affect the ubiquitin/ATP-deperndent proteolytic pathway. However, the cellular mechanisms involved in cadmium toxicity are still not well understood, especially in neuronal cells. To investigate the relationship between cadmium-induced oxidative stress and the ubiquitin/ATP-dependent pathway, we treated cultures of neuronal cells with different concentrations of the metal ion. In addition to decreases in glutathione levels, we observed marked increases in protein-mixed disulfides (Pr-SSGs) after exposure of HT4 cells (a mouse neuronal cell line) or rat primary mesencephalic cultures to Cd2+. The increases in intracellular levels of Pr-SSGs were concurrent with increases in the levels of ubiquitinated proteins (Ub proteins) when the HT4 cells were subjected to lower (25 mu M or less) concentrations of cadmium. However, higher concentrations of cadmium (50 mu M), which were toxic, led to increases in Pr-SSGs but inhibited ubiquitination, probably reflecting inhibition of ubiquitinating enzymes. The cadmium-induced changes in Pr-SSGs and Ub proteins were not affected when more than 85% of intracellular glutathione was removed from the cells by the glutathione synthetase inhibitor L-buthionine-(S,R)-sulfoximine. However, the reducing agent dithiothreitol, which prevented the build up of Pr-SSGs in the cell, also blocked the accumulation of Ub proteins induced by cadmium, In addition, dithiothreitol blocked the effects of the higher toxic (50 mu M) concentrations of cadmium on cytotoxicity and on glutathione, Pr-SSGs, and Ub proteins. Together, these results strongly suggest that changes in the levels of intracellular Pr-SSGs and ubiquitin-protein conjugates in neuronal cells are responses closely associated with the disruption of intracellular sulfhydryl homeostasis caused by cadmium-mediated oxidative stress.	CUNY Hunter Coll, Dept Biol Sci, New York, NY 10021 USA; CUNY Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA	City University of New York (CUNY) System; Hunter College (CUNY); City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Figueiredo-Pereira, ME (corresponding author), CUNY Hunter Coll, Dept Biol Sci, 695 Pk Ave, New York, NY 10021 USA.	pereira@genectr.hunter.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034018, R01NS023017] Funding Source: NIH RePORTER; NINDS NIH HHS [NS23017, NS34018] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACAN NL, 1995, BIOCHEM MOL MED, V54, P33, DOI 10.1006/bmme.1995.1005; Akerboom T P, 1981, Methods Enzymol, V77, P373; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN YP, 1995, BBA-MOL CELL RES, V1268, P59, DOI 10.1016/0167-4889(95)00044-S; CHENG L, 1994, MOL GEN GENET, V243, P358, DOI 10.1007/BF00301072; CHRISTIE NT, 1984, BIOL TRACE ELEM RES, V6, P139, DOI 10.1007/BF02916931; CIECHANOVER A, 1994, FASEB J, V8, P182, DOI 10.1096/fasebj.8.2.8119489; COHEN G, 1994, NEURODEGENER DIS, P139; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; DAVIES KJA, 1993, BIOCHEM SOC T, V21, P346, DOI 10.1042/bst0210346; FAGAN JM, 1992, J BIOL CHEM, V267, P23015; FigueiredoPereira ME, 1997, MOL BIOL REP, V24, P35, DOI 10.1023/A:1006848405975; FIGUEIREDOPEREIRA ME, 1994, J NEUROCHEM, V63, P1578; GRUNE T, 1995, J BIOL CHEM, V270, P2344, DOI 10.1074/jbc.270.5.2344; HERSHKO A, 1991, TRENDS BIOCHEM SCI, V16, P265, DOI 10.1016/0968-0004(91)90101-Z; HUSSAIN T, 1987, PHARMACOL TOXICOL, V60, P355, DOI 10.1111/j.1600-0773.1987.tb01526.x; JahngenHodge J, 1997, J BIOL CHEM, V272, P28218, DOI 10.1074/jbc.272.45.28218; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; KOIZUMI T, 1992, J TOXICOL ENV HEALTH, V37, P25, DOI 10.1080/15287399209531654; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERMA J, 1993, P NATL ACAD SCI USA, V90, P11688, DOI 10.1073/pnas.90.24.11688; Liu H, 1996, J BIOL CHEM, V271, P4805; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAYER RJ, 1991, J PATHOL, V163, P279, DOI 10.1002/path.1711630402; MAYER RJ, 1991, BIOCHIM BIOPHYS ACTA, V1089, P141, DOI 10.1016/0167-4781(91)90002-4; MILLER RM, BIOCH BIOPHYS, V276, P355; MORSELT AFW, 1991, TOXICOLOGY, V70, P1; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MULLER L, 1986, TOXICOLOGY, V40, P285, DOI 10.1016/0300-483X(86)90061-2; MYTILINEOU C, 1993, J NEUROCHEM, V61, P1470, DOI 10.1111/j.1471-4159.1993.tb13642.x; OPANASHUK LA, 1995, J NEUROSCI RES, V42, P623, DOI 10.1002/jnr.490420504; PACIFICI RE, 1991, GERONTOLOGY, V37, P166; PEREIRA ME, 1992, ARCH BIOCHEM BIOPHYS, V294, P1, DOI 10.1016/0003-9861(92)90128-J; RECHSTEINER M, 1987, ANNU REV CELL BIOL, V3, P1, DOI 10.1146/annurev.cb.03.110187.000245; REED DJ, 1990, ANNU REV PHARMACOL, V30, P603, DOI 10.1146/annurev.pa.30.040190.003131; RIVETT AJ, 1986, CURR TOP CELL REGUL, V28, P291; SAVOLAINEN H, 1995, RENAL FAILURE, V17, P483, DOI 10.3109/08860229509037613; SHANG F, 1995, BIOCHEM J, V307, P297, DOI 10.1042/bj3070297; Shang F, 1997, J BIOL CHEM, V272, P23086, DOI 10.1074/jbc.272.37.23086; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; STOHS SJ, 1995, FREE RADICAL BIO MED, V18, P321, DOI 10.1016/0891-5849(94)00159-H; VALLEE BL, 1972, ANNU REV BIOCHEM, V41, P91, DOI 10.1146/annurev.bi.41.070172.000515; WHITTEMORE SR, 1991, J NEUROSCI RES, V28, P156, DOI 10.1002/jnr.490280203; WILKINSON KD, 1992, BIOCHEM SOC T, V20, P631, DOI 10.1042/bst0200631; WILKINSON KD, 1995, ANNU REV NUTR, V15, P161, DOI 10.1146/annurev.nu.15.070195.001113; Wilkinson KD, 1997, FASEB J, V11, P1245, DOI 10.1096/fasebj.11.14.9409543; WILLIAMS LR, 1995, CEREBROVAS BRAIN MET, V7, P55	47	154	158	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					12703	12709		10.1074/jbc.273.21.12703	http://dx.doi.org/10.1074/jbc.273.21.12703			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582293	hybrid			2022-12-27	WOS:000073768500004
J	Gregorieff, A; Cloutier, JF; Veillette, A				Gregorieff, A; Cloutier, JF; Veillette, A			Sequence requirements for association of protein-tyrosine phosphatase PEP with the Src homology 3 domain of inhibitory tyrosine protein kinase p50(csk)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH3 DOMAINS; PROLINE-RICH; AMINO-ACID; BINDING; SPECIFICITY; IDENTIFICATION; P60C-SRC; PEPTIDES; RESIDUES; CLONING	Previously, we reported that the inhibitory tyrosine protein kinase p50(csk) is physically associated with the protein-tyrosine phosphatase PEP in hematopoietic cells. This interaction was shown to involve the Src homology 3 (SH3) region of Csk and a proline-rich sequence of PEP termed P1 (SRRTDDEIPPPLPERTPESFIVVEE). In this report, we have attempted to understand the structural basis for the highly specific association of these two molecules in vivo. Our studies revealed that the proline-rich core of the P1 region of PEP (PPPLPERT) was necessary but not sufficient for binding to p50(csk). Additional sequences located carboxyl to this motif were also needed for binding to the Csk SH3 domain in vitro and in vivo. Further analyses revealed that two aliphatic residues (isoleucine 625 and valine 626; PESFIVVEE) mere especially important for this effect. In addition to clarifying the molecular basis for the selective ability of PEP to associate with Csk, these results constitute further evidence that sequences outside proline-rich cores dictate the specificity of SH3 domain-mediated interactions in vivo.	McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Med, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3G 1Y6, Canada; Montreal Gen Hosp, Dept Med, Montreal, PQ H3G 1A4, Canada; Montreal Gen Hosp, Dept Oncol, Montreal, PQ H3G 1A4, Canada	McGill University; McGill University; McGill University; McGill University; McGill University; McGill University	Veillette, A (corresponding author), McGill Univ, McGill Canc Ctr, Rm 715,McIntyre Med Sci Bldg,3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.	VEILLETTE@MEDCOR.MCGILL.CA	Cloutier, Jean-François/K-2003-2012					Chow L M, 1995, Semin Immunol, V7, P207, DOI 10.1006/smim.1995.0026; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; Cloutier JF, 1996, EMBO J, V15, P4909, DOI 10.1002/j.1460-2075.1996.tb00871.x; CLOUTIER JF, 1995, MOL CELL BIOL, V15, P5937; Davidson D, 1997, J BIOL CHEM, V272, P23455, DOI 10.1074/jbc.272.37.23455; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Feng SB, 1995, P NATL ACAD SCI USA, V92, P12408, DOI 10.1073/pnas.92.26.12408; HOWELL BW, 1994, MOL CELL BIOL, V14, P5402, DOI 10.1128/MCB.14.8.5402; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; Lee CH, 1996, CELL, V85, P931, DOI 10.1016/S0092-8674(00)81276-3; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RICKLES RJ, 1995, P NATL ACAD SCI USA, V92, P10909, DOI 10.1073/pnas.92.24.10909; WENG ZG, 1995, MOL CELL BIOL, V15, P5627; YANG Q, 1993, J BIOL CHEM, V268, P6622; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	24	53	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					13217	13222		10.1074/jbc.273.21.13217	http://dx.doi.org/10.1074/jbc.273.21.13217			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582365	hybrid			2022-12-27	WOS:000073768500076
J	Lindner, H; Sarg, B; Hoertnagl, B; Helliger, W				Lindner, H; Sarg, B; Hoertnagl, B; Helliger, W			The microheterogeneity of the mammalian H1(0) histone - Evidence for an age-dependent deamidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE CAPILLARY ELECTROPHORESIS; ACETYLATED PROTEINS; CORE HISTONES; H1 SUBTYPES; CELLS; DIFFERENTIATION; ACCUMULATION; H1-DEGREES; SEPARATION; CHROMATIN	Histone H1(0) is known to consist of two subfractions named H1(0)a and H1(0)b. The present work was performed with the aim of elucidating the nature of these two subfractions. By using reversed-phase high performance liquid chromatography in combination with hydrophilic interaction liquid chromatography, we fractionated human histone H1(0) into even four subfractions. Hydrophilic interaction Liquid chromatographic analysis of the peptide fragments obtained after cleavage with cyanogen bromide and digestion with chymotrypsin suggested that the four H1(0) subfractions differ only in their small N-terminal end of the H1(0) molecule (30 residues). Edman degradation of the N-terminal H1(0) peptide fragments and mass spectra analysis have indicated that human histone H1(0) consists of intact histones H1(0) (named H1(0) Asn-3) and deamidated H1(0) forms (H1(0) Asp-3) having an aspartic acid residue at position 3 instead of asparagine, Moreover, both H1(0) Asn-3 and H1(0) Asp-3 are blocked (H1(0)a Asn-3, H1(0)a Asp-3) and unblocked (H1(0)b Asn-3, H1(0)b Asp-3) on their N terminus. Acid-urea gel electrophoretic analysis has shown that the histone subfraction, in the Literature originally named H1(0)a, actually consists of a mixture of H1(0)a Asn-3 and H1(0)a Asp-3, whereas H1(0)b consists of H1(0)b Asn-3 and H1(0)b Asp-3. Furthermore, we found that hydrophilic interaction Liquid chromatography separates rat and mouse histone H1(0) just like human H1(0) into four subfractions. Hydrophilic interaction liquid chromatographic analysis of brain and liver histone H1(0) from rats of different ages revealed an age-dependent increase of both the N-terminally acetylated and the deamidated forms of H1(0). In addition, we found that the relative proportions of the four forms of H1(0) histones differ from tissue to tissue.	Univ Innsbruck, Inst Med Chem & Biochem, A-6020 Innsbruck, Austria	University of Innsbruck	Lindner, H (corresponding author), Univ Innsbruck, Inst Med Chem & Biochem, Fritz Pregl Str 3, A-6020 Innsbruck, Austria.	Herbert.Lindner@uibk.ac.at						ALONSO A, 1988, EMBO J, V10, P3003; ARFIN SM, 1988, BIOCHEMISTRY-US, V27, P7979, DOI 10.1021/bi00421a001; BANCHEV T, 1991, BIOCHIM BIOPHYS ACTA, V1073, P230, DOI 10.1016/0304-4165(91)90208-X; BOLLA R, 1979, BIOCHEM J, V184, P669, DOI 10.1042/bj1840669; CLARKE S, 1985, ANNU REV BIOCHEM, V54, P479, DOI 10.1146/annurev.bi.54.070185.002403; CSORDAS A, 1990, BIOCHEM J, V265, P23, DOI 10.1042/bj2650023; DANNA JA, 1981, BIOCHEMISTRY-US, V20, P4501, DOI 10.1021/bi00518a041; DANNA JA, 1980, BIOCHEMISTRY-US, V19, P4331, DOI 10.1021/bi00559a029; DOENECKE D, 1986, J MOL BIOL, V187, P461, DOI 10.1016/0022-2836(86)90446-8; DOENECKE D, 1994, J CELL BIOCHEM, V54, P423, DOI 10.1002/jcb.240540409; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; GABRIELLI F, 1986, MOL CELL BIOCHEM, V71, P129, DOI 10.1007/BF00214771; GEIGER T, 1987, J BIOL CHEM, V262, P785; GJERSET R, 1982, P NATL ACAD SCI-BIOL, V79, P2333, DOI 10.1073/pnas.79.7.2333; Gros E., 1967, METHOD ENZYMOL, V11, P238; HARRIS MR, 1983, BIOCHEM J, V211, P763, DOI 10.1042/bj2110763; HELLIGER W, 1992, BIOCHEM J, V288, P77; JACKOWSKI G, 1982, CELL BIOL INT REP, V6, P867, DOI 10.1016/0309-1651(82)90147-3; JORNVALL H, 1975, J THEOR BIOL, V55, P1, DOI 10.1016/S0022-5193(75)80105-6; KEPPEL F, 1977, P NATL ACAD SCI USA, V74, P653, DOI 10.1073/pnas.74.2.653; KRESS H, 1986, NUCLEIC ACIDS RES, V14, P7189, DOI 10.1093/nar/14.18.7189; LAITINEN J, 1995, J CELL BIOCHEM, V57, P1, DOI 10.1002/jcb.240570102; LEA MA, 1987, CANCER BIOCHEM BIOPH, V9, P199; LENNOX RW, 1982, J BIOL CHEM, V257, P5183; Lindner H, 1996, J CHROMATOGR A, V743, P137, DOI 10.1016/0021-9673(96)00131-8; LINDNER H, 1992, BIOCHEM J, V283, P467, DOI 10.1042/bj2830467; Lindner H, 1997, J CHROMATOGR A, V782, P55, DOI 10.1016/S0021-9673(97)00468-8; LINDNER H, 1990, BIOCHEM J, V269, P359, DOI 10.1042/bj2690359; LINDNER H, 1993, ELECTROPHORESIS, V14, P480, DOI 10.1002/elps.1150140174; LINDNER H, 1995, ELECTROPHORESIS, V16, P604, DOI 10.1002/elps.1150160197; MEDVEDEV ZA, 1984, MECH AGEING DEV, V28, P139, DOI 10.1016/0047-6374(84)90014-9; OSBORNE HB, 1984, EXP CELL RES, V152, P449, DOI 10.1016/0014-4827(84)90646-3; PANYIM S, 1969, BIOCHEM BIOPH RES CO, V37, P1042, DOI 10.1016/0006-291X(69)90237-X; PANYIM S, 1969, BIOCHEMISTRY-US, V8, P3972, DOI 10.1021/bi00838a013; PERSSON B, 1985, EUR J BIOCHEM, V152, P523, DOI 10.1111/j.1432-1033.1985.tb09227.x; PIELER C, 1981, EUR J BIOCHEM, V115, P329, DOI 10.1111/j.1432-1033.1981.tb05242.x; PINA B, 1987, FEBS LETT, V210, P161, DOI 10.1016/0014-5793(87)81328-5; RICHARDSON A, 1985, MOL BIOL AGING GENE, P229; Robinson A B, 1974, Curr Top Cell Regul, V8, P247; ROBINSON AB, 1970, P NATL ACAD SCI USA, V66, P753, DOI 10.1073/pnas.66.3.753; SCHMIDT JG, 1997, NATURE, V387, P725; Semsei I, 1982, Arch Gerontol Geriatr, V1, P29, DOI 10.1016/0167-4943(82)90004-8; SMITH BJ, 1980, FEBS LETT, V110, P25, DOI 10.1016/0014-5793(80)80014-7; SMITH BJ, 1984, EUR J BIOCHEM, V138, P309, DOI 10.1111/j.1432-1033.1984.tb07916.x; STADTMAN E, 1988, J GERONTOL, V43, P112; VANHOLDE K, 1995, FR MOLEC B, V9, P1; VANNISPEN JW, 1987, TOP PHARM SCI, P293; VOORTER CEM, 1987, FEBS LETT, V221, P249, DOI 10.1016/0014-5793(87)80935-3; WOLFFE A, 1992, CHROMATIN STRUCTURE; WRIGHT HT, 1991, CRIT REV BIOCHEM MOL, V26, P1, DOI 10.1080/10409230490440532	50	52	54	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					13324	13330		10.1074/jbc.273.21.13324	http://dx.doi.org/10.1074/jbc.273.21.13324			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582379	hybrid			2022-12-27	WOS:000073768500090
J	McCullough, AK; Romberg, MT; Nyaga, S; Wei, YF; Wood, TG; Taylor, JS; Van Etten, JL; Dodson, ML; Lloyd, RS				McCullough, AK; Romberg, MT; Nyaga, S; Wei, YF; Wood, TG; Taylor, JS; Van Etten, JL; Dodson, ML; Lloyd, RS			Characterization of a novel cis-syn and trans-syn-II pyrimidine dimer glycosylase AP lyase from a eukaryotic algal virus, Paramecium bursaria chlorella virus-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T4 ENDONUCLEASE-V; REPAIR ENZYME; CATALYTIC ACTIVITIES; NACL CONCENTRATION; DAMAGED DNA; THYMIDYLYL-(3'->5')-THYMIDINE; MECHANISM; BINDING; T4-ENDONUCLEASE-V; PHOTOPRODUCTS	Endonuclease V from bacteriophage T4, is a cis-syn pyrimidine dimer-specific glycosylase, Recently, the first sequence homolog of T4 endonuclease V was identified from chlorella virus Paramecium bursaria chlorella virus-1 (PBCV-1). Here we present the biochemical characterization of the chlorella virus pyrimidine dimer glycosylase, cv-PDG. Interestingly, cv-PDG is specific not only for the cis-syn cyclobutane pyrimidine dimer, but also for the trans-syn-II isomer, This is the first trans-syn-II-specific glycosylase identified to date. Kinetic analysis demonstrates that DNAs containing both types of pyrimidine dimers are cleaved by the enzyme with similar catalytic efficiencies. Cleavage analysis and covalent trapping experiments demonstrate that the enzyme mechanism is consistent with the model proposed for glycosylase/AP lyase enzymes in which the glycosylase action is mediated via an imino intermediate between the C1' of the sugar and an amino group in the enzyme, followed by a beta-elimination reaction resulting in cleavage of the phosphodiester bond. cv-PDG exhibits processive cleavage kinetics which are diminished at salt concentrations greater than those determined for T4 endonuclease V, indicating a possibly stronger electrostatic attraction between enzyme and DNA. The identification of this new enzyme with broader pyrimidine dimer specificity raises the intriguing possibility that there may be other T4 endonuclease V-like enzymes with specificity toward other DNA photoproducts.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA; Washington Univ, Dept Chem, St Louis, MO 63130 USA; Univ Nebraska, Dept Plant Pathol, Lincoln, NE 68588 USA	University of Texas System; University of Texas Medical Branch Galveston; Washington University (WUSTL); University of Nebraska System; University of Nebraska Lincoln	Lloyd, RS (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA.		Wood, Thomas/B-6172-2012; Taylor, John-Stephen/AAA-3218-2020; Wood, Thomas/GWZ-2481-2022	Taylor, John-Stephen/0000-0002-8615-7257; Wood, Thomas/0000-0001-8962-8571; Lloyd, R. Stephen/0000-0001-7273-372X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [F32ES005780, P30ES006676, R01ES004091] Funding Source: NIH RePORTER; NIEHS NIH HHS [F32 ES05780-01, R01 ES04091, P30 ES06676] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANANTHASWAMY HN, 1990, PHOTOCHEM PHOTOBIOL, V52, P1119, DOI 10.1111/j.1751-1097.1990.tb08452.x; BAILLY V, 1989, BIOCHEM J, V259, P751, DOI 10.1042/bj2590751; CADET J, 1990, BIOORGANIC PHOTOCHEM, V1, P1; DODSON ML, 1993, BIOCHEMISTRY-US, V32, P8284, DOI 10.1021/bi00083a032; DOWD DR, 1989, J MOL BIOL, V208, P701, DOI 10.1016/0022-2836(89)90160-5; Fasman GD., 1975, HDB BIOCH MOL BIOL N, V1, P589; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Furuta M, 1997, APPL ENVIRON MICROB, V63, P1551, DOI 10.1128/AEM.63.4.1551-1556.1997; GANESAN AK, 1986, BIOCHEMISTRY-US, V25, P5751, DOI 10.1021/bi00367a060; GRUSKIN EA, 1986, J BIOL CHEM, V261, P9607; KAO JLF, 1993, CHEM RES TOXICOL, V6, P561, DOI 10.1021/tx00034a027; KEMMINK J, 1987, EUR BIOPHYS J BIOPHY, V14, P293, DOI 10.1007/BF00254894; KIM J, 1988, NUCLEIC ACIDS RES, V16, P1335; Kim Sang-Tae, 1993, Biochemistry, V32, P7065, DOI 10.1021/bi00079a001; KONING TMG, 1991, EUR J BIOCHEM, V195, P29, DOI 10.1111/j.1432-1033.1991.tb15672.x; LATHAM KA, 1994, BIOCHEMISTRY-US, V33, P9024, DOI 10.1021/bi00196a021; LATHAM KA, 1995, BIOCHEMISTRY-US, V34, P8796, DOI 10.1021/bi00027a031; LIU FT, 1978, BIOCHEMISTRY-US, V17, P4865, DOI 10.1021/bi00616a003; LLOYD RS, 1980, NUCLEIC ACIDS RES, V8, P5113, DOI 10.1093/nar/8.21.5113; LLOYD RS, 1995, DNA REPAIR MECH IMPA, P25; LLOYD RS, 1993, NUCLEASES, V2, P263; LU ZQ, 1995, VIROLOGY, V206, P339, DOI 10.1016/S0042-6822(95)80049-2; MANOHARAN M, 1988, J AM CHEM SOC, V110, P2690, DOI 10.1021/ja00216a074; MORIKAWA K, 1992, SCIENCE, V256, P523, DOI 10.1126/science.1575827; NAKABEPPU Y, 1981, P NATL ACAD SCI-BIOL, V78, P2742, DOI 10.1073/pnas.78.5.2742; NGAYA S, 1997, BIOCHEMISTRY-US, V36, P4080; PATRICK MH, 1976, PHOTOCHEM PHOTOBIOL, V2, P1; Patrick MH., 1976, PHOTOCHEM PHOTOBIOL, V2, P35, DOI [10.1016/B978-0-12-734602-1.50008-3, DOI 10.1016/B978-0-12-734602-1.50008-3]; PIERSEN CE, 1995, J BIOL CHEM, V270, P23475, DOI 10.1074/jbc.270.40.23475; PRINCE MA, 1991, J BIOL CHEM, V266, P10686; SCHROCK RD, 1991, J BIOL CHEM, V266, P17631; SCHROCK RD, 1993, J BIOL CHEM, V268, P880; Shiota S, 1997, P NATL ACAD SCI USA, V94, P593, DOI 10.1073/pnas.94.2.593; SMITH CA, 1993, J BIOL CHEM, V268, P11143; Smith CA, 1996, BIOCHEMISTRY-US, V35, P4146, DOI 10.1021/bi951975c; SUN B, 1995, J BIOL CHEM, V270, P19501, DOI 10.1074/jbc.270.33.19501; SVOBODA DL, 1993, J BIOL CHEM, V268, P10694; VANETTEN JL, 1991, MICROBIOL REV, V55, P586, DOI 10.1128/MMBR.55.4.586-620.1991; VANETTEN JL, 1995, MOL CELLS, V5, P99; VASSYLYEV DG, 1995, CELL, V83, P773, DOI 10.1016/0092-8674(95)90190-6; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; WANG SY, 1976, PHOTOCHEM PHOTOBIOL, V1, P169; Ziegler A, 1996, PHOTOCHEM PHOTOBIOL, V63, P432, DOI 10.1111/j.1751-1097.1996.tb03064.x	43	46	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					13136	13142		10.1074/jbc.273.21.13136	http://dx.doi.org/10.1074/jbc.273.21.13136			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582353	hybrid			2022-12-27	WOS:000073768500064
J	Melloni, E; Michetti, M; Salamino, F; Pontremoli, S				Melloni, E; Michetti, M; Salamino, F; Pontremoli, S			Molecular and functional properties of a calpain activator protein specific for mu-isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SKELETAL-MUSCLE; CALPASTATIN; SYSTEM; IDENTIFICATION; MODULATION; FORMS; SITE	A natural calpain activator protein has been isolated from bovine brain and characterized in its properties and molecular structure. The protein is a homodimer with a molecular mass of about 30 kDa and results in being almost identical to UK114 goat liver protein. Significant similarities with mouse HR12 protein were also observed, whereas at lower degree of similarity was found with a family of heat-responsive proteins named YJGF and YABJ from Haemophilus influenzae and Bacillus subtilis, respectively. The brain activator expresses a strict specificity for the mu-calpain isoform, being completely ineffective on the m-calpain form. As expected, also UK114 was found to possess calpain-activating properties, indistinguishable from those of bovine brain activator. A protein showing the same calpain-activating activity has been also isolated from human red cells, indicating that this factor is widely expressed, All these activators are efficient on CL-calpain independently from the source of the proteinase. The high degree of specificity of the calpain activator for a single calpain isoform may be relevant for the understanding of sophisticated intracellular mechanisms underlying intracellular proteolysis, These data are indicating the existence of a new component of the Ca2+ dependent proteolytic system, constituted of members of a chaperonin-like protein family and capable of promoting intracellular calpain activation.	Univ Genoa, Inst Biol Chem, I-16132 Genoa, Italy	University of Genoa	Melloni, E (corresponding author), Univ Genoa, Inst Biol Chem, Viale Benedetto XV 1, I-16132 Genoa, Italy.							AERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970; Ceciliani F, 1996, FEBS LETT, V393, P147, DOI 10.1016/0014-5793(96)00850-2; CONG JY, 1989, J BIOL CHEM, V264, P10096; CRAWFORD C, 1993, BIOCHEM J, V296, P135, DOI 10.1042/bj2960135; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; EMORI Y, 1987, P NATL ACAD SCI USA, V84, P274; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; Goll DE, 1990, INTRACELLULAR CALCIU, P3; LEVYFAVATIER F, 1993, EUR J BIOCHEM, V212, P665, DOI 10.1111/j.1432-1033.1993.tb17704.x; MELLGREN RL, 1994, BIOCHEM BIOPH RES CO, V204, P544, DOI 10.1006/bbrc.1994.2493; Melloni E, 1996, BIOCHEM BIOPH RES CO, V229, P193, DOI 10.1006/bbrc.1996.1779; MELLONI E, 1989, TRENDS NEUROSCI, V12, P438, DOI 10.1016/0166-2236(89)90093-3; Michetti M, 1997, BIOCHEM J, V325, P721, DOI 10.1042/bj3250721; MICHETTI M, 1991, EUR J BIOCHEM, V202, P1177, DOI 10.1111/j.1432-1033.1991.tb16487.x; MURACHI T, 1989, BIOCHEM INT, V18, P263; NISHIMURA T, 1991, J BIOL CHEM, V266, P11842; NIXON RA, 1994, ANN NY ACAD SCI, V747, P77; PONTREMOLI S, 1991, ARCH BIOCHEM BIOPHYS, V288, P646, DOI 10.1016/0003-9861(91)90247-G; PONTREMOLI S, 1990, BIOCHEM BIOPH RES CO, V171, P569, DOI 10.1016/0006-291X(90)91184-T; PONTREMOLI S, 1990, BIOCHEM BIOPH RES CO, V167, P373, DOI 10.1016/0006-291X(90)91775-N; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SALAMINO F, 1994, BIOCHEM BIOPH RES CO, V199, P1326, DOI 10.1006/bbrc.1994.1376; Salamino F, 1997, FEBS LETT, V412, P433, DOI 10.1016/S0014-5793(97)00819-3; SALAMINO F, 1993, BIOCHEM J, V290, P191, DOI 10.1042/bj2900191; Suzuki K., 1990, INTRACELLULAR CALCIU, P25; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6; YOSHIZAWA T, 1995, FEBS LETT, V358, P101, DOI 10.1016/0014-5793(94)01401-L	27	96	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					12827	12831		10.1074/jbc.273.21.12827	http://dx.doi.org/10.1074/jbc.273.21.12827			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582310	hybrid			2022-12-27	WOS:000073768500021
J	Osaka, H; Sugiyama, N; Taylor, P				Osaka, H; Sugiyama, N; Taylor, P			Distinctions in agonist and antagonist specificity conferred by anionic residues of the nicotinic acetylcholine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-SITE DISULFIDE; DELTA-SUBUNIT; ALPHA-SUBUNIT; MOLECULAR DISSECTION; LIGAND-BINDING; GAMMA-SUBUNIT; MUSCLE-CELLS; IDENTIFICATION; SELECTIVITY; INTERFACES	Two anionic residues in the nicotinic acetylcholine receptor, Asp-152 in the alpha-subunit and Asp-174 in the gamma-subunit or the corresponding Asp-180 in the delta-subunit, are presumed to reside near the two agonist binding sites at the alpha gamma and alpha delta subunit interfaces of the receptor and have been implicated in electrostatic attraction of cationic ligands, Through site-directed mutagenesis and analysis of state changes in the receptor elicited by agonists, we have distinguished the roles of anionic residues in conferring ligand specificity and Ligand-induced state changes. alpha Asp-152 affects agonist and antagonist affinity similarly, whereas gamma Asp-174 and delta Asp-180 primarily affect agonist affinity, Combining charge neutralization on the alpha subunit with that on the gamma and delta subunits shows an additivity in free energy changes for carbamylcholine and d-tubocurarine, suggesting independent contributions of these residues to stabilizing the bound ligands, Since both aromatic and anionic residues stabilize cationic ligands, we substituted tyrosines (Y) for the aspartyl residues. While the substitution, alpha D152Y reduced the affinities for agonists and antagonists, the gamma D174Y/delta D180Y mutations reduced the affinity for agonist binding, but surprisingly enhanced the affinity for d-tubocurarine. To ascertain whether selective changes in agonist binding stem from the capacity of agonists to form the desensitized state of the receptor, carbamylcholine binding was measured in the presence of an allosteric inhibitor, proadifen, Mutant nAChRs carrying alpha D152Y or gamma D174N/delta D180N show similar reductions in dissociation constants for the desensitized compared with activable receptor state and a similar proadifen concentration dependence, Hence, these mutations influence ligand recognition rather than the capacity of the receptor to desensitize. By contrast, the alpha D200Q mutation diminishes the ratio of dissociation constants for two states and requires higher proadifen concentrations to induce desensitization. Thus, the contributions of alpha Asp-152, gamma/delta Asp-174/180, and alpha Asp-200 in stabilizing ligand binding can be distinguished by the interactions between agonists and allosteric inhibitors.	Univ Calif San Diego, Dept Pharmacol 0636, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Osaka, H (corresponding author), Univ Calif San Diego, Dept Pharmacol 0636, La Jolla, CA 92093 USA.	priley@ucsd.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018360, R37GM018360] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 18360] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akk G, 1996, J PHYSIOL-LONDON, V496, P185, DOI 10.1113/jphysiol.1996.sp021676; AUERBACH A, 1993, J PHYSIOL-LONDON, V461, P339, DOI 10.1113/jphysiol.1993.sp019517; BOYD ND, 1984, BIOCHEMISTRY-US, V23, P4023, DOI 10.1021/bi00313a003; Bren N, 1997, J BIOL CHEM, V272, P30793, DOI 10.1074/jbc.272.49.30793; CHANGEUX JP, 1995, BIOCHEM SOC T, V23, P195, DOI 10.1042/bst0230195; COHEN JB, 1992, J CELL BIOCH E, V16, P217; CZAJKOWSKI C, 1991, J BIOL CHEM, V266, P22603; CZAJKOWSKI C, 1995, J BIOL CHEM, V270, P3160, DOI 10.1074/jbc.270.7.3160; CZAJKOWSKI C, 1993, P NATL ACAD SCI USA, V90, P6285, DOI 10.1073/pnas.90.13.6285; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; GALZI JL, 1994, CURR OPIN STRUC BIOL, V4, P554, DOI 10.1016/S0959-440X(94)90218-6; Hucho F, 1996, EUR J BIOCHEM, V239, P539, DOI 10.1111/j.1432-1033.1996.0539u.x; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; Martin M, 1996, J BIOL CHEM, V271, P13497, DOI 10.1074/jbc.271.23.13497; Martin MD, 1997, BIOCHEMISTRY-US, V36, P10742, DOI 10.1021/bi970896t; OLEARY ME, 1994, AM J PHYSIOL, V266, pC648, DOI 10.1152/ajpcell.1994.266.3.C648; PAULING P, 1973, CHEM-BIOL INTERACT, V6, P351, DOI 10.1016/0009-2797(73)90056-2; PRESSMAN D, 1946, J AM CHEM SOC, V68, P250, DOI 10.1021/ja01206a031; Prince RJ, 1996, J BIOL CHEM, V271, P25770, DOI 10.1074/jbc.271.42.25770; Radic Z, 1997, J BIOL CHEM, V272, P23265, DOI 10.1074/jbc.272.37.23265; SEGAL DM, 1974, P NATL ACAD SCI USA, V71, P4295; Shafferman A, 1996, BIOCHEM J, V318, P833, DOI 10.1042/bj3180833; SINE S, 1979, J BIOL CHEM, V254, P3315; SINE SM, 1982, J BIOL CHEM, V257, P8106; SINE SM, 1991, J BIOL CHEM, V266, P19369; Sine SM, 1997, J BIOL CHEM, V272, P23521, DOI 10.1074/jbc.272.38.23521; SINE SM, 1994, J BIOL CHEM, V269, P8808; SINE SM, 1993, P NATL ACAD SCI USA, V90, P9436, DOI 10.1073/pnas.90.20.9436; SINE SM, 1991, J BIOL CHEM, V266, P13679; SINE SM, 1981, J BIOL CHEM, V256, P6692; SINE SM, 1995, NEURON, V15, P205, DOI 10.1016/0896-6273(95)90077-2; STAUFFER DA, 1994, BIOCHEMISTRY-US, V33, P6840, DOI 10.1021/bi00188a013; Sugiyama N, 1996, J BIOL CHEM, V271, P26575, DOI 10.1074/jbc.271.43.26575; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAYLOR P, 1994, ANNU REV PHARMACOL, V34, P281, DOI 10.1146/annurev.pa.34.040194.001433; TAYLOR P, 1983, CURR TOP MEMBR TRANS, V18, P407; Tsigelny I, 1997, BIOPHYS J, V73, P52, DOI 10.1016/S0006-3495(97)78047-0; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; WEBER M, 1974, MOL PHARMACOL, V10, P15	39	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					12758	12765		10.1074/jbc.273.21.12758	http://dx.doi.org/10.1074/jbc.273.21.12758			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582301	hybrid			2022-12-27	WOS:000073768500012
J	Popov, S; Rexach, M; Ratner, L; Blobel, G; Bukrinsky, M				Popov, S; Rexach, M; Ratner, L; Blobel, G; Bukrinsky, M			Viral protein R regulates docking of the HIV-1 preintegration complex to the nuclear pore complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MATRIX PROTEIN; LOCALIZATION SIGNAL; TRANSPORT SUBSTRATE; NONDIVIDING CELLS; TARGETING COMPLEX; IMPORT SUBSTRATE; MEDIATED BINDING; INFECTION; IDENTIFICATION	Replication of human immunodeficiency virus type 1 (HIV-1) in non-dividing cells depends critically on import of the viral preintegration complex into the nucleus. Recent evidence suggests that viral protein R (Vpr) plays a key regulatory role in this process by binding to karyopherin alpha, a cellular receptor for nuclear localization signals, and increasing its affinity for the nuclear localization signals. An in vitro binding assay was used to investigate the role of Vpr in docking of the HIV-1 preintegration complex (PIC) to the nuclear pore complex. Mutant HIV-1 PICs that lack Vpr were impaired in the ability to dock to isolated nuclei and recombinant nucleoporins. Although Vpr by itself associated with nucleoporins, the docking of Vpr(+) PICs was dependent on karyopherin beta and was blocked by antibodies to beta. Vpr stabilized docking by preventing nucleoporin-stimulated dissociation of the import complex. These results suggest a biochemical mechanism for Vpr function in transport of the HIV-1 genome across the nuclear pore complex.	Picower Inst Med Res, Manhasset, NY 11030 USA; Rockefeller Univ, Howard Hughes Med Inst, Cell Biol Lab, New York, NY 10021 USA; Washington Univ, Med Ctr, Div Mol Oncol, St Louis, MO 63110 USA	Northwell Health; Howard Hughes Medical Institute; Rockefeller University; Washington University (WUSTL)	Bukrinsky, M (corresponding author), Picower Inst Med Res, 350 Community Dr, Manhasset, NY 11030 USA.			Ratner, Lee/0000-0003-2744-7294	NIAID NIH HHS [AI 36071, AI 33776] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI033776, R01AI036071, R29AI033776, R01AI033776] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; BUKRINSKY MI, 1993, P NATL ACAD SCI USA, V90, P6125, DOI 10.1073/pnas.90.13.6125; BUKRINSKY MI, 1992, P NATL ACAD SCI USA, V89, P6580, DOI 10.1073/pnas.89.14.6580; ENENKEL C, 1995, J BIOL CHEM, V270, P16499, DOI 10.1074/jbc.270.28.16499; FINLAY DR, 1991, J CELL BIOL, V114, P169, DOI 10.1083/jcb.114.1.169; Fouchier RAM, 1997, EMBO J, V16, P4531, DOI 10.1093/emboj/16.15.4531; FREED EO, 1995, J VIROL, V69, P3949, DOI 10.1128/JVI.69.6.3949-3954.1995; Gallay P, 1996, J VIROL, V70, P1027, DOI 10.1128/JVI.70.2.1027-1032.1996; GALLAY P, 1995, CELL, V80, P379, DOI 10.1016/0092-8674(95)90488-3; Gallay P, 1997, P NATL ACAD SCI USA, V94, P9825, DOI 10.1073/pnas.94.18.9825; GALLAY P, 1995, CELL, V83, P569, DOI 10.1016/0092-8674(95)90097-7; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; Hu TH, 1996, J CELL BIOL, V134, P589, DOI 10.1083/jcb.134.3.589; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; IMAMOTO N, 1995, FEBS LETT, V368, P415; Iovine MK, 1995, J CELL BIOL, V131, P1699, DOI 10.1083/jcb.131.6.1699; KITA K, 1993, J BIOCHEM-TOKYO, V113, P377, DOI 10.1093/oxfordjournals.jbchem.a124054; KRAEMER DM, 1995, J BIOL CHEM, V270, P19017, DOI 10.1074/jbc.270.32.19017; LEWIS P, 1992, EMBO J, V11, P3053, DOI 10.1002/j.1460-2075.1992.tb05376.x; MELCHIOR F, 1995, CURR OPIN CELL BIOL, V7, P310, DOI 10.1016/0955-0674(95)80084-0; Miller MD, 1997, J VIROL, V71, P5382, DOI 10.1128/JVI.71.7.5382-5390.1997; Nadler SG, 1997, J BIOL CHEM, V272, P4310, DOI 10.1074/jbc.272.7.4310; Pante N, 1996, SCIENCE, V273, P1729, DOI 10.1126/science.273.5282.1729; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; Popov S, 1998, EMBO J, V17, P909, DOI 10.1093/emboj/17.4.909; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; Vodicka MA, 1998, GENE DEV, V12, P175, DOI 10.1101/gad.12.2.175; VONSCHWEDLER U, 1994, P NATL ACAD SCI USA, V91, P6992, DOI 10.1073/pnas.91.15.6992; WEINBERG JB, 1991, J EXP MED, V174, P1477, DOI 10.1084/jem.174.6.1477; WESTERVELT P, 1992, J VIROL, V66, P3925, DOI 10.1128/JVI.66.6.3925-3931.1992; WESTERVELT P, 1992, J VIROL, V66, P2577, DOI 10.1128/JVI.66.4.2577-2582.1992	38	147	151	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					13347	13352		10.1074/jbc.273.21.13347	http://dx.doi.org/10.1074/jbc.273.21.13347			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582382	hybrid			2022-12-27	WOS:000073768500093
J	Burns, K; Martinon, F; Esslinger, C; Pahl, H; Schneider, P; Bodmer, JL; Di Marco, F; French, L; Tschopp, J				Burns, K; Martinon, F; Esslinger, C; Pahl, H; Schneider, P; Bodmer, JL; Di Marco, F; French, L; Tschopp, J			MyD88, an adapter protein involved in interleukin-1 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; DROSOPHILA TOLL PROTEIN; TNF RECEPTOR; DEATH DOMAIN; DORSOVENTRAL SIGNAL; MOLECULAR-CLONING; CELL-DEATH; KINASE; ACTIVATION; GENE	MyD88 has a modular organization, an N-terminal death domain (DD) related to the cytoplasmic signaling domains found in many members of the tumor necrosis factor receptor (TNF-R) superfamily, and a C-terminal Toll domain similar to that found in the expanding family of Toll/interleukin-1-like receptors (IL-1R). This dual domain structure, together with the following observations, supports a role for MyD88 as an adapter in IL-1 signal transduction; MyD88 forms homodimers in vivo through DD-DD and Toll-Toll interactions. Overexpression of MyD88 induces activation of the c-Jun N-terminal kinase (JNK) and the transcription factor NF-kappa B through its DD, A point mutation in MyD88, MyD88-1pr (F56N), which prevents dimerization of the DD, also blocks induction of these activities. MyD88-induced NF-kappa B activation is inhibited by the dominant negative versions of TRAF6 and IRAK, which also inhibit IL-1-induced NF-kappa B activation. Overexpression of MyD88-1pr or MyD88-Toll (expressing only the Toll domain) acted to inhibit IL-1-induced NF-kappa B and JNK activation in a 293 cell line overexpressing the IL-1R, MyD88 coimmunoprecipitates with the IL-1R signaling complex in an IL-1-dependent manner.	Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland; Univ Lausanne, Ludwig Inst Canc Res, Lausanne Branch, CH-1066 Epalinges, Switzerland; Swiss Inst Expt Canc Res, ISREC, CH-1066 Epalinges, Switzerland; Tumor Biol Ctr, D-79106 Freiburg, Germany; Univ Geneva, Sch Med, Dept Dermatol, CH-1211 Geneva 4, Switzerland	University of Lausanne; Ludwig Institute for Cancer Research; University of Lausanne; Swiss Institute Experimental Cancer Research; University of Geneva	Tschopp, J (corresponding author), Univ Lausanne, Inst Biochem, Ch Boveresses 155, CH-1066 Epalinges, Switzerland.		Pahl, Heike/AGM-5260-2022; Martinon, Fabio/A-5575-2009	Martinon, Fabio/0000-0002-6969-822X; Schneider, Pascal/0000-0003-0677-9409				Bodmer JL, 1997, IMMUNITY, V6, P79, DOI 10.1016/S1074-7613(00)80244-7; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Bonnert TP, 1997, FEBS LETT, V402, P81, DOI 10.1016/S0014-5793(96)01506-2; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; FRENCH LE, 1993, J CELL BIOL, V122, P1119, DOI 10.1083/jcb.122.5.1119; GALINDO RL, 1995, DEVELOPMENT, V121, P2209; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; GROSSHANS J, 1994, NATURE, V372, P563, DOI 10.1038/372563a0; Hardiman G, 1996, ONCOGENE, V13, P2467; HARROCH S, 1995, NUCLEIC ACIDS RES, V23, P5339; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HEGUY A, 1992, J BIOL CHEM, V267, P2605; HOFMANN K, 1995, FEBS LETT, V371, P321, DOI 10.1016/0014-5793(95)00931-X; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; Huang JN, 1997, P NATL ACAD SCI USA, V94, P12829, DOI 10.1073/pnas.94.24.12829; HULTMARK D, 1994, BIOCHEM BIOPH RES CO, V199, P144, DOI 10.1006/bbrc.1994.1206; ITOH N, 1993, J BIOL CHEM, V268, P10932; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LETSOU A, 1993, EMBO J, V12, P3449, DOI 10.1002/j.1460-2075.1993.tb06019.x; LORD KA, 1990, ONCOGENE, V5, P1095; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; MITCHAM JL, 1996, J BIOL CHEM, V271, P577; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nagata S, 1994, Semin Immunol, V6, P3, DOI 10.1006/smim.1994.1002; Pahl HL, 1996, J CELL BIOL, V132, P511, DOI 10.1083/jcb.132.4.511; Parnet P, 1996, J BIOL CHEM, V271, P3967; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; SAPPINO AP, 1991, J CLIN INVEST, V87, P962, DOI 10.1172/JCI115104; SHELTON CA, 1993, CELL, V72, P515, DOI 10.1016/0092-8674(93)90071-W; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Wesche H, 1997, J BIOL CHEM, V272, P7727, DOI 10.1074/jbc.272.12.7727; YAMAGATA M, 1994, GENE, V139, P223, DOI 10.1016/0378-1119(94)90760-9; Yamin TT, 1997, J BIOL CHEM, V272, P21540, DOI 10.1074/jbc.272.34.21540	43	511	544	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12203	12209		10.1074/jbc.273.20.12203	http://dx.doi.org/10.1074/jbc.273.20.12203			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575168	Green Published, hybrid			2022-12-27	WOS:000073629800033
J	Autieri, MV; Agrawal, N				Autieri, MV; Agrawal, N			IRT-1, a novel interferon-gamma-responsive transcript encoding a growth-suppressing basic leucine zipper protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; REGULATORY FACTOR-I; MESSENGER-RNA; CORONARY ANGIOPLASTY; NUCLEAR LOCATION; PROLIFERATION; EXPRESSION; SEQUENCE; ATHEROSCLEROSIS; RESTENOSIS	Interferon-gamma (IFN-gamma) inhibits proliferation of vascular smooth muscle cells (VSMCs) in culture and reduces arterial restenosis post-balloon angioplasty. The identification and characterization of IFN-gamma-specific transcripts in VSMCs are an important approach to discern the molecular mechanisms underlying vascular proliferative disease. In this report, we describe IRT-1, a novel mRNA transcript constitutively expressed in a number of human tissues, but expressed in human VSMCs only when they are stimulated with IFN-gamma. This mRNA expression is induced >200-fold 72 h after IFN-gamma treatment. IRT-1 mRNA is also acutely expressed in rat carotid arteries that are injured by balloon angioplasty. The IRT-1 cDNA transcript encodes a basic protein that contains a leucine zipper motif, a core nuclear localization sequence, and a single strongly hydrophobic region, Constitutive IRT-1 mRNA expression in human peripheral blood lymphocytes is reduced when these cells are stimulated to proliferate. Overexpression of IRT-1 protein in VSMCs alters their morphology and dramatically reduces their proliferative capacity. This study suggests that IRT-1 is an IFN-gamma-inducible factor that may regulate the progression of vascular proliferative diseases.	Deborah Heart & Lung Ctr, Res Inst, Dept Biol Mol, Browns Mills, NJ 08015 USA		Autieri, MV (corresponding author), Temple Univ, Sch Med, Dept Cardiol & Physiol, 3420 N Broad St, Philadelphia, PA 19140 USA.							AUSTIN GE, 1985, J AM COLL CARDIOL, V6, P369, DOI 10.1016/S0735-1097(85)80174-1; Autieri MV, 1996, BIOCHEM BIOPH RES CO, V228, P29, DOI 10.1006/bbrc.1996.1612; BANERJI J, 1990, P NATL ACAD SCI USA, V87, P2374, DOI 10.1073/pnas.87.6.2374; BANGE FC, 1994, J BIOL CHEM, V269, P1091; Bash J, 1997, MOL CELL BIOL, V17, P6526, DOI 10.1128/MCB.17.11.6526; BENNETT MR, 1994, CIRC RES, V74, P525, DOI 10.1161/01.RES.74.3.525; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; Castronuovo J J Jr, 1995, Cardiovasc Surg, V3, P463, DOI 10.1016/0967-2109(95)94442-Y; CLOWES AW, 1983, LAB INVEST, V49, P208; COPPOCK DL, 1987, MOL CELL BIOL, V7, P2925, DOI 10.1128/MCB.7.8.2925; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEMAEYER E, 1988, INTERFERONS OTHER RE, P91; HANSSON GK, 1989, ARTERIOSCLEROSIS, V9, P567, DOI 10.1161/01.ATV.9.5.567; HANSSON GK, 1991, CIRCULATION, V84, P1266, DOI 10.1161/01.CIR.84.3.1266; HANSSON GK, 1988, CIRC RES, V63, P712, DOI 10.1161/01.RES.63.4.712; HANSSON GK, 1991, P NATL ACAD SCI USA, V88, P19530; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; IRIS FJM, 1993, NAT GENET, V3, P137, DOI 10.1038/ng0293-137; JONASSON L, 1988, LAB INVEST, V58, P310; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LIBBY P, 1992, CIRCULATION, V86, P47; LIU MW, 1989, CIRCULATION, V79, P1374, DOI 10.1161/01.CIR.79.6.1374; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; NILSSON J, 1993, CARDIOVASC RES, V27, P1184, DOI 10.1093/cvr/27.7.1184; NUNOKAWA Y, 1992, BIOCHEM BIOPH RES CO, V188, P409, DOI 10.1016/0006-291X(92)92400-R; OBRIEN ER, 1993, CIRC RES, V73, P223, DOI 10.1161/01.RES.73.2.223; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; ROLFE BE, 1995, ARTERIOSCL THROM VAS, V15, P1204, DOI 10.1161/01.ATV.15.8.1204; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHWARTZ RS, 1990, CIRCULATION, V82, P2190, DOI 10.1161/01.CIR.82.6.2190; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Stopeck AT, 1997, CELL TRANSPLANT, V6, P1, DOI 10.1016/S0963-6897(96)00183-2; TANAKA N, 1992, ADV IMMUNOL, V52, P263, DOI 10.1016/S0065-2776(08)60877-9; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; Wang IM, 1996, MOL CELL BIOL, V16, P6313; WANG WZ, 1995, CIRC RES, V77, P1095, DOI 10.1161/01.RES.77.6.1095; Wang XY, 1996, BIOCHEM BIOPH RES CO, V229, P316, DOI 10.1006/bbrc.1996.1799; WELIHUA X, 1997, P NATL ACAD SCI USA, V94, P103; WILLIAMS JG, 1993, J SURG RES, V54, P79, DOI 10.1006/jsre.1993.1013; YAMADA H, 1994, MOL CELL BIOCHEM, V136, P117, DOI 10.1007/BF00926071	46	14	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14731	14737		10.1074/jbc.273.24.14731	http://dx.doi.org/10.1074/jbc.273.24.14731			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614071	hybrid			2022-12-27	WOS:000074160400013
J	Batlle, E; Verdu, J; Dominguez, D; Llosas, MD; Diaz, V; Loukili, N; Paciucci, R; Alameda, F; de Herreros, AG				Batlle, E; Verdu, J; Dominguez, D; Llosas, MD; Diaz, V; Loukili, N; Paciucci, R; Alameda, F; de Herreros, AG			Protein kinase C-alpha activity inversely modulates invasion and growth of intestinal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-COLON; CANCER-CELLS; E-CADHERIN; PHORBOL-ESTER; HT-29 CELLS; ISOZYMES; EXPRESSION; UROKINASE; METHOTREXATE; LOCALIZATION	The phorbol ester phorbol 12-myristate 13-acetate induces remarkable phenotypic changes in intestinal HT-29 M6 cells; these changes consist of loss of homotypic adhesion and inactivation of E-cadherin. In parallel, cell growth is retarded. We have transfected HT-29 M6 cells with an activated form of the conventional protein kinase C alpha (cPK-C alpha). Expression of this isoform induced the acquisition of a scattered phenotype, similar to that adopted by cells after addition of phorbol 12-myristate 13-acetate, with very low cell-to-cell aggregation and undetectable levels of functional E-cadherin. These cell clones were highly motile and rapidly invaded embryonic chick heart fragments. Furthermore, cells expressing activated-cPK-C alpha showed decreased proliferation in comparison to control clones. We have also studied how these two apparently antagonistic changes affect the tumorigenic ability of HT-29 M6 cells. When the different cell clones were xenografted into athymic mice, the effect on cell growth seemed to predominate. Expression of activated-cPK-C alpha significantly reduced the size of the tumors; the cells with the highest level of expression did not even form subcutaneous tumors. Besides their smaller size, the morphology of these tumors was clearly different from those originated by HT-29 Mg cells, and they could be defined as infiltrative on anatomo-pathological basis. These results indicate that cPK-C alpha controls both cell-to-cell adhesion and proliferation of intestinal cells.	Inst Municipal Invest Med, Unitat Biol Cellular & Mol, E-08003 Barcelona, Spain		de Herreros, AG (corresponding author), Inst Municipal Invest Med, Unitat Biol Cellular & Mol, Calle Dr Aiguader 80, E-08003 Barcelona, Spain.	agarcia@imim.es	Paciucci, Rosanna/AGP-3844-2022; Díaz, Víctor Manuel/F-5013-2016; Batlle, Eduard/K-8080-2014; de Herreros, A Garcia/H-3104-2014	Paciucci, Rosanna/0000-0001-5651-5933; Díaz, Víctor Manuel/0000-0001-8561-7576; Batlle, Eduard/0000-0003-2422-0326; de Herreros, A Garcia/0000-0001-5270-0808				BAUM CL, 1990, CANCER RES, V50, P3915; BLASI F, 1993, BIOESSAYS, V15, P105, DOI 10.1002/bies.950150206; CHOI PM, 1990, MOL CELL BIOL, V10, P4650, DOI 10.1128/MCB.10.9.4650; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAVEN PA, 1994, DIGEST DIS SCI, V39, P481, DOI 10.1007/BF02088331; DEKKER LV, 1995, CURR OPIN STRUC BIOL, V5, P396, DOI 10.1016/0959-440X(95)80103-0; DOI S, 1994, MOL CARCINOGEN, V11, P197, DOI 10.1002/mc.2940110405; FABRE M, 1993, J CELL SCI, V106, P513; GUILLEM JG, 1987, CANCER RES, V47, P2036; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; JIANG YH, 1995, CELL GROWTH DIFFER, V6, P1381; KAHLRAINER P, 1994, CARCINOGENESIS, V15, P779, DOI 10.1093/carcin/15.4.779; KOPP R, 1991, CANCER RES, V51, P205; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUSUNOKI M, 1992, CANCER, V69, P24, DOI 10.1002/1097-0142(19920101)69:1<24::AID-CNCR2820690107>3.0.CO;2-1; LESUFFLEUR T, 1991, J CELL BIOL, V115, P1409, DOI 10.1083/jcb.115.5.1409; LESUFFLEUR T, 1990, CANCER RES, V50, P6334; Llosas MD, 1996, BIOCHEM J, V315, P1049; MAREEL M, 1979, VIRCHOWS ARCH B, V30, P95; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; McGarrity TJ, 1996, CELL GROWTH DIFFER, V7, P953; MURAMATSU M, 1992, FEBS LETT, V311, P75, DOI 10.1016/0014-5793(92)81371-R; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; OJAKIAN GK, 1981, CELL, V23, P95, DOI 10.1016/0092-8674(81)90274-9; PEARS CJ, 1990, EUR J BIOCHEM, V194, P89, DOI 10.1111/j.1432-1033.1990.tb19431.x; ReifelMiller AE, 1996, J BIOL CHEM, V271, P21666, DOI 10.1074/jbc.271.35.21666; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; Rosson D, 1997, J BIOL CHEM, V272, P14950, DOI 10.1074/jbc.272.23.14950; SAXON ML, 1994, J CELL BIOL, V126, P747, DOI 10.1083/jcb.126.3.747; Skoudy A, 1996, BIOCHEM J, V317, P279, DOI 10.1042/bj3170279; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; WALI RK, 1995, CANCER RES, V55, P5257; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872	36	44	45	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15091	15098		10.1074/jbc.273.24.15091	http://dx.doi.org/10.1074/jbc.273.24.15091			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614119	hybrid			2022-12-27	WOS:000074160400061
J	Loo, TW; Clarke, DM				Loo, TW; Clarke, DM			Superfolding of the partially unfolded core-glycosylatled intermediate of human P-glycoprotein into the mature enzyme is promoted by substrate-induced transmembrane domain interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL CONSEQUENCES; MUTATIONAL ANALYSIS; NUCLEOTIDE; TRANSPORTER; RESISTANCE; PROTEASOME; MUTANTS; SITES; HALF; MDR1	Misprocessed mutants of human P-glycoprotein accumulate as core-glycosylated intermediates in the endoplasmic reticulum and are rapidly degraded. Trypsin digestion was used to test for structural differences between mature and core-glycosylated forms of P-glycoprotein. We found that the core-glycosylated wild-type and mutant P-glycoproteins were both 100-fold. more sensitive to trypsin compared with the mature form of the wild-type enzyme. This result suggested that the core-glycosylated forms of both wild-type and mutant P-glycoproteins have similar unfolded structures, whereas the mature enzyme is folded into a more compact structure. The core-glycosylated mutant P-glycoproteins could be converted to the mature trypsin-resistant form by synthesis in the presence of drug substrate. Addition of proteasome inhibitor MG-132 to stabilize the core-glycosylated intermediate resulted in the accumulation but not maturation of the mutant protein. Further analysis showed that the second transmembrane domain TMD2 also became more resistant to trypsin digestion only after coexpression with TMD1 in the presence of substrate. Taken together, these results suggest that simply stabilizing the core-glycosylated intermediate is not sufficient to promote maturation of the processing mutants and that drug substrates induce maturation by promoting superfolding of the transmembrane domains.	Univ Toronto, Dept Med, MRC, Grp Membrane Biol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Clarke, DM (corresponding author), Univ Toronto, Dept Med, MRC, Grp Membrane Biol, Room 7342,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.		Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188				AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BEAUDET L, 1995, J BIOL CHEM, V270, P17159, DOI 10.1074/jbc.270.29.17159; BRUGGEMANN EP, 1992, J BIOL CHEM, V267, P21020; Chan HSL, 1996, EUR J CANCER, V32A, P1051, DOI 10.1016/0959-8049(96)00085-8; CHEN G, 1997, J BIOL CHEM, V272, P1051; Gottesman MM, 1995, ANNU REV GENET, V29, P607, DOI 10.1146/annurev.ge.29.120195.003135; GREENBERGER LM, 1993, J BIOL CHEM, V268, P11417; HOOF T, 1994, J BIOL CHEM, V269, P20575; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; LOO TW, 1993, J BIOL CHEM, V268, P3143; Loo TW, 1997, J BIOL CHEM, V272, P31945, DOI 10.1074/jbc.272.51.31945; LOO TW, 1994, J BIOL CHEM, V269, P7243; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; LOO TW, 1994, J BIOL CHEM, V269, P7750; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; Loo TW, 1996, J BIOL CHEM, V271, P15414, DOI 10.1074/jbc.271.26.15414; LOO TW, 1994, J BIOL CHEM, V269, P28683; MORRIS DI, 1994, MOL PHARMACOL, V46, P329; SCHEUTZ EG, 1996, P NATL ACAD SCI USA, V93, P4001; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; ZHANG XP, 1995, J BIOL CHEM, V270, P5441, DOI 10.1074/jbc.270.10.5441	24	91	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14671	14674		10.1074/jbc.273.24.14671	http://dx.doi.org/10.1074/jbc.273.24.14671			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614062	hybrid			2022-12-27	WOS:000074160400004
J	Thompson, PR; Hughes, DW; Cianciotto, NP; Wright, GD				Thompson, PR; Hughes, DW; Cianciotto, NP; Wright, GD			Spectinomycin kinase from Legionella pneumophila - Characterization of substrate specificity and identification of catalytically important residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLTRANSFERASE AAD(9) DETERMINANT; PHOSPHOTRANSFERASE TYPE-III; NUCLEOTIDE-SEQUENCE; STAPHYLOCOCCUS-AUREUS; RESISTANCE GENES; ENTEROCOCCUS; APH(3')-IIIA; MECHANISM; VISCOSITY; FAECALIS	The bacterium Legionella pneumophila is the responsible agent for Legionnaires' disease and has recently been shown to harbor a gene encoding a kinase that confers resistance to the aminoglycoside antibiotic spectinomycin (Suter, T. M., Viswanathan, V. H., and Cianciotto, N. P. (1997) Antimicrob. Agents Chemother. 41, 1385-1388). We report the overproduction, purification, and characterization of this spectinomycin kinase from an expressing system in Escherichia coli. The purified protein shows stringent substrate specificity for spectinomycin with K-m = 21.5 mu m and k(cat) = 24.2 s(-1) and does not bind other aminoglycosides including kanamycin, amikacin, neomycin, butirosin, streptomycin, or apramycin. Purification of spectinomycin phosphate followed by characterization by mass spectrometry and H-1, C-13, and P-31 NMR established the site of phosphorylation to be at the hydroxyl group at position 9. Thus this enzyme is designated APH(S)-Ia (where APH is aminoglycoside kinase). The enzyme was inactivated by the electrophilic ATP analogue 5'-[p-(fluorosulfonyl)benzoyl]adenosine, consistent with a nucleophilic residue such as Lys lining the nucleotide binding pocket. Site-directed mutagenesis of Lys-52 and Asp-212 to Ala confirmed that these residues were important for catalysis, with Lys-52 playing a potential role in ATP binding and Asp-212 in phosphoryl transfer. Thio and solvent isotope effect experiments in the presence of either Mg2+ or Mn2+ were consistent with a kinetic mechanism in which phosphate transfer does not contribute significantly to the rate-limiting step. These results establish that APII(9)-Ia is a highly specific antibiotic resistance kinase and provides the requisite mechanistic information for future structural studies.	McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Chem, Hamilton, ON L8S 4M1, Canada; Northwestern Univ, Dept Microbiol Immunol, Chicago, IL 60611 USA	McMaster University; McMaster University; Northwestern University	Wright, GD (corresponding author), McMaster Univ, Dept Biochem, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	wrightge@fhs.mcmaster.ca	Wright, G/ABB-7666-2021	Wright, Gerard/0000-0002-9129-7131				BARKER JE, 1990, J ANTIMICROB CHEMOTH, V26, P45, DOI 10.1093/jac/26.1.45; Bovey F. A., 1988, NUCL MAGNETIC RESONA; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COHRAN TG, 1972, J CHEM SOC CHEM COMM, P494; COLE PA, 1995, J BIOL CHEM, V270, P22105, DOI 10.1074/jbc.270.38.22105; COLE PA, 1994, J BIOL CHEM, V269, P30880; Daigle DM, 1997, J BIOL CHEM, V272, P24755, DOI 10.1074/jbc.272.40.24755; Davies J, 1997, TRENDS MICROBIOL, V5, P234, DOI 10.1016/S0966-842X(97)01033-0; Fields BS, 1996, TRENDS MICROBIOL, V4, P286, DOI 10.1016/0966-842X(96)10041-X; GRAY GS, 1983, MOL BIOL EVOL, V1, P57; HOLLINGSHEAD S, 1985, PLASMID, V13, P17, DOI 10.1016/0147-619X(85)90052-6; Hon WC, 1997, CELL, V89, P887, DOI 10.1016/S0092-8674(00)80274-3; Leatherbarrow R. J., 1992, GRAFIT; LEBLANC DJ, 1991, ANTIMICROB AGENTS CH, V35, P1804, DOI 10.1128/AAC.35.9.1804; Lyutzkanova D, 1997, MICROBIOL-SGM, V143, P2135, DOI 10.1099/00221287-143-7-2135; MADHUSUDAN T, 1994, PROTEIN SCI, V3, P176; MCKAY GA, 1994, BIOCHEMISTRY-US, V33, P6936, DOI 10.1021/bi00188a024; MCKAY GA, 1994, BIOCHEMISTRY-US, V33, P14115, DOI 10.1021/bi00251a021; McKay GA, 1996, BIOCHEMISTRY-US, V35, P8680, DOI 10.1021/bi9603884; MURPHY E, 1985, MOL GEN GENET, V200, P33, DOI 10.1007/BF00383309; MURRAY PR, 1994, MED MICROBIOLOGY, P279; Payie KG, 1997, J BACTERIOL, V179, P4106, DOI 10.1128/jb.179.13.4106-4114.1997; SHAW KJ, 1993, MICROBIOL REV, V57, P138, DOI 10.1128/MMBR.57.1.138-163.1993; Suter TM, 1997, ANTIMICROB AGENTS CH, V41, P1385, DOI 10.1128/AAC.41.6.1385; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TRIEUCUOT P, 1983, GENE, V23, P331, DOI 10.1016/0378-1119(83)90022-7; WINN W C JR, 1988, Clinical Microbiology Reviews, V1, P60; Zhou J, 1997, BIOCHEMISTRY-US, V36, P2977, DOI 10.1021/bi9619132	28	18	18	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14788	14795		10.1074/jbc.273.24.14788	http://dx.doi.org/10.1074/jbc.273.24.14788			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614079	hybrid			2022-12-27	WOS:000074160400021
J	Walia, H; Chen, HY; Sun, JM; Holth, LT; Davie, JR				Walia, H; Chen, HY; Sun, JM; Holth, LT; Davie, JR			Histone acetylation is required to maintain the unfolded nucleosome structure associated with transcribing DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONALLY ACTIVE CHROMATIN; RNA-POLYMERASE-II; BETA-GLOBIN GENE; NUCLEAR MATRIX; CHICKEN ERYTHROCYTES; AFFINITY-CHROMATOGRAPHY; LINKER HISTONES; SEQUENCES; YEAST; ACETYLTRANSFERASE	Nucleosomes associated with transcribing chromatin of mammalian cells have an unfolded structure in which the normally buried cysteinyl-thiol group of histone H3 is exposed. In this study we analyzed transcriptionally active/competent DNA-enriched chromatin fractions from chicken mature and immature erythrocytes for the presence of thiol-reactive nucleosomes using organo-mercury-agarose column chromatography and hydroxylapatite dissociation chromatography of chromatin fractions labeled with [H-3]iodoacetate. In mature and immature erythrocytes, the active DNA-enriched chromatin fractions are associated with histones that are rapidly highly acetylated and rapidly deacetylated. When histone deacetylation was prevented by incubating cells with histone deacetylase inhibitors, sodium butyrate or trichostatin A, thiol-reactive H3 of unfolded nucleosomes was detected in the soluble chromatin and nuclear skeleton-associated chromatin of immature, but not mature, erythrocytes. We did not find thiol-reactive nucleosomes in active DNA-enriched chromatin fractions of untreated immature erythrocytes that had How levels of highly acetylated histones HS and H4 or in chromatin of immature cells incubated with inhibitors of transcription elongation. This study shows that transcription elongation is required to form, and histone acetylation is needed to maintain, the unfolded structure of transcribing nucleosomes.	Univ Manitoba, Fac Med, Dept Biochem & Mol Biol, Winnipeg, MB R3E 0W3, Canada	University of Manitoba	Davie, JR (corresponding author), Univ Manitoba, Fac Med, Dept Biochem & Mol Biol, 770 Bannatyne Ave, Winnipeg, MB R3E 0W3, Canada.	Davie@cc.umanitoba.ca		Davie, James/0000-0002-0420-6888				ALLEGRA P, 1987, J MOL BIOL, V196, P379, DOI 10.1016/0022-2836(87)90698-X; ALLFREY VG, 1991, METHOD CELL BIOL, V35, P315; ANDREEVA M, 1992, EUR J BIOCHEM, V207, P887, DOI 10.1111/j.1432-1033.1992.tb17121.x; AUSIO J, 1986, BIOCHEMISTRY-US, V25, P1421, DOI 10.1021/bi00354a035; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BazettJones DP, 1996, NUCLEIC ACIDS RES, V24, P321, DOI 10.1093/nar/24.2.321; BOFFA LC, 1990, EUR J BIOCHEM, V194, P811, DOI 10.1111/j.1432-1033.1990.tb19474.x; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; BROWN T, 1995, CURRENT PROTOCOLS MO; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Chadee DN, 1997, J BIOL CHEM, V272, P8113, DOI 10.1074/jbc.272.13.8113; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN TA, 1991, J BIOL CHEM, V266, P6489; CHENCLELAND TA, 1993, J BIOL CHEM, V268, P23409; Davie JR, 1996, J CELL BIOCHEM, V62, P149, DOI 10.1002/(SICI)1097-4644(199608)62:2<149::AID-JCB2>3.0.CO;2-S; DAVIE JR, 1994, J CELL BIOCHEM, V55, P98, DOI 10.1002/jcb.240550112; DAVIE JR, 1981, NUCLEIC ACIDS RES, V9, P3205, DOI 10.1093/nar/9.13.3205; Davie JR, 1997, MOL BIOL REP, V24, P197, DOI 10.1023/A:1006811817247; Davie JR, 1995, INT REV CYTOL, V162A, P191; DELCUVE GP, 1992, ANAL BIOCHEM, V200, P339, DOI 10.1016/0003-2697(92)90475-M; DELCUVE GP, 1989, BIOCHEM J, V263, P179, DOI 10.1042/bj2630179; EBRALIDSE KK, 1993, NUCLEIC ACIDS RES, V21, P4734, DOI 10.1093/nar/21.20.4734; EBRALIDSE KK, 1988, NATURE, V331, P365, DOI 10.1038/331365a0; GARIGLIO P, 1981, NUCLEIC ACIDS RES, V9, P2589, DOI 10.1093/nar/9.11.2589; Gavin IM, 1998, J BIOL CHEM, V273, P2429, DOI 10.1074/jbc.273.4.2429; GERDES MG, 1994, J CELL BIOL, V126, P289, DOI 10.1083/jcb.126.2.289; GROSS DS, 1987, TRENDS BIOCHEM SCI, V12, P293, DOI 10.1016/0968-0004(87)90144-7; Halle JP, 1996, TRENDS GENET, V12, P161, DOI 10.1016/0168-9525(96)30035-8; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HENDZEL MJ, 1994, J BIOL CHEM, V269, P22894; HENDZEL MJ, 1991, J BIOL CHEM, V266, P21936; HIROSE M, 1988, J BIOCHEM-TOKYO, V103, P31, DOI 10.1093/oxfordjournals.jbchem.a122234; Iborra FJ, 1996, J CELL SCI, V109, P1427; IMAI BS, 1986, J BIOL CHEM, V261, P8784; IP YT, 1988, J BIOL CHEM, V263, P14044; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LI W, 1993, BIOCHEM J, V296, P737, DOI 10.1042/bj2960737; LIN R, 1989, J CELL BIOL, V108, P1577, DOI 10.1083/jcb.108.5.1577; Ljungman M, 1996, CARCINOGENESIS, V17, P31, DOI 10.1093/carcin/17.1.31; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; McNeil S, 1998, J CELL BIOCHEM, V68, P500, DOI 10.1002/(SICI)1097-4644(19980315)68:4<500::AID-JCB9>3.3.CO;2-T; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; NACHEVA GA, 1989, CELL, V58, P27, DOI 10.1016/0092-8674(89)90399-1; NELSON DA, 1982, J BIOL CHEM, V257, P1565; NORTON VG, 1990, J BIOL CHEM, V265, P19848; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PERRY CA, 1993, BIOCHEMISTRY-US, V32, P13605, DOI 10.1021/bi00212a028; RIDSDALE JA, 1987, NUCLEIC ACIDS RES, V15, P1081, DOI 10.1093/nar/15.3.1081; RIDSDALE JA, 1988, NUCLEIC ACIDS RES, V16, P5915, DOI 10.1093/nar/16.13.5915; ROCHA E, 1984, J BIOL CHEM, V259, P8558; SMITH RM, 1989, J BIOL CHEM, V264, P10574; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; STERNER R, 1987, NUCLEIC ACIDS RES, V15, P4375, DOI 10.1093/nar/15.11.4375; STEWART AF, 1987, CELL, V50, P1109, DOI 10.1016/0092-8674(87)90177-2; STEWART AF, 1990, CELL, V60, P141; STRATLING WH, 1986, BIOCHEMISTRY-US, V25, P495, DOI 10.1021/bi00350a033; STRATLING WH, 1987, BIOCHEMISTRY-US, V26, P7893, DOI 10.1021/bi00398a053; Sun JM, 1996, CHROMOSOMA, V104, P504; THOMSEN B, 1991, EUR J BIOCHEM, V201, P107, DOI 10.1111/j.1432-1033.1991.tb16262.x; Wade PA, 1997, CURR BIOL, V7, pR82, DOI 10.1016/S0960-9822(06)00042-X; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; ZHANG DE, 1988, BIOCHEM J, V250, P241, DOI 10.1042/bj2500241; ZHANG DE, 1988, BIOCHEM J, V250, P233, DOI 10.1042/bj2500233	65	91	94	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14516	14522		10.1074/jbc.273.23.14516	http://dx.doi.org/10.1074/jbc.273.23.14516			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603965	hybrid			2022-12-27	WOS:000074021500067
J	Klee, CB; Ren, H; Wang, XT				Klee, CB; Ren, H; Wang, XT			Regulation of the calmodulin-stimulated protein phosphatase, calcineurin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							IMMUNOPHILIN-IMMUNOSUPPRESSANT COMPLEXES; CYCLOPHILIN-CYCLOSPORINE-A; CHANNEL RYANODINE RECEPTOR; B-SUBUNIT; BINDING DOMAIN; DEPHOSPHORYLATION; IDENTIFICATION; BRAIN; INHIBITION; ACTIVATION		NCI, Biochem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Klee, CB (corresponding author), NCI, Biochem Lab, NIH, Bethesda, MD 20892 USA.	ckl@helix.nih.gov						AITKEN A, 1982, FEBS LETT, V150, P314, DOI 10.1016/0014-5793(82)80759-X; AITKEN A, 1984, EUR J BIOCHEM, V139, P663, DOI 10.1111/j.1432-1033.1984.tb08055.x; Alevizopoulos A, 1997, J BIOL CHEM, V272, P23597, DOI 10.1074/jbc.272.38.23597; ANGLISTER J, 1994, BIOCHEMISTRY-US, V33, P3540, DOI 10.1021/bi00178a010; ANGLISTER J, 1995, FEBS LETT, V375, P108, DOI 10.1016/0014-5793(95)01192-H; APERIA A, 1992, P NATL ACAD SCI USA, V89, P7394, DOI 10.1073/pnas.89.16.7394; Barford D, 1996, TRENDS BIOCHEM SCI, V21, P407, DOI 10.1016/S0968-0004(96)10060-8; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; BLUMENTHAL DK, 1986, J BIOL CHEM, V261, P8140; BLUMENTHAL DK, 1985, ADV PROTEIN PHOSPHAT, V1, P163; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; Cameron AM, 1997, J BIOL CHEM, V272, P27582, DOI 10.1074/jbc.272.44.27582; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; CARDENAS ME, 1995, EMBO J, V14, P2772, DOI 10.1002/j.1460-2075.1995.tb07277.x; CLIPSTONE NA, 1994, J BIOL CHEM, V269, P26431; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; Cohen P T, 1996, Adv Pharmacol, V36, P67; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; Denton RM, 1996, ADV ENZYME REGUL, V36, P183, DOI 10.1016/0065-2571(95)00020-8; DONELLADEANA A, 1994, EUR J BIOCHEM, V219, P109, DOI 10.1111/j.1432-1033.1994.tb19920.x; ETZKORN FA, 1994, BIOCHEMISTRY-US, V33, P2380, DOI 10.1021/bi00175a005; Fruman David A., 1996, Methods (Orlando), V9, P146, DOI 10.1006/meth.1996.0020; FUTER O, 1995, J BIOL CHEM, V270, P18935, DOI 10.1074/jbc.270.32.18935; GAESTEL M, 1992, J BIOL CHEM, V267, P21607; GOTO S, 1986, ACTA NEUROPATHOL, V72, P150, DOI 10.1007/BF00685977; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; HADDY A, 1992, FEBS LETT, V314, P37, DOI 10.1016/0014-5793(92)81456-V; HALPAIN S, 1990, NATURE, V343, P369, DOI 10.1038/343369a0; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; Heitman Joseph, 1993, Methods (Orlando), V5, P176, DOI 10.1006/meth.1993.1022; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HUBBARD MJ, 1989, BIOCHEMISTRY-US, V28, P1868, DOI 10.1021/bi00430a066; HUBBARD MJ, 1991, MOL NEUROBIOL, P135; HUSI H, 1994, J BIOL CHEM, V269, P14199; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; KAKALIS LT, 1995, FEBS LETT, V362, P55, DOI 10.1016/0014-5793(95)00207-P; KAWAMURA A, 1995, J BIOL CHEM, V270, P15463, DOI 10.1074/jbc.270.26.15463; Kennedy MT, 1996, J BIOL CHEM, V271, P26517, DOI 10.1074/jbc.271.43.26517; KINCAID R, 1993, ADV SEC MESS PHOSPH, V27, P1; Kincaid R L, 1989, Adv Exp Med Biol, V255, P347; KING MM, 1984, J BIOL CHEM, V259, P8847; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; KUNO T, 1992, J NEUROCHEM, V58, P1643, DOI 10.1111/j.1471-4159.1992.tb10036.x; LAWSON MA, 1995, NATURE, V377, P75, DOI 10.1038/377075a0; LI W, 1993, J BIOL CHEM, V268, P14040; LIEBERMAN DN, 1994, NATURE, V369, P235, DOI 10.1038/369235a0; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; Mansuy IM, 1998, CELL, V92, P39, DOI 10.1016/S0092-8674(00)80897-1; Marcaida G, 1996, J NEUROCHEM, V66, P99; MARTIN BL, 1994, BBA-PROTEIN STRUCT M, V1206, P136, DOI 10.1016/0167-4838(94)90082-5; Matheos DP, 1997, GENE DEV, V11, P3445, DOI 10.1101/gad.11.24.3445; MERAT DL, 1985, J BIOL CHEM, V260, P1053; Mertz P, 1997, J BIOL CHEM, V272, P21296, DOI 10.1074/jbc.272.34.21296; MILAN D, 1994, CELL, V79, P437, DOI 10.1016/0092-8674(94)90253-4; NAKAMURA T, 1993, EMBO J, V12, P4063, DOI 10.1002/j.1460-2075.1993.tb06090.x; NICHOLS RA, 1994, J BIOL CHEM, V269, P23817; POMIES P, 1995, BIOCHEMISTRY-US, V34, P5104, DOI 10.1021/bi00015a022; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; RASMUSSEN C, 1994, EMBO J, V13, P3917, DOI 10.1002/j.1460-2075.1994.tb06703.x; RYFFEL B, 1993, BIOCHEM BIOPH RES CO, V194, P1074, DOI 10.1006/bbrc.1993.1931; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SEKI K, 1995, ARCH BIOCHEM BIOPHYS, V316, P673, DOI 10.1006/abbi.1995.1090; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; Sherman PM, 1997, P NATL ACAD SCI USA, V94, P11639, DOI 10.1073/pnas.94.21.11639; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; SIKKINK R, 1995, BIOCHEMISTRY-US, V34, P8348, DOI 10.1021/bi00026a016; SNYDER SH, 1995, NAT MED, V1, P32, DOI 10.1038/nm0195-32; Stathopoulos AM, 1997, GENE DEV, V11, P3432, DOI 10.1101/gad.11.24.3432; STEELE FR, 1992, CELL, V69, P669, DOI 10.1016/0092-8674(92)90230-A; STELZER A, 1992, INT REV NEUROBIOL, V33, P195, DOI 10.1016/S0074-7742(08)60693-5; STEMMER PM, 1994, BIOCHEMISTRY-US, V33, P6859, DOI 10.1021/bi00188a015; STEMMER PM, 1995, FEBS LETT, V374, P237, DOI 10.1016/0014-5793(95)01095-V; STEWART AA, 1982, FEBS LETT, V137, P80, DOI 10.1016/0014-5793(82)80319-0; Sugimoto T, 1997, J BIOL CHEM, V272, P29415, DOI 10.1074/jbc.272.47.29415; TANIDA I, 1995, J BIOL CHEM, V270, P10113, DOI 10.1074/jbc.270.17.10113; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; Vinos J, 1997, SCIENCE, V277, P687, DOI 10.1126/science.277.5326.687; Wang XT, 1996, NATURE, V383, P434, DOI 10.1038/383434a0; WATANABE Y, 1995, J BIOL CHEM, V270, P456, DOI 10.1074/jbc.270.1.456; Wesselborg S, 1996, J BIOL CHEM, V271, P1274, DOI 10.1074/jbc.271.3.1274; YANG D, 1993, J AM CHEM SOC, V115, P819, DOI 10.1021/ja00055a081; YAZDANBAKHSH K, 1995, P NATL ACAD SCI USA, V92, P437, DOI 10.1073/pnas.92.2.437; YOSHIDA T, 1994, J CELL SCI, V107, P1725; YU L, 1995, J AM CHEM SOC, V117, P10147, DOI 10.1021/ja00145a040; ZHU DH, 1995, J BIOL CHEM, V270, P24831, DOI 10.1074/jbc.270.42.24831; ZYDOWSKY LD, 1992, PROTEIN SCI, V1, P1092, DOI 10.1002/pro.5560010903	95	759	791	2	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13367	13370		10.1074/jbc.273.22.13367	http://dx.doi.org/10.1074/jbc.273.22.13367			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593662	hybrid			2022-12-27	WOS:000073919100001
J	Perlman, H; Suzuki, E; Simonson, M; Smith, RC; Walsh, K				Perlman, H; Suzuki, E; Simonson, M; Smith, RC; Walsh, K			GATA-6 induces p21(Cip1) expression and G(1) cell cycle arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; DEPENDENT KINASE INHIBITOR; RAT CAROTID-ARTERY; GROWTH-ARREST; TRANSCRIPTION FACTOR; HOMEOBOX GENE; P21; DIFFERENTIATION; P53; ATHEROSCLEROSIS	GATA transcription factors represent a family of highly conserved zinc finger proteins with tissue-specific expression patterns. Previous studies have shown that GATA-6 is expressed in vascular smooth muscle cells (VSMCs) and rapidly down-regulated when VSMCs are induced to proliferate. Here we investigated whether the GATA-6 transcription factor can modulate cellular proliferation. Transient transfection with a GATA-6 expression vector inhibited S-phase entry in VSMCs and in mouse embryonic fibroblasts (MEFs) lacking both p53 alleles. The GATA-6-induced growth arrest correlated with a marked increase in the expression of the general cyclin dependent kinase (Cdk) inhibitor p21. In contrast to p53-deficient MEFs and VSMCs, MEFs null for both p21 alleles were refractory to the GATA-6-induced growth inhibition. These data demonstrate that elevated GATA-6 expression can promote the quiescent phenotype in VSMCs.	Tufts Univ, Sch Med, St Elizabeths Med Ctr, Div Cardiovasc Res, Boston, MA 02135 USA; Tufts Univ, Sackler Sch Biomed Studies, Program Cell Mol & Dev Biol, Boston, MA 02111 USA; Case Western Reserve Univ, Dept Med, Div Nephrol, Cleveland, OH 44106 USA	St. Elizabeth's Medical Center; Tufts University; Tufts University; Case Western Reserve University	Walsh, K (corresponding author), Tufts Univ, Sch Med, St Elizabeths Med Ctr, Div Cardiovasc Res, 736 Cambridge St, Boston, MA 02135 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050692] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040197] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-50692] Funding Source: Medline; NIAMS NIH HHS [AR-40197] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CAMPBELL GR, 1988, ARCH PATHOL LAB MED, V112, P977; CAMPBELL GR, 1987, VASCULAR SMOOTH MUSC, V1, P39; CHANG MW, 1995, J CLIN INVEST, V96, P2260, DOI 10.1172/JCI118281; Chen DH, 1997, J CLIN INVEST, V99, P2334, DOI 10.1172/JCI119414; Clayman GL, 1996, ARCH OTOLARYNGOL, V122, P489; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; GORSKI DH, 1993, MOL CELL BIOL, V13, P3722, DOI 10.1128/MCB.13.6.3722; GORSKI DH, 1995, CARDIOVASC RES, V30, P585; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HultgardhNilsson A, 1996, CIRC RES, V78, P589, DOI 10.1161/01.RES.78.4.589; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jiang YM, 1996, DEV BIOL, V174, P258, DOI 10.1006/dbio.1996.0071; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; MADER SL, 1992, J GERONTOL, V47, pB32, DOI 10.1093/geronj/47.2.B32; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165; Morrisey EE, 1997, DEV BIOL, V183, P21, DOI 10.1006/dbio.1996.8485; Narita N, 1996, GENOMICS, V36, P345, DOI 10.1006/geno.1996.0472; Raines EW, 1996, BIOESSAYS, V18, P271, DOI 10.1002/bies.950180405; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SIMONSON MS, 1995, BIOTECHNIQUES, V18, P434; Smith RC, 1997, GENE DEV, V11, P1674, DOI 10.1101/gad.11.13.1674; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; SOUDAIS C, 1995, DEVELOPMENT, V121, P3877; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902; SUZUKI E, 1995, MOL CELL BIOL, V15, P3415; Suzuki E, 1996, CYTOGENET CELL GENET, V73, P244, DOI 10.1159/000134348; Suzuki E, 1996, GENOMICS, V38, P283, DOI 10.1006/geno.1996.0630; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Timchenko NA, 1997, MOL CELL BIOL, V17, P7353, DOI 10.1128/MCB.17.12.7353; TIMCHENKO NA, 1996, GENE DEV, V10, P805; Walsh K, 1996, Semin Interv Cardiol, V1, P173; WALSH K, 1997, CUR OPIN GENET DEV, V11, P1674; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Wei GL, 1997, CIRC RES, V80, P418, DOI 10.1161/01.res.0000435858.35902.ea; WEIR L, 1995, J BIOL CHEM, V270, P5457, DOI 10.1074/jbc.270.10.5457; WEISS MJ, 1995, EXP HEMATOL, V23, P99; Yamashita J, 1997, HYPERTENSION, V29, P381, DOI 10.1161/01.HYP.29.1.381; Yang ZY, 1996, P NATL ACAD SCI USA, V93, P7905, DOI 10.1073/pnas.93.15.7905; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	47	100	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13713	13718		10.1074/jbc.273.22.13713	http://dx.doi.org/10.1074/jbc.273.22.13713			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593712	hybrid			2022-12-27	WOS:000073919100051
J	Davey, GP; Peuchen, S; Clark, JB				Davey, GP; Peuchen, S; Clark, JB			Energy thresholds in brain mitochondria - Potential involvement in neurodegeneration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEX-I DEFICIENCY; OXIDATIVE-PHOSPHORYLATION; PARKINSONS-DISEASE; GLUTATHIONE DEFICIENCY; CYTOCHROME-OXIDASE; ALZHEIMERS-DISEASE; NEURONAL DEATH; RAT-BRAIN; RESPIRATION; CELL	Decreases in mitochondrial respiratory chain complex activities have been implicated in neurodegenerative disorders such as Parkinson's disease, Huntington's disease, and Alzheimer's disease, However, the extent to which these decreases cause a disturbance in oxidative phosphorylation and energy homeostasis in the brain is not known. We therefore examined the relative contribution of individual mitochondrial respiratory chain complexes to the control of NAD-linked substrate oxidative phosphorylation in synaptic mitochondria. Titration of complex I, III, and IV activities with specific inhibitors generated threshold curves that showed the extent to which a complex activity could be inhibited before causing impairment of mitochondrial energy metabolism. Complex I, III, and TV activities were decreased by approximately 25, 80, and 70%, respectively, before major changes in rates of oxygen consumption and ATP synthesis mere observed. These results suggest that, in mitochondria of synaptic origin, complex I activity has a major control of oxidative phosphorylation, such that when a threshold of 25% inhibition is exceeded, energy metabolism is severely impaired, resulting in a reduced synthesis of ATP. Additionally, depletion of glutathione, which has been reported to be a primary event in idiopathic Parkinson's disease, eliminated the complex I threshold in PC12 cells, suggesting that antioxidant status is important in maintaining energy thresholds in mitochondria. The implications of these findings are discussed with respect to neurodegenerative disorders and energy metabolism in the synapse.	Inst Neurol, Dept Neurochem, London WC1N 3BG, England	University of London; University College London	Davey, GP (corresponding author), Trinity Coll Dublin, Dept Biochem, Dublin 2, Ireland.	gdavey@tcd.ie	Davey, Gavin/HGB-4233-2022	Peuchen, Stephen/0000-0002-8206-4627	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABE K, 1995, STROKE, V26, P1478, DOI 10.1161/01.STR.26.8.1478; ALMEIDA A, 1995, DEV NEUROSCI-BASEL, V17, P212, DOI 10.1159/000111289; AMES BN, 1995, BBA-MOL BASIS DIS, V1271, P165, DOI 10.1016/0925-4439(95)00024-X; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; BEAL MF, 1992, ANN NEUROL, V31, P119, DOI 10.1002/ana.410310202; Bhave SV, 1996, J NEUROCHEM, V67, P557; BOWLING AC, 1993, J NEUROCHEM, V60, P1964, DOI 10.1111/j.1471-4159.1993.tb13430.x; BOWLING AC, 1995, LIFE SCI, V56, P1151, DOI 10.1016/0024-3205(95)00055-B; BRAND MD, 1988, BIOCHEM J, V255, P535; BRENNAN WA, 1985, J NEUROCHEM, V44, P1948, DOI 10.1111/j.1471-4159.1985.tb07192.x; CALNE DB, 1983, LANCET, V2, P1457, DOI 10.1016/S0140-6736(83)90802-4; Davey GP, 1996, J NEUROCHEM, V66, P1617; GELLERICH FN, 1983, BIOCHIM BIOPHYS ACTA, V722, P381, DOI 10.1016/0005-2728(83)90086-5; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GROEN AK, 1982, J BIOL CHEM, V257, P2754; HARVEY PRC, 1989, CLIN CHIM ACTA, V180, P203, DOI 10.1016/0009-8981(89)90001-6; HEALES SJR, 1995, NEUROCHEM RES, V20, P31; HEINRICH R, 1974, EUR J BIOCHEM, V42, P89, DOI 10.1111/j.1432-1033.1974.tb03318.x; HORNYKIE.O, 1973, FED PROC, V32, P183; INGEBRETSEN OC, 1982, J CHROMATOGR, V242, P119, DOI 10.1016/S0021-9673(00)87253-2; INOMOTO T, 1994, BBA-BIOENERGETICS, V1188, P311, DOI 10.1016/0005-2728(94)90050-7; JAIN A, 1991, P NATL ACAD SCI USA, V88, P1913, DOI 10.1073/pnas.88.5.1913; JENNER P, 1992, ANN NEUROL, V32, pS82, DOI 10.1002/ana.410320714; KACSER H, 1973, RATE CONTROL BIOL PR, P65; KISH SJ, 1992, J NEUROCHEM, V59, P776, DOI 10.1111/j.1471-4159.1992.tb09439.x; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Korzeniewski B, 1996, BIOCHEM J, V319, P143, DOI 10.1042/bj3190143; Lai J.C.K., 1989, NEUROMETHODS, P43; LETELLIER T, 1994, BIOCHEM J, V302, P171, DOI 10.1042/bj3020171; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Malgat Monique, 1995, Journal of Biological Systems, V3, P165, DOI 10.1142/S0218339095000162; MAREYSEMPER I, 1993, EUR J NEUROSCI, V5, P1029, DOI 10.1111/j.1460-9568.1993.tb00955.x; MAREYSEMPER I, 1995, J NEUROSCI, V15, P5912; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MEISTER A, 1991, PHARMACOL THERAPEUT, V51, P155, DOI 10.1016/0163-7258(91)90076-X; MORENOSANCHEZ R, 1991, BIOCHIM BIOPHYS ACTA, V1060, P284, DOI 10.1016/S0005-2728(05)80318-4; MORENOSANCHEZ R, 1985, J BIOL CHEM, V260, P4028; MUTISYA EM, 1994, J NEUROCHEM, V63, P2179; PAUWELS PJ, 1985, J NEUROCHEM, V44, P143, DOI 10.1111/j.1471-4159.1985.tb07123.x; PERRY TL, 1986, NEUROSCI LETT, V67, P269, DOI 10.1016/0304-3940(86)90320-4; PERRY TL, 1982, NEUROSCI LETT, V33, P305, DOI 10.1016/0304-3940(82)90390-1; Petit PX, 1996, FEBS LETT, V396, P7, DOI 10.1016/0014-5793(96)00988-X; Ragan MT, 1987, MITOCHONDRIA PRACTIC, P79; RIEDERER P, 1989, J NEUROCHEM, V52, P515, DOI 10.1111/j.1471-4159.1989.tb09150.x; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; SCHAPIRA AHV, 1989, LANCET, V1, P1269, DOI 10.1016/S0140-6736(89)92366-0; SCHAPIRA AHV, 1990, J NEUROCHEM, V55, P2142, DOI 10.1111/j.1471-4159.1990.tb05809.x; SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x; Schinder AF, 1996, J NEUROSCI, V16, P6125; SHOFFNER JM, 1993, GENOMICS, V17, P171, DOI 10.1006/geno.1993.1299; Skulachev VP, 1996, FEBS LETT, V397, P7, DOI 10.1016/0014-5793(96)00989-1; TAGER JM, 1983, FEBS LETT, V151, P1, DOI 10.1016/0014-5793(83)80330-5; WALLACE DC, 1986, SOMAT CELL MOLEC GEN, V12, P41, DOI 10.1007/BF01560726; WALZ W, 1988, GLIA, V1, P366, DOI 10.1002/glia.440010603; WALZ W, 1990, GLIA, V3, P522, DOI 10.1002/glia.440030611; WHARTON DC, 1987, METHOD ENZYMOL, V10, P245; White RJ, 1996, J NEUROSCI, V16, P5688; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zeevalk GD, 1997, J NEUROCHEM, V68, P426	59	310	311	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					12753	12757		10.1074/jbc.273.21.12753	http://dx.doi.org/10.1074/jbc.273.21.12753			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582300	hybrid			2022-12-27	WOS:000073768500011
J	Manna, SK; Zhang, HJ; Yan, T; Oberley, LW; Aggarwal, BB				Manna, SK; Zhang, HJ; Yan, T; Oberley, LW; Aggarwal, BB			Overexpression of manganese superoxide dismutase suppresses tumor necrosis factor-induced apoptosis and activation of nuclear transcription factor-KB and activated protein-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TNF-ALPHA; SIGNAL-TRANSDUCTION; INTACT-CELLS; PATHWAY; DEATH; EXPRESSION; AP-1	Several recently identified intracellular proteins associate with the tumor necrosis factor (TNF) receptor and activate nuclear transcription factor (NF)-kappa B, c-Jun kinase, and apoptosis. However, the mechanism is not understood. In the present report, we investigated the role of reactive oxygen intermediates in TNF-induced signaling. Overexpression of manganese superoxide dismutase (Mn-SOD) in human breast cancer MCF-7 cells completely abolished TNF-mediated NF-kappa B activation, I kappa B alpha degradation, p65 nuclear translocation, and NF-kappa B-dependent reporter gene expression. Besides TNF, phorbol ester-, okadaic acid-, ceramide-, and lipopolysaccharide-induced activation of NF-kappa B was blocked by Mn-SOD, indicating a common pathway of activation. H2O2-induced NF-kappa B activation, however, was potentiated. In addition, Mn-SOD blocked the TNF-mediated activation of activated protein-1, stress-activated c-Jun protein kinase, and mitogen-activated protein kinase kinase. TNF-induced antiproliferative effects and caspase-3 activation, indicators of apoptosis, were also completely suppressed by transfection of cells with Mn-SOD. Suppression of apoptosis induced by okadaic acid, H2O2, and taxol was also inhibited by Mn-SOD but not that induced by vincristine, vinblastine, or daunomycin. Overall, these results demonstrate that, in addition to several recently identified signaling molecules, reactive oxygen intermediates play a critical role in activation of NF-kappa B, activated protein-1, c-Jun kinase, and apoptosis induced by TNF and other agents.	Univ Texas, MD Anderson Cancer Ctr, Dept Med Oncol, Cytokine Res Sect, Houston, TX 77030 USA; Univ Iowa, Radiat Res Lab, Iowa City, IA 52242 USA	University of Texas System; UTMD Anderson Cancer Center; University of Iowa	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Med Oncol, Cytokine Res Sect, Houston, TX 77030 USA.		Aggarwal, Bharat B/G-3388-2013		NATIONAL CANCER INSTITUTE [P01CA066081] Funding Source: NIH RePORTER; NCI NIH HHS [CA 66081] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggarwal BB, 1996, EUR CYTOKINE NETW, V7, P93; ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; BANNISTER JV, 1987, CRC CR REV BIOCH MOL, V22, P111, DOI 10.3109/10409238709083738; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Boland MP, 1997, J BIOL CHEM, V272, P12952, DOI 10.1074/jbc.272.20.12952; Bonizzi G, 1996, EUR J BIOCHEM, V242, P544, DOI 10.1111/j.1432-1033.1996.0544r.x; BORGSTAHL GEO, 1996, BIOCHEMISTRY-US, V35, P4297; Bowie AG, 1997, J BIOL CHEM, V272, P25941, DOI 10.1074/jbc.272.41.25941; BRENNAN P, 1995, BBA-GENE STRUCT EXPR, V1260, P167, DOI 10.1016/0167-4781(94)00186-7; Chaturvedi MM, 1997, J BIOL CHEM, V272, P30129, DOI 10.1074/jbc.272.48.30129; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; Darnay BG, 1997, J LEUKOCYTE BIOL, V61, P559, DOI 10.1002/jlb.61.5.559; Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914; DAS KC, 1995, MOL CELL BIOCHEM, V148, P45, DOI 10.1007/BF00929502; DAS KC, 1995, AM J PHYSIOL-LUNG C, V269, pL588, DOI 10.1152/ajplung.1995.269.5.L588; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Haridas V, 1998, J IMMUNOL, V160, P3152; HASSAN HM, 1988, FREE RADICAL BIO MED, V5, P377, DOI 10.1016/0891-5849(88)90111-6; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kiningham KK, 1997, CANCER RES, V57, P5265; Krejsa CM, 1997, J BIOL CHEM, V272, P11541; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Li JJ, 1997, CANCER RES, V57, P1991; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Melendez JA, 1996, J BIOL CHEM, V271, P18898, DOI 10.1074/jbc.271.31.18898; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; Natoli G, 1997, J BIOL CHEM, V272, P26079, DOI 10.1074/jbc.272.42.26079; REDDY SAG, 1994, J BIOL CHEM, V269, P25369; Sambrook J., 2002, MOL CLONING LAB MANU; Schmidt KN, 1996, ADV EXP MED BIOL, V387, P63; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; SUZUKI YJ, 1994, J IMMUNOL, V153, P5008; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TOTPAL K, 1994, J IMMUNOL, V153, P2248; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Zhou G, 1997, J BIOL CHEM, V272, P15174, DOI 10.1074/jbc.272.24.15174	44	510	526	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					13245	13254		10.1074/jbc.273.21.13245	http://dx.doi.org/10.1074/jbc.273.21.13245			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582369	hybrid			2022-12-27	WOS:000073768500080
J	Ibata, K; Fukuda, M; Mikoshiba, K				Ibata, K; Fukuda, M; Mikoshiba, K			Inositol 1,3,4,5-tetrakisphosphate binding activities of neuronal and non-neuronal synaptotagmins - Identification of conserved amino acid substitutions that abolish inositol 1,3,4,5-tetrakisphosphate binding to synaptotagmins III, V, and X	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SQUID GIANT SYNAPSE; PHOSPHOLIPID-BINDING; C2A DOMAIN; ENDOPLASMIC-RETICULUM; C-2-DOMAIN PROTEINS; ANTIBODY INJECTION; RAT-BRAIN; FUSION; ISOFORM; RELEASE	Synaptotagmins I and II are essential for Ca2+-regulated exocytosis of synaptic vesicles from neurons, probably serving as Ca2+ sensors. This Ca2+-sensing function is thought to be disrupted by binding of an inositol 1,3,4,5-tetrakisphosphate (IP4) to the C2B domain of synaptotagmin I or II (Fukuda, M., Moreira, J. E., Lewis, F. M. T., Sugimori, M., Niinobe, M., Mikoshiba, K., and Llinas, R. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 10708-10712). Recently, several synaptotagmin isoforms, ex; pressed outside the nervous system, have been identified in rats and proposed to be involved in constitutive vesicle traffic. To test whether the inositol high polyphosphates also regulate constitutive vesicle traffic by binding to the non-neuronal synaptotagmins, we examined the IP4 binding properties of the recombinant C2 domains of both neuronal (III, V, X, and XI) and non-neuronal (VI-VIII and IX) synaptotagmins. The C2B domains of synaptotagmins VII-IX and XI had strong IP4 binding activity, but the C2B domain of synaptotagmin VI showed very weak IP4 binding activity. In contrast, there was no significant IP4 binding activity of the C2B domains of synaptotagmins III, V, and X or any of the C2A domains. A phylogenetic tree of the C2 domains of 11 isoforms revealed that synaptotagmins III, V, VI, and X (IP4-insensitive or very weak IP4-binding isoforms) belong to the same branch. Based on the sequence comparison between the IP4-sensitive and -insensitive isoforms, we performed site-directed mutagenesis of synaptotagmin III and identified several amino acid substitutions that abolish IP4 binding activity. Our data suggest that the inositol high polyphosphates might also regulate constitutive vesicle traffic via binding to the IP4-sensitive non-neuronal synaptotagmins.	RIKEN, Inst Phys & Chem Res, Tsukuba Life Sci Ctr, Mol Neurobiol Lab, Tsukuba, Ibaraki 3050074, Japan; Univ Tokyo, Inst Med Sci, Dept Mol Neurobiol, Minato Ku, Tokyo 1080071, Japan; Calciosignal Net Project, Meguro Ku, Tokyo 1530064, Japan	RIKEN; University of Tokyo	Fukuda, M (corresponding author), RIKEN, Brain Sci Inst, Dev Neurobiol Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.		Ibata, Keiji/L-5802-2013; Mikoshiba, Katsuhiko/N-7943-2015; Fukuda, MItsunori/I-1511-2015	Fukuda, MItsunori/0000-0002-8620-5853				Babity JM, 1997, P NATL ACAD SCI USA, V94, P2638, DOI 10.1073/pnas.94.6.2638; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BROSE N, 1995, J BIOL CHEM, V270, P25273, DOI 10.1074/jbc.270.42.25273; CRAXTON M, 1995, FEBS LETT, V361, P196, DOI 10.1016/0014-5793(95)00176-A; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; Fukuda M, 1997, BIOESSAYS, V19, P593, DOI 10.1002/bies.950190710; Fukuda M, 1996, J BIOL CHEM, V271, P8430, DOI 10.1074/jbc.271.14.8430; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; FUKUDA M, 1995, P NATL ACAD SCI USA, V92, P10708, DOI 10.1073/pnas.92.23.10708; GEPPERT M, 1991, J BIOL CHEM, V266, P13548; HILBUSH BS, 1994, P NATL ACAD SCI USA, V91, P8195, DOI 10.1073/pnas.91.17.8195; HUDSON AW, 1995, P NATL ACAD SCI USA, V92, P5895, DOI 10.1073/pnas.92.13.5895; Kojima T, 1996, J BIOCHEM-TOKYO, V120, P671; Kwon OJ, 1996, FEBS LETT, V378, P135, DOI 10.1016/0014-5793(95)01430-6; Lang JC, 1997, EMBO J, V16, P5837, DOI 10.1093/emboj/16.19.5837; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LLINAS R, 1994, P NATL ACAD SCI USA, V91, P12990, DOI 10.1073/pnas.91.26.12990; Lupashin VV, 1996, J CELL BIOL, V132, P277, DOI 10.1083/jcb.132.3.277; MARTIN KC, 1995, P NATL ACAD SCI USA, V92, P11307, DOI 10.1073/pnas.92.24.11307; Mehrotra B, 1997, J BIOL CHEM, V272, P4237, DOI 10.1074/jbc.272.7.4237; MIKOSHIBA K, 1995, P NATL ACAD SCI USA, V92, P10703, DOI 10.1073/pnas.92.23.10703; MIZUTA M, 1994, J BIOL CHEM, V269, P11675; Mizutani A, 1997, BIOCHEM BIOPH RES CO, V240, P128, DOI 10.1006/bbrc.1997.7578; Mochida S, 1997, NEUROSCIENCE, V77, P937; NIINOBE M, 1994, BIOCHEM BIOPH RES CO, V205, P1036, DOI 10.1006/bbrc.1994.2770; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; OharaImaizumi M, 1997, P NATL ACAD SCI USA, V94, P287, DOI 10.1073/pnas.94.1.287; PERIN MS, 1991, J BIOL CHEM, V266, P615; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PIND SN, 1994, J CELL BIOL, V125, P239, DOI 10.1083/jcb.125.2.239; Shears S B, 1996, Subcell Biochem, V26, P187; SOLLNER T, 1994, TRENDS NEUROSCI, V17, P344, DOI 10.1016/0166-2236(94)90178-3; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; Thompson CC, 1996, J NEUROSCI, V16, P7832; vonPoser C, 1997, J BIOL CHEM, V272, P14314, DOI 10.1074/jbc.272.22.14314	38	47	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12267	12273		10.1074/jbc.273.20.12267	http://dx.doi.org/10.1074/jbc.273.20.12267			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575177	hybrid			2022-12-27	WOS:000073629800042
J	Kosugi, A; Saitoh, S; Noda, S; Miyake, K; Yamashita, Y; Kimoto, M; Ogata, M; Hamaoka, T				Kosugi, A; Saitoh, S; Noda, S; Miyake, K; Yamashita, Y; Kimoto, M; Ogata, M; Hamaoka, T			Physical and functional association between thymic shared antigen-1 stem cell antigen-2 and the T cell receptor complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; IL-2 PRODUCTION; GAMMA-PROTEINS; CO-EXPRESSION; LYMPHOCYTE-T; LY-6 FAMILY; ACTIVATION; CAVEOLAE; MEMBER; SCA-2	Thymic shared antigen-1 (TSA-1)/stem cell Ag-2 (Sca-2) is a glycosylphosphatidylinositol (GPI)-anchored antigen expressed on lymphocytes. We have previously demonstrated that a signal via TSA-1/Sca-2 inhibits T cell receptor (TCR)-mediated T cell activation and apoptosis. To elucidate a molecular mechanism for TSA-1-mediated modulation of the TCR-signaling pathway, we examined whether TSA-1 is physically coupled to the TCR in the present study. TSA-1 was clearly associated with CD3 zeta chains in T cell hybridomas, activated T cells, and COS-7 cells transfected with TSA-1 and CD3 zeta cDNA. The physical association was confirmed on the surface of T cells in immunoprecipitation and confocal microscopy. The analysis using stable and transient transfectants expressing a transmembrane form of TSA-1 revealed that the association of CD3 zeta did not require the GPI anchor of TSA-1. Finally, tyrosine phosphorylation of CD3 zeta chains was induced after stimulation with anti-TSA-1, suggesting that a functional association between these two molecules also exists. These results imply that the physical association to CD3 zeta underlies a regulatory role of TSA-1/Sca-2 in the TCR-signaling pathway.	Osaka Univ, Fac Med, Sch Allied Hlth Sci, Suita, Osaka 565, Japan; Osaka Univ, Sch Med, Biomed Res Ctr, Suita, Osaka 565, Japan; Saga Med Sch, Dept Immunol, Saga 849, Japan	Osaka University; Osaka University; Saga University	Kosugi, A (corresponding author), Osaka Univ, Fac Med, Sch Allied Hlth Sci, 1-7 Yamada Oka, Suita, Osaka 565, Japan.							ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; Anderson RGW, 1993, CURR OPIN CELL BIOL, V5, P647, DOI 10.1016/0955-0674(93)90135-D; BAMEZAI A, 1989, J IMMUNOL, V143, P3107; BORN W, 1987, NATURE, V330, P572, DOI 10.1038/330572a0; BROWN D, 1993, CURR OPIN IMMUNOL, V5, P349, DOI 10.1016/0952-7915(93)90052-T; Capone MC, 1996, J IMMUNOL, V157, P969; CLASSON BJ, 1994, P NATL ACAD SCI USA, V91, P5296, DOI 10.1073/pnas.91.12.5296; CODIAS EK, 1990, J IMMUNOL, V145, P1407; DUMONT FJ, 1985, J IMMUNOL, V134, P2357; FRA AM, 1994, J BIOL CHEM, V269, P30745; GODFREY DI, 1992, J IMMUNOL, V148, P2006; GUNTER KC, 1987, NATURE, V326, P505, DOI 10.1038/326505a0; GUNTER KC, 1984, J EXP MED, V159, P716, DOI 10.1084/jem.159.3.716; KAPPLER J, 1982, P NATL ACAD SCI-BIOL, V79, P3604, DOI 10.1073/pnas.79.11.3604; KOSUGI A, 1994, INT IMMUNOL, V6, P1967, DOI 10.1093/intimm/6.12.1967; LEE SK, 1994, EMBO J, V13, P2167, DOI 10.1002/j.1460-2075.1994.tb06493.x; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; MACNEIL I, 1993, J IMMUNOL, V151, P6913; MIYAKE K, 1990, J EXP MED, V171, P477, DOI 10.1084/jem.171.2.477; NODA S, 1995, JPN J CANCER RES, V86, P383, DOI 10.1111/j.1349-7006.1995.tb03068.x; Noda S, 1996, J EXP MED, V183, P2355, DOI 10.1084/jem.183.5.2355; ORTEGA G, 1986, J IMMUNOL, V137, P3240; PARTON RG, 1995, SCIENCE, V269, P1398, DOI 10.1126/science.7660120; PUNT JA, 1991, J EXP MED, V174, P775, DOI 10.1084/jem.174.4.775; RANDLE ES, 1993, J IMMUNOL, V151, P6027; SAITOH SI, 1995, J IMMUNOL, V155, P5574; SAMELSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P6972, DOI 10.1073/pnas.80.22.6972; SANCHEZMADRID F, 1982, CELL IMMUNOL, V73, P1, DOI 10.1016/0008-8749(82)90431-2; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SPANGRUDE GJ, 1988, J IMMUNOL, V141, P3697; SUSSMAN JJ, 1988, J IMMUNOL, V140, P2520; VOLAREVIC S, 1990, P NATL ACAD SCI USA, V87, P7085, DOI 10.1073/pnas.87.18.7085; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WU L, 1991, J EXP MED, V174, P1617, DOI 10.1084/jem.174.6.1617	34	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12301	12306		10.1074/jbc.273.20.12301	http://dx.doi.org/10.1074/jbc.273.20.12301			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575182	hybrid			2022-12-27	WOS:000073629800047
J	Le Dain, AC; Saint, N; Kloda, A; Ghazi, A; Martinac, B				Le Dain, AC; Saint, N; Kloda, A; Ghazi, A; Martinac, B			Mechanosensitive ion channels of the archaeon Haloferax volcanii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; FUNCTIONAL RECONSTITUTION; ACTIVATED CHANNELS; PATCH-CLAMP; HAIR-CELLS; ARCHAEBACTERIA; TRANSDUCTION; PRESSURE; MEMBRANE; EUKARYOTES	Mechanosensitive (MS) ion channels have been documented in a variety of cells belonging to Eukarya and Eubacteria. We report the novel finding of two types of MS ion channels in the cell membrane of the halophilic archaeon Haloferax volcanii, a member of the Archaea that comprise the third phylogenetic domain. The two channels, MscA1 and MscA2, differed in their kinetic properties with MscA1 exhibiting more frequent open-closed transitions than MscA2. Both channels have large conductances that rectify between -40 mV and +40 mV where the conductance of MscA1 ranged from 380 to 680 picosiemens, whereas MscA2 ranged from 850 to 490 picosiemens. Both channels were blocked by submillimolar gadolinium. In addition, the channels of either membrane vesicles or detergent-solubilized membrane proteins remained functional upon reconstitution into artificial liposomes, a result that indicates that these channels are activated by mechanical force transmitted via the lipid bilayer alone. Subsequently a 37-kDa protein corresponding to the MscA1 channel activity was purified. With the possible functional similarity to bacterial MS channels, our finding of MS channels in Archaea emphasizes the ubiquity and importance of these channels in all domains of the evolutionary tree.	Univ Western Australia, Dept Pharmacol, Nedlands, WA 6907, Australia; Univ Paris Sud, Lab Biomembranes, URA CNRS 1116, F-91405 Orsay, France	University of Western Australia; UDICE-French Research Universities; Universite Paris Saclay	Martinac, B (corresponding author), Univ Western Australia, Dept Pharmacol, Nedlands, WA 6907, Australia.		Saint, Nathalie/S-5286-2016; Martinac, Boris/A-7178-2018	Saint, Nathalie/0000-0001-5219-9486; Martinac, Boris/0000-0001-8422-7082				BARINAGA M, 1994, SCIENCE, V264, P1251, DOI 10.1126/science.8191278; BENACHENHOULAHFA N, 1993, J MOL EVOL, V36, P335; Berrier C, 1996, J MEMBRANE BIOL, V151, P175, DOI 10.1007/s002329900068; BERRIER C, 1992, EUR J BIOCHEM, V206, P559, DOI 10.1111/j.1432-1033.1992.tb16960.x; BERRIER C, 1989, FEBS LETT, V259, P27, DOI 10.1016/0014-5793(89)81486-3; Besnard M, 1997, J BIOL CHEM, V272, P992, DOI 10.1074/jbc.272.2.992; BLOUNT P, 1997, METHODS ENZYMOLOGY I; Corey D. P., 1983, SINGLE CHANNEL RECOR; Cruickshank CC, 1997, BIOPHYS J, V73, P1925, DOI 10.1016/S0006-3495(97)78223-7; Csonka LNa E W, 1996, ESCHERICHIA COLI SAL, P1210; DELCOUR AH, 1989, BIOPHYS J, V56, P631, DOI 10.1016/S0006-3495(89)82710-9; Desmarais D, 1997, J BACTERIOL, V179, P3146, DOI 10.1128/jb.179.10.3146-3153.1997; Forterre P, 1996, CELL, V85, P789, DOI 10.1016/S0092-8674(00)81262-3; GarciaAnoveros J, 1997, ANNU REV NEUROSCI, V20, P567, DOI 10.1146/annurev.neuro.20.1.567; Glaasker E, 1996, J BIOL CHEM, V271, P10060, DOI 10.1074/jbc.271.17.10060; GUHARAY F, 1984, J PHYSIOL-LONDON, V352, P685, DOI 10.1113/jphysiol.1984.sp015317; Hamill OP, 1997, ANNU REV PHYSIOL, V59, P621, DOI 10.1146/annurev.physiol.59.1.621; Hamill OP, 1996, TRENDS NEUROSCI, V19, P258, DOI 10.1016/S0166-2236(96)30009-X; Hamill OP, 1996, PHARMACOL REV, V48, P231; HASE CC, 1995, J BIOL CHEM, V270, P18329, DOI 10.1074/jbc.270.31.18329; HOWARD J, 1988, ANNU REV BIOPHYS BIO, V17, P99; HUDSPETH AJ, 1994, NEURON, V12, P1, DOI 10.1016/0896-6273(94)90147-3; Margulis L, 1996, P NATL ACAD SCI USA, V93, P1071, DOI 10.1073/pnas.93.3.1071; MARKIN VS, 1991, BIOPHYS J, V60, P1120, DOI 10.1016/S0006-3495(91)82147-6; MARTINAC B, 1990, NATURE, V348, P261, DOI 10.1038/348261a0; MARTINAC B, 1987, P NATL ACAD SCI USA, V84, P2297, DOI 10.1073/pnas.84.8.2297; MARTINAC B, 1992, COMP ASPECTS MECHANO; MARTINAC B, 1993, CRC THERMODYNAMICS M; OPSAHL LR, 1994, BIOPHYS J, V66, P71, DOI 10.1016/S0006-3495(94)80751-9; Pace NR, 1997, SCIENCE, V276, P734, DOI 10.1126/science.276.5313.734; ROBERTSON DE, 1991, BIOFACTORS, V3, P1; ROWLANDS T, 1994, SCIENCE, V264, P1326, DOI 10.1126/science.8191287; Ruffert S, 1997, EUR J BIOCHEM, V247, P572, DOI 10.1111/j.1432-1033.1997.00572.x; SIGURDSON WJ, 1997, BIOPHYS J, V72, P267; Stein JL, 1996, P NATL ACAD SCI USA, V93, P6228, DOI 10.1073/pnas.93.13.6228; SUKHAREV SI, 1993, BIOPHYS J, V65, P177, DOI 10.1016/S0006-3495(93)81044-0; SUKHAREV SI, 1994, NATURE, V368, P265, DOI 10.1038/368265a0; Sukharev SI, 1997, ANNU REV PHYSIOL, V59, P633, DOI 10.1146/annurev.physiol.59.1.633; WOESE CR, 1977, P NATL ACAD SCI USA, V74, P5088, DOI 10.1073/pnas.74.11.5088; WOESE CR, 1994, MICROBIOL REV, V58, P1; ZORATTI M, 1988, FEBS LETT, V240, P105, DOI 10.1016/0014-5793(88)80348-X; ZORATTI M, 1993, ALKALI CATION TRANSP	42	60	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12116	12119		10.1074/jbc.273.20.12116	http://dx.doi.org/10.1074/jbc.273.20.12116			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575156	hybrid			2022-12-27	WOS:000073629800021
J	Okazawa, M; Shiraki, T; Ninomiya, H; Kobayashi, S; Masaki, T				Okazawa, M; Shiraki, T; Ninomiya, H; Kobayashi, S; Masaki, T			Endothelin-induced apoptosis of A375 human melanoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-SYNTHESIS; EGF RECEPTOR; P53; EXPRESSION; PROTEIN; POTENT; OVEREXPRESSION; PHARMACOLOGY; DEGRADATION; PHYSIOLOGY	Endothelin-l (ET-1) inhibited serum-dependent growth of asynchronized A375 human melanoma cells, and the growth inhibitory effect was markedly enhanced when ET-1 was applied to the cells synchronized at G(1)/S boundary by double thymidine blocks. Flow cytometric analysis revealed that ET-1 did not inhibit the cell cycle progression after the release of the block but caused a significant increase of the hypodiploid cell population that is characteristic of apoptotic cell death. ET-l-induced apoptosis was confirmed by the appearance of chromatin condensation on nuclear staining and DNA fragmentation on gel electrophoresis. The increase in the hypodiploid cell peak was manifest within 16 h of exposure to 5 nM ET-1. Within the same time range, ET-1 caused actin reorganization and drastic morphological changes of the surviving cells from epithelioid to an elongated bipolar shape. These phenotypical changes were preceded by ET-l-induced increase and nuclear accumulation of the tumor suppressor protein p53. All of these effects of ET-1 were mediated by ETB via a pertussis toxin-sensitive G protein. Flow cytometric analysis with fluorescent dye-labeled ET-1 revealed up-regulation of ETB expressed by the cells in G(1)/early S phases, and overexpression of the receptor protein by cDNA microinjection conferred the responsiveness (both apoptosis and morphological changes) to ET-1 irrespective of the position of the cell in the cell cycle. These results indicated the presence of ETB-mediated signaling pathways to apoptotic cell machinery and cytoskeletal organization. Furthermore, the densities of ET, expressed by individual A375 melanoma cells appeared to be regulated by a cell cycle-dependent mechanism, and the receptor density can be a limiting factor to control the apoptotic and cytoskeletal responses of the cells to ET-1. Although the molecular mechanisms remain to be elucidated, these findings added a new dimension to the diverse biological activities of ETs and also indicated a novel mechanism to control the responsiveness of the cell to the peptides.	Kyoto Univ, Fac Med, Dept Pharmacol, Kyoto 606, Japan; Kyoto Univ, Grad Sch Human & Environm Studies, Dept Neurosci, Kyoto 606, Japan	Kyoto University; Kyoto University	Masaki, T (corresponding author), Kyoto Univ, Fac Med, Dept Pharmacol, Kyoto 606, Japan.							ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; HOSODA K, 1994, CELL, V79, P1267, DOI 10.1016/0092-8674(94)90017-5; HOUGHTON AN, 1987, J EXP MED, V164, P812; IHARA M, 1992, LIFE SCI, V50, P247, DOI 10.1016/0024-3205(92)90331-I; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; ISHIKAWA K, 1994, P NATL ACAD SCI USA, V91, P4892, DOI 10.1073/pnas.91.11.4892; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Katsumoto T, 1995, BIOL CELL, V84, P167, DOI 10.1016/0248-4900(96)89426-3; Kikuchi K, 1996, BIOCHEM BIOPH RES CO, V219, P734, DOI 10.1006/bbrc.1996.0303; KREK W, 1995, METHOD ENZYMOL, V254, P114; KROUMPOUZOS G, 1994, PIGM CELL RES, V7, P348, DOI 10.1111/j.1600-0749.1994.tb00638.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LILLIEN L, 1995, NATURE, V377, P158, DOI 10.1038/377158a0; Maki CG, 1996, CANCER RES, V56, P2649; MALLAT A, 1995, J CLIN INVEST, V96, P42, DOI 10.1172/JCI118052; MASAKI T, 1992, MED RES REV, V12, P391, DOI 10.1002/med.2610120405; Ohtani T, 1997, BIOCHEM BIOPH RES CO, V234, P526, DOI 10.1006/bbrc.1997.6670; Okamoto Y, 1997, J BIOL CHEM, V272, P21589, DOI 10.1074/jbc.272.34.21589; Pahl HL, 1996, CURR OPIN CELL BIOL, V8, P340, DOI 10.1016/S0955-0674(96)80007-X; Pitzer F, 1996, FEBS LETT, V394, P47, DOI 10.1016/0014-5793(96)00920-9; RAMACHANDRA S, 1995, CELL GROWTH APOPTOSI, P119; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; Reid K, 1996, DEVELOPMENT, V122, P3911; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RUBANYI GM, 1994, PHARMACOL REV, V46, P325; SAKAMOTO A, 1991, BIOCHEM BIOPH RES CO, V178, P656, DOI 10.1016/0006-291X(91)90158-4; SAKURAI T, 1990, NATURE, V348, P782; Sharma K, 1996, MOL ENDOCRINOL, V10, P1688, DOI 10.1210/me.10.12.1688; SHKEDY D, 1994, FEBS LETT, V348, P126, DOI 10.1016/0014-5793(94)00582-6; SRIKANT CB, 1995, BIOCHEM BIOPH RES CO, V209, P400, DOI 10.1006/bbrc.1995.1517; STEIN GS, 1995, CELL GROWTH APOPTOSI, P193; Sugawara F, 1996, MOL PHARMACOL, V49, P447; TAKAGI Y, 1990, BIOCHEM BIOPH RES CO, V168, P537, DOI 10.1016/0006-291X(90)92354-3; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; VIGNE P, 1990, BIOCHEM J, V266, P415, DOI 10.1042/bj2660415; Yamada T, 1996, P NATL ACAD SCI USA, V93, P156, DOI 10.1073/pnas.93.1.156; Yamatsuji T, 1996, SCIENCE, V272, P1349, DOI 10.1126/science.272.5266.1349; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YOHN JJ, 1994, BIOCHEM BIOPH RES CO, V201, P449, DOI 10.1006/bbrc.1994.1722	40	97	104	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12584	12592		10.1074/jbc.273.20.12584	http://dx.doi.org/10.1074/jbc.273.20.12584			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575219	hybrid			2022-12-27	WOS:000073629800084
J	Pahan, K; Sheikh, FG; Namboodiri, AMS; Singh, I				Pahan, K; Sheikh, FG; Namboodiri, AMS; Singh, I			Inhibitors of protein phosphatase 1 and 2A differentially regulate the expression of inducible nitric-oxide synthase in rat astrocytes and macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TYROSINE KINASE INHIBITORS; C6 GLIOMA-CELLS; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; MAMMALIAN-CELLS; MESANGIAL CELLS; HERBIMYCIN-A; GLIAL-CELLS; ACTIVATION	Nitric oxide produced by inducible nitric-oxide synthase (iNOS) in different cells including brain cells in response to proinflammatory cytokines plays an important role in the pathophysiology of stroke and other neurodegenerative diseases. The present study underlines the importance of protein phosphatase (PP) 1 and 2A in the regulation of the differential expression of iNOS in rat primary astrocytes and macrophages, Compounds (calyculin A, microcystin, okadaic acid, and cantharidin) that inhibit PP 1 and 2A were found to stimulate the lipopolysaccharide (LPS)- and cytokine-mediated expression of iNOS and production of NO in rat primary astrocytes and C-6 glial cells. However, these inhibitors inhibited the LPS- and cytokine-mediated expression of iNOS and production of NO in rat resident macrophages and RAW 264.7 cells. Similarly, okadaic acid, an inhibitor of PP 1/2A, stimulated the iNOS promoter-derived chloramphenicol acetyltransferase activity in astrocytes and inhibited the iNOS promoter-derived chloramphenicol acetyltransferase activity in macrophages, indicating that okadaic acid also differentially regulates the transcription of the MOS gene in astrocytes and macrophages, The observed stimulation of the expression of iNOS in astrocytes and the inhibition of the expression of iNOS in macrophages with the inhibition of PP 1/2A activity clearly delineate a novel role of PP 1/2A in the differential regulation of iNOS in rat astrocytes and macrophages. Because the activation of NF-kappa B is necessary for the induction of MOS and the expression of tumor necrosis factor (TNF)-alpha also depends on the activation of NF-kappa B, we examined the effect of okadaic acid on the LPS-mediated activation of NF-kappa B and production of TNF-alpha in rat primary astrocytes and macrophages. Interestingly, in both cell types, okadaic acid stimulated the LPS-mediated DNA binding as well as transcriptional activity of NF-kappa B and production of TNF-alpha. This study suggests that the stimulation of iNOS expression in astrocytes by inhibitors of PP 1/2A is possibly due to the stimulation of NF-kappa B activation; however, activation of NF-kappa B is not sufficient for the induction of iNOS in macrophages and that apart from NF-kappa B some other signaling pathway(s) sensitive to PP 1 and/or PP 2A is/are possibly involved in the regulation of iNOS in macrophages, This differential induction of MOS as compared with similar activation of NF-kappa B by inhibitors of PP 1/2A indicates the involvement of different intracellular signaling events for the induction of iNOS in two cell types of the same animal species.	Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA	Medical University of South Carolina	Singh, I (corresponding author), Med Univ S Carolina, Dept Pediat, 171 Ashley Ave, Charleston, SC 29425 USA.	singhi@muscc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022576, R01NS034741, R01NS037766, R37NS022576] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-37766, NS-34741, NS-22576] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Beck KF, 1996, FEBS LETT, V394, P263, DOI 10.1016/0014-5793(96)00966-0; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; Begum N, 1996, J BIOL CHEM, V271, P31166, DOI 10.1074/jbc.271.49.31166; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BO L, 1994, ANN NEUROL, V36, P778, DOI 10.1002/ana.410360515; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CROSS AH, 1994, J CLIN INVEST, V93, P2684, DOI 10.1172/JCI117282; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dobashi K, 1997, J NEUROCHEM, V68, P1896; Dong ZY, 1995, J LEUKOCYTE BIOL, V58, P725, DOI 10.1002/jlb.58.6.725; Eberhardt W, 1996, BIOCHEM BIOPH RES CO, V223, P752, DOI 10.1006/bbrc.1996.0968; FEINSTEIN DL, 1994, J NEUROCHEM, V62, P811; FEINSTEIN DL, 1994, J NEUROCHEM, V62, P315; GALEA E, 1992, P NATL ACAD SCI USA, V89, P10945, DOI 10.1073/pnas.89.22.10945; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281; HER JH, 1993, BIOCHEM J, V296, P25, DOI 10.1042/bj2960025; Hooper DC, 1997, P NATL ACAD SCI USA, V94, P2528, DOI 10.1073/pnas.94.6.2528; Hu SX, 1995, GLIA, V15, P491, DOI 10.1002/glia.440150412; Jaffrey SR, 1995, ANNU REV CELL DEV BI, V11, P417; KOPROWSKI H, 1993, P NATL ACAD SCI USA, V90, P3024, DOI 10.1073/pnas.90.7.3024; KWON G, 1995, ENDOCRINOLOGY, V136, P4790, DOI 10.1210/en.136.11.4790; LEVITAN IB, 1994, ANNU REV PHYSIOL, V56, P193, DOI 10.1146/annurev.ph.56.030194.001205; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MEDCALF RL, 1992, J BIOL CHEM, V267, P12220; MENON SD, 1993, J BIOL CHEM, V268, P26805; MERRILL JE, 1993, J IMMUNOL, V151, P2132; MITROVIC B, 1994, NEUROSCIENCE, V61, P575, DOI 10.1016/0306-4522(94)90435-9; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NGUYEN VT, 1988, ANAL BIOCHEM, V171, P404, DOI 10.1016/0003-2697(88)90505-2; NISHIYA T, 1995, FEBS LETT, V371, P333, DOI 10.1016/0014-5793(95)00933-Z; Pahan K, 1997, J CLIN INVEST, V100, P2671, DOI 10.1172/JCI119812; Pahan K, 1997, J BIOL CHEM, V272, P7786, DOI 10.1074/jbc.272.12.7786; Pahan K, 1998, J BIOL CHEM, V273, P2591, DOI 10.1074/jbc.273.5.2591; Pahan K, 1998, FREE RADICAL BIO MED, V24, P39, DOI 10.1016/S0891-5849(97)00137-8; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; ROSSOMANDO AJ, 1994, MOL CELL BIOL, V14, P1594, DOI 10.1128/MCB.14.3.1594; Salkowski CA, 1997, J IMMUNOL, V158, P905; STEFANOVA I, 1993, J BIOL CHEM, V268, P20725; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUN SC, 1995, J BIOL CHEM, V270, P18347, DOI 10.1074/jbc.270.31.18347; SUZUKI YJ, 1994, J IMMUNOL, V153, P5008; Tetsuka T, 1996, BIOCHEM BIOPH RES CO, V218, P808, DOI 10.1006/bbrc.1996.0144; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; XIE QW, 1994, J BIOL CHEM, V269, P4705; ZIEGLERHEITBROCK HWL, 1993, J IMMUNOL, V151, P6986	47	80	80	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12219	12226		10.1074/jbc.273.20.12219	http://dx.doi.org/10.1074/jbc.273.20.12219			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575170	hybrid			2022-12-27	WOS:000073629800035
J	Anderson, KP; Crable, SC; Lingrel, JB				Anderson, KP; Crable, SC; Lingrel, JB			Multiple proteins binding to a GATA-E box-GATA motif regulate the erythroid Kruppel-like factor (EKLF) gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; BETA-THALASSEMIA; MICE LACKING; FAMILY; HEMATOPOIESIS; PROMOTER; RBTN2; LEUKEMIA; ABSENCE; GLOBIN	Erythroid Kruppel-like factor (EKLF) is a zinc finger transcription factor required for beta-globin gene expression and is implicated as one of the key factors necessary for the fetal to adult switch in globin gene expression, In an effort to identify factors involved in the expression of this important erythroid-specific regulatory protein, we have isolated the mouse EKLF gene and systematically analyzed the promoter region. Initially, a reporter construct with 1150 base pairs of the EKLF 5'-region was introduced into transgenic mice and shown to direct erythroid-specific expression. We continued the expression studies in erythroid cells and have identified a sequence element consisting of two GATA sites flanking an E box motif, The three sites act in concert to elevate the transcriptional activity of the EKLF promoter. Each site is essential for EKLF expression indicating that the three binding sites do not work additively, but rather function as a unit. We further show that GATA-1 binds to the two GATA sites and present evidence for binding of another factor from erythroid cell nuclear extracts to the E box motif. These results are consistent with the formation of a quaternary complex composed of an E box dimer and two GATA-1 proteins binding at a combined GATA-E box-GATA activator element in the distal EKLF promoter.	Univ Cincinnati, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Anderson, KP (corresponding author), Univ Cincinnati, Dept Mol Genet Microbiol & Biochem, 231 Bethesda Ave,ML 524, Cincinnati, OH 45267 USA.		Ruiter, D.J./L-4617-2015		NIDDK NIH HHS [DK39585] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK039585, R01DK039585] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON KP, 1995, MOL CELL BIOL, V15, P5957; ASKEW GR, 1993, MOL CELL BIOL, V13, P4115, DOI 10.1128/MCB.13.7.4115; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BAER R, 1993, SEMIN CANCER BIOL, V4, P341; BIEKER JJ, 1995, MOL CELL BIOL, V15, P852; BOEHM T, 1990, ONCOGENE, V5, P1103; CROSSLEY M, 1994, J BIOL CHEM, V269, P15440; DONZE D, 1995, J BIOL CHEM, V270, P1955, DOI 10.1074/jbc.270.4.1955; FENG WC, 1994, J BIOL CHEM, V269, P1493; HAGEN B, 1986, MANIPULATING MOUSE E; MCBURNEY MW, 1994, DEV DYNAM, V200, P278, DOI 10.1002/aja.1002000403; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MINIE M, 1993, J CELL CI S, V16, P15; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; Orkin SH, 1996, CURR OPIN GENET DEV, V6, P597, DOI 10.1016/S0959-437X(96)80089-X; OSADA H, 1995, P NATL ACAD SCI USA, V92, P9585, DOI 10.1073/pnas.92.21.9585; PERKINS AC, 1995, NATURE, V375, P318; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RABBITTS TH, 1990, NATURE, V346, P418, DOI 10.1038/346418a0; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WEISS MJ, 1995, EXP HEMATOL, V23, P99; Wijgerde M, 1996, GENE DEV, V10, P2894, DOI 10.1101/gad.10.22.2894	28	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14347	14354		10.1074/jbc.273.23.14347	http://dx.doi.org/10.1074/jbc.273.23.14347			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603943	hybrid			2022-12-27	WOS:000074021500045
J	Angelo, R; Rubin, CS				Angelo, R; Rubin, CS			Molecular characterization of an anchor protein (AKAP(CE)) that binds the RI subunit (R-CE) of type I protein kinase A from Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY SUBUNIT; A-KINASE; CATALYTIC SUBUNIT; MESSENGER-RNA; EXPRESSION; CLONING; GENE; SEQUENCE; BETA; CYTOSKELETON	Classical A kinase anchor proteins (AKAPs) preferentially tether type II protein kinase A (PKAII) isoforms to sites in the cytoskeleton and organelles. It is not known if distinct proteins selectively sequester regulatory (R) subunits of type I PKAs, thereby diversifying functions of these critical enzymes. In Caenorhabditis elegans, a single type I PKA mediates all aspects of cAMP signaling. We have discovered a cDNA that encodes a binding protein (AKAP(CE)) for the regulatory subunit (R-CE) of C. elegans PKAI(CE). AKAP(CE) is a novel, highly acidic RING finger protein composed of 1,280 amino acids. It binds RI-like R-CE with high affinity and neither RII alpha nor RII beta competitively inhibits formation of AKAP(CE).R-CE complexes. The R-CE-binding site was mapped to a segment of 20 amino acids in an N-terminal region of AKAP(CE). Several hydrophobic residues in the binding site align with essential Leu and Re residues in the RII-selective tethering domain of prototypic mammalian AKAPs. However, the R-CE-binding region in AKAP(CE) diverges sharply from consensus RII-binding sites by inclusion of three aromatic amino acids, exclusion of a highly conserved Leu or Ile at position 8 and replacement of C-terminal hydrophobic amino acids with basic residues. AKAP(CE). R-CE complexes accumulate in intact cells.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Atran Labs, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Rubin, CS (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Atran Labs, 1300 Morris Pk Ave,F-229, Bronx, NY 10461 USA.	rubin@aecom.yu.edu			NIGMS NIH HHS [GM07260, GM22792] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007260, R01GM022792] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Amieux PS, 1997, J BIOL CHEM, V272, P3993, DOI 10.1074/jbc.272.7.3993; BLUMENTHAL T, 1988, TRENDS GENET, V4, P305, DOI 10.1016/0168-9525(88)90107-2; BREGMAN DB, 1991, J BIOL CHEM, V266, P7207; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; BUBIS J, 1987, J BIOL CHEM, V262, P14961; Burton KA, 1997, P NATL ACAD SCI USA, V94, P11067, DOI 10.1073/pnas.94.20.11067; Chen Q, 1997, J BIOL CHEM, V272, P15247, DOI 10.1074/jbc.272.24.15247; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; GLANTZ SB, 1993, J BIOL CHEM, V268, P12796; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; GROSS RE, 1990, J BIOL CHEM, V265, P6896; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Han JD, 1997, J BIOL CHEM, V272, P26611, DOI 10.1074/jbc.272.42.26611; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HAUSKEN ZE, 1994, J BIOL CHEM, V269, P24245; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; HOFMANN F, 1977, J BIOL CHEM, V252, P1441; HU ED, 1990, J BIOL CHEM, V265, P5072; Huang LJS, 1997, J BIOL CHEM, V272, P8057, DOI 10.1074/jbc.272.12.8057; Huang LJS, 1997, P NATL ACAD SCI USA, V94, P11184, DOI 10.1073/pnas.94.21.11184; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LAND M, 1994, J BIOL CHEM, V269, P9234; Lester LB, 1996, J BIOL CHEM, V271, P9460, DOI 10.1074/jbc.271.16.9460; LI Y, 1995, J BIOL CHEM, V270, P1935, DOI 10.1074/jbc.270.4.1935; Li Y, 1996, J BIOL CHEM, V271, P16862, DOI 10.1074/jbc.271.28.16862; LIN RY, 1995, J BIOL CHEM, V270, P27804, DOI 10.1074/jbc.270.46.27804; LU XY, 1990, J BIOL CHEM, V265, P3293; NDUBUKA C, 1993, J BIOL CHEM, V268, P7621; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PHIZICKY EM, 1995, MICROBIOL REV, V59, P94, DOI 10.1128/MMBR.59.1.94-123.1995; RUBIN CS, 1972, J BIOL CHEM, V247, P6135; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SKALHEGG BS, 1994, SCIENCE, V263, P84, DOI 10.1126/science.8272870; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	41	88	92	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14633	14643		10.1074/jbc.273.23.14633	http://dx.doi.org/10.1074/jbc.273.23.14633			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603981	hybrid			2022-12-27	WOS:000074021500083
J	Beinborn, M; Quinn, SM; Kopin, AS				Beinborn, M; Quinn, SM; Kopin, AS			Minor modifications of a cholecystokinin-B/gastrin receptor non-peptide antagonist confer a broad spectrum of functional properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B GASTRIN RECEPTOR; HYPERFUNCTIONING THYROID ADENOMAS; SINGLE AMINO-ACID; CONSTITUTIVE ACTIVITY; THYROTROPIN RECEPTOR; PRECOCIOUS PUBERTY; SOMATIC MUTATIONS; HORMONE RECEPTOR; AGONIST; POTENT	The development of non-peptide agonists for peptide hormone receptors would markedly expand the treatment options for a large number of diseases. However difficulty in identifying non-peptide molecules which possess intrinsic activity has been a major obstacle in achieving this goal. At present, most of the known non-peptide ligands for peptide hormone receptors appear in standard functional assays to be antagonists, Here, we report that a constitutively active mutant of the human cholecystokinin-B/gastrin receptor, Leu(325) --> Glu, offers the potential to detect even trace agonist activity of Ligands which, at the wild type receptor isoform, appear to lack efficacy, The enhanced functional sensitivity of the mutant receptor enabled us to detect intrinsic activity of L-365,260, an established non-peptide antagonist for the cholecystokinin-B/gastrin receptor. Extending from this observation, we were able to demonstrate that minor structural modifications could convert L-365,260 into either: (i) an agonist or (ii) an inverse agonist (attenuates ligand-independent signaling). The ability to confer functional activity to small non-peptide ligands suggests that the propel-ties of endogenous peptide hormones can be mimicked, and even extended, by considerably less complex molecules.	Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA; Tufts Univ, Sch Med, Ctr Gastroenterol Res Absorpt & Secretory Proc, Tupper Res Inst,New England Med Ctr, Boston, MA 02111 USA	Tufts University; Tufts Medical Center; Tufts University	Kopin, AS (corresponding author), Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA.	akopin@msn.com			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046767] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46767] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDER SPH, 1997, TRENDS PHARM SCI S, V18, P3; BEINBORN M, 1993, NATURE, V362, P348, DOI 10.1038/362348a0; Beinborn M, 1996, GASTROENTEROLOGY, V110, pA1059; Blaker M, 1997, GASTROENTEROLOGY, V112, pA1133; CHANG RSL, 1986, P NATL ACAD SCI USA, V83, P4923, DOI 10.1073/pnas.83.13.4923; Claude PA, 1996, P NATL ACAD SCI USA, V93, P5715, DOI 10.1073/pnas.93.12.5715; CRAWLEY JN, 1994, PEPTIDES, V15, P731, DOI 10.1016/0196-9781(94)90104-X; DING XQ, 1995, GASTROENTEROLOGY, V109, P1181, DOI 10.1016/0016-5085(95)90577-4; Groblewski T, 1997, J BIOL CHEM, V272, P1822, DOI 10.1074/jbc.272.3.1822; HEINFLINK M, 1995, MOL ENDOCRINOL, V9, P1455, DOI 10.1210/me.9.11.1455; Hirst GC, 1996, J MED CHEM, V39, P5236, DOI 10.1021/jm9601664; Hogan JC, 1996, NATURE, V384, P17; HOGGER P, 1995, J BIOL CHEM, V270, P7405; Hughes J, 1996, REGUL PEPTIDES, V65, P15, DOI 10.1016/0167-0115(96)00067-5; HULME EC, 1992, RECEPTOR LIGAND INTE, P62; Kenakin T, 1996, PHARMACOL REV, V48, P413; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KOPIN AS, 1995, J BIOL CHEM, V270, P5019, DOI 10.1074/jbc.270.10.5019; LEE YM, 1993, J BIOL CHEM, V268, P8164; LEFF P, 1995, TRENDS PHARMACOL SCI, V16, P89, DOI 10.1016/S0165-6147(00)88989-0; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; Liddle Rodger A., 1994, P175; LOTTI VJ, 1989, EUR J PHARMACOL, V162, P273, DOI 10.1016/0014-2999(89)90290-2; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; MILLIGAN G, 1995, TRENDS PHARMACOL SCI, V16, P10, DOI 10.1016/S0165-6147(00)88963-4; NISHIDA A, 1994, J PHARMACOL EXP THER, V269, P725; PARMA J, 1995, MOL ENDOCRINOL, V9, P725, DOI 10.1210/me.9.6.725; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; PERLMAN S, 1995, J BIOL CHEM, V270, P1493, DOI 10.1074/jbc.270.4.1493; REISINE T, 1996, PHARMACOL BASIS THER, P521; REN Q, 1993, J BIOL CHEM, V268, P16483; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SCHMASSMANN A, 1994, GUT, V35, P270, DOI 10.1136/gut.35.2.270; SCHWARTZ TW, 1995, CURR PHARM DESIGN, V1, P325; SEIDLER U, 1991, AM J PHYSIOL, V260, pG133, DOI 10.1152/ajpgi.1991.260.1.G133; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; SHOWELL GA, 1994, J MED CHEM, V37, P719, DOI 10.1021/jm00032a002; SMITH RG, 1993, SCIENCE, V260, P1640, DOI 10.1126/science.8503009; Spalding TA, 1995, J PHARMACOL EXP THER, V275, P1274; Spiegel AM, 1996, J CLIN ENDOCR METAB, V81, P2434, DOI 10.1210/jc.81.7.2434; STRADER CD, 1989, J BIOL CHEM, V264, P16470; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; TIBERI M, 1994, J BIOL CHEM, V269, P27925; WALSH JH, 1994, GUT PEPTIDES BIOCH P, P75; WANK SA, 1995, AM J PHYSIOL-GASTR L, V269, pG628, DOI 10.1152/ajpgi.1995.269.5.G628; YANO K, 1995, J CLIN ENDOCR METAB, V80, P1162, DOI 10.1210/jc.80.4.1162	47	36	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14146	14151		10.1074/jbc.273.23.14146	http://dx.doi.org/10.1074/jbc.273.23.14146			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603914	hybrid			2022-12-27	WOS:000074021500016
J	Guenzi, E; Galli, G; Grgurina, I; Pace, E; Ferranti, P; Grandi, G				Guenzi, E; Galli, G; Grgurina, I; Pace, E; Ferranti, P; Grandi, G			Coordinate transcription and physical linkage of domains in surfactin synthetase are not essential for proper assembly and activity of the multienzyme complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS; PEPTIDE BIOSYNTHESIS; SIGNAL TRANSDUCTION; SRFA OPERON; REGION; GENES; COMPETENCE; BACTERIAL; TEMPLATES; CLEAVAGE	Bacterial peptide synthetases have two common features that appear to be strictly conserved. 1) The enzyme subunits are co-regulated at both transcriptional and translational level. 2) The organization of the different enzymatic domains constituting the enzyme fulfills the "colinearity rule" according to which the order of the domains along the chromosome parallels their functional hierarchy. Considering the high degree of conservation of these features, one would expect that mutations such as transcription uncoupling and domain dissociations, deletions, duplications, and reshuffling would result in profound effects on the quality and quantity of synthesized peptides, To start testing this hypothesis, we designed two mutants. In one mutant, the operon structure of surfactin synthetase was destroyed, thus altering the concerted expression of the enzyme subunits, In the other mutant, the thioesterase domain naturally fused to the last amino acid binding domain of surfactin was physically dissociated and independently expressed. When the lipopeptides secreted by the mutant Bacillus subtilis strains were purified and characterized, they appeared to be expressed approximately at the same level of the wild type surfactin and to be identical to it, indicating that specific domain-domain interactions rather than coordinated transcription and translation play the major role in determining the correct assembly and activity of peptide synthetases.	Chiron SPA, Dept Mol Biol, I-53100 Siena, Italy; Univ Rome La Sapienza, Dept Biochem Sci, I-00185 Rome, Italy; Univ Naples, Dept Food Sci, I-101 Naples, Italy	Novartis; Sapienza University Rome	Grandi, G (corresponding author), Chiron SPA, Dept Mol Biol, Via Fiorentina 1, I-53100 Siena, Italy.	grandi@iris02.biocine.it	Ferranti, Pasquale/ABF-8111-2021	FERRANTI, Pasquale/0000-0002-6250-6512; Grandi, Guido/0000-0001-9724-2185				Conti E, 1997, EMBO J, V16, P4174, DOI 10.1093/emboj/16.14.4174; CORTES J, 1995, SCIENCE, V268, P1487, DOI 10.1126/science.7770773; COSMINA P, 1993, MOL MICROBIOL, V8, P821, DOI 10.1111/j.1365-2958.1993.tb01629.x; Davidson JN, 1997, TRENDS GENET, V13, P281, DOI 10.1016/S0168-9525(97)01127-X; deFerra F, 1997, J BIOL CHEM, V272, P25304, DOI 10.1074/jbc.272.40.25304; FRANCHI E, 1991, J BIOTECHNOL, V18, P41, DOI 10.1016/0168-1656(91)90234-M; GALLI G, 1994, BBA-PROTEIN STRUCT M, V1205, P19, DOI 10.1016/0167-4838(94)90087-6; GLASER P, 1993, MOL MICROBIOL, V10, P371, DOI 10.1111/j.1365-2958.1993.tb01963.x; HAHN J, 1991, J BACTERIOL, V173, P7275, DOI 10.1128/jb.173.22.7275-7282.1991; KAKINUMA A, 1969, AGR BIOL CHEM TOKYO, V33, P973, DOI 10.1080/00021369.1969.10859409; Kleinkauf H, 1996, EUR J BIOCHEM, V236, P335, DOI 10.1111/j.1432-1033.1996.00335.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lipmann F, 1980, Adv Microb Physiol, V21, P227; NAKANO MM, 1991, J BACTERIOL, V173, P5487, DOI 10.1128/jb.173.17.5487-5493.1991; NAKANO MM, 1993, J BACTERIOL, V175, P3188, DOI 10.1128/JB.175.10.3188-3191.1993; PEREGO M, 1991, J BACTERIOL, V173, P2514, DOI 10.1128/jb.173.8.2514-2520.1991; SMITH DJ, 1990, EMBO J, V9, P741, DOI 10.1002/j.1460-2075.1990.tb08168.x; STACHELHAUS T, 1995, FEMS MICROBIOL LETT, V125, P3, DOI 10.1111/j.1574-6968.1995.tb07328.x; STACHELHAUS T, 1995, SCIENCE, V269, P69, DOI 10.1126/science.7604280; Stein T, 1996, J BIOL CHEM, V271, P15428, DOI 10.1074/jbc.271.26.15428; TOGNONI A, 1995, MICROBIOL-UK, V141, P645, DOI 10.1099/13500872-141-3-645; TURGAY K, 1992, MOL MICROBIOL, V6, P529, DOI 10.1111/j.1365-2958.1992.tb01498.x; VANSINDEREN D, 1993, MOL MICROBIOL, V8, P833; ZHANG JH, 1995, J BACTERIOL, V177, P4009, DOI 10.1128/jb.177.14.4009-4020.1995; Zuber Peter, 1993, P897	25	30	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14403	14410		10.1074/jbc.273.23.14403	http://dx.doi.org/10.1074/jbc.273.23.14403			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603952	hybrid			2022-12-27	WOS:000074021500054
J	Heaton, JH; Tillmann-Bogush, M; Leff, NS; Gelehrter, TD				Heaton, JH; Tillmann-Bogush, M; Leff, NS; Gelehrter, TD			Cyclic nucleotide regulation of type-1 plasminogen activator-inhibitor mRNA stability in rat hepatoma cells - Identification of cis-acting sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; FOLLICLE-STIMULATING-HORMONE; 3' UNTRANSLATED REGION; PROTEIN-KINASE-A; 3'-UNTRANSLATED REGION; GENE-EXPRESSION; SERTOLI CELLS; DOWN-REGULATION; CODING REGION; UP-REGULATION	Type-1 plasminogen activator-inhibitor (PAI-1) is a major physiologic inhibitor of plasminogen activation. Incubation of HTC rat hepatoma cells with the cyclic nucleotide analogue, 8-bromo-cAMP, causes a dramatic increase in tissue-type plasminogen activator activity secondary to a 90% decrease in PAI-1 mRNA, Although 8 bromo-cAMP causes a modest decrease in PAI-1 transcription, regulation is primarily the result of a 3-fold increase in the rate of PAI-1 mRNA degradation. To determine the cis-acting sequences required for cyclic nucleotide regulation, we have stably transfected HTC cells with chimeric genes containing sequences from the rat PAI-1 cDNA and the mouse beta-globin gene and examined the effect of cyclic nucleotides on the decay rate of these transcripts. The mRNA transcribed from the beta-globin gene is stable and not cyclic nucleotide-regulated, whereas the transcript from a construct containing the beta-globin coding region and the PAI-1 3'-untranslated region (UTR) is destabilized in the presence of 8-bromo-cAMP, suggesting that this response is mediated by sequences in the PAI-1 3'-UTR., Analyses by deletion of sequences from this chimeric construct indicate that, whereas more than one region of the PAI-1 3'-UTR can confer cyclic nucleotide responsiveness, the 3'-most 134-nucleotide sequence alone is sufficient to do so. Insertion of PAI-1 sequences within the beta-globin 3'-UTR confirms that the 3'-most 134 nucleotides of PAI-1 mRNA can confer cyclic nucleotide regulation of stability on a heterologous transcript, suggesting that this sequence may play a major role in hormonal regulation of PAI-1 mRNA stability.	Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Heaton, JH (corresponding author), Univ Michigan, Sch Med, Dept Human Genet, M4708 MSII-0618,1301 E Catherine St, Ann Arbor, MI 48109 USA.	heatonj@umich.edu			NATIONAL CANCER INSTITUTE [R37CA022729, R01CA022729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009437] Funding Source: NIH RePORTER; NCI NIH HHS [CA22729] Funding Source: Medline; NIDDK NIH HHS [DK09437] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREASEN PA, 1990, MOL CELL ENDOCRINOL, V68, P1, DOI 10.1016/0303-7207(90)90164-4; Ausubel FM, 1988, MOL REPROD DEV; BAROUSKIMILLER PA, 1982, P NATL ACAD SCI-BIOL, V79, P2319, DOI 10.1073/pnas.79.7.2319; Bijnens AP, 1997, THROMB HAEMOSTASIS, V77, P350; BLOK LJ, 1992, ENDOCRINOLOGY, V131, P1343, DOI 10.1210/en.131.3.1343; CAPONIGRO G, 1993, MOL CELL BIOL, V13, P5141, DOI 10.1128/MCB.13.9.5141; CHEDRESE PJ, 1994, ENDOCRINOLOGY, V134, P2475, DOI 10.1210/en.134.6.2475; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHEN M, 1993, J BIOL CHEM, V268, P24138; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUANG TH, 1995, GENE, V162, P303, DOI 10.1016/0378-1119(95)00261-4; Danner S, 1998, J BIOL CHEM, V273, P3223, DOI 10.1074/jbc.273.6.3223; DIBATTISTA JA, 1994, MOL CELL ENDOCRINOL, V103, P139, DOI 10.1016/0303-7207(94)90081-7; Dodson RE, 1997, J BIOL CHEM, V272, P12249, DOI 10.1074/jbc.272.19.12249; DODSON RE, 1994, MOL CELL BIOL, V14, P3130, DOI 10.1128/MCB.14.5.3130; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FUKUMOTO S, 1992, J CELL PHYSIOL, V152, P346, DOI 10.1002/jcp.1041520216; GELEHRTE.TD, 1970, P NATL ACAD SCI USA, V66, P390, DOI 10.1073/pnas.66.2.390; GELEHRTER TD, 1987, MOL ENDOCRINOL, V1, P97, DOI 10.1210/mend-1-1-97; GEORG B, 1990, MOL CELL ENDOCRINOL, V72, P103, DOI 10.1016/0303-7207(90)90100-M; GINSBURG D, 1986, J CLIN INVEST, V78, P1673, DOI 10.1172/JCI112761; GOROSPE M, 1994, J BIOL CHEM, V269, P11845; HADCOCK JR, 1989, J BIOL CHEM, V264, P19928; Han SW, 1997, BIOL REPROD, V57, P158, DOI 10.1095/biolreprod57.1.158; HARGROVE JL, 1991, BIOESSAYS, V13, P667, DOI 10.1002/bies.950131209; HEATON JH, 1990, MOL ENDOCRINOL, V4, P171, DOI 10.1210/mend-4-1-171; HEATON JH, 1989, MOL ENDOCRINOL, V3, P349, DOI 10.1210/mend-3-2-349; HEATON JH, 1992, MOL ENDOCRINOL, V6, P53, DOI 10.1210/me.6.1.53; HERRICK DJ, 1994, MOL CELL BIOL, V14, P2119, DOI 10.1128/MCB.14.3.2119; HUANG DL, 1995, MOL ENDOCRINOL, V9, P994, DOI 10.1210/me.9.8.994; KATHJU S, 1994, ENDOCRINOLOGY, V135, P1195, DOI 10.1210/en.135.3.1195; KATHJU S, 1994, THESIS U MICHGAN ANN; KONKEL DA, 1979, CELL, V18, P865, DOI 10.1016/0092-8674(79)90138-7; KONKLE BA, 1990, J BIOL CHEM, V265, P21867; LEEDMAN PJ, 1995, MOL ENDOCRINOL, V9, P375, DOI 10.1210/me.9.3.375; LOGANZO F, 1993, MOL ENDOCRINOL, V7, P434, DOI 10.1210/me.7.3.434; Lu DL, 1996, BIOCHEMISTRY-US, V35, P12347, DOI 10.1021/bi961019a; MARKSITZER R, 1995, J BIOL CHEM, V270, P21833, DOI 10.1074/jbc.270.37.21833; McGowan KM, 1997, J BIOL CHEM, V272, P1331, DOI 10.1074/jbc.272.2.1331; MIMURO J, 1989, NUCLEIC ACIDS RES, V17, P8872, DOI 10.1093/nar/17.21.8872; MUHLRAD D, 1992, GENE DEV, V6, P2100, DOI 10.1101/gad.6.11.2100; Murasawa S, 1996, Hypertens Res, V19, P271, DOI 10.1291/hypres.19.271; NACHALIEL N, 1993, J BIOL CHEM, V268, P24203; NARGOLWALLA C, 1990, MOL CELL ENDOCRINOL, V70, P73, DOI 10.1016/0303-7207(90)90060-L; Pande A, 1996, J BIOL CHEM, V271, P8493, DOI 10.1074/jbc.271.14.8493; PETERKOFSKY B, 1968, P NATL ACAD SCI USA, V60, P222, DOI 10.1073/pnas.60.1.222; PRENDERGAST GC, 1990, MOL CELL BIOL, V10, P1265, DOI 10.1128/MCB.10.3.1265; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SCHIAVI SC, 1994, J BIOL CHEM, V269, P3441; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SMITH JD, 1988, EMBO J, V7, P3711, DOI 10.1002/j.1460-2075.1988.tb03254.x; STOCKERT RJ, 1993, J BIOL CHEM, V268, P19540; STOECKLIN G, 1994, J BIOL CHEM, V269, P28591; THALACKER FW, 1992, BIOCHEM J, V287, P855, DOI 10.1042/bj2870855; THEMMEN APN, 1991, MOL CELL ENDOCRINOL, V78, pR7, DOI 10.1016/0303-7207(91)90130-K; Tholanikunnel BG, 1997, J BIOL CHEM, V272, P11471; TRANQUE P, 1992, GLIA, V6, P163, DOI 10.1002/glia.440060303; Wang XF, 1997, MOL PHARMACOL, V52, P781, DOI 10.1124/mol.52.5.781; WEISS IM, 1995, MOL CELL BIOL, V15, P2457; WELLINGTON CL, 1993, MOL CELL BIOL, V13, P5034, DOI 10.1128/MCB.13.8.5034; ZAIDI SHE, 1994, J BIOL CHEM, V269, P24000; ZAIDI SHE, 1994, J BIOL CHEM, V269, P24007; ZEHEB R, 1988, GENE, V73, P459, DOI 10.1016/0378-1119(88)90510-0; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	64	32	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14261	14268		10.1074/jbc.273.23.14261	http://dx.doi.org/10.1074/jbc.273.23.14261			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603932	hybrid			2022-12-27	WOS:000074021500034
J	Lin, XH; Hengartner, MO; Kolesnick, R				Lin, XH; Hengartner, MO; Kolesnick, R			Caenorhabditis elegans contains two distinct acid sphingomyelinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTRAL SPHINGOMYELINASE; APOPTOSIS; SEQUENCE	Mounting evidence supports a role for acid sphingomyelinase (ASM) in cellular stress signaling Only murine and human sphingomyelinases have been defined at the molecular level. These enzymes are the products of a conserved gene and at the amino acid level share 82% identity. in this study, we show that the nematode Caenorhabditis elegans possesses two ASMs, termed ASM-1 and ASM-2 encoded by two distinct genes, but lacks detectable neutral sphingomyelinase activity. The C., elegans ASMs are about 30% identical with each other and with the human and murine enzymes, The conserved regions include a saposin-like domain, proline-rich domain, and a putative signal peptide, in addition, 16 cysteines distributed throughout the molecules, and selected glycosylation sites, are conserved, The expression of these genes in C. elegans is regulated during development Asm-l is preferentially expressed in the embryo, whereas asm-2 is predominantly expressed in postembryonic stages. Whets transfected as Flag-tagged proteins into COS-7 cells, ASM-P is found almost entirely in a secreted form whereas only 20% of ASM-2 is secreted. Only the secreted forms display enzymatic activity. Furthermore, ASM-S requires addition of Zn2+ to be fully active, whereas ASM-B is active in the absence of cation, C., elegans is the first organism to display two ASMs. This finding suggests the existence of an ASM gene family.	Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, New York, NY 10021 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Memorial Sloan Kettering Cancer Center; Cold Spring Harbor Laboratory	Kolesnick, R (corresponding author), Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, 1275 York Ave, New York, NY 10021 USA.		Hengartner, Michael O/E-6235-2011; Hengartner, Michael O/A-7058-2008	Hengartner, Michael/0000-0002-7584-596X	NIGMS NIH HHS [GM 53540] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bilderback TR, 1997, J BIOL CHEM, V272, P10922; BRENNER S, 1974, GENETICS, V77, P71; Cai ZZ, 1997, J BIOL CHEM, V272, P6918, DOI 10.1074/jbc.272.11.6918; Castedo M, 1996, J IMMUNOL, V157, P512; CHATTERJEE S, 1993, ADV LIPID RES, V26, P25; Duan RD, 1996, DIGEST DIS SCI, V41, P1801, DOI 10.1007/BF02088748; DUAN RD, 1995, BBA-LIPID LIPID MET, V1259, P49, DOI 10.1016/0005-2760(95)00137-2; FERLINZ K, 1994, BIOCHEM J, V301, P855, DOI 10.1042/bj3010855; Ferlinz K, 1997, EUR J BIOCHEM, V243, P511, DOI 10.1111/j.1432-1033.1997.511_1a.x; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; Huang CS, 1997, J BIOL CHEM, V272, P27753, DOI 10.1074/jbc.272.44.27753; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; Marathe S, 1998, J BIOL CHEM, V273, P4081, DOI 10.1074/jbc.273.7.4081; MOLLBY R, 1973, BIOCHIM BIOPHYS ACTA, V321, P569, DOI 10.1016/0005-2744(73)90200-3; Newrzella D, 1996, J BIOL CHEM, V271, P32089, DOI 10.1074/jbc.271.50.32089; Nyberg L, 1996, BBA-LIPID LIPID MET, V1300, P42, DOI 10.1016/0005-2760(95)00245-6; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; OTNAESS AB, 1980, FEBS LETT, V114, P202, DOI 10.1016/0014-5793(80)81114-8; PONTING CP, 1994, PROTEIN SCI, V3, P359; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Schissel SL, 1998, J BIOL CHEM, V273, P2738, DOI 10.1074/jbc.273.5.2738; Schissel SL, 1996, J BIOL CHEM, V271, P18431, DOI 10.1074/jbc.271.31.18431; SCHUCHMAN EH, 1991, J BIOL CHEM, V266, P8531; Schuchman EH, 1997, GENET TEST, V1, P13, DOI 10.1089/gte.1997.1.13; SPENCE MW, 1989, J BIOL CHEM, V264, P5358; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; Sulston J., 1988, NEMATODE CAENORHABDI, P603; Testi R, 1996, TRENDS BIOCHEM SCI, V21, P468, DOI 10.1016/S0968-0004(96)10056-6; YEDGAR S, 1982, BIOCHEM J, V201, P597, DOI 10.1042/bj2010597	32	28	33	3	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14374	14379		10.1074/jbc.273.23.14374	http://dx.doi.org/10.1074/jbc.273.23.14374			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603947	hybrid, Green Accepted			2022-12-27	WOS:000074021500049
J	Perez-Vilar, J; Eckhardt, AE; DeLuca, A; Hill, RL				Perez-Vilar, J; Eckhardt, AE; DeLuca, A; Hill, RL			Porcine submaxillary mucin forms disulfide-linked multimers through its amino-terminal D-domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; VON-WILLEBRAND-FACTOR; VONWILLEBRAND-FACTOR; SUBCELLULAR-LOCALIZATION; INTESTINAL MUCIN; ESCHERICHIA-COLI; H+-ATPASES; CDNA; CLONING; CELLS	COS-7 cells expressing 1,360 residues from the amino terminus of porcine submaxillary mucin were used to determine whether this region, containing the D1, D2, and D3 domains, is involved in forming mucin multimers, Analysis of the proteins immunoprecipitated from the medium of transfected cells by reducing SDS-gel electrophoresis showed a single N-glycosylated protein with no indication of proteolytically processed forms. Without prior reduction, only two proteins, corresponding to monomeric and disulfide-linked trimeric species, were observed. The expressed protein devoid of N-linked oligosaccharides also formed trimers, but was secreted from cells in significantly less amounts than glycosylated trimers, Pulse-chase studies showed that the disulfide-linked trimers were assembled inside the cells no earlier than 30 min after protein synthesis commenced and after the intracellular precursors were N-glycosylated, Trimer formation was inhibited in cells treated with brefeldin A, monensin, chloroquine, or bafilolmycin A(1), although only brefeldin A prevented the secretion of the protein. These results suggest that trimerization takes place in compartments of the Golgi complex in which the vacuolar H+-ATPase maintains an acidic pH. Coexpression in the same cells of the amino-terminal region and the disulfide-rich carboxyl-terminal domain of the mucin showed that these structures were not disulfide-linked with one another, Cells expressing a DNA construct encoding a fusion protein between the amino-and carboxyl-terminal regions of the mucin secreted disulfide-linked dimeric and high molecular weight multimeric species of the recombinant mucin, The presence of monensin in the medium was without effect on dimerization, but inhibited the formation of disulfide-linked multimers, These studies suggest that disulfide-linked dimers of mucin are subsequently assembled into disulfide-linked multimers by the aminoterminal regions. They also suggest that the porcine mucin forms branched disulfide-linked multimers. This ability of the amino-terminal region of mucin to aid ire the assembly of multimers is consistent with its amino acid identities to the amino-terminal region of human von Willebrand factor, which also selves to form disulfide-linked multimers of this protein.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Hill, RL (corresponding author), Duke Univ, Med Ctr, Dept Biochem, POB 3711, Durham, NC 27710 USA.	hill@biochem.duke.edu			NIGMS NIH HHS [GM 25766] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025766, R37GM025766] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AZUMA H, 1993, J BIOL CHEM, V268, P2821; BHARGAVA AK, 1990, P NATL ACAD SCI USA, V87, P6798, DOI 10.1073/pnas.87.17.6798; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; Demaurex N, 1998, J BIOL CHEM, V273, P2044, DOI 10.1074/jbc.273.4.2044; DESCHUYTENEER M, 1988, J BIOL CHEM, V263, P2452; Desseyn JL, 1997, J BIOL CHEM, V272, P16873, DOI 10.1074/jbc.272.27.16873; DONG ZG, 1994, J BIOL CHEM, V269, P6753; ECKHARDT AE, 1991, J BIOL CHEM, V266, P9678; Eckhardt AE, 1997, J BIOL CHEM, V272, P33204, DOI 10.1074/jbc.272.52.33204; FRETTO LJ, 1986, J BIOL CHEM, V261, P5679; Gerken TA, 1997, J BIOL CHEM, V272, P9709; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUM JR, 1992, J BIOL CHEM, V267, P21375; GUM JR, 1994, J BIOL CHEM, V269, P2440; Joba W, 1997, J BIOL CHEM, V272, P1805, DOI 10.1074/jbc.272.3.1805; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KLOMP LWJ, 1995, BIOCHEM J, V308, P831, DOI 10.1042/bj3080831; LESUFFLEUR T, 1995, J BIOL CHEM, V270, P13665, DOI 10.1074/jbc.270.23.13665; Li DZ, 1998, J BIOL CHEM, V273, P6812, DOI 10.1074/jbc.273.12.6812; MAYADAS TN, 1992, P NATL ACAD SCI USA, V89, P3531, DOI 10.1073/pnas.89.8.3531; MEERZAMAN D, 1994, J BIOL CHEM, V269, P12932; MEINDL A, 1992, NAT GENET, V2, P139, DOI 10.1038/ng1092-139; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; ORCI L, 1986, J CELL BIOL, V103, P2273, DOI 10.1083/jcb.103.6.2273; PALOKANGAS H, 1994, J BIOL CHEM, V269, P17577; Perez-Vilar J, 1997, J BIOL CHEM, V272, P33410, DOI 10.1074/jbc.272.52.33410; Perez-Vilar J, 1998, J BIOL CHEM, V273, P6982, DOI 10.1074/jbc.273.12.6982; PerezVilar J, 1996, J BIOL CHEM, V271, P9845, DOI 10.1074/jbc.271.16.9845; PROBST JC, 1990, BIOCHEMISTRY-US, V29, P6240, DOI 10.1021/bi00478a018; ROTH J, 1994, P NATL ACAD SCI USA, V91, P8935, DOI 10.1073/pnas.91.19.8935; SADLER JE, 1991, J BIOL CHEM, V266, P22777; SHEEHAN JK, 1986, BIOCHEM J, V239, P147, DOI 10.1042/bj2390147; Sheehan JK, 1996, BIOCHEM J, V315, P1055, DOI 10.1042/bj3151055; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Toribara NW, 1997, J BIOL CHEM, V272, P16398, DOI 10.1074/jbc.272.26.16398; VOORBERG J, 1990, EMBO J, V9, P797, DOI 10.1002/j.1460-2075.1990.tb08176.x; VOORBERG J, 1991, J CELL BIOL, V113, P195, DOI 10.1083/jcb.113.1.195; WAGNER DD, 1990, ANNU REV CELL BIOL, V6, P217, DOI 10.1146/annurev.cellbio.6.1.217; WISE RJ, 1988, CELL, V52, P229, DOI 10.1016/0092-8674(88)90511-9; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378; XU GQ, 1992, J BIOL CHEM, V267, P5401; YILLA M, 1993, J BIOL CHEM, V268, P19092	43	63	66	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14442	14449		10.1074/jbc.273.23.14442	http://dx.doi.org/10.1074/jbc.273.23.14442			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603957	hybrid			2022-12-27	WOS:000074021500059
J	Behrmann, M; Koch, HG; Hengelage, T; Wieseler, B; Hoffschulte, HK; Muller, M				Behrmann, M; Koch, HG; Hengelage, T; Wieseler, B; Hoffschulte, HK; Muller, M			Requirements for the translocation of elongation-arrested, ribosome associated OmpA across the plasma membrane of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-RECOGNITION PARTICLE; PROTEIN EXPORT; ENDOPLASMIC-RETICULUM; SECA PROTEIN; PREPROTEIN TRANSLOCATION; SEQUENCE RECOGNITION; NASCENT POLYPEPTIDES; SECRETORY PROTEINS; DIFFERENT STEPS; BINDING	An oligodeoxynucleotide-dependent method to generate nascent polypeptide chains was adopted for use in a cell-free translation system prepared from Escherichia coli, In this way, NH2-terminal pOmpA fragments of distinct sizes were synthesized. Because most of these pOmpA fragments could be covalently linked to puromycin, precipitated with cetyltrimethylammonium bromide, and were enriched by sedimentation, they represent a population of elongation-arrested, ribosome-associated nascent chains. Translocation of these nascent pOmpA chains into inside-out membrane vesicles of E. coli required SecA and (depending on size) SecB. Whereas their translocation was strictly dependent on the H+-motive force of the vesicles, no indication for the involvement of the bacterial signal recognition particle was obtained. SecA and SecB, although required for translocation, did not mediate binding of the ribosome-associated pOmpA to membrane vesicles. However, SecA and SecB cotranslationally associated with nascent pOmpA, since they could be co-isolated with the ribosome-associated nascent chains and as such catalyzed translocation subsequent to the release of the ribosome, These results indicate that in E, coli, SecA also functionally interacts with preproteins before they are targeted to the translocase of the plasma membrane.	Univ Munich, Adolf Butenandt Inst Phys Biochem, D-80336 Munich, Germany	University of Munich	Muller, M (corresponding author), Univ Freiburg, Inst Biochem & Mol Biol, Hermann Herderstr 7, D-79104 Freiburg, Germany.	mumatthi@ruf.uni-freiburg.de		Wieseler, Beate/0000-0002-3519-754X				AKITA M, 1990, J BIOL CHEM, V265, P8164; ALTMAN E, 1990, J BIOL CHEM, V265, P18154; CABELLI RJ, 1991, J BIOL CHEM, V266, P24420; CHUN SY, 1994, J BACTERIOL, V176, P4197, DOI 10.1128/jb.176.14.4197-4203.1994; CONNOLLY T, 1986, J CELL BIOL, V103, P2253, DOI 10.1083/jcb.103.6.2253; deGier JWL, 1996, FEBS LETT, V399, P307, DOI 10.1016/S0014-5793(96)01354-3; Duong F, 1997, EMBO J, V16, P2756, DOI 10.1093/emboj/16.10.2756; Duong F, 1997, CELL, V91, P567, DOI 10.1016/S0092-8674(00)80444-4; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; ERNST F, 1994, J BIOL CHEM, V269, P12840; FREUDL R, 1985, EMBO J, V4, P3593, DOI 10.1002/j.1460-2075.1985.tb04122.x; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; HAEUPTLE MT, 1986, NUCLEIC ACIDS RES, V14, P1427, DOI 10.1093/nar/14.3.1427; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; Helde R, 1997, J BACTERIOL, V179, P4003, DOI 10.1128/jb.179.12.4003-4012.1997; HOFFSCHUTE HK, 1994, J BIOL CHEM, V269, P12833; JOSEFSSON LG, 1981, CELL, V25, P151, DOI 10.1016/0092-8674(81)90239-7; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; KLOSE M, 1988, J BIOL CHEM, V263, P13297; KREBS HO, 1989, EUR J BIOCHEM, V181, P323, DOI 10.1111/j.1432-1033.1989.tb14727.x; KUMAMOTO CA, 1993, J BACTERIOL, V175, P2184, DOI 10.1128/JB.175.8.2184-2188.1993; LAURING B, 1995, P NATL ACAD SCI USA, V92, P9435, DOI 10.1073/pnas.92.21.9435; LIEBKE HH, 1987, J BACTERIOL, V169, P1174, DOI 10.1128/jb.169.3.1174-1181.1987; LUIRINK J, 1992, NATURE, V359, P741, DOI 10.1038/359741a0; LUIRINK J, 1994, EMBO J, V13, P2289, DOI 10.1002/j.1460-2075.1994.tb06511.x; MACFARLANE J, 1995, EUR J BIOCHEM, V233, P766, DOI 10.1111/j.1432-1033.1995.766_3.x; MACINTYRE S, 1991, MOL GEN GENET, V227, P224; MULLER M, 1984, P NATL ACAD SCI-BIOL, V81, P7421, DOI 10.1073/pnas.81.23.7421; MULLER M, 1987, EMBO J, V6, P3855, DOI 10.1002/j.1460-2075.1987.tb02723.x; MULLER M, 1984, P NATL ACAD SCI-BIOL, V81, P7737, DOI 10.1073/pnas.81.24.7737; Muller M, 1994, Subcell Biochem, V22, P327; Nishiyama KI, 1996, CELL, V85, P71, DOI 10.1016/S0092-8674(00)81083-1; Patel S, 1996, EUR J BIOCHEM, V238, P760, DOI 10.1111/j.1432-1033.1996.0760w.x; PHILLIPS GJ, 1992, NATURE, V359, P744, DOI 10.1038/359744a0; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; Powers T, 1997, EMBO J, V16, P4880, DOI 10.1093/emboj/16.16.4880; Rajapandi T, 1996, MOL MICROBIOL, V20, P43, DOI 10.1111/j.1365-2958.1996.tb02487.x; RANDALL LL, 1995, TRENDS BIOCHEM SCI, V20, P65, DOI 10.1016/S0968-0004(00)88959-8; Randall LL, 1997, P NATL ACAD SCI USA, V94, P802, DOI 10.1073/pnas.94.3.802; Rapiejko PJ, 1997, CELL, V89, P703, DOI 10.1016/S0092-8674(00)80253-6; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; RICE CE, 1992, J HYDRAUL ENG-ASCE, V118, P1077, DOI 10.1061/(ASCE)0733-9429(1992)118:7(1077.2); SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; Seluanov A, 1997, J BIOL CHEM, V272, P2053; SWIDERSKY UE, 1990, EMBO J, V9, P1777, DOI 10.1002/j.1460-2075.1990.tb08302.x; THOME BM, 1991, MOL MICROBIOL, V5, P2815, DOI 10.1111/j.1365-2958.1991.tb01990.x; Uchida K, 1995, J BIOL CHEM, V270, P30862, DOI 10.1074/jbc.270.52.30862; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; Valent QA, 1997, MOL MICROBIOL, V25, P53, DOI 10.1046/j.1365-2958.1997.4431808.x; VALENT QA, 1995, EMBO J, V14, P5494, DOI 10.1002/j.1460-2075.1995.tb00236.x; WATANABE M, 1989, P NATL ACAD SCI USA, V86, P2728, DOI 10.1073/pnas.86.8.2728; WATANABE M, 1995, P NATL ACAD SCI USA, V92, P10133, DOI 10.1073/pnas.92.22.10133	52	43	45	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13898	13904		10.1074/jbc.273.22.13898	http://dx.doi.org/10.1074/jbc.273.22.13898			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593737	hybrid			2022-12-27	WOS:000073919100076
J	Chen, JJ; Hong, YH; Rustamzadeh, E; Baleja, JD; Androphy, EJ				Chen, JJ; Hong, YH; Rustamzadeh, E; Baleja, JD; Androphy, EJ			Identification of an alpha helical motif sufficient for association with papillomavirus E6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; CALCIUM-BINDING PROTEIN; OPEN READING FRAMES; P53 DNA-BINDING; HUMAN KERATINOCYTES; CERVICAL-CARCINOMA; TROPONIN-C; BOVINE PAPILLOMAVIRUS; MUTATIONAL ANALYSIS; SECONDARY STRUCTURE	We recently identified a cellular protein named E6BP or ERC-55 that binds cancer-related papillomavirus E6 proteins (Chen, J. J., Reid, C. E., Band, V., and Androphy, E. J. (1995) Science 269, 529-531), By construction of a series of deletion mutants, the region of E6BP that is necessary and sufficient for complex formation with human papillomavirus type 16 E6 has been mapped to a 25-amino acid domain. The corresponding peptide was synthesized and found by nuclear magnetic resonance spectroscopy to bind calcium and fold into a classical helix-loop-helix EF-hand conformation. Additional deletion mutagenesis showed that 13 amino acids that form the second alpha helix mediated E6 association. Alanine replacement mutagenesis indicated that amino acids of this helix were most important for E6 binding. Alignment of this alpha helical E6 binding peptide with the 18-amino acid E6 binding region of E6AP (Huibregtse, J. M., Scheffner, M., and Howley, P. M. (1993) Mol. Cell. Biol. 13, 4918-4927) and the first LD repeat of another E6-binding protein, paxillin (Tong, X. and Howley, P. M. (1997) J. Biol. Chem. 272, 33373-33376), revealed substantial similarities among these E6 binding domains, The extent of homology and the mutational data define the peptide as an E6 binding motif.	Tufts Univ New England Med Ctr, Dept Dermatol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA	Tufts Medical Center; Tufts University; Tufts University	Androphy, EJ (corresponding author), Tufts Univ New England Med Ctr, Dept Dermatol, Box 166,750 Washington St, Boston, MA 02111 USA.	eandroph@opal.tufts.edu		Androphy, Elliot/0000-0002-8104-0703	NATIONAL CANCER INSTITUTE [R01CA073558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI034918, U01AI038001] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA73558] Funding Source: Medline; NIAID NIH HHS [R29 AI34918, U01 AI38001] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDROPHY EJ, 1985, SCIENCE, V230, P442, DOI 10.1126/science.2996134; BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; BAND V, 1993, EMBO J, V12, P1847, DOI 10.1002/j.1460-2075.1993.tb05833.x; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; Blanchard H, 1997, NAT STRUCT BIOL, V4, P532, DOI 10.1038/nsb0797-532; BUTZ K, 1995, ONCOGENE, V10, P927; CAVANAGH J, 1996, PROTEIN NMR SPECTROS, P130; CHEN JJ, 1995, SCIENCE, V269, P529, DOI 10.1126/science.7624774; CHOO KB, 1993, VIROLOGY, V193, P1042; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; FINDLAY WA, 1993, BIOCHEMISTRY-US, V32, P3461, DOI 10.1021/bi00064a033; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; HUDSON JB, 1990, J VIROL, V64, P519, DOI 10.1128/JVI.64.2.519-526.1990; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; KAUR P, 1989, VIROLOGY, V173, P302, DOI 10.1016/0042-6822(89)90247-X; KAY LE, 1991, BIOCHEMISTRY-US, V30, P4323, DOI 10.1021/bi00231a031; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; LECHNER MS, 1994, J VIROL, V68, P4262, DOI 10.1128/JVI.68.7.4262-4273.1994; Li XQ, 1996, J VIROL, V70, P4509, DOI 10.1128/JVI.70.7.4509-4516.1996; Lin GD, 1997, NAT STRUCT BIOL, V4, P539, DOI 10.1038/nsb0797-539; Linse S, 1997, PROTEIN SCI, V6, P2385; LIU ZJ, 1994, VIROLOGY, V201, P388, DOI 10.1006/viro.1994.1306; MUNGER K, 1989, J VIROL, V63, P4417; NAKAGAWA S, 1995, VIROLOGY, V212, P535, DOI 10.1006/viro.1995.1511; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; PARK DJ, 1994, ONCOGENE, V9, P205; PIM D, 1994, ONCOGENE, V9, P1869; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHILLER JT, 1984, P NATL ACAD SCI-BIOL, V81, P7880, DOI 10.1073/pnas.81.24.7880; SCHILLER JT, 1986, CANC CELLS DNA TUMOR, V4, P571; SCHILLER JT, 1986, P NATL ACAD SCI USA, V4, P571; SCHLEGEL R, 1988, EMBO J, V7, P3181, DOI 10.1002/j.1460-2075.1988.tb03185.x; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SEDMAN SA, 1991, J VIROL, V65, P4860, DOI 10.1128/JVI.65.9.4860-4866.1991; SHAW GS, 1991, BIOCHEMISTRY-US, V30, P8339, DOI 10.1021/bi00098a009; Sherman L, 1996, J VIROL, V70, P3269, DOI 10.1128/JVI.70.5.3269-3279.1996; SLUPSKY CM, 1995, BIOCHEMISTRY-US, V34, P7365, DOI 10.1021/bi00022a009; SMOTKIN D, 1986, OBSTET GYNECOL, V68, P241; STEGER G, 1992, ARCH VIROL, V125, P355, DOI 10.1007/BF01309654; STOREY A, 1993, ONCOGENE, V8, P919; THOMAS M, 1995, ONCOGENE, V10, P261; Tong X, 1998, J VIROL, V72, P476, DOI 10.1128/JVI.72.1.476-482.1998; Tong X, 1997, J BIOL CHEM, V272, P33373, DOI 10.1074/jbc.272.52.33373; TONG X, 1997, MOL CELL BIOL, V272, P33373; Tong XA, 1997, P NATL ACAD SCI USA, V94, P4412, DOI 10.1073/pnas.94.9.4412; Ullman CG, 1996, BIOCHEM J, V319, P229, DOI 10.1042/bj3190229; Wagner G, 1997, NAT STRUCT BIOL, V4, P841; WATANABE S, 1989, J VIROL, V63, P965, DOI 10.1128/JVI.63.2.965-969.1989; WEIS K, 1994, J BIOL CHEM, V269, P19142; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WISHART DS, 1994, COMPUT APPL BIOSCI, V10, P121; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; Wojcik J, 1997, BIOCHEMISTRY-US, V36, P680, DOI 10.1021/bi961821c; Wuthrich K., 1986, NMR PROTEINS NUCL AC, P130; XU C, 1995, P NATL ACAD SCI USA, V92, P7829, DOI 10.1073/pnas.92.17.7829	63	81	86	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13537	13544		10.1074/jbc.273.22.13537	http://dx.doi.org/10.1074/jbc.273.22.13537			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593689	hybrid			2022-12-27	WOS:000073919100028
J	Defechereux, P; Baudoux-Tebache, L; Merville, MP; Rentier, B; Bours, V; Piette, J				Defechereux, P; Baudoux-Tebache, L; Merville, MP; Rentier, B; Bours, V; Piette, J			Activation of the human immunodeficiency virus long terminal repeat by varicella-zoster virus IE4 protein requires nuclear factor-kappa B and involves both the amino-terminal and the carboxyl-terminal cysteine-rich region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY PROTEIN; TATA-BINDING PROTEIN; TRANSCRIPTION FACTOR; GENE-EXPRESSION; HIV-1 LTR; IN-VIVO; TYPE-1; TRANSACTIVATION; DNA; INDUCTION	Varicella zoster virus open reading frame 4-encoded protein (IE4) possesses transactivating properties for varicella-zoster virus genes as well as for those of heterologous viruses such as the human immunodeficiency virus type 1 (HIV-1). Mechanisms of HIV-1 LTR (long terminal repeat) transactivation were investigated in HeLa cells transiently transfected with an IE4 expression plasmid and a CAT reporter gene under the control of the HIV-1 LTR, These results demonstrated that IE4-mediated transactivation of the HIV-1 LTR in HeLa cells required transcription factor kappa B (NF-kappa B). Using the gel retardation assay, it was shown that transfection of the IE4 expression vector in HeLa cells was not associated with induction of NF-kappa B under the p50.p65 heterodimeric form and that no direct binding of IE4 to the kappa B sites could be detected. Both Western blot and immunofluorescence analyses suggested that the ability of IE4 to activate transcription through kappa B motives was not connected with its capacity to override the inhibitory activities of I kappa B-alpha or p105. Finally, in vitro protein-protein interactions involving IE4 and basal transcription factors such as TATA binding protein and transcription factor IIB were carried out. A direct interaction between IE4 and TATA-binding protein or transcription factor IIB components of the basal complex of transcription was evidenced, as well as binding to the p50 and p65 NF-kappa B subunits, Mutagenesis analysis of IE4 indicated that the COOH-terminal cysteine-rich and arginine-rich regions (residues 82-182) were critical for transactivation, whereas the first 81 amino acids appeared dispensable. Moreover, the arginine-rich region is required for the in vitro binding activity, whereas the COOH-terminal end did not appear essential.	Univ Liege, Inst Pathol B23, Lab Fundamental Virol & Immunol, B-4000 Liege, Belgium; Univ Liege, Inst Pathol B23, Lab Med Chem & Med Oncol, B-4000 Liege, Belgium	University of Liege; University of Liege	Piette, J (corresponding author), Univ Liege, Inst Pathol B23, Lab Fundamental Virol & Immunol, B-4000 Liege, Belgium.	jpiette@ulg.ac.be						ALBRECHT MA, 1989, J VIROL, V63, P1861, DOI 10.1128/JVI.63.5.1861-1868.1989; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAUDOUX L, 1995, NUCLEIC ACIDS RES, V23, P1341, DOI 10.1093/nar/23.8.1341; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DEBRUS S, 1995, J VIROL, V69, P3240, DOI 10.1128/JVI.69.5.3240-3245.1995; Defechereux P, 1996, J GEN VIROL, V77, P1505, DOI 10.1099/0022-1317-77-7-1505; Defechereux P, 1997, J VIROL, V71, P7073, DOI 10.1128/JVI.71.9.7073-7079.1997; DEFECHEREUX P, 1993, J VIROL, V67, P4379, DOI 10.1128/JVI.67.7.4379-4385.1993; ELLENBERGER T, 1994, CURR OPIN STRUC BIOL, V4, P12, DOI 10.1016/S0959-440X(94)90054-X; FORGHANI B, 1990, VIRUS RES, V16, P195, DOI 10.1016/0168-1702(90)90023-5; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; GAYNOR R, 1992, AIDS, V6, P347, DOI 10.1097/00002030-199204000-00001; GENDELMAN HE, 1986, P NATL ACAD SCI USA, V83, P9759, DOI 10.1073/pnas.83.24.9759; GHAZAL P, 1991, J VIROL, V65, P6735, DOI 10.1128/JVI.65.12.6735-6742.1991; GIMBLE JM, 1988, J VIROL, V62, P4104, DOI 10.1128/JVI.62.11.4104-4112.1988; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; HAY J, 1994, SEMIN VIROL, V5, P241, DOI 10.1006/smvy.1994.1026; HIBBARD MK, 1995, J VIROL, V69, P4656, DOI 10.1128/JVI.69.8.4656-4667.1995; HONESS RW, 1974, J VIROL, V14, P8, DOI 10.1128/JVI.14.1.8-19.1974; INCHAUSPE G, 1989, VIROLOGY, V173, P710, DOI 10.1016/0042-6822(89)90584-9; INCHAUSPE G, 1989, VIROLOGY, V173, P700, DOI 10.1016/0042-6822(89)90583-7; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; KANNO T, 1994, MOL CELL BIOL, V14, P6443, DOI 10.1128/MCB.14.10.6443; KANNO T, 1995, J BIOL CHEM, V270, P11745, DOI 10.1074/jbc.270.20.11745; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; Kim SY, 1996, J GEN VIROL, V77, P83, DOI 10.1099/0022-1317-77-1-83; KRETZSCHMAR M, 1992, GENE DEV, V6, P761, DOI 10.1101/gad.6.5.761; LAURENCE J, 1990, J INFECT DIS, V162, P338, DOI 10.1093/infdis/162.2.338; MARGOLIS DM, 1992, VIROLOGY, V186, P788, DOI 10.1016/0042-6822(92)90048-T; MARKOVITZ DM, 1989, VIROLOGY, V173, P750, DOI 10.1016/0042-6822(89)90591-6; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; Mears WE, 1996, J VIROL, V70, P7445, DOI 10.1128/JVI.70.11.7445-7453.1996; MEIER JL, 1994, MOL CELL BIOL, V14, P6896, DOI 10.1128/MCB.14.10.6896; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; MORIUCHI H, 1993, J VIROL, V67, P4290, DOI 10.1128/JVI.67.7.4290-4295.1993; MORIUCHI H, 1993, J VIROL, V67, P2739, DOI 10.1128/JVI.67.5.2739-2746.1993; MORIUCHI M, 1995, VIROLOGY, V208, P376, DOI 10.1006/viro.1995.1164; MOSCA JD, 1987, P NATL ACAD SCI USA, V84, P7408, DOI 10.1073/pnas.84.21.7408; MUNOZ E, 1994, J VIROL, V68, P8035; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NAGPAL S, 1991, J VIROL, V65, P5289, DOI 10.1128/JVI.65.10.5289-5296.1991; OSTROVE JM, 1987, J VIROL, V61, P3726, DOI 10.1128/JVI.61.12.3726-3732.1987; PAINE E, 1995, J VIROL, V69, P4572, DOI 10.1128/JVI.69.7.4572-4576.1995; Parker SF, 1997, J VIROL, V71, P2004, DOI 10.1128/JVI.71.3.2004-2012.1997; PASCLA E, 1991, GENE DEV, V5, P155; PERERA LP, 1994, J VIROL, V68, P2468, DOI 10.1128/JVI.68.4.2468-2477.1994; PERERA LP, 1992, J VIROL, V66, P5298, DOI 10.1128/JVI.66.9.5298-5304.1992; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PIERCE JW, 1988, P NATL ACAD SCI USA, V85, P1482, DOI 10.1073/pnas.85.5.1482; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RANDO RF, 1987, ONCOGENE, V1, P13; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RIMSKY L, 1988, NATURE, V335, P738, DOI 10.1038/335738a0; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; Schafer SL, 1996, J VIROL, V70, P6937, DOI 10.1128/JVI.70.10.6937-6946.1996; SCHMITZ ML, 1995, J BIOL CHEM, V270, P7219, DOI 10.1074/jbc.270.13.7219; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Tsukada J, 1997, BLOOD, V90, P3142, DOI 10.1182/blood.V90.8.3142; VLACH J, 1992, J VIROL, V66, P3616, DOI 10.1128/JVI.66.6.3616-3623.1992	71	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13636	13644		10.1074/jbc.273.22.13636	http://dx.doi.org/10.1074/jbc.273.22.13636			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593702	Green Submitted			2022-12-27	WOS:000073919100041
J	Dewilde, S; Winnepenninckx, B; Arndt, MHL; Nascimento, DG; Santoro, MM; Knight, M; Miller, AN; Kerlavage, AR; Geoghagen, N; Van Marck, E; Liu, LX; Weber, RE; Moens, L				Dewilde, S; Winnepenninckx, B; Arndt, MHL; Nascimento, DG; Santoro, MM; Knight, M; Miller, AN; Kerlavage, AR; Geoghagen, N; Van Marck, E; Liu, LX; Weber, RE; Moens, L			Characterization of the myoglobin and its coding gene of the mollusc Biomphalaria glabrata	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONVERTEBRATE GLOBIN GENES; APLYSIA-LIMACINA MYOGLOBIN; NUCLEAR-MAGNETIC-RESONANCE; SITE-DIRECTED MUTAGENESIS; CARBON-MONOXIDE BINDING; SPERM WHALE MYOGLOBIN; RAY CRYSTAL-STRUCTURE; CRYSTALLOGRAPHIC ANALYSIS; ASCARIS HEMOGLOBIN; PHYLOGENETIC ANALYSIS	A cDNA clone isolated from a Biomphalaria glabrata (Mollusca, Gastropoda) neural cDNA library was identified as encoding a myoglobin-like protein of 148 amino acids with a single domain and a calculated mass of 16,049.29. Alignment with globin sequences with known tertiary structure confirms its overall globin nature. The expressed myoglobin was identified in the radular muscle and isolated. Oxygen equilibrium measurements on the protein reveal a high oxygen affinity. Val-B10 and Gln-E7, important residues for the determination of the oxygen affinity, are strikingly different from the standard molluscan pattern (Conti, E., Moser, C., Rizzi, M., Mattevi, A., Lionetti, C., Coda, A., Ascenzi, P., Brunori, M., Bolognesi, M. (1993) J. Mol. Biol. 233, 498-508). The single gene encoding the globin chain is interrupted by three introns at positions A3.2, B12.2, and G7.0. Comparison with other nonvertebrate globin genes reveals on the one hand conservation (B12.2 and G7.0) and on the other hand variability of the insertion positions (A3.2), The Biomphalaria myoglobin sequence was used together with all other molluscan globin sequences available to assess the origin and phylogeny of the phylum, Our results confirm the doubts raised about monophyletic origin of the Mollusca, which was first observed using SSU rRNA as a molecular marker.	Univ Antwerp, Dept Biochem, B-2610 Antwerp, Belgium; Univ Antwerp, Dept Med, B-2610 Antwerp, Belgium; Koninklijk Belg Inst Natuurwetenschappen, B-1000 Brussels, Belgium; Univ Fed Minas Gerais, Inst Ciencias Biol, Belo Horizonte, MG, Brazil; Biomed Res Inst, Rockville, MD 20852 USA; Inst Genome Res, Rockville, MD 20850 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Harvard Thorndike Lab, Boston, MA 02215 USA; Aarhus Univ, Dept Zoophysiol, DK-8000 Aarhus C, Denmark	University of Antwerp; University of Antwerp; Universidade Federal de Minas Gerais; J. Craig Venter Institute; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Aarhus University	Moens, L (corresponding author), Univ Antwerp, Dept Biochem, Univ Plein 1, B-2610 Antwerp, Belgium.	lmoens@uia.ua.ac.be		Kerlavage, Anthony/0000-0002-3954-9653				ADOUTTE A, 1993, COMP MOL NEUROBIOLOG, P1; AFONSO AMM, 1980, COMP BIOCHEM PHYS B, V67, P143, DOI 10.1016/0305-0491(80)90283-7; ALMEIDA AP, 1974, BIOCHIM BIOPHYS ACTA, V371, P140, DOI 10.1016/0005-2795(74)90162-7; AMICONI G, 1972, EUR J BIOCHEM, V31, P52, DOI 10.1111/j.1432-1033.1972.tb02499.x; APPLEBY CA, 1983, J BIOL CHEM, V258, P2254; ARNDT MHL, 1996, 11 INT C SUPR ORG FU; Bergstrom J., 1991, P25; BLAXTER ML, 1994, MOL BIOCHEM PARASIT, V68, P1, DOI 10.1016/0166-6851(94)00127-8; BLAXTER ML, 1994, J BIOL CHEM, V269, P30181; BOLOGNESI M, 1989, J MOL BIOL, V205, P529, DOI 10.1016/0022-2836(89)90224-6; BOLOGNESI M, 1990, J MOL BIOL, V213, P621, DOI 10.1016/S0022-2836(05)80249-9; BOWRING SA, 1993, SCIENCE, V261, P1293, DOI 10.1126/science.11539488; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CARVER TE, 1992, J BIOL CHEM, V267, P14443; CHEN GC, 1977, ANAL LETT, V10, P1195, DOI 10.1080/00032717708067855; CONTI E, 1993, J MOL BIOL, V233, P498, DOI 10.1006/jmbi.1993.1527; DEBAERE I, 1994, P NATL ACAD SCI USA, V91, P1594, DOI 10.1073/pnas.91.4.1594; DELEAGE G, 1995, DICROPROT VERSION 2; Dewilde S, 1996, J BIOL CHEM, V271, P19865, DOI 10.1074/jbc.271.33.19865; DIIORIO EE, 1985, J BIOL CHEM, V260, P2160; DIXON B, 1992, J MOL EVOL, V35, P131, DOI 10.1007/BF00183224; EERNISSE DJ, 1992, SYST BIOL, V41, P305, DOI 10.1093/sysbio/41.3.305; EGEBERG KD, 1990, J BIOL CHEM, V265, P11788; ERWIN DH, 1991, TRENDS ECOL EVOL, V6, P131, DOI 10.1016/0169-5347(91)90092-C; FIGUEIREDO EA, 1973, COMP BIOCHEM PHYSIOL, V44, P481, DOI 10.1016/0305-0491(73)90022-9; GAMBACURTA A, 1996, 11 INT C SUPR ORG FU; Ghiselin M.T., 1988, Oxford Surveys in Evolutionary Biology, V5, P66; GIBSON QH, 1965, PROC R SOC SER B-BIO, V163, P206, DOI 10.1098/rspb.1965.0067; GILBERT W, 1993, GENE, V135, P137, DOI 10.1016/0378-1119(93)90058-B; GILBERT W, 1987, COLD SPRING HARB SYM, V52, P901, DOI 10.1101/SQB.1987.052.01.098; GOODMAN M, 1988, J MOL EVOL, V27, P236, DOI 10.1007/BF02100080; GRAHAM JB, 1995, NATURE, V375, P117, DOI 10.1038/375117a0; Hardison RC, 1996, P NATL ACAD SCI USA, V93, P5675, DOI 10.1073/pnas.93.12.5675; HILLIS DM, 1991, Q REV BIOL, V66, P411, DOI 10.1086/417338; HILLIS DM, 1993, SYST BIOL, V42, P182, DOI 10.2307/2992540; Jellie AM, 1996, J MOL EVOL, V42, P641, DOI 10.1007/BF02338797; JHIANG SM, 1989, J BIOL CHEM, V264, P19003; JUKES T H, 1969, P21; KAO WY, 1994, J MOL EVOL, V38, P241; KAPP OH, 1995, PROTEIN SCI, V4, P2179, DOI 10.1002/pro.5560041024; KELLER EB, 1984, P NATL ACAD SCI-BIOL, V81, P7417, DOI 10.1073/pnas.81.23.7417; KLEINSCHMIDT T, 1997, IN PRESS BIOCH BIOPH; Kloek AP, 1996, J MOL EVOL, V43, P101, DOI 10.1007/BF02337354; KONNO T, 1975, ANAL BIOCHEM, V67, P226, DOI 10.1016/0003-2697(75)90290-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESH A, 1980, J MOL BIOL, V136, P225; LEWIN R, 1984, SCIENCE, V226, P328, DOI 10.1126/science.226.4672.328; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; MATSUOKA A, 1996, J COMP PHYSIOL B, V115, P483; Moens L, 1996, MOL BIOL EVOL, V13, P324, DOI 10.1093/oxfordjournals.molbev.a025592; MOENS L, 1992, FEBS LETT, V312, P105, DOI 10.1016/0014-5793(92)80915-4; NAGAI K, 1987, NATURE, V329, P858, DOI 10.1038/329858a0; NAITO Y, 1991, P NATL ACAD SCI USA, V88, P6672, DOI 10.1073/pnas.88.15.6672; NASSIF NT, 1994, J MOL EVOL, V39, P47, DOI 10.1007/BF00178248; Noren M, 1997, NATURE, V390, P31, DOI 10.1038/36242; PHILIPPE H, 1994, DEVELOPMENT, P15; Piro MC, 1996, J MOL EVOL, V43, P594; QIN J, 1992, J MOL BIOL, V224, P891, DOI 10.1016/0022-2836(92)90456-T; Rashid AK, 1997, J BIOL CHEM, V272, P2992, DOI 10.1074/jbc.272.5.3000; Rizzi M, 1996, J MOL BIOL, V258, P1, DOI 10.1006/jmbi.1996.0228; RIZZI M, 1994, J MOL BIOL, V244, P86, DOI 10.1006/jmbi.1994.1706; ROHLFS RJ, 1990, BIOCHEMISTRY-US, V34, P14658; ROSSIFANELLI A, 1958, ARCH BIOCHEM BIOPHYS, V77, P478, DOI 10.1016/0003-9861(58)90094-8; ROYER WE, 1994, J MOL BIOL, V235, P657, DOI 10.1006/jmbi.1994.1019; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sambrook J., 2002, MOL CLONING LAB MANU; SCHREIBER JK, 1984, COMP BIOCHEM PHYS A, V78, P129, DOI 10.1016/0300-9629(84)90104-X; SHERMAN DR, 1992, P NATL ACAD SCI USA, V89, P11696, DOI 10.1073/pnas.89.24.11696; SHIKAMA K, 1982, BIOCHIM BIOPHYS ACTA, V701, P138, DOI 10.1016/0167-4838(82)90322-3; SPRINGER BA, 1989, J BIOL CHEM, V264, P3057; STOLTZFUS A, 1994, SCIENCE, V265, P202, DOI 10.1126/science.8023140; SUZUKI T, 1989, BIOCHIM BIOPHYS ACTA, V999, P254, DOI 10.1016/0167-4838(89)90006-X; SWOFFORD DL, 1993, PAUP PHYLOGENETIC AN; TITCHEN DA, 1991, BIOCHIM BIOPHYS ACTA, V1089, P61, DOI 10.1016/0167-4781(91)90085-Z; Valentine J.W., 1991, P11; VANDEPEER Y, 1993, COMPUT APPL BIOSCI, V9, P177; VandePeer Y, 1996, NUCLEIC ACIDS RES, V24, P86, DOI 10.1093/nar/24.1.86; VINOGRADOV SN, 1993, COMP BIOCHEM PHYS B, V106, P1, DOI 10.1016/0305-0491(93)90002-M; VINOGRADOV SN, 1992, COMP BIOCHEM PHYS B, V103, P759, DOI 10.1016/0305-0491(92)90193-U; WEBER RE, 1987, J COMP PHYSIOL B, V157, P145, DOI 10.1007/BF00692358; WEBER RE, 1981, NATURE, V292, P386, DOI 10.1038/292386a0; WEBER RE, 1992, J APPL PHYSIOL, V72, P1611, DOI 10.1152/jappl.1992.72.4.1611; WEBER RE, 1980, AM ZOOL, V20, P79; Winnepenninckx B, 1996, MOL BIOL EVOL, V13, P1306, DOI 10.1093/oxfordjournals.molbev.a025577; WINNEPENNINCKX B, 1993, TRENDS GENET, V9, P409; WITTENBERG BA, 1965, ARCH BIOCHEM BIOPHYS, V111, P576, DOI 10.1016/0003-9861(65)90237-7; WOESE CR, 1991, EVOLUTION AT THE MOLECULAR LEVEL, P1; YAMAMOTO Y, 1992, J MOL BIOL, V228, P343, DOI 10.1016/0022-2836(92)90823-3; YANG J, 1995, P NATL ACAD SCI USA, V92, P4224, DOI 10.1073/pnas.92.10.4224; ZHAO XF, 1995, J BIOL CHEM, V270, P20763, DOI 10.1074/jbc.270.35.20763	91	31	33	0	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13583	13592		10.1074/jbc.273.22.13583	http://dx.doi.org/10.1074/jbc.273.22.13583			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593695	hybrid			2022-12-27	WOS:000073919100034
J	Kayali, AG; Eichhorn, J; Haruta, T; Morris, AJ; Nelson, JG; Vollenweider, P; Olefsky, JM; Webster, NJG				Kayali, AG; Eichhorn, J; Haruta, T; Morris, AJ; Nelson, JG; Vollenweider, P; Olefsky, JM; Webster, NJG			Association of the insulin receptor with phospholipase C-gamma (PLC gamma) in 3T3-L1 adipocytes suggests a role for PLC gamma in metabolic signaling by insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHATIDYLINOSITOL 3-KINASE ACTIVATION; STIMULATED GLUCOSE-TRANSPORT; GROWTH-FACTOR RECEPTOR; RAT SKELETAL-MUSCLE; GLUT4 TRANSLOCATION; PHORBOL ESTER; ARACHIDONIC-ACID; ADIPOSE-CELLS; BINDING-SITES	Phospholipase C-gamma (PLC?I) is the isozyme of PLC phosphorylated by multiple tyrosine kinases including epidermal growth factor, platelet-derived growth factor, nerve growth factor receptors, and nonreceptor tyrosine kinases, In this paper, we present evidence for the association of the insulin receptor (LR) with PLC gamma, Precipitation of the IR with glutathione S-transferase fusion proteins derived from PLC gamma and coimmunoprecipitation of the IR and PLC gamma were observed in 3T3-L1 adipocytes. To determine the functional significance of the interaction of PLC gamma and the IR, we used a specific inhibitor of PLC, U73122, or microinjection of SH2 domain glutathione S-transferase fusion proteins derived from PLC gamma to block insulin-stimulated GLUT4 translocation, We demonstrate inhibition of a-deoxyglucose up; take in isolated primary rat adipocytes and 3T3-L1 adipocytes pretreated with U73122. Antilipolytic effect of insulin in 3T3-L1 adipocytes is unaffected by U73122. U73122 selectively inhibits mitogen-activated protein kinase, leaving the Akt and p70 S6 kinase pathways unperturbed. We conclude that PLC gamma is an active participant in metabolic and perhaps mitogenic signaling by the insulin receptor in 3T3-L1 adipocytes.	Univ Calif San Diego, Dept Med 0673, Whittier Diabet Program, La Jolla, CA 92093 USA; Med Ctr, Dept Vet Affairs, Med Res Serv, San Diego, CA 92161 USA	University of California System; University of California San Diego	Webster, NJG (corresponding author), Univ Calif San Diego, Dept Med 0673, Whittier Diabet Program, 9500 Gilman Dr, La Jolla, CA 92093 USA.		Morris, Andrew/B-7869-2010; Webster, Nick/AAI-8410-2021					ABEL ED, 1995, CURR OPIN ENDOCRINOL, V2, P313; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; AVIGNON A, 1995, BIOCHEM J, V308, P181, DOI 10.1042/bj3080181; Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BLEASDALE JE, 1989, ADV PROSTAG THROMB L, V19, P590; CAIN CC, 1992, J BIOL CHEM, V267, P11681; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CHERQUI G, 1987, ENDOCRINOLOGY, V120, P2192, DOI 10.1210/endo-120-5-2192; CHRISTENSEN RL, 1987, INT J BIOCHEM, V19, P259; CIARALDI TP, 1989, DIABETES, V38, P951, DOI 10.2337/diabetes.38.8.951; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; Farese RV, 1996, P SOC EXP BIOL MED, V213, P1, DOI 10.3181/00379727-213-44030; FARESE RV, 1992, CELL SIGNAL, V4, P133, DOI 10.1016/0898-6568(92)90077-L; FARESE RV, 1992, BIOCHEM J, V288, P319, DOI 10.1042/bj2880319; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frevert E, 1997, DIABETES, V46, P3; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; Frevert EU, 1996, BIOCHEM J, V316, P865, DOI 10.1042/bj3160865; GIBBS EM, 1986, J BIOL CHEM, V261, P6597; HALSTEAD J, 1995, J BIOL CHEM, V270, P13600, DOI 10.1074/jbc.270.23.13600; HARDY RW, 1995, ENDOCRINOLOGY, V136, P431, DOI 10.1210/en.136.2.431; HARUTA T, 1995, J BIOL CHEM, V270, P27991; HellerHarrison RA, 1996, J BIOL CHEM, V271, P10200, DOI 10.1074/jbc.271.17.10200; HENRIKSEN EJ, 1989, J BIOL CHEM, V264, P21536; Hwang SC, 1996, J BIOL CHEM, V271, P18342, DOI 10.1074/jbc.271.31.18342; ISAKOFF SJ, 1995, P NATL ACAD SCI USA, V92, P10247, DOI 10.1073/pnas.92.22.10247; ISHIZUKA T, 1991, DIABETES, V40, P1274, DOI 10.2337/diabetes.40.10.1274; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; Ji QS, 1997, P NATL ACAD SCI USA, V94, P2999, DOI 10.1073/pnas.94.7.2999; KAMOHARA S, 1995, P NATL ACAD SCI USA, V92, P1077, DOI 10.1073/pnas.92.4.1077; Karnam P, 1997, J BIOL CHEM, V272, P6136, DOI 10.1074/jbc.272.10.6136; Katagiri H, 1996, J BIOL CHEM, V271, P16987, DOI 10.1074/jbc.271.29.16987; Kearns BG, 1997, NATURE, V387, P101, DOI 10.1038/387101a0; KELLERER M, 1991, BIOCHEM BIOPH RES CO, V181, P566, DOI 10.1016/0006-291X(91)91227-4; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; LISCOVITCH M, 1992, TRENDS BIOCHEM SCI, V17, P393, DOI 10.1016/0968-0004(92)90007-V; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; MARTIN KJ, 1994, AM J PHYSIOL, V266, pF254, DOI 10.1152/ajprenal.1994.266.2.F254; Martin S, 1996, J CELL BIOL, V134, P625, DOI 10.1083/jcb.134.3.625; MCBRIDE K, 1991, P NATL ACAD SCI USA, V88, P7111, DOI 10.1073/pnas.88.16.7111; MCGOWAN MW, 1983, CLIN CHEM, V29, P538; MIDDLEMAS DS, 1994, J BIOL CHEM, V269, P5458; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; Nave BT, 1996, BIOCHEM J, V318, P55, DOI 10.1042/bj3180055; NISHIBE S, 1990, P NATL ACAD SCI USA, V87, P424, DOI 10.1073/pnas.87.1.424; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NOH DY, 1995, BBA-REV CANCER, V1242, P99, DOI 10.1016/0304-419X(95)00006-0; OKADA T, 1994, J BIOL CHEM, V269, P3568; Olson AL, 1997, MOL CELL BIOL, V17, P2425, DOI 10.1128/MCB.17.5.2425; ONeill TJ, 1996, J BIOL CHEM, V271, P22506, DOI 10.1074/jbc.271.37.22506; PILLAY TS, 1992, FEBS LETT, V308, P38, DOI 10.1016/0014-5793(92)81045-N; Ponting CP, 1996, PROTEIN SCI, V5, P162; QUON MJ, 1994, J BIOL CHEM, V269, P27920; QUON MJ, 1995, MOL CELL BIOL, V15, P5403; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Ricort JM, 1996, EUR J BIOCHEM, V239, P17, DOI 10.1111/j.1432-1033.1996.0017u.x; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SOWELL MO, 1991, AM J PHYSIOL, V260, pE247, DOI 10.1152/ajpendo.1991.260.2.E247; Standaert ML, 1996, BIOCHEM J, V313, P1039, DOI 10.1042/bj3131039; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; STAUBS PA, 1994, J BIOL CHEM, V269, P27186; STEPHENS JM, 1995, ENDOCR REV, V16, P529, DOI 10.1210/er.16.4.529; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Summers SA, 1997, BIOCHEM SOC T, V25, P981, DOI 10.1042/bst0250981; TANTI JF, 1989, BIOCHEM J, V258, P141, DOI 10.1042/bj2580141; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VANDEWERVE G, 1987, DIABETES, V36, P310, DOI 10.2337/diabetes.36.3.310; VanEppsFung M, 1997, ENDOCRINOLOGY, V138, P5170, DOI 10.1210/en.138.12.5170; VANOBBERGHEN E, 1981, P NATL ACAD SCI-BIOL, V78, P1052; Volchuk A, 1996, MOL BIOL CELL, V7, P1075, DOI 10.1091/mbc.7.7.1075; VOLCHUK A, 1995, J BIOL CHEM, V270, P8233, DOI 10.1074/jbc.270.14.8233; WAHL MI, 1992, J BIOL CHEM, V267, P10447; WANG XD, 1994, BBA-MOL CELL RES, V1223, P101, DOI 10.1016/0167-4889(94)90078-7; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; WHITE MF, 1994, J BIOL CHEM, V269, P1; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YANG LJ, 1994, J BIOL CHEM, V269, P7156; Yeo EJ, 1997, BBA-MOL CELL RES, V1356, P308, DOI 10.1016/S0167-4889(97)00006-2; ZHENG LX, 1995, ENDOCRINOLOGY, V136, P1079, DOI 10.1210/en.136.3.1079	89	64	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13808	13818		10.1074/jbc.273.22.13808	http://dx.doi.org/10.1074/jbc.273.22.13808			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593725	hybrid			2022-12-27	WOS:000073919100064
J	Leveque, C; Pupier, S; Marqueze, B; Geslin, L; Kataoka, M; Takahashi, M; De Waard, M; Seagar, M				Leveque, C; Pupier, S; Marqueze, B; Geslin, L; Kataoka, M; Takahashi, M; De Waard, M; Seagar, M			Interaction of cysteine string proteins with the alpha(1)A subunit of the P/Q-type calcium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ CHANNELS; N-TYPE; DROSOPHILA; EXPRESSION; BRAIN; RAT; CHAPERONES; VESICLES; SYNTAXIN; MUTANTS	Cysteine string proteins (Csps) are J-domain chaperone proteins anchored at the surface of synaptic vesicles. Csps are involved in neurotransmitter release and may modulate presynaptic calcium channel activity, although the molecular mechanisms are unknown. Interactions between Csps, proteins of the synaptic core (SNARE) complex, and P/Q-type calcium channels were therefore explored. Co-immunoprecipitation suggested that Csps occur in complexes containing synaptobrevin (VAMP), but not syntaxin 1, SNAP-25, nor P/Q-type calcium channels labeled with I-125-omega-conotoxin MVIIC. However binding experiments with S-35-labeled Csp1 demonstrated an interaction (apparent K-D = 700 nM at pH 7.4 and 4 degrees C) with a fusion protein containing a segment of the cytoplasmic loop linking homologous domains II-III of the cu,A calcium channel subunit (BI isoform, residues 780-969), Binding was specific as it was displaced by unlabeled Csp1, and no interactions were detected with fusion proteins containing other calcium channel domains, VAMP, or syntaxin 1A. A Csp binding site on the P/Q-type calcium channel is thus located within the 200 residue synaptic protein interaction site that can also bind syntaxin I, SNAP-25, and synaptotagmin I. Csp may act as a molecular chaperone to direct assembly or disassembly of exocytotic complexes at the calcium channel.	Fac Med Secteur Nord, INSERM U464, Inst Jean Roche, F-13916 Marseille 20, France; Mitsubishi Kasei Inst Life Sci, Machida, Tokyo 194, Japan	Institut National de la Sante et de la Recherche Medicale (Inserm)	Seagar, M (corresponding author), Fac Med Secteur Nord, INSERM U464, Inst Jean Roche, Bd Pierre Dramard, F-13916 Marseille 20, France.		De Waard, Michel/G-7406-2014; Marquèze-Pouey, Béatrice/P-3800-2017; leveque, christian/GVU-3567-2022	De Waard, Michel/0000-0002-2782-9615; Marquèze-Pouey, Béatrice/0000-0002-8053-2685; leveque, christian/0000-0003-2583-2148				BAJJALIEH SM, 1995, J BIOL CHEM, V270, P1971, DOI 10.1074/jbc.270.5.1971; BEZPROZVANNY I, 1995, NATURE, V378, P623, DOI 10.1038/378623a0; BOHEN SP, 1995, SCIENCE, V268, P1303, DOI 10.1126/science.7761850; Braun JEA, 1996, J BIOL CHEM, V271, P25989, DOI 10.1074/jbc.271.42.25989; Chamberlain LH, 1996, J BIOL CHEM, V271, P19514, DOI 10.1074/jbc.271.32.19514; Chamberlain LH, 1996, J BIOL CHEM, V271, P7320, DOI 10.1074/jbc.271.13.7320; Chamberlain LH, 1997, J BIOL CHEM, V272, P31420, DOI 10.1074/jbc.272.50.31420; Charvin N, 1997, EMBO J, V16, P4591, DOI 10.1093/emboj/16.15.4591; Coppola T, 1996, FEBS LETT, V391, P269, DOI 10.1016/0014-5793(96)00750-8; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; DeWaard M, 1997, NATURE, V385, P446, DOI 10.1038/385446a0; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; GUNDERSEN CB, 1992, NEURON, V9, P527, DOI 10.1016/0896-6273(92)90190-O; GUNDERSEN CB, 1994, J BIOL CHEM, V269, P19197; Heckmann M, 1997, NEUROSCI LETT, V228, P167, DOI 10.1016/S0304-3940(97)00390-X; KOHAN SA, 1995, J NEUROSCI, V15, P6230; MartinMoutot N, 1996, J BIOL CHEM, V271, P6567, DOI 10.1074/jbc.271.12.6567; MASTROGIACOMO A, 1994, SCIENCE, V263, P981, DOI 10.1126/science.7906056; MASTROGIACOMO A, 1995, MOL BRAIN RES, V28, P12, DOI 10.1016/0169-328X(94)00172-B; Mochida S, 1996, NEURON, V17, P781, DOI 10.1016/S0896-6273(00)80209-3; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; Pupier S, 1997, J NEUROSCI, V17, P2722; Rettig J, 1996, P NATL ACAD SCI USA, V93, P7363, DOI 10.1073/pnas.93.14.7363; Rettig J, 1997, J NEUROSCI, V17, P6647; Sheng ZH, 1996, NATURE, V379, P451, DOI 10.1038/379451a0; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; UMBACH JA, 1994, NEURON, V13, P899, DOI 10.1016/0896-6273(94)90255-0; Umbach JA, 1997, J NEUROSCI, V17, P7203; UNGEWICKELL E, 1995, NATURE, V378, P632, DOI 10.1038/378632a0; WHEELER DB, 1994, SCIENCE, V258, P917; ZINSMAIER KE, 1994, SCIENCE, V263, P977, DOI 10.1126/science.8310297; ZINSMAIER KE, 1990, J NEUROGENET, V7, P15, DOI 10.3109/01677069009084150	34	83	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13488	13492		10.1074/jbc.273.22.13488	http://dx.doi.org/10.1074/jbc.273.22.13488			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593683	hybrid			2022-12-27	WOS:000073919100022
J	Abelson, J; Trotta, CR; Li, H				Abelson, J; Trotta, CR; Li, H			tRNA splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							TRANSFER-RNA PRECURSORS; GROUP-I INTRON; SACCHAROMYCES-CEREVISIAE; SUBSTRATE RECOGNITION; INTERVENING SEQUENCES; YEAST LIGASE; ENDONUCLEASE; MUTANT; GENES; CONFORMATION		CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Abelson, J (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.			Li, Hong/0000-0003-2046-9861				AboulEla F, 1996, NUCLEIC ACIDS RES, V24, P3974, DOI 10.1093/nar/24.20.3974; BALDI MI, 1992, SCIENCE, V255, P1404, DOI 10.1126/science.1542788; BELFORD HG, 1993, J BIOL CHEM, V268, P2444; Belfort M, 1997, CELL, V89, P1003, DOI 10.1016/S0092-8674(00)80287-1; BINISZKIEWICZ D, 1994, EMBO J, V13, P4629, DOI 10.1002/j.1460-2075.1994.tb06785.x; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; Culver GM, 1997, J BIOL CHEM, V272, P13203, DOI 10.1074/jbc.272.20.13203; CULVER GM, 1993, SCIENCE, V261, P206, DOI 10.1126/science.8392224; Fabbri S, 1998, SCIENCE, V280, P284, DOI 10.1126/science.280.5361.284; GOODMAN HM, 1977, P NATL ACAD SCI USA, V74, P5453, DOI 10.1073/pnas.74.12.5453; GREER CL, 1983, CELL, V32, P537, DOI 10.1016/0092-8674(83)90473-7; HO CK, 1990, EMBO J, V9, P1245, DOI 10.1002/j.1460-2075.1990.tb08232.x; HOPPER AK, 1978, CELL, V14, P211, DOI 10.1016/0092-8674(78)90108-3; KlemanLeyer K, 1997, CELL, V89, P839, DOI 10.1016/S0092-8674(00)80269-X; KNAPP G, 1978, CELL, V14, P221, DOI 10.1016/0092-8674(78)90109-5; KNAPP G, 1979, CELL, V18, P37, DOI 10.1016/0092-8674(79)90351-9; KUHSEL MG, 1990, SCIENCE, V250, P1570, DOI 10.1126/science.2125748; LEE MC, 1985, J BIOL CHEM, V260, P3108; Li H, 1998, SCIENCE, V280, P279, DOI 10.1126/science.280.5361.279; LykkeAndersen J, 1997, EMBO J, V16, P6290, DOI 10.1093/emboj/16.20.6290; MCCRAITH SM, 1991, J BIOL CHEM, V266, P11986; MCCRAITH SM, 1990, MOL CELL BIOL, V10, P1049, DOI 10.1128/MCB.10.3.1049; Negri ED, 1997, CELL, V89, P859, DOI 10.1016/S0092-8674(00)80271-8; OFARRELL PZ, 1978, NATURE, P438; OGDEN RC, 1984, NUCLEIC ACIDS RES, V12, P9367, DOI 10.1093/nar/12.24.9367; PALMER JR, 1994, J BACTERIOL, V176, P3820, DOI 10.1128/JB.176.12.3820-3823.1994; PEEBLES CL, 1983, CELL, V32, P525, DOI 10.1016/0092-8674(83)90472-5; PEEBLES CL, 1979, CELL, V18, P27, DOI 10.1016/0092-8674(79)90350-7; PHIZICKY EM, 1986, J BIOL CHEM, V261, P2978; RAUHUT R, 1990, J BIOL CHEM, V265, P18180; REINHOLDHUREK B, 1992, NATURE, V357, P173, DOI 10.1038/357173a0; REYES VM, 1988, CELL, V55, P719, DOI 10.1016/0092-8674(88)90230-9; SWERDLOW H, 1984, J BIOL CHEM, V259, P5197; THOMPSON JE, 1994, J AM CHEM SOC, V116, P5467, DOI 10.1021/ja00091a060; THOMPSON LD, 1988, J BIOL CHEM, V263, P17951; THOMPSON LD, 1989, CAN J MICROBIOL, V35, P36, DOI 10.1139/m89-006; Trotta CR, 1997, CELL, V89, P849, DOI 10.1016/S0092-8674(00)80270-6; VALENZUELA P, 1978, P NATL ACAD SCI USA, V75, P190, DOI 10.1073/pnas.75.1.190; WALSH C, 1979, ENZYMATIC REACTION M, P202; WESTAWAY SK, 1993, J BIOL CHEM, V268, P2435; WESTAWAY SK, 1988, J BIOL CHEM, V263, P3171; WINEY M, 1988, GENETICS, V118, P49; XU Q, 1990, BIOCHEMISTRY-US, V29, P6132, DOI 10.1021/bi00478a004	43	226	237	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					12685	12688		10.1074/jbc.273.21.12685	http://dx.doi.org/10.1074/jbc.273.21.12685			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582290	hybrid			2022-12-27	WOS:000073768500001
J	Koshimizu, T; Tomic, M; Koshimizu, M; Stojilkovic, SS				Koshimizu, T; Tomic, M; Koshimizu, M; Stojilkovic, SS			Identification of amino acid residues contributing to desensitization of the P2X(2) receptor channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED ION CHANNELS; P-2X RECEPTOR; EXTRACELLULAR ATP; SENSORY NEURONS; BRAIN; MEMBRANE; HORMONE; FAMILY	The P2X(2) receptor (P2X(2)R) is a member of the ATP-gated ion channels that mediate Ca2+ entry in several tissues, including the brain, adrenal medulla, and pituitary. Alternative usage of cryptic splice sites in the primary P2X(2)R transcript accounts for the existence of several transcript types, one of which (PSX2R) encodes a functional channel. P2X(2-2)R lacks a stretch of cytoplasmic C-terminal amino acids (Val(370)-Gln(438)) and exhibits rapid and complete desensitization, whereas P2X(2)R desensitizes slowly and incompletely, The role of the C terminus in P2X(2)R desensitization was studied by generating several channel mutants and monitoring intracellular free Ca2+ changes in transfected single GT1-7 neurons. Deletion studies indicated that the Arg(371)-Ile(391) segment of the P2XR(2)R is required for sustained Ca2+ influx. To identify the important residues within this segment, three contiguous amino acids were sequentially changed to alanine, Only two of these replacement mutants, at Arg(371)-Thr(372)-pro(373) and Lys(374)-His(375)-Pro(376), had, enhanced rate of desensitization. Single amino acid deletions in the PBX,R C terminus and a series of insertions of wild-type sequences into the corresponding spliced site identified four residues, Pro(373)-Lys(374)-His(375)-Pro(376), required for sustained Ca2+ influx through agonist-occupied wild-type channels. Thus, it is likely that the Pro(373)-Pro(376) sequence of PSX2R represents a functional motif that is critical for the development of the slow desensitization profile observed in these channels. Consequently, deletion of this motif by alternative splicing provides an effective mechanism for generating a channel with controlled Ca2+ influx.	NICHD, Endocrinol & Reprod Res Branch, UCS, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Stojilkovic, SS (corresponding author), NICHD, Endocrinol & Reprod Res Branch, UCS, NIH, Bldg 49,Room 6A-36,49 Convent Dr, Bethesda, MD 20892 USA.		Koshimizu, Taka-aki/G-2740-2015; Tomic, Melanija/C-3371-2016	Koshimizu, Taka-aki/0000-0001-5292-7535				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; Brandle U, 1997, FEBS LETT, V404, P294, DOI 10.1016/S0014-5793(97)00128-2; Buell G, 1996, EMBO J, V15, P55, DOI 10.1002/j.1460-2075.1996.tb00333.x; Buell G, 1996, EUR J NEUROSCI, V8, P2221, DOI 10.1111/j.1460-9568.1996.tb00745.x; CHEN CC, 1995, NATURE, V377, P428, DOI 10.1038/377428a0; Collo G, 1996, J NEUROSCI, V16, P2495; EVANS RJ, 1997, P2 NUCLEOTIDE RECEPT, P43; KOSHIMIZU T, 1998, IN PRESS MOL ENDOCRI; KRSMANOVIC LZ, 1992, P NATL ACAD SCI USA, V89, P8462, DOI 10.1073/pnas.89.18.8462; LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0; North RA, 1996, SEMIN NEUROSCI, V8, P187; North RA, 1996, CIBA F SYMP, V198, P91; Radford KM, 1997, J NEUROSCI, V17, P6529; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; SCHWARTZMAN RA, 1993, ENDOCR REV, V14, P133, DOI 10.1210/er.14.2.133; Seguela P, 1996, J NEUROSCI, V16, P448; Simon J, 1997, MOL PHARMACOL, V52, P237, DOI 10.1124/mol.52.2.237; Soto F, 1996, P NATL ACAD SCI USA, V93, P3684, DOI 10.1073/pnas.93.8.3684; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; SURPRENANT A, 1995, TRENDS NEUROSCI, V18, P224, DOI 10.1016/0166-2236(95)93907-F; Tomic M, 1996, J BIOL CHEM, V271, P21200, DOI 10.1074/jbc.271.35.21200; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; Werner P, 1996, P NATL ACAD SCI USA, V93, P15485, DOI 10.1073/pnas.93.26.15485	24	53	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					12853	12857		10.1074/jbc.273.21.12853	http://dx.doi.org/10.1074/jbc.273.21.12853			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582314	hybrid			2022-12-27	WOS:000073768500025
J	Levine, J; Weickert, M; Pagratis, M; Etter, J; Mathews, A; Fattor, T; Lippincott, J; Apostol, I				Levine, J; Weickert, M; Pagratis, M; Etter, J; Mathews, A; Fattor, T; Lippincott, J; Apostol, I			Identification of a nickel(II) binding site on hemoglobin which confers susceptibility to oxidative deamination and intramolecular cross-linking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL-CATALYZED OXIDATION; AMINO-ACID-RESIDUES; GLUTAMINE-SYNTHETASE; ISCHEMIA-REPERFUSION; ESCHERICHIA-COLI; PROTEINS; PEPTIDES; PROTEOLYSIS; GENERATION; RADIOLYSIS	Complexation of Ni(II) with native state recombinant hemoglobin is shown to produce NH2-terminal deamination and globin cross-linking in the presence of the oxidant potassium peroxymonosulfate (Oxone(TM)). Both the oxidative deamination and cross-linking are exclusive to the beta chains. Recombinant hemoglobin mutants have been created to identify protein sequence requirements for these reactions. It was found that His-a of the beta globin is required for redox active Ni(II) complexation, oxidative deamination, and cross-linking. The oxidative deamination results in the formation of a free carbonyl in place of the NH2-terminal amine of the beta chain. Most cross-linking of the beta globin occurs intramolecularly, forming beta globin dimers, Structural characterization of the beta globin dimers indicates the presence of heterogeneous cross-links within the central hemoglobin cavity between the NH2 terminus of one beta chain and the COOH-terminal region of the other.	Somatogen Inc, Boulder, CO 80301 USA		Apostol, I (corresponding author), Somatogen Inc, 2545 Cent Ave, Boulder, CO 80301 USA.							AMICI A, 1989, J BIOL CHEM, V264, P3341; Apostol I, 1997, J BIOL CHEM, V272, P28980, DOI 10.1074/jbc.272.46.28980; AYENE IS, 1993, ARCH BIOCHEM BIOPHYS, V303, P307, DOI 10.1006/abbi.1993.1288; BALDWIN JM, 1980, J MOL BIOL, V136, P103, DOI 10.1016/0022-2836(80)90308-3; Bravo J, 1997, PROTEIN SCI, V6, P1016, DOI 10.1002/pro.5560060507; BROWN KC, 1995, BIOCHEMISTRY-US, V34, P4733, DOI 10.1021/bi00014a030; CABISCOL E, 1995, J BIOL CHEM, V270, P14742, DOI 10.1074/jbc.270.24.14742; CLIMENT I, 1989, ANAL BIOCHEM, V182, P226, DOI 10.1016/0003-2697(89)90584-8; Cornish VW, 1996, J AM CHEM SOC, V118, P8150, DOI 10.1021/ja961216x; Dean RT, 1997, BIOCHEM J, V324, P1; Fancy DA, 1997, TETRAHEDRON, V53, P11953, DOI 10.1016/S0040-4020(97)00708-4; Fancy DA, 1996, CHEM BIOL, V3, P551, DOI 10.1016/S1074-5521(96)90146-5; FARBER JM, 1986, J BIOL CHEM, V261, P4574; GARRISON WM, 1987, CHEM REV, V87, P381, DOI 10.1021/cr00078a006; Geraci G, 1981, Methods Enzymol, V76, P262; Gill G, 1997, CHEM RES TOXICOL, V10, P302, DOI 10.1021/tx960170i; GIULIVI C, 1994, METHOD ENZYMOL, V231, P490; HEINECKE JW, 1993, J CLIN INVEST, V91, P2866, DOI 10.1172/JCI116531; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; HOFFMAN SJ, 1990, P NATL ACAD SCI USA, V87, P8521, DOI 10.1073/pnas.87.21.8521; LEE YJ, 1995, ARCH BIOCHEM BIOPHYS, V321, P175, DOI 10.1006/abbi.1995.1383; Levine RL, 1996, P NATL ACAD SCI USA, V93, P15036, DOI 10.1073/pnas.93.26.15036; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; LEWISCH SA, 1995, ANAL BIOCHEM, V231, P440, DOI 10.1006/abio.1995.9974; Lippincott J, 1997, ANAL BIOCHEM, V252, P314, DOI 10.1006/abio.1997.2334; LOOKER D, 1992, NATURE, V356, P258, DOI 10.1038/356258a0; MEUCCI E, 1991, J BIOL CHEM, V266, P4692; OLIVER CN, 1990, P NATL ACAD SCI USA, V87, P5144, DOI 10.1073/pnas.87.13.5144; RAGHOTHAMA C, 1994, CLIN CHIM ACTA, V225, P65, DOI 10.1016/0009-8981(94)90028-0; SCHONEICH C, 1993, BIOCHIM BIOPHYS ACTA, V1158, P307, DOI 10.1016/0304-4165(93)90030-C; SMITH C, 1992, BIOCHEM J, V286, P901, DOI 10.1042/bj2860901; STADTMAN ER, 1993, ANNU REV BIOCHEM, V62, P797, DOI 10.1146/annurev.bi.62.070193.004053; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; STARKEREED PE, 1989, ARCH BIOCHEM BIOPHYS, V275, P559, DOI 10.1016/0003-9861(89)90402-5; TORREILLES J, 1990, FREE RADICAL RES COM, V11, P159, DOI 10.3109/10715769009109679; Weickert MJ, 1997, APPL ENVIRON MICROB, V63, P4313, DOI 10.1128/AEM.63.11.4313-4320.1997; WITKOWSKA HE, 1993, HEMOGLOBIN, V17, P227, DOI 10.3109/03630269308998897; WOODY R, 1978, BIOCHEMICAL CLIN ASP, P279; ZHAO YJ, 1991, EUR J BIOCHEM, V202, P1115, DOI 10.1111/j.1432-1033.1991.tb16478.x; [No title captured]	40	21	21	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					13037	13046		10.1074/jbc.273.21.13037	http://dx.doi.org/10.1074/jbc.273.21.13037			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582340	hybrid			2022-12-27	WOS:000073768500051
J	Geng, D; Chura, J; Roberts, MF				Geng, D; Chura, J; Roberts, MF			Activation of phospholipase D by phosphatidic acid - Enhanced vesicle binding, phosphatidic acid Ca2+ interaction, or an allosteric effect?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFACIAL CATALYSIS; LYSOPHOSPHATIDIC ACID; SMOOTH-MUSCLE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLINOSITOL; HYDROLYSIS; CELLS; DIACYLGLYCEROL; FIBROBLASTS; INHIBITION	The activity of bacterial phospholipase D (PLD), a Ca2+-dependent enzyme, toward phosphatidylcholine bilayers was enhanced 7-fold by incorporation of 10 mol % phosphatidic acid (PA) in the vesicle bilayer. Addition of other negatively charged lipids such as phosphatidylinositol, phosphatidylmethanol, and oleic acid either inhibited or had no effect on enzyme activity. Only negatively charged lipids with a free phosphate group, phosphatidylinositol 4-phosphate and lyse-PA, had the same effect as PA on enzyme activity. Changes in vesicle curvature and fusion were not the reason for PA activation; rather, a metal ion-induced lateral segregation of PA in the vesicle bilayer correlated with PLD activation. Significant PA activation was also observed with monomer phosphatidylcholine substrate upon the addition of PA vesicles. The PA activation was caused by Ca2+. PA interacting with PLD at an allosteric site other than active site.	Boston Coll, Merkert Chem Ctr, Chestnut Hill, MA 02167 USA	Boston College	Roberts, MF (corresponding author), Boston Coll, Merkert Chem Ctr, 2609 Beacon St, Chestnut Hill, MA 02167 USA.	mary.roberts@bc.edu			NIGMS NIH HHS [GM 26762] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026762] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIAN JR, 1992, J COLLOID INTERF SCI, V153, P420, DOI 10.1016/0021-9797(92)90333-H; BLACKWELL MF, 1986, J BIOL CHEM, V261, P6993; Blackwood RA, 1997, AM J PHYSIOL-CELL PH, V272, pC1279, DOI 10.1152/ajpcell.1997.272.4.C1279; BOCCKINO SB, 1996, HDB LIPID RES, P75; EIBL A, 1981, METHOD ENZYMOL, V197, P493; Exton JH, 1997, PHYSIOL REV, V77, P303, DOI 10.1152/physrev.1997.77.2.303; FERGUSON JE, 1992, ARCH BIOCHEM BIOPHYS, V297, P388, DOI 10.1016/0003-9861(92)90689-T; GARIGAPATI VR, 1995, J COLLOID INTERF SCI, V169, P486, DOI 10.1006/jcis.1995.1059; GHOMASHCHI F, 1991, BIOCHEMISTRY-US, V30, P7318, DOI 10.1021/bi00243a037; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; HOLBROOK PG, 1991, BIOCHIM BIOPHYS ACTA, V1084, P155, DOI 10.1016/0005-2760(91)90214-3; HRESKO RC, 1987, BIOPHYS J, V51, P725, DOI 10.1016/S0006-3495(87)83399-4; IMAMURA S, 1979, J BIOCHEM, V85, P79, DOI 10.1093/oxfordjournals.jbchem.a132334; IWASAKI Y, 1994, APPL MICROBIOL BIOT, V42, P290, DOI 10.1007/s002530050252; JAIN MK, 1989, BIOCHIM BIOPHYS ACTA, V1002, P127, DOI 10.1016/0005-2760(89)90281-6; JAIN MK, 1991, METHOD ENZYMOL, V197, P112; JAIN MK, 1973, J MEMBRANE BIOL, V14, P119, DOI 10.1007/BF01868073; JALINK K, 1990, J BIOL CHEM, V265, P12232; JONES JD, 1989, BIOCHEMISTRY-US, V28, P129, DOI 10.1021/bi00427a019; KONDO T, 1992, J BIOL CHEM, V267, P23609; KUPPE A, 1990, BIOCHIM BIOPHYS ACTA, V1047, P41, DOI 10.1016/0005-2760(90)90258-Y; LEWIS K, 1992, THESIS BOSTON COLL; LISCOVITCH M, 1989, J BIOL CHEM, V264, P11762; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; Moolenaar Wouter H., 1994, Trends in Cell Biology, V4, P213, DOI 10.1016/0962-8924(94)90144-9; MURAYAMA T, 1987, J BIOL CHEM, V262, P5522; PERTILE P, 1995, J BIOL CHEM, V270, P5130, DOI 10.1074/jbc.270.10.5130; ROBERTS MF, 1996, ENCY MOL BIOL MOL ME, P415; SALMON DM, 1980, NATURE, V284, P344, DOI 10.1038/284344a0; SHEFFIELD MJ, 1995, BIOCHEMISTRY-US, V34, P7796, DOI 10.1021/bi00024a003; SOLTYS CE, 1994, BIOCHEMISTRY-US, V33, P11608, DOI 10.1021/bi00204a023; SWAIRJO MA, 1994, BBA-BIOMEMBRANES, V1191, P354, DOI 10.1016/0005-2736(94)90186-4; VANBLITTERSWIJK WJ, 1993, EMBO J, V12, P2655, DOI 10.1002/j.1460-2075.1993.tb05926.x; VANBLITTERSWIJK WJ, 1991, J BIOL CHEM, V266, P10337; YAMAMOTO I, 1995, BBA-BIOMEMBRANES, V1233, P21, DOI 10.1016/0005-2736(94)00220-J; YANG SF, 1967, J BIOL CHEM, V242, P477; Zhou C, 1997, BIOCHEMISTRY-US, V36, P347, DOI 10.1021/bi960601w; Zhou C, 1997, BIOCHEMISTRY-US, V36, P10089, DOI 10.1021/bi970846o	39	56	56	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12195	12202		10.1074/jbc.273.20.12195	http://dx.doi.org/10.1074/jbc.273.20.12195			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575167	hybrid			2022-12-27	WOS:000073629800032
J	Nemansky, M; Thotakura, NR; Lyons, CD; Ye, S; Reinhold, BB; Reinhold, VN; Blithe, DL				Nemansky, M; Thotakura, NR; Lyons, CD; Ye, S; Reinhold, BB; Reinhold, VN; Blithe, DL			Developmental changes in the glycosylation of glycoprotein hormone free alpha subunit during pregnancy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; ASPARAGINE-LINKED OLIGOSACCHARIDES; ANION-EXCHANGE CHROMATOGRAPHY; PULSED AMPEROMETRIC DETECTION; BETA-SUBUNIT; SUGAR CHAINS; TROPHOBLASTIC DISEASES; LUTEINIZING-HORMONE; CARBOHYDRATE CHAINS; MASS-SPECTROMETRY	Glycoprotein hormone alpha subunit, in its free form (free alpha), is a major placental product. Its glycosylation was found to change dramatically during the advancement of pregnancy. In this study, we have analyzed these glycosylation changes in five normal pregnancies, Binding to Lens culinaris lectin increased dramatically in all subjects between weeks 14 and 17 from the last menstrual period, indicating more core fucosylation as well as possible changes in branching of glycans, Studies using Datura stramonium agglutinin confirmed that the type of triantennary branching changed in this period of pregnancy. The precise structural nature of Obese changes was determined by high-pH anion-exchange chromatography and electrospray ionization mass spectrometry. Amounts of core fucosylation and of triantennary glycans increased substantially from early to late second trimester, and a shift was observed from 1-->4/1-->3- toward predominantly 1-->6/1-->6-branched triantennary structures. The glycosylation changes occurred in all five individuals at the same time period in gestation, suggesting developmental regulation of N-acetylglucosaminyltransferases IV and V and alpha 6-fucosyltransferase during normal pregnancy. These enzymatic activities also appear to be affected in malignant transformation of the trophoblast. Our findings have important implications for the proposed use of specific forms of glycosylation as markers for cancer, as the relative amounts of these glycans in normal pregnancy will be determined by gestational age.	NICHD, Unit Glycobiol, Dev Endocrinol Branch, Bethesda, MD 20892 USA; Boston Univ, Sch Med, Dept Microbiol & Immunol, Boston, MA 02118 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Boston University	Blithe, DL (corresponding author), NICHD, Contracept & Reprod Hlth Branch, NIH, Bldg 61E,Rm 8B13, Bethesda, MD 20892 USA.	BlitheD@exchange.nih.gov			NCRR NIH HHS [5P41RR10888] Funding Source: Medline; NIGMS NIH HHS [R01 GM54045] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR010888] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054045] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGEL AS, 1990, METHOD ENZYMOL, V193, P587, DOI 10.1016/0076-6879(90)93440-V; ARKWRIGHT PD, 1991, PLACENTA, V12, P637, DOI 10.1016/0143-4004(91)90498-5; ASHITAKA Y, 1974, ENDOCRINOL JAPON, V21, P547; BEGEOT M, 1984, SCIENCE, V226, P566, DOI 10.1126/science.6208610; BLITHE DL, 1985, ENDOCRINOLOGY, V117, P2218, DOI 10.1210/endo-117-5-2218; BLITHE DL, 1990, J BIOL CHEM, V265, P21951; BLITHE DL, 1990, ENDOCRINOLOGY, V126, P2788, DOI 10.1210/endo-126-6-2788; BLITHE DL, 1995, ENDOCRINOLOGY, V136, P903, DOI 10.1210/en.136.3.903; BLITHE DL, 1991, ENDOCRINOLOGY, V129, P2257, DOI 10.1210/endo-129-4-2257; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; COOPER GA, 1995, ANAL BIOCHEM, V226, P182, DOI 10.1006/abio.1995.1207; DAMM JBL, 1988, GLYCOCONJUGATE J, V5, P221, DOI 10.1007/BF01049083; DEMETRIOU M, 1995, J CELL BIOL, V130, P383, DOI 10.1083/jcb.130.2.383; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; ENDO T, 1987, CANCER RES, V47, P5242; ENDO Y, 1979, J BIOCHEM-TOKYO, V85, P669; GASPARD UJ, 1980, PLACENTA, V1, P135, DOI 10.1016/S0143-4004(80)80022-1; GREEN ED, 1987, ANAL BIOCHEM, V167, P62, DOI 10.1016/0003-2697(87)90134-5; HAGEN C, 1976, J ENDOCRINOL, V69, P33, DOI 10.1677/joe.0.0690033; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; HARD K, 1992, EUR J BIOCHEM, V205, P785; HARDY MR, 1988, ANAL BIOCHEM, V170, P54, DOI 10.1016/0003-2697(88)90089-9; KAWANO T, 1988, ARCH BIOCHEM BIOPHYS, V267, P787, DOI 10.1016/0003-9861(88)90088-4; KESSLER MJ, 1979, J BIOL CHEM, V254, P7901; KOBATA A, 1988, J CELL BIOCHEM, V37, P79, DOI 10.1002/jcb.240370108; KORNFELD K, 1981, J BIOL CHEM, V256, P6633; KRUSIUS T, 1985, J BIOL CHEM, V260, P4110; LINSLEY KB, 1994, ANAL BIOCHEM, V219, P207, DOI 10.1006/abio.1994.1259; MANN K, 1983, CANCER, V52, P654, DOI 10.1002/1097-0142(19830815)52:4<654::AID-CNCR2820520415>3.0.CO;2-S; MIZUOCHI T, 1985, JPN J CANCER RES, V76, P752; Moy E, 1996, ENDOCRINOLOGY, V137, P1332, DOI 10.1210/en.137.4.1332; Nakagawa H, 1996, EUR J BIOCHEM, V237, P76, DOI 10.1111/j.1432-1033.1996.0076n.x; NEMANSKY M, 1992, FEBS LETT, V312, P31, DOI 10.1016/0014-5793(92)81404-A; ORBERGER G, 1992, EUR J BIOCHEM, V205, P257, DOI 10.1111/j.1432-1033.1992.tb16776.x; REUTER AM, 1980, CLIN ENDOCRINOL, V13, P305, DOI 10.1111/j.1365-2265.1980.tb03390.x; SCHACHTER H, 1986, BIOCHEM CELL BIOL, V64, P163, DOI 10.1139/o86-026; SKARULIS MC, 1992, J CLIN ENDOCR METAB, V75, P91, DOI 10.1210/jc.75.1.91; STEWART EA, 1994, AM J OBSTET GYNECOL, V170, P677, DOI 10.1016/S0002-9378(94)70247-0; TAKAMOTO M, 1989, J BIOCHEM-TOKYO, V105, P742, DOI 10.1093/oxfordjournals.jbchem.a122738; TAKAMOTO M, 1989, J BIOCHEM-TOKYO, V106, P228, DOI 10.1093/oxfordjournals.jbchem.a122837; TAKASAKI S, 1984, J BIOL CHEM, V259, P112; THOTAKURA NR, 1995, GLYCOBIOLOGY, V5, P3, DOI 10.1093/glycob/5.1.3; THOTAKURA NR, 1985, ENDOCRINOLOGY, V117, P1300; VAITUKAITIS JL, 1972, AM J OBSTET GYNECOL, V113, P751, DOI 10.1016/0002-9378(72)90553-4; VANPELT J, 1988, EUR J BIOCHEM, V177, P327; WEISSHAAR G, 1991, Glycobiology, V1, P393, DOI 10.1093/glycob/1.4.393; WHITCOMB RW, 1988, CLIN CHEM, V34, P2022; WIDE L, 1987, ACTA ENDOCRINOL-COP, V116, P465, DOI 10.1530/acta.0.1160465; WIDE L, 1994, J CLIN ENDOCR METAB, V78, P1419, DOI 10.1210/jc.78.6.1419; YAMASHITA K, 1987, J BIOL CHEM, V262, P1602; YEH IT, 1989, LAB INVEST, V61, P1	51	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12068	12076		10.1074/jbc.273.20.12068	http://dx.doi.org/10.1074/jbc.273.20.12068			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575149	hybrid			2022-12-27	WOS:000073629800014
J	Wu, SY; Chiang, CM				Wu, SY; Chiang, CM			Properties of PC4 and an RNA polymerase II complex in directing activated and basal transcription in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-TRANSCRIPTION; HUMAN COACTIVATOR; FUNCTIONAL STEPS; INITIATION; PROMOTER; YEAST; PURIFICATION; HOLOENZYME; EXPRESSION; BINDING	A human RNA polymerase II (pol II) complex was isolated from a HeLa derived cell line that conditionally expresses an epitope-tagged RPB9 subunit of human pol II. The isolated FLAG-tagged pol II complex (f:pol II) contains a subset of general transcription factors but is devoid of TFIID and TFIIA. In conjunction with TATA-binding protein (TBP) or TFIID, f:pol II is able to mediate both basal and activated transcription by Gal4-VP16 when a transcriptional coactivator PC4 is also provided. Interestingly, PC4, in the absence of a transcriptional activator, actually functions as a repressor to inhibit basal transcription. Remarkably, TBP is able to mediate activator function in this transcription system. The presence of TBP-associated factors, however, helps overcome PC4 repression and further enhance the level of activation mediated by TBP. Alleviation of PC4 repression can also be achieved by preincubation of the transcriptional components with the DNA template. Sarkosyl disruption of preinitiation complex formation further illustrates that PC4 can only inhibit transcription prior to the assembly of a functional preinitiation complex. These results suggest that PC4 represses basal transcription by preventing the assembly of a functional preinitiation complex, but it has no effect on the later steps of the transcriptional process.	Univ Illinois, Dept Biochem, Roger Adams Lab 430, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Wu, SY (corresponding author), Univ Illinois, Dept Biochem, Roger Adams Lab 430, 600 S Mathews Ave, Urbana, IL 61801 USA.	c-chiang@uiuc.edu						ACKER J, 1993, NUCLEIC ACIDS RES, V21, P5345, DOI 10.1093/nar/21.23.5345; Apone LM, 1996, GENE DEV, V10, P2368, DOI 10.1101/gad.10.18.2368; ASO T, 1994, J BIOL CHEM, V269, P26575; BALLARD DW, 1988, J BIOL CHEM, V263, P8450; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CHIANG CM, 1993, PEPTIDE RES, V6, P62; DEJONG J, 1995, P NATL ACAD SCI USA, V92, P3313, DOI 10.1073/pnas.92.8.3313; DEJONG J, 1993, GENE DEV, V7, P2220, DOI 10.1101/gad.7.11.2220; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fang SM, 1996, J BIOL CHEM, V271, P11703, DOI 10.1074/jbc.271.20.11703; Ge H, 1996, METHOD ENZYMOL, V274, P57; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HAWLEY DK, 1987, J BIOL CHEM, V262, P3452; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; Henry NL, 1996, J BIOL CHEM, V271, P21842, DOI 10.1074/jbc.271.36.21842; Kaiser K, 1996, TRENDS BIOCHEM SCI, V21, P342, DOI 10.1016/S0968-0004(96)10043-8; KAISER K, 1995, EMBO J, V14, P3520, DOI 10.1002/j.1460-2075.1995.tb07358.x; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Knaus R, 1996, EMBO J, V15, P1933, DOI 10.1002/j.1460-2075.1996.tb00544.x; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; Lieberman PM, 1997, MOL CELL BIOL, V17, P6624, DOI 10.1128/MCB.17.11.6624; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; Malik S, 1998, P NATL ACAD SCI USA, V95, P2192, DOI 10.1073/pnas.95.5.2192; MEISTERERNST M, 1990, P NATL ACAD SCI USA, V87, P9153, DOI 10.1073/pnas.87.23.9153; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; OSSIPOW V, 1995, CELL, V83, P137, DOI 10.1016/0092-8674(95)90242-2; Pan GH, 1997, J BIOL CHEM, V272, P24563, DOI 10.1074/jbc.272.39.24563; Pan ZQ, 1996, J BIOL CHEM, V271, P22111, DOI 10.1074/jbc.271.36.22111; PARVIN JD, 1994, J BIOL CHEM, V269, P18414; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; REINBERG D, 1987, J BIOL CHEM, V262, P3310; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Shi XM, 1997, MOL CELL BIOL, V17, P1160, DOI 10.1128/MCB.17.3.1160; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; Tansey WP, 1997, CELL, V88, P729, DOI 10.1016/S0092-8674(00)81916-9; TIMMERS HTM, 1994, EMBO J, V13, P391, DOI 10.1002/j.1460-2075.1994.tb06273.x; VANDYKE MW, 1989, MOL CELL BIOL, V9, P342, DOI 10.1128/MCB.9.1.342; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; WANG BQ, 1994, PROTEIN EXPRES PURIF, V5, P476, DOI 10.1006/prep.1994.1067; WANG BQ, 1993, PROTEIN EXPRES PURIF, V4, P207, DOI 10.1006/prep.1993.1027; Wilson CJ, 1996, CELL, V84, P235, DOI 10.1016/S0092-8674(00)80978-2; WORKMAN JL, 1990, EMBO J, V9, P1299, DOI 10.1002/j.1460-2075.1990.tb08239.x; Wu SY, 1996, BIOTECHNIQUES, V21, P718	54	32	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12492	12498		10.1074/jbc.273.20.12492	http://dx.doi.org/10.1074/jbc.273.20.12492			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575207	hybrid			2022-12-27	WOS:000073629800072
J	Ciesielski-Treska, J; Ulrich, G; Taupenot, L; Chasserot-Golaz, S; Corti, A; Aunis, D; Bader, MF				Ciesielski-Treska, J; Ulrich, G; Taupenot, L; Chasserot-Golaz, S; Corti, A; Aunis, D; Bader, MF			Chromogranin A induces a neurotoxic phenotype in brain microglial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; ALZHEIMERS-DISEASE; SECRETOGRANIN-II; SENILE PLAQUES; NITRIC-OXIDE; A IMMUNOREACTIVITIES; RAT-BRAIN; SECRETION; PROTEIN; PEPTIDE	Chromogranin A (CGA) belongs to a multifunctional protein family widely distributed in secretory vesicles in neurons and neuroendocrine cells. Within the brain, CGA is localized in neurodegenerative areas associated with reactive microglia. By using cultured rodent microglia, we recently described that CGA induces an activated phenotype and the generation of nitric oxide. These findings led us to examine whether CGA might affect neuronal survival, expression of neurofilaments, and high affinity gamma-aminobutyric acid uptake in neurons cultured in the presence or absence of microglial cells. We found that CGA was unable to exert a direct toxic effect on neurons but provoked neuronal injury and degeneration in the presence of microglial cells. These effects were observed with natural and recombinant CGA and with a recombinant N-terminal fragment corresponding to residues 1-78. CGA stimulated microglial cells to secrete heat-stable diffusible neurotoxic agents. CGA also induced a marked accumulation of nitric oxide and tumor necrosis factor-alpha by microglia, but we could not establish a direct correlation between the levels of nitric oxide and tumor necrosis factor-alpha and the neuronal damage. The possibility that CGA represents an endogenous factor that triggers the microglial responses responsible for the pathogenesis of neuronal degeneration is discussed.	INSERM, U338, Ctr Neurochim, F-67084 Strasbourg, France; San Raffaele Sci Inst, Dept Biol & Technol Res, I-20132 Milan, Italy	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Bader, MF (corresponding author), INSERM, U338, Ctr Neurochim, 5 Rue Blaise Pascal, F-67084 Strasbourg, France.		Bader, Marie-France/O-2098-2016; Chasserot-Golaz, Sylvette/K-7625-2017; Corti, Angelo/F-7046-2012; Dominique, Aunis/W-1419-2019	Corti, Angelo/0000-0002-0893-6191; Taupenot, Laurent/0000-0003-2316-3825; Chasserot-Golaz, Sylvette/0000-0002-7437-2558; Subba, Rajkrishna/0000-0003-0051-0062				AARDAL S, 1993, J NEUROENDOCRINOL, V5, P405, DOI 10.1111/j.1365-2826.1993.tb00501.x; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; BADER MF, 1994, GLIA, V11, P336, DOI 10.1002/glia.440110406; BANATI RB, 1994, DEV NEUROSCI-BASEL, V16, P114, DOI 10.1159/000112098; BOOHER J, 1972, Neurobiology (Copenhagen), V2, P97; BRION JP, 1991, BRAIN RES, V539, P143, DOI 10.1016/0006-8993(91)90697-T; BRUDZYNSKI SM, 1994, BRAIN RES BULL, V35, P211, DOI 10.1016/0361-9230(94)90124-4; CETIN Y, 1993, P NATL ACAD SCI USA, V90, P2360, DOI 10.1073/pnas.90.6.2360; CHAO CC, 1995, CRIT REV NEUROBIOL, V9, P189; CIESIELSKITRESKA J, 1991, J NEUROSCI RES, V29, P362, DOI 10.1002/jnr.490290312; Corti A, 1997, EUR J BIOCHEM, V248, P692, DOI 10.1111/j.1432-1033.1997.00692.x; Crain BJ, 1996, AM J PATHOL, V149, P1087; DING AH, 1988, J IMMUNOL, V141, P2407; DREES BM, 1994, ENDOCRINOLOGY, V134, P2057, DOI 10.1210/en.134.5.2057; DREES BM, 1991, ENDOCRINOLOGY, V129, P3381, DOI 10.1210/endo-129-6-3381; elMajdoubi M, 1996, J NEUROCYTOL, V25, P405; FASCIOTTO BH, 1993, ENDOCRINOLOGY, V133, P461, DOI 10.1210/en.133.2.461; Gasparri A, 1997, J BIOL CHEM, V272, P20835, DOI 10.1074/jbc.272.33.20835; Giulian D, 1996, J NEUROSCI, V16, P6021; GIULIAN D, 1993, J NEUROSCI RES, V36, P681, DOI 10.1002/jnr.490360609; GIULIAN D, 1995, NEUROCHEM INT, V27, P119, DOI 10.1016/0197-0186(95)00067-I; ISHIZUKA J, 1989, PANCREAS, V4, P277, DOI 10.1097/00006676-198906000-00001; KIRCHMAIR R, 1994, NEUROSCIENCE, V63, P1179, DOI 10.1016/0306-4522(94)90582-7; KRASSIOUKOV AV, 1994, J AUTONOM NERV SYST, V50, P61, DOI 10.1016/0165-1838(94)90123-6; KROESEN S, 1995, NEUROSCIENCE, V69, P881, DOI 10.1016/0306-4522(95)00275-N; LARSSON OM, 1986, J NEUROSCI RES, V16, P699, DOI 10.1002/jnr.490160410; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MAHATA SK, 1991, EUR J NEUROSCI, V3, P895, DOI 10.1111/j.1460-9568.1991.tb00101.x; Mahata SK, 1997, J CLIN INVEST, V100, P1623, DOI 10.1172/JCI119686; MCGEER PL, 1993, GLIA, V7, P84, DOI 10.1002/glia.440070114; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; Metz-Boutigue MH, 1998, CELL MOL NEUROBIOL, V18, P249, DOI 10.1023/A:1022573004910; METZBOUTIGUE MH, 1993, EUR J BIOCHEM, V217, P247, DOI 10.1111/j.1432-1033.1993.tb18240.x; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MUNOZ DG, 1991, LAB INVEST, V64, P826; MUNOZ DG, 1990, NEUROSCIENCE, V34, P533, DOI 10.1016/0306-4522(90)90162-W; NISHIMURA M, 1994, BRAIN RES, V634, P339, DOI 10.1016/0006-8993(94)91940-2; SHER PK, 1990, BRAIN RES BULL, V25, P697, DOI 10.1016/0361-9230(90)90045-2; SIMON JP, 1988, P NATL ACAD SCI USA, V85, P1712, DOI 10.1073/pnas.85.5.1712; SIMON JP, 1989, BIOCHEM J, V262, P1; Strub JM, 1996, J BIOL CHEM, V271, P28533, DOI 10.1074/jbc.271.45.28533; Szabo C, 1996, BRAIN RES BULL, V41, P131, DOI 10.1016/S0361-9230(96)00159-1; TATEMOTO K, 1986, NATURE, V324, P476, DOI 10.1038/324476a0; Taupenot L, 1996, NEUROSCIENCE, V72, P377, DOI 10.1016/0306-4522(96)83172-1; TAUPENOT L, 1995, REGUL PEPTIDES, V56, P71, DOI 10.1016/0167-0115(95)00008-Y; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; YASUHARA O, 1994, NEUROSCI LETT, V170, P13, DOI 10.1016/0304-3940(94)90227-5	48	89	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14339	14346		10.1074/jbc.273.23.14339	http://dx.doi.org/10.1074/jbc.273.23.14339			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603942	hybrid			2022-12-27	WOS:000074021500044
J	Rogatsky, I; Waase, CLM; Garabedian, MJ				Rogatsky, I; Waase, CLM; Garabedian, MJ			Phosphorylation and inhibition of rat glucocorticoid receptor transcriptional activation by glycogen synthase kinase-3 (GSK-3) - Species-specific differences between human and rat glucocorticoid receptor signaling as revealed through GSK-3 phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS EMBRYOS; C-JUN; PROTEIN; EXPRESSION; GENE; HOMOLOG; SHAGGY; MUTANT; ENCODES; CDNA	Transcriptional activation by the glucocorticoid receptor (GR) is regulated by both glucocorticoid binding and phosphorylation. The rat GR N-terminal transcriptional regulatory domain contains four major phosphorylation sites: threonine 171 (Thr(171)), serine 224 (Ser(224)), serine 232 (Ser(232)), and serine 246 (Ser(246)). We have previously demonstrated that Ser224 and Ser(232) are phosphorylated by cyclin-dependent kinases, while Ser(246) is phosphorylated by the c-Jun N-terminal kinase. We report here that the remaining GR phosphorylation site, Thr(171), is a target for glycogen synthase kinase-3 (GSK-3) in vitro and in cultured mammalian cells. Increasing GSK-3 activity through its overexpression in cultured cells inhibits GR transcriptional enhancement, an effect dependent upon Thr(171). Correspondingly, over expression of a constitutively active form of the GSK-3 inhibitor, protein kinase B/Akt, increases GR transcriptional enhancement. Overexpression of GSK-3 bad no effect on GR-mediated transcriptional repression of AP1-dependent gene expression. Importantly, transcriptional activation by the human GR (hGR), which contains an alanine (Ala(150)) at the position equivalent to Thr(171) in, rat GR, is not affected by GSK-3 overexpression. Introduction of a threonine residue at this position (A150T) establishes GSK-3-mediated inhibition of hGR transcriptional activation. These findings demonstrate species-specific differences in GR signaling, as revealed through GSK-3 phosphorylation, which suggests that GR function in rodents may not fully recapitulate receptor action in humans and that hGR is capable of adopting the GSK-3 signaling pathway through a somatic mutation.	NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; NYU, Sch Med, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA	New York University; New York University	Garabedian, MJ (corresponding author), NYU, Sch Med, Dept Microbiol, 550 1st Ave, New York, NY 10016 USA.	garabm01@mcrcr.med.nyu.edu		Maurer, Carine/0000-0002-7892-7127	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007180] Funding Source: NIH RePORTER; NIAID NIH HHS [5T32AI07180-17] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; ALAM J, 1990, ANAL BIOCHEM, V188, P245, DOI 10.1016/0003-2697(90)90601-5; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; BODWELL JE, 1995, J STEROID BIOCHEM, V52, P135, DOI 10.1016/0960-0760(94)00157-H; BOYLE WJ, 1991, METHOD ENZYMOL, V201; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cha HH, 1998, J BIOL CHEM, V273, P1998, DOI 10.1074/jbc.273.4.1998; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DANIELSEN M, 1986, EMBO J, V5, P2513, DOI 10.1002/j.1460-2075.1986.tb04529.x; DEGROOT RP, 1993, ONCOGENE, V8, P841; DOMINGUEZ I, 1995, P NATL ACAD SCI USA, V92, P8498, DOI 10.1073/pnas.92.18.8498; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GAO XM, 1994, BBA-GENE STRUCT EXPR, V1218, P194, DOI 10.1016/0167-4781(94)90010-8; Garabedian Michael J., 1998, P237; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; HUGHES K, 1992, EUR J BIOCHEM, V203, P305, DOI 10.1111/j.1432-1033.1992.tb19860.x; KEIGHTLEY MC, 1994, MOL ENDOCRINOL, V8, P431, DOI 10.1210/me.8.4.431; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Krstic MD, 1997, MOL CELL BIOL, V17, P3947, DOI 10.1128/MCB.17.7.3947; KRSTIC MD, 1995, THESIS U CALIFORNIA; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MINER JN, 1991, CELL GROWTH DIFFER, V2, P525; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; ORTI E, 1989, J BIOL CHEM, V264, P231; Pierce SB, 1996, DEV BIOL, V175, P256, DOI 10.1006/dbio.1996.0113; Plyte SE, 1996, MOL CELL BIOL, V16, P179; PLYTE SE, 1992, BIOCHIM BIOPHYS ACTA, V1114, P147, DOI 10.1016/0304-419X(92)90012-N; PULVERER BJ, 1994, ONCOGENE, V9, P59; PUZISS JW, 1994, MOL CELL BIOL, V14, P831, DOI 10.1128/MCB.14.1.831; Ramalingam A, 1997, MOL ENDOCRINOL, V11, P577, DOI 10.1210/me.11.5.577; Reynolds PD, 1997, J CLIN ENDOCR METAB, V82, P465, DOI 10.1210/jc.82.2.465; Rogatsky I, 1998, P NATL ACAD SCI USA, V95, P2050, DOI 10.1073/pnas.95.5.2050; Rogatsky I, 1997, MOL CELL BIOL, V17, P3181, DOI 10.1128/MCB.17.6.3181; RUEL L, 1993, NATURE, V362, P557, DOI 10.1038/362557a0; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; Trowbridge JM, 1997, P NATL ACAD SCI USA, V94, P10132, DOI 10.1073/pnas.94.19.10132; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Welsh GI, 1996, TRENDS CELL BIOL, V6, P274, DOI 10.1016/0962-8924(96)10023-4; WOODGETT JR, 1991, TRENDS BIOCHEM SCI, V16, P177, DOI 10.1016/0968-0004(91)90071-3; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443	52	106	109	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14315	14321		10.1074/jbc.273.23.14315	http://dx.doi.org/10.1074/jbc.273.23.14315			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603939	hybrid			2022-12-27	WOS:000074021500041
J	Sablin, SO; Ramsay, RR				Sablin, SO; Ramsay, RR			Monoamine oxidase contains a redox-active disulfide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; KINETIC MECHANISM; HALF-REACTION; INACTIVATION	Mitochondrial monoamine oxidases A and B (MAO A and MAO B) are ubiquitous homodimeric FAD-containing oxidases that catalyze the oxidation of biogenic amines. Both enzymes play a vital role in the regulation of neurotransmitter levels in brain and are of interest as drug targets. However, little is known about the amino acid residues involved in the catalysis. The experiments reported here show that both MAO A and MAO B contain a redox-active disulfide at the catalytic center. The results imply that MAO may be a novel type of disulfide oxidoreductase and open the way to characterizing the catalytic and chemical mechanism of the enzyme.	Univ St Andrews, Sch Biol & Med Sci, St Andrews KY16 9AL, Fife, Scotland	University of St Andrews	Ramsay, RR (corresponding author), Univ St Andrews, Sch Biol & Med Sci, Irvine Bldg,North St, St Andrews KY16 9AL, Fife, Scotland.		Ramsay, Rona/A-4065-2009; Ramsay, Rona R./A-6681-2008	Ramsay, Rona R./0000-0003-1535-4904				Cesura AM, 1996, EUR J BIOCHEM, V236, P996, DOI 10.1111/j.1432-1033.1996.00996.x; DRAPER RD, 1968, ARCH BIOCHEM BIOPHYS, V125, P802, DOI 10.1016/0003-9861(68)90517-1; GOMES B, 1976, BIOCHIM BIOPHYS ACTA, V438, P347, DOI 10.1016/0005-2744(76)90252-7; HIRAMATSU A, 1975, EUR J BIOCHEM, V57, P587, DOI 10.1111/j.1432-1033.1975.tb02334.x; HUSAIN M, 1982, BIOCHEMISTRY-US, V21, P595, DOI 10.1021/bi00532a028; JOCELYN PC, 1967, EUR J BIOCHEM, V2, P327, DOI 10.1111/j.1432-1033.1967.tb00142.x; MILLER JR, 1995, J AM CHEM SOC, V117, P7830, DOI 10.1021/ja00134a038; PAECH C, 1980, J BIOL CHEM, V255, P2700; Ramsay RR, 1995, PROG BRAIN RES, V106, P33; RAMSAY RR, 1991, BIOCHEMISTRY-US, V30, P4624, DOI 10.1021/bi00232a038; SALACH JI, 1979, ARCH BIOCHEM BIOPHYS, V192, P128, DOI 10.1016/0003-9861(79)90078-X; SCHULTZ GE, 1984, FLAVINS FLAVOPROTEIN, P81; SILVERMAN RB, 1986, BIOCHEM BIOPH RES CO, V135, P154, DOI 10.1016/0006-291X(86)90955-1; SILVERMAN RB, 1995, ACCOUNTS CHEM RES, V28, P335, DOI 10.1021/ar00056a003; SILVERMAN RB, 1984, BIOCHEMISTRY-US, V23, P1322, DOI 10.1021/bi00301a046; SINGER TP, 1945, J BIOL CHEM, V157, P241; TAN AK, 1993, BIOCHEMISTRY-US, V32, P2137, DOI 10.1021/bi00060a003; WEYLER W, 1990, PHARMACOL THERAPEUT, V47, P391, DOI 10.1016/0163-7258(90)90064-9; WEYLER W, 1985, J BIOL CHEM, V260, P3199; WEYLER W, 1990, BIOCHEM BIOPH RES CO, V173, P1205, DOI 10.1016/S0006-291X(05)80914-3; WILLIAMS CH, 1995, FASEB J, V9, P1267, DOI 10.1096/fasebj.9.13.7557016; WOUTERS J, 1995, BIOCHEM BIOPH RES CO, V208, P773, DOI 10.1006/bbrc.1995.1404; WU HF, 1993, MOL PHARMACOL, V43, P888; YUE KT, 1993, ARCH BIOCHEM BIOPHYS, V300, P178, DOI 10.1006/abbi.1993.1025; Zhong BY, 1997, J AM CHEM SOC, V119, P6690, DOI 10.1021/ja9711369	25	20	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14074	14076		10.1074/jbc.273.23.14074	http://dx.doi.org/10.1074/jbc.273.23.14074			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603903	hybrid			2022-12-27	WOS:000074021500005
J	Zhang, J; Banfic, H; Straforini, F; Tosi, L; Volinia, S; Rittenhouse, SE				Zhang, J; Banfic, H; Straforini, F; Tosi, L; Volinia, S; Rittenhouse, SE			A type II phosphoinositide 3-kinase is stimulated via activated integrin in platelets - A source of phosphatidylinositol 3-phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; RECEPTOR; LIGAND; CELLS; POLYPHOSPHOINOSITIDES; WORTMANNIN; BINDING; DOMAIN	We have observed that aggregation of human platelets, caused by activation of integrin alpha(IIb)beta(3) and its consequent binding of fibrinogen, stimulates a novel pathway for synthesis of phosphatidylinositol 3,4-bisphosphate, thereby activating protein kinase B/Akt. Such synthesis depends upon both the generation of phosphatidylinositol 3-phosphate (PtdIns3P), which is sensitive to wortmannin (IC50 7 nM) and calpain inhibitors, and the phosphorylation of PtdIns3P by PtdIns3P 4-kinase. We now report that a recently characterized C2 domain-containing phosphoinositide 3-kinase iso form (HsC2-PI3K) is present in platelets and a leukemic cell line (CHRF-288) derived from megakaryoblasts, and is likely to be responsible for the stimulated synthesis of PtdIns3P observed in platelets. HsC2-PI3K, identifiable by Western blotting and immunoprecipitatable activity, is sensitive to wortmannin (IC50 6-10 nm), requires Mg2+, and shows strong preference for PtdIns over PtdIns4P or phosphatidylinositol 4,5-bisphosphate as substrate. HsC2-PI3K is activated severalfold when platelets aggregate in an alpha(IIb)beta(3)-dependent manner or when platelet or CHRF-288 lysates are incubated with Ca2+. Activation is prevented by calpain inhibitors. CHRF-288, which cannot undergo activation of alpha(IIb)beta(3) and thereby aggregate in response to platelet agonists, do not generate PtdIns3P or activate HsC2-PI3K under conditions that stimulate other phosphoinositide 3-kinases. HsC2-PI3K may thus be an important effector for integrin-dependent signaling.	Thomas Jefferson Univ, Kimmel Canc Inst, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Cardeza Fdn Hematol Res, Philadelphia, PA 19107 USA; Univ Ferrara, Dipartimento Morfol & Embriol, I-44100 Ferrara, Italy; Univ Bologna, Ist Istol & Embriol, Bologna, Italy	Jefferson University; Jefferson University; University of Ferrara; University of Bologna	Rittenhouse, SE (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Philadelphia, PA 19107 USA.		Volinia, Stefano/AAA-9264-2019; Volinia, Stefano/A-3029-2010	Volinia, Stefano/0000-0003-0910-3893; Volinia, Stefano/0000-0003-0910-3893	NHLBI NIH HHS [HL38622] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038622] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; Banfic H, 1998, J BIOL CHEM, V273, P13, DOI 10.1074/jbc.273.1.13; Banfic H, 1998, J BIOL CHEM, V273, P11630, DOI 10.1074/jbc.273.19.11630; Brown RA, 1997, BIOCHEM BIOPH RES CO, V233, P537, DOI 10.1006/bbrc.1997.6495; Domin J, 1997, BIOCHEM J, V326, P139, DOI 10.1042/bj3260139; FOX JEB, 1993, J CELL BIOL, V120, P1501, DOI 10.1083/jcb.120.6.1501; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; FUGMAN DA, 1990, BLOOD, V75, P1252; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KIMURA K, 1994, J BIOL CHEM, V269, P18961; KOVACSOVICS TJ, 1995, J BIOL CHEM, V270, P11358, DOI 10.1074/jbc.270.19.11358; Molz L, 1996, J BIOL CHEM, V271, P13892, DOI 10.1074/jbc.271.23.13892; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; SHATTIL SJ, 1992, J BIOL CHEM, V267, P18424; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; SINGH SS, 1993, BIOCHEM BIOPH RES CO, V195, P104, DOI 10.1006/bbrc.1993.2016; TOKER A, 1994, J BIOL CHEM, V269, P32358; Velmuri GS, 1996, BIOCHEM J, V314, P805, DOI 10.1042/bj3140805; VEMURI GS, 1994, BIOCHEM BIOPH RES CO, V202, P1619, DOI 10.1006/bbrc.1994.2118; Virbasius JV, 1996, J BIOL CHEM, V271, P13304, DOI 10.1074/jbc.271.23.13304; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zhang J, 1996, J BIOL CHEM, V271, P6265, DOI 10.1074/jbc.271.11.6265; Zvelebil MJ, 1996, PHILOS T R SOC B, V351, P217, DOI 10.1098/rstb.1996.0019	25	93	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14081	14084		10.1074/jbc.273.23.14081	http://dx.doi.org/10.1074/jbc.273.23.14081			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603905	hybrid			2022-12-27	WOS:000074021500007
J	Kiemer, AK; Vollmar, AM				Kiemer, AK; Vollmar, AM			Autocrine regulation of inducible nitric-oxide synthase in macrophages by atrial natriuretic peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; GROWTH-FACTOR-BETA; ACTIVATED PROTEIN-KINASE; MESSENGER-RNA STABILITY; FACTOR-KAPPA-B; NO SYNTHASE; ASTROCYTE PROLIFERATION; CLEARANCE RECEPTOR; EXPRESSION; CELLS	Atrial natriuretic peptide (ANP), a cardiovascular hormone, has been shown to inhibit synthesis of nitric oxide in lipopolysaccharide (LPS)-activated mouse bone marrow-derived macrophages via activation of its guanylate cyclase-coupled receptor. The goal of the present study was to elucidate the potential sites of inducible nitric-oxide synthase (iNOS) regulation affected by ANP and revealed the following. 1) ANP and dibutyryl-cGMP did not inhibit catalytic iNOS activity measured by the conversion rate of L-[(3)H]arginine to L-[(3)H]citrulline in homogenates of LPS-treated cells. 2) Pretreatment of cells with ANP dose-dependently reduced the LPS-induced L-[(3)H]citrulline production that has been shown to be due to reduced iNOS protein levels detected by Western blot. 3) ANP does not alter the ratio of catalytically active iNOS dimer versus inactive iNOS monomer considered to be a major post-translational regulatory mechanism for the enzyme. 4) Macrophages exposed to ANP display decreased LPS-induced iNOS mRNA levels. 5) Importantly, two basic mechanisms seem to be responsible for this observation, i.e. ANP specifically induced acceleration of iNOS mRNA decay and ANP reduced binding activity of NF-kappa B, the transcription factor predominantly responsible for LPS-induced iNOS expression in murine macrophages. Moreover, 6) ANP acts via an autocrine mechanism since recently ANP was shown to be secreted by LPS-activated macrophages, and we demonstrated here that LPS-induced NO synthesis was increased after blocking the binding of endogenous ANP by a receptor antagonist. These observations suggest ANP as a new autocrine macrophage factor regulating NO synthesis both transcriptionally and post-transcriptionally. ANP may help to balance NO production of activated macrophages and thus may allow successful immune response without adverse effects on host cells.	Univ Munich, Inst Pharmacol Toxicol & Pharm, D-80539 Munich, Germany	University of Munich	Vollmar, AM (corresponding author), Univ Munich, Inst Pharmacol Toxicol & Pharm, Koniginstr 16, D-80539 Munich, Germany.	vollmar@pharmtox.vetmed.uni-muenchen.de	Kiemer, Alexandra K./I-9300-2012	Kiemer, Alexandra K./0000-0002-7224-9900				AIURA K, 1995, CRIT CARE MED, V23, P1898, DOI 10.1097/00003246-199511000-00017; Albakri QA, 1996, J BIOL CHEM, V271, P5414, DOI 10.1074/jbc.271.10.5414; Biesiada E, 1996, J BIOL CHEM, V271, P18576, DOI 10.1074/jbc.271.31.18576; Boese M, 1996, BRIT J PHARMACOL, V119, P707, DOI 10.1111/j.1476-5381.1996.tb15730.x; BOGDAN C, 1993, ANN NY ACAD SCI, V685, P713, DOI 10.1111/j.1749-6632.1993.tb35934.x; BOGDAN C, 1994, INFEC DIS T, V15, P37; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; DEAKIN AM, 1995, CYTOKINE, V7, P408, DOI 10.1006/cyto.1995.0056; DEGUCHI M, 1995, J INTERF CYTOK RES, V15, P977, DOI 10.1089/jir.1995.15.977; ESTLER HC, 1992, BIOL CHEM H-S, V373, P271, DOI 10.1515/bchm3.1992.373.1.271; FORSTERMANN U, 1995, N-S ARCH PHARMACOL, V352, P351; GANZ P, 1986, P NATL ACAD SCI USA, V83, P3552, DOI 10.1073/pnas.83.10.3552; GILBERT RS, 1993, BIOCHEM BIOPH RES CO, V195, P380, DOI 10.1006/bbrc.1993.2054; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GUTKOWSKA J, 1989, ENDOCR REV, V10, P519, DOI 10.1210/edrv-10-4-519; HAUSCHILDT S, 1990, BIOCHEM J, V270, P351, DOI 10.1042/bj2700351; HERSCHMAN HR, 1994, CANCER METAST REV, V13, P241, DOI 10.1007/BF00666095; Hrabak A, 1996, COMP BIOCHEM PHYS B, V113, P375, DOI 10.1016/0305-0491(95)02054-3; INOUE T, 1995, HYPERTENSION, V25, P711, DOI 10.1161/01.HYP.25.4.711; Kastelic T, 1996, CYTOKINE, V8, P751, DOI 10.1006/cyto.1996.0100; Kiemer AK, 1997, ENDOCRINOLOGY, V138, P4282, DOI 10.1210/en.138.10.4282; Kishimoto I, 1996, P NATL ACAD SCI USA, V93, P6215, DOI 10.1073/pnas.93.12.6215; Kleinert H, 1996, MOL PHARMACOL, V49, P15; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; LePage C, 1996, IMMUNOLOGY, V89, P274, DOI 10.1046/j.1365-2567.1996.d01-728.x; LEVIN ER, 1993, AM J PHYSIOL, V264, pE483, DOI 10.1152/ajpendo.1993.264.4.E483; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maack T, 1996, KIDNEY INT, V49, P1732, DOI 10.1038/ki.1996.257; MATSUDA Y, 1993, CARDIOVASC DRUG REV, V11, P45, DOI 10.1111/j.1527-3466.1993.tb00266.x; Messmer UK, 1996, J BIOL CHEM, V271, P20192, DOI 10.1074/jbc.271.33.20192; MONCADA S, 1991, PHARMACOL REV, V43, P109; MULLER JM, 1993, IMMUNOBIOLOGY, V187, P233; OBESO J, 1990, LAB INVEST, V63, P259; Pang LH, 1997, BIOCHEM PHARMACOL, V53, P493, DOI 10.1016/S0006-2952(96)00737-X; Prins BA, 1996, J BIOL CHEM, V271, P14156, DOI 10.1074/jbc.271.24.14156; ROSENZWEIG A, 1991, ANNU REV BIOCHEM, V60, P229, DOI 10.1146/annurev.biochem.60.1.229; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; STEVENSTRUSS R, 1995, BIOCHEMISTRY-US, V34, P15638, DOI 10.1021/bi00048a006; STUEHR DJ, 1987, CANCER RES, V47, P5590; Sugimoto T, 1996, J BIOL CHEM, V271, P544, DOI 10.1074/jbc.271.1.544; Szu-Hee L., 1985, J EXP MED, V161, P475; THROSBY M, 1993, ENDOCRINOLOGY, V132, P2184, DOI 10.1210/en.132.5.2184; VANSNICK J, 1988, EUR J IMMUNOL, V18, P193; VODOVOTZ Y, 1993, J EXP MED, V178, P605, DOI 10.1084/jem.178.2.605; VOLLMAR AM, 1995, J CLIN INVEST, V95, P2442, DOI 10.1172/JCI117944; Vollmar AM, 1996, ENDOCRINOLOGY, V137, P1706, DOI 10.1210/en.137.5.1706; VOLLMAR AM, 1990, ENDOCRINOLOGY, V126, P2277, DOI 10.1210/endo-126-5-2277; Vollmar AM, 1997, J NEUROIMMUNOL, V78, P90, DOI 10.1016/S0165-5728(97)00086-6; VOLLMAR AM, 1994, J CLIN INVEST, V94, P539, DOI 10.1172/JCI117367; Xie QW, 1996, P NATL ACAD SCI USA, V93, P4891, DOI 10.1073/pnas.93.10.4891; XIE QW, 1994, J BIOL CHEM, V269, P4705	53	107	117	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13444	13451		10.1074/jbc.273.22.13444	http://dx.doi.org/10.1074/jbc.273.22.13444			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593677	hybrid			2022-12-27	WOS:000073919100016
J	Kimzey, AL; Dynan, WS				Kimzey, AL; Dynan, WS			Specific regions of contact between human T-cell leukemia virus type I Tax protein and DNA identified by photocross-linking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN; 21-BASE-PAIR REPEATS; CROSS-LINKING; TRANSCRIPTIONAL ACTIVATOR; TRANSACTIVATOR TAX; LEUCINE ZIPPER; CREB BINDING; COMPLEX; SITE; RNA	The human T-cell leukemia virus type I Tax protein forms a ternary complex on DNA in association with a host factor, the cyclic AMP response element-binding protein (CREB). An understanding of the precise geometry of this complex has been elusive. We have used photocross-linking to investigate Tax-DNA contacts. Our data show that Tax contacts the DNA at two symmetric positions 14 nucleotides apart on either side of the Tax responsive element. The presence of symmetric, widely separated regions of contact suggests that at least two molecules of Tax are present in the complex. Mapping the contacts onto a three-dimensional model of the CREB-DNA binary complex shows that they lie on the same face of the DNA near the regions where the N termini of the CREB bZIP domains enter the major groove. This location correlates well with previous evidence that CREB amino acid residues immediately N-terminal to the bZIP domain are crucial for the formation of the ternary complex. The limited number of cross-links observed suggests that contacts are primarily with the phosphate backbone and does not support the idea that a major structural element of the Tax protein inserts into the major or minor grooves of the DNA.	Med Coll Georgia, Inst Mol Med & Genet, Gene Regulat Program, Augusta, GA 30912 USA; Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA	University System of Georgia; Augusta University; University of Colorado System; University of Colorado Boulder	Dynan, WS (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, Gene Regulat Program, 1120 15th St, Augusta, GA 30912 USA.			Dynan, William/0000-0002-4045-5662				ADYA N, 1994, P NATL ACAD SCI USA, V91, P5642, DOI 10.1073/pnas.91.12.5642; ANDERSON MG, 1994, NUCLEIC ACIDS RES, V22, P3194, DOI 10.1093/nar/22.15.3194; BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; BRAUWEILER A, 1995, J BIOL CHEM, V270, P12814, DOI 10.1074/jbc.270.21.12814; BURGIN AB, 1990, EMBO J, V9, P4111, DOI 10.1002/j.1460-2075.1990.tb07633.x; DIETZ TM, 1989, PHOTOCHEM PHOTOBIOL, V49, P121, DOI 10.1111/j.1751-1097.1989.tb04085.x; DUVALL JF, 1995, J VIROL, V69, P5077, DOI 10.1128/JVI.69.8.5077-5086.1995; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; Ferreira OC, 1997, BLOOD REV, V11, P91, DOI 10.1016/S0268-960X(97)90015-1; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; GITLIN SD, 1991, J VIROL, V65, P2612, DOI 10.1128/JVI.65.5.2612-2621.1991; GOREN I, 1995, J VIROL, V69, P5806, DOI 10.1128/JVI.69.9.5806-5811.1995; Jin DY, 1997, NUCLEIC ACIDS RES, V25, P379, DOI 10.1093/nar/25.2.379; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; Lagrange T, 1996, P NATL ACAD SCI USA, V93, P10620, DOI 10.1073/pnas.93.20.10620; Lenzmeier BA, 1998, MOL CELL BIOL, V18, P721, DOI 10.1128/MCB.18.2.721; MATTHEWS MAH, 1992, MOL CELL BIOL, V12, P1986, DOI 10.1128/MCB.12.5.1986; MAYER AN, 1995, GENE, V153, P1, DOI 10.1016/0378-1119(94)00752-E; Meisenheimer KM, 1997, CRIT REV BIOCHEM MOL, V32, P101, DOI 10.3109/10409239709108550; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PACAUCCARALERTKUN S, 1994, MOL CELL BIOL, V14, P456, DOI 10.1128/MCB.14.1.456; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; SEELER JS, 1993, VIROLOGY, V196, P442, DOI 10.1006/viro.1993.1500; SEMMES OJ, 1992, J VIROL, V66, P7183, DOI 10.1128/JVI.66.12.7183-7192.1992; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; THOMPSON NE, 1990, J BIOL CHEM, V265, P7069; Tie F, 1996, J VIROL, V70, P8368, DOI 10.1128/JVI.70.12.8368-8374.1996; Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15; WILLIS MC, 1993, SCIENCE, V262, P1255, DOI 10.1126/science.7694369; YANG SW, 1994, P NATL ACAD SCI USA, V91, P12183, DOI 10.1073/pnas.91.25.12183; YIN MJ, 1995, J VIROL, V69, P3420, DOI 10.1128/JVI.69.6.3420-3432.1995; Yin MJ, 1996, J MOL BIOL, V264, P20, DOI 10.1006/jmbi.1996.0620; Yin MJ, 1996, MOL CELL BIOL, V16, P3156; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	36	57	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13768	13775		10.1074/jbc.273.22.13768	http://dx.doi.org/10.1074/jbc.273.22.13768			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593719	hybrid			2022-12-27	WOS:000073919100058
J	Willems, R; Van Bockstaele, DR; Lardon, F; Lenjou, M; Nijs, G; Snoeck, HW; Berneman, ZN; Slegers, H				Willems, R; Van Bockstaele, DR; Lardon, F; Lenjou, M; Nijs, G; Snoeck, HW; Berneman, ZN; Slegers, H			Decrease in nucleoside diphosphate kinase (NDPK/nm23) expression during hematopoietic maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATION INHIBITORY FACTOR; C-MYC; TRANSCRIPTION FACTOR; LEUKEMIA-CELLS; MYELOID CELLS; NM23; PROTEIN; GENES; SUPPRESSOR; METASTASIS	The nucleoside diphosphate kinase (NDPK/nm23) isoforms H1 and H2 were localized in hematopoietic tissues. Flow cytometric analysis and enzymatic assays were used to quantify the intracellular and extracellular concentrations of NDPK. Bone marrow CD34(+) progenitors contained the highest intracellular levels of both nm23-H1 and nm23-H2. Lower levels were measured in more mature bone marrow cells, whereas peripheral blood leukocytes had the lowest expression of nm23. These data suggest a function of NDPK in early hematopoiesis and a down-regulation of NDPK upon differentiation. In addition, an up-regulation of nm23 expression was observed in lymphocytes after induction of proliferation with phytohemagglutinin. Multiparameter flow cytometry demonstrated that this up-regulation occurred during the G(0)/G(1)-transition. Flow cytometric analysis also revealed a weak surface expression of nm23 on a number of hematopoietic cell lines, which was not detected on normal hematopoietic cells. Our data also demonstrated the presence of NDPK in human plasma, probably due to a limited in vivo lysis of red blood cells.	Univ Instelling Antwerp, Dept Biochem, Lab Cellular Biochem, B-2610 Antwerp, Belgium; Univ Antwerp Hosp, Dept Med, Lab Expt Hematol, B-2650 Edegem, Belgium	University of Antwerp; University of Antwerp	Slegers, H (corresponding author), Univ Instelling Antwerp, Dept Biochem, Lab Cellular Biochem, Univ Plein 1, B-2610 Antwerp, Belgium.		Lardon, Filip/A-3559-2010	Lardon, Filip/0000-0001-7174-4144				ADLER JR, 1979, J BIOL CHEM, V254, P3866; Anciaux K, 1997, FEBS LETT, V400, P75, DOI 10.1016/S0014-5793(96)01358-0; Aryee DNT, 1996, BRIT J CANCER, V74, P1693, DOI 10.1038/bjc.1996.616; BACKER JM, 1993, ONCOGENE, V8, P497; Caligo MA, 1996, LEUKEMIA RES, V20, P161, DOI 10.1016/0145-2126(95)00122-0; CALIGO MA, 1995, INT J CANCER, V60, P837, DOI 10.1002/ijc.2910600619; CLEVENGER CV, 1985, CYTOMETRY, V6, P208, DOI 10.1002/cyto.990060306; CONTANT G, 1983, THROMB RES, V31, P365, DOI 10.1016/0049-3848(83)90337-7; CROSBY WH, 1956, BLOOD, V11, P380, DOI 10.1182/blood.V11.4.380.380; GILLES AM, 1991, J BIOL CHEM, V266, P8784; Guignard F, 1996, BIOCHEM J, V316, P233, DOI 10.1042/bj3160233; JI L, 1995, J BIOL CHEM, V270, P13392, DOI 10.1074/jbc.270.22.13392; KEIM D, 1992, J CLIN INVEST, V89, P919, DOI 10.1172/JCI115672; LAKSO M, 1992, CELL GROWTH DIFFER, V3, P873; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LEONE A, 1993, ONCOGENE, V8, P2325; Leung SM, 1997, J BIOL CHEM, V272, P2607, DOI 10.1074/jbc.272.5.2607; LIEBERMANN DA, 1994, STEM CELLS, V12, P352, DOI 10.1002/stem.5530120402; Lu Q, 1996, J BIOL CHEM, V271, P32886, DOI 10.1074/jbc.271.51.32886; MACDONALD NJ, 1993, J BIOL CHEM, V268, P25780; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Martinez R, 1997, CANCER RES, V57, P1180; Mesnildrey S, 1998, J BIOL CHEM, V273, P4436, DOI 10.1074/jbc.273.8.4436; Milon L, 1997, HUM GENET, V99, P550, DOI 10.1007/s004390050405; Nguyen HQ, 1995, ONCOGENE, V11, P2439; OKABEKADO J, 1992, BIOCHEM BIOPH RES CO, V182, P987, DOI 10.1016/0006-291X(92)91829-F; OKABEKADO J, 1995, FEBS LETT, V363, P311, DOI 10.1016/0014-5793(95)00338-A; OKABEKADO J, 1995, BBA-MOL CELL RES, V1267, P101, DOI 10.1016/0167-4889(95)00037-S; Okada K, 1996, ONCOGENE, V13, P1937; OTERO AD, 1990, BIOCHEM PHARMACOL, V39, P1399; Paravicini G, 1996, BIOCHEM BIOPH RES CO, V227, P82, DOI 10.1006/bbrc.1996.1471; Pilz RB, 1997, CELL GROWTH DIFFER, V8, P53; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; SONNEMANN J, 1995, BIOCHEM BIOPH RES CO, V209, P490, DOI 10.1006/bbrc.1995.1528; STAHL JA, 1991, CANCER RES, V48, P6550; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; URANO T, 1993, ONCOGENE, V8, P1371; VENTURELLI D, 1995, P NATL ACAD SCI USA, V92, P7435, DOI 10.1073/pnas.92.16.7435; WAGNER PD, 1995, J BIOL CHEM, V270, P21758, DOI 10.1074/jbc.270.37.21758; Yokoyama A, 1996, BLOOD, V88, P3555, DOI 10.1182/blood.V88.9.3555.bloodjournal8893555	40	38	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13663	13668		10.1074/jbc.273.22.13663	http://dx.doi.org/10.1074/jbc.273.22.13663			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593706	hybrid			2022-12-27	WOS:000073919100045
J	Lopez, I; Arnold, RS; Lambeth, JD				Lopez, I; Arnold, RS; Lambeth, JD			Cloning and initial characterization of a human phospholipase D2 (hPLD2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; PROTEIN-KINASE-C; GTP-BINDING PROTEIN; PHOSPHATIDIC-ACID; REGULATORY COMPONENT; ADENYLATE-CYCLASE; BRAIN CYTOSOL; CHOLERA-TOXIN; HL-60 CELLS; ACTIVATION	Phospholipase D (PLD) has been implicated in a variety of cellular processes including vesicular transport, the respiratory burst, and mitogenesis. PLD1, first cloned from human, is activated by small GTPases such as ADP-ribosylation factor (ARF) and RhoA Rodent PLD2, which is approximately 50% identical to PLD1 has recently been cloned from mouse embryo (Colley, W., Sung, T., Roll, R., Jenco, J., Hammond, S., Altshuller, Y., Bar-Sagi, D., Morris, A, and Frohman, M. (1997) Curr. Biol 7, 191-201) and rat brain (Kodaki, T., and Yamashita, S. (1997) J. Biol, Chem. 272, 11408-11413). We describe herein the cloning from a B cell Library and expression of human PLD2 (hPLD2). The open reading frame is predicted to encode a 933-amino acid protein (M-r of 105,995); this corresponds to the size of the protein expressed in insect cells using recombinant baculovirus. The deduced amino acid sequence shows 53 and 90% identity to hPLD1 and rodent PLDS, respectively. The mRNA for PLDS was widely distributed in various tissues including peripheral blood leukocytes, and the distribution was distinctly different from that of hPLD1. hPLD1 and hPLD2 both showed a requirement for phosphatidylinositol 4,5-bisphosphate. Both isoforms showed optimal activity at 10-20 mol % phosphatidylcholine in a mixed lipid vesicle system and showed comparable basal activities in the presence of phosphatidylinositol 4,5-bisphosphate. Unexpectedly, ARF-1 stimulated the activity of hPLD2 expressed in insect cells about a-fold, compared with a 20-fold stimulation of hPLD1 activity. Thus, not only PLD1 but also hPLD2 activity can be positively regulated by both phosphatidylinositol 4,5-bisphosphate and ARF.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA	Emory University	Lambeth, JD (corresponding author), Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA.				NCI NIH HHS [CA45608] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Baek SH, 1997, J BIOL CHEM, V272, P32042, DOI 10.1074/jbc.272.51.32042; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; Bi K, 1997, CURR BIOL, V7, P301, DOI 10.1016/S0960-9822(06)00153-9; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; BOURGOIN S, 1995, J BIOL CHEM, V270, P3172, DOI 10.1074/jbc.270.7.3172; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BROWN HA, 1995, J BIOL CHEM, V270, P14935, DOI 10.1074/jbc.270.25.14935; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Chen YG, 1997, J CELL BIOL, V138, P495, DOI 10.1083/jcb.138.3.495; Chung JK, 1997, J BIOL CHEM, V272, P15980, DOI 10.1074/jbc.272.25.15980; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; English D, 1996, CHEM PHYS LIPIDS, V80, P117, DOI 10.1016/0009-3084(96)02549-2; EXTON JH, 1994, BIOCHIM BIOPHYS ACTA, V1212, P25; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; Han JS, 1996, J BIOL CHEM, V271, P11163, DOI 10.1074/jbc.271.19.11163; KAHN RA, 1984, J BIOL CHEM, V259, P6228; Kearns BG, 1997, NATURE, V387, P101, DOI 10.1038/387101a0; Kim JH, 1996, J BIOL CHEM, V271, P25213, DOI 10.1074/jbc.271.41.25213; Kodaki T, 1997, J BIOL CHEM, V272, P11408; Koonin EV, 1996, TRENDS BIOCHEM SCI, V21, P242, DOI 10.1016/0968-0004(96)30024-8; KURIBARA H, 1995, J BIOL CHEM, V270, P25667, DOI 10.1074/jbc.270.43.25667; KWAK JY, 1995, J BIOL CHEM, V270, P27093, DOI 10.1074/jbc.270.45.27093; LAMBETH JD, 1995, J BIOL CHEM, V270, P2431, DOI 10.1074/jbc.270.6.2431; LAMBETH JD, 1994, PROTEIN KINASE C, P121; Lambeth JD., 1996, NEW COMPREHENSIVE BI, P237; Lee CH, 1997, J BIOL CHEM, V272, P15986, DOI 10.1074/jbc.272.25.15986; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; LOPEZ I, 1995, J BIOL CHEM, V270, P19465, DOI 10.1074/jbc.270.33.19465; Lukowski S, 1996, J BIOL CHEM, V271, P24164, DOI 10.1074/jbc.271.39.24164; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; Morris AJ, 1996, TRENDS PHARMACOL SCI, V17, P182, DOI 10.1016/0165-6147(96)10016-X; Ohguchi K, 1996, J BIOL CHEM, V271, P4366; OKAMURA S, 1994, J BIOL CHEM, V269, P31207; Park SK, 1997, J BIOL CHEM, V272, P29263, DOI 10.1074/jbc.272.46.29263; PERRY DK, 1993, J BIOL CHEM, V268, P25302; POINTING CP, 1996, PROTEIN SCI, V3, P356; Provost JJ, 1996, BIOCHEM J, V319, P285, DOI 10.1042/bj3190285; RANDAZZO PA, 1992, METHOD ENZYMOL, V219, P362; Sabatini DD, 1996, BIOCELL, V20, P287; SCHLEIFER LS, 1982, J BIOL CHEM, V257, P20; SIDDIQI AR, 1995, J BIOL CHEM, V270, P8466, DOI 10.1074/jbc.270.15.8466; SINGER WD, 1995, J BIOL CHEM, V270, P14944, DOI 10.1074/jbc.270.25.14944; Singer WD, 1996, J BIOL CHEM, V271, P4504; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0; Whatmore J, 1996, BIOCHEM J, V320, P785, DOI 10.1042/bj3200785	52	216	223	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					12846	12852		10.1074/jbc.273.21.12846	http://dx.doi.org/10.1074/jbc.273.21.12846			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582313	hybrid			2022-12-27	WOS:000073768500024
J	Mehtani, S; Gong, QM; Panella, J; Subbiah, S; Peffley, DM; Frankfater, A				Mehtani, S; Gong, QM; Panella, J; Subbiah, S; Peffley, DM; Frankfater, A			In vivo expression of an alternatively spliced human tumor message that encodes a truncated form of cathepsin B - Subcellular distribution of the truncated enzyme in COS cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; CYSTEINE PROTEINASES; GENE; RNA; LOCALIZATION; NUCLEOTIDE; PROPEPTIDE; SEQUENCE; REGION; CDNAS	Cathepsin B is a lysosomal cysteine protease whose increased expression is believed to be linked to the malignant progression of tumors. Alternative splicing and the use of alternative transcription initiation sites in humans produce cathepsin B mRNAs that differ in their 5'- and 3'-untranslated ends. Some human tumors also contain cathepsin B-related transcripts that lack exon 3 which encodes the N-terminal signal peptide and 34 of the 62-amino acid inhibitory propeptide. In this study we show that one such transcript, CB(-2,3), which is missing exons 2 and 3, is likely to be a functional message in tumors. Thus, CB(-2,3) was found to be otherwise complete, containing the remainder of the cathepsin B coding sequence and the part of the 3'-untranslated region that is common to all previously characterized cathepsin B mRNAs in humans. Its in vitro translation product can be folded to produce enzymatic activity against the cathepsin B-specific substrate, N-alpha-benzyloxycarbonyl-L-Arg-L-Arg-4-methycoumaryl-7- amide, Endogenous CB(-2,3) from the metastatic human melanoma cell line, A375M, co-sediments with polysomes, indicating that it engages the eukaryotic translation machinery in these cells. Epitope-tagged forms of the truncated cathepsin B from CB(-2,3) are produced in amounts comparable to the normal protein after transient transfection into COS cells. Immunofluorescence microscopy and subcellular fractionation show this novel tumor form of cathepsin B to be associated with nuclei and other membranous organelles, where it is likely to be bound to the cytoplasmic face of the membranes. This subcellular distribution was different from the lysosomal pattern shown by the epitope-tagged, full-length cathepsin B in COS cells. These results indicate that the message missing exons 2 and 3 is likely to be translated into a catalytically active enzyme, and that alternative splicing (exon skipping) could contribute to the aberrant intracellular trafficking of cathepsin B that is observed in some human cancers.	Loyola Univ, Med Ctr, Dept Mol & Cellular Biochem, Stritch Sch Med, Maywood, IL 60153 USA; Finch Univ Hlth Sci Chicago Med Sch, Dept Mol Biol & Pharmacol, N Chicago, IL 60064 USA	Loyola University Chicago; Chicago Medical School	Frankfater, A (corresponding author), Loyola Univ, Med Ctr, Dept Mol & Cellular Biochem, Stritch Sch Med, 2160 S 1St Ave, Maywood, IL 60153 USA.	afrankf@luc.edu						ACHKAR C, 1990, J BIOL CHEM, V267, P15993; AKAO Y, 1994, CANCER RES, V54, P2468; AMBARTSUMIAN N, 1995, GENE, V159, P125, DOI 10.1016/0378-1119(94)00778-Q; BAICI A, 1986, INT J CANCER, V38, P753, DOI 10.1002/ijc.2910380520; BAMBERG K, 1994, J BIOL CHEM, V269, P16909; BECKER KF, 1992, SEMIN IMMUNOL, V5, P105; BELL GI, 1979, NATURE, V282, P525, DOI 10.1038/282525a0; BERQUIN IM, 1995, GENE, V159, P143, DOI 10.1016/0378-1119(95)00072-E; CAO LQ, 1994, GENE, V139, P163, DOI 10.1016/0378-1119(94)90750-1; CHAN SJ, 1986, P NATL ACAD SCI USA, V83, P7721, DOI 10.1073/pnas.83.20.7721; Chapman RL, 1997, J BIOL CHEM, V272, P8808, DOI 10.1074/jbc.272.13.8808; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONNER GE, 1992, J BIOL CHEM, V267, P21738; CULLEN BR, 1987, METHOD ENZYMOL, V44, P692; DUVE CD, 1955, BIOCHEM J, V60, P604, DOI 10.1042/bj0600604; Gallagher S, 1993, CURRENT PROTOCOLS MO, V2, P1081; GONG QM, 1993, DNA CELL BIOL, V12, P299, DOI 10.1089/dna.1993.12.299; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HALBAN A, 1994, DIABETOLOG, V37, pS65; Hellsten E, 1996, EMBO J, V15, P5240, DOI 10.1002/j.1460-2075.1996.tb00909.x; HIWASA T, 1987, FEBS LETT, V211, P23, DOI 10.1016/0014-5793(87)81266-8; HIWASA T, 1993, CANCER LETT, V69, P161, DOI 10.1016/0304-3835(93)90169-A; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; Ido Y, 1997, SCIENCE, V277, P563, DOI 10.1126/science.277.5325.563; ISIDORO C, 1991, BIOCHEM J, V273, P363, DOI 10.1042/bj2730363; Jaenicke R, 1989, PROTEIN STRUCTURE PR, P191; KEPPLER D, 1988, CANCER RES, V48, P6855; Kim TW, 1997, J BIOL CHEM, V272, P11006; Koronakis V, 1993, Semin Cell Biol, V4, P7, DOI 10.1006/scel.1993.1002; KULIAWAT R, 1994, J CELL BIOL, V126, P77, DOI 10.1083/jcb.126.1.77; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITHGOW T, 1994, CELL GROWTH DIFFER, V5, P411; LOWRY DR, 1993, ANNU REV BIOCHEM, V62, P851; MACH L, 1992, BIOCHEM J, V282, P577, DOI 10.1042/bj2820577; MCNULTY JA, 1995, J PINEAL RES, V19, P40, DOI 10.1111/j.1600-079X.1995.tb00169.x; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MORT JS, 1986, BIOCHEM J, V233, P57, DOI 10.1042/bj2330057; MUSIL D, 1991, EMBO J, V10, P2321, DOI 10.1002/j.1460-2075.1991.tb07771.x; Ng DTW, 1996, J CELL BIOL, V134, P269, DOI 10.1083/jcb.134.2.269; OLDEN K, 1979, P NATL ACAD SCI USA, V76, P791, DOI 10.1073/pnas.76.2.791; PAGE AE, 1992, BIOCHIM BIOPHYS ACTA, V1116, P57, DOI 10.1016/0304-4165(92)90128-H; PEFFLEY DM, 1995, SOMAT CELL MOLEC GEN, V21, P189, DOI 10.1007/BF02254770; PIETRAS RJ, 1981, J BIOL CHEM, V256, P8536; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; QIAN F, 1989, CANCER RES, V49, P4870; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; RAMOS C, 1994, J BIOL CHEM, V269, P7006; RECKLIES AD, 1980, CANCER RES, V40, P550; REILLY JJ, 1989, BIOCHEM J, V257, P493, DOI 10.1042/bj2570493; ROWAN AD, 1992, J BIOL CHEM, V267, P15993; Senda T, 1997, EXP CELL RES, V230, P163, DOI 10.1006/excr.1996.3414; SHIFRIN VI, 1993, J BIOL CHEM, V268, P25376; SHINDE U, 1993, P NATL ACAD SCI USA, V90, P6924, DOI 10.1073/pnas.90.15.6924; SINHA AA, 1989, ANAT REC, V223, P266, DOI 10.1002/ar.1092230305; Sloane B F, 1990, Semin Cancer Biol, V1, P137; SLOANE BF, 1994, J CELL SCI, V107, P373; SLOANE BF, 1987, EXP CELL BIOL, V55, P209; SPIESS E, 1994, J HISTOCHEM CYTOCHEM, V42, P917, DOI 10.1177/42.7.8014475; Steiner DF, 1997, SCIENCE, V277, P531, DOI 10.1126/science.277.5325.531; TAM SW, 1994, GENE, V139, P171, DOI 10.1016/0378-1119(94)90751-X; TAO K, 1994, ARCH BIOCHEM BIOPHYS, V311, P19, DOI 10.1006/abbi.1994.1203; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; Vito P, 1996, J BIOL CHEM, V271, P31025, DOI 10.1074/jbc.271.49.31025; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WEISS RE, 1990, J UROLOGY, V144, P798, DOI 10.1016/S0022-5347(17)39595-2; Wetmore DR, 1996, BIOCHEMISTRY-US, V35, P6549, DOI 10.1021/bi9530752; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; YON J, 1989, NUCLEIC ACIDS RES, V17, P4895, DOI 10.1093/nar/17.12.4895	70	53	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					13236	13244		10.1074/jbc.273.21.13236	http://dx.doi.org/10.1074/jbc.273.21.13236			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582368	hybrid			2022-12-27	WOS:000073768500079
J	Kokame, K; Zheng, XL; Sadler, JE				Kokame, K; Zheng, XL; Sadler, JE			Activation of thrombin-activable fibrinolysis inhibitor requires epidermal growth factor-like domain 3 of thrombomodulin and is inhibited competitively by protein C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN THROMBOMODULIN; COFACTOR ACTIVITY; FUNCTIONAL DOMAINS; HUMAN-SERUM; BINDING; CARBOXYPEPTIDASE; LOCALIZATION; PURIFICATION; EXPRESSION; RECEPTOR	Thrombomodulin is a cofactor protein on vascular endothelial cells that inhibits the procoagulant functions of thrombin and enhances thrombin-catalyzed activation of anticoagulant protein C. Thrombomodulin also accelerates the proteolytic activation of a plasma procarboxypeptidase referred to as thrombin-activable fibrinolysis inhibitor (TAFI), In this study, we describe structures on recombinant membrane-bound thrombomodulin that are required for human TAFI activation. Deletion of the N-terminal lectin-like domain and epidermal growth factor (EGF)-like domains 1 and 2 had no effect on TAFI or protein C activation, whereas deletions including EGF-like domain 3 selectively abolished thrombomodulin cofactor activity for TAFI activation. Provided that thrombomodulin EGF-like domain 3 was present, TAFI competitively inhibited protein C activation catalyzed by the thrombin-thrombomodulin complex. A thrombomodulin construct lacking EGF-like domain 3 functioned normally as a cofactor for protein C activation but was insensitive to inhibition by TAFI, Thus, the anticoagulant and antifibrinolytic cofactor activities of thrombomodulin have distinct structural requirements: protein C binding to the thrombin-thrombomodulin complex requires EGF-like domain 4, whereas TAFI binding also requires EGF-like domain 3.	Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL)	Sadler, JE (corresponding author), Washington Univ, Sch Med, Howard Hughes Med Inst, 660 S Euclid Ave,Box 8022, St Louis, MO 63110 USA.		Sadler, Evan/D-8556-2011; Zheng, X. Long/ABD-7362-2021	Zheng, X. Long/0000-0003-1680-5295; Sadler, J. Evan/0000-0001-5705-469X; Kokame, Koichi/0000-0002-9654-6299	NIDDK NIH HHS [DK50053] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050053] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bajzar L, 1996, J BIOL CHEM, V271, P16603, DOI 10.1074/jbc.271.28.16603; BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; Bertina R. M., 1988, PROTEIN C RELATED PR, P21; Boffa MB, 1998, J BIOL CHEM, V273, P2127, DOI 10.1074/jbc.273.4.2127; CLARKE JH, 1993, J BIOL CHEM, V268, P6309; EATON DL, 1991, J BIOL CHEM, V266, P21833; ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; GRIFFIN JH, 1981, J CLIN INVEST, V68, P1370, DOI 10.1172/JCI110385; HAYASHI T, 1990, J BIOL CHEM, V265, P20156; HENDRIKS D, 1990, BIOCHIM BIOPHYS ACTA, V1034, P86, DOI 10.1016/0304-4165(90)90157-R; HENDRIKS D, 1989, J CLIN CHEM CLIN BIO, V27, P277; JACKMAN RW, 1986, P NATL ACAD SCI USA, V83, P8834, DOI 10.1073/pnas.83.23.8834; KUROSAWA S, 1988, J BIOL CHEM, V263, P5993; KUROSAWA S, 1987, J BIOL CHEM, V262, P2206; LENTZ SR, 1993, J BIOL CHEM, V268, P15312; Nesheim M, 1997, THROMB HAEMOSTASIS, V78, P386; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PARKINSON JF, 1990, J BIOL CHEM, V265, P12602; PARKINSON JF, 1992, BIOCHEM BIOPH RES CO, V185, P567, DOI 10.1016/0006-291X(92)91662-A; PETERSEN TE, 1988, FEBS LETT, V231, P51, DOI 10.1016/0014-5793(88)80700-2; SADLER JE, 1993, HAEMOSTASIS, V23, P183; SUZUKI K, 1989, J BIOL CHEM, V264, P4872; SUZUKI K, 1987, EMBO J, V6, P1891, DOI 10.1002/j.1460-2075.1987.tb02448.x; TSIANG M, 1992, J BIOL CHEM, V267, P6164; TSIANG M, 1990, BIOCHEMISTRY-US, V29, P10602, DOI 10.1021/bi00499a005; WEN DZ, 1987, BIOCHEMISTRY-US, V26, P4350, DOI 10.1021/bi00388a025; ZUSHI M, 1989, J BIOL CHEM, V264, P10351	27	74	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12135	12139		10.1074/jbc.273.20.12135	http://dx.doi.org/10.1074/jbc.273.20.12135			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575159	hybrid			2022-12-27	WOS:000073629800024
J	Lodge, JK; Jackson-Machelski, E; Higgins, M; McWherter, CA; Sikorski, JA; Devadas, B; Gordon, JI				Lodge, JK; Jackson-Machelski, E; Higgins, M; McWherter, CA; Sikorski, JA; Devadas, B; Gordon, JI			Genetic and biochemical studies establish that the fungicidal effect of a fully depeptidized inhibitor of Cryptococcus neoformans myristoyl-CoA : protein N-myristoyltransferase (Nmt) is Nmt-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; SACCHAROMYCES-CEREVISIAE; CANDIDA-ALBICANS; 2 GENES; SUBSTRATE-SPECIFICITY; ACID AUXOTROPHY; CLONING; EXPRESSION; VIRULENCE; COMPLEMENTATION	Cryptococcus neoformans is a fungal pathogen that causes chronic meningitis in 10% of patients with AIDS. Genetic and biochemical studies were conducted to determine whether myristoyl-CoA:protein N-myristoyltransferase (Nmt) is a target for development of a new class of fungicidal drugs. A single copy of a conditional lethal C. neoformans NMT allele was introduced into the fungal genome by homologous recombination, The allele (nmt487D) produces temperature-sensitive myristic acid auxotrophy, This phenotype is due, in part, to under-myristoylation of a cellular ADP ribosylation factor (Arf) and can be rescued by forced expression of human Nmt. Two isogenic strains with identical growth kinetics at 35 degrees C were used 60 test the biological effects of an Nmt inhibitor. CPA8 contained a single copy of wild type C. neoformans NMT. HMC1 contained nmt487D plus 10 copies of human NMT. Since a single copy of nmt487D will not support growth at 35 degrees C, survival of HMC1 depends upon its human Nmt. ALYASKLS-NH2, an inhibitor derived from an Arf, was fully depeptidized: p-[(2-methyl-1-imidazol-1-yl)butyl]phenyl-acetyl was used to represent the GLYA tetrapeptide, whereas SKLS was replaced with a chiral tyrosinol scaffold. Kinetic studies revealed Ki ((app)) values of 1.8 +/- 1 and 9 +/- 2.4 mu M for purified fungal and human Nmts, respectively. The minimal inhibitory concentration of the compound was a-fold lower for CPAS compared with HMC1, A single dose of 100 mu M produced a 5-fold greater inhibition of protein synthesis in CPA8 versus HMC1. The strain specificity of these responses indicates that the fungicidal effect was Nmt-dependent. These two strains may be useful for screening chemical Libraries for Nmt-based fungicidal compounds with relatively little activity against the human enzyme.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; GD Searle & Co, Dept Med & Struct Chem, St Louis, MO 63198 USA	Washington University (WUSTL)	Gordon, JI (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, Box 8103,660 S Euclid Ave, St Louis, MO 63110 USA.			Lodge, Jennifer/0000-0002-2526-1210	NIAID NIH HHS [AI38200] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038200] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alspaugh JA, 1997, GENE DEV, V11, P3206, DOI 10.1101/gad.11.23.3206; Bhatnagar RS, 1997, TRENDS CELL BIOL, V7, P14, DOI 10.1016/S0962-8924(97)10044-7; BHATNAGAR RS, 1994, J BIOL CHEM, V269, P11045; Bhatnagar RS, 1997, BIOCHEMISTRY-US, V36, P6700, DOI 10.1021/bi970311v; Brown DL, 1997, BIOORG MED CHEM LETT, V7, P379, DOI 10.1016/S0960-894X(97)00030-9; Chang YC, 1996, INFECT IMMUN, V64, P1977, DOI 10.1128/IAI.64.6.1977-1983.1996; CHANG YC, 1994, MOL CELL BIOL, V14, P4912, DOI 10.1128/MCB.14.7.4912; COX GM, 1995, J MED VET MYCOL, V33, P261; Cox GM, 1996, J MED VET MYCOL, V34, P385; Devadas B, 1997, J MED CHEM, V40, P2609, DOI 10.1021/jm970094w; Devadas B, 1998, J MED CHEM, V41, P996, DOI 10.1021/jm980001q; Devadas B, 1996, BIOORG MED CHEM LETT, V6, P1977, DOI 10.1016/0960-894X(96)00354-X; DEVADAS B, 1995, J MED CHEM, V38, P1837, DOI 10.1021/jm00011a001; DOHLMAN HG, 1993, P NATL ACAD SCI USA, V90, P9688, DOI 10.1073/pnas.90.20.9688; DURONIO RJ, 1992, P NATL ACAD SCI USA, V89, P4129, DOI 10.1073/pnas.89.9.4129; DURONIO RJ, 1991, J CELL BIOL, V113, P1313, DOI 10.1083/jcb.113.6.1313; EDMAN JC, 1990, MOL CELL BIOL, V10, P4538, DOI 10.1128/MCB.10.9.4538; Glover CJ, 1997, J BIOL CHEM, V272, P28680, DOI 10.1074/jbc.272.45.28680; JACOBSON ES, 1982, J BACTERIOL, V150, P1292, DOI 10.1128/JB.150.3.1292-1296.1982; KAHN RA, 1995, J BIOL CHEM, V270, P143, DOI 10.1074/jbc.270.1.143; KISHORE NS, 1991, J BIOL CHEM, V266, P8835; KISHORE NS, 1993, J BIOL CHEM, V268, P4889; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGNER CA, 1992, J BIOL CHEM, V267, P17159; LIVI LL, 1994, GENE, V150, P221, DOI 10.1016/0378-1119(94)90430-8; LODGE JK, 1994, J BIOL CHEM, V269, P2996; LODGE JK, 1994, P NATL ACAD SCI USA, V91, P12008, DOI 10.1073/pnas.91.25.12008; Lodge JK, 1997, MICROBIOL-UK, V143, P357, DOI 10.1099/00221287-143-2-357; McWherter CA, 1997, J BIOL CHEM, V272, P11874, DOI 10.1074/jbc.272.18.11874; MITCHELL TG, 1995, CLIN MICROBIOL REV, V8, P515, DOI 10.1128/CMR.8.4.515; Nagarajan SR, 1997, J MED CHEM, V40, P1422, DOI 10.1021/jm9608671; NAGATA S, 1984, EMBO J, V3, P1825, DOI 10.1002/j.1460-2075.1984.tb02053.x; *NAT COMM CLIN LAB, 1995, 27T M NAT COMM CLIN; Odom A, 1997, EMBO J, V16, P2576, DOI 10.1093/emboj/16.10.2576; PARKER AR, 1994, GENE, V145, P135, DOI 10.1016/0378-1119(94)90336-0; PERFECT JR, 1993, INFECT IMMUN, V61, P4446, DOI 10.1128/IAI.61.10.4446-4451.1993; PERFECT JR, 1992, GENE, V122, P213, DOI 10.1016/0378-1119(92)90053-R; POWDERLY WG, 1995, NEW ENGL J MED, V332, P700, DOI 10.1056/NEJM199503163321102; RANDAZZO PA, 1995, METHOD ENZYMOL, V250, P394; ROCQUE WJ, 1993, J BIOL CHEM, V268, P9964; Rudnick D.A., 1992, LIPID MODIFICATION P, P37; RUDNICK DA, 1991, J BIOL CHEM, V266, P9732; Salas SD, 1996, J EXP MED, V184, P377, DOI 10.1084/jem.184.2.377; SCHIRMAIER F, 1984, EMBO J, V3, P3311, DOI 10.1002/j.1460-2075.1984.tb02295.x; Segel I.H., 1976, BIOCH CALCULATIONS S; Sikorski JA, 1997, BIOPOLYMERS, V43, P43, DOI 10.1002/(SICI)1097-0282(1997)43:1&lt;43::AID-BIP5&gt;3.0.CO;2-0; SIRAWARAPORN W, 1993, J BIOL CHEM, V268, P8888; SPITZER ED, 1995, GENE, V161, P113, DOI 10.1016/0378-1119(95)00231-T; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; TOFFALETTI DL, 1993, J BACTERIOL, V175, P1405, DOI 10.1128/JB.175.5.1405-1411.1993; TOLKACHEVA T, 1994, INFECT IMMUN, V62, P2849, DOI 10.1128/IAI.62.7.2849-2856.1994; vanderHorst CM, 1997, NEW ENGL J MED, V337, P15, DOI 10.1056/NEJM199707033370103; WEINBURG RA, 1995, MOL MICROBIOL, V16, P241, DOI 10.1111/j.1365-2958.1995.tb02296.x; Weston SA, 1998, NAT STRUCT BIOL, V5, P213, DOI 10.1038/nsb0398-213; Wickes BL, 1996, P NATL ACAD SCI USA, V93, P7327, DOI 10.1073/pnas.93.14.7327; WICKES BL, 1995, MOL MICROBIOL, V16, P1099, DOI 10.1111/j.1365-2958.1995.tb02335.x; Zhang LT, 1996, J BIOL CHEM, V271, P33131, DOI 10.1074/jbc.271.51.33131	57	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12482	12491		10.1074/jbc.273.20.12482	http://dx.doi.org/10.1074/jbc.273.20.12482			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575206	hybrid			2022-12-27	WOS:000073629800071
J	Polakiewicz, RD; Schieferl, SM; Dorner, LF; Kansra, V; Comb, MJ				Polakiewicz, RD; Schieferl, SM; Dorner, LF; Kansra, V; Comb, MJ			A mitogen-activated protein kinase pathway is required for mu-opioid receptor desensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; MAP KINASE; AGONIST; INTERNALIZATION; PHOSPHORYLATION; SEQUESTRATION	The mu-opioid receptor mediates not only the beneficial painkilling effects of opiates like morphine but also the detrimental effects of chronic exposure such as tolerance and dependence. Different studies have linked tolerance to opioid receptor desensitization. Agonist activation of the mu-opioid receptor stimulates a mitogen-activated protein kinase (MAPK) activity, but the functional significance of this pathway remains unclear. We have focused on the MAPK signaling cascade to study mu-opioid receptor desensitization. We report that inhibition of the MAPK pathway blocks desensitization of mu-opioid receptor signaling as well as the loss of receptor density due to internalization. Our results suggest that a feedback signal emanating from the MAPK cascade is required for mu-opioid receptor desensitization.	New England Biolabs Inc, Cell Signaling Lab, Beverly, MA 01915 USA		Polakiewicz, RD (corresponding author), New England Biolabs Inc, Cell Signaling Lab, 32 Tozer Rd, Beverly, MA 01915 USA.	polakiew@neb.com			NIDA NIH HHS [DA05706] Funding Source: Medline	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ARDEN JR, 1995, J NEUROCHEM, V65, P1636; Bohm SK, 1997, BIOCHEM J, V322, P1; Burt AR, 1996, BIOCHEM J, V320, P227, DOI 10.1042/bj3200227; Daaka Y, 1997, P NATL ACAD SCI USA, V94, P2180, DOI 10.1073/pnas.94.6.2180; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; FEIG L, 1988, MOL CELL BIOL, V8, P4822; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; Fukuda K, 1996, J NEUROCHEM, V67, P1309; Gaudriault G, 1997, J BIOL CHEM, V272, P2880, DOI 10.1074/jbc.272.5.2880; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; Kansra V, 1997, AM J PHYSIOL-RENAL, V273, pF53, DOI 10.1152/ajprenal.1997.273.1.F53; KAUFMAN DL, 1995, J BIOL CHEM, V270, P15877, DOI 10.1074/jbc.270.26.15877; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Krueger KM, 1997, J BIOL CHEM, V272, P5; LAW PY, 1983, MOL PHARMACOL, V24, P413; Li LY, 1996, MOL PHARMACOL, V50, P599; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Nestler EJ, 1996, NEURON, V16, P897, DOI 10.1016/S0896-6273(00)80110-5; Pak Y, 1996, MOL PHARMACOL, V50, P1214; PEI G, 1995, MOL PHARMACOL, V48, P173; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; RAYNOR K, 1994, J PHARMACOL EXP THER, V270, P1381; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Trapaidze N, 1996, J BIOL CHEM, V271, P29279, DOI 10.1074/jbc.271.46.29279; Yang H, 1997, J NEUROSCI, V17, P1660; YU SS, 1993, J BIOL CHEM, V268, P337	30	118	120	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12402	12406		10.1074/jbc.273.20.12402	http://dx.doi.org/10.1074/jbc.273.20.12402			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575195	hybrid			2022-12-27	WOS:000073629800060
J	Grishina, G; Berlot, CH				Grishina, G; Berlot, CH			Mutations at the domain interface of G(s alpha) impair receptor-mediated activation by altering receptor and guanine nucleotide binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE ADENYLATE-CYCLASE; BETA-ADRENERGIC RECEPTORS; HETEROTRIMERIC G-PROTEIN; TERNARY COMPLEX MODEL; GTP-GAMMA-S; ALPHA-SUBUNIT; MUSCARINIC RECEPTOR; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; SITE	G protein alpha subunits consist of two domains, a GTPase domain and a helical domain. Receptors activate G proteins by catalyzing replacement of GDP, which is buried between these two domains, with GTP, Substitution of the homologous alpha(i2) residues for four alpha(s) residues in switch III, a region that changes conformation upon GTP binding, or of one nearby helical domain residue decreases the ability of alpha(s) to be activated by the beta-adrenergic receptor and by aluminum fluoride. Both sets of mutations increase the affinity of alpha(s) for the beta-adrenergic receptor, based on an increased amount of high affinity binding of the beta-adrenergic agonist, isoproterenol, The mutations also decrease the rate of receptor-mediated activation and disrupt the ability of the beta-adrenergic receptor to increase the apparent affinity of alpha(s) for the GTP analog, guanosine 5'-O-(3-thiotriphosphate). Simultaneous replacement of the helical domain residue and one of the four switch III residues with the homologous alpha(i2) residues restores normal receptor-mediated activation, suggesting that the defects caused by mutations at the domain interface are due to altered interdomain interactions. These results suggest that interactions between residues across the domain interface are involved in two key steps of receptor-mediated activation, promotion of GTP binding and subsequent receptor-G protein dissociation.	Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA	Yale University	Berlot, CH (corresponding author), Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA.				NIGMS NIH HHS [GM50369] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050369, R01GM050369] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BOURNE HR, 1975, SCIENCE, V187, P750, DOI 10.1126/science.163487; BOURNE HR, 1981, MOL PHARMACOL, V20, P435; BRANDT DR, 1986, J BIOL CHEM, V261, P1656; CASSEL D, 1977, J CYCLIC NUCL PROT, V3, P11; CODINA J, 1994, J BIOL CHEM, V269, P29339; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DELEAN A, 1980, J BIOL CHEM, V255, P7108; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; HARRIS BA, 1985, SCIENCE, V229, P1274, DOI 10.1126/science.3839937; HILDEBRANDT JD, 1991, MOL CELL BIOL, V11, P4830, DOI 10.1128/MCB.11.10.4830; Iiri T, 1997, P NATL ACAD SCI USA, V94, P5656, DOI 10.1073/pnas.94.11.5656; IIRI T, 1994, NATURE, V371, P164, DOI 10.1038/371164a0; INSEL PA, 1975, SCIENCE, V190, P896, DOI 10.1126/science.171770; JONES DT, 1987, J BIOL CHEM, V262, P14241; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; Krumins AM, 1997, MOL PHARMACOL, V52, P144, DOI 10.1124/mol.52.1.144; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; MARSH SR, 1998, IN PRESS MOL PHARM; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; RASENICK MM, 1994, J BIOL CHEM, V269, P21519; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; SULLIVAN KA, 1986, P NATL ACAD SCI USA, V83, P6687, DOI 10.1073/pnas.83.18.6687; Sunahara RK, 1997, SCIENCE, V278, P1943, DOI 10.1126/science.278.5345.1943; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; WILSON PT, 1995, J BIOL CHEM, V270, P9667, DOI 10.1074/jbc.270.16.9667	40	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15053	15060		10.1074/jbc.273.24.15053	http://dx.doi.org/10.1074/jbc.273.24.15053			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614114	hybrid			2022-12-27	WOS:000074160400056
J	Nara, M; Dhulipala, PDK; Wang, YX; Kotlikoff, MI				Nara, M; Dhulipala, PDK; Wang, YX; Kotlikoff, MI			Reconstitution of beta-adrenergic modulation of large conductance, calcium-activated potassium (maxi-K) channels in Xenopus oocytes - Identification of the cAMP-dependent protein kinase phosphorylation site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; CYCLIC GUANOSINE-MONOPHOSPHATE; GUINEA-PIG TRACHEA; ARTERY; MYOCYTES; SUBUNIT; PURIFICATION; INHIBITORS; AGONISTS; CURRENTS	The human large conductance, calcium-activated potassium (maxi-R) channel (alpha and beta subunits) and beta(2)-adrenergic receptor genes were coexpressed in Xenopus oocytes in order to study the mechanism of beta-adrenergic modulation of channel function, Isoproterenol and forskolin increased maxi-K potassium channel currents in voltage-clamped oocytes expressing the receptor and both channel subunits by 33 +/- 5% and 35 +/- 8%, respectively, without affecting current activation or inactivation, The percentage of stimulation by isoproterenol and forskolin was not different in oocytes coexpressing the alpha and beta subunits versus those expressing the only the alpha subunit, suggesting that the ct subunit is the target for regulation, The stimulatory effect of isoproterenol was almost completely blocked by intracellular injection of the cyclic AMP dependent protein kinase (cAMP-PK) regulatory subunit, whereas injection of a cyclic GMP dependent protein kinase inhibitory peptide bad little effect, indicating that cellular coupling of beta(2)-adrenergic receptors to maxi-K channels involves endogenous cAMP-PK. Mutation of one of several potential consensus cAMP-PK phosphorylation sites (serine 869) on the alpha subunit almost completely inhibited beta-adrenergic receptor/channel stimulatory coupling, whereas forskolin still stimulated currents moderately (16 +/- 4%). These data demonstrate that physiological coupling between beta(2) receptors and maxi-K channels occurs by the cAMP-PK mediated phosphorylation of serine 869 on the alpha subunit on the channel.	Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA	University of Pennsylvania	Kotlikoff, MI (corresponding author), Univ Penn, Sch Vet Med, Dept Anim Biol, 3800 Spruce St, Philadelphia, PA 19104 USA.	mik@phila.vet.upenn.edu						ADELMAN JP, 1992, NEURON, V9, P209, DOI 10.1016/0896-6273(92)90160-F; ANWER K, 1992, AM J PHYSIOL, V263, pC1049; ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; BOLOTINA VM, 1994, NATURE, V368, P850, DOI 10.1038/368850a0; BULBRING E, 1987, PHARMACOL REV, V39, P49; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; CARL A, 1991, AM J PHYSIOL, V261, pC387, DOI 10.1152/ajpcell.1991.261.2.C387; Carrier GO, 1997, AM J PHYSIOL-HEART C, V273, pH76, DOI 10.1152/ajpheart.1997.273.1.H76; CHUNG SK, 1991, SCIENCE, V253, P560, DOI 10.1126/science.1857986; FAN SF, 1993, J GEN PHYSIOL, V102, P257, DOI 10.1085/jgp.102.2.257; GALVEZ A, 1990, J BIOL CHEM, V265, P11083; GARCIACALVO M, 1994, J BIOL CHEM, V269, P676; GEORGE MJ, 1995, J INVEST MED, V43, P451; GOLDIN AL, 1992, METHOD ENZYMOL, V207, P266; JONES TR, 1993, J APPL PHYSIOL, V74, P1879, DOI 10.1152/jappl.1993.74.4.1879; JONES TR, 1990, J PHARMACOL EXP THER, V255, P697; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KNAUS HG, 1994, J BIOL CHEM, V269, P17274; KUME H, 1992, P NATL ACAD SCI USA, V89, P11051, DOI 10.1073/pnas.89.22.11051; KUME H, 1994, J CLIN INVEST, V93, P371, DOI 10.1172/JCI116969; KUME H, 1989, NATURE, V341, P152, DOI 10.1038/341152a0; LEE MY, 1994, PFLUG ARCH EUR J PHY, V429, P150, DOI 10.1007/BF02584044; LEVITAN IB, 1994, ANNU REV PHYSIOL, V56, P193, DOI 10.1146/annurev.ph.56.030194.001205; MCMANUS OB, 1995, NEURON, V14, P645, DOI 10.1016/0896-6273(95)90321-6; Meera P, 1996, FEBS LETT, V382, P84, DOI 10.1016/0014-5793(96)00151-2; MEERA P, 1995, AM J PHYSIOL-CELL PH, V269, pC312, DOI 10.1152/ajpcell.1995.269.2.C312; MELTON DA, 1987, METHOD ENZYMOL, V152, P288; MIURA M, 1992, AM REV RESPIR DIS, V146, P132, DOI 10.1164/ajrccm/146.1.132; PALLANCK L, 1994, HUM MOL GENET, V3, P1239, DOI 10.1093/hmg/3.8.1239; ROBERTSON BE, 1993, AM J PHYSIOL, V265, pC299; SADOSHIMA JI, 1988, AM J PHYSIOL, V255, pH754, DOI 10.1152/ajpheart.1988.255.4.H754; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVARIA D, 1992, AM J PHYSIOL, V262, pL327, DOI 10.1152/ajplung.1992.262.3.L327; Schreiber M, 1997, BIOPHYS J, V73, P1355, DOI 10.1016/S0006-3495(97)78168-2; SCHREIBMAYER W, 1994, RECEPTOR CHANNEL, V2, P339; SCORNIK FS, 1993, AM J PHYSIOL, V265, pH1460, DOI 10.1152/ajpheart.1993.265.4.H1460; SONG YM, 1995, PFLUG ARCH EUR J PHY, V430, P984, DOI 10.1007/BF01837413; TANIGUCHI J, 1993, PFLUG ARCH EUR J PHY, V423, P167, DOI 10.1007/BF00374390; TsengCrank J, 1996, P NATL ACAD SCI USA, V93, P9200, DOI 10.1073/pnas.93.17.9200; WHITE RE, 1991, NATURE, V351, P570, DOI 10.1038/351570a0; WHITE RE, 1993, NATURE, V361, P263, DOI 10.1038/361263a0; WHITE RE, 1995, CIRC RES, V77, P936, DOI 10.1161/01.RES.77.5.936; WICKMAN K, 1995, PHYSIOL REV, V75, P865, DOI 10.1152/physrev.1995.75.4.865; Zhou XB, 1996, J BIOL CHEM, V271, P19760, DOI 10.1074/jbc.271.33.19760	44	62	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14920	14924		10.1074/jbc.273.24.14920	http://dx.doi.org/10.1074/jbc.273.24.14920			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614096	hybrid			2022-12-27	WOS:000074160400038
J	Zhou, BP; Wu, B; Kwan, SW; Abell, CW				Zhou, BP; Wu, B; Kwan, SW; Abell, CW			Characterization of a highly conserved FAD-binding site in human monoamine oxidase B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECTED MUTAGENESIS; 6-HYDROXY-D-NICOTINE OXIDASE; FLAVOPROTEIN SUBUNIT; COVALENT ATTACHMENT; ESCHERICHIA-COLI; BOVINE LIVER; MUTANT FORMS; DEHYDROGENASE; MITOCHONDRIA; REDUCTASE	Monoamine oxidase B (MAO B) catalyzes the oxidative deamination of biogenic and xenobiotic amines. The oxidative step is coupled to the reduction of an obligatory cofactor, FAD, which is covalently linked to the apoenzyme at Cys(397). Our previous studies identified two noncovalent flavin-binding regions in MAO B (residues 6-34 and 39-46) (Kwan, S.-W., Lewis, D. A., Zhou, B. P., and Abell, C. W. (1995) Arch. Biochem. Biophys. 316, 385-391; Zhou, B. P., Lewis, D. A, Kwan, S.-W., Kirksey, T. J., and Abell, C. W. (1995) Biochemistry 34, 9526-9531), In these regions, Glu(34) and Tyr(44) were found to be required for the initial binding of FAD. By comparing sequences with enzymes in the oxidoreductase family, we now have found an additional FAD-binding site in MAO B (residues 222-227), which is highly conserved across species (human, bovine, and rat). This conserved sequence contains adjacent glycine and aspartate residues (Gly(226) and Asp(227)). Based on the x-ray crystal structures of several oxidoreductases (Eggink, G., Engel, H., Vriend, G., Terpstra, P., and Witholt, B. (1990) J. Mol. Biol. 212, 135-142; Van Driessche, G., Kol, M., Chen, Z.-W., Mathews, F. S., Meyer, T. E., Bartsch, R. G., Cusanovich, M. A., and Van Beeumen, J. J. (1996) Protein Sci. 5, 1753-1764), the Gly residue at the end of a beta-strand facilitates a sharp turn and extends the beta-carbonyl group of Asp to interact with the 3'-hydroxyl group of the ribityl chain of FAD. To assess the hypothesis that Gly(226) and Asp(227) are involved in FAD binding in MAO B, site-specific mutants that encode substitutions sit these positions were prepared and expressed in mammalian COS-7 cells. Our results indicate that Gly(226) and the beta-carbonyl group of Asp(227) are required for covalent flavinylation and catalytic activity of MAO B, hut not for noncovalent binding of FAD. Our studies also reveal that mutagenesis at Glu(34) and Tyr(44) not only interferes with covalent flavinylation and catalytic activity of MAO B, but also with noncovalent binding of FAD. Based on these collective results, we propose that the coupling of FAD to the MAO B apoenzyme is a multistep process.	Univ Texas, Coll Pharm, Div Med Chem, Austin, TX 78712 USA; Univ Texas, Inst Neurosci, Austin, TX 78712 USA; Univ Texas, Inst Cellular & Mol Biol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Abell, CW (corresponding author), Univ Texas, Coll Pharm, Div Med Chem, Austin, TX 78712 USA.				NIAAA NIH HHS [AAO7471] Funding Source: Medline; NINDS NIH HHS [NS24932] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024932] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [T32AA007471] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BACH AWJ, 1988, P NATL ACAD SCI USA, V85, P4934, DOI 10.1073/pnas.85.13.4934; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRANDSCH R, 1992, J BIOL CHEM, V267, P20844; BRANDSCH R, 1991, J BIOL CHEM, V266, P19056; CORRELL CC, 1993, PROTEIN SCI, V2, P2112, DOI 10.1002/pro.5560021212; DAPRADA M, 1989, J NEURAL TRANSM-GEN, P5; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DENNEY RM, 1982, SCIENCE, V215, P1400, DOI 10.1126/science.7063850; DOSTERT PL, 1989, MED RES REV, V9, P45, DOI 10.1002/med.2610090104; EGGINK G, 1990, J MOL BIOL, V212, P135, DOI 10.1016/0022-2836(90)90310-I; FRIEDEN C, 1990, P NATL ACAD SCI USA, V87, P4413, DOI 10.1073/pnas.87.12.4413; Genzor CG, 1996, NAT STRUCT BIOL, V3, P329, DOI 10.1038/nsb0496-329; GONDRY M, 1995, PROTEIN SCI, V4, P925; GOTTOWIK J, 1993, FEBS LETT, V317, P152, DOI 10.1016/0014-5793(93)81512-X; GREENAWALT JW, 1970, J CELL BIOL, V46, P173, DOI 10.1083/jcb.46.1.173; Hiro I, 1996, J BIOCHEM-TOKYO, V120, P759; KEARNEY EB, 1971, EUR J BIOCHEM, V24, P321, DOI 10.1111/j.1432-1033.1971.tb19689.x; Kim J, 1995, J BIOL CHEM, V270, P31202, DOI 10.1074/jbc.270.52.31202; KOCHERSPERGER LM, 1985, J NEUROSCI, V5, P2874; KWAN SW, 1995, ARCH BIOCHEM BIOPHYS, V316, P385, DOI 10.1006/abbi.1995.1051; MANSTEIN DJ, 1986, J BIOL CHEM, V261, P6169; MASSEY V, 1966, J BIOL CHEM, V241, P3417; Ogata F, 1994, FLAVINS AND FLAVOPROTEINS 1993, P795; Otto A, 1996, J BIOL CHEM, V271, P9823, DOI 10.1074/jbc.271.16.9823; PACKMAN LC, 1995, J BIOL CHEM, V270, P13186, DOI 10.1074/jbc.270.22.13186; RASBAND W, 1997, NIH IMAGE; Robinson KM, 1996, J BIOL CHEM, V271, P4055; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; Shiloff BA, 1996, EUR J BIOCHEM, V242, P41, DOI 10.1111/j.1432-1033.1996.0041r.x; Stoltz M, 1996, J BIOL CHEM, V271, P25208, DOI 10.1074/jbc.271.41.25208; SWOBODA BEP, 1969, BIOCHIM BIOPHYS ACTA, V175, P365, DOI 10.1016/0005-2795(69)90014-2; TETRUD JW, 1989, SCIENCE, V245, P519, DOI 10.1126/science.2502843; Tsugeno Y, 1997, J BIOL CHEM, V272, P14033, DOI 10.1074/jbc.272.22.14033; VanDriessche G, 1996, PROTEIN SCI, V5, P1753; VONKORFF RW, 1979, MONOAMINE OXIDASE ST, P1; WESTLUND KN, 1988, NEUROSCIENCE, V25, P439, DOI 10.1016/0306-4522(88)90250-3; WESTLUND KN, 1985, SCIENCE, V230, P181, DOI 10.1126/science.3875898; WEYLER W, 1989, BIOCHEM J, V260, P725, DOI 10.1042/bj2600725; WEYLER W, 1990, PHARMACOL THERAPEUT, V47, P391, DOI 10.1016/0163-7258(90)90064-9; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; WU HF, 1993, MOL PHARMACOL, V43, P888; WURTMAN RJ, 1963, BIOCHEM PHARMACOL, V12, P1439, DOI 10.1016/0006-2952(63)90215-6; YEOMANSON KB, 1992, BIOCHIM BIOPHYS ACTA, V1116, P261, DOI 10.1016/0304-4165(92)90038-V; ZHOU BP, 1995, BIOCHEMISTRY-US, V34, P9526, DOI 10.1021/bi00029a029; ZHOU BP, 1995, J BIOL CHEM, V270, P23653, DOI 10.1074/jbc.270.40.23653; ZIMMERMANN U, 1982, J MEMBRANE BIOL, V67, P165, DOI 10.1007/BF01868659	47	22	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14862	14868		10.1074/jbc.273.24.14862	http://dx.doi.org/10.1074/jbc.273.24.14862			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614088	hybrid			2022-12-27	WOS:000074160400030
J	Kotelevets, L; Noe, V; Bruyneel, E; Myssiakine, E; Chastre, E; Mareel, M; Gespach, C				Kotelevets, L; Noe, V; Bruyneel, E; Myssiakine, E; Chastre, E; Mareel, M; Gespach, C			Inhibition by platelet-activating factor of Src- and hepatocyte growth factor-dependent invasiveness of intestinal and kidney epithelial cells - Phosphatidylinositol 3 '-kinase is a critical mediator of tumor invasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR GENE; MIDDLE-T-ONCOGENES; ULCERATIVE-COLITIS; COLORECTAL-CANCER; TYROSINE PHOSPHORYLATION; MOLECULAR-CLONING; COLONIC MUCOSA; CROHNS-DISEASE; CACO-2 CELLS; BETA-CATENIN	This study was designed to characterize platelet-activating factor receptor (PAF-R) expression and function in normal and cancerous human colonic epithelial cells. PAF-R gene transcripts were analyzed by reverse transcription-polymerase chain reaction and Southern blot, using three sets of primers corresponding either to the coding region of the human PAF-R sequence (polymerase chain reaction product: 682 base pairs (bp)) or to the leukocyte-and tissue-type transcripts of 166 and 252 bp, respectively. An elongated splice variant was identified in the 5'-untranslated region of the tissue-type PAF-R transcript (334 bp) in colonic epithelial crypts and tumors. In human colonic PCmsrc cells transformed by c-src oncogene, the hepatocyte growth factor (HGF)-dependent invasiveness of collagen gels was abolished by 0.1 mu M PAF and Pestered by the PAF-R antagonists WEB2086 and SR27417. PAF blocked HGF-induced tyrosine phosphorylation of p125 focal adhesion kinase, The phosphatidylinositol 3'-kinase (PI3'-K) inhibitors wortmannin and LY294002 totally blocked the HGF-induced invasion. Similar effects were observed in ts-srcMDCK kidney epithelial cells transformed by a v-Src temperature-sensitive mutant: (i) PAF and wortmannin exerted additive inhibitory effects on Src-induced invasion and (ii) activated and dominant negative forms of p110 alpha PI3'-K, respectively, amplified and abrogated the Src- and HGF-dependent invasiveness of parental and ts-src-MDCK, cells. We also provided the first evidence for the contribution of rapamycin-insensitive, pertussis toxin-dependent G-protein pathways to the integration of the signals emerging from activated Met and PAF receptors. These results indicate that PI3'-K is a critical transducer of invasiveness and strongly suggest that PAF exerts a negative control on invasion by inhibiting this signaling pathway. A possible beneficial role of PAF analogs on tumor invasion is therefore proposed.	Hop St Antoine, INSERM U482, F-75571 Paris 12, France; Hop St Antoine, IFR 65, F-75571 Paris, France; Expt Cancerol Lab, B-9000 Ghent, Belgium	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite	Gespach, C (corresponding author), Hop St Antoine, INSERM U482, F-75571 Paris 12, France.	gespach@adr.st-antoine.inserm.fr	CHASTRE, Eric/L-8446-2018	CHASTRE, Eric/0000-0002-8993-1228				ALI H, 1994, J BIOL CHEM, V269, P24557; BARONDELAGE S, 1994, J BIOL CHEM, V269, P18686; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Brentnall TA, 1996, GASTROENTEROLOGY, V110, P331, DOI 10.1053/gast.1996.v110.pm8566577; CHASTRE E, 1991, J BIOL CHEM, V266, P21239; CHASTRE E, 1993, GASTROENTEROLOGY, V105, P1776, DOI 10.1016/0016-5085(93)91076-T; CHOI PM, 1994, GUT, V35, P950, DOI 10.1136/gut.35.7.950; Craig SW, 1996, CURR OPIN CELL BIOL, V8, P74, DOI 10.1016/S0955-0674(96)80051-2; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; Empereur S, 1997, BRIT J CANCER, V75, P241, DOI 10.1038/bjc.1997.40; FERBY IM, 1994, J BIOL CHEM, V269, P30485; FERRARIS L, 1993, GUT, V34, P665, DOI 10.1136/gut.34.5.665; GIOVANNUCCI E, 1995, NEW ENGL J MED, V333, P609, DOI 10.1056/NEJM199509073331001; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HONDA Z, 1994, J BIOL CHEM, V269, P2307; Inukai K, 1997, J BIOL CHEM, V272, P7873, DOI 10.1074/jbc.272.12.7873; Irigoyen JP, 1997, J BIOL CHEM, V272, P1904, DOI 10.1074/jbc.272.3.1904; Ishii S, 1996, BIOCHEM J, V314, P671, DOI 10.1042/bj3140671; IZUMI T, 1995, BIOCHEM J, V305, P829, DOI 10.1042/bj3050829; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; KELLY P, 1997, NATURE, V390, P632; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KOBILKA BK, 1987, J BIOL CHEM, V262, P15796; KRAVCHENKO VV, 1995, J BIOL CHEM, V270, P14928, DOI 10.1074/jbc.270.25.14928; Kurosu H, 1997, J BIOL CHEM, V272, P24252, DOI 10.1074/jbc.272.39.24252; LANGHOLZ E, 1992, GASTROENTEROLOGY, V103, P1444, DOI 10.1016/0016-5085(92)91163-X; MAREEL M, 1996, ANTI-CANCER DRUG, V7, P149; MAYEUX P, 1993, EUR J BIOCHEM, V216, P821, DOI 10.1111/j.1432-1033.1993.tb18203.x; MIROSSAY L, 1994, AM J PHYSIOL, V267, pR602, DOI 10.1152/ajpregu.1994.267.2.R602; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; MUTOH H, 1993, FEBS LETT, V322, P129, DOI 10.1016/0014-5793(93)81552-B; NAGANO M, 1995, AM J PHYSIOL-GASTR L, V268, pG431, DOI 10.1152/ajpgi.1995.268.3.G431; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; NISHIOKA N, 1995, BIOCHEM BIOPH RES CO, V215, P1037, DOI 10.1006/bbrc.1995.2568; Noe V., 1996, Clinical and Experimental Metastasis, V14, P71; PARASKEVA C, 1984, INT J CANCER, V34, P49, DOI 10.1002/ijc.2910340109; Polte TR, 1997, J BIOL CHEM, V272, P5501, DOI 10.1074/jbc.272.9.5501; RIEHL T, 1995, GASTROENTEROLOGY, V109, P1826, DOI 10.1016/0016-5085(95)90749-1; ROSAM A, 1996, NATURE, V319, P54; Schmidt A, 1996, P NATL ACAD SCI USA, V93, P13780, DOI 10.1073/pnas.93.24.13780; SCHULAM PG, 1991, J IMMUNOL, V146, P1642; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; SOBHANI I, 1992, GUT, V33, P1220, DOI 10.1136/gut.33.9.1220; Sobhani I, 1996, EUR J CLIN INVEST, V26, P53, DOI 10.1046/j.1365-2362.1996.00097.x; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STOSSEL TP, 1994, BLOOD, V84, P367; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; SUGIMOTO T, 1992, BIOCHEM BIOPH RES CO, V189, P617, DOI 10.1016/0006-291X(92)92245-S; Sun H, 1997, J BIOL CHEM, V272, P5413, DOI 10.1074/jbc.272.9.5413; VERMEULEN SJ, 1995, BRIT J CANCER, V72, P1447, DOI 10.1038/bjc.1995.528; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wardle TD, 1996, GUT, V38, P355, DOI 10.1136/gut.38.3.355; YE RD, 1991, BIOCHEM BIOPH RES CO, V180, P105, DOI 10.1016/S0006-291X(05)81261-6	56	66	68	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14138	14145		10.1074/jbc.273.23.14138	http://dx.doi.org/10.1074/jbc.273.23.14138			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603913	hybrid			2022-12-27	WOS:000074021500015
J	Okino, N; Tani, M; Imayama, S; Ito, M				Okino, N; Tani, M; Imayama, S; Ito, M			Purification and characterization of a novel ceramidase from Pseudomonas aeruginosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRATUM-CORNEUM LIPIDS; ATOPIC-DERMATITIS; CELL-DIFFERENTIATION; ETIOLOGIC FACTOR; SPHINGOMYELIN; SKIN; CLEAVES; LINKAGE; ENZYME	We report here a novel type of ceramidase of Pseudomonas aeruginosa AN17 isolated from the skin of a patient with atopic dermatitis. The enzyme was purified 83,400-fold with an overall yield of 21.1% from a culture supernatant of strain AN17. After being stained with a silver staining solution, the purified enzyme showed a single protein band, and its molecular mass was estimated to be 70 kDa ore SDS-polyacrylamide gel electrophoresis. The enzyme showed quite wide specificity for various ceramides, i.e. it hydrolyzed ceramides containing C12:0-C18:0 fatty acids and 7-nitrobenz-2-oxa-1,3-diatole-labeled dodecanoic acid, and not only ceramide containing sphingosine (d18:1) or sphinganine (d18:0) but also phytosphingosine (t18:0) as the long-chain base, However, the enzyme did not hydrolyze galactosylceramide, sulfatide, GM1, or sphingomyelin, and thus was clearly distinguished from a Pseudomonas sphingolipid ceramide N-deacylase (Ito, M., Kurita, T., and Kita, Ii. (1995) J. Biol. Chem. 270, 24370-24374). This bacterial cerarmidase had a PEI optimum of 8.0-9.0, an apparent K-m, of 139 mu M, and a V-max of 5.3 mu mol/min/mg using N-palmitoylsphingosine as the substrate. The enzyme appears to require Ca2+ for expression of the activity. Interestingly, the 70-kDa protein catalyzed a reversible reaction ire which the N-acyl linkage of ceramide was either cleaved or synthesized. Our study demonstrated that ceramidase is widely distributed from bacteria to mammals.	Kyushu Univ, Fac Agr, Marine Biochem Lab, Higashi Ku, Fukuoka 8128581, Japan; Kyushu Univ, Fac Med, Dept Dermatol, Fukuoka 8128581, Japan	Kyushu University; Kyushu University	Ito, M (corresponding author), Kyushu Univ, Fac Agr, Marine Biochem Lab, Higashi Ku, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.		Okino, Nozomu/AAY-2635-2021	ito, Makoto/0000-0003-3159-7818; Tani, Motohiro/0000-0003-4316-8260				ANDERSON DS, 1951, BRIT J DERMATOL, V63, P283, DOI 10.1111/j.1365-2133.1951.tb13728.x; BERNARDO K, 1995, J BIOL CHEM, V270, P11098, DOI 10.1074/jbc.270.19.11098; Bielawska A, 1996, J BIOL CHEM, V271, P12646, DOI 10.1074/jbc.271.21.12646; BODEY GP, 1983, REV INFECT DIS, V5, P279; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Buchanan RE, 1974, BERGEYS MANUAL DETER, P217; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; GATT S, 1963, J BIOL CHEM, V238, P3131; GATT S, 1966, J BIOL CHEM, V241, P3724; HASSLER DF, 1993, ADV LIPID RES, V26, P49; IMAYAMA S, 1992, J AM ACAD DERMATOL, V27, P531, DOI 10.1016/0190-9622(92)70218-5; IMAYAMA S, 1994, J ALLERGY CLIN IMMUN, V94, P195, DOI 10.1016/0091-6749(94)90040-X; IMOKAWA G, 1986, J INVEST DERMATOL, V87, P758, DOI 10.1111/1523-1747.ep12456950; IMOKAWA G, 1991, J INVEST DERMATOL, V96, P523, DOI 10.1111/1523-1747.ep12470233; ITO M, 1986, J BIOL CHEM, V261, P14278; ITO M, 1989, J BIOL CHEM, V264, P9510; ITO M, 1995, J BIOL CHEM, V270, P24370, DOI 10.1074/jbc.270.41.24370; KITAMIKADO M, 1981, J BIOL CHEM, V256, P3906; Koch J, 1996, J BIOL CHEM, V271, P33110, DOI 10.1074/jbc.271.51.33110; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPE MA, 1983, J LIPID RES, V24, P120; Li Y.-T., 1972, METHOD ENZYMOL, V28, P702; MERRILL AH, 1988, ANAL BIOCHEM, V171, P373, DOI 10.1016/0003-2697(88)90500-3; Mitsutake S, 1997, ANAL BIOCHEM, V247, P52, DOI 10.1006/abio.1997.2022; MITSUTAKE S, 1998, IN PRESS J BIOCH TOK, V123; MOORE GL, 1969, ANAL BIOCHEM, V32, P122, DOI 10.1016/0003-2697(69)90111-0; Murata Y, 1996, J INVEST DERMATOL, V106, P1242, DOI 10.1111/1523-1747.ep12348937; NikolovaKarakashian M, 1997, J BIOL CHEM, V272, P18718, DOI 10.1074/jbc.272.30.18718; OHSAWA K, 1983, ANAL BIOCHEM, V135, P409, DOI 10.1016/0003-2697(83)90703-0; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; YADA Y, 1995, J BIOL CHEM, V270, P12677, DOI 10.1074/jbc.270.21.12677; YAMAMOTO A, 1991, ARCH DERMATOL RES, V283, P219, DOI 10.1007/BF01106105	33	83	89	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14368	14373		10.1074/jbc.273.23.14368	http://dx.doi.org/10.1074/jbc.273.23.14368			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603946	hybrid			2022-12-27	WOS:000074021500048
J	Vance, CL; Begg, CM; Lee, WL; Haase, H; Copeland, TD; McEnery, MW				Vance, CL; Begg, CM; Lee, WL; Haase, H; Copeland, TD; McEnery, MW			Differential expression and association of calcium channel alpha(1B) and beta subunits during rat brain ontogeny	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE NEURONS; DEPENDENT CA2+ CHANNELS; DEVELOPMENTAL REGULATION; FUNCTIONAL EXPRESSION; GLUTAMATE RELEASE; SYNAPSE FORMATION; CA-2+ CHANNELS; MESSENGER-RNAS; GROWTH CONES; CURRENTS	Calcium functions as an essential second messenger during neuronal development and synapse acquisition. Voltage-dependent calcium channels (VDCC), which are critical to these processes, are heteromultimeric complexes composed of alpha(1), alpha(2)/delta and beta subunits, beta subunits function to direct the VDCC complex to the plasma membrane as well as regulate its channel properties. The importance of beta to neuronal functioning was recently underscored by the identification of a truncated beta 4 isoform in the epileptic mouse lethargic (Ih) (Burgess, D. L., Jones, J. M., Meisler, M. H., and Noebels, J. L. (1997) Cell 88, 385-392). The goal of our study was to investigate the role of individual beta isoforms (beta 1b, beta 2, beta 3, and beta 4) in the assembly of N-type VDCC during rat brain development. By using quantitative Western blot analysis with anti-alpha(1B)-directed antibodies and [I-125-Tyr(22)]omega-conotoxin GVIA (I-125-CTX) radioligand binding assays, we observed that only a small fraction of the total alpha(1B) protein present in embryonic and early postnatal brain expressed high affinity I-125-CTX-binding sites. These results suggested that subsequent maturation of alpha(1B) or its assembly with auxiliary subunits was required to exhibit high affinity I-125-CTX binding. The temporal pattern of expression of beta subunits and their assembly with alpha(1B) indicated a developmental pattern of expression of beta isoforms: beta 1b increased 3-fold from PO to adult, beta 4 increased 10-fold, and both beta 2 and beta 3 expression remained unchanged, As the beta component of N-type VDCC changed during postnatal development, we were able to identify both immature and mature forms of N-type VDCC, At P2, the relative contribution of beta is beta 1b > beta 3 much greater than beta 2, whereas at P14 and adult the distribution is beta 3 > beta 1b = beta 4, Although we observed no beta 4 associated with the alpha(1B) at P2, beta 4 accounted for 14 and 25% of total alpha(1B)/beta subunit complexes in P14 and adult, respectively. Thus, of the beta isoforms analyzed, only the beta 4 was assembled with the rat a,, to form N-type VDCC with a time course that paralleled its level of expression during rat brain development. These results suggest a role for the beta 4 isoform in the assembly and maturation of the N-type VDCC.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany; NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Frederick, MD 21702 USA	Case Western Reserve University; Helmholtz Association; Max Delbruck Center for Molecular Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	McEnery, MW (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, 10900 Euclid Ave, Cleveland, OH 44106 USA.							ALCANTARA AA, 1992, J COMP NEUROL, V319, P337, DOI 10.1002/cne.903190303; ANWYL R, 1991, BRAIN RES REV, V16, P265, DOI 10.1016/0165-0173(91)90010-6; BASARSKY TA, 1994, J NEUROSCI, V14, P6402; BIRNBAUMER L, 1998, IN PRESS J BIOENERG, V30; Bourinet E, 1996, P NATL ACAD SCI USA, V93, P1486, DOI 10.1073/pnas.93.4.1486; Brice NL, 1997, EUR J NEUROSCI, V9, P749, DOI 10.1111/j.1460-9568.1997.tb01423.x; Brosenitsch TA, 1998, J NEUROSCI, V18, P1047; BRUST PF, 1993, NEUROPHARMACOLOGY, V32, P1089, DOI 10.1016/0028-3908(93)90004-M; Burgess DL, 1997, CELL, V88, P385, DOI 10.1016/S0092-8674(00)81877-2; CALLAWAY EM, 1987, NATURE, V328, P422, DOI 10.1038/328422a0; CALOVINI T, 1995, J CELL BIOCHEM, V59, P69, DOI 10.1002/jcb.240590109; CASTELLANO A, 1993, J BIOL CHEM, V268, P12359; CASTELLANO A, 1993, J BIOL CHEM, V268, P3450; COHAN CS, 1987, J NEUROSCI, V7, P3588; CONNOLD AL, 1986, DEV BRAIN RES, V28, P99, DOI 10.1016/0165-3806(86)90069-6; DeWaard M, 1996, FEBS LETT, V380, P272, DOI 10.1016/0014-5793(96)00007-5; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; DEWAARD M, 1995, J BIOL CHEM, V270, P12056, DOI 10.1074/jbc.270.20.12056; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; DUNG HC, 1972, TEX REP BIOL MED, V30, P23; Gregg RG, 1996, P NATL ACAD SCI USA, V93, P13961, DOI 10.1073/pnas.93.24.13961; GRUOL DL, 1992, J NEUROSCI, V12, P2838; HAASE H, 1993, FEBS LETT, V335, P217, DOI 10.1016/0014-5793(93)80733-B; Haus Stephanie, 1997, Society for Neuroscience Abstracts, V23, P2012; Hilaire C, 1996, NEUROSCIENCE, V75, P1219, DOI 10.1016/0306-4522(96)00347-8; HIRNING LD, 1988, SCIENCE, V239, P57, DOI 10.1126/science.2447647; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; Jones OT, 1997, J NEUROSCI, V17, P6152; KATER SB, 1991, J NEUROSCI, V11, P891; KOMURO H, 1992, SCIENCE, V257, P806, DOI 10.1126/science.1323145; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVEQUE C, 1994, J BIOL CHEM, V269, P6306; Lin ZX, 1997, NEURON, V18, P153, DOI 10.1016/S0896-6273(01)80054-4; Liu HY, 1996, J BIOL CHEM, V271, P13804, DOI 10.1074/jbc.271.23.13804; Liu HY, 1996, J NEUROSCI, V16, P7557; LO YJ, 1991, SCIENCE, V254, P1019, DOI 10.1126/science.1658939; MAHALIK TJ, 1992, DEV BRAIN RES, V67, P75, DOI 10.1016/0165-3806(92)90027-T; MANIVANNAN S, 1994, J NEUROSCI, V14, P5917; MATHEWS GC, 1994, NEURON, V13, P149, DOI 10.1016/0896-6273(94)90465-0; MCCOBB DP, 1989, NEURON, V2, P1633, DOI 10.1016/0896-6273(89)90052-4; McCool BA, 1996, MOL PHARMACOL, V50, P912; MCENERY MW, 1991, P NATL ACAD SCI USA, V88, P11095, DOI 10.1073/pnas.88.24.11095; McEnery MW, 1997, FEBS LETT, V420, P74, DOI 10.1016/S0014-5793(97)01490-7; MCENERY MW, 1993, MOL CELLULAR BIOL PH, P3; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MOORMAN SJ, 1993, J NEUROSCI, V13, P4727; NELSON PG, 1990, J NEUROBIOL, V21, P138, DOI 10.1002/neu.480210110; NISHIMURA S, 1993, FEBS LETT, V324, P283, DOI 10.1016/0014-5793(93)80135-H; Parent L, 1997, J MEMBRANE BIOL, V160, P127, DOI 10.1007/s002329900302; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; Pichler M, 1997, J BIOL CHEM, V272, P13877, DOI 10.1074/jbc.272.21.13877; PLUMMER MR, 1989, NEURON, V2, P1453, DOI 10.1016/0896-6273(89)90191-8; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; PRAGNELL M, 1991, FEBS LETT, V291, P253, DOI 10.1016/0014-5793(91)81296-K; Qin N, 1997, P NATL ACAD SCI USA, V94, P8866, DOI 10.1073/pnas.94.16.8866; RANDALL A, 1995, J NEUROSCI, V15, P2995; Rettig J, 1996, P NATL ACAD SCI USA, V93, P7363, DOI 10.1073/pnas.93.14.7363; ROSSI P, 1994, PFLUG ARCH EUR J PHY, V429, P107, DOI 10.1007/BF02584036; SATHER WA, 1993, NEURON, V11, P291, DOI 10.1016/0896-6273(93)90185-T; SCHEINMAN RI, 1989, J BIOL CHEM, V264, P10660; SCHMIDT J, 1985, P NATL ACAD SCI USA, V82, P4847, DOI 10.1073/pnas.82.14.4847; SCHOLZ KP, 1995, J NEUROSCI, V15, P4612; Scott VES, 1996, J BIOL CHEM, V271, P3207, DOI 10.1074/jbc.271.6.3207; SEWARD EP, 1990, PFLUG ARCH EUR J PHY, V417, P223, DOI 10.1007/BF00370703; STEA A, 1993, NEUROPHARMACOLOGY, V32, P1103, DOI 10.1016/0028-3908(93)90005-N; STEA A, 1995, NEURON, V15, P929, DOI 10.1016/0896-6273(95)90183-3; STEA A, 1995, HDB RECEPTORS CHANNE, P113; STREIT J, 1987, PFLUG ARCH EUR J PHY, V408, P634, DOI 10.1007/BF00581167; TANAKA O, 1995, MOL BRAIN RES, V30, P1, DOI 10.1016/0169-328X(94)00265-G; Tareilus E, 1997, P NATL ACAD SCI USA, V94, P1703, DOI 10.1073/pnas.94.5.1703; USOWICZ MM, 1990, J PHYSIOL-LONDON, V426, P95, DOI 10.1113/jphysiol.1990.sp018128; VERDERIO C, 1995, P NATL ACAD SCI USA, V92, P6449, DOI 10.1073/pnas.92.14.6449; WAGNER JA, 1988, J NEUROSCI, V8, P3354; WESTENBROEK RE, 1992, NEURON, V9, P1099, DOI 10.1016/0896-6273(92)90069-P; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501; WITCHER DR, 1993, SCIENCE, V261, P486, DOI 10.1126/science.8392754; XIE HW, 1995, J NEUROSCI, V15, P5900; ZOLI M, 1995, J NEUROSCI, V15, P1912, DOI 10.1523/JNEUROSCI.15-03-01912.1995	78	75	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14495	14502		10.1074/jbc.273.23.14495	http://dx.doi.org/10.1074/jbc.273.23.14495			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603963	hybrid			2022-12-27	WOS:000074021500065
J	White, S; Hatton, SR; Siddiqui, MA; Parker, CD; Trowbridge, IS; Collawn, JF				White, S; Hatton, SR; Siddiqui, MA; Parker, CD; Trowbridge, IS; Collawn, JF			Analysis of the structural requirements for lysosomal membrane targeting using transferrin receptor chimeras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DI-LEUCINE MOTIF; CYTOPLASMIC TAIL; PLASMA-MEMBRANE; MDCK CELLS; INTERNALIZATION SIGNAL; ENDOCYTIC PATHWAY; ACID-PHOSPHATASE; SORTING SIGNALS; FC-RECEPTORS; TYROSINE	The sorting of membrane proteins to the lysosome requires tyrosine-or dileucine-based targeting signals. Recycling receptors have similar signals, yet these proteins seldom enter the latter stages of the endocytic pathway. To determine how lysosomal and internalization signals differ, we prepared chimeric molecules consisting of the cytoplasmic tails of CDS gamma-chain, lysosomal acid phosphatase, and lysosomal-associated membrane glycoprotein-l, each fused to the transmembrane and extracellular domains of the transferrin receptor (TR), Each chimera was expressed on the cell surface and rapidly internalized. Metabolic pulse-chase experiments showed that the CD3 gamma-chain and lysosomal acid phosphatase chimeras, unlike the lysosomal-associated membrane glycoprotein chimera, were rapidly degraded in a post-Gels compartment following normal glycosylation. Transplantation of signals from CD3 gamma-chain and lysosomal acid phosphatase into the TR cytoplasmic tail in place of the native signal, (YTRF23)-T-20, indicated that each signal was sufficient to promote endocytosis but not lysosomal targeting of the resulting mutant. Transplantation of two CD3 signals at specific sites in the TR cytoplasmic tail or a single tyrosine-based signal in a truncated TR tail, however, was sufficient to promote lysosomal targeting. Our results therefore suggest that the relative position of the signal within the cytoplasmic tail is a critical feature that distinguishes lysosomal targeting signals from internalization signals.	Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Salk Inst, Dept Canc Biol, San Diego, CA 92186 USA	University of Alabama System; University of Alabama Birmingham; Salk Institute	Collawn, JF (corresponding author), Univ Alabama Birmingham, Dept Cell Biol, BHSB 392,UAB Stn, Birmingham, AL 35294 USA.	jcollawn@uab.edu		Collawn, James/0000-0002-2528-2759	NIAID NIH HHS [R01-AI40389] Funding Source: Medline; NIDDK NIH HHS [R29-DK47339] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040389] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK047339] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEAUMELLE BD, 1990, J CELL BIOL, V111, P1811, DOI 10.1083/jcb.111.5.1811; BRAUN M, 1989, EMBO J, V8, P3633, DOI 10.1002/j.1460-2075.1989.tb08537.x; BREMNES B, 1994, J CELL SCI, V107, P2021; COLLAWN JF, 1993, J BIOL CHEM, V268, P21686; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; CORVERA S, 1994, J CELL BIOL, V126, P979, DOI 10.1083/jcb.126.4.979; FUKUDA M, 1991, J BIOL CHEM, V266, P21327; FUTTER CE, 1993, J CELL BIOL, V120, P77, DOI 10.1083/jcb.120.1.77; GREEN SA, 1987, J CELL BIOL, V105, P1227, DOI 10.1083/jcb.105.3.1227; GUARNIERI FG, 1993, J BIOL CHEM, V268, P1941; HAFT CR, 1994, J BIOL CHEM, V269, P26286; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; HONING S, 1995, J CELL BIOL, V128, P321, DOI 10.1083/jcb.128.3.321; Honing S, 1996, EMBO J, V15, P5230, DOI 10.1002/j.1460-2075.1996.tb00908.x; HUGHES SH, 1990, J REPROD FERTIL, P39; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; JOHNSON LS, 1993, MOL BIOL CELL, V4, P1251, DOI 10.1091/mbc.4.12.1251; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAI A, 1995, J BIOL CHEM, V270, P3565, DOI 10.1074/jbc.270.8.3565; LEHMANN LE, 1992, EMBO J, V11, P4391, DOI 10.1002/j.1460-2075.1992.tb05539.x; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LIPPINCOTTSCHWARTZ J, 1986, J CELL BIOL, V102, P1593, DOI 10.1083/jcb.102.5.1593; LIPPINCOTTSCHWARTZ J, 1987, CELL, V49, P669, DOI 10.1016/0092-8674(87)90543-5; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; MATHEWS PM, 1992, J CELL BIOL, V118, P1027, DOI 10.1083/jcb.118.5.1027; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; ODORIZZI CG, 1994, J CELL BIOL, V126, P317, DOI 10.1083/jcb.126.2.317; OGATA S, 1994, J BIOL CHEM, V269, P5210; OMARY MB, 1981, J BIOL CHEM, V256, P2888; PIETERS J, 1993, J CELL SCI, V106, P831; PYTOWSKI B, 1995, J BIOL CHEM, V270, P9067, DOI 10.1074/jbc.270.16.9067; Rohrer J, 1996, J CELL BIOL, V132, P565, DOI 10.1083/jcb.132.4.565; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TANNER LI, 1987, J BIOL CHEM, V262, P8975; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955	44	16	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14355	14362		10.1074/jbc.273.23.14355	http://dx.doi.org/10.1074/jbc.273.23.14355			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603944	hybrid			2022-12-27	WOS:000074021500046
J	Akiba, H; Nakano, H; Nishinaka, S; Shindo, M; Kobata, T; Atsuta, M; Morimoto, C; Ware, CF; Malinin, NL; Wallach, D; Yagita, H; Okumura, K				Akiba, H; Nakano, H; Nishinaka, S; Shindo, M; Kobata, T; Atsuta, M; Morimoto, C; Ware, CF; Malinin, NL; Wallach, D; Yagita, H; Okumura, K			CD27, a member of the tumor necrosis factor receptor superfamily, activates NF-KB and stress-activated protein kinase/c-Jun N-terminal kinase via TRAF2, TRAF5, and NF-KB-inducing kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN-CONTAINING RECEPTOR; KAPPA-B ACTIVATION; CELL ACTIVATION; SIGNAL-TRANSDUCTION; FACTOR FAMILY; T-CELLS; CD40; MOLECULE; DEATH; IDENTIFICATION	CD27 is a member of the tumor necrosis factor (TNF) receptor superfamily and is expressed on T, B, and NK cells. The signal via CD27 plays pivotal roles in T-T and T-B cell interactions. Here we demonstrate that overexpression of CD27 activates NF-kappa B and stress-activated protein kinase (SAPK)/c-Jun N-terminal kinase (JNK). Deletion analysis of the cytoplasmic domain of CD27 revealed that the C-terminal PIQEDYR motif was indispensable for both NF-kappa B and SAPK/JNK activation and was also required for the interaction with TNF receptor-associated factor (TRAF) 2 and TRAF5, both of which have been implicated in NF-kappa B activation by members of the TNF-R superfamily. Co-transfection of a dominant negative TRAF2 or TRAF5 blocked NF-kappa B and SAPK/JNK activation induced by CD27. Recently, a TRAF2-interacting kinase has been identified, termed NF-kappa B-inducing kinase (NIK). A kinase-inactive mutant NIK blocked CD27-, TRAF2-, and TRAF5-mediated NF-kappa B and SAPK/JNK activation. These results indicate that TRAF2 and TRAF5 are involved in NF-kappa B and SAPK/JNK JNK activation by CD27, and MK is a common downstream kinase of TRAF2 and TRAF5 for NF-kappa B and SAPK/JNK activation.	Juntendo Univ, Sch Med, Dept Immunol, Bunkyo Ku, Tokyo 113, Japan; Sumitomo Pharmaceut Res Ctr, Exploratory Grp, Takarazuka, Hyogo 665, Japan; Univ Tokyo, Inst Med Sci, Dept Clin Immunol, Minato Ku, Tokyo 108, Japan; La Jolla Inst Allergy & Immunol, Div Mol Immunol, La Jolla, CA 92121 USA; Weizmann Inst Sci, Dept Membrane Res & Biophys, IL-76100 Rehovot, Israel; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Chiyoda Ku, Tokyo 101, Japan	Juntendo University; University of Tokyo; La Jolla Institute for Immunology; Weizmann Institute of Science; Japan Science & Technology Agency (JST)	Nakano, H (corresponding author), Juntendo Univ, Sch Med, Dept Immunol, Bunkyo Ku, 2-1-1 Hongo, Tokyo 113, Japan.	hnakano@med.juntendo.ac.jp	Malinin, Nikolay/Z-5308-2019; Malinin, Nikolay/J-4271-2012	Malinin, Nikolay/0000-0002-2654-1783; Nakano, Hiroyasu/0000-0003-4843-1427				Aizawa S, 1997, J BIOL CHEM, V272, P2042; Amakawa R, 1996, CELL, V84, P551, DOI 10.1016/S0092-8674(00)81031-4; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Ettinger R, 1996, P NATL ACAD SCI USA, V93, P13102, DOI 10.1073/pnas.93.23.13102; Gedrich RW, 1996, J BIOL CHEM, V271, P12852, DOI 10.1074/jbc.271.22.12852; Gravestein LA, 1996, J EXP MED, V184, P675, DOI 10.1084/jem.184.2.675; HINTZEN RQ, 1994, IMMUNOL TODAY, V15, P307, DOI 10.1016/0167-5699(94)90077-9; Hsu HL, 1997, J BIOL CHEM, V272, P13471, DOI 10.1074/jbc.272.21.13471; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HU HM, 1994, J BIOL CHEM, V269, P30069; INUI S, 1990, EUR J IMMUNOL, V20, P1747, DOI 10.1002/eji.1830200819; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; Kashiwada M, 1998, J EXP MED, V187, P237, DOI 10.1084/jem.187.2.237; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; KOBATA T, 1995, P NATL ACAD SCI USA, V92, P11249, DOI 10.1073/pnas.92.24.11249; KOBATA T, 1994, J IMMUNOL, V153, P5422; KOOTEN CV, 1996, ADV IMMUNOL, V61, P1; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Marsters SA, 1997, J BIOL CHEM, V272, P14029, DOI 10.1074/jbc.272.22.14029; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; MORIGUCHI T, 1995, J BIOL CHEM, V270, P12969, DOI 10.1074/jbc.270.22.12969; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Nakano H, 1997, GENOMICS, V42, P26, DOI 10.1006/geno.1997.4697; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; Rennert PD, 1996, J EXP MED, V184, P1999, DOI 10.1084/jem.184.5.1999; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; SUGITA K, 1991, J IMMUNOL, V147, P1477; VanArsdale TL, 1997, P NATL ACAD SCI USA, V94, P2460, DOI 10.1073/pnas.94.6.2460; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X	41	211	225	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					13353	13358		10.1074/jbc.273.21.13353	http://dx.doi.org/10.1074/jbc.273.21.13353			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582383	hybrid			2022-12-27	WOS:000073768500094
J	Mitchelmore, C; Troelsen, JT; Sjostrom, H; Noren, O				Mitchelmore, C; Troelsen, JT; Sjostrom, H; Noren, O			The HOXC11 homeodomain protein interacts with the lactase-phlorizin hydrolase promoter and stimulates HNF1 alpha-dependent transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONE-HYBRID SYSTEM; PHLORHIZIN HYDROLASE; INTESTINAL LACTASE; CARCINOMA-CELLS; RETINOIC ACID; EXPRESSION; GENE; YEAST; BINDING; MICE	The lactase-phlorizin hydrolase (LPH) gene is expressed specifically in the enterocytes of the small intestine. LPH levels are high in newborn mammals, but decrease after weaning. We have previously suggested that the promoter element CE-LPH1, located at -40 to -54, plays an important role in this down-regulation, because the DNA binding activity of a nuclear factor that binds to this site is present specifically in small intestinal extracts and is down-regulated after weaning, In an effort to clone CE-LPH1-binding factors, a yeast one-hybrid genetic selection was used, resulting in the isolation of a partial cDNA encoding the human homeodomain protein HOXC11, The full-length HOXC11 sequence was obtained by rapid amplification of cDNA ends. It was shown in a yeast assay and by electrophoretic mobility shift assay that HOXC11 binds to the CE-LPH1 element with similar specificity to the endogenous intestinal factor. Two HOXC11 transcript sizes were identified by Northern blot analysis, The larger transcript (2.1 kilobase pairs) is likely to contain a translational start site in good context and is present in HeLa cells. The shorter 1.7-kilobase pair transcript, present in HeLa and Caco-2 cells, probably encodes a protein lacking 114 amino acids at the N-terminal end. Both forms of HOXC11 potentiate transcriptional activation of the LPH promoter by HNF1 alpha. The expression of HOXC11 mRNA in human fetal intestine suggests a role in early intestinal development.	Univ Copenhagen, Panum Inst, Dept Med Biochem & Genet, Biochem Lab C, DK-2200 Copenhagen N, Denmark	University of Copenhagen	Mitchelmore, C (corresponding author), Univ Copenhagen, Panum Inst, Dept Med Biochem & Genet, Biochem Lab C, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark.	mitch@biobase.dk	Troelsen, Jesper Thorvald T/B-6264-2013	Troelsen, Jesper Thorvald T/0000-0002-4177-3267; Mitchelmore, Cathy/0000-0001-7292-8252				ARCIONI L, 1992, EMBO J, V11, P265, DOI 10.1002/j.1460-2075.1992.tb05049.x; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; CATRON KM, 1995, MOL CELL BIOL, V15, P861; CAVENER DR, 1991, NUCLEIC ACIDS RES, V19, P3185, DOI 10.1093/nar/19.12.3185; CHANTRET I, 1988, CANCER RES, V48, P1936; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS AP, 1995, NATURE, V375, P791, DOI 10.1038/375791a0; EKKER SC, 1994, EMBO J, V13, P3551, DOI 10.1002/j.1460-2075.1994.tb06662.x; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Hecht A, 1997, GASTROENTEROLOGY, V112, P803, DOI 10.1053/gast.1997.v112.pm9041242; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HSIEHLI HM, 1995, DEVELOPMENT, V121, P1373; INOUYE C, 1994, DNA CELL BIOL, V13, P731, DOI 10.1089/dna.1994.13.731; IZPISUABELMONTE JC, 1991, EMBO J, V10, P2279, DOI 10.1002/j.1460-2075.1991.tb07764.x; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; KRASINSKI SD, 1994, AM J PHYSIOL-GASTR L, V267, pG584, DOI 10.1152/ajpgi.1994.267.4.G584; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LLOYD M, 1992, J CLIN INVEST, V89, P524, DOI 10.1172/JCI115616; MAGLI MC, 1991, P NATL ACAD SCI USA, V88, P6348, DOI 10.1073/pnas.88.14.6348; MANTEI N, 1988, EMBO J, V7, P2705, DOI 10.1002/j.1460-2075.1988.tb03124.x; MEIJER D, 1992, NUCLEIC ACIDS RES, V20, P2241, DOI 10.1093/nar/20.9.2241; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; MONTGOMERY RK, 1991, FASEB J, V5, P2824, DOI 10.1096/fasebj.5.13.1916106; Mortlock DP, 1997, NAT GENET, V15, P179, DOI 10.1038/ng0297-179; Muragaki Y, 1996, SCIENCE, V272, P548, DOI 10.1126/science.272.5261.548; OLSEN J, 1994, FEBS LETT, V342, P325, DOI 10.1016/0014-5793(94)80525-3; Olsen WA, 1996, AM J PHYSIOL-GASTR L, V271, pG707, DOI 10.1152/ajpgi.1996.271.4.G707; PETERSON RL, 1994, MECH DEVELOP, V47, P253, DOI 10.1016/0925-4773(94)90043-4; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; Rhee KH, 1997, J MOL BIOL, V265, P20, DOI 10.1006/jmbi.1996.0708; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; SCOTT MP, 1993, NUCLEIC ACIDS RES, V21, P1687, DOI 10.1093/nar/21.8.1687; Shen WF, 1997, J BIOL CHEM, V272, P8198, DOI 10.1074/jbc.272.13.8198; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Sibley E, 1996, GASTROENTEROLOGY, V110, pA839; STORNAIUOLO A, 1990, CELL DIFFER DEV, V31, P119, DOI 10.1016/0922-3371(90)90015-O; Suh E, 1996, MOL CELL BIOL, V16, P619; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; TRABER PG, 1992, MOL CELL BIOL, V12, P3614, DOI 10.1128/MCB.12.8.3614; TROELSEN JT, 1994, FEBS LETT, V342, P297, DOI 10.1016/0014-5793(94)80520-2; TROELSEN JT, 1992, J BIOL CHEM, V267, P20407; Troelsen JT, 1997, BIOCHEM J, V322, P833, DOI 10.1042/bj3220833; TROELSEN JT, 1994, FEBS LETT, V342, P291, DOI 10.1016/0014-5793(94)80519-9; TRONCHE F, 1992, BIOESSAYS, V14, P579, DOI 10.1002/bies.950140902; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0; WU GD, 1994, J BIOL CHEM, V269, P17080	50	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					13297	13306		10.1074/jbc.273.21.13297	http://dx.doi.org/10.1074/jbc.273.21.13297			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582375	hybrid			2022-12-27	WOS:000073768500086
J	Podust, VN; Tiwari, N; Ott, R; Fanning, E				Podust, VN; Tiwari, N; Ott, R; Fanning, E			Functional interactions among the subunits of replication factor C potentiate and modulate its ATPase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-DELTA; CELL NUCLEAR ANTIGEN; NUCLEOTIDE EXCISION-REPAIR; DOUBLE-STRANDED DNA; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; ACCESSORY PROTEINS; 37-KDA SUBUNIT; HELA-CELLS; ACTIVATOR-1	Replication factor C (RF-C), a complex of five subunits, and several subassemblies of RF-C, representing intermediates along the proposed protein assembly pathway (Podust, V. N., and Fanning, E. (1997) J. Biol. Chem. 272, 6303-6310), were expressed in insect cells using baculoviruses encoding individual subunits (p140, p40, p38, p37, and p36). Purified proteins were analyzed for ATPase activity to assess the role of individual subunits in ATP hydrolysis. His-tagged p40 contained low ATPase activity, but tagged p37 and p36 did not. Complexes of p40.p37.p36 bearing a His tag on any subunit displayed DNA-stimulated ATPase activity, in agreement with a recent report (Cai, J., Gibbs, E., Uhlmann, F., Philips, B., Yao, N., O'Donnell, M., and Hurwitz, J. (1997) J. Biol. Chem. 272, 18974-18981). In contrast, complex p38.p37.p36-his displayed no ATPase, suggesting that p40 is essential for ATPase activity. Although p38 was not required for ATPase activity, the activity of the p40-his p38.p37.p36 complex was more salt-resistant than that of the p40-his.p37.p36 complex. The p140 subunit further increased the specific ATPase activity of RF-C complex by enhancing its stimulation by DNA. Taken together, the data indicate that all five RF-C subunits constitute ATPase activity, although the contributions of the individual subunits differ. Predicted ATP-binding domains of all five subunits were mutated to assess the importance of multiple ATP-binding sites of RF-C. In each case, the Lys of the conserved P-loop motif was replaced by Glu. The ATP-binding domain of p38 was found to be dispensable for the activity of the five-subunit RF-C in polymerase delta DNA synthesis. In contrast, mutation of the ATP-binding domains in other RF-C subunits impaired RF-C assembly, function, or both.	Vanderbilt Univ, Dept Mol Biol, Nashville, TN 37235 USA	Vanderbilt University	Fanning, E (corresponding author), Vanderbilt Univ, Dept Mol Biol, Box 1820,Stn B, Nashville, TN 37235 USA.	fannine@ctrvax.vanderbilt.edu			NIGMS NIH HHS [GM 52948] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052948] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; Berdis AJ, 1996, BIOCHEMISTRY-US, V35, P9253, DOI 10.1021/bi952569w; BUNZ F, 1993, P NATL ACAD SCI USA, V90, P11014, DOI 10.1073/pnas.90.23.11014; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; Cai JS, 1997, J BIOL CHEM, V272, P18974, DOI 10.1074/jbc.272.30.18974; Cai JS, 1996, P NATL ACAD SCI USA, V93, P12896, DOI 10.1073/pnas.93.23.12896; CHEN M, 1992, P NATL ACAD SCI USA, V89, P5211, DOI 10.1073/pnas.89.12.5211; CHEN M, 1992, P NATL ACAD SCI USA, V89, P2516, DOI 10.1073/pnas.89.7.2516; CULLMANN G, 1995, MOL CELL BIOL, V15, P4661; Gerik KJ, 1997, J BIOL CHEM, V272, P1256, DOI 10.1074/jbc.272.2.1256; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HUBSCHER U, 1996, DNA REPLICATION EUKA, P525; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P2541, DOI 10.1093/nar/21.11.2541; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; LEE SH, 1990, P NATL ACAD SCI USA, V87, P5672, DOI 10.1073/pnas.87.15.5672; LEE SH, 1991, J BIOL CHEM, V266, P594; LI XY, 1994, P NATL ACAD SCI USA, V91, P868, DOI 10.1073/pnas.91.3.868; LI XY, 1994, J BIOL CHEM, V269, P21880; NOSKOV V, 1994, NUCLEIC ACIDS RES, V22, P1527, DOI 10.1093/nar/22.9.1527; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; PODUST LM, 1995, MOL CELL BIOL, V15, P3072; Podust VN, 1997, J BIOL CHEM, V272, P6303, DOI 10.1074/jbc.272.10.6303; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P5003, DOI 10.1021/bi00015a011; PODUST VN, 1992, NUCLEIC ACIDS RES, V20, P4159, DOI 10.1093/nar/20.16.4159; SHIVJI MKK, 1995, BIOCHEMISTRY-US, V34, P5011, DOI 10.1021/bi00015a012; THIAGALINGAM S, 1991, J BIOL CHEM, V266, P11395; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; Uhlmann F, 1996, P NATL ACAD SCI USA, V93, P6521, DOI 10.1073/pnas.93.13.6521; Vallejo Abbe N., 1995, P603; WAGA S, 1994, J BIOL CHEM, V269, P10923; Young MC, 1996, J MOL BIOL, V264, P440, DOI 10.1006/jmbi.1996.0652	34	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					12935	12942		10.1074/jbc.273.21.12935	http://dx.doi.org/10.1074/jbc.273.21.12935			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582326	hybrid			2022-12-27	WOS:000073768500037
J	Huby, RDJ; Weiss, A; Ley, SC				Huby, RDJ; Weiss, A; Ley, SC			Nocodazole inhibits signal transduction by the T cell antigen receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; ZETA-CHAIN; ZAP-70 KINASE; ALPHA-TUBULIN; ACTIN CYTOSKELETON; MICE LACKING; SH2 DOMAIN; ACTIVATION; SYK; PHOSPHORYLATION	The potential role of the cytoskeleton in signaling via the T cell antigen receptor (TCR) was investigated using pharmacological agents. In Jurkat T cells, disruption of the actin-based cytoskeleton with cytochalasin D or disruption of the microtubules with colchicine did not affect TCR induction of proximal signaling events triggered by CD3 mAb. Polymerized actin and tubulin, therefore, were not required for TCR-mediated signal transduction. Nocodazole, however, was found to inhibit dramatically TCR signaling, independently of its ability to depolymerize microtubules. This effect was TCR-specific, because signaling via the human muscarinic acetylcholine receptor 1 in the same cells was unaffected, A mechanism for the inhibition of TCR signaling by nocodazole was suggested by in vitro assays, which revealed that the drug inhibited the kinase activity of LCK and, to a lesser extent, FYN. The kinase activity of ZAP-70 in vitro, however, was unaffected. These results, therefore, suggested that nocodazole prevented initial phosphorylation of the TCR by LCK after stimulation, and as a result, it blocked activation of downstream signaling pathways. Immunofluorescence analyses also revealed that nocodazole and the specific SRC-family kinase inhibitor PP1 delocalized ZAP-70 from its constitutive site at the cell cortex. These effects did not require the SH2 domains of ZAP-70. The localization of ZAP-70 to the cell cortex is, therefore, regulated by the activity of SRC-family kinases, independently of their ability to phosphorylate immunoreceptor tyrosine-based activation motifs of the TCR.	Natl Inst Med Res, Div Cellular Immunol, London NW7 1AA, England; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Microbiol & Immunol, San Francisco, CA 94143 USA	MRC National Institute for Medical Research; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Ley, SC (corresponding author), Natl Inst Med Res, Div Cellular Immunol, Mill Hill, London NW7 1AA, England.	s-ley@uk.ac.nimr.mrc						ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; ATASSI G, 1975, EUR J CANCER, V11, P609, DOI 10.1016/0014-2964(75)90093-6; ATASSI G, 1975, EUR J CANCER, V11, P599, DOI 10.1016/0014-2964(75)90092-4; BANIYASH M, 1988, J BIOL CHEM, V263, P18225; CAPLAN S, 1995, P NATL ACAD SCI USA, V92, P4768, DOI 10.1073/pnas.92.11.4768; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHAN AC, 1994, J IMMUNOL, V152, P4758; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; DEBRABANDER MJ, 1976, CANCER RES, V36, P905; DIETRICH J, 1994, EMBO J, V13, P2156, DOI 10.1002/j.1460-2075.1994.tb06492.x; DUPLAY P, 1994, J EXP MED, V179, P1163, DOI 10.1084/jem.179.4.1163; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; GOLDSMITH MA, 1989, J BIOL CHEM, V264, P17190; Groves T, 1996, IMMUNITY, V5, P417, DOI 10.1016/S1074-7613(00)80498-7; GUPTA S, 1994, J BIOL CHEM, V269, P17349; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HIVROZ C, 1994, CURR BIOL, V4, P731, DOI 10.1016/S0960-9822(00)00162-7; HOEBEKE J, 1976, BIOCHEM BIOPH RES CO, V69, P319, DOI 10.1016/0006-291X(76)90524-6; HSI ED, 1989, J BIOL CHEM, V264, P10836; Huby RDJ, 1997, J CELL BIOL, V137, P1639, DOI 10.1083/jcb.137.7.1639; Huby RDJ, 1995, J BIOL CHEM, V270, P30241, DOI 10.1074/jbc.270.51.30241; Isakov N, 1996, J BIOL CHEM, V271, P15753, DOI 10.1074/jbc.271.26.15753; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JUNG MK, 1992, CELL MOTIL CYTOSKEL, V22, P170, DOI 10.1002/cm.970220304; Kabouridis PS, 1997, EMBO J, V16, P4983, DOI 10.1093/emboj/16.16.4983; KANNER SB, 1994, P NATL ACAD SCI USA, V91, P10484, DOI 10.1073/pnas.91.22.10484; KATZAV S, 1994, J BIOL CHEM, V269, P32579; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; LEY SC, 1994, EUR J IMMUNOL, V24, P99, DOI 10.1002/eji.1830240116; LUTON F, 1994, J IMMUNOL, V153, P63; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mege D, 1996, J BIOL CHEM, V271, P32644, DOI 10.1074/jbc.271.51.32644; NEGISHI I, 1995, NATURE, V376, P435, DOI 10.1038/376435a0; NEUMEISTER EN, 1995, MOL CELL BIOL, V15, P3171; PASTOR MI, 1995, IMMUNOL TODAY, V16, P159, DOI 10.1016/0167-5699(95)80134-0; Peters JD, 1996, J BIOL CHEM, V271, P4755; QIAN DP, 1993, J BIOL CHEM, V268, P4488; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; ROZDZIAL MM, 1995, IMMUNITY, V3, P623, DOI 10.1016/1074-7613(95)90133-7; Rudd CE, 1996, IMMUNITY, V4, P527, DOI 10.1016/S1074-7613(00)80479-3; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; SANCHO J, 1993, EUR J IMMUNOL, V23, P1636, DOI 10.1002/eji.1830230736; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SHIUE L, 1995, J BIOL CHEM, V270, P10498, DOI 10.1074/jbc.270.18.10498; SOLOMON F, 1986, METHOD ENZYMOL, V134, P139; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; STRAUS DB, 1993, J EXP MED, V178, P1523, DOI 10.1084/jem.178.5.1523; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; Taylor N, 1996, J EXP MED, V184, P2031, DOI 10.1084/jem.184.5.2031; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; VALITUTTI S, 1995, J EXP MED, V181, P577, DOI 10.1084/jem.181.2.577; vanOers NSC, 1996, IMMUNITY, V5, P429, DOI 10.1016/S1074-7613(00)80499-9; vanOers NSC, 1996, J EXP MED, V183, P1053, DOI 10.1084/jem.183.3.1053; WANDOSELL F, 1987, J BIOL CHEM, V262, P8268; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WANGE RL, 1995, J BIOL CHEM, V270, P18730, DOI 10.1074/jbc.270.32.18730; WEISS A, 1991, ANNU REV GENET, V25, P487, DOI 10.1146/annurev.ge.25.120191.002415; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B	64	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12024	12031		10.1074/jbc.273.20.12024	http://dx.doi.org/10.1074/jbc.273.20.12024			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575143	hybrid			2022-12-27	WOS:000073629800008
J	Matsumoto, M; Nishiguchi, M; Kikkawa, S; Nishimura, H; Nagasawa, S; Seya, T				Matsumoto, M; Nishiguchi, M; Kikkawa, S; Nishimura, H; Nagasawa, S; Seya, T			Structural and functional properties of complement-activating protein M161Ag, a Mycoplasma fermentans gene product that induces cytokine production by human monocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; SELENOCYSTEINE INCORPORATION; PATHWAY ACTIVATION; ESCHERICHIA-COLI; MEMBRANE; P48; IL-1; C3; PURIFICATION; ONCOGENESIS	Human malignant cells are targeted by homologous complement C3b if they express M161Ag, a 43-kDa protein with C3-activating property, cDNA of M161Ag cloned from human leukemia cell lines predicted M161Ag as a novel secretory protein comprised of 428 amino acids including 5 amino acids encoded by TGA codons (Matsumoto M., Takeda, J., Inoue, N., Hara, T., Hatanaka, M., Takahashi, K., Nagasawa, S., Akedo, H., and Seya, T. (1997) Nat. Med. 3, 1266-1270), although the origin of this gene was obscure. Here we clarified this point through genomic and biochemical analysis: 1) 5'-UT and genomic sequences represented the prokaryote promoter and ribosomal binding site; 2) the TGA codons in M161Ag cDNA were translated not into selenocysteines but into tryptophans; 3) M161Ag anchored onto the membrane secondary to its N terminal palmitoylation like prokaryote lipoproteins; 4) genomic and cDNA clones of M161Ag were highly homologous to Mycoplasma fermentans gene encoding P48, a monocytic differentiation/activation factor, recently released in the data base, although the resultant proteins were different in the amino acid sequences. Additionally, purified soluble M161Ag efficiently provoked IL-1 beta, tumor necrosis factor alpha, and IL-6 like P48, and further IL-10 and IL-12 in human peripheral blood monocytes. Thus, M161Ag originates hom M. fermentans, and latently infected M. fermentans allows human cells to produce M161Ag. The liberated protein serves as a potent modulator of innate and cellular immune responses via its complement-activating and cytokine-producing activities.	Osaka Med Ctr Canc & Cardiovasc Dis, Dept Immunol, Higashinari Ku, Osaka 537, Japan; JST, PRESTO, Tokyo 105, Japan; Hokkaido Univ, Dept Pharmaceut Sci, Sapporo, Hokkaido 060, Japan	Osaka Medical Center for Cancer & Cardiovascular Diseases; Japan Science & Technology Agency (JST); Hokkaido University	Seya, T (corresponding author), Osaka Med Ctr Canc & Cardiovasc Dis, Dept Immunol, Higashinari Ku, Osaka 537, Japan.		美佐子, 松本/A-4497-2012; Seya, Tsukasa/A-4336-2012					BEEZHOLD DH, 1989, J IMMUNOL, V143, P3217; BIBERFELD G, 1978, INFECT IMMUN, V21, P48, DOI 10.1128/IAI.21.1.48-54.1978; BLANCHARD A, 1994, ANNU REV MICROBIOL, V48, P687, DOI 10.1146/annurev.mi.48.100194.003351; DERES K, 1989, NATURE, V342, P561, DOI 10.1038/342561a0; FENG SH, 1994, INFECT IMMUN, V62, P3916, DOI 10.1128/IAI.62.9.3916-3921.1994; GALLILY R, 1992, IMMUNOL LETT, V34, P27, DOI 10.1016/0165-2478(92)90023-H; Hall RE, 1996, BIOCHEM J, V319, P919, DOI 10.1042/bj3190919; ISHIDA Y, 1981, J CHROMATOGR, V204, P143, DOI 10.1016/S0021-9673(00)81650-7; Johnson L, 1996, LANCET, V347, P901, DOI 10.1016/S0140-6736(96)91381-1; KATSENI VL, 1993, LANCET, V341, P271, DOI 10.1016/0140-6736(93)92617-3; KESTLER DP, 1995, IMMUNOLOGY, V86, P463; KIKKAWA S, 1996, JPN BIOCH SOC, V68, P703; KOSTYAL DA, 1991, J IMMUNOL, V147, P893; LEFTWICH JA, 1989, CANCER RES, V49, P4459; LO SC, 1991, SCIENCE, V251, P1074, DOI 10.1126/science.1705362; Low SC, 1996, TRENDS BIOCHEM SCI, V21, P203, DOI 10.1016/0968-0004(96)10025-6; Matsumoto M, 1997, NAT MED, V3, P1266, DOI 10.1038/nm1197-1266; MATSUMOTO M, 1993, EUR J IMMUNOL, V23, P2270, DOI 10.1002/eji.1830230933; MATSUMOTO M, 1995, J EXP MED, V181, P115, DOI 10.1084/jem.181.1.115; MUHLRADT PF, 1991, INFECT IMMUN, V59, P3969; Muhlradt PF, 1997, J EXP MED, V185, P1951, DOI 10.1084/jem.185.11.1951; Rawadi G, 1996, J IMMUNOL, V156, P670; SHEN QC, 1993, J BIOL CHEM, V268, P11463; TALJANIDISZ J, 1987, J MOL BIOL, V193, P507, DOI 10.1016/0022-2836(87)90263-4; TaylorRobinson D, 1996, LANCET, V347, P1555, DOI 10.1016/S0140-6736(96)90708-4; TSAI S, 1995, P NATL ACAD SCI USA, V92, P10197, DOI 10.1073/pnas.92.22.10197; YAMAGUCHI K, 1988, CELL, V53, P423, DOI 10.1016/0092-8674(88)90162-6; YAMAO F, 1985, P NATL ACAD SCI USA, V82, P2306, DOI 10.1073/pnas.82.8.2306; YEFENOF E, 1994, INT IMMUNOL, V6, P1361, DOI 10.1093/intimm/6.9.1361; YEFENOF E, 1991, INT IMMUNOL, V3, P395, DOI 10.1093/intimm/3.4.395	30	25	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12407	12414		10.1074/jbc.273.20.12407	http://dx.doi.org/10.1074/jbc.273.20.12407			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575196	hybrid			2022-12-27	WOS:000073629800061
J	Swarnakar, S; Reyland, ME; Deng, JT; Azhar, S; Williams, DL				Swarnakar, S; Reyland, ME; Deng, JT; Azhar, S; Williams, DL			Selective uptake of low density lipoprotein cholesteryl ester is enhanced by inducible apolipoprotein E expression in cultured mouse adrenocortical cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E MESSENGER-RNA; HEPARAN-SULFATE PROTEOGLYCANS; RAT ADRENAL-GLAND; APOPROTEIN-A-I; PERIPHERAL-TISSUES; RICH LIPOPROTEINS; NONHUMAN-PRIMATES; PLASMA-LIPOPROTEINS; SCAVENGER RECEPTOR; LUTEINIZED OVARY	Apolipoprotein (apo) E is expressed at high levels by steroidogenic cells of the adrenal gland, ovary, and testis. The cell surface location of apoE in adrenocortical cells suggests that apoE may facilitate the uptake of lipoprotein cholesterol by either the endocytic or the selective uptake pathways, or both. To examine these possibilities, the human apoE gene was expressed in murine Y1 adrenocortical cells under control of an inducible tetracycline-regulated promoter. The results show that induction of apoE yielded a 2-2.5-fold increase in the uptake of low density lipoprotein-cholesteryl ester (LDL-CE) but had little effect on high density lipoprotein-CE uptake. Analysis of lipoprotein uptake pathways showed that apoE increased LDL-CE uptake by both endocytic and selective uptake pathways. In terms of cholesterol delivery to the adrenal cell, the apoE-mediated enhancement of LDL-CE selective uptake was quantitatively more important. Furthermore, the predominant effect of apoE expression was on the low affinity component of LDL-CE selective uptake. LDL particles incubated with apoE expressing cells contained 0.92 +/- 0.11 apoE molecules/apoB after gel filtration chromatography, indicating stable complex formation between apoE and LDL. ApoE expression by Y1 cells was necessary for enhanced LDL-CE selective uptake, This result may indicate an interaction between apoE-containing LDL and cell surface apoE. These data suggest that apoE produced locally by steroidogenic cells facilitates cholesterol acquisition by the LDL selective uptake pathway.	SUNY Stony Brook, Med Ctr, Dept Pharmacol Sci, Stony Brook, NY 11794 USA; Dept Vet Affairs, Palo Alto Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Palo Alto, CA 94304 USA; Univ Colorado, Dept Basic Sci & Oral Res, Denver, CO 80262 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; University of Colorado System; University of Colorado Denver	Williams, DL (corresponding author), SUNY Stony Brook, Med Ctr, Dept Pharmacol Sci, Stony Brook, NY 11794 USA.		Eckhardt, Erik/G-1567-2010		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032868] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 32868] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; AZHAR S, 1989, J LIPID RES, V30, P1799; AZHAR S, 1988, J LIPID RES, V29, P869; AZHAR S, 1990, BIOCHIM BIOPHYS ACTA, V1047, P148, DOI 10.1016/0005-2760(90)90041-U; BLUE ML, 1983, P NATL ACAD SCI-BIOL, V80, P283, DOI 10.1073/pnas.80.1.283; Brissette L, 1996, BIOCHEM J, V318, P841, DOI 10.1042/bj3180841; BROWN MS, 1983, J CLIN INVEST, V72, P743, DOI 10.1172/JCI111044; DeMattos RB, 1998, J BIOL CHEM, V273, P4206, DOI 10.1074/jbc.273.7.4206; DRISCOLL DM, 1984, J LIPID RES, V25, P1368; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P203, DOI 10.1073/pnas.82.1.203; FENJVES ES, 1989, P NATL ACAD SCI USA, V86, P8803, DOI 10.1073/pnas.86.22.8803; Fuki IV, 1997, J CLIN INVEST, V100, P1611, DOI 10.1172/JCI119685; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GLASS C, 1985, J BIOL CHEM, V260, P744; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GREEN SR, 1991, J LIPID RES, V32, P667; GWYNNE JT, 1980, J BIOL CHEM, V255, P875; HAMILTON RL, 1990, J LIPID RES, V31, P1589; JI ZS, 1994, J BIOL CHEM, V269, P2764; LEBOEUF RC, 1983, J BIOL CHEM, V258, P5063; LENICH C, 1988, J LIPID RES, V29, P755; LILLYSTAUDERMAN M, 1993, J LIPID RES, V34, P190; LINLEE YC, 1985, BIOCHEMISTRY-US, V24, P3751, DOI 10.1021/bi00335a050; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUSIS AJ, 1987, J BIOL CHEM, V262, P7594; MAHLEY RW, 1983, BIOCHIM BIOPHYS ACTA, V737, P197, DOI 10.1016/0304-4157(83)90001-1; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1984, J LIPID RES, V25, P1277; MAHLEY RW, 1981, J CLIN INVEST, V68, P1197, DOI 10.1172/JCI110365; MARZETTA CA, 1986, J LIPID RES, V27, P753; NEWMAN TC, 1985, J BIOL CHEM, V260, P2452; NICOSIA M, 1992, MOL ENDOCRINOL, V6, P978, DOI 10.1210/me.6.6.978; NICOSIA M, 1992, MOL ENDOCRINOL, V6, P288, DOI 10.1210/me.6.2.288; OLSEN LM, 1994, BIOL REPROD, V50, P535; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; PRACK MM, 1991, J LIPID RES, V32, P1611; PRACK MM, 1994, BIOCHEMISTRY-US, V33, P5094; REAVEN E, 1989, J LIPID RES, V30, P1551; REAVEN E, 1988, ARTERIOSCLEROSIS, V8, P298, DOI 10.1161/01.ATV.8.3.298; REAVEN E, 1984, J CLIN INVEST, V74, P1384, DOI 10.1172/JCI111549; REYLAND ME, 1991, P NATL ACAD SCI USA, V88, P2375, DOI 10.1073/pnas.88.6.2375; SCHLEICHER RL, 1993, BIOL REPROD, V48, P313, DOI 10.1095/biolreprod48.2.313; STEIN Y, 1983, BIOCHIM BIOPHYS ACTA, V752, P98, DOI 10.1016/0005-2760(83)90237-0; Temel RE, 1997, P NATL ACAD SCI USA, V94, P13600, DOI 10.1073/pnas.94.25.13600; WILLIAMS DL, 1985, J BIOL CHEM, V260, P2444; WILLIAMS DL, 1995, J LIPID RES, V36, P745; WILLIAMS DL, 1985, ANN NY ACAD SCI, V454, P222, DOI 10.1111/j.1749-6632.1985.tb11861.x; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; WINDLER E, 1980, J BIOL CHEM, V255, P5475	50	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12140	12147		10.1074/jbc.273.20.12140	http://dx.doi.org/10.1074/jbc.273.20.12140			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575160	hybrid			2022-12-27	WOS:000073629800025
J	Zuo, Z; Dean, NM; Honkanen, RE				Zuo, Z; Dean, NM; Honkanen, RE			Serine/threonine protein phosphatase type 5 acts upstream of p53 to regulate the induction of p21(WAF1/Cip1) and mediate growth arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE PHOSPHATASES; CYCLIN-DEPENDENT KINASES; OKADAIC ACID; POTENT INHIBITOR; DNA-BINDING; CELL-CYCLE; ANTISENSE OLIGONUCLEOTIDES; CATALYTIC SUBUNIT; MESSENGER-RNA; CDNA CLONE	Understanding how alterations in growth control pathways are translated into changes in the cell cycle regulatory machinery is a major challenge for understanding the development of human cancers. The ability of both tumor suppressor proteins, p53 and BRCA1, to induce the expression of p21(WAF1/Cip1) in combination with the inhibitory activity of p21(WAF1/Cip1) against cyclin-dependent kinases suggests that the regulation of p21(WAF1/Cip1) expression is an important aspect of mammalian cell cycle growth control. To elucidate the role of serine/threonine protein phosphatase type 5 (PP5) in processes regulating cell cycle progression, we developed antisense oligodeoxynucleotides targeted against PP5 (e.g. LSIS 15534) that specifically inhibit PP5 gene expression. Employing ISIS 15534, we demonstrate that the specific inhibition of PP5 gene expression has a marked antiproliferative effect on cells, characterized by induction of p21(WAF1/Cip1) and the subsequent arrest of cell growth. Investigations into the mechanisms leading to growth arrest reveal that, in the absence of PP5, the expression of p21(WAF1/Cip1) is induced in p53-competent A549 cells but not in p53 protein-deficient T-24 cells. Employing a stable cell line derived from p53-deficient human fibroblast that contains tetracycline-regulated transactivator and operator plasmids to control the ex pression of wild-type p53 (TR9-7 cells), we then show that the induction of p21(WAF1/Cip1), which occurs in response to the inhibition of PP5 expression, requires the p53 protein. Additional studies indicate that PP5 acts upstream of p53, influencing both the phosphorylation state and the ability of p53 to bind DNA, without causing an increase in p53 gene transcription. Together these studies suggest that PP5 is a regulatory component of a signaling pathway that affords replicating cells G(1) checkpoint growth control and that it is the regulation of PP5 that, in turn, controls p53-mediated expression of p21(WAF1/Cip1) and growth arrest in this pathway. In addition, since the inhibition of PP5 gene expression has marked antiproliferative activity and the overexpression of p21(WAF1/Cip1) blocks the growth of tumor cells, these studies suggest that compounds that inhibit of PP5 gene expression may be useful in the treatment of human cancers.	Univ S Alabama, Dept Biochem & Mol Biol, Mobile, AL 36688 USA; ISIS Pharmaceut, Dept Pharmacol, Carlsbad, CA 92008 USA	University of South Alabama; Isis Pharmaceuticals Inc	Honkanen, RE (corresponding author), Univ S Alabama, Dept Biochem & Mol Biol, MSB 2198, Mobile, AL 36688 USA.	honkanen@sungcg.usouthal.edu			NCI NIH HHS [CA60750] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060750, R29CA060750] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ARINO J, 1988, P NATL ACAD SCI USA, V85, P4252, DOI 10.1073/pnas.85.12.4252; BARKER HM, 1993, BIOCHIM BIOPHYS ACTA, V1178, P228, DOI 10.1016/0167-4889(93)90014-G; BARKER HM, 1994, BBA-MOL CELL RES, V1220, P212, DOI 10.1016/0167-4889(94)90138-4; Bastians H, 1996, J CELL SCI, V109, P2865; BENNETT CF, 1992, MOL PHARMACOL, V41, P1023; BREWIS ND, 1993, EMBO J, V12, P987, DOI 10.1002/j.1460-2075.1993.tb05739.x; CHEN MX, 1994, EMBO J, V13, P4278, DOI 10.1002/j.1460-2075.1994.tb06748.x; CHEN RT, 1980, CHINESE MED J-PEKING, V93, P183; CHERNOVA OB, 1995, TRENDS BIOCHEM SCI, V20, P431, DOI 10.1016/S0968-0004(00)89094-5; CHINKERS M, 1994, P NATL ACAD SCI USA, V91, P11075, DOI 10.1073/pnas.91.23.11075; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1991, METHOD ENZYMOL, V201, P389; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; Cohen PTW, 1997, TRENDS BIOCHEM SCI, V22, P245, DOI 10.1016/S0968-0004(97)01060-8; COOPER MJ, 1994, ONCOL RES, V6, P569; CROOKE ST, 1992, ANNU REV PHARMACOL, V32, P329; Dean NM, 1997, ANTISENSE NUCLEIC A, V7, P229, DOI 10.1089/oli.1.1997.7.229; DEAN NM, 1994, J BIOL CHEM, V269, P16416; deJong RS, 1997, ANTI-CANCER DRUG, V8, P413, DOI 10.1097/00001813-199706000-00001; Dynlacht BD, 1997, NATURE, V389, P149, DOI 10.1038/38225; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; FUCHS B, 1995, EUR J BIOCHEM, V228, P625, DOI 10.1111/j.1432-1033.1995.0625m.x; FUJIKI H, 1991, ENVIRON HEALTH PERSP, V93, P211, DOI 10.2307/3431191; Gomyo Y, 1997, CANCER, V79, P2067, DOI 10.1002/(SICI)1097-0142(19970601)79:11<2067::AID-CNCR3>3.0.CO;2-M; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GUERINI D, 1989, DNA-J MOLEC CELL BIO, V8, P675, DOI 10.1089/dna.1.1989.8.675; Hao MM, 1996, J BIOL CHEM, V271, P29380, DOI 10.1074/jbc.271.46.29380; HARPER JW, 1993, CELL, V75, P805; Hecker D, 1996, ONCOGENE, V12, P953; HONKANAN RE, 1994, TOXICON, V32, P339, DOI 10.1016/0041-0101(94)90086-8; HONKANEN RE, 1993, FEBS LETT, V330, P283, DOI 10.1016/0014-5793(93)80889-3; HONKANEN RE, 1990, J BIOL CHEM, V265, P19401; HONKANEN RE, 1991, MOL PHARMACOL, V40, P577; Honkanen RE, 1996, MOL BIOL CELL, V7, P3273; Hsiao M, 1997, BIOCHEM BIOPH RES CO, V233, P329, DOI 10.1006/bbrc.1997.6450; Huang XZ, 1998, J BIOL CHEM, V273, P1462, DOI 10.1074/jbc.273.3.1462; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JAMAL S, 1995, ONCOGENE, V10, P2095; KAWASAKI T, 1994, CANCER LETT, V82, P113, DOI 10.1016/0304-3835(94)90154-6; KINCAID RL, 1988, P NATL ACAD SCI USA, V85, P8983, DOI 10.1073/pnas.85.23.8983; LI YC, 1991, MOL CELL BIOL, V11, P1883, DOI 10.1128/MCB.11.4.1883; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MAYR GA, 1995, CANCER RES, V55, P2410; Ollendorf V, 1997, J BIOL CHEM, V272, P32011, DOI 10.1074/jbc.272.51.32011; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; Ramalingam A, 1997, MOL ENDOCRINOL, V11, P577, DOI 10.1210/me.11.5.577; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SILVA EFDE, 1991, BIOCHIM BIOPHYS ACTA, V1089, P269, DOI 10.1016/0167-4781(91)90023-F; Silverstein AM, 1997, J BIOL CHEM, V272, P16224, DOI 10.1074/jbc.272.26.16224; Skinner J, 1997, J BIOL CHEM, V272, P22464, DOI 10.1074/jbc.272.36.22464; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; SONG Q, 1993, GENE, V129, P291, DOI 10.1016/0378-1119(93)90282-8; STONE SR, 1987, BIOCHEMISTRY-US, V26, P7215, DOI 10.1021/bi00397a003; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Walsh AH, 1997, FEBS LETT, V416, P230, DOI 10.1016/S0014-5793(97)01210-6; WALTER G, 1993, BIOCHIM BIOPHYS ACTA, V1155, P207, DOI 10.1016/0304-419X(93)90005-W; WALTER WG, 1989, J PHARM SCI, V78, P66, DOI 10.1002/jps.2600780117; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yan Y, 1997, J BIOL CHEM, V272, P15220, DOI 10.1074/jbc.272.24.15220; YATSUNAMI J, 1993, CANCER RES, V53, P239; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZHANG W, 1994, CANCER RES, V54, P4448; Zhao SY, 1997, PHOTOCHEM PHOTOBIOL, V66, P727, DOI 10.1111/j.1751-1097.1997.tb03214.x	68	103	109	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12250	12258		10.1074/jbc.273.20.12250	http://dx.doi.org/10.1074/jbc.273.20.12250			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575175	hybrid			2022-12-27	WOS:000073629800040
J	Zhu, CY; Johansson, M; Permert, J; Karlsson, A				Zhu, CY; Johansson, M; Permert, J; Karlsson, A			Enhanced cytotoxicity of nucleoside analogs by overexpression of mitochondrial deoxyguanosine kinase in cancer cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYCYTIDINE KINASE; TOXICITY; CDNA	The cytotoxic anti-cancer purine nucleoside analogs 2-chloro-2'-deoxyadenosine (CdA), 9-beta-D-arabinofuranosylguanine (araG), and 2',2'-difluorodeoxyguanosine (dFdG) are phosphorylated by human mitochondrial deoxyguanosine kinase (dGK) in vitro. We overexpressed dGK as a fusion protein to the green fluorescent protein in the human pancreatic cancer cell lines PanC-1 and MIA PaCa-2 to determine the importance of dGK-mediated nucleoside analog phosphorylation, The transfected cells showed mitochondrial fluorescence patterns, and the mitochondrial locations of endogenous and overexpressed dGK were verified by Western blot analysis of cell extracts with polyclonal anti-dGK antibodies. The increase of dGR activity in the overexpressing cells was similar to 4-fold. These cell lines exhibited increased sensitivity to CdA, araG, and dFdG as compared with the untransfected parent cell lines. This is, to our knowledge, the first demonstration of a correlation between the activity of a mitochondrial deoxyribonucleoside kinase and the cytotoxicity of nucleoside analogs. Our data imply that the dGK activity is rate-limiting for the efficacy of nucleoside analogs in the cell lines investigated.	Huddinge Univ Hosp, Karolinska Inst, Div Clin Virol, S-14186 Stockholm, Sweden; Huddinge Univ Hosp, Karolinska Inst, Div Surg, S-14186 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet	Karlsson, A (corresponding author), Huddinge Univ Hosp, Karolinska Inst, Div Clin Virol, S-14186 Stockholm, Sweden.		Karlsson, Anna/E-7945-2018	Karlsson, Anna/0000-0001-6843-6685				ARNER ESJ, 1995, PHARMACOL THERAPEUT, V67, P155, DOI 10.1016/0163-7258(95)00015-9; ARNER ESJ, 1992, BIOCHEM BIOPH RES CO, V188, P712, DOI 10.1016/0006-291X(92)91114-6; BERK AJ, 1973, J BIOL CHEM, V248, P2722; BESTWICK RK, 1982, J BIOL CHEM, V257, P9300; CARSON DA, 1980, P NATL ACAD SCI-BIOL, V77, P6865, DOI 10.1073/pnas.77.11.6865; CHEN CH, 1992, J BIOL CHEM, V267, P2856; GANDHI V, 1995, CANCER RES, V55, P1517; Hapke DM, 1996, CANCER RES, V56, P2343; HELM R, 1995, NATURE, V373, P663; Hui YF, 1997, AM J HEALTH-SYST PH, V54, P162, DOI 10.1093/ajhp/54.2.162; Johansson M, 1997, P NATL ACAD SCI USA, V94, P11941, DOI 10.1073/pnas.94.22.11941; Johansson M, 1996, P NATL ACAD SCI USA, V93, P7258, DOI 10.1073/pnas.93.14.7258; Kurtzberg J., 1995, Blood, V86, p511A; LEWIS W, 1995, NAT MED, V1, P417, DOI 10.1038/nm0595-417; Manome Y, 1996, NAT MED, V2, P567, DOI 10.1038/nm0596-567; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; OWENS JK, 1992, CANCER RES, V52, P2389; Plunkett W, 1996, HEMATOL CELL THER, V38, pS67; RIZZUTO R, 1995, CURR BIOL, V5, P635, DOI 10.1016/S0960-9822(95)00128-X; SNYDER FF, 1994, BBA-MOL BASIS DIS, V1227, P33, DOI 10.1016/0925-4439(94)90103-1; SODERLUND JCF, 1995, ADV EXP MED BIOL, V370, P201; WANG LY, 1993, J BIOL CHEM, V268, P22847	22	51	55	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14707	14711		10.1074/jbc.273.24.14707	http://dx.doi.org/10.1074/jbc.273.24.14707			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614068	hybrid			2022-12-27	WOS:000074160400010
J	Luberto, C; Hannun, YA				Luberto, C; Hannun, YA			Sphingomyelin synthase, a potential regulator of intracellular levels of ceramide and diacylglycerol during SV40 transformation - Does sphingomyelin synthase account for the putative, phosphatidylcholine-specific phospholipase C?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; PROTEIN-KINASE-C; CANINE KIDNEY CELLS; PLASMA-MEMBRANE; GOLGI-APPARATUS; SUBCELLULAR-FRACTIONS; CULTURED FIBROBLASTS; SIGNAL-TRANSDUCTION; MOUSE FIBROBLASTS; ELEVATED LEVELS	Sphingomyelin synthase (SMS), an enzyme involved in sphingomyelin (SM) and ceramide metabolism, can potentially regulate, in opposite directions, the levels of ceramide and diacylglycerol. in this study SMS activity was investigated in normal and SV40-transformed human lung fibroblasts (WI38). The addition of [H-3]C-2-ceramide to cells resulted in a time-dependent formation of [H-3]C-2-SM. At 24 h after treatment, normal WI38 cells cleared 17% of [H-3]C-2-ceramide producing [H-3]C-2-SM, which accounted for 13% of total radioactivity. On the other hand, SV40-transformed cells cleared 45% of [H-3]C-2-ceramide and produced C-2-SM, which accounted for 24% of total radioactivity. This enhanced production of C-2-SM was also supported by an increase in the total SMS activity of cells (measured in vitro), such that SV40-transformed cells had SMS activity of 222 pmol/mg of protein/h, whereas wild type cells had 78 pmol/mg of protein/h of activity. Additional studies aimed at examining the SMS activity directed at ceramide produced in the plasma membrane. Treatment of cells with exogenous bacterial sphingomyelinase (SMase) for 25 min resulted in cleavage of 90-95% of total SM and the concomitant generation of ceramide, After bacterial SMase treatment, wild type WI38 cells cleared ceramide very slowly (19.2 pmol of ceramide/nmol of phosholipid P-i after 6 h of incubation) and hardly regenerated slay SM. On the other hand, SV40-transformed cells cleared ceramide much faster (41.1 pmol/nmol of P-i after 6 h of incubation) and regenerated approximately 80% of the original SM. These results show that the enhanced SMS activity of transformed cells is particularly pronounced when ceramide is produced in the plasma membrane. Finally, several observations led us to consider the relationship of SMS to the "putative" phosphatidylcholine-specific phospholipase C (PC-PLC), We, therefore, tested the effects of D609, a pur-ported PC-PLC-specific inhibitor on the activity of SMS, D609 inhibited SMS activity in vitro. In addition, cellular studies showed that SMS activity was dramatically inhibited by concentrations of D609 used previously to study PC-PLC (10-50 mu g/ml). These results suggest SMS as an important biochemical target for D609, and they raise the distinct possibility that many of the roles of PC-PLC, especially in cell transformation, may be attributable to SMS.	Duke Univ, Dept Med, Durham, NC 27710 USA; Duke Univ, Dept Cell Biol, Durham, NC 27710 USA	Duke University; Duke University	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem, 171 Ashley Ave, Charleston, SC 29425 USA.	hannun@musc.edu			NIGMS NIH HHS [GM-43825] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allan David, 1994, Trends in Cell Biology, V4, P350, DOI 10.1016/0962-8924(94)90076-0; AMES BN, 1960, J BIOL CHEM, V235, P769; ANDRIEU N, 1994, BIOCHEM J, V303, P341, DOI 10.1042/bj3030341; BERGELSO.LD, 1970, BIOCHIM BIOPHYS ACTA, V210, P287, DOI 10.1016/0005-2760(70)90173-6; BERNERT JT, 1981, BIOCHIM BIOPHYS ACTA, V666, P99, DOI 10.1016/0005-2760(81)90095-3; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; Bjorkoy G, 1997, J BIOL CHEM, V272, P11557; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAI H, 1992, MOL CELL BIOL, V12, P5329, DOI 10.1128/MCB.12.12.5329; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; DBAIBO GS, 1995, P NATL ACAD SCI USA, V92, P1347, DOI 10.1073/pnas.92.5.1347; DIAZLAVIADA I, 1990, EMBO J, V9, P3907, DOI 10.1002/j.1460-2075.1990.tb07611.x; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; FOLCH J, 1957, J BIOL CHEM, V226, P497; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; HAMPTON RY, 1989, SCIENCE, V246, P1050, DOI 10.1126/science.2555921; Hannun, 1997, PR MED BIOL A, V7, P487, DOI 10.1016/S1569-2582(97)80129-8; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P223, DOI 10.1016/0304-4157(93)90001-5; HATCH GM, 1992, J BIOL CHEM, V267, P12443; HEROLD P, 1988, HELV CHIM ACTA, V71, P354, DOI 10.1002/hlca.19880710208; HOSTETLER KY, 1979, CANCER RES, V39, P2978; HOSTETLER KY, 1976, BIOCHIM BIOPHYS ACTA, V441, P231, DOI 10.1016/0005-2760(76)90166-1; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; JECKEL D, 1990, FEBS LETT, V261, P155, DOI 10.1016/0014-5793(90)80659-7; KALLEN KJ, 1994, BBA-BIOMEMBRANES, V1191, P52, DOI 10.1016/0005-2736(94)90232-1; KALLEN KJ, 1993, BIOCHIM BIOPHYS ACTA, V1166, P305, DOI 10.1016/0005-2760(93)90111-L; KALLEN KJ, 1995, TRENDS CELL BIOL, V5, P149, DOI 10.1016/S0962-8924(00)88970-9; KIM MY, 1991, J BIOL CHEM, V266, P484; KOBAYASHI T, 1989, J BIOL CHEM, V264, P5966; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KOVAL M, 1995, TRENDS CELL BIOL, V5, P148, DOI 10.1016/S0962-8924(00)88969-2; LACAL JC, 1987, SCIENCE, V238, P533, DOI 10.1126/science.2821623; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; Laurenz JC, 1996, BBA-LIPID LIPID MET, V1299, P146, DOI 10.1016/0005-2760(95)00202-2; LIPSKY NG, 1983, P NATL ACAD SCI-BIOL, V80, P2608, DOI 10.1073/pnas.80.9.2608; LIPSKY NG, 1985, SCIENCE, V228, P745, DOI 10.1126/science.2581316; LIPSKY NG, 1985, J CELL BIOL, V100, P27, DOI 10.1083/jcb.100.1.27; LISCOVITCH M, 1994, CELL, V77, P329, DOI 10.1016/0092-8674(94)90148-1; LOPEZBARAHONA M, 1990, J BIOL CHEM, V265, P9022; MAJERUS PW, 1986, SCIENCE, V234, P1519, DOI 10.1126/science.3024320; MARGGRAF WD, 1987, BIOCHIM BIOPHYS ACTA, V897, P57, DOI 10.1016/0005-2736(87)90315-4; MARGGRAF WD, 1982, BIOCHIM BIOPHYS ACTA, V710, P314, DOI 10.1016/0005-2760(82)90114-X; MARGGRAF WD, 1981, BIOCHIM BIOPHYS ACTA, V664, P61, DOI 10.1016/0005-2760(81)90028-X; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MULLERDECKER K, 1989, BIOCHEM BIOPH RES CO, V162, P198, DOI 10.1016/0006-291X(89)91981-5; NINKAR S, 1988, TETRAHEDRON LETT, V29, P3037; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Obradors MJM, 1997, BBA-MOL CELL RES, V1359, P1; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; POLYAKOV V M, 1977, Biokhimiya, V42, P799; PREISS J, 1986, J BIOL CHEM, V261, P8597; PRICE BD, 1989, J BIOL CHEM, V264, P16638; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SCHWEIZER A, 1994, J BIOL CHEM, V269, P4035; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; SRIBNEY M, 1971, CAN J BIOCHEM CELL B, V49, P306, DOI 10.1139/o71-044; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; ULLMAN MD, 1974, J BIOL CHEM, V249, P1506; UPRETI GC, 1983, J NATL CANCER I, V70, P567; VAN HELVOORT A, 1994, J BIOL CHEM, V269, P1763; van Helvoort A, 1997, J CELL SCI, V110, P781; VAN MEER G, 1987, J CELL BIOL, V105, P1623, DOI 10.1083/jcb.105.4.1623; VANDENHILL A, 1985, BIOCHIM BIOPHYS ACTA, V833, P354, DOI 10.1016/0005-2760(85)90210-3; vanDijk MCM, 1997, J BIOL CHEM, V272, P11011; vanDijk MCM, 1997, BIOCHEM J, V323, P693, DOI 10.1042/bj3230693; VANGOLDE LMG, 1974, BIOCHIM BIOPHYS ACTA, V360, P17; VANVELDHOVEN PP, 1989, ANAL BIOCHEM, V183, P177, DOI 10.1016/0003-2697(89)90186-3; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; VOELKER DR, 1982, BIOCHEMISTRY-US, V21, P2753, DOI 10.1021/bi00540a027; Walev I, 1996, INFECT IMMUN, V64, P2974, DOI 10.1128/IAI.64.8.2974-2979.1996; WILKISON WO, 1989, ONCOGENE, V4, P625; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0; WYKE AW, 1992, CELL SIGNAL, V4, P267, DOI 10.1016/0898-6568(92)90066-H; Zhang P, 1997, J BIOL CHEM, V272, P9609	82	253	270	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14550	14559		10.1074/jbc.273.23.14550	http://dx.doi.org/10.1074/jbc.273.23.14550			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603970	hybrid			2022-12-27	WOS:000074021500072
J	Nomura, T; Takizawa, M; Aoki, J; Arai, H; Inoue, K; Wakisaka, E; Yoshizuka, N; Imokawa, G; Dohmae, N; Takio, K; Hattori, M; Matsuo, N				Nomura, T; Takizawa, M; Aoki, J; Arai, H; Inoue, K; Wakisaka, E; Yoshizuka, N; Imokawa, G; Dohmae, N; Takio, K; Hattori, M; Matsuo, N			Purification, cDNA cloning, and expression of UDP-Gal: Glucosylceramide beta-1,4-galactosyltransferase from rat brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CERAMIDE GLUCOSYLTRANSFERASE; HUMAN GALACTOSYLTRANSFERASE; GOLGI-APPARATUS; MESSENGER-RNAS; BINDING-SITES; PROTEIN; IDENTIFICATION; GALACTOSE; SEQUENCES; LIVER	Lactosylceramide synthase is an enzyme that catalyzes the transfer of galactose from UDP-Gal to glucosylceramide, and thus participates in the biosynthesis of most glycosphingolipids in mammals. We purified this enzyme over 61,000-fold to near homogeneity with a 29.7% yield from rat brain membrane fractions. The isolation procedure included solubilization with Triton X-100, affinity chromatography on wheat germ aggluti nin-agarose and UDP-hexanolamine-agarose, and hydroxylapatite column chromatography, followed by ion exchange chromatography. The final preparation migrated as a broad band with an apparent molecular mass of 61 kDa on SDS-polyacrylamide gel electrophoresis. This apparent molecular mass was reduced to 51 kDa by N-glycanase digestion, suggesting that the enzyme has a glycoprotein nature. The enzyme required Mn2+ for its activity, and glucosylceramide was its preferred substrate. The cDNA for the enzyme was cloned from a rat brain cDNA library. The cDNA insert encoded a polypeptide of 382 amino acid residues, with a molecular weight of 44,776. The polypeptide contained eight putative glycosylation sites and a 20-amino acid residue transmembrane domain at its N terminus. Amino acid sequence homology analysis revealed that this enzyme shared 39% homology with mouse beta-1,4-galactosyltransferase (EC 2.4.1.38), which catalyzes the transfer of Gal to beta-1,4-GlcNAc in glycoproteins.	Kao Corp, Biol Sci Labs, Haga, Tochigi 3213497, Japan; RIKEN, Inst Phys & Chem Res, Div Biomol Characterizat, Wako, Saitama 3510198, Japan; Univ Tokyo, Fac Pharmaceut Sci, Bunkyo Ku, Tokyo 113, Japan	KAO Corporation; RIKEN; University of Tokyo	Nomura, T (corresponding author), Kao Corp, Biol Sci Labs, 2606 Akabane, Haga, Tochigi 3213497, Japan.	387533@kastanet.kao.co.jp	Dohmae, Naoshi/C-2040-2011	Dohmae, Naoshi/0000-0002-5242-9410; Aoki, Junken/0000-0001-9435-1896				AOKI D, 1990, EMBO J, V9, P3171, DOI 10.1002/j.1460-2075.1990.tb07515.x; BAKKER H, 1994, J BIOL CHEM, V269, P30326; BASE M, 1987, METHOD ENZYMOL, V138, P575; BENDIAK B, 1993, EUR J BIOCHEM, V216, P405, DOI 10.1111/j.1432-1033.1993.tb18158.x; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHATTERJEE S, 1987, BIOCHIM BIOPHYS ACTA, V923, P136, DOI 10.1016/0304-4165(87)90136-X; CHATTERJEE S, 1992, J BIOL CHEM, V267, P7148; CHECHIK BE, 1987, MOL IMMUNOL, V24, P765, DOI 10.1016/0161-5890(87)90060-5; DAGOSTARO G, 1989, EUR J BIOCHEM, V183, P211, DOI 10.1111/j.1432-1033.1989.tb14915.x; Ichikawa S, 1996, P NATL ACAD SCI USA, V93, P4638, DOI 10.1073/pnas.93.10.4638; JOZIASSE DH, 1989, J BIOL CHEM, V264, P14290; KADOWAKI S, 1991, J BIOCHEM-TOKYO, V110, P17, DOI 10.1093/oxfordjournals.jbchem.a123536; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASAKI T, 1981, BIOCHIM BIOPHYS ACTA, V660, P44, DOI 10.1016/0005-2744(81)90106-6; MASRI KA, 1988, BIOCHEM BIOPH RES CO, V157, P657, DOI 10.1016/S0006-291X(88)80300-0; Miyazaki H, 1997, J BIOL CHEM, V272, P24794, DOI 10.1074/jbc.272.40.24794; NAGATA Y, 1992, J BIOL CHEM, V267, P12082; NAKAZAWA K, 1993, J BIOCHEM-TOKYO, V113, P747; Paul P, 1996, J BIOL CHEM, V271, P2287, DOI 10.1074/jbc.271.4.2287; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; SCHULTE S, 1993, P NATL ACAD SCI USA, V90, P10265, DOI 10.1073/pnas.90.21.10265; SHAPER NL, 1988, J BIOL CHEM, V263, P10420; TAKI T, 1982, J BIOCHEM-TOKYO, V91, P665, DOI 10.1093/oxfordjournals.jbchem.a133739; TRINCHERA M, 1991, BIOCHEMISTRY-US, V30, P2719, DOI 10.1021/bi00224a021; UEMURA M, 1988, CANCER RES, V48, P5325; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; WANG Y, 1994, BIOCHEM BIOPH RES CO, V204, P701, DOI 10.1006/bbrc.1994.2516; YADAV SP, 1991, J BIOL CHEM, V266, P698; YAMATO K, 1982, J BIOCHEM-TOKYO, V92, P1123, DOI 10.1093/oxfordjournals.jbchem.a134028; ZU HY, 1995, BIOCHEM BIOPH RES CO, V206, P362, DOI 10.1006/bbrc.1995.1050; [No title captured]	35	113	147	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13570	13577		10.1074/jbc.273.22.13570	http://dx.doi.org/10.1074/jbc.273.22.13570			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593693	hybrid			2022-12-27	WOS:000073919100032
J	Shin, DS; Compadre, CM; Maleki, SJ; Kopper, RA; Sampson, H; Huang, SK; Burks, AW; Bannon, GA				Shin, DS; Compadre, CM; Maleki, SJ; Kopper, RA; Sampson, H; Huang, SK; Burks, AW; Bannon, GA			Biochemical and structural analysis of the IgE binding sites on Ara h1, an abundant and highly allergenic peanut protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; FOOD HYPERSENSITIVITY; ATOPIC-DERMATITIS; NATURAL-HISTORY; CHILDREN; IDENTIFICATION; EPITOPES	Allergy to peanut is a significant IgE-mediated health problem because of the high prevalence, potential severity, and chronicity of the reaction. Ara hi, an abundant peanut protein, is recognized by serum IgE from >90% of peanut-sensitive individuals. It has been shown to belong to the vicilin family of seed storage proteins and to contain 23 linear IgE binding epitopes, In this communication, we have determined the critical amino acids within each of the IgE binding epitopes of Ara hi that are important for immunoglobulin binding. Surprisingly, substitution of a single amino acid within each of the epitopes led to loss of IgE binding. In addition, hydrophobic residues appeared to be most critical for IgE binding. The position of each of the IgE binding epitopes on a homology-based molecular model of Ara hi showed that they were clustered into two main regions, despite their more even distribution in the primary sequence, Finally, we have shown that Ara hi forms a stable trimer by the use of a reproducible fluorescence assay. This information will be important in studies designed to reduce the risk of peanut-induced anaphylaxis by lowering the IgE binding capacity of the allergen.	Univ Arkansas Med Sci, Arkansas Childrens Hosp, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Arkansas Childrens Hosp, Biomed Visualizat Ctr, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Arkansas Childrens Hosp, Dept Pediat, Little Rock, AR 72205 USA; Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA; Johns Hopkins Univ, Div Pediat Allergy & Immunol, Baltimore, MD 21287 USA	Arkansas Children's Hospital; University of Arkansas System; University of Arkansas Medical Sciences; Arkansas Children's Hospital; University of Arkansas System; University of Arkansas Medical Sciences; Arkansas Children's Hospital; University of Arkansas System; University of Arkansas Medical Sciences; Icahn School of Medicine at Mount Sinai; Johns Hopkins University	Bannon, GA (corresponding author), Univ Arkansas Med Sci, Slot 516,4301 W Markham, Little Rock, AR 72205 USA.	bannongarya@exchange.uams.edu	Huang, Shau-Ku/F-5509-2010; Compadre, Cesar M/D-1286-2009	Compadre, Cesar M/0000-0002-5652-0203	PHS HHS [R01-A33596] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Aas K, 1975, Dev Biol Stand, V29, P90; ABOLA EE, 1987, PROTEIN DATA BANK CR, P107; Astwood JD, 1996, NAT BIOTECHNOL, V14, P1269, DOI 10.1038/nbt1096-1269; BALL G, 1994, CLIN EXP ALLERGY, V24, P758, DOI 10.1111/j.1365-2222.1994.tb00987.x; BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V84, P701, DOI 10.1016/0091-6749(89)90298-4; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOCK SA, 1985, J PEDIATR-US, V107, P676, DOI 10.1016/S0022-3476(85)80391-7; BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; BOCK SA, 1987, PEDIATRICS, V79, P683; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Burks A W, 1993, Curr Probl Pediatr, V23, P230, DOI 10.1016/0097-3165(93)90015-Z; BURKS AW, 1991, J ALLERGY CLIN IMMUN, V88, P172, DOI 10.1016/0091-6749(91)90325-I; Burks AW, 1997, EUR J BIOCHEM, V245, P334, DOI 10.1111/j.1432-1033.1997.t01-1-00334.x; BURKS AW, 1995, J CLIN INVEST, V96, P1715, DOI 10.1172/JCI118216; BURKS AW, 1988, J PEDIATR-US, V113, P447, DOI 10.1016/S0022-3476(88)80626-7; Buschmann L, 1996, MONOGR ALLERGY, V32, P92; CARLSON W, 1985, HYPERTENSION, V7, P13, DOI 10.1161/01.HYP.7.1.13; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ELSAYED S, 1989, INT ARCH ALLER A IMM, V89, P410, DOI 10.1159/000234984; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; HEFLE SL, 1996, CRIT REV FOOD SCI NU, V36, P69; HERIAN AM, 1990, INT ARCH ALLER A IMM, V92, P193, DOI 10.1159/000235213; JANSEN JJN, 1994, J ALLERGY CLIN IMMUN, V93, P446; KAMINOGAWA S, 1996, BIOSCI BIOTECH BIOCH, V60, P179; KO TP, 1993, PLANT PHYSIOL, V101, P729, DOI 10.1104/pp.101.3.729; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWRENCE MC, 1994, J MOL BIOL, V238, P748, DOI 10.1006/jmbi.1994.1333; Lehrer SB, 1996, CRIT REV FOOD SCI, V36, P553, DOI 10.1080/10408399609527739; Lundblad JR, 1996, MOL ENDOCRINOL, V10, P607, DOI 10.1210/me.10.6.607; Majamaa H, 1996, J ALLERGY CLIN IMMUN, V97, P985, DOI 10.1016/S0091-6749(96)80074-1; Maleki SJ, 1997, BIOCHEMISTRY-US, V36, P6762, DOI 10.1021/bi970262m; Nordlee JA, 1996, NEW ENGL J MED, V334, P688, DOI 10.1056/NEJM199603143341103; ROYER CA, 1992, METHOD ENZYMOL, V210, P481; Sampson HA, 1996, ANNU REV NUTR, V16, P161, DOI [10.1146/annurev.nu.16.070196.001113, 10.1146/annurev.nutr.16.1.161]; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; SHANTI KN, 1993, J IMMUNOL, V151, P5354; Stanley JS, 1997, ARCH BIOCHEM BIOPHYS, V342, P244, DOI 10.1006/abbi.1997.9998; SUTTON BJ, 1993, NATURE, V366, P421, DOI 10.1038/366421a0; VEITHS S, 1996, FOOD ALLERGIES INTOL, P130	39	203	230	2	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13753	13759		10.1074/jbc.273.22.13753	http://dx.doi.org/10.1074/jbc.273.22.13753			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593717	hybrid			2022-12-27	WOS:000073919100056
J	Williams, JG; McMaster, CR				Williams, JG; McMaster, CR			Scanning alanine mutagenesis of the CDP-alcohol phosphotransferase motif of Saccharomyces cerevisiae cholinephosphotransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPT1 GENE-PRODUCTS; ESCHERICHIA-COLI; PHOSPHATIDYLSERINE SYNTHASE; NUCLEOTIDE-SEQUENCE; SN-1,2-DIACYLGLYCEROL CHOLINEPHOSPHOTRANSFERASE; CYTIDINE "5'-DIPHOSPHO-1,2-DIACYL-SN-GLYCEROL; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; PHOSPHOLIPID SYNTHASES; PSS GENE; YEAST	Cholinephosphotransferase (EC 2.7.8.2) catalyzes the formation of a phosphoester bond via the transfer of a phosphocholine moiety from CDP-choline to diacylglycerol forming phosphatidylcholine and releasing GRIP. A motif, Asp(113)-Gly(114)-(X)(2)-Ala(117)-Arg(118)-(X)(8)-Gly(127)-(X)(3)- Asp(131)-(X)(3)-Asp(135), located within the CDP-choline binding region of Saccharomyces cerevisiae cholinephosphotransferase (CPTI ?/Author: Please confirm that a gene is meant here.) is also found in several other phospholipid synthesizing enzymes that catalyze the formation of a phosphoester bond utilizing a CDP-alcohol and a second alcohol as substrates, To determine if this motif is diagnostic of the above reaction type scanning alanine mutagenesis of the conserved residues within S. cerevisiae cholinephosphotransferase was performed. Enzyme activity was assessed in vitro using a mixed micelle enzyme assay and in vivo by determining the ability of the mutant enzymes to restore phosphatidylcholine synthesis from radiolabeled choline in an S. cerevisiae strain devoid of endogenous cholinephosphotransferase activity. Alanine mutants of Gly(114), Gly(127), Asp(131), and Asp(135) were inactive; mutants, Ala(117) and Arg(118) displayed reduced enzyme activity, and Asp(113) displayed wild type activity. The analysis described is the first molecular characterization of a CDP-alcohol phosphotransferase motif and results predict a catalytic role utilizing a general base reaction proceeding through Asp(131) or Asp(135) via direct nucleophilic attack of the hydroxyl of diacylglyerol on the phosphoester bond of CDP-choline that does not proceed via an enzyme bound intermediate. Residues Ala(117) and Arg(118) do not participate directly in catalysis but are likely involved in substrate binding or positioning with Arg(118) predicted to associate with a phosphate moiety of CDP-choline.	Dalhousie Univ, Atlantic Res Ctr, Dept Pediat, Halifax, NS B3H 4H7, Canada; Dalhousie Univ, Atlantic Res Ctr, Dept Biochem, Halifax, NS B3H 4H7, Canada	Dalhousie University; Dalhousie University	McMaster, CR (corresponding author), Dalhousie Univ, Atlantic Res Ctr, Dept Pediat, 5849 Univ Ave,Rm C-302, Halifax, NS B3H 4H7, Canada.			McMaster, Christopher/0000-0003-0822-5776				AMES BN, 1960, J BIOL CHEM, V235, P769; BAELEE MS, 1984, J BIOL CHEM, V259, P857; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3026; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; CORNELL RB, 1992, METHOD ENZYMOL, V209, P267; DECHAVIGNY A, 1991, J BIOL CHEM, V266, P5323; DEWEY RE, 1994, PLANT CELL, V6, P1495, DOI 10.1105/tpc.6.10.1495; GOPALAKRISHNAN AS, 1986, J BIOL CHEM, V261, P1329; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HIRABAYASHI T, 1976, BIOCHEMISTRY-US, V15, P5205, DOI 10.1021/bi00669a002; HJELMSTAD RH, 1991, J BIOL CHEM, V266, P4357; HJELMSTAD RH, 1994, J BIOL CHEM, V269, P20995; HJELMSTAD RH, 1991, J BIOL CHEM, V266, P5094; HJELMSTAD RH, 1990, J BIOL CHEM, V265, P1755; Kaiser C., 1994, METHODS YEAST GENETI; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; Koonin EV, 1996, TRENDS BIOCHEM SCI, V21, P242, DOI 10.1016/0968-0004(96)30024-8; LARSON TJ, 1976, BIOCHEMISTRY-US, V15, P5212, DOI 10.1021/bi00669a003; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCMASTER CR, 1994, J BIOL CHEM, V269, P14776; MCMASTER CR, 1994, J BIOL CHEM, V269, P28010; McMaster CR, 1996, BIOCHEM J, V313, P729, DOI 10.1042/bj3130729; NIKAWA J, 1987, EUR J BIOCHEM, V167, P7, DOI 10.1111/j.1432-1033.1987.tb13297.x; NIKAWA J, 1987, J BIOL CHEM, V262, P4876; OKADA M, 1994, J BACTERIOL, V176, P7456, DOI 10.1128/JB.176.24.7456-7461.1994; Ponting CP, 1996, PROTEIN SCI, V5, P914; PONTONI G, 1985, BIOCHIM BIOPHYS ACTA, V826, P222; RAETZ CRH, 1987, BIOCHEMISTRY-US, V26, P4022, DOI 10.1021/bi00387a042; ROONEY SA, 1994, FASEB J, V8, P957, DOI 10.1096/fasebj.8.12.8088461; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; STERN I, 1953, J CLIN PATHOL, V6, P158, DOI 10.1136/jcp.6.2.158; Tanaka S, 1996, FEBS LETT, V393, P89, DOI 10.1016/0014-5793(96)00858-7; VANCE DE, 1996, BIOCH LIPIDS LIPOPRO, P153; WEISS SB, 1958, J BIOL CHEM, V231, P53	35	69	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13482	13487		10.1074/jbc.273.22.13482	http://dx.doi.org/10.1074/jbc.273.22.13482			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593682	hybrid			2022-12-27	WOS:000073919100021
J	Elmendorf, JS; Chen, D; Pessin, JE				Elmendorf, JS; Chen, D; Pessin, JE			Guanosine 5 '-O-(3-thiotriphosphate) (GTP gamma S) stimulation of GLUT4 translocation is tyrosine kinase-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE TRANSPORTER GLUT4; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN-KINASE; 3T3-L1 ADIPOCYTES; SKELETAL-MUSCLE; SIGNALING PATHWAYS; BROWN ADIPOCYTES; CALCIUM CHANNELS; PLASMA-MEMBRANE; SER/THR KINASE	Guanosine 5'-O-(3-thiotriphosphate) (GTP gamma S) treatment of permeabilized adipocytes results in GLUT4 translocation similar to that elicited by insulin treatment. However, although the selective phosphatidylinositol 3-kinase inhibitor, wortmannin, completely prevented insulin-stimulated GLUT4 translocation, it was without effect on GTP gamma S-stimulated GLUT4 translocation, In addition, insulin was an effective stimulant, whereas GTP gamma S was a very weak activator of the downstream Akt serine/threonine kinase, Consistent with an Akt-independent mechanism, guanosine 5'-O-2-(thio) diphosphate inhibited insulin-stimulated GLUT4 translocation without any effect on the Akt kinase, Surprisingly, two functionally distinct tyrosine kinase inhibitors, genistein and herbimycin A, as well as microinjection of a monoclonal phosphotyrosine specific antibody, inhibited both GTP gamma S- and insulin-stimulated GLUT4 translocation. Phosphotyrosine immunoblotting and specific immunoprecipitation demonstrated that GTP gamma S did not elicit tyrosine phosphorylation of insulin receptor or insulin receptor substrate-1. In contrast to insulin, proteins in the 120-130-kDa and 55-75-kDa range were tyrosine-phosphorylated following GTP gamma S stimulation. Several of these proteins were identified and include protein-tyrosine kinase 2 (also known as CAK beta, RAFTK, and CADTK), pp125 focal adhesion tyrosine kinase, pp130 Crk-associated substrate, paxillin, and Cbl, These data demonstrate that the GTP gamma S-stimulated GLUT4 translocation utilizes a novel tyrosine kinase pathway that is independent of both the phosphatidylinositol 3-kinase and the Akt kinase.	Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa	Pessin, JE (corresponding author), Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA.	jeffrey-pessin@uiowa.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033823, R37DK033823, R01DK049012] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33823, DK25925, DK49012] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; BALDINI G, 1991, J BIOL CHEM, V266, P4037; BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; BERGER J, 1994, BIOCHEM BIOPH RES CO, V205, P570, DOI 10.1006/bbrc.1994.2703; Bourinet E, 1996, P NATL ACAD SCI USA, V93, P1486, DOI 10.1073/pnas.93.4.1486; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CARTEE GD, 1991, J APPL PHYSIOL, V70, P1593, DOI 10.1152/jappl.1991.70.4.1593; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; Chen D, 1997, J BIOL CHEM, V272, P27401, DOI 10.1074/jbc.272.43.27401; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; CLAUSEN T, 1975, BIOCHIM BIOPHYS ACTA, V375, P292, DOI 10.1016/0005-2736(75)90197-2; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; CZECH MP, 1995, ANNU REV NUTR, V15, P441, DOI 10.1146/annurev.nu.15.070195.002301; DOLPHIN AC, 1986, J PHYSIOL-LONDON, V373, P47, DOI 10.1113/jphysiol.1986.sp016034; ELMENDORF JS, 1995, BIOCHEM BIOPH RES CO, V208, P1147, DOI 10.1006/bbrc.1995.1453; Fischer Y, 1996, AM J PHYSIOL-CELL PH, V270, pC1211, DOI 10.1152/ajpcell.1996.270.4.C1211; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; HERBST JJ, 1995, J BIOL CHEM, V270, P26000, DOI 10.1074/jbc.270.43.26000; HOLLOSZY JO, 1967, SCIENCE, V155, P573, DOI 10.1126/science.155.3762.573; KANAI F, 1993, J BIOL CHEM, V268, P14523; Kishi K, 1996, J BIOL CHEM, V271, P26561, DOI 10.1074/jbc.271.43.26561; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; MINTZ IM, 1993, NEURON, V10, P889, DOI 10.1016/0896-6273(93)90204-5; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; MYERS MGJ, 1992, P NATL ACAD SCI USA, V21, P10350; OBERMAIERKUSSER B, 1988, BIOCHEM J, V256, P515, DOI 10.1042/bj2560515; Okada S, 1997, J BIOL CHEM, V272, P28179, DOI 10.1074/jbc.272.45.28179; Olson AL, 1997, MOL CELL BIOL, V17, P2425, DOI 10.1128/MCB.17.5.2425; OMATSUKANBE M, 1992, FEBS LETT, V314, P246, DOI 10.1016/0014-5793(92)81481-Z; RHIM H, 1994, J NEUROSCI, V14, P7608; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; Shepherd PR, 1997, BIOCHEM SOC T, V25, P978, DOI 10.1042/bst0250978; SHIMIZU Y, 1994, BIOCHEM BIOPH RES CO, V202, P660, DOI 10.1006/bbrc.1994.1981; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; Todaka M, 1996, BIOCHEM J, V315, P875, DOI 10.1042/bj3150875; TSAKIRIDIS T, 1995, ENDOCRINOLOGY, V136, P4315, DOI 10.1210/en.136.10.4315; WHITE MF, 1994, J BIOL CHEM, V269, P1; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993	49	64	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					13289	13296		10.1074/jbc.273.21.13289	http://dx.doi.org/10.1074/jbc.273.21.13289			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582374	hybrid			2022-12-27	WOS:000073768500085
J	Formisano, P; Oriente, F; Miele, C; Caruso, M; Auricchio, R; Vigliotta, G; Condorelli, G; Beguinot, F				Formisano, P; Oriente, F; Miele, C; Caruso, M; Auricchio, R; Vigliotta, G; Condorelli, G; Beguinot, F			In NIH-3T3 fibroblasts, insulin receptor interaction with specific protein kinase C isoforms controls receptor intracellular routing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; SIGNAL-TRANSDUCTION; PHOSPHORYLATION; CELLS; BETA; LOCALIZATION; ACTIVATION; RETROENDOCYTOSIS; INTERNALIZATION; IDENTIFICATION	Insulin increased protein kinase C (PKC) activity by 2-fold in both membrane preparations and insulin receptor (IR) antibody precipitates from NIH-3T3 cells expressing human IRs (3T3(hIR)). PKC-alpha, -delta, and -zeta were barely detectable in IR antibody precipitates of unstimulated cells, while increasing by 7-, 3.5-, and 3-fold, respectively, after insulin addition. Preexposure of 3T3(hIR) cells to staurosporine reduced insulin-induced receptor coprecipitation with PKC-alpha, -delta, and -zeta by 3-, 4-, and 10-fold, respectively, accompanied by a 1.5-fold decrease in insulin degradation and a similar increase in insulin retroendocytosis. Selective depletion of cellular PKC-alpha and -delta, by 24 h of 12-O-tetradecanoylphorbol-13-acetate (TPA) exposure, reduced insulin degradation by 3-fold and similarly increased insulin retroendocytosis, with no change in PKC-zeta. In lysates of NIH-3T3 cells expressing the R1152Q/K1153A IRs (3T3(Mut)), insulin-induced coprecipitation of PKC-alpha, -delta, and -zeta with the IR was reduced by 10-, 7-, and 3-fold, respectively. Similar to the 3T3(Mut) cells chronically exposed to TPA, untreated 3T3(Mut) featured a 3-fold decrease in insulin degradation, with a 3-fold increase in intact insulin retroendocytosis. Thus, in NIH-3T3 cells, insulin elicits receptor interaction with multiple PKC isoforms, Interaction of PKC-alpha and/or -delta with the IR appears to control its intracellular routing.	Univ Naples Federico II, Sch Med, Dipartimento Biol & Patol Cellulare & Mol L Calif, I-80131 Naples, Italy; Univ Naples Federico II, Sch Med, CNR, Ctr Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II	Beguinot, F (corresponding author), Univ Naples Federico II, Sch Med, Dipartimento Biol & Patol Cellulare & Mol L Calif, Via Pansini 5, I-80131 Naples, Italy.		Vigliotta, Giovanni/GPF-7237-2022; Formisano, Pietro/J-4237-2018; Condorelli, Gerolama/AAC-3472-2022; vigliotta, giovanni/AAW-6401-2020; ORIENTE, Francesco/J-6652-2018	Condorelli, Gerolama/0000-0003-0177-8829; vigliotta, giovanni/0000-0001-5132-0037; Formisano, Pietro/0000-0001-7020-6870; ORIENTE, Francesco/0000-0003-4375-4526				AHN JC, 1993, J BIOL CHEM, V268, P7571; BENELLI C, 1994, METABOLISM, V43, P1030, DOI 10.1016/0026-0495(94)90185-6; BERTI L, 1994, J BIOL CHEM, V269, P3381; Blobe GC, 1996, J BIOL CHEM, V271, P15823, DOI 10.1074/jbc.271.26.15823; Chalfant CE, 1996, MOL ENDOCRINOL, V10, P1273, DOI 10.1210/me.10.10.1273; CHALFANT CE, 1995, J BIOL CHEM, V270, P13326, DOI 10.1074/jbc.270.22.13326; CHIN JE, 1993, J BIOL CHEM, V268, P6338; COGHLAN MP, 1994, BIOCHEM J, V303, P893, DOI 10.1042/bj3030893; FARESE RV, 1992, CELL SIGNAL, V4, P133, DOI 10.1016/0898-6568(92)90077-L; FORMISANO P, 1993, J BIOL CHEM, V268, P5241; FORMISANO P, 1994, J BIOL CHEM, V269, P16242; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; ISHIZUKA T, 1997, DIABETOLOGIA S1, V40, P139; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; KAHN CR, 1994, DIABETES, V43, P1066, DOI 10.2337/diab.43.8.1066; KING GL, 1994, ANNU REV MED, V45, P179, DOI 10.1146/annurev.med.45.1.179; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY JR, 1986, ENDOCRINOLOGY, V119, P572, DOI 10.1210/endo-119-2-572; LEVYTOLEDANO R, 1994, J BIOL CHEM, V269, P31178; LEWIS RE, 1994, J BIOL CHEM, V269, P26259; LITCHFIELD DW, 1986, BIOCHEM BIOPH RES CO, V134, P1276, DOI 10.1016/0006-291X(86)90388-8; LIU F, 1994, BIOCHEM BIOPH RES CO, V200, P1570, DOI 10.1006/bbrc.1994.1630; LIU JP, 1994, J BIOL CHEM, V269, P21043; LUND KA, 1990, J BIOL CHEM, V265, P15713; MARSHALL S, 1985, J BIOL CHEM, V260, P3524; Mendez R, 1997, MOL CELL BIOL, V17, P5184, DOI 10.1128/MCB.17.9.5184; MIELE C, 1995, J BIOL CHEM, V270, P15844, DOI 10.1074/jbc.270.26.15844; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIMURA H, 1994, BIOCHEM J, V302, P271, DOI 10.1042/bj3020271; Prekeris R, 1996, J CELL BIOL, V132, P77, DOI 10.1083/jcb.132.1.77; Schubert C, 1996, J BIOL CHEM, V271, P15311, DOI 10.1074/jbc.271.26.15311; SEEDORF K, 1995, J BIOL CHEM, V270, P18953, DOI 10.1074/jbc.270.32.18953; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TAKAYAMA S, 1988, J BIOL CHEM, V263, P3440; VANHORN DJ, 1994, J BIOL CHEM, V269, P29; WEINSTOCK RS, 1988, ENDOCRINOLOGY, V123, P366, DOI 10.1210/endo-123-1-366; White MF, 1997, DIABETOLOGIA, V40, pS2, DOI 10.1007/s001250051387; YASUDA I, 1990, BIOCHEM BIOPH RES CO, V166, P1220, DOI 10.1016/0006-291X(90)90996-Z	40	41	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					13197	13202		10.1074/jbc.273.21.13197	http://dx.doi.org/10.1074/jbc.273.21.13197			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582362	hybrid			2022-12-27	WOS:000073768500073
J	Tittmann, K; Proske, D; Spinka, M; Ghisla, S; Rudolph, R; Hubner, G; Kern, G				Tittmann, K; Proske, D; Spinka, M; Ghisla, S; Rudolph, R; Hubner, G; Kern, G			Activation of thiamin diphosphate and FAD in the phosphate-dependent pyruvate oxidase from Lactobacillus plantarum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								The phosphate- and oxygen-dependent pyruvate oxidase from Lactobacillus plantarum is a homotetrameric enzyme that binds 1 FAD and 1 thiamine diphosphate per subunit, A kinetic analysis of the partial reactions in the overall oxidative conversion of pyruvate to acetyl phosphate and CO2 shows an indirect activation of the thiamine diphosphate by FAD that is mediated by the protein moiety, The rate constant of the initial step, the deprotonation of C2-H of thiamine diphosphate, increases 10-fold in the binary apoenzyme-thiamine diphosphate complex to 10(-2) s(-1). Acceleration of this step beyond the observed overall catalytic rate constant to 20 s(-1) requires enzyme-bound FAD, FAD appears to bind in a two-step mechanism. The primarily bound form allows formation of hydroxyethylthiamine diphosphate but not the transfer of electrons from this intermediate to O-2, This intermediate form can be mimicked using 5-deaza-FAD, which is inactive toward O-2 but active in an assay using 2,6-dichlorophenolindophenol as electron acceptor. This analogue also promotes the rate constant of C2-H dissociation of thiamine diphosphate in pyruvate oxidase beyond the overall enzyme turnover. Formation of the catalytically competent FAD-thiamine-pyruvate oxidase ternary complex requires a second step, which was detected at low temperature.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Halle Wittenberg, Inst Biochem, D-06099 Halle, Germany; Univ Halle Wittenberg, Inst Biotechnol, D-06099 Halle, Germany; Univ Konstanz, Fak Biol, D-78434 Konstanz, Germany	University of California System; University of California Berkeley; Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg; University of Konstanz	Kern, G (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.							ATANASSOVA M, 1984, THESIS M LUTHER U HA; CHRISTEN P, 1970, ANAL CHIM ACTA, V51, P47, DOI 10.1016/S0003-2670(01)81830-4; COFFEY DS, 1964, BIOCHEMISTRY-US, V3, P394, DOI 10.1021/bi00891a015; COGOLIGREUTER M, 1979, EUR J BIOCHEM, V100, P295, DOI 10.1111/j.1432-1033.1979.tb02060.x; GOTZ F, 1991, BIOCHEMISTRY AND PHYSIOLOGY OF THIAMIN DIPHOSPHATE ENZYMES, P286; HOLZER H, 1957, BIOCHEM Z, V329, P192; Kern D, 1997, SCIENCE, V275, P67, DOI 10.1126/science.275.5296.67; MANSTEIN DJ, 1986, BIOCHEMISTRY-US, V25, P6807, DOI 10.1021/bi00370a012; MUELLER YA, 1994, J MOL BIOL, V237, P315; MUELLER YA, 1993, SCIENCE, V259, P965; RISSE B, 1992, PROTEIN SCI, V1, P1699, DOI 10.1002/pro.5560011218; RISSE B, 1992, THESIS U REGENSBURG; SEDEWITZ B, 1984, J BACTERIOL, V160, P462, DOI 10.1128/JB.160.1.462-465.1984; SEDEWITZ B, 1984, J BACTERIOL, V160, P273, DOI 10.1128/JB.160.1.273-278.1984; SPENCER R, 1976, BIOCHEMISTRY-US, V15, P1043, DOI 10.1021/bi00650a015; STRITTMATTER P, 1961, J BIOL CHEM, V236, P2329	16	28	28	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					12929	12934		10.1074/jbc.273.21.12929	http://dx.doi.org/10.1074/jbc.273.21.12929			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582325	hybrid			2022-12-27	WOS:000073768500036
J	Barahmand-Pour, F; Meinke, A; Groner, B; Decker, T				Barahmand-Pour, F; Meinke, A; Groner, B; Decker, T			Jak2-Stat5 interactions analyzed in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE RECEPTOR; INTERFERON ACTIVATION SITE; PROTEIN-TYROSINE KINASE; SIGNAL-TRANSDUCTION; DNA-BINDING; CYTOKINE RECEPTORS; STAT5 ACTIVATION; GENE-EXPRESSION; GAMMA RECEPTOR; IL-4 RECEPTOR	Many cytokine receptors employ Janus protein tyrosine kinases (Jaks) and signal transducers and activators of transcription (Stats) for nuclear signaling, Here, we have established yeast strains in which an autoactivated Jak2 kinase induces tyrosine phosphorylation, dimerization, nuclear translocation, and DNA binding of a concomitantly expressed Stat5 protein. Transcriptional activity of Stat5 on a stably integrated, Stat-dependent reporter gene required the C-terminal fusion of the VP16 transactivation domain. In such yeast strains, the interaction between Jak2 and Stat5 was analyzed without interference by other mammalian proteins involved in regulating Jak-Stat signaling, and mutant versions of both proteins were analyzed for their ability to productively interact. Complexes between Jab2 and Stat5 were found to be stable under stringent co-immunoprecipitation conditions. Deletion of the Jak homology regions 2-7 (JH2-JH7) of Jak2, leaving only the kinase domain (JH1) intact, reduced the ability of the kinase to phosphorylate Stat5, whereas deletion of the JH2 domain caused an increased enzymatic activity, A site-directed R618K mutation in the Stat5 SH2 domain abolished the phosphorylation by Jak2, while deletion of the C terminus led to Stat5 hyperphosphorylation. A single phosphotyrosine-SH2 domain interaction was sufficient for the dimerization of Stat5, but such dimers bound to DNA very inefficiently. Together, our data show that yeast cells are appropriate tools for studying Jak-Stat or Stat-Stat interactions. Our mutational analysis suggests that the Stat5 SH2 domain is essential for the interaction with Jak2 and that the kinase domain of Jak2 is sufficient for Jak2-Stat5 interaction. Therefore, the Jak kinase domain may be all that is needed to cause Stat phosphorylation in situations where receptor docking is dispensable.	Univ Vienna, Vienna Bioctr, Inst Genet & Microbiol, A-1030 Vienna, Austria; Inst Expt Canc Res, Tumor Biol Ctr, D-79106 Freiburg, Germany	University of Vienna; Vienna Biocenter (VBC)	Decker, T (corresponding author), Univ Vienna, Vienna Bioctr, Inst Genet & Microbiol, Dr Bohr Gasse 9, A-1030 Vienna, Austria.	decker@gem.univie.ac.at						AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; Berchtold S, 1997, J BIOL CHEM, V272, P30237, DOI 10.1074/jbc.272.48.30237; COLLUM RG, 1996, EUR CYTOKINE NETW, V7, P518; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Decker T, 1997, IMMUNOBIOLOGY, V198, P99, DOI 10.1016/S0171-2985(97)80031-9; Eilers A, 1996, CELL GROWTH DIFFER, V7, P833; EILERS A, 1994, MOL CELL BIOL, V14, P1364, DOI 10.1128/MCB.14.2.1364; Fujitani Y, 1997, ONCOGENE, V14, P751, DOI 10.1038/sj.onc.1200907; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; Goupille O, 1997, MOL CELL ENDOCRINOL, V127, P155, DOI 10.1016/S0303-7207(97)04005-7; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; Gupta S, 1996, EMBO J, V15, P1075, DOI 10.1002/j.1460-2075.1996.tb00445.x; Hansen JA, 1997, J MOL ENDOCRINOL, V18, P213, DOI 10.1677/jme.0.0180213; Hansen LH, 1996, J BIOL CHEM, V271, P12669, DOI 10.1074/jbc.271.21.12669; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; Jiang N, 1996, J BIOL CHEM, V271, P16472, DOI 10.1074/jbc.271.28.16472; Kohlhuber F, 1997, MOL CELL BIOL, V17, P695, DOI 10.1128/MCB.17.2.695; Kotenko SV, 1996, J BIOL CHEM, V271, P17174, DOI 10.1074/jbc.271.29.17174; LAI CF, 1995, J BIOL CHEM, V270, P23254, DOI 10.1074/jbc.270.40.23254; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; Liu KD, 1997, CURR BIOL, V7, P817, DOI 10.1016/S0960-9822(06)00369-1; Liu XW, 1996, MOL ENDOCRINOL, V10, P1496, DOI 10.1210/me.10.12.1496; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; LOBIE PE, 1995, J BIOL CHEM, V270, P21745, DOI 10.1074/jbc.270.37.21745; Luo H, 1997, MOL CELL BIOL, V17, P1562, DOI 10.1128/MCB.17.3.1562; Meinke A, 1996, MOL CELL BIOL, V16, P6937; Moriggl R, 1997, MOL CELL BIOL, V17, P3663, DOI 10.1128/MCB.17.7.3663; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; Moriggl R, 1998, EUR J BIOCHEM, V251, P25, DOI 10.1046/j.1432-1327.1998.2510025.x; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Nicholson SE, 1996, J BIOL CHEM, V271, P26947, DOI 10.1074/jbc.271.43.26947; Pellegrini S, 1997, EUR J BIOCHEM, V248, P615, DOI 10.1111/j.1432-1033.1997.00615.x; Pezet A, 1997, J BIOL CHEM, V272, P25043, DOI 10.1074/jbc.272.40.25043; Ryan JJ, 1996, IMMUNITY, V4, P123, DOI 10.1016/S1074-7613(00)80677-9; Sakai I, 1997, J BIOL CHEM, V272, P12350, DOI 10.1074/jbc.272.19.12350; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; VELAZQUEZ L, 1995, J BIOL CHEM, V270, P3327, DOI 10.1074/jbc.270.7.3327; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Wang HY, 1996, IMMUNITY, V4, P113, DOI 10.1016/S1074-7613(00)80676-7; Wang XZ, 1996, MOL ENDOCRINOL, V10, P1249, DOI 10.1210/me.10.10.1249; WANG YD, 1995, J BIOL CHEM, V270, P7021, DOI 10.1074/jbc.270.13.7021; WANG YP, 1995, BLOOD, V86, P1671, DOI 10.1182/blood.V86.5.1671.bloodjournal8651671; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; Ziemiecki Andrew, 1994, Trends in Cell Biology, V4, P207, DOI 10.1016/0962-8924(94)90143-0	48	36	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12567	12575		10.1074/jbc.273.20.12567	http://dx.doi.org/10.1074/jbc.273.20.12567			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575217	hybrid			2022-12-27	WOS:000073629800082
J	Onate, SA; Boonyaratanakornkit, V; Spencer, TE; Tsai, SY; Tsai, MJ; Edwards, DP; O'Malley, BW				Onate, SA; Boonyaratanakornkit, V; Spencer, TE; Tsai, SY; Tsai, MJ; Edwards, DP; O'Malley, BW			The steroid receptor coactivator-1 contains multiple receptor interacting and activation domains that cooperatively enhance the activation function 1 (AF1) and AF2 domains of steroid receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; TRANSCRIPTION FACTOR TFIIB; ESTROGEN-RECEPTOR; NUCLEAR RECEPTORS; PROGESTERONE-RECEPTOR; DEPENDENT TRANSCRIPTION; CONSERVED REGION; FUNCTION AF-2; COMPLEX; PROTEIN	Steroid receptors are ligand-inducible transcription factors, and their association with steroid receptor coactivators (SRCs) upon binding to DNA is necessary for them to achieve full transcriptional potential. To understand the mechanism of SRC-1 action, its ability to interact and enhance the transcriptional activity of steroid receptors was analyzed. First, we show that SRC-1 is a modular coactivator that possesses intrinsic transcriptional activity when tethered to DNA and that it harbors two distinct activation domains, AD1 and AD2, needed for the maximum coactivation function of steroid receptors. We also demonstrate that SRC-1 interacts with both the amino-terminal A/B or AF1-containing domain and the carboxyl-terminal D/E or AF2-containing domain of the steroid receptors, These interactions are carried out by multiple regions of SRC-1, and they are relevant for transactivation, In addition to the inherent histone acetyltransferase activity of SRC-1, the presence of multiple receptor-coactivator interaction sites in SRC-1 and its ability to interact with components of the basic transcriptional machinery appears to be, at least in part, the mechanism by which the individual activation functions of the steroid receptors act cooperatively to achieve full transcriptional activity.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Program Mol Biol, Denver, CO 80262 USA	Baylor College of Medicine; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	O'Malley, BW (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.		Spencer, Thomas/AAD-6434-2020	Spencer, Thomas/0000-0003-2815-766X	NCI NIH HHS [CA 46938] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046938] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; BAXEVANIS AD, 1993, CURR OPIN GENET DEV, V3, P278, DOI 10.1016/0959-437X(93)90035-N; Beato M, 1996, ENDOCR REV, V17, P587, DOI 10.1210/er.17.6.587; BLANCO JCG, 1995, P NATL ACAD SCI USA, V92, P1535, DOI 10.1073/pnas.92.5.1535; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chang KH, 1997, P NATL ACAD SCI USA, V94, P9040, DOI 10.1073/pnas.94.17.9040; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; ESTES PA, 1987, BIOCHEMISTRY-US, V26, P6250, DOI 10.1021/bi00393a045; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; ING NH, 1992, J BIOL CHEM, V267, P17617; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; Jeyakumar M, 1997, MOL ENDOCRINOL, V11, P755, DOI 10.1210/me.11.6.755; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; LANZ RB, 1994, ENDOCRINOLOGY, V135, P2183, DOI 10.1210/en.135.5.2183; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; May M, 1996, EMBO J, V15, P3093, DOI 10.1002/j.1460-2075.1996.tb00672.x; McEwan IJ, 1997, P NATL ACAD SCI USA, V94, P8485, DOI 10.1073/pnas.94.16.8485; McInerney EM, 1996, P NATL ACAD SCI USA, V93, P10069, DOI 10.1073/pnas.93.19.10069; Mengus G, 1997, GENE DEV, V11, P1381, DOI 10.1101/gad.11.11.1381; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; Perlmann T, 1997, CELL, V90, P391, DOI 10.1016/S0092-8674(00)80498-5; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; SCHULMAN IG, 1995, P NATL ACAD SCI USA, V92, P8288, DOI 10.1073/pnas.92.18.8288; SCHWERK C, 1995, J BIOL CHEM, V270, P21331, DOI 10.1074/jbc.270.36.21331; SHEMSHEDINI L, 1992, J BIOL CHEM, V267, P1834; SHIBATA H, 1997, RECENT PROG HORM RES, V52, P1; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Takeshita A, 1996, ENDOCRINOLOGY, V137, P3594, DOI 10.1210/en.137.8.3594; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533; Zhang YX, 1997, MOL ENDOCRINOL, V11, P823, DOI 10.1210/me.11.6.823; ZHANG YX, 1995, MOL ENDOCRINOL, V9, P1029, DOI 10.1210/me.9.8.1029	54	339	345	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12101	12108		10.1074/jbc.273.20.12101	http://dx.doi.org/10.1074/jbc.273.20.12101			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575154	hybrid			2022-12-27	WOS:000073629800019
J	Rutledge, EA; Gaston, I; Root, BJ; McGraw, TE; Enns, CA				Rutledge, EA; Gaston, I; Root, BJ; McGraw, TE; Enns, CA			The transferrin receptor cytoplasmic domain determines its rate of transport through the biosynthetic pathway and its susceptibility to cleavage early in the pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED GLYCOSYLATION SITE; STOMATITIS-VIRUS GLYCOPROTEIN; ANCHORED GROWTH-FACTORS; ENDOPLASMIC-RETICULUM; CELL-SURFACE; INTERLEUKIN-2 RECEPTORS; FUNCTIONAL EXPRESSION; FACTOR-ALPHA; SERUM; INTERNALIZATION	The soluble human transferrin receptor (TfR) found in blood is the result of a proteolytic cleavage occurring in the ectodomain of the receptor close to the transmembrane domain at Arg-100. We have discovered another cleavage site between Gly-91 and Val-92 even closer to the transmembrane domain. Cleavage at Gly-91 differs markedly from the normal cleavage site. It occurs when the entire cytoplasmic portion or the proximal 31 amino acids of the transmembrane domain are deleted. A soluble disulfide-bonded dimer of the TfR is released into the medium in contrast to the cleavage at Arg-100 where a dimer lacking intersubunit disulfide bonds is released. Whereas the cleavage at Arg-100 is generated by cycling through the endosomal system, pulse-chase experiments indicate that cleavage at Gly-91 occurs predominantly during the biosynthesis of the receptor. Pulse-chase analysis of the biosynthesis of mutant TfRs that lack the membrane-proximal cytoplasmic domain show that they exit the endoglycosidase H-sensitive compartment at a slower rate than the wild type TfR. These results suggest that the cytoplasmic domain influences the trafficking of the TfR either by influencing the folding of the ectodomain or by providing a positive signal for its transport through the biosynthetic pathway.	Oregon Hlth Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA; Cornell Univ, Coll Med, Dept Biochem, New York, NY 10021 USA; Bristol Myers Squibb, Syracuse, NY 13201 USA	Oregon Health & Science University; Cornell University; Bristol-Myers Squibb	Enns, CA (corresponding author), Oregon Hlth Sci Univ, Dept Cell & Dev Biol, L215, Portland, OR 97201 USA.				NIDDK NIH HHS [DK52852, DK40608, F32DK08910] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK052852, R01DK040608, R01DK052852, F32DK008910] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALVAREZ E, 1990, J BIOL CHEM, V265, P16644; Arribas J, 1997, J BIOL CHEM, V272, P17160, DOI 10.1074/jbc.272.27.17160; ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BAYNES RD, 1993, P SOC EXP BIOL MED, V204, P65; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; CLAIRMONT KB, 1990, ENDOCRINOLOGY, V127, P1568, DOI 10.1210/endo-127-4-1568; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; COOK JD, 1993, ANNU REV MED, V44, P63, DOI 10.1146/annurev.med.44.1.63; DO SI, 1992, GLYCOBIOLOGY, V2, P345, DOI 10.1093/glycob/2.4.345; Enns C.A., 1996, BIOMEMBRANE, V4, P255, DOI [10.1016/S1874-5342(96)80012-2, DOI 10.1016/S1874-5342(96)80012-2]; ENNS CA, 1991, J BIOL CHEM, V266, P13272; FITTING T, 1982, J BIOL CHEM, V257, P4011; FLOWERS CH, 1989, J LAB CLIN MED, V114, P368; Hayes GR, 1997, BIOCHEMISTRY-US, V36, P5276, DOI 10.1021/bi962884y; HAYES GR, 1992, GLYCOBIOLOGY, V2, P355, DOI 10.1093/glycob/2.4.355; HOE MH, 1992, J BIOL CHEM, V267, P4916; HORTON MA, 1983, EXP CELL RES, V144, P361, DOI 10.1016/0014-4827(83)90415-9; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; JING SQ, 1990, J BIOL CHEM, V265, P11555; KOHGO Y, 1990, JPN J CANCER RES, V81, P91, DOI 10.1111/j.1349-7006.1990.tb02512.x; KOHGO Y, 1986, BRIT J HAEMATOL, V64, P277, DOI 10.1111/j.1365-2141.1986.tb04120.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MCCLELLAND A, 1984, CELL, V39, P267, DOI 10.1016/0092-8674(84)90004-7; MCGRAW TE, 1991, J CELL BIOL, V112, P853, DOI 10.1083/jcb.112.5.853; MCGRAW TE, 1987, J CELL BIOL, V105, P207, DOI 10.1083/jcb.105.1.207; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; Mullberg J, 1997, FEBS LETT, V401, P235, DOI 10.1016/S0014-5793(96)01480-9; NAIR MK, 1990, BIOCHIM BIOPHYS ACTA, V1035, P306, DOI 10.1016/0304-4165(90)90093-C; NELSON DL, 1986, J CLIN IMMUNOL, V6, P114, DOI 10.1007/BF00918743; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; OSAWA H, 1986, EUR J IMMUNOL, V16, P467, DOI 10.1002/eji.1830160426; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PYTOWSKI B, 1995, J BIOL CHEM, V270, P9067, DOI 10.1074/jbc.270.16.9067; ROSE JK, 1983, CELL, V34, P513, DOI 10.1016/0092-8674(83)90384-7; RUTLEDGE EA, 1994, BLOOD, V83, P580; RUTLEDGE EA, 1994, J BIOL CHEM, V269, P31864; Rutledge EA, 1996, J CELL PHYSIOL, V168, P284, DOI 10.1002/(SICI)1097-4652(199608)168:2<284::AID-JCP7>3.0.CO;2-L; SHIH YJ, 1990, J BIOL CHEM, V265, P19077; TIESMAN J, 1993, J BIOL CHEM, V268, P9621; Tolchinsky S, 1996, J BIOL CHEM, V271, P14496, DOI 10.1074/jbc.271.24.14496; TROWBRIDGE IS, 1992, J INORG BIOCHEM, V47, P209, DOI 10.1016/0162-0134(92)84066-V; TURKEWITZ AP, 1988, J BIOL CHEM, V263, P8318; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; WILLIAMS AM, 1991, J BIOL CHEM, V266, P17648; WILLIAMS AM, 1993, J BIOL CHEM, V268, P12780; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	53	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12169	12175		10.1074/jbc.273.20.12169	http://dx.doi.org/10.1074/jbc.273.20.12169			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575164	hybrid			2022-12-27	WOS:000073629800029
J	Mandala, SM; Thornton, RA; Milligan, J; Rosenbach, M; Garcia-Calvo, M; Bull, HG; Harris, G; Abruzzo, GK; Flattery, AM; Gill, CJ; Bartizal, K; Dreikorn, S; Kurtz, MB				Mandala, SM; Thornton, RA; Milligan, J; Rosenbach, M; Garcia-Calvo, M; Bull, HG; Harris, G; Abruzzo, GK; Flattery, AM; Gill, CJ; Bartizal, K; Dreikorn, S; Kurtz, MB			Rustmicin, a potent antifungal agent, inhibits sphingolipid synthesis at inositol phosphoceramide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; SERINE PALMITOYLTRANSFERASE; CANDIDA-ALBICANS; YEAST; BIOSYNTHESIS; RESISTANCE; CERAMIDE; PROTEINS; GOLGI	Rustmicin is a 14-membered macrolide previously identified as an inhibitor of plant pathogenic fungi by a mechanism that was not defined. We discovered that rustmicin inhibits inositol phosphoceramide synthase, resulting in the accumulation of ceramide and the loss of all of the complex sphingolipids, Rustmicin has potent fungicidal activity against clinically important human pathogens that is correlated with its sphingolipid inhibition, It is especially potent against Cryptococcus neoformans, where it inhibits growth and sphingolipid synthesis at concentrations <1 ng/ml and inhibits the enzyme with an IC50 of 70 pM. This inhibition of the membrane-bound enzyme is reversible; moreover, rustmicin is nearly equipotent against the solubilized enzyme. Rustmicin was efficacious in a mouse model for cryptococcosis, but it was less active than predicted from its in vitro potency against this pathogen. Stability and drug efflux were identified as two factors limiting rustmicin's activity. in the presence of serum, rustmicin rapidly epimerizes at the C-2 position and is converted to a gamma-lactone, a product that is devoid of activity. Rustmicin was also found to be a remarkably good substrate for the Saccharomyces cerevisiae multidrug efflux pump encoded by PDR5.	Merck Res Labs, Dept Biochem, Rahway, NJ 07065 USA	Merck & Company	Mandala, SM (corresponding author), Merck Res Labs, Dept Biochem, R80Y-230,PO 2000, Rahway, NJ 07065 USA.							ABRUZZO GK, 1995, ANTIMICROB AGENTS CH, V39, P1077, DOI 10.1128/AAC.39.5.1077; Achenbach H, 1988, Ann N Y Acad Sci, V544, P128, DOI 10.1111/j.1749-6632.1988.tb40396.x; ACHENBACH H, 1985, TETRAHEDRON LETT, V26, P6167, DOI 10.1016/S0040-4039(00)95043-3; BALZI E, 1995, J BIOENERG BIOMEMBR, V27, P71, DOI 10.1007/BF02110333; BOAS MHSV, 1994, CHEM PHYS LIPIDS, V70, P11; CONZELMANN A, 1992, EMBO J, V11, P457, DOI 10.1002/j.1460-2075.1992.tb05075.x; FAUTH U, 1986, J ANTIBIOT, V39, P1760, DOI 10.7164/antibiotics.39.1760; GABER RF, 1989, MOL CELL BIOL, V9, P3447, DOI 10.1128/MCB.9.8.3447; GELDERBLOM WCA, 1988, APPL ENVIRON MICROB, V54, P1806, DOI 10.1128/AEM.54.7.1806-1811.1988; Graybill JR, 1996, CLIN INFECT DIS, V22, pS166, DOI 10.1093/clinids/22.Supplement_2.S166; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Horn W. S., 1992, J ANTIBIOT, V47, P376; HORVATH A, 1994, EMBO J, V13, P3687, DOI 10.1002/j.1460-2075.1994.tb06678.x; Kearns BG, 1997, NATURE, V387, P101, DOI 10.1038/387101a0; KO J, 1995, J FOOD BIOCHEM, V19, P253; Lavie Y, 1997, J BIOL CHEM, V272, P1682, DOI 10.1074/jbc.272.3.1682; Lavie Y, 1996, J BIOL CHEM, V271, P19530, DOI 10.1074/jbc.271.32.19530; LESTER RL, 1993, ADV LIPID RES, V26, P253; MANDALA SM, 1995, J ANTIBIOT, V48, P349, DOI 10.7164/antibiotics.48.349; Mandala SM, 1997, J ANTIBIOT, V50, P339, DOI 10.7164/antibiotics.50.339; MANDALA SM, 1994, J ANTIBIOT, V47, P376, DOI 10.7164/antibiotics.47.376; Mandala SM, 1997, J BIOL CHEM, V272, P32709, DOI 10.1074/jbc.272.51.32709; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; MEYERS S, 1992, CURR GENET, V21, P431, DOI 10.1007/BF00351651; Michel C, 1997, J BIOL CHEM, V272, P22432, DOI 10.1074/jbc.272.36.22432; MIYAKE Y, 1995, BIOCHEM BIOPH RES CO, V211, P396, DOI 10.1006/bbrc.1995.1827; MONK BC, 1991, J BACTERIOL, V173, P6826, DOI 10.1128/jb.173.21.6826-6836.1991; Mundy LM, 1997, SEMIN RESP CRIT CARE, V18, P249, DOI 10.1055/s-2008-1070994; Nagiec MM, 1997, J BIOL CHEM, V272, P9809, DOI 10.1074/jbc.272.15.9809; Nickels JT, 1996, GENE DEV, V10, P382, DOI 10.1101/gad.10.4.382; Oh CS, 1997, J BIOL CHEM, V272, P17376, DOI 10.1074/jbc.272.28.17376; Pena LA, 1997, BIOCHEM PHARMACOL, V53, P615, DOI 10.1016/S0006-2952(96)00834-9; PUOTI A, 1991, J CELL BIOL, V113, P515, DOI 10.1083/jcb.113.3.515; RILEY RT, 1994, J FOOD PROTECT, V57, P638, DOI 10.4315/0362-028X-57.7.638; SANGLARD D, 1995, ANTIMICROB AGENTS CH, V39, P2378, DOI 10.1128/AAC.39.11.2378; Schneiter R, 1997, CELL, V88, P431, DOI 10.1016/S0092-8674(00)81882-6; SPIEGEL S, 1995, J MEMBRANE BIOL, V146, P225; TAKATSU T, 1985, J ANTIBIOT, V38, P1806, DOI 10.7164/antibiotics.38.1806; TAKESAKO K, 1993, J ANTIBIOT, V46, P1414, DOI 10.7164/antibiotics.46.1414; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Tse B, 1997, J ORG CHEM, V62, P3236, DOI 10.1021/jo970106l; VINCENT VL, 1995, MICROBIOL-UK, V141, P1829, DOI 10.1099/13500872-141-8-1829; WANG E., 1991, J BIOL CHEM, V266, P1486; ZWEERINK MM, 1992, J BIOL CHEM, V267, P25032	44	94	102	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14942	14949		10.1074/jbc.273.24.14942	http://dx.doi.org/10.1074/jbc.273.24.14942			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614099	hybrid			2022-12-27	WOS:000074160400041
J	Schwappach, B; Stobrawa, S; Hechenberger, M; Steinmeyer, K; Jentsch, TJ				Schwappach, B; Stobrawa, S; Hechenberger, M; Steinmeyer, K; Jentsch, TJ			Golgi localization and functionally important domains in the NH2 and COOH terminus of the yeast CLC putative chloride channel Gef1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-LIMITED GROWTH; VACUOLAR H+-ATPASE; SACCHAROMYCES-CEREVISIAE; MEMBRANE-PROTEIN; CYTOPLASMIC DOMAIN; SECRETORY PATHWAY; AMINO-TERMINUS; GENE; SIGNAL; EXPRESSION	GEF1 encodes the single CLC putative chloride channel in yeast. Its disruption leads to a defect in iron metabolism (Greene, J. R., Brown, N. H., DiDomenico, B. J., Haplan, J., and Eide, D. (1993) Mol. Gen. Genet. 241, 542-553). Since disruption of GEF2, a subunit of the vacuolar H+-ATPase, leads to a similar phenotype, it was previously suggested that the chloride conductance provided by Gef1p is necessary for vacuolar acidification. We now show that gef1 cells indeed grow less well at less acidic pH. However, no defect in vacuolar acidification is apparent from quinacrine staining, and Gef1p co-localizes with Mnt1p in the medial Golgi. Thus, Gef1p may be important in determining Golgi pH. Systematic alanine scanning of the amino and the carboxyl terminus revealed several regions essential for Gef1p localization and function. One sequence (FVTID) in the amino terminus conforms to a class of sorting signals containing aromatic amino acids. This was further supported by point mutations. Alanine scanning of the carboxyl terminus identified a stretch of roughly 25 amino acids which coincides with the second CBS domain, a conserved protein motif recently identified. Mutations in the first CBS domain also destroyed proper function and localization. The second CBS domain can be transplanted to the amino terminus without loss of function, but could not be replaced by the corresponding domain of the homologous mammalian channel CIC-2.	Univ Hamburg, Zentrum Mol Neurobiol Hamburg, D-20246 Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf	Jentsch, TJ (corresponding author), Univ Hamburg, Zentrum Mol Neurobiol Hamburg, Martinistr 52, D-20246 Hamburg, Germany.	Jentsch@plexus.uke.uni-hamburg.de		Jentsch, Thomas/0000-0002-3509-2553; Schwappach, Blanche/0000-0003-0225-6432				Ambesi A, 1996, J BIOL CHEM, V271, P22999, DOI 10.1074/jbc.271.38.22999; Bateman A, 1997, TRENDS BIOCHEM SCI, V22, P12, DOI 10.1016/S0968-0004(96)30046-7; BERKOWER C, 1994, MOL BIOL CELL, V5, P1185, DOI 10.1091/mbc.5.11.1185; BODE HP, 1995, EUR J BIOCHEM, V228, P337; BRADBURY NA, 1992, SCIENCE, V256, P530, DOI 10.1126/science.1373908; Brandt S, 1995, FEBS LETT, V377, P15, DOI 10.1016/0014-5793(95)01298-2; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CHAPMAN RE, 1994, EMBO J, V13, P4896, DOI 10.1002/j.1460-2075.1994.tb06817.x; CHAPMAN RE, 1994, EMBO J, V13, P2305, DOI 10.1002/j.1460-2075.1994.tb06514.x; EIDE D, 1992, J GEN MICROBIOL, V138, P347, DOI 10.1099/00221287-138-2-347; EIDE DJ, 1993, MOL GEN GENET, V241, P447, DOI 10.1007/BF00284699; EMR SD, 1986, J CELL BIOL, V102, P523, DOI 10.1083/jcb.102.2.523; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; GARIPPA RJ, 1994, J CELL BIOL, V124, P705, DOI 10.1083/jcb.124.5.705; GOLDSTEIN A, 1975, METHOD ENZYMOL, V42, P505; GRAHAM TR, 1994, J CELL BIOL, V127, P667, DOI 10.1083/jcb.127.3.667; GREENE JR, 1993, MOL GEN GENET, V241, P542, DOI 10.1007/BF00279896; GRUNDER S, 1992, NATURE, V360, P759, DOI 10.1038/360759a0; HARDWICK KG, 1990, EMBO J, V9, P623, DOI 10.1002/j.1460-2075.1990.tb08154.x; HAUSLER A, 1992, P NATL ACAD SCI USA, V89, P6846, DOI 10.1073/pnas.89.15.6846; Hebert SC, 1996, NATURE, V379, P398, DOI 10.1038/379398a0; Hechenberger M, 1996, J BIOL CHEM, V271, P33632, DOI 10.1074/jbc.271.52.33632; Hryciw DH, 1998, J BIOL CHEM, V273, P4304, DOI 10.1074/jbc.273.8.4304; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; JENTSCH TJ, 1995, J PHYSIOL-LONDON, V482P, pS19; Jentsch TJ, 1997, BIOESSAYS, V19, P117, DOI 10.1002/bies.950190206; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; Jordt SE, 1997, EMBO J, V16, P1582, DOI 10.1093/emboj/16.7.1582; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; Kuehn MJ, 1996, J CELL BIOL, V135, P585, DOI 10.1083/jcb.135.3.585; Lewis MJ, 1996, CELL, V85, P205, DOI 10.1016/S0092-8674(00)81097-1; LIM CR, 1995, J BIOCHEM-TOKYO, V118, P13, DOI 10.1093/oxfordjournals.jbchem.a124868; Lloyd SE, 1996, NATURE, V379, P445, DOI 10.1038/379445a0; Maduke M, 1998, BIOCHEMISTRY-US, V37, P1315, DOI 10.1021/bi972418o; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; Morsomme P, 1996, EMBO J, V15, P5513, DOI 10.1002/j.1460-2075.1996.tb00936.x; MOUNTAIN HA, 1991, YEAST, V7, P873, DOI 10.1002/yea.320070814; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; NOTHWEHR SF, 1994, J BIOL CHEM, V269, P10185; NOTHWEHR SF, 1993, J CELL BIOL, V121, P1197, DOI 10.1083/jcb.121.6.1197; PIPER RC, 1993, J CELL BIOL, V121, P1221, DOI 10.1083/jcb.121.6.1221; Ponting CP, 1997, J MOL MED-JMM, V75, P160; Radisky DC, 1997, P NATL ACAD SCI USA, V94, P5662, DOI 10.1073/pnas.94.11.5662; RAGUZZI F, 1988, FEBS LETT, V231, P253, DOI 10.1016/0014-5793(88)80742-7; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; Rose MD., 1990, METHODS YEAST GENETI; Sakaguchi T, 1996, J CELL BIOL, V133, P733, DOI 10.1083/jcb.133.4.733; SCHAFER W, 1995, EMBO J, V14, P2424, DOI 10.1002/j.1460-2075.1995.tb07240.x; SchmidtRose T, 1997, P NATL ACAD SCI USA, V94, P7633, DOI 10.1073/pnas.94.14.7633; SchmidtRose T, 1997, J BIOL CHEM, V272, P20515, DOI 10.1074/jbc.272.33.20515; SCHRODER S, 1995, J CELL BIOL, V131, P895, DOI 10.1083/jcb.131.4.895; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; Steinmeyer K, 1995, J BIOL CHEM, V270, P31172, DOI 10.1074/jbc.270.52.31172; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; UAUSBEL FM, 1997, CURRENT PROTOCOLS MO, V2; vanWeert AWM, 1997, EUR J CELL BIOL, V74, P417; VERHEY KJ, 1993, J CELL BIOL, V123, P137, DOI 10.1083/jcb.123.1.137; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; WILCOX CA, 1992, MOL BIOL CELL, V3, P1353, DOI 10.1091/mbc.3.12.1353; WILSON DW, 1993, J BIOL CHEM, V268, P7465	65	107	113	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15110	15118		10.1074/jbc.273.24.15110	http://dx.doi.org/10.1074/jbc.273.24.15110			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614122	hybrid			2022-12-27	WOS:000074160400064
J	Ohshima, K; Montermini, L; Wells, RD; Pandolfo, M				Ohshima, K; Montermini, L; Wells, RD; Pandolfo, M			Inhibitory effects of expanded GAA center dot TTC triplet repeats from intron I of the Friedreich ataxia gene on transcription and replication in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-SEQUENCE POLYMORPHISM; HUMAN HEREDITARY-DISEASES; ESCHERICHIA-COLI; TRINUCLEOTIDE REPEAT; TRANSGENIC MICE; SWITCH REGION; MUTATION-RATE; CTG; INSTABILITY; EXPRESSION	Friedreich ataxia (FRDA) is associated with the expansion of a GAA.TTC triplet repeat in the first intron of the frataxin gene, resulting in reduced levels of frataxin mRNA and protein. To investigate the mechanisms by which the intronic expansion produces its effect, GAA.TTC repeats of various lengths (9 to 270 triplets) were cloned in both orientations in the intron of a reporter gene. Plasmids containing these repeats were transiently transfected into COS-7 cells. A length- and orientation-dependent inhibition of reporter gene expression was observed. RNase protection and Northern blot analyses showed very low levels of mature mRNA when longer GAA repeats were transcribed, with no accumulation of primary transcript. Replication of plasmids carrying long GAA.TTC tracts (similar to 250 triplets) was greatly inhibited in COS-7 cells compared with plasmids carrying (GAA.TTC)(9) and (GAA.TTC)(90). Replication inhibition was five times greater for the plasmid whose transcript contains (GAA)(230) than for the plasmid whose transcript contains (UUC)(270). Our in vivo investigation revealed that expanded GAA . TTC repeats from intron I of the FRDA gene inhibit transcription rather than posttranscriptional RNA processing and also interfere with replication. The molecular basis for these effects may be the formation of non-B DNA structures.	CHUM, Ctr Rech Louis Charles Simard, Montreal, PQ H2L 4M1, Canada; Texas A&M Univ, Texas Med Ctr, Dept Biochem & Biophys, Ctr Genome Res,Inst Biosci & Technol, Houston, TX 77030 USA; Univ Montreal, Dept Med, Montreal, PQ H2L 4M1, Canada; McGill Univ, Dept Neurol, Montreal, PQ H3A 2B4, Canada; McGill Univ, Dept Neurosurg, Montreal, PQ H3A 2B4, Canada	Universite de Montreal; Baylor College of Medicine; Texas A&M University System; Universite de Montreal; McGill University; McGill University	Pandolfo, M (corresponding author), CHUM, Ctr Rech Louis Charles Simard, Campus Notre Dame,1560 Rue Sherbrooke Est, Montreal, PQ H2L 4M1, Canada.		Pandolfo, Massimo/B-2853-2010		NINDS NIH HHS [NS34192] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034192] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMIRHAERI S, 1995, J BIOL CHEM, V270, P3313, DOI 10.1074/jbc.270.7.3313; Andreassen R, 1996, AM J HUM GENET, V59, P360; Aoki T, 1997, J MOL BIOL, V267, P229, DOI 10.1006/jmbi.1997.0890; BEARD C, 1989, VIROLOGY, V172, P659, DOI 10.1016/0042-6822(89)90211-0; Bidichandani SI, 1997, AM J HUM GENET, V60, P1251; BINGHAM PM, 1995, NAT GENET, V9, P191, DOI 10.1038/ng0295-191; Bowater RP, 1996, J MOL BIOL, V264, P82, DOI 10.1006/jmbi.1996.0625; Bowater RP, 1997, NUCLEIC ACIDS RES, V25, P2861, DOI 10.1093/nar/25.14.2861; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; BURRIGHT EN, 1995, CELL, V82, P937, DOI 10.1016/0092-8674(95)90273-2; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Campuzano V, 1997, HUM MOL GENET, V6, P1771, DOI 10.1093/hmg/6.11.1771; COLLIER DA, 1990, J BIOL CHEM, V265, P10652; Cossee M, 1997, NAT GENET, V15, P337, DOI 10.1038/ng0497-337; Durr A, 1996, NEW ENGL J MED, V335, P1169, DOI 10.1056/NEJM199610173351601; Freudenreich CH, 1997, MOL CELL BIOL, V17, P2090, DOI 10.1128/MCB.17.4.2090; GACY AM, 1995, CELL, V81, P533; Gourdon G, 1997, NAT GENET, V15, P190, DOI 10.1038/ng0297-190; GRABCZYK E, 1995, J BIOL CHEM, V270, P1791, DOI 10.1074/jbc.270.4.1791; HANSEN RS, 1993, CELL, V73, P1403, DOI 10.1016/0092-8674(93)90365-W; JAWORSKI A, 1995, P NATL ACAD SCI USA, V92, P11019, DOI 10.1073/pnas.92.24.11019; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; KANG SM, 1995, J BIOL CHEM, V270, P27014, DOI 10.1074/jbc.270.45.27014; Kaytor MD, 1997, HUM MOL GENET, V6, P2135, DOI 10.1093/hmg/6.12.2135; KOHWI Y, 1991, GENE DEV, V5, P2547, DOI 10.1101/gad.5.12b.2547; Lavedan CN, 1997, HUM GENET, V100, P407, DOI 10.1007/s004390050525; Mandel JL, 1997, NATURE, V386, P767, DOI 10.1038/386767a0; Mangiarini L, 1997, NAT GENET, V15, P197, DOI 10.1038/ng0297-197; Maurer DJ, 1996, MOL CELL BIOL, V16, P6617; Miret JJ, 1997, MOL CELL BIOL, V17, P3382, DOI 10.1128/MCB.17.6.3382; MIRKIN SM, 1994, ANNU REV BIOPH BIOM, V23, P541, DOI 10.1146/annurev.bb.23.060194.002545; Mitas M, 1997, NUCLEIC ACIDS RES, V25, P2245, DOI 10.1093/nar/25.12.2245; Monckton DG, 1997, NAT GENET, V15, P193, DOI 10.1038/ng0297-193; MONCKTON DG, 1994, NAT GENET, V8, P162, DOI 10.1038/ng1094-162; Montermini L, 1997, HUM MOL GENET, V6, P1261, DOI 10.1093/hmg/6.8.1261; Ohshima K, 1996, J BIOL CHEM, V271, P1853, DOI 10.1074/jbc.271.4.1853; Ohshima K, 1996, J BIOL CHEM, V271, P16773, DOI 10.1074/jbc.271.28.16773; Ohshima K, 1997, J BIOL CHEM, V272, P16798, DOI 10.1074/jbc.272.27.16798; Paulson HL, 1996, ANNU REV NEUROSCI, V19, P79; REABAN ME, 1994, J BIOL CHEM, V269, P21850; REABAN ME, 1990, NATURE, V348, P342, DOI 10.1038/348342a0; REABAN ME, 1991, NATURE, V351, P447; Rosche WA, 1996, J BACTERIOL, V178, P5042, DOI 10.1128/jb.178.16.5042-5044.1996; Rosenberg RN, 1996, NEW ENGL J MED, V335, P1222, DOI 10.1056/NEJM199610173351609; Samadashwily GM, 1997, NAT GENET, V17, P298, DOI 10.1038/ng1197-298; Sambrook J., 2002, MOL CLONING LAB MANU; Santee SM, 1996, J BIOL CHEM, V271, P21151, DOI 10.1074/jbc.271.35.21151; SARKAR PS, 1992, NUCLEIC ACIDS RES, V20, P5713, DOI 10.1093/nar/20.21.5713; Shimizu M, 1996, J MOL BIOL, V258, P614, DOI 10.1006/jmbi.1996.0273; USDIN K, 1995, NUCLEIC ACIDS RES, V23, P4202, DOI 10.1093/nar/23.20.4202; VANDENBERG MH, 1995, HUM GENET, V95, P723, DOI 10.1007/BF00209499; Wells RD, 1996, J BIOL CHEM, V271, P2875, DOI 10.1074/jbc.271.6.2875; WELLS RD, 1998, IN PRESS GENETIC INS	53	245	251	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14588	14595		10.1074/jbc.273.23.14588	http://dx.doi.org/10.1074/jbc.273.23.14588			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603975	hybrid			2022-12-27	WOS:000074021500077
J	Strauss, PR; Holt, CM				Strauss, PR; Holt, CM			Domain mapping of human apurinic/apyrimidinic endonuclease - Structural and functional, evidence for a disordered amino terminus and a tight globular carboxyl domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPAIR ENZYME; ALDEHYDIC ABASIC SITE; IDENTIFICATION; BINDING; REDOX; CONFORMATION; POLYMERASE; STABILITY; RESIDUES; DUPLEX	We recently described the pre-steady state enzymatic binding kinetics of apurinic/apyrimidinic endonuclease (AP endo), In this report we describe the domain structure of the enzyme in solution determined by mild protease digestion in the presence and absence of substrate, product, and an efficient competitive inhibitor (HDP), AP endo is a 35.5-kDa protein with a high degree of homology to its prokaryotic counterpart, exonuclease III (Exo III), except for the amino terminus, which is lacking in the prokaryotic enzyme. The entire conserved region plus an additional 20 residues unique to the eukaryotic enzyme was inaccessible to trypsin and V8 protease, indicating that it forms a tight globular structure. In contrast, the amino-terminal 35 residues were readily accessible to all the proteases investigated, leading us to conclude that they associate poorly with the rest of the structure and constitute a highly fluid region, When AP endo was boiled with SDS and cooled prior to the addition of V8 protease, several acidic residues within the globular domain became protease-accessible, indicating rapid renaturation except along the nuclease fold with restoration of globular conformation for the carboxyl two-thirds of the molecule, Of all the proteases tested, only chymotrypsin was able to cleave internal to the globular portion without prior denaturation, Although AP endo cleaved with chymotrypsin retained full enzymatic activity, the activity was lost when the digested peptides were recovered after denaturation by heat and/or boiling in SDS, precipitation, and renaturation or when fragments were recovered from an SDS gel and renatured, Thus, the protein is probably held together strongly by noncovalent interactions that maintain enzymatic function after protease nicking. The three major chymotrypsin cleavage sites, Tyr-144, Leu-179, and Leu-205, became strikingly less accessible to protease digestion in the presence of abasic site-containing DNA, Since the three residues form a spherical triangle on the surface of the molecule on one side of the nuclease fold, there must be multiple means by which DNA containing an abasic site associates with the enzyme. The most likely explanation is that substrate and product, both of which were present during proteolysis, bind differently to the enzyme. Finally, the two cysteine residues thought to be involved in the redox reaction of AP endo with Jun protein were entirely inaccessible to proteolysis even after prolonged exposure of AP endo to reducing agents, Consequently, if AP endo plays a role in the physiological function of Jun, it must undergo major conformational changes in the process. Alternatively, the two cysteines could maintain an appropriate conformation such that other residues participate directly in the redox activity.	Northeastern Univ, Dept Biol, Boston, MA 02115 USA	Northeastern University	Strauss, PR (corresponding author), Northeastern Univ, Dept Biol, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA072702] Funding Source: NIH RePORTER; NCI NIH HHS [CA 72702] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARZILAY G, 1995, NAT STRUCT BIOL, V2, P561, DOI 10.1038/nsb0795-561; BARZILAY G, 1995, BIOESSAYS, V17, P713, DOI 10.1002/bies.950170808; Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; CHAUDHRY MA, 1995, NUCLEIC ACIDS RES, V23, P3805, DOI 10.1093/nar/23.19.3805; Chaudhry MA, 1997, J BIOL CHEM, V272, P15650, DOI 10.1074/jbc.272.25.15650; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; GOLJER I, 1995, J BIOL CHEM, V270, P22980, DOI 10.1074/jbc.270.39.22980; GOLJER I, 1992, BIOCHEMISTRY-US, V31, P11614, DOI 10.1021/bi00161a047; Gorman MA, 1997, EMBO J, V16, P6548, DOI 10.1093/emboj/16.21.6548; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; Konigsberg WH, 1995, METHOD ENZYMOL, V262, P331; KUMAR A, 1990, J BIOL CHEM, V265, P2124; LAHM A, 1991, J MOL BIOL, V222, P645, DOI 10.1016/0022-2836(91)90502-W; MATHEWS C, 1996, BIOCHEMISTRY-US, P101; MATSUDAIRA P, 1990, METHOD ENZYMOL, V182, P602; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; Moore DD, 1995, GLOB MOB SURV; RICKWOOD D, 1990, GEL ELECTROPHORESIS, P125; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Strauss PR, 1997, J BIOL CHEM, V272, P1302, DOI 10.1074/jbc.272.2.1302; VESNAVER G, 1989, P NATL ACAD SCI USA, V86, P3614, DOI 10.1073/pnas.86.10.3614; WACHSSTOCK DH, 1994, BIOPHYS J, V67, P1260, DOI 10.1016/S0006-3495(94)80598-3; WALKER LJ, 1993, MOL CELL BIOL, V13, P5370, DOI 10.1128/MCB.13.9.5370; Wilson DM, 1997, NUCLEIC ACIDS RES, V25, P933, DOI 10.1093/nar/25.5.933; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1994, P NATL ACAD SCI USA, V91, P23, DOI 10.1073/pnas.91.1.23	27	23	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14435	14441		10.1074/jbc.273.23.14435	http://dx.doi.org/10.1074/jbc.273.23.14435			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603956	hybrid			2022-12-27	WOS:000074021500058
J	Jacob, AL; Lund, J				Jacob, AL; Lund, J			Mutations in the activation function-2 core domain of steroidogenic factor-1 dominantly suppresses PKA-dependent transactivation of the bovine CYP17 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTORS DETERMINE ACTIVITY; ORPHAN RECEPTORS; NUCLEAR RECEPTOR; TRANSCRIPTIONAL REGULATION; HORMONE RECEPTOR; BINDING DOMAIN; NGFI-B; PHOSPHORYLATION; IDENTIFICATION; AD4BP	Steroidogenic factor-1 (SF-1) is a nuclear receptor that is essential for the proper development and function of steroid hormone-producing cells. The activation function-2 (AF-2) domain in SF-1 is a short LY-helix in the C terminus that is conserved with respect to other nuclear receptors and is important for transactivation of target genes. In order to investigate the possible role of the AF-2 domain of SF-1 in cAMP-dependent transcriptional regulation of the bovine steroid hydroxylase gene CYP17, mutations were introduced and the effects were characterized. The mutant SF-1 proteins were expressed at comparable levels in nonsteroidogenic Cos-1 cells that lack SF-1, and their abilities to bind an SF-1 site from the CYP17 gene were not affected. Transient transfections of wild-type and mutant SF-1 in Cos-1 cells showed that the capacity to transactivate a reporter gene under the control of the SF-1 site from CYP17 was reduced by the mutations in the AF-2 domain of SF-1, A point mutation in the AF-2 region, E454A, resulted in a relative reporter gene activity that was 21% of that observed with wild-type SF-1. Co-transfections of adrenocortical Y-1 cells, which express endogenous SF-1, with the catalytic subunit of cAMP-dependent protein kinase (PKA-C) and the SF-1-dependent reporter gene showed on average a 16-fold increase in activity in the presence of PKA-C. Introduction of the AF-2 mutants of SF-1 into Y-1 cells completely abolished the PKA-C-mediated stimulation of the reporter gene. The transdominant negative effect of the mutant SF-1 proteins suggests that the AF-2 domain is essential for the activation of SF-1 by the cAMP-dependent protein kinase-dependent signaling pathway.	Univ Bergen, Dept Anat & Cell Biol, N-5009 Bergen, Norway	University of Bergen	Lund, J (corresponding author), Univ Bergen, Dept Anat & Cell Biol, Arstadveien 19, N-5009 Bergen, Norway.							BAKKE M, 1995, ENDOCR RES, V21, P509, DOI 10.3109/07435809509030468; BAKKE M, 1995, MOL ENDOCRINOL, V9, P327, DOI 10.1210/me.9.3.327; Crawford PA, 1997, MOL ENDOCRINOL, V11, P1626, DOI 10.1210/me.11.11.1626; ElTanani MKK, 1997, MOL ENDOCRINOL, V11, P928, DOI 10.1210/me.11.7.928; HIRATA Y, 1993, J BIOL CHEM, V268, P24808; HONDA S, 1993, J BIOL CHEM, V268, P7494; Lala DS, 1997, P NATL ACAD SCI USA, V94, P4895, DOI 10.1073/pnas.94.10.4895; Lund J, 1997, STEROIDS, V62, P43, DOI 10.1016/S0039-128X(96)00157-2; LUND J, 1990, J BIOL CHEM, V265, P3304; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; LUO XR, 1995, MOL ENDOCRINOL, V9, P1233, DOI 10.1210/me.9.9.1233; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MILLER WL, 1988, ENDOCR REV, V9, P295, DOI 10.1210/edrv-9-3-295; MOROHASHI K, 1994, MOL ENDOCRINOL, V8, P643, DOI 10.1210/me.8.5.643; Morohashi KI, 1996, FASEB J, V10, P1569, DOI 10.1096/fasebj.10.14.9002548; OBA K, 1996, BIOCH BIOPHYS RES CO; PARISSENTI AM, 1993, MOL ENDOCRINOL, V7, P283, DOI 10.1210/me.7.2.283; Parker KL, 1997, ENDOCR REV, V18, P361, DOI 10.1210/er.18.3.361; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Sambrook J., 2002, MOL CLONING LAB MANU; Taneja R, 1997, EMBO J, V16, P6452, DOI 10.1093/emboj/16.21.6452; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WATERMAN MR, 1994, J BIOL CHEM, V269, P27783; Weigel NL, 1996, BIOCHEM J, V319, P657, DOI 10.1042/bj3190657; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; Zhang PL, 1996, MOL ENDOCRINOL, V10, P147, DOI 10.1210/me.10.2.147	26	36	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13391	13394		10.1074/jbc.273.22.13391	http://dx.doi.org/10.1074/jbc.273.22.13391			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593668	hybrid			2022-12-27	WOS:000073919100007
J	Koppel, DA; Kinnally, KW; Masters, P; Forte, M; Blachly-Dyson, E; Mannella, CA				Koppel, DA; Kinnally, KW; Masters, P; Forte, M; Blachly-Dyson, E; Mannella, CA			Bacterial expression and characterization of the mitochondrial outer membrane channel - Effects of N-terminal modifications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; ANION-SELECTIVE CHANNEL; VOLTAGE-GATED CHANNEL; VDAC ION CHANNEL; CIRCULAR-DICHROISM; NEUROSPORA-CRASSA; PORIN; PORES	Several forms of the voltage-dependent anion-selective channel (VDAC) have been expressed at high yield in Escherichia coli, Full length constructs of the proteins of Neurospora crassa and Saccharomyces cerevisiae (ncVDAC and scVDAC) have been made with 20-residue-long, thrombin-cleavable, His(6)-containing N-terminal extensions, ncVDAC purified from bacteria or mitochondria displays a far-UV CD spectrum (in 1% lauryl dimethylamine oxide at pH 6-8) similar to that of bacterial porins, indicating extensive beta-sheet structure, Under the same conditions, the CD spectrum of bacterially expressed scVDAC indicates lower beta-sheet content, albeit higher than that of mitochondrial scVDAC under the same conditions. In phospholipid bilayers, the bacterially expressed proteins (with or without N-terminal extensions) form typical VDAC-like channels with stable, large conductance open states (4-4.5 nanosiemens in 1 m KCI) and voltage-dependent transitions to a predominant substate (about 2 nanosiemens). A variant of scVDAC missing the first eight residues and having no N-terminal extension also has been expressed in E, coli, The truncated protein has a CD spectrum similar to that of mitochondrial scVDAC, but its channel activity is abnormal, exhibiting an unstable open state and rapid transitions between multiple subconductance levels.	New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12201 USA; SUNY Albany, Dept Biomed Sci, Albany, NY 12222 USA; Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany; Oregon Health & Science University	Mannella, CA (corresponding author), New York State Dept Hlth, Wadsworth Ctr, Empire State Plaza, Albany, NY 12201 USA.	carmen@wadsworth.org						BENZ R, 1990, BIOCHIM BIOPHYS ACTA, V1022, P311, DOI 10.1016/0005-2736(90)90279-W; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; COLOMBINI M, 1989, J MEMBRANE BIOL, V111, P103, DOI 10.1007/BF01871775; COLOMBINI M, 1987, BIOCHIM BIOPHYS ACTA, V905, P279, DOI 10.1016/0005-2736(87)90456-1; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DEPINTO V, 1987, BIOCHIM BIOPHYS ACTA, V894, P109, DOI 10.1016/0005-2728(87)90180-0; FORTE M, 1987, J BIOENERG BIOMEMBR, V19, P341, DOI 10.1007/BF00768537; GUO XW, 1993, BIOPHYS J, V64, P545, DOI 10.1016/S0006-3495(93)81399-7; GUO XW, 1995, J STRUCT BIOL, V114, P41, DOI 10.1006/jsbi.1995.1004; HOLDEN MJ, 1993, BIOCHIM BIOPHYS ACTA, V1144, P396, DOI 10.1016/0005-2728(93)90126-Z; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; KAPLAN RS, 1995, J BIOL CHEM, V270, P4108, DOI 10.1074/jbc.270.8.4108; KLEENE R, 1987, EMBO J, V6, P2627, DOI 10.1002/j.1460-2075.1987.tb02553.x; LABARCA P, 1992, METHOD ENZYMOL, V207, P447; LIU MY, 1992, BIOCHIM BIOPHYS ACTA, V1098, P255, DOI 10.1016/S0005-2728(05)80344-5; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; MANNELLA CA, 1990, EXPERIENTIA, V46, P137, DOI 10.1007/BF02027309; Mannella CA, 1997, J BIOENERG BIOMEMBR, V29, P525, DOI 10.1023/A:1022489832594; MANNELLA CA, 1982, J CELL BIOL, V94, P680, DOI 10.1083/jcb.94.3.680; MANNELLA CA, 1996, BIOMEMBR, V6, P377; MANNELLA CA, 1996, J BIOENERG BIOMEMBR, V28, P161; MARKOVICHOUSLEY Z, 1986, BIOCHIM BIOPHYS ACTA, V869, P158, DOI 10.1016/0167-4838(86)90290-6; PENG S, 1992, BIOPHYS J, V62, P123, DOI 10.1016/S0006-3495(92)81799-X; Popp B, 1996, J BIOL CHEM, V271, P13593, DOI 10.1074/jbc.271.23.13593; Rostovtseva T, 1996, J BIOL CHEM, V271, P28006, DOI 10.1074/jbc.271.45.28006; Shao L, 1996, BIOPHYS J, V71, P778, DOI 10.1016/S0006-3495(96)79277-9; Song JM, 1996, J BIOENERG BIOMEMBR, V28, P153, DOI 10.1007/BF02110646; SREERAMA N, 1994, J MOL BIOL, V242, P497, DOI 10.1006/jmbi.1994.1597; STANLEY S, 1995, J BIOL CHEM, V270, P16694, DOI 10.1074/jbc.270.28.16694; THOMAS L, 1993, P NATL ACAD SCI USA, V90, P5446, DOI 10.1073/pnas.90.12.5446; Trembath M K, 1979, Methods Enzymol, V55, P160; WEISS MS, 1991, FEBS LETT, V280, P379, DOI 10.1016/0014-5793(91)80336-2	32	65	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13794	13800		10.1074/jbc.273.22.13794	http://dx.doi.org/10.1074/jbc.273.22.13794			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593723	hybrid			2022-12-27	WOS:000073919100062
J	Kuno, K; Matsushima, K				Kuno, K; Matsushima, K			ADAMTS-1 protein anchors at the extracellular matrix through the thrombospondin type I motifs and its spacing region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METALLOPROTEASE-DISINTEGRIN PROTEIN; IMMEDIATE EARLY GENE; GROWTH-FACTOR; CELL-SURFACE; TNF RECEPTOR; SEQUENCE; EXPRESSION; PROPERDIN; PEPTIDES; ADHESION	Cellular disintegrin and metalloproteinases (ADAMs) are a family of genes with a sequence similar to those of snake venom metalloproteinases and disintegrins. The ADAMTS-1 gene encodes a new type of ADAM protein with respect to possessing the thrombospondin (TSP) type I motifs. Expression of the gene is induced in kidney and heart by in vivo administration of lipopolysaccharide, suggesting a possible role in the inflammatory reaction. In this study, we characterized the ADAMTS-1 gene product by using a transient expression system in COS-7 cells. We found that the precursor and processed forms of ADAMTS-1 were secreted from cells. Under normal growth conditions, little or none of both forms was detected in the cell culture medium, and instead the majority was found associated with the extracellular matrix (ECM). In addition, when cells were cultured in the presence of heparin, the mature form of ADAMTS-1 protein was detected in the cell culture medium, suggesting that binding of ADAMTS-1 to the ECM is mediated through sulfated glycosaminoglycans such as heparan sulfate. Analyses of deletion mutants of the ADAMTS-1 protein revealed that the spacer region as well as three TSP type I motifs in the carboxyl-terminal region of the ADAMTS-1 protein are important for a tight interaction with the ECM. These results suggest that the ADAMTS-1 is a unique ADAM family protein that anchors at the ECM.	Univ Tokyo, Sch Med, Dept Mol Prevent Med, Bunkyo Ku, Tokyo 113, Japan; Kanazawa Univ, Canc Res Inst, Dept Pharmacol, Kanazawa, Ishikawa 920, Japan	University of Tokyo; Kanazawa University	Matsushima, K (corresponding author), Univ Tokyo, Sch Med, Dept Mol Prevent Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 113, Japan.		KUNO, Kouji/D-8439-2015					ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Bennett TA, 1996, J IMMUNOL, V156, P3093; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; CROWE PD, 1995, J EXP MED, V181, P1205, DOI 10.1084/jem.181.3.1205; EMI M, 1993, NAT GENET, V5, P151, DOI 10.1038/ng1093-151; GOUNDIS D, 1988, NATURE, V335, P82, DOI 10.1038/335082a0; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; HALBAN PA, 1994, BIOCHEM J, V299, P1; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOLT GD, 1990, J BIOL CHEM, V265, P2852; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; KATAGIRI T, 1995, CYTOGENET CELL GENET, V68, P39, DOI 10.1159/000133884; Kataoka M, 1997, J BIOL CHEM, V272, P18209, DOI 10.1074/jbc.272.29.18209; Kratzschmar J, 1996, J BIOL CHEM, V271, P4593; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; Kuno K, 1997, GENOMICS, V46, P466, DOI 10.1006/geno.1997.5064; Lunn CA, 1997, FEBS LETT, V400, P333, DOI 10.1016/S0014-5793(96)01410-X; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Mueller CGF, 1997, J EXP MED, V186, P655, DOI 10.1084/jem.186.5.655; MULLBERG J, 1995, J IMMUNOL, V155, P5198; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; PERRY ACF, 1992, BIOCHEM J, V286, P671, DOI 10.1042/bj2860671; Roberts DD, 1996, FASEB J, V10, P1183, DOI 10.1096/fasebj.10.10.8751720; Rooke J, 1996, SCIENCE, V273, P1227, DOI 10.1126/science.273.5279.1227; Rosendahl MS, 1997, J BIOL CHEM, V272, P24588, DOI 10.1074/jbc.272.39.24588; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; WOLFSBERG TG, 1995, J CELL BIOL, V131, P257; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; YANG GP, 1991, CELL GROWTH DIFFER, V2, P351; YOSHIDA S, 1990, INT IMMUNOL, V2, P585, DOI 10.1093/intimm/2.6.585	38	190	197	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13912	13917		10.1074/jbc.273.22.13912	http://dx.doi.org/10.1074/jbc.273.22.13912			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593739	hybrid			2022-12-27	WOS:000073919100078
J	Van Duijn, MM; Van der Zee, J; VanSteveninck, J; Van den Broek, PJA				Van Duijn, MM; Van der Zee, J; VanSteveninck, J; Van den Broek, PJA			Ascorbate stimulates ferricyanide reduction in HL-60 cells through a mechanism distinct from the NADH-dependent plasma membrane reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDEPENDENT IRON TRANSPORT; HUMAN ERYTHROCYTES; ALPHA-TOCOPHEROL; K562 CELLS; ACID; GROWTH; DIFFERENTIATION; OXIDOREDUCTASE; GLUTATHIONE; METABOLISM	The impermeable oxidant ferricyanide is reduced by the plasma membrane redox system of HL-60 cells. The rate of reduction is strongly enhanced by ascorbate or dehydroascorbate, The aim of this study was to determine the mechanism by which ascorbate and dehydroascorbate accelerate ferricyanide reduction in HL-60 cells. Addition of ascorbate or dehydroascorbate to cells in the presence of ferricyanide led to the intracellular accumulation of ascorbate, Control experiments showed that extracellular ascorbate was rapidly converted to dehydroascorbate in the presence of ferricyanide. These data suggest that intracellular ascorbate originates from extracellular dehydroascorbate, Accumulation of ascorbate was prevented by inhibitors of dehydroascorbate transport into the cell. These compounds also strongly inhibited ascorbate-stimulated ferricyanide reduction in HL-60 cells. Thus, it is concluded that the stimulation of ferricyanide reduction is dependent on intracellular accumulation of ascorbate, Changing the alpha-tocopherol content of the cells had no effect on the ascorbate-stimulated ferricyanide reduction, showing that a nonenzymatic redox system utilizing cu-tocopherol was not involved. p-Chloromercuribenzenesulfonic acid strongly affected ferricyanide reduction in the absence of ascorbate, whereas the stimulated reaction was much less responsive to this compound. Thus, it appears that at least two different membrane redox systems are operative in HL-60 cells, both capable of reducing ferricyanide, but through different mechanisms. The first system is the ferricyanide reductase, which uses NADH as its source for electrons, whereas the novel system proposed in this paper relies on ascorbate.	Leiden Univ, Dept Mol Cell Biol, Sylvius Lab, NL-2333 AL Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC	Van Duijn, MM (corresponding author), Leiden Univ, Dept Mol Cell Biol, POB 9503, NL-2300 RA Leiden, Netherlands.							ALCAIN FJ, 1990, CANCER RES, V50, P5887; ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; AVRON M, 1963, ANAL BIOCHEM, V6, P549, DOI 10.1016/0003-2697(63)90149-0; BODE AM, 1990, CLIN CHEM, V36, P1807; BREITMAN TR, 1980, EXP CELL RES, V126, P494, DOI 10.1016/0014-4827(80)90296-7; BUETTNER GR, 1990, FREE RADICAL RES COM, V10, P5, DOI 10.3109/10715769009145927; BURON MI, 1993, BIOCHEM BIOPH RES CO, V192, P439, DOI 10.1006/bbrc.1993.1434; CRANE FL, 1985, BIOCHIM BIOPHYS ACTA, V811, P233, DOI 10.1016/0304-4173(85)90013-8; delCastilloOlivares A, 1996, BIOCHEM J, V314, P587, DOI 10.1042/bj3140587; GRIFFITH OW, 1982, J BIOL CHEM, V257, P13704; Guaiquil VH, 1997, J BIOL CHEM, V272, P9915; Himmelreich U, 1997, EUR J BIOCHEM, V246, P638, DOI 10.1111/j.1432-1033.1997.t01-1-00638.x; HOFFMAN KE, 1991, AM J CLIN NUTR, V54, pS1188, DOI 10.1093/ajcn/54.6.1188s; ILANI A, 1987, BIOPHYS J, V51, P161, DOI 10.1016/S0006-3495(87)83321-0; INMAN RS, 1993, J BIOL CHEM, V268, P8521; INMAN RS, 1994, BIOCHEMISTRY-US, V33, P11850, DOI 10.1021/bi00205a022; Leist P, 1996, FREE RADICAL BIO MED, V21, P297, DOI 10.1016/0891-5849(96)00045-7; MALVIYA AN, 1986, FEBS LETT, V200, P265, DOI 10.1016/0014-5793(86)81149-8; May JM, 1996, J BIOL CHEM, V271, P10577, DOI 10.1074/jbc.271.18.10577; MAY JM, 1995, BBA-BIOMEMBRANES, V1238, P127, DOI 10.1016/0005-2736(95)00120-R; MAY JM, 1995, BIOCHEMISTRY-US, V34, P12721, DOI 10.1021/bi00039a031; MEDINA MA, 1994, BIOCHEM BIOPH RES CO, V205, P1109, DOI 10.1006/bbrc.1994.2780; RODRIGUEZAGUILERA JC, 1994, J BIOENERG BIOMEMBR, V26, P379, DOI 10.1007/BF00762778; RodriguezCaso L, 1997, BIOCHEM MOL BIOL INT, V41, P75; SCHWEINZER E, 1993, EUR J BIOCHEM, V218, P1057, DOI 10.1111/j.1432-1033.1993.tb18465.x; SUN IL, 1984, BIOCHEM BIOPH RES CO, V125, P649, DOI 10.1016/0006-291X(84)90588-6; Sun IL, 1996, BIOCHEM MOL BIOL INT, V38, P175; THURNHAM DI, 1988, CLIN CHEM, V34, P377; Vaillant F, 1996, J BIOENERG BIOMEMBR, V28, P531, DOI 10.1007/BF02110443; VERA JC, 1994, BLOOD, V84, P1628; VILLALBA JM, 1993, J BIOENERG BIOMEMBR, V25, P411, DOI 10.1007/BF00762467; WELLS WW, 1994, J BIOENERG BIOMEMBR, V26, P369, DOI 10.1007/BF00762777; WINKLER BS, 1987, BIOCHIM BIOPHYS ACTA, V925, P258, DOI 10.1016/0304-4165(87)90190-5	33	67	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13415	13420		10.1074/jbc.273.22.13415	http://dx.doi.org/10.1074/jbc.273.22.13415			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593673	hybrid			2022-12-27	WOS:000073919100012
J	Lee, KB; Pals-Rylaarsdam, R; Benovic, JL; Hosey, MM				Lee, KB; Pals-Rylaarsdam, R; Benovic, JL; Hosey, MM			Arrestin-independent internalization of the m1, m3, and m4 subtypes of muscarinic cholinergic receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COATED VESICLE FORMATION; ACETYLCHOLINE-RECEPTOR; BETA-ARRESTIN; PROTEIN; DYNAMIN; EXPRESSION; DESENSITIZATION; ENDOCYTOSIS; MECHANISMS; VARIANTS	To understand what processes contribute to the agonist-induced internalization of subtypes of muscarinic acetylcholine receptors, we analyzed the role of arrestins, Whereas the m2 mAChR has been shown to undergo augmented internalization when arrestins 2 and 3 are overexpressed (Pals-Rylaarsdam, R., Gurevich, V. V., Lee, K. B., Ptasienski, J. A., Benovic, J. L., and Hosey, M. M. (1997) J. Biol. Chem. 272, 23682-23689), the agonist-induced internalization of mi, m3, and m4 mAChRs was unchanged when arrestins 2 or 3 were overexpressed in transiently transfected HEK-tsA201 cells. Furthermore, when a dominant-negative arrestin was used to interrupt endogenous arrestin function, there was no change in the internalization of the mi, m3, and m4 mAChR whereas the internalization of the beta(2) adrenergic receptor was completely blocked. Wild-type and GTPase-deficient dominant-negative dynamin were used to determine which endocytic machinery played a role in the endocytosis of the subtypes of mAChRs, Interestingly, when dynamin function was blocked by overexpression of the GTPase-deficient dynamin, agonist-induced internalization of the the mi, m3, and m4 mAChRs was suppressed. These results suggested that the internalization of the mi, m3, and m4 mAChRs occurs via an arrestin-independent but dynamin-dependent pathway. To ascertain whether domains that confer arrestin sensitivity and dynamin insensitivity could be functionally exchanged between subtypes of mAChRs, chimeric m2/m3 receptors were analyzed for their properties of agonist-induced internalization. The results demonstrated that the third intracellular loop of the m2 mAChR conferred arrestin sensitivity and dynamin insensitivity to the arrestin-insensitive, dynamin-sensitive m3 mAChR while the analogous domain of the m3 mAChR conferred arrestin resistance and dynamin sensitivity to the previously arrestin-sensitive, dynamin-insensitive m2 mAChR.	Northwestern Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Inst Neurosci, Chicago, IL 60611 USA; Thomas Jefferson Univ, Dept Microbiol & Immunol, Kimmel Canc Inst, Philadelphia, PA 19107 USA	Northwestern University; Northwestern University; Jefferson University	Hosey, MM (corresponding author), Northwestern Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 303 E Chicago Ave,S-215, Chicago, IL 60611 USA.	mhosey@nwu.edu			NHLBI NIH HHS [HL50121] Funding Source: Medline; NIGMS NIH HHS [GM47417, GM44944] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050121] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047417, R37GM047417, R01GM044944] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHKENAZI A, 1989, TRENDS PHARMACOL SCI, P16; Baba T, 1995, COLD SPRING HARB SYM, V60, P235, DOI 10.1101/SQB.1995.060.01.027; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Bogatkewitsch GS, 1996, MOL PHARMACOL, V50, P424; Bohm SK, 1997, BIOCHEM J, V322, P1; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; DAMKE H, 1995, METHOD ENZYMOL, V257, P209; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DAWSON TM, 1993, SCIENCE, V259, P825, DOI 10.1126/science.8381559; DEBBURMAN SK, 1995, MOL PHARMACOL, V47, P224; DECAMILLI P, 1995, CURR OPIN NEUROBIOL, V5, P559, DOI 10.1016/0959-4388(95)80059-X; Ferguson SSG, 1996, BIOCHEM SOC T, V24, P953, DOI 10.1042/bst0240953; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Hosey MM, 1996, PROG BRAIN RES, V109, P169; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; Kallal L, 1998, J BIOL CHEM, V273, P322, DOI 10.1074/jbc.273.1.322; Krueger KM, 1997, J BIOL CHEM, V272, P5; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; KUBO T, 1986, FEBS LETT, V209, P367, DOI 10.1016/0014-5793(86)81144-9; KUBO T, 1986, NATURE, V323, P411, DOI 10.1038/323411a0; LAMEH J, 1992, J BIOL CHEM, V267, P13406; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MARGOLSKEE RF, 1993, BIOTECHNIQUES, V15, P906; MORO O, 1993, J BIOL CHEM, V268, P6862; Palczewski K, 1996, EXP EYE RES, V63, P599, DOI 10.1006/exer.1996.0151; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P14152, DOI 10.1074/jbc.272.22.14152; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P23682, DOI 10.1074/jbc.272.38.23682; PERALTA E G, 1988, Trends in Pharmacological Sciences, P6; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; PERALTA EG, 1987, SCIENCE, V236, P600, DOI 10.1126/science.3107123; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; PITCHER JA, 1995, P NATL ACAD SCI USA, V92, P8343, DOI 10.1073/pnas.92.18.8343; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; Sakuma H, 1996, FEBS LETT, V382, P105, DOI 10.1016/0014-5793(96)00163-9; Schlador ML, 1997, J BIOL CHEM, V272, P18882, DOI 10.1074/jbc.272.30.18882; STERNEMARR R, 1993, J BIOL CHEM, V268, P15640; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	40	87	89	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					12967	12972		10.1074/jbc.273.21.12967	http://dx.doi.org/10.1074/jbc.273.21.12967			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582330	hybrid			2022-12-27	WOS:000073768500041
J	Liu, H; Miller, E; van de Water, B; Stevens, JL				Liu, H; Miller, E; van de Water, B; Stevens, JL			Endoplasmic reticulum stress proteins block oxidant-induced Ca2+ increases and cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL PERMEABILITY TRANSITION; TERT-BUTYL HYDROPEROXIDE; LIPID-PEROXIDATION; CALRETICULIN INCREASES; SARCOPLASMIC-RETICULUM; INTRACELLULAR CALCIUM; OXIDATIVE STRESS; THIOLS; GLUTATHIONE; INHIBITION	Oxidants are important human toxicants. Increased intracellular free Ca2+ may be critical for oxidant toxicity, but this mechanism remains controversial. Furthermore, oxidants damage the endoplasmic reticulum (ER) and release ER Ca2+, but the role of the ER in oxidant toxicity and Ca2+ regulation during toxicity is also unclear. tert-Butylhydroperoxide (TBHP), a prototypical organic oxidant, causes oxidative stress and an increase in intracellular free Ca2+. Therefore, we addressed the mechanism of oxidant-induced cell death and investigated the role of ER stress proteins in Ca2+ regulation and cytoprotection after treating renal epithelial cells with TBHP. Prior ER stress induces expression of the ER stress proteins Grp78, Grp94, and calreticulin and rendered cells resistant to cell death caused by a subsequent TBHP challenge. Expressing antisense RNA targeted to grp78 prevents grp78 induction sensitized cells to TBHP and disrupted their ability to develop cellular tolerance. In addition, overexpressing calreticulin, another ER chaperone and Ca2+-binding protein, also protected cells against TBHP. Interestingly, neither prior ER stress nor calreticulin expression prevented Lipid peroxidation, but both blocked the rise in intracellular free Ca2+ after TBHP treatment. Loading cells with EGTA, even after peroxidation had already occurred, also prevented TBHP-induced cell death, indicating that buffering intracellular Ca2+ prevents cell killing. Thus, Ca2+ plays an important role in TBHP-induced cell death in these cells, and the ER is an important regulator of cellular Ca2+ homeostasis during oxidative stress. Given the importance of oxidants in human disease, it would appear that the role of ER stress proteins in protection from oxidant damage warrants further consideration.	Adirondack Biomed Res Inst, Lake Placid, NY 12946 USA; Leiden Univ, Leiden Amsterdam Ctr Drug Res, Div Toxicol, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC	Stevens, JL (corresponding author), Adirondack Biomed Res Inst, Old Barn Rd, Lake Placid, NY 12946 USA.	jstevens@northnet.org			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007847] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46267] Funding Source: Medline; NIEHS NIH HHS [ES07847] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; BASTIANUTTO C, 1995, J CELL BIOL, V130, P847, DOI 10.1083/jcb.130.4.847; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Black A R, 1991, Methods Achiev Exp Pathol, V15, P126; BOOTMAN MD, 1992, J BIOL CHEM, V267, P25113; BROSTROM CO, 1990, ANNU REV PHYSIOL, V52, P577; Brostrom CO, 1998, PROG NUCLEIC ACID RE, V58, P79; Brostrom CO, 1996, J BIOL CHEM, V271, P24995, DOI 10.1074/jbc.271.40.24995; BUSCIGLIO J, 1995, NATURE, V378, P776, DOI 10.1038/378776a0; CAMACHO P, 1995, CELL, V82, P765, DOI 10.1016/0092-8674(95)90473-5; CASTILHO RF, 1995, FREE RADICAL BIO MED, V18, P479, DOI 10.1016/0891-5849(94)00166-H; CASTILHO RF, 1995, FREE RADICAL BIO MED, V18, P55, DOI 10.1016/0891-5849(94)00098-5; CHEN Q, 1990, J BIOL CHEM, V265, P21603; CHEN Q, 1991, ARCH BIOCHEM BIOPHYS, V284, P422, DOI 10.1016/0003-9861(91)90318-D; Chernyak BV, 1996, EUR J BIOCHEM, V238, P623, DOI 10.1111/j.1432-1033.1996.0623w.x; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; DIX TA, 1993, CHEM RES TOXICOL, V6, P2, DOI 10.1021/tx00031a001; FARBER JL, 1990, CHEM RES TOXICOL, V3, P503, DOI 10.1021/tx00018a003; FARGNOLI J, 1990, P NATL ACAD SCI USA, V87, P846, DOI 10.1073/pnas.87.2.846; FAVERO TG, 1995, J BIOL CHEM, V270, P25557, DOI 10.1074/jbc.270.43.25557; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; Halleck MM, 1997, J BIOL CHEM, V272, P21760, DOI 10.1074/jbc.272.35.21760; HARMAN AW, 1995, ANNU REV PHARMACOL, V35, P129, DOI 10.1146/annurev.pa.35.040195.001021; HENSCHKE PN, 1995, BIOCHEM J, V312, P485, DOI 10.1042/bj3120485; Hoyal CR, 1996, J BIOL CHEM, V271, P29205, DOI 10.1074/jbc.271.46.29205; JONES DP, 1983, J BIOL CHEM, V258, P6390; KUKREJA RC, 1988, ARCH BIOCHEM BIOPHYS, V261, P447, DOI 10.1016/0003-9861(88)90361-X; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; LI LJ, 1992, J CELL PHYSIOL, V153, P575, DOI 10.1002/jcp.1041530319; Li WW, 1997, MOL CELL BIOL, V17, P54, DOI 10.1128/MCB.17.1.54; Lievremont JP, 1997, J BIOL CHEM, V272, P30873, DOI 10.1074/jbc.272.49.30873; LITTLE E, 1995, J BIOL CHEM, V270, P9526, DOI 10.1074/jbc.270.16.9526; Liu H, 1996, J BIOL CHEM, V271, P4805; Liu H, 1997, J BIOL CHEM, V272, P21751, DOI 10.1074/jbc.272.35.21751; LIU H, 1994, TOXICOLOGIST, V14, P172; LIU NG, 1994, J BIOL CHEM, V269, P28635; MACER DRJ, 1988, J CELL SCI, V91, P61; McConkey DJ, 1996, J LEUKOCYTE BIOL, V59, P775, DOI 10.1002/jlb.59.6.775; MEHENDALE HM, 1994, FASEB J, V8, P1285, DOI 10.1096/fasebj.8.15.8001741; Mery L, 1996, J BIOL CHEM, V271, P9332, DOI 10.1074/jbc.271.16.9332; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; MOORE L, 1976, J BIOL CHEM, V251, P1197; Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327; NAIRN AC, 1996, TRANSLATIONAL CONTRO, P295; NICOTERA P, 1990, CHEM RES TOXICOL, V3, P484, DOI 10.1021/tx00018a001; NIEMINEN AL, 1995, BIOCHEM J, V307, P99, DOI 10.1042/bj3070099; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; REED DJ, 1990, CHEM RES TOXICOL, V3, P495, DOI 10.1021/tx00018a002; REILAND J, 1993, J CELL SCI, V105, P1085; Roy B, 1996, J BIOL CHEM, V271, P28995, DOI 10.1074/jbc.271.46.28995; SAKAIDA I, 1991, J BIOL CHEM, V266, P717; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SHERTZER HG, 1994, CHEM RES TOXICOL, V7, P358, DOI 10.1021/tx00039a013; SRIVASTAVA SP, 1995, J BIOL CHEM, V270, P16619, DOI 10.1074/jbc.270.28.16619; VALLE VGR, 1993, ARCH BIOCHEM BIOPHYS, V307, P1, DOI 10.1006/abbi.1993.1551; VANDEWATER B, 1994, J BIOL CHEM, V269, P14546; VILLA A, 1991, J CELL BIOL, V113, P779, DOI 10.1083/jcb.113.4.779; Viner RI, 1997, BIOCHEMISTRY-US, V36, P7706, DOI 10.1021/bi970058z; Yao YH, 1996, BIOCHEMISTRY-US, V35, P2767, DOI 10.1021/bi951712i; Zhan Y, 1997, MOL CELL BIOL, V17, P6755, DOI 10.1128/MCB.17.11.6755	64	183	194	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					12858	12862		10.1074/jbc.273.21.12858	http://dx.doi.org/10.1074/jbc.273.21.12858			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582315	hybrid, Green Published			2022-12-27	WOS:000073768500026
J	Bidasee, KR; Besch, HR				Bidasee, KR; Besch, HR			Structure-function relationships among ryanodine derivatives - Pyridyl ryanodine definitively separates activation potency from high affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; SARCOPLASMIC-RETICULUM; SKELETAL-MUSCLE; RECEPTOR; RYANOIDS; BINDING; LIGAND; SITES; SUBSTITUENTS; INHIBITION	Ryanodine derivatives are differentially effective on the two limbs of the ryanodine concentration-effect curve. This study comparing ryanodine, ryanodol, and pyridyl ryanodine and nine C10Oeq esters of them focuses on structure-function relations underlying their differential effectiveness. Ryanodol and pyridyl ryanodine had significantly lower affinities than ryanodine, but their EC50act values (concentration of ryanoid that induces one-half of full efficacy), potencies, and efficacies were not diminished in like fashion. Ryanodine and ryanodol were partial agonists, whereas pyridyl ryanodine was a full agonist, having a diminished deactivation potency. C10Oeq esterifications enhanced affinities and efficacies of the base ryanoids, The C-10-O-eq ester derivatives of ryanodine and pyridyl ryanodine, but not those of ryanodol, lost their capacity to deactivate RyR1s, Thus, affinity differences among ryanoids clearly do not predicate functional differences as regards activation of Ca2+ release channels, The pyrrole carboxylate on the C-3 of ryanodine is dispensable to ryanoid activation of Ca2+ release channels. Ryanodol lacks this ring, but it nevertheless effects substantial activation. Moreover, its C-10-O-eq esters display full efficacy, The increased ability of all the C-10-O-eq derivatives to release Ca2+ from the vesicles strengthens their role in directly impeding deactivation of RyR1, perhaps by interaction with some component within the transmembrane ionic flux pathway.	Indiana Univ, Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Besch, HR (corresponding author), Indiana Univ, Sch Med, Dept Pharmacol & Toxicol, 635 Barnhill Dr, Indianapolis, IN 46202 USA.	besch@indiana.edu						BELANGER A, 1979, CAN J CHEM, V57, P3348, DOI 10.1139/v79-547; BERNATOWICZ MS, 1992, J ORG CHEM, V57, P2497, DOI 10.1021/jo00034a059; BERRIDGE MJ, 1996, RYANODINE RECEPTORS, P119; BESCH HR, 1977, CIRCULATION, V56, P128; BESCH HR, 1998, BIOPHYS J, V74, P60; BIDASEE KR, 1994, J LABELLED COMPD RAD, V34, P33, DOI 10.1002/jlcr.2580340106; BIDASEE KR, 1995, MOL CELL BIOCHEM, V149, P145, DOI 10.1007/BF01076573; BIDASEE KR, 1995, BIOPHYS J, V68, P173; BUCK E, 1992, J BIOL CHEM, V267, P23560; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; Ebashi S, 1968, Prog Biophys Mol Biol, V18, P123, DOI 10.1016/0079-6107(68)90023-0; EMMICK JT, 1994, J PHARMACOL EXP THER, V269, P717; FLEISCHER S, 1985, P NATL ACAD SCI USA, V82, P7256, DOI 10.1073/pnas.82.21.7256; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; GERZON K, 1993, J MED CHEM, V36, P1319, DOI 10.1021/jm00062a003; GOEGOR DE, 1988, BIOCHEM PHARMACOL, V37, P153; Hui CS, 1998, BIOPHYS J, V74, pA235; HUMERICKHOUSE RA, 1994, J BIOL CHEM, V269, P30243; HUMERICKHOUSE RA, 1993, MOL PHARMACOL, V44, P412; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; Jefferies PR, 1996, J MED CHEM, V39, P2331, DOI 10.1021/jm950711l; Jefferies PR, 1996, J MED CHEM, V39, P2339, DOI 10.1021/jm950712d; JEFFERIES PR, 1993, J MED CHEM, V36, P1128, DOI 10.1021/jm00061a003; JEFFERIES PR, 1991, J NAT PROD, V54, P1147, DOI 10.1021/np50076a043; JEFFERIES PR, 1992, J AGR FOOD CHEM, V40, P142, DOI 10.1021/jf00013a028; KELLY RB, 1951, CAN J CHEM, V29, P905, DOI 10.1139/v51-105; LAI FA, 1989, J BIOENERG BIOMEMBR, V21, P227, DOI 10.1007/BF00812070; LATTANZIO FA, 1987, J BIOL CHEM, V262, P2711; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; MACLENNA.DH, 1970, J BIOL CHEM, V245, P4508; MCPHERSON GA, 1983, COMPUT PROG BIOMED, V17, P107, DOI 10.1016/0010-468X(83)90031-4; Meissner G, 1997, J BIOL CHEM, V272, P1628, DOI 10.1074/jbc.272.3.1628; MEISSNER G, 1986, J BIOL CHEM, V261, P6300; NEISES B, 1978, ANGEW CHEM INT EDIT, V17, P522, DOI 10.1002/anie.197805221; PESSAH IN, 1986, J BIOL CHEM, V261, P8643; RIO E, 1992, ANNU REV PHYSIOL, V54, P109; RUEST L, 1993, CAN J CHEM, V71, P634, DOI 10.1139/v93-084; SUTKO JL, 1980, CIRC RES, V46, P332, DOI 10.1161/01.RES.46.3.332; Sutko JL, 1997, PHARMACOL REV, V49, P53; SWILLENS S, 1995, TRENDS PHARMACOL SCI, V16, P151, DOI 10.1016/S0165-6147(00)89007-0; TADA M, 1978, PHYSIOL REV, V58, P1; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Tinker A, 1996, BIOPHYS J, V70, P2110, DOI 10.1016/S0006-3495(96)79777-1; Tuk B, 1996, TRENDS PHARMACOL SCI, V17, P403, DOI 10.1016/S0165-6147(96)10049-3; WANG JP, 1993, J BIOL CHEM, V268, P20974; WATERHOUSE AL, 1987, J MED CHEM, V30, P710, DOI 10.1021/jm00387a022; Weiss JN, 1997, FASEB J, V11, P835, DOI 10.1096/fasebj.11.11.9285481; WELCH W, 1994, BIOCHEMISTRY-US, V33, P6074, DOI 10.1021/bi00186a006; Welch W, 1996, BIOCHEMISTRY-US, V35, P7165, DOI 10.1021/bi9527294; Welch W, 1997, BIOCHEMISTRY-US, V36, P2939, DOI 10.1021/bi9623901	50	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12176	12186		10.1074/jbc.273.20.12176	http://dx.doi.org/10.1074/jbc.273.20.12176			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575165	hybrid			2022-12-27	WOS:000073629800030
J	Inohara, N; del Peso, L; Koseki, T; Chen, S; Nunez, G				Inohara, N; del Peso, L; Koseki, T; Chen, S; Nunez, G			RICK, a novel protein kinase containing a caspase recruitment domain, interacts with CLARP and regulates CD95-mediated apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEATH DOMAIN; SIGNALING COMPLEX; CELL-DEATH; RECEPTOR; FADD; CD95; FAS; RIP	Signaling through the CD95/Fas/APO-1 death receptor plays a critical role in the homeostasis of the immune system, RICK, a novel protein kinase that regulates CD95-mediated apoptosis was identified and characterized. RICK is composed of an N-terminal serine-threonine kinase catalytic domain and a C-terminal region containing a caspase-recruitment domain, RICK physically interacts with CLARP, a caspase-like molecule known to bind to Fas-associated protein with death domain (FADD) and caspase-8. Expression of RICK promoted the activation of caspase-8 and potentiated apoptosis induced by Fas ligand, FADD, CLARP, and caspase-8. Deletion mutant analysis revealed that both the kinase domain and caspase-recruitment domain were required for RICK to promote apoptosis, Significantly, expression of a RICK mutant in which the lysine of the putative ATP-binding site at position 38 was replaced by a methionine functioned as an inhibitor of CD95-mediated apoptosis, Thus, RICK represents a novel kinase that may regulate apoptosis induced by the CD95/Fas receptor pathway.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Nunez, G (corresponding author), Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA.		del Peso, Luis/K-9391-2014; Nuñez, Gabriel/A-7160-2014	del Peso, Luis/0000-0003-4014-5688; 	NATIONAL CANCER INSTITUTE [R01CA064556] Funding Source: NIH RePORTER; NCI NIH HHS [CA-64556] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; delPeso L, 1997, SCIENCE, V278, P687; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Han DKM, 1997, P NATL ACAD SCI USA, V94, P11333, DOI 10.1073/pnas.94.21.11333; Hardie G., 1995, PROTEIN KINASE FACTS; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MERINO R, 1995, J IMMUNOL, V155, P3830; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Zhang J, 1996, MOL CELL BIOL, V16, P2756; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	24	210	221	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12296	12300		10.1074/jbc.273.20.12296	http://dx.doi.org/10.1074/jbc.273.20.12296			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575181	hybrid			2022-12-27	WOS:000073629800046
J	Uchiumi, F; Sato, T; Tanuma, S				Uchiumi, F; Sato, T; Tanuma, S			Identification and characterization of a tannic acid-responsive negative regulatory element in the mouse mammary tumor virus promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; TRANSCRIPTION FACTOR ACCESS; I-HYPERSENSITIVE SITES; MMTV PROMOTER; POLY(ADP-RIBOSE) GLYCOHYDROLASE; GENE-EXPRESSION; CHROMATIN DISRUPTION; LOCATED DOWNSTREAM; HORMONE RECEPTORS	Tannic acid, which comprises polyphenolic compounds from tea leaves, suppresses the glucocorticoid-induced gene expression of mouse mammary tumor virus (MMTV) integrated into 341 cells. To investigate whether this suppression is due to promoter responsiveness to tannic acid, we performed chloramphenicol acetyltransferase analysis transfecting a MMTV promoter containing a chloramphenicol acetyltransferase expression vector into mouse fibroblast L929 cells. Deletion analysis of the promoter region revealed that a 50-base pair (bp) region located downstream of the TATA element is responsible for the suppressive effect of tannic acid. The tannic acid-sensitive suppressibility was introduced into a thymidine kinase promoter by inserting the 50-bp region into the region on the 5'-upstream side of the promoter. Detailed point mutation analyses revealed that two elements, a 13-bp element and an ACTG motif in the 50-bp region, contribute to tannic acid sensitivity and promoter repressibility, respectively. Interestingly, this repressive ACTG motif is found in the human immunodeficiency virus promoter, the activity of which is also suppressed by tannic acid (Uchiumi, F., Maruta, H., Inoue, J., Yamamoto, T., and Tanuma, S. (1996) Biochem. Biophys. Res. Commun. 220, 411-417). Furthermore, electrophoretic mobility shift analysis revealed that a protein factor(s) in nuclear extracts from L929 cells binds to the 50-bp region in a sequence-specific manner and that the amount of DNA-protein complex is increased by tannic acid treatment. Moreover, the negative regulatory sequence ACTG and the tannic acid-sensitive 13-bp element in this region were shown to be responsible for the formation of the DNA-protein complex by electrophoretic mobility shift analysis and footprint analyses. These findings suggest that the suppressive effect of tannic acid on MMTV gene expression is mediated by a protein factor(s) that binds to the negative regulatory element containing the common ACTG motif in a cooperative manner with the tannic acid-sensitive 13-bp element.	Sci Univ Tokyo, Fac Pharmaceut Sci, Dept Biochem, Shinjuku Ku, Tokyo 162, Japan; Sci Univ Tokyo, Biosci Res Inst, Noda, Chiba 278, Japan	Tokyo University of Science; Tokyo University of Science	Tanuma, S (corresponding author), Sci Univ Tokyo, Fac Pharmaceut Sci, Dept Biochem, Shinjuku Ku, 12 Ichigaya Funagawara Machi, Tokyo 162, Japan.	tanuma@ps.kagu.sut.ac.jp						AOKI K, 1995, BIOCHEM BIOPH RES CO, V210, P329, DOI 10.1006/bbrc.1995.1665; AOKI K, 1993, BIOCHIM BIOPHYS ACTA, V1158, P251, DOI 10.1016/0304-4165(93)90022-Z; ARCHER TK, 1995, J STEROID BIOCHEM, V53, P421, DOI 10.1016/0960-0760(95)00088-H; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Bartsch J, 1996, P NATL ACAD SCI USA, V93, P10741, DOI 10.1073/pnas.93.20.10741; Boronat S, 1997, J BIOL CHEM, V272, P21803, DOI 10.1074/jbc.272.35.21803; BRUGGEMEIER U, 1990, EMBO J, V9, P2233, DOI 10.1002/j.1460-2075.1990.tb07393.x; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; DING HF, 1994, SCIENCE, V265, P796, DOI 10.1126/science.8047885; ElKharroubi A, 1996, MOL CELL BIOL, V16, P2958; ELKHARROUBI A, 1994, J BIOL CHEM, V269, P19916; EVANS VJ, 1953, J NATL CANCER I, V13, P773; FRAGOSO G, 1995, GENE DEV, V9, P1933, DOI 10.1101/gad.9.15.1933; FRANKEL B, 1994, P NATL ACAD SCI USA, V91, P10923; HSU CLL, 1988, J VIROL, V62, P4644, DOI 10.1128/JVI.62.12.4644-4652.1988; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LEE HL, 1994, MOL CELL BIOL, V14, P32, DOI 10.1128/MCB.14.1.32; LINT CV, 1996, EMBO J, V15, P1112; LIU J, 1997, MOL CELL BIOL, V17, P5272; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Maxam A M, 1980, Methods Enzymol, V65, P499; MELLENTINMICHELOTTI J, 1994, J BIOL CHEM, V269, P31983; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PARANJAPE SM, 1995, GENE DEV, V9, P978; Pazin MJ, 1996, GENE DEV, V10, P37, DOI 10.1101/gad.10.1.37; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; SCHEIDEREIT C, 1983, NATURE, V304, P749, DOI 10.1038/304749a0; Smith CL, 1997, J BIOL CHEM, V272, P27493, DOI 10.1074/jbc.272.44.27493; Smith CL, 1997, J BIOL CHEM, V272, P14227, DOI 10.1074/jbc.272.22.14227; Steger DJ, 1997, EMBO J, V16, P2463, DOI 10.1093/emboj/16.9.2463; TAKEBAYASHI K, 1994, J BIOL CHEM, V269, P5150; TANUMA S, 1989, BIOCHEM INT, V18, P701; TANUMA S, 1983, J BIOL CHEM, V258, P5371; TANUMA S, 1983, J BIOL CHEM, V258, P4067; TOOHEY MG, 1990, J VIROL, V64, P4477, DOI 10.1128/JVI.64.9.4477-4488.1990; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; TSAI YJ, 1992, J BIOL CHEM, V267, P14436; Uchiumi F, 1996, BIOCHEM BIOPH RES CO, V229, P310, DOI 10.1006/bbrc.1996.1798; Uchiumi F, 1996, BIOCHEM BIOPH RES CO, V220, P411, DOI 10.1006/bbrc.1996.0419; UCHIUMI F, 1992, MOL CELL BIOL, V12, P3784, DOI 10.1128/MCB.12.9.3784; VERDIN E, 1993, EMBO J, V12, P3249, DOI 10.1002/j.1460-2075.1993.tb05994.x; VERDIN E, 1991, J VIROL, V65, P6790, DOI 10.1128/JVI.65.12.6790-6799.1991; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; ZENZIEGREGORY B, 1993, J BIOL CHEM, V268, P15823	51	16	17	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12499	12508		10.1074/jbc.273.20.12499	http://dx.doi.org/10.1074/jbc.273.20.12499			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575208	hybrid			2022-12-27	WOS:000073629800073
J	Li, YF; Hata, Y; Fujii, T; Hisano, T; Nishihara, M; Kurihara, T; Esaki, N				Li, YF; Hata, Y; Fujii, T; Hisano, T; Nishihara, M; Kurihara, T; Esaki, N			Crystal structures of reaction intermediates of L-2-haloacid dehalogenase and implications for the reaction mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA/BETA-HYDROLASE FOLD; PSEUDOMONAS SP. YL; HALOALKANE DEHALOGENASE; CATALYTIC MECHANISM; ACID DEHALOGENASE; MUTAGENESIS	Crystal structures of L-2-haloacid dehalogenase from Pseudomonas sp, YL complexed with monochloroacetate, L-2-chlorobutyrate, L-2-chloro-3-methylbutyrate, or L-2-chloro-4-methylvalerate were determined at 1.83-, 2.0-, 2.2-, and 2.2-Angstrom resolutions, respectively, using the complex crystals prepared with the S175A mutant, which are isomorphous with those of the wild-type enzyme, These structures exhibit unique structural features that correspond to those of the reaction intermediates. In each case, the nucleophile Asp-10 is esterified with the dechlorinated moiety of the substrate. The substrate moieties in all but the monochloroacetate intermediate have a D-configuration at the C-2 atom. The overall polypeptide fold of each of the intermediates is similar to that of the wild-type enzyme. However, it is clear that the Asp-10-Ser-20 region moves to the active site in all of the intermediates, and the Tyr-91-Asp-102 and Leu-117-Arg-135 regions make conformational changes in all but the monochloroacetate intermediates. Ser-118 is located near the carboxyl group of the substrate moiety; this residue probably serves as a binding residue for the substrate carboxyl group. The hydrophobic pocket, which is primarily composed of the Tyr-12, Gln-42, Leu-45, Phe-60, Lys-151, Asn-177, and Trp-179 side chains, exists around the alkyl group of the substrate moiety, This pocket may play an important role in stabilizing the alkyl group of the substrate moiety through hydrophobic interactions, and may also play a role in determining the stereospecificity of the enzyme. Moreover, a water molecule, which is absent in the substrate-free enzyme, is present in the vicinities of the carboxyl carbon of Asp-10 and the side chains of Asp-180, Asn-177, and Ala-175 in each intermediate. This water molecule may hydrolyze the ester intermediate and its substrate. These findings crystallographically demonstrate that the enzyme reaction proceeds through the formation of an ester intermediate with the enzyme's nucleophile Asp-10.	Kyoto Univ, Inst Chem Res, Kyoto 6110011, Japan; Inst Phys & Chem Res, Wako, Saitama 3510106, Japan	Kyoto University; RIKEN	Esaki, N (corresponding author), Kyoto Univ, Inst Chem Res, Kyoto 6110011, Japan.							[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BENNING MW, 1996, BIOCHEMISTRY-US, V35, P3103; BRUNGER AT, 1992, XPLOR MANUAL; CROOKS GP, 1995, J AM CHEM SOC, V117, P10791, DOI 10.1021/ja00149a001; HASAN AKMQ, 1994, BIOSCI BIOTECH BIOCH, V58, P1599, DOI 10.1271/bbb.58.1599; Hisano T, 1996, PROTEINS, V24, P520, DOI 10.1002/(SICI)1097-0134(199604)24:4<520::AID-PROT12>3.0.CO;2-N; Hisano T, 1996, J BIOL CHEM, V271, P20322, DOI 10.1074/jbc.271.34.20322; IWASAKI I, 1956, B CHEM SOC JPN, V29, P860, DOI 10.1246/bcsj.29.860; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KLAGES U, 1983, H-S Z PHYSIOL CHEM, V364, P529, DOI 10.1515/bchm2.1983.364.1.529; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURIHARA T, 1995, J BIOCHEM, V117, P1317, DOI 10.1093/oxfordjournals.jbchem.a124861; LACOURCIERE GM, 1993, J AM CHEM SOC, V115, P10466, DOI 10.1021/ja00075a115; LIU JQ, 1995, J BIOL CHEM, V270, P18309, DOI 10.1074/jbc.270.31.18309; LIU JQ, 1994, APPL ENVIRON MICROB, V60, P2389, DOI 10.1128/AEM.60.7.2389-2393.1994; Liu JQ, 1997, J BIOL CHEM, V272, P3363, DOI 10.1074/jbc.272.6.3363; LIU JQ, 1994, J BIOCHEM-TOKYO, V116, P248, DOI 10.1093/oxfordjournals.jbchem.a124514; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; VANDERPLOEG J, 1991, J BACTERIOL, V173, P7925, DOI 10.1128/jb.173.24.7925-7933.1991; VERSCHUEREN KHG, 1993, J MOL BIOL, V232, P856, DOI 10.1006/jmbi.1993.1436; VERSCHUEREN KHG, 1993, NATURE, V363, P693, DOI 10.1038/363693a0; YANG G, 1994, BIOCHEMISTRY-US, V33, P3527	23	91	93	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15035	15044		10.1074/jbc.273.24.15035	http://dx.doi.org/10.1074/jbc.273.24.15035			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614112	hybrid			2022-12-27	WOS:000074160400054
J	Takeuchi, N; Kawakami, M; Omori, A; Ueda, T; Spremulli, LL; Watanabe, K				Takeuchi, N; Kawakami, M; Omori, A; Ueda, T; Spremulli, LL; Watanabe, K			Mammalian mitochondrial methionyl-tRNA transformylase from bovine liver - Purification, characterization, and gene structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA; PROTEIN-SYNTHESIS; INITIAL CHARACTERIZATION; ELONGATION-FACTORS; SEQUENCE; FORMYLTRANSFERASE; IDENTIFICATION; DNA; GEL	The mammalian mitochondrial methionyl-tRNA transformylase (MTFmt) was partially purified 2,200-fold from bovine liver mitochondria using column chromatography, The polypeptide responsible for MTFmt activity was excised from a sodium dodecyl sulfate-polyacrylamide gel and the amino acid sequences of several peptides were determined. The cDNA encoding bovine MTFmt was obtained and its nucleotide sequence was determined. The deduced amino acid sequence of the mature form of MTFmt consists of 357 amino acid. residues. This sequence is about 30% identical to the corresponding Escherichia coli and yeast mitochondrial MTFs. Kinetic parameters governing the formylation of various tRNAs were obtained. Bovine MTFmt formylates its homologous mitochondrial methionyl-tRNA and the E. coli initiator methionyl-tRNA (Met-tRNA(fMet)) with essentially equal efficiency. The E. coli elongator methionyl-tRNA (Met-tRNA(mMet)) was also formylated although with somewhat less favorable kinetics. These results suggest that the substrate specificity of MTFmt is not as rigid as that of the E. coli MTF which clearly discriminates between the bacterial initiator and elongator Met-tRNAs. These observations are discussed in terms of the presence of a single tRNA(Met) gene in mammalian mitochondria.	Univ Tokyo, Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 113, Japan; Nagoya Univ, Dept Mol Biol, Chikusa Ku, Nagoya, Aichi 46401, Japan; Mitsubishi Kasei Inst Life Sci, Tokyo 194, Japan; Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA	University of Tokyo; Nagoya University; University of North Carolina; University of North Carolina Chapel Hill	Watanabe, K (corresponding author), Univ Tokyo, Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 113, Japan.	kw@kwl.t.u-tokyo.ac.jp	Ueda, Takuya/K-5217-2014	Ueda, Takuya/0000-0002-7760-8271	FDA HHS [GENBANK/AB004316] Funding Source: Medline	FDA HHS		ANDERSON S, 1982, J MOL BIOL, V156, P683, DOI 10.1016/0022-2836(82)90137-1; Arnez JG, 1994, RNA PROTEIN INTERACT, P52; ASTROM SU, 1994, CELL, V79, P535, DOI 10.1016/0092-8674(94)90262-3; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BLANQUET S, 1984, METHOD ENZYMOL, V106, P141; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CUATRECASAS P, 1970, J BIOL CHEM, V245, P3059; DICKERMA.HW, 1967, J BIOL CHEM, V242, P1522; Dirheimer G., 1995, P93; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1997, J MOL BIOL, V266, P939; GALPER JB, 1971, J MOL BIOL, V57, P363, DOI 10.1016/0022-2836(71)90354-8; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; Gite S, 1997, J BIOL CHEM, V272, P5305, DOI 10.1074/jbc.272.8.5305; GOTTESMAN MM, 1987, METHOD ENZYMOL, V151, P363; GUILLON JM, 1992, J MOL BIOL, V224, P359, DOI 10.1016/0022-2836(92)91000-F; KOZAK M, 1983, MICROBIOL REV, V47, P1; KUMAZAWA Y, 1991, BIOCHIM BIOPHYS ACTA, V1090, P167, DOI 10.1016/0167-4781(91)90097-6; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIAO HX, 1990, J BIOL CHEM, V265, P13618; MAHLER H, 1973, CRIT REV BIOCH, V1, P625; MARCKER K, 1964, J MOL BIOL, V8, P835, DOI 10.1016/S0022-2836(64)80164-9; MEINNEL T, 1994, J BACTERIOL, V176, P7387, DOI 10.1128/JB.176.23.7387-7390.1994; NISHIMURA S, 1971, PROCEDURES NUCL ACID, V2; OMORI A, 1994, J PROTEIN CHEM, V13, P471; RAJBHANDARY UL, 1994, J BACTERIOL, V176, P547, DOI 10.1128/jb.176.3.547-552.1994; Ramesh V, 1997, P NATL ACAD SCI USA, V94, P13524, DOI 10.1073/pnas.94.25.13524; ROE BA, 1981, P 3 CLEV S MACR, P167; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schmitt E, 1996, EMBO J, V15, P4749, DOI 10.1002/j.1460-2075.1996.tb00852.x; SCHWARTZ JH, 1967, J MOL BIOL, V25, P571, DOI 10.1016/0022-2836(67)90210-0; Schwartzbach C J, 1996, Methods Enzymol, V264, P248, DOI 10.1016/S0076-6879(96)64025-7; SCHWARTZBACH CJ, 1989, J BIOL CHEM, V264, P19125; SKALA J, 1992, YEAST, V8, P777, DOI 10.1002/yea.320080911; WAKITA K, 1994, NUCLEIC ACIDS RES, V22, P347, DOI 10.1093/nar/22.3.347; WALLIS NG, 1995, BIOCHEMISTRY-US, V34, P7668, DOI 10.1021/bi00023a013; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611; YOSHIDA M, 1971, BIOCHIM BIOPHYS ACTA, V228, P153, DOI 10.1016/0005-2787(71)90555-7	40	48	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15085	15090		10.1074/jbc.273.24.15085	http://dx.doi.org/10.1074/jbc.273.24.15085			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614118	hybrid			2022-12-27	WOS:000074160400060
J	Schroers, A; Burkovski, A; Wohlrab, H; Kramer, R				Schroers, A; Burkovski, A; Wohlrab, H; Kramer, R			The phosphate carrier from yeast mitochondria - Dimerization is a prerequisite for function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BEEF-HEART MITOCHONDRIA; ASPARTATE GLUTAMATE CARRIER; ERYTHROCYTE BAND-3 PROTEIN; BROWN FAT MITOCHONDRIA; ADP-ATP CARRIER; TRANSPORT PROTEIN; OLIGOMERIC STRUCTURE; UNCOUPLING PROTEIN; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE	Wild type phosphate carrier (PIC) from Saccharomyces cerevisiae and recombinant PIC proteins with different C-terminal extensions were expressed in Escherichia coli as inclusion bodies. From these, PIC was isolated with the detergent sodium lauroyl sarcosinate in a form, partially monomeric and unfolded. This PIC associates to stable dimers after exchanging the detergent to the polyoxyethylene detergent C12E8 and dialysis. Combining two differently tagged monomers of PIC and following this with affinity chromatography yields defined homo-and heterodimeric forms of PIG, which are all fully active after reconstitution. As a member of the mitochondrial carrier family PIC is supposed to function as a homodimer, We investigated its dimeric nature in the functionally active state after reconstitution. When reconstituting PIC monomers a sigmoidal dependence of transport activity on the amount of inserted protein is observed, whereas insertion of PIC dimers leads to a linear dependence. Heterodimeric PIC constructs consisting of both an active and an inactivated subunit do not catalyze phosphate transport. In contrast, reconstitution of a mixture of active and inactive monomeric subunits led to partially active carrier. These experiments prove (i) that PIC does not function in monomeric form, (ii) that PIC dimers are stable both in the solubilized state and after membrane insertion, and (iii) that transport catalyzed by PIC dimers involves functional cross-talk between the two monomers.	Forschungszentrum Julich GMBH, Inst Biotechnol 1, D-52425 Julich, Germany; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02114 USA	Helmholtz Association; Research Center Julich; Harvard University; Harvard Medical School	Kramer, R (corresponding author), Univ Cologne, Inst Biochem, D-50674 Cologne, Germany.	r.kraemer@uni-koeln.de		Burkovski, Andreas/0000-0003-1896-4521; Wohlrab, Hartmut/0000-0002-2974-3460				AQUILA H, 1985, EMBO J, V4, P2369, DOI 10.1002/j.1460-2075.1985.tb03941.x; AQUILA H, 1987, FEBS LETT, V212, P1, DOI 10.1016/0014-5793(87)81546-6; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BELL GI, 1993, J BIOL CHEM, V268, P19161; CASEY JR, 1991, J BIOL CHEM, V266, P15726; COSTELLO MJ, 1987, J BIOL CHEM, V262, P17072; DIERKS T, 1988, BIOCHIM BIOPHYS ACTA, V943, P231, DOI 10.1016/0005-2736(88)90555-X; DIERKS T, 1990, BIOCHIM BIOPHYS ACTA, V1028, P281, DOI 10.1016/0005-2736(90)90177-P; DUPONT Y, 1982, BIOCHEMISTRY-US, V21, P6343, DOI 10.1021/bi00268a004; FIERMONTE G, 1993, BIOCHEM J, V294, P293, DOI 10.1042/bj2940293; GUERIN B, 1978, BIOCHIM BIOPHYS ACTA, V503, P223; HACKENBERG H, 1980, BIOCHEMISTRY-US, V19, P548, DOI 10.1021/bi00544a024; HEBERT DN, 1991, BIOCHEMISTRY-US, V30, P4654, DOI 10.1021/bi00233a003; HENDERSON PJF, 1990, RES MICROBIOL, V141, P316, DOI 10.1016/0923-2508(90)90005-B; JENNINGS ML, 1984, J MEMBRANE BIOL, V80, P105, DOI 10.1007/BF01868768; JUCKER W, 1987, J GEN MICROBIOL, V133, P2589; Kaback HR, 1997, P NATL ACAD SCI USA, V94, P5539, DOI 10.1073/pnas.94.11.5539; KLINGENBERG M, 1981, NATURE, V290, P449, DOI 10.1038/290449a0; KLINGENBERG M, 1985, ENZYMES BIOL MEMBR, V4, P511; KRAMER R, 1979, BIOCHEMISTRY-US, V18, P4209; KRAMER R, 1989, BIOCHIM BIOPHYS ACTA, V974, P1, DOI 10.1016/S0005-2728(89)80160-4; KRAMER R, 1986, BIOCHIM BIOPHYS ACTA, V863, P289, DOI 10.1016/0005-2736(86)90269-5; Krumer R., 1992, MOL MECHANISMS BIOEN, P359, DOI DOI 10.1016/50167-7306(08)60184-2; KUAN G, 1995, RES MICROBIOL, V146, P271, DOI 10.1016/0923-2508(96)81050-3; KYTE J, 1981, NATURE, V292, P201, DOI 10.1038/292201a0; LANOUE KF, 1984, BIOENERGETICS, P221; LIN CS, 1980, FEBS LETT, V113, P304, DOI 10.1016/0014-5793(80)80614-4; LINDENTHAL S, 1991, P NATL ACAD SCI USA, V88, P6540, DOI 10.1073/pnas.88.15.6540; MAJIMA E, 1995, J BIOL CHEM, V270, P29548, DOI 10.1074/jbc.270.49.29548; MALONEY PC, 1990, RES MICROBIOL, V141, P374, DOI 10.1016/0923-2508(90)90015-I; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; MURAKAMI H, 1993, P NATL ACAD SCI USA, V90, P3358, DOI 10.1073/pnas.90.8.3358; PAIN D, 1990, NATURE, V347, P444, DOI 10.1038/347444a0; PHELPS A, 1991, J BIOL CHEM, V266, P19882; PHELPS A, 1991, BIOCHEMISTRY-US, V30, P248, DOI 10.1021/bi00215a035; PHELPS A, 1993, FASEB J, V7, P321; REITHMEIER RAF, 1993, CURR OPIN STRUC BIOL, V3, P515, DOI 10.1016/0959-440X(93)90077-X; RICCIO P, 1975, FEBS LETT, V56, P133, DOI 10.1016/0014-5793(75)80127-X; RUNSWICK MJ, 1987, EMBO J, V6, P1367, DOI 10.1002/j.1460-2075.1987.tb02377.x; SAHINTOTH M, 1994, P NATL ACAD SCI USA, V91, P5421, DOI 10.1073/pnas.91.12.5421; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schroers A, 1997, J BIOL CHEM, V272, P10558; STAPPEN R, 1993, BIOCHIM BIOPHYS ACTA, V1149, P40, DOI 10.1016/0005-2736(93)90022-R; STAPPEN R, 1994, J BIOL CHEM, V269, P11240; WEHRLE JP, 1989, J MEMBRANE BIOL, V111, P199, DOI 10.1007/BF01871006; WEIDEMAN.MJ, 1970, EUR J BIOCHEM, V16, P313, DOI 10.1111/j.1432-1033.1970.tb01086.x; WOHLRAB H, 1984, BIOCHEMISTRY-US, V23, P1057, DOI 10.1021/bi00301a004; WOHLRAB H, 1980, J BIOL CHEM, V255, P8170; WOHLRAB H, 1994, BIOCHEMISTRY-US, V33, P9371, DOI 10.1021/bi00198a001; WOHLRAB H, 1986, BIOCHIM BIOPHYS ACTA, V853, P115, DOI 10.1016/0304-4173(86)90007-8; Yerushalmi H, 1996, J BIOL CHEM, V271, P31044, DOI 10.1074/jbc.271.49.31044; ZOTTOLA RJ, 1995, BIOCHEMISTRY-US, V34, P9734, DOI 10.1021/bi00030a011	53	74	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14269	14276		10.1074/jbc.273.23.14269	http://dx.doi.org/10.1074/jbc.273.23.14269			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603933	hybrid			2022-12-27	WOS:000074021500035
J	Wan, Y; Huang, XY				Wan, Y; Huang, XY			Analysis of the G(s)/mitogen-activated protein kinase pathway in mutant 549 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; SIGNAL-TRANSDUCTION; GS-ALPHA; PHOSPHATIDYLINOSITOL 3-KINASE; DEPENDENT ACTIVATION; COUPLED RECEPTORS; ADENYLATE-CYCLASE; TYROSINE KINASES; RAS; CASCADE	Heterotrimeric G protein-coupled receptors can activate the mitogen-activated protein kinase (MAPK) cascade. Recent studies using pharmacological inhibitors or dominant-negative mutants of signaling molecules have advanced our understanding of the pathways from G protein-coupled receptors to MAPK. However, molecular genetic analysis of these pathways is inadequate in mammalian cells. Here, using the well characterized G,cu-and protein kinase A-deficient S49 mouse lymphoma cells, we provide the molecular genetic evidence that G(s) alpha is responsible for transducing the beta-adrenergic receptor signal to MAPK in a protein kinase A-dependent pathway involving Rap1 and Raf (but not Ras) molecules.	Cornell Univ, Coll Med, Dept Physiol, New York, NY 10021 USA	Cornell University	Huang, XY (corresponding author), Cornell Univ, Coll Med, Dept Physiol, 1300 York Ave, New York, NY 10021 USA.							Bence K, 1997, NATURE, V389, P296, DOI 10.1038/38520; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BOURNE HR, 1975, SCIENCE, V187, P750, DOI 10.1126/science.163487; BOURNE HR, 1975, J CELL PHYSIOL, V85, P611, DOI 10.1002/jcp.1040850313; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CAI H, 1993, MOL CELL BIOL, V13, P7645, DOI 10.1128/MCB.13.12.7645; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COFFINO P, 1975, J CELL PHYSIOL, V85, P603, DOI 10.1002/jcp.1040850312; Cosgaya JM, 1996, ONCOGENE, V12, P2651; Cowen DS, 1996, J BIOL CHEM, V271, P22297, DOI 10.1074/jbc.271.37.22297; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DIETZEL C, 1987, CELL, V50, P1001, DOI 10.1016/0092-8674(87)90166-8; FAURE M, 1995, MOL BIOL CELL, V6, P1025, DOI 10.1091/mbc.6.8.1025; FAURE M, 1994, J BIOL CHEM, V269, P7851; FERBY IM, 1994, J BIOL CHEM, V269, P30485; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GILMAN AG, 1995, BIOSCIENCE REP, V15, P65, DOI 10.1007/BF01200143; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; HADCOCK JR, 1989, J BIOL CHEM, V264, P13956; HAGA T, 1977, P NATL ACAD SCI USA, V74, P2016, DOI 10.1073/pnas.74.5.2016; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; INSEL PA, 1975, SCIENCE, V190, P896, DOI 10.1126/science.171770; ITOH H, 1991, J BIOL CHEM, V266, P16226; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; LANGHANSRAJASEKARAN SA, 1995, P NATL ACAD SCI USA, V92, P8601, DOI 10.1073/pnas.92.19.8601; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; MIYAJIMA I, 1987, CELL, V50, P1011, DOI 10.1016/0092-8674(87)90167-X; OBARA T, 1991, P NATL ACAD SCI USA, V88, P5877, DOI 10.1073/pnas.88.13.5877; PACE AM, 1995, MOL BIOL CELL, V6, P1685, DOI 10.1091/mbc.6.12.1685; Post GR, 1996, FASEB J, V10, P741, DOI 10.1096/fasebj.10.7.8635691; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shibuya EK, 1996, CELL GROWTH DIFFER, V7, P235; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; Verheijen MHG, 1997, J BIOL CHEM, V272, P3423, DOI 10.1074/jbc.272.6.3423; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WALSH DA, 1994, FASEB J, V8, P1227, DOI 10.1096/fasebj.8.15.8001734; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; Wan Y, 1997, J BIOL CHEM, V272, P17209, DOI 10.1074/jbc.272.27.17209	45	80	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14533	14537		10.1074/jbc.273.23.14533	http://dx.doi.org/10.1074/jbc.273.23.14533			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603967	hybrid			2022-12-27	WOS:000074021500069
J	Gaudiot, N; Jaubert, AM; Charbonnier, E; Sabourault, D; Lacasa, D; Giudicelli, Y; Ribiere, C				Gaudiot, N; Jaubert, AM; Charbonnier, E; Sabourault, D; Lacasa, D; Giudicelli, Y; Ribiere, C			Modulation of white adipose tissue lipolysis by nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPROTEIN-LIPASE ACTIVITY; NECROSIS-FACTOR-ALPHA; S-NITROSOTHIOLS; PHOSPHODIESTERASE ACTIVITY; CAMP PHOSPHODIESTERASE; FAT-CELLS; INSULIN; RAT; NO; NITROSYLATION	In isolated adipocytes, the nitrosothiols S-nitroso-N-acetyl-penicillamine (SNAP) and S-nitrosoglutathione stimulate basal lipolysis, whereas the nitric oxide (NO) donor 1-propamine, 3-(2-hydroxy-2-nitroso-1-propylhydrazine) (PAPA-NONOate) or NO gas have no effect. The increase in basal lipolysis due to nitrosothiols was prevented by dithiothreitol but not by a guanylate cyclase inhibitor. In addition the cyclic GMP-inhibited low K-m, cyclic AMP phosphodiesterase activity was inhibited by SNAP suggesting that SNAP acting as NO+ donor increases basal lipolysis through a S-nitrosylation mediated inhibition of phosphodiesterase, Contrasting with these findings, SNAP reduced both isoproterenol-stimulated lipolysis and cyclic AMP production, whereas it failed to modify forskolin-, dibutyryl cyclic AMP-, or isobutylmethylxanthine-stimulated lipolysis, suggesting that SNAP interferes with the beta-adrenergic signal transduction pathway upstream the adenylate cyclase. In contrast with SNAP, PAPA-NONOate or NO gas inhibited stimulated lipolysis whatever the stimulating agents used without altering cyclic AMP production. Moreover PAPA-NONOate slightly reduces (30%) the hormone-sensitive lipase (HSL) activity indicating that stimulated lipolysis inhibition by NO is linked to both inhibition of the HSL activity and the cyclic AMP-dependent activation of HSL. These data suggest that NO or related redox species libe NO+/NO- are potential regulators of lipolysis through distinct mechanisms.	Univ Paris 05, Dept Biochem, INSERM CJF9402, Fac Med Paris Ouest, F-75270 Paris 06, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Giudicelli, Y (corresponding author), Univ Paris 05, Dept Biochem, INSERM CJF9402, Fac Med Paris Ouest, 45 Rue St Peres, F-75270 Paris 06, France.							AKAIKE T, 1993, BIOCHEMISTRY-US, V32, P827, DOI 10.1021/bi00054a013; ARNELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279, DOI 10.1006/abbi.1995.1231; BELFRAGE P, 1969, J LIPID RES, V10, P341; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Campbell DL, 1996, J GEN PHYSIOL, V108, P277, DOI 10.1085/jgp.108.4.277; CLANCY RM, 1994, P NATL ACAD SCI USA, V91, P3680, DOI 10.1073/pnas.91.9.3680; DEGERMAN E, 1987, J BIOL CHEM, V262, P5797; ELKS ML, 1983, J BIOL CHEM, V258, P8582; Feelisch M., 1996, METHODS NITRIC OXIDE, P455; Feelisch M., 1996, METHODS NITRIC OXIDE, P71; FORSTERMANN U, 1995, BIOCHEM PHARMACOL, V50, P1321, DOI 10.1016/0006-2952(95)00181-6; GARTHWAITE J, 1995, MOL PHARMACOL, V48, P184; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; GIUDICELLI Y, 1975, BIOCHEM PHARMACOL, V24, P1029, DOI 10.1016/0006-2952(75)90441-4; GIUDICELLI Y, 1975, BIOCHIMIE, V58, P979; GREEN A, 1994, ENDOCRINOLOGY, V134, P2581, DOI 10.1210/en.134.6.2581; GRUNFELD C, 1989, J LIPID RES, V30, P579; HAUNER H, 1995, DIABETOLOGIA, V38, P764, DOI 10.1007/s001250050350; HIRSCH J, 1968, J LIPID RES, V9, P110; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; IGNARRO LJ, 1990, PHARMACOL TOXICOL, V67, P1, DOI 10.1111/j.1600-0773.1990.tb00772.x; KAWAKAMI M, 1987, J BIOCHEM-TOKYO, V101, P331, DOI 10.1093/oxfordjournals.jbchem.a121917; Khoo J C, 1975, Methods Enzymol, V35, P181, DOI 10.1016/0076-6879(75)35154-9; KONO T, 1988, METHOD ENZYMOL, V159, P745; LANDER HM, 1993, J IMMUNOL, V151, P7182; LOTEN EG, 1970, BIOCHEM J, V120, P187, DOI 10.1042/bj1200187; LOWENSTEIN CJ, 1994, ANN INTERN MED, V120, P227, DOI 10.7326/0003-4819-120-3-199402010-00009; MANGANIELLO V, 1973, J BIOL CHEM, V248, P7164; MONCADA S, 1991, PHARMACOL REV, V43, P109; Ribiere C, 1996, BIOCHEM BIOPH RES CO, V222, P706, DOI 10.1006/bbrc.1996.0824; RODBELL M, 1964, J BIOL CHEM, V239, P375; SAVARESE TM, 1992, BIOCHEM J, V283, P1; Stamler J S, 1995, Curr Top Microbiol Immunol, V196, P19; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; WIELAND OH, 1984, METHOD ENZYMAT AN, V6, P504	36	87	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13475	13481		10.1074/jbc.273.22.13475	http://dx.doi.org/10.1074/jbc.273.22.13475			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593681	hybrid			2022-12-27	WOS:000073919100020
J	Ligon, B; Boyd, AE; Dunlap, K				Ligon, B; Boyd, AE; Dunlap, K			Class A calcium channel variants in pancreatic islets and their role in insulin secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ CHANNELS; SYNAPTIC TRANSMISSION; CHROMAFFIN CELLS; BETA-CELLS; CURRENTS; NEURONS; RELEASE; SUBUNIT; OSCILLATIONS; INACTIVATION	The initiation of insulin release from rat islet beta cells relies, in large part, on calcium influx through dihydropyridine-sensitive (alpha(1D)) voltage-gated calcium channels. Components of calcium-dependent insulin secretion and whole cell calcium current, however, are resistant to L-type channel blockade, as well as to omega-conotoxin GVIA, a potent inhibitor of alpha(1B) channels, suggesting the expression of additional exocytotic calcium channels in the islet. We used a reverse transcription-polymerase chain reaction-based strategy to ascertain at the molecular level whether the alpha(1A) calcium channel isoform was also present. Results revealed two new variants of the rat brain alpha(1A) channel in the islet with divergence in a putative extracellular domain and in the carboxyl terminus. Using antibodies and cRNA probes specific for alpha(1A) channels, we found that the majority of cells in rat pancreatic islets were labeled, indicating expression of the alpha(1A) channels in beta cells, the predominant islet cell type. Electrophysiologic recording from isolated islet cells demonstrated that the dihydropyridine-resistant current was sensitive to the alpha(1A) channel blocker, omega-agatoxin IVA. This toxin also inhibited the dihydropyridine-resistant component of glucose-stimulated insulin secretion, suggesting functional overlap among calcium channel classes. These findings confirm the presence of multiple high voltage-activated calcium channels in the rat islet and implicate a physiologic role for alpha(1A) channels in excitation-secretion coupling in beta cells.	Tufts Univ, Sch Med, Dept Neurosci, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Div Endocrinol, Boston, MA 02111 USA	Tufts University; Tufts University; Tufts University	Ligon, B (corresponding author), Tufts Univ, Sch Med, Dept Neurosci, 136 Harrison Ave, Boston, MA 02111 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK034447, R01DK034447] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016483, K08NS001923] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK34447] Funding Source: Medline; NINDS NIH HHS [NS16483, KO8 NS01923] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARTALEJO CR, 1994, NATURE, V367, P72, DOI 10.1038/367072a0; ASCHROFT FM, 1984, NATURE, V312, P446; BIRNBAUMER L, 1994, NEURON, V13, P505, DOI 10.1016/0896-6273(94)90021-3; BOYD AE, 1992, J CELL BIOCHEM, V48, P234, DOI 10.1002/jcb.240480303; CURRY DL, 1968, AM J PHYSIOL, V214, P174, DOI 10.1152/ajplegacy.1968.214.1.174; Davalli AM, 1996, J ENDOCRINOL, V150, P195, DOI 10.1677/joe.0.1500195; DELEON M, 1995, SCIENCE, V270, P1502, DOI 10.1126/science.270.5241.1502; DEVARGAS LM, 1997, J BIOL CHEM, V432, P179; DEVIS G, 1975, DIABETES, V24, P547, DOI 10.2337/diab.24.6.547; DiversePierluissi M, 1996, NEURON, V16, P579, DOI 10.1016/S0896-6273(00)80077-X; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; Fletcher CF, 1996, CELL, V87, P607, DOI 10.1016/S0092-8674(00)81381-1; Glassmeier G, 1997, GASTROENTEROLOGY, V113, P90, DOI 10.1016/S0016-5085(97)70084-2; GRODSKY GM, 1966, DIABETES, V15, P910, DOI 10.2337/diab.15.12.910; HALES CN, 1968, J PHYSIOL-LONDON, V199, P177, DOI 10.1113/jphysiol.1968.sp008647; Hayward LJ, 1997, BIOPHYS J, V72, P1204, DOI 10.1016/S0006-3495(97)78768-X; Jiwa F, 1997, Stat Bull Metrop Insur Co, V78, P2; KEAHEY HH, 1989, DIABETES, V38, P188, DOI 10.2337/diabetes.38.2.188; Kitamura N, 1997, PFLUG ARCH EUR J PHY, V434, P179, DOI 10.1007/s004240050381; KOMATSU M, 1989, ENDOCRINOLOGY, V125, P2008, DOI 10.1210/endo-125-4-2008; Kuryshev YA, 1996, ENDOCRINOLOGY, V137, P2269, DOI 10.1210/en.137.6.2269; Larsson O, 1996, P NATL ACAD SCI USA, V93, P5161, DOI 10.1073/pnas.93.10.5161; Leibson CL, 1997, AM J EPIDEMIOL, V146, P12, DOI 10.1093/oxfordjournals.aje.a009187; Liu HY, 1996, J NEUROSCI, V16, P7557; LLINAS R, 1989, P NATL ACAD SCI USA, V86, P1689, DOI 10.1073/pnas.86.5.1689; Loechner KJ, 1996, ENDOCRINOLOGY, V137, P1429, DOI 10.1210/en.137.4.1429; LOMAX RB, 1967, AM J PHYSIOL, V272, pC476; LONGO EA, 1991, J BIOL CHEM, V266, P9314; LOPEZ MG, 1994, FEBS LETT, V349, P331, DOI 10.1016/0014-5793(94)00696-2; LUEBKE JI, 1993, NEURON, V11, P895, DOI 10.1016/0896-6273(93)90119-C; MAGNELLI V, 1995, PFLUG ARCH EUR J PHY, V429, P762, DOI 10.1007/BF00374799; MATTHEWS EK, 1975, J PHYSIOL-LONDON, V246, P421, DOI 10.1113/jphysiol.1975.sp010897; MINTZ IM, 1992, NEURON, V9, P85, DOI 10.1016/0896-6273(92)90223-Z; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; NIIDOME T, 1994, BIOCHEM BIOPH RES CO, V203, P1821, DOI 10.1006/bbrc.1994.2399; OHTA M, 1993, J PHARMACOL EXP THER, V264, P35; Olson LK, 1996, J BIOL CHEM, V271, P16544, DOI 10.1074/jbc.271.28.16544; Ophoff RA, 1996, CELL, V87, P543, DOI 10.1016/S0092-8674(00)81373-2; ORahilly S, 1997, BRIT MED J, V314, P955, DOI 10.1136/bmj.314.7085.955; PLANT TD, 1988, J PHYSIOL-LONDON, V404, P731, DOI 10.1113/jphysiol.1988.sp017316; Poncer JC, 1997, NEURON, V18, P463, DOI 10.1016/S0896-6273(00)81246-5; RAMANADHAM S, 1994, CELL CALCIUM, V15, P259, DOI 10.1016/0143-4160(94)90065-5; RANDALL A, 1995, J NEUROSCI, V15, P2995; REGAN LJ, 1991, J NEUROSCI, V11, P2259; Richmond JE, 1997, J PHYSIOL-LONDON, V499, P589, DOI 10.1113/jphysiol.1997.sp021952; SATHER WA, 1993, NEURON, V11, P291, DOI 10.1016/0896-6273(93)90185-T; SATIN LS, 1995, ENDOCRINOLOGY, V136, P4589, DOI 10.1210/en.136.10.4589; SEABROOK GR, 1994, BRIT J PHARMACOL, V112, P728, DOI 10.1111/j.1476-5381.1994.tb13138.x; SNUTCH TP, 1990, P NATL ACAD SCI USA, V87, P3391, DOI 10.1073/pnas.87.9.3391; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; STEA A, 1994, P NATL ACAD SCI USA, V91, P10576, DOI 10.1073/pnas.91.22.10576; TAKAHASHI T, 1993, NATURE, V366, P156, DOI 10.1038/366156a0; TEITELMAN G, 1990, DEV BIOL, V142, P368, DOI 10.1016/0012-1606(90)90357-O; TURNER TJ, 1993, P NATL ACAD SCI USA, V90, P9518, DOI 10.1073/pnas.90.20.9518; YANG NB, 1994, P NATL ACAD SCI USA, V91, P12785, DOI 10.1073/pnas.91.26.12785; YU ASL, 1992, P NATL ACAD SCI USA, V89, P10494, DOI 10.1073/pnas.89.21.10494; Zamponi GW, 1996, J NEUROSCI, V16, P2430; Zhou J, 1997, P NATL ACAD SCI USA, V94, P14255, DOI 10.1073/pnas.94.26.14255; Zhuchenko O, 1997, NAT GENET, V15, P62, DOI 10.1038/ng0197-62	61	72	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13905	13911		10.1074/jbc.273.22.13905	http://dx.doi.org/10.1074/jbc.273.22.13905			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593738	hybrid			2022-12-27	WOS:000073919100077
J	Paralkar, VM; Vail, AL; Grasser, WA; Brown, TA; Xu, H; Vukicevic, S; Ke, HZ; Qi, H; Owen, TA; Thompson, DD				Paralkar, VM; Vail, AL; Grasser, WA; Brown, TA; Xu, H; Vukicevic, S; Ke, HZ; Qi, H; Owen, TA; Thompson, DD			Cloning and characterization of a novel member of the transforming growth factor-beta/bone morphogenetic protein family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA-SUPERFAMILY; HUMAN EMBRYONIC-DEVELOPMENT; MAD-RELATED PROTEIN; EXPRESSION; RECEPTORS; PATTERNS; SUGGEST; SIGNALS; COMPLEX; BINDING	Members of the transforming growth factor-beta (TGF-beta) superfamily of growth and differentiation factors have been identified in a wide variety of organisms, ranging from invertebrates to mammals. Bone morphogenetic proteins (BMPs) constitute a subgroup of proteins belonging to the TGF-beta superfamily, BMPs were initially identified by their ability to induce endochondral bone formation at ectopic sites, suggesting a critical role for this family in development and regeneration of the skeleton. They are also expressed at a variety of nonskeletal sites during development, suggesting possible extraskeletal roles for these proteins. We cloned a novel member of the BMP family that is expressed at high levels in the placenta and the prostate and that we have designated as prostate-derived factor (PDF), Based on cDNA sequence analysis, the predicted PDF protein contains two cysteines in addition to the seven conserved cysteines that are the hallmark of the members of the TGF-beta superfamily, In addition, Northern blot hybridization to poly(A)(+) RNA showed low levels of expression in the kidney and pancreas. We further characterized the expression of this member of the BMP family by in situ. hybridization and immunohistochemistry. These results show high expression in the terminal villae of the placenta. The expression of the protein as visualized by immunohistochemistry shows an expression pattern identical to that of the message in the terminal villae of the placenta. In day 18 rat embryos, protein expression was also seen in the skin and in the cartilaginous tissue of developing skeleton. Orchidectomy and dihydrotestosterone treatment of rats revealed that PDF expression is regulated by androgens in the prostate. In addition, subcutaneous implantation of recombinant PDF induced cartilage formation and the early stages of endochondral bone formation. These data indicate that PDF has a functional relationship to the BMPs.	Pfizer Inc, Div Cent Res, Dept Metab Dis, Groton, CT 06340 USA; Pfizer Inc, Div Cent Res, Dept Mol Sci, Groton, CT 06340 USA; Univ Zagreb, Sch Med, Zagreb 10000, Croatia	Pfizer; Pfizer; University of Zagreb	Paralkar, VM (corresponding author), Pfizer Inc, Cent Res, Dept Cardiovasc & Metab Dis, Groton, CT 06340 USA.	Vishwas_M_Paralkar@groton.pfizer.com	Vukicevic, Slobodan/AEG-2646-2022	Vukicevic, Slobodan/0000-0003-4076-0285				CATE RL, 1986, CELL, V45, P685, DOI 10.1016/0092-8674(86)90783-X; CHANG SC, 1994, J BIOL CHEM, V269, P28227; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; Dudley AT, 1997, DEV DYNAM, V208, P349; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Graff JM, 1997, CELL, V89, P171, DOI 10.1016/S0092-8674(00)80196-8; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; JONES WK, 1994, GROWTH FACTORS, V11, P215, DOI 10.3109/08977199409046919; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LYONS KM, 1990, DEVELOPMENT, V109, P833; LYONS KM, 1989, GENE DEV, V3, P1657, DOI 10.1101/gad.3.11.1657; MACIASSILVA M, 1997, CELL, V86, P1215; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PADGETT RW, 1993, P NATL ACAD SCI USA, V90, P2905, DOI 10.1073/pnas.90.7.2905; PARALKAR VM, 1990, J BIOL CHEM, V265, P17281; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; REDDI AH, 1995, MATRIX BIOL, V14, P599; Sambrook J., 2002, MOL CLONING LAB MANU; SAMPATH TK, 1981, P NATL ACAD SCI-BIOL, V78, P7599, DOI 10.1073/pnas.78.12.7599; SAMPATH TK, 1993, P NATL ACAD SCI USA, V90, P6004, DOI 10.1073/pnas.90.13.6004; STORM EE, 1994, NATURE, V368, P639, DOI 10.1038/368639a0; Thomas JT, 1996, NAT GENET, V12, P315, DOI 10.1038/ng0396-315; TICKLE C, 1994, NATURE, V368, P587, DOI 10.1038/368587a0; VUKICEVIC S, 1994, BIOCHEM BIOPH RES CO, V198, P693, DOI 10.1006/bbrc.1994.1100; WANG, 1997, CELL, V88, P757; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Yamashita H, 1996, BONE, V19, P569, DOI 10.1016/S8756-3282(96)00259-1; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	32	243	282	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13760	13767		10.1074/jbc.273.22.13760	http://dx.doi.org/10.1074/jbc.273.22.13760			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593718	hybrid			2022-12-27	WOS:000073919100057
J	Yang, SS; Lockwood, A; Hollett, P; Ford, R; Kao, K				Yang, SS; Lockwood, A; Hollett, P; Ford, R; Kao, K			Overexpression of a novel Xenopus Rel mRNA induces tumors in early embryos	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; LAEVIS EMBRYOS; P65 SUBUNIT; DROSOPHILA; HOMOLOG; EXPRESSION; DORSAL; IDENTIFICATION; CLONING; TRANSCRIPTION	The Rel family of transcriptional activators form a large diverse group of proteins that are involved in the activation of genes involved in immunity, development, apoptosis and cancer. So far, none of the rel genes cloned in mammals appear to be required for embryonic development. We have cloned and characterized a cDNA from an embryonic cDNA library that encodes a novel Xenopus Rel protein, called Xrel3. Xrel3 is a member of the cRel subfamily and is most closely related to but distinct from other Xenopus Rel members. The expression of Xrel3 mRNA was investigated using Northern analysis, RNase protection assay, reverse transcriptase-linked polymerase chain reaction and in situ hybridization, Messages are present maternally and are slightly enriched in the equatorial region of the blastula stage embryo. At gastrulation, the accumulation of Xrel3 messages declines to undetectable levels but then increases after neurulation. In situ RNA hybridization was used to determine the spatial location of Xrel3 messenger RNA in embryos. Messages are localized to the developing forebrain, dorsal mid-hindbrain region, the inner ear primordium, or otocyst, and in the notochord. Overexpression by microinjection of Xrel3 RNA induced tumors in the developing embryo that appeared after gastrulation, The location of the tumors depended on the location of the injection site. These results suggest that Xrel3 might have a generalized role in regulation of cell differentiation in the embryo.	Mem Univ Newfoundland, Fac Med, Div Basic Med Sci, Terry Fox Canc Res Lab, St Johns, NF A1B 3V6, Canada	Memorial University Newfoundland	Kao, K (corresponding author), Mem Univ Newfoundland, Fac Med, Div Basic Med Sci, Terry Fox Canc Res Lab, St Johns, NF A1B 3V6, Canada.							Attar RM, 1997, SEMIN CANCER BIOL, V8, P93, DOI 10.1006/scbi.1997.0060; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barinaga M, 1996, SCIENCE, V273, P735, DOI 10.1126/science.273.5276.735; BEARER EL, 1994, EUR J CELL BIOL, V63, P255; BROWNELL E, 1989, ONCOGENE, V4, P935; Ciana P, 1997, ONCOGENE, V14, P1805, DOI 10.1038/sj.onc.1201015; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; Dixon MJ, 1997, NAT GENET, V15, P3, DOI 10.1038/ng0197-3; GILLESPIE LL, 1995, J BIOL CHEM, V270, P22758, DOI 10.1074/jbc.270.39.22758; Hamdane M, 1997, ONCOGENE, V15, P2267, DOI 10.1038/sj.onc.1201411; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HEMMATIBRIVANLOU A, 1994, CELL, V77, P273, DOI 10.1016/0092-8674(94)90319-0; HOPWOOD ND, 1989, CELL, V59, P893, DOI 10.1016/0092-8674(89)90612-0; Huguet C, 1997, ONCOGENE, V15, P2965, DOI 10.1038/sj.onc.1201471; IP YT, 1991, CELL, V64, P439; KAO KR, 1991, P NATL ACAD SCI USA, V88, P2697, DOI 10.1073/pnas.88.7.2697; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; Kao KR, 1996, MECH DEVELOP, V58, P129, DOI 10.1016/S0925-4773(96)00565-5; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; Lee J, 1997, DEVELOPMENT, V124, P2537; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; NIEHRS C, 1994, SCIENCE, V263, P817, DOI 10.1126/science.7905664; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RICHARDSON JC, 1994, MECH DEVELOP, V45, P173, DOI 10.1016/0925-4773(94)90031-0; RICHARDSON JC, 1995, MECH DEVELOP, V52, P165, DOI 10.1016/0925-4773(95)00388-H; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARGENT MG, 1990, DEVELOPMENT, V109, P967; SchmidtUllrich R, 1996, DEVELOPMENT, V122, P2117; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SMITH DE, 1992, DEVELOPMENT, V116, P1033; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STOETZEL C, 1995, MECH DEVELOP, V51, P251, DOI 10.1016/0925-4773(95)00369-X; SUZUKI K, 1995, NUCLEIC ACIDS RES, V23, P4664, DOI 10.1093/nar/23.22.4664; TANNAHILL D, 1995, INT J DEV BIOL, V39, P549; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Visconti R, 1997, ONCOGENE, V15, P1987, DOI 10.1038/sj.onc.1201373; WASSERMAN SA, 1993, MOL BIOL CELL, V4, P767, DOI 10.1091/mbc.4.8.767	39	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13746	13752		10.1074/jbc.273.22.13746	http://dx.doi.org/10.1074/jbc.273.22.13746			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593716	hybrid			2022-12-27	WOS:000073919100055
J	Afonina, E; Stauber, R; Pavlakis, GN				Afonina, E; Stauber, R; Pavlakis, GN			The human Poly(A)-binding protein 1 shuttles between the nucleus and the cytoplasm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ENDOTHELIAL GROWTH-FACTOR; FACTOR MESSENGER-RNA; POSTTRANSCRIPTIONAL REGULATION; BINDING-PROTEINS; MAMMALIAN NUCLEI; REV PROTEIN; HNRNP A1; YEAST; EXPRESSION	We have studied the intracellular localization of poly(A)-binding protein 1 (PABP1) by indirect immunofluorescence as well as by tagging with the green fluorescent protein (GFP) in living cells. We show that PABP1 is able to enter the nucleus. Accumulation of PABP1 in the nuclei was observed upon transcription inhibition, suggesting that active transcription is required for PABP1 export. The nuclear import of PABP1 is an energy-dependent process since PABP1 fails to enter the nucleus upon ATP depletion and at low temperature. Transfection of PABP1 or PABP1-GFP resulted in heterogeneity of intracellular distribution of the protein. In the low expressing cells, PABP1 was localized in the cytoplasm, whereas in the high expressors, we observed accumulation of the protein in the nucleus. Nuclear PABP1 observed either after overexpression or after transcription inhibition was found in speckles and colocalized with splicing factor SC35. The ability of PABP1 to shuttle between nucleus and cytoplasm was also shown by heterokaryon formation upon cell fusion. Deletion mutagenesis showed that the minimal part of PABP1 retaining the ability to shuttle consists of the first two RNA-binding domains. This mutant interacted with poly(A) RNA with high affinity and accumulated in the nucleus. Deletion mutants exhibiting reduced RNA binding affinity did not accumulate in the nucleus. PABP1 has been proposed to participate at various steps of mRNA utilization. Our results suggest involvement of PABP1 in nuclear events associated with the formation and transport of mRNP to the cytoplasm and identify a new trafficking pattern for RNA-binding proteins.	NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Human Retrovirus Sect, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Pavlakis, GN (corresponding author), NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Human Retrovirus Sect, POB B,Bldg 535,Rm 210, Frederick, MD 21702 USA.	pavlakis@ncifcrf.gov		Stauber, Roland/0000-0002-1341-4523				Afonina E, 1997, J BIOL CHEM, V272, P2307, DOI 10.1074/jbc.272.4.2307; ANTONIOU M, 1993, J CELL BIOL, V123, P1055, DOI 10.1083/jcb.123.5.1055; Baker EJ, 1997, MOD CELL B, V17, P85; BELOSTOTSKY DA, 1993, P NATL ACAD SCI USA, V90, P6686, DOI 10.1073/pnas.90.14.6686; Berthold E, 1996, J VIROL, V70, P4667, DOI 10.1128/JVI.70.7.4667-4682.1996; BURD CG, 1991, MOL CELL BIOL, V11, P3419, DOI 10.1128/MCB.11.7.3419; CAPONIGRO G, 1995, GENE DEV, V9, P2421, DOI 10.1101/gad.9.19.2421; CARMOFONSECA M, 1991, EMBO J, V10, P195, DOI 10.1002/j.1460-2075.1991.tb07936.x; DE SA MFG, 1988, EUR J BIOCHEM, V176, P521; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; DRYSDALE CM, 1991, J VIROL, V65, P3044, DOI 10.1128/JVI.65.6.3044-3051.1991; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; GALL JG, 1991, SCIENCE, V252, P1499, DOI 10.1126/science.1828621; Gnarra JR, 1996, BBA-REV CANCER, V1242, P201, DOI 10.1016/0304-419X(95)00012-5; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; GORLACH M, 1994, EXP CELL RES, V211, P400, DOI 10.1006/excr.1994.1104; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRANGE T, 1987, NUCLEIC ACIDS RES, V15, P4771, DOI 10.1093/nar/15.12.4771; GUIOCHONMANTEL A, 1994, P NATL ACAD SCI USA, V91, P7179, DOI 10.1073/pnas.91.15.7179; GUIOCHONMANTEL A, 1991, EMBO J, V10, P3851, DOI 10.1002/j.1460-2075.1991.tb04954.x; HUANG S, 1991, Genes and Development, V5, P2288, DOI 10.1101/gad.5.12a.2288; IZAURRALDE E, 1995, CELL, V81, P153, DOI 10.1016/0092-8674(95)90323-2; JIMENEZGARCIA LF, 1993, CELL, V73, P47, DOI 10.1016/0092-8674(93)90159-N; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; MICHAEL WM, 1995, CELL, V83, P415; MinvielleSebastia L, 1997, P NATL ACAD SCI USA, V94, P7897, DOI 10.1073/pnas.94.15.7897; MOEN PT, 1995, HUM MOL GENET, V4, P1779, DOI 10.1093/hmg/4.suppl_1.1779; MUHLRAD D, 1992, GENE DEV, V6, P2100, DOI 10.1101/gad.6.11.2100; MUHLRAD D, 1995, MOL CELL BIOL, V15, P2145; OKEEFE RT, 1994, J CELL BIOL, V124, P249, DOI 10.1083/jcb.124.3.249; PINOLROMA S, 1991, SCIENCE, V253, P312, DOI 10.1126/science.1857966; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; SACHS AB, 1986, CELL, V45, P827, DOI 10.1016/0092-8674(86)90557-X; SACHS AB, 1987, MOL CELL BIOL, V7, P3268, DOI 10.1128/MCB.7.9.3268; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; SCHWARTZ S, 1992, J VIROL, V66, P150, DOI 10.1128/JVI.66.1.150-159.1992; SCHWARTZ S, 1992, J VIROL, V66, P7176, DOI 10.1128/JVI.66.12.7176-7182.1992; SCHWARTZ S, 1990, J VIROL, V64, P5448, DOI 10.1128/JVI.64.11.5448-5456.1990; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; STAUBER R, 1995, VIROLOGY, V213, P439, DOI 10.1006/viro.1995.0016; Tabernero C, 1996, J VIROL, V70, P5998, DOI 10.1128/JVI.70.9.5998-6011.1996; TAMM I, 1978, ADV VIRUS RES, V22, P188; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; WANSINK DG, 1993, J CELL BIOL, V122, P283, DOI 10.1083/jcb.122.2.283; ZELUS BD, 1989, MOL CELL BIOL, V9, P2756, DOI 10.1128/MCB.9.6.2756; ZHANG GH, 1994, NATURE, V372, P809	52	150	154	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					13015	13021		10.1074/jbc.273.21.13015	http://dx.doi.org/10.1074/jbc.273.21.13015			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582337	hybrid			2022-12-27	WOS:000073768500048
J	Zhong, L; Inesi, G				Zhong, L; Inesi, G			Role of the S3 stalk segment in the thapsigargin concentration dependence of sarco-endoplasmic reticulum Ca2+ ATPase inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+,K+-ATPASE ALPHA-SUBUNIT; SARCOPLASMIC-RETICULUM; TRANSMEMBRANE SEGMENT; TRANSPORT ATPASES; CA2+-ATPASE; PHOSPHORYLATION; SENSITIVITY; CA-2+-ATPASE; EXPRESSION; PROMOTER	The sarco-endoplasmic reticulum Ca2+ ATPase (SERCA) is specifically inhibited by thapsigargin (TG), whereas the Na+,K+-ATPase is not. Large chimeric exchanges between Ca2+ and Na+,K+-ATPases (Norregaard, A., Vilsen, B., and Andersen, J. P. (1994) J. Biol. Chem. 269, 26598-26601), as well as photolabeling with a TG azido derivative (Hua, S., and Inesi, G. (1997) Biochemistry 36, 11865-11872), suggest that the S3-M3 (stalk and membrane-bound) region of the Ca2+ ATPase is involved in TG binding. We produced small site-directed changes in the S3 stalk segment of the Ca2+ ATPase and found that mutation of five amino acids to the corresponding Na+,K+-ATPase residues increases by 3 orders of magnitude the TG concentration required for inhibition of Ca2+ ATPase and coupled Ca2+ transport. A single mutation in the S3 stalk, segment (Gly(257)-->Ile) is sufficient to increase by 1 order of magnitude the TG concentration required to produce 50% inhibition. By comparison, mutations yielding a nine-amino acid homology in the M3 transmembrane segment, or a 25-amino acid homology in the S4 stalk segment, do not affect the ATPase sensitivity to TG. We suggest that specific binding of TG to the S3 stalk segment, in addition to stacking of the TG ring structure at the membrane interface, determines the high affinity of the ATPase for the inhibitor.	Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Inesi, G (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, 108 N Greene St, Baltimore, MD 21201 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL027867] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01HL-27867] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHRISTENSEN SB, 1988, ACTA CHEM SCAND B, V42, P623, DOI 10.3891/acta.chem.scand.42b-0623; DEJESUS F, 1993, FEBS LETT, V332, P229, DOI 10.1016/0014-5793(93)80638-B; Garnett C, 1996, BIOCHEMISTRY-US, V35, P11019, DOI 10.1021/bi960718k; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUA SM, 1995, BIOCHEMISTRY-US, V34, P5137, DOI 10.1021/bi00015a026; Hua SM, 1997, BIOCHEMISTRY-US, V36, P11865, DOI 10.1021/bi970105n; ISHII T, 1993, P NATL ACAD SCI USA, V90, P8881, DOI 10.1073/pnas.90.19.8881; KARIN NJ, 1989, MOL CELL BIOL, V9, P1978, DOI 10.1128/MCB.9.5.1978; KIJIMA Y, 1991, J BIOL CHEM, V266, P22912; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Lingrel JB, 1997, ANN NY ACAD SCI, V834, P194, DOI 10.1111/j.1749-6632.1997.tb52251.x; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; NORREGAARD A, 1994, J BIOL CHEM, V269, P26598; NORREGAARD A, 1993, FEBS LETT, V336, P248, DOI 10.1016/0014-5793(93)80813-A; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SAGARA Y, 1992, J BIOL CHEM, V267, P1286; SAGARA Y, 1992, J BIOL CHEM, V267, P12606; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; STOKES DL, 1994, J BIOL CHEM, V269, P11606; SUMBILLA C, 1993, J BIOL CHEM, V268, P21185; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; VILSEN B, 1992, FEBS LETT, V314, P301, DOI 10.1016/0014-5793(92)81494-7; Witcome M., 1992, BIOCHEM J, V283, P525; ZHANG Z, 1995, J BIOL CHEM, V270, P16283	27	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					12994	12998		10.1074/jbc.273.21.12994	http://dx.doi.org/10.1074/jbc.273.21.12994			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582334	hybrid			2022-12-27	WOS:000073768500045
J	Chen, JG; Liu-Chen, S; Rudnick, G				Chen, JG; Liu-Chen, S; Rudnick, G			Determination of external loop topology in the serotonin transporter by site-directed chemical labeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NOREPINEPHRINE TRANSPORTER; GAMMA-AMINOBUTYRIC-ACID; NEUROTRANSMITTER TRANSPORTERS; RAT-BRAIN; EXPRESSION CLONING; MOLECULAR-CLONING; PLASMA-MEMBRANE; NORADRENALINE; GLYCOSYLATION; PHARMACOLOGY	The transmembrane topology of the serotonin transporter (SERT) has been examined by measuring the reactivity of selected lysine and cysteine residues with extracellular reagents. An impermeant biotinylating reagent, sulfosuccinimidyl 2-(biotinamido)ethyl-1,3-dithiopropionate (NHS-SS-biotin), was shown to label SERT transiently expressed in cultured cells. Replacement of four lysine residues that were predicted to lie in external hydrophilic loops (eK-less) largely prevented the biotinylation reaction. Likewise, the cysteine-specific biotinylation reagent N-biotinylaminoethylmethanethiosulfonate (MTSEA-biotin) labeled wild type SERT but not a mutant in which Cys-109, predicted to lie in the first external loop, was replaced with alanine, These two mutant transporters reacted with the biotinylating reagents in digitonin-permeabilized cells, demonstrating that the abundant lysine and cysteine residues predicted to lie in intracellular hydrophilic domains were reactive but not accessible in intact cells. Mutants containing a single external lysine at positions 111, 194, 243, 319, 399, 490, and 571 reacted more readily with NHS-SS-biotin than did the eK-less mutant. Similarly, mutants with a single cysteine at positions 109, 310, 406, 489, and 564 reacted more readily with MTSEA-biotin than did the C109A mutant. All of these mutants were active and therefore likely to be folded correctly. These results support the original transmembrane topology and argue against an alternative topology proposed recently for the related glycine and gamma-aminobutyric acid transporters.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA	Yale University	Rudnick, G (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06510 USA.							AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; Bennett ER, 1997, J BIOL CHEM, V272, P1203, DOI 10.1074/jbc.272.2.1203; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; Borowsky B, 1995, INT REV NEUROBIOL, V38, P139, DOI 10.1016/S0074-7742(08)60526-7; BRUSS M, 1995, J BIOL CHEM, V270, P9197; Chen JG, 1997, BIOCHEMISTRY-US, V36, P1479, DOI 10.1021/bi962256g; Chen JG, 1997, J BIOL CHEM, V272, P28321, DOI 10.1074/jbc.272.45.28321; Clark JA, 1997, J BIOL CHEM, V272, P14695, DOI 10.1074/jbc.272.23.14695; FREMEAU RT, 1992, NEURON, V8, P915, DOI 10.1016/0896-6273(92)90206-S; GU H, 1994, J BIOL CHEM, V269, P7124; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; GUIMBAL C, 1993, J BIOL CHEM, V268, P8418; HARDER R, 1985, J NEUROCHEM, V45, P1154, DOI 10.1111/j.1471-4159.1985.tb05536.x; Holmgren M, 1996, NEUROPHARMACOLOGY, V35, P797, DOI 10.1016/0028-3908(96)00129-3; IMLER JR, 1972, BIOCHIM BIOPHYS ACTA, V288, P153, DOI 10.1016/0005-2736(72)90233-7; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P1207, DOI 10.1021/bi00600a011; KUHAR MJ, 1990, EUR NEUROL, V30, P15; Lester HA, 1996, NEURON, V17, P807, DOI 10.1016/S0896-6273(00)80213-5; LINGJAERDE O, 1969, FEBS LETT, V3, P103, DOI 10.1016/0014-5793(69)80108-0; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; MELIKIAN HE, 1994, J BIOL CHEM, V269, P12290; Melikian HE, 1996, MOL PHARMACOL, V50, P266; NELSON N, 1994, J EXP BIOL, V196, P213; OLIVARES L, 1995, J BIOL CHEM, V270, P9437, DOI 10.1074/jbc.270.16.9437; Olivares L, 1997, J BIOL CHEM, V272, P1211, DOI 10.1074/jbc.272.2.1211; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; RICHELSON E, 1994, MAYO CLIN PROC, V69, P1069, DOI 10.1016/S0025-6196(12)61375-5; RITZ MC, 1990, LIFE SCI, V46, P635, DOI 10.1016/0024-3205(90)90132-B; SNEDDON JM, 1969, BRIT J PHARMACOL, V37, P680, DOI 10.1111/j.1476-5381.1969.tb08506.x; Stephan MM, 1997, BIOCHEMISTRY-US, V36, P1322, DOI 10.1021/bi962150l; TAMURA S, 1995, J BIOL CHEM, V270, P28712, DOI 10.1074/jbc.270.48.28712; TATE CG, 1994, J BIOL CHEM, V269, P26303; UCHIDA S, 1992, P NATL ACAD SCI USA, V89, P8230, DOI 10.1073/pnas.89.17.8230; UHL GR, 1994, J EXP BIOL, V196, P229; VIDAVER GA, 1968, J BIOL CHEM, V243, P6140; WALL SC, 1995, MOL PHARMACOL, V47, P544; YAMAUCHI A, 1992, J BIOL CHEM, V267, P649	38	120	122	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12675	12681		10.1074/jbc.273.20.12675	http://dx.doi.org/10.1074/jbc.273.20.12675			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575231	hybrid			2022-12-27	WOS:000073629800096
J	Guan, GM; Dai, PH; Shechter, I				Guan, GM; Dai, PH; Shechter, I			Differential transcriptional regulation of the human squalene synthase gene by sterol regulatory element-binding proteins (SREBP) 1a and 2 and involvement of 5 ' DNA sequence elements in the regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPROTEIN RECEPTOR GENE; LEUCINE ZIPPER PROTEIN; MOLECULAR-CLONING; NF-Y; PROMOTER; EXPRESSION; CELLS; CHOLESTEROL; PATHWAY; CDNA	Transcription of the human squalene synthase (HSS) gene is regulated by variations in the level of cellular cholesterol. Three regulatory elements in the HSS promoter region are known to be involved in the regulation: 1) a modified sterol regulatory element (SRE) 1 (HSS-SRE-1), 2) an inverted SRE-3 (Inv-SRE-3), 3) an inverted Y box (Inv-Y-Box). We report here the regulatory role of distinct cis-elements in the HSS promoter by using mutants of an HSS-luciferase promoter reporter. The activity of a wild-type promoter reporter transiently transfected into HepG-2 cells is increased by sterol depletion of the cells or by coexpression of mature forms of the SRE-binding proteins (SREBP) 1a and SREBP-2. Differential activation by SREBP-1a and SREBP-2 of the reporter gene mutated at various regions of the promoter is observed. Mutation of either the HSS-SRE-1 or the Inv-SRE-3 sequence diminished the activation by SREBP-1a and by sterol depletion but did not affect the activation by SREBP-2. Simultaneous mutations of both of these sequences almost completely abolished activation of the promoter by SREBP-1a or by sterol depletion, but activation by SREBP-2 was retained at 70%. Mutation of the Inv-Y-Box sequence element decreased the activity of the promoter by 50% or more, and if mutated together with both SREs, the activation was almost completely abolished. Mutation of any single GC box of the two located at -40 to -57 did not affect activity, whereas simultaneous mutation of the two decreased activation by SREBP-2 by 60%, by lipid depletion by 20%, and had no effect on the activation by SREBP-1a. A Y box motif at -159 to -166 and an SRE-like sequence element (SRE-1(8/10)) at position -101 to -108 are also involved in the sterol regulation. These results indicate that the complex sterol-mediated transcriptional of multiple copies of diverse cis elements in the HSS promoter. The differential activation of the HSS promoter may point to specific role of the SREBPs in cholesterogenesis.	Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Biochem & Mol Biol, Bethesda, MD 20814 USA	Uniformed Services University of the Health Sciences - USA	Shechter, I (corresponding author), Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Biochem & Mol Biol, Bethesda, MD 20814 USA.				NHLBI NIH HHS [HL50628, HL48540] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050628, R01HL048540] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; CLARKE CF, 1987, MOL CELL BIOL, V7, P3138, DOI 10.1128/MCB.7.9.3138; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; Ericsson J, 1996, J BIOL CHEM, V271, P24359, DOI 10.1074/jbc.271.40.24359; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Guan GM, 1997, J BIOL CHEM, V272, P10295; GUAN GM, 1995, J BIOL CHEM, V270, P21958, DOI 10.1074/jbc.270.37.21958; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; HUA XX, 1995, J BIOL CHEM, V270, P29422, DOI 10.1074/jbc.270.49.29422; JACKSON SM, 1995, J BIOL CHEM, V270, P21445, DOI 10.1074/jbc.270.37.21445; JIANG GJ, 1993, J BIOL CHEM, V268, P12818; Kawabe Y, 1996, BIOCHEM BIOPH RES CO, V219, P515, DOI 10.1006/bbrc.1996.0265; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; MCKENZIE TL, 1992, J BIOL CHEM, V267, P21368; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; Sato R, 1996, J BIOL CHEM, V271, P26461, DOI 10.1074/jbc.271.43.26461; SHECHTER I, 1992, J BIOL CHEM, V267, P8628; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; SMITH JR, 1990, J BIOL CHEM, V265, P2306; SMITH JR, 1988, J BIOL CHEM, V263, P18480; SUDHOF TC, 1987, J BIOL CHEM, V262, P10773; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; YANG JX, 1995, J BIOL CHEM, V270, P12152, DOI 10.1074/jbc.270.20.12152; YIEH L, 1995, P NATL ACAD SCI USA, V92, P6102, DOI 10.1073/pnas.92.13.6102; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	30	50	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12526	12535		10.1074/jbc.273.20.12526	http://dx.doi.org/10.1074/jbc.273.20.12526			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575211	hybrid			2022-12-27	WOS:000073629800076
J	Lesort, M; Attanavanich, K; Zhang, JW; Johnson, GVW				Lesort, M; Attanavanich, K; Zhang, JW; Johnson, GVW			Distinct nuclear localization and activity of tissue transglutaminase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUROBLASTOMA-CELLS; CROSS-LINKING; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; INTRANUCLEAR INCLUSIONS; ALZHEIMERS-DISEASE; PROTEIN; CYTOSKELETON; BRAIN; G(H); TAU	Tissue transglutaminase is a calcium-dependent transamidating enzyme that has been postulated to play a role in the pathology of expanded CAG repeat disorders with polyglutamine expansions expressed within the affected proteins. Because intranuclear inclusions have recently been shown to be a common feature of many of these codon reiteration diseases, the nuclear localization and activity of tissue transglutaminase was examined. Subcellular fractionation of human neuroblastoma SH-SY5Y cells demonstrated that 93% of tissue transglutaminase is localized to the cytosol, Of the 7% found in the nucleus, 6% copurified with the chromatin-associated proteins, and the remaining 1% was in the nuclear matrix fraction. In situ transglutaminase activity was measured in the cytosolic and nuclear compartments of control cells, as well as cells treated with the calcium-mobilizing agent maitotoxin to increase endogenous tissue transglutaminase activity. These studies revealed that tissue transglutaminase was activated in the nucleus, a finding that was further supported by cytochemical analysis. Immunofluorescence studies revealed that nuclear proteins modified by transglutaminase exhibited a discrete punctate, as well as a diffuse staining pattern. Furthermore, different proteins were modified by transglutaminase in the nucleus compared with the cytosol, The results of these experiments clearly demonstrate localization of tissue transglutaminase in the nucleus that can be activated. These findings may have important implications in the formation of the insoluble nuclear inclusions, which are characteristic of codon reiteration diseases such as Huntington's disease and the spinocerebellar ataxias.	Univ Alabama, Dept Psychiat & Behav Neurobiol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Johnson, GVW (corresponding author), Univ Alabama, Dept Psychiat & Behav Neurobiol, 1720 7th Ave S,SC1061, Birmingham, AL 35294 USA.	gvwj@uab.edu	Johnson, Gail V.W./K-4723-2012	Johnson, Gail V.W./0000-0003-3464-0404	NATIONAL INSTITUTE ON AGING [R01AG012396] Funding Source: NIH RePORTER; NIA NIH HHS [AG12396] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Appelt DM, 1996, J HISTOCHEM CYTOCHEM, V44, P1421, DOI 10.1177/44.12.8985134; Badminton MN, 1996, J BIOL CHEM, V271, P31210, DOI 10.1074/jbc.271.49.31210; Ballestar E, 1996, J BIOL CHEM, V271, P18817, DOI 10.1074/jbc.271.31.18817; Bates G, 1996, BIOESSAYS, V18, P175, DOI 10.1002/bies.950180303; Cooper AJL, 1997, P NATL ACAD SCI USA, V94, P12604, DOI 10.1073/pnas.94.23.12604; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; EITAN S, 1994, SCIENCE, V264, P1764, DOI 10.1126/science.7911602; EITAN S, 1993, SCIENCE, V261, P106, DOI 10.1126/science.8100369; Feng JF, 1996, J BIOL CHEM, V271, P16451, DOI 10.1074/jbc.271.28.16451; GREEN H, 1993, CELL, V74, P955, DOI 10.1016/0092-8674(93)90718-6; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; GREENWOOD JA, 1995, EXP CELL RES, V220, P332, DOI 10.1006/excr.1995.1323; GUSELLA JF, 1997, MOL MED, V3, P236; Johnson GVW, 1997, BRAIN RES, V751, P323, DOI 10.1016/S0006-8993(96)01431-X; Kahlem P, 1996, P NATL ACAD SCI USA, V93, P14580, DOI 10.1073/pnas.93.25.14580; Matilla A, 1997, NATURE, V389, P974, DOI 10.1038/40159; MELINO G, 1994, MOL CELL BIOL, V14, P6584, DOI 10.1128/MCB.14.10.6584; MILLER CCJ, 1986, J NEUROCHEM, V46, P1912; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Nemes Z, 1997, J BIOL CHEM, V272, P20577, DOI 10.1074/jbc.272.33.20577; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; PAULSON HL, 1996, ANNU REV NEUROSCI, V19, P322; PERRY MJM, 1995, NEUROSCIENCE, V65, P1063, DOI 10.1016/0306-4522(94)00556-K; Santella L, 1997, FASEB J, V11, P1091, DOI 10.1096/fasebj.11.13.9367344; Sawa A, 1997, P NATL ACAD SCI USA, V94, P11669, DOI 10.1073/pnas.94.21.11669; SINGH US, 1995, BIOCHEMISTRY-US, V34, P15863, DOI 10.1021/bi00048a032; Wang KKW, 1996, ARCH BIOCHEM BIOPHYS, V331, P208, DOI 10.1006/abbi.1996.0300; WANG Y, 1993, J CELL BIOL, V121, P257, DOI 10.1083/jcb.121.2.257; Zhang JW, 1998, J BIOL CHEM, V273, P2288, DOI 10.1074/jbc.273.4.2288; ZINI N, 1993, EXP CELL RES, V208, P257, DOI 10.1006/excr.1993.1245; Zoghbi HY, 1996, NAT GENET, V14, P237, DOI 10.1038/ng1196-237	31	141	146	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					11991	11994		10.1074/jbc.273.20.11991	http://dx.doi.org/10.1074/jbc.273.20.11991			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575137	hybrid			2022-12-27	WOS:000073629800002
J	Tarun, AS; Theologis, A				Tarun, AS; Theologis, A			Complementation analysis of mutants of 1-aminocyclopropane-1-carboxylate synthase reveals the enzyme is a dimer with shared active sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ETHYLENE BIOSYNTHESIS; ORNITHINE DECARBOXYLASE; INTERSUBUNIT LOCATION; ESCHERICHIA-COLI; DIRECTED MUTANTS; FORMS; HYBRIDIZATION; PURIFICATION; MUTAGENESIS; EXPRESSION	The pyridoxal phosphate-dependent enzyme 1-aminocyclopropane-1-carboxylate synthase (ACS, EC 4.4.1.14) catalyzes the rate-limiting step in the ethylene biosynthetic pathway. ACS shares the conservation of 11 invariant residues with a family of aminotransferases that includes aspartate aminotransferase. Site-directed mutagenesis on two of these residues, Tyr-92 and Lys-278, in the tomato isoenzyme Le-ACS2 greatly reduces enzymatic activity, indicating their importance in catalysis. These mutants have been used in complementation experiments either in vivo in Escherichia coli or in an in vitro transcription/translation assay to study whether the enzyme functions as a dimer. When the Y92L mutant is coexpressed with the K278A mutant protein, there is partial restoration of enzyme activity, suggesting that the mutant proteins can dimerize and form active heterodimers. Coexpressing a double mutant with the wildtype protein reduces wild-type activity, indicating that inactive heterodimers are formed between the wild-type and the double mutant protein subunits. Furthermore, hybrid complementation shows that another tomato isoenzyme, Le-ACS4, can dimerize and that Le-ACS2 and Le-ACS4 have limited capacity for heterodimerization. The data suggest that ACS functions as a dimer with shared active sites.	USDA ARS, Ctr Plant Gene Express, Albany, CA 94710 USA	United States Department of Agriculture (USDA)	Theologis, A (corresponding author), USDA ARS, Ctr Plant Gene Express, 800 Buchanan St, Albany, CA 94710 USA.			Tarun, Alice/0000-0002-0300-6657				ADAMS DO, 1979, P NATL ACAD SCI USA, V76, P170, DOI 10.1073/pnas.76.1.170; BLEECKER AB, 1986, P NATL ACAD SCI USA, V83, P7755, DOI 10.1073/pnas.83.20.7755; HUANG PL, 1991, P NATL ACAD SCI USA, V88, P7021, DOI 10.1073/pnas.88.16.7021; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LARIMER FW, 1987, J BIOL CHEM, V262, P15327; LI N, 1994, J BIOL CHEM, V269, P6908; MCPHALEN CA, 1992, J MOL BIOL, V225, P495, DOI 10.1016/0022-2836(92)90935-D; MEHTA PK, 1993, EUR J BIOCHEM, V214, P849; OSTERMAN A, 1994, BIOCHEMISTRY-US, V33, P13662, DOI 10.1021/bi00250a016; OZTURK DH, 1995, BIOCHEMISTRY-US, V34, P10764, DOI 10.1021/bi00034a008; PICCOLI R, 1988, BIOCHEM J, V253, P329, DOI 10.1042/bj2530329; RAMALINGAM K, 1985, P NATL ACAD SCI USA, V82, P7820, DOI 10.1073/pnas.82.23.7820; ROTTMANN WH, 1991, J MOL BIOL, V222, P937, DOI 10.1016/0022-2836(91)90587-V; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO T, 1991, J BIOL CHEM, V266, P3752; SATOH S, 1993, PLANT CELL PHYSIOL, V34, P753, DOI 10.1093/oxfordjournals.pcp.a078479; Tan DW, 1996, BIOCHEMISTRY-US, V35, P8934, DOI 10.1021/bi952918m; TOBIAS KE, 1993, BIOCHEMISTRY-US, V32, P5842, DOI 10.1021/bi00073a017; WENTE SR, 1987, P NATL ACAD SCI USA, V84, P31, DOI 10.1073/pnas.84.1.31; WHITE MF, 1994, P NATL ACAD SCI USA, V91, P12428, DOI 10.1073/pnas.91.26.12428; YANG SF, 1984, ANNU REV PLANT PHYS, V35, P155, DOI 10.1146/annurev.pp.35.060184.001103; YIP WK, 1990, P NATL ACAD SCI USA, V87, P7930, DOI 10.1073/pnas.87.20.7930	23	34	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12509	12514		10.1074/jbc.273.20.12509	http://dx.doi.org/10.1074/jbc.273.20.12509			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575209	hybrid			2022-12-27	WOS:000073629800074
J	Agre, P; Bonhivers, M; Borgnia, MJ				Agre, P; Bonhivers, M; Borgnia, MJ			The aquaporins, blueprints for cellular plumbing systems	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							INTEGRAL MEMBRANE-PROTEIN; WATER CHANNEL; MIP FAMILY; CHIP; KIDNEY; PERMEABILITY; EXPRESSION; MUTATIONS; TISSUES; CDNA		Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Agre, P (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.	peter.agre@qmail.bs.jhu.edu	Bonhivers, Melanie/Z-5889-2019	Bonhivers, Melanie/0000-0001-9179-8473; Borgnia, Mario/0000-0001-9159-1413	NATIONAL EYE INSTITUTE [R01EY011239] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033991, R01HL048268, R37HL048268] Funding Source: NIH RePORTER; NEI NIH HHS [EY11239] Funding Source: Medline; NHLBI NIH HHS [HL33991, HL48268] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMI L, 1995, J MEMBRANE BIOL, V143, P199; BEURON F, 1995, J BIOL CHEM, V270, P17414, DOI 10.1074/jbc.270.29.17414; Calamita G, 1998, P NATL ACAD SCI USA, V95, P3627, DOI 10.1073/pnas.95.7.3627; Chou CL, 1998, AM J PHYSIOL-CELL PH, V274, pC549, DOI 10.1152/ajpcell.1998.274.2.C549; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; Delporte C, 1996, J BIOL CHEM, V271, P22070, DOI 10.1074/jbc.271.36.22070; DENKER BM, 1988, J BIOL CHEM, V263, P15634; ECELBARGER CA, 1995, AM J PHYSIOL-RENAL, V269, pF663, DOI 10.1152/ajprenal.1995.269.5.F663; Flick KM, 1997, GENE, V195, P127, DOI 10.1016/S0378-1119(97)00078-4; FRIGERI A, 1995, J CELL SCI, V108, P2993; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; HAMANN S, 1998, IN PRESS AM J PHYSL; Han ZQ, 1998, J BIOL CHEM, V273, P6001, DOI 10.1074/jbc.273.11.6001; HEYMANN JB, 1998, IN PRESS J STRUCT BI, V116; Ishibashi K, 1997, J BIOL CHEM, V272, P20782, DOI 10.1074/jbc.272.33.20782; JUNG JS, 1994, J BIOL CHEM, V269, P14648; Knepper MA, 1997, CURR OPIN CELL BIOL, V9, P560, DOI 10.1016/S0955-0674(97)80034-8; Knepper MA, 1996, KIDNEY INT, V49, P1712, DOI 10.1038/ki.1996.253; Koyama Y, 1997, J BIOL CHEM, V272, P30329, DOI 10.1074/jbc.272.48.30329; Kuriyama H, 1997, BIOCHEM BIOPH RES CO, V241, P53, DOI 10.1006/bbrc.1997.7769; Lee MD, 1997, MEDICINE, V76, P141, DOI 10.1097/00005792-199705000-00001; Loo DDF, 1996, P NATL ACAD SCI USA, V93, P13367, DOI 10.1073/pnas.93.23.13367; Ma TH, 1998, J BIOL CHEM, V273, P4296, DOI 10.1074/jbc.273.8.4296; Ma TH, 1996, GENOMICS, V35, P543, DOI 10.1006/geno.1996.0396; MARPLES D, 1995, J CLIN INVEST, V95, P1838, DOI 10.1172/JCI117863; Matthay MA, 1996, AM J PHYSIOL-LUNG C, V270, pL487, DOI 10.1152/ajplung.1996.270.4.L487; Maunsbach AB, 1997, J AM SOC NEPHROL, V8, P1; Maurel C, 1997, ANNU REV PLANT PHYS, V48, P399, DOI 10.1146/annurev.arplant.48.1.399; Nagelhus EA, 1998, J NEUROSCI, V18, P2506; Nakhoul NL, 1998, AM J PHYSIOL-CELL PH, V274, pC543, DOI 10.1152/ajpcell.1998.274.2.C543; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; Nielsen S, 1997, P NATL ACAD SCI USA, V94, P5450, DOI 10.1073/pnas.94.10.5450; Nielsen S, 1997, J NEUROSCI, V17, P171; Nielsen S, 1997, AM J PHYSIOL-CELL PH, V273, pC1549, DOI 10.1152/ajpcell.1997.273.5.C1549; NIELSEN S, 1993, J CELL BIOL, V120, P371, DOI 10.1083/jcb.120.2.371; NIELSEN S, 1995, P NATL ACAD SCI USA, V92, P1013, DOI 10.1073/pnas.92.4.1013; Ohara M, 1998, J CLIN INVEST, V101, P1076, DOI 10.1172/JCI649; Park JH, 1996, J MEMBRANE BIOL, V153, P171, DOI 10.1007/s002329900120; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1994, J BIOL CHEM, V269, P1668; PRESTON GM, 1994, SCIENCE, V265, P1585, DOI 10.1126/science.7521540; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; Sasaki S, 1998, ANNU REV PHYSIOL, V60, P199, DOI 10.1146/annurev.physiol.60.1.199; Shiels A, 1996, NAT GENET, V12, P212, DOI 10.1038/ng0296-212; SMITH BL, 1991, J BIOL CHEM, V266, P6407; Terris J, 1995, AM J PHYSIOL-RENAL, V269, pF775, DOI 10.1152/ajprenal.1995.269.6.F775; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Verbavatz JM, 1997, J CELL SCI, V110, P2855; Walz T, 1997, NATURE, V387, P624, DOI 10.1038/42512; Weig A, 1997, PLANT PHYSIOL, V114, P1347, DOI 10.1104/pp.114.4.1347; Yasui M, 1997, J PHYSIOL-LONDON, V505, P3, DOI 10.1111/j.1469-7793.1997.003bc.x; Yool AJ, 1996, SCIENCE, V273, P1216, DOI 10.1126/science.273.5279.1216; ZEIDEL ML, 1994, BIOCHEMISTRY-US, V33, P1606, DOI 10.1021/bi00172a042	53	372	397	0	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14659	14662		10.1074/jbc.273.24.14659	http://dx.doi.org/10.1074/jbc.273.24.14659			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614059	hybrid			2022-12-27	WOS:000074160400001
J	Delacoux, F; Fichard, A; Geourjon, C; Garrone, R; Ruggiero, F				Delacoux, F; Fichard, A; Geourjon, C; Garrone, R; Ruggiero, F			Molecular features of the collagen V heparin binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL HEP-2 REGION; ALPHA-1(V) CHAIN; ADHESION; CELLS; PROTEOGLYCAN; FIBRONECTIN; SULFATE; ALPHA-1-BETA-1; ORGANIZATION; DOMAINS	A heparin binding region is known to be present within the triple helical part of the alpha 1(V) chain. Here we show that a recombinant alpha 1(V) fragment (Ile(284) to Pro(950)), referred to as HepV, is sufficient for heparin binding at physiological ionic strength. Both native individual alpha 1(V) chains and HepV are eluted at identical NaCl concentrations (0.35 M) from a heparin-Sepharose column, and this binding can be inhibited specifically by the addition of free heparin or heparan sulfate. In contrast, a shorter as-residue synthetic peptide, containing the putative heparin binding site in HepV, fails to bind heparin, Interestingly, HepV promotes cell attachment, and HepV-mediated adhesion is inhibited specifically by heparin or heparan sulfate, indicating that this region might behave as an adhesive binding site. The same site is equally functional on triple helical molecules as shown by heparin-gold labeling. However, the affinities for heparin of each of the collagen V molecular forms tested are different and increase with the number of alpha 1(V) chains incorporated in the molecules. Molecular modeling of a sequence encompassing the putative HepV binding sequence region shows that all of the basic residues cluster on one side of the helical face. A highly positively charged ring around the molecule is thus particularly evident for the alpha 1(V) homotrimer, This could strengthen its interaction with the anionic heparin molecules. We propose that a single heparin binding site is involved in heparin-related glycosaiminoglycans-collagen V interactions, but the different affinities observed likely modulate cell and matrix interactions between collagen V and heparan sulfate proteoglycans in tissues.	Univ Claude Bernard, Inst Biol & Chim Prot, CNRS, UPR 412, Lyon 07, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Ruggiero, F (corresponding author), Univ Claude Bernard, Inst Biol & Chim Prot, CNRS, UPR 412, Passage Vercors, Lyon 07, France.	f.ruggiero@ibcp.fr		RUGGIERO, Florence/0000-0003-2915-5359				CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; COLOGNATOPYKE H, 1995, J BIOL CHEM, V270, P9398, DOI 10.1074/jbc.270.16.9398; DEPREZ PN, 1995, J BIOL CHEM, V270, P11043, DOI 10.1074/jbc.270.19.11043; Fichard A, 1997, J BIOL CHEM, V272, P30083, DOI 10.1074/jbc.272.48.30083; FICHARD A, 1994, MATRIX BIOL, V14, P515; GEOURJON C, 1995, J MOL GRAPHICS, V13, P209, DOI 10.1016/0263-7855(95)00035-5; HARALSON MA, 1980, P NATL ACAD SCI-BIOL, V77, P5206, DOI 10.1073/pnas.77.9.5206; HARALSON MA, 1984, ARCH BIOCHEM BIOPHYS, V229, P509, DOI 10.1016/0003-9861(84)90182-6; INGHAM KC, 1993, BIOCHEMISTRY-US, V32, P12548, DOI 10.1021/bi00097a035; INGHAM KC, 1994, ARCH BIOCHEM BIOPHYS, V314, P242, DOI 10.1006/abbi.1994.1436; KELLER KM, 1986, BIOCHIM BIOPHYS ACTA, V882, P1, DOI 10.1016/0304-4165(86)90047-4; KODA JE, 1985, J BIOL CHEM, V260, P8157; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBARON RG, 1989, J BIOL CHEM, V264, P7950; MANN K, 1992, BIOL CHEM H-S, V373, P69, DOI 10.1515/bchm3.1992.373.1.69; MARGALIT H, 1993, J BIOL CHEM, V268, P19228; MAYO KH, 1992, BIOCHEMISTRY-US, V31, P12255, DOI 10.1021/bi00163a040; Mizuno K, 1996, J BIOCHEM-TOKYO, V120, P934; MORADIAMELI M, 1994, EUR J BIOCHEM, V221, P987, DOI 10.1111/j.1432-1033.1994.tb18815.x; RUGGIERO F, 1993, J HISTOCHEM CYTOCHEM, V41, P867, DOI 10.1177/41.6.8315278; Ruggiero F, 1996, J CELL SCI, V109, P1865; RUGGIERO F, 1994, EXP CELL RES, V210, P215, DOI 10.1006/excr.1994.1032; SANANTONIO JD, 1994, GLYCOBIOLOGY, V4, P327; SUNG U, 1993, J CELL BIOL, V123, P1255, DOI 10.1083/jcb.123.5.1255; SUZU S, 1992, J BIOL CHEM, V267, P16812; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAKAHARA K, 1991, J BIOL CHEM, V266, P13124; Tillet E, 1997, J BIOL CHEM, V272, P10769; WHINNA HC, 1993, J BIOL CHEM, V268, P3920; WOODS A, 1986, EMBO J, V5, P665, DOI 10.1002/j.1460-2075.1986.tb04265.x; WOODS A, 1994, MOL BIOL CELL, V5, P183, DOI 10.1091/mbc.5.2.183; YAOI Y, 1990, BIOCHIM BIOPHYS ACTA, V1035, P139, DOI 10.1016/0304-4165(90)90108-9	32	49	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15069	15076		10.1074/jbc.273.24.15069	http://dx.doi.org/10.1074/jbc.273.24.15069			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614116	hybrid			2022-12-27	WOS:000074160400058
J	Foukas, LC; Katsoulas, HL; Paraskevopoulou, N; Metheniti, A; Lambropoulou, M; Marmaras, VJ				Foukas, LC; Katsoulas, HL; Paraskevopoulou, N; Metheniti, A; Lambropoulou, M; Marmaras, VJ			Phagocytosis of Escherichia coli by insect hemocytes requires both activation of the Ras/mitogen-activated protein kinase signal transduction pathway for attachment and beta(3) integrin for internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; EXTRACELLULAR-MATRIX; LIPOPOLYSACCHARIDE; DROSOPHILA; RECOGNITION; MACROPHAGES; STIMULATION; CAPITATA; CELLS	Insect hemocytes in response to lipopolysaccharide (LPS) of Gram-negative bacteria facilitate binding and internalization of either cell-associated or cell-free LPS (Charalambidis, N. D., Foukas L. C., and Marmaras V. J. (1996) Eur. J. Biochem. 236, 200-206), An early event in LPS signaling in hemocytes involves protein tyrosine phosphorylation (Charalambidis N. D., Zervas C. G., Lambropoulou M., Katsoris P. G., and Marmaras V. J. (1995) Eur. J. Cell Biol. 67, 32-41). Here we report further data of LPS-mediated signal transduction responsible for Escherichia coli phagocytosis. We demonstrate that both adhesion of hemocytes to substrata and LPS stimulation can cause activation of p44(MAPK) in Ceratitis capitata hemocytes but with distinct kinetics indicating different functions. In addition, we showed that Drk, a homolog protein to the mammalian GRB2, is implicated in the transmission of LPS signaling, indicating that the Ras/mitogen-activated protein kinase pathway is involved. Either the cell-free or the cell-associated LPS appears to attach to the hemocyte surface by the same mechanism that is based on the cross-linking of LPS to membrane-associated p47 via the intermediacy of tyrosine derivatives generated by the action of phenol oxidase, By contrast, the cell-free LPS internalization into the hemocytes differs from the cell-associated LPS internalization. For E. coli internalization integrin receptors as well as cytoskeletal rearrangements are required, as judged by inhibition of E. coli internalization in the presence of the RGD peptide, beta(3)-integrin antibodies, and cytochalasin D.	Univ Patras, Dept Biol, Patras 26500, Greece	University of Patras	Marmaras, VJ (corresponding author), Univ Patras, Dept Biol, Patras 26500, Greece.	marmaras@patreas.patras.gr						BIGGS WH, 1992, P NATL ACAD SCI USA, V89, P6295, DOI 10.1073/pnas.89.14.6295; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN EJ, 1995, BIOESSAYS, V17, P109, DOI 10.1002/bies.950170206; CHARALAMBIDIS ND, 1995, EUR J CELL BIOL, V67, P32; Charalambidis ND, 1996, EUR J BIOCHEM, V236, P200, DOI 10.1111/j.1432-1033.1996.00200.x; Charalambidis ND, 1996, INSECT BIOCHEM MOLEC, V26, P867, DOI 10.1016/S0965-1748(96)00053-7; CHARALAMBIDIS ND, 1994, INSECT BIOCHEM MOLEC, V7, P655; CHEN QM, 1994, J BIOL CHEM, V269, P26602; FOGERTY FJ, 1994, DEVELOPMENT, V120, P1747; GERNER AJ, 1995, J BIOL CHEM, V270, P5320; Gillespie JP, 1997, ANNU REV ENTOMOL, V42, P611, DOI 10.1146/annurev.ento.42.1.611; Hannigan GE, 1997, J MOL MED, V75, P35, DOI 10.1007/s001090050084; JEWELL K, 1995, J CELL SCI, V108, P1165; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KAPRONBRAS C, 1993, J BIOL CHEM, V268, P20701; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARMARAS VJ, 1994, ARCH INSECT BIOCHEM, V26, P1, DOI 10.1002/arch.940260102; MARMARAS VJ, 1988, DEV BIOL, V129, P294, DOI 10.1016/0012-1606(88)90376-4; OKADA CY, 1982, CELL, V29, P33, DOI 10.1016/0092-8674(82)90087-3; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PECH LL, 1995, J INSECT PHYSIOL, V41, P481, DOI 10.1016/0022-1910(94)00136-5; RAHLOFF LH, 1994, J INSECT PHYSL, V40, P1045; SCHAEFER J, 1987, SCIENCE, V235, P1200, DOI 10.1126/science.3823880; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; Towbin H, 1979, 10 1073 PNAS 76 9 43, V76, P4350, DOI [10.1073/pnas.76.9.4350, DOI 10.1073/PNAS.76.9.4350]; WEINSTEIN SL, 1992, J BIOL CHEM, V267, P14955; WEINSTEIN SL, 1991, P NATL ACAD SCI USA, V88, P4148, DOI 10.1073/pnas.88.10.4148; WEINSTEIN SL, 1993, J IMMUNOL, V151, P3829; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	30	90	92	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14813	14818		10.1074/jbc.273.24.14813	http://dx.doi.org/10.1074/jbc.273.24.14813			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614082	hybrid			2022-12-27	WOS:000074160400024
J	Kevil, CG; Payne, DK; Mire, E; Alexander, JS				Kevil, CG; Payne, DK; Mire, E; Alexander, JS			Vascular permeability factor/vascular endothelial cell growth factor-mediated permeability occurs through disorganization of endothelial junctional proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; BIOLOGICAL PROPERTIES; SIGNAL-TRANSDUCTION; FACTOR VEGF; IN-VIVO; ANGIOGENESIS; RECEPTOR; INHIBITION; ACTIVATION; BINDING	Vascular permeability factor/vascular endothelial growth factor stimulates endothelial proliferation, angiogenesis, and increased vascular permeability in vivo. We investigated mechanisms of vascular permeability factor-mediated endothelial monolayer permeability changes in vitro, [C-14]Albumin flux across endothelial monolayers was measured following a 90-min exposure to vascular permeability factor (660 pM). Vascular permeability factor increased albumin flux to 3.4 times that of control albumin flux. Endothelial monolayers were also incubated for 90 min with vascular permeability factor plus Go6976 (10 nM), staurosporine (1 mu M), wortmannin (10 nM), AG126 (1 and 2.67 mu M), and PD98059 (20 mu M). Vascular permeability factor-mediated permeability was not blocked by Go6976, an antagonist of "classical" protein kinase C, staurosporine, a pan-protein kinase C antagonist, nor wortmannin, a PI3-kinase blocker, but was blocked by incubation with AG126 or PD98059, inhibitors of mitogen-activated protein kinase activation, Immunofluorescent staining of the junctional proteins VE-cadherin and occludin showed a loss of these proteins from the endothelial junction that was prevented by co-incubation with AG126 or PD98059. These data demonstrate that vascular permeability factor increases albumin permeability across endothelial monolayers in vitro and suggests that permeability increases through rearrangement of endothelial junctional proteins involving the mitogen-activated protein kinase signal transduction pathway.	Louisiana State Univ, Med Ctr, Dept Mol & Cellular Physiol, Shreveport, LA 71130 USA; Louisiana State Univ, Med Ctr, Dept Med, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Alexander, JS (corresponding author), Louisiana State Univ, Med Ctr, Dept Mol & Cellular Physiol, 1501 Kings Hwy, Shreveport, LA 71130 USA.		Kevil, Christopher/G-9318-2011	Kevil, Christopher/0000-0003-0863-7260	NHLBI NIH HHS [HL47615] Funding Source: Medline; NIDDK NIH HHS [DK43785] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL047615] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK043785] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ALEXANDER JS, 1993, J CELL PHYSIOL, V156, P610, DOI 10.1002/jcp.1041560321; BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; BIKFALVI A, 1991, J CELL PHYSIOL, V149, P50, DOI 10.1002/jcp.1041490108; Brown L F, 1997, EXS, V79, P233; CHARNOCKJONES DS, 1994, BIOL REPROD, V51, P524, DOI 10.1095/biolreprod51.3.524; CRISCUOLO GR, 1989, J NEUROSURG, V71, P884, DOI 10.3171/jns.1989.71.6.0884; CUNNINGHAM SA, 1995, J BIOL CHEM, V270, P20254, DOI 10.1074/jbc.270.35.20254; DEJANA E, 1997, J CLIN INVEST S, V100, P7; DVORAK HF, 1995, INT ARCH ALLERGY IMM, V107, P233, DOI 10.1159/000236988; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; Gaudry M, 1997, BLOOD, V90, P4153, DOI 10.1182/blood.V90.10.4153; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Haselton FR, 1997, J CELL PHYSIOL, V171, P243, DOI 10.1002/(SICI)1097-4652(199706)171:3<243::AID-JCP2>3.0.CO;2-O; Horiuchi T, 1997, AM J RESP CELL MOL, V17, P70, DOI 10.1165/ajrcmb.17.1.2796; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Kan H, 1996, MOL PHARMACOL, V50, P1139; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Kevil CG, 1998, FREE RADICAL BIO MED, V24, P1015, DOI 10.1016/S0891-5849(97)00433-4; Kevil CG, 1996, INT J CANCER, V65, P785, DOI 10.1002/(SICI)1097-0215(19960315)65:6<785::AID-IJC14>3.0.CO;2-3; KEVIL CG, 1998, IN PRESS MICROCIRCUL; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KOCH AE, 1994, J IMMUNOL, V152, P4149; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; LAMPUGNANI MG, 1992, J CELL BIOL, V118, P1511, DOI 10.1083/jcb.118.6.1511; MANISCALCO WM, 1995, AM J RESP CELL MOL, V13, P377, DOI 10.1165/ajrcmb.13.4.7546767; NOVOGRODSKY A, 1994, SCIENCE, V264, P1319, DOI 10.1126/science.8191285; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Payne DK, 1996, FREE RADICAL RES, V25, P229, DOI 10.3109/10715769609149048; QATSHA KA, 1993, P NATL ACAD SCI USA, V90, P4674, DOI 10.1073/pnas.90.10.4674; ROBERTS WG, 1995, J CELL SCI, V108, P2369; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; SEETHARAM L, 1995, ONCOGENE, V10, P135; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SENGER DR, 1986, CANCER RES, V46, P5629; Seymour LW, 1996, LAB INVEST, V75, P427; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Taichman NS, 1997, J LEUKOCYTE BIOL, V62, P397, DOI 10.1002/jlb.62.3.397; Terman BI, 1996, CANCER METAST REV, V15, P159, DOI 10.1007/BF00437468; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wang W, 1996, AM J PHYSIOL-CELL PH, V271, pC1973, DOI 10.1152/ajpcell.1996.271.6.C1973; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006	44	255	262	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15099	15103		10.1074/jbc.273.24.15099	http://dx.doi.org/10.1074/jbc.273.24.15099			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614120	hybrid			2022-12-27	WOS:000074160400062
J	Schmidt, VA; Nierman, WC; Maglott, DR; Cupit, LD; Moskowitz, KA; Wainer, JA; Bahou, WF				Schmidt, VA; Nierman, WC; Maglott, DR; Cupit, LD; Moskowitz, KA; Wainer, JA; Bahou, WF			The human proteinase-activated receptor-3 (PAR-3) gene - Identification within a PAR gene cluster and characterization in vascular endothelial cells and platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBIN RECEPTOR; TRANSCRIPTION FACTOR; MOLECULAR-CLONING; PROMOTER; ELEMENTS; ENVIRONMENT; EXPRESSION; MECHANISM; RESPONSES; SEQUENCES	Proteolytically activated receptors (PARs) represent an emerging subset of seven transmembrane G protein-coupled receptors that mediate cell activation events by receptor cleavage at distinct scissile bonds located within receptor amino termini. Differential genomic blotting using a yeast artificial chromosome known to contain the PAR-1 and PAR-2 genes identified the PAR-3 gene within a PAR gene cluster spanning similar to 100 kilobases at 5q13. The PAR-3 gene is relatively small (similar to 12 kilobases); and, like the PAR-1 and PAR-2 genes, it displays a two-exon structure, with the majority of the coding sequence and the proteolytic cleavage site contained within the larger second exon, Sequence analysis of the 5'-flanking region demonstrates that the promoter is TATA-less, similar to that seen with PAR-1, with the identification of nucleic acid motifs potentially involved in transcriptional gene regulation, including AP-1, GATA, and octameric sequences. PAR-3 transcripts were apparent in human vascular endothelial cells, although at considerably lower levels than those of PAR-1 and not significantly modulated by the endothelial cell stimulus tumor necrosis factor-alpha. Likewise, although PAR-3 mRNA was evident in human platelets, receptor cell surface expression was modest (similar to 10%) compared with that of PAR-1, Thus, although PAR-3 is postulated to represent a second thrombin receptor, its modest endothelial cell and platelet expression suggest that PAR-3 activation by alpha-thrombin is less relevant for physiological responses in these mature cells. Rather, given its disparately greater expression in megakaryocytes land megakaryocyte-like human erythroleukemia cells), a regulatory role in cellular development (by protease activation) could be postulated.	SUNY Stony Brook, Div Hematol, Dept Med, Stony Brook, NY 11794 USA; Amer Type Culture Collect, Dept Mol Biol, Manassas, VA 20110 USA; SUNY Stony Brook, Genet Program, Stony Brook, NY 11794 USA; Accumetr Inc, San Diego, CA 92121 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Bahou, WF (corresponding author), SUNY Stony Brook, Div Hematol, Dept Med, HSC T15-040, Stony Brook, NY 11794 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049141] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49141] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bahou WF, 1996, PLATELETS, V7, P253, DOI 10.3109/09537109609023586; BAHOU WF, 1993, J CLIN INVEST, V91, P1405, DOI 10.1172/JCI116344; BOEHNKE M, 1991, AM J HUM GENET, V49, P1174; BRASS LF, 1992, J BIOL CHEM, V267, P13795; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; COX DR, 1990, SCIENCE, V250, P245, DOI 10.1126/science.2218528; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Hollenberg MD, 1996, TRENDS PHARMACOL SCI, V17, P3, DOI 10.1016/0165-6147(96)81562-8; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; HUNG DT, 1992, J BIOL CHEM, V267, P20831; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Li FZ, 1996, J BIOL CHEM, V271, P26320, DOI 10.1074/jbc.271.42.26320; LONG MW, 1990, J CLIN INVEST, V85, P1072, DOI 10.1172/JCI114538; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; MCGOWAN EB, 1986, J BIOL CHEM, V261, P739; MIGNOTTE V, 1989, P NATL ACAD SCI USA, V86, P6548, DOI 10.1073/pnas.86.17.6548; Mirza H, 1996, J CLIN INVEST, V97, P1705, DOI 10.1172/JCI118597; Mirza H, 1997, BLOOD, V90, P3914, DOI 10.1182/blood.V90.10.3914; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NEWMAN PJ, 1988, J CLIN INVEST, V82, P739, DOI 10.1172/JCI113656; NORTON KJ, 1993, BLOOD, V82, P2125; NYSTEDT S, 1995, EUR J BIOCHEM, V232, P84, DOI 10.1111/j.1432-1033.1995.tb20784.x; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PONTE P, 1983, MOL CELL BIOL, V3, P1783, DOI 10.1128/MCB.3.10.1783; PUSTELL J, 1986, NUCLEIC ACIDS RES, V14, P479, DOI 10.1093/nar/14.1.479; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; QUINN PG, 1993, J BIOL CHEM, V268, P16999; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; Schmidt VA, 1996, J BIOL CHEM, V271, P9307, DOI 10.1074/jbc.271.16.9307; Schmidt VA, 1997, BRIT J HAEMATOL, V97, P523, DOI 10.1046/j.1365-2141.1997.922907.x; STAUDT LM, 1988, SCIENCE, V241, P577, DOI 10.1126/science.3399892; VILLAGARCIA M, 1994, BLOOD, V83, P668, DOI 10.1182/blood.V83.3.668.bloodjournal833668; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V	37	106	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15061	15068		10.1074/jbc.273.24.15061	http://dx.doi.org/10.1074/jbc.273.24.15061			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614115	hybrid			2022-12-27	WOS:000074160400057
J	Canard, B; Sarfati, SR; Richardson, CC				Canard, B; Sarfati, SR; Richardson, CC			Enhanced binding of azidothymidine-resistant human immunodeficiency virus 1 reverse transcriptase to the 3 '-azido-3 '-deoxythymidine 5 '-monophosphate-terminated primer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND DISPLACEMENT SYNTHESIS; ZIDOVUDINE AZT; CROSS-LINKING; TYPE-1; INHIBITION; TEMPLATE; HIV; 5'-TRIPHOSPHATE; TRIPHOSPHATE; SENSITIVITY	Human immunodeficiency virus type I is resistant to 3'-azido-3'-deoxythymidine (AZT) when four amino acid substitutions (D67N, K70R, T215F, and K219Q) are present simultaneously in its reverse transcriptase. Wildtype and AZT-resistant reverse transcriptases show identical binding to a 3'-azido-3'-deoxythymidine 5'-monophosphate (AZTMP)-terminated primer/RNA template. On DNA templates, the equilibrium dissociation constant (K-D) for primer/template and AZT-resistant reverse transcriptase (RT) (K-D = 4.1 nM) is similar to that of the wild-type enzyme (K-D = 6.2 nM). However, k(off) is 4-25-fold lower for the AZT-resistant enzyme than for the wild-type enzyme, depending on the nucleotide and the template. The kinetic decay of a wild-type RT/primer/AZTMP-terminated DNA template complex is biphasic, Seventy percent of the initial complex decays with a rate constant greater than 0.05 s(-1), and 30% with a rate constant of 0.0017 s(-1). Decay of an AZT-resistant RT/ AZTMP-terminated primer/DNA template complex is monophasic, with a rate constant of 0.0018 s(-1), The Past two nucleotides at the 3' end of the AZTMP-terminated DNA primer in complex with AZT-resistant RT, but not wild-type RT, and a DNA template are protected from exonuclease digestion, suggesting that enhanced binding of the 3' end of the AZTMP-terminated DNA primer to reverse transcriptase is involved in the mechanism of AZT resistance by human immunodeficiency virus type 1.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Inst Pasteur, F-75724 Paris, France	Harvard University; Harvard Medical School; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Richardson, CC (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.	ccr@bcmp.med.harvard.edu		Canard, Bruno/0000-0003-4924-1991	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI006045, R01AI006045] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-06045] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Back NKT, 1996, EMBO J, V15, P4040, DOI 10.1002/j.1460-2075.1996.tb00777.x; BARSHOP BA, 1991, ANAL BIOCHEM, V197, P266, DOI 10.1016/0003-2697(91)90387-9; BOYER PL, 1994, P NATL ACAD SCI USA, V91, P4882, DOI 10.1073/pnas.91.11.4882; Caliendo AM, 1996, J VIROL, V70, P2146, DOI 10.1128/JVI.70.4.2146-2153.1996; Canard B, 1997, P NATL ACAD SCI USA, V94, P11279, DOI 10.1073/pnas.94.21.11279; CARROLL SS, 1994, BIOCHEMISTRY-US, V33, P2113, DOI 10.1021/bi00174a018; CHENG YC, 1987, J BIOL CHEM, V262, P2187; DECLERCQ E, 1992, AIDS RES HUM RETROV, V8, P119, DOI 10.1089/aid.1992.8.119; deJong MD, 1996, P NATL ACAD SCI USA, V93, P5501, DOI 10.1073/pnas.93.11.5501; Fuentes GM, 1996, J BIOL CHEM, V271, P1966, DOI 10.1074/jbc.271.4.2063; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; HSIEH JC, 1993, J BIOL CHEM, V268, P24607; HUBER HE, 1989, J BIOL CHEM, V264, P4669; JAJU M, 1995, J BIOL CHEM, V270, P9740, DOI 10.1074/jbc.270.17.9740; KATI WM, 1992, J BIOL CHEM, V267, P25988; Kerr SG, 1997, BIOCHEMISTRY-US, V36, P14064, DOI 10.1021/bi9713862; Krebs R, 1997, BIOCHEMISTRY-US, V36, P10292, DOI 10.1021/bi970512z; LACEY SF, 1992, J BIOL CHEM, V267, P15789; Lagrange T, 1996, P NATL ACAD SCI USA, V93, P10620, DOI 10.1073/pnas.93.20.10620; LARDER B, 1987, EMBO J, V6, P3133, DOI 10.1002/j.1460-2075.1987.tb02623.x; LARDER B, 1992, REVERSE TRANSCRIPTAS, P205; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LARDER BA, 1995, SCIENCE, V269, P969; LIGHTFOOTE MM, 1986, J VIROL, V60, P771, DOI 10.1128/JVI.60.2.771-775.1986; MAYER AN, 1995, GENE, V153, P1, DOI 10.1016/0378-1119(94)00752-E; MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096; PARKER WB, 1991, J BIOL CHEM, V266, P1754; Perach M, 1997, J MOL BIOL, V268, P648, DOI 10.1006/jmbi.1997.0927; REARDON JE, 1990, J BIOL CHEM, V265, P20302; REARDON JE, 1992, BIOCHEMISTRY-US, V31, P4473, DOI 10.1021/bi00133a013; REARDON JE, 1993, J BIOL CHEM, V268, P8743; RESTLE T, 1990, J BIOL CHEM, V265, P8986; RITTINGER K, 1995, P NATL ACAD SCI USA, V92, P8046, DOI 10.1073/pnas.92.17.8046; STAMMERS DK, 1994, J MOL BIOL, V242, P586, DOI 10.1006/jmbi.1994.1604; STCLAIR MH, 1987, ANTIMICROB AGENTS CH, V31, P1972, DOI 10.1128/AAC.31.12.1972; Tachedjian G, 1996, J VIROL, V70, P7171, DOI 10.1128/JVI.70.10.7171-7181.1996; TANTILLO C, 1994, J MOL BIOL, V243, P369, DOI 10.1006/jmbi.1994.1665	38	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14596	14604		10.1074/jbc.273.23.14596	http://dx.doi.org/10.1074/jbc.273.23.14596			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603976	hybrid, Green Published			2022-12-27	WOS:000074021500078
J	Rigney, E; Kojima, M; Glithero, A; Elliott, T				Rigney, E; Kojima, M; Glithero, A; Elliott, T			A soluble major histocompatibility complex class I peptide-binding platform undergoes a conformational change in response to peptide epitopes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAINS; 3-DIMENSIONAL STRUCTURE; CELL-SURFACE; MOLECULES; MHC; ASSOCIATION; TAP; MECHANISM; ANTIGEN; LIGAND	Class I major histocompatibility complexes (MHC) are heterotrimeric structures comprising heavy chains (HC), beta(2)-microglobulin (beta(2)-m), and short antigenic peptides of 8-10 amino acids. These components assemble in the endoplasmic reticulum and are released to the cell surface only when a peptide of the appropriate length and sequence is incorporated into the structure. The binding of beta(2)-m and peptide to HC is cooperative, and there is indirect evidence that the formation of a stable heterotrimer from an unstable HC:beta(2)-m heterodimer involves a peptide-induced conformational change in the HC. Such a conformational change could ensure both a strong interaction between the three components and also signal the release of stably assembled class I MHC molecules from the endoplasmic reticulum. A peptide-induced conformational change in HC has been demonstrated in cell lysates lacking beta(2)-m to which synthetic peptides were added. Many features of this conformational change suggest that it may be physiologically relevant. In an attempt to study the peptide-induced conformational change in detail we have expressed a soluble, truncated form of the mouse H-2D(b) HC that contains only the peptide binding domains of the class I molecule. We have shown that this peptide-binding "platform" is relatively stable in physiological buffers and undergoes a conformational change that is detectable with antibodies, in response to synthetic peptides. We also show that the structural features of peptides that induce this conformational change in the platform are the same as those required to observe the conformational change in full-length HC. In this respect, therefore, the HC alpha(1), and alpha(2) domains, which together form the peptide binding site of class I MHC, are able to act independently of the rest of the molecule.	Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England	University of Oxford	Rigney, E (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; CATIPOVIC B, 1994, J EXP MED, V180, P1753, DOI 10.1084/jem.180.5.1753; CERUNDOLO V, 1991, EUR J IMMUNOL, V21, P2069, DOI 10.1002/eji.1830210915; CERUNDOLO V, 1992, EUR J IMMUNOL, V22, P2243, DOI 10.1002/eji.1830220910; CERUNDOLO V, 1992, PROG IMMUNOL, V8, P175; CERUNDOLO V, 1996, HLA MHC GENES MOL FU, P193; CLORE GM, 1991, BIOCHEMISTRY-US, V30, P2315, DOI 10.1021/bi00223a005; Elliott T, 1997, IMMUNOL TODAY, V18, P375, DOI 10.1016/S0167-5699(97)01097-9; ELLIOTT T, 1992, EUR J IMMUNOL, V22, P2085, DOI 10.1002/eji.1830220819; Elliott T, 1997, ADV IMMUNOL, V65, P47, DOI 10.1016/S0065-2776(08)60741-5; ELLIOTT T, 1992, EUR J IMMUNOL, V22, P3121, DOI 10.1002/eji.1830221214; ELLIOTT T, 1991, NATURE, V351, P402, DOI 10.1038/351402a0; HAMMERLING GJ, 1979, IMMUNOGENETICS, V8, P433, DOI 10.1007/BF01561454; HEEMELS MT, 1995, ANNU REV BIOCHEM, V64, P463, DOI 10.1146/annurev.bi.64.070195.002335; JARDETZKY T, 1996, HLA MHC GENES MOL FU, P249; LIE WR, 1990, NATURE, V344, P439, DOI 10.1038/344439a0; LJUNGGREN HG, 1985, J EXP MED, V162, P1745, DOI 10.1084/jem.162.6.1745; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LJUNGGREN HG, 1989, J IMMUNOL, V142, P2911; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; ORTMANN B, 1994, NATURE, V368, P864, DOI 10.1038/368864a0; REMEROWSKI ML, 1994, J BIOMOL NMR, V4, P257, DOI 10.1007/BF00175252; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; SMITH JD, 1992, J EXP MED, V175, P191, DOI 10.1084/jem.175.1.191; Springer S, 1998, BIOCHEMISTRY-US, V37, P3001, DOI 10.1021/bi9717441; Suh WK, 1996, J EXP MED, V184, P337, DOI 10.1084/jem.184.2.337; SUH WK, 1994, SCIENCE, V264, P1322, DOI 10.1126/science.8191286; TOWNSEND A, 1989, COLD SH Q B, V54, P299; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; WILSON R, 1995, BIOCHEM J, V307, P679, DOI 10.1042/bj3070679	30	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14200	14204		10.1074/jbc.273.23.14200	http://dx.doi.org/10.1074/jbc.273.23.14200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603922	hybrid			2022-12-27	WOS:000074021500024
J	Chintala, SK; Sawaya, R; Aggarwal, BB; Majumder, S; Giri, DK; Kyritsis, AP; Gokaslan, ZL; Rao, JS				Chintala, SK; Sawaya, R; Aggarwal, BB; Majumder, S; Giri, DK; Kyritsis, AP; Gokaslan, ZL; Rao, JS			Induction of matrix metalloproteinase-9 requires a polymerized actin cytoskeleton in human malignant glioma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; PROTEIN-KINASE-C; RABBIT SYNOVIAL FIBROBLASTS; IV COLLAGENASE; GENE-EXPRESSION; IN-VITRO; GELATINASE-B; FACTOR-ALPHA; INVASION; SHAPE	Alterations in cytoskeleton and subsequent cell shape changes exert specific effects on the expression of various genes. Our previous results suggested that malignant human gliomas express elevated levels of matrix metalloproteinases compared with normal brain tissue and low grade gliomas. To understand the role of cell shape changes on matrix metalloproteinase expression in human glioma cells, we treated SNB19 cells with cytochalasin-D, an inhibitor of actin polymerization, and colchicine-B, a tubulin inhibitor, in the presence of phorbol 12-myristate 13-acetate. Cytochalasin-D treatment of SNB19 cells resulted in the loss of phorbol 12-myristate 13-acetate-induced matrix metalloproteinase-9 (also known as gelatinase-B) expression and coincided with inhibition of actin polymerization, resulting in cell rounding. Moreover, compared with monolayers, cells grown as spheroids or cell aggregates failed to express matrix metalloproteinase-9 in the presence of phorbol 12-myristate 13-acetate. Matrix metalloproteinase-g expression was also inhibited by calphostin-C, a protein kinase inhibitor, suggesting the involvement of protein kinase C in matrix metalloproteinase-g expression. Phorbol 12-myristate 13-acetate-induced invasion of SNB19 cells through Matrigel was inhibited by cytochalasin-D and calphostin-C. These results suggest that the actin polymerization transduces signals that modulate the expression of matrix metalloproteinase-9 expression and the subsequent invasion of human glioma cells.	Univ Texas, MD Anderson Cancer Ctr, Dept Neurosurg, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Mol Oncol, Cytokine Res Lab, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Neurooncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Rao, JS (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Neurosurg, Box 064,1515 Holcombe Blvd, Houston, TX 77030 USA.		Aggarwal, Bharat B/G-3388-2013		NCI NIH HHS [CA56792] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056792] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE T, 1994, CLIN EXP METASTAS, V12, P296, DOI 10.1007/BF01753836; AGGELER J, 1984, J CELL BIOL, V98, P1662, DOI 10.1083/jcb.98.5.1662; AKASAKA T, 1995, J INVEST DERMATOL, V105, P104, DOI 10.1111/1523-1747.ep12313396; BELL E, 1979, P NATL ACAD SCI USA, V76, P1274, DOI 10.1073/pnas.76.3.1274; BENYA PD, 1982, CELL, V30, P215, DOI 10.1016/0092-8674(82)90027-7; BISSELL MJ, 1982, J THEOR BIOL, V99, P31, DOI 10.1016/0022-5193(82)90388-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CHATURVEDI MM, 1994, J BIOL CHEM, V269, P14575; CHIN JR, 1985, J BIOL CHEM, V260, P2367; Chintala SK, 1997, ONCOGENE, V15, P2049, DOI 10.1038/sj.onc.1201382; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; COULDWELL WT, 1991, NEUROSURGERY, V29, P880, DOI 10.1227/00006123-199112000-00013; COULDWELL WT, 1991, NEUROSURGERY, V76, P782; EMMERMAN JT, 1977, IN VITRO, V13, P316; GRINNELL F, 1994, J CELL BIOL, V124, P401, DOI 10.1083/jcb.124.4.401; ISAKOV N, 1991, INVAS METAST, V11, P14; ITO A, 1990, FEBS LETT, V269, P93, DOI 10.1016/0014-5793(90)81127-A; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUNDJOHANSEN M, 1991, ANTICANCER RES, V11, P1001; MACDOUGALL JR, 1995, EXP CELL RES, V218, P508, DOI 10.1006/excr.1995.1185; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MOSCATELLI D, 1988, BIOCHIM BIOPHYS ACTA, V948, P67, DOI 10.1016/0304-419X(88)90005-4; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PAGANETTI PA, 1988, J CELL BIOL, V107, P2281, DOI 10.1083/jcb.107.6.2281; Rao JS, 1996, CLIN EXP METASTAS, V14, P12, DOI 10.1007/BF00157681; RAO JS, 1994, J NEURO-ONCOL, V18, P129, DOI 10.1007/BF01050419; RAO JS, 1993, CANCER RES, V53, P2208; Rossi M, 1996, ANTICANCER RES, V16, P121; RUCKLIDGE GJ, 1994, BIOCHEM SOC T, V22, P63, DOI 10.1042/bst0220063; Sawaya RE, 1996, CLIN EXP METASTAS, V14, P35, DOI 10.1007/BF00157684; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHWARTZ GK, 1993, J NATL CANCER I, V85, P402, DOI 10.1093/jnci/85.5.402; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SPIEGELMAN BM, 1983, CELL, V35, P657, DOI 10.1016/0092-8674(83)90098-3; SPIEGELMAN BM, 1982, CELL, V29, P53, DOI 10.1016/0092-8674(82)90089-7; STETLERSTEVENSON WG, 1990, CANCER METAST REV, V9, P289, DOI 10.1007/BF00049520; Szaniawska B, 1996, CANCER LETT, V107, P205, DOI 10.1016/0304-3835(96)04369-8; TOMASEK JJ, 1982, DEV BIOL, V92, P107, DOI 10.1016/0012-1606(82)90155-5; Tomasek JJ, 1997, J BIOL CHEM, V272, P7482, DOI 10.1074/jbc.272.11.7482; TRACHSEL S, 1995, J LEUKOCYTE BIOL, V57, P587, DOI 10.1002/jlb.57.4.587; Uhm JH, 1996, CLIN EXP METASTAS, V14, P421, DOI 10.1007/BF00128958; UNEMORI EN, 1986, J CELL BIOL, V103, P1021, DOI 10.1083/jcb.103.3.1021; VASSALLI JD, 1994, NATURE, V370, P14, DOI 10.1038/370014a0; WERB Z, 1986, J CELL BIOL, V102, P697, DOI 10.1083/jcb.102.3.697; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; ZANETTI NC, 1984, J CELL BIOL, V99, P115, DOI 10.1083/jcb.99.1.115	48	63	68	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13545	13551		10.1074/jbc.273.22.13545	http://dx.doi.org/10.1074/jbc.273.22.13545			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593690	hybrid			2022-12-27	WOS:000073919100029
J	Ji, ZS; Pitas, RE; Mahley, RW				Ji, ZS; Pitas, RE; Mahley, RW			Differential cellular accumulation retention of apolipoprotein E mediated by cell surface heparan sulfate proteoglycans - Apolipoproteins E3 and E2 greater than E4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; RECEPTOR-RELATED PROTEIN; CENTRAL NERVOUS-SYSTEM; ALZHEIMERS-DISEASE; REMNANT LIPOPROTEINS; NEURITE OUTGROWTH; III HYPERLIPOPROTEINEMIA; CEREBROSPINAL-FLUID; CULTURED-CELLS; HEPATIC LIPASE	Isoform-specific effects of apolipoprotein E (apoE) on neurite outgrowth and the cytoskeleton are associated with higher intracellular levels of apoE3 than apoE4 in cultured neurons. The current studies, designed to determine the mechanism for the differential intracellular accumulation or retention of apoE, demonstrate that apoE3- and apoE4-containing beta-very low density lipoproteins (beta-VLDL) possess similar cell binding and internalization and delivery of cholesterol to the cells, However, as assessed by immunocytochemistry, analysis of extracted cellular proteins, or quantitation of I-125-apoE-enriched beta-VLDL, there was a 2-3 fold greater accumulation of apoE3 than apoE4 in Neuro-2a cells, fibroblasts, and hepatocytes (HepG2) after 1-2 h, and this differential was maintained for up to 48 h, ApoE2 also accumulated in Neuro-aa cells to a greater extent than apoE4. The differential effect was mediated by the apoE-enriched beta-VLDL and not by free apoE, Neither the low density lipoprotein receptor nor the low density lipoprotein receptor-related protein was responsible for the differential accumulation of apoE3 and apoE4, since cells deficient in either or both of these receptors also displayed the differential accumulation. The effect appears to be mediated primarily by cell surface heparan sulfate proteoglycans (HSPG), The retention of both apoE3 and apoE4 was markedly reduced, and the differential accumulation of apoE3 and apoE4 was eliminated both in mutant Chinese hamster ovary cells that did not express HSPG; and in HSPG expressing cells treated with heparinase, The data suggest that cell surface HSPG directly mediate the uptake of apoE-containing lipoproteins, that the differential accumulation/retention of apoE by cells is mediated via HSPG, and that there is a differential intracellular handling of the specific apoE isoforms.	Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, Cardiovasc Res Inst, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Mahley, RW (corresponding author), Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, Cardiovasc Res Inst, POB 419100, San Francisco, CA 94141 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013619] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41633] Funding Source: Medline; NIA NIH HHS [AG13619] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BELLOSTA S, 1995, J BIOL CHEM, V270, P27063, DOI 10.1074/jbc.270.45.27063; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BORGHINI I, 1995, BBA-LIPID LIPID MET, V1255, P192, DOI 10.1016/0005-2760(94)00232-N; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; CORLESS CL, 1992, DEV DYNAM, V193, P346, DOI 10.1002/aja.1001930408; DUNN WA, 1980, J BIOL CHEM, V255, P5971; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; Fuki IV, 1997, J CLIN INVEST, V100, P1611, DOI 10.1172/JCI119685; GANGULY P, 1977, BRIT J HAEMATOL, V37, P47, DOI 10.1111/j.1365-2141.1977.tb08762.x; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HAN SH, 1994, J NEUROPATH EXP NEUR, V53, P535, DOI 10.1097/00005072-199409000-00013; HAN SH, 1994, EXP NEUROL, V128, P13, DOI 10.1006/exnr.1994.1108; HANDELMANN GE, 1992, J LIPID RES, V33, P1677; HOLTZMAN DM, 1995, P NATL ACAD SCI USA, V92, P9480, DOI 10.1073/pnas.92.21.9480; JI ZS, 1994, J BIOL CHEM, V269, P13421; JI ZS, 1994, J BIOL CHEM, V269, P2764; JI ZS, 1994, J BIOL CHEM, V269, P13429; JI ZS, 1993, J BIOL CHEM, V268, P10160; JI ZS, 1994, ARTERIOSCLER THROMB, V14, P2025, DOI 10.1161/01.ATV.14.12.2025; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P9307, DOI 10.1074/jbc.270.16.9307; KOUNNAS MZ, 1994, ANN NY ACAD SCI, V737, P114, DOI 10.1111/j.1749-6632.1994.tb44305.x; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Lovestone S, 1996, NEUROREPORT, V7, P1005, DOI 10.1097/00001756-199604100-00010; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLEY RW, 1994, ANN NY ACAD SCI, V737, P39, DOI 10.1111/j.1749-6632.1994.tb44300.x; Mahley RW, 1996, ISRAEL J MED SCI, V32, P414; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1997, MOL GENETIC BASIS NE, P1037; MAHLEY RW, 1996, APOLIPOPROTEIN E ALZ, P49; MAYEUX R, 1993, ANN NEUROL, V34, P752, DOI 10.1002/ana.410340527; NATHAN BP, 1995, J BIOL CHEM, V270, P19791, DOI 10.1074/jbc.270.34.19791; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Pitas R.E., 1992, LIPOPROTEIN ANAL PRA, P215; PITAS RE, 1981, ARTERIOSCLEROSIS, V1, P177, DOI 10.1161/01.ATV.1.3.177; PITAS RE, 1979, P NATL ACAD SCI USA, V76, P2311, DOI 10.1073/pnas.76.5.2311; PITAS RE, 1987, J BIOL CHEM, V262, P14352; PITAS RE, 1983, ARTERIOSCLEROSIS, V3, P2, DOI 10.1161/01.ATV.3.1.2; Pitas RE, 1996, SEMIN CELL DEV BIOL, V7, P725, DOI 10.1006/scdb.1996.0089; Pitas RE, 1997, NUTR METAB CARDIOVAS, V7, P202; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; REILAND J, 1993, J CELL SCI, V105, P1085; ROSES AD, 1994, J NEUROPATH EXP NEUR, V53, P429, DOI 10.1097/00005072-199409000-00002; RUMSEY SC, 1992, J CLIN INVEST, V90, P1504, DOI 10.1172/JCI116018; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SHIEH MT, 1992, J CELL BIOL, V116, P1273, DOI 10.1083/jcb.116.5.1273; STRITTMATTER WJ, 1994, EXP NEUROL, V125, P163, DOI 10.1006/exnr.1994.1019; TABAS I, 1990, J CELL BIOL, V111, P929, DOI 10.1083/jcb.111.3.929; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; WEISGRABER KH, 1982, J BIOL CHEM, V257, P2518; Weisgraber KH, 1996, FASEB J, V10, P1485, DOI 10.1096/fasebj.10.13.8940294; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; Williams KJ, 1997, CURR OPIN LIPIDOL, V8, P253; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; WILLNOW TE, 1994, J CELL SCI, V107, P719; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9505; ZANNIS VI, 1981, BIOCHEMISTRY-US, V20, P1033, DOI 10.1021/bi00507a059	63	107	110	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13452	13460		10.1074/jbc.273.22.13452	http://dx.doi.org/10.1074/jbc.273.22.13452			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593678	hybrid			2022-12-27	WOS:000073919100017
J	Ventura, C; Maioli, M; Pintus, G; Posadino, AM; Tadolini, B				Ventura, C; Maioli, M; Pintus, G; Posadino, AM; Tadolini, B			Nuclear opioid receptors activate opioid peptide gene transcription in isolated myocardial nuclei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CARDIAC SARCOLEMMA; CALPHOSTIN-C; RAT; MYOCYTES; EXPRESSION; SUBSTRATE; AGONIST; LIGAND; CA2+	Opioid-binding sites were identified in highly purified nuclei isolated from hamster ventricular myocardial cells. A significant increase in the maximal binding capacity for a kappa opioid receptor ligand was observed in myocardial nuclei from BIO 14.6 cardiomyopathic hamsters, as compared with nuclei obtained from normal myocytes of the F1B strain. The exposure of isolated nuclei to dynorphin B, a natural agonist of kappa opioid receptors, markedly increased opioid peptide gene transcription. The transcriptional effect was mediated by nuclear protein kinase C activation and occurred at a higher rate in nuclei from cardiomyopathic myocytes than in nuclei isolated from normal cells. Thus, a nuclear endorphinergic system may play an intracrine role in the regulation of gene transcription under both normal and pathological conditions.	Univ Sassari, Div Biochem, Dept Biomed Sci, Cardiovasc Res Lab, I-07100 Sassari, Italy; Natl Inst Biostruct & Biosyst, Natl Lab, I-07100 Osilo, Italy	University of Sassari	Ventura, C (corresponding author), Univ Sassari, Div Biochem, Dept Biomed Sci, Cardiovasc Res Lab, Viale San Pietro 43-B, I-07100 Sassari, Italy.	Chim_med@SSmain.UniSS.It	Pintus, Gianfranco/C-2975-2009	Pintus, Gianfranco/0000-0002-3031-7733; Posadino, Anna Maria/0000-0002-6155-159X; MAIOLI, Margherita/0000-0003-0187-4968	Telethon [958] Funding Source: Medline	Telethon(Fondazione Telethon)		ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; CHAVKIN C, 1982, SCIENCE, V215, P413, DOI 10.1126/science.6120570; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COCCO L, 1987, BIOCHEM J, V248, P765, DOI 10.1042/bj2480765; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; FORMAN R, 1972, J MOL CELL CARDIOL, V4, P203, DOI 10.1016/0022-2828(72)90058-2; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; JASMIN G, 1982, MUSCLE NERVE, V5, P20, DOI 10.1002/mus.880050105; KO FN, 1990, BIOCHIM BIOPHYS ACTA, V1052, P360, DOI 10.1016/0167-4889(90)90144-3; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; LAHTI RA, 1985, EUR J PHARMACOL, V109, P281, DOI 10.1016/0014-2999(85)90431-5; LAMERS JMJ, 1981, BIOCHIM BIOPHYS ACTA, V640, P521, DOI 10.1016/0005-2736(81)90476-4; LEBEL D, 1976, ANAL BIOCHEM, V85, P86; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCILROY BK, 1991, ANAL BIOCHEM, V195, P148, DOI 10.1016/0003-2697(91)90310-P; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PANERAI AE, 1984, BRAIN RES, V304, P153, DOI 10.1016/0006-8993(84)90872-2; PATEL J, 1987, J BIOL CHEM, V262, P16686; SEN L, 1990, CIRC RES, V67, P599, DOI 10.1161/01.RES.67.3.599; SMITH CD, 1983, J BIOL CHEM, V258, P9368; TAI KK, 1992, LIFE SCI, V51, P909, DOI 10.1016/0024-3205(92)90398-9; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; THELEN M, 1990, P NATL ACAD SCI USA, V87, P5603, DOI 10.1073/pnas.87.15.5603; VENTURA C, 1995, J BIOL CHEM, V270, P30115; Ventura C, 1997, J BIOL CHEM, V272, P6685, DOI 10.1074/jbc.272.10.6685; Ventura C, 1997, J BIOL CHEM, V272, P6693, DOI 10.1074/jbc.272.10.6693; VENTURA C, 1991, AM J PHYSIOL, V261, pH1671, DOI 10.1152/ajpheart.1991.261.5.H1671; VENTURA C, 1992, CIRC RES, V70, P66, DOI 10.1161/01.RES.70.1.66; VENTURA C, 1989, BIOCHIM BIOPHYS ACTA, V987, P69, DOI 10.1016/0005-2736(89)90456-2; VENTURA C, 1994, J BIOL CHEM, V269, P5384; Ventura C, 1997, J BIOL CHEM, V272, P6699, DOI 10.1074/jbc.272.10.6699; VONVOIGTLANDER PF, 1983, J PHARMACOL EXP THER, V224, P7; Wittert G, 1996, BIOCHEM BIOPH RES CO, V218, P877, DOI 10.1006/bbrc.1996.0156; Zimlichman R, 1996, CIRCULATION, V93, P1020, DOI 10.1161/01.CIR.93.5.1020	35	45	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13383	13386		10.1074/jbc.273.22.13383	http://dx.doi.org/10.1074/jbc.273.22.13383			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593666	hybrid			2022-12-27	WOS:000073919100005
J	Auge, N; Escargueil-Blanc, I; Lajoie-Mazenc, I; Suc, I; Andrieu-Abadie, N; Pieraggi, MT; Chatelut, M; Thiers, JC; Jaffrezou, JP; Laurent, G; Levade, T; Negre-Salvayre, A; Salvayre, R				Auge, N; Escargueil-Blanc, I; Lajoie-Mazenc, I; Suc, I; Andrieu-Abadie, N; Pieraggi, MT; Chatelut, M; Thiers, JC; Jaffrezou, JP; Laurent, G; Levade, T; Negre-Salvayre, A; Salvayre, R			Potential role for ceramide in mitogen-activated protein kinase activation and proliferation of vascular smooth muscle cells induced by oxidized low density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; ATHEROSCLEROTIC LESIONS; ACIDIC SPHINGOMYELINASE; NUCLEAR-LOCALIZATION; FACTOR-ALPHA; PATHWAY; LDL; APOPTOSIS	Proliferation of vascular smooth muscle cells (SMC) is a hallmark in the pathogenesis of atherosclerotic lesions. Mildly oxidized low density lipoproteins (UV-oxLDL), which are mitogenic to cultured AG-08133A SMC, activate the sphingomyelin (SM)-ceramide pathway. We report here the following. (i) UV-oxLDL elicited a biphasic and sustained activation of MBP kinase activity, phosphorylation and nuclear translocation of p44/42 mitogen-activated protein kinase (MAPK), and [H-3]thymidine incorporation, which were inhibited by PD-098059, a MAPK kinase inhibitor. (ii) The use of preconditioned media (from SMC pre-activated by UV-oxLDL) transferred to native SMC and blocking antibodies against growth factors suggest that UV-oxLDL-induced activation of MAPK and [H-3]thymidine incorporation seem to be independent of any autocrine secretion of growth factors. (iii) UV-oxLDL-induced activation of a neutral sphingomyelinase, SM hydrolysis, ceramide production, and [H-3]thymidine incorporation were inhibited by two serine-protease inhibitors (serpins), suggesting that a serpin-sensitive proteolytic pathway is involved in the activation of the SM-ceramide signaling pathway. (iv) UV-oxLDL-induced MAPK activation and [H-3]thymidine incorporation were mimicked by ceramide generated in the plasma membrane by bacterial sphingomyelinase treatment or by addition of the permeant C-2-ceramide. Serpins did not inhibit the MAPK activation and [H-3]thymidine incorporation induced by C-2-ceramide, indicating that activation of the MAPK and [H-3]thymidine incorporation is subsequent to the stimulation of the SM-ceramide pathway. Taken together, these data suggest that mitogenic concentrations of UV-oxLDL are able to stimulate the SM-ceramide pathway through a protease-dependent mechanism and activate p44/42 MAPK, leading to proliferation of vascular SMC.	CHU Rangueil, Inst Louis Bugnard, INSERM U466, Biochem Lab, F-31403 Toulouse 4, France; Ctr Claudis Regaud, INSERM CJF9503, F-31052 Toulouse, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Claudius Regaud	Salvayre, R (corresponding author), CHU Rangueil, Inst Louis Bugnard, INSERM U466, Biochem Lab, 1 Ave Jean Poulhes, F-31403 Toulouse 4, France.		Levade, Thierry/O-8948-2014; Andrieu-Abadie, Nathalie/N-6793-2013; Lajoie-Mazenc, Isabelle/M-4636-2014	Andrieu-Abadie, Nathalie/0000-0003-2698-1970; Auge, Nathalie/0000-0003-2088-7211; Negre-Salvayre, Anne/0000-0003-2136-5706				ANDRIEU N, 1994, BIOCHEM J, V303, P341, DOI 10.1042/bj3030341; Auge N, 1996, J BIOL CHEM, V271, P19251, DOI 10.1074/jbc.271.32.19251; AUGE N, 1995, BIOCHEM J, V309, P1015, DOI 10.1042/bj3091015; Ballou LR, 1996, BBA-LIPID LIPID MET, V1301, P273, DOI 10.1016/0005-2760(96)00004-5; Bhunia AK, 1996, J BIOL CHEM, V271, P10660, DOI 10.1074/jbc.271.18.10660; BIRD TA, 1994, J BIOL CHEM, V269, P31836; BOUCHER LM, 1995, J EXP MED, V181, P2059, DOI 10.1084/jem.181.6.2059; BRUNET A, 1994, ONCOGENE, V9, P3379; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Chatterjee S, 1997, GLYCOBIOLOGY, V7, P703, DOI 10.1093/glycob/7.5.703; CHATTERJEE S, 1992, MOL CELL BIOCHEM, V111, P143; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; COOPER JA, 1994, CURR BIOL, V4, P1118, DOI 10.1016/S0960-9822(00)00251-7; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Dbaibo GS, 1997, J EXP MED, V185, P481, DOI 10.1084/jem.185.3.481; Deigner HP, 1996, FEBS LETT, V385, P149, DOI 10.1016/0014-5793(96)00371-7; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; ESCARGUEILBLANC I, 1994, FASEB J, V8, P1075, DOI 10.1096/fasebj.8.13.7926374; ESTERBAUER H, 1990, CHEM RES TOXICOL, V3, P77, DOI 10.1021/tx00014a001; FOLCH J, 1957, J BIOL CHEM, V226, P497; Gamen S, 1996, FEBS LETT, V390, P233, DOI 10.1016/0014-5793(96)00666-7; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; IKEDA U, 1994, ATHEROSCLEROSIS, V110, P87, DOI 10.1016/0021-9150(94)90071-X; INAGAKI N, 1994, TRENDS BIOCHEM SCI, V19, P448, DOI 10.1016/0968-0004(94)90128-7; JACQUEMINSABLON H, 1990, BIOL CELL, V187, P209; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; KIM MY, 1991, J BIOL CHEM, V266, P484; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; Kusuhara M, 1997, ARTERIOSCL THROM VAS, V17, P141, DOI 10.1161/01.ATV.17.1.141; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; Mansat V, 1997, FASEB J, V11, P695, DOI 10.1096/fasebj.11.8.9240970; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; Modur V, 1996, J BIOL CHEM, V271, P13094, DOI 10.1074/jbc.271.22.13094; NEGRESALVAYRE A, 1990, BIOCHIM BIOPHYS ACTA, V1045, P224, DOI 10.1016/0005-2760(90)90124-G; NEGRESALVAYRE A, 1992, PHOTOCHEM PHOTOBIOL, V55, P197, DOI 10.1111/j.1751-1097.1992.tb04228.x; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; POUYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195, DOI 10.1146/annurev.ph.54.030192.001211; PUSHKAREVA M, 1995, IMMUNOL TODAY, V16, P294, DOI 10.1016/0167-5699(95)80184-7; Pyne S, 1996, EUR J BIOCHEM, V237, P819, DOI 10.1111/j.1432-1033.1996.0819p.x; RAINES MA, 1993, J BIOL CHEM, V268, P14572; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; ROSS R, 1973, SCIENCE, V180, P1332, DOI 10.1126/science.180.4093.1332; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sachinidis A, 1997, MOL PHARMACOL, V52, P389, DOI 10.1124/mol.52.3.389; SALEEM A, 1995, J IMMUNOL, V154, P4150; Sambrook J., 2002, MOL CLONING LAB MANU; SANGHERA JS, 1992, MOL BIOL CELL, V3, P775, DOI 10.1091/mbc.3.7.775; SASAKI T, 1995, BIOCHEM J, V311, P829, DOI 10.1042/bj3110829; SETH A, 1992, J BIOL CHEM, V267, P24796; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24334, DOI 10.1074/jbc.270.41.24334; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; STARY HC, 1990, EUR HEART J, V11, P3, DOI 10.1093/eurheartj/11.suppl_E.3; STEINBRECHER UP, 1990, FREE RADICAL BIO MED, V9, P155, DOI 10.1016/0891-5849(90)90119-4; STIKORAHM A, 1992, ARTERIOSCLER THROMB, V12, P1099, DOI 10.1161/01.ATV.12.9.1099; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; Via D P, 1986, Methods Enzymol, V129, P848; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; WU J, 1995, J BIOL CHEM, V270, P11484, DOI 10.1074/jbc.270.19.11484; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271	68	78	82	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					12893	12900		10.1074/jbc.273.21.12893	http://dx.doi.org/10.1074/jbc.273.21.12893			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582320	hybrid			2022-12-27	WOS:000073768500031
J	Capranico, G; Guano, F; Moro, S; Zagotto, G; Sissi, C; Gatto, B; Zunino, F; Menta, E; Palumbo, M				Capranico, G; Guano, F; Moro, S; Zagotto, G; Sissi, C; Gatto, B; Zunino, F; Menta, E; Palumbo, M			Mapping drug interactions at the covalent topoisomerase II-DNA complex by bisantrene/amsacrine congeners	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLEAVAGE SITES; ANTITUMOR; SEQUENCE; BINDING; BASE; CAMPTOTHECIN; DETERMINANTS; STIMULATION; DERIVATIVES; POISONS	To identify structural determinants for the sequence-specific recognition of covalent topoisomerase II-DNA complexes by anti-cancer drugs, we investigated a number of bisantrene congeners, including a 10-azabioisoster, bearing one or two 4,5-dihydro-1H-imidazol-2-yl hydrazone side chains at positions 1, 4, or 9 of the anthracene ring system. The studied bisantrene/amsacrine (m-AMSA) hybrid and bisantrene isomers were able to poison DNA topoisomerase II with an intermediate activity between those of bisantrene and m-AMSA, Moving the side chain from the central to a lateral ring (from C-9 to C-1/C-4) only slightly modified the drug DNA affinity, whereas it dramatically affected local base preferences of poison-stimulated DNA cleavage. In contrast, switching the planar aromatic systems of bisantrene and m-AMSA did not substantially alter the sequence specificity of drug action. A computer-assisted steric and electrostatic alignment analysis of the test compounds was in agreement with the experimental data, since a common pharmacophore was shared by bisantrene, m-AMSA, and 9-substituted analogs, whereas the 1-substituted isomer showed a radically changed pharmacophoric structure. Thus, the relative space occupancy and electron distribution of putative DNA binding (aromatic rings) and enzyme binding (side chains) moieties are fundamental in directing the specific action of topoisomerase LI poisons and in determining the poison pharmacophore.	Ist Nazl Studio & Cura Tumori, Div Expt Oncol B, I-20133 Milan, Italy; Univ Padua, Dept Pharmaceut Sci, I-35131 Padua, Italy; Boehringer Mannheim Italia, Res Ctr, I-20052 Monza, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Padua	Capranico, G (corresponding author), Ist Nazl Tumori, Via Venezian 1, I-20133 Milan, Italy.		Capranico, Giovanni/K-1678-2014; Gatto, Barbara/B-1542-2013; Moro, Stefano/A-2979-2012	Capranico, Giovanni/0000-0002-8708-6454; Gatto, Barbara/0000-0001-9465-6913; Moro, Stefano/0000-0002-7514-3802; Palumbo, Manlio/0000-0002-3163-1564; SISSI, CLAUDIA/0000-0002-9713-1415				BAGULEY BC, 1991, ANTI-CANCER DRUG DES, V6, P1; Bailly C, 1996, ANTI-CANCER DRUG DES, V11, P611; CAPRANICO G, 1990, NUCLEIC ACIDS RES, V18, P6611, DOI 10.1093/nar/18.22.6611; CAPRANICO G, 1994, J MOL BIOL, V235, P1218, DOI 10.1006/jmbi.1994.1075; CAPRANICO G, 1997, TRENDS PHARMACOL SCI, V18, P303; CHEN KX, 1988, NUCLEIC ACIDS RES, V16, P3061, DOI 10.1093/nar/16.7.3061; Cornarotti M, 1996, MOL PHARMACOL, V50, P1463; DEISABELLA P, 1995, NUCLEIC ACIDS RES, V23, P223, DOI 10.1093/nar/23.2.223; DEISABELLA P, 1990, MOL PHARMACOL, V37, P11; DEISABELLA P, 1995, MOL PHARMACOL, V48, P30; DEWAR MJS, 1985, J AM CHEM SOC, V107, P3902, DOI 10.1021/ja00299a024; FREUDENREICH CH, 1994, P NATL ACAD SCI USA, V91, P11007, DOI 10.1073/pnas.91.23.11007; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; Hehre W. J., 1986, AB INITIO MOL ORBITA; JAXEL C, 1991, J BIOL CHEM, V266, P20418; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; Macdonald T. L., 1991, DNA TOPOISOMERASES C, P199; MARTIN YC, 1990, REV COMPUTATIONAL CH, P213; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; Palumbo M., 1998, ADV DNA SEQUENCE SPE, V3; POMMIER Y, 1991, NUCLEIC ACIDS RES, V19, P5973, DOI 10.1093/nar/19.21.5973; POMMIER Y, 1995, P NATL ACAD SCI USA, V92, P8861, DOI 10.1073/pnas.92.19.8861; POMMIER Y, 1991, J MOL BIOL, V222, P909, DOI 10.1016/0022-2836(91)90585-T; Pommier Yves, 1997, P153; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; WUNZ TP, 1990, J MED CHEM, V33, P1549, DOI 10.1021/jm00168a005; Zagotto G, 1998, BIOORG MED CHEM LETT, V8, P121, DOI 10.1016/S0960-894X(97)10207-4	29	28	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					12732	12739		10.1074/jbc.273.21.12732	http://dx.doi.org/10.1074/jbc.273.21.12732			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582297	hybrid			2022-12-27	WOS:000073768500008
J	Igarashi, M; Finch, PW; Aaronson, SA				Igarashi, M; Finch, PW; Aaronson, SA			Characterization of recombinant human fibroblast growth factor (FGF)-10 reveals functional similarities with keratinocyte growth factor (FGF-7)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING SPECIFICITY; SERUM-FREE MEDIUM; FACTOR RECEPTOR; FACTOR FAMILY; FACTOR EXPRESSION; ADIPOSE DIFFERENTIATION; DEVELOPMENT SUGGESTS; LARGE INDUCTION; CELL-LINE; HEPARIN	A newly identified member of the fibroblast growth factor (FGF) family, designated FGF-10, is expressed during development and preferentially in adult lung. The predicted FGF-10 protein is most related to keratinocyte growth factor (KGF, or FGF-7), The latter is unique among FGFs in that it binds and signals only through the FGF receptor (FGFR2b) isoform KGF receptor (KGFR) expressed specifically by epithelial cells. In order to examine the biological and biochemical properties of human FGF-10, we isolated the cDNA and expressed its encoded protein in bacteria. The recombinant protein (rFGF-10) was a potent mitogen for Balb/MK: mouse epidermal keratinocytes with activity detectable at 0.1 nM and maximal at around 5 nM. Within this concentration range, FGF-10 did not stimulate DNA synthesis in NIH/3T3 mouse fibroblasts. rFGF-10 bound the KGFR with high affinity comparable to that of KGF, and did not bind detectably to either the FGFR1c (Flg) or FGFR2c (Bek) receptor isoforms, The mitogenic activity of FGF-10 could be distinguished from that of KGF by its different sensitivity to heparin and lack of neutralization by a KGF monoclonal antibody. These results indicate that FGF-10 and KGF hare similar receptor binding properties and target cell specificities, but are differentially regulated by components of the extracellular matrix.	CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Aaronson, SA (corresponding author), CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, Box 1130,1 Gustave L Levy Pl, New York, NY 10029 USA.				NIDDK NIH HHS [DK47102] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047102] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AARONSON SA, 1991, ANN NY ACAD SCI, V638, P62, DOI 10.1111/j.1749-6632.1991.tb49018.x; ANDERSON KJ, 1988, NATURE, V332, P360, DOI 10.1038/332360a0; BAIRD A, 1991, CANCER CELL-MON REV, V3, P239; Beer HD, 1997, ONCOGENE, V15, P2211, DOI 10.1038/sj.onc.1201383; BOTTARO DP, 1993, J BIOL CHEM, V268, P9180; BRAUCHLE M, 1994, ONCOGENE, V9, P3199; BROAD TE, 1983, EUR J BIOCHEM, V135, P33, DOI 10.1111/j.1432-1033.1983.tb07614.x; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHEDID M, 1994, J BIOL CHEM, V269, P10753; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; COULIER F, 1991, ANN NY ACAD SCI, V638, P53, DOI 10.1111/j.1749-6632.1991.tb49017.x; DELL KR, 1992, J BIOL CHEM, V267, P21225; DICKSON C, 1991, ANN NY ACAD SCI, V638, P18, DOI 10.1111/j.1749-6632.1991.tb49014.x; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; Emoto H, 1997, J BIOL CHEM, V272, P23191, DOI 10.1074/jbc.272.37.23191; FINCH PW, 1995, DEV DYNAM, V203, P223, DOI 10.1002/aja.1002030210; Finch PW, 1997, AM J PATHOL, V151, P1619; Finch PW, 1996, GASTROENTEROLOGY, V110, P441, DOI 10.1053/gast.1996.v110.pm8566591; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GOLDFARB M, 1991, ANN NY ACAD SCI, V638, P38, DOI 10.1111/j.1749-6632.1991.tb49016.x; GOSPODAROWICZ D, 1990, J CELL PHYSIOL, V142, P325, DOI 10.1002/jcp.1041420215; Guo LF, 1996, GENE DEV, V10, P165, DOI 10.1101/gad.10.2.165; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; HUANG XQ, 1991, ADV APPL MATH, V12, P337, DOI 10.1016/0196-8858(91)90017-D; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; JEYE M, 1992, BIOCHB IOPHYS ACTA, V1135, P185; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; Klagsbrun M, 1990, CURR OPIN CELL BIOL, V2, P857, DOI 10.1016/0955-0674(90)90084-R; LAROCHELLE WJ, 1995, J CELL BIOL, V129, P357, DOI 10.1083/jcb.129.2.357; LATHROP B, 1985, J CELL BIOL, V100, P1540, DOI 10.1083/jcb.100.5.1540; LINKHART TA, 1981, DEV BIOL, V86, P19, DOI 10.1016/0012-1606(81)90311-0; MARCHESE C, 1995, J EXP MED, V182, P1369, DOI 10.1084/jem.182.5.1369; MASON IJ, 1994, MECH DEVELOP, V45, P15, DOI 10.1016/0925-4773(94)90050-7; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MORRISON RS, 1986, P NATL ACAD SCI USA, V83, P7537, DOI 10.1073/pnas.83.19.7537; Ohuchi H, 1997, DEVELOPMENT, V124, P2235; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; REICHSLOTKY R, 1994, J BIOL CHEM, V269, P32279; RON D, 1993, J BIOL CHEM, V268, P2984; RON D, 1993, J BIOL CHEM, V268, P5388; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; SERRERO G, 1982, ANAL BIOCHEM, V120, P351, DOI 10.1016/0003-2697(82)90357-8; Smallwood PM, 1996, P NATL ACAD SCI USA, V93, P9850, DOI 10.1073/pnas.93.18.9850; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Tagashira S, 1997, GENE, V197, P399, DOI 10.1016/S0378-1119(97)00187-X; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; TOGARI A, 1985, J NEUROSCI, V5, P307; WAGNER JA, 1986, J CELL BIOL, V103, P1363, DOI 10.1083/jcb.103.4.1363; WALICKE P, 1986, P NATL ACAD SCI USA, V83, P3012, DOI 10.1073/pnas.83.9.3012; WEISSMAN BE, 1983, CELL, V32, P599, DOI 10.1016/0092-8674(83)90479-8; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918; YOSHIDA T, 1991, ANN NY ACAD SCI, V638, P27, DOI 10.1111/j.1749-6632.1991.tb49015.x; ZIMMER Y, 1993, J BIOL CHEM, V268, P7899	61	264	304	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					13230	13235		10.1074/jbc.273.21.13230	http://dx.doi.org/10.1074/jbc.273.21.13230			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582367	hybrid			2022-12-27	WOS:000073768500078
J	Tsuda, M; Matozaki, T; Fukunaga, K; Fujioka, Y; Imamoto, A; Noguchi, T; Takada, T; Yamao, T; Takeda, H; Ochi, F; Yamamoto, T; Kasuga, M				Tsuda, M; Matozaki, T; Fukunaga, K; Fujioka, Y; Imamoto, A; Noguchi, T; Takada, T; Yamao, T; Takeda, H; Ochi, F; Yamamoto, T; Kasuga, M			Integrin-mediated tyrosine phosphorylation of SHPS-1 and its association with SHP-2 - Roles of Fak and Src family kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; FOCAL ADHESION KINASE; SIGNAL-TRANSDUCTION PATHWAYS; INSULIN-RECEPTOR SUBSTRATE-1; CELL-ADHESION; EXTRACELLULAR-MATRIX; HOMOLOGY-2 DOMAINS; SYP PHOSPHATASE; PROTEIN; SH-PTP2	SHPS-1 is a receptor-like glycoprotein that undergoes tyrosine phosphorylation and binds SHP-2, an Src homology 2 domain containing protein tyrosine phosphatase, in response to various mitogens. Cell adhesion to extracellular matrix proteins such as fibronectin and laminin also induced the tyrosine phosphorylation of SHPS-1 and its association with SHP-2. These responses were markedly reduced in cells overexpressing the Csk kinase or in cells that lack focal adhesion kinase or the Src family kinases Src or Fyn. However, unlike Src, focal adhesion kinase did not catalyze phosphorylation of the cytoplasmic domain of SHPS-1 in vitro. Overexpression of a catalytically inactive SHP-2 markedly inhibited activation of mitogen-activated protein (MAP) kinase in response to fibronectin stimulation without affecting the extent of tyrosine phosphorylation of focal adhesion kinase or its interaction with the docking protein Grb2. Overexpression of wild-type SHPS-1 did not enhance fibronectin-induced activation of MAP kinase, These results indicate that the binding of integrins to the extracellular matrix induces tyrosine phosphorylation of SHPS-1 and its association with SHP-2, and that such phosphorylation of SHPS-1 requires both focal adhesion kinase and an Src family kinase, In addition to its role in receptor tyrosine kinase-mediated MAP kinase activation, SHP-2 may play an important role, partly through its interaction with SHPS-1, in the activation of MAP kinase in response to the engagement of integrins by the extracellular matrix.	Kobe Univ, Sch Med, Dept Internal Med 2, Chuo Ku, Kobe, Hyogo 650, Japan; Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA; Univ Chicago, Ctr Mol Oncol, Chicago, IL 60637 USA; Univ Tokyo, Inst Med Sci, Dept Oncol, Minato Ku, Tokyo 108, Japan	Kobe University; University of Chicago; University of Chicago; University of Tokyo	Matozaki, T (corresponding author), Kobe Univ, Sch Med, Dept Internal Med 2, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 650, Japan.	matozaki@med.kobe-u.ac.jp			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD025326, R01HD024875, R01HD025326] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 25326, HD 24875] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Adachi M, 1996, CELL, V85, P15; Allard JD, 1996, DEVELOPMENT, V122, P1137; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Bohmer RM, 1996, MOL BIOL CELL, V7, P101; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cary LA, 1996, J CELL SCI, V109, P1787; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; HAMSAKI K, 1996, BIOCHEM BIOPH RES CO, V222, P338; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Matozaki T, 1996, CELL SIGNAL, V8, P13, DOI 10.1016/0898-6568(95)02015-2; MATOZAKI T, 1995, ADV PROTEIN PHOSPHAT, V9, P319; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MOTOZAKI T, 1994, BIOCHEM BIOPH RES CO, V204, P874; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Noguchi T, 1996, J BIOL CHEM, V271, P27652, DOI 10.1074/jbc.271.44.27652; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; Ohnishi H, 1996, J BIOL CHEM, V271, P25569, DOI 10.1074/jbc.271.41.25569; OKADA M, 1991, J BIOL CHEM, V266, P24249; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; Sano S, 1997, FEBS LETT, V411, P327, DOI 10.1016/S0014-5793(97)00724-2; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1993, CELL BIOL, V9, P258; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; TAUCHI T, 1995, J BIOL CHEM, V270, P5631, DOI 10.1074/jbc.270.10.5631; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Yamao T, 1997, BIOCHEM BIOPH RES CO, V231, P61, DOI 10.1006/bbrc.1996.6047; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664	57	132	132	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					13223	13229		10.1074/jbc.273.21.13223	http://dx.doi.org/10.1074/jbc.273.21.13223			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582366	hybrid			2022-12-27	WOS:000073768500077
J	Canete-Soler, R; Schwartz, ML; Hua, Y; Schlaepfer, WW				Canete-Soler, R; Schwartz, ML; Hua, Y; Schlaepfer, WW			Stability determinants are localized to the 3 '-untranslated region and 3 '-coding region of the neurofilament light subunit mRNA using a tetracycline-inducible promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; 3' UNTRANSLATED REGION; GENE-EXPRESSION; TRANSGENIC MICE; MAMMALIAN-CELLS; INDUCED STABILIZATION; UP-REGULATION; PC12 CELLS; MOUSE; DESTABILIZATION	The tetracycline-responsive expression system of Bujard was used to compare rates of decay of wild-type and mutant neurofilament (NF) Light subunit (NF-L) mRNAs, Optimal conditions for activation and inactivation of the target transgene were determined using a luciferase reporter gene. Analyses of mRNA stability were thereupon conducted on cells that were doubly transfected with transactivator and inducible target genes and derived from pooled clones of transfected cells. Rates of mRNA decay were compared upon inactivation of the transgenes after high levels of mRNA had been induced. Deletion of the 445-nucleotide (nt) 3'-untranslated region (3'-UTR) (L/+++-) or 527 nt of the 3'-coding region (3'-CR) (L/++-+) increased the stability of NF-L mRNA compared with the full-length (L/++++) transcript in neuronal (N2a and P19 cells) and non-neuronal (L cells) lines. Deletion of both the 3'-UTR and 3'-CR (L/++--) led to a further stabilization of the transcript. A major stability determinant was then localized to a 68-nt sequence that forms the junction between the 3'-CR and 3'-UTR of NF-L and is the binding site of a unique ribonucleoprotein complex (Canete-Soler, R., Schwartz, M. L., Hua, Y., and Schlaepfer, W. W. (1998) J. Biol. Chem. 273, 12655-12661). The studies establish a novel system for mapping determinants of mRNA stability and have applied the system to localize determinants that regulate the stability of the NF-L mRNA.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Div Neuropathol, Philadelphia, PA 19104 USA	University of Pennsylvania	Canete-Soler, R (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, Div Neuropathol, 435 Johnson Pavil, Philadelphia, PA 19104 USA.	racansol@mail.med.upenn.edu						Baron U, 1997, NUCLEIC ACIDS RES, V25, P2723, DOI 10.1093/nar/25.14.2723; BRUCE J, 1993, MOL BRAIN RES, V17, P269, DOI 10.1016/0169-328X(93)90011-D; Canete-Soler R, 1998, J BIOL CHEM, V273, P12655, DOI 10.1074/jbc.273.20.12655; COTE F, 1993, CELL, V73, P35, DOI 10.1016/0092-8674(93)90158-M; CZYZYKKRZESKA MF, 1994, J BIOL CHEM, V269, P760; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GOSSEN M, 1993, TRENDS BIOCHEM SCI, V18, P471, DOI 10.1016/0968-0004(93)90009-C; GOSSEN M, 1995, BIOTECHNIQUES, V19, P213; HADCOCK JR, 1989, J BIOL CHEM, V264, P19928; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; NISHIZAWA K, 1994, BIOCHEM BIOPH RES CO, V200, P789, DOI 10.1006/bbrc.1994.1520; NISHIZAWA K, 1994, BIOCHEM BIOPH RES CO, V205, P1380, DOI 10.1006/bbrc.1994.2818; PernasAlonso R, 1996, MOL BRAIN RES, V38, P267, DOI 10.1016/0169-328X(95)00344-R; PERRONEBIZZOZERO NI, 1993, J CELL BIOL, V120, P1263, DOI 10.1083/jcb.120.5.1263; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SCHWARTZ ML, 1992, J BIOL CHEM, V267, P24596; SCHWARTZ ML, 1995, J BIOL CHEM, V270, P26364, DOI 10.1074/jbc.270.44.26364; SCHWARTZ ML, 1994, MOL BRAIN RES, V27, P215, DOI 10.1016/0169-328X(94)90003-5; SHNEIDMAN PS, 1992, MOL BRAIN RES, V13, P127, DOI 10.1016/0169-328X(92)90052-D; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; TU PH, 1995, J CELL BIOL, V129, P1629, DOI 10.1083/jcb.129.6.1629; WANG XM, 1995, MOL CELL BIOL, V15, P1769; WEISS IM, 1994, MOL CELL BIOL, V14, P8123, DOI 10.1128/MCB.14.12.8123; XU ZS, 1993, CELL, V73, P23, DOI 10.1016/0092-8674(93)90157-L	28	36	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12650	12654		10.1074/jbc.273.20.12650	http://dx.doi.org/10.1074/jbc.273.20.12650			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575227	hybrid			2022-12-27	WOS:000073629800092
J	Hettmann, T; Schmidt, CL; Anemuller, S; Zahringer, U; Moll, H; Petersen, A; Schafer, G				Hettmann, T; Schmidt, CL; Anemuller, S; Zahringer, U; Moll, H; Petersen, A; Schafer, G			Cytochrome b(558/566) from the archaeon Sulfolobus acidocaldarius	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARCHAEBACTERIAL TERMINAL OXIDASE; PLASMA-MEMBRANE; PROTEINS; PURIFICATION; GENES; ELECTROPHORESIS; EVOLUTION; CLONING; SYSTEM	In this study we re-examined the inducible cytochrome b(558/566) from the archaeon Sulfolobus acidocaldarius (DSM 639), formerly thought to be a component of a terminal oxidase (Becker, M., and Schafer, G. (1991) FEBS Lett, 291, 331-335), An improved purification method increased the yield of the protein and allowed more detailed investigations. Its molecular mass and heme content have been found to be 64,210 Da and 1 mol of heme/mol of protein, respectively. It is only detectable in cells grown at low oxygen tensions. The composition of the growth medium also exerts significant influence on the cytochrome b(558/566) content of S. acidocaldarius membranes. The cytochrome exhibits an extremely high redox potential of +400 mV and shows no CO reactivity; a ligation other than a His/His-coordination of axial ligands appears likely. It turned out 60 be highly glycosylated (more than 20% of its molecular mass are sugar residues) and is probably exposed to the outer surface of the plasma membrane. The sugar moiety consists of several O-glycosidically Linked mannoses and at least one N-glycosidically linked hexasaccharide comprising two glucoses, two mannoses, and two N-acetyl-glucosamines. The gene of the cytochrome (cbsA) has been sequenced, revealing an interesting predicted secondary structure with two putative alpha-helical membrane anchors flanking the majority of a mainly beta-pleated sheet structure containing unusually high amounts of serine and threonine, A second gene (cbsB) was found to be cotranscribed. The latter displays extreme hydrophobicity and is thought to form a functional unit with cytochrome b(558/566) in vivo, although it did not copurify with the latter. Sequence comparisons show no similarity to any entry in data banks indicating that this cytochrome is indeed a novel kind of b-type hemoprotein, A cytochrome c. analogous function in the pseudoperiplasmic space of S. acidocaldarius is discussed.	Med Univ Lubeck, Inst Biochem, D-23538 Lubeck, Germany; Forschungsinst Borstel, Zentrum Med & Biowissensch, D-23845 Borstel, Germany	University of Lubeck; Forschungszentrum Borstel	Schafer, G (corresponding author), Med Univ Lubeck, Inst Biochem, Ratzeburger Allee 160, D-23538 Lubeck, Germany.	schaefer@physik.mu-luebeck.de						ANEMULLER S, 1990, EUR J BIOCHEM, V191, P297, DOI 10.1111/j.1432-1033.1990.tb19123.x; BECKER M, 1991, FEBS LETT, V291, P331, DOI 10.1016/0014-5793(91)81314-X; BECKER M, 1992, THESIS MED U LUBECK; BROCK TD, 1972, ARCH MIKROBIOL, V84, P54, DOI 10.1007/BF00408082; CASTRESANA J, 1995, J MOL BIOL, V250, P202, DOI 10.1006/jmbi.1995.0371; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; Dutton P L, 1978, Methods Enzymol, V54, P411; Faguy DM, 1996, J BACTERIOL, V178, P902, DOI 10.1128/jb.178.3.902-905.1996; Gleissner M, 1997, J BIOL CHEM, V272, P8417, DOI 10.1074/jbc.272.13.8417; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; Janssen S, 1997, J BACTERIOL, V179, P5560, DOI 10.1128/jb.179.17.5560-5569.1997; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE YC, 1993, GLYCOBIOLOGY PRACTIC, P127; LEMBERG R, 1973, CYTOCHROMES, P122; Lesuisse E, 1996, J BIOL CHEM, V271, P13578, DOI 10.1074/jbc.271.23.13578; LIN XL, 1990, J BIOL CHEM, V265, P1490; LUBBEN M, 1992, EMBO J, V11, P805, DOI 10.1002/j.1460-2075.1992.tb05117.x; LUBBEN M, 1994, EUR J BIOCHEM, V224, P151, DOI 10.1111/j.1432-1033.1994.tb20006.x; MANNHEIM B, 1993, DIG SYSTEM USERS GUI; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; MARTINEZ SE, 1994, STRUCTURE, V2, P95, DOI 10.1016/S0969-2126(00)00012-5; MATHEWS FS, 1985, PROG BIOPHYS MOL BIO, V45, P1, DOI 10.1016/0079-6107(85)90004-5; Michel H., 1980, ELECTRON MICROS, P27; MOLL R, 1991, EUR J BIOCHEM, V201, P593, DOI 10.1111/j.1432-1033.1991.tb16319.x; Moll R., 1993, Biological Chemistry Hoppe-Seyler, V374, P746; MOURA EG, 1991, ACTA ENDOCRINOL-COP, V124, P107, DOI 10.1530/acta.0.1240107; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Purschke WG, 1996, ANAL BIOCHEM, V238, P98, DOI 10.1006/abio.1996.0259; Purschke WG, 1997, J BACTERIOL, V179, P1344, DOI 10.1128/jb.179.4.1344-1353.1997; Sambrook S, 1989, MOL CLONING LAB MANU; SAWARDEKER JS, 1965, ANAL CHEM, V37, P1602, DOI 10.1021/ac60231a048; Schafer G, 1996, BBA-BIOENERGETICS, V1277, P163, DOI 10.1016/S0005-2728(96)00104-1; SCHAFER G, 1994, SYST APPL MICROBIOL, V16, P544; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schmidt CL, 1996, FEBS LETT, V388, P43, DOI 10.1016/0014-5793(96)00511-X; SHIMOZAWA O, 1993, J BIOL CHEM, V268, P21399; VanSpanning RJM, 1995, J BIOENERG BIOMEMBR, V27, P499, DOI 10.1007/BF02110190; Wallach TM, 1997, BIOCHEM J, V321, P583, DOI 10.1042/bj3210583; WARDI AH, 1972, ANAL BIOCHEM, V49, P607, DOI 10.1016/0003-2697(72)90472-1; WILLIAMS JN, 1964, ARCH BIOCHEM BIOPHYS, V107, P537, DOI 10.1016/0003-9861(64)90313-3	41	39	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12032	12040		10.1074/jbc.273.20.12032	http://dx.doi.org/10.1074/jbc.273.20.12032			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575144	hybrid			2022-12-27	WOS:000073629800009
J	Ikeda, Y; Noguchi, T				Ikeda, Y; Noguchi, T			Allosteric regulation of pyruvate kinase M-2 isozyme involves a cysteine residue in the intersubunit contact	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYL-TRANSPEPTIDASE; SITE-DIRECTED MUTAGENESIS; M-GENE; RAT; TRANSITION; EFFICIENT; SUBUNIT; MUTANT; RNA	Pyruvate kinase M-2 isozyme mutants with amino acid substitutions in the subunit interface were prepared and characterized. The substitutions were made in the allosteric M-2 isozyme by the corresponding residues of the nonallosteric M-1 isozyme to identify the residue involved in the allosteric effects. The replacement of Cys-423 by Leu led to substantial loss of both homotropic and heterotropic allosteric effects while the substitutions at Phe-389, Arg-398, Ala-401, Pro-402, Thr-408, and Ile-427 did not. The altered kinetic properties of the Cys-423-substituted mutant resulted from the shift of the allosteric transition toward the active R-state since the mutant exhibits the allosteric properties in the presence of an allosteric inhibitor, L-phenylalanine, The inverse correlation between the hydrophobicity of residue 423 and the extent of stabilization of the R-state was found by analysis of mutants with un-ionizable amino acids at position 423, Furthermore, the modification of Cys-423 with methyl methanethiosulfonate led to a shift of the allosteric transition toward the R-state, probably the result of increased hydrophobicity of the residue. These results suggest that Cys-423 is involved in the allosteric regulation of the enzyme through hydrophobic interactions.	Fukui Med Univ, Dept Biochem, Matsuoka, Fukui 9101193, Japan	University of Fukui	Noguchi, T (corresponding author), Fukui Med Univ, Dept Biochem, 23-3 Shimoaizuki, Matsuoka, Fukui 9101193, Japan.							ASHIKARI Y, 1985, J BIOCHEM-TOKYO, V97, P517, DOI 10.1093/oxfordjournals.jbchem.a135086; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLLINS RA, 1995, BIOCHEM J, V310, P117, DOI 10.1042/bj3100117; COLLINS RA, 1992, BIOCHEM SOC T, V21, pS63; CONSLER TG, 1989, BIOCHEMISTRY-US, V28, P8756, DOI 10.1021/bi00448a012; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GARDENAS JM, 1982, METHOD ENZYMOL, V90, P140; GARDENAS JM, 1975, ISOZYMES, V1, P523; IKEDA Y, 1995, P NATL ACAD SCI USA, V92, P126, DOI 10.1073/pnas.92.1.126; IKEDA Y, 1995, J BIOL CHEM, V270, P12471, DOI 10.1074/jbc.270.21.12471; IKEDA Y, 1995, J BIOL CHEM, V270, P22223, DOI 10.1074/jbc.270.38.22223; Ikeda Y, 1997, J BIOL CHEM, V272, P20495, DOI 10.1074/jbc.272.33.20495; IMAMURA K, 1982, METHOD ENZYMOL, V90, P150; IMAMURA K, 1986, MARKERS HUMAN NEUROE, P191; KAYNE FJ, 1972, BIOCHEMISTRY-US, V11, P4415, DOI 10.1021/bi00773a031; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN TM, 1994, BIOCHEMISTRY-US, V33, P6301, DOI 10.1021/bi00186a033; LONBERG N, 1983, P NATL ACAD SCI-BIOL, V80, P3661, DOI 10.1073/pnas.80.12.3661; Mattevi A, 1996, FEBS LETT, V389, P15, DOI 10.1016/0014-5793(96)00462-0; MATTEVI A, 1995, STRUCTURE, V3, P729, DOI 10.1016/S0969-2126(01)00207-6; MCNALLY T, 1990, BIOCHEM SOC T, V18, P258, DOI 10.1042/bst0180258; MUIRHEAD H, 1986, EMBO J, V5, P475, DOI 10.1002/j.1460-2075.1986.tb04236.x; MUIRHEAD H, 1990, BIOCHEM SOC T, V18, P193, DOI 10.1042/bst0180193; NOGUCHI T, 1987, J BIOL CHEM, V262, P14366; NOGUCHI T, 1986, J BIOL CHEM, V261, P3807; NOZAKI Y, 1971, J BIOL CHEM, V246, P2211; PIWNICAWORMS H, 1987, CURRENT PROTOCOLS MO; ROBERTS DD, 1986, BIOCHEMISTRY-US, V25, P5595, DOI 10.1021/bi00367a038; SMITH DJ, 1975, BIOCHEMISTRY-US, V14, P766, DOI 10.1021/bi00675a019; TAKENAKA M, 1991, EUR J BIOCHEM, V198, P101, DOI 10.1111/j.1432-1033.1991.tb15991.x; TAKENAKA M, 1989, J BIOL CHEM, V264, P2363; WALKER D, 1992, J MOL BIOL, V228, P265, DOI 10.1016/0022-2836(92)90505-E	33	48	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12227	12233		10.1074/jbc.273.20.12227	http://dx.doi.org/10.1074/jbc.273.20.12227			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575171	hybrid			2022-12-27	WOS:000073629800036
J	Keightley, JA; Sanders, D; Todaro, TR; Pastuszyn, A; Fee, JA				Keightley, JA; Sanders, D; Todaro, TR; Pastuszyn, A; Fee, JA			Cloning and expression in Escherichia coli of the cytochrome c(552) gene from Thermus thermophilus HB8 - Evidence for genetic linkage to an ATP-binding cassette protein and initial characterization of the cycA gene products	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TYPE CYTOCHROMES; RHODOBACTER-SPHAEROIDES CYTOCHROME-C2; AMINO-ACID SEQUENCE; NUCLEOTIDE-SEQUENCE; PARACOCCUS-DENITRIFICANS; HYDROGENOBACTER-THERMOPHILUS; BRADYRHIZOBIUM-JAPONICUM; RESPIRATORY PROTEINS; MOLECULAR-CLONING; EUGLENA-GRACILIS	We report sequence of Thermus thermophilus HB8 DNA containing the gene (cycA) for cytochrome c(552) and a gene (cycB) encoding a protein homologous with one subunit of an ATP-binding cassette transporter. The cycA gene encodes a 17-residue N-terminal signal peptide with following amino acid sequence identical to that reported by (Titani, K., Ericsson, L. H., Hon-nami, K., and Miyazawa, T. (1985) Biochem. Biophys, Res. Commun. 128, 781-787), A modified cycA was placed under control of the T7 promoter and expressed in Escherichia coli, Protein identical to that predicted from the gene sequence was found in two heme C-containing fractions. Fraction rC(552), characterized by an alpha-band at 552 nm, contains similar to 60-70% of a protein highly similar to native cytochrome c(552) and similar to 30-40% of a protein that contains a modified heme, Cytochrome rC(552) is monomeric and is an excellent substrate for cytochrome ba(3). Cytochrome rC(557) is characterized by an alpha-band at 557 nm, contains similar to 90% heme C and similar to 10% of non-C heme, exists primarily as a homodimer, and is essentially inactive as a substrate for cytochrome ba(3), We suggest that rC(557) is a "conformational isomer" of rC(552) having non-native, axial ligands to the heme iron and an "incorrect" protein fold that is stabilized by homodimer formation.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Los Alamos Natl Lab, Los Alamos, NM 87545 USA; Univ New Mexico, Dept Biochem & Mol Biol, Albuquerque, NM 87131 USA; Univ Calif San Diego, Prot Chem Lab, La Jolla, CA 92093 USA	University of California System; University of California San Diego; United States Department of Energy (DOE); Los Alamos National Laboratory; University of New Mexico; University of California System; University of California San Diego	Fee, JA (corresponding author), Univ Calif San Diego, Dept Biol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	jfee@ucsd.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR007273] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035342] Funding Source: NIH RePORTER; NCRR NIH HHS [RR07273] Funding Source: Medline; NIGMS NIH HHS [GM35342] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI H, 1991, FEBS LETT, V280, P351, DOI 10.1016/0014-5793(91)80329-2; ASAKURA T, 1974, J BIOL CHEM, V249, P7087; BARKER PD, 1993, P NATL ACAD SCI USA, V90, P6542, DOI 10.1073/pnas.90.14.6542; BARKER PD, 1995, BIOCHEMISTRY-US, V34, P15191, DOI 10.1021/bi00046a027; BECKMAN DL, 1992, GENE DEV, V6, P268, DOI 10.1101/gad.6.2.268; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; BERTANI G, 1951, J BACTERIOL, V62, P293, DOI 10.1128/JB.62.3.293-300.1951; BRANDNER JP, 1991, J BACTERIOL, V173, P3958, DOI 10.1128/jb.173.13.3958-3965.1991; BRYNGELSON JD, 1995, PROTEINS, V21, P167, DOI 10.1002/prot.340210302; CAFFREY M, 1992, ARCH BIOCHEM BIOPHYS, V292, P419, DOI 10.1016/0003-9861(92)90011-K; CROFT JE, 1987, MOL GEN GENET, V210, P490, DOI 10.1007/BF00327202; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DONOHUE TJ, 1986, J BACTERIOL, V168, P962, DOI 10.1128/jb.168.2.962-972.1986; DOWNER NW, 1976, BIOCHEMISTRY-US, V15, P2930, DOI 10.1021/bi00658a036; FATH MJ, 1993, MICROBIOL REV, V57, P995, DOI 10.1128/MMBR.57.4.995-1017.1993; FEE JA, 1988, ANN NY ACAD SCI, V550, P33, DOI 10.1111/j.1749-6632.1988.tb35319.x; FEE JA, 1986, BIOCHIM BIOPHYS ACTA, V853, P153, DOI 10.1016/0304-4173(86)90009-1; FRUSTACI JM, 1992, J BACTERIOL, V174, P4223, DOI 10.1128/JB.174.13.4223-4229.1992; Gabriel, 1971, METHOD ENZYMOL, V22, P565, DOI 10.1016/0076-6879(71)22041-3; GARRARD WT, 1972, J BIOL CHEM, V247, P5935; Gouterman M., 1978, PORPHYRINS, P1, DOI DOI 10.1016/B978-0-12-220103-5.50008-8; GRIBSKOV M, 1988, COMPUT APPL BIOSCI, V4, P61; GRINSTEIN M, 1947, J BIOL CHEM, V167, P515; GRISSHAMMER R, 1991, BIOCHIM BIOPHYS ACTA, V1088, P183, DOI 10.1016/0167-4781(91)90053-O; Grove J, 1996, MOL GEN GENET, V252, P332; HARTMANN RK, 1987, BIOCHIMIE, V69, P1097, DOI 10.1016/0300-9084(87)90009-5; HARTMANN RK, 1991, J BACTERIOL, V173, P2681, DOI 10.1128/jb.173.8.2681-2690.1991; HONNAMI K, 1977, J BIOCHEM, V82, P769, DOI 10.1093/oxfordjournals.jbchem.a131753; HONNAMI K, 1980, EUR J BIOCHEM, V110, P217, DOI 10.1111/j.1432-1033.1980.tb04858.x; Kai K, 1997, J FERMENT BIOENG, V84, P190, DOI 10.1016/S0922-338X(97)82053-3; KEIGHTLEY JA, 1995, J BIOL CHEM, V270, P20345, DOI 10.1074/jbc.270.35.20345; KEIGHTLEY JA, 1993, THESIS U NEW MEXICO; Lang SE, 1996, J BACTERIOL, V178, P5279, DOI 10.1128/jb.178.17.5279-5290.1996; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; LORENCE RM, 1981, BIOCHEM BIOPH RES CO, V99, P591, DOI 10.1016/0006-291X(81)91786-1; Maniatis T., 1982, MOL CLONING; MASEDA H, 1995, FEMS MICROBIOL LETT, V128, P127, DOI 10.1111/j.1574-6968.1995.tb07511.x; MATHER MW, 1990, PLASMID, V24, P45, DOI 10.1016/0147-619X(90)90024-7; MATHER MW, 1993, METHOD ENZYMOL, V218, P695; MATHER MW, 1991, J BIOL CHEM, V266, P5025; MATHER MW, 1993, J BIOL CHEM, V268, P5395; MCEWAN AG, 1989, FEMS MICROBIOL LETT, V59, P253, DOI 10.1111/j.1574-6968.1989.tb03120.x; MILLER CG, 1987, ESCHERICHIA COLI SAL, P680; MUKAI K, 1989, EUR J BIOCHEM, V178, P649, DOI 10.1111/j.1432-1033.1989.tb14494.x; NEU HC, 1965, J BIOL CHEM, V240, P3685; PAGE MD, 1995, MOL MICROBIOL, V15, P307, DOI 10.1111/j.1365-2958.1995.tb02245.x; PAUL KG, 1950, ACTA CHEM SCAND, V4, P239, DOI 10.3891/acta.chem.scand.04-0239; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; PETTIGREW GW, 1975, BIOCHEM J, V147, P291, DOI 10.1042/bj1470291; PETTIGREW GW, 1987, CYTOCHROMES BIOL ASP; RAMSEIER TM, 1991, J BIOL CHEM, V266, P7793; SAMBONGI Y, 1994, FEBS LETT, V340, P65, DOI 10.1016/0014-5793(94)80174-6; SAMBONGI Y, 1994, FEBS LETT, V353, P235, DOI 10.1016/0014-5793(94)01053-6; SANBONGI Y, 1991, EUR J BIOCHEM, V198, P7, DOI 10.1111/j.1432-1033.1991.tb15979.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO S, 1988, BIOCHIM BIOPHYS ACTA, V950, P303, DOI 10.1016/0167-4781(88)90126-1; SELF SJ, 1990, BIOCHEM J, V265, P599, DOI 10.1042/bj2650599; SIMPSON RJ, 1976, J BIOL CHEM, V251, P1936; SIUZDAK G, 1994, P NATL ACAD SCI USA, V91, P11290, DOI 10.1073/pnas.91.24.11290; SOSNICK TR, 1994, NAT STRUCT BIOL, V1, P149, DOI 10.1038/nsb0394-149; Soulimane T, 1997, BIOCHEM BIOPH RES CO, V237, P572, DOI 10.1006/bbrc.1997.7041; SOULIMANE T, 1995, FEBS LETT, V368, P132, DOI 10.1016/0014-5793(95)00623-H; STRAKA JG, 1986, METHOD ENZYMOL, V123, P352; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUTHERLAND JC, 1972, J CHEM PHYS, V57, P76, DOI 10.1063/1.1678020; SUTHERLAND JC, 1971, J CHEM PHYS, V54, P2888, DOI 10.1063/1.1675269; TAKEMORI S, 1965, J BIOL CHEM, V240, P504; TANAKA Y, 1990, J BIOCHEM-TOKYO, V108, P7, DOI 10.1093/oxfordjournals.jbchem.a123165; Than ME, 1997, J MOL BIOL, V271, P629, DOI 10.1006/jmbi.1997.1181; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; THONYMEYER L, 1991, P NATL ACAD SCI USA, V88, P5001, DOI 10.1073/pnas.88.11.5001; ThonyMeyer L, 1997, MICROBIOL MOL BIOL R, V61, P337; TITANI K, 1985, BIOCHEM BIOPH RES CO, V128, P781, DOI 10.1016/0006-291X(85)90115-9; UBBINK M, 1992, J BACTERIOL, V174, P3707, DOI 10.1128/JB.174.11.3707-3714.1992; VANSPANNING RJM, 1990, J BACTERIOL, V172, P986, DOI 10.1128/jb.172.2.986-996.1990; VARGAS C, 1994, J BACTERIOL, V176, P4117, DOI 10.1128/JB.176.13.4117-4123.1994; VONHEIJNE G, 1989, FEBS LETT, V244, P439, DOI 10.1016/0014-5793(89)80579-4; VONWACHENFELDT C, 1990, FEBS LETT, V270, P147, DOI 10.1016/0014-5793(90)81255-M; VONWACHENFELDT C, 1990, J BIOL CHEM, V265, P13939; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; YOSHIDA T, 1984, J BIOL CHEM, V259, P1031; YOSHIDA T, 1984, J BIOL CHEM, V259, P112; ZERNER M, 1966, THEOR CHIM ACTA, V6, P363, DOI 10.1007/BF00528464	83	34	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12006	12016		10.1074/jbc.273.20.12006	http://dx.doi.org/10.1074/jbc.273.20.12006			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575141	hybrid			2022-12-27	WOS:000073629800006
J	Zhou, JJ; Theodoulou, FL; Muldin, I; Ingemarsson, B; Miller, AJ				Zhou, JJ; Theodoulou, FL; Muldin, I; Ingemarsson, B; Miller, AJ			Cloning and functional characterization of a Brassica napus transporter that is able to transport nitrate and histidine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLED OLIGOPEPTIDE TRANSPORTER; PEPTIDE TRANSPORTERS; XENOPUS-OOCYTES; ARABIDOPSIS; EXPRESSION; ROOTS; MEMBRANE; PROTEINS; BARLEY; GENE	A full-length cDNA for a membrane transporter was isolated from Brassica napus by its sequence homology to a previously cloned Arabidopsis low affinity nitrate transporter. The cDNA encodes a predicted protein of 589 amino acid residues with 12 putative transmembrane domains. The transporter belongs to a multigene family with members that have been identified in bacteria, fungi, plants, and animals and that are able to transport a range of different nitrogen-containing substrates, including amino acids, peptides, and nitrate. To identify the substrates of this plant gene, we have expressed the protein in Xenopus oocytes, The properties of the transporter are consistent with a proton cotransport mechanism for nitrate, and the voltage dependence of the K-m for nitrate was determined. The K-m for nitrate was shown to increase from 4 to 14 mM as the membrane voltage became more negative from -40 to -180 mV, Oocytes expressing the gene could accumulate internal nitrate to concentrations higher than those measured in water-injected controls. A range of different substrate molecules for the transporter was tested, but of these, histidine gave the largest currents, although the affinity was in the millimolar range. The pH dependence of the activity of the transporter was different for the substrates, with histidine transport favored at alkaline and nitrate at acid external pH, Kinetic analysis of the mechanism of histidine transport suggests a cotransport of protons and the neutral form of the amino acid, with the K, for histidine decreasing at more negative membrane voltages. This gene is the first member of this family of transporters for which the transport of two very different types of substrate, nitrate and histidine, has been demonstrated.	AFRC, Inst Arable Crops Res, Dept Biochem & Physiol, Rothamsted Expt Stn, Harpenden AL5 2JQ, Herts, England; Univ Stockholm, Dept Bot, S-10691 Stockholm, Sweden	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Rothamsted Research; Stockholm University	Miller, AJ (corresponding author), AFRC, Inst Arable Crops Res, Dept Biochem & Physiol, Rothamsted Expt Stn, Harpenden AL5 2JQ, Herts, England.	tony.miller@bbsrc.ac.uk	Miller, Anthony John/B-5139-2008	Miller, Anthony John/0000-0003-0572-7607; Theodoulou, Frederica/0000-0002-8306-0716				ATTALI B, 1993, NATURE, V365, P850, DOI 10.1038/365850a0; BARRACLOUGH PB, 1986, J AGR SCI, V106, P45, DOI 10.1017/S0021859600061712; Boorer KJ, 1996, J BIOL CHEM, V271, P25139, DOI 10.1074/jbc.271.41.25139; Boorer KJ, 1997, J BIOL CHEM, V272, P13040, DOI 10.1074/jbc.272.20.13040; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; FEI YJ, 1994, NATURE, V368, P563, DOI 10.1038/368563a0; FROMMER WB, 1994, FEBS LETT, V347, P185, DOI 10.1016/0014-5793(94)00533-8; Huang NC, 1996, PLANT CELL, V8, P2183, DOI 10.1105/tpc.8.12.2183; KOWDLEY GC, 1994, J GEN PHYSIOL, V103, P217, DOI 10.1085/jgp.103.2.217; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KUSANO K, 1982, J PHYSIOL-LONDON, V328, P143, DOI 10.1113/jphysiol.1982.sp014257; KWART M, 1993, PLANT J, V4, P993, DOI 10.1046/j.1365-313X.1993.04060993.x; Lauter FR, 1996, P NATL ACAD SCI USA, V93, P8139, DOI 10.1073/pnas.93.15.8139; Mackenzie B, 1996, J BIOL CHEM, V271, P5430, DOI 10.1074/jbc.271.10.5430; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MILLER AJ, 1996, METHODS CELL BIOL A, V49, P275; MULDIN I, 1995, PLANT PHYSIOL, V108, P1341; OHLEN E, 1995, PLANTA, V196, P485, DOI 10.1007/BF00203648; PARENT L, 1992, J MEMBRANE BIOL, V125, P9; PAULSEN IT, 1994, TRENDS BIOCHEM SCI, V19, P404, DOI 10.1016/0968-0004(94)90087-6; RENTSCH D, 1995, FEBS LETT, V370, P264, DOI 10.1016/0014-5793(95)00853-2; SCHOBERT C, 1987, PLANT CELL ENVIRON, V10, P493, DOI 10.1111/j.1365-3040.1987.tb01827.x; Schroeder Julian I., 1994, Methods (Orlando), V6, P70, DOI 10.1006/meth.1994.1009; SIDDIQI MY, 1990, PLANT PHYSIOL, V93, P1426, DOI 10.1104/pp.93.4.1426; SOLDAL T, 1978, PHYSIOL PLANTARUM, V43, P181, DOI 10.1111/j.1399-3054.1978.tb02561.x; Song W, 1996, PLANT PHYSIOL, V110, P171, DOI 10.1104/pp.110.1.171; STEINER HY, 1994, PLANT CELL, V6, P1289, DOI 10.1105/tpc.6.9.1289; STEINER HY, 1995, MOL MICROBIOL, V16, P825, DOI 10.1111/j.1365-2958.1995.tb02310.x; Trueman LJ, 1996, GENE, V175, P223, DOI 10.1016/0378-1119(96)00154-0; TSAY YF, 1993, CELL, V72, P705, DOI 10.1016/0092-8674(93)90399-B; TZOUNOPOULOS T, 1995, BIOPHYS J, V69, P904, DOI 10.1016/S0006-3495(95)79964-7; Wang RC, 1996, P NATL ACAD SCI USA, V93, P9297, DOI 10.1073/pnas.93.17.9297; Yamashita T, 1997, J BIOL CHEM, V272, P10205; Zhou JJ, 1997, J MEMBRANE BIOL, V159, P113, DOI 10.1007/s002329900275	34	118	133	1	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12017	12023		10.1074/jbc.273.20.12017	http://dx.doi.org/10.1074/jbc.273.20.12017			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575142	Green Published, hybrid			2022-12-27	WOS:000073629800007
J	Foretz, M; Carling, D; Guichard, C; Ferre, P; Foufelle, F				Foretz, M; Carling, D; Guichard, C; Ferre, P; Foufelle, F			AMP-activated protein kinase inhibits the glucose-activated expression of fatty acid synthase gene in rat hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WHITE ADIPOSE-TISSUE; LIPOGENIC ENZYME; OKADAIC ACID; PRIMARY CULTURE; MESSENGER-RNA; GAMMA-SUBUNIT; BETA-SUBUNIT; INSULIN; PHOSPHORYLATION; YEAST	Although it is now clearly established that a number of genes involved in glucose and lipid metabolism are up-regulated by high glucose concentrations in both liver and adipose tissue, the signaling pathway arising from glucose to the transcriptional machinery is still poorly understood. We have analyzed the regulation of fatty acid synthase gene expression by glucose in cultured rat hepatocytes. Glucose (25 mM) induces an activation of the transcription of the fatty acid synthase gene, and this effect is markedly reduced by incubation of the cells with okadaic acid, an inhibitor of protein phosphatases 1 and 2A. A similar reduction in glucose-activated fatty acid synthase gene expression is obtained by incubation with 5-amino-imidazolecarboxamide riboside, a cell-permeable activator of the AMP-activated protein kinase. Taken together, these results indicate that the glucose-induced expression of the fatty acid synthase gene involves a phosphorylation/dephosphorylation mechanism and suggest that the AMP-activated protein kinase plays an important role in this process. This is the first evidence that implicates the AMP-activated protein kinase in the regulation of gene expression. AMP-activated protein kinase is the mammalian analog of SNF1, a kinase involved in yeast in the transcriptional regulation of genes by glucose.	Hammersmith Hosp, Royal Postgrad Med Sch, Mol Med Grp, MRC,Clin Sci Ctr, London W12 0NN, England; Ctr Biomed Cordeliers, INSERM, U465, F-75270 Paris 06, France	Imperial College London; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite	Ferre, P (corresponding author), Ctr Biomed Cordeliers, INSERM, U465, 15 Rue Ecole Med, F-75270 Paris 06, France.		FORETZ, Marc/O-7334-2017; Carling, David/F-1943-2014; Ferré, Pascal/K-1250-2013	FORETZ, Marc/0000-0001-7017-9032; Carling, David/0000-0002-2316-1830; Ferré, Pascal/0000-0003-0115-7045; FOUFELLE, Fabienne/0000-0002-0752-622X				BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; Cadefau J, 1997, BIOCHEM J, V322, P745, DOI 10.1042/bj3220745; CARLING D, 1987, FEBS LETT, V223, P217, DOI 10.1016/0014-5793(87)80292-2; CARLING D, 1989, EUR J BIOCHEM, V186, P129, DOI 10.1111/j.1432-1033.1989.tb15186.x; CARLING D, 1994, J BIOL CHEM, V269, P11442; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; COUPE C, 1990, AM J PHYSIOL, V258, pE126, DOI 10.1152/ajpendo.1990.258.1.E126; Davies SP, 1995, FEBS LETT, V377, P421, DOI 10.1016/0014-5793(95)01368-7; DECAUX JF, 1989, J BIOL CHEM, V264, P11584; DeVit MJ, 1997, MOL BIOL CELL, V8, P1603, DOI 10.1091/mbc.8.8.1603; DOIRON B, 1994, J BIOL CHEM, V269, P10213; Doiron B, 1996, J BIOL CHEM, V271, P5321, DOI 10.1074/jbc.271.10.5321; DUGAIL I, 1992, BIOCHEM J, V281, P607, DOI 10.1042/bj2810607; Dyck JRB, 1996, J BIOL CHEM, V271, P17798, DOI 10.1074/jbc.271.30.17798; FERRE P, 1979, BIOCHEM J, V182, P593, DOI 10.1042/bj1820593; FOUFELLE F, 1992, J BIOL CHEM, V267, P20543; FOUFELLE F, 1994, EUR J BIOCHEM, V223, P893, DOI 10.1111/j.1432-1033.1994.tb19066.x; GANCEDO JM, 1992, EUR J BIOCHEM, V206, P297, DOI 10.1111/j.1432-1033.1992.tb16928.x; GARRISON JC, 1984, J BIOL CHEM, V259, P3283; Girard J, 1997, ANNU REV NUTR, V17, P325, DOI 10.1146/annurev.nutr.17.1.325; HARDIE DG, 1993, PROTEIN PHOSPHORYLAT, P87; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; IYNEDJIAN PB, 1989, J BIOL CHEM, V264, P21824; Jackson S P, 1992, Trends Cell Biol, V2, P104, DOI 10.1016/0962-8924(92)90014-E; KINLAW WB, 1986, J CLIN INVEST, V78, P1091, DOI 10.1172/JCI112665; LALLI E, 1994, J BIOL CHEM, V269, P17359; LEFRANCOISMARTINEZ AM, 1994, FASEB J, V8, P89, DOI 10.1096/fasebj.8.1.8299894; Lin K, 1996, SCIENCE, V273, P1539, DOI 10.1126/science.273.5281.1539; Mourrieras F, 1997, BIOCHEM J, V326, P345, DOI 10.1042/bj3260345; NARKEWICZ MR, 1990, BIOCHEM J, V271, P585, DOI 10.1042/bj2710585; OBRIEN RM, 1994, BIOCHEM J, V303, P737, DOI 10.1042/bj3030737; PRIPBUUS C, 1995, EUR J BIOCHEM, V230, P309, DOI 10.1111/j.1432-1033.1995.tb20564.x; Rangan VS, 1996, J BIOL CHEM, V271, P2307, DOI 10.1074/jbc.271.4.2307; SPENCE JT, 1980, J CELL PHYSIOL, V103, P173, DOI 10.1002/jcp.1041030202; SUDO Y, 1994, ENDOCRINOLOGY, V134, P2532, DOI 10.1210/en.134.6.2532; SULLIVAN JE, 1994, FEBS LETT, V353, P33, DOI 10.1016/0014-5793(94)01006-4; SULLIVAN JE, 1994, BIOCHEM BIOPH RES CO, V200, P1551, DOI 10.1006/bbrc.1994.1627; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; Towle HC, 1997, ANNU REV NUTR, V17, P405, DOI 10.1146/annurev.nutr.17.1.405; Woods A, 1996, J BIOL CHEM, V271, P10282, DOI 10.1074/jbc.271.17.10282; WOODS A, 1994, J BIOL CHEM, V269, P19509	44	203	208	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14767	14771		10.1074/jbc.273.24.14767	http://dx.doi.org/10.1074/jbc.273.24.14767			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614076	hybrid			2022-12-27	WOS:000074160400018
J	Jung, SM; Moroi, M				Jung, SM; Moroi, M			Platelets interact with soluble and insoluble collagens through characteristically different reactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIVALENT-CATIONS; GLYCOPROTEIN-VI; BLOOD-PLATELETS; FLOW CONDITIONS; ADHESION; AGGREGATION; IDENTIFICATION; PROTEIN; COMPONENTS; ACTIVATION	Platelet interaction with soluble and insoluble collagens was characterized through binding studies. In contrast to resting platelets, cells reacted with activators, TS2/16 (integrin alpha(2) beta(1)-activating antibody), thrombin, collagen-related peptide, or ADP, exhibited specific soluble collagen binding that is Mg2+-dependent, but inhibited by prostaglandin I-2, Ca2+, and Gi9 (anti-integrin alpha(2) beta(1) antibody). Each platelet has 1500-3500 soluble collagen binding sites, with a dissociation constant of 3.5-9 x 10(-8) M. This is the first study to show the specific binding of soluble collagen to platelets; our data strongly suggest that the receptor is integrin alpha(2) beta(1) after it becomes activated upon platelet activation. These results suggest that activation of platelets transforms integrin alpha(2) beta(1) to a state with higher affinity binding sites for soluble collagen. The soluble collagen-platelet interaction was compared with the platelet interaction with fibrillar collagen, which has until now not been demonstrated to bind specifically to platelets. Here, we demonstrated specific, biphasic fibrillar collagen binding. One phase is rapid and metal ion-independent, and accounts for most of the binding. The other phase is slow and Mg2+-dependent. The characteristic differences in the specific bindings of soluble and fibrous collagens demonstrate the different contributions of two different collagen receptors.	Kurume Univ, Inst Life Sci, Dept Prot Biochem, Fukuoka 8398016, Japan	Kurume University	Jung, SM (corresponding author), Kurume Univ, Inst Life Sci, Dept Prot Biochem, 2432-3 Aikawa-machi, Fukuoka 8398016, Japan.							Asselin J, 1997, BLOOD, V89, P1235, DOI 10.1182/blood.V89.4.1235; Barnes MJ, 1996, BIOPOLYMERS, V40, P383, DOI 10.1002/(SICI)1097-0282(1996)40:4<383::AID-BIP4>3.0.CO;2-S; BAZZONI G, 1995, J BIOL CHEM, V270, P25570, DOI 10.1074/jbc.270.43.25570; CHAN BMC, 1993, J CELL BIOL, V120, P537, DOI 10.1083/jcb.120.2.537; CLEMETSON KJ, 1995, THROMB HAEMOSTASIS, V74, P111; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; GORDON JL, 1974, J CELL SCI, V16, P157; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HUBBELL JA, 1986, REV SCI INSTRUM, V57, P892, DOI 10.1063/1.1138830; Ichinohe T, 1997, J BIOL CHEM, V272, P63; JandrotPerrus M, 1997, J BIOL CHEM, V272, P27035, DOI 10.1074/jbc.272.43.27035; KLUNICKI TJ, 1997, BLOOD, V89, P1939; KUNICKI TJ, 1993, BLOOD, V82, P2693; LUQUE A, 1994, FEBS LETT, V346, P278, DOI 10.1016/0014-5793(94)00490-0; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; MAZUROV AV, 1988, BIOKHIMIYA, V54, P1280; MOROI M, 1992, BIOCHIM BIOPHYS ACTA, V1137, P1, DOI 10.1016/0167-4889(92)90092-P; Moroi M, 1996, BLOOD, V88, P2081, DOI 10.1182/blood.V88.6.2081.bloodjournal8862081; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; Morton LF, 1997, J BIOL CHEM, V272, P11044; MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337; MOULD AP, 1995, J BIOL CHEM, V270, P26270, DOI 10.1074/jbc.270.44.26270; MUGGLI R, 1980, J LAB CLIN MED, V95, P195; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; Polgar J, 1997, J BIOL CHEM, V272, P13576, DOI 10.1074/jbc.272.21.13576; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; SAELMAN EUM, 1994, BLOOD, V83, P1244; SAKARIASSEN KS, 1983, J LAB CLIN MED, V102, P522; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; SUGIYAMA T, 1987, BLOOD, V69, P1712; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; Yanabu M, 1997, BLOOD, V89, P1590, DOI 10.1182/blood.V89.5.1590.1590_1590_1598	34	106	114	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14827	14837		10.1074/jbc.273.24.14827	http://dx.doi.org/10.1074/jbc.273.24.14827			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614084	hybrid			2022-12-27	WOS:000074160400026
J	Roztocil, T; Matter-Sadzinski, L; Gomez, M; Ballivet, M; Matter, JM				Roztocil, T; Matter-Sadzinski, L; Gomez, M; Ballivet, M; Matter, JM			Functional properties of the neuronal nicotinic acetylcholine receptor beta 3 promoter in the developing central nervous system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT GENE; TRANSCRIPTION FACTOR; EXPRESSION; SPECIFICITY; PROTEIN; CELLS	Within the chick central nervous system, expression of the beta 3 nicotinic acetylcholine receptor gene is restricted to a subset of retinal neurons, the majority of which are ganglion cells. Transient transfection in retinal neurons and in neural and non-neural cells from other regions of the chick embryo allowed the identification of the cis-regulatory domain of the beta 3 gene. Within this domain, a 75-base pair fragment located immediately upstream of the transcription start site suffices to reproduce the neuron-specific expression pattern of beta 3, This fragment encompasses an E-box and a CAAT box, both of which are shown to be key positive regulatory elements of the beta 3 promoter. Co-transfection experiments into retinal, telencephalic, and tectal neurons with plasmid reporters of beta 3 promoter activity and a number of vectors expressing different neuronal (ASH-1, NeuroM, NeuroD, CTF-4) and non-neuronal (MyoD) basic helix-loop-helix transcription factors indicate that the cis-regulatory domain of beta 3 has the remarkable property of discriminating accurately between related members of the basic helix-loop-helix protein family. The sequence located immediately 3' of the E-box participates in this selection, and the E-box acts in concert with the nearby CAAT box.	Univ Geneva, Dept Biochem, CH-1211 Geneva 4, Switzerland	University of Geneva	Matter, JM (corresponding author), Univ Geneva, Dept Biochem, 30 Quai Ernest Ansermet, CH-1211 Geneva 4, Switzerland.							CAMPOSORTEGA JA, 1995, MOL NEUROBIOL, V10, P75, DOI 10.1007/BF02740668; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; CROSSLEY M, 1990, NATURE, V345, P444, DOI 10.1038/345444a0; DAUBAS P, 1990, NEURON, V5, P49, DOI 10.1016/0896-6273(90)90032-B; Feller MB, 1996, SCIENCE, V272, P1182, DOI 10.1126/science.272.5265.1182; Forsayeth JR, 1997, J NEUROSCI, V17, P1531; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HERNANDEZ MC, 1995, J BIOL CHEM, V270, P3224, DOI 10.1074/jbc.270.7.3224; JASONI CL, 1994, DEVELOPMENT, V120, P769; KLARSFELD A, 1987, MOL CELL BIOL, V7, P951, DOI 10.1128/MCB.7.2.951; Lee JE, 1997, CURR OPIN NEUROBIOL, V7, P13, DOI 10.1016/S0959-4388(97)80115-8; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; LYONS GE, 1995, J NEUROSCI, V15, P5727, DOI 10.1523/jneurosci.15-08-05727.1995; Ma QF, 1996, CELL, V87, P43, DOI 10.1016/S0092-8674(00)81321-5; MANDEL G, 1993, ANNU REV NEUROSCI, V16, P323, DOI 10.1146/annurev.ne.16.030193.001543; MATTER JM, 1990, EMBO J, V9, P1021, DOI 10.1002/j.1460-2075.1990.tb08205.x; MATTER JM, 1995, J NEUROSCI, V15, P5919; MATTERSADZINSKI L, 1992, EMBO J, V11, P4529, DOI 10.1002/j.1460-2075.1992.tb05554.x; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; Role LW, 1996, NEURON, V16, P1077, DOI 10.1016/S0896-6273(00)80134-8; Roztocil T, 1997, DEVELOPMENT, V124, P3263; Sambrook J., 2002, MOL CLONING LAB MANU; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; SCHOENHERR CJ, 1995, CURR OPIN NEUROBIOL, V5, P566, DOI 10.1016/0959-4388(95)80060-3; STUBER D, 1990, IMMUNOLOGICAL METHOD, V4, P121; TAJBAKHSH S, 1994, NEURON, V13, P813, DOI 10.1016/0896-6273(94)90248-8; TSAY HJ, 1992, NUCLEIC ACIDS RES, V20, P2624, DOI 10.1093/nar/20.10.2624-b; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0; WANG Y, 1988, NEURON, V1, P527, DOI 10.1016/0896-6273(88)90183-3; Yuh CH, 1996, DEVELOPMENT, V122, P1069; ZOLI M, 1995, J NEUROSCI, V15, P1912, DOI 10.1523/JNEUROSCI.15-03-01912.1995	33	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15131	15137		10.1074/jbc.273.24.15131	http://dx.doi.org/10.1074/jbc.273.24.15131			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614125	hybrid			2022-12-27	WOS:000074160400067
J	Spitz, F; De Vasconcelos, ZA; Chatelet, F; Demignon, J; Kahn, A; Mira, JC; Maire, P; Daegelen, D				Spitz, F; De Vasconcelos, ZA; Chatelet, F; Demignon, J; Kahn, A; Mira, JC; Maire, P; Daegelen, D			Proximal sequences of the aldolase A fast muscle-specific promoter direct nerve- and activity-dependent expression in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN HEAVY-CHAIN; SKELETAL-MUSCLE; GENE-EXPRESSION; A GENE; ELECTRICAL-ACTIVITY; THYROID-HORMONE; MESSENGER-RNA; CONTRACTILE ACTIVITY; MOLECULAR DIVERSITY; UPSTREAM SEQUENCES	Muscle activity is known to modulate the muscle fiber phenotype, Changes in muscle activity (normal or experimentally induced) lead to modifications of the expression status of several muscle-specific genes. However, the transcription regulatory elements involved in the adaptative response are mainly unknown. The aldolase A muscle specific promoter, pM, is expressed in adult fast twitch muscle with a preferential expression in fast glycolytic-2B fibers. Its activity is induced during postnatal muscle maturation, suggesting a role of nerve and/or muscle activity. Indeed, denervation of gastrocnemius in newborn mice prevented the activation of the promoter in this muscle, despite the nerve-independent formation of 2B fibers. Although the nerve was necessary for pM onset during development, denervating the gastrocnemius in adults had only mild effects on pM activity. By contrast, a transgene including the pM proximal regulatory sequences that are sufficient to reproduce the 2B fiber-specific expression of the endogenous promoter was shown to be highly sensitive to both neonatal and adult denervation, Transgenes containing muscle-specific pM proximal promoter elements were used to delineate the regulatory elements involved in this response to innervation and changes in the contractile activity pattern. Nerve- and activity-dependent elements could be localized in the 130-base pair-long proximal promoter region of the human aldolase A gene.	Univ Paris 05, Inst Cochin Genet Mol, INSERM, U129, F-75014 Paris, France; Univ Paris 05, Neurobiol Lab, CNRS, URA 1448, F-75006 Paris, France; Ctr Hosp Univ St Antoine, CNRS, URA 1283, F-75012 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Centre National de la Recherche Scientifique (CNRS)	Daegelen, D (corresponding author), Univ Paris 05, Inst Cochin Genet Mol, INSERM, U129, 24 Rue Fbg St Jacques, F-75014 Paris, France.	daegelen@icgm.cochin.inserm.fr	Maire, Pascal/E-6339-2016	Maire, Pascal/0000-0001-7795-0029				AUSONI S, 1990, J NEUROSCI, V10, P153; BESSEREAU JL, 1994, P NATL ACAD SCI USA, V91, P1304, DOI 10.1073/pnas.91.4.1304; BLANCHETOT A, 1986, EUR J BIOCHEM, V159, P469, DOI 10.1111/j.1432-1033.1986.tb09909.x; BUONANNO A, 1993, NUCLEIC ACIDS RES, V21, P5684, DOI 10.1093/nar/21.24.5684; Buonanno A, 1996, DEV GENET, V19, P95, DOI 10.1002/(SICI)1520-6408(1996)19:2<95::AID-DVG1>3.0.CO;2-V; BUTLERBROWNE GS, 1990, ANAT EMBRYOL, V181, P513; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLBERT MC, 1988, DEV BIOL, V130, P392, DOI 10.1016/0012-1606(88)90444-7; COLBERT MC, 1992, DEV BIOL, V149, P66, DOI 10.1016/0012-1606(92)90264-H; CONCORDET JP, 1993, MOL CELL BIOL, V13, P9, DOI 10.1128/MCB.13.1.9; DiMario JX, 1997, DEV BIOL, V188, P167, DOI 10.1006/dbio.1997.8619; EFTIMIE R, 1991, P NATL ACAD SCI USA, V88, P1349, DOI 10.1073/pnas.88.4.1349; ESSER K, 1993, DEV BIOL, V159, P173, DOI 10.1006/dbio.1993.1231; Firulli AB, 1997, TRENDS GENET, V13, P364, DOI 10.1016/S0168-9525(97)01171-2; Garry DJ, 1996, DEV GENET, V19, P146, DOI 10.1002/(SICI)1520-6408(1996)19:2<146::AID-DVG6>3.0.CO;2-9; GAUTRON S, 1991, NUCLEIC ACIDS RES, V19, P767, DOI 10.1093/nar/19.4.767; Gibney G, 1995, DEV BIOL, V172, P614, DOI 10.1006/dbio.1995.8057; GOBLET C, 1995, DEV BIOL, V170, P262, DOI 10.1006/dbio.1995.1213; GUNDERSEN K, 1988, J PHYSIOL-LONDON, V398, P177, DOI 10.1113/jphysiol.1988.sp017037; GUNDERSEN K, 1993, J CELL BIOL, V123, P1535, DOI 10.1083/jcb.123.6.1535; Hamalainen N, 1996, FEBS LETT, V399, P220, DOI 10.1016/S0014-5793(96)01325-7; HORI K, 1987, ISOZYMES-CURR T BIOL, V14, P153; IZUMO S, 1986, SCIENCE, V231, P597, DOI 10.1126/science.3945800; JOCKUSCH H, 1990, DYNAMIC STATE OF MUSCLE FIBERS, P429; KYSELOVIC J, 1994, J BIOL CHEM, V269, P21770; LEEUW T, 1993, EUR J BIOCHEM, V213, P1039, DOI 10.1111/j.1432-1033.1993.tb17851.x; MAIRE P, 1987, J MOL BIOL, V197, P425, DOI 10.1016/0022-2836(87)90556-0; MERLIE JP, 1994, J BIOL CHEM, V269, P2461; MILLER JB, 1993, BIOESSAYS, V15, P191, DOI 10.1002/bies.950150308; MUKAI T, 1986, J BIOL CHEM, V261, P3347; Pette D, 1990, Rev Physiol Biochem Pharmacol, V116, P1; Pette D, 1997, Int Rev Cytol, V170, P143, DOI 10.1016/S0074-7696(08)61622-8; REININGHAUS J, 1988, MUSCLE NERVE, V11, P433, DOI 10.1002/mus.880110504; RUSSELL SD, 1993, DEV BIOL, V157, P359, DOI 10.1006/dbio.1993.1141; RUSSELL SD, 1988, J BIOL CHEM, V263, P6370; SALMINEN M, 1995, J MOL BIOL, V253, P17, DOI 10.1006/jmbi.1995.0532; Salminen M, 1996, MOL CELL BIOL, V16, P76; SALMINEN M, 1994, MOL CELL BIOL, V14, P6797, DOI 10.1128/MCB.14.10.6797; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHIAFFINO S, 1989, J MUSCLE RES CELL M, V10, P197, DOI 10.1007/BF01739810; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; SCHLEEF M, 1994, NEUROMUSCULAR DISORD, V4, P205, DOI 10.1016/0960-8966(94)90021-3; SCHWEIGHOFFER F, 1986, J BIOL CHEM, V261, P271; SEEDORF U, 1986, BIOCHEM J, V239, P115, DOI 10.1042/bj2390115; SHACKELFORD JE, 1981, J BIOL CHEM, V256, P6423; Spitz F, 1998, J BIOL CHEM, V273, P561, DOI 10.1074/jbc.273.1.561; Spitz F, 1997, MOL CELL BIOL, V17, P656, DOI 10.1128/MCB.17.2.656; STAUFFER JK, 1990, J BIOL CHEM, V265, P11773; STEINMEYER K, 1991, NATURE, V354, P304, DOI 10.1038/354304a0; TANG JC, 1994, DEVELOPMENT, V120, P1799; VOYTIK SL, 1993, DEV DYNAM, V198, P214, DOI 10.1002/aja.1001980307; WEYDERT A, 1983, J BIOL CHEM, V258, P3867; WILLIAMS RS, 1986, J BIOL CHEM, V261, P376; WILLIAMS RS, 1987, J BIOL CHEM, V262, P2764	54	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14975	14981		10.1074/jbc.273.24.14975	http://dx.doi.org/10.1074/jbc.273.24.14975			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614104	hybrid			2022-12-27	WOS:000074160400046
J	Gigoux, V; Escrieut, C; Silvente-Poirot, S; Maigret, B; Gouilleux, L; Fehrentz, JA; Gully, D; Moroder, L; Vaysse, N; Fourmy, D				Gigoux, V; Escrieut, C; Silvente-Poirot, S; Maigret, B; Gouilleux, L; Fehrentz, JA; Gully, D; Moroder, L; Vaysse, N; Fourmy, D			Met-195 of the cholecystokinin-A receptor interacts with the sulfated tyrosine of cholecystokinin and is crucial for receptor transition to high affinity state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WEAKLY POLAR INTERACTIONS; NEUROKININ-1 RECEPTOR; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; AGONIST; BINDING; GASTRIN; LOCALIZATION; ANTAGONIST; PANCREAS	Sulfation of the tyrosine at the seventh position from the C terminus of cholecystokinin (CCK) is crucial for CCK binding to the CCK A receptor. Using three-dimensional modeling, we identified methionine 195 of the CCK-A receptor as a putative amino acid in interaction with the aromatic ring of the sulfated tyrosine of CCK. We analyzed the role played by the two partners of this interaction, The exchange of Met-195 for a leucine caused a minor decrease (2.8-fold) on the affinity of the high affinity sites for sulfated CCK-9, a strong drop (73%) of their number, and a 30-fold decrease on the affinity of the Bow and very low affinity sites for sulfated CCK-9, with no change in their number, The mutation also caused a 54-fold decrease of the potency of the receptor to induce inositol phosphates production The high affinity sites of the wild-type CCK-A receptor were highly selective (800-fold) toward sulfated versus nonsulfated CCK, whereas low and very low affinity sites were poorly selective (PO-and 18-fold). in addition, the M195L mutant bound, and responded to, sulfated CCK analogues with decreased affinities and potencies, whereas it bound and responded to nonsulfated CCK identically to the wild-type receptor. Thus, Met-195 interacts with the aromatic ring of the sulfated tyrosine to correctly position the sulfated group of CCK in the binding site of the receptor. This interaction is essential for CCK-dependent transition of the CCK-A receptor to a high affinity state. Our data should represent an important step toward the identification of the residue(s) of the receptor in interaction with the sulfate moiety of CCK and the understanding of the molecular mechanisms that govern CCK-A receptor activation.	CHU Rangueil, Inst Louis Bugnard, INSERM, U151, F-31403 Toulouse, France; Univ Nancy, Chim Theor Lab, F-54506 Vandoeuvre Les Nancy, France; Fac Pharm Montpellier, CNRS, URA 1845, F-34060 Montpellier, France; Sanofi Rech, F-31036 Toulouse, France; Max Planck Inst Biochem, D-82143 Martinsried, Germany	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lorraine; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Sanofi-Aventis; Sanofi France; Max Planck Society	Fourmy, D (corresponding author), CHU Rangueil, Inst Louis Bugnard, INSERM, U151, Bat L3, F-31403 Toulouse, France.	Daniel.Fourmy@rangueil.inserm.fr	Fourmy, Daniel/AAE-3703-2019; Poirot, Sandrine/D-5448-2017; Gigoux, Véronique/AAE-6090-2020	Fourmy, Daniel/0000-0001-9910-4827; Gigoux, Véronique/0000-0003-1408-5335; Silvente-Poirot, Sandrine/0000-0003-2245-9069; Moroder, Luis/0000-0001-9570-5713				AULD DS, 1993, PROTEIN SCI, V2, P2187, DOI 10.1002/pro.5560021218; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DEWEERTH A, 1993, BIOCHEM BIOPH RES CO, V194, P811, DOI 10.1006/bbrc.1993.1894; FONG TM, 1992, J BIOL CHEM, V267, P25664; FONG TM, 1992, BIOCHEMISTRY-US, V31, P11806, DOI 10.1021/bi00162a019; FOURMY D, 1989, EUR J BIOCHEM, V185, P397, DOI 10.1111/j.1432-1033.1989.tb15128.x; GULLY D, 1993, EUR J PHARMACOL, V232, P13, DOI 10.1016/0014-2999(93)90722-T; HUANG RRC, 1994, BIOCHEMISTRY-US, V33, P3007, DOI 10.1021/bi00176a033; HUANG S, 1994, J BIOL CHEM, V269, P26121; INNIS RB, 1980, P NATL ACAD SCI-BIOL, V77, P6917, DOI 10.1073/pnas.77.11.6917; ITO M, 1993, J BIOL CHEM, V268, P18300; JENSEN RT, 1982, J BIOL CHEM, V257, P5554; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P256, DOI 10.1016/S0165-6147(00)89037-9; KENNEDY K, 1995, BIOCHEM BIOPH RES CO, V213, P845, DOI 10.1006/bbrc.1995.2206; Kennedy K, 1997, J BIOL CHEM, V272, P2920, DOI 10.1074/jbc.272.5.2920; KOPIN AS, 1992, P NATL ACAD SCI USA, V89, P3605, DOI 10.1073/pnas.89.8.3605; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; MENOZZI D, 1991, J BIOL CHEM, V266, P10385; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NANEVICZ T, 1995, J BIOL CHEM, V270, P21619, DOI 10.1074/jbc.270.37.21619; REHFELD JF, 1994, ADV CANCER RES, V63, P295, DOI 10.1016/S0065-230X(08)60403-0; SAITO A, 1981, J NEUROCHEM, V37, P483, DOI 10.1111/j.1471-4159.1981.tb00481.x; SCHAFFER K, 1997, GASTROENTEROLOGY, V112, pA1601; SERRANO L, 1991, J MOL BIOL, V218, P465, DOI 10.1016/0022-2836(91)90725-L; Silvente-Poirot S, 1996, J BIOL CHEM, V271, P14698, DOI 10.1074/jbc.271.25.14698; SILVENTE-POIROT S, 1993, EUR J BIOCHEM, V215, P513, DOI 10.1111/j.1432-1033.1993.tb18061.x; SINGH J, 1990, J MOL BIOL, V211, P595, DOI 10.1016/0022-2836(90)90268-Q; TALKAD VD, 1994, P NATL ACAD SCI USA, V91, P1868, DOI 10.1073/pnas.91.5.1868; ULRICH CD, 1993, BIOCHEM BIOPH RES CO, V193, P204, DOI 10.1006/bbrc.1993.1610; WANK SA, 1995, AM J PHYSIOL-GASTR L, V269, pG628, DOI 10.1152/ajpgi.1995.269.5.G628; WILLIAMS JA, 1993, PHYSIOL REV, V73, P701, DOI 10.1152/physrev.1993.73.4.701	33	71	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14380	14386		10.1074/jbc.273.23.14380	http://dx.doi.org/10.1074/jbc.273.23.14380			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603948	hybrid			2022-12-27	WOS:000074021500050
J	Kimura, Y; Asahi, M; Kurzydlowski, K; Tada, M; MacLennan, DH				Kimura, Y; Asahi, M; Kurzydlowski, K; Tada, M; MacLennan, DH			Phospholamban domain Ib mutations influence functional interactions with the Ca2+-ATPase isoform of cardiac sarcoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE; CYTOPLASMIC DOMAIN; PHOSPHORYLATION; ASSOCIATION; SEQUENCE; ALTERS; SITE; GENE	Alanine-scanning mutagenesis of amino acids 21-30, forming cytoplasmic domain Ib in phospholamban (PLN), revealed that mutation to Ala of Asn(27), Gln(29), and Asn(30) results ins gain of inhibitory function, In an earlier study (Kimura, Y., Kurzydlowski, E., Tada, M., and MacLennan, D. H. (1997) J. Biol. Chem. 272, 15061-15064), gain of function in PLN transmembrane domain II mutants was correlated with pentamer destabilization, leading to proposals that the PLN monomer is the active inhibitory species, that dissociation of the PLN pentamer is one determinant of PLN inhibitory function and that dissociation of the PLN cardiac sarco(endo)plasmic Ca2+-ATPase isoform (SERCA2a) complex is a second determinant, Because each of the new domain Ib mutants contained a normal ratio of pentamer to monomer in SDS-polyacrylamide gel electrophoresis, gain of function must have resulted from mechanisms other than destabilization of pentameric structure. Evidence that domain Ib and domain II mutants act through different sites and different mechanisms was provided by a mononomeric double mutant, N30A/I40A, in which the enhanced inhibitory function of each single mutant was additive. Evidence for an alteration in stability of the PLN/SERCA2a heterodimer was obtained in a study Of double mutant N27A/N34A in which inhibitory function was regained by combining a gain of function, domain Ib mutation with a loss of function domain II mutation, These results support the proposal that PLN inhibition of SERCA2a involves, first, depolymerization of PLN and, second, the formation of inhibitory interactions between monomeric PLN and SERCA2a.	Univ Toronto, Charles H Best Inst, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Osaka Univ, Sch Med, Dept Med & Pathophysiol, Suita, Osaka 565, Japan	University of Toronto; Osaka University	MacLennan, DH (corresponding author), Univ Toronto, Charles H Best Inst, Banting & Best Dept Med Res, 112 Coll St, Toronto, ON M5G 1L6, Canada.							Autry JM, 1997, J BIOL CHEM, V272, P15872, DOI 10.1074/jbc.272.25.15872; Cornea RL, 1997, BIOCHEMISTRY-US, V36, P2960, DOI 10.1021/bi961955q; FUJII J, 1988, FEBS LETT, V227, P51, DOI 10.1016/0014-5793(88)81412-1; FUJII J, 1987, J CLIN INVEST, V79, P301, DOI 10.1172/JCI112799; FUJII J, 1991, J BIOL CHEM, V266, P11669; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; JAMES P, 1989, NATURE, V342, P90, DOI 10.1038/342090a0; JONES LR, 1985, J BIOL CHEM, V260, P7721; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; Kimura Y, 1996, J BIOL CHEM, V271, P21726, DOI 10.1074/jbc.271.36.21726; Kimura Y, 1997, J BIOL CHEM, V272, P15061, DOI 10.1074/jbc.272.24.15061; KINGSTON RE, 1990, CURRENT PROTOCOLS MO; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; Mayer EJ, 1996, J BIOL CHEM, V271, P1669, DOI 10.1074/jbc.271.3.1669; MORTISHIRESMITH RJ, 1995, BIOCHEMISTRY-US, V34, P7603, DOI 10.1021/bi00023a006; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; TADA M, 1982, ANNU REV PHYSIOL, V44, P401, DOI 10.1146/annurev.ph.44.030182.002153; TATULIAN SA, 1995, BIOCHEMISTRY-US, V34, P4448, DOI 10.1021/bi00013a038; TOYOFUKU T, 1994, J BIOL CHEM, V269, P3088; TOYOFUKU T, 1994, J BIOL CHEM, V269, P22929	21	89	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14238	14241		10.1074/jbc.273.23.14238	http://dx.doi.org/10.1074/jbc.273.23.14238			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603928	hybrid			2022-12-27	WOS:000074021500030
J	Mitkevich, OV; Shainoff, JR; DiBello, PM; Yee, VC; Teller, DC; Smejkal, GB; Bishop, PD; Kolotushkina, IS; Fickenscher, K; Samokhin, GP				Mitkevich, OV; Shainoff, JR; DiBello, PM; Yee, VC; Teller, DC; Smejkal, GB; Bishop, PD; Kolotushkina, IS; Fickenscher, K; Samokhin, GP			Coagulation factor XIIIa undergoes a conformational change evoked by glutamine substrate - Studies on kinetics of inhibition and binding of XIIIa by a cross-reacting antifibrinogen antibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; MONOCLONAL-ANTIBODY; FIBRIN; LINKING; TRANSGLUTAMINASE; ACTIVATION; SUBUNIT; RESISTANCE; PEPTIDE	Coagulation factor XIIIa, plasma transglutaminase (endo-gamma-glutamine:epsilon-lysine transferase EC 2.3.2.13) catalyzes isopeptide bond formation between glutamine and lysine residues and rapidly cross-links fibrin clots. A monoclonal antibody (5A2) directed to a fibrinogen A alpha-chain segment 529-539 was previously observed from analysis of end-stage plasma clots to block fibrin or-chain cross-linking. This prompted the study of its effect on nonfibrinogen substrates, with the prospect that 5A2 was inhibiting XIIIa directly. It inhibited XIIIa-catalyzed incorporation of the amine donor substrate dansylcadaverine into the glutamine acceptor dimethylcasein in an uncompetitive manner with respect to dimethylcasein utilization and competitively with respect to dansylcadaverine, Uncompetitive inhibition was also observed with the synthetic glutamine substrate, LGPGQSKVIG. Theoretically, uncompetitive inhibition arises from preferential interaction of the inhibitor with the enzyme-substrate complex but is also found to inhibit gamma-chain cross-linking. The conjunction of the uncompetitive and competitive modes of inhibition indicates in theory that this bireactant system involves an ordered reaction in which docking of the glutamine substrate precedes the amine exchange. The presence of substrate enhanced binding of 5A2 to XIIIa, an interaction deemed to occur through a C-terminal segment of the XIIIa A-chain (643-658, GSDMTVTVQFTNPLKE), 55% of which comprises sequences occurring in the fibrinogen epitope A alpha-(529-540) (GSESGIFTNTKE). Removal of the C-terminal domain from XIIIa abolishes the inhibitory effect of 5A2 on activity. Crystallographic studies on recombinant XIIIa place the segment 643-658 in the region of the groove through which glutamine substrates access the active site and have predicted that for catalysis, a conformational change may accompany glutamine-substrate binding. The uncompetitive inhibition and the substrate-dependent binding of 5A2 provide evidence for the conformational change.	Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA; Russian Cardiol Res Ctr, Inst Expt Cardiol, Moscow 121552, Russia; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Zymogenet Inc, Seattle, WA 98102 USA; Behring Diagnost GMBH, D-35001 Marburg, Germany; E Carolina Univ, Sch Med, Dept Med, Greenville, NC 27853 USA	Cleveland Clinic Foundation; National Medical Research Center of Cardiology; University of Washington; University of Washington Seattle; Zymogenet Inc.; Siemens AG; Siemens Germany; University of North Carolina; East Carolina University	Shainoff, JR (corresponding author), Cleveland Clin Fdn, Res Inst FF4, Cleveland, OH 44195 USA.	shainoj@cesmtp.ccf.org			NHLBI NIH HHS [HL-50355, HL-16361] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016361, R01HL050355] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARRY ELR, 1988, J BIOL CHEM, V263, P10464; BISHOP PD, 1990, BIOCHEMISTRY-US, V29, P1861, DOI 10.1021/bi00459a028; CURTIS CG, 1974, BIOCHEMISTRY-US, V13, P3774, DOI 10.1021/bi00715a024; DADABAY CY, 1989, BIOCHEM J, V264, P679, DOI 10.1042/bj2640679; DANILOV SM, 1991, LAB INVEST, V64, P118; FICKENSCHER K, 1991, THROMB HAEMOSTASIS, V65, P535; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; Folk JE., 1970, METHOD ENZYMOL, V17, P889, DOI 10.1016/0076-6879(71)17302-8; FRANCIS CW, 1988, BLOOD, V71, P1361; GREENBERG CS, 1988, BIOCHEM J, V256, P10134; ICHINOSE A, 1986, BIOCHEMISTRY-US, V25, P4633, DOI 10.1021/bi00364a027; ICHINOSE A, 1986, BIOCHEMISTRY-US, V25, P6900, DOI 10.1021/bi00370a025; Ichinose A, 1988, Adv Exp Med Biol, V231, P15; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUROCHKIN IV, 1995, J MOL BIOL, V248, P414, DOI 10.1016/S0022-2836(95)80060-3; LAKI K, 1948, SCIENCE, V108, P280, DOI 10.1126/science.108.2802.280; LORAND L, 1962, NATURE, V194, P1148, DOI 10.1038/1941148a0; LORAND L, 1964, ARCH BIOCHEM BIOPHYS, V105, P58, DOI 10.1016/0003-9861(64)90235-8; LORAND L, 1971, ANAL BIOCHEM, V44, P2221; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mitkevich O. V., 1994, Journal of Labelled Compounds and Radiopharmaceuticals, V35, P407; Mitkevich OV, 1996, BLOOD COAGUL FIBRIN, V7, P85, DOI 10.1097/00001721-199601000-00011; PEDERSEN LC, 1994, PROTEIN SCI, V3, P1131, DOI 10.1002/pro.5560030720; REED GL, 1992, THROMB HAEMOSTASIS, V68, P315; SAKATA Y, 1982, J CLIN INVEST, V69, P536, DOI 10.1172/JCI110479; SCHWARTZ ML, 1973, J BIOL CHEM, V248, P1395; Segel I. H., 1993, ENZYME KINETICS, P329; SHAINOFF JR, 1991, J BIOL CHEM, V266, P6429; SHAINOFF JR, 1962, J EXP MED, V116, P687, DOI 10.1084/jem.116.5.687; SHAINOFF JR, 1993, AD ELECTROP, V6, P61; SHAINOFF JR, 1970, THROMB DIATH HAEMO, V39, P203; TAKAHASHI N, 1986, P NATL ACAD SCI USA, V83, P8019, DOI 10.1073/pnas.83.21.8019; TAUBENFELD SM, 1995, THROMB HAEMOSTASIS, V74, P923; VALENZUELA R, 1992, AM J PATHOL, V141, P861; YEE VC, 1995, THROMB RES, V78, P389, DOI 10.1016/0049-3848(95)00072-Y; YEE VC, 1994, P NATL ACAD SCI USA, V91, P7296, DOI 10.1073/pnas.91.15.7296; Yee Vivien C., 1996, Seminars in Thrombosis and Hemostasis, V22, P377, DOI 10.1055/s-2007-999035	37	16	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14387	14391		10.1074/jbc.273.23.14387	http://dx.doi.org/10.1074/jbc.273.23.14387			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603949	hybrid, Green Published			2022-12-27	WOS:000074021500051
J	Bhaduri, T; Bagui, TK; Sikder, D; Nagaraja, V				Bhaduri, T; Bagui, TK; Sikder, D; Nagaraja, V			DNA topoisomerase i from Mycobacterium smegmatis - An enzyme with distinct features	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRION RNA-POLYMERASE; ESCHERICHIA-COLI; OMEGA-PROTEIN; BINDING; CLEAVAGE; GYRASE; PURIFICATION; TUBERCULOSIS; SEQUENCE; COMPLEX	A type I topoisomerase has been purified to homogeneity from Mycobacterium smegmatis, It is the largest single subunit enzyme of this class having molecular mass of 110 kDa. The enzyme is Mg2+ dependent and can relax negatively supercoiled DNA, catenate, and knot single-stranded DNA, thus having typical properties of type I topoisomerases, Furthermore, the enzyme makes single-stranded nicks and the 5'-phosphoryl end of the nicked DNA gets covalently linked with a tyrosine residue of the enzyme. However, M. smegmatis enzyme shows some distinctive features from the prototype Escherichia coli topoisomerase I. The enzyme is relatively stable at higher temperatures and not inhibited by spermidine. It apparently does not contain any bound Zn2+ and on modification of cysteine residues retains the activity, suggesting the absence of the zinc-finger motif in DNA binding, Partially purified Mycobacterium tuberculosis topoisomerase I exhibits very similar properties with respect to size, stability, and reaction characteristics. Sequence comparison of topoisomerase I from E. coli and M. tuberculosis shows the absence of zinc-finger motifs in mycobacterial enzyme. Using a two-substrate assay system, we demonstrate that the enzyme acts processively at low ionic strength and switches over to distributive mode at high Mg2+ concentration. Significantly, the enzyme activity is stimulated by single strand DNA-binding protein, There is a potential to exploit the characteristics of the enzyme to develop it as a molecular target against mycobacterial infections.	Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Nagaraja, V (corresponding author), Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India.							ALATOSSAVA T, 1985, J BACTERIOL, V162, P413, DOI 10.1128/JB.162.1.413-419.1985; BHADURI T, 1994, INDIAN J BIOCHEM BIO, V31, P339; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN PO, 1981, P NATL ACAD SCI-BIOL, V78, P843, DOI 10.1073/pnas.78.2.843; Cozzarelli N.R., 1990, DNA TOPOLOGY ITS BIO; Der Garabedian P A, 1991, Biochemistry, V30, P9940, DOI 10.1021/bi00105a018; DINARDO S, 1982, CELL, V31, P43, DOI 10.1016/0092-8674(82)90403-2; Dorman Charles J., 1993, Trends in Microbiology, V1, P92, DOI 10.1016/0966-842X(93)90114-7; DRLICA K, 1988, BIOCHEMISTRY-US, V27, P2253, DOI 10.1021/bi00407a001; DRLICA K, 1989, PERSPECTIVES BIOCH, V1; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FORD LO, 1974, J MOL BIOL, V88, P349, DOI 10.1016/0022-2836(74)90487-2; GlucksmannKuis MA, 1996, CELL, V84, P147, DOI 10.1016/S0092-8674(00)81001-6; Gopinathan K. P., 1993, Journal of the Indian Institute of Science, V73, P31; Kumar NV, 1997, NUCLEIC ACIDS RES, V25, P2336, DOI 10.1093/nar/25.12.2336; KUNG VT, 1977, J BIOL CHEM, V252, P5398; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE GW, 1984, MYCOBACTERIA SOURC A, V15, P25; LIU LF, 1983, J BIOL CHEM, V258, P5365; LIU LF, 1976, J MOL BIOL, V106, P439, DOI 10.1016/0022-2836(76)90095-4; LYNN RM, 1989, PROTEINS, V6, P231, DOI 10.1002/prot.340060305; MARKIEWICZ P, 1992, GENE DEV, V6, P2010, DOI 10.1101/gad.6.10.2010; MATSON SW, 1981, J BACTERIOL, V146, P275, DOI 10.1128/JB.146.1.275-284.1981; MAXWELL A, 1986, ADV PROTEIN CHEM, V38, P69, DOI 10.1016/S0065-3233(08)60526-4; MAZEN A, 1988, ANAL BIOCHEM, V172, P39, DOI 10.1016/0003-2697(88)90408-3; Quinones A, 1997, MOL MICROBIOL, V25, P237, DOI 10.1046/j.1365-2958.1997.4531718.x; Ramesh V, 1996, J MOL BIOL, V260, P22, DOI 10.1006/jmbi.1996.0379; RASTOGI N, 1993, RES MICROBIOL, V144, P103, DOI 10.1016/0923-2508(93)90022-T; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; Sambrook J., 2002, MOL CLONING LAB MANU; SMITH DJ, 1975, BIOCHEMISTRY-US, V14, P766, DOI 10.1021/bi00675a019; SRIVENUGOPAL KS, 1985, BIOCHEMISTRY-US, V24, P4766, DOI 10.1021/bi00339a009; STROL K, 1989, BIOMED BIOCHIM ACTA, V48, P69; SUGINO A, 1978, P NATL ACAD SCI USA, V75, P4838, DOI 10.1073/pnas.75.10.4838; TOUR CB, 1993, BIOCHIM BIOPHYS ACTA, V1216, P213; TSE YC, 1980, J BIOL CHEM, V255, P5560; TSEDINH YC, 1988, J BIOL CHEM, V263, P15857; TSEDINH YC, 1986, J MOL BIOL, V191, P321, DOI 10.1016/0022-2836(86)90129-4; TSEDINH YC, 1991, J BIOL CHEM, V266, P14317; VIZAN JL, 1991, EMBO J, V10, P467, DOI 10.1002/j.1460-2075.1991.tb07969.x; WANG JC, 1971, J MOL BIOL, V55, P523, DOI 10.1016/0022-2836(71)90334-2; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Yang FD, 1996, GENE, V178, P63, DOI 10.1016/0378-1119(96)00335-6	44	59	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13925	13932		10.1074/jbc.273.22.13925	http://dx.doi.org/10.1074/jbc.273.22.13925			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593741	hybrid, Green Accepted			2022-12-27	WOS:000073919100080
J	Kosari, F; Sheng, SH; Li, JQ; Mak, DOD; Foskett, JK; Kleyman, TR				Kosari, F; Sheng, SH; Li, JQ; Mak, DOD; Foskett, JK; Kleyman, TR			Subunit stoichiometry of the epithelial sodium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE NA+ CHANNEL; MEMBRANE TOPOLOGY; POTASSIUM CHANNEL; ION CHANNELS; AMILORIDE; ALDOSTERONE; EXPRESSION; TRANSPORT; MUTATIONS; CLONING	The epithelial Na+ Channel (ENaC) mediates Na+ reabsorption in a variety of epithelial tissues. ENaC is composed of three homologous subunits, termed alpha, beta, and gamma, All three subunits participate in channel formation as the absence of any one subunit results in a significant reduction or complete abrogation of Na+ current expression in Xenopus oocytes. To determine the subunit stoichiometry, a biophysical assay was employed utilizing mutant subunits that display significant differences in sensitivity to channel blockers from the wild type channel. Our results indicate that ENaC is a tetrameric channel with an alpha(2) beta gamma stoichiometry, similar to that reported for other cation selective channels, such as K-v, K-ir, as well as voltage-gated Na+ and Ca2+ channels that have 4-fold internal symmetry.	Vet Adm Med Ctr, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Physiol, Philadelphia, PA 19104 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Pennsylvania; University of Pennsylvania	Kleyman, TR (corresponding author), Vet Adm Med Ctr, Univ & Woodlands Ave, Philadelphia, PA 19104 USA.	kleyman@mail.med.upenn.edu	Sheng, Shaohu/G-7052-2016; Foskett, Kevin/R-2549-2019	Sheng, Shaohu/0000-0002-7198-1702; Foskett, J. Kevin/0000-0002-8854-0268	NHLBI NIH HHS [HL07027] Funding Source: Medline; NIDDK NIH HHS [DK50268, DK51391] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050268, R01DK051391, R37DK051391] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENOS DJ, 1995, J MEMBRANE BIOL, V143, P1; Berdiev BK, 1998, BIOPHYS J, V74, pA402; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CATTERALL WA, 1993, TRENDS NEUROSCI, V16, P500, DOI 10.1016/0166-2236(93)90193-P; Chang SS, 1996, NAT GENET, V12, P248, DOI 10.1038/ng0396-248; Corey DP, 1996, SCIENCE, V273, P323, DOI 10.1126/science.273.5273.323; DUC C, 1994, J CELL BIOL, V127, P1907, DOI 10.1083/jcb.127.6.1907; FerrerMontiel AV, 1996, P NATL ACAD SCI USA, V93, P2741, DOI 10.1073/pnas.93.7.2741; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; GarciaAnoveros J, 1997, P NATL ACAD SCI USA, V94, P1459, DOI 10.1073/pnas.94.4.1459; GARTY H, 1994, FASEB J, V8, P522, DOI 10.1096/fasebj.8.8.8181670; GARTY H, 1992, SEMIN NEPHROL, V12, P24; HANSSON JH, 1995, NAT GENET, V11, P76, DOI 10.1038/ng0995-76; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; Ismailov II, 1997, J BIOL CHEM, V272, P21075, DOI 10.1074/jbc.272.34.21075; KLEYMAN TR, 1990, METHOD ENZYMOL, V191, P739; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; LINGUEGLIA E, 1995, NATURE, V378, P730, DOI 10.1038/378730a0; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MCCORMACK K, 1992, BIOPHYS J, V63, P1406, DOI 10.1016/S0006-3495(92)81703-4; McNicholas CM, 1997, J GEN PHYSIOL, V109, P681, DOI 10.1085/jgp.109.6.681; Moore DD, 1995, GLOB MOB SURV; RENARD S, 1994, J BIOL CHEM, V269, P12981; Rossier B C, 1994, Curr Opin Nephrol Hypertens, V3, P487, DOI 10.1097/00041552-199409000-00003; Schild L, 1997, J GEN PHYSIOL, V109, P15, DOI 10.1085/jgp.109.1.15; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; SMITH PR, 1991, ANNU REV PHYSIOL, V53, P509, DOI 10.1146/annurev.ph.53.030191.002453; SNYDER PM, 1994, J BIOL CHEM, V269, P24379; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681; STAUB O, 1992, J CELL BIOL, V119, P1497, DOI 10.1083/jcb.119.6.1497; TANG JM, 1992, METHOD ENZYMOL, V207, P176; Tavernarakis N, 1997, ANNU REV PHYSIOL, V59, P659, DOI 10.1146/annurev.physiol.59.1.659; VERREY F, 1995, J MEMBRANE BIOL, V144, P93; Waldmann R, 1997, J BIOL CHEM, V272, P20975, DOI 10.1074/jbc.272.34.20975; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; WALDMANN R, 1995, J BIOL CHEM, V270, P27411, DOI 10.1074/jbc.270.46.27411; Yang J, 1995, NEURON, V15, P1441, DOI 10.1016/0896-6273(95)90021-7	39	175	178	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13469	13474		10.1074/jbc.273.22.13469	http://dx.doi.org/10.1074/jbc.273.22.13469			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593680	hybrid			2022-12-27	WOS:000073919100019
J	Roberts, LJ; Montine, TJ; Markesbery, WR; Tapper, AR; Hardy, P; Chemtob, S; Dettbarn, WD; Morrow, JD				Roberts, LJ; Montine, TJ; Markesbery, WR; Tapper, AR; Hardy, P; Chemtob, S; Dettbarn, WD; Morrow, JD			Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RADICAL-CATALYZED MECHANISM; N-3 FATTY-ACIDS; ALZHEIMERS-DISEASE; IN-VIVO; NONCYCLOOXYGENASE; GENERATION; SERIES; F-2-ISOPROSTANES; PROSTAGLANDINS; PROSTANOIDS	F-2-isoprostanes are prostaglandin F-2-like compounds that are formed nonenzymatically by free radical-induced oxidation of arachidonic acid. We explored whether oxidation of docosahexaenoic acid (C22:6 omega 3), which is highly enriched in the brain, led to the formation of F-2-isoprostane-like compounds, which we term F-4-neuroprostanes. Oxidation of docosahexaenoic acid in vitro yielded a series of compounds that were structurally established to be F-4-neuroprostanes using a number of mass spectrometric approaches. The amounts formed exceeded levels of F-2-isoprostanes generated from arachidonic acid by 3.4-fold. F-4-neuroprostanes were detected esterified in normal whole rat brain and newborn pig cortex at a level of 7.0 +/- 1.4 ng/g and 13.1 +/- 8 ng/g, respectively. Furthermore, F-4-neuroprostanes could be detected in normal human cerebrospinal fluid and levels in patients with Alzheimer's disease (110 +/- 12 pg/ml) were significantly higher than age-matched controls (64 +/- 8 pg/ml) (p < 0.05), F-4-neuroprostanes may provide a unique marker of oxidative injury to the brain and could potentially exert biological activity. Furthermore, the formation of F-4-neuroprostane-containing aminophospholipids might adversely effect neuronal function as a result of alterations they induce in the biophysical properties of neuronal membranes.	Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Pathol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA; Univ Kentucky, Sanders Brown Ctr Aging, Dept Pathol, Lexington, KY 40536 USA; Univ Kentucky, Sanders Brown Ctr Aging, Dept Neurol, Lexington, KY 40536 USA; Hop St Justine, Ctr Rech, Dept Pediat, Montreal, PQ H3T IC5, Canada; Hop St Justine, Ctr Rech, Dept Pharmacol, Montreal, PQ H3T IC5, Canada	Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Kentucky; University of Kentucky; Universite de Montreal; Universite de Montreal	Roberts, LJ (corresponding author), Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA.	jack.roberts@mcmail.vanderbilt.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM042056, R01GM042056] Funding Source: NIH RePORTER; NIA NIH HHS [AG00774] Funding Source: Medline; NIDDK NIH HHS [DK48831] Funding Source: Medline; NIGMS NIH HHS [GM42056] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOURRE JM, 1984, J NEUROCHEM, V43, P342, DOI 10.1111/j.1471-4159.1984.tb00906.x; CONNOR WE, 1992, NUTR REV, V50, P21; Dratz E. A., 1986, Health effects of polyunsaturated fatty acids in seafoods, P319; KHACHATURIAN ZS, 1985, ARCH NEUROL-CHICAGO, V42, P1097, DOI 10.1001/archneur.1985.04060100083029; Knight JA, 1997, ANN CLIN LAB SCI, V27, P11; LONGMIRE AW, 1994, BIOCHEM PHARMACOL, V47, P1173, DOI 10.1016/0006-2952(94)90389-1; Lovell MA, 1997, NEUROBIOL AGING, V18, P457, DOI 10.1016/S0197-4580(97)00108-5; Markesbery WR, 1997, FREE RADICAL BIO MED, V23, P134, DOI 10.1016/S0891-5849(96)00629-6; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; Montine TJ, 1997, AM J PATHOL, V151, P1571; MOORE SA, 1991, J NEUROCHEM, V56, P518, DOI 10.1111/j.1471-4159.1991.tb08180.x; Morrow JD, 1996, J BIOL CHEM, V271, P23185, DOI 10.1074/jbc.271.38.23185; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; MORROW JD, 1994, J BIOL CHEM, V269, P4317; Morrow JD, 1997, PROG LIPID RES, V36, P1, DOI 10.1016/S0163-7827(97)00001-5; MORROW JD, 1994, METHOD ENZYMOL, V233, P163; MORROW JD, 1990, ANAL BIOCHEM, V184, P1, DOI 10.1016/0003-2697(90)90002-Q; PACEASCIAK C, 1971, J CHROMATOGR, V56, P129, DOI 10.1016/S0021-9673(00)97786-0; PACEASCIAK CR, 1989, ADV PROSTAGLANDIN TH, V18, P322; Roberts LJ, 1997, BBA-LIPID LIPID MET, V1345, P121, DOI 10.1016/S0005-2760(96)00162-2; SALEM N, 1995, MOL MEMBR BIOL, V12, P131, DOI 10.3109/09687689509038508; Salem N. Jr., 1986, Health effects of polyunsaturated fatty acids in seafoods, P263; Simonian NA, 1996, ANNU REV PHARMACOL, V36, P83, DOI 10.1146/annurev.pa.36.040196.000503; SKINNER ER, 1993, BRAIN, V116, P717, DOI 10.1093/brain/116.3.717; Taber DF, 1997, PROSTAGLANDINS, V53, P63, DOI 10.1016/S0090-6980(97)00005-1	26	343	362	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13605	13612		10.1074/jbc.273.22.13605	http://dx.doi.org/10.1074/jbc.273.22.13605			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593698	hybrid			2022-12-27	WOS:000073919100037
J	Ziemnicka-Kotula, D; Xu, JL; Gu, H; Potempska, A; Kim, KS; Jenkins, EC; Trenkner, E; Kotula, L				Ziemnicka-Kotula, D; Xu, JL; Gu, H; Potempska, A; Kim, KS; Jenkins, EC; Trenkner, E; Kotula, L			Identification of a candidate human spectrin Src homology 3 domain-binding protein suggests a general mechanism of association of tyrosine kinases with the spectrin-based membrane skeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRAIN SPECTRIN; ALPHA-SPECTRIN; SIGNAL-TRANSDUCTION; ERYTHROCYTE SPECTRIN; PLASMA-MEMBRANE; PEST SEQUENCES; BETA-SPECTRIN; SH3 DOMAINS; SITE; FODRIN	Spectrin is a widely expressed protein with specific isoforms found in erythroid and nonerythroid cells. Spectrin contains an Src homology 3 (SH3) domain of unknown function. A cDNA encoding a candidate spectrin SH3 domain-binding protein was identified by interaction screening of a human brain expression library using the human erythroid spectrin (alpha I) SH3 domain as a bait. Five isoforms of the alpha I SH3 domain-binding protein mRNA were identified in human brain, Mapping of SH3 binding regions revealed the presence of two alpha I SH3 domain binding regions and one Abl-SH3 domain binding region. The gene encoding the candidate spectrin SH3 domain-binding protein has been located to human chromosome 10p11.2 --> p12. The gene belongs to a recently identified family of tyrosine kinase-binding proteins, and one of its isoforms is identical to e3B1, an eps8-binding protein (Biesova, Z., Piccoli, C., and Wong, W. T. (1997)Oncogene 14, 233-241). Overexpression of the green fluorescent protein fusion of the SH3 domain-binding protein in NIH3T3 cells resulted in cytoplasmic punctate fluorescence characteristic of the reticulovesicular system. This fluorescence pattern was similar to that obtained with the anti-human erythroid spectrin alpha I Sigma I/beta I Sigma I antibody in untransfected NIH3T3 cells; in addition, the anti-alpha I Sigma I/beta I Sigma I antibody also stained Golgi apparatus. Immunofluorescence obtained using antibodies against alpha I Sigma I/beta I Sigma I spectrin and Abl tyrosine kinase but not against alpha II/beta II spectrin colocalized with the overexpressed green fluorescent protein-SH3-binding protein. Based on the conservation of the spectrin SH3 binding site within members of this protein family and published interactions, a general mechanism of interactions of tyrosine kinases with the spectrin-based membrane skeleton is proposed.	New York State Inst Basic Res Dev Disabil, Mol Neurobiol Lab, Staten Isl, NY 10314 USA	Institute for Basic Research in Developmental Disabilities	Kotula, L (corresponding author), New York State Inst Basic Res Dev Disabil, Mol Neurobiol Lab, 1050 Forest Hill Rd, Staten Isl, NY 10314 USA.	kotulal@interport.net		Kotula, Leszek/0000-0002-7977-7124	NINDS NIH HHS [R29 NS032874-05S1, R29 NS032874-05, R29 NS32874] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS032874] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARNES JA, 1995, MOL CELL BIOCHEM, V149, P17, DOI 10.1007/BF01076559; Beck KA, 1996, AM J PHYSIOL-CELL PH, V270, pC1263, DOI 10.1152/ajpcell.1996.270.5.C1263; BECK KA, 1994, J CELL BIOL, V127, P707, DOI 10.1083/jcb.127.3.707; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BENNETT V, 1982, NATURE, V299, P126, DOI 10.1038/299126a0; Biesova Z, 1997, ONCOGENE, V14, P233, DOI 10.1038/sj.onc.1200822; Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARLIER MF, 1984, BIOCHIMIE, V66, P305, DOI 10.1016/0300-9084(84)90007-5; CHENEVERT J, 1992, NATURE, V356, P77, DOI 10.1038/356077a0; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK MB, 1994, BRAIN RES, V663, P223; Devarajan P, 1996, J CELL BIOL, V133, P819, DOI 10.1083/jcb.133.4.819; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRAPPIER T, 1991, BIOCHEM J, V275, P521, DOI 10.1042/bj2750521; Gallagher PG, 1997, J BIOL CHEM, V272, P19220, DOI 10.1074/jbc.272.31.19220; GALLAGHER PG, 1993, SEMIN HEMATOL, V30, P4; Genetic Computer Group, 1994, PROGR MAN WISC PACK; GOODMAN SR, 1995, BRAIN RES BULL, V36, P593, DOI 10.1016/0361-9230(94)00264-2; HARRIS AS, 1988, J BIOL CHEM, V263, P15754; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; Holleran EA, 1996, J CELL BIOL, V135, P1815, DOI 10.1083/jcb.135.6.1815; Hoock TC, 1997, J CELL BIOL, V136, P1059, DOI 10.1083/jcb.136.5.1059; HU RJ, 1992, J BIOL CHEM, V267, P18715; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; JESAITIS AJ, 1988, J CELL BIOL, V107, P921, DOI 10.1083/jcb.107.3.921; Kim K., 1988, NEUROSCI RES COMMUN, V2, P121; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KORDELI E, 1995, J BIOL CHEM, V270, P2352, DOI 10.1074/jbc.270.5.2352; KOTULA L, 1993, J BIOL CHEM, V268, P14788; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE J, 1981, J CELL BIOL, V90, P631, DOI 10.1083/jcb.90.3.631; Lux SE, 1995, BLOOD PRINCIPLES PRA, P1701; MITELMAN P, 1995, ISCN INT SYSTEM HUMA; MOON RT, 1990, J BIOL CHEM, V265, P4427; MORROW JS, 1996, HDB PHYSL, P485; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; PERRIN D, 1987, NATURE, V326, P498, DOI 10.1038/326498a0; PETERS LL, 1993, SEMIN HEMATOL, V30, P85; Porter GA, 1997, CELL MOTIL CYTOSKEL, V37, P7, DOI 10.1002/(SICI)1097-0169(1997)37:1<7::AID-CM2>3.0.CO;2-7; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; REDDY BA, 1992, MECH DEVELOP, V39, P143, DOI 10.1016/0925-4773(92)90041-H; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RIEDERER BM, 1986, J CELL BIOL, V102, P2088, DOI 10.1083/jcb.102.6.2088; RIEDERER BM, 1990, FEBS LETT, V277, P49, DOI 10.1016/0014-5793(90)80807-U; RUFF P, 1991, P NATL ACAD SCI USA, V88, P6595, DOI 10.1073/pnas.88.15.6595; SAHR KE, 1990, J BIOL CHEM, V265, P4434; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; SIKORSKI AF, 1991, J CELL BIOL, V114, P313, DOI 10.1083/jcb.114.2.313; SIMAN R, 1987, J NEUROSCI, V7, P55; SPEICHER DW, 1984, NATURE, V311, P177, DOI 10.1038/311177a0; Wang BL, 1996, ONCOGENE, V12, P1921; WASENIUS VM, 1989, J CELL BIOL, V108, P79, DOI 10.1083/jcb.108.1.79; WINKELMANN JC, 1993, BLOOD, V81, P3173; YAN Y, 1993, SCIENCE, V262, P2027, DOI 10.1126/science.8266097; YAO XL, 1994, J CELL BIOCHEM, V54, P473, DOI 10.1002/jcb.240540414; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; ZHONGHAN D, 1995, GENE DEV, V9, P2569; Zhou DX, 1997, J CELL BIOL, V136, P621, DOI 10.1083/jcb.136.3.621	65	77	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13681	13692		10.1074/jbc.273.22.13681	http://dx.doi.org/10.1074/jbc.273.22.13681			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593709	hybrid			2022-12-27	WOS:000073919100048
J	Bessereau, JL; Laudenbach, V; Le Poupon, C; Changeux, JP				Bessereau, JL; Laudenbach, V; Le Poupon, C; Changeux, JP			Nonmyogenic factors bind nicotinic acetylcholine receptor promoter elements required for response to denervation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT GENE; MUSCLE-SPECIFIC EXPRESSION; TRANSCRIPTION FACTOR USF; PREFERENTIAL SYNAPTIC EXPRESSION; MOUSE SKELETAL-MUSCLE; ELECTRICAL-ACTIVITY; MYOGENIC FACTORS; NEUROMUSCULAR-JUNCTION; TRANSGENIC MICE; E-BOX	Nicotinic acetylcholine receptors (AChRs) belong to a class of muscle proteins whose expression is regulated by muscle electrical activity. In innervated muscle fiber, AChR genes are transcriptionally repressed outside of the synapse, while after denervation they become reexpressed throughout the fiber. The myogenic determination factors (MDFs) of the MyoD family have been shown to play a central role in this innervation-dependent regulation. In the chicken AChR alpha-subunit gene promoter, two E-boxes that bind MDFs are necessary to achieve the enhancement of transcription following muscle denervation. However, the deletion of promoter sequences located upstream to these E-boxes greatly impairs the response to denervation (Bessereau, J, L,, Stratford-Perricaudet, L, D,, Piette, J,, Le Poupon, C, and Changeux, J, P, (1994) Proc. Natl Acad. Sci, U, S, A. 91, 1304-1308), Here we identified two additional cia-regulatory elements of the alpha-subunit gene promoter that cooperate with the E-boxes in the denervation response. One region binds the Sp1 and Sp3 zinc finger transcription factors. The second region binds at least three distinct factors, among which we identified an upstream stimulatory factor, a b-ZIP-HLH transcription factor. We propose that among MDF-responsive muscle promoters, a specific combination between myogenic and nonmyogenic factors specify innervation-dependent versus innervation-independent promoters.	Inst Pasteur, Dept Biotechnol, CNRS, UA D1284, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Changeux, JP (corresponding author), Inst Pasteur, Dept Biotechnol, CNRS, UA D1284, 25-28 Rue Dr Roux, F-75724 Paris 15, France.		Bessereau, Jean-Louis/M-2988-2017	Bessereau, Jean-Louis/0000-0002-3088-7621				BESSEREAU JL, 1994, P NATL ACAD SCI USA, V91, P1304, DOI 10.1073/pnas.91.4.1304; BESSEREAU JL, 1993, EMBO J, V12, P443, DOI 10.1002/j.1460-2075.1993.tb05676.x; Carter RS, 1997, MOL CELL BIOL, V17, P18, DOI 10.1128/MCB.17.1.18; CHAHINE KG, 1992, DEVELOPMENT, V115, P213; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; DAVIS HL, 1993, HUM GENE THER, V4, P733, DOI 10.1089/hum.1993.4.6-733; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; DUCLERT A, 1991, NEUROREPORT, V2, P25, DOI 10.1097/00001756-199101000-00006; DUCLERT A, 1993, P NATL ACAD SCI USA, V90, P3043, DOI 10.1073/pnas.90.7.3043; DUCLERT A, 1995, PHYSIOL REV, V75, P339, DOI 10.1152/physrev.1995.75.2.339; DUTTON K, 1993, P NATL ACAD SCI USA, V90, P2040; EFTIMIE R, 1991, P NATL ACAD SCI USA, V88, P1349, DOI 10.1073/pnas.88.4.1349; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; GILMOUR BP, 1995, DEV BIOL, V168, P416, DOI 10.1006/dbio.1995.1091; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; Huang J, 1996, MOL CELL BIOL, V16, P3893; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; Kaytor EN, 1997, J BIOL CHEM, V272, P7525, DOI 10.1074/jbc.272.11.7525; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KLARSFELD A, 1987, MOL CELL BIOL, V7, P951, DOI 10.1128/MCB.7.2.951; KLARSFELD A, 1991, EMBO J, V10, P625, DOI 10.1002/j.1460-2075.1991.tb07990.x; LEFRANCOISMARTINEZ AM, 1995, J BIOL CHEM, V270, P2640, DOI 10.1074/jbc.270.6.2640; Liang YX, 1996, J BIOL CHEM, V271, P11792, DOI 10.1074/jbc.271.20.11792; LIN H, 1991, MOL CELL BIOL, V11, P267, DOI 10.1128/MCB.11.1.267; LIN Q, 1994, J BIOL CHEM, V269, P23894; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; MENDELZON D, 1994, BIOCHEMISTRY-US, V33, P2568, DOI 10.1021/bi00175a028; MERLIE JP, 1994, J BIOL CHEM, V269, P2461; MERLIE JP, 1989, NEURON, V2, P1295, DOI 10.1016/0896-6273(89)90067-6; PIETTE J, 1989, EMBO J, V8, P687, DOI 10.1002/j.1460-2075.1989.tb03427.x; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; PRODY CA, 1991, J BIOL CHEM, V266, P22588; SALMON AM, 1992, NEUROREPORT, V3, P973, DOI 10.1097/00001756-199211000-00006; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SIMON AM, 1993, MOL CELL BIOL, V13, P5133, DOI 10.1128/MCB.13.9.5133; SIMON AM, 1992, DEVELOPMENT, V114, P545; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; SU CT, 1995, FEBS LETT, V366, P131, DOI 10.1016/0014-5793(95)00496-V; TANG JC, 1994, DEVELOPMENT, V120, P1799; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; Walke W, 1996, J NEUROSCI, V16, P3641; WITZEMANN V, 1991, FEBS LETT, V282, P259, DOI 10.1016/0014-5793(91)80490-T; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918	47	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					12786	12793		10.1074/jbc.273.21.12786	http://dx.doi.org/10.1074/jbc.273.21.12786			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582305	hybrid			2022-12-27	WOS:000073768500016
J	Blagosklonny, MV; An, WG; Romanova, LY; Trepel, J; Fojo, T; Neckers, L				Blagosklonny, MV; An, WG; Romanova, LY; Trepel, J; Fojo, T; Neckers, L			p53 inhibits hypoxia-inducible factor-stimulated transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO; ACTIVATION; ARREST; CELLS; CHECKPOINT; APOPTOSIS; PROTEIN; BINDING; MUTANT; P21	p53 is required for hypoxia-induced apoptosis in vivo, although the mechanism by which this occurs is not known. Conversely, induction of the hypoxia-inducible factor-1 (HIF-1) transactivator stimulates transcription of a number of genes crucial to survival of the hypoxic state. Here we demonstrate that p53 represses HIF-1-stimulated transcription. Although higher levels of p53 are required to inhibit HIF than are necessary to transcriptionally activate p53 target genes, these levels of p53 are similar to those that stimulate cleavage of poly(ADP-ribose) polymerase, an early event in apoptosis, Transfection of full-length p300 stimulates both p53-dependent and HIF-dependent transcription but does not relieve p53-mediated inhibition of HIF. In contrast, a p300 fragment, which binds to p53 but not to HIF-1, prevents p53-dependent repression of HIF activity. Transcriptionally inactive p53, mutated in its DNA binding domain, retains the ability to block HIF transactivating activity, whereas a transcriptionally inactive double point mutant defective for p300 binding does not inhibit HIF. Finally, depletion of doxorubicin-induced endogenous p53 by E6 protein attenuates doxorubicin-stimulated inhibition of HIF, suggesting that a p53 level sufficient for HIF inhibition can be achieved in vivo. These data support a model in which stoichiometric binding of p53 to a HIF/p300 transcriptional complex mediates inhibition of HIF activity.	NCI, Med Branch, Dept Expt Therapeut, NIH, Bethesda, MD 20892 USA; NCI, Med Branch, Dept Cell & Canc Biol, NIH, Bethesda, MD 20892 USA; NCI, Genet Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Blagosklonny, MV (corresponding author), NCI, Med Branch, Dept Expt Therapeut, NIH, Bldg 10,Rm 12N226, Bethesda, MD 20892 USA.							An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Blagosklonny MV, 1996, INT J CANCER, V67, P386, DOI 10.1002/(SICI)1097-0215(19960729)67:3<386::AID-IJC13>3.0.CO;2-6; Blagosklonny MV, 1996, P NATL ACAD SCI USA, V93, P8379, DOI 10.1073/pnas.93.16.8379; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; Mazure NM, 1996, CANCER RES, V56, P3436; ROLLEY N, 1995, ONCOGENE, V11, P763; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; WALDMAN T, 1995, CANCER RES, V55, P5187; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510	22	254	272	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					11995	11998		10.1074/jbc.273.20.11995	http://dx.doi.org/10.1074/jbc.273.20.11995			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575138	hybrid			2022-12-27	WOS:000073629800003
J	Jucker, BM; Lee, JY; Shulman, RG				Jucker, BM; Lee, JY; Shulman, RG			In vivo C-13 NMR measurements of hepatocellular tricarboxylic acid cycle flux	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFUSED-RAT-LIVER; KREBS CYCLE; HEPATOCYTE HETEROGENEITY; METABOLIC FLUX; HUMAN BRAIN; GLUTAMATE; GLUCONEOGENESIS; SPECTROSCOPY; ETHANOL; HEARTS	A combined isotopic steady state and in vivo isotopic non-steady state analysis was used to calculate tricarboxylic acid cycle flux in livers of anesthetized rats infused with ethanol, In vivo C-13 NMR spectroscopy was used to non-invasively observe label turnover of [4-C-13]glutamate, [4-C-13]glutamine, and [2-C-13]glutamate/glutamine in liver following a bolus intravenous infusion of [2-C-13]ethanol. The isotopic steady state analysis of [2-C-13], [3-C-13], and [4-C-13]glutamate isotopomers (Malloy, C. R., Sherry, A. D., and Jeffrey, F. M. H. (1988) J. Biol. Chem. 263, 6964-6971) in liver extracts was used to indirectly calculate the anaplerotic flux (0.90 +/- 0.07 x citrate synthase flux) and [2-C-13]acetyl-CoA fractional enrichment (51.4 +/- 3.4%). The [4-C-13]glutamate, [4-C-13]glutamine, and [2-C-13]glutamate fractional enrichments determined in liver extracts were 23.0 +/- 1.1, 17.2 +/- 1.5, and 7.7 +/- 0.5%, respectively. These data in addition to blood [2-C-13]acetate and [4-C-13]glutamine enrichment time course data were used in conjunction with a metabolic steady state mathematical analysis designed to account for liver glutamate and glutamine label dilution as a consequence of glutamine exchange with blood to calculate the tricarboxylic acid (tca) cycle flux (V-tca = 0.33 +/- 0.09 mu mol/g wet weight/min) in liver. In summary, It is possible to detect C-13 labeling of glutamate and glutamine in liver via non-invasive C-13 NMR, Additionally, the in vivo C-13 labeling kinetics of glutamate and glutamine in liver and glutamine in blood may be used to calculate the liver tricarboxylic acid cycle flux.	Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA; Yale Univ, Dept Chem, New Haven, CT 06510 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06510 USA	Yale University; Yale University; Yale University	Jucker, BM (corresponding author), Yale Univ, Sch Med, Dept Internal Med, 333 Cedar St,Fitkin 1,POB 208020, New Haven, CT 06520 USA.				NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA009385] Funding Source: NIH RePORTER; NIAAA NIH HHS [R01-AA09385] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BEYLOT M, 1995, J BIOL CHEM, V270, P1509, DOI 10.1074/jbc.270.4.1509; BRADBURY MWB, 1993, EXP PHYSIOL, V78, P453, DOI 10.1113/expphysiol.1993.sp003698; BUTTROSE M, 1987, AM J PHYSIOL, V252, pE746, DOI 10.1152/ajpendo.1987.252.6.E746; CHANCE EM, 1983, J BIOL CHEM, V258, P3785; CHATHAM JC, 1995, J BIOL CHEM, V270, P7999, DOI 10.1074/jbc.270.14.7999; CLINE GW, 1995, J BIOL CHEM, V270, P28062; COHEN SM, 1979, P NATL ACAD SCI USA, V76, P4808, DOI 10.1073/pnas.76.10.4808; DIDONATO L, 1993, J BIOL CHEM, V268, P4170; DRAKE RL, 1983, J BIOL CHEM, V258, P6008; ERIKSSON CJ, 1974, BIOCHEM PHARMACOL, V23, P2193, DOI 10.1016/0006-2952(74)90587-5; FAFOURNOUX P, 1983, BIOCHEM J, V216, P401, DOI 10.1042/bj2160401; FITZPATRICK SM, 1990, J CEREBR BLOOD F MET, V10, P170, DOI 10.1038/jcbfm.1990.32; FORSANDER OA, 1967, BIOCHEM J, V105, P93, DOI 10.1042/bj1050093; FRAHM J, 1987, J MAGN RESON, V72, P502, DOI 10.1016/0022-2364(87)90154-5; GRUETTER R, 1994, J NEUROCHEM, V63, P1377; HAUSSINGER D, 1983, EUR J BIOCHEM, V136, P421, DOI 10.1111/j.1432-1033.1983.tb07759.x; JACOB R, 1983, AM J PHYSIOL, V251, pE509; JORFELDT L, 1978, METABOLISM, V27, P97, DOI 10.1016/0026-0495(78)90128-2; Jucker BM, 1997, J BIOL CHEM, V272, P10464, DOI 10.1074/jbc.272.16.10464; JUNGERMANN K, 1992, ENZYME, V46, P33, DOI 10.1159/000468777; KATZ J, 1993, J BIOL CHEM, V268, P25509; KILBERG MS, 1980, J BIOL CHEM, V255, P4011; LIEBER CS, 1967, J CLIN INVEST, V46, P1451, DOI 10.1172/JCI105637; LINDENEG O, 1964, CLIN SCI, V27, P427; LOW SY, 1992, BIOCHEM J, V284, P333, DOI 10.1042/bj2840333; LUNDQUIST F, 1962, J CLIN INVEST, V41, P955, DOI 10.1172/JCI104574; MAGNUSSON I, 1991, J BIOL CHEM, V266, P6975; MALLOY CR, 1988, J BIOL CHEM, V263, P6964; MASON GF, 1992, J CEREBR BLOOD F MET, V12, P434, DOI 10.1038/jcbfm.1992.61; PARDRIDGE WM, 1997, AM J PHYSIOL, V232, pE492; RABKIN M, 1984, BIOCHEM J, V225, P761; RIFE JE, 1980, BIOCHEMISTRY-US, V19, P2321, DOI 10.1021/bi00552a007; ROSIERS CD, 1995, J BIOL CHEM, V270, P10027, DOI 10.1074/jbc.270.17.10027; ROTHMAN DL, 1991, SCIENCE, V254, P573, DOI 10.1126/science.1948033; ROTHMAN DL, 1992, P NATL ACAD SCI USA, V89, P9603, DOI 10.1073/pnas.89.20.9603; SCHUMANN WC, 1991, J BIOL CHEM, V266, P6985; SHELMET JJ, 1988, J CLIN INVEST, V81, P1137, DOI 10.1172/JCI113428; SILVER MS, 1984, NATURE, V310, P681, DOI 10.1038/310681a0; TAYLOR WM, 1986, BIOCHEM J, V233, P321, DOI 10.1042/bj2330321; THURMAN RG, 1977, EUR J BIOCHEM, V75, P13, DOI 10.1111/j.1432-1033.1977.tb11499.x; VEECH RL, 1972, BIOCHEM J, V127, P387, DOI 10.1042/bj1270387; Vogt JA, 1997, AM J PHYSIOL-CELL PH, V272, pC2049, DOI 10.1152/ajpcell.1997.272.6.C2049; WEISS RG, 1995, BBA-GEN SUBJECTS, V1243, P543, DOI 10.1016/0304-4165(95)00031-6; WEISS RG, 1992, CIRC RES, V70, P392, DOI 10.1161/01.RES.70.2.392; WELBOURNE TC, 1986, AM J PHYSIOL, V250, pE457, DOI 10.1152/ajpendo.1986.250.4.E457; WILLIAMSON JR, 1969, J BIOL CHEM, V244, P5044; Yu X, 1995, BIOPHYS J, V69, P2090, DOI 10.1016/S0006-3495(95)80080-9	47	35	35	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12187	12194		10.1074/jbc.273.20.12187	http://dx.doi.org/10.1074/jbc.273.20.12187			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575166	hybrid			2022-12-27	WOS:000073629800031
J	Robledo, MM; Sanz-Rodriguez, F; Hidalgo, A; Teixido, J				Robledo, MM; Sanz-Rodriguez, F; Hidalgo, A; Teixido, J			Differential use of very late antigen-4 and -5 integrins by hematopoietic precursors and myeloma cells to adhere to transforming growth factor-beta 1-treated bone marrow stroma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BETA; ADHESION MOLECULE-1; FIBRONECTIN; EXPRESSION; PROLIFERATION; RECEPTORS; VLA-4; LINES; PROGENITORS; PROTEINS	The very late antigen (VLA)-4 and VLA-5 integrins mediate hematopoietic progenitor cell attachment to bone marrow (BM) stroma, Transforming growth factor-beta (TGF-beta 1) is a cytokine present in the BM microenvironment that has been shown to regulate the synthesis of adhesion elements in several cell types. We have investigated whether TGF-beta 1 action on human BM stromal cells affected the adhesion of progenitor cells involving integrins VLA-4 and VLA-5. Two precursor cell lines, pre-B Nalm-6 and the multipotential UT-7, attached to untreated primary stroma and to the human BM stromal cell line Str-5 preferentially using VLA-4, However, treatment of the stroma with TGF-beta 1 resulted in a significant reduction in the participation of VLA-4 in mediating precursor cell adhesion to stroma and a concomitant increase in the utilization of VLA-5. This effect was not exclusive of normal BM stroma, Treatment with TGF-beta 1 of stroma from multiple myeloma BM samples produced a substantial increase in VLA-5 use by the myeloma cell line NCI-H929 to adhere to this stroma. The differential use of VLA-4 and VLA-5 correlated with an increase in fibronectin surface expression by stromal cells in response to TGF-beta 1. Adhesion assays to purified fibronectin using Nalm-6 cells showed a predominant utilization of VLA-4 at low concentrations of this ligand, whereas higher concentrations resulted in a preferential use of VLA-5. These results indicate that regulation of fibronectin expression on BM stromal cells by TGF-beta 1 results in a modulation of the pattern of integrins used by the precursor and myeloma cells to adhere to BM stroma, which could have important consequences on the proliferation and differentiation of hematopoietic precursor cells as well as on the localization and growth of myeloma cells.	Ctr Invest Biol, Dept Inmunol, Madrid 26006, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Teixido, J (corresponding author), Ctr Invest Biol, Dept Inmunol, Velazquez 144, Madrid 26006, Spain.		Hidalgo, Andrés/L-5643-2014; Sanz-Rodriguez, Francisco/AAK-8388-2020; Teixidó, Joaquin/J-8543-2014	Hidalgo, Andrés/0000-0001-5513-555X; 				Arroyo AG, 1996, CELL, V85, P997, DOI 10.1016/S0092-8674(00)81301-X; BAUVOIS B, 1992, J IMMUNOL, V148, P3912; DITTEL BN, 1993, BLOOD, V81, P2272; DORSHKIND K, 1990, ANNU REV IMMUNOL, V8, P111, DOI 10.1146/annurev.iy.08.040190.000551; DUBOIS CM, 1994, BLOOD, V83, P3138; FAVA RA, 1990, BLOOD, V76, P1946; GIMBLE JM, 1989, BLOOD, V74, P303; HEINO J, 1989, J BIOL CHEM, V264, P380; HURLEY RW, 1995, J CLIN INVEST, V96, P511, DOI 10.1172/JCI118063; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; KELLER JR, 1990, BLOOD, V75, P596; KOMATSU N, 1991, CANCER RES, V51, P341; LAGNEAUX L, 1993, BLOOD, V82, P2379; LEE G, 1987, J EXP MED, V166, P1290, DOI 10.1084/jem.166.5.1290; LEMKE H, 1978, NATURE, V271, P249, DOI 10.1038/271249a0; LIESVELD JL, 1993, BLOOD, V81, P112; Lundell BI, 1996, BLOOD, V87, P2450, DOI 10.1182/blood.V87.6.2450.bloodjournal8762450; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MIYAKE K, 1991, J EXP MED, V173, P599, DOI 10.1084/jem.173.3.599; PATRICK CW, 1995, BLOOD, V85, P168, DOI 10.1182/blood.V85.1.168.bloodjournal851168; Robledo MM, 1996, BRIT J HAEMATOL, V93, P507, DOI 10.1046/j.1365-2141.1996.d01-1698.x; ROLDAN E, 1992, J EXP MED, V175, P1739, DOI 10.1084/jem.175.6.1739; RYAN DH, 1991, J CLIN INVEST, V88, P995, DOI 10.1172/JCI115403; SANCHEZMADRID F, 1986, EUR J IMMUNOL, V16, P1342; SCHWARTZ BR, 1990, J CLIN INVEST, V85, P2019, DOI 10.1172/JCI114668; SUGAHARA H, 1994, J EXP MED, V179, P1757, DOI 10.1084/jem.179.6.1757; TEIXIDO J, 1992, J CLIN INVEST, V90, P358, DOI 10.1172/JCI115870; TEVELDE AA, 1988, J IMMUNOL, V140, P1548; UCHIYAMA H, 1992, BLOOD, V80, P2306; Urashima M, 1996, BLOOD, V87, P1928	30	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12056	12060		10.1074/jbc.273.20.12056	http://dx.doi.org/10.1074/jbc.273.20.12056			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575147	hybrid, Green Published			2022-12-27	WOS:000073629800012
J	Friesen, RHE; Lee, JC				Friesen, RHE; Lee, JC			The negative dominant effects of T340M mutation on mammalian pyruvate kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY HEMOLYTIC-ANEMIA; DOMAIN INTERACTION; POINT MUTATIONS; MUSCLE; ISOZYMES; GENE	A fundamental issue in allosteric regulatory enzymes is the identification of pathways of signal transmission. Rabbit muscle and kidney pyruvate kinase isozymes are ideal to address this issue because these isozymes exhibit different enzymatic regulatory patterns, and the sequence differences between these isozymes have identified the amino acid residues that alter their kinetic behavior. In an earlier study, Cheng et al. (Cheng, X., Friesen, R. H. E., and Lee, J. C. (1996) J. Biol. Chem. 271, 6313-6321), reported the effects of a threonine to methionine mutation at residue 340 in the muscle isozyme. In this study, the same mutation was effected in the kidney isozyme. Qualitatively, the same negative effects are observed in both isozymes, namely a significant decrease in catalytic efficiency and decrease in apparent affinity for phosphoenolpyruvate but no change in affinity for ADP, and a decrease in responsiveness to the presence of effectors, be it activator or inhibitor. Because the diversity in the primary sequence between these two isozymes does molt alter the negative impact of the T340M mutation, it can be concluded that this mutation exerts a dominant, negative effect. The negative effects of T340M mutation on the kinetic properties imply that there is communication between residue 340 and the active site. Residue 340 is located at the 1,4 subunit interface; however, a T340M mutation enhances the dimerization affinity along the 1,2 subunit interface. Thus, this study has identified a communication network among the active site, residue 340, and the 1,2 subunit interface.	Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Lee, JC (corresponding author), Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA.		Lee, James C/A-7849-2009		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045579] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-45579] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beutler E, 1996, HUM MUTAT, V7, P1; BOYER PD, 1962, ENZYMES, V6, P95; BUCHER T, 1955, METHOD ENZYMOL, V1, P435, DOI 10.1016/0076-6879(55)01071-9; Cann J. R., 1970, INTERACTING MACROMOL; Cheng XD, 1996, J BIOL CHEM, V271, P6313, DOI 10.1074/jbc.271.11.6313; CONSLER TG, 1988, J BIOL CHEM, V263, P2794; CONSLER TG, 1992, BIOCHEMISTRY-US, V31, P7870, DOI 10.1021/bi00149a018; CONSLER TG, 1988, J BIOL CHEM, V263, P2787; COX DJ, 1971, ARCH BIOCHEM BIOPHYS, V119, P514; Engstrom L, 1978, Curr Top Cell Regul, V13, P28; FOTHERGILL LA, 1992, PROGR MOL BIOL BIOPH, V59, P105; FRIESEN RHE, 1997, THESIS U TEXAS MED B; Gilbert L M, 1973, Methods Enzymol, V27, P273; HALL ER, 1978, INT J BIOCHEM, V9, P785, DOI 10.1016/0020-711X(78)90027-7; HARRIS SJ, 1995, BIOCHEMISTRY-US, V34, P8752, DOI 10.1021/bi00027a026; Hill AV, 1910, J PHYSIOL-LONDON, V40, P190; KANNO H, 1992, BLOOD, V79, P1347, DOI 10.1182/blood.V79.5.1347.bloodjournal7951347; KANNO H, 1991, P NATL ACAD SCI USA, V88, P8218, DOI 10.1073/pnas.88.18.8218; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN TM, 1994, BIOCHEMISTRY-US, V33, P6301, DOI 10.1021/bi00186a033; LEE JC, 1994, MODERN ANAL ULTRACEN, P138; MATTEVI A, 1995, STRUCTURE, V3, P729, DOI 10.1016/S0969-2126(01)00207-6; Mesecar AD, 1997, BIOCHEMISTRY-US, V36, P6803, DOI 10.1021/bi962870s; Mesecar AD, 1997, BIOCHEMISTRY-US, V36, P6792, DOI 10.1021/bi962869t; NEUBAUER B, 1991, BLOOD, V77, P1871; NICHOL LW, 1964, PROTEINS; NOGUCHI T, 1987, J BIOL CHEM, V262, P14366; NOGUCHI T, 1986, J BIOL CHEM, V261, P3807; OBERFELDER RW, 1984, BIOCHEMISTRY-US, V23, P3813, DOI 10.1021/bi00312a004; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; WYMAN J, 1964, ADV PROTEIN CHEM, V19, P223, DOI 10.1016/S0065-3233(08)60190-4	31	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14772	14779		10.1074/jbc.273.24.14772	http://dx.doi.org/10.1074/jbc.273.24.14772			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614077	hybrid			2022-12-27	WOS:000074160400019
J	Koval, AP; Karas, M; Zick, Y; LeRoith, D				Koval, AP; Karas, M; Zick, Y; LeRoith, D			Interplay of the proto-oncogene proteins CrkL and CrkII in insulin-like growth factor-I receptor-mediated signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-BINDING DOMAIN; MYELOGENOUS LEUKEMIA-CELLS; TYROSINE PHOSPHORYLATION; ADAPTER PROTEINS; PC12 CELLS; C-CRK; SH2; RAS; SRC; SUBSTRATE-1	The closely related proto-oncogene proteins CrkII and CrkL consist of cane SH2 and two SI43 domains and share 60% overall homology with the highest identity within their functional domains. In this study we show that CrkL and CrkII may play overlapping but different roles in insulin-like growth factor (IGF)-I receptor-mediated signal transduction. While both proteins are substrates involved in IGF-I receptor signaling, they apparently demonstrate important different properties and different biological responses. Evidence supporting this hypothesis includes (a) the oncogenic potential of CrkL versus the absence of this potential in CrkII overexpressing cell lines, (b) the inhibition of IGF-I-dependent cell cycle progression by overexpression of CrkII, and (c) the differential regulation of the phosphorylation status of selective proteins in CrkII and CrkL overexpressing cell lines. In addition we demonstrate the specific association of CrkL and CrkII with the newly characterized IRS-4 protein, again in a differential manner. Whereas CrkL strongly interacts with IRS-4 via its SH2 and N-terminal SH3 domains, CrkII interacts only via its SH2 domain, possibly explaining the unstable nature of IRS-4-CrkII association. The results obtained snow us to propose a unique mechanism of CrkL and CrkII tyrosine phosphorylation in response to IGF-I stimulation. Thus these highly homologous proteins apparently possess structural features that allow for the differential association of each protein with different effector molecules, thereby activating different signaling pathways and resulting in unique biological roles of these proteins.	NIDDK, Diabet Branch, NIH, Bethesda, MD 20892 USA; Weizmann Inst Sci, Dept MOl & Cell Biol, IL-76100 Rehovot, Israel	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Weizmann Institute of Science	LeRoith, D (corresponding author), NIDDK, Diabet Branch, NIH, Bethesda, MD 20892 USA.		Zick, Yehiel/K-1479-2012					Ahmad S, 1997, J BIOL CHEM, V272, P29991, DOI 10.1074/jbc.272.48.29991; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; BeitnerJohnson D, 1996, J BIOL CHEM, V271, P9287, DOI 10.1074/jbc.271.16.9287; Bruning JC, 1997, MOL CELL BIOL, V17, P1513; Butler AA, 1997, J BIOL CHEM, V272, P27660, DOI 10.1074/jbc.272.44.27660; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; Chin H, 1997, BIOCHEM BIOPH RES CO, V239, P412, DOI 10.1006/bbrc.1997.7480; DEJONG R, 1995, ONCOGENE, V11, P1469; deJong R, 1997, ONCOGENE, V14, P507, DOI 10.1038/sj.onc.1200885; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; He WM, 1996, J BIOL CHEM, V271, P11641, DOI 10.1074/jbc.271.20.11641; Higuchi R., 1989, PCR TECHNOLOGY, P61; Isakoff SJ, 1996, J BIOL CHEM, V271, P3959; Keller Susanne R., 1994, Trends in Cell Biology, V4, P115, DOI 10.1016/0962-8924(94)90065-5; Khwaja A, 1996, ONCOGENE, V12, P2491; KizakaKondoh S, 1996, P NATL ACAD SCI USA, V93, P12177, DOI 10.1073/pnas.93.22.12177; KNUDSEN BS, 1995, EMBO J, V14, P2191, DOI 10.1002/j.1460-2075.1995.tb07213.x; Koval AP, 1998, BIOCHEM J, V330, P923; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; Matsuda M, 1996, CELL SIGNAL, V8, P335, DOI 10.1016/0898-6568(96)00067-8; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; NICHOLS GL, 1994, BLOOD, V84, P2912; Okada S, 1996, J BIOL CHEM, V271, P25533, DOI 10.1074/jbc.271.41.25533; Parrizas M, 1997, ENDOCRINOLOGY, V138, P1427, DOI 10.1210/en.138.4.1427; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; RIBON V, 1996, J BIOL CHEM, V271, P2375; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; Sattler M, 1997, J BIOL CHEM, V272, P10248; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SEELY BL, 1995, J BIOL CHEM, V270, P19151, DOI 10.1074/jbc.270.32.19151; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; Tanaka S, 1998, J BIOL CHEM, V273, P1281, DOI 10.1074/jbc.273.3.1281; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; TENHOEVE J, 1994, CANCER RES, V54, P2563; TENHOEVE J, 1993, ONCOGENE, V8, P2469; Uemura N, 1997, LEUKEMIA, V11, P376, DOI 10.1038/sj.leu.2400590; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; Waters SB, 1996, TRENDS CELL BIOL, V6, P1, DOI 10.1016/0962-8924(96)81024-5	52	37	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14780	14787		10.1074/jbc.273.24.14780	http://dx.doi.org/10.1074/jbc.273.24.14780			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614078	hybrid			2022-12-27	WOS:000074160400020
J	Madrid, R; Gomez, MJ; Ramos, J; Rodriguez-Navarro, A				Madrid, R; Gomez, MJ; Ramos, J; Rodriguez-Navarro, A			Ectopic potassium uptake in trk1 trk2 mutants of Saccharomyces cerevisiae correlates with a highly hyperpolarized membrane potential	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RUBIDIUM TRANSPORT; NEUROSPORA-CRASSA; ESCHERICHIA-COLI; SHUTTLE VECTORS; YEAST; SYSTEM; ATPASE; PROTEIN; K+; ACTIVATION	Null trk1 trk2 mutants of Saccharomyces cerevisiae exhibit a low-affinity uptake of K+ and Rb+. We show that this low-affinity Rb+ uptake is mediated by several independent transporters, and that trk1 Delta cells and especially trk1 Delta trk2 Delta cells are highly hyperpolarized. Differences in the membrane potentials were assessed for sensitivity to hygromycin B and by flow cytometric analyses of cellular DiOC(6)(3) fluorescence. On the basis of the latter analyses, it is preposed that Tsk1p and Trk2p are involved in the control of the membrane potential, preventing excessive hyperpolarizations. K+ starvation and nitrogen starvation hyperpolarize both TRK1 TRK2 and trk1 Delta trk2 Delta cells, thus suggesting that other proteins, in addition to Trk1p and Trk2p, participate in the control of the membrane potential. The HAK1 K+-transporter from Schwanniomyces occidentalis suppresses the K+-defective transport of trk1 Delta trk2 Delta cells but not the high hyperpolarization, and the HKT1 K+ transporter from wheat suppresses both defects, in the presence of Na+. We discuss the mechanism involved in the control of the membrane potential by Trk1p and Trk2p and the causal relationship between the high membrane potential (negative inside) of trk1 Delta trk2 Delta cells and its ectopic transport of alkaki cations.	Univ Politecn Madrid, Escuela Tecn Super Ingn Agron, Dept Biotecnol, E-28040 Madrid, Spain; Univ Cordoba, Escuela Tecn Super Ingn Agron, Dept Microbiol, E-14071 Cordoba, Spain	Universidad Politecnica de Madrid; Universidad de Cordoba	Rodriguez-Navarro, A (corresponding author), Univ Politecn Madrid, Escuela Tecn Super Ingn Agron, Dept Biotecnol, E-28040 Madrid, Spain.	arodrignavar@bit.etsia.upm.es	Rodriguez-Navarro, Alonso/AAB-4574-2019	Rodriguez-Navarro, Alonso/0000-0003-0462-223X; Madrid Gonzalez, Ricardo/0000-0002-1350-9864				ALIJO R, 1993, BIOCHIM BIOPHYS ACTA, V1179, P224, DOI 10.1016/0167-4889(93)90145-F; BANUELOS MA, 1995, EMBO J, V14, P3021, DOI 10.1002/j.1460-2075.1995.tb07304.x; BORSTPAUWELS GWFH, 1981, BIOCHIM BIOPHYS ACTA, V650, P88, DOI 10.1016/0304-4157(81)90002-2; BOUILLAUD F, 1994, EMBO J, V13, P1990, DOI 10.1002/j.1460-2075.1994.tb06468.x; BRUNELLI JP, 1993, YEAST, V9, P1309, DOI 10.1002/yea.320091204; CRIDDLE RS, 1969, BIOCHEMISTRY-US, V8, P322, DOI 10.1021/bi00829a045; EDDY AA, 1989, METHOD ENZYMOL, V172, P95; Fu HH, 1998, PLANT CELL, V10, P63, DOI 10.1105/tpc.10.1.63; GABER RF, 1992, INT REV CYTOL, V137A, P299; GABER RF, 1988, MOL CELL BIOL, V8, P2848, DOI 10.1128/MCB.8.7.2848; Gassmann W, 1996, PLANT J, V10, P869, DOI 10.1046/j.1365-313X.1996.10050869.x; GOFFEAU A, 1990, MONOVALENT CATIONS B, P155; GonzalezBarroso MM, 1997, BIOCHEMISTRY-US, V36, P10930, DOI 10.1021/bi971104y; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; Kim EJ, 1998, PLANT CELL, V10, P51, DOI 10.1105/tpc.10.1.51; KO CH, 1993, MOL CELL BIOL, V13, P638, DOI 10.1128/MCB.13.1.638; KO CH, 1991, MOL CELL BIOL, V11, P4266, DOI 10.1128/MCB.11.8.4266; KO CH, 1990, GENETICS, V125, P305; KONING AJ, 1993, CELL MOTIL CYTOSKEL, V25, P111, DOI 10.1002/cm.970250202; Liang H, 1998, MOL CELL BIOL, V18, P926, DOI 10.1128/MCB.18.2.926; LichtenbergFrate H, 1996, J MEMBRANE BIOL, V152, P169, DOI 10.1007/s002329900095; NIKAWA J, 1990, J BIOL CHEM, V265, P15996; PENA A, 1984, ARCH BIOCHEM BIOPHYS, V231, P217, DOI 10.1016/0003-9861(84)90381-3; PERLIN DS, 1988, J BIOL CHEM, V263, P18118; PETERSON J, 1994, J CELL BIOL, V127, P1395, DOI 10.1083/jcb.127.5.1395; Petit PX, 1996, CYTOMETRY, V23, P28, DOI 10.1002/(SICI)1097-0320(19960101)23:1<28::AID-CYTO5>3.0.CO;2-I; QUINTERO J, 1997, FEBS LETT, V415, P206; RAMOS J, 1985, ARCH MICROBIOL, V143, P88, DOI 10.1007/BF00414774; RAMOS J, 1994, J BACTERIOL, V176, P249, DOI 10.1128/JB.176.1.249-252.1994; RAMOS J, 1990, BIOCHIM BIOPHYS ACTA, V1029, P211, DOI 10.1016/0005-2736(90)90156-I; RAMOS J, 1985, BIOCHIM BIOPHYS ACTA, V815, P97, DOI 10.1016/0005-2736(85)90479-1; RAMOS J, 1986, EUR J BIOCHEM, V154, P307, DOI 10.1111/j.1432-1033.1986.tb09398.x; RODRIGUEZNAVARRO A, 1984, J BACTERIOL, V159, P940; RODRIGUEZNAVARRO A, 1986, J GEN PHYSIOL, V87, P649, DOI 10.1085/jgp.87.5.649; RUBIO F, 1995, SCIENCE, V270, P1660, DOI 10.1126/science.270.5242.1660; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Santa-Maria GE, 1997, PLANT CELL, V9, P2281, DOI 10.1105/tpc.9.12.2281; SCHACHTMAN DP, 1994, NATURE, V370, P655, DOI 10.1038/370655a0; SERRANO R, 1983, FEBS LETT, V156, P11, DOI 10.1016/0014-5793(83)80237-3; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SERRANO R, 1985, PLASMA MEMBRANE ATPA; SIKORSKI RS, 1989, GENETICS, V122, P19; SKROWRONEK P, 1990, CURR GENET, V18, P265; ULASZEWSKI S, 1987, MOL GEN GENET, V207, P38, DOI 10.1007/BF00331488; ULASZEWSKI S, 1983, EUR J BIOCHEM, V130, P235, DOI 10.1111/j.1432-1033.1983.tb07141.x; Walker NA, 1996, SCIENCE, V273, P977, DOI 10.1126/science.273.5277.977; Wright MB, 1997, J BIOL CHEM, V272, P13647, DOI 10.1074/jbc.272.21.13647	47	165	170	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14838	14844		10.1074/jbc.273.24.14838	http://dx.doi.org/10.1074/jbc.273.24.14838			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614085	hybrid			2022-12-27	WOS:000074160400027
J	Ohyama, C; Smith, PL; Angata, K; Fukuda, MN; Lowe, JB; Fukuda, M				Ohyama, C; Smith, PL; Angata, K; Fukuda, MN; Lowe, JB; Fukuda, M			Molecular cloning and expression of GDP-D-mannose-4,6-dehydratase, a key enzyme for fucose metabolism defective in Lec13 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALYL-LEWIS-X; DEVELOPMENTALLY-REGULATED MEMBER; L-SELECTIN; CARBOHYDRATE LIGAND; POINT MUTATION; ADHESION; GENE; ELAM-1; CDNA; BIOSYNTHESIS	Subsets of mammalian cell surface oligosaccharides contain specific fucosylated moieties expressed in lineage- and/or temporal-specific patterns. The functional significance of these fucosylated structures is incompletely defined, although there is evidence that subsets of them, represented by the sialyl Le(x) determinant, are important participants in leukocyte adhesion and trafficking processes. Genetic deletion of these fucosylated structures in the mouse has been a powerful tool to address functional questions about fucosylated glycans, However, successful use of such approaches can be problematic, given the substantial redundancy in the mammalian alpha-1,3-fucosyltransferase and alpha-1,2-fucosyltransferase gene families. To circumvent this problem, we have chosen to clone the genetic locus encoding a mammalian GDP-D-mannose-4,6-dehydratase (GRD). This enzyme generates GDP-manmose-4-keto-6-D-deoxymaranose from GDP-mannose, which is then converted by the FX protein (GDP-4-keto-6-L-deoxymannose epimerase/GDP-4-keto-6-L-galactose reductase) to GDP-L-fucose. GMD is thus imperative for the synthesis of all fucosyliated oligosaccharides. An expression cloning approach and the GMD-deficient CHO host cell line Lec13 were used to generate a population of cDNA molecules enriched in GMD cDNAs, This enriched plasmid population was then screened using a human expressed sequence tag (EST AA065072) with sequence similarity to an Arabidopsis thaliana GMD cDNA. This approach, together with 5'-rapid amplification of cDNA ends, yielded a human cDNA that complements the fucosylation defect in the Lec13 cell line. Northern blot analyses indicate that the GMD transcript is absent in Lec13 cells, confirming the genetic deficiency of this locus in these cells. By contrast, the transcript encoding the FX protein, which forms GDP-L-fucose from the ketosugar intermediate produced by GMD, is present in increased amounts in the Lec13 cells. These results suggest that metabolites generated in this pathway may participate ire the transcriptional regulation of the FX protein and possibly the GMD protein. The results also suggest that the genomic structure encoding GMD in Lec13 cells likely has a defect different from a point mutation in the coding region.	Burnham Inst, La Jolla Canc Res Ctr, Glycobiol Program, La Jolla, CA 92037 USA; Univ Michigan, Med Ctr, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA	Sanford Burnham Prebys Medical Discovery Institute; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Fukuda, M (corresponding author), Burnham Inst, La Jolla Canc Res Ctr, Glycobiol Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Angata, Kiyohiko/M-2749-2018	Angata, Kiyohiko/0000-0001-5561-1368	NATIONAL CANCER INSTITUTE [R37CA033000, P01CA071932] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA71932, R37 CA33000] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERG EL, 1991, J BIOL CHEM, V266, P14869; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; Bonin CP, 1997, P NATL ACAD SCI USA, V94, P2085, DOI 10.1073/pnas.94.5.2085; CURRIE HL, 1995, CLIN DIAGN LAB IMMUN, V2, P554, DOI 10.1128/CDLI.2.5.554-562.1995; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; ETZIONI A, 1992, NEW ENGL J MED, V327, P1789, DOI 10.1056/NEJM199212173272505; FUKUDA M, 1984, J BIOL CHEM, V259, P925; Fukuda M., 1994, MOL GLYCOBIOLOGY, P1; FUKUDA MN, 1990, P NATL ACAD SCI USA, V87, P7443, DOI 10.1073/pnas.87.19.7443; GERSTEN KM, 1995, J BIOL CHEM, V270, P25047, DOI 10.1074/jbc.270.42.25047; GINSBURG V, 1960, J BIOL CHEM, V235, P2196; GOELZ S, 1994, J BIOL CHEM, V269, P1033; GOTSCHLICH EC, 1994, J EXP MED, V180, P2181, DOI 10.1084/jem.180.6.2181; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; IMAI Y, 1992, GLYCOBIOLOGY, V2, P373, DOI 10.1093/glycob/2.4.373; IMAI Y, 1993, NATURE, V361, P555; Jarvis DL, 1997, GLYCOBIOLOGY, V7, P113, DOI 10.1093/glycob/7.1.113; KELLY RJ, 1995, J BIOL CHEM, V270, P4640, DOI 10.1074/jbc.270.9.4640; KOJIMA N, 1995, FEBS LETT, V360, P1, DOI 10.1016/0014-5793(95)00059-I; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LIAO TH, 1971, BIOCHIM BIOPHYS ACTA, V230, P64; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; MAQUAT LE, 1995, RNA, V1, P453; NAKAYAMA J, 1995, P NATL ACAD SCI USA, V92, P7031, DOI 10.1073/pnas.92.15.7031; NATSUKA S, 1994, CURR OPIN STRUC BIOL, V4, P683, DOI 10.1016/S0959-440X(94)90166-X; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; Puthalakath H, 1996, J BIOL CHEM, V271, P27818, DOI 10.1074/jbc.271.44.27818; RIPKA J, 1986, ARCH BIOCHEM BIOPHYS, V249, P533, DOI 10.1016/0003-9861(86)90031-7; Sasaki K, 1997, P NATL ACAD SCI USA, V94, P14294, DOI 10.1073/pnas.94.26.14294; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SCHEIDEGGER EP, 1995, J BIOL CHEM, V270, P22685, DOI 10.1074/jbc.270.39.22685; Smith PL, 1996, J BIOL CHEM, V271, P8250, DOI 10.1074/jbc.271.14.8250; TAKADA A, 1991, BIOCHEM BIOPH RES CO, V179, P713, DOI 10.1016/0006-291X(91)91875-D; Tan J, 1996, AM J HUM GENET, V59, P810; Tonetti M, 1996, J BIOL CHEM, V271, P27274, DOI 10.1074/jbc.271.44.27274; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; Tsuboi S, 1996, J BIOL CHEM, V271, P27213, DOI 10.1074/jbc.271.44.27213; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; Weinstein J, 1996, J BIOL CHEM, V271, P27462, DOI 10.1074/jbc.271.44.27462	43	71	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14582	14587		10.1074/jbc.273.23.14582	http://dx.doi.org/10.1074/jbc.273.23.14582			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603974	hybrid			2022-12-27	WOS:000074021500076
J	Kultz, D; Madhany, S; Burg, MB				Kultz, D; Madhany, S; Burg, MB			Hyperosmolality causes growth arrest of murine kidney cells - Induction of GADD45 and GADD153 by osmosensing via stress-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGING AGENTS; MAMMALIAN-CELLS; OSMOTIC-STRESS; GENE; PATHWAY; INHIBITOR; TRANSCRIPTION; IRRADIATION; EXPRESSION; ELEMENT	Murine kidney cells of the inner medullary collecting duct (mIMCD) were exposed to either isosmotic (300 mosmol/kg) or hyperosmotic medium (isosmotic medium + 150 mM NaCl) after seeding. We determined cell numbers, total nucleic acid, DNA, and RNA contents in both groups every day for a total period of 7 days, Based on all 4 parameters it was evident that growth of mIMCD3 cells is arrested for similar to 18 h following onset of hyperosmolality, However, none of the parameters measured indicated cell death because of hyperosmolality, Growth curves of hyperosmotic samples were shifted compared with isosmotic samples showing a gap of 18 h but had the same shape otherwise. We demonstrated that at 24 and 48 h after onset of hyperosmolality, but not in isosmotic controls, growth arrest and DNA damage-inducible (GADD) proteins GADD45 and GADD153 are strongly induced. This result is consistent with growth arrest observed in hyperosmotic medium. We tested if mitogen-and stress-activated protein kinase (SAPK) cascades are involved in osmosignaling that leads to GADD45 and GADD153 induction. Using phosphospecific antibodies we showed that extracellular signal-regulated kinases 1 and 2 (ERK), SAPK1 (JNK), and SAPK2 (p38) are hyperosmotically activated in mIMCD cells. Hyperosmotic GADD45 induction was significantly decreased by 37.5% following inhibition of the SAPK2 pathway, whereas it was significantly increased (65.2%) after inhibition of the ERK pathway. We observed similar, although less pronounced effects of SAPK2 and ERK inhibition on hyperosmotic GADD153 induction. In conclusion, we demonstrate that mIMCD cells arrest growth following hyperosmotic shock, that this causes strong induction of GADD45 and GADD153, that GADD induction is partially dependent on osmosignaling via SAPK2 and ERK, and that SAPK2 and ERK pathways have opposite effects on GADD expression.	NHLBI, Kidney & Electrolyte Metab Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Kultz, D (corresponding author), NHLBI, Kidney & Electrolyte Metab Lab, NIH, 10 Ctr Dr,MSC 1603,Bldg 10,Rm 6N260, Bethesda, MD 20892 USA.	kultzd@gwgate.nhlbi.nih.gov	, DK/AAU-3163-2021					Adler V, 1997, P NATL ACAD SCI USA, V94, P1686, DOI 10.1073/pnas.94.5.1686; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; Berl T, 1997, AM J PHYSIOL-RENAL, V272, pF305, DOI 10.1152/ajprenal.1997.272.3.F305; BOGUSLAWSKI G, 1992, J GEN MICROBIOL, V138, P2425, DOI 10.1099/00221287-138-11-2425; Bokemeyer D, 1996, J BIOL CHEM, V271, P639, DOI 10.1074/jbc.271.2.639; BREWSTER JL, 1994, YEAST, V10, P425, DOI 10.1002/yea.320100402; Burg MB, 1997, ANNU REV PHYSIOL, V59, P437, DOI 10.1146/annurev.physiol.59.1.437; BURG MB, 1995, AM J PHYSIOL-RENAL, V268, pF983, DOI 10.1152/ajprenal.1995.268.6.F983; Burg MB, 1996, FASEB J, V10, P1598, DOI 10.1096/fasebj.10.14.9002551; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DOUZOU P, 1994, P NATL ACAD SCI USA, V91, P1657, DOI 10.1073/pnas.91.5.1657; Fawcett TW, 1996, J BIOL CHEM, V271, P14285, DOI 10.1074/jbc.271.24.14285; Ferraris JD, 1996, J BIOL CHEM, V271, P18318, DOI 10.1074/jbc.271.31.18318; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Freshney RI, 1994, CULTURE ANIMAL CELLS; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; Gullans SR, 1996, KIDNEY INT, V49, P1678, DOI 10.1038/ki.1996.245; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hollander Jr M.C., 1995, DNA REPAIR MECH IMPA, P219; Ivanov V. I., 1993, Molekulyarnaya Biologiya (Moscow), V27, P1150; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Kultz D, 1996, J COMP PHYSIOL B, V166, P88, DOI 10.1007/BF00301172; Kultz D, 1996, AM J PHYSIOL-CELL PH, V271, pC1181, DOI 10.1152/ajpcell.1996.271.4.C1181; Kultz D, 1997, J BIOL CHEM, V272, P13165, DOI 10.1074/jbc.272.20.13165; Kultz D, 1998, J MOL EVOL, V46, P571, DOI 10.1007/PL00006338; KWON HM, 1995, BIOCHEM BIOPH RES CO, V213, P975, DOI 10.1006/bbrc.1995.2224; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; NYSTROM T, 1994, MOL MICROBIOL, V11, P537, DOI 10.1111/j.1365-2958.1994.tb00334.x; PODGORNIK R, 1995, BIOPHYS CHEM, V57, P111, DOI 10.1016/0301-4622(95)00058-6; RAUCHMAN MI, 1993, AM J PHYSIOL, V265, pF416, DOI 10.1152/ajprenal.1993.265.3.F416; Rauchman MI, 1997, AM J PHYSIOL-RENAL, V273, pF9, DOI 10.1152/ajprenal.1997.273.1.F9; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Sheikh-Hamad D, 1998, J BIOL CHEM, V273, P1832, DOI 10.1074/jbc.273.3.1832; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TAKENAKA M, 1994, J BIOL CHEM, V269, P29379; VANDENBROECK J, 1992, INT J BIOCHEM, V24, P1907; Wojtaszek PA, 1998, J BIOL CHEM, V273, P800, DOI 10.1074/jbc.273.2.800; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZHAN QM, 1994, CANCER RES, V54, P2755	44	180	181	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13645	13651		10.1074/jbc.273.22.13645	http://dx.doi.org/10.1074/jbc.273.22.13645			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593703	hybrid			2022-12-27	WOS:000073919100042
J	Guttmann, RP; Johnson, GVW				Guttmann, RP; Johnson, GVW			Oxidative stress inhibits calpain activity in situ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTRAL PROTEINASE CALPAIN; ALZHEIMERS-DISEASE; BRAIN SPECTRIN; MU-CALPAIN; DIFFERENTIAL SENSITIVITY; CYSTEINE PROTEINASES; FODRIN PROTEOLYSIS; HYPOXIC-ISCHEMIA; RAT-BRAIN; CALCIUM	In this study, the effects of oxidative stress on calpain-mediated proteolysis and calpain I autolysis in situ were examined. Calpain activity was stimulated in SH-SY5Y human neuroblastoma cells with the calcium ionophore, ionomycin, Calpain-mediated proteolysis of the membrane-permeable fluorescent substrate N-succinyl-L-leucyl-L-leucyl-L-valyl-L-tyrosine-7-amido-4-methylcoumarin, as well as the endogenous protein substrates microtubule-associated protein 2, tau and spectrin, was measured. Oxidative stress, induced by addition of either doxorubicin or 2-mercaptopyridine N-oxide, resulted in a significant decrease in the extent of ionophore-stimulated calpain activity of both the fluorescent compound and the endogenous substrates compared with control, normoxic conditions, Addition of glutathione ethyl ester, as well as other antioxidants, resulted in the retention/recovery of calpain activity, indicating that oxidation-induced calpain inactivation was preventable/reversible. The rate of autolytic conversion of the large subunit of calpain I from 80 to 78 to 76 kDa was decreased during oxidative stress; however, the extent of calpain autolysis was not altered, These data indicate that oxidative stress may reversibly inactivate calpain I in vivo.	Univ Alabama, Dept Psychiat, Sparks Ctr 1061, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Johnson, GVW (corresponding author), Univ Alabama, Dept Psychiat, Sparks Ctr 1061, Birmingham, AL 35294 USA.	gvwj@uab.edu	Johnson, Gail V.W./K-4723-2012; guttmann, rodney/AAN-8880-2021	Johnson, Gail V.W./0000-0003-3464-0404; guttmann, rodney/0000-0001-5553-3099	NIA NIH HHS [AG12396, AG06569] Funding Source: Medline; NINDS NIH HHS [NS27538] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS027538, R01NS027538] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG006569, R01AG012396] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANAGLI J, 1991, BIOCHEM J, V274, P497, DOI 10.1042/bj2740497; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Baki A, 1996, BIOCHEM J, V318, P897, DOI 10.1042/bj3180897; BARTUS RT, 1994, J CEREBR BLOOD F MET, V14, P537, DOI 10.1038/jcbfm.1994.67; BARTUS RT, 1995, NEUROL RES, V17, P249, DOI 10.1080/01616412.1995.11740322; BEDNARSKI E, 1995, BRAIN RES, V694, P147, DOI 10.1016/0006-8993(95)00851-G; BENUCK M, 1993, LIFE SCI, V52, P877, DOI 10.1016/0024-3205(93)90517-7; BENZI G, 1995, NEUROBIOL AGING, V16, P661, DOI 10.1016/0197-4580(95)00066-N; Bi XN, 1996, BRAIN RES, V726, P98, DOI 10.1016/0006-8993(95)01360-1; BLOMGREN K, 1995, BRAIN RES, V684, P143, DOI 10.1016/0006-8993(95)00399-B; Bouton C, 1997, J BIOL CHEM, V272, P19969, DOI 10.1074/jbc.272.32.19969; BRONK SF, 1993, AM J PHYSIOL, V264, pG744, DOI 10.1152/ajpgi.1993.264.4.G744; Carmel G, 1996, J BIOL CHEM, V271, P32789, DOI 10.1074/jbc.271.51.32789; CHOI BH, 1995, NEUROBIOL AGING, V16, P675, DOI 10.1016/0197-4580(95)00065-M; CONG JY, 1989, J BIOL CHEM, V264, P10096; COTTIN P, 1991, BIOCHIM BIOPHYS ACTA, V1079, P139, DOI 10.1016/0167-4838(91)90118-J; CRAWFORD C, 1988, BIOCHEM J, V253, P751, DOI 10.1042/bj2530751; CROALL DE, 1994, BIOCHEMISTRY-US, V33, P13223, DOI 10.1021/bi00249a008; Davis PK, 1997, J NEUROCHEM, V68, P2338; DAYTON WR, 1982, BIOCHIM BIOPHYS ACTA, V709, P166, DOI 10.1016/0167-4838(82)90457-5; Demuth HU, 1996, BBA-PROTEIN STRUCT M, V1295, P179, DOI 10.1016/0167-4838(96)00038-6; DUBINSKY JM, 1995, J NEUROSCI, V15, P7071; Elce JS, 1997, J BIOL CHEM, V272, P11268; Epe B, 1996, NUCLEIC ACIDS RES, V24, P1625, DOI 10.1093/nar/24.9.1625; GOLL DE, 1992, BIOESSAYS, V14, P549, DOI 10.1002/bies.950140810; GOODMAN J, 1977, BIOCHEM BIOPH RES CO, V77, P797, DOI 10.1016/S0006-291X(77)80048-X; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUEHMANN S, 1992, NUCLEIC ACIDS RES, V20, P2279, DOI 10.1093/nar/20.9.2279; Guttmann RP, 1997, J BIOL CHEM, V272, P2005, DOI 10.1074/jbc.272.3.2005; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; HONG SC, 1994, BRAIN RES, V661, P43, DOI 10.1016/0006-8993(94)91178-9; JOHNSON GVW, 1991, J NEUROCHEM, V56, P1630, DOI 10.1111/j.1471-4159.1991.tb02061.x; JOHNSON GVW, 1989, BIOCHEM BIOPH RES CO, V163, P1505, DOI 10.1016/0006-291X(89)91150-9; Johnson GVW, 1997, J NEUROCHEM, V68, P430; Jonas EA, 1997, NATURE, V385, P343, DOI 10.1038/385343a0; Kampfl A, 1996, EUR J NEUROSCI, V8, P344, DOI 10.1111/j.1460-9568.1996.tb01218.x; KARLSSON JO, 1995, NEUROBIOL AGING, V16, P901, DOI 10.1016/0197-4580(95)02004-7; KAVITA U, 1995, J BIOL CHEM, V270, P27758, DOI 10.1074/jbc.270.46.27758; KUDO Y, 1986, BRIT J PHARMACOL, V89, P191, DOI 10.1111/j.1476-5381.1986.tb11135.x; LAL M, 1975, INT J RADIAT BIOL, V28, P549, DOI 10.1080/09553007514551411; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; Lin GD, 1997, NAT STRUCT BIOL, V4, P539, DOI 10.1038/nsb0797-539; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; LYNCH G, 1987, BRAIN RES BULL, V18, P809, DOI 10.1016/0361-9230(87)90220-6; MACINTOSH LJ, 1996, EXP NEUROL, V141, P201; MEHDI S, 1991, TRENDS BIOCHEM SCI, V16, P150, DOI 10.1016/0968-0004(91)90058-4; MELLGREN RL, 1994, EXP CELL RES, V215, P164, DOI 10.1006/excr.1994.1328; Mellgren RL, 1997, J BIOL CHEM, V272, P29899, DOI 10.1074/jbc.272.47.29899; Melloni E, 1996, BIOCHEM BIOPH RES CO, V229, P193, DOI 10.1006/bbrc.1996.1779; MELLONI E, 1989, TRENDS NEUROSCI, V12, P438, DOI 10.1016/0166-2236(89)90093-3; MERCKEN M, 1995, FEBS LETT, V368, P10, DOI 10.1016/0014-5793(95)00590-6; Michetti M, 1996, FEBS LETT, V392, P11, DOI 10.1016/0014-5793(96)00775-2; MINAMI Y, 1987, J BIOCHEM-TOKYO, V101, P889, DOI 10.1093/oxfordjournals.jbchem.a121956; MOLINARI M, 1994, J BIOL CHEM, V269, P27992; Molinari M, 1997, J MEMBRANE BIOL, V156, P1, DOI 10.1007/s002329900181; MURACHI T, 1989, BIOCHEM INT, V18, P263; Neumann N P, 1972, Methods Enzymol, V25, P393, DOI 10.1016/S0076-6879(72)25034-0; Neumar RW, 1996, J NEUROCHEM, V66, P421; NILSSON E, 1990, NEUROBIOL AGING, V11, P425, DOI 10.1016/0197-4580(90)90009-O; NIXON RA, 1994, ANN NY ACAD SCI, V747, P77; Norris FA, 1997, J BIOL CHEM, V272, P10987; OSTWALD K, 1993, BRAIN RES, V630, P289, DOI 10.1016/0006-8993(93)90668-D; PONTREMOLI S, 1986, ANNU REV BIOCHEM, V55, P455, DOI 10.1146/annurev.biochem.55.1.455; RAMI A, 1993, BRAIN RES, V609, P67, DOI 10.1016/0006-8993(93)90856-I; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; ROSENKRANZ AR, 1992, J IMMUNOL METHODS, V156, P39, DOI 10.1016/0022-1759(92)90008-H; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; SAIDO TC, 1993, J BIOL CHEM, V268, P25239; SAIDO TC, 1994, FEBS LETT, V346, P263, DOI 10.1016/0014-5793(94)00487-0; SAITO KI, 1993, NEUROCHEM RES, V18, P231, DOI 10.1007/BF01474689; SAITO KI, 1993, P NATL ACAD SCI USA, V90, P2628, DOI 10.1073/pnas.90.7.2628; SALAMINO F, 1993, BIOCHEM J, V290, P191, DOI 10.1042/bj2900191; Sarvazyan N, 1996, AM J PHYSIOL-HEART C, V271, pH2079, DOI 10.1152/ajpheart.1996.271.5.H2079; SASAKI T, 1984, J BIOL CHEM, V259, P2489; Schoenwaelder SM, 1997, J BIOL CHEM, V272, P1694, DOI 10.1074/jbc.272.3.1694; SCHOLLMEYER JE, 1988, SCIENCE, V240, P911, DOI 10.1126/science.2834825; SEUBERT P, 1987, SYNAPSE, V1, P20, DOI 10.1002/syn.890010105; SONG DK, 1994, J NEUROSCI RES, V39, P74; SORIMACHI H, 1994, FEBS LETT, V343, P1, DOI 10.1016/0014-5793(94)80595-4; SORIMACHI H, 1993, J BIOL CHEM, V268, P19476; Springer JE, 1997, J NEUROCHEM, V69, P1592, DOI 10.1046/j.1471-4159.1997.69041592.x; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; SUZUKI K, 1995, BIOL CHEM H-S, V376, P523; TAKANO E, 1995, FEBS LETT, V362, P93, DOI 10.1016/0014-5793(95)00219-Y; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YOKOTA M, 1995, STROKE, V26, P1901, DOI 10.1161/01.STR.26.10.1901; Zhang WL, 1996, J BIOL CHEM, V271, P18825, DOI 10.1074/jbc.271.31.18825; ZHU H, 1994, ARCH TOXICOL, V68, P582, DOI 10.1007/s002040050118; ZIMMERMAN UJP, 1982, BIOCHEMISTRY-US, V21, P3977, DOI 10.1021/bi00260a012	90	81	86	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					13331	13338		10.1074/jbc.273.21.13331	http://dx.doi.org/10.1074/jbc.273.21.13331			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582380	hybrid			2022-12-27	WOS:000073768500091
J	Lucien, N; Sidoux-Walter, F; Olives, B; Moulds, J; Le Pennec, PY; Cartron, JP; Bailly, P				Lucien, N; Sidoux-Walter, F; Olives, B; Moulds, J; Le Pennec, PY; Cartron, JP; Bailly, P			Characterization of the gene encoding the human Kidd blood group urea transporter protein - Evidence for splice site mutations in Jk(null) individuals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; TRANSCRIPTION FACTORS; MESSENGER-RNA; RAT-KIDNEY; CELLS; CLONING; ERYTHROCYTES; AQUAPORIN-1; CHANNELS; OOCYTES	The Kidd (JK) blood group is carried by an integral membrane glycoprotein which transports urea through the red cell membrane and is also present on endothelial cells of the vasa recta in the kidney. The exon-intron structure of the human blood group Kidd/urea transporter gene has been determined, It is organized into 11 exons distributed over 30 kilobase pairs. The mature protein is encoded by exons 4-11, The transcription initiation site was identified by 5'-rapid amplification of cDNA ends-polymerase chain reaction at 335 base pairs upstream of the translation start point located in exon 4, The 5'-flanking region, from nucleotide -837 to -336, contains TATA and inverted CAAT boxes as well as GATA-1/SP1 erythroid-specific cis-acting regulatory elements. Analysis of the S'-untranslated region reveals that the two equally abundant erythroid transcripts of 4.4 and 2.0 kilobase pairs arise from usage of different alternative polyadenylation signals. No obvious abnormality of the Kidd/urea transporter gene, including the 5'- and 3'-untranslated regions, has been detected by Southern blot analysis of the blood of two unrelated Jk(null) individuals (B.S. and L.P.), which lacks all Jk antigens and Jk proteins on red cells, but was genotyped as homozygous for a "silent" Jk(b) allele, Further analysis indicated that different splice site mutations occurred in each variant. The first mutation affected the invariant G residue of the 3'-acceptor splice site of intron 5 (variant B.S.), while the second mutation affected the invariant G residue of the 5'-donor splice site of intron 7 (variant L.P.), These mutations caused the skipping of exon 6 and 7, respectively, as seen by sequence analysis of the Jk transcripts present in reticulocytes, Expression studies in Xenopus oocytes demonstrated that the truncated proteins encoded by the spliced transcripts did not mediate a facilitated urea transport compared with the wild type Kidd/urea transporter protein and mere not expressed on the oocyte's plasma membrane. These findings provide a rational explanation for the lack of Kidd/urea transporter protein and defect in urea transport of Jk(null) cells.	Inst Natl Transfus Sanguine, INSERM U76, F-75015 Paris, France; Univ Texas, Sch Med, Houston, TX 77030 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); University of Texas System	Cartron, JP (corresponding author), Inst Natl Transfus Sanguine, INSERM U76, 6 Rue Alexandre Cabanel, F-75015 Paris, France.	cartron@infobiogen.fr						AHUJA SK, 1994, J BIOL CHEM, V269, P26381; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Daniels G., 1995, HUMAN BLOOD GROUPS, P257; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FROHLICH O, 1991, AM J PHYSIOL, V260, pC778, DOI 10.1152/ajpcell.1991.260.4.C778; GILLIN AG, 1993, SEMIN NEPHROL, V13, P146; HEATON DC, 1982, TRANSFUSION, V22, P70, DOI 10.1046/j.1537-2995.1982.22182154224.x; Hediger MA, 1996, KIDNEY INT, V49, P1615, DOI 10.1038/ki.1996.235; IZRAELI S, 1991, NUCLEIC ACIDS RES, V19, P6051; JACKSON RJ, 1993, CELL, V74, P9, DOI 10.1016/0092-8674(93)90290-7; KNEPPER MA, 1990, AM J PHYSIOL, V259, pF393, DOI 10.1152/ajprenal.1990.259.3.F393; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACEY RI, 1988, AM J PHYSIOL, V254, pC669, DOI 10.1152/ajpcell.1988.254.5.C669; MACEY RI, 1984, AM J PHYSIOL, V246, pC195, DOI 10.1152/ajpcell.1984.246.3.C195; Maquat LE, 1996, AM J HUM GENET, V59, P279; Martial S, 1996, AM J PHYSIOL-RENAL, V271, pF1264, DOI 10.1152/ajprenal.1996.271.6.F1264; MARTIAL S, 1991, BIOCHIM BIOPHYS ACTA, V1090, P86, DOI 10.1016/0167-4781(91)90040-S; Mathai JC, 1996, J BIOL CHEM, V271, P1309, DOI 10.1074/jbc.271.3.1309; MIGNOTTE V, 1995, HEMATOLOGIE, V1, P19; MOULDS JM, 1995, BLOOD CEL B, V6, P267; Olives B, 1997, HUM MOL GENET, V6, P1017, DOI 10.1093/hmg/6.7.1017; OLIVES B, 1994, J BIOL CHEM, V269, P31649; Olives B, 1996, FEBS LETT, V386, P156, DOI 10.1016/0014-5793(96)00425-5; OLIVES B, 1995, J BIOL CHEM, V270, P15607, DOI 10.1074/jbc.270.26.15607; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; PINKERTON F J, 1959, Vox Sang, V4, P155; PRESTON GM, 1994, SCIENCE, V265, P1585, DOI 10.1126/science.7521540; Promeneur D, 1996, J AM SOC NEPHROL, V7, P852; RACE RR, 1975, BLOOD GROUPS MAN, P178; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; RASTINEJAD F, 1993, CELL, V72, P903, DOI 10.1016/0092-8674(93)90579-F; Rousselet G, 1996, AM J PHYSIOL-RENAL, V270, pF554, DOI 10.1152/ajprenal.1996.270.3.F554; SANDS JM, 1992, J AM SOC NEPHROL, V2, P1689; Shayakul C, 1996, J CLIN INVEST, V98, P2580, DOI 10.1172/JCI119077; Tsukaguchi H, 1997, J CLIN INVEST, V99, P1506, DOI 10.1172/JCI119313; WALL DA, 1989, J MEMBRANE BIOL, V107, P189, DOI 10.1007/BF01871724; Xu YC, 1997, KIDNEY INT, V51, P138, DOI 10.1038/ki.1997.17; YOU GF, 1993, NATURE, V365, P844, DOI 10.1038/365844a0	38	123	137	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					12973	12980		10.1074/jbc.273.21.12973	http://dx.doi.org/10.1074/jbc.273.21.12973			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582331	hybrid			2022-12-27	WOS:000073768500042
J	van Kuppevelt, TH; Dennissen, MABA; van Venrooij, WJ; Hoet, RMA; Veerkamp, JH				van Kuppevelt, TH; Dennissen, MABA; van Venrooij, WJ; Hoet, RMA; Veerkamp, JH			Generation and application of type-specific anti-heparan sulfate antibodies using phage display technology - Further evidence for heparan sulfate heterogeneity in the kidney	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; MONOCLONAL-ANTIBODY; SEQUENCES REVEALS; DOMAIN-STRUCTURE; BINDING DOMAIN; FINE-STRUCTURE; PROTEOGLYCANS; OLIGOSACCHARIDE; IDENTIFICATION; SYNDECAN-1	Detailed analysis of various heparan sulfate (HS) species is seriously hampered by a lack of appropriate tools, such as antibodies. We adopted phage display technology to generate anti-HS antibodies. A "single pot" semisynthetic human antibody phage display library was subjected to four rounds of selection on HS from bovine kidney using panning methodology. Three different phage clones expressing anti-HS single chain variable fragment antibodies (HS4C3, HS4D10, and HS3G8) were isolated, with an amino acid sequence of the complementarity -determining region 3 of GRRLKD (V(H)3 gene, DP-38), SLRMNGCGAHQ (V(H)3 gene, DP-42), and YY-HYKVN (V(H)1 gene, DP-8), respectively. The antibodies react with HS and heparin, but not with DNA or other glycosaminoglycans. K-d values for MS are about 0.1 mu M. The three antibodies react differently toward various HS preparations and show different staining patterns on rat kidney sections, indicating recognition of different HS molecules. This also holds for two described mouse anti-HS IgMs (JM403 and 10E4; both generated by conventional hybridoma technique) and indicates the presence of at least 5 different HS species in the kidney. O- and N-sulfation are important for binding of HS to HS4C3 and HS3G8. The three single chain antibodies, but not JM403, block a basic fibroblast growth factor binding site of IIS. It is concluded that phage display technology presents a powerful technique to generate antibodies specific for HS epitopes. This is the first time this technique has been successfully applied to obtain directly antibodies to (poly)saccharides.	Univ Nijmegen, Fac Med Sci, Dept Biochem, NL-6500 HB Nijmegen, Netherlands; Univ Nijmegen, Fac Sci, Dept Biochem, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen	van Kuppevelt, TH (corresponding author), Univ Nijmegen, Fac Med Sci, Dept Biochem, POB 9101, NL-6500 HB Nijmegen, Netherlands.		van Kuppevelt, A.H.M.S.M./L-4463-2015					BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; DALE BA, 1985, J CELL BIOL, V101, P1257, DOI 10.1083/jcb.101.4.1257; DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961; ELENIUS K, 1994, J CELL SCI, V107, P2975; FRIQUET B, 1985, J IMMUNOL METHODS, V77, P305; GALLAGHER JT, 1992, GLYCOBIOLOGY, V2, P523, DOI 10.1093/glycob/2.6.523; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; IHRCKE NS, 1993, IMMUNOL TODAY, V14, P500, DOI 10.1016/0167-5699(93)90265-M; ISHIHARA M, 1994, GLYCOBIOLOGY, V4, P451, DOI 10.1093/glycob/4.4.451; KATO M, 1994, J BIOL CHEM, V269, P18881; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; LINDBLOM A, 1991, BIOCHEM J, V279, P821, DOI 10.1042/bj2790821; LYON M, 1994, J BIOL CHEM, V269, P11208; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; MARGALIT H, 1993, J BIOL CHEM, V268, P19228; MARKS JD, 1991, J MOL BIOL, V222, P581, DOI 10.1016/0022-2836(91)90498-U; MORITA H, 1994, LAB INVEST, V71, P528; NAKANISHI H, 1992, BIOCHEM J, V288, P215, DOI 10.1042/bj2880215; NISSIM A, 1994, EMBO J, V13, P692, DOI 10.1002/j.1460-2075.1994.tb06308.x; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; SANDERSON RD, 1994, J BIOL CHEM, V269, P13100; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDTCHEN A, 1994, EUR J BIOCHEM, V223, P211, DOI 10.1111/j.1432-1033.1994.tb18985.x; SPILLMANN D, 1994, CURR OPIN STRUC BIOL, V4, P677, DOI 10.1016/S0959-440X(94)90165-1; Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166; TEKOTTE H, 1994, J NEUROCHEM, V62, P1126; TERSARIOL ILS, 1994, BRAZ J MED BIOL RES, V27, P2097; TOMLINSON IM, 1992, J MOL BIOL, V227, P776, DOI 10.1016/0022-2836(92)90223-7; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; TURNBULL JE, 1991, BIOCHEM J, V273, P553, DOI 10.1042/bj2730553; vandenBorn J, 1995, J BIOL CHEM, V270, P31303, DOI 10.1074/jbc.270.52.31303; VANDENBORN J, 1992, KIDNEY INT, V41, P115, DOI 10.1038/ki.1992.15; Walker A, 1996, BIOCHEM J, V317, P871, DOI 10.1042/bj3170871	34	218	222	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					12960	12966		10.1074/jbc.273.21.12960	http://dx.doi.org/10.1074/jbc.273.21.12960			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582329	hybrid, Green Published			2022-12-27	WOS:000073768500040
J	Dam, TK; Cavada, BS; Grangeiro, TB; Santos, CF; de Sousa, FAM; Oscarson, S; Brewer, CF				Dam, TK; Cavada, BS; Grangeiro, TB; Santos, CF; de Sousa, FAM; Oscarson, S; Brewer, CF			Diocleinae lectins are a group of proteins with conserved binding sites for the core trimannoside of asparagine-linked oligosaccharides and differential specificities for complex carbohydrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONCANAVALIN-A; HISTAMINE-RELEASE; LEGUME LECTINS; PLANT-LECTINS; STIMULATION; SEEDS	The seed lectin from Dioclea grandiflora and jack, bean lectin concanavalin A (ConA) are both members of the Diocleinae subtribe of Leguminosae lectins. Both lectins have recently been shown to possess enhanced affinities and extended binding sites for the trisaccharide, 3,6-di-O-(alpha-D-mannopyranosyl)-D-mannose which is present in the core region of all asparagine-linked carbohydrates (Gupta, D., Oscarson, S., Raju, S., Stanley, P. Toone, E. J. and Brewer, C. F. (1996) Eur. J. Biochem, 242, 320-326). In the present study, the binding specificities of seven other lectins from the Diocleinae subtribe have been investigated by hemagglutination inhibition and isothermal titration microcalorimetry (ITC). The lectins are from Canavalia brasiliensis, Canavalia bonariensis, Cratylia floribunda, Dioclea rostrata, Dioclea virgata, Dioclea violacea, and Dioclea guianensis. Hemagglutination inhibition and ITC experiments show that all seven lectins are Man/Glc-specific and have high affinities for the core trimannoside, like ConA and D. grandiflora lectin. All seven lectins also exhibit the same pattern of binding to a series of monodeoxy analogs and a tetradeoxy analog of the trimannoside, similar to that of ConA and D. grandiflora lectin. However, C. bonariensis, C. floribunda, D. rostrata, and D. violacea, like D. grandiflora, show substantially reduced affinities for a biantennary complex carbohydrate with terminal GlcNAc residues, while C. brasiliensis, D. guianensis, and D. virgata, Like ConA, exhibit affinities for the oligosaccharide comparable with that of the trimannoside. Thermodynamic data obtained by ITC indicate different energetic mechanisms of binding of the above two groups of lectins to the complex carbohydrate. The ability of the lectins to induce histamine release from rat peritoneal mast cells is shown to correlate with the relative affinities of the proteins for the biantennary carbohydrate.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Univ Fed Ceara, Dept Bioquim & Biol Mol, Lab Lectinas, BR-60451970 Fortaleza, Ceara, Brazil; Univ Fed Ceara, Dept Biol, BR-60451970 Fortaleza, Ceara, Brazil; Stockholm Univ, Dept Organ Chem, S-10691 Stockholm, Sweden	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Universidade Federal do Ceara; Universidade Federal do Ceara; Stockholm University	Brewer, CF (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		Grangeiro, Thalles Barbosa/E-9606-2010; Cavada, Benildo/CEA-4997-2022	Grangeiro, Thalles Barbosa/0000-0001-8276-3092; Cavada, Benildo/0000-0002-5791-6170; Oscarson, Stefan/0000-0002-8273-4918	NCI NIH HHS [CA-16054, P30 CA-13330] Funding Source: Medline; NCRR NIH HHS [I-S10-RR02309] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA016054, P30CA013330] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR002309] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AGRAWAL BBL, 1967, BIOCHIM BIOPHYS ACTA, V147, P262, DOI 10.1016/0005-2795(67)90404-7; BARRALNETTO M, 1992, IMMUNOL INVEST, V21, P297, DOI 10.3109/08820139209069369; BENTO CAM, 1993, AGENTS ACTIONS, V38, P48, DOI 10.1007/BF02027213; BREWER CF, 1986, J BIOL CHEM, V261, P7306; Cavada Benildo Sousa, 1996, Revista Brasileira de Fisiologia Vegetal, V8, P37; Cavada Benildo Sousa, 1996, Revista Brasileira de Fisiologia Vegetal, V8, P31; CAVADA BS, 1996, LECTINS BIOL BIOCH C, V11, P74; CHERVENAK MC, 1995, BIOCHEMISTRY-US, V34, P5685, DOI 10.1021/bi00016a045; DEREWENDA Z, 1989, EMBO J, V8, P2189, DOI 10.1002/j.1460-2075.1989.tb08341.x; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Goldstein I. J., 1986, LECTINS PROPERTIES F, P35; GOMES JC, 1994, AGENTS ACTIONS, V41, P132, DOI 10.1007/BF02001905; Gupta D, 1996, EUR J BIOCHEM, V242, P320, DOI 10.1111/j.1432-1033.1996.0320r.x; Gupta D, 1997, J BIOL CHEM, V272, P6388, DOI 10.1074/jbc.272.10.6388; HARDMAN KD, 1972, BIOCHEMISTRY-US, V11, P4910, DOI 10.1021/bi00776a006; Liener I.E., 1986, LECTINS PROPERTIES F; MANDAL DK, 1994, BIOCHEMISTRY-US, V33, P1157, DOI 10.1021/bi00171a015; MANDAL DK, 1994, BIOCHEMISTRY-US, V33, P1149, DOI 10.1021/bi00171a014; MOREIRA RA, 1984, BIOL PLANTARUM, V26, P113, DOI 10.1007/BF02902274; MOREIRA RA, 1983, PLANTA, V158, P63, DOI 10.1007/BF00395404; Moreira Renato De Azevedo, 1996, Revista Brasileira de Fisiologia Vegetal, V8, P23; Naismith JH, 1996, J BIOL CHEM, V271, P972, DOI 10.1074/jbc.271.2.972; OLIVEIRA JTA, 1991, REV BRAS BOT, V14, P61; Osawa TMI, 1972, METHODS ENZYMOL B, V28, P323; Oscarson S, 1995, CARBOHYD RES, V278, P271, DOI 10.1016/0008-6215(95)00268-5; RODRIGUEZ D, 1992, BRAZ J MED BIOL RES, V25, P823; SAHA SK, 1994, CARBOHYD RES, V254, P157; SanzAparicio J, 1997, FEBS LETT, V405, P114, DOI 10.1016/S0014-5793(97)00137-3; SHARON N, 1990, FASEB J, V4, P3198, DOI 10.1096/fasebj.4.14.2227211; SUGIYAMA K, 1975, JPN J PHARMACOL, V25, P485, DOI 10.1254/jjp.25.485; SULLIVAN TJ, 1975, J IMMUNOL, V115, P278; VASCONCELOS IM, 1991, J FOOD BIOCHEM, V15, P137, DOI 10.1111/j.1745-4514.1991.tb00150.x; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	33	79	88	0	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12082	12088		10.1074/jbc.273.20.12082	http://dx.doi.org/10.1074/jbc.273.20.12082			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575151	hybrid			2022-12-27	WOS:000073629800016
J	Ward, NE; Pierce, DS; Chung, SE; Gravitt, KR; O'Brian, CA				Ward, NE; Pierce, DS; Chung, SE; Gravitt, KR; O'Brian, CA			Irreversible inactivation of protein kinase C by glutathione	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE-SUBSTRATE-ANALOG; S-THIOLATION; CANCER CELLS; PKC-ALPHA; ACTIVATION; INHIBITION; ISOZYMES; SITE; PHOSPHORYLATION; IDENTIFICATION	The tripeptide glutathione (GSH) is the predominant low molecular weight thiol reductant in mammalian cells. In this report, we show that at concentrations at which GSH is typically present in the intracellular milieu, GSH and the oxidized GSH derivatives GSH disulfide (GSSG) and glutathione sulfonate each irreversibly inactivate up to 100% of the activity of purified Ca2+-and phosphatidylserine (PS)-dependent protein kinase C (PKC) isozymes in a concentration-dependent manner by a novel nonredox mechanism that requires neither glutathiolation of PKC nor the reduction, formation, or isomerization of disulfide bridges within PRC. Our evidence for a nonredox mechanism of PKC inactivation can be summarized as follows. GSSG antagonized the Ca2+-and PS-dependent activity of purified rat brain PKC with the same efficacy (IC50 = 3 mM) whether or not the reductant dithiothreitol was present. Glutathione sulfonate, which is distinguished from GSSG and GSH by its inability to undergo disulfide/thiol exchange reactions, was as effective as GSSG in antagonizing Ca2+-and PS-dependent PKC catalysis. The irreversibility of the inactivation mechanism was indicated by the stability of the inactivated form of PKC to dilution and extensive dialysis. The inactivation mechanism did not involve the nonspecific phenomena of denaturation and aggregation of PKC because it obeyed pseudo-first order kinetics and because the hinge region of PKC-alpha remained a preferential target of tryptic attack following GSH inactivation. The selectivity of GSH in the inactivation of PKC was also indicated by the lack, of effect of the tripeptides Tyr-Gly-Gly and Gly-Ala-Gly on the activity of PRC. Furthermore, GSH antagonism of the Ser/Thr kinase casein kinase 2 was by comparison weak (<25%). Inactivation of PKC-alpha was not accompanied by covalent modification of the isozyme by GSH or other irreversible binding interactions between PKC-alpha and the tripeptide, but it was associated with an increase in the susceptibility of PKC-alpha to trypsinolysis. Treatment of cultured rat fibroblast and human breast cancer cell lines with N-acetylcysteine resulted in a substantial loss of Ca2+-and PS-dependent PKC activity in the cells within 30 min. These results suggest that GSH exerts negative regulation over cellular PKC isozymes that may be lost when oxidative stress depletes the cellular GSH pool.	Univ Texas, Md Anderson Canc Ctr, Dept Cell Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	O'Brian, CA (corresponding author), Univ Texas, Md Anderson Canc Ctr, Dept Cell Biol, 1515 Holcombe Blvd,Box 173, Houston, TX 77030 USA.				NCI NIH HHS [CA 74831] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074831, R55CA074831] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATZORI L, 1994, EXP CELL RES, V211, P115, DOI 10.1006/excr.1994.1066; BLOBE GC, 1993, J BIOL CHEM, V268, P658; Blobe GC, 1996, CANCER SURV, V27, P213; Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; Bruins RH, 1995, ARCH BIOCHEM BIOPHYS, V324, P216, DOI 10.1006/abbi.1995.0033; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; Cabiscol E, 1996, P NATL ACAD SCI USA, V93, P4170, DOI 10.1073/pnas.93.9.4170; Cappiello M, 1996, J BIOL CHEM, V271, P33539, DOI 10.1074/jbc.271.52.33539; CAZAUBON SM, 1993, J BIOL CHEM, V268, P17559; CHAI YC, 1994, ARCH BIOCHEM BIOPHYS, V310, P273, DOI 10.1006/abbi.1994.1167; Davis DA, 1996, BIOCHEMISTRY-US, V35, P2482, DOI 10.1021/bi951525k; FINKENZELLER G, 1990, NUCLEIC ACIDS RES, V18, P2183, DOI 10.1093/nar/18.8.2183; Foresti R, 1997, J BIOL CHEM, V272, P18411, DOI 10.1074/jbc.272.29.18411; GRAVITT KR, 1994, BIOCHEM PHARMACOL, V48, P375, DOI 10.1016/0006-2952(94)90110-4; GRAVITT KR, 1994, BIOCHEM PHARMACOL, V47, P425, DOI 10.1016/0006-2952(94)90037-X; GUNDIMEDA U, 1993, ARCH BIOCHEM BIOPHYS, V300, P526, DOI 10.1006/abbi.1993.1072; Gupta KP, 1996, J BIOL CHEM, V271, P2102, DOI 10.1074/jbc.271.4.2102; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; Hansra G, 1996, J BIOL CHEM, V271, P32785, DOI 10.1074/jbc.271.51.32785; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; Keranen LM, 1997, J BIOL CHEM, V272, P25959, DOI 10.1074/jbc.272.41.25959; KIKKAWA U, 1987, FEBS LETT, V223, P212, DOI 10.1016/0014-5793(87)80291-0; KUO JF, 1994, PROETIN KINASE C; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; LESTER DS, 1992, PROTEIN KINASE C; Liu B, 1997, J BIOL CHEM, V272, P16281, DOI 10.1074/jbc.272.26.16281; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Mehlen P, 1997, J BIOL CHEM, V272, P31657, DOI 10.1074/jbc.272.50.31657; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Morales A, 1997, J BIOL CHEM, V272, P30371, DOI 10.1074/jbc.272.48.30371; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OBRIAN CA, 1990, BIOCHEMISTRY-US, V29, P4278, DOI 10.1021/bi00470a003; ORR JW, 1994, J BIOL CHEM, V269, P27715; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; SHINOMURA T, 1991, P NATL ACAD SCI USA, V88, P5149, DOI 10.1073/pnas.88.12.5149; Tanford C., 1961, PHYS CHEM MACROMOLEC; THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261; Tiganis T, 1996, ARCH BIOCHEM BIOPHYS, V325, P289, DOI 10.1006/abbi.1996.0036; VANZANDWIJK N, 1995, J CELL BIOCHEM, P24; WARD NE, 1993, BIOCHEMISTRY-US, V32, P11903, DOI 10.1021/bi00095a020; Ward NE, 1996, J BIOL CHEM, V271, P24193, DOI 10.1074/jbc.271.39.24193; WARD NE, 1995, J BIOL CHEM, V270, P8056, DOI 10.1074/jbc.270.14.8056; YAN CYI, 1995, J BIOL CHEM, V270, P26827, DOI 10.1074/jbc.270.45.26827; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X; ZHANG J, 1994, J BIOL CHEM, V269, P19578; ZOLLER MJ, 1979, J BIOL CHEM, V254, P8363	48	83	86	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12558	12566		10.1074/jbc.273.20.12558	http://dx.doi.org/10.1074/jbc.273.20.12558			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575216	hybrid			2022-12-27	WOS:000073629800081
J	Branstrom, R; Efendic, S; Berggren, PO; Larsson, O				Branstrom, R; Efendic, S; Berggren, PO; Larsson, O			Direct inhibition of the pancreatic beta-cell ATP-regulated potassium channel by alpha-ketoisocaproate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED INSULIN RELEASE; PIG VENTRICULAR CELLS; K+ CHANNELS; L-LEUCINE; SECRETION; ISLETS; ACID; METABOLISM; GLUCOSE	The ATP-regulated potassium (K-ATP) channel plays an essential role in the control of insulin release from the pancreatic beta-cell. In the present study we have used the patch-clamp technique to study the direct effects of alpha-ketoisocaproate on the K-ATP channel in isolated patches and intact pancreatic beta-cells. In excised inside-out patches, the activity of the K-ATP channel was dose dependently inhibited by alpha-ketoisocaproate, half-maximal concentration being approximately 8 mM. The blocking effect of alpha-ketoisocaproate was fully reversible. Stimulation of channel activity by the addition of ATP/ADP (ratio 1) did not counteract the inhibitory effect of alpha-ketoisocaproate. In the presence of the metabolic inhibitor sodium azide, alpha-ketoisocaproate was still able to inhibit single channel activity in excised patches and to block whole cell K-ATP, currents in intact cells. No effect of alpha-ketoisocaproate could be obtained on either the large or the small conductance Ca2+-regulated K+ channel. Enzymatic treatment of the patches with trypsin prevented the inhibitory effect of alpha-ketoisocaproate. Based on these observations, it is unlikely that the blocking effect of alpha-ketoisocaproate is due to an unspecific effect on K+ channel pores. Leucine, the precursor of alpha-ketoisocaproate, did not affect K-ATP, channel activity in excised patches. Our findings are compatible with the view that alpha-ketoisocaproate not only affects the beta-cell stimulus secretion coupling by generation of ATP but also by direct inhibition of the K-ATP, channel.	Karolinska Inst, Karolinska Hosp, Rolf Luft Ctr Diabet Res, Dept Mol Med, S-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital	Larsson, O (corresponding author), Karolinska Inst, Karolinska Hosp, Rolf Luft Ctr Diabet Res, Dept Mol Med, L1-02, S-17176 Stockholm, Sweden.			Berggren, Per-Olof/0000-0001-8991-413X; Branstrom, Robert/0000-0001-6245-7223				ARKHAMMAR P, 1987, J BIOL CHEM, V262, P5448; ASHCROFT FM, 1990, BIOCHEM SOC T, V18, P109, DOI 10.1042/bst0180109; ASHCROFT FM, 1987, J PHYSIOL-LONDON, V385, P517, DOI 10.1113/jphysiol.1987.sp016505; Benyon RJ, 1989, PROTEOLYTIC ENZYMES; BERGGREN PO, 1994, BIOCHEM SOC T, V22, P12, DOI 10.1042/bst0220012; Branstrom R, 1997, J BIOL CHEM, V272, P17390, DOI 10.1074/jbc.272.28.17390; Colquhoun D, 1983, SINGLE CHANNEL RECOR, P191; COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0; EDDLESTONE GT, 1989, J MEMBRANE BIOL, V109, P123, DOI 10.1007/BF01870851; FREINKEL N, 1976, P NATL ACAD SCI USA, V73, P3403, DOI 10.1073/pnas.73.10.3403; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HELLMAN B, 1965, ANN NY ACAD SCI, V131, P541, DOI 10.1111/j.1749-6632.1965.tb34819.x; HENQUIN JC, 1981, AM J PHYSIOL, V240, pE245, DOI 10.1152/ajpendo.1981.240.3.E245; HOPKINS WF, 1992, J MEMBRANE BIOL, V129, P287; HORIE M, 1987, J PHYSIOL-LONDON, V387, P251, DOI 10.1113/jphysiol.1987.sp016572; HUTTON JC, 1980, ENDOCRINOLOGY, V106, P203, DOI 10.1210/endo-106-1-203; KAKEI M, 1985, J PHYSIOL-LONDON, V363, P441, DOI 10.1113/jphysiol.1985.sp015721; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; LARSSON O, 1993, J PHYSIOL-LONDON, V463, P349, DOI 10.1113/jphysiol.1993.sp019598; LERNMARK A, 1974, DIABETOLOGIA, V10, P431, DOI 10.1007/BF01221634; PANTEN U, 1972, FEBS LETT, V20, P225, DOI 10.1016/0014-5793(72)80801-9; PANTEN U, 1974, DIABETOLOGIA, V10, P149, DOI 10.1007/BF01219672; PROKS P, 1993, PFLUG ARCH EUR J PHY, V424, P63, DOI 10.1007/BF00375103; RIBALET B, 1988, J GEN PHYSIOL, V92, P219, DOI 10.1085/jgp.92.2.219	24	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14113	14118		10.1074/jbc.273.23.14113	http://dx.doi.org/10.1074/jbc.273.23.14113			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603910	hybrid			2022-12-27	WOS:000074021500012
J	Dailey, TA; Dailey, HA				Dailey, TA; Dailey, HA			Identification of an FAD superfamily containing protoporphyrinogen oxidases, monoamine oxidases, and phytoene desaturase - Expression and characterization of phytoene desaturase of Myxococcus xanthus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHENYL ETHER HERBICIDES; VARIEGATE PORPHYRIA; CAROTENOID BIOSYNTHESIS; PIGMENT BIOSYNTHESIS; DESULFOVIBRIO-GIGAS; ENZYMATIC DEFECT; ESCHERICHIA-COLI; CLONED ENZYME; PURIFICATION; SEQUENCE	A large number of FAD-containing proteins have previously been shown to contain a signature sequence that is referred to as the dinucleotide binding motif. Protoporphyrinogen oxidase (PPO), the penultimate enzyme of the heme biosynthetic pathway, is an FAD-containing protein that catalyzes the six electron oxidation of protoporphyrinogen M. Sequence analysis demonstrates the presence of the dinucleotide binding motif at the amino-terminal end of the protein. Analysis of the current data base reveals that PPO has significant sequence similarities to mammalian monoamine oxidases (MAO) A and B, as well as to bacterial and plant phytoene desaturases (PHD), Previously MAOs have been shown to contain FAD, but there are no publications demonstrating the presence of FAD in purified PHDs. We have carried out the expression and purification of PHD from the bacterium Myxococcus xanthus and demonstrate the presence of noncovalently bound FAD, Sequence analysis demonstrate that PPO is closely related to bacterial PHDs and more distantly to plant PHDs and animal MAOs. Interestingly bacterial MAOs are no more closely related to PPOs, PHDs, and animal MAO's than they are to the unrelated Pseudomonas phenyl hydroxylase, All of the related sequences contain not only the basic putative dinucleotide binding motif that is found frequently for PAD-binding proteins, but they also have high similarity in an approximately 60-residue long region that extends beyond the dinucleotide motif, This region is not found among any other proteins in the current data base and, therefore, we propose that this region is a signature motif for a superfamily of FAD-containing enzymes that is comprised of PPOs, animal MAOs, and PHDs.	Univ Georgia, Dept Biochem & Mol Biol, Dept Microbiol, Athens, GA 30602 USA	University System of Georgia; University of Georgia	Dailey, HA (corresponding author), Univ Georgia, Dept Biochem & Mol Biol, Dept Microbiol, A 222 Life Sci Bldg, Athens, GA 30602 USA.				NIDDK NIH HHS [DK32303, DK35898, R56 DK032303] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035898, R56DK032303, R01DK032303] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Armstrong GA, 1996, FASEB J, V10, P228, DOI 10.1096/fasebj.10.2.8641556; ARMSTRONG GA, 1993, J GEN MICROBIOL, V139, P897, DOI 10.1099/00221287-139-5-897; BOGER P, 1993, PHOTOSYNTHETICA, V28, P481; BRENNER DA, 1980, NEW ENGL J MED, V302, P765, DOI 10.1056/NEJM198004033021401; COHENBAZIRE G, 1957, J CELL COMPAR PHYSL, V49, P25, DOI 10.1002/jcp.1030490104; Dailey HA, 1996, J BIOL CHEM, V271, P8714, DOI 10.1074/jbc.271.15.8714; Dailey HA, 1997, CELL MOL BIOL, V43, P67; Dailey TA, 1996, PROTEIN SCI, V5, P98; DAILEY TA, 1994, J BIOL CHEM, V269, P813; Dailey TA, 1997, METHOD ENZYMOL, V281, P340; Dailey TA, 1995, ARCH BIOCHEM BIOPHYS, V324, P379, DOI 10.1006/abbi.1995.0051; DAY RS, 1986, SEMIN DERMATOL, V5, P138; DEYBACH JC, 1981, HUM GENET, V58, P425, DOI 10.1007/BF00282829; DIALEY HA, 1990, BIOSYNTHESIS HEME CH, P123; Genetic Computer Group, 1994, PROGR MAN WISC PACK; HANSSON M, 1994, J BACTERIOL, V176, P5962, DOI 10.1128/jb.176.19.5962-5970.1994; JACOBS JM, 1991, PLANT PHYSIOL, V97, P197, DOI 10.1104/pp.97.1.197; JACOBS NJ, 1976, BIOCHIM BIOPHYS ACTA, V449, P1, DOI 10.1016/0005-2728(76)90002-5; JACOBS NJ, 1981, ARCH BIOCHEM BIOPHYS, V211, P305, DOI 10.1016/0003-9861(81)90458-6; KLEMM DJ, 1987, J BACTERIOL, V169, P5209, DOI 10.1128/jb.169.11.5209-5215.1987; KLEMM DJ, 1989, FEMS MICROBIOL LETT, V61, P61, DOI 10.1111/j.1574-6968.1989.tb03553.x; KOZIOL J, 1970, METHODS ENZYMOL B, V18, P2697; LANG HP, 1994, J BACTERIOL, V176, P3859, DOI 10.1128/JB.176.13.3859-3869.1994; LINDEN H, 1994, PLANT MOL BIOL, V24, P369, DOI 10.1007/BF00020174; MATRINGE M, 1989, BIOCHEM J, V260, P231, DOI 10.1042/bj2600231; Meissner PN, 1996, NAT GENET, V13, P95, DOI 10.1038/ng0596-95; Raisig A, 1996, J BIOCHEM-TOKYO, V119, P559; SANDMANN G, 1991, PHYSIOL PLANTARUM, V83, P186, DOI 10.1034/j.1399-3054.1991.830128.x; SASSARMAN A, 1993, CAN J MICROBIOL, V39, P1155; WEYLER W, 1990, PHARMACOL THERAPEUT, V47, P391, DOI 10.1016/0163-7258(90)90064-9; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2	31	63	67	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13658	13662		10.1074/jbc.273.22.13658	http://dx.doi.org/10.1074/jbc.273.22.13658			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593705	hybrid			2022-12-27	WOS:000073919100044
J	Guo, CH; Davis, AT; Ahmed, K				Guo, CH; Davis, AT; Ahmed, K			Dynamics of protein kinase CK2 association with nucleosomes in relation to transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT VENTRAL PROSTATE; CASEIN KINASE-2; AFFINITY-CHROMATOGRAPHY; ANDROGENIC REGULATION; CELLULAR-REGULATION; NUCLEAR MATRIX; PHOSPHORYLATION; PROLIFERATION; ANTIBODIES; CHROMATIN	Protein kinase CK2 has been implicated in control of cell growth and proliferation. Since growth stimuli evoke its preferential association with chromatin and nuclear matrix, we examined the dynamics of CK2 in nucleosomes fractionated on the basis of their transcriptional activity in the rat prostate. In this model, androgens induce expression of androgen-dependent genes but inhibit the androgen-repressed genes, whereas absence of androgens has the reverse effect. The level of CK2 was higher in the active than in inactive nucleosomes from normal prostate. Differential alterations in the levels of CK2 activity in the transcriptionally active versus inactive nucleosomes were evoked by androgen deprivation or administration. Comparison of the distribution of CK2 in active and inactive nucleosomes under varying androgenic conditions showed that the relative CK2 activity intrinsic to the transcriptionally active nucleosomes remained fairly stable, concordant with gene activity specific to the androgenic status. However, CK2 associated with inactive nucleosomes declined to a minimal level on androgen deprivation but increased rapidly on androgen administration (reflecting expression of multiple androgen-dependent genes). We suggest a role for CK2 in promoting the conformational transition of inactive nucleosomes to the active form and in the function of transcriptionally active nucleosomes.	Vet Affairs Med Ctr, Cellular & Mol Biochem Res Lab 151, Minneapolis, MN 55417 USA; Univ Minnesota, Dept Lab Med & Pathol, Cellular & Mol Biochem Res Lab, Minneapolis, MN 55417 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities	Ahmed, K (corresponding author), Vet Affairs Med Ctr, Cellular & Mol Biochem Res Lab 151, 1 Vet Dr, Minneapolis, MN 55417 USA.	ahmedk@maroon.tc.umn.edu			NATIONAL CANCER INSTITUTE [R01CA015062, U01CA015062, R37CA015062] Funding Source: NIH RePORTER; NCI NIH HHS [CA-15062] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMED K, 1993, P NATL ACAD SCI USA, V90, P4426, DOI 10.1073/pnas.90.10.4426; AHMED K, 1994, CELL MOL BIOL RES, V40, P1; Ahmed RL, 1996, ANAL BIOCHEM, V237, P76, DOI 10.1006/abio.1996.0203; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; ALLFREY VG, 1991, METHOD CELL BIOL, V35, P315; Beato M, 1996, ENDOCR REV, V17, P587, DOI 10.1210/er.17.6.587; BEREZNEY R, 1991, J CELL BIOCHEM, V47, P109, DOI 10.1002/jcb.240470204; Boldyreff B, 1997, FEBS LETT, V403, P197, DOI 10.1016/S0014-5793(97)00010-0; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; CHEN TA, 1991, J BIOL CHEM, V266, P6489; Coffey D.S., 1988, P1081; FILHOL O, 1992, J BIOL CHEM, V267, P20577; FURUYA Y, 1993, ENDOCRINOLOGY, V133, P2660, DOI 10.1210/en.133.6.2660; GETZENBERG RH, 1990, ENDOCR REV, V11, P399, DOI 10.1210/edrv-11-3-399; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; Janosch P, 1996, J BIOL CHEM, V271, P13868, DOI 10.1074/jbc.271.23.13868; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; LEGER JG, 1987, BIOCHEM BIOPH RES CO, V147, P196, DOI 10.1016/S0006-291X(87)80106-7; Li DX, 1997, J BIOL CHEM, V272, P3773, DOI 10.1074/jbc.272.6.3773; Li DX, 1996, J BIOL CHEM, V271, P15662, DOI 10.1074/jbc.271.26.15662; LIAO S, 1989, J STEROID BIOCHEM, V34, P41, DOI 10.1016/0022-4731(89)90064-2; LITCHFIELD DW, 1993, MOL CELL BIOCHEM, V128, P187, DOI 10.1007/BF01076770; LORENZ P, 1993, J BIOL CHEM, V268, P2733; MARIN O, 1994, BIOCHEM BIOPH RES CO, V198, P898, DOI 10.1006/bbrc.1994.1128; NICKERSON JA, 1992, MOL CELLULAR APPROAC, P343; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; SALTZMAN AG, 1987, J BIOL CHEM, V262, P432; Stein GS, 1996, AM SCI, V84, P28; TAWFIC S, 1994, J BIOL CHEM, V269, P7489; TAWFIC S, 1995, J BIOL CHEM, V270, P21009, DOI 10.1074/jbc.270.36.21009; TAWFIC S, 1994, J BIOL CHEM, V269, P24615; Tawfic S, 1997, J CELL BIOCHEM, V64, P499; TAWFIC S, 1994, PROSTATE, V24, P101, DOI 10.1002/pros.2990240208; Tawfic S, 1996, J CELL BIOCHEM, V62, P165, DOI 10.1002/(SICI)1097-4644(199608)62:2<165::AID-JCB4>3.0.CO;2-Q; Tuazon P. T., 1991, ADV 2 MESSENGER PHOS, V23, P123; van Holde K. E., 1989, CHROMATIN, P1; VOIT R, 1992, EMBO J, V11, P2211, DOI 10.1002/j.1460-2075.1992.tb05280.x; Wada T, 1996, NUCLEIC ACIDS RES, V24, P876, DOI 10.1093/nar/24.5.876; Wang Z, 1997, P NATL ACAD SCI USA, V94, P12999, DOI 10.1073/pnas.94.24.12999; WILLIAMSASHMAN HG, 1979, ENDOCRINOLOGY, V3, P1527; WOLFFE A, 1992, CHROMATIN STRUCTURE, P1	41	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13675	13680		10.1074/jbc.273.22.13675	http://dx.doi.org/10.1074/jbc.273.22.13675			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593708	hybrid			2022-12-27	WOS:000073919100047
J	Hong, SH; Phang, T; Ji, IH; Ji, TH				Hong, SH; Phang, T; Ji, IH; Ji, TH			The amino-terminal region of the luteinizing hormone choriogonadotropin receptor contacts both subunits of human choriogonadotropin I. Mutational analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHORIONIC-GONADOTROPIN RECEPTOR; EXTRACELLULAR DOMAIN; HIGH-AFFINITY; LH RECEPTOR; BINDING; ACTIVATION; PEPTIDE; GENE; IDENTIFICATION; RESIDUES	The luteinizing hormone/choriogonadotropin receptor is a seven-transmembrane receptor. Unlike most seven-transmembrane receptors, it is composed of two halves of equal size, the N-terminal extracellular exodomain and the C-terminal membrane-associated endodomain. The exodomain is exclusively responsible for high affinity hormone binding, whereas receptor activation occurs only in the endodomain. This mutually exclusive physical separation of the two functional domains sets the lutropin receptor and its subfamily of receptors apart from all other seven-transmembrane receptors, The mechanisms of hormone binding and receptor activation also appear to be different from those of other receptors in that binding occurs in at least two steps. However, the precise hormone contact sites in the exodomain are unknown. To determine the hormone/receptor contact sites, we have examined the receptor using progressive truncation from the C terminus, Ala scanning, immunofluorescence microscopy, and antibody binding. Progressive truncation from the C terminus of the receptor indicates several discrete regions that impact hormone binding. These regions are around the boundaries of exons 1-2, 4-5, 6-7, and 9-10, Ala scanning of the Asp(17)-Arg(26) region near the exon 1-2 junction uncovered three alternating residues (Leu(20), Cys(22),and Gly(24)) crucial for hormone binding. Ala substitution for any one of these residues abolished hormone binding, although the resulting mutant receptors were successfully expressed on the cell surface. In contrast, Ala substitution for their flanking and intervening residues did not impair hormone binding. These results and the data in the accompanying article (Phang, T,, Kundu, G,, Hong, S,, Ji, I., and Ji, T, (1998) J, Biol, Chem, 273, 13841-13847) indicate that this region directly contacts the hormone and suggest a novel mode of embracing the hormone.	Univ Wyoming, Dept Mol Biol, Laramie, WY 82071 USA	University of Wyoming	Ji, TH (corresponding author), Univ Wyoming, Dept Mol Biol, Laramie, WY 82071 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051469] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-18702] Funding Source: Medline; NIDDK NIH HHS [DK-51469] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bhowmick N, 1996, MOL ENDOCRINOL, V10, P1147, DOI 10.1210/me.10.9.1147; CHIANG CM, 1993, PEPTIDE RES, V6, P62; Couture L, 1996, J MOL ENDOCRINOL, V16, P15, DOI 10.1677/jme.0.0160015; DAVIS D, 1995, MOL ENDOCRINOL, V9, P159, DOI 10.1210/me.9.2.159; GUAN XM, 1992, J BIOL CHEM, V267, P21995; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; JI I, 1993, J BIOL CHEM, V268, P20851; JI I, 1981, P NATL ACAD SCI-BIOL, V78, P5465, DOI 10.1073/pnas.78.9.5465; JI IH, 1991, ENDOCRINOLOGY, V128, P2648, DOI 10.1210/endo-128-5-2648; JI TH, 1995, ENDOCRINE, V3, P187, DOI 10.1007/BF02994442; Jiang XL, 1995, STRUCTURE, V3, P1341, DOI 10.1016/S0969-2126(01)00272-6; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOO YB, 1991, ENDOCRINOLOGY, V128, P2297, DOI 10.1210/endo-128-5-2297; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; PHANG, 1998, J BIOL CHEM, V273, P13841; PRIKETT K, 1989, BIOTECHNIQUES, V7, P580; REMY JJ, 1993, BIOCHEM BIOPH RES CO, V193, P1023, DOI 10.1006/bbrc.1993.1727; ROCHE PC, 1992, ENDOCRINOLOGY, V131, P268, DOI 10.1210/en.131.1.268; Ryu KS, 1996, J BIOL CHEM, V271, P7301, DOI 10.1074/jbc.271.13.7301; SEETHARAMAIAH GS, 1994, ENDOCRINOLOGY, V134, P549, DOI 10.1210/en.134.2.549; Thomas D, 1996, MOL ENDOCRINOL, V10, P760, DOI 10.1210/me.10.6.760; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; TSAIMORRIS CH, 1991, J BIOL CHEM, V266, P11355; XIE YB, 1990, J BIOL CHEM, V265, P21411; Zhang R, 1996, J BIOL CHEM, V271, P5755, DOI 10.1074/jbc.271.10.5755	26	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13835	13840		10.1074/jbc.273.22.13835	http://dx.doi.org/10.1074/jbc.273.22.13835			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593728	hybrid			2022-12-27	WOS:000073919100067
J	Olivier, M; Romero-Gallo, BJ; Matte, C; Blanchette, J; Posner, BI; Tremblay, MJ; Faure, R				Olivier, M; Romero-Gallo, BJ; Matte, C; Blanchette, J; Posner, BI; Tremblay, MJ; Faure, R			Modulation of interferon-gamma-induced macrophage activation by phosphotyrosine phosphatases inhibition - Effect on murine Leishmaniasis progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; TYROSINE KINASE INHIBITORS; SIGNAL-TRANSDUCTION; DRUG-RESISTANCE; PHOSPHORYLATION; INDUCTION; INFECTION; DONOVANI; ATTENUATION; DYSFUNCTION	Phagocyte functions are markedly inhibited after infection with the intracellular protozoan parasite Leishmania. This situation strongly favors the installation and propagation of this pathogen within its mammalian host. Previous findings by us and others have established that alteration of several signaling pathways (protein kinase C-, Ca2+- and protein-tyrosine kinases-dependent signaling events) were directly responsible for Leishmania-induced macrophage (MO) dysfunctions, Here we report that modulation of phosphotyrosine-dependent events with a protein tyrosine phosphatases (PTP) inhibitor, the peroxovanadium (pV) compound bpV(phen) (potassium bisperoxo(1,10-phenanthroline)oxovanadate(V-i)), can control host-pathogen interactions by different mechanisms. We observed that the inhibition of parasite PTP resulted in an arrest of proliferation and death of the latter in coincidence with cyclin-dependent kinase (CDK1) tyrosine 15 phosphorylation. Moreover the treatment of MO with bpV(phen) resulted in an increased sensitivity to interferon-gamma- stimulation, which was reflected by enhanced nitric oxide (NO) production. This enhanced LFN-gamma-induced NO generation was accompanied by a marked increase of inducible nitric oxide synthase (iNOS) mRNA gene and protein expression. Finally we have verified the in vivo potency of bpV(phen) over a B-week period of daily administration of a sub-toxic dose. The results revealed its effectiveness in controlling the progression of visceral and cutaneous leishmaniasis. Therefore PTP inhibition of Leishmania and MO by the pV compound bpV(phen) can differentially affect these eukaryotic cells. This strongly suggests that PTP plays an important role in the progression of Leishmania infection and pathogenesis. The apparent potency of pV compounds along with their relatively simple and versatile structure render them attractive pharmacological agents for the management of parasitic infections.	Univ Laval, Fac Med, Ctr Hosp Univ Quebec, Ctr Rech Infectiol, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Fac Med, Ctr Hosp Univ Quebec, Dept Med Biol, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Fac Med, Ctr Hosp Univ Quebec, Unite Rech Neurosci, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Fac Med, Ctr Hosp Univ Quebec, Dept Med, Quebec City, PQ G1V 4G2, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 1A1, Canada	Laval University; Laval University; Laval University; Laval University; McGill University	Olivier, M (corresponding author), Univ Laval, Fac Med, Ctr Hosp Univ Quebec, Ctr Rech Infectiol, RC-709,Pavillon CHUL,2705 Boul Laurier, Quebec City, PQ G1V 4G2, Canada.	martin.olivier@crchul.ulaval.ca	Posner, Barry/B-6733-2008					ASHFORD RW, 1992, PARASITOL TODAY, V8, P104, DOI 10.1016/0169-4758(92)90249-2; BALDWIN GC, 1990, P NATL ACAD SCI USA, V87, P3933, DOI 10.1073/pnas.87.10.3933; Barbeau B, 1997, J BIOL CHEM, V272, P12968, DOI 10.1074/jbc.272.20.12968; BEVAN AP, 1995, AM J PHYSIOL-ENDOC M, V268, pE60, DOI 10.1152/ajpendo.1995.268.1.E60; BLISKA JB, 1991, P NATL ACAD SCI USA, V88, P1187, DOI 10.1073/pnas.88.4.1187; BUCHMULLERROUILLER Y, 1987, INFECT IMMUN, V55, P587; COOL DE, 1993, MOL CELL BIOCHEM, V128, P143, DOI 10.1007/BF01076765; DONG ZY, 1993, J IMMUNOL, V151, P2717; EVANS TG, 1993, J IMMUNOL, V151, P907; FAURE R, 1995, J CELL BIOCHEM, V59, P389, DOI 10.1002/jcb.240590310; GLASER KB, 1993, BIOCHEM PHARMACOL, V45, P711, DOI 10.1016/0006-2952(93)90147-O; GREEN SP, 1992, BIOCHEM J, V288, P427, DOI 10.1042/bj2880427; GREENBERG S, 1994, J BIOL CHEM, V269, P3897; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; NANDAN D, 1995, INFECT IMMUN, V63, P4495, DOI 10.1128/IAI.63.11.4495-4500.1995; Olivier M, 1996, PARASITOL TODAY, V12, P145, DOI 10.1016/0169-4758(96)10006-5; OLIVIER M, 1987, INFECT IMMUN, V55, P467, DOI 10.1128/IAI.55.2.467-471.1987; OLIVIER M, 1989, TROP MED PARASITOL, V40, P32; OLIVIER M, 1992, P NATL ACAD SCI USA, V89, P7481, DOI 10.1073/pnas.89.16.7481; OLIVIER M, 1992, J IMMUNOL, V148, P1188; OUELLETTE M, 1993, PARASITOL TODAY, V9, P150, DOI 10.1016/0169-4758(93)90135-3; Pan JM, 1996, BIOCHEM J, V314, P889, DOI 10.1042/bj3140889; PARSONS M, 1991, MOL BIOCHEM PARASIT, V45, P241, DOI 10.1016/0166-6851(91)90091-J; PARSONS M, 1994, MOL BIOCHEM PARASIT, V63, P69, DOI 10.1016/0166-6851(94)90009-4; PINCHING AJ, 1990, IMMUNOL TODAY, V11, P256, DOI 10.1016/0167-5699(90)90100-N; POSNER BI, 1994, J BIOL CHEM, V269, P4596; REINER NE, 1988, P NATL ACAD SCI USA, V85, P4330, DOI 10.1073/pnas.85.12.4330; RENIER G, 1994, J LIPID RES, V35, P1413; ROWE TC, 1986, CANCER RES, V46, P2021; Ruff SJ, 1997, J BIOL CHEM, V272, P1263, DOI 10.1074/jbc.272.2.1263; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; STENGER S, 1994, J EXP MED, V180, P783, DOI 10.1084/jem.180.3.783; Tsiani E, 1997, TRENDS ENDOCRIN MET, V8, P51, DOI 10.1016/S1043-2760(96)00262-7; TURCO SJ, 1992, ANNU REV MICROBIOL, V46, P65, DOI 10.1146/annurev.mi.46.100192.000433; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WHITE TC, 1988, J BIOL CHEM, V263, P16977; XIE QW, 1994, J BIOL CHEM, V269, P4705	38	102	113	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13944	13949		10.1074/jbc.273.22.13944	http://dx.doi.org/10.1074/jbc.273.22.13944			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593743	hybrid			2022-12-27	WOS:000073919100082
J	Phang, T; Kundu, G; Hong, SH; Ji, IH; Ji, TH				Phang, T; Kundu, G; Hong, SH; Ji, IH; Ji, TH			The amino-terminal region of the luteinizing hormone choriogonadotropin receptor contacts both subunits of human choriogonadotropin II. Photoaffinity labeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHORIONIC-GONADOTROPIN RECEPTOR; LEUCINE-RICH REPEATS; EXTRACELLULAR DOMAIN; HIGH-AFFINITY; LUTROPIN RECEPTOR; BINDING-SITE; LH RECEPTOR; PROTEIN; IDENTIFICATION; HCG	The luteinizing hormone/choriogonadotropin receptor, a seven-transmembrane receptor, is composed of two equal halves, the N-terminal extracellular exodomain and the C-terminal membrane-associated endodomain. Unlike most seven-transmembrane receptors, the exodomain alone is responsible for high affinity hormone binding, whereas signal is generated in the endodomain. These physical separations of hormone-binding and receptor activation sites are attributed to unique mechanisms for hormone binding and receptor activation of this receptor and its subfamily members. However, the precise hormone contact sites in the exodomain are unclear. In the preceding article (Hong, S,, Phang, T,, Ji, I., and Ji, T, H, (1998) J, Biol. Chem, 273, 13835-13840), a region immediately downstream of the N terminus of the exodomain was shown to be crucial for hormone binding. To test if the region interacts with the hormone, human choriogonadotropin (hCG) was photoaffinity-labeled with a peptide mimic corresponding to Gly(18)-Tyr(36) Of the receptor. This peptide mimic specifically photoaffinity-labeled both the alpha- and beta-subunits of hCG:, Interestingly, hCG alpha was preferentially labeled, On the other hand, denatured hCG was not labeled, and a mutant analog of the peptide failed to label hCG, Furthermore, the affinity labeling was UV-dependent and saturable, indicating the specificity of the photoaffinity labeling. Our results indicate that the region of the exodomain interacts with hCG and that the contact points are near both subunits of hCG, Particularly, the alternate residues (Leu(20), Cys(22), and Gly(24)) are crucial for hCG; binding, In addition, the results underscore the fact that there is a crucial hormone contact site outside of the popularly believed primary hormone-binding site that is composed of Leu-rich repeats and is located in the middle of the exodomain, Our observations are crucial for understanding the molecular mechanism through which the initial high affinity hormone binding leads to receptor activation in the endodomain.	Univ Wyoming, Dept Mol Biol, Laramie, WY 82071 USA	University of Wyoming	Ji, TH (corresponding author), Univ Wyoming, Dept Mol Biol, Laramie, WY 82071 USA.		Kundu, Gopal C./ABA-9897-2020		NICHD NIH HHS [HD-18702] Funding Source: Medline; NIDDK NIH HHS [DK-51469] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051469] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bhowmick N, 1996, MOL ENDOCRINOL, V10, P1147, DOI 10.1210/me.10.9.1147; Cosowsky L, 1997, J BIOL CHEM, V272, P3309, DOI 10.1074/jbc.272.6.3309; Couture L, 1996, J MOL ENDOCRINOL, V16, P15, DOI 10.1677/jme.0.0160015; DAVIS D, 1995, MOL ENDOCRINOL, V9, P159, DOI 10.1210/me.9.2.159; Hong SH, 1998, J BIOL CHEM, V273, P13835, DOI 10.1074/jbc.273.22.13835; JI I, 1980, P NATL ACAD SCI-BIOL, V77, P7167, DOI 10.1073/pnas.77.12.7167; JI I, 1981, P NATL ACAD SCI-BIOL, V78, P5465, DOI 10.1073/pnas.78.9.5465; JI IH, 1985, J BIOL CHEM, V260, P2815; JI IH, 1991, ENDOCRINOLOGY, V128, P2648, DOI 10.1210/endo-128-5-2648; JI TH, 1979, BIOCHIM BIOPHYS ACTA, V559, P39, DOI 10.1016/0304-4157(79)90007-8; JI TH, 1995, ENDOCRINE, V3, P187, DOI 10.1007/BF02994442; Jiang XL, 1995, STRUCTURE, V3, P1341, DOI 10.1016/S0969-2126(01)00272-6; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; LEPTHORN JP, 1994, NATURE, V369, P455; LIU C, 1993, J BIOL CHEM, V268, P21613; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MORBECK DE, 1993, MOL CELL ENDOCRINOL, V97, P173, DOI 10.1016/0303-7207(93)90225-9; Puett D, 1996, MOL CELL ENDOCRINOL, V125, P55, DOI 10.1016/S0303-7207(96)03954-8; Remy JJ, 1996, MOL CELL ENDOCRINOL, V125, P79, DOI 10.1016/S0303-7207(96)03955-X; REMY JJ, 1993, BIOCHEM BIOPH RES CO, V193, P1023, DOI 10.1006/bbrc.1993.1727; ROCHE PC, 1992, ENDOCRINOLOGY, V131, P268, DOI 10.1210/en.131.1.268; Ryu KS, 1996, J BIOL CHEM, V271, P7301, DOI 10.1074/jbc.271.13.7301; SEETHARAMAIAH GS, 1994, ENDOCRINOLOGY, V134, P549, DOI 10.1210/en.134.2.549; Thomas D, 1996, MOL ENDOCRINOL, V10, P760, DOI 10.1210/me.10.6.760; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; XIE YB, 1990, J BIOL CHEM, V265, P21411	29	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13841	13847		10.1074/jbc.273.22.13841	http://dx.doi.org/10.1074/jbc.273.22.13841			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593729	hybrid			2022-12-27	WOS:000073919100068
J	Poulin, F; Gingras, AC; Olsen, H; Chevalier, S; Sonenberg, N				Poulin, F; Gingras, AC; Olsen, H; Chevalier, S; Sonenberg, N			4E-BP3, a new member of the eukaryotic initiation factor 4E-kinding protein family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAP-BINDING PROTEIN; 5' NONCODING REGION; AMINO-ACID-SEQUENCE; TRANSLATION INITIATION; TRANSCRIPTION TERMINATION; DEPENDENT TRANSLATION; INTERNAL INITIATION; FACTOR EIF-4E; FACTOR 4E; RNA	Translation initiation in eukaryotes is mediated by the cap structure (m(7)GpppN, where N is any nucleotide) present at the 5' end of all cellular mRNAs, except organellar, The cap is recognized by eukaryotic initiation factor 4F (eIF4F), which consists of three polypeptides, including eIF4E, the cap binding protein subunit, The interaction of the cap with eIF4E facilitates the binding of the ribosome to the mRNA eIF4E activity is regulated in part by two translational repressors, 4E-BP1 and 4E-BP2, which bind to it and prevent its assembly into eIF4F, We report here the isolation of 4E-BP3, a new member of the 4E-BP family. 4E-BP3 is homologous to 4E-BP1 and 4E-BP2, exhibiting 57 and 59% identity, respectively. The homology is most striking in the middle region of the protein, which contains the eIF4E binding motif and residues that are phosphorylated in 4E-BP1, 4E-BP3 is a heat stable protein that binds to eIF4E in vitro as well as in vivo, Further, 4E-BP3 overexpression specifically reduces eIF4E-dependent translation. The overlapping function and expression of the different 4E-BP family members imply that there is redundancy in this translational control mechanism, underscoring its importance.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; Human Genome Sci Inc, Rockville, MD 20850 USA; Montreal Gen Hosp, Res Inst, McGill Urol Oncol Reg Grp, Montreal, PQ H3J 1A4, Canada	McGill University; McGill University; GlaxoSmithKline; Human Genome Sciences Inc; McGill University	Sonenberg, N (corresponding author), McGill Univ, Dept Biochem, 3655 Drummond St,Rm 807, Montreal, PQ H3G 1Y6, Canada.		Gingras, Anne-Claude/ABA-8341-2020; Gingras, Anne-Claude/E-9982-2010	Gingras, Anne-Claude/0000-0002-6090-4437; Gingras, Anne-Claude/0000-0002-6090-4437				ADAMS MD, 1995, NATURE, V377, P3; Altmann M, 1997, EMBO J, V16, P1114, DOI 10.1093/emboj/16.5.1114; BELSHAM GJ, 1990, J VIROL, V64, P5389, DOI 10.1128/JVI.64.11.5389-5395.1990; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; Blackshear PJ, 1997, J BIOL CHEM, V272, P31510, DOI 10.1074/jbc.272.50.31510; CHAMBERS JC, 1988, J BIOL CHEM, V263, P18043; DUNCAN R, 1987, J BIOL CHEM, V262, P380; EDERY I, 1988, GENE, V74, P517, DOI 10.1016/0378-1119(88)90184-9; Fadden P, 1997, J BIOL CHEM, V272, P10240; Feigenblum D, 1996, MOL CELL BIOL, V16, P5450; Fleurent M, 1997, J BIOL CHEM, V272, P4006, DOI 10.1074/jbc.272.7.4006; FREDERICKSON RM, 1991, MOL CELL BIOL, V11, P2896, DOI 10.1128/MCB.11.5.2896; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Gingras AC, 1997, VIROLOGY, V237, P182, DOI 10.1006/viro.1997.8757; Gingras AC, 1996, P NATL ACAD SCI USA, V93, P5578, DOI 10.1073/pnas.93.11.5578; GOYER C, 1993, MOL CELL BIOL, V13, P4860, DOI 10.1128/MCB.13.8.4860; Gradi A, 1998, MOL CELL BIOL, V18, P334, DOI 10.1128/MCB.18.1.334; GUNTAKA RV, 1993, MICROBIOL REV, V57, P511, DOI 10.1128/MMBR.57.3.511-521.1993; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; HIREMATH LS, 1985, J BIOL CHEM, V260, P7843; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; Imataka H, 1997, EMBO J, V16, P817, DOI 10.1093/emboj/16.4.817; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMONICA N, 1986, J VIROL, V57, P515, DOI 10.1128/JVI.57.2.515-525.1986; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Lin TA, 1996, J BIOL CHEM, V271, P30199, DOI 10.1074/jbc.271.47.30199; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MADER S, 1995, MOL CELL BIOL, V15, P4990; Mathews M. B., 1996, TRANSLATIONAL CONTRO, P1; Merrick WC., 1996, TRANSLATION CONTROL, P31; Ohlmann T, 1996, EMBO J, V15, P1371, DOI 10.1002/j.1460-2075.1996.tb00479.x; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; Rau M, 1996, J BIOL CHEM, V271, P8983, DOI 10.1074/jbc.271.15.8983; Rousseau D, 1996, ONCOGENE, V13, P2415; See Y., 1989, PROTEIN STRUCTURE PR, P1; SHATKIN AJ, 1985, CELL, V40, P223, DOI 10.1016/0092-8674(85)90132-1; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TsukiyamaKohara K, 1996, GENOMICS, V38, P353, DOI 10.1006/geno.1996.0638; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; Webber MM, 1997, PROSTATE, V30, P58; YAN RQ, 1992, J BIOL CHEM, V267, P23226	45	216	220	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					14002	14007		10.1074/jbc.273.22.14002	http://dx.doi.org/10.1074/jbc.273.22.14002			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593750	hybrid			2022-12-27	WOS:000073919100089
J	Mourey, L; Pedelacq, JD; Birck, C; Fabre, C; Rouge, P; Samama, JP				Mourey, L; Pedelacq, JD; Birck, C; Fabre, C; Rouge, P; Samama, JP			Crystal structure of the arcelin-1 dimer from Phaseolus vulgaris at 1.9-angstrom resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-AMYLASE INHIBITOR; CONCANAVALIN-A; 3-DIMENSIONAL STRUCTURE; QUATERNARY STRUCTURE; LATHYRUS-OCHRUS; LEGUME LECTINS; SEED PROTEIN; BINDING SITE; ISOLECTIN-I; CARBOHYDRATE	Arcelin-1 is a glycoprotein from kidney beans (Phaseolus vulgaris) which displays insecticidal properties and protects the seeds from predation by larvae of various bruchids, This lectin-like protein is devoid of monosaccharide binding properties and belongs to the phytohemagglutinin protein family. The x-ray structure determination at 1.9-Angstrom resolution of native arcelin-1 dimers, which correspond to the functional state of the protein in solution, was solved using multiple isomorphous replacement and refined to a crystallographic R factor of 0.208, The three glycosylation sites on each monomer are all covalently modified. One of these oligosaccharide chains provides interactions with protein atoms at the dimer interface, and another one may act by preventing the formation of higher oligomeric species in the arcelin variants. The dimeric structure and the severe alteration of the monosaccharide binding site in arcelin-1 correlate with the hemagglutinating properties of the protein, which are unaffected by simple sugars and sugar derivatives. Sequence analysis and structure comparisons of arcelin-1 with the other insecticidal proteins from kidney beans, arcelin-5, and alpha-amylase inhibitor and with legume lectins, yield insights into the molecular basis of the different biological functions of these proteins.	CNRS, IPBS, Grp Cristallog Biol, UPR 9062, F-31077 Toulouse, France; CNRS, IPBS, Grp Lectines & Reconnaissance, UPR 9062, F-31077 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS)	Samama, JP (corresponding author), CNRS, IPBS, Grp Cristallog Biol, UPR 9062, 205 Route Narbonne, F-31077 Toulouse, France.		Pedelacq, Jean-Denis/C-6053-2011; Rouge, Pierre/T-2059-2019; Mourey, Lionel/B-5662-2009	Mourey, Lionel/0000-0002-8259-1259; PEDELACQ, Jean-Denis/0000-0002-3202-2517				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Adar R, 1996, EUR J BIOCHEM, V239, P668, DOI 10.1111/j.1432-1033.1996.0668u.x; ALTABELLA T, 1990, PLANT PHYSIOL, V93, P805, DOI 10.1104/pp.93.2.805; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BANERJEE R, 1994, P NATL ACAD SCI USA, V91, P227, DOI 10.1073/pnas.91.1.227; BompardGilles C, 1996, STRUCTURE, V4, P1441, DOI 10.1016/S0969-2126(96)00151-7; BOULTER D, 1993, PHYTOCHEMISTRY, V34, P1453, DOI 10.1016/S0031-9422(00)90828-8; BOURNE Y, 1990, PROTEINS, V8, P365, DOI 10.1002/prot.340080410; BOURNE Y, 1990, J MOL BIOL, V214, P571, DOI 10.1016/0022-2836(90)90199-V; BROWN RD, 1977, BIOCHEMISTRY-US, V16, P3883, DOI 10.1021/bi00636a026; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, X PLOR VERSION 3 1; CHRISPEELS MJ, 1991, PLANT CELL, V3, P1, DOI 10.1105/tpc.3.1.1; COWTAN K, 1994, JONNT CCP4 ESF EACBM, V31; DELBAERE LTJ, 1993, J MOL BIOL, V230, P950, DOI 10.1006/jmbi.1993.1212; DESSEN A, 1995, BIOCHEMISTRY-US, V34, P4933, DOI 10.1021/bi00015a004; DRIESSEN H, 1989, J APPL CRYSTALLOGR, V22, P510, DOI 10.1107/S0021889889004097; EDELMAN GM, 1978, J BIOL CHEM, V253, P3016; EINSPAHR H, 1986, J BIOL CHEM, V261, P6518; Fabre C, 1998, BIOCHEM J, V329, P551, DOI 10.1042/bj3290551; GOOSSENS A, 1994, EUR J BIOCHEM, V225, P787, DOI 10.1111/j.1432-1033.1994.0787b.x; Hamelryck TW, 1996, J BIOL CHEM, V271, P32796, DOI 10.1074/jbc.271.51.32796; Hamelryck TW, 1996, J BIOL CHEM, V271, P20479, DOI 10.1074/jbc.271.34.20479; HARDMAN KD, 1972, BIOCHEMISTRY-US, V11, P4910, DOI 10.1021/bi00776a006; HARDMAN KD, 1973, BIOCHEMISTRY-US, V12, P442; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; JONES TA, 1982, COMPUTATIONAL CRYSTA, P303; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KLEYWEGTY GJ, 1993, JOINT CCP4 ESF EACBM, V28; KORNEGAY J, 1993, CROP SCI, V33, P589, DOI 10.2135/cropsci1993.0011183X003300030034x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie A. G. W., 1992, JOINT CCP4 ESF EACBM, V26; LORIS R, 1993, BIOCHEMISTRY-US, V32, P8772, DOI 10.1021/bi00085a007; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; Mourey L, 1997, PROTEINS, V29, P433, DOI 10.1002/(SICI)1097-0134(199712)29:4<433::AID-PROT4>3.0.CO;2-9; OSBORN TC, 1988, SCIENCE, V240, P207, DOI 10.1126/science.240.4849.207; OSBORN TC, 1988, PLANT PHYSIOL, V86, P399, DOI 10.1104/pp.86.2.399; Osinaga E, 1997, FEBS LETT, V412, P190, DOI 10.1016/S0014-5793(97)00677-7; PUEYO JJ, 1993, PLANT PHYSIOL, V101, P1341, DOI 10.1104/pp.101.4.1341; REEKE GN, 1975, J BIOL CHEM, V250, P1525; REEKE GN, 1986, SCIENCE, V234, P1108, DOI 10.1126/science.3775378; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RINI JM, 1995, ANNU REV BIOPH BIOM, V24, P551, DOI 10.1146/annurev.biophys.24.1.551; ROUGE P, 1993, BIOCHEM SYST ECOL, V21, P695, DOI 10.1016/0305-1978(93)90074-2; SCHILTZ M, 1995, STRUCTURE, V3, P309, DOI 10.1016/S0969-2126(01)00161-7; SCHILTZ M, 1994, J APPL CRYSTALLOGR, V27, P950, DOI 10.1107/S0021889894005923; SCHILTZ M, 1997, THESIS U PARIS 11 OR; SCHROEDER HE, 1995, PLANT PHYSIOL, V107, P1233, DOI 10.1104/pp.107.4.1233; SHAANAN B, 1991, SCIENCE, V254, P862, DOI 10.1126/science.1948067; SHADE RE, 1994, BIO-TECHNOL, V12, P793, DOI 10.1038/nbt0894-793; SHARON N, 1990, FASEB J, V4, P3198, DOI 10.1096/fasebj.4.14.2227211; Tsai CJ, 1997, PROTEIN SCI, V6, P53; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; YOUNG NM, 1992, J MOL BIOL, V228, P924, DOI 10.1016/0022-2836(92)90875-K; YOUNG NM, 1995, J BIOL CHEM, V270, P2563, DOI 10.1074/jbc.270.6.2563	56	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					12914	12922		10.1074/jbc.273.21.12914	http://dx.doi.org/10.1074/jbc.273.21.12914			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582323	Green Published, hybrid			2022-12-27	WOS:000073768500034
J	Toyofuku, T; Yabuki, M; Otsu, K; Kuzuya, T; Hori, M; Tada, M				Toyofuku, T; Yabuki, M; Otsu, K; Kuzuya, T; Hori, M; Tada, M			Direct association of the gap junction protein connexin-43 with ZO-1 in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; TIGHT JUNCTION; CHANNEL; CELLS; COMMUNICATION; RAT; PDZ; LOCALIZATION; CYTOPLASM; SKELETON	The gap junction protein connexin-43 is normally located at the intercalated discs of cardiac myocytes, and it plays a critical role in the synchronization of their contraction. The mechanism by which connexin-43 is localized within cardiac myocytes is unknown. However, localization of connexin 43 likely involves an interaction with the cytoskeleton; immunofluorescence microscopy showed that in cardiac myocytes, connexin-43 specifically colocalizes with the cytoskeletal proteins ZO-1 and cu-spectrin. In transfected HEK293 cells, immunoprecipitation experiments using coexpressed epitope-tagged connexin-43 and ZO-1 indicated that ZO-1 links connexin-43 with alpha-spectrin, The domains responsible for the protein-protein interaction between connexin-43 and ZO-1 were identified using affinity binding assays with deleted ZO-1 and connexin-43 fusion proteins, Immunoblot analysis of associated proteins showed that the C-terminal domain of connexin-43 binds to the N-terminal domain of ZO-1, The role of this linkage in gap junction formation was examined by a dominant-negative assay using the N-terminal domain of ZO-1, Overexpression of the N-terminal domain of ZO-1 in connexin-43-expressing cells resulted in redistribution of connexin-43 from cell-cell interfaces to cytoplasmic structures; this intracellular redistribution of connexin-43 coincided with a loss of electrical coupling. We therefore conclude that the linkage between connexin-43 and alpha-spectrin, via ZO-1, may serve to localize connexin-43 at the intercalated discs, thereby generating functional gap junctions in cardiac myocytes.	Osaka Univ, Sch Med, Dept Med & Pathophysiol, Suita, Osaka 565, Japan	Osaka University	Toyofuku, T (corresponding author), Osaka Univ, Sch Med, Dept Med & Pathophysiol, 2-2 Yamadaoka, Suita, Osaka 565, Japan.							ANDERSON JM, 1988, J CELL BIOL, V106, P1141, DOI 10.1083/jcb.106.4.1141; BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q; BENNETT V, 1992, J BIOL CHEM, V267, P8703; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BEYER EC, 1987, J CELL BIOL, V105, P2621, DOI 10.1083/jcb.105.6.2621; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; COLE WC, 1988, BIOPHYS J, V53, P809, DOI 10.1016/S0006-3495(88)83160-6; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; ELFGANG C, 1995, J CELL BIOL, V129, P805, DOI 10.1083/jcb.129.3.805; FISHMAN GI, 1990, J CELL BIOL, V111, P589, DOI 10.1083/jcb.111.2.589; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; Harrison SC, 1996, CELL, V86, P341, DOI 10.1016/S0092-8674(00)80105-1; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; ITOH M, 1991, J CELL BIOL, V115, P1449, DOI 10.1083/jcb.115.5.1449; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; JONGEN WMF, 1991, J CELL BIOL, V114, P545, DOI 10.1083/jcb.114.3.545; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; LOEWENSTEIN WR, 1981, PHYSIOL REV, V61, P829, DOI 10.1152/physrev.1981.61.4.829; MEIDELL RS, 1986, AM J PHYSIOL, V251, P1076; MEYER RA, 1992, J CELL BIOL, V119, P179, DOI 10.1083/jcb.119.1.179; MUSIL LS, 1993, CELL, V74, P1065, DOI 10.1016/0092-8674(93)90728-9; NEYTON J, 1985, NATURE, V317, P331, DOI 10.1038/317331a0; Rajasekaran AK, 1996, J CELL BIOL, V132, P451, DOI 10.1083/jcb.132.3.451; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; SOSINSKY GE, 1988, BIOPHYS J, V53, P709, DOI 10.1016/S0006-3495(88)83152-7; SPRAY DC, 1990, AM J PHYSIOL, V258, pC195, DOI 10.1152/ajpcell.1990.258.2.C195; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; Toyofuku T, 1998, J BIOL CHEM, V273, P1519, DOI 10.1074/jbc.273.3.1519; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Verheule S, 1997, CIRC RES, V80, P673, DOI 10.1161/01.RES.80.5.673; WEINGART R, 1988, CIRC RES, V63, P72, DOI 10.1161/01.RES.63.1.72	39	424	430	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					12725	12731		10.1074/jbc.273.21.12725	http://dx.doi.org/10.1074/jbc.273.21.12725			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582296	hybrid			2022-12-27	WOS:000073768500007
J	Feifel, B; Schonfeld, HJ; Christen, P				Feifel, B; Schonfeld, HJ; Christen, P			D-peptide ligands for the co-chaperone DnaJ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; MOLECULAR-CHAPERONE; ESCHERICHIA-COLI; ATP BINDING; KINETICS; SYSTEM	The molecular chaperone DnaK, the Hsp70 homolog of Escherichia coli, binds hydrophobic polypeptide segments in extended conformation. The co-chaperone DnaJ (Hsp40) has been reported to bind native and denatured proteins as well as peptides. We tested pseudopeptides of D-amino acids as ligands for both chaperones. In comparison to the parent all-L, peptide, these mimetics had either enantiomorphic side chain positions combined with retained main chain direction (normal all-D peptide) or unchanged side chain topology together with reverse direction of the peptide backbone (retro all-D peptide). The peptides were labeled with acrylodan (a), and their binding to DnaK and DnaJ was monitored by the accompanying increase in fluorescence intensity. The parent all-L peptide a-CALLLSAARR bound to both DnaK (K-d = 0.1 mu M) and DnaJ (K-d = 9.2 mu M). In contrast, the normal all-D and retro all-D peptides did not bind to DnaK; they bound, however, to DnaJ with K-d values of 6.8 mu M and 0.9 mu M, respectively. The emission spectra of the DnaJ-bound peptides suggests that DnaJ bound both D-peptides with the same main chain direction as L-peptides. Binding of the normal all-D and all-L peptides inhibited the DnaJ-induced stimulation of DnaK ATPase, However, binding of the retro all-D analog to DnaJ did not impair the stimulation, indicating the existence of separate binding sites for peptides and DnaK.	Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland; F Hoffmann La Roche & Co Ltd, Pharmaceut Res Infect Dis, CH-4070 Basle, Switzerland	University of Zurich; Roche Holding	Christen, P (corresponding author), Univ Zurich, Inst Biochem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.							Bartnes K, 1997, EUR J IMMUNOL, V27, P1387, DOI 10.1002/eji.1830270614; BINKIRANE N, 1995, J BIOL CHEM, V270, P11921; BORK P, 1992, TRENDS BIOCHEM SCI, V17, P129, DOI 10.1016/0968-0004(92)90319-5; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHOREV M, 1995, TRENDS BIOTECHNOL, V13, P438, DOI 10.1016/S0167-7799(00)88999-4; Feifel B, 1996, EUR J BIOCHEM, V237, P318, DOI 10.1111/j.1432-1033.1996.0318n.x; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; GEORGOPOULOS C, 1993, BIOL HEAT SHOCK PROT, P209; HARRISON JC, 1997, SCIENCE, V276, P431; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Horst M, 1996, PROTEIN SCI, V5, P759; JORDAN R, 1995, J BIOL CHEM, V270, P4563, DOI 10.1074/jbc.270.9.4563; Kudlicki W, 1996, J BIOL CHEM, V271, P31160, DOI 10.1074/jbc.271.49.31160; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; Martin J, 1997, CURR OPIN STRUC BIOL, V7, P41, DOI 10.1016/S0959-440X(97)80006-1; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; Pierpaoli EV, 1997, J MOL BIOL, V269, P757, DOI 10.1006/jmbi.1997.1072; RUOVO M, 1995, INT J PEPT PROT RES, V45, P356; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SCHONFELD HJ, 1995, J BIOL CHEM, V270, P2183, DOI 10.1074/jbc.270.5.2183; Schonfeld HJ, 1995, PROG COLL POL SCI S, V99, P7; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SZYPERSKI T, 1994, P NATL ACAD SCI USA, V91, P11343, DOI 10.1073/pnas.91.24.11343; Takeda S, 1996, BIOCHEMISTRY-US, V35, P4636, DOI 10.1021/bi952903o; Theyssen H, 1996, J MOL BIOL, V263, P657, DOI 10.1006/jmbi.1996.0606; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	27	31	32	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					11999	12002		10.1074/jbc.273.20.11999	http://dx.doi.org/10.1074/jbc.273.20.11999			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575139	hybrid			2022-12-27	WOS:000073629800004
J	Zhang, YL; Keng, YF; Zhao, Y; Wu, L; Zhang, ZY				Zhang, YL; Keng, YF; Zhao, Y; Wu, L; Zhang, ZY			Suramin is an active site-directed, reversible, and tight-binding inhibitor of protein-tyrosine phosphatases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; EXPERIMENTAL CHEMOTHERAPEUTIC DRUG; DUAL-SPECIFICITY PHOSPHATASE; CRYSTAL-STRUCTURE; TRANSITION-STATE; KINASE-C; CATALYZED REACTION; IN-VITRO; CELLS; MECHANISM	The effect of suramin, a well known antitrypanosomal drug and a novel experimental agent for the treatment of several cancers, on protein-tyrosine phosphatases (PTPases) has been examined. Suramin is a reversible and competitive PTPase inhibitor with K-is values in the low mu M range, whereas the K-is for the dual specificity phosphatase VHR is at least 10-fold higher. Although suramin can also inhibit the activity of the potato acid phosphatase at a slightly higher concentration, it is 2-3 orders of magnitude less effective against the protein Ser/Thr phosphatase la and the bovine intestinal alkaline phosphatase, Suramin binds to the active site of PTPases with a binding stoichiometry of 1:1. Furthermore, when suramin is bound to the active site of PTPases, its fluorescence is enhanced approximately by 10-fold, This property has allowed the determination of the binding affinity of suramin for PTPases and several catalytically impaired mutant PTPases by fluorescence titration techniques. Thus, the active site Cys to Ser mutants bind suramin with similar affinity as the wild type, while the active site Arg to Ala mutant exhibits a 20-fold reduced affinity toward suramin. Interestingly, the general acid deficient Asp to Ala mutant PTPases display an enhanced affinity toward suramin, which is in accord with their use as improved "substrate-trapping" agents. That suramin is a high affinity PTPase inhibitor is consistent with the observation that suramin treatment of cancer cell lines leads to an increase in tyrosine phosphorylation of several cellular proteins. Given the pleiotropic effects of suramin on many enzyme systems and growth factor-receptor interactions, the exact in vivo actions of suramin require further detailed structure-activity investigation of suramin and its structural analogs.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Zhang, ZY (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	zyzhang@aecom.yu.edu			NATIONAL CANCER INSTITUTE [R01CA069202] Funding Source: NIH RePORTER; NCI NIH HHS [CA69202] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALZANI R, 1995, BIOCHEMISTRY-US, V34, P6344, DOI 10.1021/bi00019a012; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BETSHOLTZ C, 1986, P NATL ACAD SCI USA, V83, P6440, DOI 10.1073/pnas.83.17.6440; Black DS, 1997, EMBO J, V16, P2730, DOI 10.1093/emboj/16.10.2730; BOJANOWSKI K, 1994, BIOCHEM BIOPH RES CO, V203, P1574, DOI 10.1006/bbrc.1994.2366; BOJANOWSKI K, 1992, P NATL ACAD SCI USA, V89, P3025, DOI 10.1073/pnas.89.7.3025; BOS OJM, 1990, BIOCHEM PHARMACOL, V40, P1595, DOI 10.1016/0006-2952(90)90460-3; Burke TR, 1996, BIOCHEMISTRY-US, V35, P15989, DOI 10.1021/bi961256d; Cadene M, 1997, J BIOL CHEM, V272, P9950, DOI 10.1074/jbc.272.15.9950; CARDINALI M, 1992, J CLIN INVEST, V89, P1242, DOI 10.1172/JCI115708; CHO HJ, 1992, J AM CHEM SOC, V114, P7296, DOI 10.1021/ja00044a052; COFFEY RJ, 1987, J CELL PHYSIOL, V132, P143, DOI 10.1002/jcp.1041320120; COLLINS JM, 1986, J CLIN PHARMACOL, V26, P22; DECLERCQ E, 1979, CANCER LETT, V8, P9, DOI 10.1016/0304-3835(79)90017-X; Denu JM, 1996, P NATL ACAD SCI USA, V93, P2493, DOI 10.1073/pnas.93.6.2493; DRESSEL O, 1961, J CHEM EDUC, V38, P620; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; GHOSH J, 1993, BIOCHEM BIOPH RES CO, V194, P36, DOI 10.1006/bbrc.1993.1781; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; GUAN KL, 1991, J BIOL CHEM, V266, P17026; Hawking F, 1978, Adv Pharmacol Chemother, V15, P289, DOI 10.1016/S1054-3589(08)60486-X; HENGGE AC, 1995, BIOCHEMISTRY-US, V34, P13982, DOI 10.1021/bi00043a003; HENSEY CE, 1989, FEBS LETT, V258, P156, DOI 10.1016/0014-5793(89)81639-4; HOSANG M, 1985, J CELL BIOCHEM, V29, P265, DOI 10.1002/jcb.240290310; Hunter T, 1996, BIOCHEM SOC T, V24, P307, DOI 10.1042/bst0240307; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; JINDAL HK, 1990, CANCER RES, V50, P7754; KOPP R, 1990, CANCER RES, V50, P6490; LAROCCA RV, 1990, J STEROID BIOCHEM, V37, P893, DOI 10.1016/0960-0760(90)90439-R; Lohse DL, 1997, BIOCHEMISTRY-US, V36, P4568, DOI 10.1021/bi963094r; MAHONEY CW, 1990, J BIOL CHEM, V265, P5424; MILARSKI KL, 1993, J BIOL CHEM, V268, P23634; MITSUYA H, 1984, SCIENCE, V226, P172, DOI 10.1126/science.6091268; MORIYAMA Y, 1988, FEBS LETT, V234, P383, DOI 10.1016/0014-5793(88)80121-2; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; ONO K, 1988, EUR J BIOCHEM, V172, P149; PRESTA M, 1991, CELL REGUL, V2, P719, DOI 10.1091/mbc.2.9.719; Puius YA, 1997, P NATL ACAD SCI USA, V94, P13420, DOI 10.1073/pnas.94.25.13420; SARTOR O, 1992, J CLIN INVEST, V90, P2166, DOI 10.1172/JCI116102; STEIN CA, 1993, CANCER RES, V53, P2239; STEIN CA, 1989, J CLIN ONCOL, V7, P499, DOI 10.1200/JCO.1989.7.4.499; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TAYLOR MF, 1995, STEROIDS, V60, P452, DOI 10.1016/0039-128X(95)00037-Q; WILLIAMS LT, 1984, J BIOL CHEM, V259, P5287; Wu L, 1996, BIOCHEMISTRY-US, V35, P5426, DOI 10.1021/bi952885a; Yuvaniyama J, 1996, SCIENCE, V272, P1328, DOI 10.1126/science.272.5266.1328; ZHANG ZY, 1992, J BIOL CHEM, V267, P23759; Zhang ZY, 1997, CURR TOP CELL REGUL, V35, P21, DOI 10.1016/S0070-2137(97)80002-7; Zhang ZY, 1995, BIOCHEMISTRY-US, V34, P16088, DOI 10.1021/bi00049a024; ZHANG ZY, 1995, J BIOL CHEM, V270, P11199, DOI 10.1074/jbc.270.19.11199; Zhang ZY, 1997, BIOCHEMISTRY-US, V36, P1362, DOI 10.1021/bi9624043; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P15266, DOI 10.1021/bi00255a007	54	97	105	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12281	12287		10.1074/jbc.273.20.12281	http://dx.doi.org/10.1074/jbc.273.20.12281			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575179	hybrid			2022-12-27	WOS:000073629800044
J	Kohn, AD; Barthel, A; Kovacina, KS; Boge, A; Wallach, B; Summers, SA; Birnbaum, MJ; Scott, PH; Lawrence, JC; Roth, RA				Kohn, AD; Barthel, A; Kovacina, KS; Boge, A; Wallach, B; Summers, SA; Birnbaum, MJ; Scott, PH; Lawrence, JC; Roth, RA			Construction and characterization of a conditionally active version of the serine/threonine kinase Akt	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; B C-AKT; PROTEIN-KINASE; 3T3-L1 ADIPOCYTES; BINDING DOMAIN; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; ESTROGEN-RECEPTOR; GLUCOSE-TRANSPORT; SER/THR KINASE	Akt is a serine/threonine kinase that requires a functional phosphatidylinositol 3-kinase to be stimulated by insulin and other growth factors. When directed to membranes by the addition of a src myristoylation sequence, Akt becomes constitutively active. In the present study, a conditionally active version of Akt was constructed by fusing the Akt containing the myristoylation sequence to the hormone binding domain of a mutant murine estrogen receptor that selectively binds 4-hydroxytamoxifen. The chimeric protein was expressed in NIH3T3 cells and was shown to be stimulated by hormone treatment 17-fold after only a 20-min treatment. This hormone treatment also stimulated an approximate 3-fold increase in the phosphorylation of the chimeric protein and a shift in its migration on SDS gels. Activation of this conditionally active Akt resulted in the rapid stimulation of the 70-kDa S6 kinase, This conditionally active Akt was also found to rapidly stimulate in these cells the phosphorylation of properties of PHAS-I, a key protein in the regulation of protein synthesis, The conditionally active Akt, when expressed in 3T3-L1 adipocytes, was also stimulated, although its rate and extent of activation was less then in the NIH3T3 cells, Its stimulation was shown to be capable of inducing glucose uptake into adipocytes by stimulating translocation of the insulin-responsive glucose transporter GLUT4 to the plasma membrane.	Stanford Univ, Med Ctr, Dept Mol Pharmacol, Sch Med, Stanford, CA 94305 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Virginia, Sch Med, Dept Pharmacol, Charlottesville, VA 22908 USA	Stanford University; Howard Hughes Medical Institute; University of Pennsylvania; University of Virginia	Roth, RA (corresponding author), Stanford Univ, Med Ctr, Dept Mol Pharmacol, Sch Med, Stanford, CA 94305 USA.	roth@cmgm.stanford.edu	/AAE-5384-2020	Scott, Pam/0000-0001-5548-4039; Birnbaum, Morris/0000-0001-9972-8680	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034926, R37DK034926, R01DK039615] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007365] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 39615, DK 34926] Funding Source: Medline; NIGMS NIH HHS [5T32 GM07365] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; BARTHEL A, 1997, ENDOCRINOLOGY, V138, P3877; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHIN JE, 1993, J BIOL CHEM, V268, P6338; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DANIELIAN PS, 1993, MOL ENDOCRINOL, V7, P232, DOI 10.1210/me.7.2.232; DEHERREROS AG, 1989, J BIOL CHEM, V264, P19994; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FINGAR DC, 1993, J BIOL CHEM, V268, P3005; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; JACKSON P, 1993, EMBO J, V12, P2809, DOI 10.1002/j.1460-2075.1993.tb05942.x; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; KOZMA SC, 1994, SEMIN CANCER BIOL, V5, P255; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Lawrence JC, 1997, TRENDS BIOCHEM SCI, V22, P345, DOI 10.1016/S0968-0004(97)01101-8; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Magun R, 1996, ENDOCRINOLOGY, V137, P3590, DOI 10.1210/en.137.8.3590; OKADA T, 1994, J BIOL CHEM, V269, P3568; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SCHERRER LC, 1993, BIOCHEMISTRY-US, V32, P5381, DOI 10.1021/bi00071a013; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241	36	264	272	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 8	1998	273	19					11937	11943		10.1074/jbc.273.19.11937	http://dx.doi.org/10.1074/jbc.273.19.11937			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZM408	9565622	hybrid			2022-12-27	WOS:000073536700076
J	Chang, SC; Heacock, PN; Mileykovskaya, E; Voelker, DR; Dowhan, W				Chang, SC; Heacock, PN; Mileykovskaya, E; Voelker, DR; Dowhan, W			Isolation and characterization of the gene (CLS1) encoding cardiolipin synthase in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CLS; PHOSPHOLIPID BIOSYNTHESIS; PHOSPHATIDYLGLYCEROPHOSPHATE SYNTHASE; CYTOCHROME-OXIDASE; PHOSPHATIDYLSERINE SYNTHASE; ACIDIC PHOSPHOLIPIDS; PRESEQUENCE PEPTIDE; MITOCHONDRIAL DECAY; SECONDARY STRUCTURE; 2D H-1-NMR	In eukaryotic cells, cardiolipin (CL) synthase catalyzes the final step in the synthesis of CL from phosphatidylglycerol and CDP-diacylglycerol. CL and its synthesis are localized predominantly to the mitochondrial inner membrane, and CL is generally thought to be an essential component of many mitochondrial processes. By using homology searches for genes potentially encoding phospholipid biosynthetic enzymes, we have cloned the gene (CLS1) encoding CL synthase in Saccharomyces cerevisiae, Overexpression of the CLS1 gene under its endogenous promoter or the inducible GAL1 promoter in yeast and expression of CLS1 in baculovirus-infected insect cells resulted in elevated CL synthase activity. Disruption of the CLS1 gene in a haploid yeast strain resulted in the loss of CL synthase activity, no detectable CL, a 5-fold elevation in phosphatidylglycerol levels, and lack of staining of mitochondria by a dye with high affinity for CL. The cls1::TRP1 null mutant grew on both fermentable and non-fermentable carbon sources but more poorly on the latter. The level and activity of cytochrome c oxidase was normal, and a dye whose accumulation is dependent on membrane proton electrochemical potential effectively stained the mitochondria, These results definitively identify the gene encoding the CL synthase of yeast.	Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77225 USA; Natl Jewish Ctr Immunol & Resp Med, Denver, CO 80206 USA	University of Texas System; National Jewish Health	Dowhan, W (corresponding author), Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77225 USA.	wdowhan@bmb.med.uth.tmc.edu		Mileykovskaya, Eugenia/0000-0002-8775-4467	NIGMS NIH HHS [GM32453, GM20478, GM54273] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054273, R37GM032453, R01GM020478, R37GM020478, R01GM032453] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADOLPHUS, 1983, EMBO J, V2, P1765, DOI 10.1002/j.1460-2075.1983.tb01655.x; AMES BN, 1995, BBA-MOL BASIS DIS, V1271, P165, DOI 10.1016/0925-4439(95)00024-X; AWASTHI YC, 1971, BIOCHIM BIOPHYS ACTA, V226, P42, DOI 10.1016/0005-2728(71)90176-9; BACHHAWAT N, 1995, J BIOL CHEM, V270, P25087, DOI 10.1074/jbc.270.42.25087; BEREITERHAHN J, 1976, BIOCHIM BIOPHYS ACTA, V423, P1, DOI 10.1016/0005-2728(76)90096-7; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; CARMAN GM, 1992, METHOD ENZYMOL, V209, P305; Chang SC, 1998, J BIOL CHEM, V273, P9829, DOI 10.1074/jbc.273.16.9829; Chang SC, 1997, FASEB J, V11, pA1079; Chupin V, 1996, BIOCHEMISTRY-US, V35, P3141, DOI 10.1021/bi952482a; CHUPIN V, 1995, FEBS LETT, V373, P239, DOI 10.1016/0014-5793(95)01054-I; CULLIS PR, 1979, BIOCHIM BIOPHYS ACTA, V559, P399, DOI 10.1016/0304-4157(79)90012-1; DECHAVIGNY A, 1991, J BIOL CHEM, V266, P5323; Dowhan W, 1997, ANNU REV BIOCHEM, V66, P199, DOI 10.1146/annurev.biochem.66.1.199; DOWHAN W, 1992, METHOD ENZYMOL, V209, P7; Dryden SC, 1996, J BACTERIOL, V178, P1030, DOI 10.1128/jb.178.4.1030-1038.1996; EILERS M, 1989, J BIOL CHEM, V264, P2945; ENDO T, 1989, J BIOL CHEM, V264, P2951; ESKO JD, 1980, J BIOL CHEM, V255, P4474; FINE JB, 1982, J LIPID RES, V23, P660; Gallet PF, 1997, BIOCHEM J, V324, P627, DOI 10.1042/bj3240627; GALLET PF, 1995, EUR J BIOCHEM, V228, P113, DOI 10.1111/j.1432-1033.1995.tb20238.x; Greenberg ML, 1996, MICROBIOL REV, V60, P1; Hatch GM, 1996, MOL CELL BIOCHEM, V159, P139, DOI 10.1007/BF00420916; HEACOCK PN, 1987, J BIOL CHEM, V262, P13044; HIRAOKA S, 1993, FEBS LETT, V336, P221, DOI 10.1016/0014-5793(93)80807-7; HIRSCHBERG CB, 1972, P NATL ACAD SCI USA, V69, P648, DOI 10.1073/pnas.69.3.648; HJELMSTAD RH, 1991, J BIOL CHEM, V266, P5094; HOCH FL, 1992, BIOCHIM BIOPHYS ACTA, V1113, P71, DOI 10.1016/0304-4157(92)90035-9; Janitor M, 1996, FEMS MICROBIOL LETT, V140, P43; JANITOR M, 1993, CURR GENET, V24, P307, DOI 10.1007/BF00336781; JANITOR M, 1995, YEAST, V11, P1223, DOI 10.1002/yea.320111302; Jiang F, 1997, MOL MICROBIOL, V26, P481, DOI 10.1046/j.1365-2958.1997.5841950.x; KELLY BL, 1990, BIOCHIM BIOPHYS ACTA, V1046, P144, DOI 10.1016/0005-2760(90)90181-V; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; KREBS JJR, 1979, J BIOL CHEM, V254, P5308; Maniatis T., 1982, MOL CLONING; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; NIKOLOFF DM, 1991, ANNU REV GENET, V25, P559; NISHIJIMA S, 1988, J BACTERIOL, V170, P775, DOI 10.1128/jb.170.2.775-780.1988; OHTSUKA T, 1993, J BIOL CHEM, V268, P22914; OHTSUKA T, 1993, J BIOL CHEM, V268, P22908; OU WJ, 1988, J BIOCHEM-TOKYO, V103, P589, DOI 10.1093/oxfordjournals.jbchem.a122312; RAETZ CRH, 1990, J BIOL CHEM, V265, P1235; RAND RP, 1972, BIOCHIM BIOPHYS ACTA, V225, P484, DOI 10.1016/0005-2736(72)90152-6; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schlame M, 1997, BBA-LIPID LIPID MET, V1348, P201, DOI 10.1016/S0005-2760(97)00117-3; SCHLAME M, 1993, EUR J BIOCHEM, V212, P727, DOI 10.1111/j.1432-1033.1993.tb17711.x; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SHIBUYA I, 1992, METHOD ENZYMOL, V209, P321; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; SIKORSKI RS, 1989, GENETICS, V122, P19; Spencer J.F.T., 1989, YEAST GENETICS MANUA; SUBIK J, 1974, FEBS LETT, V42, P309, DOI 10.1016/0014-5793(74)80753-2; TAMAI KT, 1990, BIOCHIM BIOPHYS ACTA, V1046, P214, DOI 10.1016/0005-2760(90)90192-Z; TROPP BE, 1995, J BACTERIOL, V177, P5155, DOI 10.1128/jb.177.17.5155-5157.1995; Tuller G, 1998, FEBS LETT, V421, P15, DOI 10.1016/S0014-5793(97)01525-1; USUI M, 1994, J BACTERIOL, V176, P3389, DOI 10.1128/jb.176.11.3389-3392.1994; White T.J., 1990, PCR PROTOCOLS GUIDE, V18, P315; WIKSTROM M, 1992, J BIOL CHEM, V267, P10266; Zhao M, 1998, J BIOL CHEM, V273, P2402, DOI 10.1074/jbc.273.4.2402; ZINSER E, 1991, J BACTERIOL, V173, P2026, DOI 10.1128/jb.173.6.2026-2034.1991	62	165	167	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14933	14941		10.1074/jbc.273.24.14933	http://dx.doi.org/10.1074/jbc.273.24.14933			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614098	hybrid			2022-12-27	WOS:000074160400040
J	Feranchak, AP; Roman, RM; Schwiebert, EM; Fitz, JG				Feranchak, AP; Roman, RM; Schwiebert, EM; Fitz, JG			Phosphatidylinositol 3-kinase contributes to cell volume regulation through effects on ATP release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT HEPATOCYTES; PDGF BETA-RECEPTOR; SIGNAL-TRANSDUCTION; PHOSPHOINOSITIDE 3-KINASE; 3T3-L1 ADIPOCYTES; BINDING-SITE; PROTEIN; WORTMANNIN; KINASE; LIVER	Regulated changes in cell volume represent a signal that modulates a broad range of cell and organ functions. In HTC hepatoma cells, increases in volume are coupled to membrane ion permeability through a pathway involving (i) ATP efflux, (ii) autocrine stimulation of P-2 receptors, and (iii) increases in anion permeability and Cl- efflux, contributing to recovery of volume toward basal values. Based on recent evidence that cell volume increases also stimulate phosphoinositide kinases, the purpose of these studies was to determine if phosphatidylinositol 3-kinase (PI 3-kinase) modulates these pathways. Exposure of cells to hypotonic buffer (20 or 40% less NaCl) caused an initial increase in cell volume and stimulated a rapid increase in ATP release. Subsequent opening of Cl- channels was followed by recovery of cell volume toward basal values, despite the continuous presence of hypotonic buffer. Inhibition of PI 3-kinase with wortmannin (K-i = 3 nM) significantly inhibited both the rate of volume recovery and activation of Cl- currents; similar results were obtained with LY294002 (10 mu M). Additionally, current activation was inhibited by intracellular dialysis with antibodies specific for the 110-kDa catalytic subunit of PI 3-kinase. Since release of ATP is a critical element in the volume-regulatory pathway, the role of PP 3-kinase on volume-stimulated ATP release was assessed. Both wortmannin and LY294002 decreased basal and volume-stimulated ATP permeability hut had no effect on the current response to exogenous ATP (10 mu M). These findings indicate that PI 3-kinase plays a significant role in regulation of cell volume and suggest that the effects are mediated in part through modulation of cellular ATP release.	Univ Colorado, Hlth Sci Ctr, Denver, CO 80262 USA; Childrens Hosp, Dept Pediat, Denver, CO 80262 USA; Childrens Hosp, Dept Med, Denver, CO 80262 USA; Univ Alabama, Dept Physiol & Biophys, Birmingham, AL 35294 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Children's Hospital Colorado; Children's Hospital Colorado; University of Alabama System; University of Alabama Birmingham	Feranchak, AP (corresponding author), Univ Colorado, Hlth Sci Ctr, Campus Box B-158,Room 6412,4200 E 9th Ave, Denver, CO 80262 USA.	drew.feranchak@UCHSC.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043278, R01DK046082, R37DK046082] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-46082, DK-43278] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALHABORI M, 1992, BIOCHEM J, V282, P789, DOI 10.1042/bj2820789; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BASAVAPPA S, 1993, GASTROENTEROLOGY, V104, P1796, DOI 10.1016/0016-5085(93)90661-U; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; Bodily K, 1997, HEPATOLOGY, V25, P403; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CHANG D, 1988, COMPUT BIOL MED, V18, P351, DOI 10.1016/0010-4825(88)90022-4; DAVIDSON HW, 1995, J CELL BIOL, V130, P797, DOI 10.1083/jcb.130.4.797; DePaolo D, 1996, MOL CELL BIOL, V16, P1450; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FITZ JG, 1994, AM J PHYSIOL, V266, pG677, DOI 10.1152/ajpgi.1994.266.4.G677; FITZ JG, 1994, AM J PHYSIOL, V266, pG544, DOI 10.1152/ajpgi.1994.266.4.G544; Folli F, 1997, GASTROENTEROLOGY, V113, P954, DOI 10.1016/S0016-5085(97)70192-6; Grygorczyk R, 1997, AM J PHYSIOL-CELL PH, V272, pC1058; HARDEN TK, 1995, ANNU REV PHARMACOL, V35, P541, DOI 10.1146/annurev.pharmtox.35.1.541; HAUSSINGER D, 1994, AM J PHYSIOL, V267, pE343, DOI 10.1152/ajpendo.1994.267.3.E343; HAUSSINGER D, 1996, PROGR LIVER DIS, P29; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Katagiri H, 1997, AM J PHYSIOL-ENDOC M, V272, pE326, DOI 10.1152/ajpendo.1997.272.2.E326; Krause U, 1996, J BIOL CHEM, V271, P16668, DOI 10.1074/jbc.271.28.16668; LIDOFSKY SD, 1993, J BIOL CHEM, V268, P14632; Lidofsky SD, 1997, AM J PHYSIOL-GASTR L, V273, pG849, DOI 10.1152/ajpgi.1997.273.4.G849; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; Meng XJ, 1996, AM J PHYSIOL-CELL PH, V271, pC112, DOI 10.1152/ajpcell.1996.271.1.C112; Merlin D, 1996, AM J PHYSIOL-CELL PH, V271, pC612, DOI 10.1152/ajpcell.1996.271.2.C612; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; Noe B, 1996, GASTROENTEROLOGY, V110, P858, DOI 10.1053/gast.1996.v110.pm8608896; OKADA T, 1994, J BIOL CHEM, V269, P3563; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; Roman RM, 1997, J BIOL CHEM, V272, P21970, DOI 10.1074/jbc.272.35.21970; SCHLIESS F, 1995, BIOCHEM J, V309, P13, DOI 10.1042/bj3090013; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; VARTICOVSKI L, 1994, BBA-MOL BASIS DIS, V1226, P1, DOI 10.1016/0925-4439(94)90051-5; VLAHOS CJ, 1995, J IMMUNOL, V154, P2413; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Walters RJ, 1996, FEBS LETT, V392, P66, DOI 10.1016/0014-5793(96)00679-5; Wang Y, 1996, P NATL ACAD SCI USA, V93, P12020, DOI 10.1073/pnas.93.21.12020; WENNSTROM S, 1994, ONCOGENE, V9, P651; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WONG K, 1994, J BIOL CHEM, V269, P28878	48	103	104	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14906	14911		10.1074/jbc.273.24.14906	http://dx.doi.org/10.1074/jbc.273.24.14906			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614094	hybrid			2022-12-27	WOS:000074160400036
J	Gilchrist, A; Mazzoni, MR; Dineen, B; Dice, A; Linden, J; Proctor, WR; Lupica, CR; Dunwiddie, TV; Hamm, HE				Gilchrist, A; Mazzoni, MR; Dineen, B; Dice, A; Linden, J; Proctor, WR; Lupica, CR; Dunwiddie, TV; Hamm, HE			Antagonists of the receptor-G protein interface block G(1)-coupled signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-BINDING; A(1) ADENOSINE RECEPTORS; HIPPOCAMPAL-FORMATION; SYNTHETIC PEPTIDES; PERTUSSIS TOXIN; CEREBRAL-CORTEX; BOVINE BRAIN; RAT-BRAIN; CONFORMATIONAL-CHANGES; TERMINAL MUTATIONS	The carboxyl terminus of heterotrimeric G protein alpha subunits plays an important Pole in receptor interaction. We demonstrate that peptides corresponding to the last 11 residues of G alpha(i1/2) or G alpha(o1) impair agonist binding to A(1) adenosine receptors, whereas G alpha(s) or G alpha(t) peptides have mo effect. Previously, by using a combinatorial library we identified a series of G alpha(t) peptide analogs that bind rhodopsin with high affinity (Martin, E. L., Rens-Domiano, S., Schatz, P. J., and Hamm, H. E. (1996) J. Biol. Chem. 271, 361-366). Native G alpha(i1/2) peptide as well as several analogs were tested for their ability to modulate agonist binding or antagonist-agonist competition using cells overexpressing human A(1) adenosine receptors. Three peptide analogs decreased the K-i, suggesting that they disrupt the high affinity receptor-G protein interaction and stabilize am intermediate affinity state. To study the ability of the peptides to compete with endogenous G alpha(i) proteins and block signal transduction in a native setting we measured activation of G protein-coupled K+ channels through A(1) adenosine or gamma-aminobutyric acid, type B, receptors in hippocampal CA1 pyramidal neurons. Native G alpha(i1/2), peptide, and certain analog peptides inhibited receptor-mediated K+ channel gating, dependent can which receptor was activated. This differential perturbation of receptor-G protein interaction suggests that receptors that act on the same G protein can be selectively disrupted.	Northwestern Univ, Inst Neurosci, Dept Mol Pharmacol & Biochem, Chicago, IL 60611 USA; Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA; Univ Illinois, Dept Physiol & Biophys, Chicago, IL 60612 USA; Univ Pisa, Dept Psychiat Neurobiol Pharmacol & Biotechnol, Neurobiol & Pharmacol Lab, I-56126 Pisa, Italy; Univ Virginia, Dept Internal Med, Div Cardiovasc, Charlottesville, VA 22908 USA; Univ Colorado, Dept Pharmacol, Denver, CO 80262 USA	Northwestern University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Pisa; University of Virginia; University of Colorado System; University of Colorado Denver	Hamm, HE (corresponding author), Northwestern Univ, Inst Neurosci, Dept Mol Pharmacol & Biochem, 320 E Super 5-555 Searle, Chicago, IL 60611 USA.		Gilchrist, Annette/I-4465-2014; Hamm, Heidi E/G-2374-2014; Lupica, Carl/AAY-3193-2021; Mazzoni, Maria Rosa/AAA-2366-2022	Gilchrist, Annette/0000-0003-2386-7646; Lupica, Carl/0000-0002-5375-3263; Mazzoni, Maria Rosa/0000-0003-2612-432X	NEI NIH HHS [EY 06062, EY10291] Funding Source: Medline; NHLBI NIH HHS [HL 37942] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY006062, R01EY010291] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R55HL037942, R01HL037942] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acharya S, 1997, J BIOL CHEM, V272, P6519, DOI 10.1074/jbc.272.10.6519; ARNIS S, 1995, BIOCHEMISTRY-US, V34, P9333, DOI 10.1021/bi00029a008; ARNIS S, 1993, P NATL ACAD SCI USA, V90, P7849, DOI 10.1073/pnas.90.16.7849; ASANO T, 1985, J BIOL CHEM, V260, P2653; Bae H, 1997, J BIOL CHEM, V272, P32071, DOI 10.1074/jbc.272.51.32071; Beindl W, 1996, MOL PHARMACOL, V50, P415; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Conklin BR, 1996, MOL PHARMACOL, V50, P885; Danialou G, 1997, BRIT J PHARMACOL, V121, P1355, DOI 10.1038/sj.bjp.0701247; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; DUTAR P, 1988, NEURON, V1, P585, DOI 10.1016/0896-6273(88)90108-0; FARAHBAKHSH ZT, 1993, SCIENCE, V262, P1416, DOI 10.1126/science.8248781; FASTBOM J, 1987, ACTA PHYSIOL SCAND, V131, P467, DOI 10.1111/j.1748-1716.1987.tb08263.x; Figler RA, 1997, BIOCHEMISTRY-US, V36, P16288, DOI 10.1021/bi972000q; FREISSMUTH M, 1991, J BIOL CHEM, V266, P17778; FREUND S, 1994, N-S ARCH PHARMACOL, V350, P49; GARCIA PD, 1995, EMBO J, V14, P4460, DOI 10.1002/j.1460-2075.1995.tb00125.x; GERWINS P, 1992, P NATL ACAD SCI USA, V89, P7330, DOI 10.1073/pnas.89.16.7330; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; Hohenegger M, 1998, P NATL ACAD SCI USA, V95, P346, DOI 10.1073/pnas.95.1.346; Huang CL, 1997, FEBS LETT, V405, P291, DOI 10.1016/S0014-5793(97)00197-X; JOCKERS R, 1994, J BIOL CHEM, V269, P32077; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; KNOWLES WD, 1992, J CLIN NEUROPHYSIOL, V9, P252; KOFUJI P, 1995, P NATL ACAD SCI USA, V92, P6542, DOI 10.1073/pnas.92.14.6542; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; LEE KS, 1986, NEUROSCIENCE, V19, P535, DOI 10.1016/0306-4522(86)90279-4; LINDEN J, 1985, CIRC RES, V56, P279, DOI 10.1161/01.RES.56.2.279; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Luscher C, 1997, NEURON, V19, P687, DOI 10.1016/S0896-6273(00)80381-5; MAHAN LC, 1991, MOL PHARMACOL, V40, P1; Martin EL, 1996, J BIOL CHEM, V271, P361, DOI 10.1074/jbc.271.1.361; Mazzoni MR, 1996, J BIOL CHEM, V271, P30034, DOI 10.1074/jbc.271.47.30034; Mei YA, 1996, J NEUROENDOCRINOL, V8, P85, DOI 10.1111/j.1365-2826.1996.tb00827.x; MORISHITA R, 1990, FEBS LETT, V271, P231, DOI 10.1016/0014-5793(90)80413-D; MUNSHI R, 1991, J BIOL CHEM, V266, P22285; MUNSHI R, 1989, J BIOL CHEM, V264, P14853; NICOLL RA, 1988, SCIENCE, V241, P545, DOI 10.1126/science.2456612; OLAH ME, 1995, ARCH INT PHARMACOD T, V329, P135; OLAH ME, 1995, ANNU REV PHARMACOL, V35, P581, DOI 10.1146/annurev.pa.35.040195.003053; Osawa S, 1995, J BIOL CHEM, V270, P31052, DOI 10.1074/jbc.270.52.31052; PALM D, 1990, FEBS LETT, V261, P294, DOI 10.1016/0014-5793(90)80575-4; PALMER TM, 1995, NEUROPHARMACOLOGY, V34, P683, DOI 10.1016/0028-3908(95)00044-7; RAMKUMAR V, 1988, J PHARMACOL EXP THER, V246, P1194; RARICK HM, 1994, METHOD ENZYMOL, V238, P13; RASENICK MM, 1994, J BIOL CHEM, V269, P21519; REPPERT SM, 1991, MOL ENDOCRINOL, V5, P1037, DOI 10.1210/mend-5-8-1037; RESEK JF, 1993, BIOCHEMISTRY-US, V32, P12025, DOI 10.1021/bi00096a012; RIVKEES SA, 1994, ENDOCRINOLOGY, V135, P2307, DOI 10.1210/en.135.6.2307; RIVKEES SA, 1995, BRAIN RES, V677, P193, DOI 10.1016/0006-8993(95)00062-U; Schreibmayer W, 1996, NATURE, V380, P624, DOI 10.1038/380624a0; SCOTT RH, 1987, INHIBITION NEURONAL, P549; SIMONDS WF, 1989, FEBS LETT, V249, P189, DOI 10.1016/0014-5793(89)80622-2; STILES GL, 1992, J BIOL CHEM, V267, P6451; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; Swanson TH, 1995, J COMP NEUROL, V363, P517, DOI 10.1002/cne.903630402; SWEENEY MI, 1995, J NEUROCHEM, V64, P2034; TETZLAFF W, 1987, NEUROSCIENCE, V21, P869, DOI 10.1016/0306-4522(87)90043-1; Tomura H, 1997, J BIOL CHEM, V272, P23130, DOI 10.1074/jbc.272.37.23130; TRUSSELL LO, 1987, J NEUROSCI, V7, P3306; VANCALKER D, 1979, J NEUROCHEM, V33, P999, DOI 10.1111/j.1471-4159.1979.tb05236.x; Verrall S, 1997, J BIOL CHEM, V272, P6898, DOI 10.1074/jbc.272.11.6898; WEAVER DR, 1992, AM J PHYSIOL, V263, pF991, DOI 10.1152/ajprenal.1992.263.6.F991; WEST RE, 1985, J BIOL CHEM, V260, P4428; Zapata R, 1997, J NEUROCHEM, V69, P2546	69	84	119	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14912	14919		10.1074/jbc.273.24.14912	http://dx.doi.org/10.1074/jbc.273.24.14912			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614095	hybrid			2022-12-27	WOS:000074160400037
J	Halvorson, LM; Ito, M; Jameson, JL; Chin, WW				Halvorson, LM; Ito, M; Jameson, JL; Chin, WW			Steroidogenic factor-1 and early growth response protein 1 act through two composite DNA binding sites to regulate luteinizing hormone beta-subunit gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORPHAN NUCLEAR RECEPTOR; FACTOR-I; TRANSGENIC MICE; CHORIONIC-GONADOTROPIN; KEY REGULATOR; PITUITARY; PROMOTER; ENCODES; CELL; LH	Recent in vivo and in vitro studies have implicated the orphan nuclear receptor, steroidogenic factor-1 (SF-1), and the early growth response protein 1 (Egr-1) in the transcriptional regulation of the luteinizing hormone beta-subunit (LH beta) gene. We have previously demonstrated the ability of SF-1 to bind to and transactivate the rat LH beta gene promoter acting at a consensus gonadotrope-specific element (GSE) located at position -127. We have now identified a second functional GSE site at position -59. In addition, based on electrophoretic mobility shift assay, in vitro translated Egr-1 is shown to bind to two putative Egr-1 binding sites (positions -112 and -50), which appear to be paired with the identified GSE sites. By transient transfection assay in pituitary-derived GH, cells, it was seen that Egr-1 increases promoter activity of region -207/+5 of the rat LH beta gene promoter through action at both Egr-1 sites. Furthermore, LHP gene promoter activity is markedly augmented in the presence of both factors together relative to activity in the presence of SF-1 or Egr-1 alone (150-fold versus 14-fold and 12-fold, respectively). These data define two composite SF-1-Egr-1 response-elements in the proximal LH beta gene promoter and suggest that SF-1 and Egr-1 act synergistically to increase expression of the LH beta gene in the gonadotrope.	Brigham & Womens Hosp, Dept Med, Div Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Tufts Univ, Sch Med, Dept Obstet & Gynecol, Boston, MA 02111 USA; Northwestern Univ, Sch Med, Div Endocrinol Metab & Mol Med, Chicago, IL 60611 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Tufts University; Northwestern University	Halvorson, LM (corresponding author), Brigham & Womens Hosp, Dept Med, Div Genet, GW Thorn Res Bldg,Rm 1013,20 Shattuck St, Boston, MA 02115 USA.	Halvorson@rascal.med.harvard.edu		Jameson, James/0000-0001-9538-4059	NICHD NIH HHS [R01-HD19938, R03-HD34692, U54-HD29164] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD019938] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD029164, R03HD034692] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARNHART KM, 1994, MOL ENDOCRINOL, V8, P878, DOI 10.1210/me.8.7.878; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; BROWN P, 1993, MOL CELL ENDOCRINOL, V93, P157, DOI 10.1016/0303-7207(93)90119-5; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CLAYTON RN, 1991, MOL CELL ENDOCRINOL, V80, P193, DOI 10.1016/0303-7207(91)90156-M; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; EZASHI T, 1990, J MOL ENDOCRINOL, V5, P137, DOI 10.1677/jme.0.0050137; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; Halvorson LM, 1996, J BIOL CHEM, V271, P6645, DOI 10.1074/jbc.271.12.6645; HONDA S, 1993, J BIOL CHEM, V268, P7494; HORN F, 1992, MOL CELL BIOL, V12, P2143, DOI 10.1128/MCB.12.5.2143; IKEDA Y, 1993, MOL ENDOCRINOL, V7, P852, DOI 10.1210/me.7.7.852; IKEDA Y, 1995, MOL ENDOCRINOL, V9, P478, DOI 10.1210/me.9.4.478; INGRAHAM HA, 1994, GENE DEV, V8, P2302, DOI 10.1101/gad.8.19.2302; Ito M, 1997, MOL CELL BIOL, V17, P1476, DOI 10.1128/MCB.17.3.1476; JAMESON L, 1984, J BIOL CHEM, V259, P5474; Kaiser UB, 1995, P NATL ACAD SCI USA, V92, P12280, DOI 10.1073/pnas.92.26.12280; Keri RA, 1996, J BIOL CHEM, V271, P10782, DOI 10.1074/jbc.271.18.10782; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; Lala DS, 1997, P NATL ACAD SCI USA, V94, P4895, DOI 10.1073/pnas.94.10.4895; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; Liu Z, 1997, MOL ENDOCRINOL, V11, P127, DOI 10.1210/me.11.2.127; LYNCH JP, 1993, MOL ENDOCRINOL, V7, P776, DOI 10.1210/me.7.6.776; MORRIS AE, 1990, GENE, V94, P289, DOI 10.1016/0378-1119(90)90400-L; MUSCATELLI F, 1994, NATURE, V372, P672, DOI 10.1038/372672a0; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; RICE DA, 1991, MOL ENDOCRINOL, V5, P1552, DOI 10.1210/mend-5-10-1552; Sambrook J., 2002, MOL CLONING LAB MANU; SHEN WH, 1994, CELL, V77, P651, DOI 10.1016/0092-8674(94)90050-7; SHERMAN GB, 1992, MOL ENDOCRINOL, V6, P951, DOI 10.1210/me.6.6.951; SHUPNIK MA, 1989, J BIOL CHEM, V264, P80; SUEN CS, 1993, MOL CELL BIOL, V13, P1719, DOI 10.1128/MCB.13.3.1719; TALMADGE K, 1984, NATURE, V307, P37, DOI 10.1038/307037a0; Thomas P, 1996, ENDOCRINOLOGY, V137, P2979, DOI 10.1210/en.137.7.2979; Topilko P, 1998, MOL ENDOCRINOL, V12, P107, DOI 10.1210/mend.12.1.0049; VIRGIN JB, 1985, J BIOL CHEM, V260, P7072; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; WINDLE JJ, 1990, MOL ENDOCRINOL, V4, P597, DOI 10.1210/mend-4-4-597	40	116	117	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14712	14720		10.1074/jbc.273.24.14712	http://dx.doi.org/10.1074/jbc.273.24.14712			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614069	hybrid			2022-12-27	WOS:000074160400011
J	Arts, EJ; Miller, JT; Ehresmann, B; Le Grice, SFJ				Arts, EJ; Miller, JT; Ehresmann, B; Le Grice, SFJ			Mutating a region of HIV-1 reverse transcriptase implicated in tRNA(Lys-3) binding and the consequences for (-)-strand DNA synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; GEL RETARDATION ASSAYS; PRIMER TRANSFER-RNA; ANGSTROM RESOLUTION; TRANSFER RNA(LYS-3); CRYSTAL-STRUCTURE; TYPE-1 PARTICLES; WILD-TYPE; SITE; TRNA(3)(LYS)	Recently, tRNA(Lys-3) Was cross-linked via its anticodon loop to human immunodeficiency virus type I (HIV-1) reverse transcriptase (RT) between residues 230 and 357 (Mishima, Y., and Steitz, J. A. (1995) EMBO J. 14, 2679-2687), Scanning the surface of this region identified three basic amino acids Lys(249), Arg(307), and Lys(311) flanking a small crevice on the p66 thumb subdomain outside the primer-template binding cleft. To assess an interaction of this region with the tRNA anticodon loop, these p66 residues were altered to Glu or Gin. p66 subunits containing K249Q, K311Q, K311E, and a dual R307E/K311E K311E mutation formed a stable dimer with wild type p51. All mutants showed reduced affinity for tRNA(Lys-3) and supported significantly less (-)-strand DNA synthesis from this primer than the parental heterodimer. In contrast, these variants efficiently synthesized HIV-1 (-)-strand strong-stop DNA from oligonucleotide primers and had minimal effect on RNase H activity, retaining endonucleolytic and directed cleavage of an RNA/DNA hybrid. Structural features of binary RT.tRNA(Lys-3) complexes were examined by in situ footprinting, via susceptibility to 1,10-phenanthroline-copper-mediated cleavage. Unlike wild type RT, mutants p66(K311Q)/p51 and p66(K311E)/p51 failed to protect the tRNA anticodon domain from chemical cleavage, indicating a significant structural alteration in the binary RT tRNA complex. These results suggest a crevice in the p66 thumb subdomain of HIV-1 RT supports an interaction with the tRNA(Lys-3) anticodon loop critical for efficient (-)-strand DNA synthesis.	Case Western Reserve Univ, Univ Hosp Cleveland, Dept Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ctr AIDS Res, Cleveland, OH 44106 USA; CNRS, Inst Biol Mol & Cellulaire, F-67084 Strasbourg, France	Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Case Western Reserve University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Le Grice, SFJ (corresponding author), Case Western Reserve Univ, Univ Hosp Cleveland, Dept Med, 10900 Euclid Ave, Cleveland, OH 44106 USA.	sfl@po.cwru.edu		Arts, Eric/0000-0002-4880-7968	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031147, P30AI036219] Funding Source: NIH RePORTER; NIAID NIH HHS [AI36219, AI31147] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agris PF, 1997, RNA, V3, P420; Arion D, 1996, BIOCHEM BIOPH RES CO, V225, P839, DOI 10.1006/bbrc.1996.1260; ARTS EJ, 1994, J GEN VIROL, V75, P1605, DOI 10.1099/0022-1317-75-7-1605; Arts EJ, 1996, J BIOL CHEM, V271, P9054, DOI 10.1074/jbc.271.15.9054; Arts EJ, 1996, P NATL ACAD SCI USA, V93, P10063, DOI 10.1073/pnas.93.19.10063; Arts Eric J., 1995, Journal of Biomedical Science, V2, P314, DOI 10.1007/BF02255218; BARAT C, 1989, EMBO J, V8, P3279, DOI 10.1002/j.1460-2075.1989.tb08488.x; BAUDIN F, 1993, J MOL BIOL, V229, P382, DOI 10.1006/jmbi.1993.1041; Berkhout B, 1997, NUCLEIC ACIDS RES, V25, P4013, DOI 10.1093/nar/25.20.4013; BOYER PL, 1994, P NATL ACAD SCI USA, V91, P4882, DOI 10.1073/pnas.91.11.4882; Cameron CE, 1997, P NATL ACAD SCI USA, V94, P6700, DOI 10.1073/pnas.94.13.6700; Canard B, 1997, P NATL ACAD SCI USA, V94, P11279, DOI 10.1073/pnas.94.21.11279; DAS AT, 1995, J VIROL, V69, P3090, DOI 10.1128/JVI.69.5.3090-3097.1995; Essink BBO, 1996, J MOL BIOL, V264, P243, DOI 10.1006/jmbi.1996.0638; ESSINK BBO, 1995, J BIOL CHEM, V270, P23867, DOI 10.1074/jbc.270.40.23867; Ghosh M, 1997, BIOCHEMISTRY-US, V36, P5758, DOI 10.1021/bi963045e; Ghosh M, 1996, BIOCHEMISTRY-US, V35, P8553, DOI 10.1021/bi952773j; Hermann T, 1995, RNA, V1, P1009; Huang Y, 1997, J VIROL, V71, P726, DOI 10.1128/JVI.71.1.726-728.1997; ISEL C, 1993, J BIOL CHEM, V268, P25269; ISEL C, 1995, J MOL BIOL, V247, P236, DOI 10.1006/jmbi.1994.0136; Isel C, 1996, EMBO J, V15, P917, DOI 10.1002/j.1460-2075.1996.tb00426.x; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JACQUES PS, 1994, J BIOL CHEM, V269, P1388; JIANG M, 1993, J VIROL, V67, P3246, DOI 10.1128/JVI.67.6.3246-3253.1993; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KUWABARA MD, 1987, BIOCHEMISTRY-US, V26, P7234, DOI 10.1021/bi00397a006; Lanchy JM, 1996, EMBO J, V15, P7178, DOI 10.1002/j.1460-2075.1996.tb01109.x; LeGrice SFJ, 1995, METHOD ENZYMOL, V262, P130, DOI 10.1016/0076-6879(95)62015-X; LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307, DOI 10.1111/j.1432-1033.1990.tb15306.x; Leis J, 1993, REVERSE TRANSCRIPTAS, P33; LI XG, 1994, J VIROL, V68, P6198, DOI 10.1128/JVI.68.10.6198-6206.1994; Liang C, 1997, J VIROL, V71, P5750, DOI 10.1128/JVI.71.8.5750-5757.1997; Mak J, 1997, J MOL BIOL, V265, P419, DOI 10.1006/jmbi.1996.0742; MAK J, 1994, J VIROL, V68, P2065, DOI 10.1128/JVI.68.4.2065-2072.1994; METZGER W, 1993, P NATL ACAD SCI USA, V90, P5909, DOI 10.1073/pnas.90.13.5909; MISHIMA Y, 1995, EMBO J, V14, P2679, DOI 10.1002/j.1460-2075.1995.tb07266.x; Myers GK, 1995, HUMAN RETROVIRUSES A; NAGASHUNMUGAM T, 1992, P NATL ACAD SCI USA, V89, P4114, DOI 10.1073/pnas.89.9.4114; PEARSON L, 1994, NUCLEIC ACIDS RES, V22, P2255, DOI 10.1093/nar/22.12.2255; Rausch JW, 1996, J MOL BIOL, V257, P500, DOI 10.1006/jmbi.1996.0181; RHIM H, 1991, J VIROL, V65, P4555, DOI 10.1128/JVI.65.9.4555-4564.1991; RICHTERCOOK NJ, 1992, J BIOL CHEM, V267, P15952; RODGERS DW, 1995, P NATL ACAD SCI USA, V92, P1222, DOI 10.1073/pnas.92.4.1222; SARIHCOTTIN L, 1992, J MOL BIOL, V226, P1, DOI 10.1016/0022-2836(92)90117-3; Thrall SH, 1996, BIOCHEMISTRY-US, V35, P4609, DOI 10.1021/bi9526387; WAKEFIELD JK, 1994, J VIROL, V68, P1605, DOI 10.1128/JVI.68.3.1605-1614.1994; Wakefield JK, 1996, J VIROL, V70, P966, DOI 10.1128/JVI.70.2.966-975.1996; WOHRL BM, 1993, J BIOL CHEM, V268, P13617; WOHRL BM, 1995, BIOCHEMISTRY-US, V34, P5343	50	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14523	14532		10.1074/jbc.273.23.14523	http://dx.doi.org/10.1074/jbc.273.23.14523			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603966	hybrid			2022-12-27	WOS:000074021500068
J	Emery, JG; McDonnell, P; Burke, MB; Deen, KC; Lyn, S; Silverman, C; Dul, E; Appelbaum, ER; Eichman, C; DiPrinzio, R; Dodds, RA; James, IE; Rosenberg, M; Lee, JC; Young, PR				Emery, JG; McDonnell, P; Burke, MB; Deen, KC; Lyn, S; Silverman, C; Dul, E; Appelbaum, ER; Eichman, C; DiPrinzio, R; Dodds, RA; James, IE; Rosenberg, M; Lee, JC; Young, PR			Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-RECEPTOR; DOMAIN-CONTAINING RECEPTOR; SURFACE-PLASMON RESONANCE; DEATH-DOMAIN; TNF RECEPTOR; FAMILY; APOPTOSIS; BINDING; MEMBER; PROTEINS	TRAIL is a tumor necrosis factor-related ligand that induces apoptosis upon binding to its death domain-containing receptors, DR4 and DR5. Two additional TRAIL receptors, TRID/DcR1 and DcR2, lack functional death domains and function as decoy receptors for TRAIL. We have identified a fifth TRAIL receptor, namely osteoprotegerin (OPG), a secreted tumor necrosis factor receptor homologue that inhibits osteoclastogenesis and increases bone density in vivo. OPG-Fc binds TRAIL with an affinity of 3.0 nM, which is slightly weaker than the interaction of TRID-Fc or DR5-Fc with TRAIL. OPG inhibits TRAIL-induced apoptosis of Jurkat cells, Conversely, TRAIL blocks the anti-osteoclastogenic activity of OPG, These data suggest potential cross-regulatory mechanisms by OPG and TRAIL.	SmithKline Beecham Pharmaceut, Dept Mol Biol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Biol Struct, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Mol & Cellular Immunol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Prot Biochem, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Gene Express Sci, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Bone & Cartilage Biol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Antiinfect, Collegeville, PA 19426 USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Young, PR (corresponding author), SmithKline Beecham Pharmaceut, Dept Mol Biol, Mail Code UW2101,709 Swedeland Rd, King Of Prussia, PA 19406 USA.							AbuAmer Y, 1997, J CLIN INVEST, V100, P1557, DOI 10.1172/JCI119679; AIYAR N, 1994, MOL CELL BIOCHEM, V131, P75, DOI 10.1007/BF01075727; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Harlow E., 1988, ANTIBODIES LAB MANUA; Hsu HL, 1997, J BIOL CHEM, V272, P13471, DOI 10.1074/jbc.272.21.13471; JOHANSON K, 1995, J BIOL CHEM, V270, P9459, DOI 10.1074/jbc.270.16.9459; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; KUMAR S, 1995, J BIOL CHEM, V270, P27905, DOI 10.1074/jbc.270.46.27905; Kwon BS, 1997, J BIOL CHEM, V272, P14272, DOI 10.1074/jbc.272.22.14272; LACEY DL, 1995, ENDOCRINOLOGY, V136, P2367, DOI 10.1210/en.136.6.2367; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LOETSCHER H, 1991, J BIOL CHEM, V266, P18324; Lotz M, 1996, J LEUKOCYTE BIOL, V60, P1; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; Marsters SA, 1996, CURR BIOL, V6, P1669, DOI 10.1016/S0960-9822(02)70791-4; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OSHANNESSY DJ, 1994, METHOD ENZYMOL, V240, P323; OSHANNESSY DJ, 1992, ANAL BIOCHEM, V205, P132, DOI 10.1016/0003-2697(92)90589-Y; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; PENNICA D, 1992, J BIOL CHEM, V267, P21172; Pinckard JK, 1997, J IMMUNOL, V158, P3869; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; ROTHE J, 1992, IMMUNOL RES, V11, P81, DOI 10.1007/BF02918612; Schneider P, 1997, FEBS LETT, V416, P329, DOI 10.1016/S0014-5793(97)01231-3; Screaton GR, 1997, CURR BIOL, V7, P693, DOI 10.1016/S0960-9822(06)00297-1; Sedger L, 1996, IMMUNOL CELL BIOL, V74, P538, DOI 10.1038/icb.1996.87; SHATZMAN AR, 1987, METHOD ENZYMOL, V152, P661; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; SMITH CA, 1993, CELL, V73, P1349, DOI 10.1016/0092-8674(93)90361-S; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yuan JY, 1997, CURR OPIN CELL BIOL, V9, P247, DOI 10.1016/S0955-0674(97)80069-5	37	997	1082	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14363	14367		10.1074/jbc.273.23.14363	http://dx.doi.org/10.1074/jbc.273.23.14363			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603945	hybrid			2022-12-27	WOS:000074021500047
J	Mossi, R; Ferrari, E; Hubscher, U				Mossi, R; Ferrari, E; Hubscher, U			DNA ligase I selectively affects DNA synthesis by DNA polymerases delta and epsilon suggesting differential functions in DNA replication and repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; BASE EXCISION-REPAIR; DOUBLE-STRANDED DNA; SACCHAROMYCES-CEREVISIAE; CALF THYMUS; FACTOR-C; AUXILIARY PROTEIN; LAGGING STRAND; HELA-CELLS; ALPHA	The joining of single-stranded breaks in double-stranded DNA is an essential step in many important processes such as DNA replication DNA repair, and genetic recombination. Several data implicate a role for DNA Ligase I in DNA replication, probably coordinated by the action of other enzymes and proteins, Since both DNA polymerases delta and epsilon show multiple functions in different DNA transactions, we investigated the effect of DNA ligase I on various DNA synthesis events catalyzed by these two essential DNA polymerases. DNA ligase I inhibited replication factor C-independent DNA synthesis by polymerase delta., Our results suggest that the inhibition may be due to DNA ligase I interaction with proliferating cell nuclear antigen (PCNA) and not to a direct interaction with the DNA polymerase delta itself Strand displacement activity by DNA polymerase delta was also affected by DNA ligase I. The DNA polymerase delta holoenzyme (composed of DNA polymerase delta, PCNA, and replication factor C) was inhibited in the same way as the DNA polymerase delta core, strengthening the hypothesis of a PCNA interaction. Contrary to DNA polymerase delta, DNA synthesis by DNA polymerase epsilon was stimulated by DNA ligase I in a PCNA-dependent manner. We conclude that DNA Ligase I displays different influences on the two multipotent DNA polymerases delta and epsilon through PCNA. This might be of importance in the selective involvement in DNA transactions such as DNA replication and various mechanisms of DNA repair.	Univ Zurich, Inst Vet Biochem, CH-8057 Zurich, Switzerland	University of Zurich	Hubscher, U (corresponding author), Univ Zurich, Inst Vet Biochem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.							AMACKER M, 1995, J VIROL, V69, P6273, DOI 10.1128/JVI.69.10.6273-6279.1995; BAMBARA RA, 1991, BIOCHIM BIOPHYS ACTA, V1088, P11, DOI 10.1016/0167-4781(91)90147-E; BARNES DE, 1990, P NATL ACAD SCI USA, V87, P6679, DOI 10.1073/pnas.87.17.6679; BOULET A, 1989, EMBO J, V8, P1849, DOI 10.1002/j.1460-2075.1989.tb03580.x; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; Cai JS, 1996, P NATL ACAD SCI USA, V93, P12896, DOI 10.1073/pnas.93.23.12896; ELDER RH, 1990, BIOCHEMISTRY-US, V29, P6009, DOI 10.1021/bi00477a019; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; FOCHER F, 1989, NUCLEIC ACIDS RES, V17, P1805, DOI 10.1093/nar/17.5.1805; FOCHER F, 1988, NUCLEIC ACIDS RES, V16, P6279, DOI 10.1093/nar/16.14.6279; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Hindges R, 1997, BIOL CHEM, V378, P345; HUBSCHER U, 1979, P NATL ACAD SCI USA, V76, P6284, DOI 10.1073/pnas.76.12.6284; JESSBERGER R, 1993, J BIOL CHEM, V268, P15070; Jessberger R, 1997, NUCLEIC ACIDS RES, V25, P289, DOI 10.1093/nar/25.2.289; JOHNSON LM, 1985, CELL, V43, P369, DOI 10.1016/0092-8674(85)90042-X; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; Kornberg A., 1992, DNA REPLICATION; LASKO DD, 1990, J BIOL CHEM, V265, P12618; LEHMANN AR, 1988, CANCER RES, V48, P6343; LEVIN DS, 1997, P NATL ACAD SCI USA, V94, P12868; LI CG, 1994, NUCLEIC ACIDS RES, V22, P632, DOI 10.1093/nar/22.4.632; LINDAHL T, 1992, ANNU REV BIOCHEM, V61, P251, DOI 10.1146/annurev.bi.61.070192.001343; Mackenney VJ, 1997, J BIOL CHEM, V272, P11550; MAGA G, 1995, BIOCHEMISTRY-US, V34, P891, DOI 10.1021/bi00003a023; MONTECUCCO A, 1992, NUCLEIC ACIDS RES, V20, P6209, DOI 10.1093/nar/20.23.6209; MONTECUCCO A, 1995, EMBO J, V14, P5379, DOI 10.1002/j.1460-2075.1995.tb00222.x; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; Mossi R, 1998, EUR J BIOCHEM, V254, P209, DOI 10.1046/j.1432-1327.1998.254209.x; OTTIGER HP, 1984, P NATL ACAD SCI-BIOL, V81, P3993, DOI 10.1073/pnas.81.13.3993; PIGNEDE G, 1992, CHROMOSOMA, V102, P128; PODUST LM, 1995, MOL CELL BIOL, V15, P3072; PODUST LM, 1994, NUCLEIC ACIDS RES, V22, P2970, DOI 10.1093/nar/22.15.2970; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P5003, DOI 10.1021/bi00015a011; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P8869, DOI 10.1021/bi00027a039; PODUST VN, 1993, NUCLEIC ACIDS RES, V21, P841, DOI 10.1093/nar/21.4.841; PODUST VN, 1992, CHROMOSOMA, V102, P133; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PRIGENT C, 1994, MOL CELL BIOL, V14, P310, DOI 10.1128/MCB.14.1.310; SABATINO RD, 1988, BIOCHEMISTRY-US, V27, P2998, DOI 10.1021/bi00408a050; SHIVJI MKK, 1995, BIOCHEMISTRY-US, V34, P5011, DOI 10.1021/bi00015a012; SIEGAL G, 1992, P NATL ACAD SCI USA, V89, P9377, DOI 10.1073/pnas.89.20.9377; SIMON M, 1991, EMBO J, V10, P2165, DOI 10.1002/j.1460-2075.1991.tb07751.x; Sugimoto K, 1996, P NATL ACAD SCI USA, V93, P7048, DOI 10.1073/pnas.93.14.7048; SYVAOJA J, 1990, P NATL ACAD SCI USA, V87, P6664, DOI 10.1073/pnas.87.17.6664; TAN CK, 1986, J BIOL CHEM, V261, P2310; TOMKINSON AE, 1990, J BIOL CHEM, V265, P12611; Tomkinson AE, 1997, BIOESSAYS, V19, P893, DOI 10.1002/bies.950191009; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; WAGA S, 1994, J BIOL CHEM, V269, P10923; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WANG TSF, 1996, DNA REPLICATION EUKA, P461; WANG ZG, 1993, MOL CELL BIOL, V13, P1051, DOI 10.1128/MCB.13.2.1051; WEI YF, 1995, MOL CELL BIOL, V15, P3206; WEISER T, 1991, J BIOL CHEM, V266, P10420; Zlotkin T, 1996, EMBO J, V15, P2298, DOI 10.1002/j.1460-2075.1996.tb00583.x	58	29	29	6	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14322	14330		10.1074/jbc.273.23.14322	http://dx.doi.org/10.1074/jbc.273.23.14322			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603940	hybrid, Green Accepted			2022-12-27	WOS:000074021500042
J	Paquette, J; Giannoukakis, N; Polychronakos, C; Vafiadis, P; Deal, C				Paquette, J; Giannoukakis, N; Polychronakos, C; Vafiadis, P; Deal, C			The INS 5 ' variable number of tandem repeats is associated with IGF2 expression in humans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-II; INSULIN GENE; MINISATELLITE LOCUS; HRAS1 MINISATELLITE; COMPETITIVE PCR; WILMS-TUMOR; HUMAN-FETUS; CANCER; SUSCEPTIBILITY; RELAXATION	The minisatellite DNA polymorphism consisting of a variable number of tandem repeats (VNTR) at the human INS (insulin gene) 5'-flanking region has demonstrated allelic effects ore insulin gene transcription in vitro and has been associated with the level of insulin gene expression in vivo. We now show that this VNTR also has effects on the nearby insulin-like growth factor ZI gene (IGF2) in human placenta in vivo and in the HepG2 hepatoma cell line in vitro. We show that higher steady-state IGF2 mRNA levels are associated with shorter alleles (class I) than the longer class III alleles in term placentae. In vitro, reporter gene activity was greater from reporter gene constructs with IGF2 promoter 3 in the presence of class I alleles than from those with class PII, Taken together with the documented transcriptional effects on the insulin gene, we propose that the VNTR, may act as a long range control element affecting the expression of both INS and IGF2. The localization of a type 1 diabetes susceptibility locus (IDDM2) to the VNTR itself suggests that either or both of these genes may be involved in the biologic effects of IDDM2.	Hop St Justine, Endocrine Serv, Res Ctr, Dept Pediat, Montreal, PQ H3T 1C5, Canada; McGill Univ, Montreal Childrens Hosp, Dept Pediat, Montreal, PQ H3H 1P3, Canada	Universite de Montreal; McGill University	Deal, C (corresponding author), Hop St Justine, Endocrine Serv, Res Ctr, Dept Pediat, Rm 1706,3175 Cote Ste Catherine, Montreal, PQ H3T 1C5, Canada.	dealc@ere.umontreal.ca	Polychronakos, Constantin/B-8151-2008	Polychronakos, Constantin/0000-0002-7624-6635				Bailly S, 1996, MOL IMMUNOL, V33, P999, DOI 10.1016/S0161-5890(96)00042-9; BANERJEE S, 1995, NAT GENET, V11, P237, DOI 10.1038/ng1195-237; BELL GI, 1985, P NATL ACAD SCI USA, V82, P6450, DOI 10.1073/pnas.82.19.6450; BENNETT ST, 1995, NAT GENET, V9, P284, DOI 10.1038/ng0395-284; Bennett ST, 1997, NAT GENET, V17, P350, DOI 10.1038/ng1197-350; BRICE AL, 1989, DEVELOPMENT, V106, P543; CATIGNANIKENNED.G, 1995, NAT GENET, V9, P293; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dahlquist G, 1996, BRIT MED J, V313, P1174, DOI 10.1136/bmj.313.7066.1174; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; FORSTER E, 1994, BIOTECHNIQUES, V16, P18; GERMAN M, 1995, DIABETES, V44, P1002, DOI 10.2337/diab.44.8.1002; Giannoukakis N, 1996, BIOCHEM BIOPH RES CO, V220, P1014, DOI 10.1006/bbrc.1996.0524; GIANNOUKAKIS N, 1993, NAT GENET, V4, P98, DOI 10.1038/ng0593-98; GRAY A, 1987, DNA-J MOLEC CELL BIO, V6, P283, DOI 10.1089/dna.1987.6.283; GREEN M, 1993, GENOMICS, V17, P429, DOI 10.1006/geno.1993.1343; HAN VKM, 1988, J CLIN ENDOCR METAB, V66, P422, DOI 10.1210/jcem-66-2-422; Harrela M, 1996, J CLIN INVEST, V98, P2612, DOI 10.1172/JCI119081; HASHIMOTO K, 1995, NAT GENET, V9, P109, DOI 10.1038/ng0295-109; JOHN SWM, 1991, NUCLEIC ACIDS RES, V19, P408, DOI 10.1093/nar/19.2.408; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; JULIER C, 1991, NATURE, V354, P155, DOI 10.1038/354155a0; Kinouchi Y, 1996, CANCER LETT, V107, P105, DOI 10.1016/0304-3835(96)04348-0; KRONTIRIS TG, 1993, NEW ENGL J MED, V329, P517, DOI 10.1056/NEJM199308193290801; KRONTIRIS TG, 1995, SCIENCE, V269, P1682, DOI 10.1126/science.7569893; Li XR, 1997, CANCER RES, V57, P2048; LUCASSEN AM, 1995, HUM MOL GENET, V4, P501, DOI 10.1093/hmg/4.4.501; LUCASSEN AM, 1993, NAT GENET, V4, P305, DOI 10.1038/ng0793-305; Morison IM, 1996, NAT MED, V2, P311, DOI 10.1038/nm0396-311; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OGAWA O, 1993, NAT GENET, V5, P408, DOI 10.1038/ng1293-408; OHLSSON R, 1993, NAT GENET, V4, P94, DOI 10.1038/ng0593-94; Owerbach D, 1996, DIABETES, V45, P544, DOI 10.2337/diabetes.45.5.544; PEDONE PV, 1994, HUM MOL GENET, V3, P117; Phelan CM, 1996, NAT GENET, V12, P309, DOI 10.1038/ng0396-309; POLYCHRONAKOS C, 1995, DEV GENET, V17, P253, DOI 10.1002/dvg.1020170310; Pugliese A, 1997, NAT GENET, V15, P293, DOI 10.1038/ng0397-293; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; RAIZIS AM, 1993, BIOCHEM J, V289, P133, DOI 10.1042/bj2890133; RODENBURG RJT, 1995, MOL ENDOCRINOL, V9, P424, DOI 10.1210/me.9.4.424; RYBERG D, 1993, INT J CANCER, V53, P938; SIEBERT PD, 1992, NATURE, V359, P557, DOI 10.1038/359557a0; Sun FL, 1997, NATURE, V389, P809, DOI 10.1038/39797; SUSSENBACH JS, 1992, GROWTH REGULAT, V2, P1; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; TADOKORO K, 1991, NUCLEIC ACIDS RES, V19, P6967, DOI 10.1093/nar/19.24.6967; TODD JA, 1995, P NATL ACAD SCI USA, V92, P8560, DOI 10.1073/pnas.92.19.8560; TURNER PR, 1995, ATHEROSCLEROSIS, V116, P221, DOI 10.1016/0021-9150(94)05550-3; Uyeno S, 1996, CANCER RES, V56, P5356; Vafiadis P, 1997, NAT GENET, V15, P289, DOI 10.1038/ng0397-289; Vafiadis P, 1996, J AUTOIMMUN, V9, P397, DOI 10.1006/jaut.1996.0054; Vafiadis P, 1998, DIABETES, V47, P831, DOI 10.2337/diabetes.47.5.831; VETVICKA V, 1994, CELL IMMUNOL, V156, P332, DOI 10.1006/cimm.1994.1179; WARRAM JH, 1984, NEW ENGL J MED, V311, P149, DOI 10.1056/NEJM198407193110304; Wu JH, 1996, CLIN CHEM, V42, P927; YE P, 1995, ATHEROSCLEROSIS, V117, P43, DOI 10.1016/0021-9150(95)05556-C; YEZEL MW, 1997, J PEDIATR, V131, P671	57	126	127	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14158	14164		10.1074/jbc.273.23.14158	http://dx.doi.org/10.1074/jbc.273.23.14158			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603916	hybrid			2022-12-27	WOS:000074021500018
J	von der Kammer, H; Mayhaus, M; Albrecht, C; Enderich, J; Wegner, M; Nitsch, RM				von der Kammer, H; Mayhaus, M; Albrecht, C; Enderich, J; Wegner, M; Nitsch, RM			Muscarinic acetylcholine receptors activate expression of the Egr gene family of transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; RAT-BRAIN; CHOLINERGIC STIMULATION; DIFFERENTIAL DISPLAY; MEDIATED INDUCTION; NG108-15 CELLS; CULTURED-CELLS; GROWTH-FACTORS; BETA-PROTEIN; SUBTYPES	In order to search for genes that are activated by muscarinic acetylcholine receptors (mAChRs), we used an mRNA differential display approach in HEK293 cells expressing m1AChR. The zinc-finger transcription factor genes Egr-1, Egr-2, and Egr-3 were identified. Northern blot analyses confirmed that mRNA levels of Egr-1, Egr-2, and Egr-3 increased readily after m1AChR stimulation and that a maximum was attained within 50 min. At that time, Egr-4 mRNA was also detectable. Western blots and electromobility shift assays demonstrated synthesis of EGR-1 and EGR-3, as well as binding to DNA recognition sites in response to m1AChR activation. Activation of m1AChR increased transcription from EGR-dependent promoters, including the acetylcholinesterase gene promoter. Activity-dependent regulation of Egr-1 mRNA expression and EGR-1 protein synthesis was also observed in cells expressing m2, m3, or m4AChR subtypes, Increased EGR-1 synthesis was mimicked by phorbol myristate acetate, but not by forskolin, and receptor-stimulated EGR-1 synthesis was partially inhibited by phorbol myristate acetate down-regulation. Together, our results demonstrate that muscarinic receptor signaling activates the EGR transcription factor family and that PKC may be involved in intracellular signaling. The data suggest that transcription of EGR-dependent target genes, including the AChE gene, can be under the control of extracellular and intracellular signals coupled to muscarinic receptors.	Univ Hamburg, Ctr Mol Neurobiol, D-20246 Hamburg, Germany; Univ Hamburg, Alzheimers Dis Res Grp, D-20246 Hamburg, Germany	University of Hamburg; University of Hamburg	Nitsch, RM (corresponding author), Univ Hamburg, Ctr Mol Neurobiol, Martinistr 52, D-20246 Hamburg, Germany.	nitsch@plexus.uke.uni-hamburg.de		Wegner, Michael/0000-0002-4586-3294				ABUSHAKRA SR, 1994, MOL BRAIN RES, V26, P55, DOI 10.1016/0169-328X(94)90073-6; ALTIN JG, 1991, J BIOL CHEM, V266, P5401; BERNARD V, 1993, EUR J NEUROSCI, V5, P1218, DOI 10.1111/j.1460-9568.1993.tb00976.x; BONNER TI, 1989, TRENDS NEUROSCI, V12, P148, DOI 10.1016/0166-2236(89)90054-4; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; Coleman BA, 1996, J BIOL CHEM, V271, P4410; CONKLIN BR, 1988, P NATL ACAD SCI USA, V85, P8698, DOI 10.1073/pnas.85.22.8698; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CROSBY SD, 1991, MOL CELL BIOL, V11, P3835, DOI 10.1128/MCB.11.8.3835; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DICHIARA G, 1994, TRENDS NEUROSCI, V17, P228, DOI 10.1016/0166-2236(94)90005-1; Dragunow M, 1996, BEHAV GENET, V26, P293, DOI 10.1007/BF02359385; EBHIHARA T, 1997, J NEUROCHEM, V68, P1001; FARBER SA, 1995, J NEUROSCI, V15, P7442; FELDER CC, 1992, P NATL ACAD SCI USA, V89, P509, DOI 10.1073/pnas.89.2.509; FELDER CC, 1989, J BIOL CHEM, V264, P20356; FELDER CC, 1993, P NATL ACAD SCI USA, V90, P1706, DOI 10.1073/pnas.90.5.1706; FUKUDA K, 1988, NATURE, V335, P355, DOI 10.1038/335355a0; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GETMAN DK, 1995, J BIOL CHEM, V270, P23511, DOI 10.1074/jbc.270.40.23511; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; HUERTA PT, 1993, NATURE, V364, P723, DOI 10.1038/364723a0; HUGHES P, 1994, MOL BRAIN RES, V24, P166, DOI 10.1016/0169-328X(94)90129-5; HUGHES P, 1993, NEUROSCI LETT, V150, P122, DOI 10.1016/0304-3940(93)90122-2; HUNG AY, 1993, J BIOL CHEM, V268, P22959; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; KATAYAMA N, 1993, J NEUROCHEM, V60, P902, DOI 10.1111/j.1471-4159.1993.tb03235.x; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; LEE RKK, 1995, P NATL ACAD SCI USA, V92, P8083, DOI 10.1073/pnas.92.17.8083; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LIANG P, 1994, NUCLEIC ACIDS RES, V22, P5763, DOI 10.1093/nar/22.25.5763; LIM RW, 1987, ONCOGENE, V1, P263; LIN Y, 1991, BRAIN RES, V551, P342, DOI 10.1016/0006-8993(91)90955-U; Liu CT, 1996, P NATL ACAD SCI USA, V93, P11831, DOI 10.1073/pnas.93.21.11831; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; Morita K, 1996, J NEUROCHEM, V67, P1344; MULLER HJ, 1991, P NATL ACAD SCI USA, V88, P10079, DOI 10.1073/pnas.88.22.10079; MUTERO A, 1995, J BIOL CHEM, V270, P1866, DOI 10.1074/jbc.270.40.23511; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; NITSCH RM, 1993, P NATL ACAD SCI USA, V90, P5191, DOI 10.1073/pnas.90.11.5191; Nitsch RM, 1996, J BIOL CHEM, V271, P4188; Nitsch RM, 1997, J NEUROCHEM, V69, P704; PATWARDHAN S, 1991, ONCOGENE, V6, P917; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; POMBOVILLAR E, 1992, EUR J PHARM-MOLEC PH, V226, P317, DOI 10.1016/0922-4106(92)90049-2; SAFFEN DW, 1988, P NATL ACAD SCI USA, V85, P7795, DOI 10.1073/pnas.85.20.7795; Sambrook J., 2002, MOL CLONING LAB MANU; SANDMANN J, 1991, J BIOL CHEM, V266, P6031; SKERKA C, 1995, J BIOL CHEM, V270, P22500, DOI 10.1074/jbc.270.38.22500; SUGGS SV, 1990, NUCLEIC ACIDS RES, V18, P4283, DOI 10.1093/nar/18.14.4283; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; WESS J, 1993, TRENDS PHARMACOL SCI, V14, P308, DOI 10.1016/0165-6147(93)90049-P; ZHAO S, 1995, BIOTECHNIQUES, V18, P842	62	70	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14538	14544		10.1074/jbc.273.23.14538	http://dx.doi.org/10.1074/jbc.273.23.14538			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603968	hybrid			2022-12-27	WOS:000074021500070
J	Ward, DT; Brown, EM; Harris, HW				Ward, DT; Brown, EM; Harris, HW			Disulfide bonds in the extracellular calcium-polyvalent cation-sensing receptor correlate with dimer formation and its response to divalent cations in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; ELECTROPHORETIC TRANSFER; CA2+-SENSING RECEPTOR; MEMBRANE PROTEINS; XENOPUS-OOCYTES; SOLUBILIZATION; BINDING; KIDNEY	Extracellular calciun/polyvalent cation-sensing receptors (CaR) couple to G proteins and contain highly conserved extracellular cysteine residues. Immunoblotting of proteins from rat kidney inner medullary collecting duct endosomes with CaR-specific antibodies reveals alterations in the apparent molecular mass of CaR depending on protein denaturation conditions. When denatured by SDS under nonreducing conditions, CaR migrates as a putative dimer ic species of 240-310 kDa, This is twice the predicted molecular mass of the CaR monomer observed after SDS denaturation in the presence of sulfhydryl-reducing agents. In sucrose density gradients, Triton X-100-solubilized CaR sediments as a 220-kDa complex, not explainable by binding of G proteins to CaR monomers. Treatment of Triton-soluble CaR with divalent (Ca2+, Mg2+) and trivalent (Gd3+) metal ion CaR agonists, but not monovalent ions (Na+), partially shifts the electrophoretic mobility of CaR under reducing conditions from a predominantly monomeric to this putative dimeric species on immunoblots in a manner similar to their rank order of functional potency for CaR activation (Gd3+ much greater than Ca2+ > Mg2+). This Ca2+ effect is blocked by pretreatment with N-ethyl-maleimide. We conclude that disulfide bonds present in CaRs mediate formation of dimers that are preserved in Triton X-100 solution. In addition, CaR exposure to Ca2+ induces formation of additional disulfide bonds within the Triton-soluble CaR complex.	Harvard Univ, Childrens Hosp, Sch Med, Renal Res Lab,Div Nephrol, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Endocrine Hypertens, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Harris, HW (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, Renal Res Lab,Div Nephrol, Enders Bldg,Rm 1260,300 Longwood Ave, Boston, MA 02115 USA.	harris@hub.tch.harvard.edu	Centeno, Patricia Pacios/O-8368-2016	Ward, Donald/0000-0003-1342-9458	NHLBI NIH HHS [HL-15157] Funding Source: Medline; NIDDK NIH HHS [DK-38874, DK-43955] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL015157] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043955, R01DK038874] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABE T, 1992, J BIOL CHEM, V267, P13361; AIDA K, 1995, BIOCHEM BIOPH RES CO, V214, P524, DOI 10.1006/bbrc.1995.2318; Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; BARRETT P, 1994, J NEUROENDOCRINOL, V6, P509, DOI 10.1111/j.1365-2826.1994.tb00613.x; Bobovnikova Y, 1997, ENDOCRINOLOGY, V138, P588, DOI 10.1210/en.138.2.588; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN EM, 1995, NEW ENGL J MED, V333, P234, DOI 10.1056/NEJM199507273330407; BROWN EM, 1991, J BONE MINER RES, V6, P1217; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Chattopadhyay N, 1996, ENDOCR REV, V17, P289, DOI 10.1210/er.17.4.289; Chattopadhyay N, 1996, AM J PHYSIOL-RENAL, V271, pF736, DOI 10.1152/ajprenal.1996.271.3.F736; CHEN TH, 1994, J BONE MINER RES, V9, P293; CHEN YH, 1992, BIOCHEMISTRY-US, V31, P2415, DOI 10.1021/bi00123a029; CLARKE S, 1975, J BIOL CHEM, V250, P5459; Cook JVF, 1996, ENDOCRINOLOGY, V137, P2851, DOI 10.1210/en.137.7.2851; Cook JVF, 1997, ENDOCRINOLOGY, V138, P2800, DOI 10.1210/en.138.7.2800; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; FELDMAN RI, 1990, J BIOL CHEM, V265, P17364; FURTHMAYR H, 1976, BIOCHEMISTRY-US, V15, P1137, DOI 10.1021/bi00650a028; GARRETT JE, 1995, J BIOL CHEM, V270, P12919, DOI 10.1074/jbc.270.21.12919; HAMMERLAND LG, 1995, J BONE MINER RES, V10, P156; HARRIS HW, 1994, J BIOL CHEM, V269, P11993; Hebert SC, 1997, J EXP BIOL, V200, P295; HELENIUS A, 1975, BIOCHIM BIOPHYS ACTA, V415, P29, DOI 10.1016/0304-4157(75)90016-7; KERMODE JC, 1992, J BIOL CHEM, V267, P3382; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAKINO S, 1973, J BIOL CHEM, V248, P4926; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MAZELLA J, 1988, J BIOL CHEM, V263, P144; OFRI D, 1992, J NEUROCHEM, V58, P628, DOI 10.1111/j.1471-4159.1992.tb09764.x; Pearce SHS, 1996, J CLIN INVEST, V98, P1860, DOI 10.1172/JCI118987; Petralia RS, 1996, NEUROSCIENCE, V71, P949, DOI 10.1016/0306-4522(95)00533-1; RACKE FK, 1993, FEBS LETT, V333, P132, DOI 10.1016/0014-5793(93)80390-G; Ray K, 1997, J BIOL CHEM, V272, P31355, DOI 10.1074/jbc.272.50.31355; RICCARDI D, 1995, P NATL ACAD SCI USA, V92, P131, DOI 10.1073/pnas.92.1.131; ROGERS KV, 1995, ENDOCRINOLOGY, V136, P499, DOI 10.1210/en.136.2.499; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; RUAT M, 1995, P NATL ACAD SCI USA, V92, P3161, DOI 10.1073/pnas.92.8.3161; Ryba NJP, 1997, NEURON, V19, P371, DOI 10.1016/S0896-6273(00)80946-0; SanchezMargalet V, 1997, ENDOCRINOLOGY, V138, P1712, DOI 10.1210/en.138.4.1712; Sands JM, 1997, J CLIN INVEST, V99, P1399, DOI 10.1172/JCI119299; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; TANFORD C, 1976, BIOCHIM BIOPHYS ACTA, V457, P133, DOI 10.1016/0304-4157(76)90009-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAISH A, 1991, J RECEPTOR RES, V11, P965, DOI 10.3109/10799899109064691; WANG K, 1989, METHOD ENZYMOL, V172, P687, DOI 10.1016/S0076-6879(89)72038-3; YU J, 1975, J BIOL CHEM, V250, P9176; ZIEGRA CJ, 1992, P NATL ACAD SCI USA, V89, P4134, DOI 10.1073/pnas.89.9.4134	49	155	161	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14476	14483		10.1074/jbc.273.23.14476	http://dx.doi.org/10.1074/jbc.273.23.14476			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603961	hybrid			2022-12-27	WOS:000074021500063
J	Canosa, I; Lurz, R; Rojo, F; Alonso, JC				Canosa, I; Lurz, R; Rojo, F; Alonso, JC			beta recombinase catalyzes inversion and resolution between two inversely oriented six sites on a supercoiled DNA substrate and only inversion on relaxed or linear substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYOGENES PLASMID PSM19035; TN3 RESOLVASE; PROTEIN HBSU; HU; BINDING; MUTANTS; RES	The beta recombinase, in the presence of a chromatin-associated protein such as Hbsu, catalyzes DNA resolution or DNA inversion on supercoiled substrates containing two directly or inversely oriented six sites. Hbsu stabilizes the formation of the recombination complex (Alonso, J, C,, Weise, F,, and Rojo, F, (1995) J, Biol, Chem. 270, 2938-2945), In this study we show that resolution by beta recombinase strictly requires supercoiled DNA, but inversion does not, On a substrate with two inversely oriented six sites, beta recombinase catalyzed both resolution and inversion if the DNA was supercoiled but only inversion if the substrate was relaxed or linear. Hbsu was critical for the formation of synaptic complexes; its concentration relative to that of the supercoiled DNA substrate determined whether resolution or inversion products were preferentially formed. The results suggest that the beta recombinase forms unproductive short-lived synaptic complexes between two juxtaposed inversely oriented six sites; the presence of 3 to 13 Hbsu dimers per supercoiled DNA molecule would stabilize a synaptic complex with a relative geometry of the six sites allowing beta recombinase preferentially to achieve resolution. Supercoiling probably helps to overcome an energetic barrier, since resolution does not occur in relaxed DNA. The presence of >30 Hbsu dimers per DNA molecule probably favors the formation of a recombination complex with a different geometry since the reaction is directed preferentially toward DNA inversion.	CSIC, Dept Biotecnol Microbiana, Ctr Nacl Biotecnol, E-28049 Madrid, Spain; Max Planck Inst Mol Genet, D-14195 Berlin, Germany	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Max Planck Society	Alonso, JC (corresponding author), CSIC, Dept Biotecnol Microbiana, Ctr Nacl Biotecnol, Campus Univ Autonoma Madrid, E-28049 Madrid, Spain.	jcalonso@cnb.uam.es	Rojo, Fernando/A-7038-2008; Canosa, Ines/L-1186-2014; Alonso, Juan Carlos/D-2595-2009	Rojo, Fernando/0000-0003-1848-7745; Canosa, Ines/0000-0002-5883-9728; Alonso, Juan Carlos/0000-0002-5178-7179				ALONSO JC, 1995, MOL MICROBIOL, V18, P471, DOI 10.1111/j.1365-2958.1995.mmi_18030471.x; ALONSO JC, 1995, J BIOL CHEM, V270, P2938, DOI 10.1074/jbc.270.7.2938; Alonso JC, 1996, FEMS MICROBIOL LETT, V142, P1; BENJAMIN HW, 1986, P RA WELCH F C CHEM, V29, P107; Benjamin KR, 1996, J MOL BIOL, V256, P50, DOI 10.1006/jmbi.1996.0067; BIANCHI ME, 1994, MOL MICROBIOL, V14, P1, DOI 10.1111/j.1365-2958.1994.tb01261.x; BONNEFOY E, 1994, J MOL BIOL, V242, P116, DOI 10.1006/jmbi.1994.1563; BOOCOCK MR, 1986, BIOCHEM SOC T, V14, P214; Canosa I, 1997, MOL GEN GENET, V255, P467, DOI 10.1007/s004380050519; Canosa I, 1996, NUCLEIC ACIDS RES, V24, P2712, DOI 10.1093/nar/24.14.2712; CRAIGIE R, 1986, CELL, V45, P793, DOI 10.1016/0092-8674(86)90554-4; DRLICA K, 1992, MOL MICROBIOL, V6, P425, DOI 10.1111/j.1365-2958.1992.tb01486.x; DROGE P, 1989, P NATL ACAD SCI USA, V86, P6062, DOI 10.1073/pnas.86.16.6062; Grasser KD, 1997, EUR J BIOCHEM, V249, P70; GRINDLEY NDF, 1994, NUCLEIC ACIDS MOL BI, V8, P236; JOHNSON RC, 1987, NATURE, V329, P462, DOI 10.1038/329462a0; Johnson RC, 1991, CURR OPIN GENET DEV, V1, P404, DOI 10.1016/S0959-437X(05)80307-7; KANAAR R, 1989, CELL, V58, P147, DOI 10.1016/0092-8674(89)90411-X; KLIPPEL A, 1988, EMBO J, V7, P3983, DOI 10.1002/j.1460-2075.1988.tb03286.x; KLIPPEL A, 1993, EMBO J, V12, P1047, DOI 10.1002/j.1460-2075.1993.tb05746.x; MEIKLEJOHN AL, 1989, J MOL BIOL, V207, P661, DOI 10.1016/0022-2836(89)90236-2; PONTIGGIA A, 1993, MOL MICROBIOL, V7, P343, DOI 10.1111/j.1365-2958.1993.tb01126.x; ROJO F, 1995, NUCLEIC ACIDS RES, V23, P3181, DOI 10.1093/nar/23.16.3181; ROJO F, 1993, FEBS LETT, V328, P169, DOI 10.1016/0014-5793(93)80987-6; ROJO F, 1994, J MOL BIOL, V238, P159, DOI 10.1006/jmbi.1994.1278; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SOGO JM, 1987, ELECTRON MICROS, P61; STARK WM, 1989, CELL, V58, P779, DOI 10.1016/0092-8674(89)90111-6; STARK WM, 1995, MOBILE GENETIC ELEME, P101; VANPUTTE P, 1992, TRENDS GENET, V8, P457; WANG JC, 1982, COLD SPRING HARB SYM, V47, P85, DOI 10.1101/SQB.1983.047.01.011; Watson MA, 1996, J MOL BIOL, V257, P317, DOI 10.1006/jmbi.1996.0165	32	14	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13886	13891		10.1074/jbc.273.22.13886	http://dx.doi.org/10.1074/jbc.273.22.13886			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593735	hybrid			2022-12-27	WOS:000073919100074
J	Delagebeaudeuf, C; Gassama-Diagne, A; Nauze, M; Ragab, A; Li, RY; Capdevielle, J; Ferrara, P; Fauvel, J; Chap, H				Delagebeaudeuf, C; Gassama-Diagne, A; Nauze, M; Ragab, A; Li, RY; Capdevielle, J; Ferrara, P; Fauvel, J; Chap, H			Ectopic epididymal expression of guinea pig intestinal phospholipase B - Possible role in sperm maturation and activation by limited proteolytic digestion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; PANCREATIC-TYPE PHOSPHOLIPASE-A2; HUMAN SEMINAL PLASMA; MESSENGER-RNA LEVELS; SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; TORULASPORA-DELBRUECKII; CELL-DIFFERENTIATION; PENICILLIUM-NOTATUM; CDNA CLONING	Guinea pig intestinal phospholipase B is a calcium-independent phospholipase hydrolyzing sequentially the acyl ester bonds at sn-2 and sn-1 positions of glycerophospholipids, promoting the formation of sn-glycero-3-phosphocholine from phosphatidylcholine. This 140-kDa glycoprotein from the brush border membrane of differentiated enterocytes contributes to lipid digestion as an ectoenzyme, The cDNA coding for guinea pig phospholipase B was revealed to be the homologue of AdRab-B, an mRNA appearing in rabbit upon intestine development. The sequence predicts a polypeptide of 1463 amino acids displaying four homologous repeats, two of them containing the lipase consensus sequence GXSXG, A 5-kilobase transcript was particularly abundant in mature ileal and jejunal enterocytes but was also detected in epididymis, where phospholipase B displayed a higher molecular mass (170 kDa versus 140 kDa in intestine), with no obvious evidence for enzyme activity. Trypsin treatment of phospholipase B immunoprecipitated from epididymal membranes reduced its size to 140 kDa, coinciding with the appearance of a significant phospholipase A, activity. The same results were obtained in COS cells transfected with phospholipase B cDNA. Since sn-glycero-3-phosphocholine present at high concentrations in seminal plasma mainly stems from epididymis, this suggests a possible role of phospholipase B in male reproduction, This novel localization also unravels a mechanism of phospholipase B activation by limited proteolysis involving either trypsin in the intestinal lumen or a trypsin-like endopeptidase in the male reproductive tract.	Ctr Hosp Univ Toulouse, INSERM U326, Hop Purpan, Inst Federat Rech Immunol Cellulaire & Mol, F-31059 Toulouse, France; Sanofi Elf Biorech, Lab Biochim Prot, F-31676 Labege, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Sanofi-Aventis	Chap, H (corresponding author), Ctr Hosp Univ Toulouse, INSERM U326, Hop Purpan, Inst Federat Rech Immunol Cellulaire & Mol, F-31059 Toulouse, France.	chap@purpan.inserm.fr						ACKERMANN EJ, 1995, BBA-LIPID LIPID MET, V1259, P125, DOI 10.1016/0005-2760(95)00143-Z; ARCARI P, 1984, NUCLEIC ACIDS RES, V12, P9179, DOI 10.1093/nar/12.23.9179; BECK B, 1980, INT J ANDROL, V3, P349, DOI 10.1111/j.1365-2605.1980.tb00124.x; BJERVE KS, 1978, INT J ANDROL, P574, DOI 10.1111/j.1365-2605.1978.tb00510.x; BOLL W, 1993, J BIOL CHEM, V268, P12901; BRENNER S, 1988, NATURE, V334, P528, DOI 10.1038/334528a0; BROWNWOODMAN PDC, 1980, ARCH ANDROLOGY, V4, P149, DOI 10.3109/01485018008986482; CHAP HJ, 1988, CLIN CHEM, V34, P106; DARMOUL D, 1992, J BIOL CHEM, V267, P4824; DAWSON R. M. C, 1959, QUART JOUR EXPTL PHYSIOL, V44, P26; DAWSON RMC, 1957, BIOCHEM J, V65, P627, DOI 10.1042/bj0650627; Delagebeaudeuf C, 1996, BBA-LIPID LIPID MET, V1303, P119, DOI 10.1016/0005-2760(96)00090-2; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; DEREWENDA ZS, 1993, TRENDS BIOCHEM SCI, V18, P20, DOI 10.1016/0968-0004(93)90082-X; DIAGNE A, 1987, LIPIDS, V22, P33, DOI 10.1007/BF02534872; Eddy E. M., 1994, P29; FAUVEL J, 1981, BIOCHIM BIOPHYS ACTA, V663, P446, DOI 10.1016/0005-2760(81)90173-9; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; FRENKEL G, 1974, FERTIL STERIL, V25, P84; FUJII S, 1994, J BIOCHEM, V116, P204, DOI 10.1093/oxfordjournals.jbchem.a124494; GASSAMADIAGNE A, 1992, J BIOL CHEM, V267, P13418; GASSAMADIAGNE A, 1989, J BIOL CHEM, V264, P9470; GILLER T, 1992, J BIOL CHEM, V267, P16509; GRUSBY MJ, 1990, CELL, V60, P451, DOI 10.1016/0092-8674(90)90596-7; HAMMERSTEDT RH, 1982, BIOCHIM BIOPHYS ACTA, V710, P370, DOI 10.1016/0005-2760(82)90120-5; HARA S, 1995, BBA-LIPID LIPID MET, V1257, P11, DOI 10.1016/0005-2760(95)00011-Z; HJORTH A, 1993, BIOCHEMISTRY-US, V32, P4702, DOI 10.1021/bi00069a003; HUNZIKER W, 1986, CELL, V46, P227, DOI 10.1016/0092-8674(86)90739-7; ICHIMASA M, 1984, J BIOCHEM, V95, P137; KENNY AJ, 1982, PHYSIOL REV, V62, P91, DOI 10.1152/physrev.1982.62.1.91; Kerfelec B, 1986, Pancreas, V1, P430, DOI 10.1097/00006676-198609000-00007; KORTESUO PT, 1993, INT J PANCREATOL, V13, P111; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; KUWABARA Y, 1988, AGR BIOL CHEM TOKYO, V52, P2451, DOI 10.1080/00021369.1988.10869065; KUWABARA Y, 1988, J BIOCHEM, V104, P236, DOI 10.1093/oxfordjournals.jbchem.a122449; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBEAU G, 1994, J BIOL CHEM, V269, P1575; LEE KS, 1994, J BIOL CHEM, V269, P19725; LUNDQUIST F, 1953, NATURE, V172, P587, DOI 10.1038/172587a0; MARGUET D, 1992, J BIOL CHEM, V267, P2200; Marshall R D, 1974, Biochem Soc Symp, P17; MATSUDA H, 1979, BIOCHIM BIOPHYS ACTA, V573, P155, DOI 10.1016/0005-2760(79)90182-6; METZ S, 1991, FEBS LETT, V295, P110, DOI 10.1016/0014-5793(91)81397-Q; MIEUSSET R, 1988, INT J ANDROL, V11, P405, DOI 10.1111/j.1365-2605.1988.tb01013.x; Moore HDM, 1996, HUM REPROD, V11, P103; OHARA O, 1995, PROG LIPID RES, V34, P117, DOI 10.1016/0163-7827(94)00009-B; Pickard RT, 1996, J BIOL CHEM, V271, P19225, DOI 10.1074/jbc.271.32.19225; PIND S, 1991, BIOCHEM CELL BIOL, V69, P346, DOI 10.1139/o91-054; PIND S, 1988, BIOCHIM BIOPHYS ACTA, V938, P211, DOI 10.1016/0005-2736(88)90160-5; PIND S, 1989, LIPIDS, V24, P357, DOI 10.1007/BF02535141; PIND S, 1987, BIOCHIM BIOPHYS ACTA, V901, P78, DOI 10.1016/0005-2736(87)90258-6; POULOS A, 1973, BIOCHIM BIOPHYS ACTA, V306, P194, DOI 10.1016/0005-2760(73)90225-7; QUARONI A, 1975, FEBS LETT, V52, P481; QUINN PJ, 1967, AUST J BIOL SCI, V20, P1205, DOI 10.1071/BI9671205; RIGTRUP KM, 1992, BIOCHEMISTRY-US, V33, P2661; Robaire B., 1988, P999; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; RUF J, 1990, J BIOL CHEM, V265, P15034; SAITO K, 1991, METHOD ENZYMOL, V197, P446; SAKATA T, 1989, BIOCHIM BIOPHYS ACTA, V1007, P124, DOI 10.1016/0167-4781(89)90141-3; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHMITZ J, 1973, BIOCHIM BIOPHYS ACTA, V323, P98, DOI 10.1016/0005-2736(73)90434-3; SCOTT TW, 1963, BIOCHEM J, V87, P507, DOI 10.1042/bj0870507; SCOTT TW, 1963, J REPROD FERTIL, V6, P49, DOI 10.1530/jrf.0.0060049; SCOTT TW, 1967, BIOCHEM J, V102, P456, DOI 10.1042/bj1020456; SEILHAMER JJ, 1986, DNA-J MOLEC CELL BIO, V5, P519, DOI 10.1089/dna.1.1986.5.519; SEMENZA G, 1986, ANNU REV CELL BIOL, V2, P255, DOI 10.1146/annurev.cellbio.2.1.255; SHARP JD, 1994, J BIOL CHEM, V269, P23250; Slotboom A., 1982, PHOSPHOLIPIDS, P359; TATSUMI H, 1990, HISTOCHEMISTRY, V94, P135, DOI 10.1007/BF02440179; THIRSTRUP K, 1994, BIOCHEMISTRY-US, V33, P2748, DOI 10.1021/bi00176a002; TOJO H, 1988, J BIOL CHEM, V263, P5724; VANBEERS EH, 1995, BIOCHEM J, V308, P769, DOI 10.1042/bj3080769; VANBEERS EH, 1995, CRIT REV BIOCHEM MOL, V30, P197, DOI 10.3109/10409239509085143; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Wacker H, 1997, BIOCHEMISTRY-US, V36, P3336, DOI 10.1021/bi962398a; Waite M, 1987, HDB LIPID RES, V5, P155; WEISER MM, 1973, J BIOL CHEM, V248, P2536; WILLIAM F, 1988, J CELL PHYSIOL, V137, P402, DOI 10.1002/jcp.1041370303; WISHART MJ, 1993, J BIOL CHEM, V268, P10303; WithersMartinez C, 1996, STRUCTURE, V4, P1363, DOI 10.1016/S0969-2126(96)00143-8; WITT W, 1984, BIOCHIM BIOPHYS ACTA, V795, P117, DOI 10.1016/0005-2760(84)90111-5; WITT W, 1984, BIOCHIM BIOPHYS ACTA, V795, P108, DOI 10.1016/0005-2760(84)90110-3; Yanagimachi R., 1994, P189; Zvaritch E, 1996, J BIOL CHEM, V271, P250, DOI 10.1074/jbc.271.1.250; [No title captured]	89	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13407	13414		10.1074/jbc.273.22.13407	http://dx.doi.org/10.1074/jbc.273.22.13407			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593672	hybrid			2022-12-27	WOS:000073919100011
J	Koch, T; Schulz, S; Schroder, H; Wolf, R; Raulf, E; Hollt, V				Koch, T; Schulz, S; Schroder, H; Wolf, R; Raulf, E; Hollt, V			Carboxyl-terminal splicing of the rat mu opioid receptor modulates agonist-mediated internalization and receptor resensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; BETA-ADRENERGIC-RECEPTOR; DOWN-REGULATION; XENOPUS OOCYTES; DESENSITIZATION; CELLS; EXPRESSION; CLONING; SEQUESTRATION; ENDOCYTOSIS	The rat mu opioid receptor is alternatively spliced into two isoforms (MOR1 and MOR1B) which differ in length and amino acid composition at the carboxyl terminus. When stably expressed in HEK 293 cells, both splice variants bind the mu receptor agonist [D-Ala(2),N-Me-Phe(4), -Gly-ol(5)]enkephalin (DAMGO) with similar affinity and exhibit functional coupling to adenylyl cyclase with similar efficiency. However, the shorter isoform, MOR1B, desensitized at a slower rate during prolonged DAMGO exposure (4 h) but resensitized at a faster rate than MOR1 during agonist withdrawal (20 min). Immunocytochemical analysis revealed that DAMGO-induced internalization of MOR1B proceeded much faster than that of MOR1 followed by rapid recycling of the receptor to the cell surface. In addition, the greater resistance of MOR1B to homologous desensitization compared with MOR1 as well as MOR1B resensitization was abolished when receptor reactivation/recycling was blocked with monensin, an inhibitor of endosomal acidification. It is concluded that the sequence at the cytoplasmic tail of MOR1B facilitates clathrin-coated vesicle-mediated endocytosis which, in turn, promotes accelerated receptor reactivation, Taken together, our findings suggest that carboxyl-terminal splicing of the rat mu opioid receptor modulates agonist induced internalization and receptor resensitization.	Otto Von Guericke Univ, Dept Pharmacol & Toxicol, D-39120 Magdeburg, Germany	Otto von Guericke University	Hollt, V (corresponding author), Otto Von Guericke Univ, Dept Pharmacol & Toxicol, Leipziger Str 44, D-39120 Magdeburg, Germany.	Volker.Hoellt@Medizin.Uni-Magdeburg.de	Schulz, Stefan/A-6928-2017	Schulz, Stefan/0000-0002-5997-8885				ASHWORTH R, 1995, P NATL ACAD SCI USA, V92, P512, DOI 10.1073/pnas.92.2.512; BENYA RV, 1994, J BIOL CHEM, V269, P11721; CAMPBELL PT, 1991, MOL PHARMACOL, V39, P192; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHEN Y, 1994, J BIOL CHEM, V269, P7839; Cvejic S, 1996, J BIOL CHEM, V271, P4073; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; HERTEL C, 1985, J BIOL CHEM, V260, P2547; KASSIS S, 1986, J BIOL CHEM, V261, P2233; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; KIM JK, 1994, J RECEPTOR RES, V14, P139, DOI 10.3109/10799899409067001; Koch T, 1997, J NEUROCHEM, V69, P1767; KOCH T, 1997, N-S ARCH PHARMACOL, V355, pR37; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MESTEK A, 1995, J NEUROSCI, V15, P2396, DOI 10.1523/JNEUROSCI.15-03-02396.1995; Pak Y, 1997, J BIOL CHEM, V272, P24961, DOI 10.1074/jbc.272.40.24961; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Schulz S, 1998, NEUROSCIENCE, V82, P613; Segredo V, 1997, J NEUROCHEM, V68, P2395; UEDA H, 1994, NEUROREPORT, V5, P1985, DOI 10.1097/00001756-199410000-00037; UEDA H, 1995, J NEUROSCI, V15, P7485; WANG JM, 1993, CYTOKINE, V5, P264, DOI 10.1016/1043-4666(93)90014-V; ZIMPRICH A, 1995, FEBS LETT, V359, P142, DOI 10.1016/0014-5793(95)00028-8	26	172	178	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13652	13657		10.1074/jbc.273.22.13652	http://dx.doi.org/10.1074/jbc.273.22.13652			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593704	hybrid			2022-12-27	WOS:000073919100043
J	Le Gac, NT; Villani, G; Boehmer, PE				Le Gac, NT; Villani, G; Boehmer, PE			Herpes simplex virus type-1 single-strand DNA-binding protein (ICP8) enhances the ability of the viral DNA helicase-primase to unwind cisplatin-modified DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION; ADDUCT; POLYMERASE; COMPLEX	The herpes simplex virus type-1 UL5, UL8, and UL52 genes encode an essential heterotrimeric DNA helicase-primase that is responsible for concomitant DNA unwinding and primer synthesis at the viral DNA replication fork. The viral single-strand DNA-binding protein (ICP8) can stimulate DNA unwinding by the helicase-primase as a result of a physical interaction that is mediated by the UL8 subunit, In this study, we investigated the ability of the helicase-primase to unwind a fork-like substrate that contains an intrastrand d(GpG) DNA cross-link produced by the antitumor drug cisplatin. We also examined the ability of ICP8 to modulate the effect of the cisplatin lesion. The data show that the lesion inhibited the helicase-primase when located on the DNA strand along which it translocates, However, the lesion did not represent a permanent obstacle to its progression. In contrast, the adduct did not affect the helicase-primase when located on the opposite DNA strand. ICP8 specifically stimulated DNA unwinding by the helicase-primase, Coating concentrations of ICP8 were necessary for optimal unwinding of damaged DNA, Addition of competitor DNA to helicase reactions led to substantial reduction of DNA unwinding by the helicase-primase, suggesting that the enzyme is distributive. ICP8 did not abolish the competition, indicating that it did not stimulate the helicase by increasing its processivity, Rather, ICPS may stimulate DNA unwinding and enable bypass of cisplatin damaged DNA by recruiting the helicase-primase to the DNA.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Newark, NJ 07103 USA; CNRS, Inst Pharmacol & Biol Struct, F-31077 Toulouse, France	Rutgers State University New Brunswick; Rutgers State University Medical Center; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Boehmer, PE (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, 185 S Orange Ave, Newark, NJ 07103 USA.	boehmepe@njmsa.umdnj.edu		Boehmer, Paul/0000-0003-4479-0529	NIAID NIH HHS [AI 38335] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038335] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Boehmer PE, 1998, J BIOL CHEM, V273, P2676, DOI 10.1074/jbc.273.5.2676; BOEHMER PE, 1993, J VIROL, V67, P711, DOI 10.1128/JVI.67.2.711-715.1993; Boehmer PE, 1997, ANNU REV BIOCHEM, V66, P347, DOI 10.1146/annurev.biochem.66.1.347; BRUHN SL, 1990, PROG INORG CHEM, V38, P477; CHIOU HC, 1985, VIROLOGY, V145, P213, DOI 10.1016/0042-6822(85)90155-2; CRUTE JJ, 1989, P NATL ACAD SCI USA, V86, P2186, DOI 10.1073/pnas.86.7.2186; Falkenberg M, 1997, J BIOL CHEM, V272, P22766, DOI 10.1074/jbc.272.36.22766; GAC NTL, 1996, J BIOL CHEM, V271, P21645; Hamatake RK, 1997, J GEN VIROL, V78, P857, DOI 10.1099/0022-1317-78-4-857; HERNANDEZ TR, 1990, J BIOL CHEM, V265, P11227; Hoffmann JS, 1996, P NATL ACAD SCI USA, V93, P13766, DOI 10.1073/pnas.93.24.13766; HUANG L, 1993, J BIOL CHEM, V268, P26731; IWAMOTO M, 1994, J AM CHEM SOC, V116, P6238, DOI 10.1021/ja00093a025; Johnson N.P., 1989, PROG CLIN BIOCH MED, V10, P1, DOI [DOI 10.1007/978-3-642-74760-1, 10.1007/978-3-642-74760-1_1, DOI 10.1007/978-3-642-74760-1_1]; Lee SSK, 1997, P NATL ACAD SCI USA, V94, P2838, DOI 10.1073/pnas.94.7.2838; Liptak LM, 1996, J VIROL, V70, P1759, DOI 10.1128/JVI.70.3.1759-1767.1996; LITTLER E, 1983, J GEN VIROL, V64, P983, DOI 10.1099/0022-1317-64-5-983; Lukonis CJ, 1996, J VIROL, V70, P1751, DOI 10.1128/JVI.70.3.1751-1758.1996; MAINE IP, 1992, BIOCHEMISTRY-US, V31, P3968, DOI 10.1021/bi00131a012; Makhov AM, 1996, EMBO J, V15, P1742, DOI 10.1002/j.1460-2075.1996.tb00520.x; MARROT L, 1989, BIOCHEMISTRY-US, V28, P1454, DOI 10.1021/bi00430a005; Marsden HS, 1997, J VIROL, V71, P6390, DOI 10.1128/JVI.71.9.6390-6397.1997; NAEGELI H, 1993, BIOCHEMISTRY-US, V32, P613, DOI 10.1021/bi00053a029; ODONNELL ME, 1987, J BIOL CHEM, V262, P4260; SKALITER R, 1994, P NATL ACAD SCI USA, V91, P10665, DOI 10.1073/pnas.91.22.10665; TAKAHARA PM, 1995, NATURE, V377, P649, DOI 10.1038/377649a0; TILBY MJ, 1991, CANCER RES, V51, P123; VAUGHAN PJ, 1984, J GEN VIROL, V65, P2033, DOI 10.1099/0022-1317-65-11-2033; VILLANI G, 1994, J BIOL CHEM, V269, P21676; VILLANI G, 1993, FEBS LETT, V333, P89, DOI 10.1016/0014-5793(93)80380-D; ZAMBLE DB, 1995, TRENDS BIOCHEM SCI, V20, P435, DOI 10.1016/S0968-0004(00)89095-7	31	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13801	13807		10.1074/jbc.273.22.13801	http://dx.doi.org/10.1074/jbc.273.22.13801			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593724	hybrid			2022-12-27	WOS:000073919100063
J	Nakai, J; Sekiguchi, N; Rando, TA; Allen, PD; Beam, KG				Nakai, J; Sekiguchi, N; Rando, TA; Allen, PD; Beam, KG			Two regions of the ryanodine receptor involved in coupling with L-type Ca2+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; MUSCLE SARCOPLASMIC-RETICULUM; II-III-LOOP; SKELETAL-MUSCLE; DIHYDROPYRIDINE RECEPTOR; FUNCTIONAL EXPRESSION; COMPLEMENTARY-DNA; MOLECULAR-CLONING; MICE LACKING; RABBIT BRAIN	Ryanodine receptors (RyRs) are present in the endoplasmic reticulum of virtually every cell type and serve critical roles, including excitation-contraction (EC) coupling in muscle cells. In skeletal muscle the primary control of RyR-1 (the predominant skeletal RyR isoform) occurs via an interaction with plasmalemmal dihydropyridine receptors (DHPRs), which function as both voltage sensors for EC coupling and as L-type Ca2+ channels (Rios, E., and Brum, G. (1987) Nature 325, 717-720). In addition to "receiving" the EC coupling signal from the DHPR, RyR-1 also "transmits" a retrograde signal that enhances the Ca2+ channel activity of the DHPR (Nakai, J., Dirksen, R. T., Nguyen, H. T., Pessah, I. N., Beam, K. G., and Alien, P. D. (1996) Nature 380, 72-76). A similar kind of retrograde signaling (from RyRs to L-type Ca2+ channels) has also been reported in neurons (Chavis, P., Fagni, L., Lansman, J. B., and Bockaert, J. (1996) Nature 382, 719-722). To investigate the molecular mechanism of reciprocal signaling, we constructed cDNAs encoding chimeras of RyR-1 and RyR-2 (the predominant cardiac RyR isoform) and expressed them in dyspedic myotubes, which lack an endogenous RyR-1. We found that a chimera that contained residues 1,635-2,636 of RyR-1 both mediated skeletal-type EC coupling and enhanced Ca2+ channel function, whereas a chimera containing adjacent RyR-1 residues (2,659-3,720) was only able to enhance Ca2+ channel function. These results demonstrate that two distinct regions are involved in the reciprocal interactions of RyR-1 with the skeletal DHPR.	Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Neurobiol & Anat, Ft Collins, CO 80523 USA; Natl Inst Physiol Sci, Dept Informat Physiol, Okazaki, Aichi 444, Japan; Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Dept Vet Affairs, Stanford, CA 94305 USA; Brigham & Womens Hosp, Dept Anesthesiol, Boston, MA 02115 USA	Colorado State University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Harvard University; Brigham & Women's Hospital	Beam, KG (corresponding author), Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Neurobiol & Anat, Ft Collins, CO 80523 USA.		Tuluc, Petronel/C-2527-2011		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR044750] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024444] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR44750] Funding Source: Medline; NINDS NIH HHS [NS24444] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARMSTRONG CM, 1972, BIOCHIM BIOPHYS ACTA, V267, P605, DOI 10.1016/0005-2728(72)90194-6; BEAM KG, 1986, NATURE, V320, P168, DOI 10.1038/320168a0; Bhat MB, 1997, BIOPHYS J, V73, P1329, DOI 10.1016/S0006-3495(97)78166-9; ELHAYEK R, 1995, J BIOL CHEM, V270, P22116, DOI 10.1074/jbc.270.38.22116; Fleig A, 1996, J PHYSIOL-LONDON, V496, P339, DOI 10.1113/jphysiol.1996.sp021689; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; FURUICHI T, 1994, J NEUROSCI, V14, P4794; GARCIA J, 1994, J GEN PHYSIOL, V103, P107, DOI 10.1085/jgp.103.1.107; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; GLUECKSOHNWAELS.S, 1963, SCIENCE, V142, P1269, DOI 10.1126/science.142.3597.1269; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; HYMEL L, 1988, P NATL ACAD SCI USA, V85, P441, DOI 10.1073/pnas.85.2.441; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; INUI M, 1987, J BIOL CHEM, V262, P1740; JURMAN ME, 1994, BIOTECHNIQUES, V17, P876; KUWAJIMA G, 1992, NEURON, V9, P1133, DOI 10.1016/0896-6273(92)90071-K; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LU XY, 1995, J BIOL CHEM, V270, P18459, DOI 10.1074/jbc.270.31.18459; LU XY, 1994, J BIOL CHEM, V269, P6511; Nakai J, 1996, NATURE, V380, P72, DOI 10.1038/380072a0; Nakai J, 1997, P NATL ACAD SCI USA, V94, P1019, DOI 10.1073/pnas.94.3.1019; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; OTSU K, 1990, J BIOL CHEM, V265, P13472; RANDO TA, 1994, J CELL BIOL, V125, P1275, DOI 10.1083/jcb.125.6.1275; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; SCHNEIDER MF, 1973, NATURE, V242, P244, DOI 10.1038/242244a0; SORRENTINO V, 1993, TRENDS PHARMACOL SCI, V14, P98, DOI 10.1016/0165-6147(93)90072-R; TAKEKURA H, 1995, P NATL ACAD SCI USA, V92, P3381, DOI 10.1073/pnas.92.8.3381; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TAKESHIMA H, 1994, NATURE, V369, P556, DOI 10.1038/369556a0; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; Wu YL, 1997, J BIOL CHEM, V272, P25051, DOI 10.1074/jbc.272.40.25051; Yamazawa T, 1996, EMBO J, V15, P6172, DOI 10.1002/j.1460-2075.1996.tb01005.x; Yamazawa T, 1997, J BIOL CHEM, V272, P8161, DOI 10.1074/jbc.272.13.8161; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	36	156	158	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13403	13406		10.1074/jbc.273.22.13403	http://dx.doi.org/10.1074/jbc.273.22.13403			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593671	hybrid			2022-12-27	WOS:000073919100010
J	Kimball, SR; Fabian, JR; Pavitt, GD; Hinnebusch, AG; Jefferson, LS				Kimball, SR; Fabian, JR; Pavitt, GD; Hinnebusch, AG; Jefferson, LS			Regulation of guanine nucleotide exchange through phosphorylation of eukaryotic initiation factor eIF2 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE GCN2; FACTOR-II; TRANSLATIONAL CONTROL; SACCHAROMYCES-CEREVISIAE; CHAIN INITIATION; RAT-LIVER; YEAST; MECHANISM; FACTOR-2-ALPHA; INHIBITION	The guanine nucleotide exchange activity of eIF2B plays a key regulatory role in the translation initiation phase of protein synthesis. The activity is markedly inhibited when the substrate, i,e, eIF2, is phosphorylated on Ser(51) of its alpha-subunit. Genetic studies in yeast implicate the alpha-, beta-, and delta-subunits of eLF2B in mediating the inhibition by substrate phosphorylation. However, the mechanism involved in the inhibition has not been defined biochemically. In the present study, we have coexpressed the five subunits of rat eIF2B in Sf9 cells using the baculovirus system and have purified the recombinant holoprotein to >90% homogeneity, We have also expressed and purified a four-subunit eIF2B complex lacking the alpha-subunit, Both the five-and four-subunit forms of eIF2B exhibit similar rates of guanine nucleotide exchange activity using unphosphorylated eIF2 as substrate. The five-subunit form is inhibited by preincubation with phosphorylated eIF2 (eIFS(alpha P)) and exhibits little exchange activity when eIF2(alpha P) is used as substrate. In contrast, eIF2B lacking the cu-subunit is insensitive to inhibition by eIF2(alpha P) and is able to exchange guanine nucleotide using eIF2(alpha P) as substrate at a faster rate compared with five-subunit eIF2B, Finally, a double point mutation in the S-subunit of eIF2B has been identified that results in insensitivity to inhibition by eIF2(alpha P) and exhibits little exchange activity when eIFS(alpha P) is used as substrate. The results provide the first direct biochemical evidence that the alpha- and delta-subunits of eIF2B are involved in mediating the effect of substrate phosphorylation.	Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA; NICHD, Lab Eukaryot Gene Regulat, NIH, Bethesda, MD 20892 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Kimball, SR (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Cellular & Mol Physiol, POB 850, Hershey, PA 17033 USA.		Pavitt, Graham D/A-1363-2010	Pavitt, Graham D/0000-0002-8593-2418	NIDDK NIH HHS [DK15658, DK13499] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015658, R01DK013499, R37DK013499] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BUSHMAN JL, 1993, MOL CELL BIOL, V13, P1920, DOI 10.1128/MCB.13.3.1920; CIGAN AM, 1991, MOL CELL BIOL, V11, P3217, DOI 10.1128/MCB.11.6.3217; DEALDANA CRV, 1994, MOL CELL BIOL, V14, P3208, DOI 10.1128/MCB.14.5.3208; DeGracia DJ, 1997, J CEREBR BLOOD F MET, V17, P1291, DOI 10.1097/00004647-199712000-00004; DEVER TE, 1993, P NATL ACAD SCI USA, V90, P4616, DOI 10.1073/pnas.90.10.4616; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; Fabian JR, 1997, J BIOL CHEM, V272, P12359, DOI 10.1074/jbc.272.19.12359; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; HINNEBUSCH AG, 1993, MOL MICROBIOL, V10, P215, DOI 10.1111/j.1365-2958.1993.tb01947.x; HINNEBUSCH AG, 1994, TRENDS BIOCHEM SCI, V19, P409, DOI 10.1016/0968-0004(94)90089-2; HINNEBUSCH AG, 1991, TRANSLATION EUKARYOT, P243; KIMBALL SR, 1987, J BIOL CHEM, V262, P2220; KIMBALL SR, 1991, J BIOL CHEM, V266, P1969; KIMBALL SR, 1989, AM J PHYSIOL, V256, pC28, DOI 10.1152/ajpcell.1989.256.1.C28; MARTON MJ, 1993, MOL CELL BIOL, V13, P3541, DOI 10.1128/MCB.13.6.3541; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Pavitt GD, 1997, MOL CELL BIOL, V17, P1298, DOI 10.1128/MCB.17.3.1298; PRICE N, 1994, BIOCHIMIE, V76, P748, DOI 10.1016/0300-9084(94)90079-5; ROLFES RJ, 1993, MOL CELL BIOL, V13, P5099, DOI 10.1128/MCB.13.8.5099; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; SAFER B, 1982, INTERACTION TRANSLAT, P311; SCORSONE KA, 1987, J BIOL CHEM, V262, P14538; SIEKIERKA J, 1982, P NATL ACAD SCI-BIOL, V79, P2537, DOI 10.1073/pnas.79.8.2537; TRACHSEL H, 1978, P NATL ACAD SCI USA, V75, P204, DOI 10.1073/pnas.75.1.204; Yang WM, 1996, MOL CELL BIOL, V16, P6603	25	72	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					12841	12845		10.1074/jbc.273.21.12841	http://dx.doi.org/10.1074/jbc.273.21.12841			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582312	hybrid			2022-12-27	WOS:000073768500023
J	Montaner, S; Perona, R; Saniger, L; Lacal, JC				Montaner, S; Perona, R; Saniger, L; Lacal, JC			Multiple signalling pathways lead to the activation of the nuclear factor kB by the Rho family of GTPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; GUANINE-NUCLEOTIDE EXCHANGE; BINDING PROTEIN-RHO; JNK/SAPK SIGNALING PATHWAY; DBL ONCOGENE PRODUCT; ACTIN STRESS FIBERS; CELL-TRANSFORMATION; RAS TRANSFORMATION; NIH3T3 CELLS; T-CELLS	Members of the Rho family of small GTPases activate the nuclear factor kappa B (NF-kappa B) (Perona, R., Montaner, S., Saniger, L,, Sanchez-Perez, I., Bravo, R,, and Lacal, J. C, (1997), Genes & Dev. 11, 463-475), We have investigated whether different members of the family of exchange factors specific for Rho proteins (Dbl family) could activate the transcription factor NF-kappa B and have explored both their specificity under in vivo conditions and the mechanisms involved. Activated forms of Dbl, Ost, and Vav proteins induce NF-kappa B activation. While the activation induced by the Vav oncogen was efficiently inhibited by a dominant negative mutant of Rad, the corresponding mutant of Cdc42Hs was able to block selectively NF-KB activation mediated by Dbl, Finally, mutants of RhoA and Cdc42Hs, but not that of Rad, inhibited the activation of NF-kappa B by Ost. Thus, under in vivo conditions, different members of the Dbl family are related to specific Rho GTPases for the regulation of NF-kappa B, Activation of NF-KB by Rho or Ras proteins is mutually independent. However, there is a link between the NF-kappa B and the c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) cascades since a dominant negative mutant of MEKK1 is able to inhibit NF-kappa B activation induced by Rad and Cdc42Hs proteins, but not by RhoA These results indicate that, in mammalian cells, multiple pathways coexist for the activation of NF-kappa B, some of which are mediated by specific members of the Ras and Rho families of small GTPases.	CSIC, Inst Invest Biomed, E-28029 Madrid, Spain; Univ Autonoma Madrid, Sch Med, Dept Biochem, Madrid 28029, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid	Lacal, JC (corresponding author), CSIC, Inst Invest Biomed, Arturo Duperier 4, E-28029 Madrid, Spain.		Lacal, Juan Carlos/AAL-2235-2020; Lacal, Juan Carlos/N-9064-2015	Lacal, Juan Carlos/0000-0002-1908-2777				Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crespo P, 1996, ONCOGENE, V13, P455; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; Esteve P, 1995, ONCOGENE, V11, P2657; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; FINCO TS, 1993, J BIOL CHEM, V268, P17676; GENOT EM, 1995, J BIOL CHEM, V270, P9833, DOI 10.1074/jbc.270.17.9833; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; JIMENEZ B, 1995, ONCOGENE, V10, P811; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KOONG AC, 1994, CANCER RES, V54, P5273; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LACAL JC, 1993, RAS SUPERFAMILY GTPA, P259; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Meyer CF, 1996, J BIOL CHEM, V271, P8971, DOI 10.1074/jbc.271.15.8971; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; MONTANER S, 1995, ONCOGENE, V10, P2213; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PERONA R, 1993, ONCOGENE, V8, P1285; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0; Zheng Y, 1996, J BIOL CHEM, V271, P33169, DOI 10.1074/jbc.271.52.33169; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031	45	195	199	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					12779	12785		10.1074/jbc.273.21.12779	http://dx.doi.org/10.1074/jbc.273.21.12779			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582304	hybrid			2022-12-27	WOS:000073768500015
J	Satoh, H; Susaki, M; Shukunami, C; Iyama, K; Negoro, T; Hiraki, Y				Satoh, H; Susaki, M; Shukunami, C; Iyama, K; Negoro, T; Hiraki, Y			Functional analysis of diastrophic dysplasia sulfate transporter - Its involvement in growth regulation of chondrocytes mediated by sulfated proteoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT CHONDROCYTES; GENE ENCODES; MUTATIONS; EXPRESSION; HEPARIN; CELLS; ANGIOGENESIS; LOCALIZATION; DIARRHEA; CLONING	Mutations in the diastrophic dysplasia sulfate transporter (DTDST) gene constitute a family of recessively inherited osteochondrodysplasias including achondrogenesis type 1B, atelosteogenesis type II, and diastrophic dysplasia. However, the functional properties of the gene product have yet to be elucidated. We cloned rat DTDST cDNA from rat UMR-106 osteoblastic cells. Northern blot analysis suggested that cartilage and intestine were the major expression sites for DTDST mRNA. Analysis of the genomic sequence revealed that the rat DTDST gene was composed of at least five exons. Two distinct transcripts were expressed in chondrocytes due to alternative utilization of the third exon, corresponding to an internal portion of the 5'-untranslated region of the cDNA. Injection of rat and human DTDST cRNA into Xenopus laevis oocytes induced Na+-independent sulfate transport. Transport activity of the expressed DTDST was markedly inhibited by extracellular chloride and bicarbonate. In contrast, canalicular Na+-independent sulfate transporter Sat-1 required the presence of extracellular chloride in the cRNA-injected oocytes. The activity profile of sulfate transport in growth plate chondrocytes was studied in the extracellular presence of various anions and found substantially identical to DTDST expressed in oocytes. Thus, sulfate transport of chondrocytes is dominantly dependent on the DTDST system. Finally, we demonstrate that undersulfation of proteoglycans by the chlorate treatment of chondrocytes significantly impaired growth response of the cells to fibroblast growth factor, suggesting a role for DTDST in endochondral bone formation.	Osaka Univ, Fac Dent, Dept Biochem, Suita, Osaka 565, Japan; Sumitomo Pharmaceut Co Ltd, Res Ctr, Discovery Res Labs 1, Osaka 544, Japan; Kumamoto Univ Hosp, Sch Med, Dept Surg Pathol, Kumamoto 860, Japan; Osaka Univ, Fac Dent, Dept Biochem, Suita, Osaka 565, Japan	Osaka University; Kumamoto University; Osaka University	Hiraki, Y (corresponding author), Osaka Univ, Fac Dent, Dept Biochem, 1-8 Yamadaoka, Suita, Osaka 565, Japan.	hiraki@dent.osaka-u.ac.jp	Shukunami, Chisa/G-2887-2019	Shukunami, Chisa/0000-0001-5616-6761; Negoro, Takaharu/0000-0002-4159-6352				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; BIEBERDO.FA, 1972, J CLIN INVEST, V51, P1958, DOI 10.1172/JCI107002; BISSIG M, 1994, J BIOL CHEM, V269, P3017; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHN MJ, 1995, CELL, V80, P739, DOI 10.1016/0092-8674(95)90352-6; Comper W.D., 1991, CARTILAGE MOL ASPECT, P59; ELGAVISH A, 1985, J CELL PHYSIOL, V125, P243, DOI 10.1002/jcp.1041250211; GONZALEZ AM, 1990, J CELL BIOL, V110, P753, DOI 10.1083/jcb.110.3.753; GUTIERREZ GE, 1984, ENDOCRINOLOGY, V115, P2342, DOI 10.1210/endo-115-6-2342; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; Hastbacka J, 1996, AM J HUM GENET, V58, P255; HIRAKI Y, 1991, J BONE MINER RES, V6, P1373; HIRAKI Y, 1987, MOL CELL BIOCHEM, V76, P185; Hoglund P, 1996, NAT GENET, V14, P316, DOI 10.1038/ng1196-316; HOLMBERG C, 1975, J CLIN INVEST, V56, P302, DOI 10.1172/JCI108094; Horton W. A., 1990, GROWTH GENET HORM, V6, P1; HUMPHRIES DE, 1989, METHOD ENZYMOL, V179, P428; ISHIHARA M, 1994, GLYCOBIOLOGY, V4, P451, DOI 10.1093/glycob/4.4.451; ISHIHARA M, 1993, J BIOL CHEM, V268, P4675; MARKOVICH D, 1994, J BIOL CHEM, V269, P3022; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MATSUZAKI K, 1989, P NATL ACAD SCI USA, V86, P9911, DOI 10.1073/pnas.86.24.9911; MEIER PJ, 1987, AM J PHYSIOL, V253, pG461, DOI 10.1152/ajpgi.1987.253.4.G461; Mulder GJ, 1981, SULFATION DRUGS RELA, P31; Poole CA, 1997, J ANAT, V191, P1, DOI 10.1046/j.1469-7580.1997.19110001.x; Poole CA, 1990, METHODS CARTILAGE RE, P78; Rossi A, 1996, J BIOL CHEM, V271, P18456, DOI 10.1074/jbc.271.31.18456; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SHIMOMURA Y, 1975, CALC TISS RES, V19, P179, DOI 10.1007/BF02564002; SILBERG DG, 1995, J BIOL CHEM, V270, P11897, DOI 10.1074/jbc.270.20.11897; SupertiFurga A, 1996, AM J MED GENET, V63, P144, DOI 10.1002/(SICI)1096-8628(19960503)63:1<144::AID-AJMG25>3.0.CO;2-N; SupertiFurga A, 1996, NAT GENET, V12, P100, DOI 10.1038/ng0196-100; TWAL WO, 1994, J BONE MINER RES, V9, P1737	36	117	122	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12307	12315		10.1074/jbc.273.20.12307	http://dx.doi.org/10.1074/jbc.273.20.12307			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575183	hybrid			2022-12-27	WOS:000073629800048
J	Zhang, JM; Kang, DE; Xia, WM; Okochi, M; Mori, H; Selkoe, DJ; Koo, EH				Zhang, JM; Kang, DE; Xia, WM; Okochi, M; Mori, H; Selkoe, DJ; Koo, EH			Subcellular distribution and turnover of presenilins in transfected cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; IN-VIVO; MISSENSE MUTATIONS; GENE	The mechanisms by which mutations in presenilin-1 (PS1) and presenilin-2 (PS2) result in the Alzheimer's disease phenotype are unclear. Full-length PS1 and PS2 are each processed into stable proteolytic fragments after their biosynthesis in transfected cells. PS1 and PS2 have been localized by immunocytochemistry to the endoplasmic reticulum (ER) and Golgi compartments, but previous studies could not differentiate between the full-length presenilin proteins and their fragments. We carried out subcellular fractionation of cells stably transfected with PS1 or PS2 to determine the localization of full-length presenilins and their fragments. Full-length PS1 and PS2 were principally distributed in ER fractions, whereas the N- and C-terminal fragments were localized predominantly to the Golgi fractions. In cells expressing the PS1 mutant lacking exon 9 (Delta E9), we observed only full-length molecules that were present in the ER and Gels fractions. The turnover rate was considerably slower for the Delta E9 holoprotein, apparently due to decreased degradation within the ER. Our results suggest that that full-length presenilin proteins are primarily ER resident molecules and undergo endoproteolysis within the ER. The fragments are subsequently transported to the Golgi compartment, where their turnover rate is much slower than that of the full-length presenilin in the ER.	Univ Calif San Diego, Dept Neurosci 0691, La Jolla, CA 92093 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; Tokyo Inst Psychiat, Dept Biol Mol, Tokyo 156, Japan	University of California System; University of California San Diego; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Tokyo Institute of Psychiatry	Koo, EH (corresponding author), Univ Calif San Diego, Dept Neurosci 0691, La Jolla, CA 92093 USA.		xia, weiming/E-5465-2016; Kang, David E./E-5234-2012	xia, weiming/0000-0002-7463-3295; Okochi, Masayasu/0000-0002-2318-7651; Kang, David E./0000-0002-7132-821X	NIA NIH HHS [AG 12376, AG 05134] Funding Source: Medline; NINDS NIH HHS [NS 01812] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K04NS001812] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG005134, R01AG012376] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Baumeister R, 1997, Genes Funct, V1, P149; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; BRETZ R, 1977, EUR J BIOCHEM, V77, P181, DOI 10.1111/j.1432-1033.1977.tb11656.x; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Kim TW, 1997, J BIOL CHEM, V272, P11006; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; LE AQ, 1994, J BIOL CHEM, V269, P7514; Lehmann S, 1997, J BIOL CHEM, V272, P12047, DOI 10.1074/jbc.272.18.12047; Levitan D, 1996, P NATL ACAD SCI USA, V93, P14940, DOI 10.1073/pnas.93.25.14940; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li JH, 1997, CELL, V90, P917, DOI 10.1016/S0092-8674(00)80356-6; Okochi M, 1997, FEBS LETT, V418, P162, DOI 10.1016/S0014-5793(97)01378-1; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Ratovitski T, 1997, J BIOL CHEM, V272, P24536, DOI 10.1074/jbc.272.39.24536; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SISODIA SS, 1993, J NEUROSCI, V13, P3136; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Weidemann A, 1997, NAT MED, V3, P328, DOI 10.1038/nm0397-328; Xia W., 1997, Society for Neuroscience Abstracts, V23, P294; Xia WM, 1997, J BIOL CHEM, V272, P7977, DOI 10.1074/jbc.272.12.7977; Xia WM, 1997, P NATL ACAD SCI USA, V94, P8208, DOI 10.1073/pnas.94.15.8208	27	129	130	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12436	12442		10.1074/jbc.273.20.12436	http://dx.doi.org/10.1074/jbc.273.20.12436			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575200	hybrid			2022-12-27	WOS:000073629800065
J	Appleyard, MVCL; Sloan, J; Kana'n, GJM; Heck, IS; Kinghorn, JR; Unkles, SE				Appleyard, MVCL; Sloan, J; Kana'n, GJM; Heck, IS; Kinghorn, JR; Unkles, SE			The Aspergillus nidulans cnxF gene and its involvement in molybdopterin biosynthesis - Molecular characterization and analysis of in vivo generated mutans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; NITRATE REDUCTASE; NEUROSPORA MUTANT; CONVERTING FACTOR; CLONING; ENZYMES	The product of the Aspergillus nidulans cnxF gene was found by biochemical analysis of cnxF mutants to be involved in the conversion of precursor Z to molybdopterin, Mutants cnxF1242 and cnxF8 accumulate precursor Z, while the level of molybdopterin is undetectable. The DNA sequence of the cnxF gene was determined, and the inferred protein of 560 amino acids was found to contain a central region (residues around 157 to 396) similar in sequence to the prokaryotic proteins MoeB, which is thought to encode molybdopterin synthase sulfurylase, ThiF, required for thiamine biosynthesis, and HesA, involved in heterocyst formation, as well as eukaryotic ubiquitin-activating protein E1. Based on these similarities, a possible mechanism of action is discussed. Sequence comparisons indicate the presence of one and possibly two nucleotide binding motifs, Gly-X-Gly-X-X-Gly, as well as two metal binding Cys-X-X-Cys motifs in this central region of the CnxF protein, Seven in vivo generated A. nidulans cnxF mutants were found to have amino acid substitutions of conserved residues within this central region of similarity to molybdopterin synthase sulfurylase, indicating that these seven amino acids are essential and that this domain is crucial for function. Of these seven, the cnxF1285 mutation results in the replacement of Gly-178, the last glycine residue of the N-proximal Gly-X-Gly-X-X-Gly motif, indicating that this motif is essential. Mutation of the conserved Arg-208, also probably involved in nucleotide binding, leads to a loss-of-function phenotype in cnxF200, Alteration of Cys-263, the only conserved Cys residue (apart from the metal binding motifs), in cnxF472 suggests this residue as a candidate for thioester formation between molybdopterin synthase and the sulfurylase, Substitution of Gly-160 in two independently isolated mutants, cnxF21 and cnxF24, results in temperature-sensitive phenotypes and indicates that this residue is important in protein conformation. The C-terminal CnxF stretch (residues 397-560) shows substantial sequence conservation to a yeast hypothetical protein, Yhr1, such conservation between species suggesting that this region has function. Not inconsistent with this proposition is the observation that mutant cnxF8 results from loss of the 34 C-terminal residues of CnxF, There is no obvious similarity of the CnxF C-terminal region with other proteins of known function. Two cnxF transcripts are found in low abundance and similar levels were observed in nitrate- or ammonium-grown cells.	Univ St Andrews, Sch Environm & Evolutionary Biol, St Andrews KY16 9TH, Fife, Scotland; Monash Univ, Dept Microbiol, Clayton, Vic 3168, Australia	University of St Andrews; Monash University	Unkles, SE (corresponding author), Univ St Andrews, Sch Environm & Evolutionary Biol, St Andrews KY16 9TH, Fife, Scotland.	shiela.unkles@med.monash.edu.au						ABERG B, 1947, KUNGL LANTBRUKSHOGSK, V15, P37; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARST HN, 1997, MICROBIOLOGY, V143, P1437; Bellamacina CR, 1996, FASEB J, V10, P1257, DOI 10.1096/fasebj.10.11.8836039; BORTHAKUR D, 1990, MOL GEN GENET, V221, P227, DOI 10.1007/BF00261725; Bragg PD, 1997, ARCH BIOCHEM BIOPHYS, V338, P57, DOI 10.1006/abbi.1996.9797; BRODY H, 1991, NUCLEIC ACIDS RES, V19, P3105, DOI 10.1093/nar/19.11.3105; Clutterbuck A.J, 1974, HDB GENETICS, V1, P447; COVE DJ, 1963, NATURE, V198, P262, DOI 10.1038/198262a0; COVE DJ, 1966, BIOCHIM BIOPHYS ACTA, V113, P51, DOI 10.1016/S0926-6593(66)80120-0; FIDEL S, 1988, GENE, V70, P283, DOI 10.1016/0378-1119(88)90200-4; GARRETT RG, 1976, MOL GEN GENET, V147, P179; GEMS DH, 1993, CURR GENET, V24, P520, DOI 10.1007/BF00351716; Gurr SJ, 1987, GENE STRUCTURE EUKAR, P93; HINTON SM, 1990, CRIT REV MICROBIOL, V17, P169, DOI 10.3109/10408419009105724; JOHNSON ME, 1987, J BACTERIOL, V169, P117, DOI 10.1128/jb.169.1.117-125.1987; JOHNSON ME, 1987, J BACTERIOL, V169, P110, DOI 10.1128/jb.169.1.110-116.1987; KETCHUM PA, 1970, P NATL ACAD SCI USA, V66, P1016, DOI 10.1073/pnas.66.3.1016; KETCHUM PA, 1973, BIOCHEM BIOPH RES CO, V552, P1450; MACCABE AP, 1990, EMBO J, V9, P279, DOI 10.1002/j.1460-2075.1990.tb08106.x; MACDONALD DW, 1974, EUR J BIOCHEM, V47, P107, DOI 10.1111/j.1432-1033.1974.tb03673.x; MCGRATH JP, 1991, EMBO J, V10, P227, DOI 10.1002/j.1460-2075.1991.tb07940.x; NASON A, 1971, P NATL ACAD SCI USA, V68, P3242, DOI 10.1073/pnas.68.12.3242; NOHNO T, 1988, J BACTERIOL, V170, P4097, DOI 10.1128/jb.170.9.4097-4102.1988; PATEMAN JA, 1964, NATURE, V201, P58, DOI 10.1038/201058a0; PITTERLE DM, 1993, J BIOL CHEM, V268, P13499; PITTERLE DM, 1993, J BIOL CHEM, V268, P13506; RAJAGOPALAN KV, 1991, ADV ENZYMOL RAMB, V64, P215; RAJAGOPALAN KV, 1996, ESCHERICHIA COLI SAL, P674; Unkles SE, 1997, J BIOL CHEM, V272, P28381, DOI 10.1074/jbc.272.45.28381; VANDERHORN PB, 1993, J BACTERIOL, V175, P982, DOI 10.1128/JB.175.4.982-992.1993; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; WEILAND KL, 1991, BIOCHEM J, V275, P227, DOI 10.1042/bj2750227	33	31	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14869	14876		10.1074/jbc.273.24.14869	http://dx.doi.org/10.1074/jbc.273.24.14869			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614089	hybrid			2022-12-27	WOS:000074160400031
J	Mitrovic, AD; Amara, SG; Johnston, GAR; Vandenberg, RJ				Mitrovic, AD; Amara, SG; Johnston, GAR; Vandenberg, RJ			Identification of functional domains of the human glutamate transporters EAAT1 and EAAT2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; HIGH-AFFINITY; ION FLUXES; EXPRESSION; CLONING	Glutamate transporters serve the important function of mediating removal of glutamate released at excitatory synapses and maintaining extracellular concentrations below excitotoxic levels. Excitatory amino acid transporter subtypes EAAT1 and EAAT2 have a high degree of sequence homology and similar predicted topology and yet display a number of functional differences. Several recombinant chimeric transporters were generated to identify domains that contribute to functional differences between EAAT1 and EAAT2. Wild-type transporters and chimeric transporters were expressed in Xenopus laevis oocytes, and electrogenic transport was studied under voltage clamp conditions. The differential sensitivity of EAAT1 and EAAT2 to transport blockers, kainate, threo-3-methylglutamate, and (2S,4R)-4-methylglutamate as well as L-serine-O-sulfate transport and chloride permeability were employed to characterize chimeric transporters. One particular region, transmembrane domains 9 and 10, plays an important role in defining these functional differences. The intracellular carboxyl-terminal region may also play a minor role in conferring an effect on chloride permeability. This study provides important insight into the identification of functional domains that determine differences among glutamate transporter subtypes.	Univ Sydney, Dept Pharmacol, Sydney, NSW 2006, Australia; Oregon Hlth & Sci Univ, Vollum Inst Adv Biomed Res, Howard Hughes Med Inst, Portland, OR 97201 USA	University of Sydney; Howard Hughes Medical Institute; Oregon Health & Science University	Vandenberg, RJ (corresponding author), Univ Sydney, Dept Pharmacol, Sydney, NSW 2006, Australia.	robv@pharmacol.usyd.edu.au	Vandenberg, Robert John/E-6018-2016; Johnston, Graham/AAJ-9569-2021; Johnston, Graham AR/B-9827-2009	Vandenberg, Robert John/0000-0003-1523-4814; Johnston, Graham/0000-0001-8872-4078; Amara, Susan/0000-0001-8914-1106				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARRIZA JL, 1994, J NEUROSCI, V14, P5559; Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; BUCK KJ, 1994, P NATL ACAD SCI USA, V91, P12584, DOI 10.1073/pnas.91.26.12584; CONRADT M, 1995, J BIOL CHEM, V270, P25207, DOI 10.1074/jbc.270.42.25207; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; Kanai Y., 1997, Society for Neuroscience Abstracts, V23, P1485; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; Kavanaugh MP, 1997, J BIOL CHEM, V272, P1703, DOI 10.1074/jbc.272.3.1703; Lebrun B, 1997, J BIOL CHEM, V272, P20336, DOI 10.1074/jbc.272.33.20336; Otis TS, 1997, SCIENCE, V277, P1515, DOI 10.1126/science.277.5331.1515; PINES G, 1995, J BIOL CHEM, V270, P17093, DOI 10.1074/jbc.270.29.17093; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; SEAL B, 1995, SOC NEUR ABSTR, V21, P1861; Slotboom DJ, 1996, J BIOL CHEM, V271, P31317, DOI 10.1074/jbc.271.49.31317; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; TONG G, 1994, NEURON, V13, P1195, DOI 10.1016/0896-6273(94)90057-4; VANDENBERG RJ, 1995, J BIOL CHEM, V270, P17668, DOI 10.1074/jbc.270.30.17668; Vandenberg RJ, 1997, MOL PHARMACOL, V51, P809, DOI 10.1124/mol.51.5.809; Vandenberg RJ, 1998, BRIT J PHARMACOL, V123, P1593, DOI 10.1038/sj.bjp.0701776; WADICHE JI, 1995, NEURON, V14, P1019, DOI 10.1016/0896-6273(95)90340-2; WADICHE JI, 1995, NEURON, V15, P721, DOI 10.1016/0896-6273(95)90159-0; Wahle S, 1996, J CELL BIOL, V135, P1867, DOI 10.1083/jcb.135.6.1867	23	42	43	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14698	14706		10.1074/jbc.273.24.14698	http://dx.doi.org/10.1074/jbc.273.24.14698			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614067	hybrid			2022-12-27	WOS:000074160400009
J	Ushio-Fukai, M; Alexander, RW; Akers, M; Griendling, KK				Ushio-Fukai, M; Alexander, RW; Akers, M; Griendling, KK			p38 mitogen-activated protein kinase is a critical component of the redox-sensitive signaling pathways activated by angiotensin II - Role in vascular smooth muscle cell hypertrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; HYDROGEN-PEROXIDE; PHOSPHORYLATION; STRESS; GROWTH; INHIBITION; S6; INDUCTION; PLATELETS; CASCADE	Angiotensin II induces an oxidant stress-dependent hypertrophy in cultured vascular smooth muscle cells. To investigate the growth-related molecular targets of H2O2, we examined the redox sensitivity of agonist-stimulated activation of the mitogen-activated protein kinase (MAPK) family. We show here that angiotensin II elicits a rapid increase in intracellular H2O2 and a rapid and robust phosphorylation of both p42/44MAPK (16-fold) and p38MAPK (15-fold). However, exogenous H2O2 activates only p38MAPK (14-fold), and diphenylene iodonium, an NADH/NADPH oxidase inhibitor, attenuates angiotensin II-stimulated phosphorylation of p38MAPK, but not p42/44MAPK. Furthermore, in cells stably transfected with human catalase, angiotensin II-induced intracellular H2O2 generation is almost completely blocked, resulting in inhibition of phosphorylation of p38MAPK,, but not p42/44MAPK, and a subsequent partial decrease in angiotensin II-induced hypertrophy. Specific inhibition of either the p38MAPK pathway with SB203580 (4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole) or the p42/44MAPK pathway with PD98059 (2-(2'-amino-3'-methoxyphenyl)oxanaphthalen-4-one) also partially, but significantly, attenuates angiotensin II-induced hypertrophy; however, simultaneous blockade of both pathways has an additive inhibitory effect, indicating that the hypertrophic response to angiotensin II requires parallel, independent activation of both MAPK pathways. These results provide the first evidence that p38MAPK is a critical component of the oxidant stress (H2O2)-sensitive signaling pathways activated by angiotensin II in vascular smooth muscle cells and indicate that it plays a crucial role in vascular hypertrophy.	Emory Univ, Sch Med, Dept Med, Div Cardiol, Atlanta, GA 30322 USA	Emory University	Ushio-Fukai, M (corresponding author), Emory Univ, Sch Med, Dept Med, Div Cardiol, 1639 Pierce Dr,Rm 319, Atlanta, GA 30322 USA.			Griendling, Kathy/0000-0002-9456-8582	NHLBI NIH HHS [HL38206] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038206, R37HL038206, R29HL038206] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; BAAS AS, 1995, CIRC RES, V77, P29, DOI 10.1161/01.RES.77.1.29; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BOSCOBOINIK D, 1991, J BIOL CHEM, V266, P6188; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Crawley JB, 1997, J BIOL CHEM, V272, P15023, DOI 10.1074/jbc.272.23.15023; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DUFF JL, 1995, J BIOL CHEM, V270, P7161, DOI 10.1074/jbc.270.13.7161; FIORANI M, 1995, BBA-MOL CELL RES, V1269, P98, DOI 10.1016/0167-4889(95)00109-6; Foltz IN, 1997, J BIOL CHEM, V272, P3296, DOI 10.1074/jbc.272.6.3296; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; GRIENDLING KK, 1991, J BIOL CHEM, V266, P15498; Guan ZH, 1997, J BIOL CHEM, V272, P8083, DOI 10.1074/jbc.272.12.8083; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Huot J, 1997, CIRC RES, V80, P383, DOI 10.1161/01.RES.80.3.383; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; Krump E, 1997, J BIOL CHEM, V272, P937, DOI 10.1074/jbc.272.2.937; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LASSEGUE B, 1995, MOL PHARMACOL, V48, P601; Li PF, 1997, FEBS LETT, V404, P249, DOI 10.1016/S0014-5793(97)00093-8; Liao DF, 1997, J BIOL CHEM, V272, P6146, DOI 10.1074/jbc.272.10.6146; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; NIELSEN PJ, 1982, P NATL ACAD SCI-BIOL, V79, P2937, DOI 10.1073/pnas.79.9.2937; NOVAKHOFER I, 1985, J BIOL CHEM, V260, P314; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; Paul A, 1997, CELL SIGNAL, V9, P403, DOI 10.1016/S0898-6568(97)00042-9; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; PURI PL, 1995, J BIOL CHEM, V270, P22129, DOI 10.1074/jbc.270.38.22129; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Servant MJ, 1996, J BIOL CHEM, V271, P16047, DOI 10.1074/jbc.271.27.16047; SOCORRO L, 1990, BIOCHEM J, V265, P799, DOI 10.1042/bj2650799; Tsai JC, 1996, J BIOL CHEM, V271, P3667; UshioFukai M, 1996, J BIOL CHEM, V271, P23317, DOI 10.1074/jbc.271.38.23317; Wang XM, 1997, BIOCHEM BIOPH RES CO, V238, P207, DOI 10.1006/bbrc.1997.7273; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Yamauchi JJ, 1997, J BIOL CHEM, V272, P27771, DOI 10.1074/jbc.272.44.27771; Zechner D, 1997, J CELL BIOL, V139, P115, DOI 10.1083/jcb.139.1.115; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	54	553	575	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15022	15029		10.1074/jbc.273.24.15022	http://dx.doi.org/10.1074/jbc.273.24.15022			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614110	hybrid			2022-12-27	WOS:000074160400052
J	Wang, ZX; Berson, JF; Zhang, TY; Cen, YH; Sun, Y; Sharron, M; Lu, ZH; Peiper, SC				Wang, ZX; Berson, JF; Zhang, TY; Cen, YH; Sun, Y; Sharron, M; Lu, ZH; Peiper, SC			CXCR4 sequences involved in coreceptor determination of human immunodeficiency virus type-1 tropism - Unmasking of activity with M-tropic Env glycoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 ENTRY; ENVELOPE GLYCOPROTEIN; MONONUCLEAR PHAGOCYTES; CD4-MEDIATED FUSION; MACROPHAGE TROPISM; CELL-LINES; T-CELLS; RECEPTOR; INFECTION; DOMAIN	The interaction of human immunodeficiency virus type 1 (HIV-1) with CD4 and one of a cadre of chemokine receptors triggers conformational changes in the HIV-1 envelope (Env) glycoprotein that lead to membrane fusion. The coreceptor activity of the second extracellular loop of CXCR4, which is restricted to dual tropic and T-tropic strains, was insensitive to the removal of charged residues either singly or in combinations by alanine scanning mutagenesis or to the conversion of acidic residues to lysine. Conversion of Asp-187 to a neutral residue exclusively unmasked activity with M-tropic Env in fusion and infection experiments. Insertion of the D187V mutation into chimeras containing extracellular loop 2 of CXCR4 in a CXCR2 framework also resulted in the acquisition of M-tropic coreceptor activity. The independence of CXCR4 coreceptor activity from charged residues and the extension of its repertoire by removing Asp-187 suggest that this interaction is not electrostatic and that coreceptors have the potential to be utilized by a spectrum of Env, which may be masked by charged amino acids in extracellular domains. These findings indicate that the primary structural determinants of coreceptors that program reactivity with M-, dual, and T-tropic Env are surprisingly subtle and that relatively insignificant changes in CXCR4 can dramatically alter utilization by Env of varying tropism.	Univ Louisville, James Graham Brown Canc Ctr, Henry Vogt Canc Res Inst, Louisville, KY 40202 USA; Univ Louisville, Dept Biochem & Mol Biol, Louisville, KY 40202 USA; Univ Louisville, Dept Pathol & Lab Med, Louisville, KY 40202 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Louisville; University of Louisville; University of Louisville; University of Pennsylvania	Peiper, SC (corresponding author), Univ Louisville, James Graham Brown Canc Ctr, Henry Vogt Canc Res Inst, 529 S Jackson St, Louisville, KY 40202 USA.	scp@bcc.louisville.edu			NIAID NIH HHS [AI 41346] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041346] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Alkhatib G, 1997, J BIOL CHEM, V272, P19771, DOI 10.1074/jbc.272.32.19771; ASHORN PA, 1990, J VIROL, V64, P2149, DOI 10.1128/JVI.64.5.2149-2156.1990; Atchison RE, 1996, SCIENCE, V274, P1924, DOI 10.1126/science.274.5294.1924; Bieniasz PD, 1997, EMBO J, V16, P2599, DOI 10.1093/emboj/16.10.2599; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Brelot A, 1997, J VIROL, V71, P4744, DOI 10.1128/JVI.71.6.4744-4751.1997; CHEN BK, 1994, J VIROL, V68, P654, DOI 10.1128/JVI.68.2.654-660.1994; CHENGMAYER C, 1990, J VIROL, V64, P4390, DOI 10.1128/JVI.64.9.4390-4398.1990; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Connor RI, 1997, J EXP MED, V185, P621, DOI 10.1084/jem.185.4.621; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DEJONG JJ, 1992, J VIROL, V66, P6777, DOI 10.1128/JVI.66.11.6777-6780.1992; Deng HK, 1997, NATURE, V388, P296, DOI 10.1038/40894; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doms RW, 1997, VIROLOGY, V235, P179, DOI 10.1006/viro.1997.8703; Doranz BJ, 1997, J EXP MED, V186, P1395, DOI 10.1084/jem.186.8.1395; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Doranz BJ, 1997, J VIROL, V71, P6305, DOI 10.1128/JVI.71.9.6305-6314.1997; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; DRAGIC T, 1992, J VIROL, V66, P4794, DOI 10.1128/JVI.66.8.4794-4802.1992; Endres MJ, 1997, SCIENCE, V278, P1462, DOI 10.1126/science.278.5342.1462; Farzan M, 1997, J EXP MED, V186, P405, DOI 10.1084/jem.186.3.405; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FOUCHIER RAM, 1992, J VIROL, V66, P3183, DOI 10.1128/JVI.66.5.3183-3187.1992; HWANG SS, 1991, SCIENCE, V253, P71, DOI 10.1126/science.1905842; Jansson M, 1996, P NATL ACAD SCI USA, V93, P15382, DOI 10.1073/pnas.93.26.15382; LANDAU NR, 1988, NATURE, V334, P159, DOI 10.1038/334159a0; Lapham CK, 1996, SCIENCE, V274, P602, DOI 10.1126/science.274.5287.602; Liao F, 1997, J EXP MED, V185, P2015, DOI 10.1084/jem.185.11.2015; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Lu ZH, 1997, P NATL ACAD SCI USA, V94, P6426, DOI 10.1073/pnas.94.12.6426; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934; Mebatsion T, 1997, CELL, V90, P841, DOI 10.1016/S0092-8674(00)80349-9; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; NUSSBAUM O, 1994, J VIROL, V68, P5411, DOI 10.1128/JVI.68.9.5411-5422.1994; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; OBRIEN WA, 1990, NATURE, V348, P69, DOI 10.1038/348069a0; Platt EJ, 1997, J VIROL, V71, P883, DOI 10.1128/JVI.71.2.883-890.1997; Pleskoff O, 1997, SCIENCE, V276, P1874, DOI 10.1126/science.276.5320.1874; Rana S, 1997, J VIROL, V71, P3219, DOI 10.1128/JVI.71.4.3219-3227.1997; Rucker J, 1997, J VIROL, V71, P8999, DOI 10.1128/JVI.71.12.8999-9007.1997; Rucker J, 1996, CELL, V87, P437, DOI 10.1016/S0092-8674(00)81364-1; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; SATTENTAU QJ, 1991, J EXP MED, V174, P407, DOI 10.1084/jem.174.2.407; SATTENTAU QJ, 1993, J VIROL, V67, P7383, DOI 10.1128/JVI.67.12.7383-7393.1993; Schnell MJ, 1997, CELL, V90, P849, DOI 10.1016/S0092-8674(00)80350-5; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; WESTERVELT P, 1992, J VIROL, V66, P2577, DOI 10.1128/JVI.66.4.2577-2582.1992; WHITE JM, 1990, ANNU REV PHYSIOL, V52, P675, DOI 10.1146/annurev.ph.52.030190.003331; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; WYATT LS, 1995, VIROLOGY, V210, P202, DOI 10.1006/viro.1995.1332	56	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15007	15015		10.1074/jbc.273.24.15007	http://dx.doi.org/10.1074/jbc.273.24.15007			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614108	hybrid			2022-12-27	WOS:000074160400050
J	Nagata, K; Yu, H; Nishikawa, M; Kashiba, M; Nakamura, A; Sato, EF; Tamura, T; Inoue, M				Nagata, K; Yu, H; Nishikawa, M; Kashiba, M; Nakamura, A; Sato, EF; Tamura, T; Inoue, M			Helicobacter pylori generates superoxide radicals and modulates nitric oxide metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ELECTRON-TRANSPORT; OXYGEN-DEPENDENT-REGULATION; PEROXYNITRITE; INHIBITION; CELLS; RESISTANCE; INFECTION; DNA	During studies of the bactericidal action of nitric oxide (NO), we found that it reversibly inhibited the respiration of Escherichia coli and irreversibly inhibited the respiration of Helicobacter pylori. Peroxynitrite, a reaction product of NO and superoxide, irreversibly inhibited the respiration of both H. pylori and E. coli. H. pylori, but not E. coli, generated substantial amounts of superoxide radicals. These results suggest that NO directly inhibits the respiration of E. coli whereas it rapidly reacts with endogenously generated superoxide radicals in H. pylori. The resulting peroxynitrite inactivates the respiration of H. pylori.	Osaka City Univ, Sch Med, Dept Biochem, Osaka 545, Japan; Hyogo Coll Med, Dept Bacteriol, Nishinomiya, Hyogo 663, Japan	Osaka Metropolitan University; Hyogo College of Medicine	Inoue, M (corresponding author), Osaka City Univ, Sch Med, Dept Biochem, 1-4-54 Asahimachi, Osaka 545, Japan.	masainoue@msic.med.osaka-cu.ac.jp	Sato, Eisuke/AAO-3468-2020					AKAIKE T, 1993, BIOCHEMISTRY-US, V32, P827, DOI 10.1021/bi00054a013; AKIBA Y, 1993, GASTROENTEROLOGY, V104, pA31; BASU AK, 1989, P NATL ACAD SCI USA, V86, P7677, DOI 10.1073/pnas.86.20.7677; BECKERMAN KP, 1993, J IMMUNOL, V150, P888; BLASER MJ, 1990, J INFECT DIS, V161, P626, DOI 10.1093/infdis/161.4.626; BLASER MJ, 1996, GENETIC BASIS HETERO, P33; BROWN JF, 1992, BIOCHEM BIOPH RES CO, V184, P680, DOI 10.1016/0006-291X(92)90643-Y; DOYLE MP, 1981, J INORG BIOCHEM, V14, P351, DOI 10.1016/S0162-0134(00)80291-3; DRAPIER JC, 1986, J CLIN INVEST, V78, P790, DOI 10.1172/JCI112642; GRANGER DL, 1982, J CELL BIOL, V95, P527, DOI 10.1083/jcb.95.2.527; Inai Y, 1996, CELL STRUCT FUNCT, V21, P151, DOI 10.1247/csf.21.151; Jorgensen M, 1996, J INFECT DIS, V174, P631, DOI 10.1093/infdis/174.3.631; LIE JL, 1987, CANCER RES, V47, P1867; LIN JY, 1992, J IMMUNOL, V148, P3999; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDBERG JON, 1994, GUT, V35, P1543, DOI 10.1136/gut.35.11.1543; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MEYER J, 1981, ARCH BIOCHEM BIOPHYS, V210, P246, DOI 10.1016/0003-9861(81)90186-7; NAGATA K, 1993, ANTIMICROB AGENTS CH, V37, P769, DOI 10.1128/AAC.37.4.769; NAKANO M, 1986, ANAL BIOCHEM, V159, P363, DOI 10.1016/0003-2697(86)90354-4; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NEBOT C, 1993, ANAL BIOCHEM, V214, P442, DOI 10.1006/abio.1993.1521; Nishikawa M, 1996, CANCER RES, V56, P4535; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; PERCHELLET JP, 1989, FREE RADICAL BIO MED, V7, P377, DOI 10.1016/0891-5849(89)90124-X; RABENECK L, 1991, AM J MED, V91, P566; RADI R, 1994, ARCH BIOCHEM BIOPHYS, V308, P89, DOI 10.1006/abbi.1994.1013; REDDY D, 1983, SCIENCE, V221, P769, DOI 10.1126/science.6308761; SALGO MG, 1995, BIOCHEM BIOPH RES CO, V210, P1025, DOI 10.1006/bbrc.1995.1759; TAKEHARA Y, 1995, ARCH BIOCHEM BIOPHYS, V323, P27, DOI 10.1006/abbi.1995.0005; YERMILOV V, 1995, FEBS LETT, V376, P207, DOI 10.1016/0014-5793(95)01281-6; Yu H, 1997, FEBS LETT, V409, P161, DOI 10.1016/S0014-5793(97)00494-8	33	94	95	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14071	14073		10.1074/jbc.273.23.14071	http://dx.doi.org/10.1074/jbc.273.23.14071			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603902	hybrid			2022-12-27	WOS:000074021500004
J	Ohtani, K; Tsujimoto, A; Tsukahara, T; Numata, N; Miura, S; Sugamura, K; Nakamura, M				Ohtani, K; Tsujimoto, A; Tsukahara, T; Numata, N; Miura, S; Sugamura, K; Nakamura, M			Molecular mechanisms of promoter regulation of the gp34 gene that is trans-activated by an oncoprotein tax of human T cell leukemia virus type I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; LONG TERMINAL REPEAT; ACTING TRANSCRIPTIONAL ACTIVATOR; HUMAN IMMUNODEFICIENCY VIRUS; TUMOR-NECROSIS-FACTOR; RECEPTOR-ALPHA-GENE; 2 DISTINCT ELEMENTS; HYPER-IGM SYNDROME; HTLV-I; CD40 LIGAND	We investigated the molecular mechanism of transcriptional activation of the gp34 gene by the Tax oncoprotein of human T cell leukemia virus type I (HTLV-I), gp34 is a type II transmembrane molecule belonging to the tumor necrosis factor family and is constitutively expressed on HTLV-I-producing cells but not normal resting T cells. The transcriptional regulatory region of the gp34 gene was activated by HTLV-I Tax in the human T cell line Jurkat, in which endogenous gp34 is induced by Tax. Sequence analysis demonstrated that two NF-kappa B-like elements (1 and 2) were present in the regulatory region, Both NF-kappa B-like elements were able to bind to NF-kappa B or its related factor(s) in a Tax-dependent manner. Chloramphenicol acetyltransferase assays indicated that NF-kappa B-like element 1 was Tax-responsive, although the activity was lower than that the native promoter. NF-kappa B-like element 2 elevated promoter activity when combined with NF-kappa B-like element 1, indicating cooperative function of the elements for maximum promoter function. Unlike typical NF-kappa B elements, the NF-kappa B-like elements in gp34 were not activated by treatment of Jurkat cells with phorbol ester despite induction of the NF-kappa B-like binding activity. Chloramphenicol acetyltransferase reporter assays using the region upstream of the NF-kappa B-like elements identified an upstream region that reduced transcription from cognate and noncognate core promoters in a Tax-independent manner. Our results imply complex regulation of expression of the gp34 gene and suggest implication of gp34 in proliferation of HTLV-I infected T cells.	Tokyo Med & Dent Univ, Human Gene Sci Ctr, Bunkyo Ku, Tokyo 1138510, Japan; Tokyo Med & Dent Univ, Dept Immunotherapeut, Div Med Res, Bunkyo Ku, Tokyo 1138510, Japan; Sendai Municipal Inst Publ Hlth, Dept Microbiol, Wakabayashi Ku, Sendai, Miyagi 9830002, Japan; Tohoku Univ, Sch Med, Dept Microbiol & Immunol, Aoba Ku, Sendai, Miyagi 9808575, Japan; Japan Sci & Technol Corp, Kawaguchi 3320012, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tohoku University; Japan Science & Technology Agency (JST)	Nakamura, M (corresponding author), Tokyo Med & Dent Univ, Human Gene Sci Ctr, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.							AKAGI Y, 1997, ONCOGENE, V14, P2071; ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BAUM PR, 1994, EMBO J, V13, P3992, DOI 10.1002/j.1460-2075.1994.tb06715.x; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P1023; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; GESSAIN A, 1985, LANCET, V2, P407; GODFREY WR, 1994, J EXP MED, V180, P757, DOI 10.1084/jem.180.2.757; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRUSS HJ, 1995, BLOOD, V85, P3378, DOI 10.1182/blood.V85.12.3378.bloodjournal85123378; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; Higashimura N, 1996, JPN J CANCER RES, V87, P227, DOI 10.1111/j.1349-7006.1996.tb00210.x; HIMES SR, 1993, ONCOGENE, V8, P3189; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HIRAI H, 1992, ONCOGENE, V7, P1737; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; JEANG KT, 1988, P NATL ACAD SCI USA, V85, P8291, DOI 10.1073/pnas.85.21.8291; KAPLAN J, 1976, AM J HEMATOL, V1, P219, DOI 10.1002/ajh.2830010206; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LI M, 1993, MOL CELL BIOL, V13, P6490, DOI 10.1128/MCB.13.10.6490; MALLETT S, 1990, EMBO J, V9, P1063, DOI 10.1002/j.1460-2075.1990.tb08211.x; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MCGUIRE KL, 1993, J VIROL, V67, P1590, DOI 10.1128/JVI.67.3.1590-1599.1993; MIURA S, 1991, MOL CELL BIOL, V11, P1313, DOI 10.1128/MCB.11.3.1313; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NAGASHIMA K, 1986, J VIROL, V60, P394, DOI 10.1128/JVI.60.2.394-399.1986; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; NAKAMURA M, 1989, NUCLEIC ACIDS RES, V17, P5207, DOI 10.1093/nar/17.13.5207; NAKAMURA M, 1989, J BIOL CHEM, V264, P20189; NIMER S, 1991, NEW BIOL, V3, P997; NUMATA N, 1991, NEW BIOL, V3, P896; OHBO K, 1995, J BIOL CHEM, V270, P7479, DOI 10.1074/jbc.270.13.7479; OHTANI K, 1987, EMBO J, V6, P389, DOI 10.1002/j.1460-2075.1987.tb04767.x; OHTANI K, 1989, NUCLEIC ACIDS RES, V17, P1589, DOI 10.1093/nar/17.4.1589; OSAME M, 1986, LANCET, V1, P1031; PATERSON DJ, 1987, MOL IMMUNOL, V24, P1281, DOI 10.1016/0161-5890(87)90122-2; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POTEAT HT, 1990, J VIROL, V64, P1264, DOI 10.1128/JVI.64.3.1264-1270.1990; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; Sakitani M, 1987, Virus Genes, V1, P35; SEIKI M, 1986, EMBO J, V5, P561, DOI 10.1002/j.1460-2075.1986.tb04247.x; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SMITH MR, 1992, VIROLOGY, V187, P316, DOI 10.1016/0042-6822(92)90320-O; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; STUBER E, 1995, IMMUNITY, V2, P507, DOI 10.1016/1074-7613(95)90031-4; Stuber E, 1996, J EXP MED, V183, P979, DOI 10.1084/jem.183.3.979; SUGAMURA K, 1984, INT J CANCER, V34, P221, DOI 10.1002/ijc.2910340213; SUZUKI T, 1993, ONCOGENE, V8, P2391; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; TAN TH, 1989, MOL CELL BIOL, V9, P1733, DOI 10.1128/MCB.9.4.1733; TANAKA Y, 1985, INT J CANCER, V36, P549, DOI 10.1002/ijc.2910360506; UCHIUMI F, 1992, MOL CELL BIOL, V12, P3784, DOI 10.1128/MCB.12.9.3784; WATANABE M, 1993, ONCOGENE, V8, P2949; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	65	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14119	14129		10.1074/jbc.273.23.14119	http://dx.doi.org/10.1074/jbc.273.23.14119			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603911	hybrid			2022-12-27	WOS:000074021500013
J	Roy, S; Garges, S; Adhya, S				Roy, S; Garges, S; Adhya, S			Activation and repression of transcription by differential contact: Two sides of a coin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							OPEN-COMPLEX-FORMATION; COLI RNA-POLYMERASE; LAMBDA-PRM PROMOTER; ESCHERICHIA-COLI; LAC REPRESSOR; ALPHA-SUBUNIT; CONFORMATIONAL-CHANGES; BACTERIOPHAGE-LAMBDA; INITIATION; PROTEIN		NCI, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Adhya, S (corresponding author), NCI, Mol Biol Lab, NIH, Bldg 37, Bethesda, MD 20892 USA.	sadhya@helix.nih.gov						ADHYA S, 1989, ANNU REV GENET, V23, P227, DOI 10.1146/annurev.genet.23.1.227; ADHYA S, 1990, J BIOL CHEM, V265, P10797; ADHYA S, 1993, GENE, V132, P1, DOI 10.1016/0378-1119(93)90507-Y; ADHYA S, 1982, CELL, V29, P287, DOI 10.1016/0092-8674(82)90145-3; ANSARI AZ, 1995, NATURE, V374, P371; Bandyopadhyay S, 1996, BIOCHEMISTRY-US, V35, P5033, DOI 10.1021/bi952123f; BELYAEVA TA, 1996, NUCLEIC ACIDS RES, V24, P2242; BLATTER EE, 1994, CELL, V78, P889, DOI 10.1016/S0092-8674(94)90682-3; BUSBY S, 1994, CELL, V79, P743, DOI 10.1016/0092-8674(94)90063-9; BUSHMAN FD, 1989, CELL, V58, P1163, DOI 10.1016/0092-8674(89)90514-X; BUSHMAN FD, 1988, CELL, V54, P191, DOI 10.1016/0092-8674(88)90551-X; Casaz P, 1997, P NATL ACAD SCI USA, V94, P12145, DOI 10.1073/pnas.94.22.12145; Caslake LF, 1997, J BACTERIOL, V179, P1787, DOI 10.1128/jb.179.5.1787-1795.1997; CHAMBERLIN MJ, 1974, ANNU REV BIOCHEM, V43, P721, DOI 10.1146/annurev.bi.43.070174.003445; CHOY HE, 1995, EMBO J, V14, P4523, DOI 10.1002/j.1460-2075.1995.tb00131.x; Choy HE, 1997, J MOL BIOL, V272, P293, DOI 10.1006/jmbi.1997.1221; Dove SL, 1997, NATURE, V386, P627, DOI 10.1038/386627a0; Eyring H, 1935, CHEM REV, V17, P65, DOI 10.1021/cr60056a006; FERSHT A, 1984, ENZYME STRUCTURE MEC, P311; Friedl EM, 1996, J BIOL CHEM, V271, P13927, DOI 10.1074/jbc.271.24.13927; GEISELMANN J, 1997, J BIOL CHEM, V378, P599; GOODRICH JA, 1992, J MOL BIOL, V224, P15, DOI 10.1016/0022-2836(92)90573-3; HAWLEY DK, 1982, J MOL BIOL, V157, P493, DOI 10.1016/0022-2836(82)90473-9; HAWLEY DK, 1985, J BIOL CHEM, V260, P8618; HEYDUK T, 1993, NATURE, V364, P548, DOI 10.1038/364548a0; HUANG W, 1997, J BIOL CHEM, V272, P3853; HWANG JJ, 1988, J MOL BIOL, V200, P735, DOI 10.1016/0022-2836(88)90484-6; ISHIHAMA A, 1993, J BACTERIOL, V175, P2483, DOI 10.1128/JB.175.9.2483-2489.1993; Jeon YH, 1997, J MOL BIOL, V267, P953, DOI 10.1006/jmbi.1997.0902; Katan Y, 1997, NUCLEIC ACIDS RES, V25, P3621, DOI 10.1093/nar/25.18.3621; LEE JY, 1991, CELL, V66, P793, DOI 10.1016/0092-8674(91)90122-F; Li M, 1997, P NATL ACAD SCI USA, V94, P3691, DOI 10.1073/pnas.94.8.3691; LI M, 1994, SCIENCE, V263, P75, DOI 10.1126/science.8272867; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; MALAN TP, 1984, J MOL BIOL, V180, P881, DOI 10.1016/0022-2836(84)90262-6; MCCLURE WR, 1980, P NATL ACAD SCI-BIOL, V77, P5634, DOI 10.1073/pnas.77.10.5634; MENENDEZ M, 1987, EMBO J, V6, P4227, DOI 10.1002/j.1460-2075.1987.tb02771.x; Monsalve M, 1996, EMBO J, V15, P383, DOI 10.1002/j.1460-2075.1996.tb00368.x; Monsalve M, 1997, MOL CELL, V1, P99, DOI 10.1016/S1097-2765(00)80011-8; Monsalve M, 1996, P NATL ACAD SCI USA, V93, P8913, DOI 10.1073/pnas.93.17.8913; MORETT E, 1988, P NATL ACAD SCI USA, V85, P9401, DOI 10.1073/pnas.85.24.9401; Niu W, 1996, CELL, V87, P1123, DOI 10.1016/S0092-8674(00)81806-1; Pelzer H, 1932, Z PHYS CHEM B-CHEM E, V15, P445; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Record Jr MT, 1996, ESCHERICHIA COLI SAL, P792; RYU S, 1994, P NATL ACAD SCI USA, V91, P8582, DOI 10.1073/pnas.91.18.8582; SASSEDWIGHT S, 1988, P NATL ACAD SCI USA, V85, P8934, DOI 10.1073/pnas.85.23.8934; SCHLAX PJ, 1995, J MOL BIOL, V245, P331, DOI 10.1006/jmbi.1994.0028; SEGEL IH, 1993, ENZYME KINETICS BEHA, P934; Sen RJ, 1996, BIOPHYS CHEM, V57, P269, DOI 10.1016/0301-4622(95)00065-2; SHIH MC, 1983, CELL, V34, P941, DOI 10.1016/0092-8674(83)90551-2; SHIH MC, 1983, P NATL ACAD SCI-BIOL, V80, P496, DOI 10.1073/pnas.80.2.496; SHORE D, 1994, TRENDS GENET, V10, P408, DOI 10.1016/0168-9525(94)90058-2; Smith TL, 1996, P NATL ACAD SCI USA, V93, P8868, DOI 10.1073/pnas.93.17.8868; STRAHS D, 1994, J MOL BIOL, V244, P494, DOI 10.1006/jmbi.1994.1748; STRANEY SB, 1987, CELL, V51, P699, DOI 10.1016/0092-8674(87)90093-6; WEDEL A, 1990, SCIENCE, V248, P486, DOI 10.1126/science.1970441	58	79	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14059	14062		10.1074/jbc.273.23.14059	http://dx.doi.org/10.1074/jbc.273.23.14059			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603899	Green Submitted, hybrid			2022-12-27	WOS:000074021500001
J	Jaburek, M; Yarov-Yarovoy, V; Paucek, P; Garlid, KD				Jaburek, M; Yarov-Yarovoy, V; Paucek, P; Garlid, KD			State-dependent inhibition of the mitochondrial K-ATP channel by glyburide and 5-hydroxydecanoate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM 5-HYDROXYDECANOATE; MYOCARDIAL-ISCHEMIA; LIGHT-SCATTERING; MATRIX VOLUME; RAT-LIVER; NUCLEOTIDES; CONTRACTION; METABOLISM; CROMAKALIM; TRANSPORT	The mitochondrial K-ATP channel (mitoK(ATP)) is hypothesized to be the receptor for the cardioprotective effects of K+ channel openers (KCO) and for the blocking of cardioprotection by glyburide and 5-hydroxydecanoate (5-HD). Studies on glyburide have indicated that this drug is inactive in isolated mitochondria. No studies of the effects of 5-HD on isolated mitochondria have been reported. This paper examines the effects of glyburide and 5-HD on K+ flux in isolated, respiring mitochondria. We show that mitoK(ATP) is completely insensitive to glyburide and 5-HD under the experimental conditions in which the open state of the channel is induced by the absence of ATP and Mg2+. On the other hand, mitoK(ATP) became highly sensitive to glyburide and 5-HD when the open state was induced by Mg2+, ATP, and a physiological opener, such as GTP, or a pharmacological opener, such as diazoxide. In these open states, glyburide (K-1/2 values 1-6 mu M) and 5-HD (K-1/2 values 45-75 mu M) inhibited specific, mitoK(ATP)-mediated K+ flux in both heart and liver mitochondria from rat. These results are consistent with a role for mitoK(ATP) in cardioprotection and show that different open states of mitoK(ATP), although catalyzing identical K+ fluxes, exhibit very different susceptibilities to channel inhibitors.	Oregon Grad Inst Sci & Technol, Dept Biochem & Mol Biol, Portland, OR 97291 USA		Garlid, KD (corresponding author), Oregon Grad Inst Sci & Technol, Dept Biochem & Mol Biol, POB 91000, Portland, OR 97291 USA.		Jabůrek, Martin/H-1114-2019; Jaburek, Martin/B-9652-2012	Jabůrek, Martin/0000-0002-4357-1116; Garlid, Keith/0000-0002-6777-1235; Yarov-Yarovoy, Vladimir/0000-0002-2325-4834	NIGMS NIH HHS [GM55324] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUCHAMPACH JA, 1992, CARDIOVASC RES, V26, P1054, DOI 10.1093/cvr/26.11.1054; BEAVIS AD, 1985, J BIOL CHEM, V260, P3424; BEAVIS AD, 1993, J BIOL CHEM, V268, P997; BELYAEVA EA, 1993, BIOCHEM MOL BIOL INT, V31, P493; DEBEER L, 1974, BIOCHEM PHARMACOL, V23, P251, DOI 10.1016/0006-2952(74)90416-X; Garlid K. D., 1997, Biophysical Journal, V72, pA39; GARLID KD, 1989, BIOCHIM BIOPHYS ACTA, V976, P109, DOI 10.1016/S0005-2728(89)80219-1; GARLID KD, 1985, J BIOL CHEM, V260, P3434; Garlid KD, 1997, CIRC RES, V81, P1072; Garlid KD, 1996, BBA-BIOENERGETICS, V1275, P123, DOI 10.1016/0005-2728(96)00061-8; Garlid KD, 1996, J BIOL CHEM, V271, P8796, DOI 10.1074/jbc.271.15.8796; GROSS GJ, 1992, CARDIOVASC RES, V26, P1011, DOI 10.1093/cvr/26.11.1011; Grover GJ, 1997, CAN J PHYSIOL PHARM, V75, P309, DOI 10.1139/cjpp-75-4-309; GROVER GJ, 1989, J PHARMACOL EXP THER, V251, P98; GROVER GJ, 1994, J CARDIOVASC PHARM, V24, pS18, DOI 10.1097/00005344-199424014-00004; HALESTRAP AP, 1994, BIOCHEM SOC T, V22, P522, DOI 10.1042/bst0220522; Hide EJ, 1996, CARDIOVASC RES, V31, P941; MATLIB MA, 1984, METHOD PHARMACOL, V5, P25; MCCULLOUGH JR, 1991, CIRC RES, V69, P949, DOI 10.1161/01.RES.69.4.949; MCGUINNESS DP, 1990, AM J MED, V89, pS26; Paucek P, 1996, J BIOL CHEM, V271, P32084, DOI 10.1074/jbc.271.50.32084; PAUCEK P, 1992, J BIOL CHEM, V267, P26062; Pedersen P L, 1978, Methods Cell Biol, V20, P411, DOI 10.1016/S0091-679X(08)62030-0; Schultz JE, 1997, J MOL CELL CARDIOL, V29, P1055, DOI 10.1006/jmcc.1996.0358; SOMOGYI J, 1995, ACTA PHYSL HUNG, V83, P229; Szewczyk A, 1996, INT J BIOCHEM CELL B, V28, P863, DOI 10.1016/1357-2725(96)00040-4	26	214	223	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13578	13582						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593694				2022-12-27	WOS:000073919100033
J	Lipman, ML; Panda, D; Bennett, HPJ; Henderson, JE; Shane, E; Shen, YN; Goltzman, D; Karaplis, AC				Lipman, ML; Panda, D; Bennett, HPJ; Henderson, JE; Shane, E; Shen, YN; Goltzman, D; Karaplis, AC			Cloning of human PEX cDNA - Expression, subcellular localization, and endopeptidase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED HYPOPHOSPHATEMIA; D-RESISTANT RICKETS; TUMOR-INDUCED OSTEOMALACIA; DEFECTIVE BONE-FORMATION; ONCOGENIC OSTEOMALACIA; NORMAL MICE; MOUSE; HORMONE; CELLS; PHENOTYPE	Mutations in the PEX gene are responsible for X-linked hypophosphatemic rickets, To gain insight into the role of PEX in normal physiology we have cloned the human full-length cDNA and studied its tissue expression, subcellular localization, and peptidase activity. We show that the cDNA encodes a 749-amino acid protein structurally related to a family of neutral endopeptidases that include neprilysin as prototype. By Northern blot analysis, the size of the full-length PEX transcript is 6.5 kilobases, PEX expression, as determined by semiquantitative polymerase chain reaction, is high in bone and in tumor tissue associated with the paraneoplastic syndrome of renal phosphate wasting. PEX is glycosylated in the presence of canine microsomal. membranes and partitions exclusively in the detergent phase from Triton X-114 extractions of transiently transfected COS cells. Immunofluorescence studies in A293 cells expressing PEX tagged with a c-myc epitope show a predominant cell-surface location for the protein with its COOH-terminal domain in the extracellular compartment, substantiating the assumption that PEX, like other members of the neutral endopeptidase family, is a type II integral membrane glycoprotein, Cell membranes from cultured COS cells transiently expressing PEX efficiently degrade exogenously added parathyroid hormone-derived peptides, demonstrating for the first time that recombinant PEX can function as an endopeptidase, PEX peptidase activity may provide a convenient target for pharmacological intervention in states of altered phosphate homeostasis and in metabolic bone diseases.	McGill Univ, Dept Med, Div Nephrol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Div Endocrinol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; McGill Univ, Royal Victoria Hosp, Dept Med, Calcium Res Lab, Montreal, PQ H3A 1A1, Canada; McGill Univ, Royal Victoria Hosp, Dept Med, Endocrine Labs, Montreal, PQ H3A 1A1, Canada; McGill Univ, Sheldon Biotechnol Ctr, Montreal, PQ H3A 1A1, Canada; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA	McGill University; McGill University; Lady Davis Institute; McGill University; McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; McGill University; Columbia University	Karaplis, AC (corresponding author), McGill Univ, Dept Med, Div Nephrol, 3755 Cote St Catherine Rd, Montreal, PQ H3T 1E2, Canada.	akarapli@ldi.jgh.mcgill.ca						Amizuka N, 1996, DEV BIOL, V175, P166, DOI 10.1006/dbio.1996.0104; ASCHINBERG LC, 1977, J PEDIATR-US, V91, P56, DOI 10.1016/S0022-3476(77)80444-7; Beck L, 1997, J CLIN INVEST, V99, P1200, DOI 10.1172/JCI119276; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAI Q, 1994, NEW ENGL J MED, V330, P1645, DOI 10.1056/NEJM199406093302304; CHOW M, 1992, CURR BIOL, V4, P626; Cox Adrienne D., 1992, Current Opinion in Cell Biology, V4, P1008, DOI 10.1016/0955-0674(92)90133-W; DIXON PH, 1997, J BONE MINER RES  S1, V12, pS128; Du L, 1996, GENOMICS, V36, P22, DOI 10.1006/geno.1996.0421; ECAROT B, 1992, J BONE MINER RES, V7, P215; ECAROTCHARRIER B, 1988, ENDOCRINOLOGY, V123, P768, DOI 10.1210/endo-123-2-768; ECONS MJ, 1994, NEW ENGL J MED, V330, P1679, DOI 10.1056/NEJM199406093302310; EICHER EM, 1976, P NATL ACAD SCI USA, V73, P4667, DOI 10.1073/pnas.73.12.4667; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FRANCIS F, 1995, NAT GENET, V11, P130, DOI 10.1038/ng1095-130; GLORIEUX FH, 1980, NEW ENGL J MED, V303, P1023, DOI 10.1056/NEJM198010303031802; Grieff M, 1997, BIOCHEM BIOPH RES CO, V231, P635, DOI 10.1006/bbrc.1997.6153; Guo R, 1997, J BONE MINER RES, V12, P1009, DOI 10.1359/jbmr.1997.12.7.1009; KARAPLIS AC, 1995, J BIOL CHEM, V270, P1629, DOI 10.1074/jbc.270.4.1629; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LYON MF, 1986, P NATL ACAD SCI USA, V83, P4899, DOI 10.1073/pnas.83.13.4899; MIYAUCHI A, 1988, J CLIN ENDOCR METAB, V67, P46, DOI 10.1210/jcem-67-1-46; NESBITT T, 1992, J CLIN INVEST, V89, P1453, DOI 10.1172/JCI115735; Rowe PSN, 1997, HUM MOL GENET, V6, P539, DOI 10.1093/hmg/6.4.539; RYAN EA, 1984, AM J MED, V77, P501, DOI 10.1016/0002-9343(84)90112-8; SCRIVER CR, 1992, J INHERIT METAB DIS, V15, P610, DOI 10.1007/BF01799618; SEGRE GV, 1989, NEW ENGL J MED, V321, P1812; SESHADRI MS, 1985, CLIN ENDOCRINOL, V23, P689, DOI 10.1111/j.1365-2265.1985.tb01130.x; Shane E, 1997, J BONE MINER RES, V12, P1502, DOI 10.1359/jbmr.1997.12.9.1502; SIRIS ES, 1987, AM J MED, V82, P307, DOI 10.1016/0002-9343(87)90075-1; TAKAHASHI M, 1995, BIOCHEM J, V311, P657, DOI 10.1042/bj3110657; WEIDNER N, 1985, CANCER-AM CANCER SOC, V55, P1691, DOI 10.1002/1097-0142(19850415)55:8<1691::AID-CNCR2820550814>3.0.CO;2-S; WILKINS GE, 1995, J CLIN ENDOCR METAB, V80, P1628, DOI 10.1210/jc.80.5.1628; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1	35	107	114	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13729	13737		10.1074/jbc.273.22.13729	http://dx.doi.org/10.1074/jbc.273.22.13729			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593714	hybrid			2022-12-27	WOS:000073919100053
J	Simbulan-Rosenthal, CM; Rosenthal, DS; Iyer, S; Boulares, AH; Smulson, ME				Simbulan-Rosenthal, CM; Rosenthal, DS; Iyer, S; Boulares, AH; Smulson, ME			Transient poly(ADP-ribosyl)ation of nuclear proteins and role of poly(ADP-ribose) polymerase in the early stages of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAS-MEDIATED APOPTOSIS; INTERNUCLEOSOMAL DNA FRAGMENTATION; ANTISENSE RNA EXPRESSION; CELL-DEATH; ICE/CED-3 PROTEASE; INTERPHASE DEATH; GRANZYME-B; ACTIVATION; CPP32; DIFFERENTIATION	A transient burst of poly(ADP-ribosyl)ation of nuclear proteins occurs early, prior to commitment to death, in human osteosarcoma cells undergoing apoptosis, followed by caspase-3-mediated cleavage of poly(ADP-ribose) polymerase (PARP). The generality of this early burst of poly(ADP-ribosyl)ation has now been investigated with human HL-60 cells, mouse 3T3-L1, and immortalized fibroblasts derived from wild-type mice. The effects of eliminating this early transient modification of nuclear proteins by depletion of PARP protein either by antisense RNA expression or by gene disruption on various morphological and biochemical markers of apoptosis were then examined. Marked caspase-3-like PARP cleavage activity, proteolytic processing of CPP32 to its active form, internucleosomal DNA fragmentation and nuclear morphological changes associated with apoptosis were induced in control 3T3-L1 cells treated for 24 h with anti-Fas and cycloheximide but not in PARP-depleted 3T3-L1 antisense cells exposed to these inducers. Similar results were obtained with control and PARP-depleted human Jurkat T cells. Whereas immortalized PARP +/+ fibroblasts showed the early burst of poly(ADP-ribosyl)ation and a rapid apoptotic response when exposed to anti-Fas and cycloheximide, PARP -/- fibroblasts exhibited neither the early poly (ADP-ribosyl)ation nor any of the biochemical or morphological changes characteristic of apoptosis when similarly treated. Stable transfection of PARP -/- fibroblasts with wild-type PARP rendered the cells sensitive to Fas-mediated apoptosis, These results suggest that PARP and poly(ADP-ribosyl)ation may trigger key steps in the apoptotic program. Subsequent degradation of PARP by caspase-3-like proteases may prevent depletion of NAD and ATP or release certain nuclear proteins from poly(ADP-ribosyl)ation-induced inhibition, both of which might be required for late stages of apoptosis.	Georgetown Univ, Sch Med, Dept Biochem & Mol Biol, Washington, DC 20007 USA	Georgetown University	Smulson, ME (corresponding author), Georgetown Univ, Sch Med, Dept Biochem & Mol Biol, Basic Sci Bldg,Rm 351,3900 Reservoir Rd NW, Washington, DC 20007 USA.	smulson@bc.georgetown.edu	Simbulan-Rosenthal, Cynthia M./W-8429-2019; Rosenthal, Dean S/J-2360-2014	Simbulan-Rosenthal, Ph.D, Cynthia M./0000-0002-5070-0342; Rosenthal, Dean/0000-0002-7624-0209	NATIONAL CANCER INSTITUTE [R01CA013195, R01CA025344] Funding Source: NIH RePORTER; NCI NIH HHS [CA13195, CA25344] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1968, J CELL PHYSIOL, V72, P141, DOI 10.1002/jcp.1040720208; Agarwal ML, 1997, ONCOGENE, V15, P1035, DOI 10.1038/sj.onc.1201274; ALKHATIB HM, 1987, P NATL ACAD SCI USA, V84, P1224, DOI 10.1073/pnas.84.5.1224; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Althaus F R, 1987, Mol Biol Biochem Biophys, V37, P1; Berger N A, 1983, Princess Takamatsu Symp, V13, P219; BERTRAND R, 1993, EXP CELL RES, V207, P388, DOI 10.1006/excr.1993.1206; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; CHERNEY BW, 1985, DEV BIOL, V112, P115, DOI 10.1016/0012-1606(85)90125-3; Chiba T, 1996, EUR J IMMUNOL, V26, P1164, DOI 10.1002/eji.1830260530; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; CLEAVER JE, 1985, PHARMACOL THERAPEUT, V31, P269, DOI 10.1016/0163-7258(85)90026-9; Darmon AJ, 1996, J BIOL CHEM, V271, P21709, DOI 10.1074/jbc.271.36.21709; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; DING RC, 1994, CANCER RES, V54, P4627; DING RC, 1992, J BIOL CHEM, V267, P12804; Dubrez L, 1996, EMBO J, V15, P5504, DOI 10.1002/j.1460-2075.1996.tb00935.x; Eldadah BA, 1996, NUCLEIC ACIDS RES, V24, P4092, DOI 10.1093/nar/24.20.4092; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Erhardt P, 1996, J BIOL CHEM, V271, P17601, DOI 10.1074/jbc.271.30.17601; HUNTING D, 1985, BIOCHEM PHARMACOL, V34, P3999, DOI 10.1016/0006-2952(85)90379-X; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; JONES DP, 1989, J BIOL CHEM, V264, P6398; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KAWAMITSU H, 1984, BIOCHEMISTRY-US, V23, P3771, DOI 10.1021/bi00311a032; KNIDA K, 1996, NATURE, V384, P368; KOHLHUBER F, 1995, J BIOL CHEM, V270, P28797, DOI 10.1074/jbc.270.48.28797; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; KUMARI S, 1907, 12 INT S ADP RIB REA; LUDWIG A, 1988, J BIOL CHEM, V263, P6993; MALANGA M, 1997, 12 INT S ADP ROB REA; MANOME Y, 1993, BIOCHEMISTRY-US, V32, P10607, DOI 10.1021/bi00091a010; MARKS DI, 1991, BIOCHEM PHARMACOL, V42, P1859, DOI 10.1016/0006-2952(91)90582-P; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; MILAM KM, 1984, SCIENCE, V223, P589, DOI 10.1126/science.6420886; NATOLI G, 1995, ONCOGENE, V11, P1157; NEAMATI N, 1995, J IMMUNOL, V154, P3788; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NOSSERI C, 1994, EXP CELL RES, V212, P367, DOI 10.1006/excr.1994.1156; NOZAKI T, 1997, 12 INT S ADP RIB REA; OGASAWARA J, 1995, J EXP MED, V181, P485, DOI 10.1084/jem.181.2.485; Rosenthal DS, 1997, EXP CELL RES, V232, P313, DOI 10.1006/excr.1997.3536; ROSENTHAL DS, 1995, J INVEST DERMATOL, V105, P38, DOI 10.1111/1523-1747.ep12312525; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Shiokawa D, 1997, FEBS LETT, V413, P99, DOI 10.1016/S0014-5793(97)00887-9; SHIOKAWA D, 1994, EUR J BIOCHEM, V226, P23, DOI 10.1111/j.1432-1033.1994.tb20022.x; SIMBULANROSENTH.C, 1998, IN PRESS BIOCHEMISTR; SimbulanRosenthal CM, 1996, BIOCHEMISTRY-US, V35, P11622, DOI 10.1021/bi953010z; SMULSON ME, 1995, J BIOL CHEM, V270, P119, DOI 10.1074/jbc.270.1.119; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; TANAKA Y, 1984, J BIOL CHEM, V259, P6579; TANIZAWA A, 1989, EXP CELL RES, V185, P237, DOI 10.1016/0014-4827(89)90052-9; TANIZAWA A, 1987, BIOCHEM BIOPH RES CO, V144, P1031, DOI 10.1016/S0006-291X(87)80067-0; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Totpal K, 1996, J INTERF CYTOK RES, V16, P259, DOI 10.1089/jir.1996.16.259; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; WHITACRE CM, 1995, CANCER RES, V55, P3697; WRIGHT SC, 1992, J CELL BIOCHEM, V48, P344, DOI 10.1002/jcb.240480403; Wu YL, 1996, J CELL PHYSIOL, V168, P499, DOI 10.1002/(SICI)1097-4652(199609)168:3<499::AID-JCP2>3.0.CO;2-K; Yoon YS, 1996, J BIOL CHEM, V271, P9129, DOI 10.1074/jbc.271.15.9129; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	64	253	256	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13703	13712		10.1074/jbc.273.22.13703	http://dx.doi.org/10.1074/jbc.273.22.13703			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593711	hybrid			2022-12-27	WOS:000073919100050
J	Chabry, J; Caughey, B; Chesebro, B				Chabry, J; Caughey, B; Chesebro, B			Specific inhibition of in vitro formation of protease-resistant prion protein by synthetic peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROBLASTOMA-CELLS; PRP 27-30; SCRAPIE; CONVERSION; NEUROTOXICITY; DISEASES; MODEL; FORM	The transmissible spongiform encephalopathies are characterized by the conversion of the protease-sensitive prion protein (PrPsen) into a protease-resistant isoform (PrPres) associated with the neuropathogenic process in vivo. Recently, PrPres has been shown to be capable of directly inducing the conversion of PrPsen to PrPres in a cell-free in vitro system. In the present experiments, various PrP peptides were studied for their ability to enhance or inhibit this cell-free conversion reaction. None of the synthetic peptides was able to confer protease-resistance to the labeled PrPsen molecules on their own. On the contrary, peptides from the central part of the hamster PrP sequence from 106 to 141 could completely inhibit the conversion induced by preformed PrPres. The presence of residues 119 and 120 from the highly hydrophobic sequence AGAAAAGA (position 113 to 120) was crucial for an efficient inhibitory effect. Fourier transform infrared spectroscopy analysis indicated that inhibitory peptides formed high P-sheet aggregates under the conditions of the conversion reaction, but this was also true of certain peptides that were not inhibitory. Thus, the potential to form P-sheeted aggregates may be necessary, but not sufficient, for peptides to act as inhibitors of PrPres formation, Clearly, the amino acid sequence of the peptide is also important for inhibition. The sequence specificity of the inhibition is consistent with the idea that residues in the vicinity of positions 106-141 of PrPres and/or PrPsen are critically involved in the intermolecular interactions that lead to PrPres formation.	NIAID, Rocky Mt Labs, Persistent Viral Dis Lab, NIH, Hamilton, MT 59840 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Chesebro, B (corresponding author), NIAID, Rocky Mt Labs, Persistent Viral Dis Lab, NIH, 903 S 4th St, Hamilton, MT 59840 USA.		Chabry, Joelle/O-2101-2016					BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; Bossers A, 1997, P NATL ACAD SCI USA, V94, P4931, DOI 10.1073/pnas.94.10.4931; Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; Caughey B, 1997, TRENDS CELL BIOL, V7, P56, DOI 10.1016/S0962-8924(96)10054-4; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; COME JH, 1993, P NATL ACAD SCI USA, V90, P5959, DOI 10.1073/pnas.90.13.5959; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; GASSET M, 1992, P NATL ACAD SCI USA, V89, P10940, DOI 10.1073/pnas.89.22.10940; Holscher C, 1998, J VIROL, V72, P1153; Hope J, 1996, NEURODEGENERATION, V5, P1, DOI 10.1006/neur.1996.0001; HOPE J, 1986, EMBO J, V5, P2591, DOI 10.1002/j.1460-2075.1986.tb04539.x; Kaneko K, 1997, J MOL BIOL, V270, P574, DOI 10.1006/jmbi.1997.1135; KANEKO K, 1995, P NATL ACAD SCI USA, V92, P11160, DOI 10.1073/pnas.92.24.11160; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KOCISKO DA, 1995, P NATL ACAD SCI USA, V92, P3923, DOI 10.1073/pnas.92.9.3923; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PRIOLA SA, 1995, J VIROL, V69, P7754, DOI 10.1128/JVI.69.12.7754-7758.1995; PRIOLA SA, 1994, J VIROL, V68, P4873, DOI 10.1128/JVI.68.8.4873-4878.1994; Prusiner SB, 1996, SEMIN VIROL, V7, P159, DOI 10.1006/smvy.1996.0021; Raymond GJ, 1997, NATURE, V388, P285, DOI 10.1038/40876; SAFAR J, 1993, J BIOL CHEM, V268, P20276	24	151	159	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					13203	13207		10.1074/jbc.273.21.13203	http://dx.doi.org/10.1074/jbc.273.21.13203			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582363	hybrid			2022-12-27	WOS:000073768500074
J	van Weeren, PC; de Bruyn, KMT; de Vries-Smits, AMM; van Lint, J; Burgering, BMT				van Weeren, PC; de Bruyn, KMT; de Vries-Smits, AMM; van Lint, J; Burgering, BMT			Essential role for protein kinase B (PKB) in insulin-induced glycogen synthase kinase 3 inactivation - Characterization of dominant-negative mutant of PKB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALING PATHWAY; PHOSPHATIDYLINOSITOL 3-KINASE; GROWTH-FACTOR; C-AKT; ACTIVATION; PHOSPHORYLATION; CELLS; RAS; KINASE-3-BETA; MEMBRANE	Activation of phosphatidylinositide 3'-OH kinase (PI 3-kinase) is implicated in mediating a variety of growth factor-induced responses, among which are the inactivation of glycogen synthase kinase-3 (GSK-3) and the activation of the serine/threonine protein kinase B (PKB), GSK-3 inactivation occurs through phosphorylation of Ser-9, and several kinases, such as protein kinase C, mitogen-activated protein kinase-activated protein kinase-1 (p90(Rsk)), p70(S6kinase), and also PKB have been shown to phosphorylate this site in vitro. In the light of the many candidates to mediate insulin-induced GSK-3 inactivation Fee have investigated the role of PKB by constructing a PKB mutant that exhibits dominant-negative function (inhibition of growth factor-induced activation of PKB at expression levels similar to wild-type PKB), as currently no such mutant has been reported. We observed that the PKB mutant (PKB-CAAX) acts as an efficient inhibitor of PKB activation and also of insulin-induced GSK-3 regulation, Furthermore, it is shown that PKB and GSF-3 co-immunoprecipitate, indicating a direct interaction between GSK-3 and PKB. An additional functional consequence of this interaction is implicated by the observation that the oncogenic form of PRE, gagPKB induces a cellular relocalization of GSK-3 from the cytosolic to the membrane fraction. Our results demonstrate that PKB activation is both necessary and sufficient for insulin-induced GSK-3 inactivation and establish a linear pathway from insulin receptor to GSK-3. Regulation of GSK-3 by PKB is likely through direct interaction, as both proteins co-immunoprecipitate. This interaction also resulted in a translocation of GSK-3 to the membrane in cells expressing transforming gagPKB.	Univ Utrecht, Physiol Chem Lab, NL-3584 CG Utrecht, Netherlands; Catholic Univ Louvain, Fac Geneeskunde, Afdeling Biochem, B-3000 Louvain, Belgium	Utrecht University; Universite Catholique Louvain	Burgering, BMT (corresponding author), Univ Utrecht, Physiol Chem Lab, Univ Weg 100, NL-3584 CG Utrecht, Netherlands.		Van Lint, Johan/P-9073-2019	Van Lint, Johan/0000-0002-0275-571X				AHMED NN, 1993, ONCOGENE, V8, P1957; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DATTA K, 1995, MOL CELL BIOL, V15, P2304; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Didichenko SA, 1996, CURR BIOL, V6, P1271, DOI 10.1016/S0960-9822(02)70713-6; ELDARFINKELMAN H, 1995, J BIOL CHEM, V270, P987, DOI 10.1074/jbc.270.3.987; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GOODE N, 1992, J BIOL CHEM, V267, P16878; GUAN RJ, 1991, J BIOL CHEM, V266, P8262; HANGER DP, 1992, NEUROSCI LETT, V147, P58, DOI 10.1016/0304-3940(92)90774-2; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; Hurel SJ, 1996, BIOCHEM J, V320, P871, DOI 10.1042/bj3200871; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; KAUFFMANN ZA, 1997, NATURE, V385, P544; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MEDEMA RH, 1991, J BIOL CHEM, V266, P21186; Nusse R, 1997, CELL, V89, P321, DOI 10.1016/S0092-8674(00)80210-X; RODRIGUEZ VP, 1994, NATURE, V370, P527; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; SAKAUE H, 1995, J BIOL CHEM, V270, P11304, DOI 10.1074/jbc.270.19.11304; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; VANLINT J, 1993, ANAL BIOCHEM, V208, P132, DOI 10.1006/abio.1993.1018; VANWEERING DHJ, 1997, MOL CELL BIOL, V18, P1812; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748	38	305	313	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					13150	13156		10.1074/jbc.273.21.13150	http://dx.doi.org/10.1074/jbc.273.21.13150			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582355	hybrid			2022-12-27	WOS:000073768500066
J	Wynn, RM; Davie, JR; Chuang, JL; Cote, CD; Chuang, DT				Wynn, RM; Davie, JR; Chuang, JL; Cote, CD; Chuang, DT			Impaired assembly of E1 decarboxylase of the branched-chain alpha-ketoacid dehydrogenase complex in type IA maple syrup urine disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID DEHYDROGENASE; ESCHERICHIA-COLI; PYRUVATE-DEHYDROGENASE; CHAPERONINS GROEL; COFACTOR-BINDING; Y393N MUTATION; E1-ALPHA LOCUS; IN-VITRO; EXPRESSION; E2	The E1 decarboxylase component of the human branched-chain ketoacid dehydrogenase complex comprises two E1 alpha (45.5 kDa) and two E1 beta (37.5 kDa) subunits forming an alpha(2) beta(2) tetramer, In patients with type IA maple syrup urine disease, the E1 alpha subunit is affected, resulting in the loss of E1 and branched-chain ketoacid dehydrogenase catalytic activities. To study the effect of human E1 alpha missense mutations on E1 subunit assembly, we have developed a pulse-chase labeling protocol based on efficient expression and assembly of human (His)(6)-E1 alpha and untagged E1 beta subunits in Escherichia coli in the presence of overexpressed chaperonins GroEL and GroES, Assembly of the two S-35-labeled E1 subunits was indicated by their co-extraction with Ni2+-nitrilotriacetic acid resin, The nine E1 alpha maple syrup urine disease mutants studied showed aberrant kinetics of assembly with normal E1 beta in the 2-h chase compared with the wild type and can be classified into four categories of normal (N222S-alpha and R220W-alpha), moderately slow (G245R-alpha), slow (G204S-alpha, A240P-alpha, F364C-alpha, Y368C-alpha, and Y393N-alpha), and no (T265R-alpha) assembly. Prolonged induction in E. coli grown in the YTGK medium or lowering of induction temperature from 37 to 28 degrees C (in the case of T265R-alpha), however, resulted in the production of mutant E1 proteins. Separation of purified E1 proteins by sucrose density gradient centrifugation showed that the wild-type E1 existed entirely as alpha(2) beta(2) tetramers, In contrast, a subset of E1 alpha missense mutations caused the occurrence of exclusive alpha beta dimers (Y393N-alpha and F364C-alpha) or of both alpha(2) beta(2) tetramers and lower molecular weight species (Y368C-alpha and T265R-alpha). Thermal denaturation at 50 degrees C indicated that mutant E1 proteins aggregated more rapidly than wild type (rate constant, 0.19 min(-1)), with the T265R-alpha mutant E1 most severely affected (rate constant, 4.45 min(-1)). The results establish that the human E1 alpha mutations in the putative thiamine pyrophosphate-binding pocket that are studied, with the exception of G204S-alpha, have no effect on E1 subunit assembly. The T265R-alpha mutation adversely impacts both E1 alpha folding and subunit interactions, The mutations involving the C-terminal aromatic residues impede both the kinetics of subunit assembly and the formation of the native alpha(2) beta(2) structure.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Chuang, DT (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	chuang01@utsw.swmed.edu		Wynn, Richard/0000-0002-1879-2136; Davie, James/0000-0002-0420-6888	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026758] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK26758] Funding Source: Medline; NIGMS NIH HHS [5-P32 GM08014] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BROWNER MF, 1991, PROTEIN ENG, V4, P351, DOI 10.1093/protein/4.3.351; CANDY JM, 1994, BIOCHEM J, V300, P7, DOI 10.1042/bj3000007; CHUANG DT, 1988, METHOD ENZYMOL, V166, P146; CHUANG DT, 1988, METHOD ENZYMOL, V166, P135; CHUANG DT, 1995, METABOLIC MOL BASES, P1333; CHUANG JL, 1994, AM J HUM GENET, V55, P297; CHUANG JL, 1995, J CLIN INVEST, V95, P954, DOI 10.1172/JCI117804; COX RP, 1997, MOL GENETIC BASIS NE, P1175; DAVIE JR, 1992, J BIOL CHEM, V267, P16601; DYDA F, 1993, BIOCHEMISTRY-US, V32, P6165, DOI 10.1021/bi00075a008; FISHER CR, 1991, J CLIN INVEST, V88, P1034, DOI 10.1172/JCI115363; FISHER CR, 1991, AM J HUM GENET, V49, P429; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GUZMANVERDUZCO LM, 1987, J BACTERIOL, V169, P5201, DOI 10.1128/jb.169.11.5201-5208.1987; HARRIS RA, 1986, ADV ENZYME REGUL, V25, P219, DOI 10.1016/0065-2571(86)90016-6; HAWKINS CF, 1989, FEBS LETT, V255, P77, DOI 10.1016/0014-5793(89)81064-6; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; KENNARD J, 1995, J GEN VIROL, V76, P1611, DOI 10.1099/0022-1317-76-7-1611; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAU KS, 1990, BIOCHIM BIOPHYS ACTA, V1038, P360, DOI 10.1016/0167-4838(90)90249-F; LESSARD IAD, 1994, J BIOL CHEM, V269, P10378; MATSUDA I, 1990, BIOCHEM BIOPH RES CO, V172, P646, DOI 10.1016/0006-291X(90)90723-Z; MATTEVI A, 1992, SCIENCE, V255, P1544, DOI 10.1126/science.1549782; MULLER YA, 1993, SCIENCE, V259, P965, DOI 10.1126/science.8438155; NIKKOLA M, 1994, J MOL BIOL, V238, P387, DOI 10.1006/jmbi.1994.1299; PETTIT FH, 1978, P NATL ACAD SCI USA, V75, P4881, DOI 10.1073/pnas.75.10.4881; REED LJ, 1990, J BIOL CHEM, V265, P8971; ROBINSON BH, 1993, FEBS LETT, V328, P99, DOI 10.1016/0014-5793(93)80973-X; Sambrook J., 1989, MOL CLONING LABORATO, V3, pA3; SUNDSTROM M, 1992, FEBS LETT, V313, P229, DOI 10.1016/0014-5793(92)81197-T; WEXLER ID, 1991, FEBS LETT, V282, P209, DOI 10.1016/0014-5793(91)80479-M; Wynn R. M., 1996, ALPHA KETO ACID DEHY, P101; WYNN RM, 1992, J BIOL CHEM, V267, P1881; WYNN RM, 1992, J BIOL CHEM, V267, P12400; WYNN RM, 1994, BIOCHEMISTRY-US, V33, P8962, DOI 10.1021/bi00196a014; YEAMAN SJ, 1989, BIOCHEM J, V257, P625, DOI 10.1042/bj2570625; ZHANG B, 1989, J CLIN INVEST, V83, P1425, DOI 10.1172/JCI114033	38	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					13110	13118		10.1074/jbc.273.21.13110	http://dx.doi.org/10.1074/jbc.273.21.13110			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582350	hybrid			2022-12-27	WOS:000073768500061
J	Zhu, JH; Zhou, WJ; Jiang, JY; Chen, XB				Zhu, JH; Zhou, WJ; Jiang, JY; Chen, XB			Identification of a novel p53 functional domain that is necessary for mediating apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; HYDROPHOBIC AMINO-ACIDS; TATA-BINDING PROTEIN; TRANSCRIPTIONAL ACTIVATION; TUMOR-SUPPRESSOR; MAMMALIAN-CELLS; GENE-EXPRESSION; IN-VIVO; INDUCTION; P21	The ability of p53 to induce apoptosis requires its sequence-specific DNA binding activity; however, the transactivation-deficient p53(Gln(22)-Ser(23)) can still induce apoptosis, Previously, we have shown that the region between residues 23 and 97 in p53 is necessary for such activity, In an effort to more precisely map a domain necessary for apoptosis within the N terminus, we found that deletion of the N-terminal 23 amino acids compromises, but does not abolish, p53 induction of apoptosis, Surprisingly, p53(Delta 1-42), which lacks the N-terminal 42 amino acids and the previously defined activation domain, retains the ability to induce apoptosis to an even higher level than wild-type p53, A more extensive deletion, which eliminates the N-terminal 63 amino acids, renders p53 completely inert in mediating apoptosis. In addition, we found that both p53(Delta 1-42) and p53(Gln(22)-Ser(23)) can activate a subset of cellular p53 targets. Furthermore, we showed that residues 53 and 54 are critical for the apoptotic and transcriptional activities of both p53(Delta 1-42) and p53(Gln(22)-Ser(23)). Taken together, these data suggest that within residues 43-63 lie an apoptotic domain as web as another transcriptional activation domain. We therefore postulate that the apoptotic activity in p53(Gln(22)-Ser(23)) and p53(Delta 1-42) is still transcription-dependent.	Med Coll Georgia, IMMAG, Program Gene Regulat, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Chen, XB (corresponding author), Med Coll Georgia, IMMAG, Program Gene Regulat, 1120 15th St,CB-2803, Augusta, GA 30912 USA.	xchen@mail.mcg.edu			NATIONAL CANCER INSTITUTE [R01CA076069, R29CA076069] Funding Source: NIH RePORTER; NCI NIH HHS [CA76069-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; CHANG J, 1995, J BIOL CHEM, V270, P25014, DOI 10.1074/jbc.270.42.25014; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHEN XB, 1995, CANCER RES, V55, P4257; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; GOTTLIEB MT, 1996, BIOCHIM BIOPHYS ACTA, V1287, P77; HARPER JW, 1993, CELL, V75, P805; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; Israeli D, 1997, EMBO J, V16, P4384, DOI 10.1093/emboj/16.14.4384; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVINE AJ, 1994, J LAB CLIN MED, V123, P817; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Ronen D, 1996, CELL GROWTH DIFFER, V7, P21; Ruaro EM, 1997, P NATL ACAD SCI USA, V94, P4675, DOI 10.1073/pnas.94.9.4675; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yin DX, 1996, ANAL BIOCHEM, V235, P195, DOI 10.1006/abio.1996.0112	50	149	153	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					13030	13036		10.1074/jbc.273.21.13030	http://dx.doi.org/10.1074/jbc.273.21.13030			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582339	hybrid			2022-12-27	WOS:000073768500050
J	Biemesderfer, D; DeGray, B; Aronson, PS				Biemesderfer, D; DeGray, B; Aronson, PS			Membrane topology of NHE3 - Epitopes within the carboxyl-terminal hydrophilic domain are exoplasmic	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-H+ EXCHANGER; BRUSH-BORDER; ACETYLCHOLINE-RECEPTOR; MONOCLONAL-ANTIBODIES; MOLECULAR-CLONING; PROTEINS; ISOFORM; EXPRESSION; ANTIPORTER; BINDING	Experimental data indicate that the relatively hydrophilic carboxyl-terminal domains of Na+-H+ exchangers mediate the regulation of transporter activity through interactions with cytoskeletal effecters. It has therefore been assumed that this entire domain lies on the cytoplasmic surface of the plasma membrane. The purpose of the present study was to determine the membrane orientation of the COOH-terminal 131 amino acids of Na+-H+ exchanger isoform NHE3 by use of three monoclonal-antibodies that recognize at least two distinct epitopes within this region. Enzyme-linked immunosorbent assay studies demonstrated binding of these monoclonal antibodies (mAbs) to intact right-side-out renal brush border membrane vesicles in the absence of detergent, Moreover, when coupled to an affinity matrix to isolate membrane vesicles, the anti-NHE3 mAbs bound structures that were morphologically identical to intact microvilli, To confirm the identity of the exoplasmic antigen bound by the antibodies, immunoprecipitation studies were performed. Intact right-side-out brush border membrane vesicles were incubated with the mAbs in the absence of detergent. The membranes were pelleted, supernatant with unbound antibody was removed, the pellet was solubilized, and then immunoprecipitation with secondary antibody was performed. Immunoblot analysis indicated that NHE3 was precipitated after binding of the mAbs to intact membranes, Finally, the localization of the mAb epitopes was determined using high resolution immunocytochemistry, Ultrathin cryosections of rat kidney were labeled with the mAbs and bound antibody detected with the colloidal gold technique. Labeling was restricted to the exoplasmic surface of microvilli of the proximal tubule, Taken together, these findings indicate that epitopes within the carboxyl terminus of the Na+-H+ exchanger isoform NHE3 are exposed to the outside of the plasma membrane.	Yale Univ, Sch Med, Dept Internal Med, Nephrol Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA	Yale University; Yale University	Biemesderfer, D (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Nephrol Sect, 333 Cedar St,LMP 2073,POB 208029, New Haven, CT 06520 USA.	daniel.biemesderfer@yale.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033793, R37DK033793] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-33793] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONSON PS, 1978, J MEMBRANE BIOL, V42, P81, DOI 10.1007/BF01870395; ARONSON PS, 1985, ANNU REV PHYSIOL, V47, P545, DOI 10.1146/annurev.ph.47.030185.002553; BERTRAND B, 1994, J BIOL CHEM, V269, P13703; Biemesderfer D., 1996, Journal of the American Society of Nephrology, V7, P1276; BIEMESDERFER D, 1992, AM J PHYSIOL, V263, pF833, DOI 10.1152/ajprenal.1992.263.5.F833; Biemesderfer D, 1997, AM J PHYSIOL-RENAL, V273, pF289, DOI 10.1152/ajprenal.1997.273.2.F289; BIEMESDERFER D, 1992, AM J PHYSIOL, V262, pF55, DOI 10.1152/ajprenal.1992.262.1.F55; BORGESE F, 1994, P NATL ACAD SCI USA, V91, P5431, DOI 10.1073/pnas.91.12.5431; Cabado AG, 1996, J BIOL CHEM, V271, P3590; DUDOUET B, 1987, J CELL BIOL, V105, P359, DOI 10.1083/jcb.105.1.359; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; HAASE W, 1978, BIOCHEM J, V172, P57, DOI 10.1042/bj1720057; Ikeda T, 1997, J BIOCHEM-TOKYO, V121, P295; KASHGARIAN M, 1985, KIDNEY INT, V28, P899, DOI 10.1038/ki.1985.216; Kurashima K, 1997, J BIOL CHEM, V272, P28672, DOI 10.1074/jbc.272.45.28672; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE SA, 1995, J BIOL CHEM, V270, P13716, DOI 10.1074/jbc.270.23.13716; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCLEAN W, 1973, J HISTOCHEM CYTOCHEM, V22, P1077; MIELKE DL, 1988, J BIOL CHEM, V263, P3177; MIETTINEN A, 1990, AM J PATHOL, V137, P929; MURER H, 1976, BIOCHEM J, V154, P597, DOI 10.1042/bj1540597; NODA M, 1983, NATURE, V301, P251, DOI 10.1038/301251a0; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; RADDING W, 1991, J THEOR BIOL, V150, P239, DOI 10.1016/S0022-5193(05)80335-2; Rutherford PA, 1997, EXP NEPHROL, V5, P490; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; TOKUYASU KT, 1989, HISTOCHEM J, V21, P163, DOI 10.1007/BF01007491; TOKUYASU KT, 1986, J MICROSC-OXFORD, V143, P139, DOI 10.1111/j.1365-2818.1986.tb02772.x; TSE CM, 1993, J BIOL CHEM, V268, P11917; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; VENIEN C, 1988, ANAL BIOCHEM, V174, P325, DOI 10.1016/0003-2697(88)90553-2; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P13710	34	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12391	12396		10.1074/jbc.273.20.12391	http://dx.doi.org/10.1074/jbc.273.20.12391			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575193	hybrid			2022-12-27	WOS:000073629800058
J	Garcia, GE; Wirtz, RA; Barr, JR; Woolfitt, A; Rosenberg, R				Garcia, GE; Wirtz, RA; Barr, JR; Woolfitt, A; Rosenberg, R			Xanthurenic acid induces gametogenesis in Plasmodium, the malaria parasite	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALLINACEUM	A small, heat stable chromophore extracted from mosquitoes has recently been implicated as the signal that induces mating of Plasmodium, the malaria parasite. We have used high resolution electrospray mass spectrometry to determine that this gamete activation factor (GAF) has a m/z = 205.0450, suggesting a molecular species composition of C10H7NO4. Xanthurenic acid (XA), a product of tryptophan catabolism, was determined to have an elemental composition, ultraviolet absorbance maxima, and mass spectrum consistent with those characteristics of GAF. XA activated gametogenesis of Plasmodium gallinaceum and P. falciparum in vitro at concentrations lower than 0.5 mu M in saline buffered to pH 7.4. A structural analog of XA, kynurenic acid (C10H6NO3), also activated gametogenesis but only at higher concentrations and with less effect. We propose that XA is GAF, This is the first evidence that XA has induction activity.	Walter Reed Army Med Ctr, Dept Biochem & Entomol, Washington, DC 20307 USA; Ctr Dis Control & Prevent, Atlanta, GA 30341 USA	United States Department of Defense; United States Army; Walter Reed National Military Medical Center; Centers for Disease Control & Prevention - USA	Rosenberg, R (corresponding author), Walter Reed Army Med Ctr, Dept Biochem & Entomol, Washington, DC 20307 USA.							AIKAWA M, 1984, J PROTOZOOL, V31, P403, DOI 10.1111/j.1550-7408.1984.tb02987.x; Garcia GE, 1997, MOL BIOCHEM PARASIT, V88, P127, DOI 10.1016/S0166-6851(97)00086-8; KAWAMOTO F, 1993, EUR J CELL BIOL, V60, P101; Kayser H., 1985, P367; KESSLER M, 1989, J NEUROCHEM, V52, P1319, DOI 10.1111/j.1471-4159.1989.tb01881.x; Liu MS, 1996, CLIN CHEM, V42, P397; NIJHOUT MM, 1979, EXP PARASITOL, V48, P75, DOI 10.1016/0014-4894(79)90056-0; OGWANG R, 1993, BIOCHEM PHARMACOL, V46, P1601, DOI 10.1016/0006-2952(93)90329-U; Sinden RE, 1996, ADV PARASIT, V38, P53, DOI 10.1016/S0065-308X(08)60033-0; TRUSCOTT RJW, 1995, CLIN SCI, V89, P591, DOI 10.1042/cs0890591; Williamson KC, 1996, MOL BIOCHEM PARASIT, V78, P161, DOI 10.1016/S0166-6851(96)02621-7	11	112	118	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12003	12005		10.1074/jbc.273.20.12003	http://dx.doi.org/10.1074/jbc.273.20.12003			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575140	hybrid			2022-12-27	WOS:000073629800005
J	Brady, MJ; Bourbonais, FJ; Saltiel, AR				Brady, MJ; Bourbonais, FJ; Saltiel, AR			The activation of glycogen synthase by insulin switches from kinase inhibition to phosphatase activation during adipogenesis in 3T3-L1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; SKELETAL-MUSCLE; PHOSPHOINOSITIDE 3-KINASE; GLUCOSE-UPTAKE; GROWTH-FACTOR; ADIPOCYTES; STIMULATION; PHOSPHORYLATION; WORTMANNIN; EXPRESSION	The effects of insulin and platelet-derived growth factor (PDGF) on glycogen synthase activation were compared in 3T3-L1 fibroblasts and adipocytes, In the fibroblasts, PDGF elicited a stronger phosphorylation of mitogen-activated protein kinase (MAPK) and AKT than did insulin. Both agents caused a comparable stimulation of receptor autophosphorylation, MAPK, and phosphatidylinositol 3-kinase (PI3-K) activation in the adipocytes, However, adipogenesis resulted in the uncoupling of PI3-K activation by PDGF from subsequent AKT phosphorylation, The relative contributions of glycogen synthase kinase-3 (GSK-3) inactivation and protein phosphatase-1 (PP1) activation in the regulation of glycogen synthase in both cell types were evaluated. Insulin and PDGF caused a small increase in glycogen synthase a activity in the fibroblasts, Additionally, both agents caused a similar inhibition of GSK-3, while having no effect on PP1 activity. Following differentiation, insulin treatment resulted in a 5-fold stimulation of glycogen synthase, whereas PDGF was without effect. Both agents caused a comparable inhibition of GSK-3 activity in the adipocytes, whereas only insulin activated PP1. Finally, wortmannin completely blocked the stimulation of PP1 by insulin in 3T3-L1 adipocytes, indicating that PI3-K inhibition can impinge on PP1 activation. Cumulatively these results suggest that the weak activation of glycogen synthase in 3T3-L1 fibroblasts is mediated by GSK-3 inactivation, whereas in the more metabolically active adipocytes, the insulin-specific activation of glycogen synthase is mediated by PP1 activation.	Warner Lambert Parke Davis, Parke Davis Pharmaceut Res Div, Dept Cell Biol, Ann Arbor, MI 48105 USA; Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA	Pfizer; University of Michigan System; University of Michigan	Saltiel, AR (corresponding author), Warner Lambert Parke Davis, Parke Davis Pharmaceut Res Div, Dept Cell Biol, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.		Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828				BENJAMIN WB, 1994, BIOCHEM J, V300, P477, DOI 10.1042/bj3000477; BORTHWICK AC, 1995, BIOCHEM BIOPH RES CO, V210, P738, DOI 10.1006/bbrc.1995.1721; Brady MJ, 1997, J BIOL CHEM, V272, P29698, DOI 10.1074/jbc.272.47.29698; Brady MJ, 1997, J BIOL CHEM, V272, P20198, DOI 10.1074/jbc.272.32.20198; Cohen P, 1997, FEBS LETT, V410, P3, DOI 10.1016/S0014-5793(97)00490-0; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; Cross DAE, 1997, FEBS LETT, V406, P211, DOI 10.1016/S0014-5793(97)00240-8; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; EldarFinkelman H, 1996, P NATL ACAD SCI USA, V93, P10228, DOI 10.1073/pnas.93.19.10228; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; Hurel SJ, 1996, BIOCHEM J, V320, P871, DOI 10.1042/bj3200871; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Lawrence JC, 1997, DIABETES, V46, P541, DOI 10.2337/diabetes.46.4.541; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; MOULE SK, 1995, BIOCHEM J, V311, P595, DOI 10.1042/bj3110595; Nave BT, 1996, BIOCHEM J, V318, P55, DOI 10.1042/bj3180055; Ricort JM, 1996, EUR J BIOCHEM, V239, P17, DOI 10.1111/j.1432-1033.1996.0017u.x; SAKAUE H, 1995, J BIOL CHEM, V270, P11304, DOI 10.1074/jbc.270.19.11304; Saltiel AR, 1996, AM J PHYSIOL-ENDOC M, V270, pE375, DOI 10.1152/ajpendo.1996.270.3.E375; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; Shulman RG, 1996, P NATL ACAD SCI USA, V93, P7491, DOI 10.1073/pnas.93.15.7491; SKURAT AV, 1995, J BIOL CHEM, V270, P12491, DOI 10.1074/jbc.270.21.12491; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; Welsh GI, 1997, ANAL BIOCHEM, V244, P16, DOI 10.1006/abio.1996.9838; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442	32	101	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14063	14066		10.1074/jbc.273.23.14063	http://dx.doi.org/10.1074/jbc.273.23.14063			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603900	hybrid			2022-12-27	WOS:000074021500002
J	Hirabayashi, J; Dutta, SK; Kasai, K				Hirabayashi, J; Dutta, SK; Kasai, K			Novel galactose-binding proteins in annelida - Characterization of 29-kDa tandem repeat-type lectins from the earthworm Lumbricus terrestris	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; AMINO-ACID-SEQUENCE; ANIMAL LECTINS; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; SERINE-PROTEASE; CDNA CLONING; RICIN; PURIFICATION; GALECTIN	Novel type lectins were found in the phylum Annelida, i.e. in the earthworm, tubifex, leech, and lugworm. The lectins (29-31 kDa) were extracted from the worms without the use of detergent and purified by affinity chromatography on asialofetuin-agarose. On the basis of the partial primary structures of the earthworm Lumbricus terrestris 29-kDa lectin (EW29), degenerate primers were synthesized for use in the reverse transcriptase-polymerase chain reaction. An amplified 155-base pair fragment was used to screen a cDNA library. Four types of full-length clones were obtained, all of which encoded 260 amino acids, but which were found to differ at 29 nucleotide positions. Since three of them resulted in non-silent substitutions, EW29 mRNA was considered to be a mixture of at least three distinct polynucleotides encoding the following proteins: Ala(44)-Gln(191)-Ile(213) (clone 5), Gly(44)-Gln(197)-Val(213) (clone 7) and Ala(44)-His(197)-Ile(213) (clones 8 and 9; different at the nucleotide level, but encoding an identical polypeptide). Genomic polymerase chain reaction using DNA hom a single worm revealed that the single worm already had four sets of cDNAs. The EW29 protein showed two features. First, the lectin was composed of two homologous domains (14,500 Da) showing 27% identity with each other. When each of the domains was separately expressed in Escherichia coli, the C-terminal domain was found to bind to asialofetuin-agarose as strongly as the whole protein, whereas the N-terminal domain did not bind and only retardation was observed. EW29 was found to exist as st monomer under non-denaturing conditions. It had significant hemagglutinating activity, which was inhibited by a wide range of galactose-containing saccharides. Second, EW29 contained multiple short conserved motifs, "GBy-X-X-X-Gln-X-Trp." Similar motifs have been found in many carbohydrate-recognizing proteins from an extensive variety of organisms, e.g. plant lectin ricin B-chain and Clostridium botulinum 33-kDa hemagglutinin, Therefore, these carbohydrate-recognition proteins appear to form a protein superfamily.	Teikyo Univ, Fac Pharmaceut Sci, Dept Biol Chem, Sagamiko, Kanagawa 1990195, Japan	Teikyo University	Hirabayashi, J (corresponding author), Teikyo Univ, Fac Pharmaceut Sci, Dept Biol Chem, Sagamiko, Kanagawa 1990195, Japan.	j-hira@pharm.teikyo-u.ac.jp						Arata Y, 1996, HISTOCHEM J, V28, P201, DOI 10.1007/BF02331444; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; BLAKE C, 1983, NATURE, V306, P535, DOI 10.1038/306535a0; CHIU ML, 1992, J CELL BIOL, V119, P1689, DOI 10.1083/jcb.119.6.1689; COLE RN, 1994, J NEUROCHEM, V63, P66; COLE RN, 1994, J NEUROCHEM, V63, P75; Cooper DNW, 1997, J BIOL CHEM, V272, P1514, DOI 10.1074/jbc.272.3.1514; DEWAARD A, 1976, J BIOL CHEM, V251, P7581; Doyle R. J., 1994, P1; GABIUS HJ, 1992, ANTICANCER RES, V12, P669; GO M, 1981, NATURE, V291, P90, DOI 10.1038/291090a0; HAKOMORI SI, 1992, HISTOCHEM J, V24, P771, DOI 10.1007/BF01046348; Hirabayashi J, 1996, Q REV BIOL, V71, P365, DOI 10.1086/419443; HIRABAYASHI J, 1992, J BIOL CHEM, V267, P15485; Hirabayashi J, 1996, J BIOL CHEM, V271, P2497, DOI 10.1074/jbc.271.5.2497; HIRABAYASHI J, 1984, BIOCHEM BIOPH RES CO, V122, P938, DOI 10.1016/0006-291X(84)91181-1; HIRABAYASHI J, 1987, J BIOCHEM-TOKYO, V101, P775, DOI 10.1093/jb/101.3.775; HIRABAYASHI J, 1997, TRENDS GLYCOSCI GLYC, V9; HIRABAYASHI J, 1993, LECTINS GLYCOBIOLOGY, P474; HUGHES RC, 1994, GLYCOBIOLOGY, V4, P5, DOI 10.1093/glycob/4.1.5; Kaku H, 1996, J BIOL CHEM, V271, P1480, DOI 10.1074/jbc.271.3.1480; Kasai K, 1996, J BIOCHEM-TOKYO, V119, P1; KLION AD, 1994, MOL BIOCHEM PARASIT, V65, P305, DOI 10.1016/0166-6851(94)90081-7; Kolatkar AR, 1996, J BIOL CHEM, V271, P6679, DOI 10.1074/jbc.271.12.6679; LAMB FI, 1985, EUR J BIOCHEM, V148, P265, DOI 10.1111/j.1432-1033.1985.tb08834.x; MATSUI T, 1984, BIOL BULL, V166, P178, DOI 10.2307/1541440; MONTFORT W, 1987, J BIOL CHEM, V262, P5398; MOREMEN KW, 1994, GLYCOBIOLOGY, V4, P113, DOI 10.1093/glycob/4.2.113; Newton SE, 1997, MOL BIOCHEM PARASIT, V86, P143, DOI 10.1016/S0166-6851(97)02834-X; NOWAK TP, 1976, BIOCHEM BIOPH RES CO, V68, P650, DOI 10.1016/0006-291X(76)91195-5; ODA T, 1994, J BIOL CHEM, V269, P22925; Ozeki Y, 1997, COMP BIOCHEM PHYS B, V118, P1, DOI 10.1016/S0305-0491(97)00014-X; PFEIFER K, 1993, GLYCOBIOLOGY, V3, P179, DOI 10.1093/glycob/3.2.179; READY M, 1984, J BIOL CHEM, V259, P5252; RINI JM, 1995, ANNU REV BIOPH BIOM, V24, P551, DOI 10.1146/annurev.biophys.24.1.551; ROBERTS LM, 1985, J BIOL CHEM, V260, P5682; Rojo MA, 1997, ARCH BIOCHEM BIOPHYS, V340, P185, DOI 10.1006/abbi.1997.9927; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SEKI N, 1994, J BIOL CHEM, V269, P1370; SHARECK F, 1991, GENE, V107, P75, DOI 10.1016/0378-1119(91)90299-Q; SHEN SH, 1991, J BIOL CHEM, V266, P1058; SHIMOI H, 1992, J BIOL CHEM, V267, P25189; SPECK JC, 1958, ADV CARBOHYD CHEM, V13, P63; Tai MH, 1996, J COMP NEUROL, V371, P235, DOI 10.1002/(SICI)1096-9861(19960722)371:2<235::AID-CNE4>3.0.CO;2-3; TRIMBLE RB, 1995, TRENDS GLYCOSCI GLYC, V7, P1, DOI 10.4052/tigg.7.1; TSUZUKI K, 1990, INFECT IMMUN, V58, P3173, DOI 10.1128/IAI.58.10.3173-3177.1990; WOOD KA, 1991, EUR J BIOCHEM, V198, P723, DOI 10.1111/j.1432-1033.1991.tb16072.x	47	78	82	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14450	14460		10.1074/jbc.273.23.14450	http://dx.doi.org/10.1074/jbc.273.23.14450			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603958	hybrid			2022-12-27	WOS:000074021500060
J	Ward, DG; Cavieres, JD				Ward, DG; Cavieres, JD			Photoinactivation of fluorescein isothiocyanate-modified Na,K-ATPase by 2 '(3 ')-O-(2,4,6-trinitrophenyl)8-azidoadenosine 5 '-diphosphate - Abolition of E1 and E2 partial reactions by sequential block of high and low affinity nucleotide sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; TRANSPORT ADENOSINE-TRIPHOSPHATASE; ATP BINDING DOMAIN; (NA+ + K+)-ATPASE; ACTIVE-SITE; SARCOPLASMIC-RETICULUM; INORGANIC-PHOSPHATE; SUBSTRATE SITES; CATALYTIC SITE; NA+/K+-ATPASE	The Na,K-ATPase activity of the sodium pump exhibits apparent multisite kinetics toward ATP, a feature that is inherent to the minimal enzyme unit, the alpha beta protomer. We have argued that this should arise from separate catalytic and noncatalytic sites on the alpha beta protomer as fluorescein isothiocyanate (FITC) blocks a high affinity ATP site on all alpha subunits and yet the modified Na,K-ATPase retains a low affinity response to nucleotides (Ward, D. G., and Cavieres, J. D. (1996) J. Biol, Chem. 271, 12317-12321), We now find that 2'(3')-O-(2,4,6-trinitrophenyl)8-azido-adenosine 5'-diphosphate (TNP-8N(3)-ADP), a high affinity photoactivatable analogue of ATP, can inhibit the K+-phosphatase activity of the FITC-modified enzyme during assays in dimmed light. The inhibition occurs with a K-i of 140 mu M at 20 mM K+; it requires the adenine ring as 2'(3')-O-(2,4 B-trinitrophenyl) (TNP)-UDP or TNP-uridine are less potent and 2,4,6-trinitrobenzene-sulfonate is ineffective. Under irradiation with UV light, TNP-8N(3)-ADP inactivates the K+-phosphatase activity of the fluorescein-enzyme and also its phosphorylation by [P-32]P-i. The photoinactivation process is stimulated by Na+ or Mg2+, and is inhibited by K+ or excess TNP-ADP. In the presence of 50 mM Na+ and 1 mM Mg2+, TNP-8N(3)-ADP photoinactivates with a K-0.5 of 15 mu M. Furthermore, TNP-8N(3)-ADP photoinactivates the FITC-modified, solubilized alpha beta protomers, even more effectively than the membrane-bound fluorescein-enzyme, These results strongly suggest that catalytic and allosteric ATP sites coexist on the alpha beta protomer of Na,K-ATPase.	Univ Leicester, Dept Cell Physiol & Pharmacol, Transport ATPase Lab, Leicester LE1 9HN, Leics, England	University of Leicester	Cavieres, JD (corresponding author), Univ Leicester, Dept Cell Physiol & Pharmacol, Transport ATPase Lab, Leicester LE1 9HN, Leics, England.	jdc7@le.ac.uk		Ward, Douglas/0000-0002-2328-1445	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABBOTT AJ, 1991, BIOCHEMISTRY-US, V30, P1692, DOI 10.1021/bi00220a035; ASKARI A, 1984, J BIOL CHEM, V259, P4169; ASKARI A, 1988, J BIOL CHEM, V263, P235; ASKARI A, 1987, J BIOENERG BIOMEMBR, V19, P359, DOI 10.1007/BF00768539; BROTHERUS JR, 1981, BIOCHEM BIOPH RES CO, V100, P146, DOI 10.1016/S0006-291X(81)80075-7; BUXBAUM E, 1991, EUR J BIOCHEM, V195, P407, DOI 10.1111/j.1432-1033.1991.tb15720.x; CARILLI CT, 1982, J BIOL CHEM, V257, P5601; CAVIERES JD, 1987, FEBS LETT, V225, P145, DOI 10.1016/0014-5793(87)81147-X; DAVIS RL, 1988, BIOCHIM BIOPHYS ACTA, V953, P26, DOI 10.1016/0167-4838(88)90006-4; Dixon M., 1979, ENZYMES, Vthird; ELLISDAVIES GCR, 1993, J BIOL CHEM, V268, P11622; ELLISDAVIES GCR, 1990, J BIOL CHEM, V265, P20570; FARLEY RA, 1984, J BIOL CHEM, V259, P9532; Fiske CH, 1925, J BIOL CHEM, V66, P375; FLETTERICK RJ, 1975, P NATL ACAD SCI USA, V72, P38, DOI 10.1073/pnas.72.1.38; FORBUSH B, 1987, J BIOL CHEM, V262, P11104; GLYNN IM, 1982, J PHYSIOL-LONDON, V330, P17, DOI 10.1113/jphysiol.1982.sp014326; HALEY BE, 1974, P NATL ACAD SCI USA, V71, P3367, DOI 10.1073/pnas.71.9.3367; HASENAUER J, 1993, J BIOL CHEM, V268, P3289; HUANG W, 1984, J BIOL CHEM, V259, P3287; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; KANAZAWA T, 1970, J BIOCHEM-TOKYO, V67, P693, DOI 10.1093/oxfordjournals.jbchem.a129297; KAPLAN JH, 1982, ANN NY ACAD SCI, V402, P292, DOI 10.1111/j.1749-6632.1982.tb25750.x; KARLISH SJD, 1974, ANN NY ACAD SCI, V242, P461, DOI 10.1111/j.1749-6632.1974.tb19110.x; KARLISH SJD, 1980, J BIOENERG BIOMEMBR, V12, P111, DOI 10.1007/BF00744678; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P4566, DOI 10.1073/pnas.87.12.4566; KAWAKAMI K, 1985, NATURE, V316, P733, DOI 10.1038/316733a0; KAYA SJ, 1994, J BIOL CHEM, V269, P7419; KITZ R, 1962, J BIOL CHEM, V237, P3245; KNOWLES JR, 1972, ACCOUNTS CHEM RES, V5, P155, DOI 10.1021/ar50052a006; KOEPSELL H, 1982, J BIOL CHEM, V257, P733; LINNERTZ H, 1995, EUR J BIOCHEM, V232, P420, DOI 10.1111/j.1432-1033.1995.tb20827.x; Liu LQ, 1997, J BIOL CHEM, V272, P14380, DOI 10.1074/jbc.272.22.14380; MCINTOSH DB, 1992, J BIOL CHEM, V267, P5301; MOCZYDLOWSKI EG, 1981, J BIOL CHEM, V256, P2357; NEUFELD AH, 1969, J BIOL CHEM, V244, P6493; OHTA T, 1986, P NATL ACAD SCI USA, V83, P2071, DOI 10.1073/pnas.83.7.2071; OTTOLENGHI P, 1983, BIOCHIM BIOPHYS ACTA, V727, P89, DOI 10.1016/0005-2736(83)90372-3; OVCHINNIKOV YA, 1987, FEBS LETT, V217, P111, DOI 10.1016/0014-5793(87)81253-X; PELUFFO RD, 1994, J BIOL CHEM, V269, P1051; PLAPP BV, 1996, CONT ENZYME KINETICS, P259; POST RL, 1975, J BIOL CHEM, V250, P691; POST RL, 1972, J BIOL CHEM, V247, P6530; ROBINSON JD, 1976, BIOCHIM BIOPHYS ACTA, V429, P1006, DOI 10.1016/0005-2744(76)90345-4; SCHEINERBOBIS G, 1993, BIOCHEMISTRY-US, V32, P9592, DOI 10.1021/bi00088a011; SCHEINERBOBIS G, 1985, EUR J BIOCHEM, V153, P739; SEEBREGTS CJ, 1989, J BIOL CHEM, V264, P2043; SHULL GE, 1986, NATURE, V321, P429, DOI 10.1038/321429a0; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SIEGEL GJ, 1972, J BIOL CHEM, V247, P3630; SIMONS TJB, 1975, J PHYSIOL-LONDON, V244, P731, DOI 10.1113/jphysiol.1975.sp010822; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITH RL, 1980, J BIOL CHEM, V255, P9852; TANIGUCHI K, 1988, J BIOL CHEM, V263, P12943; TRAN CM, 1994, J BIOL CHEM, V269, P6558; TRAN CM, 1994, BIOCHEMISTRY-US, V33, P4140, DOI 10.1021/bi00180a006; Tsuda T, 1998, J BIOCHEM, V123, P169; Ward DG, 1996, J BIOL CHEM, V271, P12317, DOI 10.1074/jbc.271.21.12317; WARD DG, 1993, P NATL ACAD SCI USA, V90, P5332, DOI 10.1073/pnas.90.11.5332; Ward DG, 1997, J PHYSIOL-LONDON, V504P, pP35; WASSARMAN PM, 1971, J MOL BIOL, V60, P509, DOI 10.1016/0022-2836(71)90185-9; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324; XU KY, 1989, BIOCHEMISTRY-US, V28, P5764, DOI 10.1021/bi00440a010; YAMAZAKI A, 1994, J BIOCHEM, V116, P1360, DOI 10.1093/oxfordjournals.jbchem.a124688	64	25	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14277	14284		10.1074/jbc.273.23.14277	http://dx.doi.org/10.1074/jbc.273.23.14277			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603934	hybrid			2022-12-27	WOS:000074021500036
J	Hsu, TC; Shore, SK; Seshsmma, T; Bagasra, O; Walsh, PN				Hsu, TC; Shore, SK; Seshsmma, T; Bagasra, O; Walsh, PN			Molecular cloning of platelet factor XI, an alternative splicing product of the plasma factor XI gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-COAGULATION FACTOR; POLYMERASE CHAIN-REACTION; ACTIVATED FACTOR-XI; FACTOR-IX; THROMBOPLASTIN ANTECEDENT; BINDING-SITE; PURIFICATION; DNA; AMPLIFICATION; MECHANISM	Platelet factor XI is associated with the platelet plasma membrane and has an apparent M-r (220,000 nonreduced, 55,000 reduced) different from that of plasma factor XI, However, the site of synthesis and the nature of platelet factor XI are not known. Using reverse transcriptase polymerase chain reaction, 12 out of 13 exons (all except exon V) coding for mature plasma factor XI: were amplified from human platelet mRNA, The sequence of each of these exons was identical to that of plasma factor XI, In situ amplification and hybridization of factor XI mRNA was positive for exon III and negative for exon V in platelets and negative for both exons in other blood cells. By Northern hybridization, a factor XI mRNA transcript of similar to 1.9 kilobases was detected in megakaryocytic cells, and one of similar to 2.1 kilobases was detected in liver cells. Factor XI cDNA was cloned from a megakaryocyte library and sequenced. Exon V was absent, and the splicing of exon IV to exon VI maintained the open reading frame without alteration of the amino acid sequence except for the deletion of amino acids Ala(91)-Arg(144) within the amino-terminal portion of the Apple 2 domain. Thus, platelet factor XI is an alternative splicing product of the factor XI gene, localized to platelets and megakaryocytes but absent from other blood cells.	Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Med, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Thomas Jefferson Univ, Mol Retrovirol Labs, Philadelphia, PA 19107 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Jefferson University	Walsh, PN (corresponding author), Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, 3400 N Broad St, Philadelphia, PA 19140 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055407, R01HL056153, R01HL046213] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56153, HL55407, HL46213] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMAD SS, 1989, J BIOL CHEM, V264, P20012; ASAKAI R, 1987, BIOCHEMISTRY-US, V26, P7221, DOI 10.1021/bi00397a004; ASAKAI R, 1991, NEW ENGL J MED, V325, P153, DOI 10.1056/NEJM199107183250303; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BAGASRA O, 1993, J IMMUNOL METHODS, V158, P131, DOI 10.1016/0022-1759(93)90265-9; BAGLIA FA, 1991, J BIOL CHEM, V266, P24190; BOUMA BN, 1977, J BIOL CHEM, V252, P6432; BRAY PF, 1990, J BIOL CHEM, V265, P9587; CHELLY J, 1991, J CLIN INVEST, V88, P1161, DOI 10.1172/JCI115417; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUGMAN DA, 1990, BLOOD, V75, P1252; FUJIKAWA K, 1974, BIOCHEMISTRY-US, V13, P4508, DOI 10.1021/bi00719a006; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; IWAMOTO S, 1994, BLOOD, V83, P1017; JOHNSTON GI, 1990, J BIOL CHEM, V265, P21381; KOMIYAMA Y, 1993, THROMB HAEMOSTASIS, V69, P1238; KURACHI K, 1977, BIOCHEMISTRY-US, V16, P5831, DOI 10.1021/bi00645a030; LIPSCOMB MS, 1979, J CLIN INVEST, V63, P1006, DOI 10.1172/JCI109368; NAITO K, 1991, J BIOL CHEM, V266, P7353; NEWMAN PJ, 1988, J CLIN INVEST, V82, P739, DOI 10.1172/JCI113656; OSTERUD B, 1978, J BIOL CHEM, V253, P5946; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; RAGNI MV, 1985, BLOOD, V65, P719; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIFFMAN S, 1990, THROMB RES, V60, P87, DOI 10.1016/0049-3848(90)90343-B; SCHIFFMAN S, 1977, BRIT J HAEMATOL, V35, P429, DOI 10.1111/j.1365-2141.1977.tb00603.x; Sun YH, 1996, J BIOL CHEM, V271, P29023, DOI 10.1074/jbc.271.46.29023; TUSZYNSKI GP, 1982, BLOOD, V59, P1148; WALSH PN, 1972, BRIT J HAEMATOL, V22, P393, DOI 10.1111/j.1365-2141.1972.tb05687.x; WALSH PN, 1975, BRIT J HAEMATOL, V29, P639, DOI 10.1111/j.1365-2141.1975.tb02750.x; WALSH PN, 1974, BLOOD, V43, P597, DOI 10.1182/blood.V43.4.597.597; WALSH PN, 1972, BRIT J HAEMATOL, V22, P205, DOI 10.1111/j.1365-2141.1972.tb08801.x; WALSH PN, 1972, BRIT J HAEMATOL, V22, P743, DOI 10.1111/j.1365-2141.1972.tb05719.x; Zieger B, 1997, J CLIN INVEST, V99, P520, DOI 10.1172/JCI119188	35	40	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13787	13793		10.1074/jbc.273.22.13787	http://dx.doi.org/10.1074/jbc.273.22.13787			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593722	hybrid			2022-12-27	WOS:000073919100061
J	Ryan, RR; Weber, HC; Hou, W; Sainz, E; Mantey, SA; Battey, JF; Coy, DH; Jensen, RT				Ryan, RR; Weber, HC; Hou, W; Sainz, E; Mantey, SA; Battey, JF; Coy, DH; Jensen, RT			Ability of various bombesin receptor agonists and antagonists to alter intracellular signaling of the human orphan receptor BRS-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; GASTRIN-RELEASING PEPTIDE; PROTEIN-KINASE-C; NEUROMEDIN-B RECEPTORS; STIMULATE TYROSINE PHOSPHORYLATION; NUCLEOTIDE-BINDING PROTEINS; LUNG-CARCINOMA CELLS; SMOOTH-MUSCLE CELLS; ADENYLATE-CYCLASE; ANGIOTENSIN-II	Bombesin (Bn) receptor subtype 3 (BRS-3) is an orphan receptor that is a predicted member of the hepta-helical G-protein receptor family and so named because it shares a 50% amino acid homology with receptors for the mammalian bombesin-like peptides neuromedin B (NMB) and gastrin-releasing peptide. In a recent targeted disruption study, in which BRS-3-deficient mice were generated, the mice developed obesity, diabetes, and hypertension. To date, BRS-3's natural ligand remains unknown, its pharmacology unclear, and cellular basis of action undetermined. Furthermore, there are few tissues or cell lines found that express sufficient levels of BRS-3 protein for study. To define the intracellular signaling properties of BRS-3, we examined the ability of [D-Phe(6),beta-Ala(11),Phe(13),Nle(14)]Bn-(6-14), a newly discovered peptide with high affinity for BRS-3, and various Bn receptor agonists and antagonists to alter cellular function in hBRS-3-transfected BALB 3T3 cells and hBRS-3-transfected NCI-H1299 non-small cell lung cancer cells, which natively express very low levels of hBRS-3. This ligand stimulated a 4-9-fold increase in [H-3]inositol phosphate formation in both cell lines under conditions where it caused no stimulation in untransfected cells and also stimulated an increase in [H-3]IP1, [H-3]IP2, and H-3]IP3. The elevation of [H-3]IP was concentration dependent, with an EC50 of 20-35 nM in both cell lines. [D-Phe(6),beta-Ala(11),Phe(13),Nle(14)]Bn-(6-14) stimulated a 2-3-fold increase in [Ca2+](i), a 3-fold increase in tyrosine phosphorylation of p125(FAK) with an EC50 of 0.2-0.7 nm, but failed to either stimulate increases in cyclic AMP or inhibit forskolin-stimulated increases. None of nine naturally occurring Bn peptides or three synthetic Bn analogues reported to activate hBRS-3 did so with high affinity. No high affinity Bn receptor antagonists had high affinity for the hBRS-3 receptor, although two low affinity antagonists for gastrin-releasing peptide and NMB receptors, [D-Arg(1),n-Trp(7,9),Leu(11)]substance P and [D.Pro(4),D-Trp(7,9,10)]substance P-(4-11), inhibited hBRS-3 receptor activation. The NMB receptor-specific antagonist D-Nal,Cys,Tyr,D-Trp,Lys,Val, Cys,Nal-NH2 inhibited hBRS-3 receptor activation in a competitive fashion (K-i = 0.5 mu M) Stimulation of p125(FAK) tyrosine phosphorylation by hBRS-3 activation was not inhibited by the protein kinase C inhibitor, GF109203X, or thapsigargin, alone or in combination. These results show that hBRS-3 receptor activation increases phospholipase C activity, which causes generation of inositol phosphates and changes in [Ca2+](i) and is also coupled to tyrosine kinase activation, but is not coupled to adenylate cyclase activation or inhibition. hBRS-3 receptor activation results in tyrosine phosphorylation of p125(FAK) and it is not dependent on activation of either limb of the phospholipase C cascade. Although the natural ligand is not a known bombesin-related peptide, the availability of [D-Phe(6),beta-Ala(11),Phe(13),Nle(14)]Bn-(6-14), which functions as a high affinity agonist in conjunction with hBRS-3-transfected cell lines and the recognition of three classes of receptor antagonists including one with affinity of 0. 5 mu M, should provide important tools to assist in the identification of its natural ligand, the development of more potent selective receptor antagonists and agonists, and further exploration of the signaling properties of the hBRS-3 receptor.	NIDDK, NIH, Digest Dis Branch, Bethesda, MD 20892 USA; NIDCD, NIH, Rockville, MD 20892 USA; Tulane Univ, Med Ctr, Peptide Res Labs, New Orleans, LA 70112 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); Tulane University	Jensen, RT (corresponding author), NIDDK, NIH, Digest Dis Branch, Bldg 10,Rm 9C-103,10 Ctr Dr,MSC 1804, Bethesda, MD 20892 USA.			Weber, Horst Christian/0000-0001-9005-6988				ALBERS HE, 1991, J NEUROSCI, V11, P846; BATTEY J, 1991, TRENDS NEUROSCI, V14, P524, DOI 10.1016/0166-2236(91)90005-F; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BENYA RV, 1992, MOL PHARMACOL, V42, P1058; BENYA RV, 1994, MOL PHARMACOL, V46, P235; BENYA RV, 1994, J BIOL CHEM, V269, P11721; BENYA RV, 1995, MOL PHARMACOL, V47, P10; BOLOGNA M, 1989, CANCER, V63, P1714; BROWN MR, 1988, ANN NY ACAD SCI, V547, P174, DOI 10.1111/j.1749-6632.1988.tb23885.x; BUNNETT N, 1994, GUT PEPTIDES BIOCH P, P423; CORJAY MH, 1991, J BIOL CHEM, V266, P18771; COY DH, 1988, J BIOL CHEM, V263, P5056; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; Davis LG, 1994, BASIC METHODS MOL BI; DELAFUENTE M, 1993, J NEUROIMMUNOL, V48, P143, DOI 10.1016/0165-5728(93)90186-3; DELVALLE J, 1992, AM J PHYSIOL, V263, pG967; DEUTSCH PJ, 1992, J BIOL CHEM, V267, P5108; EGUCHI S, 1993, ENDOCRINOLOGY, V132, P524, DOI 10.1210/en.132.2.524; ENDO T, 1991, J ENDOCRINOL, V131, P313, DOI 10.1677/joe.0.1310313; FATHI Z, 1993, J BIOL CHEM, V268, P5979; Fathi Z, 1996, J CELL BIOCHEM, P237; FORCE T, 1991, J BIOL CHEM, V266, P6650; Garcia LJ, 1997, BIOCHEM J, V327, P461; Garcia LJ, 1997, BBA-MOL CELL RES, V1356, P343, DOI 10.1016/S0167-4889(97)00007-4; GHATEI MA, 1982, J CLIN ENDOCR METAB, V54, P980, DOI 10.1210/jcem-54-5-980; GORBULEV V, 1992, EUR J BIOCHEM, V208, P405, DOI 10.1111/j.1432-1033.1992.tb17201.x; GORBULEV V, 1994, FEBS LETT, V340, P260, DOI 10.1016/0014-5793(94)80150-9; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HILL DJ, 1992, ENDOCRINOLOGY, V130, P2811, DOI 10.1210/en.130.5.2811; HUCKLE WR, 1992, P NATL ACAD SCI USA, V89, P8837, DOI 10.1073/pnas.89.18.8837; ITOH H, 1993, AM J PHYSIOL, V265, pC1319; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; Jensen Robert T., 1994, P1377; JENSEN RT, 1988, AM J PHYSIOL, V254, pG883, DOI 10.1152/ajpgi.1988.254.6.G883; JENSEN RT, 1988, ANN NY ACAD SCI, V547, P138, DOI 10.1111/j.1749-6632.1988.tb23882.x; JENSEN RT, 1991, TRENDS PHARMACOL SCI, V12, P13, DOI 10.1016/0165-6147(91)90483-9; JENSEN RT, 1984, NATURE, V309, P61, DOI 10.1038/309061a0; KROOG GS, 1995, MED RES REV, V15, P389, DOI 10.1002/med.2610150502; KUSUI T, 1997, GASTROENTEROLOGY, V108, pA984; LACH EB, 1995, CELL GROWTH DIFFER, V6, P1427; LEBAN JJ, 1993, P NATL ACAD SCI USA, V90, P1922, DOI 10.1073/pnas.90.5.1922; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LIN JT, 1995, J PHARMACOL EXP THER, V275, P285; Lin JT, 1995, EUR J PHARMACOL, V294, P55, DOI 10.1016/0014-2999(95)00510-2; Mantey SA, 1997, J BIOL CHEM, V272, P26062, DOI 10.1074/jbc.272.41.26062; Mantey SA, 1997, GASTROENTEROLOGY, V112, pA1168; MCCOY JG, 1990, PEPTIDES, V11, P595, DOI 10.1016/0196-9781(90)90064-C; MILLAR JBA, 1988, J CELL PHYSIOL, V137, P214, DOI 10.1002/jcp.1041370203; Moody TW., 1996, GROWTH FACTORS, P491; Nagalla SR, 1996, J BIOL CHEM, V271, P7731, DOI 10.1074/jbc.271.13.7731; NAGALLA SR, 1995, P NATL ACAD SCI USA, V92, P6205, DOI 10.1073/pnas.92.13.6205; OhkiHamazaki H, 1997, NATURE, V390, P165, DOI 10.1038/36568; ORBUCH M, 1993, MOL PHARMACOL, V44, P841; RAUFMAN JP, 1983, AM J PHYSIOL, V245, pG525, DOI 10.1152/ajpgi.1983.245.4.G525; ROWLEY WH, 1990, AM J PHYSIOL, V259, pG655, DOI 10.1152/ajpgi.1990.259.4.G655; ROZENGURT E, 1988, ANN NY ACAD SCI, V547, P277, DOI 10.1111/j.1749-6632.1988.tb23896.x; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SASAKI Y, 1987, PEPTIDES, V8, P119, DOI 10.1016/0196-9781(87)90174-4; SAVILLE MK, 1994, BIOCHEM J, V301, P407, DOI 10.1042/bj3010407; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schieffer B, 1996, J MOL MED-JMM, V74, P85, DOI 10.1007/BF00196783; SCHILD HO, 1949, BRIT J PHARM CHEMOTH, V4, P277, DOI 10.1111/j.1476-5381.1949.tb00548.x; SCHREY MP, 1992, CANCER RES, V52, P1786; SECKL M, 1993, J BIOL CHEM, V268, P9548; SEGLEN PO, 1989, CARCINOGENESIS, V10, P21, DOI 10.1093/carcin/10.1.21; SEVERI C, 1991, AM J PHYSIOL, V260, pG683, DOI 10.1152/ajpgi.1991.260.5.G683; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; SPINDEL ER, 1990, MOL ENDOCRINOL, V4, P1956, DOI 10.1210/mend-4-12-1956; SUNDAY ME, 1993, ANAT REC, V236, P25, DOI 10.1002/ar.1092360107; TACHE Y, 1988, ANN NY ACAD SCI, V547, P183, DOI 10.1111/j.1749-6632.1988.tb23886.x; THASTRUP O, 1990, AGENTS ACTIONS, V29, P8, DOI 10.1007/BF01964706; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Tsuda T, 1997, MOL PHARMACOL, V51, P721, DOI 10.1124/mol.51.5.721; Tsuda T, 1997, BIOCHEMISTRY-US, V36, P16328, DOI 10.1021/bi971448o; TURNER CE, 1995, J CELL SCI, V108, P333; VIGNA SR, 1987, GASTROENTEROLOGY, V93, P1287, DOI 10.1016/0016-5085(87)90257-5; VONSCHRENCK T, 1990, AM J PHYSIOL, V259, pG468, DOI 10.1152/ajpgi.1990.259.3.G468; VONSCHRENCK T, 1989, AM J PHYSIOL, V256, pG747, DOI 10.1152/ajpgi.1989.256.4.G747; WADA E, 1991, NEURON, V6, P421, DOI 10.1016/0896-6273(91)90250-4; WANG LH, 1990, BIOCHEMISTRY-US, V29, P616, DOI 10.1021/bi00455a004; WANG LH, 1993, BIOCHIM BIOPHYS ACTA, V1175, P232, DOI 10.1016/0167-4889(93)90028-N; WANG LH, 1992, BIOCHEM J, V286, P641, DOI 10.1042/bj2860641; WANG LH, 1990, J BIOL CHEM, V265, P15695; WILLEY JC, 1984, EXP CELL RES, V153, P245, DOI 10.1016/0014-4827(84)90466-X; Williams John A., 1993, P167; Wu JM, 1996, MOL PHARMACOL, V50, P1355; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1991, J BIOL CHEM, V266, P24126; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	91	62	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13613	13624		10.1074/jbc.273.22.13613	http://dx.doi.org/10.1074/jbc.273.22.13613			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593699	hybrid			2022-12-27	WOS:000073919100038
J	Xu, M; Dittmar, KD; Giannoukos, G; Pratt, WB; Simons, SS				Xu, M; Dittmar, KD; Giannoukos, G; Pratt, WB; Simons, SS			Binding of hsp90 to the glucocorticoid receptor requires a specific 7-amino acid sequence at the amino terminus of the hormone-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; DNA-BINDING; FUNCTIONAL HETEROCOMPLEX; EXPRESSION; 90-KDA; REGION; SYSTEM; CDNA; RECONSTITUTION; COMPLEXES	The glucocorticoid receptor (GR) HBD must be bound to the protein chaperone hsp90 in order to acquire the high affinity steroid binding conformation. Despite this crucial role of hsp90, its binding site in GR remains poorly defined. Large portions of the GR HBD have been implicated and no similarity has been established between steroid receptor HBDs and the catalytic domains of the protein kinases (e,g. pp60(src), Raf) that also form stable heterocomplexes with hsp90, Thus, it has been thought that some general property of the proteins, such as exposure of hydrophobic residues in partially denatured regions, determines the assembly of stable hsp90 heterocomplexes, In this work, we have studied fusion proteins containing glutathione S-transferase (GST) and very short amino-terminal truncations just before and at the beginning of the rat GR HBD that are otherwise intact to the carboxyl terminus. Overexpression in COS cells of the chimeras GST537C and GST547C was found to yield receptors that were bound to hsp90 and had wild-type steroid binding affinity. However, removal of 7 more amino acids to form GST554C resulted in a fusion protein that did not bind either hsp90 or steroid. Additional mutations revealed that the role of these 7 amino acids was neither to provide a spacer between protein domains nor to expose a protein surface by introducing a bend in the conserved alpha-helix. Instead, these observations support a model in which the sequence of the 7 amino acids directly or indirectly affects hsp90 binding to the GR HBD. Thus, a region of GB that has not been thought to be relevant for hsp90 binding is now seen to be of critical importance, and these data argue strongly against the commonly accepted model of receptor-hsp90 heterocomplex assembly in which the chaperone initially interacts nonspecifically with hydrophobic regions of the partially denatured HBD and subsequently assists its folding to the steroid binding confirmation.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA; NIDDK, Steroid Hormones Sect, LMCB, NIH, Bethesda, MD 20892 USA	University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Simons, SS (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, Med Sci Res Bldg 3, Ann Arbor, MI 48109 USA.	steroids@helix.nih.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031573, R37DK031573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007767] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK31573] Funding Source: Medline; NIGMS NIH HHS [GM07767] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; CADEPOND F, 1991, J BIOL CHEM, V266, P5834; CHANG CS, 1988, P NATL ACAD SCI USA, V85, P7211, DOI 10.1073/pnas.85.19.7211; DALMAN FC, 1989, J BIOL CHEM, V264, P19815; DALMAN FC, 1991, J BIOL CHEM, V266, P3482; DENIS M, 1988, J BIOL CHEM, V263, P18520; Dittmar KD, 1996, J BIOL CHEM, V271, P12833, DOI 10.1074/jbc.271.22.12833; GREEN S, 1986, EMBO J, V6, P3985; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; HOWARD KJ, 1990, J BIOL CHEM, V265, P11928; HUTCHISON KA, 1992, J BIOL CHEM, V267, P3190; HUTCHISON KA, 1994, J BIOL CHEM, V269, P27894; HUTCHISON KA, 1992, J BIOL CHEM, V267, P14047; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MILHON J, 1994, J STEROID BIOCHEM, V51, P11, DOI 10.1016/0960-0760(94)90110-4; MISRAHI M, 1987, BIOCHEM BIOPH RES CO, V143, P740, DOI 10.1016/0006-291X(87)91416-1; Norris JD, 1997, MOL ENDOCRINOL, V11, P747, DOI 10.1210/me.11.6.747; Picard Didier, 1998, P1; PIERRAT B, 1994, GENE, V143, P193, DOI 10.1016/0378-1119(94)90096-5; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Pratt WB, 1997, ANNU REV PHARMACOL, V37, P297, DOI 10.1146/annurev.pharmtox.37.1.297; PRATT WB, 1988, J BIOL CHEM, V263, P267; PRATT WB, 1993, STEROID HORMONE ACTI, P64; Ruddon RW, 1997, J BIOL CHEM, V272, P3125, DOI 10.1074/jbc.272.6.3125; SCHERRER LC, 1993, BIOCHEMISTRY-US, V32, P5381, DOI 10.1021/bi00071a013; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SCHOWALTER DB, 1991, J BIOL CHEM, V266, P21165; SIMONS SS, 1994, VITAM HORM, V49, P49; SIMONS SS, 1984, BIOCHEMISTRY-US, V23, P6876, DOI 10.1021/bi00321a092; SIMONS SS, 1998, PROG GENE EXPRESS, P35; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; Stancato LF, 1996, BIOCHEMISTRY-US, V35, P554, DOI 10.1021/bi9511649; Stancato LF, 1996, J BIOL CHEM, V271, P8831, DOI 10.1074/jbc.271.15.8831; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; SZAPARY D, 1993, MOL ENDOCRINOL, V7, P941, DOI 10.1210/me.7.8.941; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; Xu M, 1996, J BIOL CHEM, V271, P21430, DOI 10.1074/jbc.271.35.21430; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	41	51	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13918	13924		10.1074/jbc.273.22.13918	http://dx.doi.org/10.1074/jbc.273.22.13918			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593740	hybrid			2022-12-27	WOS:000073919100079
J	Borroto, A; Mallabiabarrena, A; Albar, JP; Martinez-A, C; Alarcon, B				Borroto, A; Mallabiabarrena, A; Albar, JP; Martinez-A, C; Alarcon, B			Characterization of the region involved in CD3 pairwise interactions within the T cell receptor complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TCR-ZETA-CHAINS; ANTIGEN RECEPTOR; SIGNAL TRANSDUCTION; INVARIANT COMPONENTS; IMMATURE THYMOCYTES; CYTOPLASMIC DOMAINS; SURFACE EXPRESSION; CD3-EPSILON; ASSOCIATION; CD3-GAMMA	Assembly of the six-chain T cell antigen receptor-CD3 complex takes place by pairwise interactions. Thus, CD3-epsilon interacts with either CD3-gamma or CD3-delta, and these dimers then associate with the TCR heterodimer (alpha.beta or gamma.delta) and the CD3-zeta homodimer to constitute a full complex. We have now mapped the site in CD3-E responsible for the interaction with CD3-gamma and CD3-delta by analysis of a series of deletional mutants encompassing the most conserved regions. We found that the highly conserved juxtamembrane domain is mainly responsible for the interaction. Thus, deletion of this 16-amino acid extracellular sequence resulted in the inhibition of up to 95% of the CD3-epsilon/gamma interaction. A highly conserved sequence is also present in both CD3-gamma and CD3-delta, suggesting that the domain in these two chains may reciprocally be involved in the interaction with CD3-E, Indeed, an immobilized synthetic peptide corresponding to the CD3-gamma sequence specifically associated to a bacterially expressed CD3-epsilon protein, suggesting the le-amino acid domain is sufficient to promote CD3-epsilon/CD3-gamma assembly. The conservation of the motif in the CD3 chains suggest that, in addition to CD3-epsilon/CD3-gamma and CD3-epsilon/CD3-delta interactions, it may also mediate homotypic interactions. Indeed, it is shown that it mediates the formation of disulfide-linked homodimers and that the formation of homo-and heterodimers are mutually excluded. Finally, this domain contains a Cys-X-X-Cys sequence that resembles that of p56(lck), which is responsible for the interaction with the cytoplasmic tails of CD4 and CD8. Since the replacement of the two cysteines (Cys(97) and Cys(100)) in CD3-epsilon by alanines strongly inhibited pair formation, the existence of a Cys-X-X-Cys motif involved in protein-protein interactions is suggested.	Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain; Ctr Nacl Biotecnol, Dept Immunol & Oncol, Madrid 28049, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Alarcon, B (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.		Alarcon, Balbino/N-9648-2016	Alarcon, Balbino/0000-0001-7820-1070				ALARCON B, 1991, EMBO J, V10, P903, DOI 10.1002/j.1460-2075.1991.tb08023.x; BAUER A, 1991, P NATL ACAD SCI USA, V88, P3842, DOI 10.1073/pnas.88.9.3842; BERNOT A, 1991, P NATL ACAD SCI USA, V88, P2550, DOI 10.1073/pnas.88.6.2550; CAMBIER JC, 1992, CURR OPIN IMMUNOL, V4, P257, DOI 10.1016/0952-7915(92)90074-O; CHAN AC, 1992, CURR OPIN IMMUNOL, V4, P246, DOI 10.1016/0952-7915(92)90072-M; CHIEVERS PT, 1996, EMBO J, V15, P2659; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; Dietrich J, 1996, J CELL BIOL, V132, P299, DOI 10.1083/jcb.132.3.299; EVANS GA, 1988, IMMUNOGENETICS, V28, P365, DOI 10.1007/BF00364236; Gobel TWF, 1997, EUR J IMMUNOL, V27, P194, DOI 10.1002/eji.1830270129; GOLD DP, 1987, P NATL ACAD SCI USA, V84, P7649, DOI 10.1073/pnas.84.21.7649; GROETTRUP M, 1993, CELL, V75, P283, DOI 10.1016/0092-8674(93)80070-U; Hagens G, 1996, GENE, V169, P165, DOI 10.1016/0378-1119(95)00769-5; HALL C, 1991, INT IMMUNOL, V3, P359, DOI 10.1093/intimm/3.4.359; HEIN WR, 1993, IMMUNOGENETICS, V37, P279, DOI 10.1007/BF00187454; JACOBS H, 1994, EUR J IMMUNOL, V24, P934, DOI 10.1002/eji.1830240423; Kirkham PA, 1996, IMMUNOLOGY, V87, P616, DOI 10.1046/j.1365-2567.1996.498566.x; KRISSANSEN GW, 1986, EMBO J, V5, P1799, DOI 10.1002/j.1460-2075.1986.tb04429.x; LEY SC, 1989, EUR J IMMUNOL, V19, P2309, DOI 10.1002/eji.1830191220; MALISSEN B, 1993, CURR OPIN IMMUNOL, V5, P324, DOI 10.1016/0952-7915(93)90049-X; MALLABIABARRENA A, 1992, NATURE, V357, P593, DOI 10.1038/357593a0; MANOLIOS N, 1991, EMBO J, V10, P1643, DOI 10.1002/j.1460-2075.1991.tb07687.x; MCCONAHEY P, 1980, IMMUNOCHEMICAL TEC A, V70, P210; NASH RA, 1991, IMMUNOGENETICS, V33, P396, DOI 10.1007/BF00216700; QIAN DP, 1993, P NATL ACAD SCI USA, V90, P11875, DOI 10.1073/pnas.90.24.11875; RUTLEDGE T, 1992, EMBO J, V11, P3245, DOI 10.1002/j.1460-2075.1992.tb05402.x; SAINTRUF C, 1994, SCIENCE, V266, P1208, DOI 10.1126/science.7973703; SALMERON A, 1991, J IMMUNOL, V147, P3047; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; TUNNACLIFFE A, 1987, EMBO J, V6, P2953, DOI 10.1002/j.1460-2075.1987.tb02600.x; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; WIEST DL, 1995, EMBO J, V14, P3425, DOI 10.1002/j.1460-2075.1995.tb07348.x; WIEST DL, 1994, J EXP MED, V180, P1375, DOI 10.1084/jem.180.4.1375	34	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					12807	12816		10.1074/jbc.273.21.12807	http://dx.doi.org/10.1074/jbc.273.21.12807			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582308	hybrid			2022-12-27	WOS:000073768500019
J	Chen, HY; Sun, JM; Zhang, Y; Davie, JR; Meistrich, ML				Chen, HY; Sun, JM; Zhang, Y; Davie, JR; Meistrich, ML			Ubiquitination of histone H3 in elongating spermatids of rat testes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN MODIFICATION; SPERMATOGENESIS; TRANSCRIPTION; EXPRESSION; VARIANT; H2B; SPERMIOGENESIS; PURIFICATION; ATTACHMENT; ENZYME	Because of the potential role of histone ubiquitination in altering chromatin structure, we characterized the levels of ubiquitination of specific histones in meiotic and postmeiotic germ cells in rat testes by two-dimensional gel electrophoresis, The levels of the major ubiquitinated histone forms, mono-and poly-ubiquitinated H2A, were highest in the pachytene spermatocyte stage, declined thereafter through the round spermatid stage, and reached their lowest levels in elongating spermatids. Three additional ubiquitinated histone species, besides H2A, were detected using anti-ubiquitin antibodies specifically in the fraction enriched in elongating spermatids. Based on their electrophoretic mobilities, they corresponded to uH3, uTH3, and uH2B. Polyubiquitinated forms of these proteins were also observed. The identity of these proteins was confirmed by immunoblotting with anti-H3 antisera and by differential extraction of the proteins from the nucleus with increasing salt concentrations. This is the first report of ubiquitination of H3 in vivo. We speculate that its ubiquitination could loosen the nucleosome structure in preparation for histone removal, be a consequence of nucleosome relaxation or disruption caused by other means, or target H3 for degradation.	Univ Texas, MD Anderson Cancer Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; Univ Manitoba, Dept Biochem & Mol Biol, Winnipeg, MB R3E 0W3, Canada	University of Texas System; UTMD Anderson Cancer Center; University of Manitoba	Meistrich, ML (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Expt Radiat Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.			Davie, James/0000-0002-0420-6888	NCI NIH HHS [CA-16672] Funding Source: Medline; NICHD NIH HHS [HD-16843] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016843] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGELL N, 1983, FEBS LETT, V155, P209, DOI 10.1016/0014-5793(82)80604-2; BHATNAGAR YM, 1983, BIOCHIM BIOPHYS ACTA, V760, P25, DOI 10.1016/0304-4165(83)90120-4; BONNER WM, 1987, UBIQUITIN; DAVIE JR, 1990, BIOCHEMISTRY-US, V29, P4752, DOI 10.1021/bi00472a002; DAVIE JR, 1982, ANAL BIOCHEM, V120, P276, DOI 10.1016/0003-2697(82)90348-7; DAVIE JR, 1994, BIOCHEM BIOPH RES CO, V203, P344, DOI 10.1006/bbrc.1994.2188; DELCUVE GP, 1992, ANAL BIOCHEM, V200, P339, DOI 10.1016/0003-2697(92)90475-M; DELCUVE GP, 1989, BIOCHEM J, V263, P179, DOI 10.1042/bj2630179; GOLDKNOPF IL, 1977, P NATL ACAD SCI USA, V74, P864, DOI 10.1073/pnas.74.3.864; GRIMES SR, 1985, BIOCHIM BIOPHYS ACTA, V824, P128, DOI 10.1016/0167-4781(85)90089-2; HAAS A, 1990, J BIOL CHEM, V265, P21664; HENDRIKSEN PJM, 1995, DEV BIOL, V170, P730, DOI 10.1006/dbio.1995.1252; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Kistler WS, 1996, EXP CELL RES, V225, P374, DOI 10.1006/excr.1996.0188; Koken MHM, 1996, DEV BIOL, V173, P119, DOI 10.1006/dbio.1996.0011; LEBLOND CP, 1952, ANN NY ACAD SCI, V55, P548, DOI 10.1111/j.1749-6632.1952.tb26576.x; LEVINGER L, 1982, CELL, V28, P375, DOI 10.1016/0092-8674(82)90355-5; LI W, 1993, BIOCHEM J, V296, P737, DOI 10.1042/bj2960737; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MATSUI SI, 1979, P NATL ACAD SCI USA, V76, P6386, DOI 10.1073/pnas.76.12.6386; Meistrich M., 1989, HISTONES OTHER BASIC, P165; Meistrich M L, 1977, Methods Cell Biol, V15, P15, DOI 10.1016/S0091-679X(08)60207-1; MEISTRICH ML, 1992, MOL REPROD DEV, V31, P170, DOI 10.1002/mrd.1080310303; MEISTRICH ML, 1994, BIOL REPROD, V51, P334, DOI 10.1095/biolreprod51.2.334; MEISTRICH ML, 1981, BIOL REPROD, V25, P1065, DOI 10.1095/biolreprod25.5.1065; MEISTRICH ML, 1985, DEV BIOL, V112, P230, DOI 10.1016/0012-1606(85)90137-X; NICKEL BE, 1987, BIOCHEMISTRY-US, V26, P4417, DOI 10.1021/bi00388a034; NICKEL BE, 1989, BIOCHEMISTRY-US, V28, P958, DOI 10.1021/bi00429a006; NICKEL BE, 1989, BIOCHEMISTRY-US, V28, P964, DOI 10.1021/bi00429a007; PICKART CM, 1988, J BIOL CHEM, V263, P15076; PLATZ RD, 1977, METHOD CELL BIOL, V16, P267; Roest HP, 1996, CELL, V86, P799, DOI 10.1016/S0092-8674(00)80154-3; SODERSTROM KO, 1976, MOL CELL ENDOCRINOL, V5, P181, DOI 10.1016/0303-7207(76)90082-4; Stemmer C, 1997, J MOL BIOL, V273, P52, DOI 10.1006/jmbi.1997.1270; TROSTLEWEIGE PK, 1984, J BIOL CHEM, V259, P8769; UNNI E, 1992, J BIOL CHEM, V267, P25359; UNNI E, 1995, MOL REPROD DEV, V42, P210, DOI 10.1002/mrd.1080420210; WELLS D, 1991, NUCLEIC ACIDS RES, V19, P2173, DOI 10.1093/nar/19.suppl.2173; WEST MHP, 1980, NUCLEIC ACIDS RES, V8, P4671, DOI 10.1093/nar/8.20.4671; Wing SS, 1996, MOL CELL BIOL, V16, P4064; WING SS, 1995, BIOCHEM J, V305, P125, DOI 10.1042/bj3050125; WU RS, 1981, J BIOL CHEM, V256, P5916	42	115	125	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					13165	13169		10.1074/jbc.273.21.13165	http://dx.doi.org/10.1074/jbc.273.21.13165			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582357	hybrid			2022-12-27	WOS:000073768500068
J	Kaiser, UB; Sabbagh, E; Chen, MT; Chin, WW; Saunders, BD				Kaiser, UB; Sabbagh, E; Chen, MT; Chin, WW; Saunders, BD			Sp1 binds to the rat luteinizing hormone beta (LH beta) gene promoter and mediates gonadotropin-releasing hormone-stimulated expression of the LH beta subunit gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENTARY DEOXYRIBONUCLEIC-ACID; STEROIDOGENIC FACTOR-I; NUCLEAR RECEPTOR; GH(3) CELLS; DIFFERENTIAL REGULATION; RESPONSE ELEMENTS; TRANSGENIC MICE; MAMMALIAN-CELLS; PROTEIN-KINASE; GNRH RECEPTOR	The hypothalamic hormone gonadotropin-releasing hormone (GnRH) plays a critical role in reproductive function by regulating the biosynthesis and secretion of the pituitary gonadotropins. Although it is known that GnRH induces luteinizing hormone beta (LH beta) gene transcription, the mechanisms by which this occurs remain to be elucidated. We have shown previously that GH(3) cells transfected with the rat GnRH receptor cDNA (GGH(3)-1' cells) support the expression of a cotransfected fusion gene composed of 797 base pairs of rat LH beta gene 5'-flanking sequence and the first 5 base pairs of the 5'-untranslated region fused to a luciferase reporter (-797/+5LH beta LUC) and respond to a GnRH agonist with a 10-fold stimulation of activity. Furthermore, we have shown that DNA sequences at -490/-352 confer GnRH responsiveness to the rat LH beta gene. We have now identified two putative binding sites for Spl, a three-zinc-finger transcription factor, within this region. Using electrophoretic mobility shift assay, DNase I footprinting, and methylation interference assays, we demonstrate that Spl can bind to these sites and that Spl is responsible for DNA-protein complexes formed using GGH(3)-1' and alpha T3-1 nuclear extracts. Mutations of the Spl binding sites, which block binding of Spl, blunt the stimulation of the LH beta gene promoter by GnRH, These data define GnRH-responsive elements in the LH beta 5'-flanking sequence and suggest that Spl plays an important role in conferring GnRH responsiveness to the LH beta subunit gene.	Brigham & Womens Hosp, Dept Med, Div Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Kaiser, UB (corresponding author), Brigham & Womens Hosp, Dept Med, Div Genet, GW Thorn Res Bldg,Rm 1009,20 Shattuck St, Boston, MA 02115 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD019938, R37HD019938] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD033001, R01HD033001] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-19938, HD-33001] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alarid ET, 1996, DEVELOPMENT, V122, P3319; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Crowley W F Jr, 1985, Recent Prog Horm Res, V41, P473; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; HAISENLEDER DJ, 1991, ENDOCRINOLOGY, V128, P509, DOI 10.1210/endo-128-1-509; Halvorson LM, 1996, J BIOL CHEM, V271, P6645, DOI 10.1074/jbc.271.12.6645; HUDSON JM, 1989, BIOTECHNIQUES, V7, P812; IKEDA M, 1994, ENDOCRINOLOGY, V135, P1628, DOI 10.1210/en.135.4.1628; INGRAHAM HA, 1994, GENE DEV, V8, P2302, DOI 10.1101/gad.8.19.2302; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JANOVICK JA, 1995, ENDOCRINOLOGY, V136, P202, DOI 10.1210/en.136.1.202; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KAISER UB, 1994, MOL ENDOCRINOL, V8, P1038, DOI 10.1210/me.8.8.1038; Kaiser UB, 1998, ENDOCRINOLOGY, V139, P2443, DOI 10.1210/en.139.5.2443; Kaiser UB, 1995, P NATL ACAD SCI USA, V92, P12280, DOI 10.1073/pnas.92.26.12280; Keri RA, 1996, J BIOL CHEM, V271, P10782, DOI 10.1074/jbc.271.18.10782; KRISHNAN V, 1994, J BIOL CHEM, V269, P15912; KUPHAL D, 1994, ENDOCRINOLOGY, V135, P315, DOI 10.1210/en.135.1.315; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; LEVINE JE, 1982, ENDOCRINOLOGY, V111, P1439, DOI 10.1210/endo-111-5-1439; Liu Z, 1997, MOL ENDOCRINOL, V11, P127, DOI 10.1210/me.11.2.127; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; Maxam A M, 1980, Methods Enzymol, V65, P499; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Penabad JL, 1996, J CLIN ENDOCR METAB, V81, P3397, DOI 10.1210/jc.81.9.3397; Porter W, 1996, MOL ENDOCRINOL, V10, P1371, DOI 10.1210/me.10.11.1371; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; SHUPNIK MA, 1990, MOL ENDOCRINOL, V4, P1444, DOI 10.1210/mend-4-10-1444; STANISLAUS D, 1994, ENDOCRINOLOGY, V135, P2220, DOI 10.1210/en.135.5.2220; SUEN CS, 1994, J BIOL CHEM, V269, P1314; SUEN CS, 1993, MOL CELL BIOL, V13, P1719, DOI 10.1128/MCB.13.3.1719; Turgeon JL, 1996, MOL ENDOCRINOL, V10, P439, DOI 10.1210/me.10.4.439; VALK TW, 1980, J CLIN ENDOCR METAB, V51, P730, DOI 10.1210/jcem-51-4-730; VENEPALLY P, 1995, J BIOL CHEM, V270, P25402, DOI 10.1074/jbc.270.43.25402; WIERMAN ME, 1989, ENDOCRINOLOGY, V124, P272, DOI 10.1210/endo-124-1-272; XU J, 1993, J BIOL CHEM, V268, P16065	41	51	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					12943	12951		10.1074/jbc.273.21.12943	http://dx.doi.org/10.1074/jbc.273.21.12943			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582327	hybrid			2022-12-27	WOS:000073768500038
J	Landini, P; Bown, JA; Volkert, MR; Busby, SJW				Landini, P; Bown, JA; Volkert, MR; Busby, SJW			Ada protein-RNA polymerase sigma subunit interaction and alpha subunit-promoter DNA interaction are necessary at different steps in transcription initiation at the Escherichia coli ada and aidB promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKYLATING-AGENTS; ADAPTIVE RESPONSE; REGULATORY PROTEIN; ACTIVATION; GENE; BINDING; EXPRESSION; INDUCTION; RECOGNITION; ACTS	The methylated form of the Ada protein ((me)Ada) binds the ada and aidB promoters between 60 and 40 base pairs upstream from the transcription start and activates transcription of the Escherichia coli ada and aidB genes. This region is also a binding site for the a subunit of RNA polymerase and resembles the rrnB P1 UP element in A/T content and location relative to the core promoter, In this report, we show that deletion of the C-terminal domain of the a subunit severely decreases (me)Ada-independent binding of RNA polymerase to ada and aidB, affecting transcription initiation at these promoters, We provide evidence that (me)Ada activates transcription by direct interaction with the C-terminal domain of RNA polymerase sigma(70) subunit (amino acids 574-613), Several negatively charged residues in the sigma(70) C-terminal domain are important for transcription activation by (me)Ada; in particular, a glutamic acid to valine substitution at position 575 has a dramatic effect on (me)Ada-dependent transcription. Based on these observations, we propose that the role of the a subunit at ada and aidB is to allow initial binding of RNA polymerase to the promoters. However, transcription initiation is dependent on (me)Ada-sigma(70) interaction.	Univ Birmingham, Sch Biochem, Birmingham B15 2TT, W Midlands, England; Univ Massachusetts, Sch Med, Dept Mol Genet & Microbiol, Worcester, MA 01655 USA	University of Birmingham; University of Massachusetts System; University of Massachusetts Worcester	Landini, P (corresponding author), Univ Birmingham, Sch Biochem, POB 363, Birmingham B15 2TT, W Midlands, England.	p.landini@bham.ac.uk	Landini, Paolo/B-7859-2017	Landini, Paolo/0000-0003-0999-426X; Volkert, Michael/0000-0002-0045-0912				AKIMARU H, 1990, J MOL BIOL, V216, P261, DOI 10.1016/S0022-2836(05)80318-3; BUSBY S, 1994, CELL, V79, P743, DOI 10.1016/0092-8674(94)90063-9; DOMBROSKI AJ, 1993, GENE DEV, V7, P2446, DOI 10.1101/gad.7.12a.2446; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; ISHIHAMA A, 1993, J BACTERIOL, V175, P2483, DOI 10.1128/JB.175.9.2483-2489.1993; KARRAN P, 1982, NATURE, V296, P770, DOI 10.1038/296770a0; KATAOKA H, 1983, J BACTERIOL, V153, P1301, DOI 10.1128/JB.153.3.1301-1307.1983; KIM SK, 1995, MOL GEN GENET, V248, P1, DOI 10.1007/BF02456607; KULDELL N, 1994, J BACTERIOL, V176, P2991, DOI 10.1128/JB.176.10.2991-2998.1994; KUMAR A, 1994, J MOL BIOL, V235, P405, DOI 10.1006/jmbi.1994.1001; LANDINI P, 1995, EMBO J, V14, P4329, DOI 10.1002/j.1460-2075.1995.tb00107.x; LANDINI P, 1995, J BIOL CHEM, V270, P8285, DOI 10.1074/jbc.270.14.8285; Landini P, 1996, MOL MICROBIOL, V20, P947, DOI 10.1111/j.1365-2958.1996.tb02536.x; Landini P, 1997, J BIOL CHEM, V272, P15914, DOI 10.1074/jbc.272.25.15914; LANGE R, 1991, MOL MICROBIOL, V5, P49, DOI 10.1111/j.1365-2958.1991.tb01825.x; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; MAKINO K, 1993, GENE DEV, V7, P149, DOI 10.1101/gad.7.1.149; MCCARTHY TV, 1985, NUCLEIC ACIDS RES, V13, P2683, DOI 10.1093/nar/13.8.2683; MILLER JH, 1972, EXPT MOL GNEETICS; NAKABEPPU Y, 1984, J BIOL CHEM, V259, P3730; NAKABEPPU Y, 1986, P NATL ACAD SCI USA, V83, P6297, DOI 10.1073/pnas.83.17.6297; NAKAMURA T, 1988, J MOL BIOL, V202, P483, DOI 10.1016/0022-2836(88)90280-X; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; SAGET BM, 1994, P NATL ACAD SCI USA, V91, P9730, DOI 10.1073/pnas.91.21.9730; SAKUMI K, 1989, J MOL BIOL, V205, P373, DOI 10.1016/0022-2836(89)90348-3; SAKUMI K, 1993, J BACTERIOL, V175, P2455, DOI 10.1128/JB.175.8.2455-2457.1993; SEDGWICK B, 1980, MOL GEN GENET, V180, P85, DOI 10.1007/BF00267355; SHEVELL DE, 1991, P NATL ACAD SCI USA, V88, P9001, DOI 10.1073/pnas.88.20.9001; Tang H, 1996, METHOD ENZYMOL, V273, P130; Taverna P, 1996, J BACTERIOL, V178, P5105, DOI 10.1128/jb.178.17.5105-5111.1996; TEO I, 1986, CELL, V45, P315, DOI 10.1016/0092-8674(86)90396-X; VOLKERT MR, 1984, P NATL ACAD SCI-BIOL, V81, P4110, DOI 10.1073/pnas.81.13.4110; VOLKERT MR, 1994, J BACTERIOL, V176, P7368	33	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					13307	13312		10.1074/jbc.273.21.13307	http://dx.doi.org/10.1074/jbc.273.21.13307			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582376	hybrid			2022-12-27	WOS:000073768500087
J	Blanco-Aparicio, C; Molina, MA; Fernandez-Salas, E; Frazier, ML; Mas, JM; Querol, E; Aviles, FX; de Llorens, R				Blanco-Aparicio, C; Molina, MA; Fernandez-Salas, E; Frazier, ML; Mas, JM; Querol, E; Aviles, FX; de Llorens, R			Potato carboxypeptidase inhibitor, a T-knot protein, is an epidermal growth factor antagonist that inhibits tumor cell growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PANCREATIC-CANCER; FACTOR RECEPTOR; FACTOR-ALPHA; SIGNAL-TRANSDUCTION; THERAPY; COMPLEX; STIMULATION; SUPERFAMILY; EXPRESSION; ACTIVATION	Epidermal growth factor (EGF) and its receptor (EGFR) are involved in many aspects of the development of carcinomas, including tumor cell growth, vascularization, invasiveness, and metastasis. Because EGFR has been found to be overexpressed in many tumors of epithelial origin, it is a potential target for antitumor therapy. Here we report that potato carboxypeptidase inhibitor (PCI), a 39-amino acid protease inhibitor with three disulfide bridges, is an antagonist of human EGF. It competed with EGF for binding to EGFR and inhibited EGFR activation and cell proliferation induced by this growth factor. PCI suppressed the growth of several human pancreatic adenocarcinoma cell lines, both in vitro and in nude mice. PCI has a special disulfide scaffold called a T-knot that is also present in several growth factors including EGF and transforming growth factor alpha. PCI shows structural similarities with these factors, a fact that can explain the antagonistic effect of the former. This is the first reported example of an antagonistic analogue of human EGF.	Univ Autonoma Barcelona, Inst Biol Fonamental, Bellaterra 08193, Barcelona, Spain; Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, Bellaterra 08193, Barcelona, Spain; Univ Texas, MD Anderson Cancer Ctr, Dept Gastrointestinal Med Oncol & Digest Dis, Houston, TX 77030 USA	Autonomous University of Barcelona; Autonomous University of Barcelona; University of Texas System; UTMD Anderson Cancer Center	Aviles, FX (corresponding author), Univ Autonoma Barcelona, Inst Biol Fonamental, Bellaterra 08193, Barcelona, Spain.	fx.aviles@blues.uab.es	Avilés, Francesc Xavier/A-2664-2015; Blanco-Aparicio, Carmen/I-3162-2015; Aviles, Francesc Xavier/F-3482-2019	Avilés, Francesc Xavier/0000-0002-1399-6789; Blanco-Aparicio, Carmen/0000-0002-3249-6595; Aviles, Francesc Xavier/0000-0002-1399-6789	NCI NIH HHS [R0I-CA46687] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046687] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BASELGA J, 1994, PHARMACOL THERAPEUT, V64, P127, DOI 10.1016/0163-7258(94)90036-1; BILLINGS PC, 1989, CARCINOGENESIS, V10, P687, DOI 10.1093/carcin/10.4.687; CANALS F, 1992, BIOCHEMISTRY-US, V31, P4493, DOI 10.1021/bi00133a016; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CARPENTER G, 1991, PEPTIDE GROWTH FACTO, V1, P69; CLORE GM, 1987, BIOCHEMISTRY-US, V26, P8012, DOI 10.1021/bi00398a069; DEAN C, 1994, INT J CANCER, P103; DERYNCK R, 1992, ADV CANCER RES, V58, P27, DOI 10.1016/S0065-230X(08)60289-4; DERYNCK R, 1988, CELL, V54, P593, DOI 10.1016/S0092-8674(88)80001-1; DONATO NJ, 1989, J CELL BIOCHEM, V41, P139, DOI 10.1002/jcb.240410305; ENGEBRAATEN O, 1993, INT J CANCER, V53, P209, DOI 10.1002/ijc.2910530206; FISH EN, 1993, CANCER RES, V53, P5148; FRENCH AR, 1995, J BIOL CHEM, V270, P4334, DOI 10.1074/jbc.270.9.4334; GROENEN LC, 1994, GROWTH FACTORS, V11, P235, DOI 10.3109/08977199409010997; HASS GM, 1981, METHOD ENZYMOL, V80, P778; HYNES NE, 1995, NAT MED, V1, P631, DOI 10.1038/nm0795-631; IMAMOTO A, 1991, MOL CARCINOGEN, V4, P52, DOI 10.1002/mc.2940040109; Kennedy AR, 1996, CANCER RES, V56, P679; KENNEDY AR, 1994, CANCER RES, V54, pS1999; KORC M, 1992, J CLIN INVEST, V90, P1352, DOI 10.1172/JCI116001; Lee D C, 1992, Cancer Treat Res, V63, P233; Lemmon MA, 1997, EMBO J, V16, P281, DOI 10.1093/emboj/16.2.281; LEMOINE NR, 1992, J PATHOL, V166, P7, DOI 10.1002/path.1711660103; Levitzki A, 1996, CURR OPIN CELL BIOL, V8, P239, DOI 10.1016/S0955-0674(96)80071-8; LING SL, 1995, NAT STRUCT BIOL, V2, P835; MARINOBUSLJE C, 1994, APPL MICROBIOL BIOT, V41, P632; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; MERLINO GT, 1984, SCIENCE, V224, P417, DOI 10.1126/science.6200934; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; MOLINA MA, 1992, GENE, V116, P129, DOI 10.1016/0378-1119(92)90508-M; MOLINA MA, 1994, J BIOL CHEM, V269, P21467; NELSON J, 1991, CARCINOGENESIS, V12, P1823, DOI 10.1093/carcin/12.10.1823; Oliva B, 1997, J MOL BIOL, V266, P814, DOI 10.1006/jmbi.1996.0819; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; REES DC, 1982, J MOL BIOL, V160, P475, DOI 10.1016/0022-2836(82)90309-6; ROUSSEL A, 1991, SILICON GRAPHICS DIR; RYAN CA, 1974, J BIOL CHEM, V249, P5495; SCHWEITZER R, 1995, NATURE, V376, P699, DOI 10.1038/376699a0; SMITH JJ, 1987, P NATL ACAD SCI USA, V84, P7567, DOI 10.1073/pnas.84.21.7567; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; SUN PD, 1995, ANNU REV BIOPH BIOM, V24, P269, DOI 10.1146/annurev.bb.24.060195.001413; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WU XP, 1995, J CLIN INVEST, V95, P1897, DOI 10.1172/JCI117871; YARDEN Y, 1988, BIOCHEMISTRY-US, V27, P3113, DOI 10.1021/bi00409a001; ZUMKELLER W, 1995, ANTICANCER RES, V15, P343	47	72	76	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12370	12377		10.1074/jbc.273.20.12370	http://dx.doi.org/10.1074/jbc.273.20.12370			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575190	hybrid			2022-12-27	WOS:000073629800055
J	Chang, ZF; Huang, DY; Chi, LM				Chang, ZF; Huang, DY; Chi, LM			Serine 13 is the site of mitotic phosphorylation of human thymidine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; MESSENGER-RNA; POTENT INHIBITOR; HELA-CELLS; ENZYME; PROMOTER; GENE; FIBROBLASTS; DEGRADATION; INDUCTION	It has been reported that the polypeptide of thymidine kinase type 1 (TK1) from human and mouse cells can be modified by phosphorylation, Our laboratory has further shown that the level of human TK phosphorylation increases during mitotic arrest in different cell types (Chang, Z.-F., Huang, D.-Y., and Hsue, N.-C. (1994) J. Biol, Chem. 269:21249-21254). In the present study, we demonstrated that a mutation converting Ser(13) to Ala abolished the mitotic phosphorylation of native TK1 expressed in Ltk(-) cells. Furthermore, we expressed recombinant proteins of wild-type and mutated human TK1 with fused FLAG epitope in HeLa cells, and confirmed the occurrence of mitotic phosphorylation on Ser(13) of hTK1. By using an in vitro phosphorylation assay, it was shown that wild-type hTK1, but not mutant TK1(Ala13), could serve as a good substrate for Cdc2 or Cdk2 kinase. Coexpression of p21(waf1/cip1), which is a universal inhibitor of Cdk kinases, in Ltk(-) fibroblasts also suppressed mitotic phosphorylation of hTK1 expressed in this cell line. Thus, Cdc2 or related kinase(s) is probably involved in mitotic phosphorylation on Ser(13) of the hTK1 polypeptide. We also found that mutation on Ser(13) did not affect the functional activity of hTK1, As the sequences around Ser(13) are highly conserved in vertebrate TK1s, we speculate that phosphorylation of Ser(13) may play a role in the regulation of TK1 expression in the cell cycle.	Natl Taiwan Univ, Coll Med, Inst Biochem, Taipei, Taiwan; Chang Gung Univ, Dept Microbiol & Immunol, Tao Yuan, Taiwan	National Taiwan University; Chang Gung University	Chang, ZF (corresponding author), Natl Taiwan Univ, Coll Med, Inst Biochem, 1 Jen Ai Rd,1 St Sect, Taipei, Taiwan.							ALDER R, 1974, CELL, V2, P113; BELLO LJ, 1974, EXP CELL RES, V89, P263, DOI 10.1016/0014-4827(74)90790-3; BOCKAMP O, 1990, GENE AMST, V100, P9; BRADSHAW HD, 1984, MOL CELL BIOL, V4, P2316, DOI 10.1128/MCB.4.11.2316; CHANG ZF, 1994, J BIOL CHEM, V269, P21249; CHANG ZF, 1995, J BIOL CHEM, V270, P27374, DOI 10.1074/jbc.270.45.27374; CHANG ZF, 1993, J BIOL CHEM, V268, P1266; COPPOCK DL, 1987, MOL CELL BIOL, V7, P2925, DOI 10.1128/MCB.7.8.2925; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; GADBOIS DM, 1992, BIOCHEM BIOPH RES CO, V184, P80, DOI 10.1016/0006-291X(92)91160-R; GEIDO E, 1992, METHOD CELL BIOL, V33, P149; GROSS MK, 1989, P NATL ACAD SCI USA, V86, P4987, DOI 10.1073/pnas.86.13.4987; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HALLEK M, 1992, ANN HEMATOL, V65, P1, DOI 10.1007/BF01715117; HARPER JW, 1993, CELL, V75, P805; He QM, 1996, BBA-GEN SUBJECTS, V1289, P25, DOI 10.1016/0304-4165(95)00127-1; HENGSTSCHLAGER M, 1994, J BIOL CHEM, V269, P13836; ITO M, 1990, J BIOL CHEM, V265, P6954; JOHNSON LF, 1982, EXP CELL RES, V138, P79, DOI 10.1016/0014-4827(82)90093-3; KAUFFMAN MG, 1991, MOL CELL BIOL, V11, P2538, DOI 10.1128/MCB.11.5.2538; KAUFFMAN MG, 1991, ONCOGENE, V6, P1427; KIM YK, 1991, MOL CELL BIOL, V11, P2296, DOI 10.1128/MCB.11.4.2296; KIT S, 1976, MOL CELL BIOCHEM, V11, P161, DOI 10.1007/BF01744997; KNOFLER M, 1993, J BIOL CHEM, V268, P11409; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LIPSON KE, 1989, P NATL ACAD SCI USA, V86, P6848, DOI 10.1073/pnas.86.18.6848; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MUNCHPETERSEN B, 1993, J BIOL CHEM, V268, P15621; MUNCHPETERSEN B, 1977, BIOCHIM BIOPHYS ACTA, V478, P364, DOI 10.1016/0005-2787(77)90152-6; PIPER AA, 1980, BIOCHIM BIOPHYS ACTA, V633, P400, DOI 10.1016/0304-4165(80)90198-1; PONDAVEN P, 1990, GENE DEV, V4, P9, DOI 10.1101/gad.4.1.9; ROHEL HH, 1990, MOL CELL BIOL, V19, P3834; SHERLEY JL, 1988, J BIOL CHEM, V263, P375; SHERLEY JL, 1988, J BIOL CHEM, V263, P8350; STUART P, 1985, MOL CELL BIOL, V5, P1490, DOI 10.1128/MCB.5.6.1490; Sutterluety H, 1997, J MOL BIOL, V265, P153, DOI 10.1006/jmbi.1996.0721; Sutterluety H, 1996, J MOL BIOL, V259, P383, DOI 10.1006/jmbi.1996.0327; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	39	29	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12095	12100		10.1074/jbc.273.20.12095	http://dx.doi.org/10.1074/jbc.273.20.12095			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575153	hybrid			2022-12-27	WOS:000073629800018
J	Hunter, MJ; Chazin, WJ				Hunter, MJ; Chazin, WJ			High level expression and dimer characterization of the S100 EF-hand proteins, migration inhibitory factor-related proteins 8 and 14	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEINS; CYSTIC-FIBROSIS ANTIGEN; MONOCYTIC DIFFERENTIATION; CIRCULAR-DICHROISM; SERUM-PROTEIN; CA2+ BINDING; MRP14; FAMILY; MACROPHAGES; COMPLEX	The phenotypical and functional heterogeneity of different macrophage subpopulations are defined by discrete changes in the expression of two S100 calcium-binding proteins, migration inhibitory factor-related proteins (MRPs) 8 and 14. To further our understanding of MRP8 and MRP14 in the developmental stages of inflammatory responses, overexpression of the MRPs was obtained through a combination of a T7-based expression vector and the Escherichia coli BL21 (DE3) cell line. An efficient, two-step chromatographic protocol was then developed for rapid, facile purification. Extensive biophysical characterization and chemical cross linking experiments show that MRP8 and MRP14 form oligomers with a strong preference to associate as a heterodimer. Heteronuclear NMR experiments indicate that a specific well packed dimer is formed only in equimolar mixtures of the two proteins. Our results suggest that there is a unique complementarity in the interface of the MRP8/MRP14 complex that cannot be fully reproduced in the MRP8 and MRP14 homodimers.	Scripps Res Inst, Dept Mol Biol MB9, La Jolla, CA 92037 USA	Scripps Research Institute	Hunter, MJ (corresponding author), Scripps Res Inst, Dept Mol Biol MB9, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	chazin@scripps.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM048495] Funding Source: NIH RePORTER; NIGMS NIH HHS [P01 GM48495] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARGER SW, 1992, BIOCHIM BIOPHYS ACTA, V1160, P105, DOI 10.1016/0167-4838(92)90043-D; BAUDIER J, 1989, BIOCHEM J, V264, P79, DOI 10.1042/bj2640079; BHARDWAJ RS, 1992, EUR J IMMUNOL, V22, P1891, DOI 10.1002/eji.1830220732; BRANDTZAEG P, 1987, AM J CLIN PATHOL, V87, P700, DOI 10.1093/ajcp/87.6.700; BRUN JG, 1994, J RHEUMATOL, V21, P733; CARLSTROM G, 1993, J MOL BIOL, V231, P415, DOI 10.1006/jmbi.1993.1291; Cavanagh J., 1996, PROTEIN NMR SPECTROS; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CLOHESSY PA, 1995, SCAND J IMMUNOL, V42, P551, DOI 10.1111/j.1365-3083.1995.tb03695.x; DALE I, 1983, EUR J BIOCHEM, V134, P1, DOI 10.1111/j.1432-1033.1983.tb07522.x; DELABIE J, 1990, CLIN EXP IMMUNOL, V81, P123; DELLANGELICA EC, 1994, J BIOL CHEM, V269, P28929; DONATO R, 1991, CELL CALCIUM, V12, P713, DOI 10.1016/0143-4160(91)90040-L; Drohat AC, 1998, BIOCHEMISTRY-US, V37, P2729, DOI 10.1021/bi972635p; Drohat AC, 1997, PROTEIN SCI, V6, P1577, DOI 10.1002/pro.5560060721; EDGEWORTH J, 1991, J BIOL CHEM, V266, P7706; EDGEWORTH J, 1989, NATURE, V342, P189, DOI 10.1038/342189a0; Evenas J, 1997, BIOCHEMISTRY-US, V36, P3448, DOI 10.1021/bi9628275; FAGERHOL MK, 1980, SCAND J HAEMATOL, V24, P393; GAGNE SM, 1994, PROTEIN SCI, V3, P1961, DOI 10.1002/pro.5560031108; GOEBELER M, 1994, TRANSPLANTATION, V58, P355; GRECZY C, 1996, BIOCHIM BIOPHYS ACTA, V1313, P246; Guignard F, 1996, EUR J BIOCHEM, V241, P265, DOI 10.1111/j.1432-1033.1996.0265t.x; HAYWARD C, 1986, J IMMUNOL METHODS, V91, P117, DOI 10.1016/0022-1759(86)90109-2; HESSIAN PA, 1993, J LEUKOCYTE BIOL, V53, P197, DOI 10.1002/jlb.53.2.197; HESSIAN PA, 1995, FEBS LETT, V371, P271, DOI 10.1016/0014-5793(95)00905-O; HOGG N, 1989, EUR J IMMUNOL, V19, P1053, DOI 10.1002/eji.1830190615; Hu SP, 1996, BLOOD, V87, P3919, DOI 10.1182/blood.V87.9.3919.bloodjournal8793919; KAWASAKI H, 1995, PROTEIN PROFILE, V2, P305; KELLY SE, 1989, J PATHOL, V159, P17, DOI 10.1002/path.1711590107; Klempt M, 1997, FEBS LETT, V408, P81, DOI 10.1016/S0014-5793(97)00394-3; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LACKMANN M, 1992, J BIOL CHEM, V267, P7499; LACKMANN M, 1993, J IMMUNOL, V150, P2981; LAGASSE E, 1992, BLOOD, V79, P1907; LAGASSE E, 1988, MOL CELL BIOL, V8, P2402, DOI 10.1128/MCB.8.6.2402; Li MX, 1997, BIOCHEMISTRY-US, V36, P12519, DOI 10.1021/bi971222l; MANI RS, 1983, BIOCHEMISTRY-US, V22, P1734, DOI 10.1021/bi00276a033; MAUNE JF, 1992, BIOCHEMISTRY-US, V31, P7779, DOI 10.1021/bi00149a006; MURAO S, 1989, J BIOL CHEM, V264, P8356; ODINK K, 1987, NATURE, V330, P80, DOI 10.1038/330080a0; POTTS BCM, 1995, NAT STRUCT BIOL, V2, P790, DOI 10.1038/nsb0995-790; ROTH J, 1992, IMMUNOBIOLOGY, V186, P304, DOI 10.1016/S0171-2985(11)80259-7; ROTH J, 1993, BIOCHEM BIOPH RES CO, V191, P565, DOI 10.1006/bbrc.1993.1255; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sastry M, 1998, STRUCTURE, V6, P223, DOI 10.1016/S0969-2126(98)00023-9; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; SCHAFER BW, 1995, GENOMICS, V25, P638, DOI 10.1016/0888-7543(95)80005-7; Smith SP, 1998, STRUCTURE, V6, P211, DOI 10.1016/S0969-2126(98)00022-7; Sorg C, 1992, Behring Inst Mitt, P126; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; STEINBAKK M, 1990, LANCET, V336, P763, DOI 10.1016/0140-6736(90)93237-J; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; SUNDERKOTTER C, 1991, AM J PATHOL, V138, P931; TEIGELKAMP S, 1991, J BIOL CHEM, V266, P13462; TROWER MK, 1995, NUCLEIC ACIDS RES, V23, P2348, DOI 10.1093/nar/23.12.2348; vandenBos C, 1996, J IMMUNOL, V156, P1247; VANHEYNINGEN V, 1985, NATURE, V315, P513, DOI 10.1038/315513a0; WATT KWK, 1983, IMMUNOLOGY, V48, P79; WILSON GB, 1973, CLIN CHIM ACTA, V49, P79, DOI 10.1016/0009-8981(73)90346-X; WOJDA U, 1994, BBA-PROTEIN STRUCT M, V1209, P248, DOI 10.1016/0167-4838(94)90192-9; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413; Zimmer DB, 1996, BBA-MOL CELL RES, V1313, P229, DOI 10.1016/0167-4889(96)00094-8	64	178	186	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12427	12435		10.1074/jbc.273.20.12427	http://dx.doi.org/10.1074/jbc.273.20.12427			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575199	hybrid			2022-12-27	WOS:000073629800064
J	van Weering, DHJ; Moen, TC; Braakman, I; Baas, PD; Bos, JL				van Weering, DHJ; Moen, TC; Braakman, I; Baas, PD; Bos, JL			Expression of the receptor tyrosine kinase Ret on the plasma membrane is dependent on calcium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; ENDOPLASMIC-RETICULUM; PROTOONCOGENE PRODUCTS; HIRSCHSPRUNGS-DISEASE; EXTRACELLULAR DOMAIN; SEQUENCE SIMILARITY; CELL-ADHESION; CADHERIN; MUTATIONS; PROTEINS	Mutations in the Ret receptor tyrosine kinase are responsible for a variety of human syndromes, including multiple endocrine neoplasia 2 and Hirschsprung's disease. Ret is expressed as a 180-kDa precursor form in the endoplasmic reticulum and a 170-kDa mature form at the plasma membrane. Here we show that expression of p170(ret) is dependent on calcium. Depletion of extracellular calcium completely blocks p170(ret) expression, which is not caused by a decrease in half-life of p170(ret) at the plasma membrane but by a defect in processing of p150(ret) into p170(ret). This processing defect can be mimicked by treating the cells with thapsigargin, a drug that releases calcium from internal stores, indicating that reduction in luminal calcium is responsible for the processing defect. We propose that a relatively high concentration of luminal calcium is necessary for the proper folding of Bet in the endoplasmic reticulum.	Univ Amsterdam, Dept Biochem, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam	Bos, JL (corresponding author), Univ Amsterdam, Dept Biochem, Meibergdreef 15, NL-1105 AZ Amsterdam, Netherlands.			Braakman, Ineke/0000-0003-1592-4364				ASAI N, 1995, MOL CELL BIOL, V15, P1613; Baloh RH, 1997, NEURON, V18, P793, DOI 10.1016/S0896-6273(00)80318-9; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; BujBello A, 1997, NATURE, V387, P721, DOI 10.1038/42729; Carlomagno F, 1996, EMBO J, V15, P2717, DOI 10.1002/j.1460-2075.1996.tb00632.x; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DURICK K, 1995, J BIOL CHEM, V270, P24642, DOI 10.1074/jbc.270.42.24642; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; IWAMOTO T, 1993, ONCOGENE, V8, P1087; Iwashita T, 1996, HUM MOL GENET, V5, P1577, DOI 10.1093/hmg/5.10.1577; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; KEATING MT, 1987, J BIOL CHEM, V262, P7932; Klein RD, 1997, NATURE, V387, P717, DOI 10.1038/42722; KUMA K, 1993, MOL BIOL EVOL, V10, P539; LE AQ, 1994, J BIOL CHEM, V269, P7514; LODISH HF, 1990, J BIOL CHEM, V265, P10893; LODISH HF, 1992, J BIOL CHEM, V267, P12753; MACER DRJ, 1988, J CELL SCI, V91, P61; MENON GK, 1991, ARCH DERMATOL, V127, P57, DOI 10.1001/archderm.127.1.57; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; POKUTTA S, 1994, EUR J BIOCHEM, V223, P1019, DOI 10.1111/j.1432-1033.1994.tb19080.x; Polley, 1986, PEDIATR SURG INT, V1, P80, DOI 10.1007/BF00166865; REED BC, 1980, P NATL ACAD SCI-BIOL, V77, P285, DOI 10.1073/pnas.77.1.285; Sanicola M, 1997, P NATL ACAD SCI USA, V94, P6238, DOI 10.1073/pnas.94.12.6238; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SCHUCHARDT A, 1995, J INTERN MED, V238, P327, DOI 10.1111/j.1365-2796.1995.tb01206.x; SUZUKI CK, 1991, J CELL BIOL, V114, P189, DOI 10.1083/jcb.114.2.189; TAKAHASHI M, 1991, ONCOGENE, V6, P297; TAKAHASHI M, 1993, ONCOGENE, V8, P2925; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; vanWeering DHJ, 1995, ONCOGENE, V11, P2207; vanWeering DHJ, 1997, J BIOL CHEM, V272, P249; WADA I, 1995, J BIOL CHEM, V270, P20298, DOI 10.1074/jbc.270.35.20298; Worby CA, 1996, J BIOL CHEM, V271, P23619, DOI 10.1074/jbc.271.39.23619	41	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12077	12081		10.1074/jbc.273.20.12077	http://dx.doi.org/10.1074/jbc.273.20.12077			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575150	hybrid			2022-12-27	WOS:000073629800015
J	Xia, Y; Buja, LM; McMillin, JB				Xia, Y; Buja, LM; McMillin, JB			Activation of the cytochrome c gene by electrical stimulation in neonatal rat cardiac myocytes - Role of NRF-1 and c-Jun	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RESPIRATORY FACTORS; PROTEIN-KINASE-C; TRANSCRIPTION FACTOR; EXPRESSION; CELLS; DIMERIZATION; HYPERTROPHY; INDUCTION; APOPTOSIS; CREB	Activation of cytochrome c (cyt c) transcription in electrically stimulated neonatal rat cardiac myocytes is preceded by transient expression of the activating protein-1 family of transcription factors, c-Fos, c-Jun, and JunB, as well as nuclear respiratory factor-1 (NRF-1), Mutations in either the NRF-1 or in the two cyclic AMP response elements on the cyt c promoter significantly reduce cyt c promoter activation produced either by electrical stimulation (Xia, Y., Buja, L. M., Scarpulla, R. C., and McMillin, J. B. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 11399-11404) or by transfection of c-jun into nonpaced cardiac myocytes, Electrical stimulation of cardiac myocytes activates the c-Jun N-terminal kinase (McDonough, P. M., Hanford, D. S., Sprenkle, A. B., Mellon, N. R., and Glembotski, C. C. (1997) J. Biol. Chem. 272, 24046-24053) so that the fold-activation of the cyt c promoter is increased by pacing when either c-jun or c-fos/c-jun were cotransfected, Physical association of NRF-1 protein with the NRF-1 enhancer element and of c-Jun with the cyclic AMP response element binding sites on the cyt c promoter was demonstrated by gel shift competition assays and by antibody super shifts. This is the first demonstration that induction of NRF-1 and c-Jun by pacing of cardiac myocytes directly mediates cyt c gene expression and mitochondrial proliferation in response to hypertrophic stimuli in the heart.	Univ Texas, Sch Med, Dept Pathol & Lab Med, Houston, TX 77030 USA	University of Texas System	McMillin, JB (corresponding author), Univ Texas, Sch Med, Dept Pathol & Lab Med, 6431 Fannin, Houston, TX 77030 USA.			Buja, Louis Maximilian/0000-0001-8386-7029	NHLBI NIH HHS [R01-HL38863] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038863] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDRISANI OM, 1989, P NATL ACAD SCI USA, V86, P2181, DOI 10.1073/pnas.86.7.2181; ANSUBEL FM, 1995, CURRENT PROTOCOLS MO, V1; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; BREVET A, 1976, SCIENCE, V193, P1152, DOI 10.1126/science.959833; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; GREENGARD P, 1978, SCIENCE, V199, P146, DOI 10.1126/science.22932; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KOMURO I, 1993, ANNU REV PHYSIOL, V55, P55, DOI 10.1146/annurev.ph.55.030193.000415; KOMURO I, 1991, J BIOL CHEM, V266, P1265; Krippner A, 1996, J BIOL CHEM, V271, P21629, DOI 10.1074/jbc.271.35.21629; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; McDonough PM, 1997, J BIOL CHEM, V272, P24046, DOI 10.1074/jbc.272.38.24046; MCDONOUGH PM, 1992, J BIOL CHEM, V267, P11665; MITCHELL FM, 1995, BIOCHEM J, V309, P381, DOI 10.1042/bj3090381; Narula J, 1996, NEW ENGL J MED, V335, P1182, DOI 10.1056/NEJM199610173351603; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; POYTON RO, 1988, ANN NY ACAD SCI, V550, P289, DOI 10.1111/j.1749-6632.1988.tb35344.x; Ramirez MT, 1997, J BIOL CHEM, V272, P14057, DOI 10.1074/jbc.272.22.14057; SADOSHIMA J, 1992, J BIOL CHEM, V267, P10551; Scarpulla RC, 1996, TRENDS CARDIOVAS MED, V6, P39, DOI 10.1016/1050-1738(95)00129-8; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; THOMPSON MA, 1995, J BIOL CHEM, V270, P4224, DOI 10.1074/jbc.270.9.4224; VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309; Xia Y, 1996, J BIOL CHEM, V271, P12082, DOI 10.1074/jbc.271.20.12082; Xia Y, 1997, P NATL ACAD SCI USA, V94, P11399, DOI 10.1073/pnas.94.21.11399; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	32	34	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12593	12598		10.1074/jbc.273.20.12593	http://dx.doi.org/10.1074/jbc.273.20.12593			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575220	hybrid			2022-12-27	WOS:000073629800085
J	Kim, S; Nelson, PG				Kim, S; Nelson, PG			Transcriptional regulation of the prothrombin gene in muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING-FACTOR; THROMBIN RECEPTOR; NEURITE RETRACTION; MESSENGER-RNA; ACTIN GENE; EXPRESSION; CELLS; ACTIVATION; DIFFERENTIATION; LOCALIZATION	Thrombin has been shown to mediate neurite retraction in neurons and synapse elimination at the neuromuscular junction. The presence of prothrombin mRNA has been demonstrated in brain and in muscle, but extra-hepatic regulation of the prothrombin gene has not been investigated. To identify cis-acting DNA elements involved in the expression of the prothrombin gene in muscle, we have isolated and analyzed a 1.3-kilobase pair promoter region of the mouse prothrombin gene. Using a series of transiently transfected plasmid constructs in which gene segments of the prothrombin promoter were linked to the luciferase gene, we have identified a sequence, -302 to -210, essential for prothrombin promoter activity in Ca-myotubes. Fine analysis revealed that deletion of nucleotides between -248 and -235 eliminated prothrombin promoter activity in C2-myotubes, Furthermore, electrophoretic mobility shift assays demonstrated that a nuclear factor present in C2-myotubes, but not in Ca-myoblasts or HepG2 hepatocytes, specifically binds to the sequence -241 to -225, Substitutional mutation of nucleotides -237 to -231 abolished myotube-specific promoter activity and inhibited the nuclear factor binding. Quantitative reverse transcription polymerase chain reaction demonstrated the expression of prothrombin mRNA in myotubes, but not in myoblasts, of primary, C2, and G8 muscle cells. This result correlates with the lack of prothrombin promoter activity in C2-myoblasts, The data thus suggest that a myotube-specific nuclear factor binds to a cis-acting sequence encompassing the core nucleotides -237 to -231 and plays a critical role in muscle-specific, differentiation-dependent expression of the mouse prothrombin gene.	NICHD, Dev Neurobiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Kim, S (corresponding author), NICHD, Dev Neurobiol Lab, NIH, Bldg 49,Rm 5A38,9000 Rockville Pike, Bethesda, MD 20892 USA.	shkim@helix.nih.gov						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BONNEROT C, 1988, NUCLEIC ACIDS RES, V16, P7180, DOI 10.1093/nar/16.14.7180; CAVANAUGH KP, 1990, J NEUROCHEM, V54, P1735, DOI 10.1111/j.1471-4159.1990.tb01228.x; CHOW BKC, 1991, J BIOL CHEM, V266, P18927; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; DEGEN SJF, 1990, DNA CELL BIOL, V9, P487, DOI 10.1089/dna.1990.9.487; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIHANICH M, 1991, NEURON, V6, P575, DOI 10.1016/0896-6273(91)90060-D; DUDOV KP, 1984, CELL, V37, P457, DOI 10.1016/0092-8674(84)90376-3; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; FENTON JW, 1986, ANN NY ACAD SCI, V485, P5, DOI 10.1111/j.1749-6632.1986.tb34563.x; Glazner GW, 1997, DEV BRAIN RES, V99, P148, DOI 10.1016/S0165-3806(96)00213-1; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GRAND RJA, 1989, EMBO J, V8, P2209, DOI 10.1002/j.1460-2075.1989.tb08344.x; GURWITZ D, 1988, P NATL ACAD SCI USA, V85, P3440, DOI 10.1073/pnas.85.10.3440; Guttridge DC, 1997, J BIOL CHEM, V272, P24117, DOI 10.1074/jbc.272.39.24117; JALINK K, 1992, J CELL BIOL, V118, P411, DOI 10.1083/jcb.118.2.411; LASSAR A, 1994, CURR OPIN CELL BIOL, V6, P432, DOI 10.1016/0955-0674(94)90037-X; LIN H, 1991, MOL CELL BIOL, V11, P267, DOI 10.1128/MCB.11.1.267; LIU Y, 1994, P NATL ACAD SCI USA, V91, P10300, DOI 10.1073/pnas.91.22.10300; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MOHUN TJ, 1989, EMBO J, V8, P1153, DOI 10.1002/j.1460-2075.1989.tb03486.x; NELSON RB, 1990, DEV BRAIN RES, V54, P93, DOI 10.1016/0165-3806(90)90069-B; PERKINS KK, 1988, GENE DEV, V2, P1615, DOI 10.1101/gad.2.12a.1615; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SIMON AM, 1993, MOL CELL BIOL, V13, P5133, DOI 10.1128/MCB.13.9.5133; SOIFER SJ, 1994, AM J PATHOL, V144, P60; Suidan HS, 1996, J BIOL CHEM, V271, P29162, DOI 10.1074/jbc.271.46.29162; SUIDAN HS, 1992, NEURON, V8, P363, DOI 10.1016/0896-6273(92)90302-T; THOMPSON WR, 1991, J BIOL CHEM, V266, P22678; WEINSTEIN JR, 1995, J NEUROSCI, V15, P2906; Zoubine MN, 1996, DEV BIOL, V179, P447, DOI 10.1006/dbio.1996.0274	34	17	17	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 8	1998	273	19					11923	11929		10.1074/jbc.273.19.11923	http://dx.doi.org/10.1074/jbc.273.19.11923			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZM408	9565620	hybrid			2022-12-27	WOS:000073536700074
J	Cheng, ZF; Zuo, YH; Li, ZW; Rudd, KE; Deutscher, MP				Cheng, ZF; Zuo, YH; Li, ZW; Rudd, KE; Deutscher, MP			The vacB gene required for virulence in Shigella flexneri and Escherichia coli encodes the exoribonuclease RNase R	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIABILITY; TURNOVER	vacB, a gene previously shown to be required for expression of virulence in Shigella and enteroinvasive Escherichia coli, has been found to encode the 3'-5' exoribonuclease, RNase R. Thus, cloning off. coli vacB led to overexpression of RNase R activity, and partial deletion or interruption of the cloned gene abolished this overexpression, Interruption of the chromosomal copy of vacB eliminated endogenous RNase R activity; however, the absence of RNase R by itself had no effect on cell growth. In contrast, cells lacking both RNase R and polynucleotide phosphorylase were found to be inviable. These data indicate that RNase R participates in an essential cell function in addition to its role in virulence. The identification of the vacB gene product as RNase R should aid in understanding how the virulence phenotype in enterobacteria is expressed and regulated. On the basis of this information we propose that vacB be renamed rnr.	Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA	University of Miami	Deutscher, MP (corresponding author), Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA.		Zuo, Yuhong/H-7392-2012	Zuo, Yuhong/0000-0003-1810-4580	NIGMS NIH HHS [GM16317] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHELLIER S, 1996, ESCHERICHIA COLI SAL, P2012; Bycroft M, 1997, CELL, V88, P235, DOI 10.1016/S0092-8674(00)81844-9; DEUTSCHER MP, 1993, J BACTERIOL, V175, P4577, DOI 10.1128/JB.175.15.4577-4583.1993; DEUTSCHER MP, 1984, P NATL ACAD SCI-BIOL, V81, P4290, DOI 10.1073/pnas.81.14.4290; DEUTSCHER MP, 1993, J BIOL CHEM, V268, P13011; DONOVAN WP, 1986, P NATL ACAD SCI USA, V83, P120, DOI 10.1073/pnas.83.1.120; KASAI T, 1977, J BIOL CHEM, V252, P8950; KELLY KO, 1992, J BACTERIOL, V174, P6682, DOI 10.1128/JB.174.20.6682-6684.1992; KELLY KO, 1992, J BIOL CHEM, V267, P16015; Li ZW, 1998, P NATL ACAD SCI USA, V95, P2856, DOI 10.1073/pnas.95.6.2856; Li ZW, 1996, CELL, V86, P503, DOI 10.1016/S0092-8674(00)80123-3; Mian IS, 1997, NUCLEIC ACIDS RES, V25, P3187, DOI 10.1093/nar/25.16.3187; Miller J. H., 1972, EXPT MOL GENETICS, P431; NIKOLAEV N, 1976, BIOCHEM BIOPH RES CO, V70, P920, DOI 10.1016/0006-291X(76)90679-3; Persson BC, 1997, NUCLEIC ACIDS RES, V25, P4093, DOI 10.1093/nar/25.20.4093; TOBE T, 1992, J BACTERIOL, V174, P6359, DOI 10.1128/JB.174.20.6359-6367.1992	16	135	141	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14077	14080		10.1074/jbc.273.23.14077	http://dx.doi.org/10.1074/jbc.273.23.14077			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603904	hybrid			2022-12-27	WOS:000074021500006
J	Raju, TS; Stanley, P				Raju, TS; Stanley, P			Gain-of-function Chinese hamster ovary mutants LEC18 and LEC14 each express a novel N-acetylglucosaminyltransferase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLCNAC-GLYCOPEPTIDE BETA-4-N-ACETYLGLUCOSAMINYLTRANSFERASE-III; LINKED SUGAR CHAINS; CHO CELLS; GLYCOPROTEIN-SYNTHESIS; SUBSTRATE-SPECIFICITY; CORE; GLYCOSYLTRANSFERASE; OLIGOSACCHARIDES; CARBOHYDRATE; SYSTEM	LEC18 and LEC14 cells are gain-of-function glycosylation mutants isolated from Chinese hamster ovary cells for resistance to pea lectin. Structural studies have shown that LEC18 cells synthesize complex N-glycans with a GlcNAc residue linked at the O-6 position of the core GlcNAc (Raju, T. S.,, Ray, M. K., and Stanley, P. (1995) J. Biol. Chem. 270, 30294-30302), whereas LEC14 cells synthesize complex N-glycans with a GlcNAc residue linked at the O-2 position of the core beta-linked Man residue (Raju, T. S., and Stanley, P., (1996) J. Biol. Chem. 271, 7484-7493). Both modifications are novel and have not been reported in glycoproteins from any other source. We now show that, in both LEC18 and LEC14 cells, GlcNAc transfer is mediated by a distinct N-acetylglucosaminyltransferase (GlcNAc-T) activity. The LEC18 activity, termed GlcNAc-TVIII, transfers GlcNAc to GlcNAc beta 1-O-pNP and to a GlcNAc-terminating, biantennary, complex N-glycan, with or without a core fucose. By contrast, the LEC14 transferase, termed GlcNAc-TVII, does not have significant activity with simple accepters, and transfers GlcNAc preferentially to a GlcNAc-terminating biantennary glycopeptide that contains a core fucose residue. The acceptor specificities and other biochemical properties of GlcNAc-TVII and GlcNAc-TVIII differ from previously characterized GlcNAc-transferases including GlcNAc-TIII, indicating that they represent new members of the mammalian GlcNAc-T group of transferases.	Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Genentech Inc, S San Francisco, CA 94080 USA	Yeshiva University; Albert Einstein College of Medicine; Roche Holding; Genentech	Stanley, P (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	stanley@aecom.yu.edu		Stanley, Pamela/0000-0001-5704-3747	PHS HHS [R01 36434] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bakker H, 1997, J BIOL CHEM, V272, P18580, DOI 10.1074/jbc.272.30.18580; BAKKER H, 1994, J BIOL CHEM, V269, P30326; Bakker H, 1997, GLYCOBIOLOGY, V7, P539, DOI 10.1093/glycob/7.4.539; Bakkers J, 1997, P NATL ACAD SCI USA, V94, P7982, DOI 10.1073/pnas.94.15.7982; BHAUMIK M, 1995, GENE, V164, P295, DOI 10.1016/0378-1119(95)00260-D; BIERHUIZEN MFA, 1993, GENE DEV, V7, P468, DOI 10.1101/gad.7.3.468; CAMPBELL C, 1984, J BIOL CHEM, V259, P3370; CAMPBELL C, 1983, CELL, V35, P303, DOI 10.1016/0092-8674(83)90233-7; CHANEY W, 1989, J CELL BIOL, V109, P2089, DOI 10.1083/jcb.109.5.2089; DINTER A, 1995, ADV EXP MED BIOL, V376, P53; HARDY MR, 1994, METHOD ENZYMOL, V230, P208; Haslam SM, 1996, J BIOL CHEM, V271, P30561, DOI 10.1074/jbc.271.48.30561; HOWARD DR, 1987, J BIOL CHEM, V262, P16830; HUANG CC, 1970, CARBOHYD RES, V13, P127, DOI 10.1016/S0008-6215(00)84902-2; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LONGMORE GD, 1982, CARBOHYD RES, V100, P365, DOI 10.1016/S0008-6215(00)81049-6; NARASIMHAN S, 1982, J BIOL CHEM, V257, P235; POTVIN B, 1991, CELL REGUL, V2, P969; Raju TS, 1996, J BIOL CHEM, V271, P7484, DOI 10.1074/jbc.271.13.7484; Raju TS, 1995, J BIOL CHEM, V270, P30294, DOI 10.1074/jbc.270.51.30294; RIPKA J, 1986, SOMAT CELL MOLEC GEN, V12, P51, DOI 10.1007/BF01560727; RUPLEY JA, 1964, BIOCHIM BIOPHYS ACTA, V83, P245, DOI 10.1016/0926-6526(64)90001-1; SALLUSTIO S, 1989, SOMAT CELL MOLEC GEN, V15, P387, DOI 10.1007/BF01534890; SCHACHTER H, 1991, Glycobiology, V1, P453, DOI 10.1093/glycob/1.5.453; Srikrishna G, 1997, J BIOL CHEM, V272, P25743, DOI 10.1074/jbc.272.41.25743; STANLEY ER, 1981, J IMMUNOL METHODS, V42, P253, DOI 10.1016/0022-1759(81)90156-3; STANLEY P, 1984, ANNU REV GENET, V18, P525, DOI 10.1146/annurev.ge.18.120184.002521; Stanley P, 1996, GLYCOBIOLOGY, V6, P695, DOI 10.1093/glycob/6.7.695; TAKEUCHI M, 1988, J BIOL CHEM, V263, P3657; TOWNSEND RR, 1982, J BIOL CHEM, V257, P9704; Wagner G.P., 1994, P559; WILKES C, 1995, ANAL BIOCHEM, V224, P173, DOI 10.1006/abio.1995.1025; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0; YAMASHITA K, 1983, J BIOL CHEM, V258, P1098; YAMASHITA K, 1981, BIOCHEM BIOPH RES CO, V100, P226, DOI 10.1016/S0006-291X(81)80086-1; Zeng YC, 1997, J BIOL CHEM, V272, P31340, DOI 10.1074/jbc.272.50.31340; ZHANG A, 1996, CLYGOBIOLOGY, V6, P771	37	9	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14090	14098		10.1074/jbc.273.23.14090	http://dx.doi.org/10.1074/jbc.273.23.14090			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603907	hybrid			2022-12-27	WOS:000074021500009
J	Chapman, ER; Davis, AF				Chapman, ER; Davis, AF			Direct interaction of a Ca2+-binding loop of synaptotagmin with lipid bilayers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHOLIPID-BINDING; NEUROTRANSMITTER RELEASE; CALCIUM-DEPENDENCE; DOMAIN; DROSOPHILA; ASSOCIATION; MECHANISM; SYNTAXIN; VESICLES	Synaptotagmin 1 binds Ca2+ and membranes via its C2A-domain and plays an essential role in excitation-secretion coupling. In this study, we sought to identify Ca2+- and membrane-induced local conformational changes in the C2A-domain of synaptotagmin and to delineate the C2A-lipid binding interface. To address these questions native phenylalanine residues were replaced, at each face of the domain, with tryptophan reporters. Changes in tryptophanyl fluorescence indicated that Ca2+ induced long range conformational changes throughout C2A, including regions distant from an established Ca2+-binding site. Addition of liposomes resulted in Ca2+-dependent increases in the fluorescence of tryptophans 193, 231, and 234. Only the tryptophan residues at positions 234 and 231, which lie within a Ca2+-binding loop of C2A, exhibited liposome-induced blue shifts in their emission spectra, Quenching experiments, using membrane-imbedded doxyl spin labels, revealed that tryptophan residues 231 and 234 penetrated lipid bilayers. These data delineate the lipid binding interface of C2A and provide the first evidence for adjacent Ca2+- and lipid-binding sites within a Ca-domain, The penetration of C2A into membranes may function to bring components of the fusion machinery into contact with the lipid bilayer to initiate exocytosis.	Univ Wisconsin, Sch Med, Dept Physiol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Chapman, ER (corresponding author), Univ Wisconsin, Sch Med, Dept Physiol, SMI 1129,1300 Univ Ave, Madison, WI 53706 USA.	erchapma@facstaff.wisc.edu		Chapman, Edwin/0000-0001-9787-8140	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056827] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 56827-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Babity JM, 1997, P NATL ACAD SCI USA, V94, P2638, DOI 10.1073/pnas.94.6.2638; BAZZI MD, 1990, BIOCHEMISTRY-US, V29, P7624, DOI 10.1021/bi00485a012; BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CHAPMAN ER, 1994, J BIOL CHEM, V269, P5735; Chapman ER, 1996, J BIOL CHEM, V271, P5844, DOI 10.1074/jbc.271.10.5844; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; CHUNG LA, 1992, BIOCHEMISTRY-US, V31, P6608, DOI 10.1021/bi00143a035; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; Damer CK, 1996, J NEUROCHEM, V67, P1661; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; DIANTONIO A, 1994, NEURON, V12, P909, DOI 10.1016/0896-6273(94)90342-5; Essen LO, 1997, BIOCHEMISTRY-US, V36, P2753, DOI 10.1021/bi962466t; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; Fasshauer D, 1997, J BIOL CHEM, V272, P28036, DOI 10.1074/jbc.272.44.28036; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; Grobler JA, 1996, NAT STRUCT BIOL, V3, P788, DOI 10.1038/nsb0996-788; Grobler JA, 1997, NAT STRUCT BIOL, V4, P261, DOI 10.1038/nsb0497-261; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; Katz B., 1969, SHERRINGTON LECT; Kee Y, 1996, J NEUROSCI, V16, P1975; Kojima T, 1996, J BIOCHEM-TOKYO, V120, P671; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LECKBAND DE, 1993, BIOCHEMISTRY-US, V32, P1127, DOI 10.1021/bi00055a019; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LITTLETON JT, 1994, P NATL ACAD SCI USA, V91, P10888, DOI 10.1073/pnas.91.23.10888; LLINAS R, 1981, BIOPHYS J, V33, P323, DOI 10.1016/S0006-3495(81)84899-0; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; Mennerick S, 1996, NEURON, V17, P1241, DOI 10.1016/S0896-6273(00)80254-8; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MOSIOR M, 1995, J BIOL CHEM, V270, P25526, DOI 10.1074/jbc.270.43.25526; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Nalefski EA, 1997, BIOCHEMISTRY-US, V36, P12011, DOI 10.1021/bi9717340; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; SCHELLER RH, 1995, NEURON, V14, P893; Schiavo G, 1997, P NATL ACAD SCI USA, V94, P997, DOI 10.1073/pnas.94.3.997; SCHULZE KL, 1995, CELL, V80, P311, DOI 10.1016/0092-8674(95)90414-X; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; SUGITA S, 1996, J BIOL CHEM, V271, P162; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; Uellner R, 1997, EMBO J, V16, P7287, DOI 10.1093/emboj/16.24.7287; vonPoser C, 1997, J BIOL CHEM, V272, P14314, DOI 10.1074/jbc.272.22.14314; YAMAGUCHI T, 1993, J BIOL CHEM, V268, P27164	53	209	214	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13995	14001		10.1074/jbc.273.22.13995	http://dx.doi.org/10.1074/jbc.273.22.13995			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593749	hybrid			2022-12-27	WOS:000073919100088
J	Hosaka, M; Sudhof, TC				Hosaka, M; Sudhof, TC			Synapsin III, a novel synapsin with an unusual regulation by Ca2+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BUNDLING PROTEIN; BINDING-PROTEIN; PHOSPHOPROTEINS; CALMODULIN; DOMAINS; ACTIN; MICE	Synapsins I and II are synaptic vesicle proteins essential for normal Ca2+ regulation of neurotransmitter release. Synapsins are composed of combinations of common and variable sequences, with the central C-domain as the largest conserved domain. The C-domain is structurally homologous to ATPases, suggesting that synapsins function as ATP-dependent phosphotransfer enzymes. We have now identified an unanticipated third synapsin gene that is also expressed in brain, The product of this gene, synapsin IIIa, shares with synapsins Ia and IIa three conserved domains that are connected by variable sequences: the phosphorylated A-domain at the amino terminus, the large ATP-binding C domain in the center, and the E-domain at the carboxyl terminus, Like other synapsins, synapsin IIIa binds ATP with high affinity and ADP with a lower affinity, consistent with a cycle of ATP binding and hydrolysis, ATP binding to the different synapsins is directly regulated by Ca2+ in a dramatically different fashion: Ca2+ activates ATP binding to synapsin I, has no effect on synapsin II, and inhibits synapsin III. Thus vertebrates express three distinct synapsins that utilize ATP but are specialized for different modes of direct Ca2+ regulation in synaptic function.	Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dept Mol Genet, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sudhof, TC (corresponding author), Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.			Hosaka, Masahiro/0000-0002-1422-1774				Artymiuk PJ, 1996, NAT STRUCT BIOL, V3, P128, DOI 10.1038/nsb0296-128; BAHLER M, 1987, NATURE, V326, P704, DOI 10.1038/326704a0; BAINES AJ, 1986, NATURE, V319, P145, DOI 10.1038/319145a0; BAINES AJ, 1985, NATURE, V315, P410, DOI 10.1038/315410a0; DECAMILLI P, 1983, J CELL BIOL, V96, P1337, DOI 10.1083/jcb.96.5.1337; Esser L, 1998, EMBO J, V17, P977, DOI 10.1093/emboj/17.4.977; GREENGARD P, 1987, MOL NEUROBIOL, V1, P81, DOI 10.1007/BF02935265; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAYES NVL, 1991, BIOCHEM J, V275, P93, DOI 10.1042/bj2750093; Hosaka M, 1998, J BIOL CHEM, V273, P1425, DOI 10.1074/jbc.273.3.1425; INUI M, 1994, J NEUROCHEM, V63, P1917; Klagges BRE, 1996, J NEUROSCI, V16, P3154; Matsuda K, 1996, PROTEIN ENG, V9, P1083, DOI 10.1093/protein/9.12.1083; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; MIZUTANI A, 1992, BIOCHEM BIOPH RES CO, V182, P1395, DOI 10.1016/0006-291X(92)91888-W; PETRUCCI TC, 1987, J CELL BIOL, V105, P1355, DOI 10.1083/jcb.105.3.1355; ROSAHL TW, 1995, NATURE, V375, P488, DOI 10.1038/375488a0; ROSAHL TW, 1993, CELL, V75, P661, DOI 10.1016/0092-8674(93)90487-B; Ryan TA, 1996, J CELL BIOL, V134, P1219, DOI 10.1083/jcb.134.5.1219; SIHRA TS, 1989, P NATL ACAD SCI USA, V86, P8108, DOI 10.1073/pnas.86.20.8108; STEINER JP, 1987, J BIOL CHEM, V262, P905; SUDHOF TC, 1990, J BIOL CHEM, V265, P7849; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642; SUDHOF TC, 1996, P UEH MEM FDT S, P3	25	83	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13371	13374		10.1074/jbc.273.22.13371	http://dx.doi.org/10.1074/jbc.273.22.13371			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593663	hybrid			2022-12-27	WOS:000073919100002
J	Lee, YF; Young, WJ; Burbach, JPH; Chang, CS				Lee, YF; Young, WJ; Burbach, JPH; Chang, CS			Negative feedback control of the retinoid-retinoic acid/retinoid X receptor pathway by the human TR4 orphan receptor, a member of the steroid receptor superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR HORMONE RECEPTORS; MAJOR LATE PROMOTER; THYROID-HORMONE; TRANSCRIPTION FACTOR; RESPONSE ELEMENT; GENE-EXPRESSION; LIGAND-BINDING; ACID RECEPTORS; MESSENGER-RNA; NGFI-B	Amino acid sequence analysis indicates that the human TR4 orphan receptor (TR4) is a member of the estrogen/thyroid receptor subfamily of the steroid/thyroid receptor superfamily and recognizes the AGGTCA direct repeat (DR) of the hormone response element. Here we demonstrate using the electrophoretic mobility shift assay that TR4 binds specifically to DR with a spacing of 1 and 5 base pairs (DR1 and DR5), which are the response elements for retinoic acid receptor (RAR) and retinoid X receptor (RXR), respectively. A reporter gene assay using chloramphenicol acetyltransferase demonstrated that TR4 repressed RA-induced transactivation in a TR4 dose-dependent manner. Inhibition of the retinoid signal pathway also occurs through natural response elements found in CRBPII and RAR beta genes. Our data suggest that the mechanism of repression may not involve the formation of functionally inactive heterodimers between TR4 and RAR or RXR, Instead, we show that TR4 may compete for hormone response elements with RAR and RXR due to its higher binding affinity. Furthermore, treatment of F9 murine teratocarcinoma (F9) cells with 10(-6) in all-trans-retinoic acid increased TRA mRNA levels, and this change was accompanied by an increased amount of endogenous TR4 protein that can bind to RXRE in electrophoretic mobility shift assay. Our data therefore strongly suggest that the retinoid signal pathway can be regulated by TR4 in a negative feedback control mechanism, which may restrict retinoic acid signaling to certain elements in a cell-specific fashion.	Univ Rochester, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Dept Pathol, Rochester, NY 14642 USA; Univ Rochester, Dept Urol, Rochester, NY 14642 USA; Univ Rochester, Dept Biochem, Rochester, NY 14642 USA; Univ Utrecht, Dept Med Pharmacol, NL-3584 CG Utrecht, Netherlands	University of Rochester; University of Rochester; University of Rochester; University of Rochester; Utrecht University	Chang, CS (corresponding author), Univ Rochester, George Whipple Lab Canc Res, 601 Elmwood Ave, Rochester, NY 14642 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047258] Funding Source: NIH RePORTER; NCI NIH HHS [CA68568] Funding Source: Medline; NIDDK NIH HHS [DK47258] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENSHUSHAN E, 1995, MOL CELL BIOL, V15, P1034; CHANG C, 1988, BIOCHEM BIOPH RES CO, V155, P971, DOI 10.1016/S0006-291X(88)80591-6; CHANG C, 1989, BIOCHEM BIOPH RES CO, V165, P735, DOI 10.1016/S0006-291X(89)80028-2; CHANG CS, 1994, P NATL ACAD SCI USA, V91, P6040, DOI 10.1073/pnas.91.13.6040; CHAO YC, 1992, J VIROL, V66, P1442, DOI 10.1128/JVI.66.3.1442-1448.1992; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; DASILVA SL, 1995, ENDOCRINOLOGY, V136, P2276; DOLLE P, 1990, DEVELOPMENT, V110, P1133; DOLLE P, 1994, MECH DEVELOP, V45, P91, DOI 10.1016/0925-4773(94)90023-X; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; IDETA R, 1995, ENDOCRINE, V3, P277, DOI 10.1007/BF03021406; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LEE HJ, 1995, J BIOL CHEM, V270, P5434, DOI 10.1074/jbc.270.10.5434; LEE HJ, 1995, J BIOL CHEM, V270, P30129; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; Lee YF, 1997, J BIOL CHEM, V272, P12215, DOI 10.1074/jbc.272.18.12215; LIN TM, 1995, J BIOL CHEM, V270, P30121; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MIZOKAMI A, 1994, J BIOL CHEM, V269, P25655; RUBERTE E, 1990, DEVELOPMENT, V108, P213; SCHRADER M, 1994, J BIOL CHEM, V269, P6444; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; Young WJ, 1997, J BIOL CHEM, V272, P3109, DOI 10.1074/jbc.272.5.3109	29	56	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13437	13443		10.1074/jbc.273.22.13437	http://dx.doi.org/10.1074/jbc.273.22.13437			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593676	hybrid			2022-12-27	WOS:000073919100015
J	Ploug, M; Rahbek-Nielsen, H; Nielsen, PF; Roepstorff, P; Dano, K				Ploug, M; Rahbek-Nielsen, H; Nielsen, PF; Roepstorff, P; Dano, K			Glycosylation profile of a recombinant urokinase-type plasminogen activator receptor expressed in Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL-MYRISTATE ACETATE; REGULATORY PROTEIN CD59; LIGAND-BINDING DOMAIN; GROWTH-FACTOR; CELLULAR RECEPTOR; U937 CELLS; SURFACE; LINE; SITE; NEUROTOXINS	Association of urokinase-type plasminogen activator (uPA) to cells via binding to its specific cellular receptor (uPAR) augments the potential of these cells to support plasminogen activation, a process that has been implicated in the degradation of extracellular matrix proteins during cell migration and tissue remodeling, The uPA receptor is a glycolipid-anchored membrane protein belonging to the Ly-6/uPAR superfamily and is the only multidomain member identified so far. We have now purified the three individual domains of a recombinant soluble uPAR variant, expressed in Chinese hamster ovary cells, after limited proteolysis using chymotrypsin and pepsin. The glycosylation patterns of these domains have been determined by matrix assisted laser desorption ionization and electrospray ionization mass spectrometry, Of the five potential attachment sites for asparagine-linked carbohydrate in uPAR only four are utilized, as the tryptic peptide derived from domain III containing Asn(233) was quantitatively recovered without carbohydrate, The remaining four attachment sites were shown to exhibit site-specific microheterogeneity of the asparagine-linked carbohydrate. The glycosylation on Asn(52) (domain I) and Asn(172) (domain II) is dominated by the smaller biantennary complex-type oligosaccharides, while Asn(162) (domain II) and Asn(200) (domain III) predominantly carry tri- and tetraantennary complex-type oligosaccharides, The carbohydrate moiety on Asn(52) in uPAR domain I could be selectively removed by N-glycanase treatment under nondenaturing conditions. This susceptibility was abrogated when uPAR participitated in a bimolecular complex with pro-uPA or smaller receptor binding derivatives thereof, demonstrating the proximity of the ligand-binding site to this particular carbohydrate moiety, uPAR preparations devoid of carbohydrate on domain I exhibited altered binding kinetics toward uPA (a 4-6-fold increase in K-d) as assessed by real time biomolecular interaction analysis.	Rigshosp, Finsen Lab, DK-2100 Copenhagen O, Denmark; Odense Univ, Dept Mol Biol, DK-5230 Odense, Denmark; NOVO Nord AS, Dept Prot Chem, Bagsvaerd, Denmark	Rigshospitalet; University of Southern Denmark; Novo Nordisk	Ploug, M (corresponding author), Rigshosp, Finsen Lab, Strandboulevarden 49,Opg 8621, DK-2100 Copenhagen O, Denmark.	m-ploug@finsenlab.dk		Ploug, Michael/0000-0003-2215-4265				APPELLA E, 1987, J BIOL CHEM, V262, P4437; BARKHOLT V, 1989, ANAL BIOCHEM, V177, P318, DOI 10.1016/0003-2697(89)90059-6; Behrendt N, 1996, J BIOL CHEM, V271, P22885, DOI 10.1074/jbc.271.37.22885; BEHRENDT N, 1991, J BIOL CHEM, V266, P7842; BEHRENDT N, 1990, J BIOL CHEM, V265, P6453; BERGWERFF AA, 1995, EUR J BIOCHEM, V228, P1009; Blikstad I, 1996, ANAL BIOCHEM, V233, P42, DOI 10.1006/abio.1996.0005; BORK P, 1995, TRENDS BIOCH SCI, V20; BUKO AM, 1991, P NATL ACAD SCI USA, V88, P3992, DOI 10.1073/pnas.88.9.3992; DANO K, 1994, FIBRINOLYSIS, V8, P189, DOI 10.1016/0268-9499(94)90717-X; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DAVIDSON DJ, 1991, BIOCHEMISTRY-US, V30, P625, DOI 10.1021/bi00217a006; ELLIS V, 1995, FIBRINOLYSIS DIS MOL, P30; ESTREICHER A, 1989, J BIOL CHEM, V264, P1180; FLETCHER CM, 1994, STRUCTURE, V2, P185, DOI 10.1016/S0969-2126(00)00020-4; GOODSON RJ, 1994, P NATL ACAD SCI USA, V91, P7129, DOI 10.1073/pnas.91.15.7129; HENKIN J, 1991, PROG CARDIOVASC DIS, V34, P135, DOI 10.1016/0033-0620(91)90010-J; HUBERTY MC, 1993, ANAL CHEM, V65, P2971; KARAS M, 1995, ANAL CHEM, V67, P675, DOI 10.1021/ac00099a029; KIEFFER B, 1994, BIOCHEMISTRY-US, V33, P4471, DOI 10.1021/bi00181a006; Kussmann M, 1997, J MASS SPECTROM, V32, P593; LIJNEN HR, 1981, EUR J BIOCHEM, V120, P149, DOI 10.1111/j.1432-1033.1981.tb05682.x; LIJNEN HR, 1994, EUR J BIOCHEM, V224, P567, DOI 10.1111/j.1432-1033.1994.00567.x; LUND LR, 1991, J BIOL CHEM, V266, P5177; LUND LR, 1995, BIOCHEM J, V310, P345, DOI 10.1042/bj3100345; MIGNATTI P, 1991, J CELL BIOL, V113, P1193, DOI 10.1083/jcb.113.5.1193; MOLLER LB, 1993, J BIOL CHEM, V268, P11152; NIELSEN LS, 1988, J BIOL CHEM, V263, P2358; Nykjaer A., 1996, Fibrinolysis, V10, P5; NYKJAER A, 1990, BIOCHIM BIOPHYS ACTA, V1052, P399, DOI 10.1016/0167-4889(90)90149-8; PAREKH RB, 1989, BIOCHEMISTRY-US, V28, P7670, DOI 10.1021/bi00445a023; PAREKH RB, 1994, ADV DRUG DELIVER REV, V13, P251, DOI 10.1016/0169-409X(94)90014-0; PICONE R, 1989, J CELL BIOL, V108, P693, DOI 10.1083/jcb.108.2.693; PIRIESHEPHERD SR, 1995, J BIOL CHEM, V270, P5877, DOI 10.1074/jbc.270.11.5877; PLOUG M, 1994, FEBS LETT, V349, P163, DOI 10.1016/0014-5793(94)00674-1; PLOUG M, 1994, BIOCHEMISTRY-US, V33, P8991, DOI 10.1021/bi00196a017; PLOUG M, 1992, EUR J BIOCHEM, V208, P397, DOI 10.1111/j.1432-1033.1992.tb17200.x; PLOUG M, 1995, BIOCHEMISTRY-US, V34, P12524, DOI 10.1021/bi00039a006; PLOUG M, 1993, J BIOL CHEM, V268, P17539; PLOUG M, 1991, J BIOL CHEM, V266, P1926; Ploug M, 1998, BIOCHEMISTRY-US, V37, P3612, DOI 10.1021/bi972787k; PRESS EM, 1967, BIOCHEM J, V104, pC30, DOI 10.1042/bj1040030C; RABBANI SA, 1992, J BIOL CHEM, V267, P14151; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; Romer J, 1996, NAT MED, V2, P287, DOI 10.1038/nm0396-287; RONNE E, 1994, J IMMUNOL METHODS, V167, P91, DOI 10.1016/0022-1759(94)90078-7; SPELLMAN MW, 1989, J BIOL CHEM, V264, P14100; WILKINSON JM, 1986, PRACTICAL PROTEIN CH, P122; WITTWER AJ, 1990, BIOCHEMISTRY-US, V29, P4175, DOI 10.1021/bi00469a021	49	59	63	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13933	13943		10.1074/jbc.273.22.13933	http://dx.doi.org/10.1074/jbc.273.22.13933			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593742	hybrid			2022-12-27	WOS:000073919100081
J	Vaillant, AR; Muller, R; Langkopf, A; Brown, DL				Vaillant, AR; Muller, R; Langkopf, A; Brown, DL			Characterization of the microtubule-binding domain of microtubule-associated protein 1A and its effects on microtubule dynamics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; NEURITE OUTGROWTH; DEVELOPING BRAIN; BETA-TUBULIN; EXPRESSION; MAP1A; MAP-1A; DIFFERENTIATION; IDENTIFICATION; LOCALIZATION	To determine how MAP1a interacts with microtubules we expressed several 6myc-tagged MAP1a fragments in P19 EC and HeLa cells. Confocal immunofluorescence microscopy showed that the fragment consisting of amino acids (aa) 1-281 of MAP1a did not bind while the fragment consisting of aa 1-630 did, indicating that the region of MAP1a between aa 281 and 630 contains a microtubule-binding domain. Deletion of the basic repeats from aa 336-540 did not result in loss of microtubule binding, suggesting that the regions flanking the basic repeats can bind MAP1a to microtubules. These observations were confirmed using an in vitro microtubule binding assay. The levels of acetylation and detyrosination of polymerized microtubules were assessed by quantitative dot blotting in cells expressing MAP1a fragments or MAP2c. Compared with untransfected cells, the polymerized tubulin in cells expressing full-length MAP1a was more acetylated and detyrosinated, but these increases were smaller than those seen in cells expressing MAP2c. Consistent with this, the microtubules in MAP2c expressing cells were more resistant to colchicine than those in cells overexpressing MAP1a. These data implicate aa 281-336 and/or 540-630 of MAP1a in microtubule binding and suggest that MAP1a is less able to stabilize microtubules than MAP2c.	Univ Ottawa, Dept Biol, Ottawa, ON K1N 6N5, Canada; Univ Bremen, Biotechnol & Mol Genet Dept, FB 02, D-28357 Bremen, Germany; Inst Jacques Monod, CNRS, Dept Dev Biol, F-75251 Paris, France	University of Ottawa; University of Bremen; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Brown, DL (corresponding author), Univ Ottawa, Dept Biol, 30 Marie Curie, Ottawa, ON K1N 6N5, Canada.	dbrown@science.uottawa.ca		VAILLANT, Andrew/0000-0002-1433-0700				BLACK MM, 1982, J CELL BIOL, V95, P379, DOI 10.1083/jcb.95.2.379; BLOOM GS, 1984, J CELL BIOL, V98, P331, DOI 10.1083/jcb.98.1.331; BRUGG B, 1993, NEUROSCIENCE, V52, P489, DOI 10.1016/0306-4522(93)90401-Z; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COLLINS CA, 1987, J CELL BIOL, V105, P2847, DOI 10.1083/jcb.105.6.2847; CRAVCHIK A, 1994, J CELL SCI, V107, P661; DRUBIN DG, 1985, J CELL BIOL, V101, P1799, DOI 10.1083/jcb.101.5.1799; Edelmann W, 1996, P NATL ACAD SCI USA, V93, P1270, DOI 10.1073/pnas.93.3.1270; FALCONER MM, 1992, CELL MOTIL CYTOSKEL, V21, P313, DOI 10.1002/cm.970210407; GARNER CC, 1990, J NEUROCHEM, V55, P146, DOI 10.1111/j.1471-4159.1990.tb08832.x; GUSTKE N, 1994, BIOCHEMISTRY-US, V33, P9511, DOI 10.1021/bi00198a017; HAMMARBACK JA, 1991, NEURON, V7, P129, DOI 10.1016/0896-6273(91)90081-A; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laferriere NB, 1996, CELL MOTIL CYTOSKEL, V35, P188, DOI 10.1002/(SICI)1097-0169(1996)35:3<188::AID-CM2>3.3.CO;2-0; LANGKOPF A, 1992, J BIOL CHEM, V267, P16561; Li Y, 1996, J NEUROSCI, V16, P531; LIM SS, 1989, J CELL BIOL, V109, P253, DOI 10.1083/jcb.109.1.253; Mann SS, 1996, J NEUROSCI RES, V43, P535, DOI 10.1002/(SICI)1097-4547(19960301)43:5<535::AID-JNR3>3.0.CO;2-J; MATUS A, 1990, J PHYSIOL-PARIS, V84, P134; MCBURNEY MW, 1982, DEV BIOL, V89, P503, DOI 10.1016/0012-1606(82)90338-4; MCKERRACHER L, 1989, VISUAL NEUROSCI, V2, P349, DOI 10.1017/S0952523800002157; NOBLE M, 1989, J CELL BIOL, V109, P3367, DOI 10.1083/jcb.109.6.3367; PEDROTTI B, 1993, CELL MOTIL CYTOSKEL, V25, P234, DOI 10.1002/cm.970250304; PEDROTTI B, 1994, BIOCHEMISTRY-US, V33, P12463, DOI 10.1021/bi00207a013; SATOYOSHITAKE R, 1989, NEURON, V3, P229, DOI 10.1016/0896-6273(89)90036-6; SCHOENFELD TA, 1989, J NEUROSCI, V9, P1712; STEFANINI M, 1967, NATURE, V216, P173, DOI 10.1038/216173a0; Takei Y, 1997, J CELL BIOL, V137, P1615, DOI 10.1083/jcb.137.7.1615; Vaillant AR, 1995, BIOCHEM CELL BIOL, V73, P695, DOI 10.1139/o95-077; VALLEE RB, 1982, J CELL BIOL, V92, P435, DOI 10.1083/jcb.92.2.435; VIERECK C, 1989, J NEUROSCI, V9, P3547; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; WEISSHRR B, 1992, DEVELOPMENT, V161, P1151; Xiang H, 1995, BIOCHEM CELL BIOL, V73, P673, DOI 10.1139/o95-075	34	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13973	13981		10.1074/jbc.273.22.13973	http://dx.doi.org/10.1074/jbc.273.22.13973			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593747	hybrid			2022-12-27	WOS:000073919100086
J	Remington, KM; Bennett, SE; Harris, CM; Harris, TM; Bebenek, K				Remington, KM; Bennett, SE; Harris, CM; Harris, TM; Bebenek, K			Highly mutagenic bypass synthesis by T7 RNA polymerase of site-specific benzo[a]pyrene diol epoxide-adducted template DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYADENOSINE N-6-AMINO GROUP; DOSE-DEPENDENT DIFFERENCES; REPORTER GENE-EXPRESSION; IN-VITRO REPLICATION; TRANSCRIPTION ELONGATION; ESCHERICHIA-COLI; TRANS ADDITION; V-79 CELLS; STRAND; CARCINOGEN	We have previously developed an in vitro system that allows quantitative evaluation of the fidelity of transcription during synthesis on a natural template in the presence of all four nucleotides. Here, we have employed this system using a TAA ochre codon reversion assay to examine the fidelity of transcription by T7 RNA polymerase past an adenine residue adducted at the N-6-position with (-)-anti-trans- or (+)-anti-trans-benzo[a]pyrene diol epoxide (BPDE), T7 RNAP was capable of transcribing past either BPDE isomer to generate full-length run-off transcripts, The extent of bypass was found to be 32% for the (-)-anti-trans-isomer and 18% for the (C)-anti-trans-isomer, Transcription past both adducts was highly mutagenic. The reversion frequency of bypass synthesis of the (-)-anti-trans-isomer was elevated 11,000-fold and that of the (+)-anti-trans-isomer 6000-fold, relative to the reversion frequency of transcription on unadducted template. Adenine was misinserted preferentially, followed by guanine, opposite the adenine adducted with either BPDE isomer, Although base substitution errors were by far the most frequent mutation on the adducted template, three- and six-base deletions were also observed. These results suggest that transcriptional errors, particularly with regard to damage bypass, may contribute to the mutational burden of the cell.	NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA; Vanderbilt Univ, Dept Chem, Nashville, TN 37235 USA; Vanderbilt Univ, Ctr Mol Toxicol, Nashville, TN 37235 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Vanderbilt University; Vanderbilt University	Bebenek, K (corresponding author), NIEHS, Mol Genet Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	bebenek@niehs.nih.gov			NIEHS NIH HHS [ES 03755, ES 00267] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003755, P30ES000267] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bebenek K, 1995, METHOD ENZYMOL, V262, P217; BELAND FA, 1989, PATHOBIOLOGY NEOPLAS, P57; BOYER JC, 1992, P NATL ACAD SCI USA, V89, P6919, DOI 10.1073/pnas.89.15.6919; CHARY P, 1995, J BIOL CHEM, V270, P4990, DOI 10.1074/jbc.270.10.4990; CHARY P, 1995, NUCLEIC ACIDS RES, V23, P1398, DOI 10.1093/nar/23.8.1398; CHEN YH, 1993, J BIOL CHEM, V268, P5849; Choi DJ, 1996, J MOL BIOL, V264, P213, DOI 10.1006/jmbi.1996.0635; CHOI DJ, 1994, BIOCHEMISTRY-US, V33, P780, DOI 10.1021/bi00169a020; CHRISTNER DF, 1994, BIOCHEMISTRY-US, V33, P14297, DOI 10.1021/bi00251a043; GRASLUND A, 1989, Q REV BIOPHYS, V22, P1; HARRIS CM, 1991, J AM CHEM SOC, V113, P4328, DOI 10.1021/ja00011a044; Harvey RG, 1991, POLYCYCL AROMAT COMP, P1; HRUSZKEWYCZ A, 1992, CARCINOGENESIS, V13, P2347, DOI 10.1093/carcin/13.12.2347; KIM SJ, 1992, J AM CHEM SOC, V114, P5480, DOI 10.1021/ja00039a101; KIM SJ, 1995, BIOORGAN MED CHEM, V3, P811, DOI 10.1016/0968-0896(95)00065-O; KOCH KS, 1993, CANCER RES, V53, P2279; KUNKEL TA, 1988, J BIOL CHEM, V263, P4450; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LIU J, 1995, MOL CELL BIOL, V15, P6729; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; Moriya M, 1996, BIOCHEMISTRY-US, V35, P16646, DOI 10.1021/bi9608875; NATH ST, 1987, NUCLEIC ACIDS RES, V15, P4257, DOI 10.1093/nar/15.10.4257; NATH ST, 1991, CARCINOGENESIS, V12, P973, DOI 10.1093/carcin/12.6.973; ROBERTS JD, 1988, P NATL ACAD SCI USA, V85, P7064, DOI 10.1073/pnas.85.19.7064; ROBERTS JD, 1993, METHODS MOL GENET, V2, P295; SCHURTER EJ, 1995, BIOCHEMISTRY-US, V34, P9009, DOI 10.1021/bi00028a009; SCHURTER EJ, 1995, BIOCHEMISTRY-US, V34, P1364, DOI 10.1021/bi00004a031; Schwartz JL, 1997, BIOCHEMISTRY-US, V36, P11069, DOI 10.1021/bi971306u; SELBY CP, 1990, J BIOL CHEM, V265, P21330; SHAH GM, 1992, J BIOCHEM TOXICOL, V7, P13, DOI 10.1002/jbt.2570070104; SHIBUTANI S, 1993, BIOCHEMISTRY-US, V32, P7531, DOI 10.1021/bi00080a027; Slupska MM, 1996, P NATL ACAD SCI USA, V93, P4380, DOI 10.1073/pnas.93.9.4380; SORSCHER DH, 1994, CARCINOGENESIS, V15, P1093, DOI 10.1093/carcin/15.5.1093; Taddei F, 1997, SCIENCE, V278, P128, DOI 10.1126/science.278.5335.128; TAJIRI T, 1995, MUTAT RES-DNA REPAIR, V336, P257, DOI 10.1016/0921-8777(94)00062-B; THRALL BD, 1992, CARCINOGENESIS, V13, P1529, DOI 10.1093/carcin/13.9.1529; van Leeuwen FW, 1998, SCIENCE, V279, P242, DOI 10.1126/science.279.5348.242; WEI SJC, 1993, CANCER RES, V53, P3294; WEI SJC, 1994, CARCINOGENESIS, V15, P1729, DOI 10.1093/carcin/15.8.1729; WEI SJC, 1991, P NATL ACAD SCI USA, V88, P11227, DOI 10.1073/pnas.88.24.11227; ZEGAR IS, 1996, BIOCHEMISTRY-US, V35, P1529; ZHOU W, 1993, P NATL ACAD SCI USA, V90, P6601, DOI 10.1073/pnas.90.14.6601	43	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					13170	13176		10.1074/jbc.273.21.13170	http://dx.doi.org/10.1074/jbc.273.21.13170			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582358	hybrid			2022-12-27	WOS:000073768500069
J	Burke, JR; Millers, KR; Wood, MK; Meyers, CA				Burke, JR; Millers, KR; Wood, MK; Meyers, CA			The multisubunit I kappa B kinase complex shows random sequential kinetics and is activated by the C-terminal domain of I kappa B alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; PHOSPHORYLATION; DEGRADATION; UBIQUITINATION; PROTEOLYSIS	The multisubunit I kappa B kinase (IKK) catalyzes the signal-inducible phosphorylation of N-terminal serines of I kappa B, This phosphorylation is the key step in regulating the subsequent ubiquitination and proteolysis of I kappa B, which then releases NF-kappa B to promote gene transcription. As measured by P-33 incorporation into a GST-I kappa B alpha fusion protein, varying both the concentration of GST-I kappa B alpha and [gamma-P-33]ATP resulted in a kinetic pattern consistent with a random, sequential binding mechanism. Values of 55 nM and 7 mu M were obtained for the dissociation constants of GST-I kappa B alpha and ATP, respectively. The value of alpha, a factor by which binding of one substrate changes the dissociation constant for the other substrate, was determined to be 0.11. This indicates that the two substrates bind in a cooperative fashion, Peptides corresponding to either amino acids 26-42 (N-terminal peptide) or amino acids 279-303 (C-terminal peptide) of I kappa B alpha inhibited the IKK-catalyzed phosphorylation of GST-I kappa B alpha; the C-terminal peptide, unexpectedly, was more potent. The inhibition by the C-terminal peptide was competitive with respect to GST-I kappa B alpha and mixed with respect to ATP, which verified the sequential binding mechanism. The C-terminal peptide was also a substrate for the enzyme, and a dissociation constant of 2.9-6.2 pw was obtained. Additionally, the N-terminal peptide was a substrate (K-m = 140 mu M), Competitive inhibition of the IKK-catalyzed phosphorylation of the C-terminal peptide by the N-terminal peptide indicated that the peptides are phosphorylated by the same active site. Surprisingly, the presence of the C-terminal peptide greatly accelerated the rate of phosphorylation of the N-terminal peptide as represented by a 160-fold increase in the apparent second-order rate constant (k(cat)/K-m), These results are consistent with an allosteric site present within IKK that recognizes the C terminus of I kappa B alpha and activates the enzyme. This previously unobserved interaction with the C terminus may represent an important mechanism by which the enzyme recognizes and phosphorylates I kappa B.	Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Drug Discovery Res, Buffalo, NY 14213 USA; Bristol Myers Squibb Pharmaceut Res Inst, Dept Drug Discovery Res, Princeton, NJ 08543 USA	Bristol-Myers Squibb; Bristol-Myers Squibb	Burke, JR (corresponding author), Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Drug Discovery Res, 100 Forest Ave, Buffalo, NY 14213 USA.							Aoki T, 1996, ONCOGENE, V12, P1159; Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; Bauerle PA, 1996, CELL, V87, P13; Beauparlant P, 1996, J BIOL CHEM, V271, P10690, DOI 10.1074/jbc.271.18.10690; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Brown K, 1997, MOL CELL BIOL, V17, P3021, DOI 10.1128/MCB.17.6.3021; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Cleland W W, 1979, Methods Enzymol, V63, P103; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Fersht A, 1985, ENZYME STRUCTURE MEC, V2, P107; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; Kroll M, 1997, ONCOGENE, V15, P1841, DOI 10.1038/sj.onc.1201560; KUNO K, 1995, J BIOL CHEM, V270, P27914, DOI 10.1074/jbc.270.46.27914; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; Segel, 1975, ENZYME KINETICS BEHA, P274; SEGEL IH, 1975, ENZYME KINETICS, P328; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Weil R, 1997, J BIOL CHEM, V272, P9942; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; WHTIESIDE ST, 1997, SEMIN CANCER BIOL, V8, P75; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	27	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12041	12046		10.1074/jbc.273.20.12041	http://dx.doi.org/10.1074/jbc.273.20.12041			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575145	hybrid			2022-12-27	WOS:000073629800010
J	Lu, CF; Oxvig, C; Springer, TA				Lu, CF; Oxvig, C; Springer, TA			The structure of the beta-propeller domain and C-terminal region of the integrin alpha M subunit - Dependence on beta subunit association and prediction of domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET GLYCOPROTEIN-IIB; INTRACHAIN DISULFIDE BONDS; I-DOMAIN; LIGAND-BINDING; MONOCLONAL-ANTIBODIES; ELECTRON-MICROSCOPY; DYNAMIC REGULATION; OVERLAP EXTENSION; CRYSTAL-STRUCTURE; MAC-1 CD11B/CD18	The alpha M subunit of integrin Mac-1 contains several distinct regions in its extracellular segment. The N-terminal region has been predicted to fold into a beta-propeller domain composed of seven beta-sheets each about 60 amino acid residues long, with the I-domain inserted between beta-sheets 2 and 3. The structure of the C-terminal region is unknown. We have used monoclonal antibodies (mAbs) as probes to study the dependence of the structure of different regions of the alpha M subunit on association with the beta 2 subunit in the alpha M/beta 2 heterodimer. All of the mAbs to the I-domain immunoprecipitated the unassociated alpha M precursor and reacted with the alpha M subunit expressed alone on the surface of COS cells. By contrast, four mAbs to the beta-propeller domain did not react with the unassociated alpha M precursor nor with the uncomplexed alpha M subunit expressed on COS cell surface. The four mAbs were mapped to three subregions in three different beta-sheets, making it unlikely that each recognized an interface between the alpha and beta subunits. These results suggest that folding of different beta-propeller subregions is coordinate and is dependent on association with the beta 2 subunit. The segment C-terminal to the beta-propeller domain, residues 599-1092, was studied with nine mAbs. A subset of four mAbs that reacted with the alpha M/beta 2 complex but not with the unassociated alpha M subunit were mapped to one subregion, residues 718-759, and five other mAbs that recognized both the unassociated and the complexed alpha M subunit were localized to three other subregions, residues 599-679, 820-882, and 943-1047. This suggests that much of the region C-terminal to the beta-propeller domain folds independently of association with the beta 2 subunit. Our data provide new insights irate how different domains in the integrin alpha and beta subunits may interact.	Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard University; Harvard Medical School	Springer, TA (corresponding author), Ctr Blood Res, 200 Longwood Ave, Boston, MA 02115 USA.	springer@sprsgi.med.harvard.edu		Oxvig, Claus/0000-0002-4715-9719	NATIONAL CANCER INSTITUTE [R37CA031799, R01CA031799] Funding Source: NIH RePORTER; NCI NIH HHS [CA31799] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BILSLAND CAG, 1994, J LEUKOCYTE BIOL, V55, P501, DOI 10.1002/jlb.55.4.501; BRIESEWITZ R, 1993, J BIOL CHEM, V268, P2989; BrõndÚn CI., 1991, INTRO PROTEIN STRUCT; CALVETE JJ, 1992, BIOCHEM J, V282, P523, DOI 10.1042/bj2820523; CALVETE JJ, 1989, BIOCHEM J, V261, P551, DOI 10.1042/bj2610551; CALVETE JJ, 1994, BIOCHEM J, V298, P1; CALVETE JJ, 1989, BIOCHEM J, V261, P561, DOI 10.1042/bj2610561; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DIAMOND MS, 1994, CURR BIOL, V4, P506, DOI 10.1016/S0960-9822(00)00111-1; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; GarciaHiguera I, 1996, BIOCHEMISTRY-US, V35, P13985, DOI 10.1021/bi9612879; GINSBERG MH, 1995, BIOCHEM SOC T, V23, P439, DOI 10.1042/bst0230439; Gotoh O, 1996, J MOL BIOL, V264, P823, DOI 10.1006/jmbi.1996.0679; HEINZEL SS, 1988, J VIROL, V62, P3738, DOI 10.1128/JVI.62.10.3738-3746.1988; HO MK, 1983, J BIOL CHEM, V258, P2766; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Huang CC, 1997, P NATL ACAD SCI USA, V94, P3156, DOI 10.1073/pnas.94.7.3156; Huang CC, 1997, P NATL ACAD SCI USA, V94, P3162, DOI 10.1073/pnas.94.7.3162; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM SCT, 1992, J BIOL CHEM, V267, P5649; LARSON RS, 1989, J CELL BIOL, V108, P703, DOI 10.1083/jcb.108.2.703; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; Lu CF, 1997, J IMMUNOL, V159, P268; MILLER LJ, 1987, J IMMUNOL, V139, P842; NERMUT MV, 1988, EMBO J, V7, P4093, DOI 10.1002/j.1460-2075.1988.tb03303.x; PETRUZZELLI L, 1995, J IMMUNOL, V155, P854; PuzonMcLaughlin W, 1996, J BIOL CHEM, V271, P20438, DOI 10.1074/jbc.271.34.20438; PYTELA R, 1988, EMBO J, V7, P1371, DOI 10.1002/j.1460-2075.1988.tb02953.x; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; Rost B, 1996, METHOD ENZYMOL, V266, P525; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SANCHEZMADRID F, 1983, J EXP MED, V158, P1785, DOI 10.1084/jem.158.6.1785; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SHAW SK, 1994, J BIOL CHEM, V269, P6016; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; Tuckwell DS, 1997, FEBS LETT, V400, P297, DOI 10.1016/S0014-5793(96)01368-3; Uciechowski P., 1989, LEUCOCYTE TYPING, P543; VanderVieren M, 1995, IMMUNITY, V3, P683, DOI 10.1016/1074-7613(95)90058-6; WEISEL JW, 1992, J BIOL CHEM, V267, P16637; WIPPLER J, 1994, J BIOL CHEM, V269, P8754; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; ZHOU LB, 1994, J BIOL CHEM, V269, P17075	51	58	59	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15138	15147		10.1074/jbc.273.24.15138	http://dx.doi.org/10.1074/jbc.273.24.15138			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614126	hybrid			2022-12-27	WOS:000074160400068
J	Parekh, AB				Parekh, AB			Slow feedback inhibition of calcium release-activated calcium current by calcium entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPLETION; CELLS; RECEPTOR; INACTIVATION; STORES; INFLUX	In many nonexcitable cells, depletion of the inositol 1,4,5-trisphosphate-sensitive store activates Ca(2+) influx, a process termed store-operated Ca(2+) entry. In rat basophilic leukemia cells, emptying of the stores activates a highly selective Ca(2+) release-activated Ca(2+) current (CRAC), I(CRAC). We have recently found that I(CRAC) activates in an essentially all-or-none manner when the current is evoked by receptor stimulation, dialysis with inositol 1,4,5-trisphosphate via the patch pipette, or through the Ca(2+) ATPase inhibitor thapsigargin (Parekh, A. B., Fleig, A., and Penner, R. (1997) Cell 89, 973-980), Regulatory mechanisms must therefore operate to control the overall amount of Ca(2+) that enters through CRAC channels. Such mechanisms include membrane potential and protein kinase C. In the present study, we have investigated additional inhibitory pathways that serve to determine just how much Ca(2+) can enter through I(CRAC). We have directly measured the current using the whole cell patch clamp technique. We report the presence of a slow Ca(2+)-dependent inactivation mechanism that curtails Ca(2+) entry through CRAC channels. This inactivation mechanism is switched on by Ca(2+) entering through CRAC channels, and therefore constitutes a slow negative feedback process. Although it requires a rise in intracellular Ca(2+) for activation, it maintains CRAC channels inactive even under conditions that lower intracellular Ca(2+) levels. The inactivation mechanism does not involve store refilling, protein phosphorylation, G proteins, nor Ca(2+)-dependent enzymes. It accounts for up to 70% of the total inactivation of I(CRAC), and therefore appears to be a dominant inhibitory mechanism. It is likely to be an important factor that shapes the profile of the Ca(2+) signal in these non-excitable cells.	Univ Oxford, Dept Physiol, Oxford OX1 3PT, England	University of Oxford	Parekh, AB (corresponding author), Univ Oxford, Dept Physiol, Parks Rd, Oxford OX1 3PT, England.	anant.parekh@physiol.ox.ac.uk			Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CHAD JE, 1986, J PHYSIOL-LONDON, V378, P31, DOI 10.1113/jphysiol.1986.sp016206; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; JACOB R, 1990, J PHYSIOL-LONDON, V421, P55, DOI 10.1113/jphysiol.1990.sp017933; Khan AA, 1996, SCIENCE, V273, P503, DOI 10.1126/science.273.5274.503; Lewis RS, 1996, SOC GEN PHY, V51, P241; Louzao MC, 1996, J BIOL CHEM, V271, P14807, DOI 10.1074/jbc.271.25.14807; Parekh AB, 1995, J PHYSIOL-LONDON, V489, P377, DOI 10.1113/jphysiol.1995.sp021058; Parekh AB, 1996, J BIOL CHEM, V271, P23161, DOI 10.1074/jbc.271.38.23161; PAREKH AB, 1995, P NATL ACAD SCI USA, V92, P7907, DOI 10.1073/pnas.92.17.7907; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Parekh AB, 1997, CELL, V89, P973, DOI 10.1016/S0092-8674(00)80282-2; Petersen CCH, 1996, PFLUG ARCH EUR J PHY, V432, P286, DOI 10.1007/s004240050135; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; ZWEIFACH A, 1995, J GEN PHYSIOL, V105, P209, DOI 10.1085/jgp.105.2.209; ZWEIFACH A, 1995, J BIOL CHEM, V270, P14445, DOI 10.1074/jbc.270.24.14445	19	87	88	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14925	14932		10.1074/jbc.273.24.14925	http://dx.doi.org/10.1074/jbc.273.24.14925			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614097	hybrid			2022-12-27	WOS:000074160400039
J	Mio, T; Yabe, T; Arisawa, M; Yamada-Okabe, H				Mio, T; Yabe, T; Arisawa, M; Yamada-Okabe, H			The eukaryotic UDP-N-acetylglucosamine pyrophosphorylases - Gene cloning, protein expression, and catalytic mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; N-ACETYLGLUCOSAMINE-1-PHOSPHATE URIDYLTRANSFERASE; GLUCOSE PYROPHOSPHORYLASE; SACCHAROMYCES-CEREVISIAE; DNA-SEQUENCE; YEAST; ENZYME; TRANSCRIPTION; PURIFICATION; SYNTHETASE	A search of the yeast data base for a protein homologous to Escherichia coli UDP-N-acetylglucosamine pyrophosphorylase yielded UAP1 (UDP-N-acetylglucosamine pyrophosphorylase), the Saccharomyces cerevisiae gene for UDP-N-acetylglucosamine pyrophosphorylase. The Candida albicans and human homologs were also cloned by screening a C. albicans genomic library and a human testis cDNA library, respectively. Sequence analysis revealed that the human UAP1 cDNA was identical to previously reported AGX1., A null mutation of the S. cerevisiae UAP1 (ScUAP1) gene was lethal, and when expressed under the control of ScUAP1 promoter, both C. albicans and Homo sapiens UAP1 (CaUAP1 and HsUAP1) rescued the ScUAP1-deficient S., cerevisiae cells. All the recombinant ScUap1p, CaUap1p, and HsUap1p possessed UDP-N-acelylglucosamine pyrophosphorylase activities in vitro. The yeast Uap1p utilized N-acetylglucosamirne-1-phosphate as the substrate, and together with Agm1p, it produced UDP-N-acetylglucosamine from N-acetylglucosamine-6-phosphate. These results demonstrate that the UAP1 genes indeed specify eukaryotic UDP-GlcNAc pyrophosphorylase and that phosphomutase reaction precedes uridyltransfer., Sequence comparison with other UDP-sugar pyrophosphorylases revealed that amino acid residues, Gly(112) Gly(114), Thr(115), Arg(116), Pro(122), and Lys(123) of ScUap1p are highly conserved in UDP-sugar pyrophosphorylases reported to date, Among these amino acids, alanine substitution for Gly(112), Arg(116), or Lys(123) severely diminished the activity, suggesting that Gly(112), Arg(116), or Lys(123) are possible catalytic residues of the enzyme.	Nippon Roche Res Ctr, Dept Mycol, Kamakura, Kanagawa 2478530, Japan	Roche Holding	Yamada-Okabe, H (corresponding author), Nippon Roche Res Ctr, Dept Mycol, 200 Kajiwara, Kamakura, Kanagawa 2478530, Japan.	hisafumi.okabe@roche.com	Yabe, Tomio/B-5900-2013	Yabe, Tomio/0000-0002-9295-8560				BOLES E, 1994, EUR J BIOCHEM, V220, P83, DOI 10.1111/j.1432-1033.1994.tb18601.x; CABIB E, 1982, ANNU REV BIOCHEM, V51, P763, DOI 10.1146/annurev.bi.51.070182.003555; Cabib E.., 1981, ENCY PLANT PHYSL N B, V13, P395; DARAN JM, 1995, EUR J BIOCHEM, V233, P520, DOI 10.1111/j.1432-1033.1995.520_2.x; DIEKMAN AB, 1994, BIOL REPROD, V50, P1087, DOI 10.1095/biolreprod50.5.1087; DOBROGOS.WJ, 1968, J BACTERIOL, V95, P578, DOI 10.1128/JB.95.2.578-584.1968; DUTKAMALEN S, 1988, BIOCHIMIE, V70, P287, DOI 10.1016/0300-9084(88)90073-9; FloresDiaz M, 1997, J BIOL CHEM, V272, P23784, DOI 10.1074/jbc.272.38.23784; Freese EB, 1970, J BACTERIOL, V101, P1046, DOI 10.1128/JB.101.3.1046-1062.1970; GUHA SK, 1985, ARCH BIOCHEM BIOPHYS, V243, P168, DOI 10.1016/0003-9861(85)90785-4; Hashimoto H, 1997, J BIOL CHEM, V272, P16308, DOI 10.1074/jbc.272.26.16308; HASHIMOTOGOTOH T, 1995, GENE, V152, P271, DOI 10.1016/0378-1119(94)00750-M; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; HOFMANN M, 1994, EUR J BIOCHEM, V221, P741, DOI 10.1111/j.1432-1033.1994.tb18787.x; HOLTJE JV, 1985, MOL CYTOLOGY ESCHERI, P77; KEPES F, 1988, J BIOL CHEM, V263, P9155; MENGINLECREULX D, 1994, J BACTERIOL, V176, P5788, DOI 10.1128/JB.176.18.5788-5795.1994; MENGINLECREULX D, 1993, J BACTERIOL, V175, P6150, DOI 10.1128/JB.175.19.6150-6157.1993; Oesterhelt C, 1997, FEBS LETT, V401, P35, DOI 10.1016/S0014-5793(96)01425-1; OH D, 1990, MOL CELL BIOL, V10, P1415, DOI 10.1128/MCB.10.4.1415; PARK JT, 1987, ESCHERICHIA COLI SAL, V1, P663; PENG HL, 1993, FEBS LETT, V329, P153, DOI 10.1016/0014-5793(93)80213-E; RAETZ CRH, 1987, ESCHERICHIA COLI SAL, V1, P498; RANDERATH K, 1965, ANAL BIOCHEM, V13, P575, DOI 10.1016/0003-2697(65)90356-8; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH DJ, 1992, MOL CELL BIOL, V12, P2924, DOI 10.1128/MCB.12.7.2924; Tajima M, 1985, Yeast, V1, P67, DOI 10.1002/yea.320010108; WALKER JE, 1984, BIOCHEM J, V224, P799, DOI 10.1042/bj2240799; WATZELE G, 1989, J BIOL CHEM, V264, P8753; WEISSBORN AC, 1994, J BACTERIOL, V176, P2611, DOI 10.1128/JB.176.9.2611-2618.1994; WHITE RJ, 1968, BIOCHEM J, V106, P847, DOI 10.1042/bj1060847; WU HC, 1971, J BACTERIOL, V105, P455, DOI 10.1128/JB.105.2.455-466.1971; YamadaOkabe T, 1996, MICROBIOL-UK, V142, P2515, DOI 10.1099/00221287-142-9-2515	34	126	135	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14392	14397		10.1074/jbc.273.23.14392	http://dx.doi.org/10.1074/jbc.273.23.14392			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603950	hybrid			2022-12-27	WOS:000074021500052
J	Needham, LK; Rozengurt, E				Needham, LK; Rozengurt, E			G alpha(12) and G alpha(13) stimulate rho-dependent tyrosine phosphorylation of focal adhesion kinase, paxillin, and p130 Crk-associated substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; STRESS FIBER FORMATION; MUTANT ALPHA-SUBUNITS; LYSOPHOSPHATIDIC ACID; GROWTH-FACTOR; G-PROTEINS; TRANSFORMING ACTIVITY; ACTIN CYTOSKELETON; RAT-1 FIBROBLASTS; PHOSPHOLIPASE-C	We examined whether constitutively active mutants of the G alpha proteins G alpha(12) and G alpha(13), which together comprise the G(12) subfamily of G alpha proteins, induce Rho-dependent tyrosine phosphoaylation of the focal adhesion proteins p125 focal adhesion kinase, paxillin, and p130 Crk-associated substrate. We report that transient expression of the constitutively active mutants of G alpha(12) Or of G alpha(13) in human embryonic kidney 293 cells stimulates tyrosine phosphorylation of a set of proteins of M-r of 110,000-130,000, 97,000, and 60,000-70,000. We identified p125 focal adhesion kinase, paxillin, and p130 Crk-associated substrate as prominent tyrosine-phosphorylated proteins in human embryonic kidney 293 cells expressing constitutively active G alpha(12) and G alpha(13). In common with the increased tyrosine phosphorylation of these proteins mediated by mitogens acting through heptahelical receptors, the G alpha(12)- and G alpha(13)-mediated increase in tyrosine phosphorylation is blocked by cytochalasin D, which specifically disrupts the actin cytoskeleton, and by the Clostridium botulinum C3 exoenzyme, which ADP-ribosylates and inactivates Rho. Our results support the hypothesis that G alpha(12) and G alpha(13) activate Rho and suggest that G alpha(12) and G alpha(13) may mediate the tyrosine phosphorylation of p125 focal adhesion kinase, paxillin, and p130 Crk-associated substrate.	Imperial Canc Res Fund, London WC2A 3PX, England	Cancer Research UK	Rozengurt, E (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, 900 Vet Ave,Warren Hall Room 11-124, Los Angeles, CA 90095 USA.							Aktories K, 1997, J CLIN INVEST, V99, P827, DOI 10.1172/JCI119245; Althoefer H, 1997, J BIOL CHEM, V272, P24380, DOI 10.1074/jbc.272.39.24380; ARAGAY AM, 1995, J BIOL CHEM, V270, P20073, DOI 10.1074/jbc.270.34.20073; AUVINEN M, 1995, MOL CELL BIOL, V15, P6513; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Cary LA, 1996, J CELL SCI, V109, P1787; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Casamassima A, 1997, J BIOL CHEM, V272, P9363; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Charlesworth A, 1996, ONCOGENE, V12, P1337; Collins LR, 1997, ONCOGENE, V15, P595, DOI 10.1038/sj.onc.1201220; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; Exton JH, 1996, ANNU REV PHARMACOL, V36, P481, DOI 10.1146/annurev.pa.36.040196.002405; Fleming IN, 1997, J BIOL CHEM, V272, P33105, DOI 10.1074/jbc.272.52.33105; Flinn HM, 1996, J CELL SCI, V109, P1133; FOHLA A, 1998, J BIOL CHEM, V273, P4653; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HAYCOCK JW, 1993, ANAL BIOCHEM, V208, P397, DOI 10.1006/abio.1993.1068; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; Ilic D, 1997, J CELL SCI, V110, P401; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; KUMAGAI N, 1993, FEBS LETT, V329, P273, DOI 10.1016/0014-5793(93)80236-N; KUMAGAI N, 1993, J BIOL CHEM, V268, P24536; Lacerda HM, 1997, J BIOL CHEM, V272, P9587; Lacerda HM, 1996, J BIOL CHEM, V271, P439, DOI 10.1074/jbc.271.1.439; LACH EB, 1995, CELL GROWTH DIFFER, V6, P1427; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LEEBLUNDBERG LMF, 1994, J BIOL CHEM, V269, P24328; Lin X, 1996, J BIOL CHEM, V271, P22604, DOI 10.1074/jbc.271.37.22604; Mitsui H, 1997, J BIOL CHEM, V272, P4904, DOI 10.1074/jbc.272.8.4904; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; Plonk SG, 1998, J BIOL CHEM, V273, P4823, DOI 10.1074/jbc.273.9.4823; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; RANKIN S, 1994, J BIOL CHEM, V269, P704; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROZENGURT E, 1995, CANCER SURV, V24, P81; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SECKL MJ, 1995, J BIOL CHEM, V270, P6984, DOI 10.1074/jbc.270.12.6984; SEUFFERLEIN T, 1995, CELL GROWTH DIFFER, V6, P383; Seufferlein T, 1996, MOL BIOL CELL, V7, P1865, DOI 10.1091/mbc.7.12.1865; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P27610; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24343, DOI 10.1074/jbc.270.41.24343; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; SPICHER K, 1994, BIOCHEM BIOPH RES CO, V198, P906, DOI 10.1006/bbrc.1994.1129; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TURNER CE, 1994, J CELL SCI, V107, P1583; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; WILSON SP, 1995, ANAL BIOCHEM, V226, P212, DOI 10.1006/abio.1995.1216; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; WU DQ, 1992, J BIOL CHEM, V267, P1811; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980; YULE DI, 1992, J BIOL CHEM, V267, P13830; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1991, J BIOL CHEM, V266, P24126; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	76	100	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14626	14632		10.1074/jbc.273.23.14626	http://dx.doi.org/10.1074/jbc.273.23.14626			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603980	hybrid			2022-12-27	WOS:000074021500082
J	Misra, UK; Pizzo, SV				Misra, UK; Pizzo, SV			Binding of receptor-recognized forms of alpha(2)-macroglobulin to the alpha(2)-macroglobulin signaling receptor activates phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE PERITONEAL-MACROPHAGES; CA2+ POOL DEPLETION; PHOSPHOINOSITIDE 3-KINASE; CELL-GROWTH; ALPHA(2)M RECEPTORS; PROTEIN; LIGATION; CALCIUM; KINASE; STIMULATION	Ligation of the alpha(2)-macroglobulin (alpha(2)M) signaling receptor by receptor-recognized forms of alpha(2)M (alpha(2)M*) initiates mitogenesis secondary to increased intracellular Ca2+. We report here that ligation of the alpha(2)M signaling receptor also causes a 1.5-2.5-fold increase in wortmannin-sensitive phosphatidylinositol 3-kinase (PI3K) activity as measured by the quantitation of phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 formation was alpha(2)M* concentration-dependent with a maximal response at similar to 50 pM ligand concentration. The peak formation of PIP3 occurred at 10 min of incubation. The alpha(2)M receptor binding fragment mutant K1370R which binds to the alpha(2)M signaling receptor activating the signaling cascade, increased PIP3 formation by 2-fold. The mutant K1374A, which binds very poorly to the alpha(2)M signaling receptor, did not cause any increase in PIP3 formation. alpha(2)M*-induced DNA synthesis was inhibited by wortmannin. 1,2-Bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acetoxymethylester a chelator of intracellular Ca2+, drastically reduced alpha(2)M*-induced increases in PIP3 formation. We conclude that PI3K is involved in alpha(2)M*-induced mitogenesis in macrophages and intracellular Ca2+ plays a role in PI3K activation.	Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA	Duke University	Pizzo, SV (corresponding author), Duke Univ, Med Ctr, Dept Pathol, Box 3712, Durham, NC 27710 USA.	pizzo001@mc.duke.edu						BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BOS JL, 1995, TRENDS BIOCHEM SCI, V20, P441, DOI 10.1016/S0968-0004(00)89097-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carpenter CL, 1996, BBA-REV CANCER, V1288, pM11, DOI 10.1016/0304-419X(96)00018-2; CHARLESWORTH A, 1994, J BIOL CHEM, V269, P32528; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; CHU CT, 1994, LAB INVEST, V71, P792; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; DING JB, 1995, J BIOL CHEM, V270, P11684, DOI 10.1074/jbc.270.19.11684; DITTMER JC, 1964, J LIPID RES, V5, P126; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; GHOSH TK, 1991, J BIOL CHEM, V266, P24690; Graber MN, 1996, J BIOL CHEM, V271, P883, DOI 10.1074/jbc.271.2.883; Howard GC, 1996, J BIOL CHEM, V271, P14105, DOI 10.1074/jbc.271.24.14105; Howard GC, 1996, J CLIN INVEST, V97, P1193, DOI 10.1172/JCI118533; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; MISRA UK, 1995, BIOCHEM J, V309, P151, DOI 10.1042/bj3090151; Misra UK, 1998, BBA-MOL CELL RES, V1401, P121, DOI 10.1016/S0167-4889(97)00123-7; Misra UK, 1997, J BIOL CHEM, V272, P497; MISRA UK, 1994, ANN NY ACAD SCI, V737, P486, DOI 10.1111/j.1749-6632.1994.tb44347.x; MISRA UK, 1993, BIOCHEM J, V290, P885, DOI 10.1042/bj2900885; MISRA UK, 1994, J BIOL CHEM, V269, P12541; MISRA UK, 1994, J BIOL CHEM, V269, P18303; Misra UK, 1996, J CELL BIOCHEM, V61, P39, DOI 10.1002/(SICI)1097-4644(19960401)61:1<39::AID-JCB6>3.3.CO;2-8; MISRA UK, 1998, IN PRESS CELL SIGNAL; OKADA T, 1994, J BIOL CHEM, V269, P3563; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SALVESEN G, 1993, HEMOSTASIS THROMBOSE, P241; Santella L, 1997, FASEB J, V11, P1091, DOI 10.1096/fasebj.11.13.9367344; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; Sottrup-Jensen L., 1987, PLASMA PROTEINS, V5, P191; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; UFRETVINCENTY CA, 1995, J BIOL CHEM, V270, P26790, DOI 10.1074/jbc.270.45.26790; UHING RJ, 1991, BIOCHIM BIOPHYS ACTA, V1093, P115, DOI 10.1016/0167-4889(91)90111-A; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Webb DJ, 1995, EUR J BIOCHEM, V234, P714, DOI 10.1111/j.1432-1033.1995.714_a.x	44	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13399	13402		10.1074/jbc.273.22.13399	http://dx.doi.org/10.1074/jbc.273.22.13399			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593670	hybrid			2022-12-27	WOS:000073919100009
J	Pepinsky, RB; Zeng, CH; Wen, DY; Rayhorn, P; Baker, DP; Williams, KP; Bixler, SA; Ambrose, CM; Garber, EA; Miatkowski, K; Taylor, FR; Wang, EA; Galdes, A				Pepinsky, RB; Zeng, CH; Wen, DY; Rayhorn, P; Baker, DP; Williams, KP; Bixler, SA; Ambrose, CM; Garber, EA; Miatkowski, K; Taylor, FR; Wang, EA; Galdes, A			Identification of a palmitic acid-modified form of human Sonic hedgehog	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESORPTION MASS-SPECTROMETRY; MOTOR-NEURON INDUCTION; CUBITUS-INTERRUPTUS; FLOOR PLATE; PROTEIN; DROSOPHILA; RECEPTOR; MATRIX; AUTOPROTEOLYSIS; POLARITY	During hedgehog biosynthesis, autocatalytic processing produces a lipid-modified amino-terminal fragment (residues 24-197 in the human Sonic hedgehog sequence) that is responsible for all known hedgehog signaling activity and that is highly conserved evolutionarily. Published in vitro biochemical studies using Drosophila hedgehog identified the membrane anchor as a cholesterol, and localized the site of attachment to the COOH terminus of the fragment. We have expressed full-length human Sonic hedgehog in insect and in mammalian cells and determined by mass spectrometry that, in addition to cholesterol, the human hedgehog protein is palmitoylated, Peptide mapping and sequencing data indicate that the palmitoyl group is attached to the NH, terminus of the protein on the a-amino group of Cys-24, Cell-free palmitoylation studies demonstrate that radioactive palmitic acid is readily incorporated into wild type Sonic hedgehog, but not into variant forms lacking the Cys-24 attachment site. The lipid-tethered forms of hedgehog showed about a 30-fold increase in potency over unmodified soluble hedgehog in a cell-based (C3H10T1/2 alkaline phosphatase induction) assay, suggesting that the lipid tether plays an important role in hedgehog function. The observation that an extracellular protein such as Shh is palmitoylated is highly unusual and further adds to the complex nature of this protein.	Biogen Inc, Dept Prot Chem, Cambridge, MA 02142 USA; Ontogeny Inc, Cambridge, MA 02139 USA	Biogen	Pepinsky, RB (corresponding author), Biogen Inc, Dept Prot Chem, 14 Cambridge Ctr, Cambridge, MA 02142 USA.							Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092-8674(00)80094-X; Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; BEAVIS RC, 1992, ORG MASS SPECTROM, V27, P156, DOI 10.1002/oms.1210270217; BIZZOZERO OA, 1995, METHOD ENZYMOL, V250, P361; BUMCROT DA, 1995, MOL CELL BIOL, V15, P2294; Caron JM, 1997, MOL BIOL CELL, V8, P621, DOI 10.1091/mbc.8.4.621; Dominguez M, 1996, SCIENCE, V272, P1621, DOI 10.1126/science.272.5268.1621; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; Grosenbach DW, 1997, J BIOL CHEM, V272, P1956, DOI 10.1074/jbc.272.3.1956; HALL TMT, 1995, NATURE, V378, P212, DOI 10.1038/378212a0; JOHNSON RL, 1995, CELL, V81, P313, DOI 10.1016/0092-8674(95)90381-X; Kinto N, 1997, FEBS LETT, V404, P319, DOI 10.1016/S0014-5793(97)00014-8; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; MARIGO V, 1995, GENOMICS, V28, P44, DOI 10.1006/geno.1995.1104; Motoyama J, 1998, NAT GENET, V18, P104, DOI 10.1038/ng0298-104; PEPINSKY RB, 1991, J BIOL CHEM, V266, P18244; PERRIMON N, 1995, CELL, V80, P517, DOI 10.1016/0092-8674(95)90503-0; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Porter JA, 1996, CELL, V86, P21, DOI 10.1016/S0092-8674(00)80074-4; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; Sanicola M, 1997, P NATL ACAD SCI USA, V94, P6238, DOI 10.1073/pnas.94.12.6238; SPENGLER B, 1992, J PHYS CHEM-US, V96, P9678, DOI 10.1021/j100203a022; SPENGLER B, 1992, RAPID COMMUN MASS SP, V6, P105, DOI 10.1002/rcm.1290060207; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9; Therond PP, 1996, P NATL ACAD SCI USA, V93, P4224, DOI 10.1073/pnas.93.9.4224; WANG EA, 1993, GROWTH FACTORS, V9, P57, DOI 10.3109/08977199308991582; WANG MZ, 1995, NAT MED, V1, P1184, DOI 10.1038/nm1195-1184; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WEN D, 1996, BIOCHEMISTRY-US, V30, P9700	35	556	587	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					14037	14045		10.1074/jbc.273.22.14037	http://dx.doi.org/10.1074/jbc.273.22.14037			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593755	hybrid			2022-12-27	WOS:000073919100094
J	Eichinger, L; Bahler, M; Dietz, M; Eckerskorn, C; Schleicher, M				Eichinger, L; Bahler, M; Dietz, M; Eckerskorn, C; Schleicher, M			Characterization and cloning of a Dictyostelium Ste20-like protein kinase that phosphorylates the actin-binding protein severin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN KINASE; PHEROMONE RESPONSE; CALCIUM-ION; DISCOIDEUM; MYOSIN; EXPRESSION; STRESS; DOMAIN; YEAST; CDC42	After receiving an external stimulus Dictyostelium amoebae are able to rearrange their actin cytoskeleton within seconds, and phosphorylation is a prime candidate for quick modification of cytoskeletal components. We isolated a kinase from cytosolic extracts that specifically phosphorylated severin, a Ca2+-dependent F-actin fragmenting protein. In gel filtration chromatography severin kinase eluted with a molecular mass of about 300 kDa and contained a 62-kDa component whose autophosphorylation caused a mobility shift in SDS-polyacrylamide gel electrophoresis and stimulated phosphorylation of severin. Severin kinase activity could be specifically precipitated with antibodies raised against the 62-kDa polypeptide. Phosphorylation of severin was strongly reduced in the presence of Ca2+, indicating additional regulation at the substrate level. Peptide sequencing and cloning of the cDNA demonstrated that the 62-kDa protein belongs to the Ste20p- or pal-activated protein kinase family. It is most closely related to the germinal center kinase subfamily with its N-terminal positioned catalytic domain followed by a presumptive regulatory domain at the C terminus. The presence of a Ste20-like severin kinase in Dictyostelium suggests a direct signal transduction from the plasma membrane to the cytoskeleton by phosphorylation of actin-binding proteins.	Ludwigs Maximillian Universitat, Adolf Butenandt Inst Zellbiol, D-80336 Munich, Germany; Max Planck Inst Biochem, D-82152 Martinsried, Germany	University of Munich; Max Planck Society	Schleicher, M (corresponding author), Ludwigs Maximillian Universitat, Adolf Butenandt Inst Zellbiol, Schillerstr 42, D-80336 Munich, Germany.	schleicher@bio.med.uni-muenchen.de		Eichinger, Ludwig/0000-0003-1594-6117				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRETSCHER A, 1979, P NATL ACAD SCI USA, V76, P2321, DOI 10.1073/pnas.76.5.2321; Brzeska H, 1996, J BIOL CHEM, V271, P16983, DOI 10.1074/jbc.271.29.16983; Brzeska H, 1996, J BIOL CHEM, V271, P27056, DOI 10.1074/jbc.271.43.27056; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; CONDEELIS J, 1993, ANNU REV CELL BIOL, V9, P411, DOI 10.1146/annurev.cb.09.110193.002211; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; Creasy CL, 1996, J BIOL CHEM, V271, P21049, DOI 10.1074/jbc.271.35.21049; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; Creasy CL, 1995, GENE, V167, P303, DOI 10.1016/0378-1119(95)00653-2; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; DeCorte V, 1996, BIOCHEMISTRY-US, V35, P5472, DOI 10.1021/bi952237r; Dharmawardhane S, 1997, J CELL BIOL, V138, P1265, DOI 10.1083/jcb.138.6.1265; DORING V, 1991, J BIOL CHEM, V266, P17509; ECKERSKORN C, 1988, EUR J BIOCHEM, V176, P509, DOI 10.1111/j.1432-1033.1988.tb14308.x; EICHINGER L, 1992, BIOCHEMISTRY-US, V31, P4779, DOI 10.1021/bi00135a006; EICHINGER L, 1991, J CELL BIOL, V112, P665, DOI 10.1083/jcb.112.4.665; FRIESEN H, 1994, GENE DEV, V8, P2162, DOI 10.1101/gad.8.18.2162; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; HASEGAWA T, 1980, BIOCHEMISTRY-US, V19, P2677, DOI 10.1021/bi00553a021; HATZ P, 1994, J BIOL CHEM, V269, P16802; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LACOMBE ML, 1986, J BIOL CHEM, V261, P6811; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; Lee SF, 1996, J BIOL CHEM, V271, P27044, DOI 10.1074/jbc.271.43.27044; LEE SF, 1995, J BIOL CHEM, V270, P11776, DOI 10.1074/jbc.270.20.11776; LEEUW T, 1995, SCIENCE, V270, P1210, DOI 10.1126/science.270.5239.1210; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MATSUDAIRA P, 1988, CELL, V54, P139, DOI 10.1016/0092-8674(88)90542-9; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; NOEGEL A, 1985, J MOL BIOL, V185, P447, DOI 10.1016/0022-2836(85)90416-4; ONODA K, 1993, J BIOL CHEM, V268, P4106; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; Ren MD, 1996, P NATL ACAD SCI USA, V93, P5151, DOI 10.1073/pnas.93.10.5151; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEEL J, 1989, J BIOL CHEM, V264, P2832; SCHLEICHER M, 1992, NEW BIOL, V4, P461; SCHLEICHER M, 1984, EMBO J, V3, P2095, DOI 10.1002/j.1460-2075.1984.tb02096.x; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Taylor LK, 1996, P NATL ACAD SCI USA, V93, P10099, DOI 10.1073/pnas.93.19.10099; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; WITKE W, 1995, CELL, V81, P41, DOI 10.1016/0092-8674(95)90369-0; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912	55	32	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					12952	12959		10.1074/jbc.273.21.12952	http://dx.doi.org/10.1074/jbc.273.21.12952			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582328	hybrid			2022-12-27	WOS:000073768500039
J	Legeai-Mallet, L; Benoist-Lasselin, C; Delezoide, AL; Munnich, A; Bonaventure, J				Legeai-Mallet, L; Benoist-Lasselin, C; Delezoide, AL; Munnich, A; Bonaventure, J			Fibroblast growth factor receptor 3 mutations promote apoptosis but do not alter chondrocyte proliferation in thanatophoric dysplasia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR FGF RECEPTOR-1; KINASE ACTIVATION; MOUSE; ACHONDROPLASIA; EXPRESSION; DOMAIN; DIFFERENTIATION; ORGANOGENESIS; RESIDUES; NUCLEUS	Thanatophoric dysplasia (TD) is a lethal skeletal disorder caused by recurrent mutations in the fibroblast growth factor receptor 3 (FGFR 3) gene. The mitogenic response of fetal TD I chondrocytes in primary cultures upon stimulation by either FGF 2 or FGF 9 did not significantly differ from controls. Although the levels of FGFR 3 mRNAs in cultured TD chondrocytes were similar to controls, an abundant immunoreactive material was observed at the perinuclear level using an anti-FGFR 3 antibody in TD cells. Transduction signaling via the mitogen-activated protein kinase pathway was assessed by measuring extracellular signal-regulated kinase activity (ERK 1 and ERK 2). Early ERKs activation following FGF 9 supplementation was observed in TD chondrocytes (2 min) as compared with controls (5 min) but no signal was detected in the absence of ligand, By contrast ligand-independent activation of the STAT signaling pathway was demonstrated in cultured TD cells and confirmed by immunodetection of Stat 1 in the nuclei of hypertrophic TD chondrocytes. Moreover, the presence of an increased number of apoptotic chondrocytes in TD fetuses was associated with a higher expression of Bar and the simultaneous decrease of Bcl-2 levels. Taken together, these results indicate that FGFR 3 mutations in TD I fetuses do not hamper chondrocyte proliferation but rather alter their differentiation by triggering premature apoptosis through activation of the STAT signaling pathway.	Hop Necker Enfants Malad, INSERM U393, Unite Rech Handicaps Genet Enfant, F-75743 Paris 15, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Bonaventure, J (corresponding author), Hop Necker Enfants Malad, INSERM U393, Unite Rech Handicaps Genet Enfant, F-75743 Paris 15, France.	Bonavent@necker.fr	Legeai-Mallet, Laurence/E-6112-2016	Legeai-Mallet, Laurence/0000-0003-4989-5856				Amling M, 1997, J CELL BIOL, V136, P205, DOI 10.1083/jcb.136.1.205; BELLUS GA, 1995, NAT GENET, V10, P357, DOI 10.1038/ng0795-357; BONAVENTURE J, 1994, EXP CELL RES, V212, P97, DOI 10.1006/excr.1994.1123; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Chow RL, 1995, DEVELOPMENT, V121, P4383; Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496-390; Delezoide AL, 1997, HUM MOL GENET, V6, P1899, DOI 10.1093/hmg/6.11.1899; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; Gibson G, 1997, EXP CELL RES, V233, P372, DOI 10.1006/excr.1997.3576; HECHT D, 1995, GROWTH FACTORS, V12, P223, DOI 10.3109/08977199509036882; HUANG JT, 1995, J BIOL CHEM, V270, P5065, DOI 10.1074/jbc.270.10.5065; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Johnston CL, 1995, J BIOL CHEM, V270, P30643, DOI 10.1074/jbc.270.51.30643; Kanai M, 1997, J BIOL CHEM, V272, P6621, DOI 10.1074/jbc.272.10.6621; Kilkenny DM, 1996, ENDOCRINOLOGY, V137, P5078, DOI 10.1210/en.137.11.5078; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Maher PA, 1996, J CELL BIOL, V134, P529, DOI 10.1083/jcb.134.2.529; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; ORRURTREGER A, 1991, DEVELOPMENT, V113, P1419; PETERS K, 1993, DEV BIOL, V155, P423, DOI 10.1006/dbio.1993.1040; PETERS KG, 1992, DEVELOPMENT, V114, P233; POSADA J, 1992, SCIENCE, V255, P182; PRUDOVSKY I, 1994, J BIOL CHEM, V269, P31720; ROACH HI, 1995, J CELL BIOL, V131, P483, DOI 10.1083/jcb.131.2.483; Rousseau F, 1996, HUM MOL GENET, V5, P509, DOI 10.1093/hmg/5.4.509; ROUSSEAU F, 1995, NAT GENET, V10, P11, DOI 10.1038/ng0595-11; ROUSSEAU F, 1994, NATURE, V371, P252, DOI 10.1038/371252a0; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SantosOcampo S, 1996, J BIOL CHEM, V271, P1726, DOI 10.1074/jbc.271.3.1726; SEGER R, 1994, J BIOL CHEM, V269, P25699; SHIANG R, 1994, CELL, V78, P336; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; Thompson LM, 1997, MOL CELL BIOL, V17, P4169, DOI 10.1128/MCB.17.7.4169; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; Webster MK, 1996, MOL CELL BIOL, V16, P4081; Zha HB, 1996, MOL CELL BIOL, V16, P6494	41	120	125	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					13007	13014		10.1074/jbc.273.21.13007	http://dx.doi.org/10.1074/jbc.273.21.13007			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582336	hybrid			2022-12-27	WOS:000073768500047
J	Decottignies, A; Grant, AM; Nichols, JW; de Wet, H; McIntosh, DB; Goffeau, A				Decottignies, A; Grant, AM; Nichols, JW; de Wet, H; McIntosh, DB; Goffeau, A			ATPase and multidrug transport activities of the overexpressed yeast ABC protein Yor1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING CASSETTE TRANSPORTER; TRANSMEMBRANE CONDUCTANCE REGULATOR; RESISTANCE-ASSOCIATED PROTEIN; PURIFIED P-GLYCOPROTEIN; PLASMA-MEMBRANE ATPASE; SACCHAROMYCES-CEREVISIAE; DRUG TRANSPORT; ENCODING GENE; FUNCTIONAL RECONSTITUTION; H+-ATPASE	The Saccharomyces cerevisiae genome encodes 15 full-size ATP binding cassette transporters (ABC), of which PDR5, SNQ2, and YOR1 are known to be regulated by the transcription factors Pdr1p and Pdr3p (pleiotropic drug resistance). We have identified two new ABC transporter-encoding genes, PDR10 and PDR15, which were upregulated by the PDR1-3 mutation. These genes, as well as four other ABC transporter-encoding genes, were deleted in order to study the properties of Yor1p. The PDR1-3 gain-of-function mutant was then used to overproduce Yor1p up to 10% of the total plasma membrane proteins. Overexpressed Yor1p was photolabeled by [gamma-P-32]2',3'-O-(2,4,6-trinitrophenyl)-8-azido-ATP (K-0.5 = 45 mu m) and inhibited by ATP (K-D = 0.3 mM) in plasma membranes. Solubilization and partial purification on sucrose gradient allowed to detect significant Yor1p ATP hydrolysis activity (similar to 100 nmol of P-i . min(-1). mg(-1)). This activity was phospholipid-dependent and sensitive to low concentrations of vanadate (I-50 = 0.3 mu M) and oligomycin (I-50 = 8.5 mu g/ml). In vivo, we observed a correlation between the amount of Yor1p in the plasma membrane and the level of resistance to oligomycin. We also demonstrated that Yor1p drives an energy-dependent, proton uncoupler-insensitive, cellular extrusion of rhodamine B. Furthermore, cells lacking both Yor1p and Pdr5p (but not Snq2p) showed increased accumulation of the fluorescent derivative of 1-myristoyl-2-[6-(NBD)aminocaproyl]phosphatidylethanolamine. Despite their different topologies, both Yor1p and Pdr5p mediated the ATP-dependent translocation of similar drugs and phospholipids across the yeast cell membrane. Both ABC transporters exhibit ATP hydrolysis in vitro, but Pdr5p ATPase activity is about 15 times higher than that of Yor1p, which may indicate mechanistic or regulatory differences between the two enzymes.	Catholic Univ Louvain, Unite Biochim Physiol, B-1348 Louvain, Belgium; Emory Univ, Sch Med, Dept Physiol, Atlanta, GA 30322 USA; Univ Cape Town, Dept Chem Pathol, ZA-7925 Cape Town, South Africa	Universite Catholique Louvain; Emory University; University of Cape Town	Goffeau, A (corresponding author), Catholic Univ Louvain, Unite Biochim Physiol, Pl Croix Sud 2-20, B-1348 Louvain, Belgium.	goffeau@fysa.ucl.ac.be		de Wet, Heidi/0000-0002-9871-6909	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM052410] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52410] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ALSHAWI MK, 1994, J BIOL CHEM, V269, P8986; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMES BN, 1960, J BIOL CHEM, V235, P769; BALZI E, 1987, J BIOL CHEM, V262, P16871; BALZI E, 1994, J BIOL CHEM, V269, P2206; BAUBICHONCORTAY H, 1994, J BIOL CHEM, V269, P22983; Bolhuis H, 1996, EMBO J, V15, P4239, DOI 10.1002/j.1460-2075.1996.tb00798.x; Borgnia MJ, 1996, J BIOL CHEM, V271, P3163, DOI 10.1074/jbc.271.6.3163; Carvajal E, 1997, MOL GEN GENET, V256, P406, DOI 10.1007/s004380050584; Chang XB, 1997, J BIOL CHEM, V272, P30962, DOI 10.1074/jbc.272.49.30962; Churcher C, 1997, NATURE, V387, P84, DOI 10.1038/387s084; Cui ZF, 1996, J BIOL CHEM, V271, P14712, DOI 10.1074/jbc.271.25.14712; Dayan G, 1996, J BIOL CHEM, V271, P11652, DOI 10.1074/jbc.271.20.11652; Decottignies A, 1997, NAT GENET, V15, P137, DOI 10.1038/ng0297-137; DECOTTIGNIES A, 1995, J BIOL CHEM, V270, P18150, DOI 10.1074/jbc.270.30.18150; DECOTTIGNIES A, 1994, J BIOL CHEM, V269, P12797; DELAVEAU T, 1994, MOL GEN GENET, V244, P501, DOI 10.1007/BF00583901; dExaerde AD, 1996, YEAST, V12, P907; ERASO P, 1985, FEBS LETT, V191, P51, DOI 10.1016/0014-5793(85)80991-1; Eytan GD, 1996, J BIOL CHEM, V271, P3172, DOI 10.1074/jbc.271.6.3172; GOFFEAU A, 1988, METHOD ENZYMOL, V157, P528; Gottesman MM, 1995, ANNU REV GENET, V29, P607, DOI 10.1146/annurev.ge.29.120195.003135; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; Jacq C, 1997, NATURE, V387, P75, DOI 10.1038/387s075; KATZMANN DJ, 1995, MOL CELL BIOL, V15, P6875; KATZMANN DJ, 1994, MOL CELL BIOL, V14, P4653, DOI 10.1128/MCB.14.7.4653; Katzmann DJ, 1996, J BIOL CHEM, V271, P23049, DOI 10.1074/jbc.271.38.23049; Kean LS, 1997, J CELL BIOL, V138, P255, DOI 10.1083/jcb.138.2.255; Kolaczkowski M, 1996, J BIOL CHEM, V271, P31543, DOI 10.1074/jbc.271.49.31543; KUO CL, 1983, MOL CELL BIOL, V3, P1730, DOI 10.1128/MCB.3.10.1730; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li CH, 1996, J BIOL CHEM, V271, P28463, DOI 10.1074/jbc.271.45.28463; Li ZS, 1996, J BIOL CHEM, V271, P6509, DOI 10.1074/jbc.271.11.6509; Liu RH, 1997, BIOCHEMISTRY-US, V36, P2836, DOI 10.1021/bi9627119; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mahe Y, 1996, MOL MICROBIOL, V20, P109, DOI 10.1111/j.1365-2958.1996.tb02493.x; Mahe Y, 1996, J BIOL CHEM, V271, P25167, DOI 10.1074/jbc.271.41.25167; Mao QC, 1997, BBA-BIOMEMBRANES, V1327, P107, DOI 10.1016/S0005-2736(97)00050-3; MCINTOSH DB, 1996, J BIOL CHEM, V271, P25779; MEYERS S, 1992, CURR GENET, V21, P431, DOI 10.1007/BF00351651; MICHAELIS S, 1996, COLD SPRING HARB SYM, V40, P291; ParleMcDermott AG, 1996, YEAST, V12, P999; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SEEBREGTS CJ, 1989, J BIOL CHEM, V264, P2043; SHAPIRO AB, 1995, J BIOL CHEM, V270, P16167, DOI 10.1074/jbc.270.27.16167; SHAROM FJ, 1993, J BIOL CHEM, V268, P24197; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; SMITH AJ, 1994, FEBS LETT, V354, P263, DOI 10.1016/0014-5793(94)01135-4; SZCZYPKA MS, 1994, J BIOL CHEM, V269, P22853; THOMAS PJ, 1992, J BIOL CHEM, V267, P5727; Tommasini R, 1996, P NATL ACAD SCI USA, V93, P6743, DOI 10.1073/pnas.93.13.6743; ULASZEWSKI S, 1987, MOL GEN GENET, V207, P38, DOI 10.1007/BF00331488; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; Wach A, 1996, BIOCHEMISTRY-US, V35, P883, DOI 10.1021/bi951998r; WEMMIE JA, 1994, J BIOL CHEM, V269, P32592	57	313	323	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12612	12622		10.1074/jbc.273.20.12612	http://dx.doi.org/10.1074/jbc.273.20.12612			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575223	hybrid, Green Published			2022-12-27	WOS:000073629800088
J	Kocken, CHM; van der Wel, AM; Dubbeld, MA; Narum, DL; van de Rijke, FM; van Gemert, GJ; van der Linde, X; Bannister, LH; Janse, C; Waters, AP; Thomas, AW				Kocken, CHM; van der Wel, AM; Dubbeld, MA; Narum, DL; van de Rijke, FM; van Gemert, GJ; van der Linde, X; Bannister, LH; Janse, C; Waters, AP; Thomas, AW			Precise timing of expression of a Plasmodium falciparum-derived transgene in Plasmodium berghei is a critical determinant of subsequent subcellular localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APICAL MEMBRANE ANTIGEN; STABLE TRANSFECTION; MEROZOITE ANTIGEN; FULL-LENGTH; KNOWLESI; MALARIA; PF83/AMA-1; PARASITES	The development of transfection technology for malaria parasites holds significant promise for a more detailed characterization of molecules targeted by vaccines or drugs. One asexual blood stage vaccine candidate, apical membrane antigen-1 (AMA-1) of merozoite rhoptries has been shown to be the target of inhibitory, protective antibodies in both in vitro and in vivo studies. We have investigated heterologous (trans-species) expression of the human malaria Plasmodium falciparum AMA-1 (PF83/AMA-1) in the rodent parasite Plasmodium berghei, Transfected P. berghei expressed correctly folded and processed PF83/AMA-1 under control of both pb66/ama-1 and dhfr-ts promoters. Timing of expression was highly promoter-dependent and was critical for subsequent subcellular localization. Under control of pb66/ama-1, PF83/AMA-1 expression and localization in P. berghei was limited to the rhoptries of mature schizonts, similar to that observed for PF83/AMA-1 in P. falciparum. In contrast the dhfr-ts promoter permitted PF83/AMA-1 expression throughout schizogony as well as in gametocytes and gametes, Localization was aberrant and included direct expression at the merozoite and gamete surface, Processing from the full-length 83-kDa protein to a 66-kDa protein was observed not only in schizonts but also in gametocytes, indicating that processing could be mediated outside of rhoptries by a common protease, Trans-species expressed PF83/AMA-1 was highly immunogenic in mice, resulting in a response against a functionally critical domain of the molecule.	Biomed Primate Res Ctr, Dept Parasitol, NL-2280 GJ Rijswijk, Netherlands; Leiden Univ, Med Ctr, Dept Mol Cell Biol, Lab Cytochem & Cytometry, NL-2333 AL Leiden, Netherlands; Univ Nijmegen, Dept Med Microbiol, NL-6500 HB Nijmegen, Netherlands; Guys Hosp, Sch Med, Dept Anat, London SE1 9RT, England; Leiden Univ, Dept Parasitol, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Radboud University Nijmegen; Guy's & St Thomas' NHS Foundation Trust; Leiden University; Leiden University - Excl LUMC	Thomas, AW (corresponding author), Biomed Primate Res Ctr, Dept Parasitol, Lange Kleiweg 157, NL-2280 GJ Rijswijk, Netherlands.	thomas@bprc.nl	Waters, Andy P/C-9377-2009	Waters, Andy P/0000-0001-8900-2982; Narum, David/0000-0003-3041-5402; Janse, Chris J/0000-0002-6410-6205; Voorberg - van der Wel, Annemarie/0000-0001-9403-0515; Kocken, Clemens/0000-0002-4784-1734	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bannister L H, 1993, Methods Mol Biol, V21, P415; COLLINS WE, 1994, AM J TROP MED HYG, V51, P711, DOI 10.4269/ajtmh.1994.51.711; Crabb BS, 1996, P NATL ACAD SCI USA, V93, P7289, DOI 10.1073/pnas.93.14.7289; Crabb BS, 1997, CELL, V89, P287, DOI 10.1016/S0092-8674(00)80207-X; Crewther PE, 1996, INFECT IMMUN, V64, P3310, DOI 10.1128/IAI.64.8.3310-3317.1996; DEANS JA, 1988, PARASITE IMMUNOL, V10, P535, DOI 10.1111/j.1365-3024.1988.tb00241.x; DEANS JA, 1987, MOL BIOCHEM PARASIT, V26, P155, DOI 10.1016/0166-6851(87)90139-3; ELING W, 1977, TROPENMED PARASITOL, V28, P158; HARLOW E, 1988, ANTIBODIES LAB MANUA, P321; Hodder AN, 1996, J BIOL CHEM, V271, P29446, DOI 10.1074/jbc.271.46.29446; Horrocks P, 1996, MOL BIOCHEM PARASIT, V82, P207, DOI 10.1016/0166-6851(96)02737-5; HYMAN BC, 1979, J PARASITOL, V65, P421, DOI 10.2307/3280288; JAIKARIA NS, 1993, MOL BIOCHEM PARASIT, V57, P269, DOI 10.1016/0166-6851(93)90203-A; JANSE CJ, 1995, PARASITOL TODAY, V11, P138, DOI 10.1016/0169-4758(95)80133-2; LANZER M, 1993, EXP PARASITOL, V77, P121, DOI 10.1006/expr.1993.1068; Menard R, 1997, NATURE, V385, P336, DOI 10.1038/385336a0; MONS B, 1985, ANN SOC BELG MED TR, V65, P1; NARUM DL, 1993, J CHROMATOGR A, V657, P357, DOI 10.1016/0021-9673(93)80291-F; NARUM DL, 1994, MOL BIOCHEM PARASIT, V67, P59, DOI 10.1016/0166-6851(94)90096-5; Sambrook J., 2002, MOL CLONING LAB MANU; Sultan AA, 1997, CELL, V90, P511, DOI 10.1016/S0092-8674(00)80511-5; THOMAS AW, 1990, PARASITE IMMUNOL, V12, P105, DOI 10.1111/j.1365-3024.1990.tb00940.x; THOMAS AW, 1994, AM J TROP MED HYG, V51, P730, DOI 10.4269/ajtmh.1994.51.730; THOMAS AW, 1990, MOL BIOCHEM PARASIT, V42, P285, DOI 10.1016/0166-6851(90)90172-I; THOMAS AW, 1984, MOL BIOCHEM PARASIT, V13, P187, DOI 10.1016/0166-6851(84)90112-9; TOMAS AM, 1998, IN PRESS PARASITOL T; vanderWel AM, 1997, J EXP MED, V185, P1499, DOI 10.1084/jem.185.8.1499; VANDIJK MR, 1995, SCIENCE, V268, P1358, DOI 10.1126/science.7761856; vanDijk MR, 1997, MOL BIOCHEM PARASIT, V86, P155, DOI 10.1016/S0166-6851(97)02843-0; vanDijk MR, 1996, SCIENCE, V271, P662, DOI 10.1126/science.271.5249.662; WU YM, 1995, P NATL ACAD SCI USA, V92, P973, DOI 10.1073/pnas.92.4.973	31	138	140	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15119	15124		10.1074/jbc.273.24.15119	http://dx.doi.org/10.1074/jbc.273.24.15119			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614123	hybrid			2022-12-27	WOS:000074160400065
J	Frigerio, L; Vitale, A; Lord, JM; Ceriotti, A; Roberts, LM				Frigerio, L; Vitale, A; Lord, JM; Ceriotti, A; Roberts, LM			Free ricin a chain, proricin, and native toxin have different cellular fates when expressed in tobacco protoplasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; A-CHAIN; PROTEIN-DEGRADATION; STORAGE PROTEINS; INTRACELLULAR-TRANSPORT; COMMUNIS AGGLUTININ; TRANSGENIC TOBACCO; RIBOSOMAL-RNA; WILD-TYPE; INHIBITION	The catalytic A subunit of ricin can inactivate eukaryotic ribosomes, including those of Ricinus communis where the toxin is naturally produced. How such plant cells avoid intoxication has remained an open question. Here we report the transient expression of a number of ricin A chain-encoding cDNA constructs ill tobacco protoplasts, Ricin A chain entered the endoplasmic reticulum lumen, where it was efficiently glycosylated, but it was toxic to the cells and disappeared with time in a brefeldin A-insensitive manner, suggesting reverse translocation to the cytosol and eventual degradation. Proricin (the natural precursor form containing A and B chains joined together by a Linker sequence) was glycosylated, transported to the vacuole, and processed to its mature form, but was not toxic, Free ricin A chain and proricin were not secreted, whereas free ricin B chain was found entirely in the extracellular medium. The coexpression of ricin A and B chains resulted in the formation of disulfide-linked, transport-competent heterodimers, which were secreted, with a concomitant reduction in the observed cytotoxicity. These results suggest that the production of ricin as a precursor is essential for its routing to the vacuole and for protection of ricin-producing cells.	CNR, Inst Biosintesi Vegetali, I-20133 Milan, Italy; Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England	Consiglio Nazionale delle Ricerche (CNR); University of Warwick	Roberts, LM (corresponding author), CNR, Inst Biosintesi Vegetali, Via Bassini 15, I-20133 Milan, Italy.	LM@dna.bio.warwick.ac.uk	Ceriotti, Aldo/A-1448-2016; Frigerio, Lorenzo/D-2685-2009; Frigerio, Lorenzo/M-6013-2019	Ceriotti, Aldo/0000-0002-8230-8863; Frigerio, Lorenzo/0000-0003-4100-6022; Frigerio, Lorenzo/0000-0003-4100-6022; Vitale, Alessandro/0000-0001-5586-2255				BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BUTTERWORTH AG, 1983, EUR J BIOCHEM, V137, P57, DOI 10.1111/j.1432-1033.1983.tb07795.x; CERIOTTI A, 1991, EUR J BIOCHEM, V202, P959, DOI 10.1111/j.1432-1033.1991.tb16456.x; DAMICO L, 1992, PLANT J, V2, P443; EDWARDS GA, 1991, PLANT MOL BIOL, V17, P89, DOI 10.1007/BF00036809; ENDO Y, 1988, J BIOL CHEM, V263, P8735; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GOMEZ L, 1993, PLANT CELL, V5, P1113, DOI 10.1105/tpc.5.9.1113; Gomord V, 1997, PLANT J, V11, P313, DOI 10.1046/j.1365-313X.1997.11020313.x; HALLING KC, 1985, NUCLEIC ACIDS RES, V13, P8019, DOI 10.1093/nar/13.22.8019; HARAHISHIMURA I, 1993, PLANT J, V4, P793, DOI 10.1046/j.1365-313X.1993.04050793.x; HARLEY SM, 1985, PLANT SCI, V41, P111, DOI 10.1016/0168-9452(85)90111-6; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; LAMB FI, 1985, EUR J BIOCHEM, V148, P265, DOI 10.1111/j.1432-1033.1985.tb08834.x; Lee DH, 1996, J BIOL CHEM, V271, P27280, DOI 10.1074/jbc.271.44.27280; LEVANONY H, 1992, J CELL BIOL, V119, P1117, DOI 10.1083/jcb.119.5.1117; LORD JM, 1994, FASEB J, V8, P201, DOI 10.1096/fasebj.8.2.8119491; LORD JM, 1985, EUR J BIOCHEM, V146, P411, DOI 10.1111/j.1432-1033.1985.tb08667.x; MAY MJ, 1989, EMBO J, V8, P301, DOI 10.1002/j.1460-2075.1989.tb03377.x; OHARE M, 1987, FEBS LETT, V216, P73, DOI 10.1016/0014-5793(87)80759-7; OSBORN RW, 1990, EUR J BIOCHEM, V193, P401, DOI 10.1111/j.1432-1033.1990.tb19353.x; Pedrazzini E, 1997, PLANT CELL, V9, P1869, DOI 10.1105/tpc.9.10.1869; RICHARDSON PT, 1989, FEBS LETT, V255, P15, DOI 10.1016/0014-5793(89)81052-X; SEHNKE PC, 1994, J BIOL CHEM, V269, P22473; SHAILUBHAI K, 1988, J BIOL CHEM, V263, P15964; SIMPSON JC, 1995, J BIOL CHEM, V270, P20078, DOI 10.1074/jbc.270.34.20078; Simpson JC, 1996, EXP CELL RES, V229, P447, DOI 10.1006/excr.1996.0390; SLIGHTOM JL, 1985, NUCLEIC ACIDS RES, V13, P6483, DOI 10.1093/nar/13.18.6483; TABE LM, 1995, J ANIM SCI, V73, P2752; TAYLOR S, 1994, PLANT J, V5, P827, DOI 10.1046/j.1365-313X.1994.5060827.x; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; WILKINS TA, 1990, PLANT CELL, V2, P301, DOI 10.1105/tpc.2.4.301	35	77	83	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14194	14199		10.1074/jbc.273.23.14194	http://dx.doi.org/10.1074/jbc.273.23.14194			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603921	hybrid			2022-12-27	WOS:000074021500023
J	Murakami, M; Shimbara, S; Kambe, T; Kuwata, H; Winstead, MV; Tischfield, JA; Kudo, I				Murakami, M; Shimbara, S; Kambe, T; Kuwata, H; Winstead, MV; Tischfield, JA; Kudo, I			The functions of five distinct mammalian phospholipase A(2)S in regulating arachidonic acid release - Type IIA and type V secretory phospholipase A(2)S are functionally redundant and act in concert with cytosolic phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING-FACTOR ACETYLHYDROLASE; LOW-MOLECULAR-WEIGHT; PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-1; TUMOR-NECROSIS-FACTOR; RAT MESANGIAL CELLS; MOUSE MAST-CELLS; P388D(1) MACROPHAGES; NUCLEAR-ENVELOPE; RECOMBINANT EXPRESSION; CALCIUM IONOPHORE	We examined the relative contributions of five distinct mammalian phospholipase A(2) (PLA(2)) enzymes (cytosolic PLA(2) (cPLA(2); type IV), secretory PLA(2)s (sPLA(2)s; types IIA, V, and IIC), and Ca2+-independent PLA(2) (iPLA(2); type VI)) to arachidonic acid (AA) metabolism by overexpressing them in human embryonic kidney 293 fibroblasts and Chinese hamster ovary cells. Analyses using these transfectants revealed that cPLA(2) was a prerequisite for both the calcium ionophore-stimulated immediate and the interleukin (IL)-1- and serum-induced delayed phases of AA release, Type IIA sPLA, (sPLA(2)-IIA) mediated delayed AA release and, when expressed in larger amounts, also participated in immediate AA release. sPLA(2)-V, but not sPLA(2)-IIC, behaved in a manner similar to sPLA(2)-IIA. Both sPLA(2)s-IIA and -V, but not sPLA(2)-IIC, were heparin-binding PLA(2)s that exhibited significant affinity for cell-surface proteoglycans, and site-directed mutations in residues responsible for their membrane association or catalytic activity markedly reduced their ability to release AA from activated cells. Pharmacological studies using selective inhibitors as well as co-expression experiments supported the proposal that cPLA(2) is crucial for these sPLA(2)s to act properly. The AA-releasing effects of these sPLA(2)s were independent of the expression of the M-type sPLA(2) receptor. Both cPLA(2) sPLA(2)s-IIA, and -V were able to supply AA to downstream cyclooxygenase-2 for IL-1-induced prostaglandin E-2 biosynthesis, iPLA(2) increased the spontaneous release of fatty acids, and this was further augmented by serum but not by IL-1, Finally, iPLA(2)-derived AA was not metabolized to prostaglandin E-2. These observations provide evidence for the functional cross-talk or segregation of distinct PLA(2)s in mammalian cells in regulating AA metabolism and phospholipid turnover.	Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, Tokyo 142, Japan; Indiana Univ, Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA	Showa University; Indiana University System; Indiana University-Purdue University Indianapolis	Kudo, I (corresponding author), Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 142, Japan.		Kuwata, Hiro/N-2023-2019	Kuwata, Hiro/0000-0002-5023-1777; Tischfield, Jay/0000-0003-3217-8287	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038185] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38185] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Atsumi G, 1997, BBA-LIPID LIPID MET, V1349, P43, DOI 10.1016/S0005-2760(97)00082-9; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Balboa MA, 1997, J BIOL CHEM, V272, P8576, DOI 10.1074/jbc.272.13.8576; Balsinde J, 1997, J BIOL CHEM, V272, P20373, DOI 10.1074/jbc.272.33.20373; Balsinde J, 1996, J BIOL CHEM, V271, P31937, DOI 10.1074/jbc.271.50.31937; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; Balsinde J, 1997, J BIOL CHEM, V272, P29317, DOI 10.1074/jbc.272.46.29317; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Chen J, 1997, J CELL BIOCHEM, V64, P369, DOI 10.1002/(SICI)1097-4644(19970301)64:3<369::AID-JCB3>3.0.CO;2-T; CHEN J, 1994, J BIOL CHEM, V269, P2365; CHEN J, 1994, J BIOL CHEM, V269, P23018; CHEN J, 1994, BBA-LIPID LIPID MET, V1215, P115, DOI 10.1016/0005-2760(94)90099-X; Chen QR, 1997, J BIOL CHEM, V272, P5952, DOI 10.1074/jbc.272.9.5952; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; Cupillard L, 1997, J BIOL CHEM, V272, P15745, DOI 10.1074/jbc.272.25.15745; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; DIEZ E, 1994, BIOCHEM J, V301, P721, DOI 10.1042/bj3010721; DOLE VP, 1960, J BIOL CHEM, V235, P2595; FONTEH AN, 1994, J IMMUNOL, V152, P5438; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; FUTAKI N, 1993, GEN PHARMACOL, V24, P105, DOI 10.1016/0306-3623(93)90018-S; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; HARA S, 1995, BBA-LIPID LIPID MET, V1257, P11, DOI 10.1016/0005-2760(95)00011-Z; Hattori K, 1996, J BIOL CHEM, V271, P33032, DOI 10.1074/jbc.271.51.33032; Hattori M, 1995, J BIOL CHEM, V270, P31345, DOI 10.1074/jbc.270.52.31345; HATTORI M, 1994, J BIOL CHEM, V269, P23150; Hernandez M, 1998, J BIOL CHEM, V273, P606, DOI 10.1074/jbc.273.1.606; HOECK WG, 1993, P NATL ACAD SCI USA, V90, P4475, DOI 10.1073/pnas.90.10.4475; Hofmeister R, 1997, J BIOL CHEM, V272, P27730, DOI 10.1074/jbc.272.44.27730; Huang Z, 1996, BIOCHEMISTRY-US, V35, P3712, DOI 10.1021/bi952541k; Huang Z., 1994, MEDIAT INFLAMM, V3, P307; Huwiler A, 1997, BBA-LIPID LIPID MET, V1348, P257, DOI 10.1016/S0005-2760(97)00073-8; ISHIZAKI J, 1994, J BIOL CHEM, V269, P5897; Kim TS, 1997, J BIOL CHEM, V272, P2542; KISHINO J, 1995, J BIOCHEM-TOKYO, V117, P420, DOI 10.1093/jb/117.2.420; Koumanov K, 1997, BIOCHEM J, V326, P227, DOI 10.1042/bj3260227; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; Kuwata H, 1998, J BIOL CHEM, V273, P1733, DOI 10.1074/jbc.273.3.1733; LAMBEAU G, 1994, J BIOL CHEM, V269, P1575; LECHLEITER J, 1991, NATURE, V350, P505, DOI 10.1038/350505a0; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIN LL, 1992, J BIOL CHEM, V267, P23451; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Marshall LA, 1997, J BIOL CHEM, V272, P759, DOI 10.1074/jbc.272.2.759; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; MURAKAMI M, 1991, FEBS LETT, V294, P247, DOI 10.1016/0014-5793(91)81440-J; MURAKAMI M, 1995, J BIOL CHEM, V270, P22653, DOI 10.1074/jbc.270.39.22653; Murakami M, 1996, J BIOL CHEM, V271, P30041, DOI 10.1074/jbc.271.47.30041; Murakami M, 1997, J BIOL CHEM, V272, P19891, DOI 10.1074/jbc.272.32.19891; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; MURAKAMI M, 1995, J BIOL CHEM, V270, P3239, DOI 10.1074/jbc.270.7.3239; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; MURAKAMI M, 1989, BIOCHIM BIOPHYS ACTA, V1043, P34; NAKAZATO Y, 1991, J BIOL CHEM, V266, P14119; Naraba H, 1998, J IMMUNOL, V160, P2974; PFEILSCHIFTER J, 1993, J CLIN INVEST, V92, P2516, DOI 10.1172/JCI116860; Reddy ST, 1997, J BIOL CHEM, V272, P13591, DOI 10.1074/jbc.272.21.13591; RIENDEAU D, 1994, J BIOL CHEM, V269, P15619; ROLDAN ERS, 1993, J BIOL CHEM, V268, P13962; ROSHAK A, 1994, J BIOL CHEM, V269, P25999; SCHEVITZ RW, 1995, NAT STRUCT BIOL, V2, P458, DOI 10.1038/nsb0695-458; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; SHARP JD, 1991, J BIOL CHEM, V266, P14850; Soubeyrand S, 1997, J BIOL CHEM, V272, P222, DOI 10.1074/jbc.272.1.222; SUGA H, 1993, EUR J BIOCHEM, V218, P807, DOI 10.1111/j.1432-1033.1993.tb18435.x; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; Tischfield JA, 1996, GENOMICS, V32, P328, DOI 10.1006/geno.1996.0126; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; TOHKIN M, 1993, J BIOL CHEM, V268, P2865; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; VOLAREVIC S, 1992, J EXP MED, V176, P835, DOI 10.1084/jem.176.3.835; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WIJKANDER J, 1995, J BIOL CHEM, V270, P26543, DOI 10.1074/jbc.270.44.26543; Wolf MJ, 1996, J BIOL CHEM, V271, P20989, DOI 10.1074/jbc.271.35.20989; Wolf MJ, 1997, J BIOL CHEM, V272, P1522, DOI 10.1074/jbc.272.3.1522; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935	84	329	335	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14411	14423		10.1074/jbc.273.23.14411	http://dx.doi.org/10.1074/jbc.273.23.14411			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603953	hybrid			2022-12-27	WOS:000074021500055
J	Toke, DA; Bennett, WL; Oshiro, J; Wu, WI; Voelker, DR; Carman, GM				Toke, DA; Bennett, WL; Oshiro, J; Wu, WI; Voelker, DR; Carman, GM			Isolation and characterization of the Saccharomyces cerevisiae LPP1 gene encoding a Mg2+-independent phosphatidate phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIACYLGLYCEROL PYROPHOSPHATE PHOSPHATASE; MEMBRANE PHOSPHOLIPID-COMPOSITION; ESCHERICHIA-COLI; RAT-LIVER; PHOSPHATIDYLSERINE DECARBOXYLASE; ACID PHOSPHATASE; SHUTTLE VECTORS; MIXED MICELLES; 104-KDA FORMS; YEAST	The DPP1-encoded diacylglycerol pyrophosphate (DGPP) phosphatase enzyme accounts for half of the Mg2+-independent phosphatidate (PA) phosphatase activity in Saccharomyces cerevisiae, The LPP1 (lipid phosphate phosphatase) gene encodes a protein that contains a novel phosphatase sequence motif found in DGPP phosphatase and in the mouse Mg2+-independent PA phosphatase. A genomic copy of the S. cerevisiae LPP1 gene was isolated and was used to construct lpp1 Delta and lpp1 Delta dpp1 Delta mutants. A multicopy plasmid containing the LPP1 gene directed a 12.9-fold overexpression of Mg2+-independent PA phosphatase activity in the S. cerevisiae lpp1 Delta dpp1 Delta double mutant. The heterologous expression of the S. cerevisiae LPP1 gene in Sf-9 insect cells resulted in a 715-fold overexpression of Mg2+-independent PA phosphatase activity relative to control insect cells. The Mg2+-independent PA phosphatase activity encoded by the LPP1 gene was associated with the membrane fraction of the cell. The LPP1 gene product also exhibited lyse-PA phosphatase and DGPP phosphatase activities. The order of substrate preference was PA > lyse-PA > DGPP. Like the dpp1 Delta mutant, the lpp1 Delta mutant and the lpp1 Delta dpp1 Delta double mutant were viable and did not exhibit obvious growth defects. Biochemical analyses of lpp1 Delta, dpp1 Delta, and lpp1 Delta dpp1 Delta mutants showed that the LPP1 and DPP1 gene products encoded nearly all of the Mg2+-independent PA phosphatase and lyse-PA phosphatase activities and all of the DG;PP phosphatase activity in S. cerevisiae. Moreover, the analyses of the mutants showed that the LPP1 and DPP1 gene products played a role in the regulation of phospholipid metabolism and the cellular levels of phosphatidylinositol and PA.	Rutgers State Univ, Cook Coll, Dept Food Sci, New Jersey Agr Expt Stn, New Brunswick, NJ 08903 USA; Natl Jewish Ctr Immunol & Resp Med, Lord & Taylor Lab Lung Biochem, Denver, CO 80206 USA; Natl Jewish Ctr Immunol & Resp Med, Anna Perahia Adatto Clin Res Ctr, Denver, CO 80206 USA	Rutgers State University New Brunswick; National Jewish Health; National Jewish Health	Carman, GM (corresponding author), Rutgers State Univ, Cook Coll, Dept Food Sci, New Jersey Agr Expt Stn, New Brunswick, NJ 08903 USA.	carman@aesop.rutgers.edu	Oshiro, June/ACF-4163-2022	Oshiro, June/0000-0003-1134-5023; Bennett, Wendy/0000-0001-9828-0706	NIGMS NIH HHS [GM-32453, GM-28140] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028140, R01GM028140, R37GM032453, R01GM032453] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN JB, 1994, YEAST, V10, P1267, DOI 10.1002/yea.320101003; ATKINSON K, 1980, J BIOL CHEM, V255, P6653; ATKINSON KD, 1980, J BACTERIOL, V141, P558, DOI 10.1128/JB.141.2.558-564.1980; BAELEE M, 1990, J BIOL CHEM, V265, P7221; Balsinde J, 1996, J BIOL CHEM, V271, P31937, DOI 10.1074/jbc.271.50.31937; BHAT BG, 1994, J BIOL CHEM, V269, P13172; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brindley DN, 1996, CHEM PHYS LIPIDS, V80, P45, DOI 10.1016/0009-3084(96)02545-5; CARMAN GM, 1991, METHOD ENZYMOL, V197, P548; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; Carman GM, 1996, J BIOL CHEM, V271, P13293, DOI 10.1074/jbc.271.23.13293; Carman GM, 1997, BBA-LIPID LIPID MET, V1348, P45, DOI 10.1016/S0005-2760(97)00095-7; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CLANCEY CJ, 1993, J BIOL CHEM, V268, P24580; CULBERTSON MR, 1975, GENETICS, V80, P23; Dillon DA, 1997, J BIOL CHEM, V272, P10361; Dillon DA, 1996, J BIOL CHEM, V271, P30548, DOI 10.1074/jbc.271.48.30548; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; Dove SK, 1997, NATURE, V390, P187, DOI 10.1038/36613; DOWNES CP, 1990, EUR J BIOCHEM, V193, P1, DOI 10.1111/j.1432-1033.1990.tb19297.x; English D, 1996, CELL SIGNAL, V8, P341, DOI 10.1016/0898-6568(95)00076-3; ESKO JD, 1980, J BIOL CHEM, V255, P4474; FLEMING IN, 1995, BIOCHEM J, V308, P983, DOI 10.1042/bj3080983; GOMEZMUNOZ A, 1994, J BIOL CHEM, V269, P8937; Greenberg ML, 1996, MICROBIOL REV, V60, P1; GREENBERG ML, 1982, GENETICS, V100, P19; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HJELMSTAD RH, 1987, J BIOL CHEM, V262, P3909; Hofmann K., 1993, BIOL CHEM H-S, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; HOMANN MJ, 1987, J BACTERIOL, V169, P533, DOI 10.1128/jb.169.2.533-539.1987; HOSAKA K, 1989, J BIOL CHEM, V264, P2053; HOSAKA K, 1984, BIOCHIM BIOPHYS ACTA, V796, P110; Innis MA, 1990, PCR PROTOCOLS GUIDE, P1, DOI [10.1016/0167-7799(90)90215-J, DOI 10.1016/0167-7799(90)90215-J]; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jacq C, 1997, NATURE, V387, P75, DOI 10.1038/387s075; JAMAL Z, 1991, J BIOL CHEM, V266, P2988; JONES GA, 1993, J BIOL CHEM, V268, P20845; Kai M, 1997, J BIOL CHEM, V272, P24572, DOI 10.1074/jbc.272.39.24572; Kai M, 1996, J BIOL CHEM, V271, P18931, DOI 10.1074/jbc.271.31.18931; Kanoh H, 1997, BBA-LIPID LIPID MET, V1348, P56, DOI 10.1016/S0005-2760(97)00094-5; KANOH H, 1992, J BIOL CHEM, V267, P25309; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; KLIG LS, 1988, J BACTERIOL, V170, P1878, DOI 10.1128/jb.170.4.1878-1886.1988; Kocsis MG, 1996, LIPIDS, V31, P785, DOI 10.1007/BF02522974; LESTER RL, 1993, ADV LIPID RES, V26, P253; LETTS VA, 1983, P NATL ACAD SCI-BIOL, V80, P7279, DOI 10.1073/pnas.80.23.7279; LIN YP, 1989, J BIOL CHEM, V264, P8641; MCGEE TP, 1994, J BACTERIOL, V176, P6861, DOI 10.1128/JB.176.22.6861-6868.1994; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; MORITZ A, 1992, J BIOL CHEM, V267, P7207; MORLOCK KR, 1991, J BIOL CHEM, V266, P3586; MORLOCK KR, 1988, J BACTERIOL, V170, P3561, DOI 10.1128/jb.170.8.3561-3566.1988; Munnik T, 1996, J BIOL CHEM, V271, P15708, DOI 10.1074/jbc.271.26.15708; NIKAWA J, 1984, EUR J BIOCHEM, V143, P251, DOI 10.1111/j.1432-1033.1984.tb08366.x; O'Reilly D., 1992, BACULOVIRUS EXPRESSI, P109; PALTAUF F, 1992, MOL CELLULAR BIOL YE, P415; QUINLAN JJ, 1992, J BIOL CHEM, V267, P18013; Rosenberg M., 1990, MICROBIAL CELL SURFA, P1; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Shen HF, 1997, J BIOL CHEM, V272, P11215; Siess EA, 1996, FEBS LETT, V381, P169, DOI 10.1016/0014-5793(96)00111-1; SMITH SW, 1957, J BIOL CHEM, V228, P915; Stukey J, 1997, PROTEIN SCI, V6, P469; TAYLOR FR, 1979, BIOCHIM BIOPHYS ACTA, V575, P204, DOI 10.1016/0005-2760(79)90022-5; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Toke DA, 1998, J BIOL CHEM, V273, P3278, DOI 10.1074/jbc.273.6.3278; TROTTER PJ, 1993, J BIOL CHEM, V268, P21416; Waggoner DW, 1996, J BIOL CHEM, V271, P16506, DOI 10.1074/jbc.271.28.16506; WAGGONER DW, 1995, J BIOL CHEM, V270, P19422, DOI 10.1074/jbc.270.33.19422; WALSH JP, 1986, J BIOL CHEM, V261, P6239; WHITE MJ, 1991, ADV MICROB PHYSIOL, V32, P1, DOI 10.1016/S0065-2911(08)60004-1; Wu WI, 1996, J BIOL CHEM, V271, P1868, DOI 10.1074/jbc.271.4.1868; WU WI, 1994, J BIOL CHEM, V269, P29495; WU WI, 1993, J BIOL CHEM, V268, P13830; Wu WI, 1996, BIOCHEMISTRY-US, V35, P3790, DOI 10.1021/bi952808f; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4	80	98	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14331	14338		10.1074/jbc.273.23.14331	http://dx.doi.org/10.1074/jbc.273.23.14331			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603941	hybrid			2022-12-27	WOS:000074021500043
J	Yamakura, F; Taka, H; Fujimura, T; Murayama, K				Yamakura, F; Taka, H; Fujimura, T; Murayama, K			Inactivation of human manganese-superoxide dismutase by peroxynitrite is caused by exclusive nitration of tyrosine 34 to 3-nitrotyrosine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; THERMUS-THERMOPHILUS; CRYSTAL-STRUCTURE; RESOLUTION; ELECTRON; OXIDATIONS; REVEALS; DAMAGE; OXYGEN; CELLS	Peroxynitrite has recently been implicated in the inactivation of many enzymes. However, little has been reported on the structural basis of the inactivation reaction. This study proposes that nitration of a specific tyrosine residue is responsible for inactivation of recombinant human mitochondrial manganese-superoxide dismutase (Mn-SOD) by peroxynitrite. Mass spectroscopic analysis of the peroxynitrite-inactivated Mn-SOD showed an increased molecular mass because of a single nitro group substituted onto a tyrosine residue. Single peptides that had different elution positions between samples from the native and peroxynitrite-inactivated Mn-SOD on reverse phase high performance liquid chromatography were isolated after successive digestion of the samples by staphylococcal serine protease and lysylendopeptidase and subjected to amino acid sequence and molecular mass analyses. We found that tyrosine 34 of the enzyme was exclusively nitrated to 3-nitrotyrosine by peroxynitrite. This residue is located near manganese and in a substrate O-2(radical anion) gateway in Mn-SOD.	Juntendo Univ, Sch Med, Dept Chem, Chiba 27016, Japan; Juntendo Univ, Sch Med, Div Biochem Anal, Cent Lab Med Sci,Bunkyo Ku, Tokyo 113, Japan	Juntendo University; Juntendo University	Yamakura, F (corresponding author), Juntendo Univ, Sch Med, Dept Chem, 1-1 Hiraga Gakuendai, Chiba 27016, Japan.	yamakura@sakura.juntendo.ac.jp		Fujimura, Tsutomu/0000-0003-1744-7725				Alvarez B, 1996, CHEM RES TOXICOL, V9, P390, DOI 10.1021/tx950133b; Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; Berlett BS, 1996, P NATL ACAD SCI USA, V93, P1776, DOI 10.1073/pnas.93.5.1776; BORGSTAHL GEO, 1992, CELL, V71, P107, DOI 10.1016/0092-8674(92)90270-M; Cassina A, 1996, ARCH BIOCHEM BIOPHYS, V328, P309, DOI 10.1006/abbi.1996.0178; COOPER JB, 1995, J MOL BIOL, V246, P531, DOI 10.1006/jmbi.1994.0105; CROW JP, 1995, BIOCHEMISTRY-US, V34, P3544, DOI 10.1021/bi00011a008; Denicola A, 1996, ARCH BIOCHEM BIOPHYS, V333, P49, DOI 10.1006/abbi.1996.0363; Frears ER, 1996, FEBS LETT, V381, P21, DOI 10.1016/0014-5793(96)00065-8; Gow A, 1996, ARCH BIOCHEM BIOPHYS, V333, P42, DOI 10.1006/abbi.1996.0362; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; Hsu JL, 1996, J BIOL CHEM, V271, P17687, DOI 10.1074/jbc.271.30.17687; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; Hunter T, 1997, BIOCHEMISTRY-US, V36, P4925, DOI 10.1021/bi9629541; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P446, DOI 10.1016/0003-9861(92)90433-W; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; KOBAYASHI K, 1995, J CHEM SOC DALTON, P2885, DOI 10.1039/dt9950002885; KOOY NW, 1994, ARCH BIOCHEM BIOPHYS, V310, P352, DOI 10.1006/abbi.1994.1178; LAH MS, 1995, BIOCHEMISTRY-US, V34, P1646, DOI 10.1021/bi00005a021; LEMERCIER N, 1997, ARCH BIOCHEM BIOPHYS, V345, P160; Lim JH, 1997, J MOL BIOL, V270, P259, DOI 10.1006/jmbi.1997.1105; LUDWIG ML, 1991, J MOL BIOL, V219, P335, DOI 10.1016/0022-2836(91)90569-R; MacMillanCrow LA, 1996, P NATL ACAD SCI USA, V93, P11853, DOI 10.1073/pnas.93.21.11853; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; PARKER MW, 1988, J MOL BIOL, V199, P649, DOI 10.1016/0022-2836(88)90308-7; Poderoso JJ, 1996, ARCH BIOCHEM BIOPHYS, V328, P85, DOI 10.1006/abbi.1996.0146; PRYOR WA, 1994, P NATL ACAD SCI USA, V91, P11173, DOI 10.1073/pnas.91.23.11173; RADI R, 1991, J BIOL CHEM, V266, P4244; Ramezanian MS, 1996, CHEM RES TOXICOL, V9, P232, DOI 10.1021/tx950135w; Schmidt M, 1996, J BIOL INORG CHEM, V1, P532, DOI 10.1007/s007750050089; SMITH CD, 1992, ARCH BIOCHEM BIOPHYS, V299, P350, DOI 10.1016/0003-9861(92)90286-6; Sorkin DL, 1997, BIOCHEMISTRY-US, V36, P8202, DOI 10.1021/bi970533t; STALLINGS WC, 1991, FREE RADICAL RES COM, V12-3, P259, DOI 10.3109/10715769109145794; STODDARD BL, 1990, BIOCHEMISTRY-US, V29, P8885, DOI 10.1021/bi00490a002; Takehara Y, 1996, CELL STRUCT FUNCT, V21, P251, DOI 10.1247/csf.21.251; WAGNER UG, 1993, PROTEIN SCI, V2, P814, DOI 10.1002/pro.5560020511; WANG JF, 1991, BIOCHEM J, V279, P311, DOI 10.1042/bj2790311; WEBSTER GC, 1970, BIOCHIM BIOPHYS ACTA, V207, P371, DOI 10.1016/0005-2795(70)90031-0; Whittaker MM, 1997, BIOCHEMISTRY-US, V36, P8923, DOI 10.1021/bi9704212; Wiseman H, 1996, BIOCHEM J, V313, P17, DOI 10.1042/bj3130017; YAMAKURA F, 1998, IN PRESS EUR J BIOCH; Yamakura F., 1998, BIOL NITRIC OXIDE, P34	42	388	394	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14085	14089		10.1074/jbc.273.23.14085	http://dx.doi.org/10.1074/jbc.273.23.14085			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603906	hybrid			2022-12-27	WOS:000074021500008
J	Zarbiv, R; Grunewald, M; Kavanaugh, MP; Kanner, BI				Zarbiv, R; Grunewald, M; Kavanaugh, MP; Kanner, BI			Cysteine scanning of the surroundings of an alkali-ion binding site of the glutamate transporter GLT-1 reveals a conformationally sensitive residue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; ACID TRANSPORTER; MEMBRANE-VESICLES; CHLORIDE CHANNEL; GLIAL-CELLS; EXPRESSION; ASPARTATE; TOPOLOGY; CARRIER; MUTANTS	Glutamate transporters remove this transmitter from the extracellular space by cotransport with three sodium ions and a proton. The cycle is completed by translocation of a potassium ion in the opposite direction. Recently we have identified two adjacent amino acid residues of the glutamate transporter GLT-1 that influence potassium coupling. Using the scanning cysteine accessibility method we have now explored the highly conserved region surrounding them. Replacement of each of the five consecutive residues 396-400 by cysteine abolished transport activity but at several other positions the substitution is tolerated. One residue, tyrosine 403, was identified where cysteine substitution renders the transporter sensitive to modification by positively charged methanethiosulfonate derivates in a sodium-protectable fashion. In the presence of sodium, the nontransported glutamate analogue dihydrokainate potentiated the covalent modification, presumably by binding to the glutamate site and locking the protein in a conformation in which tyrosine 403 is accessible from the external bulk medium. In contrast, transported substrates significantly slowed the reaction, suggesting that during the transport cycle residue 403 becomes occluded, On the other hand, transportable substrates are not able to protect Y403C transporters against N-ethylmaleimide, which is highly permeant but unable to modify cysteine residues buried within membrane proteins. These results indicate that tyrosine 403 is alternately accessible from either side of the membrane, consistent with its role as structural determinant of the potassium binding site.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel; Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA	Hebrew University of Jerusalem; Oregon Health & Science University	Kanner, BI (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, POB 12272, IL-91120 Jerusalem, Israel.							AKABAS MH, 1994, J BIOL CHEM, V269, P14865; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; ARRIZA JL, 1994, J NEUROSCI, V14, P5559; Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; BARBOUR B, 1991, J PHYSIOL-LONDON, V436, P169, DOI 10.1113/jphysiol.1991.sp018545; BENDAHAN A, 1993, FEBS LETT, V318, P41, DOI 10.1016/0014-5793(93)81323-R; BREW H, 1987, NATURE, V327, P707, DOI 10.1038/327707a0; CASADO M, 1993, J BIOL CHEM, V268, P27313; DANBOLT NC, 1992, NEUROSCIENCE, V51, P295, DOI 10.1016/0306-4522(92)90316-T; DANBOLT NC, 1990, BIOCHEMISTRY-US, V29, P6734, DOI 10.1021/bi00480a025; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GRUNEWALD M, 1995, J BIOL CHEM, V270, P17017, DOI 10.1074/jbc.270.28.17017; Holmgren M, 1996, NEUROPHARMACOLOGY, V35, P797, DOI 10.1016/0028-3908(96)00129-3; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P3949, DOI 10.1021/bi00612a011; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KANNER BI, 1982, BIOCHEMISTRY-US, V21, P6327, DOI 10.1021/bi00267a044; Kavanaugh MP, 1997, J BIOL CHEM, V272, P1703, DOI 10.1074/jbc.272.3.1703; KEYNAN S, 1992, BIOCHEMISTRY-US, V31, P1974, DOI 10.1021/bi00122a011; Kimura T, 1996, BIOCHEMISTRY-US, V35, P15896, DOI 10.1021/bi961568g; Kuner T, 1996, NEURON, V17, P343, DOI 10.1016/S0896-6273(00)80165-8; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MENNERICK S, 1994, NATURE, V368, P59, DOI 10.1038/368059a0; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; Olami Y, 1997, J BIOL CHEM, V272, P1761, DOI 10.1074/jbc.272.3.1761; PINES G, 1995, J BIOL CHEM, V270, P17093, DOI 10.1074/jbc.270.29.17093; PINES G, 1990, BIOCHEMISTRY-US, V29, P11209, DOI 10.1021/bi00503a008; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; POCOCK JM, 1988, J NEUROCHEM, V50, P745, DOI 10.1111/j.1471-4159.1988.tb02977.x; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Slotboom DJ, 1996, J BIOL CHEM, V271, P31317, DOI 10.1074/jbc.271.49.31317; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; TONG G, 1994, NEURON, V13, P1195, DOI 10.1016/0896-6273(94)90057-4; VANDENBERG RJ, 1995, J BIOL CHEM, V270, P17668, DOI 10.1074/jbc.270.30.17668; WADICHE JI, 1995, NEURON, V14, P1019, DOI 10.1016/0896-6273(95)90340-2; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0; Zhang YM, 1998, P NATL ACAD SCI USA, V95, P751, DOI 10.1073/pnas.95.2.751	39	70	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14231	14237		10.1074/jbc.273.23.14231	http://dx.doi.org/10.1074/jbc.273.23.14231			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603927	Green Published, hybrid			2022-12-27	WOS:000074021500029
J	Amrolia, PJ; Gabbard, W; Cunningham, JM; Jane, SM				Amrolia, PJ; Gabbard, W; Cunningham, JM; Jane, SM			Maximal activity of an erythroid-specific enhancer requires the presence of specific protein binding sites in linked promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUS-CONTROL REGION; BETA-GLOBIN GENE; DOMINANT CONTROL REGION; HUMAN GAMMA-GLOBIN; TRANSGENIC MICE; TRANSCRIPTIONAL ACTIVATION; DEVELOPMENTAL REGULATION; HYPERSENSITIVE SITE-2; COMPLEX; EXPRESSION	High level expression of many eukaryotic genes is achieved through the action of distal regulatory sequences or enhancers. We have utilized the interaction between the erythroid-specific enhancer in hypersensitivity site 2 (HS2) of the human beta-globin locus control region and the globin gene promoters as a model to elucidate the mechanisms governing promoter/enhancer interactions. HS2 contains a 400-base pair core element consisting of tandem AP1/NF-E2 motifs flanked by binding sites for multiple ubiquitous and erythroid-specific factors. We have compared the enhancer activity of this core element with a synthetic enhancer lacking the factor binding sites flanking the AP1/NF-E2 motif (HS2(M)). In fetal/erythroid K562 cells, enhancement of a linked gamma-promoter was significantly greater with wild-type HS2 than with HS2(M). In contrast, the increase in beta-promoter activity in these cells was equivalent with either enhancer fragment. Truncation of the binding site for the fetal/erythroid-specific stage selector protein in the gamma-promoter abolished the additional enhancer activity of HS2. Similarly, insertion of the stage selector protein site into the beta-promoter boosted enhancer activity observed with HS2 but not HS2(M). In adult erythroid MEL cells, enhancement of a linked beta-promoter was significantly greater with HS2 than with HS2(M). This effect was dependent on the binding of the adult stage-specific factor, erythroid Kruppel-like factor, to the beta-promoter. Taken together, this data suggests that the stage-specific factors binding the proximal globin promoters and the factors flanking the AP1/NF-EB motif of HS2 act in synergy.	St Jude Childrens Res Hosp, Memphis, TN 38105 USA; Royal Melbourne Hosp, Bone Marrow Res Lab, Parkville, Vic 3050, Australia	St Jude Children's Research Hospital; Royal Melbourne Hospital	Jane, SM (corresponding author), St Jude Childrens Res Hosp, 332 N Lauderdale St, Memphis, TN 38105 USA.		Jane, Stephen/D-6659-2011	Jane, Stephen Marsden/0000-0002-1045-0481	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL053749] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA21765] Funding Source: Medline; NHLBI NIH HHS [P01 HL53749-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amrolia PJ, 1997, P NATL ACAD SCI USA, V94, P10051, DOI 10.1073/pnas.94.19.10051; AMROLIA PJ, 1995, J BIOL CHEM, V270, P12892, DOI 10.1074/jbc.270.21.12892; ANTONIOU M, 1990, GENE DEV, V4, P1007, DOI 10.1101/gad.4.6.1007; CATERINA JJ, 1991, P NATL ACAD SCI USA, V88, P1626, DOI 10.1073/pnas.88.5.1626; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; DILLON N, 1994, CURR OPIN GENET DEV, V4, P260, DOI 10.1016/S0959-437X(05)80053-X; DONZE D, 1995, J BIOL CHEM, V270, P1955, DOI 10.1074/jbc.270.4.1955; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; ELLIS J, 1993, EMBO J, V12, P127, DOI 10.1002/j.1460-2075.1993.tb05638.x; Elnitski L, 1997, J BIOL CHEM, V272, P369; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; GERBER HP, 1995, NATURE, V374, P660, DOI 10.1038/374660a0; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; Hug BA, 1996, MOL CELL BIOL, V16, P2906; Jackson JD, 1996, NUCLEIC ACIDS RES, V24, P4327, DOI 10.1093/nar/24.21.4327; JANE SM, 1995, EMBO J, V14, P97, DOI 10.1002/j.1460-2075.1995.tb06979.x; JANE SM, 1992, EMBO J, V11, P2961, DOI 10.1002/j.1460-2075.1992.tb05366.x; Kitsberg D, 1991, CURR OPIN GENET DEV, V1, P534, DOI 10.1016/S0959-437X(05)80204-7; Laemmli UK, 1992, CURR OPIN GENET DEV, V2, P275, DOI 10.1016/S0959-437X(05)80285-0; Lam LT, 1996, J BIOL CHEM, V271, P32421, DOI 10.1074/jbc.271.50.32421; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIU DP, 1992, P NATL ACAD SCI USA, V89, P3899, DOI 10.1073/pnas.89.9.3899; LLOYD JA, 1992, MOL CELL BIOL, V12, P1561, DOI 10.1128/MCB.12.4.1561; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MAJUMDER S, 1995, BIOESSAYS, V17, P879, DOI 10.1002/bies.950171010; MAJUMDER S, 1994, MOL CELL BIOL, V14, P4258, DOI 10.1128/MCB.14.6.4258; McKnight SL, 1996, GENE DEV, V10, P367, DOI 10.1101/gad.10.4.367; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MORLEY BJ, 1992, MOL CELL BIOL, V12, P2057, DOI 10.1128/MCB.12.5.2057; NEY PA, 1990, NUCLEIC ACIDS RES, V18, P6011, DOI 10.1093/nar/18.20.6011; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; PERKINS AC, 1995, NATURE, V375, P318; Peterson KR, 1996, P NATL ACAD SCI USA, V93, P6605, DOI 10.1073/pnas.93.13.6605; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; SCHLEIF R, 1992, ANNU REV BIOCHEM, V61, P199, DOI 10.1146/annurev.bi.61.070192.001215; SORRENTINO B, 1990, NUCLEIC ACIDS RES, V18, P2721, DOI 10.1093/nar/18.9.2721; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TALBOT D, 1991, EMBO J, V10, P1391, DOI 10.1002/j.1460-2075.1991.tb07659.x; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; TUAN DYH, 1989, P NATL ACAD SCI USA, V86, P2554, DOI 10.1073/pnas.86.8.2554; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0	51	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13593	13598		10.1074/jbc.273.22.13593	http://dx.doi.org/10.1074/jbc.273.22.13593			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593696	hybrid			2022-12-27	WOS:000073919100035
J	Andreu, T; Beckers, T; Thoenes, E; Hilgard, P; von Melchner, H				Andreu, T; Beckers, T; Thoenes, E; Hilgard, P; von Melchner, H			Gene trapping identifies inhibitors of oncogenic transformation - The tissue inhibitor of metalloproteinases-3 (TIMP3) and collagen type I alpha 2 (COL1A2) are epidermal growth factor-regulated growth repressors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETROVIRUS PROMOTER-TRAP; RECEPTOR TYROSINE KINASE; EMBRYONIC STEM-CELLS; MOLECULAR-CLONING; MAMMALIAN-CELLS; MATRIX METALLOPROTEINASES; TRANSCRIPTIONAL ENHANCER; CELLULAR PROMOTERS; LACZ-GENE; EXPRESSION	A gene trap strategy has been used to identify genes that are repressed in cells transformed by an activated epidermal growth factor (EGF)/EGF receptor signal transduction pathway, EGF receptor expressing NIH3T3 cells (HER1 cells) were infected with a retrovirus containing coding sequences for the human CD2 antigen and for secreted alkaline phosphatase in the U3 region. By selecting for and against CD2 expression, we obtained clones in which the gene trap had integrated into genes selectively repressed by EGF. Two of these clones encoded for the secreted extracellular matrix proteins TIMP3 and COL1A2, We show here that both genes are downstream targets of RAS and are specifically repressed by EGF-induced transformation. Moreover, this strategy tags tumor suppressor genes in their normal chromosomal location, thereby improving target-specific screens for antineoplastic drugs.	Univ Frankfurt, Sch Med, Dept Hematol, Lab Mol Hematol, D-60590 Frankfurt, Germany; ASTA Med AG, Dept Canc Res, Frankfurt, Germany	Goethe University Frankfurt	von Melchner, H (corresponding author), Univ Frankfurt, Sch Med, Dept Hematol, Lab Mol Hematol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.							Aftab DT, 1997, P NATL ACAD SCI USA, V94, P3028, DOI 10.1073/pnas.94.7.3028; AnandApte B, 1996, BIOCHEM CELL BIOL, V74, P853, DOI 10.1139/o96-090; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Baasner S, 1996, ONCOGENE, V13, P901; BACUS SS, 1994, AM J CLIN PATHOL S1, V102, P13; Bian JH, 1996, CARCINOGENESIS, V17, P1805, DOI 10.1093/carcin/17.9.1805; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BRENNER DG, 1989, P NATL ACAD SCI USA, V86, P5517, DOI 10.1073/pnas.86.14.5517; Brown PD, 1995, ANN ONCOL, V6, P967, DOI 10.1093/oxfordjournals.annonc.a059091; CHANG W, 1993, VIROLOGY, V193, P737, DOI 10.1006/viro.1993.1182; CHEN Z, 1994, GENE DEV, V8, P2293, DOI 10.1101/gad.8.19.2293; Coligan JKA, 1991, CURRENT PROTOCOLS IM; Coussens LM, 1996, CHEM BIOL, V3, P895, DOI 10.1016/S1074-5521(96)90178-7; DEGREGORI J, 1994, GENE DEV, V8, P265, DOI 10.1101/gad.8.3.265; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIRKS W, 1993, GENE, V128, P247, DOI 10.1016/0378-1119(93)90569-O; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSLER A, 1989, SCIENCE, V244, P463, DOI 10.1126/science.2497519; Hicks GG, 1997, NAT GENET, V16, P338, DOI 10.1038/ng0897-338; HILL CS, 1995, CELL, V80, P190; Kerr WG, 1996, P NATL ACAD SCI USA, V93, P3947, DOI 10.1073/pnas.93.9.3947; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOHN EC, 1995, CANCER RES, V55, P1856; KRZYZOSIAK WJ, 1992, P NATL ACAD SCI USA, V89, P4879, DOI 10.1073/pnas.89.11.4879; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Lischke A, 1996, ANAL BIOCHEM, V236, P322, DOI 10.1006/abio.1996.0173; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; OLSEN BR, 1995, CURR OPIN CELL BIOL, V7, P720, DOI 10.1016/0955-0674(95)80115-4; PHILLIPS CL, 1991, J INVEST DERMATOL, V97, P980, DOI 10.1111/1523-1747.ep12491894; REDDY S, 1992, P NATL ACAD SCI USA, V89, P6721, DOI 10.1073/pnas.89.15.6721; REDDY S, 1991, J VIROL, V65, P1507, DOI 10.1128/JVI.65.3.1507-1515.1991; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; ROSSI P, 1987, P NATL ACAD SCI USA, V84, P5590, DOI 10.1073/pnas.84.16.5590; Russ AP, 1996, P NATL ACAD SCI USA, V93, P15279, DOI 10.1073/pnas.93.26.15279; Russ AP, 1996, J VIROL, V70, P4927, DOI 10.1128/JVI.70.8.4927-4932.1996; Scherer CA, 1996, CELL GROWTH DIFFER, V7, P1393; SCHUERMANN M, 1990, NUCLEIC ACIDS RES, V18, P4945, DOI 10.1093/nar/18.16.4945; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; Sers C, 1997, J CELL BIOL, V136, P935, DOI 10.1083/jcb.136.4.935; SKARNES WC, 1992, GENE DEV, V6, P903, DOI 10.1101/gad.6.6.903; SKARNES WC, 1995, P NATL ACAD SCI USA, V92, P6592, DOI 10.1073/pnas.92.14.6592; SUN Y, 1994, CANCER RES, V54, P1139; SUN Y, 1995, J BIOL CHEM, V270, P19312, DOI 10.1074/jbc.270.33.19312; THOREY IS, 1998, IN PRESS MOL CELL BI; Travers H, 1996, CELL GROWTH DIFFER, V7, P1353; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VONMELCHNER H, 1989, J VIROL, V63, P3227, DOI 10.1128/JVI.63.8.3227-3233.1989; VONMELCHNER H, 1990, P NATL ACAD SCI USA, V87, P3733, DOI 10.1073/pnas.87.10.3733; VONMELCHNER H, 1992, GENE DEV, V6, P919, DOI 10.1101/gad.6.6.919; WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352; WICK M, 1994, J BIOL CHEM, V269, P18953; YANG TT, 1992, P NATL ACAD SCI USA, V89, P10676, DOI 10.1073/pnas.89.22.10676; YUASA Y, 1983, NATURE, V303, P775, DOI 10.1038/303775a0	58	40	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13848	13854		10.1074/jbc.273.22.13848	http://dx.doi.org/10.1074/jbc.273.22.13848			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593730	hybrid			2022-12-27	WOS:000073919100069
J	Fath, MA; Wu, XJ; Hileman, RE; Linhardt, RJ; Kashem, MA; Nelson, RM; Wright, CD; Abraham, WM				Fath, MA; Wu, XJ; Hileman, RE; Linhardt, RJ; Kashem, MA; Nelson, RM; Wright, CD; Abraham, WM			Interaction of secretory leukocyte protease inhibitor with heparin inhibits proteases involved in asthma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUCUS PROTEINASE-INHIBITOR; BINDING-SITE; CATHEPSIN-G; ELASTASE; SUBSTRATE	Protease inhibition by secretory leukocyte protease inhibitor (SLPI) is accelerated by the sulfated polysaccharides. The nature of the SLPI-polysaccharide interaction, explored with affinity chromatography, indicated that this interaction was sensitive to the charge and type of polysaccharide, Dextran and chondroitin had the lowest affinity for SLPI, followed by dermatan, heparan, and dextran sulfates. While heparin bound SLPI tightly, the highest affinity heparin chains unexpectedly contained a lower level of sulfation than more weakly interacting chains. Heparin oligosaccharides, prepared using heparin lyase I were SLPI-affinity fractionated, Surprisingly, undersulfated heparin oligosaccharides bound SLPI with the highest affinity, suggesting the importance of free hydroxyl groups for high affinity interaction. Isothermal titration calorimetry was used to determine the thermodynamics of SLPI interaction with a low molecular weight heparin, an undersulfated decasaccharide and a tetrasaccharide, The studies showed 12-14 saccharide units, corresponding to molecular weight of similar to 4,800, were required for a 1:1 (SLPI:heparin) binding stoichiometry. Furthermore, an undersulfated decasaccharide was able to bind SLPI tightly (K-d similar to 13 nM), resulting in its activation and the inhibition of neutrophil elastase and pancreatic chymotrypsin, The in vitro assessment of heparin and the decasaccharide and tetrasaccharide using stopped-flow kinetics suggested that heparin was the optimal choice to study SLPI-based in vivo protease inhibition. SLPI and heparin were co-administered by inhalation in therapy against antigen-induced airway hyperresponsiveness in a sheep bronchoprovocation model. Heparin, in combination with SLPI demonstrated in vivo efficacy reducing early and late phase bronchoconstriction. Heparin also increased the therapeutic activity of SLPI against antigen-induced airway hyperresponsiveness.	Univ Iowa, Coll Pharm, Div Med & Nat Prod Chem, Iowa City, IA 52242 USA; Univ Iowa, Dept Chem & Biochem Engn, Iowa City, IA 52242 USA; Amgen Inc, Boulder, CO 80301 USA; Univ Miami, Sch Med, Miami Beach, FL 33140 USA	University of Iowa; University of Iowa; Amgen; University of Miami	Linhardt, RJ (corresponding author), Univ Iowa, Coll Pharm, Div Med & Nat Prod Chem, PHAR-S328, Iowa City, IA 52242 USA.	robert-linhardt@uiowa.edu		Fath, Melissa/0000-0002-7272-2120				ABRAHAM WM, 1992, EUR J PHARMACOL, V217, P119, DOI 10.1016/0014-2999(92)90829-S; ABRAHAM WM, 1996, AIRWAYS SMOOTH MUSCL, P171; ALHAKIM A, 1990, ELECTROPHORESIS, V29, P2611; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; DELMAR EG, 1979, ANAL BIOCHEM, V99, P316, DOI 10.1016/S0003-2697(79)80013-5; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; EDENS RE, 1992, J PHARM SCI, V81, P823, DOI 10.1002/jps.2600810821; EISENBERG SP, 1990, J BIOL CHEM, V265, P7976; Eklund KK, 1997, J IMMUNOL, V158, P4373; FALLER B, 1992, BIOCHEMISTRY-US, V31, P8285, DOI 10.1021/bi00150a023; FALLER B, 1992, ARZNEIM FORSCH DRUG, V73, P503; FROMM JR, 1995, ARCH BIOCHEM BIOPHYS, V323, P279, DOI 10.1006/abbi.1995.9963; GRIFFIN CC, 1995, CARBOHYD RES, V276, P183, DOI 10.1016/0008-6215(95)00166-Q; GROUTAS WC, 1992, ARCH BIOCHEM BIOPHYS, V294, P144, DOI 10.1016/0003-9861(92)90148-P; GRUTTER MG, 1988, EMBO J, V7, P345, DOI 10.1002/j.1460-2075.1988.tb02819.x; Hileman RE, 1998, BIOESSAYS, V20, P156, DOI 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.3.CO;2-#; JACOBY AS, 1993, EUR J BIOCHEM, V218, P951, DOI 10.1111/j.1432-1033.1993.tb18452.x; JOHNSON KA, 1986, METHOD ENZYMOL, V134, P677; JUNGER WG, 1992, BIOL CHEM H-S, V373, P119, DOI 10.1515/bchm3.1992.373.1.119; KAZATCHKINE MD, 1981, J CLIN INVEST, V67, P223, DOI 10.1172/JCI110017; LINHARD RJ, 1995, CARBOHYDRATES DRUGS, P277; LINHARD TRJ, 1994, CURRENT PROTOCOLS MO; LINHARDT RJ, 1997, BIOMETHODS, V9, P183; MELLET P, 1995, BIOCHEMISTRY-US, V34, P2645, DOI 10.1021/bi00008a031; Mohr P., 1985, AFFINITY CHROMATOGRA; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; NAKAJIMA K, 1979, J BIOL CHEM, V254, P4027; Pejler G, 1996, FEBS LETT, V383, P170, DOI 10.1016/0014-5793(96)00239-6; PERVIN A, 1995, GLYCOBIOLOGY, V5, P83, DOI 10.1093/glycob/5.1.83; Pineo GF, 1997, ANNU REV MED, V48, P79; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; THOMPSON RC, 1986, P NATL ACAD SCI USA, V83, P6692, DOI 10.1073/pnas.83.18.6692; Toida T, 1997, BIOCHEM J, V322, P499, DOI 10.1042/bj3220499; VANSEUNINGEN I, 1992, INT J BIOCHEM, V24, P303, DOI 10.1016/0020-711X(92)90262-Y; Walter M, 1996, ARCH BIOCHEM BIOPHYS, V327, P81, DOI 10.1006/abbi.1996.0095; Ying QL, 1997, AM J PHYSIOL-LUNG C, V272, pL533, DOI 10.1152/ajplung.1997.272.3.L533; Zitnik RJ, 1997, BIOCHEM BIOPH RES CO, V232, P687, DOI 10.1006/bbrc.1997.6358	37	76	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13563	13569		10.1074/jbc.273.22.13563	http://dx.doi.org/10.1074/jbc.273.22.13563			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593692	hybrid			2022-12-27	WOS:000073919100031
J	Lannoy, VJ; Burglin, TR; Rousseau, GG; Lemaigre, FP				Lannoy, VJ; Burglin, TR; Rousseau, GG; Lemaigre, FP			Isoforms of hepatocyte nuclear factor-6 differ in DNA-binding properties, contain a bifunctional homeodomain, and define the new ONECUT class of homeodomain proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CUT REPEATS; TRANSCRIPTIONAL REPRESSION; ACTIVATOR PROTEIN; DROSOPHILA CUT; HOMEO DOMAIN; SPECIFICITY; GENE; RECOGNITION; EXPRESSION; SEQUENCE	Hepatocyte nuclear factor-6 (HNF-6) contains a single cut domain and a homeodomain characterized by a phenylalanine at position 48 and a methionine at position 50. We describe here two isoforms of HNF-6 which differ by the linker that separates these domains. Both isoforms stimulated transcription. The affinity of HNF-6 alpha and HNF-6 beta for DNA differed, depending on the target sequence. Binding of HNF-6 to DNA involved the cut domain and the homeodomain, but the latter was not required for binding to a subset of sites. Mutations of the F48M50 dyad that did not affect DNA binding reduced the transcriptional stimulation of constructs that do not require the homeodomain for DNA binding, but did not affect the stimulation of constructs that do require the homeodomain, Comparative trees of mammalian, Drosophila, and Caenorhabditis elegans proteins showed that HNF-6 defines a new class, which we call ONECUT, of homeodomain proteins. C. elegans proteins of this class bound to HNF-6 DNA targets. Thus, depending on their sequence, these targets determine for HNF-6 at least two modes of DNA binding, which hinge on the homeodomain and on the linker that separates it from the cut domain, and two modes of transcriptional stimulation, which hinge on the homeodomain.	Univ Catholique Louvain, Sch Med, Hormone & Metab Res Unit, B-1200 Brussels, Belgium; Christian de Duve Inst Cellular Pathol, ICP, B-1200 Brussels, Belgium; Univ Basel, Bioctr, Dept Cell Biol, CH-4056 Basel, Switzerland	Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Basel	Lemaigre, FP (corresponding author), Univ Catholique Louvain, Sch Med, Hormone & Metab Res Unit, Ave Hippocrate 75, B-1200 Brussels, Belgium.	lemaigre@horm.ucl.ac.be		Lemaigre, Frederic/0000-0002-3609-434X				ADES SE, 1994, BIOCHEMISTRY-US, V33, P9187, DOI 10.1021/bi00197a022; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDRES V, 1994, GENE DEV, V8, P245, DOI 10.1101/gad.8.2.245; ANDRES V, 1992, DEVELOPMENT, V116, P321; AUFIERO B, 1994, P NATL ACAD SCI USA, V91, P7757, DOI 10.1073/pnas.91.16.7757; AURORA R, 1992, MOL CELL BIOL, V12, P455, DOI 10.1128/MCB.12.2.455; BLOCHLINGER K, 1988, NATURE, V333, P629, DOI 10.1038/333629a0; Burglin Thomas R., 1994, P25; BURGLIN TR, 1995, BIODIVERSITY EVOLUTI, P291; CASSATA G, 1988, IN PRESS GENE AMST; CATRON KM, 1995, MOL CELL BIOL, V15, P861; Cereghini S, 1996, FASEB J, V10, P267, DOI 10.1096/fasebj.10.2.8641560; Coqueret O, 1996, J BIOL CHEM, V271, P24862, DOI 10.1074/jbc.271.40.24862; DERMAN E, 1981, CELL, V23, P731, DOI 10.1016/0092-8674(81)90436-0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Dickinson LA, 1997, J BIOL CHEM, V272, P11463; DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C; DURBIN R, 1991, C ELEGANS DATABASE; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; HARADA R, 1995, MOL CELL BIOL, V15, P129, DOI 10.1128/MCB.15.1.129; HARADA R, 1994, J BIOL CHEM, V269, P2062; HOLLAND PWH, 1994, DEVELOPMENT, P125; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; Klemm JD, 1996, GENE DEV, V10, P27, DOI 10.1101/gad.10.1.27; Lahuna O, 1997, P NATL ACAD SCI USA, V94, P12309, DOI 10.1073/pnas.94.23.12309; Landry C, 1997, DEV BIOL, V192, P247, DOI 10.1006/dbio.1997.8757; LEMAIGRE FP, 1993, J BIOL CHEM, V268, P19896; Lemaigre FP, 1996, P NATL ACAD SCI USA, V93, P9460, DOI 10.1073/pnas.93.18.9460; NEUFELD EJ, 1992, NAT GENET, V1, P50, DOI 10.1038/ng0492-50; PENDLETON JW, 1993, P NATL ACAD SCI USA, V90, P6300, DOI 10.1073/pnas.90.13.6300; Quaggin SE, 1996, J BIOL CHEM, V271, P22624, DOI 10.1074/jbc.271.37.22624; RUDDLE FH, 1994, DEVELOPMENT, P155; Samadani U, 1996, MOL CELL BIOL, V16, P6273; Schnabel CA, 1996, MOL CELL BIOL, V16, P2678; Sladek FM, 1992, CURR OPIN GENET DEV, V2, P256, DOI 10.1016/S0959-437X(05)80282-5; Stepchenko AG, 1997, NUCLEIC ACIDS RES, V25, P2847, DOI 10.1093/nar/25.14.2847; VALARCHE I, 1993, DEVELOPMENT, V119, P881; vanLeeuwen HC, 1997, EMBO J, V16, P2043, DOI 10.1093/emboj/16.8.2043; WATERSTON R, 1992, NAT GENET, V1, P114, DOI 10.1038/ng0592-114; Wilson DS, 1996, P NATL ACAD SCI USA, V93, P6886, DOI 10.1073/pnas.93.14.6886; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YOON SO, 1994, J BIOL CHEM, V269, P18453; ZAPPAVIGNA V, 1994, GENE DEV, V8, P732, DOI 10.1101/gad.8.6.732; Zhang HL, 1996, P NATL ACAD SCI USA, V93, P1764, DOI 10.1073/pnas.93.5.1764	46	94	101	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13552	13562		10.1074/jbc.273.22.13552	http://dx.doi.org/10.1074/jbc.273.22.13552			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593691	hybrid			2022-12-27	WOS:000073919100030
J	Silacci, P; Dayer, JM; Desgeorges, A; Peter, R; Manueddu, C; Guerne, PA				Silacci, P; Dayer, JM; Desgeorges, A; Peter, R; Manueddu, C; Guerne, PA			Interleukin (IL)-6 and its soluble receptor induce TIMP-1 expression in synoviocytes and chondrocytes, and block IL-1-induced collagenolytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-TISSUE INHIBITOR; ERYTHROID-POTENTIATING ACTIVITY; GROWTH-FACTOR-BETA; FIBROBLAST COLLAGENASE INHIBITOR; HUMAN ARTICULAR CHONDROCYTES; HUMAN SYNOVIAL FIBROBLASTS; IL-6 RECEPTOR; METALLOPROTEINASE INHIBITOR; MOLECULAR-CLONING; SIGNAL TRANSDUCER	To define the potential role of interleukin-6 (IL-6) and its soluble receptor alpha in cartilage metabolism, we analyzed their effects on tissue inhibitor of metalloproteases (TIMP) synthesis by synoviocytes and chondrocytes, TIMP-1 production by isolated human articular synovial fibroblasts and chondrocytes, stimulated by IL-6 and/or its soluble receptor, was first assayed by specific enzyme-linked immunosorbent assay; the slight stimulatory effect of IL-6 on TIMP-1 production by both types of cells was markedly amplified by the addition of soluble receptor, the maximal secretion being observed only at 96 h. TIMP-1 mRNA expression, determined by ribonuclease protection assay, was induced by IL-6 together with its soluble receptor, but TIMP-2 and -3 mRNAs were not affected by these factors. A specific neutralizing antibody abolished the effects of the soluble receptor. Finally, supernatant from synoviocytes stimulated by IL-6 plus its soluble receptor blocked almost completely the collagenolytic activity of supernatant from IL-1-induced synoviocytes. These observations indicate that IL-6 and its soluble receptor have a protective role in the metabolism of cartilage. Given the high levels of soluble receptor in synovial fluid and the marked induction of IL-6 by IL-1 or TNF-alpha, it is likely that IL-6 and its soluble receptor are critical in controlling the catabolic effects of pro-inflammatory cytokines.	Hop Cantonal Univ Geneva, Div Rheumatol, CH-1211 Geneva 14, Switzerland; Hop Cantonal Univ Geneva, Div Immunol & Allergy, CH-1211 Geneva, Switzerland; Hop Cantonal Univ Geneva, Div Orthoped Surg, CH-1211 Geneva 14, Switzerland	University of Geneva; University of Geneva; University of Geneva	Guerne, PA (corresponding author), Hop Cantonal Univ Geneva, Div Rheumatol, 26 Av Beau Sejour, CH-1211 Geneva 14, Switzerland.		peter, robin/N-2514-2014					APTE SS, 1994, GENOMICS, V19, P86, DOI 10.1006/geno.1994.1016; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; Bugno M, 1995, NUCLEIC ACIDS RES, V23, P5041, DOI 10.1093/nar/23.24.5041; CARMICHAEL DF, 1986, P NATL ACAD SCI USA, V83, P2407, DOI 10.1073/pnas.83.8.2407; CIRCOLO A, 1991, J BIOL CHEM, V266, P12283; DECLERCK YA, 1994, GENE, V139, P185, DOI 10.1016/0378-1119(94)90753-6; DENHARDT DT, 1994, ANN NY ACAD SCI, V732, P65, DOI 10.1111/j.1749-6632.1994.tb24725.x; Desgeorges A, 1997, J RHEUMATOL, V24, P1510; DIBATTISTA JA, 1995, J CELL BIOCHEM, V57, P619, DOI 10.1002/jcb.240570406; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; Franchimont N, 1997, J BIOL CHEM, V272, P12144, DOI 10.1074/jbc.272.18.12144; FRIELING JTM, 1995, J INFECT DIS, V171, P469, DOI 10.1093/infdis/171.2.469; GABAY C, 1995, EUR J IMMUNOL, V25, P2378, DOI 10.1002/eji.1830250838; Gabay C, 1997, J CLIN INVEST, V99, P2930, DOI 10.1172/JCI119488; GAILLARD JP, 1993, EUR J IMMUNOL, V23, P820, DOI 10.1002/eji.1830230408; GASSON JC, 1985, NATURE, V315, P768, DOI 10.1038/315768a0; Greene J, 1996, J BIOL CHEM, V271, P30375, DOI 10.1074/jbc.271.48.30375; GUERNE PA, 1994, J CELL PHYSIOL, V158, P476, DOI 10.1002/jcp.1041580312; GUERNE PA, 1989, J CLIN INVEST, V83, P585, DOI 10.1172/JCI113921; GUNTHER M, 1994, ARTHRITIS RHEUM, V37, P395, DOI 10.1002/art.1780370314; Hauptmann B, 1991, Eur Cytokine Netw, V2, P39; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HONDA M, 1992, J IMMUNOL, V148, P2175; IGLESIAS M, 1995, AM J PATHOL, V146, P944; ITO A, 1988, FEBS LETT, V234, P326, DOI 10.1016/0014-5793(88)80109-1; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; LOTZ M, 1991, J BIOL CHEM, V266, P2017; MACKIEWICZ A, 1992, J IMMUNOL, V149, P2021; MACNAUL KL, 1990, J BIOL CHEM, V265, P17238; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MIHARA M, 1995, BRIT J RHEUMATOL, V34, P321; MURPHY G, 1985, J BIOL CHEM, V260, P3079; Nemoto O, 1996, ARTHRITIS RHEUM, V39, P560, DOI 10.1002/art.1780390404; NOVICK D, 1989, J EXP MED, V170, P1409, DOI 10.1084/jem.170.4.1409; Okamoto H, 1997, ARTHRITIS RHEUM, V40, P1096, DOI 10.1002/art.1780400614; OVERALL CM, 1989, J BIOL CHEM, V264, P1860; PAVLOFF N, 1992, J BIOL CHEM, V267, P17321; ROBERTS AB, 1992, KIDNEY INT, V41, P557, DOI 10.1038/ki.1992.81; SATO H, 1992, ONCOGENE, V7, P77; SATO T, 1990, BIOCHEM BIOPH RES CO, V170, P824, DOI 10.1016/0006-291X(90)92165-V; SILBIGER SM, 1994, GENE, V141, P293, DOI 10.1016/0378-1119(94)90588-6; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; Su SM, 1996, DNA CELL BIOL, V15, P1039, DOI 10.1089/dna.1996.15.1039; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAMURA T, 1993, P NATL ACAD SCI USA, V90, P11294; UCHIJIMA M, 1994, J BIOL CHEM, V269, P14946; URIA JA, 1994, CANCER RES, V54, P2091; VILLIGER PM, 1993, J IMMUNOL, V151, P3337; WELGUS HG, 1983, J BIOL CHEM, V258, P2259; WICK M, 1995, BIOCHEM J, V311, P549, DOI 10.1042/bj3110549; WICK M, 1994, J BIOL CHEM, V269, P18953; WILDE CG, 1994, DNA CELL BIOL, V13, P711, DOI 10.1089/dna.1994.13.711; YANG TT, 1992, P NATL ACAD SCI USA, V89, P10676, DOI 10.1073/pnas.89.22.10676; YASUKAWA K, 1990, J BIOCHEM-TOKYO, V108, P673, DOI 10.1093/oxfordjournals.jbchem.a123261; YOKOYAMA A, 1995, CLIN EXP IMMUNOL, V100, P325	57	88	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13625	13629		10.1074/jbc.273.22.13625	http://dx.doi.org/10.1074/jbc.273.22.13625			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593700	hybrid			2022-12-27	WOS:000073919100039
J	Atwood, CS; Moir, RD; Huang, XD; Scarpa, RC; Bacarra, NME; Romano, DM; Hartshorn, MK; Tanzi, RE; Bush, AI				Atwood, CS; Moir, RD; Huang, XD; Scarpa, RC; Bacarra, NME; Romano, DM; Hartshorn, MK; Tanzi, RE; Bush, AI			Dramatic aggregation of Alzheimer A beta by Cu(II) is induced by conditions representing physiological acidosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							AMYLOID PROTEIN DEPOSITION; C-REACTIVE PROTEIN; SEVERE HEAD-INJURY; CEREBROSPINAL-FLUID; APOLIPOPROTEIN-E; RAT-BRAIN; DENSITY-LIPOPROTEIN; HUMAN TRANSFERRIN; BINDING SITES; HIGH-AFFINITY	The cortical deposition of A beta is an event that occurs in Alzheimer's disease, Down's syndrome, head injury, and normal aging. Previously, in appraising the effects of different neurochemical factors that impact upon the solubility of A beta, we observed that Zn2+ was the predominant bioessential metal to induce the aggregation of soluble A beta at pH 7.4 in vitro and that this reaction is totally reversible with chelation. We now report that unlike other biometals tested at maximal biological concentrations, marked Cu2+-induced aggregation of A beta(1-40) emerged as the solution pH was lowered from 7.4 to 6.8 and that the reaction was completely reversible with either chelation or alkalinization. This interaction was comparable to the pH-dependent effect of Cu2+ On insulin aggregation but was not seen for aprotinin or albumin. A beta(1-40) bound three to four Cu2+ ions when precipitated at pH 7.0. Rapid, pH-sensitive aggregation occurred at low nanomolar concentrations of both A beta(1-40) and A beta(1-42) with submicromolar concentrations of Cu2+. Unlike A beta(1-40) AP(1-42) was precipitated by submicromolar Cu2+ concentrations at pH 7.4, Rat A beta(1-40) and histidine-modified human A beta(1-40) were not aggregated by Zn2+, Cu2+, Or Fe3+, indicating that histidine residues are essential for metal-mediated A beta assembly. These results indicate that H+-induced conformational changes unmask a metal-binding site on A beta that mediates reversible assembly of the peptide. Since a mildly acidic environment together with increased Zn2+ and Cu2+ are common features of inflammation, we propose that AP aggregation by these factors may be a response to local injury. Cu2+, Zn2+ and Fe3+ association with A beta explains the recently reported enrichment of these metal ions in amyloid plaques in Alzheimer's disease.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Boston, MA 02114 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Genet & Aging Unit, Boston, MA 02114 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Bush, AI (corresponding author), Massachusetts Gen Hosp E, Ctr Neurosci, Genet & Aging Unit, Bldg 149,13th St, Charlestown, MA 02129 USA.	bush@helix.mgh.harvard.edu	Tanzi, Rudolph/AAE-9622-2019; Bush, Ashley I/A-1186-2007; Moir, Robert D./M-7612-2017; , Craig/AAB-3963-2022; Bush, Ashley/Y-2457-2019	Tanzi, Rudolph/0000-0002-7032-1454; Bush, Ashley I/0000-0001-8259-9069; Moir, Robert D./0000-0001-5431-3553; Bush, Ashley/0000-0001-8259-9069	NATIONAL INSTITUTE ON AGING [R29AG012686] Funding Source: NIH RePORTER; NIA NIH HHS [1R29AG1268601] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Askanas Valerie, 1993, Current Opinion in Rheumatology, V5, P732; BADETDENISOT MA, 1992, ARCH BIOCHEM BIOPHYS, V292, P475, DOI 10.1016/0003-9861(92)90018-R; BALDWIN DA, 1982, BIOCHIM BIOPHYS ACTA, V719, P140, DOI 10.1016/0304-4165(82)90317-8; BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; BARROW CJ, 1991, SCIENCE, V253, P179, DOI 10.1126/science.1853202; BRIELAND JK, 1991, ARCH BIOCHEM BIOPHYS, V284, P78, DOI 10.1016/0003-9861(91)90266-L; BRILL AS, 1968, J MOL BIOL, V36, P343, DOI 10.1016/0022-2836(68)90160-5; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; BURDICK D, 1992, J BIOL CHEM, V267, P546; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; BUSH AI, 1995, SCIENCE, V268, P1921, DOI 10.1126/science.268.5219.1921; BUSH AI, 1994, J BIOL CHEM, V269, P12152; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; Chan W, 1996, BIOCHEMISTRY-US, V35, P7123, DOI 10.1021/bi952852v; Cherny R. A., 1997, Society for Neuroscience Abstracts, V23, P534; Clements A, 1996, J NEUROCHEM, V66, P740; COHEN AS, 1989, ARTHRITIS ALLIED CON, P1273; CORIA F, 1988, LAB INVEST, V58, P454; DAVISSALINAS J, 1995, J NEUROCHEM, V65, P931; FRASER PE, 1991, BIOPHYS J, V60, P1190, DOI 10.1016/S0006-3495(91)82154-3; FREDERICKSON CJ, 1989, INT REV NEUROBIOL, V31, P145; FRIEDEN E, 1980, INFLAMMATORY DIS COP, P159; GIAMPAOLO V, 1980, INFLAMMATORY DIS COP, P329; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; GOREVIC PD, 1982, ANN NY ACAD SCI, V389, P380, DOI 10.1111/j.1749-6632.1982.tb22151.x; GRAAE J, 1968, BIOCHEM J, V106, P777, DOI 10.1042/bj1060777; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; GRIFFIN WST, 1997, MOL MECH DEMENTIA, P169; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HALEY JV, 1979, J SURG RES, V27, P168, DOI 10.1016/0022-4804(79)90127-6; HARTTER DE, 1988, J BIOL CHEM, V263, P799; HSU JM, 1969, J NUTR, V99, P425; Huang XD, 1997, J BIOL CHEM, V272, P26464, DOI 10.1074/jbc.272.42.26464; Ida N, 1996, J BIOL CHEM, V271, P22908, DOI 10.1074/jbc.271.37.22908; IWATSUBO T, 1995, ANN NEUROL, V37, P294, DOI 10.1002/ana.410370305; JOACHIM CL, 1988, BRAIN RES, V474, P100, DOI 10.1016/0006-8993(88)90673-7; JOACHIM CL, 1989, NATURE, V341, P226, DOI 10.1038/341226a0; JOHNSON C, 1991, MAT APL COMPUT, V10, P229; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KIRSHENBAUM K, 1995, BIOCHEMISTRY-US, V34, P7629, DOI 10.1021/bi00023a009; KISILEVSKY R, 1994, MOL NEUROBIOL, V8, P65, DOI 10.1007/BF02778008; KISILEVSKY R, 1983, LAB INVEST, V49, P381; KOUDINOV A, 1994, BIOCHEM BIOPH RES CO, V205, P1164, DOI 10.1006/bbrc.1994.2788; Kuo YM, 1996, J BIOL CHEM, V271, P4077; LAMB DJ, 1994, FEBS LETT, V338, P122, DOI 10.1016/0014-5793(94)80348-X; LESTAS AN, 1976, BRIT J HAEMATOL, V32, P341, DOI 10.1111/j.1365-2141.1976.tb00937.x; LINDEMAN RD, 1973, J LAB CLIN MED, V81, P194; LINDER MC, 1991, BIOCH COPPER, P220; LOUGHEED WD, 1980, DIABETOLOGIA, V19, P1, DOI 10.1007/BF00258302; LOVELL MA, 1998, IN PRESS J NEUROL SC; LUNDBLAD RL, 1988, CHEM REAGENTS PROTEI, V1, P105; MACKENZIE I, 1993, J NEUROPATHOL EXP NE, V156, P437; MAK K, 1994, BRAIN RES, V667, P138, DOI 10.1016/0006-8993(94)91725-6; Mann DMA, 1996, AM J PATHOL, V148, P1257; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MASUOKA J, 1993, J BIOL CHEM, V268, P21533; MATSUBA Y, 1970, ANAL BIOCHEM, V36, P182, DOI 10.1016/0003-2697(70)90346-5; MAURY CPJ, 1995, LAB INVEST, V72, P4; Menkin V, 1934, AM J PATHOL, V10, P193; Messier C, 1996, BEHAV BRAIN RES, V75, P1, DOI 10.1016/0166-4328(95)00153-0; MILANINO R, 1979, ADV INFLAMMAT RES, V1, P281; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; MOTTER R, 1995, ANN NEUROL, V38, P643, DOI 10.1002/ana.410380413; MURAKAMI N, 1995, ACTA NEUROPATHOL, V89, P29, DOI 10.1007/BF00294256; MURPHY GM, 1994, AM J PATHOL, V144, P1082; NAKAMURA T, 1994, ANN NEUROL, V36, P903, DOI 10.1002/ana.410360616; NITSCH RM, 1995, ANN NEUROL, V37, P512, DOI 10.1002/ana.410370414; OWEN CA, 1975, P SOC EXP BIOL MED, V149, P681; OWEN CA, 1982, BIOCH ASPECTS COPPER, P129; OWEN CA, 1982, PHYSL ASPECTS COPPER, P160; PEACOCK EE, 1976, WOUND REPAIR, P145; PEPYS MB, 1983, ADV IMMUNOL, V34, P141, DOI 10.1016/S0065-2776(08)60379-X; Pierce JES, 1996, J NEUROSCI, V16, P1083; POTEMPA LA, 1985, J BIOL CHEM, V260, P2142; PRINCIOTTO JV, 1976, BIOCHIM BIOPHYS ACTA, V428, P766, DOI 10.1016/0304-4165(76)90207-5; Prior R, 1996, AM J PATHOL, V148, P1749; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; ROGERS J, 1997, MOL MECH DEMENTIA, P177; Roher AE, 1996, J BIOL CHEM, V271, P20631, DOI 10.1074/jbc.271.34.20631; SETTE M, 1993, EUR J BIOCHEM, V213, P391, DOI 10.1111/j.1432-1033.1993.tb17773.x; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHINOBU LA, 1997, METALS OXIDATIVE DAM, P237; SHIVERS BD, 1988, EMBO J, V7, P1365, DOI 10.1002/j.1460-2075.1988.tb02952.x; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SKODRAS G, 1993, ANN CLIN LAB SCI, V23, P275; Smith MA, 1997, P NATL ACAD SCI USA, V94, P9866, DOI 10.1073/pnas.94.18.9866; SNOW AD, 1994, NEURON, V12, P219, DOI 10.1016/0896-6273(94)90165-1; SOREGHAN B, 1994, J BIOL CHEM, V269, P28551; SOTO C, 1994, J NEUROCHEM, V63, P1191; Southwick PC, 1996, J NEUROCHEM, V66, P259; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; TABATON M, 1994, BIOCHEM BIOPH RES CO, V200, P1598, DOI 10.1006/bbrc.1994.1634; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TERHUNE MW, 1972, SCIENCE, V177, P68, DOI 10.1126/science.177.4043.68; TREHALT PS, 1971, ARTHRITIS RHEUM, V14, P475; VAUGHAN DW, 1981, J NEUROPATH EXP NEUR, V40, P472, DOI 10.1097/00005072-198107000-00009; WARDESKA JG, 1985, PROTEINS IRON STORAG, P85; WARREN PJ, 1960, BRAIN, V83, P709, DOI 10.1093/brain/83.4.709; Wood SJ, 1996, J MOL BIOL, V256, P870, DOI 10.1006/jmbi.1996.0133; Yang DS, 1997, J NEUROCHEM, V68, P721; YATES CM, 1990, J NEUROCHEM, V55, P1624, DOI 10.1111/j.1471-4159.1990.tb04948.x; ZAGORSKI MG, 1992, BIOCHEMISTRY-US, V31, P5621, DOI 10.1021/bi00139a028; Zhou ZM, 1996, MOL MED, V2, P175, DOI 10.1007/BF03401614	106	909	950	1	131	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					12817	12826		10.1074/jbc.273.21.12817	http://dx.doi.org/10.1074/jbc.273.21.12817			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582309	hybrid			2022-12-27	WOS:000073768500020
J	Najjar, SM; Choice, CV; Soni, P; Whitman, CM; Poy, MN				Najjar, SM; Choice, CV; Soni, P; Whitman, CM; Poy, MN			Effect of pp120 on receptor-mediated insulin endocytosis is regulated by the juxtamembrane domain of the insulin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; TYROSINE KINASE; BETA-SUBUNIT; ENDOGENOUS SUBSTRATE; ACID-SEQUENCE; INTERNALIZATION; SHC; PROTEIN; SIGNAL; PHOSPHORYLATION	pp120, a substrate of the insulin receptor tyrosine kinase, does not undergo ligand-stimulated phosphorylation by the insulin-like growth factor-1 (IGF-1) receptor. However, replacement of the C-terminal domain of the IGF-1 receptor beta-subunit with the corresponding segment of the insulin receptor restored pp120 phosphorylation by the chimeric receptor. Since pp120 stimulates receptor-mediated insulin endocytosis when it is phosphorylated, we examined whether pp120 regulates IGF-1 receptor endocytosis in transfected NIH 3T3 cells. pp120 failed to alter IGF-1 receptor endocytosis via either wild-type or chimeric IGF-1 receptors. Thus, the effect of pp120 on hormone endocytosis is specific to insulin, and the C-terminal domain of the beta-subunit of the insulin receptor does not regulate the effect of pp120 on insulin endocytosis. Mutation of Tyr(960) in the juxtamembrane domain of the insulin receptor abolished the effect of pp120 to stimulate receptor endocytosis, without affecting pp120 phosphorylation by the insulin receptor. These findings suggest that pp120 interacts with two separate domains of the insulin receptor as follows: a C-terminal domain required for pp120 phosphorylation and a juxtamembrane domain required for internalization. We propose that the interaction of pp120 with the juxtamembrane domain is indirect and requires one or more substrates that bind to Tyr(960) in the insulin receptor.	Med Coll Ohio, Dept Pharmacol & Therapeut, Toledo, OH 43614 USA		Najjar, SM (corresponding author), Med Coll Ohio, Dept Pharmacol & Therapeut, 3035 Arlington Ave,HSci Bldg,Rm 270, Toledo, OH 43614 USA.	snajjal@opus.mco.edu	Poy, Matthew/F-6914-2017; Najjar, Sonia M/GXW-2217-2022	Poy, Matthew/0000-0002-4904-2426; 				Accili D, 1996, NAT GENET, V12, P106, DOI 10.1038/ng0196-106; BACKER JM, 1990, J BIOL CHEM, V265, P16450; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BERHANU P, 1995, BIOCHEM BIOPH RES CO, V209, P730, DOI 10.1006/bbrc.1995.1560; CARPENTIER JL, 1993, J CELL BIOL, V122, P1243, DOI 10.1083/jcb.122.6.1243; CLAUSSEN M, 1995, MOL ENDOCRINOL, V9, P902, DOI 10.1210/me.9.7.902; FARIA TN, 1994, J BIOL CHEM, V269, P13922; FORMISANO P, 1995, J BIOL CHEM, V270, P24073, DOI 10.1074/jbc.270.41.24073; GORDEN P, 1978, SCIENCE, V200, P782, DOI 10.1126/science.644321; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HARI J, 1987, J BIOL CHEM, V262, P15341; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HSU D, 1994, ENDOCRINOLOGY, V134, P744, DOI 10.1210/en.134.2.744; KABURAGI Y, 1993, J BIOL CHEM, V268, P16610; KASUGA M, 1982, J BIOL CHEM, V257, P9891; KATO H, 1994, MOL ENDOCRINOL, V8, P40, DOI 10.1210/me.8.1.40; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; LEE JS, 1994, AM J PHYSIOL, V266, pC319, DOI 10.1152/ajpcell.1994.266.2.C319; LEVYTOLEDANO R, 1994, EMBO J, V13, P835, DOI 10.1002/j.1460-2075.1994.tb06326.x; LiCalzi S, 1997, AM J PHYSIOL-ENDOC M, V273, pE801, DOI 10.1152/ajpendo.1997.273.4.E801; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; MORGAN DO, 1986, BIOCHEMISTRY-US, V25, P5560, DOI 10.1021/bi00367a032; NAJJAR SM, 1995, BIOCHEMISTRY-US, V34, P9341, DOI 10.1021/bi00029a009; NAJJAR SM, 1993, J BIOL CHEM, V268, P1201; Najjar SM, 1997, BIOCHEMISTRY-US, V36, P6827, DOI 10.1021/bi962634h; Okabayashi Y, 1996, J BIOL CHEM, V271, P5265; PERROTTI N, 1987, P NATL ACAD SCI USA, V84, P3137, DOI 10.1073/pnas.84.10.3137; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; REESJONES RW, 1985, J BIOL CHEM, V260, P4461; RENFREWHAFT C, 1994, J BIOL CHEM, V269, P26286; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STAUBS PA, 1994, J BIOL CHEM, V269, P27186; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TARTAREDECKERT S, 1995, J BIOL CHEM, V270, P23456, DOI 10.1074/jbc.270.40.23456; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; YAMADA K, 1995, J BIOL CHEM, V270, P3115, DOI 10.1074/jbc.270.7.3115; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608	42	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					12923	12928		10.1074/jbc.273.21.12923	http://dx.doi.org/10.1074/jbc.273.21.12923			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582324	hybrid			2022-12-27	WOS:000073768500035
J	Rosmarin, AG; Luo, ML; Caprio, DG; Shang, J; Simkevich, CP				Rosmarin, AG; Luo, ML; Caprio, DG; Shang, J; Simkevich, CP			Sp1 cooperates with the ets transcription factor, GABP, to activate the CD18 (beta(2) leukocyte integrin) promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOX-BINDING-PROTEINS; TATA-LESS PROMOTER; SYNERGISTIC ACTIVATION; GENE-EXPRESSION; CELL-DIFFERENTIATION; KRUPPEL FAMILY; ELEMENT; ENHANCER; REGION; IDENTIFICATION	CD18, the beta chain of the leukocyte integrins, plays a crucial role in immune and inflammatory responses. CD18 is expressed exclusively by leukocytes, and it is transcriptionally regulated during the differentiation of myeloid cells. The ets factors, PU.1 and GABP, bind to three ets sites in the CD18 promoter, which are essential for high level myeloid expression of CD18, We now identify two binding sites for the transcription factor, Sp1, that flank these ets sites. Sp1 is the only factor from myeloid cells that binds to these sites in a sequence-specific manner. Mutagenesis of these sites abrogates Spl binding and significantly reduces the activity of the transfected CD18 promoter in myeloid cells. Transfection of Sp1 into Drosophila Schneider cells, which otherwise lack Sp1, activates the CD18 promoter dramatically. GABP also activates the CD18 promoter in Schneider cells. Co-transfection of Sp1 and GABP activates CD18 more than the sum of their individual effects, indicating that these factors cooperate to transcriptionally activate myeloid expression of CD18, These studies support a model of high level, lineage-restricted gene expression mediated by cooperative interactions between widely expressed transcription factors.	Miriam Hosp, Div Hematol Oncol, Providence, RI 02906 USA; Brown Univ, Dept Med, Div Hematol, Providence, RI 02906 USA	Lifespan Health Rhode Island; Miriam Hospital; Brown University	Rosmarin, AG (corresponding author), Miriam Hosp, Div Hematol Oncol, Res 215,164 Summit Ave, Providence, RI 02906 USA.				NIDDK NIH HHS [R29 DK 44728] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK044728] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGURA ED, 1992, BLOOD, V79, P602; ANDERSSON G, 1994, CELL GROWTH DIFFER, V5, P27; ARNAOUT MA, 1990, BLOOD, V75, P1037; Block KL, 1996, BLOOD, V88, P2071, DOI 10.1182/blood.V88.6.2071.bloodjournal8862071; BOISCLAIR YR, 1993, J BIOL CHEM, V268, P24892; BOTTINGER EP, 1994, MOL CELL BIOL, V14, P2604; CARTER RS, 1994, J BIOL CHEM, V269, P4381; CHEN HM, 1993, J BIOL CHEM, V268, P8230; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; Costa MW, 1996, BIOCHEMISTRY-US, V35, P8662, DOI 10.1021/bi952801y; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; Crossley M, 1996, MOL CELL BIOL, V16, P1695; DITTMER J, 1994, J BIOL CHEM, V269, P21428; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; EBERT SN, 1995, J BIOL CHEM, V270, P17299, DOI 10.1074/jbc.270.29.17299; EMILI A, 1994, MOL CELL BIOL, V14, P1582, DOI 10.1128/MCB.14.3.1582; FISCHER KD, 1993, J BIOL CHEM, V268, P23915; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; Heydemann A, 1996, MOL CELL BIOL, V16, P1676; HICKSTEIN DD, 1988, J BIOL CHEM, V263, P13863; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JANSON L, 1990, P NATL ACAD SCI USA, V87, P4732, DOI 10.1073/pnas.87.12.4732; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; Lee JH, 1996, J BIOL CHEM, V271, P4561; LETOVSKY J, 1989, NUCLEIC ACIDS RES, V17, P2639, DOI 10.1093/nar/17.7.2639; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; MAJELLO B, 1995, ONCOGENE, V10, P1841; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Noti JD, 1996, MOL IMMUNOL, V33, P115, DOI 10.1016/0161-5890(95)00140-9; PAHL HL, 1992, BLOOD, V79, P865; Parks CL, 1996, J BIOL CHEM, V271, P4417; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; Piedrafita FJ, 1996, J BIOL CHEM, V271, P14412, DOI 10.1074/jbc.271.24.14412; ROSMARIN AG, 1989, BLOOD, V73, P131; Rosmarin AG, 1997, BIOTECHNIQUES, V22, P434, DOI 10.2144/97223bm12; ROSMARIN AG, 1995, P NATL ACAD SCI USA, V92, P801, DOI 10.1073/pnas.92.3.801; ROSMARIN AG, 1995, J BIOL CHEM, V270, P23627, DOI 10.1074/jbc.270.40.23627; ROSMARIN AG, 1992, BLOOD, V79, P2598; SADASIVAN E, 1994, J BIOL CHEM, V269, P4725; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; SPRINGER TA, 1984, J EXP MED, V160, P1901, DOI 10.1084/jem.160.6.1901; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; Ye JP, 1996, MOL CELL BIOL, V16, P6178; Ye JP, 1996, MOL CELL BIOL, V16, P157; Youn BS, 1996, J IMMUNOL, V157, P3499; ZARET KS, 1990, P NATL ACAD SCI USA, V87, P5469, DOI 10.1073/pnas.87.14.5469; ZHANG DE, 1994, J IMMUNOL, V153, P3276	57	87	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					13097	13103		10.1074/jbc.273.21.13097	http://dx.doi.org/10.1074/jbc.273.21.13097			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582348	hybrid			2022-12-27	WOS:000073768500059
J	Canete-Soler, R; Schwartz, ML; Hua, Y; Schlaepfer, WW				Canete-Soler, R; Schwartz, ML; Hua, Y; Schlaepfer, WW			Characterization of ribonucleoprotein complexes and their binding sites on the neurofilament light subunit mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE PROTEIN-BINDING; MESSENGER-RNA STABILITY; MOTOR-NEURON DISEASE; UNIQUE CIS-ELEMENT; 3'-UNTRANSLATED REGION; UP-REGULATION; GENE-EXPRESSION; POSTNATAL-DEVELOPMENT; NF-L; GROWTH	Levels of neurofilament (NF) gene expression are important determinants of basic neuronal properties, but overexpression can lead to motoneuron degeneration in transgenic mice. In a companion study (Canete-Soler, R., Schwartz, M. L., Hua, Y., and Schlaepfer, W. W. (1998) J. Biol. Chem. 273, 12650-12654), we show that levels of NF expression are regulated by altering mRNA stability and that stability determinants are present in the 3'-coding region (3'-CR) and 3'-untranslated region (3'-UTR) of the NF light subunit (NF-L) transcript. This study characterizes the ribonucleoprotein complexes that bind to the NF-L mRNA when cytoplasmic brain extracts are incubated with radioactive probes. Gel retardation assays reveal ribonucleoprotein complexes that are selectively competed with poly(C) or poly(U))/poly(A) homoribopolymers and are referred to as C-binding and U/A-binding complexes, respectively. The C-binding complex forms on the proximal 45 nucleotides of 3'-UTR, but its assembly is markedly enhanced by 23 nucleotides of flanking 3'-CR sequence. U/A-binding complexes form at multiple binding sites in the 3'-CR and 3'-UTR, A pattern of reciprocal binding suggests that the C-binding and U/A-binding complexes interact and may compete for common components or binding sites. Cross-linking studies reveal unique polypeptides in the C-binding and U/A-binding complexes. The findings provide the basis for probing mechanisms regulating NF-L mRNA stability and the relationship between NF overexpression and motoneuron degeneration in transgenic mice.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Div Neuropathol, Philadelphia, PA 19104 USA	University of Pennsylvania	Canete-Soler, R (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, Div Neuropathol, 435 Johnson Pavil, Philadelphia, PA 19104 USA.	racansol@mail.med.upenn.edu						Amara FM, 1996, J BIOL CHEM, V271, P15279, DOI 10.1074/jbc.271.25.15279; Amara FM, 1996, J BIOL CHEM, V271, P20126, DOI 10.1074/jbc.271.33.20126; BABU N, 1993, FASEB J, V7, P702; BUSTELO XR, 1995, MOL CELL BIOL, V15, P1324; Canete-Soler R, 1998, J BIOL CHEM, V273, P12650, DOI 10.1074/jbc.273.20.12650; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chung SM, 1997, J BIOL CHEM, V272, P6593, DOI 10.1074/jbc.272.10.6593; COLLIDGE CJ, 1997, NUCLEIC ACIDS RES, V25, P888; COTE F, 1993, CELL, V73, P35, DOI 10.1016/0092-8674(93)90158-M; CzyzykKrzeska MF, 1996, J BIOL CHEM, V271, P3293, DOI 10.1074/jbc.271.6.3293; Darnell RB, 1996, P NATL ACAD SCI USA, V93, P4529, DOI 10.1073/pnas.93.10.4529; GORLACH M, 1994, J BIOL CHEM, V269, P23074; Gutmann E, 1943, J PHYSIOL-LONDON, V101, P489, DOI 10.1113/jphysiol.1943.sp004002; JULIEN JP, 1987, BIOCHIM BIOPHYS ACTA, V909, P10, DOI 10.1016/0167-4781(87)90041-8; Kohn DT, 1996, MOL BRAIN RES, V36, P240, DOI 10.1016/0169-328X(95)00239-O; LEE MK, 1994, NEURON, V13, P975, DOI 10.1016/0896-6273(94)90263-1; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; LEWIS SA, 1985, J CELL BIOL, V100, P843, DOI 10.1083/jcb.100.3.843; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MANZELLA JM, 1992, J BIOL CHEM, V267, P7077; MORRISON BM, 1996, J COMP NEUROL, V363, P617; MOSKOWITZ PF, 1995, MOL BRAIN RES, V30, P211, DOI 10.1016/0169-328X(95)00006-E; MUMA NA, 1991, J NEUROCYTOL, V20, P844, DOI 10.1007/BF01191735; PernasAlonso R, 1996, MOL BRAIN RES, V38, P267, DOI 10.1016/0169-328X(95)00344-R; Scheper W, 1996, NUCLEIC ACIDS RES, V24, P1000, DOI 10.1093/nar/24.6.1000; SCHLAEPFER WW, 1990, J NEUROSCI RES, V25, P39, DOI 10.1002/jnr.490250106; SCHWARTZ ML, 1992, J BIOL CHEM, V267, P24596; SCHWARTZ ML, 1990, J NEUROSCI RES, V27, P193, DOI 10.1002/jnr.490270209; SCHWARTZ ML, 1995, J BIOL CHEM, V270, P26364, DOI 10.1074/jbc.270.44.26364; SCHWARTZ ML, 1994, MOL BRAIN RES, V27, P215, DOI 10.1016/0169-328X(94)90003-5; SCHWARTZ ML, 1994, J BIOL CHEM, V269, P13444; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; SOPPET DR, 1991, J NEUROSCI RES, V30, P421; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; WANG XM, 1995, MOL CELL BIOL, V15, P1769; Wang XM, 1996, EMBO J, V15, P5040, DOI 10.1002/j.1460-2075.1996.tb00884.x; XU ZS, 1993, CELL, V73, P23, DOI 10.1016/0092-8674(93)90157-L; ZAIDI SHE, 1994, J BIOL CHEM, V269, P24000; ZUKER M, 1991, NUCLEIC ACIDS RES, V19, P2707, DOI 10.1093/nar/19.10.2707	40	21	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12655	12661		10.1074/jbc.273.20.12655	http://dx.doi.org/10.1074/jbc.273.20.12655			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575228	hybrid			2022-12-27	WOS:000073629800093
J	Feller, G; D'Amico, S; Benotmane, AM; Joly, F; Van Beeumen, J; Gerday, C				Feller, G; D'Amico, S; Benotmane, AM; Joly, F; Van Beeumen, J; Gerday, C			Characterization of the C-terminal propeptide involved in bacterial wall spanning of alpha-amylase from the psychrophile Alteromonas haloplanctis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; IGA PROTEASE-TYPE; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; PRO-SEQUENCE; SECRETION; MEMBRANE; PROTEINS; PURIFICATION; GENE	The antarctic psychrophile Alteromonas haloplanctis secretes a Ca2+- and Cl--dependent alpha-amylase. The nucleotide sequence of the amy gene and the amino acid sequences of the gene products indicate that the alpha-amylase precursor is a preproenzyme composed by the signal peptide (24 residues), the mature alpha-amylase (453 residues, 49 kDa), and a long C-terminal propeptide or secretion helper (192 residues, 21 kDa). In cultures of the wild-type strain, the 70-kDa precursor is secreted at the mid-exponential phase and is cleaved by a nonspecific protease into the mature enzyme and the propeptide. The purified C-terminal propeptide displays several features common to beta-pleated transmembrane proteins. It has no intramolecular chaperone function because active alpha-amylase is expressed by Escherichia coli in the absence of the propeptide coding region, In E. coli, the 70-kDa precursor is directed toward the supernatant, When the alpha-amylase coding region is excised from the gene, the secretion helper can still promote its own membrane spanning. It can also accept a foreign passenger, as shown by the extracellular routing of a beta-lactamase-propeptide fusion protein.	Univ Liege, Inst Phys B6, Biochem Lab, B-4000 Liege, Belgium; State Univ Ghent, Lab Prot Biochem & Prot Engn, B-9000 Gent, Belgium	University of Liege; Ghent University	Feller, G (corresponding author), Univ Liege, Inst Phys B6, Biochem Lab, B-4000 Liege, Belgium.	gfeller@ulg.ac.be		Benotmane, Rafi/0000-0002-8985-1578				Aghajari N, 1998, PROTEIN SCI, V7, P564, DOI 10.1002/pro.5560070304; Aghajari N, 1996, PROTEIN SCI, V5, P2128, DOI 10.1002/pro.5560051021; ANDERSSON H, 1991, P NATL ACAD SCI USA, V88, P9751, DOI 10.1073/pnas.88.21.9751; AU S, 1991, J BACTERIOL, V173, P4551, DOI 10.1128/jb.173.15.4551-4557.1991; CEASE KB, 1994, PCR METH APPL, V3, P298; CHARLES I, 1994, MICROBIOL-SGM, V140, P3301, DOI 10.1099/13500872-140-12-3301; DAVAIL S, 1994, J BIOL CHEM, V269, P17448; EDER J, 1995, MOL MICROBIOL, V16, P609, DOI 10.1111/j.1365-2958.1995.tb02423.x; Feller G, 1996, J BIOL CHEM, V271, P23836, DOI 10.1074/jbc.271.39.23836; Feller G, 1997, EUR J BIOCHEM, V244, P186, DOI 10.1111/j.1432-1033.1997.00186.x; FELLER G, 1994, EUR J BIOCHEM, V222, P441, DOI 10.1111/j.1432-1033.1994.tb18883.x; FELLER G, 1992, J BIOL CHEM, V267, P5217; Gennity J M, 1991, Curr Opin Biotechnol, V2, P661, DOI 10.1016/0958-1669(91)90031-Y; HABEEB AFSA, 1973, ANAL BIOCHEM, V56, P60, DOI 10.1016/0003-2697(73)90169-3; HIRST TR, 1988, TRENDS BIOCHEM SCI, V13, P265, DOI 10.1016/0968-0004(88)90160-0; KLAUSER T, 1993, BIOESSAYS, V15, P799, DOI 10.1002/bies.950151205; KLAUSER T, 1993, J MOL BIOL, V234, P579, DOI 10.1006/jmbi.1993.1613; KLAUSER T, 1992, EMBO J, V11, P2327, DOI 10.1002/j.1460-2075.1992.tb05292.x; Kurosaka K, 1996, MOL MICROBIOL, V20, P385, DOI 10.1111/j.1365-2958.1996.tb02625.x; OCALLAGHAN CH, 1972, ANTIMICROB AGENTS CH, V1, P283, DOI 10.1128/AAC.1.4.283; OHNISHI Y, 1994, J BIOL CHEM, V269, P32800; POHLNER J, 1987, NATURE, V325, P458, DOI 10.1038/325458a0; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; RASMUSSEN BA, 1987, GENE DEV, V1, P185, DOI 10.1101/gad.1.2.185; RAUSCHER E, 1985, CLIN CHEM, V31, P14; SALMOND GPC, 1993, TRENDS BIOCHEM SCI, V18, P7, DOI 10.1016/0968-0004(93)90080-7; SCHMITT W, 1994, MOL MICROBIOL, V12, P307, DOI 10.1111/j.1365-2958.1994.tb01019.x; SHINDE U, 1993, TRENDS BIOCHEM SCI, V18, P442, DOI 10.1016/0968-0004(93)90146-E; SPRATT BG, 1986, GENE, V41, P337, DOI 10.1016/0378-1119(86)90117-4; Stein M, 1996, J BACTERIOL, V178, P6546, DOI 10.1128/jb.178.22.6546-6554.1996; STRUYVE M, 1991, J MOL BIOL, V218, P141, DOI 10.1016/0022-2836(91)90880-F; Suzuki T, 1995, J BIOL CHEM, V270, P30874, DOI 10.1074/jbc.270.52.30874; VIROLLE MJ, 1988, GENE, V74, P321, DOI 10.1016/0378-1119(88)90166-7	34	30	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12109	12115		10.1074/jbc.273.20.12109	http://dx.doi.org/10.1074/jbc.273.20.12109			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575155	Green Published, hybrid			2022-12-27	WOS:000073629800020
J	Grimaud, R; Kessel, M; Beuron, F; Steven, AC; Maurizi, MR				Grimaud, R; Kessel, M; Beuron, F; Steven, AC; Maurizi, MR			Enzymatic and structural similarities between the Escherichia coli ATP-dependent proteases, ClpXP and ClpAP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPECIFICITY COMPONENT; MOLECULAR CHAPERONE; PROTEIN; SEQUENCE; PURIFICATION; PROTEOLYSIS; DEGRADATION; ACTIVATOR; HSLV	Escherichia coli ClpX, a member of the Clp family of ATPases, has ATP-dependent chaperone activity and is required for specific ATP-dependent proteolytic activities expressed by ClpP, Gel filtration and electron microscopy showed that ClpX subunits (M-r 46,000) associate to form a six-membered ring (M-r similar to 280,000) that is stabilized by binding of ATP or nonhydrolyzable analogs of ATP, ClpP, which is composed of two seven-membered rings stacked face-to-face, interacts with the nucleotide-stabilized hexamer of ClpX to form a complex that could be isolated by gel filtration. Electron micrographs of negatively stained ClpXP preparations showed side views of 1:1 and 2:1 ClpXP complexes in which ClpP was flanked on either one or both sides by a ring of ClpX, Thus, as was seen for ClpAP, a symmetry mismatch exists in the bonding interactions between the seven-membered rings of ClpP and the six-membered rings of ClpX, Competition studies showed that ClpA may have a slightly higher affinity (similar to 2-fold) for binding to ClpP, Mixed complexes of ClpA, ClpX, and ClpP with the two ATPases bound simultaneously to opposite faces of a single ClpP molecule were seen by electron microscopy, In the presence of ATP or nonhydrolyzable analogs of ATP, ClpXP had nearly the same activity as ClpAP against oligopeptide substrates (>10,000 min(-1)/tetradecamer of ClpP), Thus, ClpX and ClpA interactions with ClpP result in structurally analogous complexes and induce similar conformational changes that affect the accessibility and the catalytic efficiency of ClpP active sites.	NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; NIAMS, Struct Biol Res Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Maurizi, MR (corresponding author), NCI, Cell Biol Lab, NIH, Bldg 37,Rm 1B07,37 Convent Dr,MSC 4255, Bethesda, MD 20892 USA.		Grimaud, Régis/AAA-1730-2021	Grimaud, Régis/0000-0002-5017-7571				Bochtler M, 1997, P NATL ACAD SCI USA, V94, P6070, DOI 10.1073/pnas.94.12.6070; CHUANG SE, 1993, GENE, V134, P1, DOI 10.1016/0378-1119(93)90167-2; Gottesman S, 1995, COLD SPRING HARB SYM, V60, P533, DOI 10.1101/SQB.1995.060.01.057; Gottesman S, 1997, CELL, V91, P435, DOI 10.1016/S0092-8674(00)80428-6; GOTTESMAN S, 1993, J BIOL CHEM, V268, P22618; Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; GRAY CW, 1994, J MOL BIOL, V236, P7, DOI 10.1006/jmbi.1994.1113; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HWANG BJ, 1988, J BIOL CHEM, V263, P8727; Kessel M, 1996, FEBS LETT, V398, P274, DOI 10.1016/S0014-5793(96)01261-6; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; Knowlton JR, 1997, NATURE, V390, P639, DOI 10.1038/37670; Kocsis E, 1995, ULTRAMICROSCOPY, V60, P219, DOI 10.1016/0304-3991(95)00070-2; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Larsen CN, 1997, CELL, V91, P431, DOI 10.1016/S0092-8674(00)80427-4; Lupas A, 1997, TRENDS BIOCHEM SCI, V22, P399, DOI 10.1016/S0968-0004(97)01117-1; MAURIZI MR, 1994, METHOD ENZYMOL, V244, P314; MAURIZI MR, 1990, J BIOL CHEM, V265, P12546; MAURIZI MR, 1990, J BIOL CHEM, V265, P12536; MAURIZI MR, 1992, EXPERIENTIA, V48, P178, DOI 10.1007/BF01923511; MAURIZI MR, 1998, IN PRESS BIOCHEMISTR; MOODY MF, 1981, J MOL BIOL, V150, P217, DOI 10.1016/0022-2836(81)90450-2; Rohrwild M, 1996, P NATL ACAD SCI USA, V93, P5808, DOI 10.1073/pnas.93.12.5808; Rohrwild M, 1997, NAT STRUCT BIOL, V4, P133, DOI 10.1038/nsb0297-133; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; THOMPSON MW, 1994, J BIOL CHEM, V269, P18201; THOMPSON MW, 1994, J BIOL CHEM, V269, P18209; Trus BL, 1996, J STRUCT BIOL, V116, P61, DOI 10.1006/jsbi.1996.0011; TRUS BL, 1992, SCANNING MICROSCOPY, V6, P441; UNSER M, 1986, ULTRAMICROSCOPY, V19, P337, DOI 10.1016/0304-3991(86)90094-X; WAWRZYNOW A, 1995, EMBO J, V14, P1867, DOI 10.1002/j.1460-2075.1995.tb07179.x; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; Yoo SJ, 1996, J BIOL CHEM, V271, P14035, DOI 10.1074/jbc.271.24.14035	37	222	224	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12476	12481		10.1074/jbc.273.20.12476	http://dx.doi.org/10.1074/jbc.273.20.12476			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575205	Green Submitted, hybrid			2022-12-27	WOS:000073629800070
J	Morimoto, S; Tateishi, N; Matsuda, T; Tanaka, H; Taura, F; Furuya, N; Matsuyama, N; Shoyama, Y				Morimoto, S; Tateishi, N; Matsuda, T; Tanaka, H; Taura, F; Furuya, N; Matsuyama, N; Shoyama, Y			Novel hydrogen peroxide metabolism in suspension cells of Scutellaria baicalensis Georgi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED HYPERSENSITIVE REACTION; LIPID-PEROXIDATION; PUERARIA-LOBATA; ACTIVE OXYGEN; TOBACCO; GENERATION; CULTURES; PURIFICATION; INVOLVEMENT; INFECTION	We identified a rapid and novel system to effectively metabolize a large amount of H2O2 in the suspension cells of Scutellaria baicalensis Georgi. In response to an elicitor, the cells immediately initiate the hydrolysis of baicalein 7-O-beta-D-glucuronide by beta-glucuronidase, and the released baicalein is then quickly oxidized to 6,7-dehydrobaicalein by peroxidases. Hydrogen peroxide is effectively consumed during the peroxidase reaction. The beta-glucuronidase inhibitor, saccharic acid 1,4-lactone, significantly reduced the H2O2-metabolizing ability of the Scutellaria cells, indicating that beta-glucuronidase, which does not catalyze the H2O2 degradation, plays an important role in the H2O2 metabolism. As H2O2-metabolizing enzymes, we purified two peroxidases using ammonium sulfate precipitation followed by sequential chromatography on CM-cellulose and hydroxylapatite. Both peroxidases show high H2O2-metabolizing activity using baicalein, whereas other endogenous flavones are not substrates of the peroxidase reaction. Therefore, baicalein predominantly contributed to H2O2 metabolism. Because beta-glucuronidase, cell wall peroxidases, and baicalein pre-exist in Scutellaria cells, their constitutive presence enables the cells to rapidly induce the H2O2-metabolizing system.	Kyushu Univ, Fac Pharmaceut Sci, Higashi Ku, Fukuoka 81282, Japan; Kyushu Univ, Fac Agr, Higashi Ku, Fukuoka 81281, Japan	Kyushu University; Kyushu University	Morimoto, S (corresponding author), Kyushu Univ, Fac Pharmaceut Sci, Higashi Ku, 3-1-1 Maidashi, Fukuoka 81282, Japan.	morimoto@shoyaku.phar.kyushu-u.ac.jp						ADAM A, 1989, PHYSIOL MOL PLANT P, V34, P13, DOI 10.1016/0885-5765(89)90013-1; ANHALT S, 1992, PLANTA, V187, P83, DOI 10.1007/BF00201627; ASADA K, 1992, PHYSIOL PLANTARUM, V85, P235, DOI 10.1111/j.1399-3054.1992.tb04728.x; AUSTIN CA, 1992, BIOCHEM J, V282, P883, DOI 10.1042/bj2820883; BAKER CJ, 1995, ANNU REV PHYTOPATHOL, V33, P299, DOI 10.1146/annurev.py.33.090195.001503; Billman JH, 1944, J AM CHEM SOC, V66, P540, DOI 10.1021/ja01232a011; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADLEY J, 1992, CELL, V700, P21; BROWNLEADER MD, 1995, PLANT PHYSIOL, V109, P1115, DOI 10.1104/pp.109.3.1115; DOKE N, 1983, PHYSIOL PLANT PATHOL, V23, P345, DOI 10.1016/0048-4059(83)90019-X; HOSEL W, 1975, EUR J BIOCHEM, V57, P607, DOI 10.1111/j.1432-1033.1975.tb02336.x; KEPPLER LD, 1989, PHYTOPATHOLOGY, V79, P555, DOI 10.1094/Phyto-79-555; KEPPLER LD, 1987, PHYSIOL MOL PLANT P, V30, P233, DOI 10.1016/0885-5765(87)90037-3; KUBO M, 1981, PLANTA MED, V43, P194, DOI 10.1055/s-2007-971499; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVVY GA, 1954, BIOCHEM J, V56, P462; MARSHALL WS, 1993, P NATL ACAD SCI USA, V90, P5504, DOI 10.1073/pnas.90.12.5504; MEHDY MC, 1994, PLANT PHYSIOL, V105, P467, DOI 10.1104/pp.105.2.467; MORIMOTO S, 1995, PLANTA, V195, P535, DOI 10.1007/BF00195712; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; NEGREL J, 1987, PLANTA, V172, P494, DOI 10.1007/BF00393865; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PARK HH, 1995, PHYTOCHEMISTRY, V38, P373, DOI 10.1016/0031-9422(94)00640-F; Park HH, 1995, Z NATURFORSCH C, V50, P824; PENG M, 1992, PHYTOPATHOLOGY, V82, P696, DOI 10.1094/Phyto-82-696; PODSTOLSKI A, 1970, Phytochemistry (Oxford), V9, P289, DOI 10.1016/S0031-9422(00)85137-7; So FV, 1997, CANCER LETT, V112, P127, DOI 10.1016/S0304-3835(96)04557-0; SUTHERLAND MW, 1991, PHYSIOL MOL PLANT P, V39, P79, DOI 10.1016/0885-5765(91)90020-I; Wojtaszek P, 1997, BIOCHEM J, V322, P681, DOI 10.1042/bj3220681; Wollenweber E., 1988, FLAVONOIDS ADV RES 1, P233; Yamamoto H., 1991, BIOTECHNOLOGY AGR FO, V15, P398	31	55	61	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12606	12611		10.1074/jbc.273.20.12606	http://dx.doi.org/10.1074/jbc.273.20.12606			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575222	hybrid			2022-12-27	WOS:000073629800087
J	Murray, CA; Lynch, MA				Murray, CA; Lynch, MA			Dietary supplementation with vitamin E reverses the age-related deficit in long term potentiation in dentate gyrus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; RAT-BRAIN; LIPID-PEROXIDATION; AGING BRAIN; FREE-RADICALS; HIPPOCAMPUS; INDUCTION; REGIONS; TISSUES; MEMORY	Long term potentiation (LTP) in dentate gyrus is impaired in aged rats, and this has been associated with an age-related decrease in membrane arachidonic acid concentration. In this study, we considered whether the trigger for this age-related decrease in arachidonic acid might be increased lipid peroxidation stimulated by the proinflammatory cytokine, interleukin-1 beta. Groups of aged and young rats were fed on a control diet or a diet supplemented with alpha-tocopherol and assessed for their ability to sustain LTP. Aged rats fed on the control diet exhibited an impaired ability to sustain LTP and analysis of tissue prepared from these rats exhibited increased interleukin-1 beta, increased lipid peroxidation, and decreased membrane arachidonic acid concentration compared with young rats fed on either diet; Aged rats fed on the supplemented diet sustained LTP in a manner indistinguishable from young rats, and the age-related increases in interleukin-1 beta and lipid peroxidation and the decrease in membrane arachidonic acid concentration were all reversed. We propose that interleukin-1 beta may be the trigger that induces these age-related changes and may therefore be responsible for the deficit in long term potentiation in aged rats. The observation that alpha-tocopherol reverses these changes is consistent with the hypothesis that some age-related changes in hippocampus might derive from oxidative stress.	Univ Dublin Trinity Coll, Dept Physiol, Dublin 2, Ireland	Trinity College Dublin	Lynch, MA (corresponding author), Univ Dublin Trinity Coll, Dept Physiol, Dublin 2, Ireland.	lynchma@tcd.ie		Lynch, Marina/0000-0002-4631-0499				BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; BATTAINI F, 1995, NEUROBIOL AGING, V16, P137, DOI 10.1016/0197-4580(94)00154-5; BENKOVIC SA, 1993, J COMP NEUROL, V338, P97, DOI 10.1002/cne.903380108; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALDERINI G, 1983, NEUROCHEM RES, V8, P483, DOI 10.1007/BF00965104; CHOE M, 1995, FREE RADICAL BIO MED, V18, P977, DOI 10.1016/0891-5849(94)00217-8; CINI M, 1995, NEUROBIOL AGING, V16, P53, DOI 10.1016/0197-4580(95)80007-E; CRISTIANO F, 1995, MECH AGEING DEV, V80, P93, DOI 10.1016/0047-6374(94)01561-Y; Cunningham AJ, 1996, NEUROSCI LETT, V203, P17, DOI 10.1016/0304-3940(95)12252-4; DAVIS S, 1993, NEUROBIOL AGING, V14, P107, DOI 10.1016/0197-4580(93)90030-F; DIANA G, 1995, BRAIN RES, V686, P107, DOI 10.1016/0006-8993(95)00440-2; GAITI A, 1989, ANN NY ACAD SCI, V559, P365; GEINISMAN Y, 1994, ANN NY ACAD SCI, V747, P452; GEINISMAN Y, 1991, BRAIN RES, V566, P77, DOI 10.1016/0006-8993(91)91683-R; GUPTA A, 1991, GERONTOLOGY, V37, P305, DOI 10.1159/000213277; HAAN EA, 1981, J NEUROCHEM, V37, P243, DOI 10.1111/j.1471-4159.1981.tb05315.x; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; KRUG M, 1984, BRAIN RES BULL, V13, P39, DOI 10.1016/0361-9230(84)90005-4; LANDFIELD PW, 1978, BRAIN RES, V150, P85, DOI 10.1016/0006-8993(78)90655-8; LEBEL CP, 1990, NEUROCHEM INT, V17, P435, DOI 10.1016/0197-0186(90)90025-O; LYNCH MA, 1994, EUR J NEUROSCI, V6, P1008, DOI 10.1111/j.1460-9568.1994.tb00595.x; Lynch MA, 1997, J PHYSIOL-LONDON, V501P, pS5; MacEvilly CJ, 1996, FREE RADICAL BIO MED, V20, P639, DOI 10.1016/0891-5849(95)02147-7; McGahon B, 1997, NEUROSCIENCE, V81, P9, DOI 10.1016/S0306-4522(97)00116-4; MIWA H, 1986, CLIN CHIM ACTA, V155, P95, DOI 10.1016/0009-8981(86)90104-X; MIZUNO Y, 1986, J NEUROCHEM, V46, P1344, DOI 10.1111/j.1471-4159.1986.tb01745.x; Mo ZL, 1996, BRAIN RES BULL, V41, P249, DOI 10.1016/S0361-9230(96)00196-7; Mullany P, 1996, EUR J PHARMACOL, V309, P311, DOI 10.1016/0014-2999(96)00464-5; Mullany P, 1997, NEUROPHARMACOLOGY, V36, P973, DOI 10.1016/S0028-3908(97)00073-7; MULLER DPR, 1990, CRIT REV NEUROBIOL, V5, P239; Murray CA, 1997, J PHYSIOL-LONDON, V501P, pP87; Murray CA, 1997, NEUROBIOL AGING, V18, P343, DOI 10.1016/S0197-4580(97)80317-X; NODA Y, 1982, NEUROBIOL AGING, V3, P173, DOI 10.1016/0197-4580(82)90037-9; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; OTANI S, 1989, NEUROSCIENCE, V28, P519, DOI 10.1016/0306-4522(89)90001-8; PACKER JE, 1979, NATURE, V278, P737, DOI 10.1038/278737a0; PELLMAR TC, 1991, NEUROSCIENCE, V44, P353, DOI 10.1016/0306-4522(91)90060-2; RAVINDRANATH V, 1989, NEUROSCI LETT, V101, P187, DOI 10.1016/0304-3940(89)90528-4; REITER RJ, 1995, FASEB J, V9, P526, DOI 10.1096/fasebj.9.7.7737461; RICEEVANS C, 1993, PROG LIPID RES, V32, P71, DOI 10.1016/0163-7827(93)90006-I; Rothwell NJ, 1996, PHARMACOL THERAPEUT, V69, P85, DOI 10.1016/0163-7258(95)02033-0; SUMOSKI W, 1989, DIABETOLOGIA, V32, P792; TAPPEL AL, 1968, GERIATRICS, V23, P97; TRAN K, 1988, BIOCHIM BIOPHYS ACTA, V963, P468, DOI 10.1016/0005-2760(88)90315-3; Urano S, 1997, EUR J BIOCHEM, V245, P64, DOI 10.1111/j.1432-1033.1997.00064.x; VATASSERY GT, 1984, J NEUROCHEM, V43, P409, DOI 10.1111/j.1471-4159.1984.tb00916.x; VATASSERY GT, 1992, ANN NY ACAD SCI, V669, P97; XIE Z, 1995, BRAIN RES, V681, P193, DOI 10.1016/0006-8993(95)00271-Q; XIE Z, 1993, BRAIN RES, V604, P173, DOI 10.1016/0006-8993(93)90365-T; ZHANG JR, 1993, J NEUROCHEM, V61, P1640, DOI 10.1111/j.1471-4159.1993.tb09798.x; Zs-Nagy I., 1994, MEMBRANE HYPOTHESIS	54	132	138	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12161	12168		10.1074/jbc.273.20.12161	http://dx.doi.org/10.1074/jbc.273.20.12161			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575163	hybrid			2022-12-27	WOS:000073629800028
J	Bridgewater, LC; Lefebvre, V; de Crombrugghe, B				Bridgewater, LC; Lefebvre, V; de Crombrugghe, B			Chondrocyte-specific enhancer elements in the Col11a2 gene resemble the Col2a1 tissue-specific enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRO-ALPHA-1(II) COLLAGEN GENE; AUTOSOMAL SEX REVERSAL; SRY-RELATED GENE; TRANSGENIC MICE; CAMPOMELIC DYSPLASIA; EXPRESSION; CARTILAGE; SOX9; DIFFERENTIATION; CHONDROGENESIS	Type XI collagen and type II collagen are coexpressed in all cartilage, and both are essential for normal cartilage differentiation and skeletal morphogenesis, This laboratory has recently identified a 48-base pair (bp) enhancer element in the type II collagen gene Col2a1 that contains several HMG-type protein-binding sites and that can direct chondrocyte-specific expression in transient transfection and in transgenic mice. The present study has identified two short chondrocyte-specific enhancer elements within a region in the 5' portion of the type XI collagen gene Col11a2 that has previously been shown to influence chondrocyte-specific expression in transgenic mice. These Col11a2 enhancer elements, like the Col2a1 enhancer, contain several sites with homology to the high mobility group (HMG) protein-binding consensus sequence. In electrophoretic mobility shift assays, the Col11a2 elements formed a DNA-protein complex that was dependent on the presence of the HMG-like sites. It had the same mobility as the complex formed with the Col2a1 48-bp enhancer and appeared to contain the same or similar proteins, including SOX9, The Col11a2 elements directed gene expression in transient transfections of chondrocytes but not fibroblasts, and their activity was abolished by mutation of the HMG-like sites. Ectopically expressed SOX9 activated these enhancers in non-chondrocytic cells, as it also activates the Col2a1 enhancer. Finally, the Col11a2 enhancer elements both directed transgene expression to cartilage in developing mouse embryos. Overall, our results indicate that the two Col11a2 chondrocyte-specific enhancer elements share many similarities with the Col2a1 48-bp enhancer. These similarities suggest the existence of a genetic program designed to coordinately regulate the expression of these and perhaps other genes involved in the chondrocyte differentiation pathway.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	de Crombrugghe, B (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Bridgewater, Laura C/I-2999-2015	Bridgewater, Laura C/0000-0002-4664-6144	NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR042919] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672] Funding Source: Medline; NIAMS NIH HHS [AR42919] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; CHAN D, 1995, J BIOL CHEM, V270, P1747, DOI 10.1074/jbc.270.4.1747; CHEAH KSE, 1991, DEVELOPMENT, V111, P945; daSilva SM, 1996, NAT GENET, V14, P62, DOI 10.1038/ng0996-62; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; GAROFALO S, 1991, P NATL ACAD SCI USA, V88, P9648, DOI 10.1073/pnas.88.21.9648; GOLDBERG H, 1992, J BIOL CHEM, V267, P19622; HARLEY VR, 1994, NUCLEIC ACIDS RES, V22, P1500, DOI 10.1093/nar/22.8.1500; HARLOW E, 1988, ANTIBODIES LAB MANUA, P314; Healy C, 1996, ANN NY ACAD SCI, V785, P261, DOI 10.1111/j.1749-6632.1996.tb56278.x; KWOK C, 1995, AM J HUM GENET, V57, P1028; Lefebvre V, 1996, MOL CELL BIOL, V16, P4512; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; LI SW, 1995, GENE DEV, V9, P2821, DOI 10.1101/gad.9.22.2821; LI Y, 1995, CELL, V80, P423, DOI 10.1016/0092-8674(95)90492-1; MUKHOPADHYAY K, 1995, J BIOL CHEM, V270, P27711, DOI 10.1074/jbc.270.46.27711; Ng LJ, 1997, DEV BIOL, V183, P108, DOI 10.1006/dbio.1996.8487; Sudbeck P, 1996, NAT GENET, V13, P230, DOI 10.1038/ng0696-230; Tsumaki N, 1996, J CELL BIOL, V134, P1573, DOI 10.1083/jcb.134.6.1573; VIKKULA M, 1995, CELL, V80, P431, DOI 10.1016/0092-8674(95)90493-X; von der Mark K, 1980, Curr Top Dev Biol, V14, P199; VUORISTO MM, 1995, J BIOL CHEM, V270, P22873, DOI 10.1074/jbc.270.39.22873; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; WRIGHT E, 1995, NAT GENET, V9, P15, DOI 10.1038/ng0195-15; Zhao Q, 1997, DEV DYNAM, V209, P377, DOI 10.1002/(SICI)1097-0177(199708)209:4<377::AID-AJA5>3.0.CO;2-F; Zhou G, 1998, J BIOL CHEM, V273, P14989, DOI 10.1074/jbc.273.24.14989; ZHOU G, 1995, J CELL SCI, V108, P3677	28	220	229	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14998	15006		10.1074/jbc.273.24.14998	http://dx.doi.org/10.1074/jbc.273.24.14998			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614107	hybrid			2022-12-27	WOS:000074160400049
J	Chen, SRW; Ebisawa, K; Li, XL; Zhang, L				Chen, SRW; Ebisawa, K; Li, XL; Zhang, L			Molecular identification of the ryanodine receptor Ca2+ sensor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; MUSCLE SARCOPLASMIC-RETICULUM; SKELETAL-MUSCLE; CDNA; EXPRESSION; ISOFORMS; CLONING; CELL	We have investigated the molecular basis for ryanodine receptor (RyR) activation by Ca2+ by using site-directed mutagenesis together with functional assays consisting of Ca2+ release measurements and single channel recordings in planar lipid bilayers, We report here that a single substitution of alanine for glutamate at position 3885 (located in the putative transmembrane sequence M2 of the type 3 RyR) reduces the Ca2+ sensitivity, as measured by single channel activation, by more than 10,000-fold, without apparent changes in channel conductance and in modulation by other ligands (e.g. ATP and ryanodine). Co-expression of the wild type and mutant RyR proteins results in the synthesis of single channels that have intermediate Ca2+ sensitivities. These results suggest that the glutamates at position 3885 of each monomer may act in a coordinated way to form the Ca2+ sensor in the tetrameric structure corresponding to RyR.	Univ Calgary, Dept Med Biochem, Cardiovasc Res Grp, Calgary, AB T2N 4N1, Canada	University of Calgary	Chen, SRW (corresponding author), Univ Calgary, Dept Med Biochem, Cardiovasc Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	swchen@acs.ucalgary.ca						BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Chen SRW, 1997, J BIOL CHEM, V272, P24234, DOI 10.1074/jbc.272.39.24234; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; EBASHI E, 1991, ANNU REV PHYSIOL, V53, P1; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Meissner G, 1997, J BIOL CHEM, V272, P1628, DOI 10.1074/jbc.272.3.1628; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P236, DOI 10.1021/bi00349a033; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; Mickelson JR, 1996, PHYSIOL REV, V76, P537, DOI 10.1152/physrev.1996.76.2.537; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; OGAWA Y, 1994, CRIT REV BIOCHEM MOL, V29, P229, DOI 10.3109/10409239409083482; OTSU K, 1990, J BIOL CHEM, V265, P13472; Ottini L, 1996, BIOCHEM J, V315, P207, DOI 10.1042/bj3150207; OYAMADA H, 1994, J BIOL CHEM, V269, P17206; Sakube Y, 1997, J MOL BIOL, V267, P849, DOI 10.1006/jmbi.1997.0910; Sorrentino V, 1995, Adv Pharmacol, V33, P67, DOI 10.1016/S1054-3589(08)60666-3; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TAKESHIMA H, 1994, FEBS LETT, V337, P81, DOI 10.1016/0014-5793(94)80634-9; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0; ZORZATO F, 1990, J BIOL CHEM, V265, P2244; Zucchi R, 1997, PHARMACOL REV, V49, P1	29	109	110	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14675	14678		10.1074/jbc.273.24.14675	http://dx.doi.org/10.1074/jbc.273.24.14675			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614063	hybrid			2022-12-27	WOS:000074160400005
J	Lavagna-Sevenier, C; Marchetto, S; Birnbaum, D; Rosnet, O				Lavagna-Sevenier, C; Marchetto, S; Birnbaum, D; Rosnet, O			The CBL-related protein CBLB participates in FLT3 and interleukin-7 receptor signal transduction in pro-B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE RECEPTOR; EPIDERMAL GROWTH-FACTOR; C-CBL; HEMATOPOIETIC-CELLS; ANTIGEN RECEPTOR; EXCHANGE PROTEIN; BINDING-SITE; JURKAT CELLS; EGF RECEPTOR; MURINE FLT3	The FLT3 receptor tyrosine kinase and its ligand, FL, play an important role in early hematopoietic development. We have found that CBLB, a recently characterized molecule closely related to the CBL protooncogene product, is phosphorylated on tyrosine(s) following FL treatment of JEA2 human pro-B cells and THP1 monocytic cells. Treatment of JEA2 cells with interleukin (IL)-7 induces CBLB phosphorylation as well. FL and IL-7, respectively, induce and increase association of tyrosine-phosphorylated SHC and the p85 subunit of phosphatidylinositol 3'-kinase with CBLB. In these cells, CBLB constitutively binds the GRB2 adaptor predominantly through its N-terminal SH3 domain, to form a complex that is distinct from the GRB2.CBL and GRB2.SOS1 complexes. Together with the fact that CBLB is consistently found in blast cells from acute leukemias and in peripheral blood mononuclear cells, this suggests that CBLB has a role in tyrosine kinase-regulated signaling pathways in many hematolymphoid cells.	INSERM, U119, Mol Oncol Lab, F-13009 Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Rosnet, O (corresponding author), INSERM, U119, Mol Oncol Lab, 27 Blvd Lei Roure, F-13009 Marseille, France.	rosnet@marseille.inserm.fr	Rosnet, Olivier/G-3536-2013	Rosnet, Olivier/0000-0002-3020-910X				BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; Beslu N, 1996, J BIOL CHEM, V271, P20075, DOI 10.1074/jbc.271.33.20075; BIRG F, 1992, BLOOD, V80, P2584; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BRASEL K, 1995, LEUKEMIA, V9, P1212; Brizzi MF, 1996, ONCOGENE, V13, P2067; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; CASTERAN N, 1994, CELL MOL BIOL, V40, P443; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; DOSIL M, 1993, MOL CELL BIOL, V13, P6572, DOI 10.1128/MCB.13.10.6572; Drexler HG, 1996, LEUKEMIA, V10, P588; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FOURNIER E, 1995, ONCOGENE, V11, P921; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; GABBIANELLI M, 1995, BLOOD, V86, P1661, DOI 10.1182/blood.V86.5.1661.bloodjournal8651661; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HANNUM C, 1994, NATURE, V368, P643, DOI 10.1038/368643a0; Hunte BE, 1996, J IMMUNOL, V156, P489; KEANE MM, 1995, ONCOGENE, V10, P2367; KIM TJ, 1995, J BIOL CHEM, V270, P27504, DOI 10.1074/jbc.270.46.27504; LANGDON W, 1996, AUST NZ J MED, V25, P859; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Lavagna-Sevenier C, 1998, LEUKEMIA, V12, P301, DOI 10.1038/sj.leu.2400921; Liu YC, 1997, J BIOL CHEM, V272, P168; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Lyman S D, 1995, Curr Opin Hematol, V2, P177; LYMAN SD, 1993, CELL, V75, P1157, DOI 10.1016/0092-8674(93)90325-K; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Ojaniemi M, 1997, J BIOL CHEM, V272, P3780, DOI 10.1074/jbc.272.6.3780; Ota Y, 1996, J EXP MED, V184, P1713, DOI 10.1084/jem.184.5.1713; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Rappold I, 1997, BLOOD, V90, P111; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; Rosnet O, 1996, LEUKEMIA, V10, P238; ROSNET O, 1991, ONCOGENE, V6, P1641; ROTTAPEL R, 1994, ONCOGENE, V9, P1755; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Sawasdikosol S, 1996, J IMMUNOL, V157, P110; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; Tanaka S, 1996, NATURE, V383, P528, DOI 10.1038/383528a0; Veiby OP, 1996, BLOOD, V88, P1256, DOI 10.1182/blood.V88.4.1256.bloodjournal8841256; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; WASSERMAN R, 1995, J IMMUNOL, V155, P644; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	48	50	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14962	14967		10.1074/jbc.273.24.14962	http://dx.doi.org/10.1074/jbc.273.24.14962			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614102	hybrid			2022-12-27	WOS:000074160400044
J	Kearse, KP				Kearse, KP			Calnexin associates with monomeric and oligomeric (disulfide-linked) CD3 delta proteins in murine T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; MOLECULAR CHAPERONE CALNEXIN; TCR-ALPHA-PROTEINS; ENDOPLASMIC-RETICULUM; IMMATURE THYMOCYTES; MONOCLONAL-ANTIBODY; INITIAL STEP; DELTA-CHAIN; COMPLEXES; OLIGOSACCHARIDE	The antigen-binding receptor expressed on most T lymphocytes consists of disulfide-linked clonotypic alpha beta heterodimers noncovalently associated with monomeric CD3 gamma,delta,epsilon proteins and disulfide-linked xi xi homodimers, collectively referred to as the T cell antigen receptor (TCR) complex. Here, we examined and compared the disulfide linkage status of newly synthesized TCR proteins in murine CD4(+)CD8(+) thymocytes and splenic T cells. These studies demonstrate that CD3 delta proteins exist as both monomeric and oligomeric (disulfide-linked) species that differentially assemble with CD3 epsilon subunits in CD4(+)CD8(+) thymocytes and splenic T cells. Interestingly, unlike previous results on glucose trimming and TCR assembly of CD3 delta proteins ire splenic T cells (Vam Leeuwen, J. E. M., and K. P. Kearse (1996) J. Biol. Chem. 271, 9660-9665), we found that glucose residues were mot invariably removed from CD3 delta glycoproteins prior to their assembly with CD3 epsilon subunits in CD4(+)CD8(+) thymocytes. Finally, these studies show that calnexin associates with both monomeric and disulfide-linked CD3 delta proteins in murine T cells. The data in the current report demonstrate that CD3 delta proteins exist as both monomeric and disulfide-linked molecules in murine T cells that differentially associate with partner TCR chains in CD4(+)CD8(+) thymocytes and splenic T cells. These results are consistent with the concept that folding and assembly of CD3 delta proteins is a function of their oxidation state.	E Carolina Univ, Dept Microbiol & Immunol, Sch Med, Greenville, NC 27858 USA	University of North Carolina; East Carolina University	Kearse, KP (corresponding author), E Carolina Univ, Dept Microbiol & Immunol, Sch Med, Greenville, NC 27858 USA.							BECKER MLB, 1989, CELL, V58, P911, DOI 10.1016/0092-8674(89)90943-4; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BORN W, 1987, NATURE, V330, P572, DOI 10.1038/330572a0; CENCIARELLI C, 1992, SCIENCE, V257, P795, DOI 10.1126/science.1323144; Exley M, 1991, Semin Immunol, V3, P283; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; Huppa JB, 1997, J EXP MED, V186, P393, DOI 10.1084/jem.186.3.393; JIN YJ, 1990, J BIOL CHEM, V265, P15850; KEARSE KP, 1994, EMBO J, V13, P4504, DOI 10.1002/j.1460-2075.1994.tb06772.x; KEARSE KP, 1995, IMMUNITY, V2, P391; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KUBO RT, 1989, J IMMUNOL, V142, P2736; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; MOREMEN KW, 1994, GLYCOBIOLOGY, V4, P113, DOI 10.1093/glycob/4.2.113; SAMELSON LE, 1986, J IMMUNOL, V137, P3254; SANCHO J, 1989, J BIOL CHEM, V264, P20760; Spiro RG, 1996, J BIOL CHEM, V271, P11588, DOI 10.1074/jbc.271.19.11588; Takase K, 1997, J IMMUNOL, V159, P741; TARENTINO AL, 1974, J BIOL CHEM, V249, P811; VanLeeuwen JEM, 1996, J BIOL CHEM, V271, P25345, DOI 10.1074/jbc.271.41.25345; vanLeeuwen JEM, 1996, J BIOL CHEM, V271, P9660, DOI 10.1074/jbc.271.16.9660; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; Wiest DL, 1997, P NATL ACAD SCI USA, V94, P1884, DOI 10.1073/pnas.94.5.1884; WIEST DL, 1995, EMBO J, V14, P3425, DOI 10.1002/j.1460-2075.1995.tb07348.x; WIEST DL, 1994, J EXP MED, V180, P1375, DOI 10.1084/jem.180.4.1375	26	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14152	14157		10.1074/jbc.273.23.14152	http://dx.doi.org/10.1074/jbc.273.23.14152			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603915	hybrid			2022-12-27	WOS:000074021500017
J	Ozer, J; Mitsouras, K; Zerby, D; Carey, M; Lieberman, PM				Ozer, J; Mitsouras, K; Zerby, D; Carey, M; Lieberman, PM			Transcription factor IIA derepresses TATA-binding protein (TBP)-associated factor inhibition of TBP-DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; YEAST TFIIA/TBP/DNA COMPLEX; TFIID-PROMOTER COMPLEX; IN-VIVO; BOX-BINDING; ACTIVATED TRANSCRIPTION; CRYSTAL-STRUCTURE; MECHANISM; DOMAINS; CLONING	The interaction of the general transcription factor (TF) IIA with TFIID is required for transcription activation in, vitro. TFIID consists of the TATA-binding protein (TBP) and TBP associated factors (TAF(II)s). TFIIA binds directly to TBP and stabilizes its interaction with TATA-containing DNA. In this work, we present evidence that TAF(II)s inhibit TBP-DNA and TBP-TFIIA binding, and that TFIIA stimulates transcription, in part, by overcoming this TAF(II)-mediated inhibition of TBP-DNA binding. TFIIA mutants modestly compromised for interaction with TBP were found to be significantly more defective in forming complexes with TFIID. Subtle changes in the stability or conformation of the TFIIA-TBP complex resulted in a failure of TFIIA to overcome TAF(II)-mediated inhibition of TBP-DNA binding and transcription function. Inhibition of TBP-DNA binding by TAF(II)s could be partially relieved by limited proteolysis of TFIID, Proteolysis significantly stimulated TFIIA-TFIID-TATA binding in both electrophoresis mobility shift assay and DNase I footprinting but had little effect on complexes formed with TBP, Recombinant TAF(II)250 inhibits TBP-DNA binding, whereas preincubation of TFIIA with TBP prevents this inhibition. Thus, TFIIA competes with TAF(II)250 for access to TBP and alters the TATA binding properties of the resulting complex. Transcriptional activation by Zta was enhanced by temperature shift inactivation of TAF(II)250 in the ts13 cell line, suggesting that TAF(II)250 has transcriptional inhibitory activity in vivo. Together, these results suggest that TAF(II)s may regulate transcription initiation by inhibiting TBP-TFIIA and TBP-DNA complex formation.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA	The Wistar Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Lieberman, PM (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St,Rm 351, Philadelphia, PA 19104 USA.	lieberman@wista.wistar.upenn.edu		Mitsouras, Katherine/0000-0002-2264-9447; Carey, Michael/0000-0003-3899-6280	NIGMS NIH HHS [GM07185, GM54687] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054687] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNDT KM, 1995, EMBO J, V14, P1490, DOI 10.1002/j.1460-2075.1995.tb07135.x; AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; Bai Y, 1997, MOL CELL BIOL, V17, P3081, DOI 10.1128/MCB.17.6.3081; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CHATTERJEE S, 1995, NATURE, V374, P820, DOI 10.1038/374820a0; CHI TH, 1995, NATURE, V377, P254, DOI 10.1038/377254a0; Chi TH, 1996, GENE DEV, V10, P2540, DOI 10.1101/gad.10.20.2540; Clemens KE, 1996, MOL CELL BIOL, V16, P4656; COLGAN J, 1992, GENE DEV, V6, P304, DOI 10.1101/gad.6.2.304; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; Dikstein R, 1996, CELL, V84, P781, DOI 10.1016/S0092-8674(00)81055-7; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; Geiger JH, 1996, SCIENCE, V272, P830, DOI 10.1126/science.272.5263.830; Gill G, 1992, CURR OPIN GENET DEV, V2, P236, DOI 10.1016/S0959-437X(05)80279-5; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; Hoffmann A, 1997, P NATL ACAD SCI USA, V94, P8928, DOI 10.1073/pnas.94.17.8928; Hoffmann A, 1996, NATURE, V380, P356, DOI 10.1038/380356a0; Hori R, 1997, J BIOL CHEM, V272, P1180, DOI 10.1074/jbc.272.2.1180; IMBALZANO AN, 1994, J BIOL CHEM, V269, P8280; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; Kim J, 1996, J BIOL CHEM, V271, P18405, DOI 10.1074/jbc.271.31.18405; Kirov NC, 1996, EMBO J, V15, P7079, DOI 10.1002/j.1460-2075.1996.tb01099.x; KLEIN C, 1994, SCIENCE, V266, P280, DOI 10.1126/science.7939664; KOBAYASHI N, 1995, MOL CELL BIOL, V15, P6465; KOKUBO T, 1993, GENE DEV, V7, P1033, DOI 10.1101/gad.7.6.1033; KOKUBO T, 1994, P NATL ACAD SCI USA, V91, P3520, DOI 10.1073/pnas.91.9.3520; Kokubo T, 1998, MOL CELL BIOL, V18, P1003, DOI 10.1128/MCB.18.2.1003; Lagrange T, 1996, P NATL ACAD SCI USA, V93, P10620, DOI 10.1073/pnas.93.20.10620; LEE DK, 1992, MOL CELL BIOL, V12, P5189, DOI 10.1128/MCB.12.11.5189; LIEBERMAN PM, 1991, MOL CELL BIOL, V11, P63, DOI 10.1128/MCB.11.1.63; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; Lieberman PM, 1997, MOL CELL BIOL, V17, P6624, DOI 10.1128/MCB.17.11.6624; Ma DM, 1996, P NATL ACAD SCI USA, V93, P6583, DOI 10.1073/pnas.93.13.6583; MARTINEZ E, 1995, P NATL ACAD SCI USA, V92, P11864, DOI 10.1073/pnas.92.25.11864; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; Mittal V, 1997, SCIENCE, V275, P1136, DOI 10.1126/science.275.5303.1136; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Oelgeschlager T, 1996, NATURE, V382, P735, DOI 10.1038/382735a0; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Ozer J, 1996, J BIOL CHEM, V271, P11182, DOI 10.1074/jbc.271.19.11182; OZER J, 1994, GENE DEV, V8, P2324, DOI 10.1101/gad.8.19.2324; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; Sauer F, 1996, CELL, V87, P1271, DOI 10.1016/S0092-8674(00)81822-X; Shen WC, 1997, CELL, V90, P615, DOI 10.1016/S0092-8674(00)80523-1; Stargell LA, 1996, TRENDS GENET, V12, P311, DOI 10.1016/0168-9525(96)10028-7; Tan S, 1996, NATURE, V381, P127, DOI 10.1038/381127a0; TANSEY WP, 1994, GENE DEV, V8, P2756, DOI 10.1101/gad.8.22.2756; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; Walker SS, 1997, CELL, V90, P607, DOI 10.1016/S0092-8674(00)80522-X; Wang EH, 1997, GENE DEV, V11, P2658, DOI 10.1101/gad.11.20.2658; WANG EH, 1994, SCIENCE, V263, P811, DOI 10.1126/science.8303298; YOKOMORI K, 1994, GENE DEV, V8, P2313, DOI 10.1101/gad.8.19.2313; Zerby D, 1997, METHODS, V12, P217, DOI 10.1006/meth.1997.0474; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	62	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14293	14300		10.1074/jbc.273.23.14293	http://dx.doi.org/10.1074/jbc.273.23.14293			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603936	hybrid			2022-12-27	WOS:000074021500038
J	Ruscetti, T; Lehnert, BE; Halbrook, J; Le Trong, H; Hoekstra, MF; Chen, DJ; Peterson, SR				Ruscetti, T; Lehnert, BE; Halbrook, J; Le Trong, H; Hoekstra, MF; Chen, DJ; Peterson, SR			Stimulation of the DNA-dependent protein kinase by poly(ADP-ribose) polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND-BREAK-REPAIR; V(D)J RECOMBINATION; BINDING-PROTEIN; CATALYTIC SUBUNIT; KU AUTOANTIGEN; END-BINDING; NUCLEAR; INHIBITION; CELLS; PK	The DNA-dependent protein kinase (DNA-PK) is a heterotrimeric enzyme that binds to double-stranded DNA and is required for the rejoining of double-stranded DNA breaks in mammalian cells. It has been proposed that DNA-PK functions in this DNA repair pathway by binding to the ends of broken DNA molecules and phosphorylating proteins that bind to the damaged DNA ends. Another enzyme that binds to DNA strand breaks and may also function in the cellular response to DNA damage is the poly(ADP-ribose) polymerase (PARP), Here, we show that PARP can be phosphorylated by purified DNA-PK, and the catalytic subunit of DNA-PK is ADP-ribosylated by PARP, The protein kinase activity of DNA-PK can be stimulated by PARP in the presence of NAD(+) in a reaction that is blocked by the PARP inhibitor 1,5-dihydroxyiso-quinoline. The stimulation of DNA-PK by PARP-mediated protein ADP-ribosylation occurs independent of the Ku70/80 complex. Taken together, these results show that PARP can modify the activity of DNA-PK in vitro and suggest that these enzymes may function coordinately in vivo in response to DNA damage.	Univ Calif Los Alamos Natl Lab, Cell & Mol Biol Grp LS4, Los Alamos, NM 87545 USA; Univ Calif Los Alamos Natl Lab, Div Life Sci, DNA Damage & Repair Grp LS6, Los Alamos, NM 87545 USA; ICOS Corp, Bothell, WA 98021 USA	United States Department of Energy (DOE); Los Alamos National Laboratory; United States Department of Energy (DOE); Los Alamos National Laboratory; Icos Corporation	Peterson, SR (corresponding author), Mail Stop M888, Los Alamos, NM 87545 USA.				NCI NIH HHS [CA50519] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050519, R37CA050519] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; BAUER PI, 1992, BIOCHEM BIOPH RES CO, V187, P730, DOI 10.1016/0006-291X(92)91256-P; BAUER PI, 1994, BBA-MOL CELL RES, V1223, P234, DOI 10.1016/0167-4889(94)90231-3; BENJAMIN RC, 1980, J BIOL CHEM, V255, P502; BLIER PR, 1993, J BIOL CHEM, V268, P7594; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; BOUBNOV NV, 1995, P NATL ACAD SCI USA, V92, P890, DOI 10.1073/pnas.92.3.890; BOULIKAS T, 1993, TOXICOL LETT, V67, P129, DOI 10.1016/0378-4274(93)90051-X; Cary RB, 1997, P NATL ACAD SCI USA, V94, P4267, DOI 10.1073/pnas.94.9.4267; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; CHEN F, 1995, MUTAT RES, V362, P9; DARBY MK, 1985, EMBO J, V4, P2129, DOI 10.1002/j.1460-2075.1985.tb03903.x; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; DURKACZ BW, 1980, NATURE, V283, P593, DOI 10.1038/283593a0; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; FACKELMAYER FO, 1994, EUR J BIOCHEM, V221, P749, DOI 10.1111/j.1432-1033.1994.tb18788.x; FERRO AM, 1983, J BIOL CHEM, V258, P6000; GETTS RC, 1994, J BIOL CHEM, V269, P15981; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; GRIFFITH AJ, 1992, J BIOL CHEM, V267, P331; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; JEGGO PA, 1995, BIOESSAYS, V17, P949, DOI 10.1002/bies.950171108; KAWAICHI M, 1981, J BIOL CHEM, V256, P9483; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; LEESMILLER SP, 1991, CANCER CELL-MON REV, V3, P341; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; LI LL, 1992, EXP CELL RES, V199, P262, DOI 10.1016/0014-4827(92)90433-9; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; MENISSIERDEMURCIA J, 1989, J MOL BIOL, V210, P229, DOI 10.1016/0022-2836(89)90302-1; MIMORI T, 1986, J BIOL CHEM, V261, P2274; MIMORI T, 1986, J BIOL CHEM, V261, P375; MOROZOV VE, 1994, J BIOL CHEM, V269, P16684; Morrison C, 1997, NAT GENET, V17, P479, DOI 10.1038/ng1297-479; Peterson SR, 1997, J BIOL CHEM, V272, P10227; PETERSON SR, 1992, GENE DEV, V6, P426, DOI 10.1101/gad.6.3.426; PETERSON SR, 1995, P NATL ACAD SCI USA, V92, P3171, DOI 10.1073/pnas.92.8.3171; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; RATHMELL WK, 1994, MOL CELL BIOL, V14, P4741, DOI 10.1128/MCB.14.7.4741; ROMIG H, 1992, EMBO J, V11, P3431, DOI 10.1002/j.1460-2075.1992.tb05422.x; ROTH DB, 1995, CURR BIOL, V5, P496, DOI 10.1016/S0960-9822(95)00101-1; SASTRY SS, 1989, BIOCHEMISTRY-US, V28, P5670, DOI 10.1021/bi00439a050; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; Shah GM, 1996, BBA-MOL CELL RES, V1312, P1, DOI 10.1016/0167-4889(96)00004-3; SIMBULAN CMG, 1993, J BIOL CHEM, V268, P93; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TSUTSUI K, 1993, J BIOL CHEM, V268, P12886; VONKRIES JP, 1994, NUCLEIC ACIDS RES, V22, P1215, DOI 10.1093/nar/22.7.1215; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; YOSHIHARA K, 1985, BIOCHEM BIOPH RES CO, V128, P61, DOI 10.1016/0006-291X(85)91644-4	53	197	206	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14461	14467		10.1074/jbc.273.23.14461	http://dx.doi.org/10.1074/jbc.273.23.14461			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603959	hybrid			2022-12-27	WOS:000074021500061
J	Yamashita, RA; May, GS				Yamashita, RA; May, GS			Constitutive activation of endocytosis by mutation of myoA, the myosin I gene of Aspergillus nidulans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN KINASE; SACCHAROMYCES-CEREVISIAE; YEAST; ACTIN; IDENTIFICATION; MORPHOGENESIS; CYTOSKELETON; INVOLVEMENT; EXPRESSION; SECRETION	Class I myosins function in cell motility, intracellular vesicle trafficking and endocytosis, Recently, it was shown that class I myosins are phosphorylated by a member of the pal-activated kinase (PAK) family. PAK phosphorylates a conserved serine or threonine residue in the myosin heavy chain. Phosphorylation at this site is required for maximal activation of the actin-activated Mg2+-ATPase activity in vitro. This serine or threonine residue is conserved En all known class I myosins of microbial origin and in the human and mouse class VI myosins. We have investigated the in vivo significance of this phosphorylation by mutating serine 371 of the class I myosin heavy chain gene myoA of Aspergillus nidulans. Mutation to glutamic acid, which mimics phosphorylation and therefore activation of the myosin, results in ale accumulation of membranes in growing hyphae. This accumulation of membranes results from an activation of endocytosis, In contrast, mutation of serine 371 to alanine had no discernible effect ore endocytosis. These studies are the first to demonstrate the in vivo significance of a regulatory phosphorylation on a class I myosin. Furthermore, our results suggest that MYOA has two functions, one dependent and one independent of phosphorylation.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	Baylor College of Medicine	May, GS (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.							AMATRUDA JF, 1992, J CELL BIOL, V119, P1151, DOI 10.1083/jcb.119.5.1151; Brzeska H, 1996, J BIOL CHEM, V271, P27056, DOI 10.1074/jbc.271.43.27056; CHOWDHURY S, 1992, J CELL BIOL, V118, P561, DOI 10.1083/jcb.118.3.561; DRUBIN DG, 1993, MOL BIOL CELL, V4, P1277, DOI 10.1091/mbc.4.12.1277; Geli MI, 1996, SCIENCE, V272, P533, DOI 10.1126/science.272.5261.533; Goodson HV, 1996, J CELL BIOL, V133, P1277, DOI 10.1083/jcb.133.6.1277; HAARER BK, 1990, J CELL BIOL, V110, P105, DOI 10.1083/jcb.110.1.105; HANSON T, 1995, CURR OPIN CELL BIOL, V7, P587; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jakobi R, 1996, J BIOL CHEM, V271, P6206, DOI 10.1074/jbc.271.11.6206; JOHNSTON GC, 1991, J CELL BIOL, V113, P539, DOI 10.1083/jcb.113.3.539; KUBLER E, 1993, EMBO J, V12, P2855, DOI 10.1002/j.1460-2075.1993.tb05947.x; LAZZARINO DA, 1994, MOL BIOL CELL, V5, P807, DOI 10.1091/mbc.5.7.807; Lee SF, 1996, J BIOL CHEM, V271, P27044, DOI 10.1074/jbc.271.43.27044; LIU HP, 1992, J CELL BIOL, V118, P285, DOI 10.1083/jcb.118.2.285; MCGOLDRICK CA, 1995, J CELL BIOL, V128, P577, DOI 10.1083/jcb.128.4.577; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; NOVICK P, 1985, CELL, V40, P405, DOI 10.1016/0092-8674(85)90154-0; PONTECORVO G, 1953, ADV GENET, V5, P141, DOI 10.1016/S0065-2660(08)60408-3; RODRIGUEZ JR, 1990, CELL MOTIL CYTOSKEL, V17, P301, DOI 10.1002/cm.970170405; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; SIMON VR, 1995, J CELL BIOL, V130, P345, DOI 10.1083/jcb.130.2.345; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; WARING RB, 1989, GENE, V79, P119, DOI 10.1016/0378-1119(89)90097-8; WEATHERBEE JA, 1985, J CELL BIOL, V101, P706, DOI 10.1083/jcb.101.3.706	26	70	74	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14644	14648		10.1074/jbc.273.23.14644	http://dx.doi.org/10.1074/jbc.273.23.14644			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603982	hybrid			2022-12-27	WOS:000074021500084
J	Candi, E; Melino, G; Lahm, A; Ceci, R; Rossi, A; Kim, IG; Ciani, B; Steinert, PM				Candi, E; Melino, G; Lahm, A; Ceci, R; Rossi, A; Kim, IG; Ciani, B; Steinert, PM			Transglutaminase 1 mutations in lamellar ichthyosis - Loss of activity due to failure of activation by proteolytic processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORNIFIED CELL-ENVELOPE; COAGULATION-FACTOR-XIII; CROSS-LINKING ENZYMES; KERATINOCYTE TRANSGLUTAMINASE; EPIDERMAL-KERATINOCYTES; RECESSIVE ICHTHYOSIS; EXPRESSION; DIFFERENTIATION; PROTEIN; GENE	Lamellar ichthyosis is a congenital recessive skin disorder characterized by generalized scaling and hyperkeratosis. It is caused by mutations in the TGM1 gene that encodes the transglutaminase 1 (TGase 1) enzyme, which is critical for the assembly of the cornified cell envelope in terminally differentiating keratinocytes. TGase 1 is a complex enzyme existing as both cytosolic and membrane-bound forms. Moreover, TGase 1 is proteolytically processed, and the major functionally active form consists of a membrane-bound 67/33/10-kDa complex with a myristoylated and palmitoylated amino-terminal 10-kDa membrane anchorage fragment. To understand better how point mutations, deletions, and truncations found in lamellar ichthyosis disease affect the structure and function of TGase 1, we have expressed in baculovirus and keratinocytes a number of reported TGase 1 mutants. The structural implications of these mutations were examined using a homology-derived three-dimensional model of TGase 1 generated from the known x-ray structure of the related coagulation factor XIIIa enzyme. The present studies demonstrate that loss of TGase 1 activity is not restricted to mutations that directly affect the enzymatic activity. We report a new class of mutations that impair the subsequent post-synthetic processing of the protein into its highly active functional forms.	NIAMS, Skin Biol Lab, NIH, Bethesda, MD 20892 USA; Univ Roma Tor Vergata, Ist Ricovero & Cura Carattere Sci, Ist Dermopat Immacolata, I-00133 Rome, Italy; Univ Roma Tor Vergata, Biochem Lab, I-00133 Rome, Italy; Univ Aquila, I-00133 Rome, Italy; Ist Ric Biol Mol P Angeletti, Dept Biol & Chem Computat, I-00040 Pomezia, Italy; Seoul Natl Univ, Dept Biochem, Seoul 449900, South Korea	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Rome Tor Vergata; University of Rome Tor Vergata; University of L'Aquila; Merck & Company; Seoul National University (SNU)	Steinert, PM (corresponding author), NIAMS, Skin Biol Lab, NIH, Bldg 6,Rm 425, Bethesda, MD 20892 USA.	pemast@helix.nih.gov	Ciani, Barbara/A-1679-2012	Ciani, Barbara/0000-0001-7223-4154; Ceci, Roberta/0000-0002-8900-8839	Telethon [E.0413] Funding Source: Medline	Telethon(Fondazione Telethon)		AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; Ausubel FM, 1991, CURRENT PROTOCOLS MO; Bale SJ, 1996, J INVEST DERMATOL, V107, P808, DOI 10.1111/1523-1747.ep12330566; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; CANDI E, 1995, J BIOL CHEM, V270, P26382, DOI 10.1074/jbc.270.44.26382; DAYRINGER HE, 1986, J MOL GRAPHICS, V4, P82; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; FOLK JE, 1985, METHOD ENZYMOL, V113, P358; GAN SQ, 1990, BIOCHEMISTRY-US, V29, P8432; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HAZELL M, 1985, ARCH DERMATOL, V121, P489, DOI 10.1001/archderm.121.4.489; HOHL D, 1993, ARCH DERMATOL, V129, P618, DOI 10.1001/archderm.129.5.618; HUBER M, 1995, J INVEST DERMATOL, V105, P653, DOI 10.1111/1523-1747.ep12324122; Huber M, 1997, J BIOL CHEM, V272, P21018, DOI 10.1074/jbc.272.34.21018; HUBER M, 1995, SCIENCE, V267, P525, DOI 10.1126/science.7824952; Jang SI, 1996, J BIOL CHEM, V271, P24105, DOI 10.1074/jbc.271.39.24105; KIM IG, 1992, J BIOL CHEM, V267, P7710; KIM SY, 1995, J BIOL CHEM, V270, P18026, DOI 10.1074/jbc.270.30.18026; KIM SY, 1995, J INVEST DERMATOL, V104, P211, DOI 10.1111/1523-1747.ep12612769; KIM SY, 1994, J BIOL CHEM, V269, P27979; MICHEL S, 1992, J INVEST DERMATOL, V98, P364, DOI 10.1111/1523-1747.ep12499806; Mikkola H, 1996, BLOOD, V87, P141; PARMENTIER L, 1995, HUM MOL GENET, V4, P1391, DOI 10.1093/hmg/4.8.1391; Parmentier L, 1996, HUM MOL GENET, V5, P555, DOI 10.1093/hmg/5.4.555; Reichert Uwe, 1993, P107; Robinson NA, 1997, J BIOL CHEM, V272, P12035, DOI 10.1074/jbc.272.18.12035; RUSSEL LJ, 1996, J INVEST DERMATOL, V170, P843; RUSSELL LJ, 1995, NAT GENET, V9, P279, DOI 10.1038/ng0395-279; RUSSELL LJ, 1994, AM J HUM GENET, V55, P1148; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Steinert P M, 1995, Cell Death Differ, V2, P33; Steinert PM, 1996, J BIOL CHEM, V271, P26242, DOI 10.1074/jbc.271.42.26242; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; Steinert PM, 1996, BIOCHEM BIOPH RES CO, V221, P101, DOI 10.1006/bbrc.1996.0552; Steinert PM, 1997, J BIOL CHEM, V272, P2021, DOI 10.1074/jbc.272.3.2021; Summers M.D., 1987, B TEXAS AGR EXPT STA, V1555; THACHER SM, 1989, J INVEST DERMATOL, V92, P578; TRAUPE H, 1984, CLIN GENET, V26, P457; Traupe H., 1989, ICHTHYOSES GUIDE CLI; VANHOOIJDONK CAEM, 1991, ACTA DERM-VENEREOL, V71, P173; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WILLIAMS ML, 1985, ARCH DERMATOL, V121, P477, DOI 10.1001/archderm.121.4.477; WILLIAMS ML, 1992, PEDIATR DERMATOL, V9, P365, DOI 10.1111/j.1525-1470.1992.tb00632.x; WILLIAMS ML, 1993, PEDIAT DERMATOL, V129, P618; YEE VC, 1995, THROMB RES, V78, P389, DOI 10.1016/0049-3848(95)00072-Y; YEE VC, 1994, P NATL ACAD SCI USA, V91, P7296, DOI 10.1073/pnas.91.15.7296	46	66	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13693	13702		10.1074/jbc.273.22.13693	http://dx.doi.org/10.1074/jbc.273.22.13693			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593710	hybrid			2022-12-27	WOS:000073919100049
J	Dode, L; De Greef, C; Mountian, I; Attard, M; Town, MM; Casteels, R; Wuytack, F				Dode, L; De Greef, C; Mountian, I; Attard, M; Town, MM; Casteels, R; Wuytack, F			Structure of the human sarco/endoplasmic reticulum Ca(2+)-ATPase 3 gene - Promoter analysis and alternative splicing of the SERCA3 pre-mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; PIG SMOOTH-MUSCLE; CA-ATPASE GENE; CA-2+ PUMP; CA-2+-ATPASE GENE; CA2+-TRANSPORT ATPASE; TRANSCRIPTION FACTORS; ARTEMIA-FRANCISCANA; MOLECULAR-CLONING; ENCODING SERCA1	Human chromosome 17-specific genomic clones extending over 90 kilobases (kb) of DNA and coding for sarco/endoplasmic reticulum Ca(2+)-ATPase 3 (SERCA3) were isolated. The presence of the D17S1828 genetic marker in the cosmid contig enabled us to map the SERCA3 gene (ATP2A3) 11 centimorgans from the top of the short arm p of chromosome 17, in the vicinity of the cystinosis gene locus. The SERCA3 gene contains 22 exons spread over 50 kb of genomic DNA. The exon/intron boundaries are well conserved between human SERCA3 and SERCA1 genes, except for the junction between exons 8 and 9 which is found in the SERCA1 gene but not in SERCA3 and SERCA2 genes, The transcription start site (+1) is located 152 nucleotides (nt) upstream of the AUG codon, The 5'-flanking region, including exon 1, is embedded in a 1.5-kb CpG island and is characterized by the absence of a TATA box and by the presence of 14 putative Sp1 sites, 11 CACCC boxes, 5 AP-2-binding motifs, 3 GGCTGGGG; motifs, 3 CANNTG boxes, a GATA motif, as well as single sites for Ets-1, c-Myc, and TFIIIc, Functional promoter analysis indicated that the GC-rich region (87% G + C) from -135 to -31 is of critical importance in initiating SERCA3 gene transcription in Jurkat cells. Exon 21 (human, 101 base pairs; mouse, 86 base pairs) can be alternatively excluded, partially included, or totally included, thus generating, respectively, SERCA3a (human and mouse, 999 amino acids (aa)), SERCA3b (human, 1043 aa; mouse, 1038 aa), or SERCA3c (human, 1024 aa; mouse, 1021 aa) isoforms with different C termini, Expression of the mouse SERCA3 isoforms in COS-1 cells demonstrated their ability to function as active pumps, although with different apparent affinities for Ca(2+).	Katholieke Univ Leuven, Fysiol Lab, B-3000 Louvain, Belgium; Guys Hosp, Div Med & Mol Genet, London SE1 9RT, England	KU Leuven; Guy's & St Thomas' NHS Foundation Trust	Dode, L (corresponding author), Katholieke Univ Leuven, Fysiol Lab, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.	Leo.Dode@med.kuleuven.ac.be						ANGER M, 1993, FEBS LETT, V334, P45, DOI 10.1016/0014-5793(93)81677-R; ARIGA H, 1989, EMBO J, V8, P4273, DOI 10.1002/j.1460-2075.1989.tb08613.x; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BabaAissa F, 1996, MOL BRAIN RES, V41, P169, DOI 10.1016/0169-328X(96)00088-5; Baker DL, 1996, J BIOL CHEM, V271, P5921, DOI 10.1074/jbc.271.10.5921; BERWAER M, 1994, MOL ENDOCRINOL, V8, P635, DOI 10.1210/me.8.5.635; BUCKIN VA, 1989, NATURE, V340, P321, DOI 10.1038/340321a0; BURK SE, 1989, J BIOL CHEM, V264, P18561; CALLEN DF, 1991, AM J HUM GENET, V49, P1372; CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1; Dode L, 1996, BIOCHEM J, V318, P689, DOI 10.1042/bj3180689; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; EGGERMONT JA, 1989, BIOCHEM J, V260, P757, DOI 10.1042/bj2600757; EGGERMONT JA, 1990, BIOCHEM J, V266, P901; EICHBAUM QG, 1994, J EXP MED, V179, P1985, DOI 10.1084/jem.179.6.1985; ESCALANTE R, 1995, DNA CELL BIOL, V14, P893, DOI 10.1089/dna.1995.14.893; ESCALANTE R, 1994, J BIOL CHEM, V269, P13005; FISHER SA, 1993, CIRC RES, V73, P622, DOI 10.1161/01.RES.73.4.622; GALLARDA JL, 1989, GENE DEV, V3, P1845, DOI 10.1101/gad.3.12a.1845; Grover AK, 1997, AM J PHYSIOL-CELL PH, V273, pC420, DOI 10.1152/ajpcell.1997.273.2.C420; GUNTESKIHAMBLIN AM, 1988, J BIOL CHEM, V263, P15032; HARTONG R, 1994, J BIOL CHEM, V269, P13021; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; Jean G, 1996, AM J HUM GENET, V58, P535; KORCZAK B, 1988, J BIOL CHEM, V263, P4813; LEHRACH H., 1990, GENOME ANAL, P39; LYTTON J, 1992, J BIOL CHEM, V267, P14483; LYTTON J, 1988, J BIOL CHEM, V263, P15024; MAGYAR A, 1995, BIOCHEM J, V310, P757, DOI 10.1042/bj3100757; MAJOWSKI K, 1987, EMBO J, V6, P3057, DOI 10.1002/j.1460-2075.1987.tb02612.x; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; Novina CD, 1996, TRENDS GENET, V12, P351, DOI 10.1016/0168-9525(96)10034-2; Odermatt A, 1996, NAT GENET, V14, P191, DOI 10.1038/ng1096-191; OLSON EN, 1993, CIRC RES, V72, P1, DOI 10.1161/01.RES.72.1.1; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; OTSU K, 1993, GENOMICS, V17, P507, DOI 10.1006/geno.1993.1357; ROHRER DK, 1991, J BIOL CHEM, V266, P8638; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SMALE S.T., 1994, TRANSCRIPTION MECHAN, P63; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SONG Y, 1994, SOC GEN PHY, V49, P271; SUKOVICH DA, 1993, NUCLEIC ACIDS RES, V21, P2723, DOI 10.1093/nar/21.11.2723; TOYOFUKU T, 1992, J BIOL CHEM, V267, P14490; VERBOOMEN H, 1992, BIOCHEM J, V286, P591, DOI 10.1042/bj2860591; VERBOOMEN H, 1994, BIOCHEM J, V303, P979, DOI 10.1042/bj3030979; Wankerl M, 1996, J MOL CELL CARDIOL, V28, P2139, DOI 10.1006/jmcc.1996.0206; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WU KD, 1995, AM J PHYSIOL-CELL PH, V269, pC775, DOI 10.1152/ajpcell.1995.269.3.C775; Wuytack F, 1995, BIOSCIENCE REP, V15, P299, DOI 10.1007/BF01788362; WUYTACK F, 1994, J BIOL CHEM, V269, P1410; WUYTACK F, 1992, ANN NY ACAD SCI, V671, P82, DOI 10.1111/j.1749-6632.1992.tb43786.x; ZARAINHERZBERG A, 1990, J BIOL CHEM, V265, P4670; Zhang YL, 1995, GENOMICS, V30, P415, DOI 10.1006/geno.1995.1259	56	75	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13982	13994		10.1074/jbc.273.22.13982	http://dx.doi.org/10.1074/jbc.273.22.13982			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593748	hybrid			2022-12-27	WOS:000073919100087
J	Hinds, MG; Maurer, T; Zhang, JG; Nicola, NA; Norton, RS				Hinds, MG; Maurer, T; Zhang, JG; Nicola, NA; Norton, RS			Solution structure of leukemia inhibitory factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CILIARY NEUROTROPHIC FACTOR; COUPLING-CONSTANTS; RECEPTOR-BINDING; CRYSTAL-STRUCTURE; LARGER PROTEINS; GROWTH-FACTORS; FACTOR LIF; MURINE; EXPRESSION; CYTOKINES	The solution structure of a murine-human chimera of leukemia inhibitory factor (LIF), a 180-residue cytokine with a molecular mass of 20 kDa, has been determined using multidimensional heteronuclear NMR techniques, The protein contains four alpha-helices, the relative orientations of which are well defined on the basis of long-range range interhelical nuclear Overhauser effects. The helices are arranged in an up-up-down-down orientation, as found in other four-helix bundle cytokines, and the overall topology of the chimera is similar to that of the crystal structure of murine LIF (Robinson, R. C., Grey, L. M., Staunton, D,, Vankelecom, H. Vernallis, A. B., Moreau, J. F,, Stuart, D, I., Heath, J, K., and Jones, E, Y, (1994) Cell 77, 1101-1116), Differences between the structures are evident in the N-terminal region, where the peptide bond preceding pro(17) has a trans-conformation in solution but a cis-conformation in the crystal, and in the small antiparallel beta-sheet encompassing residues in the N terminus and the CD loop in the crystal structure, which is not apparent in solution. There are also minor differences in the extent of the helices. Other than at the N terminus, the main difference between the two structures occurs at the C-terminal end of the CD loop. As this loop is close to a receptor-binding site on LIF that makes a major contribution to high affinity binding to the LIF receptor alpha-chain, these differences between the solution and crystal structures should be taken into account in structural models of LIF receptor interactions.	Biomol Res Inst, Parkville, Vic 3052, Australia; Cooperat Res Ctr Cellular Growth Factors, Melbourne, Vic 3050, Australia; Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia	Walter & Eliza Hall Institute	Norton, RS (corresponding author), Biomol Res Inst, 343 Royal Parade, Parkville, Vic 3052, Australia.	ray.norton@molsci.csiro.au	Maurer, Tobias/R-7561-2017; Nicola, Nicos/D-2989-2011; Hinds, Mark Gavin/AAD-3653-2020	Maurer, Tobias/0000-0002-5660-7691; Nicola, Nicos/0000-0003-1054-7889; Hinds, Mark Gavin/0000-0002-2856-5375; Norton, Raymond/0000-0001-8893-0584				ARCHER SJ, 1991, J MAGN RESON, V95, P636, DOI 10.1016/0022-2364(91)90182-S; Barnham KJ, 1997, J MOL BIOL, V268, P886, DOI 10.1006/jmbi.1997.0980; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; CHEEMA SS, 1994, J NEUROSCI RES, V37, P213, DOI 10.1002/jnr.490370207; CLORE G M, 1991, Journal of Biomolecular NMR, V1, P13, DOI 10.1007/BF01874566; Fujii I, 1997, FEBS LETT, V410, P131, DOI 10.1016/S0014-5793(97)00538-3; GEARING DP, 1987, EMBO J, V6, P3995, DOI 10.1002/j.1460-2075.1987.tb02742.x; Gervais V, 1997, EUR J BIOCHEM, V247, P386, DOI 10.1111/j.1432-1033.1997.00386.x; GRZESIEK S, 1995, J AM CHEM SOC, V117, P5312, DOI 10.1021/ja00124a014; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; HILL CP, 1993, P NATL ACAD SCI USA, V90, P5167, DOI 10.1073/pnas.90.11.5167; HILTON DJ, 1988, J BIOL CHEM, V263, P9238; HILTON DJ, 1992, TRENDS BIOCHEM SCI, V17, P72, DOI 10.1016/0968-0004(92)90505-4; HILTON DJ, 1994, GUIDEBOOK CYTOKINES, P124; Hinds MG, 1997, J BIOMOL NMR, V9, P113, DOI 10.1023/A:1018636018243; Hoffman RC, 1996, J BIOMOL NMR, V7, P273; Hudson KR, 1996, J BIOL CHEM, V271, P11971, DOI 10.1074/jbc.271.20.11971; HYBERTS SG, 1992, PROTEIN SCI, V1, P736, DOI 10.1002/pro.5560010606; INOUE M, 1995, P NATL ACAD SCI USA, V92, P8579, DOI 10.1073/pnas.92.19.8579; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LAKSOWSKI RA, 1996, J BIOMOL NMR, V8, P477; LAYTON MJ, 1994, J BIOL CHEM, V269, P29891; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MAURER T, 1994, GROWTH FACTORS, V11, P271, DOI 10.3109/08977199409010999; MCDONALD NQ, 1995, EMBO J, V14, P2689, DOI 10.1002/j.1460-2075.1995.tb07269.x; MOTT HR, 1995, CURR OPIN STRUC BIOL, V5, P114, DOI 10.1016/0959-440X(95)80016-T; MUHANDIRAM DR, 1993, J MAGN RESON SER B, V102, P317, DOI 10.1006/jmrb.1993.1102; NICOLA NA, 1997, GROW FACT CYTOK  A&B, V2, P613; NICOLA NA, 1994, GUIDEBOOK CYTOKINES, P1; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; OWCZAREK CM, 1993, EMBO J, V12, P3487, DOI 10.1002/j.1460-2075.1993.tb06023.x; PALLAGHY PK, 1993, J MOL BIOL, V234, P405, DOI 10.1006/jmbi.1993.1595; PANAYOTATOS N, 1995, J BIOL CHEM, V270, P14007, DOI 10.1074/jbc.270.23.14007; Peppard JV, 1996, J BIOL CHEM, V271, P7281, DOI 10.1074/jbc.271.13.7281; ROBINSON RC, 1994, CELL, V77, P1101, DOI 10.1016/0092-8674(94)90449-9; SHMELZER CH, 1993, ARCH BIOCHEM BIOPHYS, V302, P484; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; SMITH DK, 1996, THESIS U MELBOURNE; Somers W, 1997, EMBO J, V16, P989, DOI 10.1093/emboj/16.5.989; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; VUISTER GW, 1993, J BIOMOL NMR, V3, P67; WARE CB, 1995, DEVELOPMENT, V121, P1283; Xu GY, 1997, J MOL BIOL, V268, P468, DOI 10.1006/jmbi.1997.0933; Zhang FM, 1997, NATURE, V387, P206, DOI 10.1038/387206a0	48	28	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13738	13745		10.1074/jbc.273.22.13738	http://dx.doi.org/10.1074/jbc.273.22.13738			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593715	hybrid			2022-12-27	WOS:000073919100054
J	Brumme, S; Kruft, V; Schmitz, UK; Braun, HP				Brumme, S; Kruft, V; Schmitz, UK; Braun, HP			New insights into the co-evolution of cytochrome c reductase and the mitochondrial processing peptidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN COMPLEXES; NATIVE ELECTROPHORESIS; PLANT-MITOCHONDRIA; RESPIRATORY-CHAIN; BC(1) COMPLEX; BINDING SITE; BC1 COMPLEX; UBIQUINOL; SUBUNIT; POTATO	The mitochondrial processing peptidase (MPP) is a heterodimeric enzyme that forms part of the cytochrome c reductase complex from higher plants, Mitochondria from mammals and yeast contain two homologous enzymes: (i) an active MPP within the mitochondrial matrix and (ii) an inactive MPP within the cytochrome c reductase complex. To elucidate the evolution of MPP, the cytochrome c reductase complexes from lower plants were isolated and tested for processing activity. Mitochondria were prepared from the staghorn fern Platycerium bifurcatum, from the horsetail Equisetum arvense, and from the colorless algae Polytomella, and cytochrome c reductase complexes were purified by a micro-isolation procedure based on Blue-native polyacrylamide gel electrophoresis and electroelution. This is the first report on the subunit composition of a respiratory enzyme complex from a fern or a horsetail. The cytochrome c reductase complexes from P. bifurcatum and E. arvense are shown to efficiently process mitochondrial precursor proteins, whereas the enzyme complex from Polytomella lacks proteolytic activity. An evolutionary model is suggested that assumes a correlation between the presence of an active MPP within the cytochrome c reductase complex and the occurrence of chloroplasts.	Leibniz Univ Hannover, Inst Angew Genet, D-30419 Hannover, Germany; Appl Biosyst GMBH, D-64331 Weiterstadt, Germany	Leibniz University Hannover; Thermo Fisher Scientific; Applied Biosystems	Braun, HP (corresponding author), Leibniz Univ Hannover, Inst Angew Genet, Herrenhauser Str 2, D-30419 Hannover, Germany.	braun@mpimg-berlin-dahlem.mpg.de	Braun, Hans-Peter/E-7149-2011	Braun, Hans-Peter/0000-0002-4459-9727				BORCHART U, 1985, FEBS LETT, V191, P125, DOI 10.1016/0014-5793(85)81007-3; BRANDT U, 1994, J BIOL CHEM, V269, P12947; BRANDT U, 1993, J BIOL CHEM, V268, P8387; BRAUN HP, 1995, PLANTA, V195, P396, DOI 10.1007/BF00202597; BRAUN HP, 1992, MOL GEN GENET, V231, P217, DOI 10.1007/BF00279794; BRAUN HP, 1995, BBA-BIOENERGETICS, V1229, P181, DOI 10.1016/0005-2728(94)00199-F; BRAUN HP, 1995, TRENDS BIOCHEM SCI, V20, P171, DOI 10.1016/S0968-0004(00)88999-9; BRAUN HP, 1992, EMBO J, V11, P3219, DOI 10.1002/j.1460-2075.1992.tb05399.x; BRAUN HP, 1995, J BIOENERG BIOMEMBR, V27, P423, DOI 10.1007/BF02110005; Braun HP, 1997, BIOM HLTH R, V13, P290; Braun HP, 1997, INT J BIOCHEM CELL B, V29, P1043, DOI 10.1016/S1357-2725(97)00032-0; Brunner M., 1994, SIGNAL PEPTIDASES, P73; CRIVELLONE MD, 1988, J BIOL CHEM, V263, P14323; EMMERMANN M, 1993, J BIOL CHEM, V268, P18936; ERIKSSON AC, 1994, BBA-BIOENERGETICS, V1186, P221, DOI 10.1016/0005-2728(94)90181-3; GATTI DL, 1990, J BIOL CHEM, V265, P21468; GRAY MW, 1993, CURR OPIN GENET DEV, V3, P884, DOI 10.1016/0959-437X(93)90009-E; GUTIERREZCIRLOS EB, 1994, J BIOL CHEM, V269, P9147; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; Jansch L, 1996, PLANT J, V9, P357, DOI 10.1046/j.1365-313X.1996.09030357.x; KITADA S, 1995, J BIOCHEM-TOKYO, V117, P1148, DOI 10.1093/oxfordjournals.jbchem.a124836; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lang BF, 1997, NATURE, V387, P493, DOI 10.1038/387493a0; LEONARD K, 1981, J MOL BIOL, V149, P259, DOI 10.1016/0022-2836(81)90301-6; Luciano P, 1996, EXPERIENTIA, V52, P1077, DOI 10.1007/BF01952105; OU WJ, 1989, EMBO J, V8, P2605, DOI 10.1002/j.1460-2075.1989.tb08400.x; OUDSHOORN P, 1987, EUR J BIOCHEM, V163, P97, DOI 10.1111/j.1432-1033.1987.tb10741.x; Schagger H, 1995, METHOD ENZYMOL, V260, P190, DOI 10.1016/0076-6879(95)60137-6; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SCHAGGER H, 1986, METHOD ENZYMOL, V126, P181; SCHULTE U, 1989, NATURE, V339, P147, DOI 10.1038/339147a0; Spring J, 1997, FEBS LETT, V400, P2, DOI 10.1016/S0014-5793(96)01351-8; Striebel HM, 1996, ARCH BIOCHEM BIOPHYS, V335, P211, DOI 10.1006/abbi.1996.0500; TRUMPOWER BL, 1990, MICROBIOL REV, V54, P101, DOI 10.1128/MMBR.54.2.101-129.1990; WCHLOSSER UG, 1994, SAG SAMMLUNG ALGENKU, V3, P113; WEISS H, 1990, TRENDS BIOCHEM SCI, V15, P178, DOI 10.1016/0968-0004(90)90155-5; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; YANG M, 1988, EMBO J, V7, P3857, DOI 10.1002/j.1460-2075.1988.tb03271.x	40	42	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					13143	13149		10.1074/jbc.273.21.13143	http://dx.doi.org/10.1074/jbc.273.21.13143			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582354	hybrid, Green Published			2022-12-27	WOS:000073768500065
J	Green, NC; Rambaldi, I; Teakles, J; Featherstone, MS				Green, NC; Rambaldi, I; Teakles, J; Featherstone, MS			A conserved C-terminal domain in PBX increases DNA binding by the PBX homeodomain and is not a primary site of contact for the YPWM motif of HOXA1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROTOONCOGENE PBX1; HOMEOBOX GENE; COOPERATIVE INTERACTIONS; ONCOPROTEIN E2A-PBX1; MYELOID-LEUKEMIA; PRE-B; PROTEINS; EXTRADENTICLE; TRANSLOCATION; FUSION	HOX proteins are dependent upon cofactors of the PBX family for specificity of DNA binding. Two regions that have been implicated in HOX/PBX cooperative interactions are the YPWM motif, found N-terminal to the HOX homeodomain, and the GKFQ domain (also known as the Hox cooperativity motif) immediately C-terminal to the PBX homeodomain. Using derivatives of the E2A-PBX oncoprotein, we find that the GKFQ domain is not essential for cooperative interaction with HOXA1 but contributes to the stability of the complex. By contrast, the YPWM motif is strictly required for cooperative interactions in vitro and in vivo, even with mutants of E2A-PBX lacking the GKFQ domain. Using truncated PBX proteins, we show that the YPWM motif contacts the PBX homeodomain, The presence of the GKFQ domain increases monomer binding by the PBX homeodomain 5-fold, and the stability of the HOXA1.E2A-PBX complex 2-fold, These data suggest that the GKFQ domain acts mainly to increase DNA binding by PBX, rather than providing a primary contact site for the YPWM motif of HOXA1. We have identified 2 residues, Glu-301 and Tyr-305, required for GKFQ function and suggest that this is dependent on cw-helical character.	McGill Univ, Ctr Canc, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Med, Div Expt Med, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University; McGill University	Featherstone, MS (corresponding author), McGill Univ, Ctr Canc, 3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.		Featherstone, Mark/E-8057-2010	Featherstone, Mark/0000-0003-1576-046X				BLATT C, 1988, EMBO J, V7, P4283, DOI 10.1002/j.1460-2075.1988.tb03326.x; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGLIN TR, 1992, NAT GENET, V1, P319, DOI 10.1038/ng0892-319; Chan SK, 1996, EMBO J, V15, P2476, DOI 10.1002/j.1460-2075.1996.tb00605.x; Chan SK, 1996, P NATL ACAD SCI USA, V93, P5223, DOI 10.1073/pnas.93.11.5223; Chan SK, 1997, DEVELOPMENT, V124, P2007; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; Chang CP, 1997, MOL CELL BIOL, V17, P81, DOI 10.1128/MCB.17.1.81; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chang CP, 1996, MOL CELL BIOL, V16, P1734; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; JOHNSON FB, 1995, P NATL ACAD SCI USA, V92, P739, DOI 10.1073/pnas.92.3.739; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; Kamps MP, 1996, ONCOGENE, V12, P19; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KAMPS MP, 1994, ONCOGENE, V9, P3159; Knoepfler PS, 1996, NUCLEIC ACIDS RES, V24, P2288, DOI 10.1093/nar/24.12.2288; KNOEPFLER PS, 1995, MOL CELL BIOL, V15, P5811; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Lawrence HJ, 1996, STEM CELLS, V14, P281, DOI 10.1002/stem.140281; Leatherbarrow R. J., 1992, GRAFIT VERSION 3 0; LI T, 1995, SCIENCE, V270, P262, DOI 10.1126/science.270.5234.262; Lu Q, 1996, P NATL ACAD SCI USA, V93, P470, DOI 10.1073/pnas.93.1.470; Lu Q, 1996, MOL CELL BIOL, V16, P1632; Lu QA, 1997, ONCOGENE, V14, P75, DOI 10.1038/sj.onc.1200799; LU QA, 1995, MOL CELL BIOL, V15, P3786; MAVILIO F, 1986, NATURE, V324, P664, DOI 10.1038/324664a0; MONICA K, 1994, MOL CELL BIOL, V14, P8304, DOI 10.1128/MCB.14.12.8304; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; NEUTEBOOM STC, 1995, P NATL ACAD SCI USA, V92, P9166, DOI 10.1073/pnas.92.20.9166; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PEIFER M, 1990, GENE DEV, V4, P1209, DOI 10.1101/gad.4.7.1209; Peltenburg LTC, 1996, EMBO J, V15, P3385, DOI 10.1002/j.1460-2075.1996.tb00704.x; Peltenburg LTC, 1997, DEVELOPMENT, V124, P1089; PHELAN ML, 1994, MOL CELL BIOL, V14, P5066, DOI 10.1128/MCB.14.8.5066; Phelan ML, 1997, J BIOL CHEM, V272, P8635, DOI 10.1074/jbc.272.13.8635; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; PHILLIPS CL, 1994, BIOCHEMISTRY-US, V33, P9294, DOI 10.1021/bi00197a033; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; Ptashne M., 1992, A GENETIC SWITCH; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; Richardson JS., 1989, PREDICT PROTEIN STRU; Shanmugam K, 1997, J BIOL CHEM, V272, P19081, DOI 10.1074/jbc.272.30.19081; Shen WF, 1996, NUCLEIC ACIDS RES, V24, P898, DOI 10.1093/nar/24.5.898; Shen WF, 1997, J BIOL CHEM, V272, P8198, DOI 10.1074/jbc.272.13.8198; STARK MR, 1994, NATURE, V371, P429, DOI 10.1038/371429a0; VANDIJK MA, 1995, MECH DEVELOP, V52, P99, DOI 10.1016/0925-4773(95)00394-G; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; WATERSTON R, 1992, NAT GENET, V1, P114, DOI 10.1038/ng0592-114; Zeltser L, 1996, DEVELOPMENT, V122, P2475; Zhao JJG, 1996, EMBO J, V15, P1313, DOI 10.1002/j.1460-2075.1996.tb00473.x	57	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					13273	13279		10.1074/jbc.273.21.13273	http://dx.doi.org/10.1074/jbc.273.21.13273			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582372	hybrid			2022-12-27	WOS:000073768500083
J	Vindevoghel, L; Kon, A; Lechleider, RJ; Uitto, J; Roberts, AB; Mauviel, A				Vindevoghel, L; Kon, A; Lechleider, RJ; Uitto, J; Roberts, AB; Mauviel, A			Smad-dependent transcriptional activation of human type VII collagen gene (COL7A1) promoter by transforming growth factor-beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHIC EPIDERMOLYSIS-BULLOSA; ANCHORING FIBRILS; MAMMALIAN-CELLS; EXPRESSION; IDENTIFICATION; FIBROBLASTS; RESPONSES; PROTEINS; DNA; MAD	We have previously shown that transforming growth factor-beta (TGF-beta) increases type VII collagen gene (COL7A1) expression in human dermal fibroblasts in culture (Mauviel, A., Lapiere, J.-C., Halcin, C., Evans, C. H., and Uitto, J. (1994) J. Biol. Chem, 269, 25-28), To gain insight into the molecular mechanisms underlying the up-regulation of COL7A1 by this growth factor, we performed transient cell transfections with a series of 5'-deletion promoter/chloramphenicol acetyltransferase reporter gene constructs. We identified a 68-base pair region between nucleotides -524 and -456, relative to the transcription start site, as critical for TGF-beta response. Using electrophoresis mobility shift assays (EMSAs) with an oligonucleotide spanning the region from -524 to -444, we discovered that a TGF-beta-specific protein-DNA complex was formed as early as 11 min after TGF-beta stimulation and persisted for 1 h after addition of the growth factor. Deletion analysis of the TGF-beta-responsive region of the COL7A1 promoter by EMSA identified segment -496/-444 as the minimal fragment capable of binding the TGF-beta-induced complex. Furthermore, two distinct segments, -496/-490 and -453/-444, appeared to be necessary for TGF-beta-induced DNA binding activity, suggesting a bipartite element. Supershift experiments with a pan-Smad antibody unambiguously identified the TGF-beta-induced complex as containing a Smad member. This is the first direct identification of binding of endogenous Smad proteins to regulatory sequences of a human gene.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Biochem & Mol Pharmacol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Inst Mol Med, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA	Jefferson University; Jefferson University; Jefferson University; Jefferson University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Mauviel, A (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Dermatol & Cutaneous Biol, 233 S 10th St,Rm 430, Philadelphia, PA 19107 USA.	mauviel1@jeflin.tju.edu	MAUVIEL, Alain/F-6251-2013	Mauviel, Alain/0000-0002-0438-2793	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR043751, R01AR041439] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01-AR41439, T32-AR07651, 29-AR43751] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BURGESON RE, 1993, J INVEST DERMATOL, V101, P252, DOI 10.1111/1523-1747.ep12365129; Chen M, 1997, J INVEST DERMATOL, V108, P125, DOI 10.1111/1523-1747.ep12332300; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; CHEN YQ, 1994, J INVEST DERMATOL, V102, P205, DOI 10.1111/1523-1747.ep12371763; CHRISTIANO AM, 1993, NAT GENET, V4, P62, DOI 10.1038/ng0593-62; CHRISTIANO AM, 1994, P NATL ACAD SCI USA, V91, P3549, DOI 10.1073/pnas.91.9.3549; CHRISTIANO AM, 1996, CURR OPIN DERMATOL, V3, P225; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; Derynck R, 1996, CURR BIOL, V6, P1226, DOI 10.1016/S0960-9822(96)00702-6; FAZIO MJ, 1990, J INVEST DERMATOL, V94, P191, DOI 10.1111/1523-1747.ep12874495; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HUANG HC, 1995, EMBO J, V14, P5965, DOI 10.1002/j.1460-2075.1995.tb00285.x; INAGAKI Y, 1995, J BIOL CHEM, V270, P3353, DOI 10.1074/jbc.270.7.3353; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; KONIG A, 1992, J CELL BIOL, V117, P679, DOI 10.1083/jcb.117.3.679; Lechleider RJ, 1996, J BIOL CHEM, V271, P17617, DOI 10.1074/jbc.271.30.17617; LIU F, 1998, GENE DEV, V12, P3158; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; MAUVIEL A, 1994, J BIOL CHEM, V269, P25; SAKAI LY, 1986, J CELL BIOL, V103, P1577, DOI 10.1083/jcb.103.4.1577; Sambrook J., 2002, MOL CLONING LAB MANU; Uitto J, 1992, Exp Dermatol, V1, P2, DOI 10.1111/j.1600-0625.1992.tb00065.x; Vindevoghel L, 1997, J BIOL CHEM, V272, P10196; WETZELS RHW, 1991, AM J PATHOL, V139, P451; Wrana JL, 1996, TRENDS GENET, V12, P493, DOI 10.1016/S0168-9525(96)30109-1; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019	31	98	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					13053	13057		10.1074/jbc.273.21.13053	http://dx.doi.org/10.1074/jbc.273.21.13053			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582342	hybrid			2022-12-27	WOS:000073768500053
J	Webb, DJ; Wen, J; Karns, LR; Kurilla, MG; Gonias, SL				Webb, DJ; Wen, J; Karns, LR; Kurilla, MG; Gonias, SL			Localization of the binding site for transforming growth factor-beta in human alpha 2-macroglobulin to a 20-kDa peptide that also contains the bait region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APPARENT EQUILIBRIUM CONDITIONS; RECEPTOR-RELATED PROTEIN; NITRIC-OXIDE SYNTHESIS; HUMAN ALPHA(2)-MACROGLOBULIN; ALPHA-MACROGLOBULINS; THIOL-ESTER; STRUCTURAL CHARACTERIZATION; CRYSTAL-STRUCTURE; PRIMARY AMINES; LATENT FORM	alpha(2)-Macroglobulin (alpha(2)M) functions as a major carrier of transforming growth factor-beta (TGF-beta) in vivo. The goal of this investigation was to characterize the TGF-beta-binding site in alpha(2)M, Human alpha(2)M, which was reduced and denatured to generate 180-kDa subunits, bound TGF-beta 1, TGF-beta 2, and NGF-beta in ligand blotting experiments. Cytokine binding was not detected with bovine serum albumin that had been reduced and alkylated, and only minimal binding was detected with purified murinoglobulin. To localize the TGF-beta-binding site in alpha(2)M, five cDNA fragments, collectively encoding amino acids 122-1302, were expressed as glutathione S-transferase (GST) fusion proteins. In ligand blotting experiments, TGF-beta 2 bound only to the fusion protein (FP3) that includes amino acids 614-797, FP3 bound I-125-TGF-beta 1 and I-125-TGF-beta 2 TGF-beta 2 in solution, preventing the binding of these growth factors to immobilized alpha(2)M-methylamine (alpha(2)M-MA). The IC50 values were 33 +/- 5 and 26 +/- 6 nM for TGF-beta 1 and TGF-beta 2, respectively; these values were comparable with or lower than those determined with native alpha(2)M or alpha(2)M-MA. A GST fusion protein that includes amino acids 798-1082 of alpha(2)M (FP4) and purified GST did not inhibit the binding of TGF-beta to immobilized alpha(2)M-MA. FP3 (0.2 mu m) neutralized the activity of TGF-beta 1 and TGF-beta 2 in fetal bovine heart endothelial (FBHE) cell proliferation assays; FP4 was inactive in this assay. FP3 also increased NO synthesis by RAW 264.7 cells, mimicking an alpha(2)M activity that has been attributed to the neutralization of endogenously synthesized TGF-beta. Thus, we have isolated a peptide corresponding to 13% of the alpha(2)M sequence that binds TGF-beta and neutralizes the activity of TGF-beta in two separate biological assays.	Univ Virginia, Hlth Sci Ctr, Dept Pathol, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Biochem, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Biomed Engn, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Gonias, SL (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Pathol, Box 214, Charlottesville, VA 22908 USA.	SLG2T@VIRGINIA.EDU			NATIONAL CANCER INSTITUTE [R01CA053462] Funding Source: NIH RePORTER; NCI NIH HHS [CA-53462] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSEN GR, 1995, J BIOL CHEM, V270, P25133, DOI 10.1074/jbc.270.42.25133; ARCHER SJ, 1993, BIOCHEMISTRY-US, V32, P1164, DOI 10.1021/bi00055a022; BARRETT AJ, 1979, BIOCHEM J, V181, P401, DOI 10.1042/bj1810401; BARRETT AJ, 1973, BIOCHEM J, V133, P709, DOI 10.1042/bj1330709; BJORK I, 1982, BIOCHEM J, V207, P347; Boisset N, 1996, J BIOL CHEM, V271, P25762, DOI 10.1074/jbc.271.42.25762; BURMESTER JK, 1993, P NATL ACAD SCI USA, V90, P8628, DOI 10.1073/pnas.90.18.8628; CROOKSTON KP, 1993, BIOCHEM J, V293, P443, DOI 10.1042/bj2930443; CROOKSTON KP, 1994, BIOCHEM BIOPH RES CO, V200, P1578, DOI 10.1006/bbrc.1994.1631; CROOKSTON KP, 1994, J BIOL CHEM, V269, P1533; DANIELPOUR D, 1990, J BIOL CHEM, V265, P6973; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; DARLING TL, 1984, CELL CULTURE METHODS, V4, P79; DELAIN E, 1992, ELECTRON MICROSC REV, V5, P231, DOI 10.1016/0892-0354(92)90012-F; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GANROT PO, 1967, CLIN CHIM ACTA, V16, P328, DOI 10.1016/0009-8981(67)90201-X; GENTRY LE, 1990, BIOCHEMISTRY-US, V29, P6851, DOI 10.1021/bi00481a014; GETTINS P, 1988, BIOCHEMISTRY-US, V27, P2905, DOI 10.1021/bi00408a036; GETTINS PGW, 1994, FEBS LETT, V339, P276, DOI 10.1016/0014-5793(94)80430-3; GETTINS PGW, 1995, BIOCHEMISTRY-US, V34, P12233, DOI 10.1021/bi00038a018; GETTINS PGW, 1995, FEBS LETT, V367, P137, DOI 10.1016/0014-5793(95)00530-M; GETTINS PGW, 1993, FEBS LETT, V332, P211, DOI 10.1016/0014-5793(93)80633-6; GONIAS SL, 1994, ANN NY ACAD SCI, V737, P273, DOI 10.1111/j.1749-6632.1994.tb44318.x; GONIAS SL, 1982, BIOCHIM BIOPHYS ACTA, V705, P306, DOI 10.1016/0167-4838(82)90252-7; GONIAS SL, 1983, J BIOL CHEM, V258, P4682; GONIAS SL, 1993, ARCH BIOCHEM BIOPHYS, V302, P42, DOI 10.1006/abbi.1993.1178; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; HARPEL PC, 1973, J EXP MED, V138, P508, DOI 10.1084/jem.138.3.508; Howard GC, 1996, J BIOL CHEM, V271, P14105, DOI 10.1074/jbc.271.24.14105; HUANG SS, 1988, J BIOL CHEM, V263, P1535; IMBER MJ, 1981, J BIOL CHEM, V256, P8134; KAN CC, 1985, P NATL ACAD SCI USA, V82, P2282, DOI 10.1073/pnas.82.8.2282; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; LAMARRE J, 1991, LAB INVEST, V65, P3; LAMARRE J, 1991, J CLIN INVEST, V87, P39, DOI 10.1172/JCI114998; LAWRENCE DA, 1984, J CELL PHYSIOL, V121, P184, DOI 10.1002/jcp.1041210123; LYONS RM, 1988, J CELL BIOL, V106, P1659, DOI 10.1083/jcb.106.5.1659; LYSIAK JJ, 1995, J BIOL CHEM, V270, P21919, DOI 10.1074/jbc.270.37.21919; Mikhailenko I, 1997, J BIOL CHEM, V272, P6784, DOI 10.1074/jbc.272.10.6784; MIYAZONO K, 1988, J BIOL CHEM, V263, P6407; MONCINO MD, 1991, BIOCHEMISTRY-US, V30, P1545, DOI 10.1021/bi00220a015; Nielsen KL, 1996, J BIOL CHEM, V271, P12909, DOI 10.1074/jbc.271.22.12909; OCONNORMCCOURT MD, 1987, J BIOL CHEM, V262, P14090; PHILIP A, 1991, J BIOL CHEM, V266, P22290; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; RUFF E, 1986, BIOCHEM BIOPH RES CO, V138, P714, DOI 10.1016/S0006-291X(86)80555-1; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; SCHULTZCHERRY S, 1993, J CELL BIOL, V122, P923, DOI 10.1083/jcb.122.4.923; SOTTRUPJENSEN L, 1980, FEBS LETT, V121, P275, DOI 10.1016/0014-5793(80)80361-9; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P15781; SOTTRUPJENSEN L, 1986, FEBS LETT, V205, P20, DOI 10.1016/0014-5793(86)80857-2; SOTTRUPJENSEN L, 1984, J BIOL CHEM, V259, P8318; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; SWENSON RP, 1980, J BIOL CHEM, V255, P8087; SWENSON RP, 1979, P NATL ACAD SCI USA, V76, P4313, DOI 10.1073/pnas.76.9.4313; SWENSON RP, 1979, J BIOL CHEM, V254, P4452; UMANS L, 1995, J BIOL CHEM, V270, P19778, DOI 10.1074/jbc.270.34.19778; VANLEUVEN F, 1981, J BIOL CHEM, V256, P9016; VANLEUVEN F, 1986, J BIOL CHEM, V261, P1369; Weaver AM, 1995, J BIOL CHEM, V270, P30741, DOI 10.1074/jbc.270.51.30741; WEBB DJ, 1992, ARCH BIOCHEM BIOPHYS, V292, P487, DOI 10.1016/0003-9861(92)90020-W; WEBB DJ, 1995, BIOCHEM J, V312, P579, DOI 10.1042/bj3120579; Webb DJ, 1996, J BIOL CHEM, V271, P24982, DOI 10.1074/jbc.271.40.24982; WEBB DJ, 1994, J BIOL CHEM, V269, P30402; Webb DJ, 1996, BIOCHEM J, V320, P551, DOI 10.1042/bj3200551; WOLF BB, 1994, BIOCHEMISTRY-US, V33, P11270, DOI 10.1021/bi00203a024	68	31	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					13339	13346		10.1074/jbc.273.21.13339	http://dx.doi.org/10.1074/jbc.273.21.13339			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582381	hybrid			2022-12-27	WOS:000073768500092
J	Zou, Y; Crowley, DJ; Van Houten, B				Zou, Y; Crowley, DJ; Van Houten, B			Involvement of molecular chaperonins in nucleotide excision repair - DnaK leads to increased thermal stability of UvrA, catalytic UvrB loading, enhanced repair, and increased UV resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; RNA-POLYMERASE; ATP HYDROLYSIS; UNFOLDED PROTEINS; PEPTIDE-BINDING; GROEL; COMPLEX; HSP70; NUCLEASE	UvrA is one of the key Escherichia coli proteins involved in removing DNA damage during the process of nucleotide excision repair. The relatively low concentrations (nanomolar) of the protein in the normal cells raise the potential questions about its stability in vivo under both normal and stress conditions. In, vitro, UvrA at low concentrations is shown to be stabilized to heat inactivation by E. coli molecular chaperones DnaK or the combination of DnaK, DnaJ, and GrpE. These chaperone proteins allow sub-nanomolar concentrations of UvrA to load UvrB through >10 cycles of incision. Guanidine hydrochloride-denatured UvrA was reactivated by DnaK, DnaJ, and GrpE to as much as 50% of the native protein activity. Co-immunoprecipitation assays showed that DnaK bound denatured UvrA in the absence of ATP. UV survival studies of a DnaK-deficient strain indicated an 80-fold increased sensitivity to 100 J/m(2) of ultraviolet light (254 nm) as compared with an isogenic wild-type strain. Global repair analysis indicated a reduction in the extent of pyrimidine dimer and 6-4 photoproduct removal in the DnaK-deficient cells. These results suggest that molecular chaperonins participate in nucleotide excision repair by maintaining repair proteins in their properly folded state.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA; Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	University of Texas System; University of Texas Medical Branch Galveston; Stanford University	Van Houten, B (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, 5-138 MRB 1071, Galveston, TX 77555 USA.	bvanhout@SCMS.utmb.edu	Van Houten, Bennett/K-2284-2019; Zou, Yue/ABA-8429-2020		NIEHS NIH HHS [ES7955, ES06676] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007955, P30ES006676] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Banecki B, 1996, J BIOL CHEM, V271, P6137, DOI 10.1074/jbc.271.11.6137; BERTRANDBURGGRAF E, 1991, J MOL BIOL, V219, P27, DOI 10.1016/0022-2836(91)90854-Y; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; BUKAU B, 1990, EMBO J, V9, P4027, DOI 10.1002/j.1460-2075.1990.tb07624.x; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DONNELLY CE, 1989, J BACTERIOL, V171, P6117, DOI 10.1128/jb.171.11.6117-6125.1989; Duina AA, 1996, SCIENCE, V274, P1713, DOI 10.1126/science.274.5293.1713; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOERGOPOULOS C, 1993, ANN REV CELL BIOL, V9, P601; GRAGEROV A, 1994, J MOL BIOL, V235, P848, DOI 10.1006/jmbi.1994.1043; GREENE LE, 1995, J BIOL CHEM, V270, P2967, DOI 10.1074/jbc.270.7.2967; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; KRUEGER JH, 1984, P NATL ACAD SCI-BIOL, V81, P1499, DOI 10.1073/pnas.81.5.1499; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LLOYD S, 1995, DNA REPAIR MECH IMPA, P25; MCCARTY JS, 1994, J BACTERIOL, V176, P764, DOI 10.1128/jb.176.3.764-780.1994; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT; MURLI S, 1993, CURR OPIN GENET DEV, V3, P719, DOI 10.1016/S0959-437X(05)80089-9; ORREN DK, 1992, J BIOL CHEM, V267, P780; PALLEROS DR, 1994, J BIOL CHEM, V269, P13107; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; PEDERSEN S, 1978, CELL, V14, P179, DOI 10.1016/0092-8674(78)90312-4; PHILLIPS GJ, 1990, NATURE, V344, P882, DOI 10.1038/344882a0; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; Sepehrnia B, 1996, J BIOL CHEM, V271, P15084, DOI 10.1074/jbc.271.25.15084; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; SMITH DF, 1995, SCI MED, V2, P38; SNOWDEN A, 1991, J MOL BIOL, V220, P19, DOI 10.1016/0022-2836(91)90378-J; SPRINGER TA, 1983, CURRENT PROTOCOLS IM; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; VANHOUTEN B, 1993, BIOESSAYS, V15, P51, DOI 10.1002/bies.950150108; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; VISSE R, 1992, J BIOL CHEM, V267, P6736; VISSE R, 1993, MUTAT RES, V294, P263, DOI 10.1016/0921-8777(93)90009-6; WICKNER S, 1991, P NATL ACAD SCI USA, V88, P7903, DOI 10.1073/pnas.88.18.7903; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; YOCHEM J, 1978, MOL GEN GENET, V164, P9, DOI 10.1007/BF00267593; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606; ZIEMIENOWICZ A, 1993, J BIOL CHEM, V268, P25425; ZIMMERMANN R, 1988, EMBO J, V7, P2875, DOI 10.1002/j.1460-2075.1988.tb03144.x; ZOU Y, 1995, BIOCHEMISTRY-US, V34, P13582, DOI 10.1021/bi00041a038; Zou Y, 1997, J BIOL CHEM, V272, P4820, DOI 10.1074/jbc.272.8.4820	51	53	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					12887	12892		10.1074/jbc.273.21.12887	http://dx.doi.org/10.1074/jbc.273.21.12887			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582319	hybrid			2022-12-27	WOS:000073768500030
J	Greer, SF; Lin, JJ; Clarke, CH; Justement, LB				Greer, SF; Lin, JJ; Clarke, CH; Justement, LB			Major histocompatibility class II-mediated signal transduction is regulated by the protein-tyrosine phosphatase CD45	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; B-CELL ACTIVATION; ANTIGEN RECEPTOR; CROSS-LINKING; LYMPHOCYTES-B; STRUCTURAL COMPARTMENTALIZATION; IA MOLECULES; MEMBRANE IGM; KINASE; MICE	Major histocompatibility complex class II molecules and the B cell antigen receptor (BCR) transduce similar signals when cross-linked by Ligand, Therefore, studies were conducted to determine whether the protein tyrosine phosphatase CD45 regulates signaling via these transmembrane receptors in an analogous manner. Cross-linking of either class II molecules or the BCR on CD45-positive K46-17 mu m lambda B lymphoma cells was observed to induce activation of the Src family protein-tyrosine kinase Lyn, tyrosine phosphorylation of Syk and phospholipase C gamma, and the production of inositol 1,4,5-trisphosphate leading to intracellular mobilization as well as extracellular influx of Ca2+. In the absence of CD45, cross-linking of either class II molecules or the BCR failed to induce activation of Lyn, Syk was inducibly phosphorylated on tyrosine in a normal manner, whereas phospholipase C gamma exhibited a high basal level of tyrosine phosphorylation that was not significantly increased upon stimulation. Nevertheless, phospholipase C gamma appeared to be functional because CD45-negative cells produced elevated levels of inositol 1,4,5-trisphosphate following stimulation through class II or the BCR, Regardless of this, CD45-negative cells exhibited Ca2+ mobilization responses that were greatly diminished and transient in nature. Whereas little or no mobilization of Ca2+ was observed in response to class II cross-linking, CD45-deficient cells mobilized Ca2+ from intracellular stores but not the extracellular environment in response to BCR cross-linking. These results demonstrate that CD45 regulates both Src family kinase activation and Ca2+ mobilization associated with class II-and BCR-mediated signal transduction.	Univ Alabama, Wallace Tumor Inst 378, Div Dev & Clin Immunol, Birmingham, AL 35294 USA; Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA; Univ Texas, Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Texas System; University of Texas Medical Branch Galveston	Justement, LB (corresponding author), Univ Alabama, Wallace Tumor Inst 378, Div Dev & Clin Immunol, Birmingham, AL 35294 USA.	louis.justement@ccc.uab.edu		Justement, Louis/0000-0001-7058-867X	NIGMS NIH HHS [GM46524] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046524, R29GM046524] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRE P, 1994, J EXP MED, V179, P763, DOI 10.1084/jem.179.2.763; Benatar T, 1996, J EXP MED, V183, P329, DOI 10.1084/jem.183.1.329; BISHOP GA, 1993, J IMMUNOL, V150, P2565; BISHOP GA, 1994, INT IMMUNOL, V6, P1049, DOI 10.1093/intimm/6.7.1049; BISHOP GA, 1991, J IMMUNOL, V147, P1107; BRICKGHANNAM C, 1991, J BIOL CHEM, V266, P24169; BROWN VK, 1994, J BIOL CHEM, V269, P17238; CAMBIER JC, 1991, J IMMUNOL, V146, P2075; CAMBIER JC, 1989, J EXP MED, V170, P877, DOI 10.1084/jem.170.3.877; CAMBIER JC, 1987, NATURE, V327, P629, DOI 10.1038/327629a0; Chu DH, 1996, EMBO J, V15, P6251, DOI 10.1002/j.1460-2075.1996.tb01015.x; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; FAASSEN AE, 1995, J IMMUNOL, V155, P1737; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; GOLD MR, 1994, J IMMUNOL, V153, P2369; GRUSBY MJ, 1993, P NATL ACAD SCI USA, V90, P3913, DOI 10.1073/pnas.90.9.3913; HAMANO T, 1990, J IMMUNOL, V144, P811; HARTON JA, 1995, IMMUNITY, V3, P349, DOI 10.1016/1074-7613(95)90119-1; JUSTEMENT LB, 1990, J IMMUNOL, V144, P3272; JUSTEMENT LB, 1989, J IMMUNOL, V143, P881; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; Justement LB, 1997, ADV IMMUNOL, V66, P1, DOI 10.1016/S0065-2776(08)60595-7; JUSTEMENT LB, 1994, IMMUNOL TODAY, V15, P399, DOI 10.1016/0167-5699(94)90268-2; KANNER SB, 1995, TISSUE ANTIGENS, V46, P145, DOI 10.1111/j.1399-0039.1995.tb03113.x; KANSAS GS, 1992, EUR J IMMUNOL, V22, P147, DOI 10.1002/eji.1830220122; KANSAS GS, 1991, J IMMUNOL, V147, P4094; KAWAUCHI K, 1994, J IMMUNOL, V152, P3306; KIM KM, 1993, IMMUNOL REV, V132, P124; KORETZKY GA, 1993, J BIOL CHEM, V268, P8958; LANE PJL, 1990, J IMMUNOL, V144, P3684; LEE KM, 1993, J BIOL CHEM, V268, P9945; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; MADDEN DR, 1995, ANNU REV IMMUNOL, V13, P587, DOI 10.1146/annurev.iy.13.040195.003103; MOONEY NA, 1990, J IMMUNOL, V145, P2070; MORIO T, 1994, EUR J IMMUNOL, V24, P651, DOI 10.1002/eji.1830240325; NABAVI N, 1989, J IMMUNOL, V142, P1444; NBAVI N, 1992, NATURE, V360, P266; NEWELL MK, 1993, P NATL ACAD SCI USA, V90, P10459, DOI 10.1073/pnas.90.22.10459; Pao LI, 1997, J IMMUNOL, V158, P2663; Pao LI, 1997, J IMMUNOL, V158, P1116; SCHOLL PR, 1994, IMMUNOL TODAY, V15, P418, DOI 10.1016/0167-5699(94)90271-2; SMILEY ST, 1995, INT IMMUNOL, V7, P665, DOI 10.1093/intimm/7.4.665; STPIERRE Y, 1991, J IMMUNOL, V147, P2875; TAKAHAMA Y, 1990, EUR J IMMUNOL, V19, P2227; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; VOSTAL JG, 1991, J BIOL CHEM, V266, P16911; WADE WF, 1989, P NATL ACAD SCI USA, V86, P6297, DOI 10.1073/pnas.86.16.6297; WADE WF, 1993, IMMUNOL TODAY, V14, P539, DOI 10.1016/0167-5699(93)90184-M; Yanagi S, 1996, J BIOL CHEM, V271, P30487, DOI 10.1074/jbc.271.48.30487	50	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 8	1998	273	19					11970	11979		10.1074/jbc.273.19.11970	http://dx.doi.org/10.1074/jbc.273.19.11970			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZM408	9565626	hybrid			2022-12-27	WOS:000073536700080
J	Bing, W; Razzaq, A; Sparrow, J; Marston, S				Bing, W; Razzaq, A; Sparrow, J; Marston, S			Tropomyosin and troponin regulation of wild type and E93K mutant actin filaments from Drosophila flight muscle - Charge reversal on actin changes actin-tropomyosin from on to off state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO MOTILITY; MYOSIN SUBFRAGMENT-1; THIN FILAMENT; DIFFRACTION DATA; F-ACTIN; MOVEMENT; BINDING; CALCIUM; SMOOTH; MODEL	In the Drosophila flight muscle actin mutant E93K there is a charge reversal on the surface of actin close to the proposed position of tropomyosin when it is in the off state. Using a quantitative in vitro motility assay we have found that the wild type Drosophila ACT88F actin behaved like rabbit skeletal muscle actin when tropomyosin and troponin were added at pCa5 and pCa9. In contrast the effect of tropomyosin upon the E93K mutant actin filament movement was completely different from wild type and resembled the response of wild type with tropomyosin+troponin at pCa9 (i.e. the filaments were switched off), Velocity of E93K actin did not increase, and the fraction of filaments motile was reduced to less than 15% by adding up to 30 nM tropomyosin. When myosin subfragment-1 modified by N-ethylmaleimide was mixed with mutant E93K actin-tropomyosin filaments we observed that it restored motility of the filaments to the level observed with E93K actin alone. We conclude that electrostatic charge on the surface of domain 2 of actin plays a critical role in determining the state of actin-tropomyosin that is a central feature of the steric blocking mechanism of actin filament regulation.	Imperial Coll, Sch Med, Natl Heart & Lung Inst, London SW3 6LY, England; Univ York, Dept Biol, York YO1 5YW, N Yorkshire, England	Imperial College London; University of York - UK	Marston, S (corresponding author), Imperial Coll, Sch Med, Natl Heart & Lung Inst, Dovehouse St, London SW3 6LY, England.	s.marston@ic.ac.uk			Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALHILLAWI E, 1995, EUR J BIOCHEM, V228, P962; ALKHAYAT HA, 1995, J MOL BIOL, V252, P611, DOI 10.1006/jmbi.1995.0524; ANSON M, 1995, BIOPHYS J, V68, P1991, DOI 10.1016/S0006-3495(95)80376-0; BULLARD B, 1988, J MOL BIOL, V204, P621, DOI 10.1016/0022-2836(88)90360-9; BULLARD B, 1973, BIOCHEM J, V135, P277, DOI 10.1042/bj1350277; DOSREMEDIOS CG, 1995, BBA-BIOENERGETICS, V1228, P99, DOI 10.1016/0005-2728(94)00169-6; EGELMAN EH, 1985, J MUSCLE RES CELL M, V6, P129, DOI 10.1007/BF00713056; ELSALEH SC, 1984, J BIOL CHEM, V259, P1014; ELSALEH SC, 1986, J MUSCLE RES CELL M, V7, P387, DOI 10.1007/BF01753582; FRASER IDC, 1995, J BIOL CHEM, V270, P19688, DOI 10.1074/jbc.270.34.19688; FRASER IDC, 1995, J BIOL CHEM, V270, P7836, DOI 10.1074/jbc.270.14.7836; GEEVES MA, 1987, BIOPHYS J, V52, P215, DOI 10.1016/S0006-3495(87)83208-3; Gerson Jack H., 1997, Biophysical Journal, V72, pA57; Gordon AM, 1997, BIOPHYS J, V72, P1295, DOI 10.1016/S0006-3495(97)78776-9; HILL TL, 1980, P NATL ACAD SCI-BIOL, V77, P3186, DOI 10.1073/pnas.77.6.3186; HOLMES KC, 1995, BIOPHYS J S, V68, P2; Homsher E, 1996, BIOPHYS J, V70, P1881, DOI 10.1016/S0006-3495(96)79753-9; Korman V, 1998, BIOPHYS J, V74, pA347; KRON SJ, 1991, METHOD ENZYMOL, V196, P399; Landis CA, 1997, J BIOL CHEM, V272, P14051, DOI 10.1074/jbc.272.22.14051; LEHMAN W, 1994, NATURE, V368, P65, DOI 10.1038/368065a0; LEHMAN W, 1995, J MOL BIOL, V251, P191, DOI 10.1006/jmbi.1995.0425; LEHRER SS, 1994, J MUSCLE RES CELL M, V15, P232; LEHRER SS, 1984, J BIOL CHEM, V259, P2070; LEVINE BA, 1988, EUR J BIOCHEM, V172, P389, DOI 10.1111/j.1432-1033.1988.tb13899.x; LORENZ M, 1993, J MOL BIOL, V234, P826, DOI 10.1006/jmbi.1993.1628; MAHAFFEY JW, 1987, CELL, V40, P101; MARSTON S, 1995, INT J BIOCHEM CELL B, V27, P97, DOI 10.1016/1357-2725(94)00080-U; Marston S. B., 1996, Biophysical Journal, V70, pA25; Marston SB, 1996, J MUSCLE RES CELL M, V17, P497, DOI 10.1007/BF00123365; MOLLOY JE, 1995, BIOPHYS J, V68, pS198; NAGASHIMA H, 1982, J MOL BIOL, V155, P409, DOI 10.1016/0022-2836(82)90479-X; PARDEE JD, 1982, METHOD CELL BIOL, V24, P271; Perry SV, 1979, BIOCHEM SOC T, V7, P593, DOI 10.1042/bst0070593; PERRY SV, 1972, COLD SPRING HARB SYM, V37, P251; PHILLIPS GN, 1986, J MOL BIOL, V192, P111, DOI 10.1016/0022-2836(86)90468-7; Razzaq A., 1997, Biophysical Journal, V72, pA56; Saeki K, 1996, BIOCHEMISTRY-US, V35, P14465, DOI 10.1021/bi961292c; SAIDE JD, 1989, J CELL BIOL, V109, P2157, DOI 10.1083/jcb.109.5.2157; Snyder C. H., 1995, Biophysical Journal, V68, pA164; SPARROW J, 1991, J MOL BIOL, V222, P963, DOI 10.1016/0022-2836(91)90588-W; SWARTZ DR, 1992, J BIOL CHEM, V267, P20497; Vibert P, 1997, J MOL BIOL, V266, P8, DOI 10.1006/jmbi.1996.0800; WANG F, 1993, J BIOL CHEM, V268, P3776; WERTMAN KF, 1992, GENETICS, V132, P337; WILLIAMS DL, 1984, BIOCHEMISTRY-US, V23, P4150, DOI 10.1021/bi00313a022; Wong WW, 1998, BIOPHYS J, V74, pA264; WU B, 1997, BIOCHEM BIOPH RES CO, V236, P760; WU B, 1997, BIOCHEM J, V327, P335	49	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15016	15021		10.1074/jbc.273.24.15016	http://dx.doi.org/10.1074/jbc.273.24.15016			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614109	hybrid			2022-12-27	WOS:000074160400051
J	Cieslik, K; Zembowicz, A; Tang, JL; Wu, KK				Cieslik, K; Zembowicz, A; Tang, JL; Wu, KK			Transcriptional regulation of endothelial nitric-oxide synthase by lysophosphatidylcholine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; MAMMALIAN-CELLS; GENE-EXPRESSION; CULTURED HUMAN; SP1; ACTIVATION; INDUCTION; GROWTH; MESSENGER; PROTEIN	We have shown that lysophosphatidylcholine (lyso-PC) increases endothelial nitric-oxide synthase (eNOS) expression at the transcriptional level (Zembowicz, A., Tang, J.-L., and Wu, K. K. (1995) J. Biol. Chem. 270, 17006-17010). To elucidate the mechanism by which lyso-PC increases the eNOS transcription, we identified Sp1 sites at -104 to -90 and PEA3 sites at -40 to -24 as being involved in lyso-PC-induced promoter activity. Site-directed mutagenesis of Sp1 sites resulted in a marked reduction of basal and lyso-PC-induced activity whereas PEA3 site mutation abrogated response to lyso-PC. Band shift assays revealed that lyso-PC augmented Sp1 binding activity. Pretreatment of cells or nuclear extracts with okadaic acid reduced the Sp1 binding activity. Furthermore, okadaic acid treatment abrogated the lyso-PC induced promoter augmentation. Lyse-PC increased the nuclear extract protein phosphatase 2A (PP2A) activity, which was suppressed by okadaic acid treatment. These results suggest that lyso-PC up-regulates eNOS transcription by a PP2A-dependent increase in Sp1 binding activity.	Univ Texas, Sch Med, Vasc Biol Res Ctr, Houston, TX 77030 USA; Univ Texas, Sch Med, Div Hematol, Houston, TX 77030 USA; Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; Natl Taiwan Univ, Coll Med, Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan	University of Texas System; University of Texas System; Academia Sinica - Taiwan; National Taiwan University; National Taiwan University Hospital	Wu, KK (corresponding author), Univ Texas, Sch Med, Vasc Biol Res Ctr, 6431 Fannin,MSB 5-016, Houston, TX 77030 USA.		Cieslik, Katarzyna/AAO-1982-2021; Wu, Kenneth Kun-Yu/B-1070-2010	Cieslik, Katarzyna/0000-0002-2167-7921; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS023327] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL-50675] Funding Source: Medline; NINDS NIH HHS [P50 NS-23327] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; Arnet UA, 1996, J BIOL CHEM, V271, P15069, DOI 10.1074/jbc.271.25.15069; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Daniel S, 1996, J BIOL CHEM, V271, P14692, DOI 10.1074/jbc.271.25.14692; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Fang XJ, 1997, J BIOL CHEM, V272, P13683, DOI 10.1074/jbc.272.21.13683; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; Felgner P L, 1991, Methods Mol Biol, V7, P81, DOI 10.1385/0-89603-178-0:81; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; HIRATA K, 1995, CIRC RES, V76, P958, DOI 10.1161/01.RES.76.6.958; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; KUME N, 1992, J CLIN INVEST, V90, P1138, DOI 10.1172/JCI115932; KUME N, 1994, J CLIN INVEST, V93, P907, DOI 10.1172/JCI117047; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MARSDEN PA, 1993, J BIOL CHEM, V268, P17478; MONCADA S, 1991, PHARMACOL REV, V43, P109; Nadaud S, 1996, CIRC RES, V79, P857, DOI 10.1161/01.RES.79.4.857; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN C, 1994, J BIOL CHEM, V269, P13725; PARTHASARATHY S, 1985, P NATL ACAD SCI USA, V82, P3000, DOI 10.1073/pnas.82.9.3000; PORTMAN OW, 1969, J LIPID RES, V10, P158; SAKAI M, 1994, J BIOL CHEM, V269, P31430; SESSA WC, 1992, J BIOL CHEM, V267, P15274; SESSA WC, 1994, CIRC RES, V74, P349, DOI 10.1161/01.RES.74.2.349; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; TANG JL, 1995, BIOCHEM BIOPH RES CO, V213, P673, DOI 10.1006/bbrc.1995.2184; WANG LG, 1994, CELL GROWTH DIFFER, V5, P1243; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WEINER CP, 1994, P NATL ACAD SCI USA, V91, P5212, DOI 10.1073/pnas.91.11.5212; Wu K K, 1995, Adv Pharmacol, V33, P179, DOI 10.1016/S1054-3589(08)60669-9; ZEMBOWICZ A, 1995, J CLIN INVEST, V96, P1688, DOI 10.1172/JCI118211; ZEMBOWICZ A, 1995, J BIOL CHEM, V270, P17006, DOI 10.1074/jbc.270.28.17006	33	72	74	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14885	14890		10.1074/jbc.273.24.14885	http://dx.doi.org/10.1074/jbc.273.24.14885			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614091	hybrid			2022-12-27	WOS:000074160400033
J	Dennis, PB; Pullen, N; Pearson, RB; Kozma, SC; Thomas, G				Dennis, PB; Pullen, N; Pearson, RB; Kozma, SC; Thomas, G			Phosphorylation sites in the autoinhibitory domain participate in p70(s6k) activation loop phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; P70 S6 KINASE; RAPAMYCIN SENSITIVITY; CELL-CYCLE; IN-VIVO; DEPHOSPHORYLATION; INACTIVATION; ENTRY; PHASE; GENE	Here we have employed p70(s6k) truncation and point mutants to elucidate the role played by the carboxyl-terminal autoinhibitory domain <(S/T)under bar>P phosphorylation sites in kinase activation. Earlier studies showed that truncation of the p70(s6k) amino terminus severely impaired kinase activation but that this effect was reversed by deleting the carboxyl terminus, which in parallel led to deregulation of Thr(229) phosphorylation in the activation loop (Dennis, P. B., Pullen, N., Kozma, S. C., and Thomas, G. (1996) Mol. Cell. Biol. 16, 6242-6251). In this study, substitution of acidic residues for the four autoinhibitory domain <(S/T)under bar>P sites mimics the carboxyl-terminal deletion largely by rescuing kinase activation caused by the amino-terminal truncation. However, these mutations do not deregulate Thr(229) phosphorylation, suggesting the involvement of another regulatory element in the intact kinase. This element appears to be Thr(389) phosphorylation, because substitution of an acidic residue at this position in the p70(s6k) variant containing the <(S/T)under bar>P mutations leads to a large increase in basal Thr(229) phosphorylation and kinase activity. In contrast, an alanine substitution at Thr(389) blocks both responses. Consistent with these data, we, show that a mutant harboring the acidic <(S/T)under bar>P and Thr(389) substitutions is an excellent in vitro substrate for the newly identified Thr(229) kinase, phosphoinositide-dependent kinase-1 (Pullen, N., Dennis, P. B., Andjelkovic, M., Dufner, A., Kozma, S., Hemmings, B. A., and Thomas, G. (1998) Science 279, 707-710), whereas phosphoinositide-dependent kinase-l poorly utilizes the two p70(s6k) variants that have only one set of mutations. These findings indicate that phosphorylation of the <(S/T)under bar>P sites, in cooperation with Thr(389) phosphorylation, controls Thr(229) phosphorylation through an intrasteric mechanism.	Friedrich Miescher Inst, Dept Growth Control, CH-4002 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Thomas, G (corresponding author), Friedrich Miescher Inst, Dept Growth Control, POB 2543, CH-4002 Basel, Switzerland.		Pearson, Richard Bruce/I-1451-2013; Thomas, George/K-9235-2014	Pearson, Richard Bruce/0000-0001-5919-5090; Thomas, George/0000-0003-3518-8149; Pullen, Nicholas/0000-0002-4014-9278				Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; BROOKS RF, 1977, CELL, V12, P311, DOI 10.1016/0092-8674(77)90209-4; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; CHEATHAM L, 1995, P NATL ACAD SCI USA, V92, P11696, DOI 10.1073/pnas.92.25.11696; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; Edelmann HML, 1996, J BIOL CHEM, V271, P963, DOI 10.1074/jbc.271.2.963; Fadden P, 1997, J BIOL CHEM, V272, P10240; FERRARI S, 1993, J BIOL CHEM, V268, P16091; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895; FLOTOW H, 1992, J BIOL CHEM, V267, P3074; FRANCO R, 1990, J BIOL CHEM, V265, P4321; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; HANKS SK, 1995, PROTEIN KINASE FACTS, P7; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; JEFFERIES HBJ, 1996, TRANSLATIONAL CONTRO, P389; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; Mahalingam M, 1996, MOL CELL BIOL, V16, P405; MARSHALL CJ, 1994, NATURE, V367, P686, DOI 10.1038/367686a0; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; Moser BA, 1997, MOL CELL BIOL, V17, P5648, DOI 10.1128/MCB.17.9.5648; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; ORR JW, 1994, J BIOL CHEM, V269, P8383; Pearson R B, 1995, Prog Cell Cycle Res, V1, P21; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; PRICE DJ, 1991, J BIOL CHEM, V266, P16281; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; REINHARD C, 1992, P NATL ACAD SCI USA, V89, P4052, DOI 10.1073/pnas.89.9.4052; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; Stewart MJ, 1996, P NATL ACAD SCI USA, V93, P10791, DOI 10.1073/pnas.93.20.10791; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; TSUTAKAWA SE, 1995, J BIOL CHEM, V270, P26807, DOI 10.1074/jbc.270.45.26807; vonManteuffel SR, 1997, MOL CELL BIOL, V17, P5426, DOI 10.1128/MCB.17.9.5426; Watson KL, 1996, P NATL ACAD SCI USA, V93, P13694, DOI 10.1073/pnas.93.24.13694; WENG QP, 1995, MOL CELL BIOL, V15, P2333; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957	43	118	121	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14845	14852		10.1074/jbc.273.24.14845	http://dx.doi.org/10.1074/jbc.273.24.14845			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614086	hybrid			2022-12-27	WOS:000074160400028
J	Kozaki, K; Miyaishi, O; Koiwai, O; Yasui, Y; Kashiwai, A; Nishikawa, Y; Shimizu, S; Saga, S				Kozaki, K; Miyaishi, O; Koiwai, O; Yasui, Y; Kashiwai, A; Nishikawa, Y; Shimizu, S; Saga, S			Isolation, purification, and characterization of a collagen-associated serpin, caspin, produced by murine colon adenocarcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; EMBRYO FIBROBLASTS; BINDING-PROTEIN; STRESS PROTEIN; HUMAN-PLASMA; INHIBITORS; HSP47; ALPHA-1-ANTITRYPSIN; IDENTIFICATION; VITRONECTIN	A 45-kDa serpin secreted by a murine colon adenocarcinoma cell line, colon26, was isolated, purified, and characterized, It was found to bind specifically to type I collagen with high affinity and to type III collagen with lower affinity, Immunohistochemical studies of murine embryonic tissues showed a specific distribution of this collagen-associated serpin, named caspin, in relation to the formation of bone, cartilage, teeth, and basement membrane. The expression of caspin in high and low lung metastatic subclones of colon26 cell lines was inversely correlated with their metastatic capacity: low lung metastatic cells secreted higher amounts of caspin than their high lung metastatic counterparts. Caspin also demonstrated high homology with human pigment epithelium-derived factor/early population doubling level cDNA-1, which reportedly induces neuronal differentiation of human retinoblastoma cells and is expressed in association with G(0) growth arrest. These findings suggest that caspin/pigment epithelium-derived factor/early population doubling level cDNA-1 is a novel factor that might play a crucial role in embryogenesis and tumor metastasis through binding to the extracellular matrix.	Aichi Canc Ctr, Res Inst, Pathophysiol Unit, Chikusa Ku, Aichi 4648681, Japan; Aichi Canc Ctr, Res Inst, Biochem Lab, Chikusa Ku, Aichi 4648681, Japan; Natl Inst Longev Sci, Dept Basic Gerontol, Pathol Lab, Aichi 4748522, Japan; Tokyo Univ Sci, Fac Sci & Technol, Dept Appl Biol Sci, Noda, Chiba 2788510, Japan; Aichi Human Serv Ctr, Inst Dev Res, Aichi 4800304, Japan; Aichi Med Univ, Dept Pathol 2, Aichi 4801195, Japan	Aichi Cancer Center; Aichi Cancer Center; Tokyo University of Science; Aichi Medical University	Kozaki, K (corresponding author), Aichi Canc Ctr, Res Inst, Pathophysiol Unit, Chikusa Ku, Aichi 4648681, Japan.	kkozaki@aichi-cc.pref.aichi.jp	Kozaki, Ken-ichi/M-6281-2014	Kozaki, Ken-ichi/0000-0003-3286-819X				CARRELL R, 1985, TRENDS BIOCHEM SCI, V10, P20, DOI 10.1016/0968-0004(85)90011-8; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; DONOVAN FM, 1994, J BIOL CHEM, V269, P17199; HIRAYOSHI K, 1991, MOL CELL BIOL, V11, P4036, DOI 10.1128/MCB.11.8.4036; HOPKINS PCR, 1994, SCIENCE, V265, P1893; Horton William A., 1993, P73; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; KOZAKI KI, 1994, EXP CELL RES, V213, P348, DOI 10.1006/excr.1994.1209; MONARD D, 1988, TRENDS NEUROSCI, V11, P541, DOI 10.1016/0166-2236(88)90182-8; Nagata K, 1996, TRENDS BIOCHEM SCI, V21, P23, DOI 10.1016/0968-0004(96)80881-4; NAGATA K, 1986, J CELL BIOL, V103, P223, DOI 10.1083/jcb.103.1.223; NAKAI A, 1992, J CELL BIOL, V117, P903, DOI 10.1083/jcb.117.4.903; PIGNOLO RJ, 1993, J BIOL CHEM, V268, P8949; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; RINEHART AR, 1993, AM J RESP CELL MOL, V9, P666, DOI 10.1165/ajrcmb/9.6.666; SAGA S, 1987, J CELL BIOL, V105, P517, DOI 10.1083/jcb.105.1.517; Sakata K, 1996, JPN J CANCER RES, V87, P78, DOI 10.1111/j.1349-7006.1996.tb00203.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Shimizu S, 1996, CANCER RES, V56, P3366; STEELE FR, 1993, P NATL ACAD SCI USA, V90, P1526, DOI 10.1073/pnas.90.4.1526; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; TAKECHI H, 1992, EUR J BIOCHEM, V206, P323, DOI 10.1111/j.1432-1033.1992.tb16930.x; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	24	56	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15125	15130		10.1074/jbc.273.24.15125	http://dx.doi.org/10.1074/jbc.273.24.15125			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614124	hybrid			2022-12-27	WOS:000074160400066
J	Lewis, JM; Schwartz, MA				Lewis, JM; Schwartz, MA			Integrins regulate the association and phosphorylation of paxillin by c-Abl	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; CHRONIC MYELOGENOUS LEUKEMIA; SRC HOMOLOGY-2 DOMAIN; TYROSINE KINASE; CELL-CYCLE; PROTEIN; BINDING; P210(BCR/ABL); IDENTIFICATION; CYTOSKELETAL	The c-Abl proto-oncogene is a non-receptor tyrosine kinase whose activity and localization are regulated by integrins. Cell adhesion to fibronectin triggers the transient recruitment of c-Abl from the nucleus to focal adhesions and activation of its tyrosine kinase. To investigate the integrin regulation of c-Abl, proteins that interact with c-Abl following cell adhesion were assayed. Several proteins that were phosphorylated on tyrosine were found to transiently co-precipitate with c-Abl during cell adhesion, and one was identified as the focal adhesion protein paxillin. Abl also became transiently phosphorylated in response to cell adhesion. In addition, paxillin was found to serve as substrate for the adhesion-activated c-Abl kinase. These results suggest that c-Abl may mediate effects of integrins on cell functions by phosphorylating paxillin.	Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Lewis, JM (corresponding author), Scripps Res Inst, Dept Vasc Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Lewis, Jean/0000-0001-6978-5166; schwartz, martin/0000-0002-2071-1243	NATIONAL CANCER INSTITUTE [R29CA074230] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057900] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047214] Funding Source: NIH RePORTER; NCI NIH HHS [R29 CA74230] Funding Source: Medline; NHLBI NIH HHS [P01 HL57900] Funding Source: Medline; NIGMS NIH HHS [R01 GM47214] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CHEN HC, 1994, J BIOL CHEM, V269, P31229; DeNichilo MO, 1996, J BIOL CHEM, V271, P11016, DOI 10.1074/jbc.271.18.11016; DUYSTER J, 1995, P NATL ACAD SCI USA, V92, P1555, DOI 10.1073/pnas.92.5.1555; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JACKSON P, 1993, EMBO J, V12, P2809, DOI 10.1002/j.1460-2075.1993.tb05942.x; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Lewis JM, 1996, J CELL BIOL, V134, P1323, DOI 10.1083/jcb.134.5.1323; MIEKKA SI, 1982, THROMB RES, V27, P1, DOI 10.1016/0049-3848(82)90272-9; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; ODA T, 1994, J BIOL CHEM, V269, P22925; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PLATH K, 1994, BIOCHEM BIOPH RES CO, V203, P1188, DOI 10.1006/bbrc.1994.2308; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SALGIA R, 1995, ONCOGENE, V11, P1149; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; TURNER CE, 1994, J CELL SCI, V107, P1583; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WENG ZG, 1993, J BIOL CHEM, V268, P14956	35	88	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14225	14230		10.1074/jbc.273.23.14225	http://dx.doi.org/10.1074/jbc.273.23.14225			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603926	hybrid			2022-12-27	WOS:000074021500028
J	Whitworth, ST; Blum, MS; Travis, J				Whitworth, ST; Blum, MS; Travis, J			Proteolytic enzymes from larvae of the fire ant, Solenopsis invicta - Isolation and characterization of four serine endopeptidases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYMENOPTERA; FORMICIDAE; COMPONENTS; VENOM	The imported red fire ant (Solenopsis invicta) is a problematic pest in the Southern United States. The stages of development for these ants are as follows: egg, 1st, 2nd, 3rd, and 4th instar larvae, prepupae, pupae, and adult. The 4th instar larvae plays an important role in the survival of the colony in that it is totally responsible for the digestion of solid foods and the source of nutrients for the queen and adult workers. In our studies we have been successful in purifying and characterizing four proteinases from the 4th instar larvae. Based on substrate specificity, they appear to represent two chymotrypsin-like and two elastase-like proteinases. These are referred to as Soli C1, Soli C2, Soli E1, and Soli E2, with molecular masses of 25, 28, 23, and 24 kDa, respectively, based on SDS-PAGE. All enzymes were inhibited by diisopropyl fluorophosphate, a general serine class inhibitor. Various synthetic substrates with either Phe or Val in the P-1 position, were readily cleaved by Soli C1/C2 or E1/E2, respectively. Each enzyme has been characterized as to pH optimum, pH stability, isoelectrofocusing and susceptibility to inhibition by a broad range of natural and synthetic proteinase inhibitors. Such compounds may prove useful for the development of insecticides to control fire ant infestation.	Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA; Univ Georgia, Dept Entomol, Athens, GA 30602 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Travis, J (corresponding author), Univ Georgia, Dept Biochem & Mol Biol, Life Sci Bldg, Athens, GA 30602 USA.	jtravis@uga.cc.uga.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026148] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL26148] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAER H, 1979, TOXICON, V17, P397, DOI 10.1016/0041-0101(79)90267-8; BRAND JM, 1972, TOXICON, V10, P259, DOI 10.1016/0041-0101(72)90011-6; BUREN W F, 1972, Journal of the Georgia Entomological Society, V7, P1; DREES BM, 1990, J ENTOMOL SCI, V25, P317, DOI 10.18474/0749-8004-25.2.317; GLANCEY B M, 1973, Journal of the Georgia Entomological Society, V8, P237; HOFFMAN DR, 1988, J ALLERGY CLIN IMMUN, V82, P818, DOI 10.1016/0091-6749(88)90084-X; Holldobler B., 1990, pi; HUNG ACF, 1974, ANN ENTOMOL SOC AM, V67, P909, DOI 10.1093/aesa/67.6.909; LOCKEY RF, 1979, ADV ALLERGOLOGY CLIN, P441; Lofgren C.S., 1986, P227; MACCONNELL JG, 1971, TETRAHEDRON, V27, P1129, DOI 10.1016/S0040-4020(01)90860-9; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; PETRALIA RS, 1978, ANN ENTOMOL SOC AM, V71, P643, DOI 10.1093/aesa/71.4.643; PORTER SD, 1991, J ECON ENTOMOL, V84, P866, DOI 10.1093/jee/84.3.866; SHAGGAR H, 1987, ANAL BIOCHEM, V166, P168; SORENSEN AA, 1983, J INSECT PHYSIOL, V29, P163, DOI 10.1016/0022-1910(83)90140-3; TSCHINKEL WR, 1987, ENTOMOL SOC AM, V81, P76; Vinson SB, 1986, IMPORTED FIRE ANTS L	18	21	23	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14430	14434		10.1074/jbc.273.23.14430	http://dx.doi.org/10.1074/jbc.273.23.14430			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603955	hybrid			2022-12-27	WOS:000074021500057
J	Bec, N; Gorren, ACF; Voelker, C; Mayer, B; Lange, R				Bec, N; Gorren, ACF; Voelker, C; Mayer, B; Lange, R			Reaction of neuronal nitric-oxide synthase with oxygen at low temperature - Evidence for reductive activation of the oxy-ferrous complex by tetrahydrobiopterin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYZED CONVERSION; CYTOCHROME P-450CAM; INSECT CELLS; L-ARGININE; HEME; CITRULLINE; CHLOROPEROXIDASE; INTERMEDIATE; BINDING; IDENTIFICATION	The reaction of reduced NO synthase (NOS) with molecular oxygen was studied at -30 degrees C. In the absence of substrate, the complex formed between ferrous NOS and O-2 was sufficiently long lived for a precise spectroscopic characterization. This complex displayed similar spectral characteristics as the oxyferrous complex of cytochrome P450 (lambda(max) = 416.5 nm), It then decomposed to the ferric state. The oxidation of the flavin components was much slower and could be observed only at temperatures higher than -20 degrees C. In the presence of substrate (L-arginine), another, 12-nm blue-shifted, intermediate spectrum was formed. The breakdown of the latter species resulted in the production of N-omega-hydroxy-L-arginine in a stoichiometry of maximally 52% per NOS heme. This product formation took place also in the absence of the reductase domain of NOS, Both formation of the blueshifted intermediate and of N-omega-hydroxy-L-arginine required the presence of tetrahydrobiopterin (BH4). We propose that the blue-shifted intermediate is the result of reductive activation of the oxygenated complex, and the electron is provided by BH4. These observations suggest that the reduction of the oxyferroheme complex may be the main function of BH4 in NOS catalysis.	CNRS, INSERM U128, Inst Federat Rech 24, Montpellier 5, France; Karl Franzens Univ Graz, Inst Pharmakol & Toxikol, A-8010 Graz, Austria	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); University of Graz	Lange, R (corresponding author), CNRS, INSERM U128, Inst Federat Rech 24, 1919 Route Mende, Montpellier 5, France.		Mayer, Bernd/B-9391-2008	Gorren, Antonius Cornelis Franciscus/0000-0003-3476-6162; bec, nicole/0000-0001-7608-2434; Mayer, Bernd/0000-0002-2921-3494				AbuSoud HM, 1997, J BIOL CHEM, V272, P17349, DOI 10.1074/jbc.272.28.17349; AbuSoud HM, 1997, BIOCHEMISTRY-US, V36, P10811, DOI 10.1021/bi971414g; ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; BANGCHAROENPAURPONG O, 1986, J BIOL CHEM, V261, P8089; Benson DE, 1997, BIOCHEMISTRY-US, V36, P5104, DOI 10.1021/bi963170q; BLANCK J, 1984, CYTOCHROME P450, P111; BLUMBERG WE, 1968, J BIOL CHEM, V243, P1854; BONFILS C, 1979, BIOCHEM BIOPH RES CO, V88, P1301, DOI 10.1016/0006-291X(79)91122-7; CAMPOS KL, 1995, J BIOL CHEM, V270, P1721, DOI 10.1074/jbc.270.4.1721; Coon M J, 1978, Methods Enzymol, V52, P109; Crane BR, 1997, SCIENCE, V278, P425, DOI 10.1126/science.278.5337.425; DAWSON JH, 1983, J BIOL CHEM, V258, P3637; DAWSON JH, 1987, CHEM REV, V87, P1255, DOI 10.1021/cr00081a015; DINELLO RK, 1981, J BIOL CHEM, V256, P6903; DOUZOU P, 1977, CRYOBIOCHEMISTRY INT, P45; EISENSTEIN L, 1977, BIOCHEM BIOPH RES CO, V77, P1377, DOI 10.1016/S0006-291X(77)80131-9; GERBER NC, 1994, J BIOL CHEM, V269, P4260; Gorren ACF, 1997, BIOCHEMISTRY-US, V36, P4360, DOI 10.1021/bi962381s; Gorren ACF, 1996, BIOCHEMISTRY-US, V35, P16735, DOI 10.1021/bi961931j; Gunsalus I. C., 1974, MOL MECHANISMS OXYGE, P561; HARTENECK C, 1994, BIOCHEM J, V304, P683, DOI 10.1042/bj3040683; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; HEMMENS B, 1997, METHOD MOL BIOL, V100, P1; KAUFMAN S, 1993, ANNU REV NUTR, V13, P261, DOI 10.1146/annurev.nu.13.070193.001401; KLATT P, 1994, J BIOL CHEM, V269, P13861; KLATT P, 1993, J BIOL CHEM, V268, P14781; KORTH HG, 1994, J BIOL CHEM, V269, P17776; KWON NS, 1990, J BIOL CHEM, V265, P13442; LANGE R, 1989, CYTOCHROME P-450 : BIOCHEMISTRY AND BIOPHYSICS /, P272; LANGE R, 1988, BIOCH LIFE SCI ADV, V7, P137; LARROQUE C, 1980, FEBS LETT, V115, P175, DOI 10.1016/0014-5793(80)81161-6; LARROQUE C, 1990, ARCH BIOCHEM BIOPHYS, V282, P198, DOI 10.1016/0003-9861(90)90104-7; LEONE AM, 1991, J BIOL CHEM, V266, P23790; List BM, 1996, BIOCHEM J, V315, P57, DOI 10.1042/bj3150057; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; MAYER B, 1995, N-S ARCH PHARMACOL, V351, P453; MAYER B, 1994, NEUROPHARMACOLOGY, V33, P1253, DOI 10.1016/0028-3908(94)90024-8; Mayer B, 1997, BIOCHEMISTRY-US, V36, P8422, DOI 10.1021/bi970144z; Mayer Bernd, 1995, P21, DOI 10.1016/B978-012721985-1/50004-6; Ortiz de Montellano PR, 1986, CYTOCHROME P450 STRU, P217; PALCIC MM, 1980, BIOCHEM BIOPH RES CO, V94, P1123, DOI 10.1016/0006-291X(80)90535-5; Pfeiffer S, 1997, BIOCHEM J, V328, P349, DOI 10.1042/bj3280349; POU S, 1992, J BIOL CHEM, V267, P24173; RENAUD JP, 1993, BIOCHEM BIOPH RES CO, V192, P53, DOI 10.1006/bbrc.1993.1380; SHETA EA, 1994, J BIOL CHEM, V269, P15147; Siddhanta U, 1996, J BIOL CHEM, V271, P7309, DOI 10.1074/jbc.271.13.7309; SONO M, 1995, J BIOL CHEM, V270, P19943, DOI 10.1074/jbc.270.34.19943; TUCKEY RC, 1982, J BIOL CHEM, V257, P9309; TZENG E, 1995, P NATL ACAD SCI USA, V92, P11771, DOI 10.1073/pnas.92.25.11771; Vaz ADN, 1996, P NATL ACAD SCI USA, V93, P4644, DOI 10.1073/pnas.93.10.4644; Werner ER, 1996, BIOCHEM J, V320, P193, DOI 10.1042/bj3200193; Witteveen CFB, 1996, J BIOL CHEM, V271, P4143	52	175	176	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13502	13508		10.1074/jbc.273.22.13502	http://dx.doi.org/10.1074/jbc.273.22.13502			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593685	hybrid			2022-12-27	WOS:000073919100024
J	Hass, S; Fresser, F; Kochl, S; Beyreuther, K; Utermann, G; Baier, G				Hass, S; Fresser, F; Kochl, S; Beyreuther, K; Utermann, G; Baier, G			Physical interaction of ApoE with amyloid precursor protein independent of the amyloid A beta region in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONSET ALZHEIMER-DISEASE; APOLIPOPROTEIN-E POLYMORPHISM; CHOLESTEROL TRANSPORT; NERVOUS-SYSTEM; E GENOTYPE; ALLELE; EXPRESSION; EPSILON-4; BINDING; EPIDEMIOLOGY	Variation at the APOE gene locus has been shown to affect the risk for Alzheimer's disease, To gain deeper insight into the postulated apoE-mediated amyloid formation, we have characterized the three common apoE isoforms (apoE2, apoE3, and apoE4) regarding their binding to amyloid precursor protein (APP). We employed the yeast two-hybrid system and co-immunoprecipitation experiments in cell culture supernatants of COS-l cells, ectopically expressing apoE isoforms and APP(751) holoprotein or a COOH-terminal AP deletion mutant protein, designated APP(trunc) We found that all three apoE isoforms were able to bind APP(751) holoprotein in an AP-independent fashion. The interacting domains could be mapped to the NH(2) termini of APP (amino acids 1-207) and apoE (amino acids 1-191). As a functional consequence of this novel APP(751) ectodo- main-mediated apoE binding, the secretion of soluble APP(751) is differentially affected by distinct apoE isoforms in vitro, suggesting a new "chaperon-like" mechanism by which apoE isoforms may modulate APP metabolism and consequently the risk for Alzheimer's disease.	Univ Innsbruck, Inst Med Biol & Human Genet, A-6020 Innsbruck, Austria; Univ Heidelberg, Ctr Mol Biol, D-69120 Heidelberg, Germany	University of Innsbruck; Ruprecht Karls University Heidelberg	Baier, G (corresponding author), Univ Innsbruck, Inst Med Biol & Human Genet, Schoepfstr 41, A-6020 Innsbruck, Austria.	Gottfried.Baier@uibk.ac.at	Baier, Gottfried/E-8755-2012	Baier, Gottfried/0000-0002-2085-8325				BAIER G, 1994, BIOTECHNIQUES, V17, P94; Barger SW, 1997, J NEUROCHEM, V69, P60; BOYLES JK, 1985, J CLIN INVEST, V76, P1501, DOI 10.1172/JCI112130; BOYLES JK, 1989, J CLIN INVEST, V83, P1015, DOI 10.1172/JCI113943; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Furukawa K, 1996, J NEUROCHEM, V67, P1882, DOI 10.1046/j.1471-4159.1996.67051882.x; GomezIsla T, 1996, ANN NEUROL, V39, P62, DOI 10.1002/ana.410390110; HARDY J, 1995, AM J MED GENET, V60, P456, DOI 10.1002/ajmg.1320600519; HYMAN BT, 1995, P NATL ACAD SCI USA, V92, P3586, DOI 10.1073/pnas.92.8.3586; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KAWARABAYASHI T, 1991, BRAIN RES, V563, P334, DOI 10.1016/0006-8993(91)91558-I; LADU MJ, 1994, J BIOL CHEM, V269, P23403; Mahley Robert W., 1995, Current Opinion in Lipidology, V6, P86, DOI 10.1097/00041433-199504000-00005; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAYEUX R, 1993, ANN NEUROL, V34, P752, DOI 10.1002/ana.410340527; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; REBECK GW, 1993, NEURON, V11, P575; ROSES AD, 1994, LANCET, V343, P1564, DOI 10.1016/S0140-6736(94)92960-2; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCHELLENBERG GD, 1995, P NATL ACAD SCI USA, V92, P8552, DOI 10.1073/pnas.92.19.8552; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SIMAN R, 1989, NEURON, V3, P275, DOI 10.1016/0896-6273(89)90252-3; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; Suh YH, 1997, J NEUROCHEM, V68, P1781; UTERMANN G, 1980, AM J HUM GENET, V32, P339; UTERMANN G, 1987, AM HEART J, V113, P433, DOI 10.1016/0002-8703(87)90610-7; UTERMANN G, 1977, NATURE, V269, P604, DOI 10.1038/269604a0; Weisgraber Karl H., 1994, Current Opinion in Lipidology, V5, P110, DOI 10.1097/00041433-199404000-00007; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C	32	33	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13892	13897						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593736				2022-12-27	WOS:000073919100075
J	Jolly-Tornetta, C; Gao, ZY; Lee, VMY; Wolf, BA				Jolly-Tornetta, C; Gao, ZY; Lee, VMY; Wolf, BA			Regulation of amyloid precursor protein seer receptors in human Ntera 2 neurons (NT2N)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; FAMILIAL ALZHEIMERS-DISEASE; ISOLATED PANCREATIC-ISLETS; BETA-PROTEIN; CELL-LINE; EXPRESSION; DERIVATIVES; ACID; APP; DIACYLGLYCEROL	The amyloid precursor protein (APP) can be cleaved by a beta-secretase to generate a beta-amyloid peptide, which has been implicated in the pathogenesis of Alzheimer's disease. However, APP can also be cleaved by an alpha-secretase to form a non-amyloidogenic secreted form of APP (APP-S). APP-S secretion can be physiologically regulated. This study examined the glutamatergic regulation of APP in the human neuronal Ntera 2 (NT2N) cell line. Metabotropic glutamate receptor subtypes 1 alpha/beta and 5 alpha were identified in the NT2N neurons by reverse transcription-polymerase chain reaction. Stimulation of these phosphatidylinositol-linked receptors with glutamate or specific receptor agonists resulted in a dose- and time-dependent increase in the secretion of the amyloid precursor protein (APP-S), measured by the immunoprecipitation of APP-S from the medium of [S-35]methionine-labeled NT2N neurons. The glutamate-induced APP-S secretion was maximal at 30 min and at a concentration of 1 mM glutamate, Glutamate-induced APP-S secretion required activation of phospholipase C, which resulted in inositol 1,4,5-trisphosphate production, as shown by the rapid glutamate-induced accumulation of inositol 1,4,5-trisphosphate, Glutamate also caused an increase in intracellular Ca2+, The protein kinase C activator phorbol 12-myristate 13-acetate, a phorbol ester, as well as 1-oleoyl-2-acetoyl-3-glycerol, a cell-permeable diacylglycerol analog, also stimulated APP-S secretion. These findings suggest that APP-S secretion from NT2N neurons can be regulated by the activation of phosphatidylinositol-linked metabotropic glutamate receptor signaling pathway.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Wolf, BA (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, 230 John Morgan Bldg,3620 Hamilton Walk, Philadelphia, PA 19104 USA.	wolfb@mail.med.upenn.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K04DK002217] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG009215, P01AG011542] Funding Source: NIH RePORTER; NIA NIH HHS [AG09215, AG11542] Funding Source: Medline; NIDDK NIH HHS [K04 DK02217] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAI H, 1991, ANN NEUROL, V30, P686, DOI 10.1002/ana.410300509; Barnard EA, 1997, TRENDS PHARMACOL SCI, V18, P141, DOI 10.1016/S0165-6147(97)01053-5; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; DESAI MA, 1995, MOL PHARMACOL, V48, P648; Efthimiopoulos S, 1996, J NEUROCHEM, V67, P872; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GOLDE TE, 1993, ANN NY ACAD SCI, V695, P103, DOI 10.1111/j.1749-6632.1993.tb23036.x; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; HARDY J, 1991, TRENDS PHARMACOL SCI, V12, P383, DOI 10.1016/0165-6147(91)90609-V; HARDY M, 1994, J NEUROCHEM, V63, P482; HAYASHI Y, 1992, BRIT J PHARMACOL, V107, P539, DOI 10.1111/j.1476-5381.1992.tb12780.x; Horsburgh K, 1997, EXP NEUROL, V143, P207, DOI 10.1006/exnr.1996.6356; JANE DE, 1995, NEUROPHARMACOLOGY, V34, P851, DOI 10.1016/0028-3908(95)00063-C; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Kirazov L, 1997, NEUROCHEM INT, V30, P557, DOI 10.1016/S0197-0186(96)00119-2; KONRAD RJ, 1994, BIOCHEMISTRY-US, V33, P13284, DOI 10.1021/bi00249a015; Lee RKK, 1997, J NEUROCHEM, V68, P1830; Lee RKK, 1997, P NATL ACAD SCI USA, V94, P5422, DOI 10.1073/pnas.94.10.5422; LEE RKK, 1995, P NATL ACAD SCI USA, V92, P8083, DOI 10.1073/pnas.92.17.8083; MINAKAMI R, 1994, BIOCHEM BIOPH RES CO, V199, P1136, DOI 10.1006/bbrc.1994.1349; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; PELLICCIARI R, 1995, J MED CHEM, V38, P3717, DOI 10.1021/jm00019a002; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; Selkoe DJ, 1996, ANN NY ACAD SCI, V777, P57, DOI 10.1111/j.1749-6632.1996.tb34401.x; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; Sisodia S S, 1992, Curr Opin Neurobiol, V2, P648, DOI 10.1016/0959-4388(92)90033-H; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SUZUKI T, 1997, BIOCHEM BIOPH RES CO, V238, P740; Thomas P, 1996, HUM MOL GENET, V5, P1809, DOI 10.1093/hmg/5.11.1809; Ulus IH, 1997, J PHARMACOL EXP THER, V281, P149; WERTKIN AM, 1993, P NATL ACAD SCI USA, V90, P9513, DOI 10.1073/pnas.90.20.9513; Westbrook Gary L., 1994, Current Opinion in Neurobiology, V4, P337, DOI 10.1016/0959-4388(94)90094-9; WOLF BA, 1995, J BIOL CHEM, V270, P4916, DOI 10.1074/jbc.270.9.4916; WOLF BA, 1989, BIOCHEMISTRY-US, V28, P4291, DOI 10.1021/bi00436a026; Xia WM, 1997, J BIOL CHEM, V272, P7977, DOI 10.1074/jbc.272.12.7977; Xu HX, 1996, P NATL ACAD SCI USA, V93, P4081, DOI 10.1073/pnas.93.9.4081; YANKNER BA, 1991, NEW ENGL J MED, V325, P1849; YOUNKIN DP, 1993, P NATL ACAD SCI USA, V90, P2174, DOI 10.1073/pnas.90.6.2174	44	62	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					14015	14021		10.1074/jbc.273.22.14015	http://dx.doi.org/10.1074/jbc.273.22.14015			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593752	hybrid			2022-12-27	WOS:000073919100091
J	Lambrecht, N; Corbett, Z; Bayle, D; Karlish, SJD; Sachs, G				Lambrecht, N; Corbett, Z; Bayle, D; Karlish, SJD; Sachs, G			Identification of the site of inhibition by omeprazole of a alpha-beta fusion protein of the H,K-ATPase using site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIC H+/K+-ATPASE; IN-VITRO TRANSLATION; SARCOPLASMIC-RETICULUM; MEMBRANE TOPOLOGY; K+-ATPASE; FUNCTIONAL CONSEQUENCES; INTRACELLULAR-TRANSPORT; TRANSMEMBRANE SEGMENTS; BINDING-PROPERTIES; SUBUNIT	The alpha subunit of eukaryotic P-type ATPases has ten experimentally defined transmembrane or membrane inserted segments. The fifth and sixth of these are short, not predicted by hydropathy analysis, do not insert independently into microsomal membranes, and are readily removed after tryptic digestion and therefore may be membrane inserted sequences. Acid transport by the gastric H,K-ATPase is covalently inhibited by several substituted pyridyl methylsulfinyl benzimidazoles, such as omeprazole. These act as probes of accessible extracytoplasmic thiols because they are accumulated in the acid transporting gastric vesicles and then convert to thiol reactive, cationic tetracyclic sulfenamides. Inhibition is due mainly to disulfide formation with Cys(813) or Cys(822) in M5/6 and perhaps with a contribution from Cys(892) in the loop between transmembrane segment (TM) 7 and TM8. Identification of the specific cysteine responsible for inhibition should be able to define the turn between M5 and M6. The gastric H,K-ATPase alpha-beta heterodimer was expressed as a fusion protein in HEK 293 cells. Transient transfection resulted in most of the protein being retained in the endoplasmic reticulum with only core glycosylation and minor activity of the ATPase evident. Stable transfection resulted in plasma membrane localization of the protein and complex glycosylation, The transfected but not the control cells displayed cation-stimulated, SCH 28080-inhibited ATPase activity and SCH 28080- and omeprazole-inhibited Rb-86 uptake. The two cysteines in M5/6 and Cys(892) in the TM7/8 loop were mutated to the amino acids found in the Na,K-ATPase in order to determine which of the three cysteine residues were important for benzimidazole inhibition. Mutation of one, two, or all three cysteines did not alter enzyme activity, Rb-86 transport, or SCH 28080 inhibition. Only removal of Cys(822) blocked omeprazole inhibition of Rb-86 transport. These data suggest that Cys(822) is present in a region of the enzyme most easily accessed by the cationic sulfenamide formed by omeprazole, presumably the turn between M5 and M6.	Wadsworth Vet Affairs Hosp, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, Dept Physiol & Med, Los Angeles, CA 90073 USA; Weizmann Inst Sci, IL-76100 Rehovot, Israel	University of California System; University of California Los Angeles; Weizmann Institute of Science	Sachs, G (corresponding author), Wadsworth Vet Affairs Hosp, Bldg 113,Rm 326, Los Angeles, CA 90073 USA.			Lambrecht, Nils/0000-0002-1275-1384	NIDDK NIH HHS [DK41301, DK43462, DK46917] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK041301, S15DK043462, R01DK046917] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACKERMANN U, 1990, FEBS LETT, V269, P105, DOI 10.1016/0014-5793(90)81130-G; ANDERSEN JP, 1995, FEBS LETT, V359, P101, DOI 10.1016/0014-5793(95)00019-6; Asano S, 1997, J BIOL CHEM, V272, P17668, DOI 10.1074/jbc.272.28.17668; BAMBERG K, 1994, J BIOL CHEM, V269, P16909; BAMBERG K, 1992, BIOCHIM BIOPHYS ACTA, V1131, P69, DOI 10.1016/0167-4781(92)90100-E; BAYLE D, 1995, J BIOL CHEM, V270, P25678, DOI 10.1074/jbc.270.43.25678; Beguin P, 1997, ANN NY ACAD SCI, V834, P540, DOI 10.1111/j.1749-6632.1997.tb52312.x; BESANCON M, 1993, BIOCHEMISTRY-US, V32, P2345, DOI 10.1021/bi00060a028; Besancon M, 1997, J BIOL CHEM, V272, P22438, DOI 10.1074/jbc.272.36.22438; BLOSTEIN R, 1993, J BIOL CHEM, V268, P10654; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOW DC, 1993, AM J PHYSIOL, V265, pC1562, DOI 10.1152/ajpcell.1993.265.6.C1562; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; EMANUEL JR, 1988, J BIOL CHEM, V263, P7726; EMERICK MC, 1993, J BIOL CHEM, V268, P23455; Falson P, 1997, J BIOL CHEM, V272, P17258, DOI 10.1074/jbc.272.28.17258; Fendler K, 1988, Prog Clin Biol Res, V268A, P501; FENG JN, 1994, BIOCHEMISTRY-US, V33, P4218, DOI 10.1021/bi00180a015; GEERING K, 1990, J MEMBRANE BIOL, V115, P109, DOI 10.1007/BF01869450; GEERING K, 1991, FEBS LETT, V285, P189, DOI 10.1016/0014-5793(91)80801-9; GOLDSHLEGER R, 1995, BIOCHEMISTRY-US, V34, P8668, DOI 10.1021/bi00027a016; GOTTARDI CJ, 1993, SCIENCE, V260, P552, DOI 10.1126/science.8386395; GOTTARDI CJ, 1993, J CELL BIOL, V121, P283, DOI 10.1083/jcb.121.2.283; GOTTARDI CJ, 1993, J BIOL CHEM, V268, P14342; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HALL K, 1990, BIOCHEMISTRY-US, V29, P701, DOI 10.1021/bi00455a016; HALL K, 1991, BIOCHIM BIOPHYS ACTA, V1077, P173, DOI 10.1016/0167-4838(91)90055-5; HARA Y, 1988, FEBS LETT, V238, P27, DOI 10.1016/0014-5793(88)80218-7; JAISSER F, 1994, J GEN PHYSIOL, V103, P605, DOI 10.1085/jgp.103.4.605; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13523, DOI 10.1021/bi00212a018; JUUL B, 1995, J BIOL CHEM, V270, P20123, DOI 10.1074/jbc.270.34.20123; KARLISH SJD, 1993, J BIOL CHEM, V268, P3471; KUNTZWEILER TA, 1995, J BIOL CHEM, V270, P16206, DOI 10.1074/jbc.270.27.16206; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; LUTSENKO S, 1995, P NATL ACAD SCI USA, V92, P7936, DOI 10.1073/pnas.92.17.7936; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MERCIER F, 1993, BIOCHIM BIOPHYS ACTA, V1149, P151, DOI 10.1016/0005-2736(93)90036-Y; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; Or E, 1996, BIOCHEMISTRY-US, V35, P6853, DOI 10.1021/bi960093q; Palasis M, 1996, J BIOL CHEM, V271, P14176, DOI 10.1074/jbc.271.24.14176; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; RABON EC, 1988, METHOD ENZYMOL, V157, P649; REUBEN MA, 1990, P NATL ACAD SCI USA, V87, P6767, DOI 10.1073/pnas.87.17.6767; SHIN JM, 1994, J BIOL CHEM, V269, P8642; SHIN JM, 1993, BIOCHIM BIOPHYS ACTA, V1148, P223, DOI 10.1016/0005-2736(93)90133-K; SHIN JM, 1994, J BIOL CHEM, V269, P22533; SHULL GE, 1986, J BIOL CHEM, V261, P6788; STOKES DL, 1994, FEBS LETT, V346, P32, DOI 10.1016/0014-5793(94)00297-5; Swarts HGP, 1996, J BIOL CHEM, V271, P29764, DOI 10.1074/jbc.271.47.29764; TOH BH, 1990, P NATL ACAD SCI USA, V87, P6418, DOI 10.1073/pnas.87.16.6418; VILSEN B, 1993, BIOCHEMISTRY-US, V32, P13340, DOI 10.1021/bi00211a048; VILSEN B, 1989, J BIOL CHEM, V264, P21024; WALLMARK B, 1987, J BIOL CHEM, V262, P2077; WOLOSIN JM, 1984, AM J PHYSIOL, V246, pC537, DOI 10.1152/ajpcell.1984.246.5.C537; Xie YH, 1996, J BIOL CHEM, V271, P2563, DOI 10.1074/jbc.271.5.2563; YODA A, 1970, BIOCHEM BIOPH RES CO, V40, P880, DOI 10.1016/0006-291X(70)90985-X	57	36	37	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13719	13728		10.1074/jbc.273.22.13719	http://dx.doi.org/10.1074/jbc.273.22.13719			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593713	hybrid			2022-12-27	WOS:000073919100052
J	Yogalingam, G; Hopwood, JJ; Crawley, A; Anson, DS				Yogalingam, G; Hopwood, JJ; Crawley, A; Anson, DS			Mild feline mucopolysaccharidosis type VI - Identification of an N-acetylgalactosamine-4-sulfatase mutation causing instability and increased specific activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAROTEAUX-LAMY SYNDROME; N-ACETYLGALACTOSAMINE 4-SULFATASE; ALPHA-L-IDURONIDASE; ARYLSULFATASE-B; ENZYME; FIBROBLASTS; DIAGNOSIS; LEUKOCYTE; PROTEIN; DISEASE	The missense mutation, L476P, in the N-acetylgalactosamine 4-sulfatase (4S) gene, has previously been shown to be associated with a severe feline mucopolysaccharidosis type VI (MPS VI) phenotype, The present study describes a second mutation, D520N, in the same MPS VI cat colony, which is inherited independently of L476P and is associated with a clinically mild MPS VI phenotype in D520N/L476P compound heterozygous cats. Biochemical and clinical assessment of L476P homozygous, D520N/L476P compound heterozygous, and D520N homozygous cats demonstrated that the entire range of clinical phenotypes, from severe MPS VI, to mild MPS VI, to normal are clustered within a narrow range of residual 4S activity from 0.5% to 4.6% of normal levels. When overexpressed in CHO-KI cells, the secreted form of D520N 4S was inactivated in neutral pH conditions. In addition, intracellular D520N 4S protein was rapidly degraded and corresponded to 37%, 14.5%, and 0.67% of normal 4S protein levels in the microsomal, endosomal, and lysosomal compartments, respectively. However, the specific activity of lysosomal D520N 4S was elevated 22.5-fold when compared with wild-type 4S, These results suggest that the D520N mutation causes a rapid degradation of 4S protein, The effect of this is partially ameliorated as a result of a significant elevation in the specific activity of mutant D520N 4S reaching the lysosomal compartment.	Womens & Childrens Hosp, Dept Chem Pathol, Lysosomal Dis Res Unit, N Adelaide, SA 5006, Australia		Anson, DS (corresponding author), Womens & Childrens Hosp, Dept Chem Pathol, Lysosomal Dis Res Unit, 72 King William Rd, N Adelaide, SA 5006, Australia.							ANSON DS, 1992, BIOCHEM J, V284, P789, DOI 10.1042/bj2840789; ARLT G, 1994, J BIOL CHEM, V269, P9638; Bond CS, 1997, STRUCTURE, V5, P277, DOI 10.1016/S0969-2126(97)00185-8; BROOKS DA, 1994, BIOCHEM MED METAB B, V53, P58, DOI 10.1006/bmmb.1994.1058; Brooks DA, 1997, BBA-MOL BASIS DIS, V1361, P203, DOI 10.1016/S0925-4439(97)00036-7; BROOKS DA, 1991, AM J HUM GENET, V48, P710; BROOKS DA, 1992, BIOCHEM MED METAB B, V47, P211, DOI 10.1016/0885-4505(92)90028-W; Byers S, 1997, BONE, V21, P425, DOI 10.1016/S8756-3282(97)00175-0; Crawley AC, 1998, J CLIN INVEST, V101, P109, DOI 10.1172/JCI935; Crawley AC, 1997, J CLIN INVEST, V99, P651, DOI 10.1172/JCI119208; Crawley AC, 1996, J CLIN INVEST, V97, P1864, DOI 10.1172/JCI118617; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; GIBSON GJ, 1987, BIOCHEM J, V248, P755, DOI 10.1042/bj2480755; HARPER GS, 1993, GLYCOCONJUGATE J, V10, P407, DOI 10.1007/BF00731045; HASKINS ME, 1979, PEDIATR RES, V13, P1203, DOI 10.1203/00006450-197911000-00001; HOPWOOD JJ, 1986, BIOCHEM J, V234, P507, DOI 10.1042/bj2340507; HOPWOOD JJ, 1990, MOL BIOL MED, V7, P381; JACKSON CE, 1992, GENOMICS, V14, P403, DOI 10.1016/S0888-7543(05)80233-2; KOLODNY EH, 1976, CLIN CHIM ACTA, V70, P247, DOI 10.1016/0009-8981(76)90426-5; LEABACK DH, 1961, BIOCHEM J, V78, P151, DOI 10.1042/bj0780151; Neufeld EF, 1995, METABOLIC MOL BASES, P2465; SINGH H, 1987, ARCH BIOCHEM BIOPHYS, V259, P382, DOI 10.1016/0003-9861(87)90504-2; UNGER EG, 1994, BIOCHEM J, V304, P43, DOI 10.1042/bj3040043; Yogalingam G, 1996, J BIOL CHEM, V271, P27259, DOI 10.1074/jbc.271.44.27259; Yogalingam G, 1996, AM J PHYSIOL-LUNG C, V270, pL320, DOI 10.1152/ajplung.1996.270.3.L320	25	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13421	13429		10.1074/jbc.273.22.13421	http://dx.doi.org/10.1074/jbc.273.22.13421			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593674	hybrid			2022-12-27	WOS:000073919100013
J	Rom, E; Kim, HC; Gingras, AC; Marcotrigiano, J; Favre, D; Olsen, H; Burley, SK; Sonenberg, N				Rom, E; Kim, HC; Gingras, AC; Marcotrigiano, J; Favre, D; Olsen, H; Burley, SK; Sonenberg, N			Cloning and characterization of 4EHP, a novel mammalian eIF4E-related cap-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR 4E; EUKARYOTIC MESSENGER-RNAS; HELA NUCLEAR EXTRACT; TRANSLATION INITIATION; 5'-TERMINAL CAP; CROSS-LINKING; U-SNRNA; PHAS-I; PHOSPHORYLATION; CELLS	All eukaryotic mRNAs (except organellar) are capped at their 5' end. The cap structure (m(7)GpppN, where N is any nucleotide) is extremely important for the processing and translation of mRNA. Several cap-binding proteins that facilitate these processes have been characterized. Here we describe a novel human cytoplasmic protein that is 30% identical and 60% similar to the human translation initiation factor 4E (eIF4E). We demonstrate that this protein, named 4E Homologous Protein (4EHP), binds specifically to capped RNA in an ATP-and divalent ion-independent manner. The three-dimensional structure of 4EHP, as predicted by homology modeling, closely resembles that of eIF4E and site-directed mutagenesis analysis of 4EHP strongly suggests that it shares with eIF4E a common mechanism for cap binding. A putative function for 4EHP is discussed.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; Rockefeller Univ, Mol Biophys Lab, New York, NY 10021 USA; Howard Hughes Med Inst, Rockville, MD 20850 USA; Hunam Genome Sci Inc, Rockville, MD 20850 USA	McGill University; Rockefeller University; Howard Hughes Medical Institute	Sonenberg, N (corresponding author), McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada.	sonenberg@medcor.mcgill.ca	Gingras, Anne-Claude/ABA-8341-2020; Gingras, Anne-Claude/E-9982-2010; Marcotrigiano, Joseph/K-6697-2016	Gingras, Anne-Claude/0000-0002-6090-4437; Gingras, Anne-Claude/0000-0002-6090-4437; Marcotrigiano, Joseph/0000-0003-0346-3353; Burley, Stephen K./0000-0002-2487-9713	NIGMS NIH HHS [GM07982] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMANN M, 1988, J BIOL CHEM, V263, P17229; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BANERJEE AK, 1980, MICROBIOL REV, V44, P175, DOI 10.1128/MMBR.44.2.175-205.1980; Beelman CA, 1996, NATURE, V382, P642, DOI 10.1038/382642a0; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; DUNCAN R, 1987, J BIOL CHEM, V262, P380; EDERY I, 1995, MOL CELL BIOL, V15, P3363; EDERY I, 1988, GENE, V74, P517, DOI 10.1016/0378-1119(88)90184-9; EDERY I, 1985, P NATL ACAD SCI USA, V82, P7590, DOI 10.1073/pnas.82.22.7590; FREDERICKSON RM, 1991, MOL CELL BIOL, V11, P2896, DOI 10.1128/MCB.11.5.2896; FURUICHI Y, 1977, NATURE, V266, P235, DOI 10.1038/266235a0; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; HART RP, 1985, CELL, V43, P677, DOI 10.1016/0092-8674(85)90240-5; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; HIREMATH LS, 1985, J BIOL CHEM, V260, P7843; Hodel AE, 1996, CELL, V85, P247, DOI 10.1016/S0092-8674(00)81101-0; Hodel AE, 1997, NAT STRUCT BIOL, V4, P350, DOI 10.1038/nsb0597-350; INOUE K, 1989, GENE DEV, V3, P1472, DOI 10.1101/gad.3.9.1472; IZAURRALDE E, 1992, J CELL BIOL, V118, P1287, DOI 10.1083/jcb.118.6.1287; IZAURRALDE E, 1994, CELL, V78, P657, DOI 10.1016/0092-8674(94)90530-4; IZAURRALDE E, 1995, NATURE, V376, P709, DOI 10.1038/376709a0; Jones RM, 1996, MOL CELL BIOL, V16, P4754; JOSHIBARVE S, 1990, J BIOL CHEM, V265, P2979; KLEIN PS, 1994, SCIENCE, V265, P803, DOI 10.1126/science.8047887; KONARSKA MM, 1984, CELL, V38, P731, DOI 10.1016/0092-8674(84)90268-X; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANGBERG SR, 1981, J BIOL CHEM, V256, P54; LAVERS GC, 1977, MOL BIOL REP, V3, P413, DOI 10.1007/BF00808382; LEJBKOWICZ F, 1992, P NATL ACAD SCI USA, V89, P9612, DOI 10.1073/pnas.89.20.9612; Lewis JD, 1995, J CELL SCI, P13; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Marcotrigiano J, 1997, CELL, V89, P951, DOI 10.1016/S0092-8674(00)80280-9; MATTAJ IW, 1986, CELL, V46, P905, DOI 10.1016/0092-8674(86)90072-3; MORLEY SJ, 1993, BIOCHIMIE, V75, P985, DOI 10.1016/0300-9084(93)90149-M; MURTHY KGK, 1991, NUCLEIC ACIDS RES, V19, P2685, DOI 10.1093/nar/19.10.2685; NUSS DL, 1975, CELL, V6, P21, DOI 10.1016/0092-8674(75)90069-0; NUSS DL, 1977, J BIOL CHEM, V252, P2815; OHNO M, 1987, P NATL ACAD SCI USA, V84, P5187, DOI 10.1073/pnas.84.15.5187; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PELLETIER J, 1985, MOL CELL BIOL, V5, P3222, DOI 10.1128/MCB.5.11.3222; Polunovsky VA, 1996, MOL CELL BIOL, V16, P6573; Rau M, 1996, J BIOL CHEM, V271, P8983, DOI 10.1074/jbc.271.15.8983; REDDY R, 1992, PHARMACOL THERAPEUT, V54, P249, DOI 10.1016/0163-7258(92)90002-H; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; RINKERSCHAEFFER CW, 1992, J BIOL CHEM, V267, P10659; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; SALDITTGEORGIEFF M, 1980, CELL, V19, P69, DOI 10.1016/0092-8674(80)90389-X; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sambrook J, 1989, MOL CLONING LAB MANU, V2; SHATKIN AJ, 1985, CELL, V40, P223, DOI 10.1016/0092-8674(85)90132-1; SHATKIN AJ, 1976, CELL, V9, P645, DOI 10.1016/0092-8674(76)90128-8; Shi XN, 1996, RNA, V2, P88; SHIMOTOHNO K, 1977, P NATL ACAD SCI USA, V74, P2734, DOI 10.1073/pnas.74.7.2734; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; SMITH M R, 1990, New Biologist, V2, P648; SONENBERG N, 1978, P NATL ACAD SCI USA, V75, P4843, DOI 10.1073/pnas.75.10.4843; SONENBERG N, 1981, NUCLEIC ACIDS RES, V9, P1643, DOI 10.1093/nar/9.7.1643; SONENBERG N, 1996, MRNA  CAP BINDING PR, P245; Visa N, 1996, J CELL BIOL, V133, P5, DOI 10.1083/jcb.133.1.5	61	104	105	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					13104	13109		10.1074/jbc.273.21.13104	http://dx.doi.org/10.1074/jbc.273.21.13104			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582349	hybrid			2022-12-27	WOS:000073768500060
J	Su, C; Oliw, EH				Su, C; Oliw, EH			Manganese lipoxygenase - Purification and characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNGUS GAEUMANNOMYCES-GRAMINIS; ARACHIDONIC-ACID 15-LIPOXYGENASE; UNSATURATED FATTY-ACIDS; LINOLEIC-ACID; MAMMALIAN LIPOXYGENASES; HYDROPEROXIDE ISOMERASE; EXTRADIOL DIOXYGENASE; SUPEROXIDE-DISMUTASE; PLEXAURA-HOMOMALLA; MOLECULAR-BIOLOGY	A Linoleic acid (13R)-lipoxygenase was purified to homogeneity from the culture medium of Gaumannomyces graminis, the take-all fungus, by hydrophobic interaction, cation exchange, lectin affinity, and size-exclusion chromatography The purified dioxygenase lacked light absorption between 300 and 700 nm. Gel filtration indicated an apparent molecular mass of similar to 135 kDa in 6 M urea and similar to 160 kDa in buffer. SDS-polyacrylamide gel electrophoresis (PAGE) showed that the enzyme was heterogeneous in size and consisted of diffuse protein bands of 100-140 kDa, Treatment with glycosidases for N- and O-linked oligosaccharides yielded a distinct protein of similar to 73 kDa on SDS-PAGE, Atomic emission spectroscopy indicated 0.5-1.0 manganese atom/enzyme molecule. The isoelectric point was similar to 9.7, and the enzyme was active between pH 5 and 11 with optimum activity at pH 7.0. For molecular oxygen, K-m was 30 mu M and V-max 10 mu mol mg(-1)min(-1); for linoleic acid, K-m was 4.4 mu mol, V-max 8.2 mu mol mg(-1)min(-1), and the turnover number 1100 min(-1). The enzyme oxidized linolenic acid twice as fast as Linoleic acid. The main products were identified by mass spectrometry as 13-hydroperoxy-(9Z,11E,15Z)-octadecatrienoic and 13-hydroperoxy-(9Z,11E)-octadecadienoic acids, respectively. After reduction of the hydroperoxide, steric analysis of methyl 13-hydroxyoctadecadienoate by chiral high performance liquid chromatography yielded one enantiomer (>95%), which co-eluted with the R-stereoisomer of methyl (13R,13S)-hydroxyoctadecadienoate. Arachidonic and dihomogammalinolenic acids were not substrates, while oxygen consumption, UV analysis, and mass spectrometric analysis indicated that gamma-linolenic acid was oxygenated both at C-11 and C-13. The enzyme was active at 60 degrees C and after treatment with 6 M urea. It was strongly inhibited by 10-50 mu M concentrations of eicosatetraynoic acid and a lipoxygenase inhibitor (N-(3-phenoxycinnamyl)acetohydroxamic acid), but many other lipoxygenase inhibitors (100 mu M) were without effect. We conclude that, after deglycosylation, the enzyme has the same size on SDS-PAGE as mammalian and marine Lipoxygenases, but it differs from all previously described lipoxygenases in three ways. It is secreted, it forms (13R)-hydroperoxy-(9Z,11E)-octadecadienoic acid, and it contains manganese.	Uppsala Univ, Dept Pharmaceut Biosci, Div Biochem Pharmacol, Uppsala Biomed Ctr, S-75124 Uppsala, Sweden	Uppsala University	Oliw, EH (corresponding author), Uppsala Univ, Dept Pharmaceut Biosci, Div Biochem Pharmacol, Uppsala Biomed Ctr, POB 591, S-75124 Uppsala, Sweden.			Oliw, Ernst/0000-0002-7986-8130				ABELSON PH, 1995, SCIENCE, V269, P1027, DOI 10.1126/science.269.5227.1027; BARRA D, 1985, FEBS LETT, V179, P329, DOI 10.1016/0014-5793(85)80545-7; BOLDT YR, 1995, J BACTERIOL, V177, P1225, DOI 10.1128/jb.177.5.1225-1232.1995; Boldt YR, 1997, BIOCHEMISTRY-US, V36, P2147, DOI 10.1021/bi962362i; BOYINGTON JC, 1993, SCIENCE, V260, P1482, DOI 10.1126/science.8502991; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brash AR, 1997, P NATL ACAD SCI USA, V94, P6148, DOI 10.1073/pnas.94.12.6148; Brash AR, 1996, J BIOL CHEM, V271, P20949, DOI 10.1074/jbc.271.34.20949; BRASH AR, 1987, J BIOL CHEM, V262, P15829; BRODOWSKY ID, 1992, BIOCHIM BIOPHYS ACTA, V1124, P59, DOI 10.1016/0005-2760(92)90126-G; BRODOWSKY ID, 1992, J BIOL CHEM, V267, P14738; BROWNER M, 1997, KEYST C LIP MED JAN, P9; BUNDY GL, 1986, J BIOL CHEM, V261, P747; COREY EJ, 1988, TETRAHEDRON LETT, V29, P2555, DOI 10.1016/S0040-4039(00)86110-9; Funk CD, 1996, BBA-LIPID LIPID MET, V1304, P65, DOI 10.1016/S0005-2760(96)00107-5; FUNK CD, 1993, PROG NUCLEIC ACID RE, V45, P67, DOI 10.1016/S0079-6603(08)60867-3; GARDNER HW, 1989, BIOCHIM BIOPHYS ACTA, V1001, P274, DOI 10.1016/0005-2760(89)90111-2; Hada T, 1997, BBA-LIPID LIPID MET, V1346, P109, DOI 10.1016/S0005-2760(96)00179-8; HAMBERG M, 1967, J BIOL CHEM, V242, P5329; Hamberg M, 1998, J BIOL CHEM, V273, P13080, DOI 10.1074/jbc.273.21.13080; HAMBERG M, 1994, ARCH BIOCHEM BIOPHYS, V309, P77, DOI 10.1006/abbi.1994.1087; HAMBERG M, 1986, BIOCHIM BIOPHYS ACTA, V877, P447, DOI 10.1016/0005-2760(86)90211-0; HAMBERG M, 1993, J CHEM SOC P1, V1, P3065; HAN S, 1995, SCIENCE, V270, P976, DOI 10.1126/science.270.5238.976; HAWKINS DJ, 1987, J BIOL CHEM, V262, P7629; HERMAN RP, 1987, PROSTAGLANDINS, V34, P129; Hornsten L, 1996, ARCH BIOCHEM BIOPHYS, V332, P261, DOI 10.1006/abbi.1996.0341; INGRAM CD, 1988, LIPIDS, V23, P340, DOI 10.1007/BF02537345; Jisaka M, 1997, J BIOL CHEM, V272, P24410, DOI 10.1074/jbc.272.39.24410; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAH MS, 1995, BIOCHEMISTRY-US, V34, P1646, DOI 10.1021/bi00005a021; MEIER B, 1995, BIOCHEM J, V310, P945, DOI 10.1042/bj3100945; MELAN MA, 1993, PLANT PHYSIOL, V101, P441, DOI 10.1104/pp.101.2.441; Minor W, 1996, BIOCHEMISTRY-US, V35, P10687, DOI 10.1021/bi960576u; OLIW EH, 1989, J BIOL CHEM, V264, P17845; OLIW EH, 1989, BIOCHIM BIOPHYS ACTA, V1002, P283, DOI 10.1016/0005-2760(89)90342-1; OLIW EH, 1993, J REPROD FERTIL, V99, P195; OLIW EH, 1993, ARCH BIOCHEM BIOPHYS, V305, P288, DOI 10.1006/abbi.1993.1425; PACEASCIAK CR, 1989, ADV PROSTAGLANDIN TH, V18, P26; PEBERDY JF, 1994, TRENDS BIOTECHNOL, V12, P50, DOI 10.1016/0167-7799(94)90100-7; PEEVER TL, 1989, PLANT PHYSIOL, V90, P867, DOI 10.1104/pp.90.3.867; PENG YL, 1994, J BIOL CHEM, V269, P3755; QUE L, 1981, J BIOL CHEM, V256, P941; Rosahl S, 1996, Z NATURFORSCH C, V51, P123; SCHECHTER G, 1983, INT J BIOCHEM, V15, P1295; SHIBATA D, 1995, J LIPID MEDIAT CELL, V12, P213, DOI 10.1016/0929-7855(95)00020-Q; SIH CJ, 1969, J AM CHEM SOC, V91, P3685, DOI 10.1021/ja01041a065; SkrzypczakJankun E, 1997, PROTEINS, V29, P15, DOI [10.1002/(SICI)1097-0134(199709)29:1&lt;15::AID-PROT2&gt;3.0.CO;2-E, 10.1002/(SICI)1097-0134(199709)29:1<15::AID-PROT2>3.3.CO;2-F]; Steel DJ, 1997, J BIOL CHEM, V272, P18673, DOI 10.1074/jbc.272.30.18673; Su C, 1996, J BIOL CHEM, V271, P14112, DOI 10.1074/jbc.271.24.14112; THEORELL H, 1947, ARCH BIOCHEM, V14, P250; Wang YZ, 1997, PROTEIN EXPRES PURIF, V10, P1, DOI 10.1006/prep.1996.0703; WEETE DJ, 1980, LIPID BIOH FUNGI OTH, P49; WHEELAN P, 1993, BIOL MASS SPECTROM, V22, P465, DOI 10.1002/bms.1200220808; YAMAMOTO H, 1986, J PHYTOPATHOL, V116, P329, DOI 10.1111/j.1439-0434.1986.tb00928.x; YAMAMOTO S, 1992, BIOCHIM BIOPHYS ACTA, V1128, P117, DOI 10.1016/0005-2760(92)90297-9	56	148	154	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					13072	13079		10.1074/jbc.273.21.13072	http://dx.doi.org/10.1074/jbc.273.21.13072			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582345	hybrid			2022-12-27	WOS:000073768500056
J	Zheng, J; Luo, W; Tanzer, ML				Zheng, J; Luo, W; Tanzer, ML			Aggrecan synthesis and secretion - A paradigm for molecular and cellular coordination of multiglobular protein folding and intracellular trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; INTRAMOLECULAR CHAPERONE; CARTILAGE; CHONDROCYTES; EXPRESSION; PATHWAY; HSP27; PROTEOGLYCANS; ORGANIZATION; APOPTOSIS	Each globular domain of exported multiglobular proteins putatively undergoes chaperone surveillance in the endoplasmic reticulum lumen. It is difficult to visualize how surveillance of multiple globular domains might be orchestrated and regulated. Aggrecan core protein has been used as a prototype for this problem by examining transfection of informative constructs into Chinese hamster ovary cells. The salient results are as follows: 1) aggrecan's N-terminal G1 domain is minimally secreted, and its flanking Gels reporter sites are not decorated with glycsoaminoglycan chains; in contrast, its C-terminal G3 domain is readily secreted with flanking GAG chains, and G3 also facilitates G1 secretion; 2) G3 but not G1 can be intracellularly cross-linked to chaperone Hsp25; 3) G3 and Hsp25 remain noncovalently bound and are secreted together when G3 is situated N-terminal to its normal location; 4) exon 15, which encodes the center of G3's C-lectin subdomain, is necessary and sufficient for G3 secretion. A model is proposed in which Hsp25 piggybacks onto nascent G3 in the cytosol during a translocational pause and enters the ER lumen with G3, and once G3 properly folds, Hsp25 releases G3 and recycles to the nucleus while G3 continues to the Gels stacks, providing passage for the entire core protein.	Univ Connecticut, Ctr Hlth, Sch Dent Med, Dept Biostruct & Funct, Farmington, CT 06030 USA	University of Connecticut	Tanzer, ML (corresponding author), Univ Connecticut, Ctr Hlth, Sch Dent Med, Dept Biostruct & Funct, Farmington, CT 06030 USA.							ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; Arrigo AP, 1995, NEUROPATH APPL NEURO, V21, P488, DOI 10.1111/j.1365-2990.1995.tb01094.x; Aspberg A, 1997, P NATL ACAD SCI USA, V94, P10116, DOI 10.1073/pnas.94.19.10116; Brissett NC, 1998, BIOCHEM J, V329, P415; Carelli S, 1997, SCIENCE, V277, P1681, DOI 10.1126/science.277.5332.1681; CASPERS GJ, 1995, J MOL EVOL, V40, P238, DOI 10.1007/BF00163229; CIOCCA DR, 1993, JNCI-J NATL CANCER I, V85, P1558, DOI 10.1093/jnci/85.19.1558; COOPER LF, 1994, J BIOL CHEM, V269, P7869; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; Dudhia J, 1996, BIOCHEM J, V313, P933, DOI 10.1042/bj3130933; ENGEL K, 1991, BIOMED BIOCHIM ACTA, V50, P1065; GAESTEL M, 1993, GENE, V128, P279, DOI 10.1016/0378-1119(93)90575-N; Gething MJ, 1996, CURR BIOL, V6, P1573, DOI 10.1016/S0960-9822(02)70775-6; Golovina VA, 1997, SCIENCE, V275, P1643, DOI 10.1126/science.275.5306.1643; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HARDINGHAM TE, 1994, EUR J CLIN CHEM CLIN, V32, P249; HATORI M, 1995, J BONE MINER RES, V10, P1960, DOI 10.1002/jbmr.5650101216; Hegde RS, 1996, CELL, V85, P217, DOI 10.1016/S0092-8674(00)81098-3; HELM KW, 1993, MOL CELL BIOL, V13, P238, DOI 10.1128/MCB.13.1.238; JAKOB U, 1993, J BIOL CHEM, V268, P1517; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; LI H, 1993, J BIOL CHEM, V268, P23504; Luo W, 1996, J BIOL CHEM, V271, P16447, DOI 10.1074/jbc.271.28.16447; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; Mehlen P, 1997, J BIOL CHEM, V272, P31657, DOI 10.1074/jbc.272.50.31657; MEHLEN P, 1995, BIOCHEM J, V312, P367, DOI 10.1042/bj3120367; Ohyama K, 1997, J BONE MINER RES, V12, P1647, DOI 10.1359/jbmr.1997.12.10.1647; PADLAN EA, 1993, RECEPTOR, V3, P325; Ruoslahti E, 1996, GLYCOBIOLOGY, V6, P489, DOI 10.1093/glycob/6.5.489; SALEQUE S, 1993, GLYCOBIOLOGY, V3, P185, DOI 10.1093/glycob/3.2.185; SANDY JD, 1989, ARCH BIOCHEM BIOPHYS, V271, P300, DOI 10.1016/0003-9861(89)90280-4; SANDY JD, 1989, BIOCHEM J, V258, P875, DOI 10.1042/bj2580875; Schneider R, 1997, NUCLEIC ACIDS RES, V25, P226, DOI 10.1093/nar/25.1.226; SHINDE U, 1993, P NATL ACAD SCI USA, V90, P6924, DOI 10.1073/pnas.90.15.6924; SHINDE U, 1995, J MOL BIOL, V252, P25, DOI 10.1006/jmbi.1995.0472; Teixeira CC, 1996, BIOCHEM J, V314, P21, DOI 10.1042/bj3140021; Vanmuylder N, 1997, ANAT EMBRYOL, V195, P359, DOI 10.1007/s004290050056; VERTEL BM, 1993, J CELL SCI, V104, P939; Wei J, 1996, EXS, V77, P41; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; Zenmyo M, 1996, J PATHOL, V180, P430	41	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					12999	13006		10.1074/jbc.273.21.12999	http://dx.doi.org/10.1074/jbc.273.21.12999			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582335	hybrid			2022-12-27	WOS:000073768500046
J	Moran, GR; Daubner, SC; Fitzpatrick, PF				Moran, GR; Daubner, SC; Fitzpatrick, PF			Expression and characterization of the catalytic core of tryptophan hydroxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER PHENYLALANINE-HYDROXYLASE; RAT TYROSINE-HYDROXYLASE; AMINO-ACID HYDROXYLASES; TETRAHYDROPTERIN OXIDATION; DELETION MUTAGENESIS; IRON; PURIFICATION; MECHANISM; RABBIT; IDENTIFICATION	Wild type rabbit tryptophan hydroxylase (TRH) and two truncated mutant proteins have been expressed in Escherichia coli, The wild type protein was only expressed at low levels, whereas the mutant protein lacking the 101 amino-terminal regulatory domain was predominantly found in inclusion bodies, The protein that also lacked the carboxyl-terminal 28 amino acids, TRH102-416, was expressed as 30% of total cell protein. Analytical ultracentrifugation showed that TRH102-416 was predominantly a monomer in solution. The enzyme exhibited an absolute requirement for iron (ferrous or ferric) for activity and did not turn over in the presence of cobalt or copper. With either phenylalanine or tryptophan as substrate, stoichiometric formation of the 4 alpha-hydroxypterin was found. Steady state kinetic parameters were determined with both of these amino acids using both tetrahydrobiopterin and 6-methyltetrahydropterin.	Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Fitzpatrick, PF (corresponding author), Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA.			Moran, Graham/0000-0002-6807-1302	NIGMS NIH HHS [GM47291] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047291] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCHER MC, 1970, CAN J BIOCHEM CELL B, V48, P278, DOI 10.1139/o70-049; BLOOM LM, 1986, BIOCHEMISTRY-US, V25, P4204, DOI 10.1021/bi00363a006; CASH CD, 1985, EUR J BIOCHEM, V149, P239, DOI 10.1111/j.1432-1033.1985.tb08918.x; Daubner SC, 1997, BIOCHEMISTRY-US, V36, P11574, DOI 10.1021/bi9711137; DAUBNER SC, 1993, PROTEIN SCI, V2, P1452, DOI 10.1002/pro.5560020909; Daubner SC, 1997, ARCH BIOCHEM BIOPHYS, V348, P295, DOI 10.1006/abbi.1997.0435; DICKSON PW, 1994, J BIOL CHEM, V269, P20369; DIX TA, 1987, BIOCHEMISTRY-US, V26, P3354, DOI 10.1021/bi00386a016; DSa CM, 1996, J NEUROCHEM, V67, P900; DSa CM, 1996, J NEUROCHEM, V67, P917; FISHER DB, 1973, J BIOL CHEM, V248, P4300; FISHER DB, 1972, J BIOL CHEM, V247, P5161; FITZPATRICK PF, 1989, BIOCHEM BIOPH RES CO, V161, P211, DOI 10.1016/0006-291X(89)91582-9; FITZPATRICK PF, 1994, J AM CHEM SOC, V116, P1133, DOI 10.1021/ja00082a046; FITZPATRICK PF, 1991, BIOCHEMISTRY-US, V30, P6386, DOI 10.1021/bi00240a006; FITZPATRICK PF, 1988, J BIOL CHEM, V263, P16058; FRIEDMAN PA, 1972, J BIOL CHEM, V247, P4165; FUKAMI MH, 1990, BIOCHEM J, V268, P525, DOI 10.1042/bj2680525; Goodwill KE, 1997, NAT STRUCT BIOL, V4, P578, DOI 10.1038/nsb0797-578; GOTTSCHALL DW, 1982, J BIOL CHEM, V257, P845; GRENETT HE, 1987, P NATL ACAD SCI USA, V84, P5530, DOI 10.1073/pnas.84.16.5530; HAAVIK J, 1987, EUR J BIOCHEM, V168, P21, DOI 10.1111/j.1432-1033.1987.tb13381.x; HAYCOCK JW, 1990, J BIOL CHEM, V265, P11682; Hillas PJ, 1996, BIOCHEMISTRY-US, V35, P6969, DOI 10.1021/bi9606861; HOELDTKE R, 1977, J BIOL CHEM, V252, P3160; HUFTON SE, 1995, BIOCHEM J, V311, P353, DOI 10.1042/bj3110353; KAUFMAN S, 1982, J BIOL CHEM, V257, P4667; KAUFMAN S, 1985, FOLATES PTERINS, V2, P251; KUHN DM, 1980, J BIOL CHEM, V255, P4137; KUHN DM, 1979, J NEUROCHEM, V33, P15, DOI 10.1111/j.1471-4159.1979.tb11700.x; Kumer SC, 1997, J NEUROCHEM, V69, P1738; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAZARUS RA, 1981, BIOCHEMISTRY-US, V20, P6834, DOI 10.1021/bi00527a015; LAZARUS RA, 1982, J AM CHEM SOC, V104, P6869, DOI 10.1021/ja00388a105; LOHSE DL, 1993, BIOCHEM BIOPH RES CO, V197, P1543, DOI 10.1006/bbrc.1993.2653; MAROTA JJA, 1984, BIOCHEMISTRY-US, V23, P1303, DOI 10.1021/bi00301a044; Mockus SM, 1997, BBA-PROTEIN STRUCT M, V1342, P132, DOI 10.1016/S0167-4838(97)00069-1; Mockus SM, 1997, J MOL NEUROSCI, V9, P35, DOI 10.1007/BF02789393; NAKATA H, 1982, EUR J BIOCHEM, V124, P595; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; RAMSEY AJ, 1995, PROTEIN SCI, V4, P2082; Ramsey AJ, 1996, J BIOL CHEM, V271, P24395, DOI 10.1074/jbc.271.40.24395; RIBEIRO P, 1993, J MOL NEUROSCI, V4, P125, DOI 10.1007/BF02782125; SHIMAN R, 1990, J BIOL CHEM, V265, P11633; SHIMAN R, 1985, FOLATES PTERINS, V2, P179; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TIPPER JP, 1994, ARCH BIOCHEM BIOPHYS, V315, P445, DOI 10.1006/abbi.1994.1523; TONG JH, 1975, J BIOL CHEM, V250, P4152; VRANA KE, 1994, LIFE SCI, V55, P1045, DOI 10.1016/0024-3205(94)00639-3; WALLICK DE, 1984, BIOCHEMISTRY-US, V23, P1295, DOI 10.1021/bi00301a043; WRETBORN M, 1980, BIOCHEM BIOPH RES CO, V93, P403, DOI 10.1016/0006-291X(80)91091-8; YANG XJ, 1994, P NATL ACAD SCI USA, V91, P6659, DOI 10.1073/pnas.91.14.6659	52	57	62	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12259	12266		10.1074/jbc.273.20.12259	http://dx.doi.org/10.1074/jbc.273.20.12259			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575176	hybrid			2022-12-27	WOS:000073629800041
J	Ruiz-Garcia, AB; Sendra, R; Galiana, M; Pamblanco, M; Perez-Ortin, JE; Tordera, V				Ruiz-Garcia, AB; Sendra, R; Galiana, M; Pamblanco, M; Perez-Ortin, JE; Tordera, V			HAT1 and HAT2 proteins are components of a yeast nuclear histone acetyltransferase enzyme specific for free histone H4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION INVITRO; SACCHAROMYCES-CEREVISIAE; ACETYLATION; CHROMATIN; PURIFICATION; TRANSCRIPTION; SINGLE; GCN5P	We have analyzed the histone acetyltransferase enzymes obtained from a series of yeast hat1, hat2, and gcn5 single mutants and hat1,hat2 and hat1,gcn5 double mutants. Extracts prepared from both hat1 and hat2 mutant strains specifically lack the following two histone acetyltransferase activities: the well known cytoplasmic type B enzyme and a free histone MB-specific histone acetyltransferase located in the nucleus. The catalytic subunits of both cytoplasmic and nuclear enzymes have identical molecular masses (42 kDa), the same as that of HAT1, However, the cytoplasmic complex has a molecular mass (150 kDa) greater than that of the nuclear complex (110 kDa), The possible functions of HAT1 and HATS in the yeast nucleus are discussed. In addition, we have detected a yeast histone acetyltransferase not previously described, designated HAT-A4, This enzyme is located in the nucleus and is able to acetylate free and nucleosome-bound histones H3 and H4, Finally, we show that the hat1,gcn5 double mutant is viable and does not exhibit a new phenotype, thus suggesting the existence of several histone acetyltransferases with overlapping functions.	Univ Valencia, Dept Bioquim & Biol Mol, E-46100 Burjassot, Spain; CSIC, Inst Agroquim & Tecnol Alimentos, E-46100 Burjassot, Valencia, Spain	University of Valencia; Consejo Superior de Investigaciones Cientificas (CSIC); Instituto de Agroquimica y Tecnologia de los Alimentos (IATA)	Tordera, V (corresponding author), Univ Valencia, Dept Bioquim & Biol Mol, Dr Moliner 50, E-46100 Burjassot, Spain.	vicente.tordera@uv.es	Ruiz-Garcia, Ana Belen/ABB-1915-2021; Sendra, Ramón/K-3549-2014; Pérez-Ortín, José E./K-8582-2014; Pamblanco, Merce/H-6688-2015	Ruiz-Garcia, Ana Belen/0000-0001-5704-2138; Sendra, Ramón/0000-0002-5519-4362; Pérez-Ortín, José E./0000-0002-1992-513X; Pamblanco, Merce/0000-0003-0180-5751				AMATI BB, 1988, CELL, V54, P967, DOI 10.1016/0092-8674(88)90111-0; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CSORDAS A, 1990, BIOCHEM J, V265, P23, DOI 10.1042/bj2650023; Enomoto S, 1997, GENE DEV, V11, P358, DOI 10.1101/gad.11.3.358; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Kaufman PD, 1997, GENE DEV, V11, P345, DOI 10.1101/gad.11.3.345; KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7; KLEFF S, 1995, J BIOL CHEM, V270, P24674, DOI 10.1074/jbc.270.42.24674; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; LOIDL P, 1994, CHROMOSOMA, V103, P441; LOPEZRODAS G, 1989, J BIOL CHEM, V264, P19028; LOPEZRODAS G, 1991, BIOCHEMISTRY-US, V30, P3728, DOI 10.1021/bi00229a020; LOPEZRODAS G, 1985, ARCH BIOCHEM BIOPHYS, V239, P184, DOI 10.1016/0003-9861(85)90825-2; MINGARRO I, 1993, J BIOL CHEM, V268, P13248; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Parthun MR, 1996, CELL, V87, P85, DOI 10.1016/S0092-8674(00)81325-2; RICHMAN R, 1988, J CELL BIOL, V106, P1017, DOI 10.1083/jcb.106.4.1017; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; RuizGarcia AB, 1997, FEBS LETT, V403, P186, DOI 10.1016/S0014-5793(97)00049-5; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; SOBEL RE, 1994, J BIOL CHEM, V269, P18576; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; STILLMAN B, 1986, CELL, V45, P555, DOI 10.1016/0092-8674(86)90287-4; TORDERA V, 1993, EXPERIENTIA, V49, P780, DOI 10.1007/BF01923548; TRAVIS GH, 1984, J BIOL CHEM, V259, P4406; TURNER BM, 1995, SEMIN CELL BIOL, V6, P229, DOI 10.1006/scel.1995.0031; VANHOLDE KE, 1988, CHROMATIN, P111; Verreault A, 1998, CURR BIOL, V8, P96, DOI 10.1016/S0960-9822(98)70040-5; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WEINGAND RC, 1981, J BIOL CHEM, V256, P4578; WEINTRAUB H, 1975, CELL, V6, P83; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	38	84	89	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12599	12605		10.1074/jbc.273.20.12599	http://dx.doi.org/10.1074/jbc.273.20.12599			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575221	hybrid			2022-12-27	WOS:000073629800086
J	Setty, S; Kim, Y; Fields, GB; Clegg, DO; Wayner, EA; Tsilibary, EC				Setty, S; Kim, Y; Fields, GB; Clegg, DO; Wayner, EA; Tsilibary, EC			Interactions of type IV collagen and its domains with human mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE COLLAGEN; EXTRACELLULAR-MATRIX; ALPHA-2-BETA-1 INTEGRIN; SUBSTRATE ADHESION; ENDOTHELIAL-CELLS; LAMININ RECEPTOR; BETA-SUBUNITS; HUMAN-KIDNEY; NC1 DOMAIN; BINDING	Type IV collagen (COL-IV) interacts with a variety of cell types, We present evidence that human mesangial cells (HMC) bind directly to COL-IV, its major triple helical domain, and the main non-collagenous, NC1 domain. A synthetic peptide, HEP-III, and its triple helical counterpart (THP-III), previously reported to be a heparin-binding domain, also promoted approximate to 15% adhesion of HMC. HMC bound to solid-phase-immobilized, intact COL-IV (approximate to 75%), isolated NC1 domain (approximate to 15%), and a pepsin-derived triple helical fragment, which lacks Hep-III (approximate to 65%). We further examined inhibition of HMC adhesion to COL-IV and its domains by using anti-integrin antibodies. Blocking monoclonal antibodies against the alpha(2) integrin resulted in 70% inhibition of adhesion to COL-IV and 80% inhibition to HEP-III. Moderate inhibition was observed on the NC1 and triple helical fragments. Anti-alpha(1) antibodies inhibited the binding of HMC to COL-IV, the NC1, and triple helical domains, but not to peptide HEP-III. Anti-beta(1) antibodies inhibited almost completely (>95%) the adhesion to COL-IV, the NC1, and triple helical fragments; inhibition on HEP-III was approximate to 30%. Affinity chromatography studies with solid-phase HEP-III and mesangial cell lysate also demonstrated the presence of integrin alpha(2) beta(1) along with alpha(3) beta(1). We conclude that alpha(2) beta(1) and alpha(1) beta(1) integrins mediate HMC adhesion to COL-IV. Peptide HEP-III is a major, specific site for alpha(2) integrin-mediated binding of mesangial cells to COL-IV. Both the alpha(2) beta(1) and alpha(1) beta(1) integrins interact with the NC1 and triple helical fragments of COL-IV, Therefore, we demonstrate that several sites for integrin-mediated interactions exist on several collagenous and non-collagenous domains of COL-IV.	Univ Minnesota, Sch Med, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Dept Pediat, Minneapolis, MN 55455 USA; NRCPS Demokritos, Inst Biol, Athens, Greece; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Univ Calif Santa Barbara, Dept Biol Sci, Santa Barbara, CA 93106 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; National Centre of Scientific Research "Demokritos"; Fred Hutchinson Cancer Center; University of California System; University of California Santa Barbara	Setty, S (corresponding author), Univ Minnesota, Sch Med, Dept Lab Med & Pathol, 420 Delaware St SE, Minneapolis, MN 55455 USA.				NIDDK NIH HHS [DK44494, DK39216, DK43574] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK044494, R29DK039216, R01DK043574] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUMAILLEY M, 1986, J CELL BIOL, V103, P1569, DOI 10.1083/jcb.103.4.1569; BARANY G, 1980, PEPTIDES, P1; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CARTER WG, 1990, J CELL BIOL, V110, P1387, DOI 10.1083/jcb.110.4.1387; CLYMAN RI, 1990, ARTERIOSCLEROSIS, V10, P402, DOI 10.1161/01.ATV.10.3.402; COLIGAN JE, 1992, CURRENT PROTOCOLS S, V4; COSIO FG, 1990, KIDNEY INT, V38, P886, DOI 10.1038/ki.1990.287; COSIO FG, 1992, AM J KIDNEY DIS, V20, P294, DOI 10.1016/S0272-6386(12)80705-0; DIPERSIO CM, 1995, J CELL SCI, V108, P2321; EBLE JA, 1993, EMBO J, V12, P4795, DOI 10.1002/j.1460-2075.1993.tb06168.x; FIELDS CG, 1993, BIOPOLYMERS, V33, P1685; GLANVILLE RW, 1981, H-S Z PHYSIOL CHEM, V362, P943, DOI 10.1515/bchm2.1981.362.2.943; HEMLER ME, 1988, IMMUNOL TODAY, V9, P109, DOI 10.1016/0167-5699(88)91280-7; HERBST TJ, 1988, J CELL BIOL, V106, P1365, DOI 10.1083/jcb.106.4.1365; HUMPHRIES MJ, 1993, BIOESSAYS, V15, P391, DOI 10.1002/bies.950150605; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IGNATIUS MJ, 1988, NEURON, V1, P713, DOI 10.1016/0896-6273(88)90170-5; KERJASCHKI D, 1989, AM J PATHOL, V134, P481; KERN A, 1993, EUR J BIOCHEM, V215, P151, DOI 10.1111/j.1432-1033.1993.tb18017.x; KIM Y, 1991, AM J PATHOL, V138, P413; KLEIN G, 1988, CELL, V55, P331, DOI 10.1016/0092-8674(88)90056-6; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; KOLIAKOS GG, 1989, J BIOL CHEM, V264, P2313; KOLIAKOS GG, 1989, J CELL BIOL, V109, P200; KORHONEN M, 1990, J CELL BIOL, V111, P1245, DOI 10.1083/jcb.111.3.1245; KRAMER RH, 1989, J BIOL CHEM, V264, P4684; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LEIN PJ, 1991, J CELL BIOL, V113, P417, DOI 10.1083/jcb.113.2.417; MACKRELL AJ, 1988, P NATL ACAD SCI USA, V85, P2633, DOI 10.1073/pnas.85.8.2633; MCDONALD JA, 1988, ANNU REV CELL BIOL, V4, P183, DOI 10.1146/annurev.cb.04.110188.001151; MENDRICK DL, 1995, LAB INVEST, V72, P367; MENKO AS, 1987, CELL, V51, P51, DOI 10.1016/0092-8674(87)90009-2; MILES AJ, 1994, J BIOL CHEM, V269, P30939; MILES AJ, 1995, J BIOL CHEM, V270, P29047, DOI 10.1074/jbc.270.49.29047; MONTESANO R, 1983, J CELL BIOL, V97, P1648, DOI 10.1083/jcb.97.5.1648; RETTIG WJ, 1984, P NATL ACAD SCI-BIOL, V81, P6437, DOI 10.1073/pnas.81.20.6437; ROMAN J, 1989, J CELL BIOL, V108, P2529, DOI 10.1083/jcb.108.6.2529; RUBIN K, 1981, CELL, V24, P463, DOI 10.1016/0092-8674(81)90337-8; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SANTORO SA, 1988, BIOCHEM BIOPH RES CO, V153, P217, DOI 10.1016/S0006-291X(88)81211-7; SCHUPPAN D, 1980, FEBS LETT, V115, P297, DOI 10.1016/0014-5793(80)81191-4; SETTY S, 1995, CELL ADHES COMMUN, V3, P187, DOI 10.3109/15419069509081286; STAATZ WD, 1990, J BIOL CHEM, V265, P4778; STRIKER GE, 1985, LAB INVEST, V53, P122; SUNG U, 1993, J CELL BIOL, V123, P1255, DOI 10.1083/jcb.123.5.1255; TIMPL R, 1979, EUR J BIOCHEM, V95, P255, DOI 10.1111/j.1432-1033.1979.tb12961.x; TIMPL R, 1981, EUR J BIOCHEM, V120, P203, DOI 10.1111/j.1432-1033.1981.tb05690.x; TSILIBARY EC, 1988, J BIOL CHEM, V263, P4302; TSILIBARY EC, 1986, J CELL BIOL, V103, P2467, DOI 10.1083/jcb.103.6.2467; VANDENBERG P, 1991, J CELL BIOL, V113, P1475, DOI 10.1083/jcb.113.6.1475; VONDERMARK K, 1992, KIDNEY INT, V41, P632, DOI 10.1038/ki.1992.97; WAYNER EA, 1993, J CELL BIOL, V121, P1141, DOI 10.1083/jcb.121.5.1141; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; YURCHENCO PD, 1984, BIOCHEMISTRY-US, V23, P1839, DOI 10.1021/bi00303a040; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767	55	33	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12244	12249		10.1074/jbc.273.20.12244	http://dx.doi.org/10.1074/jbc.273.20.12244			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575174				2022-12-27	WOS:000073629800039
J	Richards, RG; Walker, MP; Sebastian, J; DiAugustine, RP				Richards, RG; Walker, MP; Sebastian, J; DiAugustine, RP			Insulin-like growth factor-1 (IGF-1) receptor-insulin receptor substrate complexes in the uterus - Altered signaling response to estradiol in the IGF-1(m/m) mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; YEAST 2-HYBRID SYSTEM; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; GENE-EXPRESSION; PHOSPHOINOSITIDE 3-KINASE; REGULATORY SUBUNIT; EGF-RECEPTOR; SH3 DOMAINS; P85 SUBUNIT	Some of the actions of estradiol occur through stimulation of growth factor pathways in target organs. Tyrosine-phosphorylated (Tyr(P)) insulin-like growth factor-1 receptor (IGF-1R) and the insulin receptor substrate (IRS)-1 are found in the uterus of mice treated with estradiol, Immunoprecipitates of uterine Tyr(P) IRS-1 contained both p85, the regulatory subunit of phosphatidylinositol (PI) 3-kinase, and PI 3-kinase catalytic activity. Estradiol also stimulated binding of IRS-1 and PI 3-kinase to the IGF-1R, Depletion of IRS-1 from uterine extracts reduced PI 3-kinase associated with the receptor, which suggests that binding of the enzyme to IGF-1R occurs primarily in a complex that also contains IRS-1, Following treatment with estradiol, formation of Tyr(P) IGF-1R, Tyr(P) IRS-1, and the p85 IRS-I complex was very weak in the uterus of IGF-1(m/m) mice, which are severely deficient in IGF-1, This indicated that most, if not all, of the estradiol-stimulated Tyr phosphorylation of uterine IRS-1 originates from ligand activation of IGF-1R kinase. IRS-2 was also Tyr-phosphorylated in the normal uterus and bound more IGF-1R and p85 in response to estradiol; however, a marked decrease in levels of uterine IRS-2 occurred 12-24 h after treatment with estradiol, Since IRS-2 was present in IGF-1R precipitates and a recombinant form of IGF-1 (long R-3 IGF-1) stimulated formation of Tyr(P) IRS-2, hormonal activation of this docking protein probably occurs through the IGF-1R In summary, our findings show that estrogen activation of uterine IGF-1R kinase results in enhanced binding of p85 (PI 3-kinase) to IRS-1 and IRS-S, The formation of one or both of these complexes may be important for the potent mitogenic action of this steroid. That estradiol stimulated a decrease of IRS-2, but not of IRS-1, suggests that these docking proteins have different roles in hormone-induced signaling in the uterus.	NIEHS, Hormones & Canc Grp, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	DiAugustine, RP (corresponding author), NIEHS, Hormones & Canc Grp, Mol Carcinogenesis Lab, NIH, 111 TW Alexander Dr,MD D4-04, Res Triangle Pk, NC 27709 USA.	diaugus2@niehs.nih.gov						Adesanya OO, 1996, J CLIN ENDOCR METAB, V81, P1967, DOI 10.1210/jc.81.5.1967; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; Baker J, 1996, MOL ENDOCRINOL, V10, P903, DOI 10.1210/me.10.7.903; BRIGSTOCK DR, 1991, BAILLIERE CLIN ENDOC, V5, P791, DOI 10.1016/S0950-351X(10)80015-1; Bruning JC, 1997, MOL CELL BIOL, V17, P1513; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; Carpenter CL, 1996, BBA-REV CANCER, V1288, pM11, DOI 10.1016/0304-419X(96)00018-2; CUNHA GR, 1985, CELL DIFFER DEV, V17, P137, DOI 10.1016/0045-6039(85)90481-6; Dey BR, 1996, MOL ENDOCRINOL, V10, P631, DOI 10.1210/me.10.6.631; FRANCIS GL, 1992, J MOL ENDOCRINOL, V8, P213, DOI 10.1677/jme.0.0080213; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; GIUDICE LC, 1994, FERTIL STERIL, V61, P1; Haddad TC, 1997, J BIOL CHEM, V272, P19525, DOI 10.1074/jbc.272.31.19525; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HUYNH HT, 1993, CANCER RES, V53, P5585; Inukai K, 1997, J BIOL CHEM, V272, P7873, DOI 10.1074/jbc.272.12.7873; JOHNSTON JA, 1995, J BIOL CHEM, V270, P28527, DOI 10.1074/jbc.270.48.28527; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; KAPUR S, 1992, BIOL REPROD, V46, P208, DOI 10.1095/biolreprod46.2.208; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAM K, 1994, J BIOL CHEM, V269, P20648; LAMOTHE B, 1995, FEBS LETT, V373, P51, DOI 10.1016/0014-5793(95)01011-3; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; Lembo G, 1996, J CLIN INVEST, V98, P2648, DOI 10.1172/JCI119086; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MURPHY LJ, 1990, ENDOCR REV, V11, P443, DOI 10.1210/edrv-11-3-443; MURPHY LJ, 1987, MOL ENDOCRINOL, V1, P445, DOI 10.1210/mend-1-7-445; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; Ogihara T, 1997, J BIOL CHEM, V272, P12868, DOI 10.1074/jbc.272.19.12868; ONeill TJ, 1996, J BIOL CHEM, V271, P22506, DOI 10.1074/jbc.271.37.22506; PONS S, 1995, MOL CELL BIOL, V15, P4453; POWELLBRAXTON L, 1993, GENE DEV, V7, P2609, DOI 10.1101/gad.7.12b.2609; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Rajkumar K, 1996, ENDOCRINOLOGY, V137, P1258, DOI 10.1210/en.137.4.1258; RICE KM, 1993, BIOCHEM BIOPH RES CO, V190, P961, DOI 10.1006/bbrc.1993.1143; Richards RG, 1996, P NATL ACAD SCI USA, V93, P12002, DOI 10.1073/pnas.93.21.12002; Robertson SA, 1996, BIOL REPROD, V54, P183, DOI 10.1095/biolreprod54.1.183; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SANCHEZMARGALET V, 1995, MOL ENDOCRINOL, V9, P435, DOI 10.1210/me.9.4.435; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SEELY BL, 1995, J BIOL CHEM, V270, P19151, DOI 10.1074/jbc.270.32.19151; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SmithHall J, 1997, BIOCHEMISTRY-US, V36, P8304, DOI 10.1021/bi9630974; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUN XJ, 1992, J BIOL CHEM, V267, P22662; TABIBZADEH S, 1991, ENDOCR REV, V12, P272, DOI 10.1210/edrv-12-3-272; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TANTI JF, 1994, J BIOL CHEM, V269, P6051; TARTAREDECKERT S, 1995, J BIOL CHEM, V270, P23456, DOI 10.1074/jbc.270.40.23456; TartareDeckert S, 1996, ENDOCRINOLOGY, V137, P1019, DOI 10.1210/en.137.3.1019; TOBE K, 1995, J BIOL CHEM, V270, P5698, DOI 10.1074/jbc.270.11.5698; UDDIN S, 1995, J BIOL CHEM, V270, P24627, DOI 10.1074/jbc.270.42.24627; WANG LM, 1995, BLOOD, V86, P4218, DOI 10.1182/blood.V86.11.4218.bloodjournal86114218; Welham MJ, 1997, J BIOL CHEM, V272, P1377, DOI 10.1074/jbc.272.2.1377; Wilden PA, 1996, MOL CELL ENDOCRINOL, V122, P131, DOI 10.1016/0303-7207(96)03872-5; YIN TG, 1995, J BIOL CHEM, V270, P20497, DOI 10.1074/jbc.270.35.20497	64	44	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 8	1998	273	19					11962	11969		10.1074/jbc.273.19.11962	http://dx.doi.org/10.1074/jbc.273.19.11962			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZM408	9565625	hybrid			2022-12-27	WOS:000073536700079
J	Bell, SD; Denu, JM; Dixon, JE; Ellington, AD				Bell, SD; Denu, JM; Dixon, JE; Ellington, AD			RNA molecules that bind to and inhibit the active site of a tyrosine phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; IN-VITRO SELECTION; VIRULENCE DETERMINANT; CRYSTAL-STRUCTURE; SUBSTRATE-SPECIFICITY; PROTEIN; YERSINIA; AFFINITY; LIGANDS; HIV-1	Protein tyrosine phosphatases (PTPases) are essential proteins in many cellular processes. In vitro selection was used to evolve high affinity RNA aptamers to the Yersinia PTPase from two random pools varying in length. Selected aptamers from the two different pools share a 21-residue conserved sequence. They bind to their target with dissociation constants of 18 and 28 nM and inhibit the enzyme with IC50 values of 10 and 35 nM, but do not bind a related PTPase. Modification of the PTPase's active site cysteine with the alkylating agent iodoacetate results in a loss of binding affinity. These experiments suggest that the selected aptamers act by binding at or near the active site and might therefore be useful in defining the interactions between PTPases and their targets.	Indiana Univ, Dept Chem, Bloomington, IN 47405 USA	Indiana University System; Indiana University Bloomington	Ellington, AD (corresponding author), Univ Texas, ICMB A4800-MBB 1-206,26th & Speedway, Austin, TX 78712 USA.	andy.ellington@mail.utexas.edu						BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BASKERVILLE S, 1995, J VIROL, V69, P7559, DOI 10.1128/JVI.69.12.7559-7569.1995; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; BLISKA JB, 1991, P NATL ACAD SCI USA, V88, P1187, DOI 10.1073/pnas.88.4.1187; BOLIN I, 1988, MOL MICROBIOL, V2, P237, DOI 10.1111/j.1365-2958.1988.tb00025.x; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHO HJ, 1993, PROTEIN SCI, V2, P977, DOI 10.1002/pro.5560020611; CONRAD R, 1994, J BIOL CHEM, V269, P32051; CONRAD RC, 1998, NUCL ACID PROTEIN IN, P285; Dunn D, 1996, J BIOL CHEM, V271, P168, DOI 10.1074/jbc.271.1.168; EATON BE, 1995, CHEM BIOL, V2, P633, DOI 10.1016/1074-5521(95)90023-3; Fauman EB, 1996, J BIOL CHEM, V271, P18780, DOI 10.1074/jbc.271.31.18780; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GIVER L, 1993, NUCLEIC ACIDS RES, V21, P5509, DOI 10.1093/nar/21.23.5509; GREEN LS, 1995, CHEM BIOL, V2, P683, DOI 10.1016/1074-5521(95)90032-2; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; HENGGE AC, 1995, BIOCHEMISTRY-US, V34, P13982, DOI 10.1021/bi00043a003; HIPPEN KL, 1993, BIOCHEMISTRY-US, V32, P12405, DOI 10.1021/bi00097a019; Hoffmann KMV, 1997, J BIOL CHEM, V272, P27505, DOI 10.1074/jbc.272.44.27505; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JAEGER JA, 1990, METHODS ENZYMOL, V183, P281; JELLINEK D, 1994, BIOCHEMISTRY-US, V33, P10450, DOI 10.1021/bi00200a028; JELLINEK D, 1995, BIOCHEMISTRY-US, V34, P11363, DOI 10.1021/bi00036a009; JELLINEK D, 1993, P NATL ACAD SCI USA, V90, P1127; JENSEN KB, 1994, J MOL BIOL, V235, P237, DOI 10.1016/S0022-2836(05)80030-0; JOHNSON P, 1992, J BIOL CHEM, V267, P8035; KUBIK MF, 1994, NUCLEIC ACIDS RES, V22, P2619, DOI 10.1093/nar/22.13.2619; LATO SM, 1995, CHEM BIOL, V2, P291, DOI 10.1016/1074-5521(95)90048-9; Osborne SE, 1997, CHEM REV, V97, P349, DOI 10.1021/cr960009c; POT DA, 1992, BIOCHIM BIOPHYS ACTA, V1136, P35, DOI 10.1016/0167-4889(92)90082-M; SCHUBERT HL, 1995, PROTEIN SCI, V4, P1904, DOI 10.1002/pro.5560040924; STONE RL, 1994, J BIOL CHEM, V269, P31323; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; THOMAS KA, 1987, FASEB J, V1, P434, DOI 10.1096/fasebj.1.6.3315806; TIAN Y, 1995, RNA, V1, P317; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; TUERK C, 1993, GENE, V137, P33, DOI 10.1016/0378-1119(93)90248-2; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WEEKS KM, 1995, BIOCHEMISTRY-US, V34, P7728, DOI 10.1021/bi00023a020; Yuvaniyama J, 1996, SCIENCE, V272, P1328, DOI 10.1126/science.272.5266.1328; ZHANG ZY, 1992, J BIOL CHEM, V267, P23759; ZHANG ZY, 1993, BIOCHEMISTRY-US, V32, P9340, DOI 10.1021/bi00087a012; ZHANG ZY, 1994, J BIOL CHEM, V269, P8140; ZHANG ZY, 1993, P NATL ACAD SCI USA, V90, P4446, DOI 10.1073/pnas.90.10.4446; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P2285, DOI 10.1021/bi00174a040; ZHANG ZY, 1994, ADV ENZYMOL RAMB, V68, P1; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P15266, DOI 10.1021/bi00255a007	49	48	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14309	14314		10.1074/jbc.273.23.14309	http://dx.doi.org/10.1074/jbc.273.23.14309			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603938	hybrid			2022-12-27	WOS:000074021500040
J	Porter, DJT				Porter, DJT			A kinetic analysis of the oligonucleotide-modulated ATPase activity of the helicase domain of the NS3 protein from hepatitis C virus - The first cycle of interaction of ATP with the enzyme is unique	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI REP HELICASE; DNA-INDUCED DIMERIZATION; ADENINE-NUCLEOTIDE BINDING; MECHANISM; HYDROLYSIS; MONOMER; PRIMASE	Hepatitis C virus (HCV) helicase (E) formed spectrofluorometrically detectable complexes with a 16-mer and HF16 (a 16-mer with 5'-hexachlorofluoresceinyl moiety). The interaction of helicase with these effecters was investigated by kinetic techniques to determine if the complexes were kinetically competent for ATP hydrolysis. k(cat) values with the 16-mer and HF16 were 2.7 and 36 s(-1), respectively. The maximal value of the rate constant for the approach of an intermediate to the steady-state level has to be at least 4-fold greater than k(cat) for it to be kinetically competent. This value was 1.2 s(-1) with HF16 and "E-ATP" and was 1.82 s(-1) with ATP and E-HF16. These values were too small for formation of these intermediates to be kinetically competent in ATP hydrolysis. Dissociation of "E . HF16 . ATP" (0.34 s(-1)) was also too slow to contribute significantly to catalysis. Furthermore, the K-m of E . HF16 for ATP (3 mu M) was significantly less than the K-m for ATP hydrolysis at a saturating concentration of HF16 (320 mu M). HCV helicase has two nucleotide-binding sites per monomer. If the fluorescence changes observed were associated with structure changes preceding steady-state catalysis (isomerization), pre-steady-state data could be reconciled with the turnover data. Data for the 16-mer yielded similar conclusions.	Glaxo Wellcome, Res Triangle Pk, NC 27709 USA	GlaxoSmithKline	Porter, DJT (corresponding author), Glaxo Wellcome, 5 Moore Dr, Res Triangle Pk, NC 27709 USA.							ABDELMONEM M, 1976, EUR J BIOCHEM, V65, P441, DOI 10.1111/j.1432-1033.1976.tb10359.x; Ali JA, 1997, SCIENCE, V275, P377, DOI 10.1126/science.275.5298.377; AMARATUNGA M, 1993, BIOCHEMISTRY-US, V32, P6815, DOI 10.1021/bi00078a003; BJORNSON KP, 1994, BIOCHEMISTRY-US, V33, P14306, DOI 10.1021/bi00251a044; Bjornson KP, 1996, BIOCHEMISTRY-US, V35, P2268, DOI 10.1021/bi9522763; Bjornson KP, 1996, J MOL BIOL, V263, P411, DOI 10.1006/jmbi.1996.0585; Brosh RM, 1996, J BIOL CHEM, V271, P25360, DOI 10.1074/jbc.271.41.25360; CHAO KL, 1991, J MOL BIOL, V221, P1165, DOI 10.1016/0022-2836(91)80119-F; Dong F, 1996, J BIOL CHEM, V271, P19625, DOI 10.1074/jbc.271.32.19625; GEORGE JW, 1994, J MOL BIOL, V235, P424, DOI 10.1006/jmbi.1994.1003; GravesWoodward KL, 1997, J BIOL CHEM, V272, P4623, DOI 10.1074/jbc.272.7.4623; Hall MC, 1997, J BIOL CHEM, V272, P18614, DOI 10.1074/jbc.272.30.18614; Kayne FJ, 1973, ENZYMES, V8, P353, DOI 10.1016/S1874-6047(08)60071-2; KIM DW, 1995, BIOCHEM BIOPH RES CO, V215, P160, DOI 10.1006/bbrc.1995.2447; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MOORE KJM, 1994, BIOCHEMISTRY-US, V33, P14565, DOI 10.1021/bi00252a024; MOORE KJM, 1994, BIOCHEMISTRY-US, V33, P14550, DOI 10.1021/bi00252a023; NOTARNICOLA SM, 1995, J BIOL CHEM, V270, P20215, DOI 10.1074/jbc.270.34.20215; Porter DJT, 1998, J BIOL CHEM, V273, P7390, DOI 10.1074/jbc.273.13.7390; Preugschat F, 1996, J BIOL CHEM, V271, P24449, DOI 10.1074/jbc.271.40.24449; Raney KD, 1996, J BIOL CHEM, V271, P14074, DOI 10.1074/jbc.271.24.14074; Stole E, 1997, BIOCHEMISTRY-US, V36, P3483, DOI 10.1021/bi962881l; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; WONG I, 1992, J BIOL CHEM, V267, P7596; Wong I, 1997, BIOCHEMISTRY-US, V36, P3115, DOI 10.1021/bi9621977; Wong I, 1996, BIOCHEMISTRY-US, V35, P5726, DOI 10.1021/bi952959i; Yao NH, 1997, NAT STRUCT BIOL, V4, P463, DOI 10.1038/nsb0697-463	30	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14247	14253		10.1074/jbc.273.23.14247	http://dx.doi.org/10.1074/jbc.273.23.14247			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603930	hybrid			2022-12-27	WOS:000074021500032
J	Jenkins, AL; Nannizzi-Alaimo, L; Silver, D; Sellers, JR; Ginsberg, MH; Law, DA; Phillips, DR				Jenkins, AL; Nannizzi-Alaimo, L; Silver, D; Sellers, JR; Ginsberg, MH; Law, DA; Phillips, DR			Tyrosine phosphorylation of the beta(3) cytoplasmic domain mediates integrin-cytoskeletal interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; HUMAN-PLATELETS; SIGNAL-TRANSDUCTION; GLANZMANNS THROMBASTHENIA; MONOCLONAL-ANTIBODIES; FIBRONECTIN RECEPTOR; CELL-ADHESION; GPIIB-IIIA; SUBUNIT; PROTEIN	Tyrosine phosphorylation of the beta(3) subunit of the major platelet integrin alpha(IIb)beta(3) has been shown to occur during thrombin-induced platelet aggregation (1), We now show that a wide variety of platelet stimuli induced beta(3) tyrosine phosphorylation, but that this phosphorylation occurred only following platelet aggregation. Several lines of evidence suggest that the beta(3) cytoplasmic domain tyrosine residues and/or their phosphorylation function to mediate interactions between beta(3) integrins and cytoskeletal proteins. First, phospho-beta(3) was retained preferentially in a Triton X-100 insoluble cytoskeletal fraction of thrombin aggregated platelets. Second, in vitro experiments show that the cytoskeletal protein, myosin, associated in a phosphotyrosine-dependent manner with a diphosphorylated peptide corresponding to residues 740-762 of beta(3), Third, mutation of both tyrosines in the beta(3) cytoplasmic domain to phenylalanines markedly reduced beta(3)-dependent fibrin clot retraction. Thus, our data indicate that platelet aggregation is both necessary and sufficient for beta(3) tyrosine phosphorylation, and this phosphorylation results in the physical linkage of alpha(IIb)beta(3) to the cytoskeleton. We hypothesize that this linkage may involve direct binding of the phosphorylated integrin to the contractile protein myosin in order to mediate transmission of force to the fibrin clot during the process of clot retraction.	COR Therapeut Inc, San Francisco, CA 94080 USA; NHLBI, NIH, Sect Cellular & Mol Motil, Mol Cardiol Lab, Bethesda, MD 20892 USA; Scripps Res Inst, La Jolla, CA 92037 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Scripps Research Institute	Phillips, DR (corresponding author), COR Therapeut Inc, 256 E Grand Ave, San Francisco, CA 94080 USA.	david_phillips@corr.com		Silver, Debra/0000-0001-9189-844X	NHLBI NIH HHS [HL 48728] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048728] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHEN YP, 1994, BLOOD, V84, P1857; CHEN YP, 1995, BLOOD, V86, P2606, DOI 10.1182/blood.V86.7.2606.bloodjournal8672606; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10169, DOI 10.1073/pnas.89.21.10169; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; DANIEL JL, 1992, METHOD ENZYMOL, V215, P78; Davies MJ, 1996, CIRCULATION, V94, P2013, DOI 10.1161/01.CIR.94.8.2013; DORAHY DJ, 1995, BIOCHEM J, V309, P481, DOI 10.1042/bj3090481; FILARDO EJ, 1995, J CELL BIOL, V130, P441, DOI 10.1083/jcb.130.2.441; FOX JEB, 1982, J BIOL CHEM, V257, P4120; FOX JEB, 1993, J BIOL CHEM, V268, P25973; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GEORGE JN, 1990, BLOOD, V75, P1383; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; Knezevic I, 1996, J BIOL CHEM, V271, P16416, DOI 10.1074/jbc.271.27.16416; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; Law DA, 1996, J BIOL CHEM, V271, P10811, DOI 10.1074/jbc.271.18.10811; Lefkovits J, 1996, EUR HEART J, V17, P9; MARGUERIE GA, 1979, J BIOL CHEM, V254, P5357; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MUSTARD JF, 1975, AM J PHYSIOL, V228, P1757, DOI 10.1152/ajplegacy.1975.228.6.1757; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; PHILLIPS DR, 1980, J CELL BIOL, V86, P77, DOI 10.1083/jcb.86.1.77; PHILLIPS DR, 1988, BLOOD, V71, P831; PHILLIPS DR, 1977, J CLIN INVEST, V60, P535, DOI 10.1172/JCI108805; PLAFF M, 1997, J BIOL CHEM, V273, P6104; REDDY KB, 1996, CIRCULATION, V94, P98; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1066; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; SCHOENWAELDER SM, 1994, J BIOL CHEM, V269, P32479; SELLERS JR, 1995, PROTEIN PROFILE, V2, P1323; SELLERS JR, 1988, BIOCHEMISTRY-US, V27, P6977, DOI 10.1021/bi00418a046; SHARMA CP, 1995, J IMMUNOL, V154, P3461; SHATTIL SJ, 1994, CURR OPIN CELL BIOL, V6, P695, DOI 10.1016/0955-0674(94)90096-5; SIMMONS SR, 1997, J LAB CLIN MED, V128, P39; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; YLANNE J, 1995, J BIOL CHEM, V270, P9550; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223	48	110	112	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13878	13885		10.1074/jbc.273.22.13878	http://dx.doi.org/10.1074/jbc.273.22.13878			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593734	hybrid			2022-12-27	WOS:000073919100073
J	Lewis, T; Gueydan, C; Huez, G; Toulme, JJ; Kruys, V				Lewis, T; Gueydan, C; Huez, G; Toulme, JJ; Kruys, V			Mapping of a minimal AU-rich sequence required for lipopolysaccharide-induced binding of a 55-kDa protein on tumor necrosis factor-alpha mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; FACTOR MESSENGER-RNA; 3'-UNTRANSLATED REGION; GM-CSF; DEGRADATION; AUUUA	In monocyte/macrophage cells, the translation of tumor necrosis factor-alpha (TNF-alpha) mRNA is tightly controlled. In unstimulated cells, TNF-alpha mRNA is translationally repressed. However, upon stimulation of the cells with various agents (e.g. lipopolysaccharides (LPS) and viruses), this repression is overcome and translation occurs. The key element in this regulation is the AU-rich sequence present in the 3'-untranslated region of TNF-alpha mRNA, Several groups have described the binding of proteins on AU-rich elements (AREs), We have previously reported the binding of two cytosolic protein complexes (1 and 2) to the TNF-alpha mRNA ARE, one of which (complex 2) is observed only following induction of TNF-alpha production by LPS, In this report, we have demonstrated that complex 1 involves a long fragment of the ARE, whereas the formation of the LPS-inducible complex 2 requires a minimal sequence which corresponds to the nonanucleotide UUAUUUAUU. Furthermore, we show that the RNA-binding protein involved in complex 2 has an apparent molecular mass of 55 kDa, Finally, we tested other AREs for their ability to form com plex 2. We observed that the ARE derived from granulocyte/macrophage colony-stimulating factor mRNA which does contain the nonanucleotide, is able to sustain the LPS-induced binding of the 55-kDa protein. However, c-myc mRNA which does not contain the nonanucleotide, is unable to promote the formation of any LPS-induced complex.	Free Univ Brussels, Chim Biol Lab, B-1640 Rhode St Genese, Belgium; Univ Victor Segalen, INSERM U386, Inst Format & Rech Pathol Infect, F-33076 Bordeaux, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux	Kruys, V (corresponding author), Free Univ Brussels, Chim Biol Lab, 67 Rue Chevaux, B-1640 Rhode St Genese, Belgium.		Kruys, Veronique I/N-6613-2018	Kruys, Veronique/0000-0002-3144-5403; Toulme, Jean-jacques/0000-0002-8432-5034; Gueydan, Cyril/0000-0003-3097-7667				BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; Espel E, 1996, EUR J IMMUNOL, V26, P2417, DOI 10.1002/eji.1830261023; Fu LN, 1997, EMBO J, V16, P4117, DOI 10.1093/emboj/16.13.4117; Gueydan C, 1996, MOL MED, V2, P479, DOI 10.1007/BF03401907; Gueydan C, 1996, MOL MED, V2, P786, DOI 10.1007/BF03401661; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; HAN JH, 1991, BIOCHIM BIOPHYS ACTA, V1090, P22, DOI 10.1016/0167-4781(91)90032-H; Hel Z, 1996, MOL CELL BIOL, V16, P5579; Kern JA, 1997, J IMMUNOL, V158, P1187; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Xu NH, 1997, MOL CELL BIOL, V17, P4611, DOI 10.1128/MCB.17.8.4611	16	40	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13781	13786		10.1074/jbc.273.22.13781	http://dx.doi.org/10.1074/jbc.273.22.13781			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593721	hybrid			2022-12-27	WOS:000073919100060
J	Mallo, GV; Soubeyran, P; Lissitzky, JC; Andre, F; Farnarier, C; Marvaldi, J; Dagorn, JC; Iovanna, JL				Mallo, GV; Soubeyran, P; Lissitzky, JC; Andre, F; Farnarier, C; Marvaldi, J; Dagorn, JC; Iovanna, JL			Expression of the Cdx1 and Cdx2 homeotic genes leads to reduced malignancy in colon cancer-derived cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION	We have previously described an inverse relationship between Cdx1 and Cdx2 mRNA levels and the extent of dysplasia and severity of clinical outcome in colorectal carcinoma, suggesting that altered expression of these genes was associated with colorectal carcinogenesis or tumor progression. To investigate further their involvement in the physiopathology of colorectal cancer, HT29 colon carcinoma cells that show very low Cdx expression were transfected with Cdx1 and/or Cdx2 cDNA to elicit their overexpression, Growth rate, tumorigenicity, resistance to apoptosis, and migration potential of the corresponding cells mere analyzed. Growth rate of cells overexpressing Cdx2 decreased by half, whereas overexpression of Cdx1 had no effect. However, cells overexpressing both Cdxs had a growth rate reduced to 20% of control. In cells overexpressing Cdx1 or Cdx2, tumorigenicity and resistance to apoptosis induced by serum starvation, ceramide, or staurosporine were not changed compared with control cells; yet phorbol ester-stimulated cell migration was decreased by 50%, In cells overexpressing both Cdx1 and Cdx2, tumorigenicity was decreased by 50%, resistance to apoptosis was significantly lowered, and stimulated cell migration was further decreased to 15% of control compared with cells expressing Cdx1 or Cdx2, Finally, cells overexpressing both Cdxs showed strongly decreased Bcl-2 expression, which could account for their increased sensitivity to apoptosis, These findings show that, in HT29 cells, both Cdx1 and Cdx2 genes must be expressed to reduce tumorigenic potential, to increase sensitivity to apoptosis, and to reduce cell migration, suggesting that the two genes control the normal phenotype by independent pathways. This may explain why loss of Cdx1 or Cdx2 expression is associated with tumor development and invasiveness in colorectal tumors.	INSERM, U315, F-13009 Marseille, France; INSERM, U387, Immunol Lab, F-13009 Marseille, France; Univ Aix Marseille 2, Biochim Cellulaire Lab, CNRS, URA 1924,Fac Pharm, F-13385 Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Iovanna, JL (corresponding author), INSERM, U315, 46 Bd Gaye, F-13009 Marseille, France.	iovanna@marseille.inserm.fr	Iovanna, Juan/M-9805-2017; Soubeyran, Philippe/P-1758-2018	Iovanna, Juan/0000-0003-1822-2237; Soubeyran, Philippe/0000-0002-5876-3217				BARBA P, 1993, ADV EXP MED BIOL, V348, P45; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURK RR, 1973, P NATL ACAD SCI USA, V70, P369, DOI 10.1073/pnas.70.2.369; Chariot A, 1996, BIOCHEM BIOPH RES CO, V222, P292, DOI 10.1006/bbrc.1996.0737; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; DEVITA G, 1993, EUR J CANCER, V29A, P887, DOI 10.1016/S0959-8049(05)80432-0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EE HC, 1995, AM J PATHOL, V147, P586; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FRIGERIO JM, 1995, HUM MOL GENET, V4, P37, DOI 10.1093/hmg/4.1.37; Hague A, 1997, INT J CANCER, V72, P898, DOI 10.1002/(SICI)1097-0215(19970904)72:5<898::AID-IJC30>3.0.CO;2-2; KNITTEL T, 1995, DEVELOPMENT, V121, P1077; LICHTY BD, 1995, LEUKEMIA LYMPHOMA, V16, P209, DOI 10.3109/10428199509049759; MALLO GV, 1997, INT J CANCER, V74, P1; Sambrook J., 2002, MOL CLONING LAB MANU; Silberg DG, 1997, GASTROENTEROLOGY, V113, P478, DOI 10.1053/gast.1997.v113.pm9247467; STRACKE ML, 1991, CELL MOTILITY FACTOR; SUBRAMANIAN V, 1995, CELL, V83, P641, DOI 10.1016/0092-8674(95)90104-3; Suh E, 1996, MOL CELL BIOL, V16, P619; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; TIBERIO C, 1994, INT J CANCER, V58, P608, DOI 10.1002/ijc.2910580426; Valente P, 1996, ONCOGENE, V13, P1169; Vider BZ, 1997, BIOCHEM BIOPH RES CO, V232, P742, DOI 10.1006/bbrc.1997.6364	24	155	166	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					14030	14036		10.1074/jbc.273.22.14030	http://dx.doi.org/10.1074/jbc.273.22.14030			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593754	hybrid			2022-12-27	WOS:000073919100093
J	Williams, SC; Du, Y; Schwartz, RC; Weiler, SR; Ortiz, M; Keller, JR; Johnson, PF				Williams, SC; Du, Y; Schwartz, RC; Weiler, SR; Ortiz, M; Keller, JR; Johnson, PF			C/EBP epsilon is a myeloid-specific activator of cytokine, chemokine, and macrophage-colony-stimulating factor receptor genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRANSCRIPTION-FACTOR; FAMILY MEMBERS; NUCLEAR FACTOR; GROWTH-FACTOR; CELL-LINE; EXPRESSION; INTERLEUKIN-6; BINDING; NF-IL6	C/EBP epsilon is a member of the CCAAT/enhancer binding protein family of basic region/leucine zipper transcriptional activators. The C/EBP epsilon protein is highly conserved between rodents and humans, and its domain structure is very similar to C/EBP alpha, In mice C/EBP epsilon mRNA is only detected in hematopoietic tissues, including embryonic liver and adult bone marrow and spleen. Within the hematopoietic system, C/EBP epsilon is expressed primarily in myeloid cells, including promyelocytes, myelomonocytes, and their differentiated progeny. To identify potential functions of C/EBP epsilon, cell lines overexpressing the C/EBP epsilon protein were generated in the P388 lymphoblastic cell line. In contrast to the parental cell line, C/EBPE-expressing cell lines displayed lipopolysaccharide-inducible expression of the interleukin-6 and monocyte chemoattractant protein 1 (MCP-1) genes as well as elevated basal expression of the MIP-1 alpha and MIP-1 beta chemokine genes. In the EML-C1 hematopoietic stem cell line, C/EBP epsilon mRNA levels increased as the cells progressed along the myeloid lineage, just preceding activation of the gene encoding the receptor for macrophage-colony-stimulating factor (M-CSFR). M-CSFR expression was stimulated in C/EBP epsilon-expressing P388 cell lines, when compared with either the parental P388 cells or P388 cell lines expressing either C/EBP alpha or C/EBP beta, These results suggest that C/EBP epsilon may be an important regulator of differentiation of a subset of myeloid cell types and may also participate in the regulation of cytokine gene expression in mature cells.	Texas Tech Univ, Hlth Sci Ctr, Dept Biochem & Cell Biol, Lubbock, TX 79430 USA; Michigan State Univ, Dept Microbiol, E Lansing, MI 48824 USA; Sci Applicat Int Corp, Lab Leukocyte Biol, Div Basic Sci, Frederick, MD 21702 USA; Sci Applicat Int Corp, Intramural Res Support Program, Frederick, MD 21702 USA; NCI, Frederick Canc Res & Dev Ctr, Basic Res Program, Adv Biosci Labs, Frederick, MD 21702 USA	Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Michigan State University; Science Applications International Corporation (SAIC); Science Applications International Corporation (SAIC); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Williams, SC (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Biochem & Cell Biol, 3601 4th St, Lubbock, TX 79430 USA.	cbbscw@ttuhsc.edu	Keller, Jonathan R./O-6677-2018; Johnson, Peter/A-1940-2012	Johnson, Peter/0000-0002-4145-4725				AKIRA S, 1992, CIBA F SYMP, V167, P47; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; Antonson P, 1996, GENOMICS, V35, P30, DOI 10.1006/geno.1996.0319; BRETZ JD, 1994, P NATL ACAD SCI USA, V91, P7306, DOI 10.1073/pnas.91.15.7306; Calkhoven CF, 1996, BIOCHEM J, V317, P329, DOI 10.1042/bj3170329; Cheng T, 1996, P NATL ACAD SCI USA, V93, P13158, DOI 10.1073/pnas.93.23.13158; CHIU CP, 1988, P NATL ACAD SCI USA, V85, P7099, DOI 10.1073/pnas.85.19.7099; Chumakov AM, 1997, MOL CELL BIOL, V17, P1375, DOI 10.1128/MCB.17.3.1375; COOPER CL, 1994, J IMMUNOL, V153, P5049; CUMANO A, 1992, NATURE, V356, P612, DOI 10.1038/356612a0; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GILLIS S, 1980, J EXP MED, V152, P1709, DOI 10.1084/jem.152.6.1709; GROVE M, 1993, MOL CELL BIOL, V13, P5276, DOI 10.1128/MCB.13.9.5276; Hu HM, 1998, J IMMUNOL, V160, P2334; JENKINS NA, 1995, GENOMICS, V28, P333, DOI 10.1006/geno.1995.1150; JOHNSON PF, 1993, MOL CELL BIOL, V13, P6919, DOI 10.1128/MCB.13.11.6919; JOHNSON PF, 1994, LIVER GENE EXPRESSIO, P231; KAWAHARA RS, 1989, J BIOL CHEM, V264, P679; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; MARTIN CA, 1991, CELL IMMUNOL, V135, P245, DOI 10.1016/0008-8749(91)90269-H; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; Nalbant D, 1998, ENDOCRINOLOGY, V139, P272, DOI 10.1210/en.139.1.272; NATSUKA S, 1992, BLOOD, V79, P460; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; *NIH, 1985, PUBL NIH, V8623; ROLLINS BJ, 1988, P NATL ACAD SCI USA, V85, P3738, DOI 10.1073/pnas.85.11.3738; SAWADA M, 1993, NEUROSCI LETT, V160, P131, DOI 10.1016/0304-3940(93)90396-3; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SCOTT LM, 1992, BLOOD, V80, P1725; SCREPANTI I, 1995, EMBO J, V14, P1932, DOI 10.1002/j.1460-2075.1995.tb07185.x; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; Tan S S, 1992, PCR Methods Appl, V2, P137; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; TSAI S, 1994, GENE DEV, V8, P2831, DOI 10.1101/gad.8.23.2831; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P6462, DOI 10.1073/pnas.94.12.6462; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; ZHANG Y, 1993, MOL CELL BIOL, V13, P3831, DOI 10.1128/MCB.13.6.3831; ZHOU LJ, 1995, BLOOD, V86, P3295, DOI 10.1182/blood.V86.9.3295.bloodjournal8693295; ZIPFEL PF, 1989, J IMMUNOL, V142, P1582	43	61	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13493	13501		10.1074/jbc.273.22.13493	http://dx.doi.org/10.1074/jbc.273.22.13493			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593684	hybrid			2022-12-27	WOS:000073919100023
J	Briggs, MW; Burkard, KTD; Butler, JS				Briggs, MW; Burkard, KTD; Butler, JS			Rrp6p, the yeast homologue of the human PM-Scl 100-kDa autoantigen, is essential for efficient 5.8 S rRNA 3 ' end formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-RIBOSOMAL-RNA; SCLERODERMA OVERLAP SYNDROME; SACCHAROMYCES-CEREVISIAE; POLY(A) POLYMERASE; ESCHERICHIA-COLI; PROTEIN; VIRUS; MRP; TRANSFORMATION; AUTOANTIBODIES	The eukaryotic 25 S, 18 S, and 5.8 S rRNAs are synthesized as a single transcript with two internal transcribed spacers (ITS1 and ITS2), which are removed by endo-and exoribonucleolytic steps to produce mature rRNA. Genetic selection for suppressors of a polyadenylation defect yielded two cold-sensitive alleles of a gene that we named RRP6 (ribosomal RNA processing), Molecular cloning of RRP6 revealed its homology to a 100-kDa human, nucleolar PM-Sd autoantigen and to Escherichia coli RNase D, a 3'-5' exoribonuclease, Recessive mutations in rrp6 result in the accumulation of a novel 5.8 S rRNA processing intermediate, called 5.8 S*, which has normal 5' ends, but retains similar to 30 nucleotides of ITS2, Pulse-chase analysis of 5.8 S rRNA processing in an rrp6-strain revealed a precursor-product relationship between 5.8 S* and 5.8 S rRNAs, suggesting that Rrp6p plays a role in the removal of the last 30 nucleotides of ITS2 from 5.8 S precursors. A portion of 5.8 S* rRNA assembles into 60 S ribosomes which form polyribosomes, suggesting that they function in protein synthesis. These findings indicate that Rrp6p plays a role in 5.8 S rRNA 3' end formation, and they identify a functional intermediate in the rRNA processing pathway.	Univ Rochester, Sch Med & Dent, Dept Microbiol & Immunol, Rochester, NY 14618 USA	University of Rochester	Butler, JS (corresponding author), Univ Rochester, Sch Med & Dent, Dept Microbiol & Immunol, 601 Elmwood Ave,Box 672, Rochester, NY 14618 USA.	btlr@uhura.cc.rochester.edu			NIAID NIH HHS [5-T32-AI070362] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALDERUCCIO F, 1991, J EXP MED, V173, P941, DOI 10.1084/jem.173.4.941; BLUTHNER M, 1992, J EXP MED, V176, P973, DOI 10.1084/jem.176.4.973; Briggs MW, 1996, GENETICS, V143, P1149; CAPONIGRO G, 1995, GENE DEV, V9, P2421, DOI 10.1101/gad.9.19.2421; Chamberlain JR, 1996, NUCLEIC ACIDS RES, V24, P3158, DOI 10.1093/nar/24.16.3158; CHU S, 1994, P NATL ACAD SCI USA, V91, P659, DOI 10.1073/pnas.91.2.659; DERBYSHIRE V, 1991, EMBO J, V10, P17, DOI 10.1002/j.1460-2075.1991.tb07916.x; DEUTSCHER MP, 1993, J BACTERIOL, V175, P4577, DOI 10.1128/JB.175.15.4577-4583.1993; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; GE Q, 1992, J CLIN INVEST, V90, P559, DOI 10.1172/JCI115895; GEITZ RD, 1988, GENE, V74, P527; GELPI C, 1990, CLIN EXP IMMUNOL, V81, P59; GUDNY H, 1980, P NATL ACAD SCI USA, V77, P837; Hatfield L, 1996, MOL CELL BIOL, V16, P5830; HENRY Y, 1994, EMBO J, V13, P2452, DOI 10.1002/j.1460-2075.1994.tb06530.x; JOHNSON AW, 1995, MOL CELL BIOL, V15, P2719; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; LINDAHL L, 1992, NUCLEIC ACIDS RES, V20, P295, DOI 10.1093/nar/20.2.295; MASISON DC, 1995, MOL CELL BIOL, V15, P2763; Mian IS, 1997, NUCLEIC ACIDS RES, V25, P3187, DOI 10.1093/nar/25.16.3187; Mitchell P, 1997, CELL, V91, P457, DOI 10.1016/S0092-8674(00)80432-8; Mitchell P, 1996, GENE DEV, V10, P502, DOI 10.1101/gad.10.4.502; MORRISSEY JP, 1995, TRENDS BIOCHEM SCI, V20, P78, DOI 10.1016/S0968-0004(00)88962-8; NICHOLS RC, 1995, GENOMICS, V30, P131, DOI 10.1006/geno.1995.0028; OHTAKE Y, 1995, MOL CELL BIOL, V15, P2772; PATEL D, 1992, MOL CELL BIOL, V12, P3297, DOI 10.1128/MCB.12.7.3297; PIKIELNY CW, 1985, CELL, V41, P119, DOI 10.1016/0092-8674(85)90066-2; PLOTZ PH, 1995, ANN INTERN MED, V122, P715, DOI 10.7326/0003-4819-122-9-199505010-00010; PROWELLER A, 1994, GENE DEV, V8, P2629, DOI 10.1101/gad.8.21.2629; Proweller A, 1997, J BIOL CHEM, V272, P6004, DOI 10.1074/jbc.272.9.6004; REIMER G, 1988, ARTHRITIS RHEUM, V31, P525, DOI 10.1002/art.1780310409; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; RUBIN GM, 1974, EUR J BIOCHEM, V41, P197, DOI 10.1111/j.1432-1033.1974.tb03260.x; SACHS A, 1980, CELL, V58, P857; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHMITT ME, 1993, MOL CELL BIOL, V13, P7935, DOI 10.1128/MCB.13.12.7935; Sherman F., 1986, METHODS YEAST GENETI; SHUAI K, 1991, NUCLEIC ACIDS RES, V19, P5059, DOI 10.1093/nar/19.18.5059; TARGOFF IN, 1985, ARTHRITIS RHEUM, V28, P226, DOI 10.1002/art.1780280221; Venema J, 1996, EMBO J, V15, P5701, DOI 10.1002/j.1460-2075.1996.tb00954.x; Venema J, 1995, YEAST, V11, P1629, DOI 10.1002/yea.320111607; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; ZHANG J, 1988, NUCLEIC ACIDS RES, V16, P6265, DOI 10.1093/nar/16.14.6265	43	241	244	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					13255	13263		10.1074/jbc.273.21.13255	http://dx.doi.org/10.1074/jbc.273.21.13255			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582370	hybrid			2022-12-27	WOS:000073768500081
J	Gatot, JS; Callebaut, I; Mornon, JP; Portetelle, D; Burny, A; Kerkhofs, P; Kettmann, R; Willems, L				Gatot, JS; Callebaut, I; Mornon, JP; Portetelle, D; Burny, A; Kerkhofs, P; Kettmann, R; Willems, L			Conservative mutations in the immunosuppressive region of the bovine leukemia virus transmembrane protein affect fusion but not infectivity in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROPHOBIC CLUSTER-ANALYSIS; EPSTEIN-BARR-VIRUS; IMMUNODEFICIENCY-VIRUS; ENVELOPE GLYCOPROTEIN; INFLUENZA HEMAGGLUTININ; SYNTHETIC PEPTIDE; VIRAL REPLICATION; SIGNALING MOTIF; IN-VIVO; SEQUENCES	Many retroviruses, including bovine leukemia virus (BLV), contain a highly conserved region located about 40 amino acids downstream from the fusion peptide within the sequence of the external domain of the transmembrane (TM) protein. This region is notably thought to be involved in the presentation of the NH2-terminal peptide to allow cell fusion, By using hydrophobic cluster analysis and by analogy with the influenza A hemagglutinin structures, the core of the TM structure including this particular region was predicted to consist, in the BLV and other retroviral envelope proteins, of an alpha-helix followed by a loop region, both docked against a subsequent alpha-helix that forms a triple-stranded coiled coil. The loop region could undergo, as in hemagglutinin, a major refolding into an alpha-helix integrating the coiled coil structure and putting the fusion peptide to one tip of the molecule. Based on this model, we have identified amino acids that may be essential to the BLV TRI structure, and a series of mutations were introduced in the BLV env gene of an infectious molecular clone. A first series of mutations was designed to disturb the coiled coil structure (substitutions with proline residues), whereas others would maintain the general TM structure. When expressed by Semliki Forest virus recombinants, all the mutated envelope proteins were stable and efficiently synthesized in baby hamster kidney cells. Both proline-substituted and conservative mutants were strongly affected in their capacity to fuse to CC81 indicator cells. In addition, it appeared that the integrity of the TRI coiled coil structure is essential for envelope protein multimerization, as analyzed by metrizamide gradient centrifugation, Finally, to gain insight into the role of this coiled coil in the infectious potential of BLV in vivo, the mutated TM genes were introduced in an infectious and pathogenic molecular clone and injected into sheep. It appeared that only the conservative mutations (A60V and A64S) allowed maintenance of viral infectivity in rico, Since these mutations destroyed the ability to induce syncytia, we conclude that efficient fusion capacity of the recombinant envelopes is not a prerequisite for the infectious potential of BLV in vivo. Viral propagation of these mutants was strongly affected in some of the infected sheep. However, the proviral loads within half of the infected animals (2 out of 2 for A60V and 1 out of 4 for A64S) were close to the wild-type levels, In these sheep, it thus appears that the A60V and A64S mutants propagate efficiently despite being unable to induce syncytia in cell culture.	Fac Univ Sci Agron, Unite Biol Mol, B-5030 Gembloux, Belgium; Inst Natl Rech Vet, B-1180 Uccle, Belgium; Univ Paris 06, CNRS UMR7590, LMCP, Equipe Syst Mol & Biol Struct, F-75252 Paris, France	University of Liege; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Sorbonne Universite; Institut de Recherche pour le Developpement (IRD)	Willems, L (corresponding author), Fac Univ Sci Agron, Unite Biol Mol, Ave Marechal Juin 13, B-5030 Gembloux, Belgium.	millems.1@fsagx.ac.be		Willems, Luc/0000-0002-0563-2213				ALBER G, 1993, CURR BIOL, V3, P333, DOI 10.1016/0960-9822(93)90196-U; BEAUFILS P, 1993, EMBO J, V12, P5105, DOI 10.1002/j.1460-2075.1993.tb06205.x; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; Burny A., 1987, ENZOOTIC BOVINE LEUK; CALLEBAUT I, 1994, EUR J BIOCHEM, V222, P405, DOI 10.1111/j.1432-1033.1994.tb18879.x; Callebaut I, 1997, CELL MOL LIFE SCI, V53, P621, DOI 10.1007/s000180050082; CALLEBAUT I, 1994, J COMPUT AID MOL DES, V8, P175, DOI 10.1007/BF00119866; CAMBIER JC, 1995, IMMUNOL TODAY, V16, P110, DOI 10.1016/0167-5699(95)80105-7; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; CHAKRABARTI S, 1990, VIROLOGY, V178, P134, DOI 10.1016/0042-6822(90)90386-6; CHAMBERS P, 1990, J GEN VIROL, V71, P3075, DOI 10.1099/0022-1317-71-12-3075; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; CHERFILS J, 1988, J MOL GRAPH MODEL, V6, P155, DOI 10.1016/0263-7855(88)80068-7; CIANCIOLO GJ, 1985, SCIENCE, V230, P453, DOI 10.1126/science.2996136; Cockerell GL, 1996, BLOOD, V87, P1030, DOI 10.1182/blood.V87.3.1030.bloodjournal8731030; Delamarre L, 1997, J VIROL, V71, P259, DOI 10.1128/JVI.71.1.259-266.1997; DELWART EL, 1990, AIDS RES HUM RETROV, V6, P703, DOI 10.1089/aid.1990.6.703; Denner J, 1996, J ACQ IMMUN DEF SYND, V12, P442, DOI 10.1097/00042560-199608150-00002; Fass D, 1996, NAT STRUCT BIOL, V3, P465, DOI 10.1038/nsb0596-465; GABORIAUD C, 1987, FEBS LETT, V224, P149, DOI 10.1016/0014-5793(87)80439-8; GALLAHER WR, 1989, AIDS RES HUM RETROV, V5, P431, DOI 10.1089/aid.1989.5.431; GREEN PL, 1995, J VIROL, V69, P387, DOI 10.1128/JVI.69.1.387-394.1995; HARAGUCHI S, 1995, IMMUNOL TODAY, V16, P595, DOI 10.1016/0167-5699(95)80083-2; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HELSETH E, 1990, J VIROL, V64, P2416, DOI 10.1128/JVI.64.5.2416-2420.1990; Kettmann R., 1994, The retroviridae: Volume 3, P39; LEMESLEVARLOOT L, 1990, BIOCHIMIE, V72, P555, DOI 10.1016/0300-9084(90)90120-6; LILJESTROM P, 1991, BIO-TECHNOL, V9, P1356, DOI 10.1038/nbt1291-1356; Macosko JC, 1997, J MOL BIOL, V267, P1139, DOI 10.1006/jmbi.1997.0931; MALVOISIN E, 1994, J GEN VIROL, V75, P839, DOI 10.1099/0022-1317-75-4-839; MAMOUN RZ, 1990, J VIROL, V64, P4180, DOI 10.1128/JVI.64.9.4180-4188.1990; PORTETELLE D, 1989, J VIROL METHODS, V23, P211, DOI 10.1016/0166-0934(89)90135-3; PORTETELLE D, 1980, VIROLOGY, V105, P223, DOI 10.1016/0042-6822(80)90169-5; POUMBOURIOS P, 1995, J VIROL, V69, P1209, DOI 10.1128/JVI.69.2.1209-1218.1995; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; Rice N. R., 1987, Enzootic bovine leukosis and bovine leukemia virus, P115; Rosenberg JR, 1997, J VIROL, V71, P7180, DOI 10.1128/JVI.71.10.7180-7186.1997; RUEGG CL, 1989, J VIROL, V63, P3257, DOI 10.1128/JVI.63.8.3257-3260.1989; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; TUCKER SP, 1991, VIROLOGY, V185, P710, DOI 10.1016/0042-6822(91)90542-J; Varmus H. E., 1982, RNA TUMOR VIRUSES, P369; VONECHE V, 1992, P NATL ACAD SCI USA, V89, P3810, DOI 10.1073/pnas.89.9.3810; WATTEL E, 1995, J VIROL, V69, P2863, DOI 10.1128/JVI.69.5.2863-2868.1995; WEIS WI, 1990, J MOL BIOL, V212, P737, DOI 10.1016/0022-2836(90)90234-D; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WILLEMS L, 1993, J VIROL, V67, P4078, DOI 10.1128/JVI.67.7.4078-4085.1993; WILLEMS L, 1995, J VIROL, V69, P4137, DOI 10.1128/JVI.69.7.4137-4141.1995; WILLEMS L, 1994, P NATL ACAD SCI USA, V91, P11532, DOI 10.1073/pnas.91.24.11532; WILLEMS L, 1992, VIROLOGY, V189, P775, DOI 10.1016/0042-6822(92)90604-N; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; WOODCOCK S, 1992, PROTEIN ENG, V5, P629, DOI 10.1093/protein/5.7.629	52	19	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					12870	12880		10.1074/jbc.273.21.12870	http://dx.doi.org/10.1074/jbc.273.21.12870			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582317	hybrid			2022-12-27	WOS:000073768500028
J	Kowaltowski, AJ; Netto, LES; Vercesi, AE				Kowaltowski, AJ; Netto, LES; Vercesi, AE			The thiol-specific antioxidant enzyme prevents mitochondrial permeability transition - Evidence for the participation of reactive oxygen species in this mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLUS PROOXIDANTS; MEMBRANE PERMEABILIZATION; INORGANIC-PHOSPHATE; HYDROGEN-PEROXIDE; CROSS-LINKING; CA2+ IONS; PROTEIN; REDUCTASE; HYDROPEROXIDE; PORES	Mitochondrial swelling and membrane protein thiol oxidation associated with mitochondrial permeability transition induced by Ca2+ and inorganic phosphate are inhibited in a dose-dependent manner either by catalase, the thiol-specific antioxidant enzyme (TSA), a protein recently demonstrated to present thiol peroxidase activity, or ebselen, a selenium-containing heterocycle which also possesses thiol peroxidase activity. This inhibition of mitochondrial permeability transition is due to the removal of mitochondrial-generated H2O2, which can easily diffuse to the extramitochondrial space. Whereas ebselen required the presence of reduced glutathione as a reductant to grant its protective effect, TSA was fully reduced by mitochondrial components. Decrease in the oxygen concentration of the reaction medium also inhibits mitochondrial permeabilization and membrane protein thioloxidation, in a concentration-dependent manner. The results presented in this report confirm that mitochondrial permeability transition induced by Ca2+ and inorganic phosphate is reactive oxygen species-dependent. The possible importance of TSA as an intracellular antioxidant, avoiding the onset of mitochondrial permeability transition, is discussed in the text.	Univ Estadual Campinas, Fac Ciencias Med, Dept Patol Clin, BR-13083970 Campinas, SP, Brazil; Univ Estadual Campinas, Inst Biol, Dept Bioquim, BR-13083970 Campinas, SP, Brazil	Universidade Estadual de Campinas; Universidade de Sao Paulo; Universidade Estadual de Campinas	Kowaltowski, AJ (corresponding author), Univ Estadual Campinas, Fac Ciencias Med, Dept Patol Clin, BR-13083970 Campinas, SP, Brazil.		Vercesi, Aníbal E/C-8767-2012; Kowaltowski, Alicia J/H-8698-2012; Netto, Luis/A-3783-2008	Netto, Luis/0000-0002-4250-9177; Vercesi, Anibal Eugenio/0000-0001-6671-7125				BOVERIS A, 1977, ANAL BIOCHEM, V80, P145, DOI 10.1016/0003-2697(77)90634-0; CASTILHO RF, 1995, FREE RADICAL BIO MED, V18, P479, DOI 10.1016/0891-5849(94)00166-H; Castilho RF, 1996, J BIOENERG BIOMEMBR, V28, P523, DOI 10.1007/BF02110442; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7022, DOI 10.1073/pnas.91.15.7022; FAGIAN MM, 1990, J BIOL CHEM, V265, P19955; GRIFFITHS EJ, 1995, BIOCHEM J, V307, P93, DOI 10.1042/bj3070093; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313, DOI 10.1152/ajpcell.1994.267.2.C313; ISHII T, 1995, BIOCHEM BIOPH RES CO, V216, P970, DOI 10.1006/bbrc.1995.2715; KIM IH, 1989, P NATL ACAD SCI USA, V86, P6018, DOI 10.1073/pnas.86.16.6018; KIM KW, 1988, J BIOL CHEM, V263, P4704; KOWALTOWSKI AJ, 1995, AM J PHYSIOL-CELL PH, V269, pC141, DOI 10.1152/ajpcell.1995.269.1.C141; Kowaltowski AJ, 1997, BBA-BIOENERGETICS, V1318, P395, DOI 10.1016/S0005-2728(96)00111-9; Kowaltowski AJ, 1996, FEBS LETT, V378, P150, DOI 10.1016/0014-5793(95)01449-7; Kowaltowski AJ, 1996, J BIOL CHEM, V271, P2929, DOI 10.1074/jbc.271.6.2929; LEHNINGER AL, 1978, P NATL ACAD SCI USA, V79, P6842; Netto LES, 1996, J BIOL CHEM, V271, P15315, DOI 10.1074/jbc.271.26.15315; Nogoceke E, 1997, BIOL CHEM, V378, P827, DOI 10.1515/bchm.1997.378.8.827; PASTORINO JG, 1993, J BIOL CHEM, V268, P13791; Scorrano L, 1997, J BIOL CHEM, V272, P12295, DOI 10.1074/jbc.272.19.12295; SIES H, 1993, FREE RADICAL BIO MED, V14, P313, DOI 10.1016/0891-5849(93)90028-S; Skulachev VP, 1996, FEBS LETT, V397, P7, DOI 10.1016/0014-5793(96)00989-1; TSUJI K, 1995, BIOCHEM J, V307, P377, DOI 10.1042/bj3070377; VALLE VGR, 1993, ARCH BIOCHEM BIOPHYS, V307, P1, DOI 10.1006/abbi.1993.1551; Vercesi AE, 1997, BIOSCIENCE REP, V17, P43, DOI 10.1023/A:1027335217774; WATABE S, 1994, J BIOCHEM, V115, P648, DOI 10.1093/oxfordjournals.jbchem.a124390; Zamzami N, 1997, J BIOENERG BIOMEMBR, V29, P185, DOI 10.1023/A:1022694131572; Zhang P, 1997, J BIOL CHEM, V272, P30615, DOI 10.1074/jbc.272.49.30615; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	30	154	160	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					12766	12769		10.1074/jbc.273.21.12766	http://dx.doi.org/10.1074/jbc.273.21.12766			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582302	hybrid			2022-12-27	WOS:000073768500013
J	Lan, KL; Sarvazyan, NA; Taussig, R; Mackenzie, RG; DiBello, PR; Dohlman, HG; Neubig, RR				Lan, KL; Sarvazyan, NA; Taussig, R; Mackenzie, RG; DiBello, PR; Dohlman, HG; Neubig, RR			A point mutation in G alpha(o) and G alpha(i1) blocks interaction with regulator of G protein signaling proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; ALPHA-SUBUNITS; C-ELEGANS; INHIBITION; ACTIVATION; MODULATION; HYDROLYSIS; CHANNELS	Regulator of G protein-signaling (RGS) proteins accelerate GTP hydrolysis by G alpha subunits and are thought to be responsible for rapid deactivation of enzymes and ion channels controlled by G proteins, We wanted to identify and characterize G(i)-family alpha subunits that were insensitive to RGS action. Based on a glycine to serine mutation in the yeast G alpha subunit Gpa1(sst) that prevents deactivation by Sst2 (DiBello, P, R,, Garrison, T, R,, Apanovitch, D, M., Hoffman, G,, Shuey, D, J,, Mason, R,, Cockett, M. I., and Dohlman, II, G, (1998) J. Biol Chem. 273, 5780-5784), site-directed mutagenesis of alpha(o) and alpha(i1) was done. G184S alpha(o) and G183S alpha(i1) show kinetics of GDP release and GTP hydrolysis similar to wild type. In contrast, GTP hydrolysis by the G --> S mutant proteins is not stimulated by RGS4 or by a truncated RGS7, Quantitative flow cytometry binding studies show IC50 values of 30 and 96 nM, respectively, for aluminum fluoride-activated wild type alpha(o) and alpha(i1) to compete with fluorescein isothiocyanate-alpha(o) binding to glutathione S-transferase-RGS4, The G --> S mutant proteins showed a greater than 30-100-fold lower affinity for RGS4. Thus, we have defined the mechanism of a point mutation in alpha(o) and alpha(i1) that prevents RGS binding and GTPase activating activity, These mutant subunits should be useful in biochemical or expression studies to evaluate the role of endogenous RGS proteins in G(i) function.	Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med Hypertens, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; Parke Davis Pharmaceut Res Div, Ann Arbor, MI 48105 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Yale University; Pfizer	Neubig, RR (corresponding author), Univ Michigan, Dept Pharmacol, 1301 MSRB III,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	RNeubig@umich.edu		Dohlman, Henrik/0000-0003-2443-0729; Neubig, Richard/0000-0003-0501-0008	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055316, R01GM053645, R29GM055316] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 39561, GM 53645, GM 55316, R01 GM055316] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Apanovitch DM, 1998, BIOCHEMISTRY-US, V37, P4815, DOI 10.1021/bi9729965; ARSHAVSKY VY, 1994, J BIOL CHEM, V269, P19882; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CHAN RK, 1982, MOL CELL BIOL, V2, P21, DOI 10.1128/MCB.2.1.21; CHEN BW, 1994, BIOTECHNIQUES, V17, P657; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; DiBello PR, 1998, J BIOL CHEM, V273, P5780, DOI 10.1074/jbc.273.10.5780; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Doupnik CA, 1997, P NATL ACAD SCI USA, V94, P10461, DOI 10.1073/pnas.94.19.10461; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Druey KM, 1997, P NATL ACAD SCI USA, V94, P12851, DOI 10.1073/pnas.94.24.12851; FREISSMUTH M, 1989, FASEB J, V3, P2125, DOI 10.1096/fasebj.3.10.2546847; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lan KL, 1998, BIOCHEMISTRY-US, V37, P837, DOI 10.1021/bi972122i; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEE E, 1994, METHOD ENZYMOL, V237, P146; Natochin M, 1998, J BIOL CHEM, V273, P4300, DOI 10.1074/jbc.273.8.4300; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; REMMERS AE, 1994, J BIOL CHEM, V269, P13771; Saitoh O, 1997, NATURE, V390, P525, DOI 10.1038/37385; Sarvazyan NA, 1998, J BIOL CHEM, V273, P7934, DOI 10.1074/jbc.273.14.7934; SZABO G, 1989, TRENDS PHARMACOL SCI, P46; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; THOMSEN WJ, 1989, BIOCHEMISTRY-US, V28, P8778, DOI 10.1021/bi00448a015; Wieland T, 1997, J BIOL CHEM, V272, P8853; WU LJ, 1994, MOL BIOL CELL, V5, P691, DOI 10.1091/mbc.5.6.691	38	152	154	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					12794	12797		10.1074/jbc.273.21.12794	http://dx.doi.org/10.1074/jbc.273.21.12794			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582306	hybrid			2022-12-27	WOS:000073768500017
J	Kristupaitis, D; Dibirdik, I; Vassilev, A; Mahajan, S; Kurosaki, T; Chu, A; Tuel-Ahlgren, L; Tuong, D; Pond, D; Luben, R; Uckun, FM				Kristupaitis, D; Dibirdik, I; Vassilev, A; Mahajan, S; Kurosaki, T; Chu, A; Tuel-Ahlgren, L; Tuong, D; Pond, D; Luben, R; Uckun, FM			Electromagnetic field-induced stimulation of Bruton's tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED AGAMMAGLOBULINEMIA; B-CELL DEVELOPMENT; SRC-FAMILY; PHOSPHOLIPASE C-GAMMA-2; OCCUPATIONAL EXPOSURE; CLONAL PROLIFERATION; RECEPTOR; ACTIVATION; PHOSPHORYLATION; APOPTOSIS	Here we present evidence that exposure of DT40 lymphoma B-cells to low energy electromagnetic fields (EMF) results in activation of phospholipase C-gamma 2 (PLC-gamma 2), leading to increased inositol phospholipid turnover. PLC-gamma 2 activation in EMF-stimulated cells is mediated by stimulation of the Bruton's tyrosine kinase (BTK), a member of the Src-related TEC family of protein tyrosine kinases, which acts downstream of LYN kinase and upstream of PLC-gamma 2, B-cells rendered BTK-deficient by targeted disruption of the btk gene did not show enhanced PLC-gamma 2 activation in response to EMF exposure. Introduction of the wild-type (but nota kinase domain mutant) human btk gene into BTK-deficient B-cells restored their EMF responsiveness, Thus, BTK exerts a pivotal and mandatory function in initiation of EMF-induced signaling cascades in B-cells.	Wayne Hughes Inst, St Paul, MN 55113 USA; Univ Minnesota, Biotherapy Program, Minneapolis, MN 55455 USA; Univ Calif Riverside, Div Biomed Sci, Riverside, CA 92521 USA; Kansai Med Univ, Dept Mol Genet, Inst Hepat Res, Moriguchi, Osaka 570, Japan	University of Minnesota System; University of Minnesota Twin Cities; University of California System; University of California Riverside; Kansai Medical University	Uckun, FM (corresponding author), Wayne Hughes Inst, 2665 Long Lake Rd,Suite 330, St Paul, MN 55113 USA.		Kurosaki, Tomohiro/D-1306-2009	Kurosaki, Tomohiro/0000-0002-6352-304X; Uckun, Fatih M./0000-0001-9334-183X	NIEHS NIH HHS [R01-ES-07175] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007175] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Anderson JS, 1996, P NATL ACAD SCI USA, V93, P10966, DOI 10.1073/pnas.93.20.10966; BOLEN JB, 1995, CURR OPIN IMMUNOL, V7, P306, DOI 10.1016/0952-7915(95)80103-0; BRADLEY LAD, 1994, HUM MOL GENET, V3, P79, DOI 10.1093/hmg/3.1.79; CARTWRIGHT RA, 1989, BRIT J CANCER, V60, P649, DOI 10.1038/bjc.1989.332; DEMERS PA, 1991, AM J EPIDEMIOL, V134, P340, DOI 10.1093/oxfordjournals.aje.a116095; Dibirdik I, 1998, J BIOL CHEM, V273, P4035, DOI 10.1074/jbc.273.7.4035; DIBIRDIK I, 1991, BLOOD, V78, P564, DOI 10.1182/blood.V78.3.564.bloodjournal783564; GUENEL P, 1993, BRIT J IND MED, V50, P758; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; Hemmings BA, 1997, SCIENCE, V275, P1899, DOI 10.1126/science.275.5308.1899; Kawakami Y, 1997, P NATL ACAD SCI USA, V94, P3938, DOI 10.1073/pnas.94.8.3938; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; KOBAYASHI H, 1994, ANU RES NAGOYA U HOS, V28, P39; KUROSAKI T, 1995, J EXP MED, V182, P1815, DOI 10.1084/jem.182.6.1815; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; Linet MS, 1997, NEW ENGL J MED, V337, P1, DOI 10.1056/NEJM199707033370101; MAHAJAN S, 1995, MOL CELL BIOL, V15, P5304; NAGAI K, 1995, J BIOL CHEM, V270, P6824, DOI 10.1074/jbc.270.12.6824; Norimura Toshiyuki, 1993, Journal of UOEH, V15, P103; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RAWLINGS DJ, 1994, IMMUNOL REV, V138, P105, DOI 10.1111/j.1600-065X.1994.tb00849.x; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; SAVITZ DA, 1988, AM J EPIDEMIOL, V128, P21, DOI 10.1093/oxfordjournals.aje.a114943; SMITH CIE, 1994, IMMUNOL REV, V138, P159, DOI 10.1111/j.1600-065X.1994.tb00851.x; TAKATA M, 1995, J EXP MED, V182, P907, DOI 10.1084/jem.182.4.907; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; TORNQVIST S, 1991, British Journal of Industrial Medicine, V48, P597; TSUKADA S, 1994, CURR OPIN IMMUNOL, V6, P623, DOI 10.1016/0952-7915(94)90151-1; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; UCKUN FM, 1991, P NATL ACAD SCI USA, V88, P3589, DOI 10.1073/pnas.88.9.3589; UCKUN FM, 1992, P NATL ACAD SCI USA, V89, P9005, DOI 10.1073/pnas.89.19.9005; UCKUN FM, 1995, J BIOL CHEM, V270, P27666, DOI 10.1074/jbc.270.46.27666; UCKUN FM, 1993, J BIOL CHEM, V268, P21172; Uckun FM, 1996, SCIENCE, V273, P1096, DOI 10.1126/science.273.5278.1096; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; VIHINEN M, 1995, IMMUNOL TODAY, V16, P460, DOI 10.1016/0167-5699(95)80027-1; Zhang X R, 1995, Nagoya J Med Sci, V58, P157	40	32	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12397	12401		10.1074/jbc.273.20.12397	http://dx.doi.org/10.1074/jbc.273.20.12397			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575194	hybrid			2022-12-27	WOS:000073629800059
J	Banki, K; Hutter, E; Gonchoroff, NJ; Perl, A				Banki, K; Hutter, E; Gonchoroff, NJ; Perl, A			Molecular ordering in HIV-induced apoptosis - Oxidative stress, activation of caspases, and cell survival are regulated by transaldolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TUMOR-NECROSIS-FACTOR; T-CELLS; N-ACETYLCYSTEINE; TNF RECEPTOR; MONOCLONAL-ANTIBODY; PROTEASE INHIBITORS; ICE/CED-3 PROTEASE; GLUCOSE-METABOLISM; HUMAN-LYMPHOBLASTS	Dysregulated apoptosis may underlie the etiology of T cell depletion by human immunodeficiency virus type 1 (HIV-1). We show that HIV-induced apoptosis is preceded by an exponential increase in reactive oxygen intermediates (ROIs) produced in mitochondria. This leads to caspase-3 activation, phosphatidylserine (PS) externalization, and GSH depletion. Since mitochondrial ROI levels are regulated by the supply of NADPH from the pentose phosphate pathway (PPP), the effect of transaldolase (TAL), a key enzyme of PPP, was investigated. Jurkat and H9 human CD4+ T cells were transfected with TAL expression vectors oriented in the sense or antisense direction. TAL overexpression down-regulated glucose-6-phosphate dehydrogenase activities and GSH levels. Alternatively, decreased TAT, expression upregulated glucose-g-phosphate dehydrogenase activities and GSH levels. HIV-induced 1) mitochondrial ROI production, 2) caspase-3 activation, 3) proteolysis of poly(ADP-ribose) polymerase, and 4) PS externalization were accelerated in cells overexpressing TAL. In contrast, suppression of TAL abrogated these four activities. Thus, susceptibility to HIV-induced apoptosis can be regulated by TAL through controlling the balance between mitochondrial ROI production and the metabolic supply of reducing equivalents by the PPP. The dominant effect of TAL expression on oxidative stress, caspase activation, PS externalization, and cell death suggests that this balance plays a pivotal role in HIV-induced apoptosis.	SUNY Hlth Sci Ctr, Coll Med, Dept Med, Syracuse, NY 13210 USA; SUNY Hlth Sci Ctr, Coll Med, Dept Pathol, Syracuse, NY 13210 USA; SUNY Hlth Sci Ctr, Coll Med, Dept Microbiol & Immunol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Perl, A (corresponding author), SUNY Hlth Sci Ctr, Coll Med, Dept Med, 750 E Adams St, Syracuse, NY 13210 USA.	perla@vax.cs.hscsyr.edu	Hutter, Eliza/A-6766-2009	Perl, Andras/0000-0002-5017-1348	NIDDK NIH HHS [R01 DK 49221] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049221] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMES BN, 1989, FREE RADICAL RES COM, V7, P121, DOI 10.3109/10715768909087933; Aries SP, 1995, J MOL MED-JMM, V73, P591; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; AUKRUST P, 1995, BLOOD, V86, P258, DOI 10.1182/blood.V86.1.258.bloodjournal861258; BANKI K, 1994, J BIOL CHEM, V269, P2847; Banki K, 1996, J BIOL CHEM, V271, P32994, DOI 10.1074/jbc.271.51.32994; BANKI K, 1994, J EXP MED, V180, P1649, DOI 10.1084/jem.180.5.1649; BANKI K, 1994, AIDS RES HUM RETROV, V10, P303, DOI 10.1089/aid.1994.10.303; BAQUER NZ, 1977, DEV MED CHILD NEUROL, V19, P81; BHATNAGAR A, 1990, CIRC RES, V67, P535, DOI 10.1161/01.RES.67.3.535; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BOSS GR, 1984, J BIOL CHEM, V259, P2936; BUHL R, 1989, LANCET, V2, P1294; BUROW S, 1987, EUR J CELL BIOL, V43, P128; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CAPUTO A, 1990, J ACQ IMMUN DEF SYND, V3, P372; CHENG W, 1995, J CLIN INVEST, V96, P2247, DOI 10.1172/JCI118280; Constantini P., 1996, J BIOL CHEM, V271, P6746; COODLEY GO, 1994, J ACQ IMMUN DEF SYND, V7, P681; DROGE W, 1992, IMMUNOL TODAY, V13, P211, DOI 10.1016/0167-5699(92)90156-2; Ehret A, 1996, J VIROL, V70, P6502, DOI 10.1128/JVI.70.9.6502-6507.1996; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; FREDRIKSSON R, 1991, VIROLOGY, V181, P55, DOI 10.1016/0042-6822(91)90469-R; Galera RML, 1996, CLIN CHIM ACTA, V254, P63, DOI 10.1016/0009-8981(96)06366-8; Glynn JM, 1996, J IMMUNOL, V157, P2754; GORNY MK, 1989, P NATL ACAD SCI USA, V86, P1624, DOI 10.1073/pnas.86.5.1624; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HAMILOS DL, 1985, J IMMUNOL, V135, P2740; HEINRICH PC, 1976, CANCER RES, V36, P3189; HELD KD, 1993, RADIAT RES, V134, P383, DOI 10.2307/3578201; HENNET T, 1993, BIOCHEM J, V289, P587, DOI 10.1042/bj2890587; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; JACOBSON S, 1963, J COMP NEUROL, V121, P5, DOI 10.1002/cne.901210103; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KARACOSTAS V, 1989, P NATL ACAD SCI USA, V86, P8964, DOI 10.1073/pnas.86.22.8964; KELSO TB, 1989, AM J PHYSIOL, V257, pE885, DOI 10.1152/ajpendo.1989.257.6.E885; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; LAHDEVIRTA J, 1988, AM J MED, V85, P289, DOI 10.1016/0002-9343(88)90576-1; LAMARRE D, 1988, BIOCHIM BIOPHYS ACTA, V950, P147, DOI 10.1016/0167-4781(88)90007-3; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; LOS M, 1995, EUR J IMMUNOL, V25, P159, DOI 10.1002/eji.1830250127; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lutz NW, 1997, AIDS, V11, P147, DOI 10.1097/00002030-199702000-00003; MALORNI W, 1993, FEBS LETT, V327, P75, DOI 10.1016/0014-5793(93)81043-Y; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Mayes P., 1993, HARPERS BIOCH, P201; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; NAGY K, 1994, J VIROL, V68, P757, DOI 10.1128/JVI.68.2.757-765.1994; Ni TC, 1996, J BIOL CHEM, V271, P7927, DOI 10.1074/jbc.271.14.7927; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NOVELLO F, 1968, BIOCHEM J, V107, P775, DOI 10.1042/bj1070775; Ohnimus H, 1997, J IMMUNOL, V159, P5246; ORAVECZ T, 1993, AIDS RES HUM RETROV, V9, P945, DOI 10.1089/aid.1993.9.945; Orlinick JR, 1997, J BIOL CHEM, V272, P28889, DOI 10.1074/jbc.272.46.28889; Packham G, 1996, J IMMUNOL, V156, P2792; Paxton WA, 1996, AIDS RES HUM RETROV, V12, P1203, DOI 10.1089/aid.1996.12.1203; PETIT PX, 1990, EUR J BIOCHEM, V194, P389, DOI 10.1111/j.1432-1033.1990.tb15632.x; PILZ RB, 1984, J BIOL CHEM, V259, P2927; PONTREMOLI S, 1961, P NATL ACAD SCI USA, V47, P1942, DOI 10.1073/pnas.47.12.1942; ROSA LFBPC, 1993, PHYSIOL BEHAV, V53, P651, DOI 10.1016/0031-9384(93)90169-G; Rottenberg DA, 1996, J NUCL MED, V37, P1133; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; RUDACK D, 1971, J BIOL CHEM, V246, P1249; SARAFIAN TA, 1994, FREE RADICAL RES, V21, P1, DOI 10.3109/10715769409056549; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; Sharpstone DR, 1996, AIDS, V10, P1377, DOI 10.1097/00002030-199610000-00010; Sorbara LR, 1996, J VIROL, V70, P7275, DOI 10.1128/JVI.70.10.7275-7279.1996; SPOLARICS Z, 1991, BIOCHEM J, V278, P515, DOI 10.1042/bj2780515; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; STARK KL, 1989, BIOCHEM PHARMACOL, V38, P2685, DOI 10.1016/0006-2952(89)90555-8; STEIMER KS, 1986, VIROLOGY, V150, P283, DOI 10.1016/0042-6822(86)90289-8; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; TANNER MK, 1993, CYTOMETRY, V14, P59, DOI 10.1002/cyto.990140111; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; TUTTLE SW, 1992, INT J RADIAT ONCOL, V22, P671, DOI 10.1016/0360-3016(92)90500-H; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; VENKATARAMAN R, 1961, J BIOL CHEM, V236, P1876; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; WITSCHI A, 1995, AIDS RES HUM RETROV, V11, P141, DOI 10.1089/aid.1995.11.141; WOOD T, 1985, PENTOSE PHOSPHATE PA; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YONEHARA S, 1994, INT IMMUNOL, V6, P1849, DOI 10.1093/intimm/6.12.1849; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	100	98	104	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 8	1998	273	19					11944	11953		10.1074/jbc.273.19.11944	http://dx.doi.org/10.1074/jbc.273.19.11944			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZM408	9565623	hybrid			2022-12-27	WOS:000073536700077
J	Zhou, M; Demo, SD; McClure, TN; Crea, R; Bitler, CM				Zhou, M; Demo, SD; McClure, TN; Crea, R; Bitler, CM			A novel splice variant of the cell death-promoting protein BAX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 RELATED GENE; IN-VIVO; MITOCHONDRIAL-MEMBRANES; ENDOPLASMIC-RETICULUM; ANTIOXIDANT PATHWAY; CONSERVED DOMAINS; APOPTOSIS; SURVIVAL; HETERODIMERIZATION; PHOSPHORYLATION	Cell death plays an important role in a number of physiological processes in all complex multicellular organisms. One of the molecules that regulates this process is BAX, an integral membrane protein, that promotes apoptosis. The function of BAX is countered by BCL-2 and BCL-X-L. The differential expression of these proteins can influence the ability of the cell to die or survive. In this paper, we describe the cloning, biochemical, and functional characterization of a novel splice isoform of BAX, called BAX-omega. Transient overexpression of BAX-omega protein potentiates cell death at levels comparable to that of BAX-alpha overexpression.	Neurex Corp, Dept Cell Biol, Menlo Pk, CA 94025 USA		Bitler, CM (corresponding author), Neurex Corp, Dept Cell Biol, Menlo Pk, CA 94025 USA.							AKAO Y, 1994, CANCER RES, V54, P2468; APTE SS, 1995, GENOMICS, V26, P592, DOI 10.1016/0888-7543(95)80180-T; Blagosklonny MV, 1996, CANCER RES, V56, P1851; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; CHOI SS, 1995, ONCOGENE, V11, P1693; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Das R, 1996, ONCOGENE, V12, P947; DAVIES AM, 1995, TRENDS NEUROSCI, V18, P355, DOI 10.1016/0166-2236(95)93928-Q; Diaz JL, 1997, J BIOL CHEM, V272, P11350; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GONZALEZGARCIA M, 1995, P NATL ACAD SCI USA, V92, P4304, DOI 10.1073/pnas.92.10.4304; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; HARPER JF, 1984, COMPUT BIOL MED, V14, P437, DOI 10.1016/0010-4825(84)90044-1; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; Lawrence MS, 1996, J NEUROSCI, V16, P486; LIN EY, 1993, J IMMUNOL, V151, P1979; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; NGUYEN M, 1994, J BIOL CHEM, V269, P16521; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; REED JC, 1990, MOL CELL BIOL, V10, P4370, DOI 10.1128/MCB.10.8.4370; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; REED JC, 1988, NATURE, V336, P259, DOI 10.1038/336259a0; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; TANAKA S, 1993, J BIOL CHEM, V268, P10920; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P4304; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; ZEHAVA CL, 1990, J BIOL CHEM, V265, P4929; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; Zha HB, 1996, MOL CELL BIOL, V16, P6494	42	47	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 8	1998	273	19					11930	11936		10.1074/jbc.273.19.11930	http://dx.doi.org/10.1074/jbc.273.19.11930			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZM408	9565621	hybrid			2022-12-27	WOS:000073536700075
J	Charpentier, S; Amiche, M; Mester, J; Vouille, V; Le Caer, JP; Nicolas, P; Delfour, A				Charpentier, S; Amiche, M; Mester, J; Vouille, V; Le Caer, JP; Nicolas, P; Delfour, A			Structure, synthesis, and molecular cloning of dermaseptins B, a family of skin peptide antibiotics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-POSITIVE BACTERIA; DELTA-OPIOID RECEPTORS; FROG-SKIN; ANTIMICROBIAL PEPTIDES; DEFENSIVE PEPTIDES; AMPHIBIAN SKIN; RANA-ESCULENTA; HIGH-AFFINITY; SEQUENCE; DERMORPHIN	Analysis of antimicrobial activities that are present in the skin secretions of the South American frog Phyllomedusa bicolor revealed six polycationic (lysine-rich) and amphipathic alpha-helical peptides, 24-33 residues long, termed dermaseptins B1 to B6, respectively, Prepro-dermaseptins B all contain an almost identical signal peptide, which is followed by a conserved acidic propiece, a processing signal Lys-Arg, and a dermaseptin progenitor sequence. The 22-residue signal peptide plus the first 3 residues of the acidic propiece are encoded by conserved nucleotides encompassed by the first coding exon of the dermaseptin genes. The 25-residue amino-terminal region of prepro-dermaseptins B shares 50% identity with the corresponding region of precursors for D-amino acid containing opioid peptides or for antimicrobial peptides originating from the skin of distantly related frog species. The remarkable similarity found between prepro-proteins that encode end products with strikingly different sequences, conformations, biological activities and modes of action suggests that the corresponding genes have evolved through dissemination of a conserved "secretory cassette" exon.	Univ Paris 07, Inst Jacques Monod, Lab Bioactivat Peptides, F-75251 Paris 05, France; INSERM, U55, F-75571 Paris, France; ESPCI, Lab Neurobiol & Divers Cellulaire, CNRS, URA 2054, F-75231 Paris 05, France	UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI)	Delfour, A (corresponding author), Univ Paris 07, Inst Jacques Monod, Lab Bioactivat Peptides, 2 Pl Jussieu, F-75251 Paris 05, France.		Nicolas, Pierre/C-7908-2009; AMICHE, Mohamed/R-3684-2018					AMICHE M, 1994, J BIOL CHEM, V269, P17847; AMICHE M, 1993, BIOCHEM BIOPH RES CO, V191, P983, DOI 10.1006/bbrc.1993.1314; BIERBAUM G, 1993, ZBL BAKT-INT J MED M, V278, P1; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; BRADBURY AF, 1991, TRENDS BIOCHEM SCI, V16, P112, DOI 10.1016/0968-0004(91)90044-V; BUCHOU T, 1989, EXP CELL RES, V182, P129, DOI 10.1016/0014-4827(89)90285-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DALY JW, 1992, P NATL ACAD SCI USA, V89, P10960, DOI 10.1073/pnas.89.22.10960; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; ERSPAMER V, 1989, P NATL ACAD SCI USA, V86, P5188, DOI 10.1073/pnas.86.13.5188; Fleury Y, 1996, J BIOL CHEM, V271, P14421, DOI 10.1074/jbc.271.24.14421; GRAY HE, 1987, EXP CELL RES, V169, P95, DOI 10.1016/0014-4827(87)90228-X; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; James R, 1992, BACTERIOCINS MICROCI; JUNG G, 1991, ANGEW CHEM INT EDIT, V30, P1051, DOI 10.1002/anie.199110513; KLAENHAMMER TR, 1993, FEMS MICROBIOL REV, V12, P39, DOI 10.1111/j.1574-6976.1993.tb00012.x; KOLTER R, 1992, ANNU REV MICROBIOL, V46, P141, DOI 10.1146/annurev.mi.46.100192.001041; KREIL G, 1989, EUR J PHARMACOL, V162, P123, DOI 10.1016/0014-2999(89)90611-0; LAZARUS LH, 1989, J BIOL CHEM, V264, P3047; LAZARUS LH, 1993, PROG NEUROBIOL, V41, P473, DOI 10.1016/0301-0082(93)90027-P; MONTECUCCHI PC, 1981, INT J PEPT PROT RES, V17, P275; MOR A, 1994, BIOCHEMISTRY-US, V33, P6642, DOI 10.1021/bi00187a034; MOR A, 1994, J BIOL CHEM, V269, P31635; MOR A, 1994, EUR J BIOCHEM, V219, P145, DOI 10.1111/j.1432-1033.1994.tb19924.x; MOR A, 1991, BIOCHEMISTRY-US, V30, P8824, DOI 10.1021/bi00100a014; MORIKAWA N, 1992, BIOCHEM BIOPH RES CO, V189, P184, DOI 10.1016/0006-291X(92)91542-X; NICOLAS P, 1995, ANNU REV MICROBIOL, V49, P277, DOI 10.1146/annurev.mi.49.100195.001425; PARK JM, 1995, BBA-GENE STRUCT EXPR, V1264, P23, DOI 10.1016/0167-4781(95)00149-B; PARK JM, 1994, BIOCHEM BIOPH RES CO, V205, P948, DOI 10.1006/bbrc.1994.2757; RICHTER K, 1990, P NATL ACAD SCI USA, V87, P4836, DOI 10.1073/pnas.87.12.4836; RICHTER K, 1987, SCIENCE, V238, P200, DOI 10.1126/science.3659910; SAGAN S, 1989, J BIOL CHEM, V264, P17100; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMMACO M, 1993, FEBS LETT, V324, P159, DOI 10.1016/0014-5793(93)81384-C; SIMMACO M, 1994, J BIOL CHEM, V269, P11956; Simmaco M, 1996, EUR J BIOCHEM, V242, P788, DOI 10.1111/j.1432-1033.1996.0788r.x; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; Vouille V, 1997, FEBS LETT, V414, P27, DOI 10.1016/S0014-5793(97)00972-1; WILBUR WJ, 1983, P NATL ACAD SCI-BIOL, V80, P726, DOI 10.1073/pnas.80.3.726; ZAVA DT, 1977, SCIENCE, V196, P663, DOI 10.1126/science.193182	41	93	102	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14690	14697		10.1074/jbc.273.24.14690	http://dx.doi.org/10.1074/jbc.273.24.14690			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614066	hybrid			2022-12-27	WOS:000074160400008
J	Rosen, H; Reshef, A; Maeda, N; Lippoldt, A; Shpizen, S; Triger, L; Eggertsen, G; Bjorkhem, I; Leitersdorf, E				Rosen, H; Reshef, A; Maeda, N; Lippoldt, A; Shpizen, S; Triger, L; Eggertsen, G; Bjorkhem, I; Leitersdorf, E			Markedly reduced bile acid synthesis but maintained levels of cholesterol and vitamin D metabolites in mice with disrupted sterol 27-hydroxylase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HMG-COA REDUCTASE; DILUTION MASS-SPECTROMETRY; CAUSES CEREBROTENDINOUS XANTHOMATOSIS; PREMATURE TERMINATION CODON; RAT-LIVER; MITOCHONDRIAL CYTOCHROME-P-450; BIOSYNTHETIC ENZYME; MOLECULAR-GENETICS; MESSENGER-RNA; SERUM LEVELS	Sterol 27-hydroxylase is important for the degradation of the steroid side chain in conversion of cholesterol into bile acids and has been ascribed a regulatory role in cholesterol homeostasis. Its deficiency causes the autosomal recessive disease cerebrotendinous xanthomatosis (CTX), characterized by progressive dementia, xanthomatosis, and accelerated atherosclerosis. Mice with a disrupted cyp27 (cyp27(-/-)) had normal plasma levels of cholesterol, retinol, tocopherol, and 1,25-dihydroxyvitamin D. Excretion of fecal bile acids was decreased (<20% of normal), and formation of bile acids from tritium-labeled 7 alpha-hydroxycholesterol was less than 15% of normal. Compensatory upregulation of hepatic cholesterol 7 alpha-hydroxylase and hydroxymethylglutaryl-CoA reductase (9- and 2-3-fold increases in mRNA levels, respectively) was found. No CTX-related pathological abnormalities were observed. In CTX, there is an increased formation of 25-hydroxylated bile alcohols and cholestanol. In bile and feces of the cyp27(-/-) mice only traces of bile alcohols were found, and there was no cholestanol accumulation. It is evident that sterol 27-hydroxylase is more important for bile acid synthesis in mice than in humans. The results do not support the contention that 27-hydroxylated steroids are critical for maintenance of cholesterol homeostasis or levels of vitamin D metabolites in the circulation.	Hadassah Univ Hosp, Dept Med, Ctr Res Prevent & Treatment Atherosclerosis, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Fac Med, Dept Mol Virol, Jerusalem, Israel; Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; Max Delbruck Ctr Mol Med, Dept Nephrol Hypertens & Genet, D-13122 Berlin, Germany; Huddinge Univ Hosp, Karolinska Inst, Dept Med Lab Sci & Technol, Div Clin Chem, S-14186 Huddinge, Sweden	Hebrew University of Jerusalem; Hebrew University of Jerusalem; University of North Carolina; University of North Carolina Chapel Hill; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Karolinska Institutet	Leitersdorf, E (corresponding author), Hadassah Univ Hosp, Dept Med, Ctr Res Prevent & Treatment Atherosclerosis, IL-91120 Jerusalem, Israel.			Bjorkhem, Ingemar/0000-0002-0575-9425; Bjorkhem, Ingemar/0000-0001-6087-9190	NHLBI NIH HHS [HL42630] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL042630, R01HL042630] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKERLUND JE, 1990, J LIPID RES, V31, P2159; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; AXEN E, 1994, P NATL ACAD SCI USA, V91, P10014, DOI 10.1073/pnas.91.21.10014; BECK E, 1982, GENE, V19, P327, DOI 10.1016/0378-1119(82)90023-3; BELSEY R, 1974, AM J MED, V57, P50, DOI 10.1016/0002-9343(74)90767-0; BERGINER VM, 1989, NEUROL CLIN, V7, P55, DOI 10.1016/S0733-8619(18)30828-4; BJORKHEM I, 1979, BIOCHEM BIOPH RES CO, V90, P615, DOI 10.1016/0006-291X(79)91279-8; BJORKHEM I, 1975, J CLIN INVEST, V55, P478, DOI 10.1172/JCI107954; BJORKHEM I, 1973, EUR J BIOCHEM, V36, P201, DOI 10.1111/j.1432-1033.1973.tb02902.x; BJORKHEM I, 1987, J LIPID RES, V28, P889; BJORKHEM I, 1983, SCAND J CLIN LAB INV, V43, P163, DOI 10.3109/00365518309168239; BJORKHEM I, 1992, J LIPID RES, V33, P455; BJORKHEM I, 1987, J LIPID RES, V28, P1137; BJORKHEM I, 1974, CLIN CHIM ACTA, V54, P185, DOI 10.1016/0009-8981(74)90236-8; BJORKHEM I, 1994, P NATL ACAD SCI USA, V91, P8592, DOI 10.1073/pnas.91.18.8592; BJORKHEM I, 1994, METABOLIC BASIS INHE, P2073; CALI JJ, 1991, J BIOL CHEM, V266, P7774; CALI JJ, 1991, J BIOL CHEM, V266, P7779; CATAGNINI GL, 1983, CLIM CHEM, V29, P708; DANIELSS.H, 1966, J BIOL CHEM, V241, P1449; DUANE WC, 1988, J CLIN INVEST, V82, P82, DOI 10.1172/JCI113605; DUANE WC, 1988, HEPATOLOGY, V8, P613, DOI 10.1002/hep.1840080329; DZELETOVIC S, 1995, ANAL BIOCHEM, V225, P73, DOI 10.1006/abio.1995.1110; EGESTAD B, 1985, SCAND J CLIN LAB INV, V45, P443, DOI 10.3109/00365518509155241; GEHRING MR, 1987, J BIOL CHEM, V262, P446; GONZALEZ FJ, 1989, PHARMACOL REV, V40, P243; HOLLIS BW, 1986, CLIN CHEM, V32, P2060; JAVITT NB, 1990, J LIPID RES, V31, P1527; KIM KS, 1994, J LIPID RES, V35, P1031; LEITERSDORF E, 1994, AM J HUM GENET, V55, P907; LEITERSDORF E, 1993, J CLIN INVEST, V91, P2488, DOI 10.1172/JCI116484; LINDBACK B, 1987, CLIN CHEM, V33, P1226; Lund E, 1996, ARTERIOSCL THROM VAS, V16, P208, DOI 10.1161/01.ATV.16.2.208; LUND E, 1989, SCAND J CLIN LAB INV, V49, P165, DOI 10.3109/00365518909105417; LUND E, 1992, J BIOL CHEM, V267, P25092; LUND E, 1995, ACCOUNTS CHEM RES, V28, P241, DOI 10.1021/ar00054a001; Lutjohann D, 1996, P NATL ACAD SCI USA, V93, P9799, DOI 10.1073/pnas.93.18.9799; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MEINER V, 1994, HUM MOL GENET, V3, P193, DOI 10.1093/hmg/3.1.193; MEINER V, 1994, NEUROLOGY, V44, P288, DOI 10.1212/WNL.44.2.288; NAKASHIMA N, 1994, J LIPID RES, V35, P663; OFTEBRO H, 1980, J CLIN INVEST, V65, P1418, DOI 10.1172/JCI109806; OHYAMA Y, 1991, J BIOCHEM-TOKYO, V109, P389, DOI 10.1093/oxfordjournals.jbchem.a123391; PIEDRAHITA JA, 1992, P NATL ACAD SCI USA, V89, P4471, DOI 10.1073/pnas.89.10.4471; RESHEF A, 1994, J LIPID RES, V35, P478; Sambrook J., 2002, MOL CLONING LAB MANU; Schwarz M, 1996, J BIOL CHEM, V271, P18024, DOI 10.1074/jbc.271.30.18017; SEGEV H, 1995, HUM GENET, V95, P238; SKREDE S, 1988, J LIPID RES, V29, P157; SPADY DK, 1995, J CLIN INVEST, V96, P700, DOI 10.1172/JCI118113; SU P, 1990, DNA CELL BIOL, V9, P657, DOI 10.1089/dna.1990.9.657; SUDJANASUGIAMAN E, 1994, J LIPID RES, V35, P319; SUDJANASUGIAMAN E, 1994, BIOCHEM BIOPH RES CO, V202, P896, DOI 10.1006/bbrc.1994.2014; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; USUI E, 1990, FEBS LETT, V262, P135, DOI 10.1016/0014-5793(90)80172-F; Watts GF, 1996, QJM-MON J ASSOC PHYS, V89, P55, DOI 10.1093/oxfordjournals.qjmed.a030138	56	196	196	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14805	14812		10.1074/jbc.273.24.14805	http://dx.doi.org/10.1074/jbc.273.24.14805			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614081	hybrid, Green Published			2022-12-27	WOS:000074160400023
J	Strock, C; Cavagna, M; Peiffer, WE; Sumbilla, C; Lewis, D; Inesi, G				Strock, C; Cavagna, M; Peiffer, WE; Sumbilla, C; Lewis, D; Inesi, G			Direct demonstration of Ca2+ binding defects in sarco-endoplasmic reticulum Ca2+ ATPase mutants overexpressed in COS-1 cells transfected with adenovirus vectors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM; CALCIUM-BINDING; TRANSMEMBRANE DOMAIN; HIGH-AFFINITY; AMINO-ACIDS; CA2+-ATPASE; MECHANISM; SITE; PHOSPHORYLATION; CA-2+-ATPASE	Single mutations of specific amino acids within the membrane-bound region of the sarco-endoplasmic reticulum Ca2+ (SERCA)-1 ATPase interfere with Ca2+ inhibition of ATPase phosphorylation by P-i (1), suggesting that these residues may be involved in complexation of two Ca2+ that are known to bind to the enzyme. However, direct measurements of Ca2+ binding in the absence of ATP have been limited by the low quantities of available mutant protein. We have improved the transfection efficiency by means of recombinant adenovirus vectors, yielding sufficient expression of wild type and mutant SERCA-1 ATPase for measurements of Ca2+ binding to the microsomal fraction of the transfected cells. We find that in the presence of 20 mu M Ca2+ and in the absence of ATP, the Glu(771) --> Gln, Thr(799), Ala, Asp(800) --> Asn, and Glu(908) --> Ala mutants exhibit negligible binding, indicating that the oxygen functions of Glu(771), Thr(799), Asp(800) and Glu(908) are involved in interactions whose single disruption causes major changes in the highly cooperative "duplex" binding. Total loss of Ca2+ binding is accompanied by loss of Ca2+ inhibition of the P-i reaction. We also find that, at pK 7.0, the Glu(309) --> Gln and the Asn(796) --> APa mutants bind approximately half as much Ca2+ as the wild type ATPase and do not interfere with Ca2+ inhibition of the P-i reaction. At pH 6.2, the Glu(309), Gln mutant does not bind any Ca2+, and its phosphorylation by P-i is not inhibited by Ca2+, On the contrary, the Asn(796) --> Ala mutant retains the behavior displayed at pH 7.0. This suggests that in the Glu(309) --> Gln mutant, ionization of acidic functions in other amino acids (e.g. Glu(771) and Asp(800)) occurs as the pH is shifted, thereby rendering Ca2+ binding possible. In the Asn(796) --> Ala mutant, on the other hand, the Glu(309) carboxylic function allows binding of inhibitory Ca2+ even at pH 6.2, In all eases mutational interference with the inhibition of the P-i reaction by Ca2+ can be overcome by raising the Ca2+ concentration to the mM range, consistent with a general effect of mutations on the affinity of the ATPase for Ca2+.	Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Inesi, G (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, 108 N Greene St, Baltimore, MD 21201 USA.	ginesi@umaryland.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL027867] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007592] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01HL-27867] Funding Source: Medline; NIAMS NIH HHS [5-T32-AR07592] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Andersen JP, 1995, BIOSCIENCE REP, V15, P243, DOI 10.1007/BF01788358; Autry JM, 1997, J BIOL CHEM, V272, P15872, DOI 10.1074/jbc.272.25.15872; Chen L, 1996, J BIOL CHEM, V271, P10745, DOI 10.1074/jbc.271.18.10745; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; DUPONT Y, 1982, BIOCHIM BIOPHYS ACTA, V688, P75, DOI 10.1016/0005-2736(82)90580-6; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Falson P, 1997, J BIOL CHEM, V272, P17258, DOI 10.1074/jbc.272.28.17258; FUJIMORI T, 1992, J BIOL CHEM, V267, P18475; GRAHAM FL, 1992, VACCINES NEW APPROAC, P363; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLMES MA, 1982, J MOL BIOL, V160, P623, DOI 10.1016/0022-2836(82)90319-9; INESI G, 1987, J BIOL CHEM, V262, P16338; INESI G, 1992, ARCH BIOCHEM BIOPHYS, V298, P313, DOI 10.1016/0003-9861(92)90416-T; INESI G, 1980, J BIOL CHEM, V255, P3025; INESI G, 1988, METHOD ENZYMOL, V157, P154; INESI G, 1992, ADV ENZYMOL RAMB, V65, P185; KARIN NJ, 1989, MOL CELL BIOL, V9, P1978, DOI 10.1128/MCB.9.5.1978; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Rice WJ, 1997, J BIOL CHEM, V272, P31412, DOI 10.1074/jbc.272.50.31412; SKERJANC IS, 1993, J BIOL CHEM, V268, P15944; SUMBILLA C, 1993, J BIOL CHEM, V268, P21185; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; VILSEN B, 1992, J BIOL CHEM, V267, P25739; VILSEN B, 1992, FEBS LETT, V306, P247, DOI 10.1016/0014-5793(92)81010-J	27	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15104	15109		10.1074/jbc.273.24.15104	http://dx.doi.org/10.1074/jbc.273.24.15104			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614121	hybrid			2022-12-27	WOS:000074160400063
J	Van Dort, HM; Moriyama, R; Low, PS				Van Dort, HM; Moriyama, R; Low, PS			Effect of band 3 subunit equilibrium on the kinetics and affinity of ankyrin binding to erythrocyte membrane vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-BLOOD-CELL; ELECTRON-PARAMAGNETIC RESONANCE; SOUTHEAST-ASIAN OVALOCYTOSIS; SER THR-PHOSPHORYLATION; ANION TRANSPORT; CYTOPLASMIC DOMAIN; HEREDITARY SPHEROCYTOSIS; ROTATIONAL DIFFUSION; SELF-ASSOCIATION; COVALENT DIMERS	The membrane-spanning protein, band 3, anchors the spectrin-based membrane skeleton to the lipid bilayer via the bridging protein, ankyrin, To understand how band 3 subunit stoichiometry influences this membrane-skeletal junction, we have induced changes in the band 3 association equilibrium and assayed the kinetics and equilibrium properties of ankyrin binding. We observe that band 3 oligomers convert slowly to dimers and ultimately monomers following removal of ankyrin. Addition of excess ankyrin back to these membranes enriched in dissociated band 3 then shifts band 3 almost entirely to tetramers, confirming that the tetrameric form of band 3 constitutes the preferred oligomeric state of ankyrin binding. 4,4'-Diisothiocyanostilbene-2,2'-disulfonic acid (DIDS) labeling of band 3, which is shown to shift most of the band 3 population to dimers, eliminates the majority of ankyrin-binding sites on the membrane and greatly reduces retention of band 3 in detergent-extracted membrane skeletons. Furthermore, DIDS- modified membranes lack all low affinity ankyrin-binding sites and roughly half of all high affinity sites. Since labeled membranes lack the rapid kinetic phase of ankyrin binding and exhibit only half of the normal amplitude of the slow kinetic phase, it can be concluded that the rapid phase of ankyrin association involves low affinity sites and the slow phase involves high affinity sites. A model accounting for these data and most previous data on ankyrin-band 3 interactions is provided.	Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Low, PS (corresponding author), Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA.			Low, Philip/0000-0001-9042-5528	NIGMS NIH HHS [GM 24417] Funding Source: Medline; PHS HHS [T32 G08296] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024417, R37GM024417] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALPER SL, 1992, PROG CELL RES, V2, P9; Ando K, 1997, ARCH BIOCHEM BIOPHYS, V339, P250, DOI 10.1006/abbi.1996.9831; APPELL KC, 1981, J BIOL CHEM, V256, P1104; APPELL KC, 1982, BIOCHEMISTRY-US, V21, P2151, DOI 10.1021/bi00538a026; BAGGIO B, 1993, BIOCHIM BIOPHYS ACTA, V1148, P157, DOI 10.1016/0005-2736(93)90173-W; BENNETT V, 1979, J BIOL CHEM, V254, P2533; BENNETT V, 1980, J BIOL CHEM, V255, P6424; BENNETT V, 1979, NATURE, V280, P468, DOI 10.1038/280468a0; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BENNETT V, 1983, METHOD ENZYMOL, V70, P247; BETH AH, 1981, P NATL ACAD SCI-BIOL, V78, P4955, DOI 10.1073/pnas.78.8.4955; BRUCE LJ, 1993, BIOCHEM J, V293, P317, DOI 10.1042/bj2930317; CABANTCHIK ZI, 1978, BIOCHIM BIOPHYS ACTA, V515, P239; CASEY JR, 1991, J BIOL CHEM, V266, P15726; CASSOLY R, 1982, BIOCHIM BIOPHYS ACTA, V689, P203, DOI 10.1016/0005-2736(82)90252-8; CHE A, 1993, J CELL SCI, V105, P655; CLARI G, 1992, BIOCHEM INT, V26, P1065; COHEN CM, 1993, SEMIN HEMATOL, V30, P119; DAVIS L, 1989, J BIOL CHEM, V264, P9665; DAVIS LH, 1990, J BIOL CHEM, V265, P10589; DEMPSEY CE, 1986, BIOCHEMISTRY-US, V25, P2180, DOI 10.1021/bi00356a049; Ding Y, 1996, J BIOL CHEM, V271, P22494, DOI 10.1074/jbc.271.37.22494; DING Y, 1994, J BIOL CHEM, V269, P32201; DUCIS J, 1988, J BIOL CHEM, V263, P8544; EATON JW, 1980, AM J HEMATOL, V9, P391; FUKUDA MN, 1986, BLOOD, V68, P521; GRINSTEIN S, 1978, BIOCHIM BIOPHYS ACTA, V507, P294, DOI 10.1016/0005-2736(78)90424-8; HANSPAL M, 1994, BLOOD, V84, pA4; HARGREAVES WR, 1980, J BIOL CHEM, V255, P1965; IDEGUCHI H, 1992, BRIT J HAEMATOL, V82, P122, DOI 10.1111/j.1365-2141.1992.tb04603.x; IMAMURA T, 1984, JPN J MED, V23, P216; JAROLIM P, 1991, P NATL ACAD SCI USA, V88, P11022, DOI 10.1073/pnas.88.24.11022; JAROLIM P, 1994, J CLIN INVEST, V93, P121, DOI 10.1172/JCI116935; JENKINS JD, 1985, J BIOL CHEM, V260, P426; JENNINGS ML, 1979, BIOCHIM BIOPHYS ACTA, V554, P498, DOI 10.1016/0005-2736(79)90387-0; JENNINGS ML, 1985, J BIOL CHEM, V260, P15714; KANNAN R, 1991, BIOCHEM J, V278, P57, DOI 10.1042/bj2780057; KUNIMOTO M, 1989, J BIOCHEM-TOKYO, V105, P190, DOI 10.1093/oxfordjournals.jbchem.a122638; LEPKE S, 1992, BIOCHIM BIOPHYS ACTA, V1106, P13, DOI 10.1016/0005-2736(92)90215-8; LEPKE S, 1976, BIOCHIM BIOPHYS ACTA, V455, P353, DOI 10.1016/0005-2736(76)90311-4; LING E, 1988, J BIOL CHEM, V263, P2209; LIU SC, 1995, BLOOD, V86, P349, DOI 10.1182/blood.V86.1.349.bloodjournal861349; LOMBARDO CR, 1992, J BIOL CHEM, V267, P9540; LOW PS, 1978, BIOCHIM BIOPHYS ACTA, V514, P264, DOI 10.1016/0005-2736(78)90297-3; LOW PS, 1986, BIOCHIM BIOPHYS ACTA, V864, P145, DOI 10.1016/0304-4157(86)90009-2; LOW PS, 1984, J BIOL CHEM, V259, P3070; LOW PS, 1985, SCIENCE, V227, P531, DOI 10.1126/science.2578228; LOW PS, 1993, J BIOL CHEM, V268, P14627; LOW PS, 1992, PROG CELL RES, V2, P219; LUTZ HU, 1987, P NATL ACAD SCI USA, V84, P7368, DOI 10.1073/pnas.84.21.7368; LUX SE, 1989, P NATL ACAD SCI USA, V86, P9089, DOI 10.1073/pnas.86.23.9089; MALIK S, 1993, BIOCHEMISTRY-US, V32, P10078, DOI 10.1021/bi00089a024; MICHAELY P, 1993, J BIOL CHEM, V268, P22703; MICHAELY P, 1995, J BIOL CHEM, V270, P22050, DOI 10.1074/jbc.270.37.22050; MOHANDAS N, 1992, J CLIN INVEST, V89, P686, DOI 10.1172/JCI115636; MORGAN M, 1985, EMBO J, V4, P1927, DOI 10.1002/j.1460-2075.1985.tb03872.x; MORI A, 1995, J BIOCHEM-TOKYO, V118, P1192, DOI 10.1093/oxfordjournals.jbchem.a125006; MORIYAMA R, 1993, J BIOL CHEM, V268, P10990; MUHLEBACH T, 1985, BIOCHEMISTRY-US, V24, P975; MULZER K, 1989, STUD BIOPHYS, V134, P17; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PASTERNACK GR, 1985, J BIOL CHEM, V260, P3676; PINDER JC, 1995, BLOOD, V85, P2951, DOI 10.1182/blood.V85.10.2951.bloodjournal85102951; RICE WR, 1977, BIOCHIM BIOPHYS ACTA, V468, P305, DOI 10.1016/0005-2736(77)90123-7; SALHANY JM, 1980, BIOCHEMISTRY-US, V19, P1447, DOI 10.1021/bi00548a028; SALHANY JM, 1990, J BIOL CHEM, V265, P17688; SALHANY JM, 1991, BIOCHEM BIOPH RES CO, V174, P975, DOI 10.1016/0006-291X(91)91514-D; SALHANY JM, 1992, PROG CELL RES, V2, P191; SCHOFIELD AE, 1992, NATURE, V355, P836, DOI 10.1038/355836a0; SCHUBERT D, 1983, FEBS LETT, V163, P81, DOI 10.1016/0014-5793(83)81168-5; STECK T L, 1973, Journal of Supramolecular Structure, V1, P220, DOI 10.1002/jss.400010307; TANNER MJA, 1993, SEMIN HEMATOL, V30, P34; THEVENIN BJM, 1990, J BIOL CHEM, V265, P16166; THEVENIN BJM, 1989, J BIOL CHEM, V264, P15886; THEVENIN BJM, 1994, P NATL ACAD SCI USA, V91, P1741, DOI 10.1073/pnas.91.5.1741; TOMIDA M, 1988, BIOCHIM BIOPHYS ACTA, V943, P493, DOI 10.1016/0005-2736(88)90382-3; TSUJI A, 1988, BIOCHEMISTRY-US, V27, P7447, DOI 10.1021/bi00419a041; TURRINI F, 1993, BLOOD, V81, P3146; Vince JW, 1997, BBA-BIOMEMBRANES, V1326, P295, DOI 10.1016/S0005-2736(97)00033-3; WALDER JA, 1984, J BIOL CHEM, V259, P238; WAUGH SM, 1987, BIOCHEMISTRY-US, V26, P1777, DOI 10.1021/bi00380a041; WAUGH SM, 1986, J CLIN INVEST, V78, P1155, DOI 10.1172/JCI112696; WILLARDSON BM, 1989, J BIOL CHEM, V264, P15893; YAMAGUCHI T, 1992, BIOCHEMISTRY-US, V31, P1968, DOI 10.1021/bi00122a010; YUAN J, 1992, BLOOD, V79, P3007	86	62	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14819	14826		10.1074/jbc.273.24.14819	http://dx.doi.org/10.1074/jbc.273.24.14819			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614083	hybrid			2022-12-27	WOS:000074160400025
J	Wagle, A; Jivraj, S; Garlock, GL; Stapleton, SR				Wagle, A; Jivraj, S; Garlock, GL; Stapleton, SR			Insulin regulation of glucose-6-phosphate dehydrogenase gene expression is rapamycin-sensitive and requires phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; GLYCOGEN-SYNTHASE KINASE-3; MESSENGER-RNA LEVELS; PHOSPHOENOLPYRUVATE CARBOXYKINASE; SIGNAL-TRANSDUCTION; 3T3-L1 ADIPOCYTES; PHOSPHOINOSITIDE 3-KINASE; GLUCOSE-TRANSPORT; GLUCOKINASE GENE; RESPONSE ELEMENT	Glucose-6-phosphate dehydrogenase (G6PDH) controls the flow of carbon through the pentose phosphate pathway and also produces NADPH needed for maintenance of reduced glutathione and reductive biosynthesis. Hepatic expression of G6PDH is known to respond to several dietary and hormonal factors, but the mechanism behind regulation of this expression has not been characterized. We show that insulin similarly induces expression of endogenous hepatic G6PDH and a reporter construct containing 935 base pairs of the G6PDH promoter linked to luciferase in transient transfection assays. Using well tested and structurally distinct inhibitors of Ras farnesylation, lovastatin and B581, and a specific inhibitor of mitogen-activated protein kinase kinase activation, PD 98059, we show that the Ras/Raf/mitogen-activated protein kinase pathway is not utilized for the insulin-induced stimulation of G6PDH gene expression in primary rat hepatocytes, Similarly, using well characterized inhibitors of phosphatidylinositol 3-kinase, wortmannin and LY 294002, me show that PI 3-kinase activity is necessary for the induction of G6PDH expression by insulin. Rapamycin, an inhibitor of FRAP protein, which is involved in the activation of pp70 S6 kinase, blocks the insulin induction of G6PDH, suggesting that SG kinase is also necessary for the insulin induction of G6PDH expression.	Western Michigan Univ, Dept Chem, Kalamazoo, MI 49008 USA; Western Michigan Univ, Dept Biol Sci, Kalamazoo, MI 49008 USA; Western Michigan Univ, Ctr Res Environm Signal Transduct, Kalamazoo, MI 49008 USA	Western Michigan University; Western Michigan University; Western Michigan University	Stapleton, SR (corresponding author), Western Michigan Univ, Dept Chem, Kalamazoo, MI 49008 USA.	stapleton@wmich.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R15DK043917] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43917] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; Cohen P, 1997, FEBS LETT, V410, P3, DOI 10.1016/S0014-5793(97)00490-0; COHEN P, 1993, BIOCHEM SOC T, V21, P555, DOI 10.1042/bst0210555; COX AD, 1994, J BIOL CHEM, V269, P19203; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DECLUE JE, 1991, CANCER RES, V51, P712; DEFEOJONES D, 1991, MOL CELL BIOL, V11, P2307, DOI 10.1128/MCB.11.4.2307; Fourney R.M., 1988, FOCUS, V10, P5; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; FRITZ RS, 1986, BIOCHEM J, V237, P637; Gabbay RA, 1996, J BIOL CHEM, V271, P1890, DOI 10.1074/jbc.271.4.1890; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; IYNEDJIAN PB, 1988, J BIOL CHEM, V263, P740; KAHN CR, 1993, RECENT PROG HORM RES, V48, P291; KLETZIEN RF, 1985, J BIOL CHEM, V260, P5621; KLETZIEN RF, 1994, FASEB J, V8, P174, DOI 10.1096/fasebj.8.2.8119488; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; KOVACINA KS, 1993, BIOCHEM BIOPH RES CO, V192, P1303, DOI 10.1006/bbrc.1993.1558; Lavan BE, 1997, J BIOL CHEM, V272, P11439; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Lefebvre V, 1996, J BIOL CHEM, V271, P22289, DOI 10.1074/jbc.271.37.22289; MAGNUSON MA, 1989, P NATL ACAD SCI USA, V86, P4838, DOI 10.1073/pnas.86.13.4838; MCGUIRE TF, 1994, BIOCHEM BIOPH RES CO, V204, P399, DOI 10.1006/bbrc.1994.2472; MCGUIRE TF, 1993, J BIOL CHEM, V268, P22227; MOUSTAID N, 1994, J BIOL CHEM, V269, P5629; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; OKADA T, 1994, J BIOL CHEM, V269, P3568; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RANK KB, 1994, BIOCHIM BIOPHYS ACTA, V1212, P90; REUSCH JEB, 1995, J BIOL CHEM, V270, P2036, DOI 10.1074/jbc.270.5.2036; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; SAKAUE H, 1995, J BIOL CHEM, V270, P11304, DOI 10.1074/jbc.270.19.11304; SAKAUE M, 1995, MOL CELL BIOL, V15, P379, DOI 10.1128/MCB.15.1.379; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SERUNIAN LA, 1991, METHOD ENZYMOL, V271, P77; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; SHORT JM, 1986, J BIOL CHEM, V261, P9721; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; Stapleton SR, 1997, BBA-MOL CELL RES, V1355, P259, DOI 10.1016/S0167-4889(96)00140-1; STAPLETON SR, 1990, J BIOL CHEM, V265, P18442; STAPLETON SR, 1993, BIOCHIMIE, V75, P971, DOI 10.1016/0300-9084(93)90147-K; STUMPO DJ, 1984, EUR J BIOCHEM, V144, P497, DOI 10.1111/j.1432-1033.1984.tb08493.x; SUTHERLAND C, 1995, J BIOL CHEM, V270, P15501, DOI 10.1074/jbc.270.26.15501; TOBE K, 1992, J BIOL CHEM, V267, P21089; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015; WHITEHURST CE, 1995, J BIOL CHEM, V270, P5594, DOI 10.1074/jbc.270.10.5594; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442; Wijkander J, 1997, J BIOL CHEM, V272, P21520, DOI 10.1074/jbc.272.34.21520; Xu XQ, 1996, ARCH BIOCHEM BIOPHYS, V326, P233, DOI 10.1006/abbi.1996.0070; YAMAMOTOHONDA R, 1995, J BIOL CHEM, V270, P2729, DOI 10.1074/jbc.270.6.2729; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597; YANG SH, 1995, BIOCHEM J, V310, P375, DOI 10.1042/bj3100375	67	79	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14968	14974		10.1074/jbc.273.24.14968	http://dx.doi.org/10.1074/jbc.273.24.14968			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614103	hybrid			2022-12-27	WOS:000074160400045
J	Hashemolhosseini, S; Nagamine, Y; Morley, SJ; Desrivieres, S; Mercep, L; Ferrari, S				Hashemolhosseini, S; Nagamine, Y; Morley, SJ; Desrivieres, S; Mercep, L; Ferrari, S			Rapamycin inhibition of the G(1) to S transition is mediated by effects on cyclin D1 mRNA and protein stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITOR; INITIATION-FACTOR 4E; FIBROBLAST CELL-CYCLE; GROWTH-FACTOR-BETA; TRANSLATION INITIATION; MESSENGER-RNA; G1 PHASE; MAMMALIAN-CELLS; NUCLEAR-PROTEIN; CDK INHIBITORS	The immunosuppressant rapamycin has been shown previously to inhibit the G(1)/S transition in several cell types by prolonging the G, phase of the cell cycle. This process appears to be controlled in part, by the rapamycin-sensitive FK506-binding protein-rapamycin-associated protein-p70 S6 kinase (p70(S6k)) pathway and the cyclin-dependent kinases (Cdk). We now show that in serum-stimulated NIH 3T3 cells, rapamycin treatment delays the accumulation of cyclin D1 mRNA during progression through G,. Rapamycin also appears to affect stability of the transcript. The combined transcriptional and post-transcriptional effects of the drug ultimately result in decreased levels of cyclin D1 protein. Moreover, degradation of newly synthesized cyclin D1 protein is accelerated by rapamycin, a process prevented by inclusion of the proteasome inhibitor, N-acetyl-Leu-Leu-norleucinal. The overall effect of rapamycin on cyclin D1 leads, in turn, to impaired formation of active complexes with Cdk4, a process which triggers retargeting of the p27(Kip1) inhibitor to cyclin E/Cdk2. In view of this novel experimental evidence, we discuss a possible mechanism for the rapamycin-induced cell cycle arrest at the G(1)/S transition.	Inst Expt Canc Res, Tumor Biol Ctr, D-79011 Freiburg, Germany; Friedrich Miescher Inst, CH-4002 Basel, Switzerland; Univ Sussex, Sch Biol Sci, Dept Biochem, Brighton BN1 9QG, E Sussex, England	Friedrich Miescher Institute for Biomedical Research; University of Sussex	Ferrari, S (corresponding author), Novartis Pharma Ltd, Dept Oncol, Klybeckstr 141, CH-4002 Basel, Switzerland.	stefferrari@hotmail.com	Hashemolhosseini, Said/N-2464-2013; Ferrari, Stefano/I-7357-2016; Desrivières, Sylvane/ABC-4336-2021; Desrivieres, Sylvane/B-7399-2011	Hashemolhosseini, Said/0000-0002-6564-5649; Ferrari, Stefano/0000-0002-6607-215X; Desrivières, Sylvane/0000-0002-9120-7060; Desrivieres, Sylvane/0000-0002-9120-7060	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Agrawal D, 1996, MOL CELL BIOL, V16, P4327; ALBERS MW, 1993, J BIOL CHEM, V268, P22825; Avni D, 1997, NUCLEIC ACIDS RES, V25, P995, DOI 10.1093/nar/25.5.995; Banholzer R, 1997, MOL CELL BIOL, V17, P3254, DOI 10.1128/MCB.17.6.3254; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; CALVO V, 1994, EUR J IMMUNOL, V24, P2664, DOI 10.1002/eji.1830241115; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DOU QP, 1993, CANCER RES, V53, P1493; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Flynn A, 1996, FEBS LETT, V389, P162, DOI 10.1016/0014-5793(96)00564-9; FROST V, 1995, J BIOL CHEM, V270, P26698, DOI 10.1074/jbc.270.44.26698; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HERBER B, 1994, ONCOGENE, V9, P1295; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JAYARAMAN T, 1993, J BIOL CHEM, V268, P25385; JEFFERIES HBJ, 1994, J BIOL CHEM, V269, P4367; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; Luo Y, 1996, MOL CELL BIOL, V16, P6744; MASSAGUE J, 1995, CURR OPIN GENET DEV, V5, P91, DOI 10.1016/S0959-437X(95)90059-4; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Mendez R, 1996, MOL CELL BIOL, V16, P2857; Meyuhas Oded, 1996, V30, P363; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORICE WG, 1993, J BIOL CHEM, V268, P3734; MORLEY SJ, 1995, J CELL SCI, V108, P1751; MORLEY SJ, 1995, BIOCHEM J, V312, P627, DOI 10.1042/bj3120627; MORLEY SJ, 1996, PROTEIN PHOSPHORYLAT, P197; MULLER H, 1994, P NATL ACAD SCI USA, V91, P1945; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PETERS G, 1994, NATURE, V371, P204, DOI 10.1038/371204a0; PINES J, 1995, SEMIN CANCER BIOL, V6, P63, DOI 10.1006/scbi.1995.0009; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; REDDY KB, 1994, J CELL BIOCHEM, V56, P418, DOI 10.1002/jcb.240560318; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; TERADA N, 1993, J BIOL CHEM, V268, P12062; TERADA N, 1995, J IMMUNOL, V155, P3418; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Welcker M, 1996, ONCOGENE, V13, P419; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910	71	279	295	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14424	14429		10.1074/jbc.273.23.14424	http://dx.doi.org/10.1074/jbc.273.23.14424			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603954	hybrid			2022-12-27	WOS:000074021500056
J	Crawford, DR; Leahy, P; Hu, CY; Chaudhry, A; Gronostajski, R; Grossman, G; Woods, J; Hakimi, P; Roesler, WJ; Hanson, RW				Crawford, DR; Leahy, P; Hu, CY; Chaudhry, A; Gronostajski, R; Grossman, G; Woods, J; Hakimi, P; Roesler, WJ; Hanson, RW			Nuclear factor I regulates expression of the gene for phosphoenolpyruvate carboxykinase (GTP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; ELEMENT-BINDING PROTEIN; TRANSGENIC MICE; JC-VIRUS; TRANSCRIPTION; PROMOTER; DNA; LIVER; SITES; REPLICATION	Nuclear factor-I (NFI) binds to the phosphoenolpyruvate carboxykinase (GTP) (PEPCK) gene promoter immediately 5' to the cAMP regulatory element (CRE), This suggests an interaction between NFI and factors that bind the CRE. Of the four NFI isoforms expressed in mammalian tissues, NFI-A and -B stimulate basal transcription from the PEPCK gene promoter in HepG2 cells, while NFI-C and -X are slightly inhibitory. AU four NFI isoforms abrogate the 20-fold protein kinase Ac (PKAc)-mediated induction of transcription from the PEPCK gene promoter. Normal PKAc-mediated induction was noted when the CRE was moved 10 base pairs 3' of its original location. However if the CRE was moved 5 base pairs 3', placing it out of phase with the other elements in the promoter, or moved 5' to -285 (the P3(I) site in the promoter), some PKA-mediated stimulation was lost. The NFI-C isoform effectively inhibited PKAc induction regardless of the relative positions of the CBE and the NFI binding sites. NFI-C also abrogated cAMP regulatory element-binding protein (CREB)-induced activity of wild type and mutant PEPCK promoters. There was some cooperativity in the binding of CREB and NFI to their respective binding sites but this did not appear to be physiologically important.	Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44106 USA; Univ Saskatchewan, Dept Biochem, Saskatoon, SK S7N 5E5, Canada	Case Western Reserve University; Cleveland Clinic Foundation; University of Saskatchewan	Hanson, RW (corresponding author), Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA.		Hakimi, Parvin/AAB-1643-2021	Hu, Ching Yuan/0000-0002-3829-7343; Gronostajski, Richard/0000-0003-4264-208X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD034908] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-34908] Funding Source: Medline; NIDDK NIH HHS [DK-22465, DK 07319] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLGOOD VE, 1993, J BIOL CHEM, V268, P20870; AMEMIYA K, 1992, J BIOL CHEM, V267, P14204; CEREGHINI S, 1987, CELL, V50, P627, DOI 10.1016/0092-8674(87)90036-5; Chaudhry AZ, 1997, DEV DYNAM, V208, P313; CHRIST B, 1991, BIOCHEM BIOPH RES CO, V181, P367, DOI 10.1016/S0006-291X(05)81428-7; CORTHESY B, 1989, MOL CELL BIOL, V9, P5548, DOI 10.1128/MCB.9.12.5548; CUIF MH, 1993, J BIOL CHEM, V268, P13769; FABER S, 1993, J BIOL CHEM, V268, P24976; FABER S, 1991, NUCLEIC ACIDS RES, V19, P4681, DOI 10.1093/nar/19.17.4681; Garlatti M, 1996, J BIOL CHEM, V271, P32629, DOI 10.1074/jbc.271.51.32629; Hanson R W, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P203; JACKSON DA, 1993, MOL CELL BIOL, V13, P2401, DOI 10.1128/MCB.13.4.2401; KALVAKOLANU DVR, 1992, J BIOL CHEM, V267, P2530; Kumar KU, 1996, J MED VIROL, V49, P199, DOI 10.1002/(SICI)1096-9071(199607)49:3<199::AID-JMV7>3.0.CO;2-#; LEAHY P, 1995, BIOTECHNIQUES, V19, P894; LIU JS, 1991, J BIOL CHEM, V266, P19095; LU GH, 1992, INT J BIOCHEM, V24, P455, DOI 10.1016/0020-711X(92)90039-4; MANDEL HG, 1995, ANAL BIOCHEM, V230, P191, DOI 10.1006/abio.1995.1460; MEISTERERNST M, 1989, BIOCHEMISTRY-US, V28, P8191, DOI 10.1021/bi00446a034; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MINK S, 1992, MOL CELL BIOL, V12, P4906, DOI 10.1128/MCB.12.11.4906; PARK EA, 1993, J BIOL CHEM, V268, P613; PATEL YM, 1994, J BIOL CHEM, V269, P5619; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; RUPP RAW, 1990, NUCLEIC ACIDS RES, V18, P2607, DOI 10.1093/nar/18.9.2607; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0	26	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13387	13390		10.1074/jbc.273.22.13387	http://dx.doi.org/10.1074/jbc.273.22.13387			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593667	hybrid			2022-12-27	WOS:000073919100006
J	Liliom, K; Fischer, DJ; Virag, T; Sun, GP; Miller, DD; Tseng, JL; Desiderio, DM; Seidel, MC; Erickson, JR; Tigyi, G				Liliom, K; Fischer, DJ; Virag, T; Sun, GP; Miller, DD; Tseng, JL; Desiderio, DM; Seidel, MC; Erickson, JR; Tigyi, G			Identification of a novel growth factor-like lipid, 1-O-cis-alk-1 '-enyl-2-lyso-sn-glycero-3-phosphate (alkenyl-GP) that is present in commercial sphingolipid preparations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-ACTIVATING FACTOR; LYSOPHOSPHATIDIC ACID; CELL-PROLIFERATION; XENOPUS OOCYTES; G-PROTEIN; SIGNALING PATHWAYS; SPHINGOSYLPHOSPHORYLCHOLINE; SPHINGOSINE-1-PHOSPHATE; RECEPTOR; MITOGEN	Lysophosphatidic acid, a member of the acidic phospholipid autacoid (APA) family of lipid mediators, elicits diverse cellular effects that range from mitogenesis to the prevention of programmed cell death. Sphingosine 1-phosphate and sphingosylphosphorylcholine have also been proposed to be ligands of the APA receptors, However, key observations that provide the foundation of this hypothesis have not been universally reproducible, leading to a controversy in the field. We provide evidence that 1-O-cis-alk-1'-enyl-2-lyso-sn-glycero-3-phosphate (alkenyl-GP) is present in some commercial sphingolipid preparations and is responsible for many of their APA-like effects, which were previously attributed to sphingosylphosphorylcholine. Alkenyl-GP was generated by acidic and basic methanolysis from ethanolamine lysoplasmalogen, which was present in the sphingomyelin fraction that is used to manufacture sphingosylphosphorylcholine. We present the structural identification of alkenyl-GP, using H-1 and C-13 NMR, Fourier transform infrared spectrometry, and mass spectrometry. Alkenyl-GP was a potent activator of the mitogen-activated protein kinases ERK1/2 and elicited a mitogenic response in Swiss 3T3 fibroblasts. In contrast, sphingosylphosphorylcholine at a concentration of 10 mu M was only a weak mitogen and only weakly activated the extracellular signal-regulated protein kinases, Alkenyl-GP has recently been detected as an injury-induced component in the anterior chamber of the eye (Liliom, K., Guan, Z., Tseng, H., Desiderio, D. M., Tigyi, G., and Watsky, M. (1998) Am. J, Physiol. 274, C1065-C1074), indicating that this lipid is a naturally occurring member of the APA mediator family.	Univ Tennessee, Coll Med, Dept Physiol & Biophys, Memphis, TN 38163 USA; Univ Tennessee, Dept Pharmaceut Sci, Memphis, TN 38163 USA; Univ Tennessee, Charles B Stout Neurosci Mass Spectrometry Lab, Memphis, TN 38163 USA; Univ Tennessee, Dept Neurol, Memphis, TN 38163 USA; Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA; Matreya Inc, Pleasant Gap, PA 16823 USA; LXR Biotechnol Inc, Richmond, CA 94804 USA; Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, H-1113 Budapest, Hungary	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences	Tigyi, G (corresponding author), Univ Tennessee, Coll Med, Dept Physiol & Biophys, 894 Union Ave, Memphis, TN 38163 USA.	gtigyi@physiol.utmem.edu	Liliom, Karoly/A-6563-2011	Liliom, Karoly/0000-0002-7177-6872	NHLBI NIH HHS [HL07746] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMES BN, 1960, J BIOL CHEM, V235, P769; BERGER A, 1995, P NATL ACAD SCI USA, V92, P5885, DOI 10.1073/pnas.92.13.5885; BLANK ML, 1970, BIOCHEMISTRY-US, V9, P5034; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUENEMANN M, 1996, EMBO J, V15, P5524; Cadwallader K, 1997, BIOCHEM J, V321, P795, DOI 10.1042/bj3210795; Cook SJ, 1997, J BIOL CHEM, V272, P13309, DOI 10.1074/jbc.272.20.13309; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DESAI NN, 1991, BIOCHEM BIOPH RES CO, V181, P361, DOI 10.1016/S0006-291X(05)81427-5; DESAI NN, 1993, J CELL BIOL, V121, P1385, DOI 10.1083/jcb.121.6.1385; DURIEUX ME, 1993, AM J PHYSIOL, V264, pC1360, DOI 10.1152/ajpcell.1993.264.5.C1360; DURIEUX ME, 1993, TRENDS PHARMACOL SCI, V14, P249, DOI 10.1016/0165-6147(93)90021-B; Erickson JP, 1998, J BIOL CHEM, V273, P1506, DOI 10.1074/jbc.273.3.1506; FOLCH J, 1957, J BIOL CHEM, V226, P497; GAVER RC, 1965, J AM OIL CHEM SOC, V42, P294, DOI 10.1007/BF02540132; GROSS RW, 1985, BIOCHEMISTRY-US, V24, P1662, DOI 10.1021/bi00328a014; GUNAWAN J, 1982, J NEUROCHEM, V39, P693, DOI 10.1111/j.1471-4159.1982.tb07948.x; Guo Z, 1996, P NATL ACAD SCI USA, V93, P14367, DOI 10.1073/pnas.93.25.14367; HANAHAN DJ, 1985, J LIPID RES, V26, P1345; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; HOWE LR, 1993, J BIOL CHEM, V268, P20717; IMAMURA F, 1993, BIOCHEM BIOPH RES CO, V193, P497, DOI 10.1006/bbrc.1993.1651; JALINK K, 1995, BIOCHEM J, V307, P609, DOI 10.1042/bj3070609; KATES M, 1986, TECHNIQUES LIPIDOLOG, P405; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liliom K, 1998, AM J PHYSIOL-CELL PH, V274, pC1065, DOI 10.1152/ajpcell.1998.274.4.C1065; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; MURAKAMIMUROFUSHI K, 1993, CELL STRUCT FUNCT, V18, P363, DOI 10.1247/csf.18.363; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; POSTMA FR, 1996, EMBO J, V15, P2389; PUSHKAREVA MY, 1994, BBA-MOL CELL RES, V1221, P54, DOI 10.1016/0167-4889(94)90215-1; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SADAHIRA Y, 1992, P NATL ACAD SCI USA, V89, P9686, DOI 10.1073/pnas.89.20.9686; SCHMID HHO, 1966, BIOCHIM BIOPHYS ACTA, V125, P182, DOI 10.1016/0005-2760(66)90158-5; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24343, DOI 10.1074/jbc.270.41.24343; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24334, DOI 10.1074/jbc.270.41.24334; SNYDER F, 1997, ADV LIPOBIOL, V2, P261; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; SUN GY, 1973, BIOCHIM BIOPHYS ACTA, V316, P19, DOI 10.1016/0005-2760(73)90162-8; TESSNER TG, 1987, J BIOL CHEM, V262, P12660; TIGYI G, 1990, P NATL ACAD SCI USA, V87, P1521, DOI 10.1073/pnas.87.4.1521; TIGYI G, 1992, J BIOL CHEM, V267, P21360; TIGYI G, 1994, P NATL ACAD SCI USA, V91, P1908, DOI 10.1073/pnas.91.5.1908; TIGYI G, 1998, EICOSANOIDS OTHER LI, V5; TOKUMURA A, 1995, PROG LIPID RES, V34, P151, DOI 10.1016/0163-7827(95)00001-G; Umansky SR, 1997, CELL DEATH DIFFER, V4, P608, DOI 10.1038/sj.cdd.4400282; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; WRIGHT RS, 1971, J CHROMATOGR, V59, P220, DOI 10.1016/S0021-9673(01)80033-9; WYKLE RL, 1974, J BIOL CHEM, V249, P1742; WYKLE RL, 1977, ARCH BIOCHEM BIOPHYS, V184, P149, DOI 10.1016/0003-9861(77)90336-8; XU Y, 1995, J CELL PHYSIOL, V163, P441, DOI 10.1002/jcp.1041630303; XU Y, 1995, BIOCHEM J, V309, P933, DOI 10.1042/bj3090933	54	42	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13461	13468		10.1074/jbc.273.22.13461	http://dx.doi.org/10.1074/jbc.273.22.13461			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593679	hybrid			2022-12-27	WOS:000073919100018
J	Watt, WC; Lazarowski, ER; Boucher, RC				Watt, WC; Lazarowski, ER; Boucher, RC			Cystic fibrosis transmembrane regulator-independent release of ATP - Its implications for the regulation of P2Y(2) receptors in airway epithelia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR ATP; CONDUCTANCE REGULATOR; ENDOTHELIAL-CELLS; NUCLEOTIDES; CHANNELS; TRANSPORT; CALCIUM; SIGNAL	The cystic fibrosis (CF) transmembrane regulator (CFTR) is a cyclic AMP-dependent Cl- channel that is defective in CF cells. It has been hypothesized that CFTR exhibits an ATP release function that controls the airway surface ATP concentrations. In airway epithelial cells, CFTR-independent Ca2+-activated Cl- conductance is regulated by the P2Y(2) receptor. Thus, ATP may function as an autocrine signaling factor promoting Cl- secretion in normal but not CF epithelia if ATP release is defective. We have tested for CFTR-dependent ATP release using four independent detection systems. First, a luciferase assay detected no differences in ATP concentrations in the medium from control versus cyclic AMP-stimulated primary normal human nasal epithelial (HNE) cells. A marked accumulation of extracellular ATP resulted from mechanical stimulation effected by a medium displacement. Second, high pressure liquid chromatography analysis of H-3-labeled species released from [H-3]adenine-loaded HNE cells revealed no differences between basal and cyclic AMP-stimulated cells, Mechanical stimulation of HNE cells again resulted in enhanced accumulation of extracellular [H-3]ATP and [H-3]ADP, Third, when measuring ATP concentrations via nucleoside diphosphokinase-catalyzed phosphorylation of [alpha-P-33]dADP, equivalent formation of [P-33]dATP was observed in the media of control and cyclic AMP-stimulated HNE cells and nasal epithelial cells from wild-type and CF mice. Mechanically stimulated [P-33]dATP formation was similar in both cell types. Fourth, 1321N1 cells stably expressing the human P2Y(2) receptor were used as a reporter system for detection of ATP via P2Y(2) receptor-promoted formation of [H-3]inositol phosphates, Basal [H-3]inositol phosphate accumulation was of the same magnitude in control and CFTR-transduced cells, and no change was observed following addition of forskolin and isoproterenol, In both cell types, mechanical stimulation resulted in hexokinase-attenuable [H-3]inositol phosphate formation. In summary, our data suggest that ATP release may be triggered by mechanical stimulation of cell surfaces. No evidence was found supporting a role for CFTR in the release of ATP.	Univ N Carolina, Dept Med, Cyst Fibrosis Res & Treatment Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Lazarowski, ER (corresponding author), Univ N Carolina, Dept Med, Cyst Fibrosis Res & Treatment Ctr, CB 7248, Chapel Hill, NC 27599 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042384, P01HL034322] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL34322, HL42384] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abraham EH, 1997, SCIENCE, V275, P1324, DOI 10.1126/science.275.5304.1324; BROWN HA, 1991, MOL PHARMACOL, V40, P648; DAVIS CW, 1992, AM J PHYSIOL, V262, pC1313, DOI 10.1152/ajpcell.1992.262.5.C1313; DEKORTE D, 1990, THROMB HAEMOSTASIS, V63, P275; Devidas S, 1997, CURR OPIN CELL BIOL, V9, P547, DOI 10.1016/S0955-0674(97)80032-4; DONALDSON SH, 1996, PEDIAT PULMONOL S13, V22, P289; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; Ferguson DR, 1997, J PHYSIOL-LONDON, V505, P503, DOI 10.1111/j.1469-7793.1997.503bb.x; Fredholm BB, 1997, TRENDS PHARMACOL SCI, V18, P79, DOI 10.1016/S0165-6147(96)01038-3; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; GRIERSON JP, 1995, J BIOL CHEM, V270, P4451, DOI 10.1074/jbc.270.9.4451; GRUBB B, 1993, AM J RESP CELL MOL, V8, P454, DOI 10.1165/ajrcmb/8.4.454; Grygorczyk R, 1997, AM J PHYSIOL-CELL PH, V272, pC1058; Grygorczyk R, 1997, SCIENCE, V275, P1325; Grygorczyk R, 1996, J MEMBRANE BIOL, V151, P139, DOI 10.1007/s002329900065; JIANG CW, 1993, SCIENCE, V262, P424, DOI 10.1126/science.8211164; LAZAROSKIER, 1997, P NATL ACAD SCI US, V94, P2599; LAZAROWSKI ER, 1995, BRIT J PHARMACOL, V116, P1619, DOI 10.1111/j.1476-5381.1995.tb16382.x; Lazarowski ER, 1997, J BIOL CHEM, V272, P24348, DOI 10.1074/jbc.272.39.24348; LETHEM MI, 1993, AM J RESP CELL MOL, V9, P315, DOI 10.1165/ajrcmb/9.3.315; Li CH, 1996, J BIOL CHEM, V271, P11623, DOI 10.1074/jbc.271.20.11623; MASON SJ, 1991, BRIT J PHARMACOL, V103, P1649, DOI 10.1111/j.1476-5381.1991.tb09842.x; MILNER P, 1990, BIOCHEM BIOPH RES CO, V170, P649, DOI 10.1016/0006-291X(90)92141-L; MILNER P, 1992, J VASC RES, V29, P420, DOI 10.1159/000158960; OSIPCHUK Y, 1992, NATURE, V359, P241, DOI 10.1038/359241a0; PARR CE, 1994, P NATL ACAD SCI USA, V91, P3275, DOI 10.1073/pnas.91.8.3275; Pasyk EA, 1997, J BIOL CHEM, V272, P7746, DOI 10.1074/jbc.272.12.7746; PRAT AG, 1995, AM J PHYSIOL-CELL PH, V268, pC1552, DOI 10.1152/ajpcell.1995.268.6.C1552; RATLIFF RL, 1964, J BIOL CHEM, V239, P301; Reddy MM, 1997, SCIENCE, V275, P1325; Reddy MM, 1996, SCIENCE, V271, P1876, DOI 10.1126/science.271.5257.1876; REISIN IL, 1994, J BIOL CHEM, V269, P20584; SARKADI B, 1992, J BIOL CHEM, V267, P2087; Schlosser SF, 1996, P NATL ACAD SCI USA, V93, P9948, DOI 10.1073/pnas.93.18.9948; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; STUTTS MJ, 1995, J BIOL CHEM, V268, pC425; TAKAHASHI T, 1994, J BIOL CHEM, V269, P17853; THOMAS SA, 1990, J GEN PHYSIOL, V95, P569, DOI 10.1085/jgp.95.4.569; YANKASKAS JR, 1994, PEDIAT PULMONAL S10, V18, P195; Zimmermann H, 1996, DRUG DEVELOP RES, V39, P337, DOI 10.1002/(SICI)1098-2299(199611/12)39:3/4<337::AID-DDR15>3.0.CO;2-Z	40	148	148	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					14053	14058		10.1074/jbc.273.22.14053	http://dx.doi.org/10.1074/jbc.273.22.14053			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593757	hybrid			2022-12-27	WOS:000073919100096
J	Albrecht, G; Mosch, HU; Hoffmann, B; Reusser, U; Braus, GH				Albrecht, G; Mosch, HU; Hoffmann, B; Reusser, U; Braus, GH			Monitoring the GCN4 protein-mediated response in the yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATOR PROTEIN; ACID BIOSYNTHETIC GENES; RNA-SYNTHETASE GENE; TRANSLATIONAL CONTROL; MESSENGER-RNA; DNA-BINDING; ENCODED PROTEIN; SHUTTLE VECTORS; UPSTREAM; SEQUENCES	In Saccharomyces cerevisiae the GCN4 gene encodes the transcriptional activator of the "general control" system of amino acid bioynthesis, a network of at least 12 different biosynthetic pathways. We characterized the consequences of the general control response upon the signal "amino acid starvation" induced by the histidine analogue 3-aminotriazole with respect to Gcn4p levels in more detail, Therefore, we established test systems to monitor the time course of different parameters, including GCN4 mRNA, Gcn4 protein, Gcn4p DNA binding activity, as well as Gcn4p transactivation ability. me observed a biphasic response of Gcn4p activity in the cell. At first, translation of GCN4 mRNA is induced within 20 min after switch to starvation conditions. However, an additional increase in GCN4 transcript steady state level was observed, leading to an additional second phase of GCN4 expression after 3-4 h of starvation. The DNA binding activity of Gcn4p, as web as the ability to activate transcription of target genes, correlate with the amount of Gcn4 protein in the cell, suggesting that under the tested conditions there is no additional regulation of DNA binding or transactivation ability of Gcn4p, respectively.	Univ Gottingen, Inst Mikrobiol & Genet, Abt Mol Mikrobiol, D-37077 Gottingen, Germany	University of Gottingen	Braus, GH (corresponding author), Univ Gottingen, Inst Mikrobiol & Genet, Abt Mol Mikrobiol, Grisebachstr 8, D-37077 Gottingen, Germany.	gbraus@gwdg.de	Braus, Gerhard H/G-3999-2012; Braus, Gerhard/ABC-6293-2021	Braus, Gerhard H/0000-0002-3117-5626; Braus, Gerhard/0000-0002-3117-5626; Hoffmann, Bernd/0000-0002-3803-8835				ABASTADO JP, 1991, MOL CELL BIOL, V11, P486, DOI 10.1128/MCB.11.1.486; ARNDT K, 1986, P NATL ACAD SCI USA, V83, P8516, DOI 10.1073/pnas.83.22.8516; ARNDT KT, 1987, SCIENCE, V237, P874, DOI 10.1126/science.3303332; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BERBEN G, 1988, GENE, V66, P307, DOI 10.1016/0378-1119(88)90367-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUS G, 1989, EMBO J, V8, P939, DOI 10.1002/j.1460-2075.1989.tb03455.x; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; HINNEBUSCH AG, 1984, P NATL ACAD SCI-BIOL, V81, P6442, DOI 10.1073/pnas.81.20.6442; HINNEBUSCH AG, 1985, MOL CELL BIOL, V5, P2349, DOI 10.1128/MCB.5.9.2349; HINNEBUSCH AG, 1992, MOL CELLULAR BIOL YE, V2, P319; HOPE IA, 1985, CELL, V43, P177, DOI 10.1016/0092-8674(85)90022-4; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; ITO H, 1983, J BACTERIOL, V134, P48; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; KLOPOTOW.T, 1965, ARCH BIOCHEM BIOPHYS, V112, P562, DOI 10.1016/0003-9861(65)90096-2; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; Kuge S, 1997, EMBO J, V16, P1710, DOI 10.1093/emboj/16.7.1710; KUNZLER M, 1993, J BACTERIOL, V175, P5548; LANKER S, 1992, CELL, V70, P647, DOI 10.1016/0092-8674(92)90433-D; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; MEUSSDOERFFER F, 1983, J BIOL CHEM, V258, P6293; MIOZZARI G, 1978, J BACTERIOL, V134, P48, DOI 10.1128/JB.134.1.48-59.1978; MIRANDE M, 1988, J BIOL CHEM, V263, P18443; MOSCH HU, 1990, EMBO J, V9, P2951, DOI 10.1002/j.1460-2075.1990.tb07487.x; MOSCH HU, 1991, J BIOL CHEM, V266, P20453; MOYEROWLEY WS, 1989, GENE DEV, V3, P283, DOI 10.1101/gad.3.3.283; MUELLER PP, 1987, P NATL ACAD SCI USA, V84, P2863, DOI 10.1073/pnas.84.9.2863; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; OLIPHANT AR, 1989, MOL CELL BIOL, V9, P2944, DOI 10.1128/MCB.9.7.2944; PALUH JL, 1988, P NATL ACAD SCI USA, V85, P3728, DOI 10.1073/pnas.85.11.3728; PELTZ SW, 1994, PROG NUCLEIC ACID RE, V47, P271, DOI 10.1016/S0079-6603(08)60254-8; Rose MD., 1990, METHODS YEAST GENETI; RuizEchevarria MJ, 1996, EMBO J, V15, P2810, DOI 10.1002/j.1460-2075.1996.tb00641.x; Sambrook J., 2002, MOL CLONING LAB MANU; SENGSTAG C, 1988, GENE, V67, P223, DOI 10.1016/0378-1119(88)90399-X; SIKORSKI RS, 1989, GENETICS, V122, P19; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STRUHL K, 1987, CELL, V50, P841, DOI 10.1016/0092-8674(87)90511-3; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; THIREOS G, 1984, P NATL ACAD SCI-BIOL, V81, P5096, DOI 10.1073/pnas.81.16.5096; Wanke C, 1997, MOL MICROBIOL, V23, P23, DOI 10.1046/j.1365-2958.1997.1741549.x; WOLFNER M, 1975, J MOL BIOL, V96, P273, DOI 10.1016/0022-2836(75)90348-4; ZITOMER RS, 1976, J BIOL CHEM, V251, P6320	49	60	60	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					12696	12702		10.1074/jbc.273.21.12696	http://dx.doi.org/10.1074/jbc.273.21.12696			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582292	hybrid			2022-12-27	WOS:000073768500003
J	Deterding, LJ; Barr, DP; Mason, RP; Tomer, KB				Deterding, LJ; Barr, DP; Mason, RP; Tomer, KB			Characterization of cytochrome c free radical reactions with peptides by mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRAMOLECULAR ELECTRON-TRANSFER; LIPID-PEROXIDATION; HYDROGEN-PEROXIDE; PULSE-RADIOLYSIS; HYDROPEROXIDE; TRYPTOPHAN; REDUCTION; CATALASE; HEART; IONS	The reactions of horse heart cytochrome c, hydrogen peroxide, and the spin trap 3,5-dibromo-4-nitrosobenzenesulfonic acid with a series of polypeptides were investigated using mass spectrometry. The mass spectra obtained from these reactions revealed that after a free radical has been generated on the heme containing protein horse heart cytochrome c, it can be transferred to other biomolecules. Zn addition, the number of free radicals transferred to the target molecule could be determined. Recipient peptides/proteins that contained a tyrosine and/or tryptophan amino acid residue were most susceptible to free radical transfer. Using tandem mass spectrometry, the location of the 3,5-dibromo-4-nitrosobenzenesulfonic acid radical adduct on the nonapeptide RWIILGLNK was unequivocally determined to be at the tryptophan residue. We also demonstrated that the presence of an antioxidant in the reaction mixture not only inhibits free radical formation on horse heart cytochrome c, but also interferes with the transfer of the free radical, once it has been formed on cytochrome c.	NIEHS, Struct Biol Lab, Res Triangle Pk, NC 27709 USA; NIEHS, Lab Pharmacol & Chem, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Deterding, LJ (corresponding author), NIEHS, Struct Biol Lab, POB 12233,MD F0-03, Res Triangle Pk, NC 27709 USA.		Tomer, Kenneth B/E-8018-2013; Mason, Ronald P/G-5967-2019	Mason, Ronald P/0000-0002-1859-9109				Barr DP, 1996, CHEM RES TOXICOL, V9, P318, DOI 10.1021/tx9501501; Barr DP, 1996, J BIOL CHEM, V271, P15498, DOI 10.1074/jbc.271.26.15498; BIEMANN K, 1988, BIOMED ENVIRON MASS, V16, P99, DOI 10.1002/bms.1200160119; BOBROWSKI K, 1992, INT J RADIAT BIOL, V62, P507, DOI 10.1080/09553009214552431; BOBROWSKI K, 1990, INT J RADIAT BIOL, V57, P919, DOI 10.1080/09553009014551041; Brigellius R., 1985, OXIDATIVE STRESS, P243; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; COTGREAVE IA, 1988, ANNU REV PHARMACOL, V28, P189; DeGray JA, 1997, J BIOL CHEM, V272, P2359; FLAHERTY JT, 1988, FREE RADICAL BIO MED, V5, P409, DOI 10.1016/0891-5849(88)90115-3; GUNTHER MR, 1995, J BIOL CHEM, V270, P16075, DOI 10.1074/jbc.270.27.16075; Hawkins CL, 1997, BBA-MOL BASIS DIS, V1360, P84, DOI 10.1016/S0925-4439(96)00069-5; ICHIMORI K, 1993, FREE RADICAL RES COM, V19, pS129, DOI 10.3109/10715769309056s129; JANSSEN YMW, 1993, LAB INVEST, V69, P261; Kappus H., 1985, OXIDATIVE STRESS, V40, P273, DOI [DOI 10.1016/B978-0-12-642760-8.50016-8, 10.1016/B978-0-12-642760-8.50016-8]; KATTA V, 1991, ANAL CHEM, V63, P174, DOI 10.1021/ac00002a016; KAUR H, 1981, J CHEM SOC CHEM COMM, P142, DOI 10.1039/c39810000142; MILLER DM, 1990, FREE RADICAL BIO MED, V8, P95, DOI 10.1016/0891-5849(90)90148-C; Minetti M, 1996, BIOCHEM J, V319, P369, DOI 10.1042/bj3190369; Moreau S, 1996, J BIOL CHEM, V271, P32557, DOI 10.1074/jbc.271.51.32557; Ostdal H, 1997, FREE RADICAL BIO MED, V23, P754, DOI 10.1016/S0891-5849(97)00023-3; Pietraforte D, 1997, BIOCHEM J, V321, P743, DOI 10.1042/bj3210743; RADI R, 1993, FREE RADICAL BIO MED, V15, P653, DOI 10.1016/0891-5849(93)90169-U; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P112, DOI 10.1016/0003-9861(91)90171-E; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P118, DOI 10.1016/0003-9861(91)90172-F; RADI R, 1993, ARCH BIOCHEM BIOPHYS, V300, P409, DOI 10.1006/abbi.1993.1055; RICHTER C, 1995, BBA-MOL BASIS DIS, V1271, P67, DOI 10.1016/0925-4439(95)00012-S; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; SENTJURC M, 1990, ARCH BIOCHEM BIOPHYS, V282, P207, DOI 10.1016/0003-9861(90)90106-9; SENTJURC M, 1992, FREE RADICAL BIO MED, V13, P151, DOI 10.1016/0891-5849(92)90077-T; TAPPEL AL, 1953, FOOD RES, V18, P560; TOMER KB, 1994, MASS SPECTROM REV, V13, P431, DOI 10.1002/mas.1280130504; VanderZee J, 1997, BIOCHEM J, V322, P633	34	49	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					12863	12869		10.1074/jbc.273.21.12863	http://dx.doi.org/10.1074/jbc.273.21.12863			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582316	hybrid			2022-12-27	WOS:000073768500027
J	Eriksson, O; Fontaine, E; Bernardi, P				Eriksson, O; Fontaine, E; Bernardi, P			Chemical modification of arginines by 2,3-butanedione and phenylglyoxal causes closure of the mitochondrial permeability transition pore	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOSPORINE-A; HEART-MITOCHONDRIA; ARGINYL RESIDUES; CYCLOPHILIN; MODULATION; MEMBRANE; BINDING; INHIBITION; CHANNEL; ISOMERASE	We have investigated the role of arginine residues in the regulation of the mitochondrial permeability transition pore, a cyclosporin A-sensitive inner membrane channel. Isolated rat liver mitochondria were treated with the arginine-specific chemical reagent 2,3-butanedione or phenylglyoxal, followed by removal of excess free reagent. After this treatment, mitochondria accumulated Ca2+ normally, but did not undergo permeability transition following depolarization, a condition that normally triggers opening of the permeability transition pore. Inhibition by 2,3-butanedione and phenylglyoxal correlated with matrix pH, suggesting that the relevant arginine(s) are exposed to the matrix aqueous phase. Inhibition by 2,3-butanedione was potentiated by berate and was reversed upon its removal, whereas inhibition by phenylglyoxal was irreversible. Treatment with 2,3-butanedione or phenylglyoxal after induction of the permeability transition by Ca2+ overload resulted in pore closure despite the presence of 0.5 mM Ca2+. At concentrations that were fully effective at inhibiting the permeability transition, these arginine reagents (i) had no effect on the isomerase activity of cyclophilin D and (ii) did not affect the rate of ATP translocation and hydrolysis, as measured by the production of a membrane potential upon ATP addition in the presence of rotenone, We conclude that reaction with 2,3-butanedione and phenylglyoxal results in a stable chemical modification of critical arginine residue(s) located on the matrix side of the inner membrane, which, in turn, strongly favors a closed state of the pore.	Univ Grenoble 1, Lab Bioenerget Fondamentale & Appl, F-38041 Grenoble, France; Univ Padua, Sch Med, Dept Biomed Sci, Lab Biophys & Membrane Biol, I-35121 Padua, Italy; CNR, Unit Study Biomembranes, I-35121 Padua, Italy	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); University of Padua; Consiglio Nazionale delle Ricerche (CNR)	Bernardi, P (corresponding author), Dipartimento Sci Biomed Sperimentali, Viale Giuseppe Colombo 3, I-35121 Padua, Italy.		Eriksson-Rosenberg, Ove/GVU-6692-2022; Bernardi, Paolo/C-3656-2008; Fontaine, Eric/ABA-8853-2020	Bernardi, Paolo/0000-0001-9187-3736; Fontaine, Eric/0000-0002-5204-9477				Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BABURAJ K, 1991, BIOCHIM BIOPHYS ACTA, V1078, P258, DOI 10.1016/0167-4838(91)90567-J; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; BERNARDI P, 1992, J BIOL CHEM, V267, P8834; Bernardi P, 1996, J BIOENERG BIOMEMBR, V28, P131, DOI 10.1007/BF02110643; BERNARDI P, 1993, J BIOL CHEM, V268, P105; Beutner G, 1996, FEBS LETT, V396, P189, DOI 10.1016/0014-5793(96)01092-7; Broekemeier KM, 1995, BIOCHEMISTRY-US, V34, P16440, DOI 10.1021/bi00050a027; Brustovetsky N, 1996, BIOCHEMISTRY-US, V35, P8483, DOI 10.1021/bi960833v; CONNERN CP, 1992, BIOCHEM J, V284, P381, DOI 10.1042/bj2840381; Connern CP, 1996, BIOCHEMISTRY-US, V35, P8172, DOI 10.1021/bi9525177; COSTANTINI P, 1995, FEBS LETT, V362, P239, DOI 10.1016/0014-5793(95)00256-9; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; Eriksson O, 1997, FEBS LETT, V409, P361, DOI 10.1016/S0014-5793(97)00549-8; Garlid KD, 1996, BBA-BIOENERGETICS, V1275, P123, DOI 10.1016/0005-2728(96)00061-8; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KOFRON JL, 1991, BIOCHEMISTRY-US, V30, P6127, DOI 10.1021/bi00239a007; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; NICOLLI A, 1993, BIOCHEMISTRY-US, V32, P4461, DOI 10.1021/bi00067a039; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; NOVGORODOV SA, 1992, J BIOL CHEM, V267, P16274; PATTHY L, 1980, EUR J BIOCHEM, V105, P387, DOI 10.1111/j.1432-1033.1980.tb04512.x; PFEIFFER DR, 1995, J BIOL CHEM, V270, P4923, DOI 10.1074/jbc.270.9.4923; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; RIORDAN JF, 1973, BIOCHEMISTRY-US, V12, P3915, DOI 10.1021/bi00744a020; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; TAKAHASHI K, 1968, J BIOL CHEM, V243, P6171; Woodfield KY, 1997, BBA-GENE STRUCT EXPR, V1351, P27, DOI 10.1016/S0167-4781(97)00017-1; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YANKEELOV JA, 1968, J AM CHEM SOC, V90, P1664, DOI 10.1021/ja01008a056; YU LP, 1994, BBA-PROTEIN STRUCT M, V1209, P24, DOI 10.1016/0167-4838(94)90132-5; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	37	41	42	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12669	12674		10.1074/jbc.273.20.12669	http://dx.doi.org/10.1074/jbc.273.20.12669			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575230	hybrid			2022-12-27	WOS:000073629800095
J	Fathy, DB; Mathis, SA; Leeb, T; Leeb-Lundberg, LMF				Fathy, DB; Mathis, SA; Leeb, T; Leeb-Lundberg, LMF			A single position in the third transmembrane domains of the human B1 and B2 bradykinin receptors is adjacent to and discriminates between the C-terminal residues of subtype-selective ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARTIC-ACID; AGONIST BINDING; KININ RECEPTORS; ANTAGONISTS; AFFINITY; PEPTIDES; MUTATIONS; SITE; MUTAGENESIS; RHODOPSIN	In order to identify agonist-and antagonist-binding epitopes in the human B1 and B2 bradyknin (BK) receptors, we exploited the ability of these receptors to discriminate between peptide Ligands that differ only by the absence (B1) and presence (B2) of a C-terminal Arg, This was done by constructing chimeric proteins in which specific domains were exchanged between these receptors as recently described by us (Leeb, T., Mathis, S. A. and Leeb-Lundberg, L. M. F. (1997) J. Biol. Chem. 272, 311-317). The constructs were then expressed in HEK293 and A10 cells and assayed by radioligand binding and by agonist-stimulated inositol phospholipid hydrolysis and intracellular Ca2+ mobilization. Substitution of the third transmembrane domain (TM-III) of the B1 receptor in the B2 receptor (B2(B1III)) dramatically reduced the affinities of Ba-selective peptide ligands including both the agonist BK and the antagonist NPC17731. High affinity binding of both ligands to B2(E1III) was fully regained when one residue, Lys(111), in TM-III of this chimera was replaced with the corresponding wild-type (WT) B2 receptor residue, Ser (B2(B1IIIS(111))). Replacement of Ser(111) with Lys in the WT B2 receptor decreased the affinities of BK and NPC17731 and increased the affinity of the B1-selective des-Arg(10) analog of NPC17731, NPC18565. The results show that the C-terminal residue of peptide agonists and antagonists when bound to the B2 receptor is adjacent to Ser(111) in the receptor. A Lys at this position, as is the case in the WT B1 receptor, provides a positive charge that repels the C-terminal Arg in Ba-selective peptides and attracts the negative charge of the C terminus of B1-selective peptides, which lack the C-terminal Arg. Therefore, the residues at this one single position are crucial in determining the peptide selectivity of B1 and B2 BK receptors.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio	Leeb-Lundberg, LMF (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.		Leeb, Tosso/G-3187-2014	Leeb, Tosso/0000-0003-0553-4880	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM041659, R01GM041659] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41659] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALI SA, 1995, BIOTECHNIQUES, V18, P746; Alla SA, 1996, J BIOL CHEM, V271, P1748, DOI 10.1074/jbc.271.3.1748; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P8812, DOI 10.1021/bi00027a033; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; FRAZER CM, 1988, MOL PHARMACOL, V36, P840; Gobeil F, 1996, HYPERTENSION, V28, P833, DOI 10.1161/01.HYP.28.5.833; Herzig MCS, 1996, J BIOL CHEM, V271, P29746, DOI 10.1074/jbc.271.47.29746; HERZIG MCS, 1995, J BIOL CHEM, V270, P20591, DOI 10.1074/jbc.270.35.20591; HESS JF, 1992, BIOCHEM BIOPH RES CO, V184, P260, DOI 10.1016/0006-291X(92)91187-U; HOCK FJ, 1991, BRIT J PHARMACOL, V102, P769, DOI 10.1111/j.1476-5381.1991.tb12248.x; Jarnagin K, 1996, J BIOL CHEM, V271, P28277, DOI 10.1074/jbc.271.45.28277; KYLE DJ, 1994, J MED CHEM, V37, P1347, DOI 10.1021/jm00035a015; KYLE DJ, 1993, J MED CHEM, V36, P1450, DOI 10.1021/jm00062a018; KYLE DJ, 1991, J MED CHEM, V34, P2649, DOI 10.1021/jm00112a047; KYLE DJ, 1991, J MED CHEM, V34, P1230, DOI 10.1021/jm00107a052; LEE JA, 1994, BIOCHEMISTRY-US, V33, P14543, DOI 10.1021/bi00252a022; LEE SC, 1990, INT J PEPT PROT RES, V35, P367; Leeb T, 1997, J BIOL CHEM, V272, P311; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; MANSOUR A, 1992, EUR J PHARM-MOLEC PH, V227, P205, DOI 10.1016/0922-4106(92)90129-J; Mathis SA, 1996, MOL PHARMACOL, V50, P128; MENKE JG, 1994, J BIOL CHEM, V269, P21583; Minami M, 1996, MOL PHARMACOL, V50, P1413; NARDONE J, 1994, P NATL ACAD SCI USA, V91, P4417, DOI 10.1073/pnas.91.10.4417; NEHRING RB, 1995, DNA CELL BIOL, V14, P939, DOI 10.1089/dna.1995.14.939; NOVOTNY EA, 1994, BIOCHEM BIOPH RES CO, V201, P523, DOI 10.1006/bbrc.1994.1733; PERLMAN JH, 1994, J BIOL CHEM, V269, P1610; REGOLI D, 1980, PHARMACOL REV, V32, P1; RHALEB NE, 1990, BRIT J PHARMACOL, V99, P445, DOI 10.1111/j.1476-5381.1990.tb12947.x; ROSENKILDE MM, 1994, J BIOL CHEM, V269, P28160; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; STEWART JM, 1990, J CARDIOVASC PHARM, V15, pS69, DOI 10.1097/00005344-199000156-00013; STRADER CD, 1988, J BIOL CHEM, V263, P10267; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; TOMIC M, 1993, BIOCHEM BIOPH RES CO, V191, P102; TROPEA MM, 1992, CAN J PHYSIOL PHARM, V70, P1360, DOI 10.1139/y92-191; Wirth K J, 1992, Agents Actions Suppl, V38 ( Pt 2), P406; YOUNG JK, 1994, BIOPOLYMERS, V34, P611, DOI 10.1002/bip.360340504; ZHU GC, 1992, J CELL BIOCHEM, V50, P159	40	43	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12210	12218		10.1074/jbc.273.20.12210	http://dx.doi.org/10.1074/jbc.273.20.12210			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575169	hybrid			2022-12-27	WOS:000073629800034
J	Guo, Q; Robinson, N; Mattson, MP				Guo, Q; Robinson, N; Mattson, MP			Secreted beta-amyloid precursor protein counteracts the proapoptotic action of mutant presenilin-1 by activation of NF-kappa B and stabilization of calcium homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; CELL-DEATH; HIPPOCAMPAL-NEURONS; CEREBROSPINAL-FLUID; PEPTIDE TOXICITY; CEREBRAL-CORTEX; PC12 CELLS; IN-VIVO; APOPTOSIS; EXPRESSION	Mutations in the presenilin-1 (PS-1) gene account for approximately 50% of the cases of autosomal dominant, early onset, inherited forms of Alzheimer's disease (AD), PS-1 is an integral membrane protein expressed in neurons and is localized primarily in the endoplasmic reticulum (ER), PS-1 mutations may promote neuronal degeneration by altering the processing of the beta-amyloid precursor protein (APP) and/or by engaging apoptotic pathways. Alternative processing of APP in AD may increase production of neurotoxic amyloid beta-peptide (AP) and reduce production of the neuroprotective alpha-secretase-derived form of APP (sAPP alpha). In differentiated PC12 cells expressing an AD-linked PS-1 mutation (L286V), sAPP alpha activated the transcription factor NF-kappa B and prevented apoptosis induced by A beta. Treatment of cells with K beta decoy DNA blocked the antiapoptotic action of sAPP alpha, demonstrating the requirement for NF-kappa B activation in the cytoprotective action of sAPP alpha. Cells expressing mutant PS-1 exhibited an aberrant pattern of NF-kappa B activity following exposure to A beta, which was characterized by enhanced early activation of NF-kappa B followed by a prolonged depression of activity. Blockade of NF-kappa B activity in cells expressing mutant PS-1 by kappa B decoy DNA was associated with enhanced A beta-induced increases of [Ca2+](i) and mitochondrial dysfunction. Treatment of cells with sAPP alpha stabilized [Ca2+](i) and mitochondrial function and suppressed oxidative stress by a mechanism involving activation of NF-kappa B. Blockade of ER calcium release prevented (and stimulation of ER calcium release by thapsigarin induced) apoptosis in cells expressing mutant PS-1, suggesting a pivotal role for ER calcium release in the proapoptotic action of mutant PS-1. Finally, a role for NF-kappa B in preventing apoptosis induced by ER calcium release was demonstrated by data showing that sAPP alpha prevents thapsigargin-induced apoptosis, an effect blocked by kappa B decoy DNA. We conclude that sAPP alpha stabilizes cellular calcium homeostasis and protects neural cells against the proapoptotic action of mutant PS-1 by a mechanism involving activation of NF-kappa B. The data further suggest that PS-1 mutations result in aberrant NF-kappa B regulation that may render neurons vulnerable to apoptosis.	Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Mattson, MP (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging, 211 Sanders Brown Bldg, Lexington, KY 40536 USA.		Mattson, Mark P/F-6038-2012		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035253] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG005144, R01AG014554] Funding Source: NIH RePORTER; NIA NIH HHS [AG14554, AG05144] Funding Source: Medline; NINDS NIH HHS [NS35253] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARGER SW, 1995, P NATL ACAD SCI USA, V92, P9328, DOI 10.1073/pnas.92.20.9328; Barger SW, 1996, MOL BRAIN RES, V40, P116; BEAL MF, 1995, ANN NEUROL, V38, P357, DOI 10.1002/ana.410380304; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604; Busciglio J, 1997, J NEUROSCI, V17, P5101, DOI 10.1523/jneurosci.17-13-05101.1997; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; CLARK RF, 1995, NAT GENET, V11, P219, DOI 10.1038/ng1095-219; Cook DG, 1996, P NATL ACAD SCI USA, V93, P9223, DOI 10.1073/pnas.93.17.9223; Cribbs DH, 1996, AM J PATHOL, V148, P1797; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Elder GA, 1996, J NEUROSCI RES, V45, P308; Flohe L, 1997, FREE RADICAL BIO MED, V22, P1115, DOI 10.1016/S0891-5849(96)00501-1; FORLONI G, 1993, NEUROREPORT, V4, P523, DOI 10.1097/00001756-199305000-00015; FUKUYAMA R, 1994, BRAIN RES, V667, P269, DOI 10.1016/0006-8993(94)91505-9; Furukawa K, 1996, J NEUROCHEM, V67, P1882, DOI 10.1046/j.1471-4159.1996.67051882.x; GABUZDA D, 1994, J BIOL CHEM, V269, P13623; Giannakopoulos P, 1997, AM J PATHOL, V150, P429; GOODMAN Y, 1994, EXP NEUROL, V128, P1, DOI 10.1006/exnr.1994.1107; Goodman Y, 1996, J NEUROCHEM, V66, P869, DOI 10.1046/j.1471-4159.1996.66020869.x; Guo Q, 1996, NEUROREPORT, V8, P379, DOI 10.1097/00001756-199612200-00074; Guo Q, 1997, J NEUROSCI, V17, P4212; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Haug LS, 1996, NEURODEGENERATION, V5, P169, DOI 10.1006/neur.1996.0024; ITO E, 1994, P NATL ACAD SCI USA, V91, P534, DOI 10.1073/pnas.91.2.534; Janicki S, 1997, J CELL BIOL, V139, P485, DOI 10.1083/jcb.139.2.485; Jordan J, 1997, J NEUROCHEM, V68, P1612; Kaltschmidt B, 1997, P NATL ACAD SCI USA, V94, P2642, DOI 10.1073/pnas.94.6.2642; KANEKO Y, 1994, CANCER LETT, V97, P147; Keller JN, 1998, J NEUROSCI, V18, P687; Khan AA, 1996, SCIENCE, V273, P503, DOI 10.1126/science.273.5274.503; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kruman I, 1997, J NEUROSCI, V17, P5089; Lah JJ, 1997, J NEUROSCI, V17, P1971; Lee MK, 1996, J NEUROSCI, V16, P7513, DOI 10.1523/jneurosci.16-23-07513.1996; Lehmann S, 1997, J BIOL CHEM, V272, P12047, DOI 10.1074/jbc.272.18.12047; Li XJ, 1996, NEURON, V17, P1015, DOI 10.1016/S0896-6273(00)80231-7; Liguri G, 1996, NEUROSCI LETT, V210, P153, DOI 10.1016/0304-3940(96)12696-3; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; Marin MC, 1996, ONCOGENE, V12, P2259; MARK RJ, 1995, J NEUROSCI, V15, P6239; Mark RJ, 1997, J NEUROCHEM, V68, P255; Markesbery WR, 1997, FREE RADICAL BIO MED, V23, P134, DOI 10.1016/S0891-5849(96)00629-6; Mattson MP, 1997, J NEUROSCI RES, V49, P681, DOI 10.1002/(SICI)1097-4547(19970915)49:6<681::AID-JNR3>3.0.CO;2-3; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; MATTSON MP, 1993, BRAIN RES, V621, P35, DOI 10.1016/0006-8993(93)90295-X; MATTSON MP, 1993, EXP NEUROL, V121, P1, DOI 10.1006/exnr.1993.1066; Mattson MP, 1998, INT REV NEUROBIOL, V42, P103, DOI 10.1016/S0074-7742(08)60609-1; Moretti A., 1997, ADV CELL AGING GERON, V2, P129; Murphy GM, 1996, AM J PATHOL, V149, P1839; NIXON RA, 1994, ANN NY ACAD SCI, V747, P77; PALMERT MR, 1990, NEUROLOGY, V40, P1028, DOI 10.1212/WNL.40.7.1028; Pedersen WA, 1997, J BIOL CHEM, V272, P22397, DOI 10.1074/jbc.272.36.22397; Prehn JHM, 1997, J NEUROCHEM, V68, P1679; QUERFURTH HW, 1994, BIOCHEMISTRY-US, V33, P4550, DOI 10.1021/bi00181a016; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SHEARMAN MS, 1994, P NATL ACAD SCI USA, V91, P1470, DOI 10.1073/pnas.91.4.1470; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SMALE G, 1995, EXP NEUROL, V133, P225, DOI 10.1006/exnr.1995.1025; SU JH, 1976, NEUROREPORT, V2529, P94; Taglialatela G, 1997, J NEUROSCI RES, V47, P155; TANAKA H, 1994, NUCLEIC ACIDS RES, V22, P3069, DOI 10.1093/nar/22.15.3069; Terai K, 1996, BRAIN RES, V735, P159; Tong L, 1996, J NEUROSCI RES, V45, P1, DOI 10.1002/(SICI)1097-4547(19960701)45:1<1::AID-JNR1>3.0.CO;2-I; URAKAMI K, 1992, ACTA NEUROL SCAND, V85, P343; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; Weidemann A, 1997, NAT MED, V3, P328, DOI 10.1038/nm0397-328; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Xia WM, 1997, P NATL ACAD SCI USA, V94, P8208, DOI 10.1073/pnas.94.15.8208; YAN SD, 1995, NAT MED, V1, P693, DOI 10.1038/nm0795-693	82	164	179	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12341	12351		10.1074/jbc.273.20.12341	http://dx.doi.org/10.1074/jbc.273.20.12341			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575187	hybrid			2022-12-27	WOS:000073629800052
J	Schaffner-Reckinger, E; Gouon, V; Melchior, C; Plancon, S; Kieffer, N				Schaffner-Reckinger, E; Gouon, V; Melchior, C; Plancon, S; Kieffer, N			Distinct involvement of beta(3) integrin cytoplasmic domain tyrosine residues 747 and 759 in integrin-mediated cytoskeletal assembly and phosphotyrosine signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESIONS; EXTRACELLULAR-MATRIX; CELL-ADHESION; NPXY MOTIF; ALPHA-V; SUBUNIT; PHOSPHORYLATION; TAIL; TRANSDUCTION; BINDING	We have investigated the structural requirements of the beta(3) integrin subunit cytoplasmic domain necessary for tyrosine phosphorylation of focal adhesion kinase (FAK) and paxillin during alpha(v) beta(3)-mediated cell spreading. Using CHO cells transfected with various beta(3) mutants, we demonstrate a close correlation between alpha(v) beta(3)-mediated cell spreading and tyrosine phosphorylation of FAK and paxillin, and highlight a distinct involvement of the NPLY747 and NITY759 motifs in these signaling processes. Deletion of the NITY759 motif alone was sufficient to completely prevent alpha(v) beta(3)-dependent focal contact formation, cell spreading, and FAK/paxillin phosphorylation, The single Y759A substitution induced a strong inhibitory phenotype, while the more conservative, but still phosphorylation-defective, Y759F mutation restored wild type receptor function. Alanine substitution of the highly conserved Tyr(747) completely abolished gp,dependent formation of focal adhesion plaques, cell spreading, and FAK/paxillin phosphorylation, whereas a Y747F substitution only partially restored these events. As none of these mutations affected receptor-ligand interaction, our results suggest that the structural integrity of the NITU759 motif, rather than the phosphorylation status of Tyr(759) is important for beta(3)-mediated cytoskeleton reorganization and tyrosine phosphorylation of FAK and paxillin, while the presence of Tyr at residue 747 within the NPLY747 motif is required for optimal beta(3) post-ligand binding events.	Ctr Univ, CNRS, Lab Francoluxembourgeois Rech Biomed, L-1511 Luxembourg, Luxembourg; Ctr Univ, CRP Sante, L-1511 Luxembourg, Luxembourg	University of Luxembourg; Luxembourg Institute of Health; University of Luxembourg	Kieffer, N (corresponding author), Ctr Univ, CNRS, Lab Francoluxembourgeois Rech Biomed, 162A Ave Faiencerie, L-1511 Luxembourg, Luxembourg.	kieffer@cu.lu						AKIYAMA SK, 1994, J BIOL CHEM, V269, P15961; BALZAC F, 1994, J CELL BIOL, V127, P557, DOI 10.1083/jcb.127.2.557; Blystone SD, 1996, J BIOL CHEM, V271, P31458, DOI 10.1074/jbc.271.49.31458; Blystone SD, 1997, J BIOL CHEM, V272, P28757, DOI 10.1074/jbc.272.45.28757; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; Chang DD, 1997, J CELL BIOL, V138, P1149, DOI 10.1083/jcb.138.5.1149; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CONE RI, 1994, CELL ADHES COMMUN, V2, P101, DOI 10.3109/15419069409004430; DECKMYN H, 1994, BRIT J HAEMATOL, V87, P562, DOI 10.1111/j.1365-2141.1994.tb08313.x; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; Eigenthaler R, 1997, J BIOL CHEM, V272, P7693, DOI 10.1074/jbc.272.12.7693; FILARDO EJ, 1995, J CELL BIOL, V130, P441, DOI 10.1083/jcb.130.2.441; FILARDO EJ, 1994, J BIOL CHEM, V269, P4641; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; FREED E, 1989, EMBO J, V8, P2955, DOI 10.1002/j.1460-2075.1989.tb08445.x; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; HIRST R, 1986, P NATL ACAD SCI USA, V83, P6470, DOI 10.1073/pnas.83.17.6470; JOHANSSON MW, 1994, J CELL BIOL, V126, P1299, DOI 10.1083/jcb.126.5.1299; Kashiwagi H, 1997, J CELL BIOL, V137, P1433, DOI 10.1083/jcb.137.6.1433; Kieffer N, 1996, CELL ADHES COMMUN, V4, P25, DOI 10.3109/15419069609010761; KIEFFER N, 1991, J CELL BIOL, V113, P451, DOI 10.1083/jcb.113.2.451; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; Law DA, 1996, J BIOL CHEM, V271, P10811, DOI 10.1074/jbc.271.18.10811; LEONG L, 1995, J CELL SCI, V108, P3817; LIN TH, 1995, J BIOL CHEM, V270, P16189, DOI 10.1074/jbc.270.27.16189; Liu XY, 1996, P NATL ACAD SCI USA, V93, P11819, DOI 10.1073/pnas.93.21.11819; MARCANTONIO EE, 1990, CELL REGUL, V1, P597, DOI 10.1091/mbc.1.8.597; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; OTOOLE TE, 1995, J BIOL CHEM, V270, P8553, DOI 10.1074/jbc.270.15.8553; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHATTIL SJ, 1995, J CELL BIOL, V131, P807, DOI 10.1083/jcb.131.3.807; SOLOWSKA J, 1989, J CELL BIOL, V109, P853, DOI 10.1083/jcb.109.2.853; Tahiliani PD, 1997, J BIOL CHEM, V272, P7892, DOI 10.1074/jbc.272.12.7892; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; vanderGeer P, 1996, P NATL ACAD SCI USA, V93, P963, DOI 10.1073/pnas.93.3.963; Vignoud L, 1997, J CELL SCI, V110, P1421; YLANNE J, 1995, J BIOL CHEM, V270, P9550	46	72	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12623	12632		10.1074/jbc.273.20.12623	http://dx.doi.org/10.1074/jbc.273.20.12623			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575224	hybrid			2022-12-27	WOS:000073629800089
J	Tseng, YH; Schuler, LA				Tseng, YH; Schuler, LA			Transcriptional regulation of interleukin-1 beta gene by interleukin-1 beta itself is mediated in part by Oct-1 in thymic stromal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROINTERLEUKIN 1-BETA GENE; COLONY-STIMULATING FACTOR; DNA-BINDING ACTIVITY; NF-KAPPA-B; EPITHELIAL-CELLS; CYTOKINE PRODUCTION; IL-1-BETA TRANSCRIPTION; IFN-GAMMA; EXPRESSION; IL-1	Interleukin (IL)-1 is involved in many processes, including thymic development. However, control of IL-1 expression in thymic-derived stromal cells (TSC) has not been reported. We found that IL-1 beta increased steady-state mRNA levels for IL-1 alpha and IL-1 beta in TSC-936 and TSC-2C4 cells; stability was not a major determinant of this effect. To study transcriptional regulation of IL-1 beta, we functionally characterized 4 kilobase pairs of the 5'-flanking region and first intron of the bovine IL-1 beta gene. The -470/+14 fragment was sufficient to confer maximal responsiveness to IL-1 beta upon transfection into these cell lines. Progressive 5' deletions identified several IL-1 beta-responsive regions, including -308 to -226, which we further characterized. Electrophoretic mobility shift and supershift analyses showed that IL-1 beta induced the ability to form multiple protein complexes with -261/-226 and that one of these contained nuclear factor Oct-1. A competitor containing: a mutated Oct consensus site failed to compete not only for this complex but others as well, suggesting that this sequence regulates binding of other proteins to this region. Functional analysis confirmed that this element was essential for maximal induction of transcription. These findings document a heretofore undescribed mechanism utilized by TSC for regulation of IL-1 beta transcription by IL-1 beta itself.	Univ Wisconsin, Dept Comparat Biosci, Program Dev Biol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Schuler, LA (corresponding author), Univ Wisconsin, Dept Comparat Biosci, Program Dev Biol, 2015 Linden Dr W, Madison, WI 53706 USA.		Tseng, Yu-Hua/AAE-6471-2021	Tseng, Yu-Hua/0000-0003-2053-9559				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; AURON PE, 1994, EUR CYTOKINE NETW, V5, P573; BankersFulbright JL, 1996, LIFE SCI, V59, P61, DOI 10.1016/0024-3205(96)00135-X; Bonizzi G, 1996, EUR J BIOCHEM, V242, P544, DOI 10.1111/j.1432-1033.1996.0544r.x; Bungert J, 1996, ANN MED, V28, P47, DOI 10.3109/07853899608999074; BURAS JA, 1994, J IMMUNOL, V152, P4444; CARDING SR, 1991, IMMUNOL TODAY, V12, P239, DOI 10.1016/0167-5699(91)90037-T; CHASE CCL, 1993, VIROLOGY, V194, P365, DOI 10.1006/viro.1993.1269; CHODOSH LA, 1993, CURRENT PROTOCOLS MO; CLARK BD, 1986, NUCLEIC ACIDS RES, V14, P7897, DOI 10.1093/nar/14.20.7897; COGSWELL JP, 1994, J IMMUNOL, V153, P712; Delhase M, 1996, J BIOL CHEM, V271, P32349, DOI 10.1074/jbc.271.50.32349; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; DINARELLO CA, 1987, J IMMUNOL, V139, P1902; DONNELLY RP, 1990, J IMMUNOL, V145, P569; DOWER SK, 1992, CHEM IMMUNOL, V51, P33; FENTON MJ, 1992, INT J IMMUNOPHARMACO, V14, P401, DOI 10.1016/0192-0561(92)90170-P; GALY AHM, 1990, CELL IMMUNOL, V129, P161, DOI 10.1016/0008-8749(90)90195-W; GALY AHM, 1989, CELL IMMUNOL, V124, P13, DOI 10.1016/0008-8749(89)90108-1; GALY AHM, 1991, J IMMUNOL, V147, P3823; GERY I, 1972, J EXP MED, V136, P128, DOI 10.1084/jem.136.1.128; GODAMBE SA, 1994, DNA CELL BIOL, V13, P561, DOI 10.1089/dna.1994.13.561; GODAMBE SA, 1993, CYTOKINE, V5, P327, DOI 10.1016/1043-4666(93)90064-C; GOTLIEB WH, 1990, J IMMUNOL, V144, P2072; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; GRACE TM, 1997, DEVELOPMENT, V124, P907; Grenfell SJ, 1996, BIOCHEM J, V315, P889, DOI 10.1042/bj3150889; Hattori N, 1996, J EXP MED, V184, P1137, DOI 10.1084/jem.184.3.1137; HEDGES SR, 1995, TRENDS MICROBIOL, V3, P266, DOI 10.1016/S0966-842X(00)88941-6; HERBELIN A, 1994, J IMMUNOL, V153, P1973; HERR W, 1995, GENE DEV, V9, P1679, DOI 10.1101/gad.9.14.1679; KAUSHANSKY K, 1994, J IMMUNOL, V152, P1812; KINGSTON RE, 1990, CURRENT PROTOCOLS MO; KOMINATO Y, 1995, MOL CELL BIOL, V15, P58; Koyama Y, 1996, J IMMUNOL, V157, P5097; LE PT, 1991, J EXP MED, V174, P1147, DOI 10.1084/jem.174.5.1147; LEDERER J, 1993, MOL IMMUNOL, V30, P191, DOI 10.1016/0161-5890(93)90091-O; MALISZEWSKI CR, 1988, MOL IMMUNOL, V25, P429, DOI 10.1016/0161-5890(88)90162-9; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; Martin MU, 1997, EUR CYTOKINE NETW, V8, P5; MCCONKEY DJ, 1990, J BIOL CHEM, V265, P3009; Newton R, 1996, BIOCHEM BIOPH RES CO, V218, P518, DOI 10.1006/bbrc.1996.0093; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; Peltz Stuart W., 1992, Current Opinion in Cell Biology, V4, P979, DOI 10.1016/0955-0674(92)90129-Z; Pezzano M, 1996, CELL IMMUNOL, V169, P174, DOI 10.1006/cimm.1996.0108; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; Schluns KS, 1997, J IMMUNOL, V158, P2704; SCOTT P, 1994, 76 ANN M END SOC AN; SEGIL N, 1991, SCIENCE, V254, P1814, DOI 10.1126/science.1684878; SHIRAKAWA F, 1993, MOL CELL BIOL, V13, P1332, DOI 10.1128/MCB.13.3.1332; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; Shu SZ, 1996, THYMUS, V24, P89; STAUDT LM, 1991, ANNU REV IMMUNOL, V9, P373; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Tseng YH, 1997, MOL CELL ENDOCRINOL, V128, P117, DOI 10.1016/S0303-7207(97)04028-8; Tsukada J, 1996, MOL CELL BIOL, V16, P2183; TSUKADA J, 1994, MOL CELL BIOL, V14, P7285, DOI 10.1128/MCB.14.11.7285; ULLMAN KS, 1991, SCIENCE, V254, P558, DOI 10.1126/science.1683003; WARNER SJC, 1987, J EXP MED, V165, P1316, DOI 10.1084/jem.165.5.1316; WARNER SJC, 1987, J IMMUNOL, V139, P1911; Wegner M, 1993, CURR OPIN CELL BIOL, V5, P488, DOI 10.1016/0955-0674(93)90015-I; Wu GD, 1997, J BIOL CHEM, V272, P2396; Yu PW, 1997, CYTOKINE, V9, P1, DOI 10.1006/cyto.1996.0129; ZHANG Y, 1993, MOL CELL BIOL, V13, P3831, DOI 10.1128/MCB.13.6.3831; ZLOTNIK A, 1995, CURR OPIN IMMUNOL, V7, P206, DOI 10.1016/0952-7915(95)80005-0; ZUNIGAPFLUCKER JC, 1995, SCIENCE, V268, P1906, DOI 10.1126/science.7541554	68	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12633	12641		10.1074/jbc.273.20.12633	http://dx.doi.org/10.1074/jbc.273.20.12633			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575225	hybrid			2022-12-27	WOS:000073629800090
J	Vogler, O; Bogatkewitsch, GS; Wriske, C; Krummenerl, P; Jakobs, KH; van Koppen, CJ				Vogler, O; Bogatkewitsch, GS; Wriske, C; Krummenerl, P; Jakobs, KH; van Koppen, CJ			Receptor subtype-specific regulation of muscarinic acetylcholine receptor sequestration by dynamin - Distinct sequestration of m2 receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; BETA-ADRENERGIC-RECEPTOR; FUNCTIONAL EXPRESSION; CHOLINERGIC RECEPTOR; COATED VESICLES; INTERNALIZATION; CELLS; RESENSITIZATION; DESENSITIZATION; MECHANISMS	Sustained stimulation of muscarinic acetylcholine receptors (mAChRs) and other G protein-coupled receptors usually leads to a loss of receptor binding sites from the plasma membrane, referred to as receptor sequestration. Receptor sequestration can occur via endocytosis of clathrin-coated vesicles that bud from the plasma membrane into the cell but may also be accomplished by other, as yet ill-defined, mechanisms. Previous work has indicated that the monomeric GTPase dynamin controls the endocytosis of plasma membrane receptors via clathrin-coated vesicles. To investigate whether mAChRs sequester in a receptor subtype-specific manner via dynamin-dependent clathrin-coated vesicles, we tested the effect of overexpressing the dominant-negative dynamin mutant K44A on m1, m2, m3, and m4 mAChR sequestration in HEK-293 cells. The m1, m2, m3, and m4 mAChRs sequestered rapidly in HEK-293 cells following agonist exposure but displayed dissimilar sequestration pathways. Overexpression of dynamin K44A mutant fully blocked m1 and m3 mAChR sequestration, whereas m2 mAChR sequestration was not affected. Also, m4 mAChRs, which like m2 mAChRs preferentially couple to pertussis toxin-sensitive G proteins, sequestered in a completely dynamin-dependent manner. Following agonist removal, sequestered m1 mAChRs fully reappeared on the cell surface, whereas sequestered m2 mAChRs did not. The distinct sequestration of m2 mAChRs was also apparent in COS-7 and Chinese hamster ovary cells. We conclude that the m2 mAChR displays unique subtype-specific sequestration that distinguishes this receptor from the m1, m3, and m4 subtypes, These results are the first to demonstrate that receptor sequestration represents a new type of receptor subtype-specific regulation within the family of mAChRs.	Univ Essen Gesamthsch, Inst Pharmakol, D-45122 Essen, Germany	University of Duisburg Essen	van Koppen, CJ (corresponding author), Univ Essen Gesamthsch, Inst Pharmakol, D-45122 Essen, Germany.	van_koppen@uni-essen.de	Vögler, Oliver/D-7658-2011					Bogatkewitsch GS, 1996, MOL PHARMACOL, V50, P424; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; Daunt DA, 1997, MOL PHARMACOL, V51, P711, DOI 10.1124/mol.51.5.711; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; Goldman PS, 1996, J BIOL CHEM, V271, P4215; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GUREVICH VV, 1993, J BIOL CHEM, V268, P16879; Holtmann MH, 1996, J BIOL CHEM, V271, P23566, DOI 10.1074/jbc.271.38.23566; HULME EC, 1990, ANNU REV PHARMACOL, V30, P633, DOI 10.1146/annurev.pa.30.040190.003221; Kurzchalia TV, 1996, FEBS LETT, V389, P52, DOI 10.1016/0014-5793(96)00585-6; MARGOLSKEE RF, 1993, BIOTECHNIQUES, V15, P906; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P23682, DOI 10.1074/jbc.272.38.23682; PERALTA EG, 1987, SCIENCE, V236, P600, DOI 10.1126/science.3107123; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; RAPOSO G, 1989, EUR J CELL BIOL, V50, P340; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; ROETTGER BF, 1995, J CELL BIOL, V130, P579, DOI 10.1083/jcb.130.3.579; SCHERER NM, 1990, BIOCHEMISTRY-US, V29, P8475, DOI 10.1021/bi00488a039; SHAPIRO RA, 1988, J BIOL CHEM, V263, P18397; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; Tolbert LM, 1996, J BIOL CHEM, V271, P17335, DOI 10.1074/jbc.271.29.17335; TSUGA H, 1994, J BIOL CHEM, V269, P32522; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; VANKOPPEN CJ, 1994, EUR J BIOCHEM, V222, P525; VANKOPPEN CJ, 1993, BIOCHIM BIOPHYS ACTA, V1173, P342, DOI 10.1016/0167-4781(93)90135-Z; VONZASTROW M, 1993, J BIOL CHEM, V268, P763; YANG J, 1995, MOL PHARMACOL, V48, P477; YU SS, 1993, J BIOL CHEM, V268, P337; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	32	70	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12155	12160		10.1074/jbc.273.20.12155	http://dx.doi.org/10.1074/jbc.273.20.12155			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575162	hybrid			2022-12-27	WOS:000073629800027
J	Zhao, H; Okada, S; Pessin, JE; Koretzky, GA				Zhao, H; Okada, S; Pessin, JE; Koretzky, GA			Insulin receptor-mediated dissociation of Grb2 from Sos involves phosphorylation of Sos by kinase(s) other than extracellular signal-regulated kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; ACTIVATED PROTEIN-KINASE; RAS ACTIVATION; SUBSTRATE RECOGNITION; SOS-GRB2 COMPLEX; TYROSINE KINASES; GENE-EXPRESSION; DOWN-REGULATION; FACTOR HSOS1; STIMULATION	The Ras signaling pathway is rapidly activated and then down-regulated following stimulation of multiple cell-surface receptors including the insulin receptor (IR), Much recent attention has focused on elucidating the mechanism of Ras inactivation following IR engagement. Previous data suggest that IR-mediated serine/threonine phosphorylation of the Ras guanine nucleotide exchange factor Sos correlates with its decreased affinity for the adapter protein Grb2. This phosphorylation-induced disassembly of the Grb2.Sos complex is thought to be responsible, at least in part, for diminishing Ras activity in Chinese hamster ovary cells. In this report, we confirm the causal relationship between Sos phosphorylation and Grb2/Sos dissociation, We then examine several putative phosphorylation sites of Sos that could potentially regulate this event. Since a number of reports suggest that extracellular signal-regulated kinase (ERK) phosphorylates Sos, we generated a Sos mutant lacking all seven canonical phosphorylation sites for ERK, This mutant is a poor substrate of activated ERK in vitro and fails to undergo a change in its electrophoretic mobility following IR stimulation. It is, however, phosphorylated after IR stimulation when ex pressed in Chinese hamster ovary cells, Interestingly, the mutant protein still dissociates from Grb2 following insulin stimulation, suggesting that ERK is not the kinase responsible for regulating the stability of the Grb2.Sos complex.	Univ Iowa, Coll Med, Program Mol Biol, Iowa City, IA 52242 USA; Univ Iowa, Dept Phys & Biophys, Iowa City, IA 52242 USA; Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Interdisciplinary Program Immunol, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa; University of Iowa	Koretzky, GA (corresponding author), Univ Iowa, Coll Med, Program Mol Biol, 540 EMRB, Iowa City, IA 52242 USA.		Koretzky, Gary/AAU-5381-2021		NCI NIH HHS [P01CA66570] Funding Source: Medline; NIDDK NIH HHS [DK33823, DK49781] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA066570] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033823, R37DK033823, R01DK049781] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUDAY L, 1995, ONCOGENE, V11, P1327; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; CorbalanGarcia S, 1996, MOL CELL BIOL, V16, P5674; CorbalanGarcia S, 1996, ONCOGENE, V12, P1063; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Foschi M, 1997, EMBO J, V16, P6439, DOI 10.1093/emboj/16.21.6439; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; Holt KH, 1996, MOL CELL BIOL, V16, P577; LANGLOIS WJ, 1995, J BIOL CHEM, V270, P25320, DOI 10.1074/jbc.270.43.25320; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Li YY, 1996, J IMMUNOL, V157, P1440; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOTTO DG, 1994, J BIOL CHEM, V269, P21608; POMERANCE M, 1992, J BIOL CHEM, V267, P16155; Porfiri E, 1996, J BIOL CHEM, V271, P5871, DOI 10.1074/jbc.271.10.5871; ROZAKISADCOCK M, 1995, ONCOGENE, V11, P1417; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SATOH T, 1992, J BIOL CHEM, V267, P24149; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; YAMAUCHI K, 1994, J BIOL CHEM, V269, P31107; Zhao H, 1997, J BIOL CHEM, V272, P21625, DOI 10.1074/jbc.272.34.21625	36	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12061	12067		10.1074/jbc.273.20.12061	http://dx.doi.org/10.1074/jbc.273.20.12061			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575148	hybrid			2022-12-27	WOS:000073629800013
J	Cho, HS; Ha, NC; Kang, LW; Chung, KM; Back, SH; Jang, SK; Oh, BH				Cho, HS; Ha, NC; Kang, LW; Chung, KM; Back, SH; Jang, SK; Oh, BH			Crystal structure of RNA helicase from genotype 1b hepatitis C virus - A feasible mechanism of unwinding duplex RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI REP HELICASE; NONSTRUCTURAL PROTEIN-3; NS3 PROTEIN; DNA; BINDING; ENZYME; REPLICATION; SEPARATION; CLEAVAGE; ENCODES	Crystal structure of RNA helicase domain from genotype 1b hepatitis C virus has been determined at 2.3 Angstrom resolution by the multiple isomorphous replacement method. The structure consists of three domains that form a Y-shaped molecule. One is a NTPase domain containing two highly conserved NTP binding motifs. Another is an RNA binding domain containing a conserved RNA binding motif. The third is a helical domain that contains no beta-strand. The RNA binding domain of the molecule is distinctively separated from the other two domains forming an interdomain cleft into which single stranded RNA can be modeled. A channel is found between a pair of symmetry-related molecules which exhibit the most extensive crystal packing interactions. A stretch of single stranded RNA can be modeled with electrostatic complementarity into the interdomain cleft and continuously through the channel. These observations suggest that some form of this dimer is likely to be the functional form that unwinds double stranded RNA processively by passing one strand of RNA through the channel and passing the other strand outside of the dimer. A "descending molecular see-saw" model is proposed that is consistent with directionality of unwinding and other physicochemical properties of RNA helicases.	Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, Kyungbuk, South Korea; Pohang Univ Sci & Technol, Sch Environm Engn, Pohang 790784, Kyungbuk, South Korea	Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH)	Oh, BH (corresponding author), Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, Kyungbuk, South Korea.	bhoh@vision.postech.ac.kr	Oh, Byung-Ha/C-2061-2011					ABDELMONEM M, 1976, EUR J BIOCHEM, V65, P441, DOI 10.1111/j.1432-1033.1976.tb10359.x; ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Ali JA, 1997, SCIENCE, V275, P377, DOI 10.1126/science.275.5298.377; AMARATUNGA M, 1993, BIOCHEMISTRY-US, V32, P6815, DOI 10.1021/bi00078a003; BARTENSCHLAGER R, 1993, J VIROL, V67, P3835, DOI 10.1128/JVI.67.7.3835-3844.1993; BRUNGER AT, 1992, XPLOR MANUAL VERSION; CHAO KL, 1991, J MOL BIOL, V221, P1165, DOI 10.1016/0022-2836(91)80119-F; ECKART MR, 1993, BIOCHEM BIOPH RES CO, V192, P399, DOI 10.1006/bbrc.1993.1429; Egelman EH, 1996, STRUCTURE, V4, P759, DOI 10.1016/S0969-2126(96)00081-0; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GRAKOUI A, 1993, J VIROL, V67, P2832, DOI 10.1128/JVI.67.5.2832-2843.1993; Gross CH, 1996, J VIROL, V70, P1706, DOI 10.1128/JVI.70.3.1706-1713.1996; GROSS CH, 1995, J VIROL, V69, P4727, DOI 10.1128/JVI.69.8.4727-4736.1995; Gwack Y, 1996, BIOCHEM BIOPH RES CO, V225, P654, DOI 10.1006/bbrc.1996.1225; HAHM B, 1995, J VIROL, V69, P2534, DOI 10.1128/JVI.69.4.2534-2539.1995; Heilek GM, 1997, J VIROL, V71, P6264, DOI 10.1128/JVI.71.8.6264-6266.1997; JONES TA, 1993, O VERSION 6 0; Kang LW, 1998, ACTA CRYSTALLOGR D, V54, P121, DOI 10.1107/S0907444997008883; KATO N, 1990, P NATL ACAD SCI USA, V87, P9524, DOI 10.1073/pnas.87.24.9524; KIM DW, 1995, BIOCHEM BIOPH RES CO, V215, P160, DOI 10.1006/bbrc.1995.2447; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; Kovall R, 1997, SCIENCE, V277, P1824, DOI 10.1126/science.277.5333.1824; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LEE CG, 1992, J BIOL CHEM, V267, P4398; LEONARD GA, 1994, STRUCTURE, V2, P483, DOI 10.1016/S0969-2126(00)00049-6; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM; OTWINOWSKI Z, 1993, P CCP 4 STUD WEEK; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; Preugschat F, 1996, J BIOL CHEM, V271, P24449, DOI 10.1074/jbc.271.40.24449; RAY BK, 1985, J BIOL CHEM, V260, P7651; RICE CM, 1986, TOGAVIRIDAE FLAVIVIR; SCOTT JF, 1977, P NATL ACAD SCI USA, V74, P193, DOI 10.1073/pnas.74.1.193; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; Tai CL, 1996, J VIROL, V70, P8477, DOI 10.1128/JVI.70.12.8477-8484.1996; TRAUT TW, 1994, EUR J BIOCHEM, V222, P9, DOI 10.1111/j.1432-1033.1994.tb18835.x; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WARRENER P, 1995, J VIROL, V69, P1720, DOI 10.1128/JVI.69.3.1720-1726.1995; Yao NH, 1997, NAT STRUCT BIOL, V4, P463, DOI 10.1038/nsb0697-463; YARRANTON GT, 1979, P NATL ACAD SCI USA, V76, P1658, DOI 10.1073/pnas.76.4.1658; Zhou YT, 1997, P NATL ACAD SCI USA, V94, P10583, DOI 10.1073/pnas.94.20.10583	42	166	168	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15045	15052		10.1074/jbc.273.24.15045	http://dx.doi.org/10.1074/jbc.273.24.15045			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614113	hybrid			2022-12-27	WOS:000074160400055
J	Kojima, Y; Heeb, MJ; Gale, AJ; Hackeng, TM; Griffin, JH				Kojima, Y; Heeb, MJ; Gale, AJ; Hackeng, TM; Griffin, JH			Binding site for blood coagulation factor Xa involving residues 311-325 in factor Va	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-C; PEPTIDE-BOND CLEAVAGES; PROTHROMBINASE COMPLEX; FACTOR-VIII; STRUCTURAL MODEL; FACTOR VA(R506Q); COMPLETE CDNA; MASS ANALYSIS; INACTIVATION; SEQUENCE	Factor Va inactivation by activated protein C is associated with cleavages at Arg(306), Arg(506), and Arg(679) with Arg(306) cleavage causing the major activity loss. To study functional roles of the Arg(306) region, overlapping 15-mer peptides representing the sequence of factor Va residues 271-345 were synthesized and screened for anticoagulant activities. The peptide containing residues 311-325 (VP311) noncompetitively inhibited prothrombin activation by factor Xa, but only in the presence of factor Va. Fluorescence studies showed that VP311 bound to fluorescence-labeled 5-dimethylaminonaphthalene-1-sulfonyl-Glu-Gly-Arg factor Xa in solution with a K-d of 70 mu M. Diisopropylphosphoryl factor Xa and factor Xa but not factor VII/VIIa or prothrombin bound to immobilized VP311 with relatively high affinity, These results support the hypothesis that residues 311-325, which are positioned between the A1 and A2 domains of factor Va and likely exposed to solvent, contribute to the binding of factor Xa by factor Va. Based on this hypothesis, it is suggested that cleavage by activated protein C at Arg(306) ire factor Va not only severs the covalent connection between the A1 and A2 domains but also disrupts the environment and structure of residues 311-325, thereby down-regulating the binding of factor Xa to factor Va.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Griffin, JH (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, SBR-5,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Griffin, John/0000-0002-4302-2547; Hackeng, Tilman/0000-0003-0142-0843	NHLBI NIH HHS [R37HL52246, R01HL21544] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021544, R37HL052246] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANNAMALAI AE, 1987, BLOOD, V70, P139; CHATTOPADHYAY A, 1992, J BIOL CHEM, V267, P12323; DAHLBACK B, 1980, J CLIN INVEST, V66, P583, DOI 10.1172/JCI109890; ESMON CT, 1993, THROMB HAEMOSTASIS, V70, P29; ESMON CT, 1979, J BIOL CHEM, V254, P964; FOWLER WE, 1990, P NATL ACAD SCI USA, V87, P7648, DOI 10.1073/pnas.87.19.7648; GALE AJ, 1997, THROMB HAEMOSTASIS S, P599; GUINTO ER, 1984, J BIOL CHEM, V259, P3986; GUINTO ER, 1992, J BIOL CHEM, V267, P2971; HEEB MJ, 1994, P NATL ACAD SCI USA, V91, P2728, DOI 10.1073/pnas.91.7.2728; HEEB MJ, 1995, BLOOD, V85, P3405, DOI 10.1182/blood.V85.12.3405.bloodjournal85123405; HEEB MJ, 1993, J BIOL CHEM, V268, P2872; Heeb MJ, 1996, PROTEIN SCI, V5, P1883, DOI 10.1002/pro.5560050914; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; JANE SM, 1991, BLOOD COAGUL FIBRIN, V2, P723, DOI 10.1097/00001721-199112000-00005; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; KALAFATIS M, 1994, BIOCHEMISTRY-US, V33, P6538, DOI 10.1021/bi00187a022; KALAFATIS M, 1995, J BIOL CHEM, V270, P4053, DOI 10.1074/jbc.270.8.4053; KALAFATIS M, 1994, J BIOL CHEM, V269, P31869; KANE WH, 1988, BLOOD, V71, P539; KRISHNASWAMY S, 1993, METHOD ENZYMOL, V222, P260; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LILES DK, 1997, BLOOD, V90, P463; Mann K G, 1981, Ann N Y Acad Sci, V370, P378, DOI 10.1111/j.1749-6632.1981.tb29750.x; Mann KG, 1997, J BIOL CHEM, V272, P20678, DOI 10.1074/jbc.272.33.20678; MESSERSCHMIDT A, 1990, EUR J BIOCHEM, V187, P341, DOI 10.1111/j.1432-1033.1990.tb15311.x; MESTERS RM, 1991, J BIOL CHEM, V266, P24514; MESTERS RM, 1993, BIOCHEMISTRY-US, V32, P12656, DOI 10.1021/bi00210a014; MOSESSON MW, 1990, J CLIN INVEST, V85, P1983, DOI 10.1172/JCI114662; MOSESSON MW, 1990, J BIOL CHEM, V265, P8863; MOUNIER C, 1997, THROMB HAEMOSTASIS S, V20, P293; NESHEIM ME, 1982, J BIOL CHEM, V257, P1443; NICOLAES GAF, 1995, J BIOL CHEM, V270, P21158, DOI 10.1074/jbc.270.36.21158; PAN Y, 1995, NAT STRUCT BIOL, V2, P740, DOI 10.1038/nsb0995-740; Pemberton S, 1997, BLOOD, V89, P2413, DOI 10.1182/blood.V89.7.2413; ROSING J, 1995, J BIOL CHEM, V270, P27852, DOI 10.1074/jbc.270.46.27852; ROSING J, 1980, J BIOL CHEM, V255, P274; SOLYMOSS S, 1988, J BIOL CHEM, V263, P14884; STENFLO J, 1976, J BIOL CHEM, V251, P355; SUZUKI K, 1983, J BIOL CHEM, V258, P1914; TRACY PB, 1983, P NATL ACAD SCI-BIOL, V80, P2380, DOI 10.1073/pnas.80.8.2380; WALKER FJ, 1979, BIOCHIM BIOPHYS ACTA, V571, P333, DOI 10.1016/0005-2744(79)90103-7; Zaitseva I, 1996, J BIOL INORG CHEM, V1, P15, DOI 10.1007/s007750050018	45	31	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14900	14905		10.1074/jbc.273.24.14900	http://dx.doi.org/10.1074/jbc.273.24.14900			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614093	hybrid			2022-12-27	WOS:000074160400035
J	Kullmann, M; Schneikert, J; Moll, J; Heck, S; Zeiner, M; Gehring, U; Cato, ACB				Kullmann, M; Schneikert, J; Moll, J; Heck, S; Zeiner, M; Gehring, U; Cato, ACB			RAP46 is a negative regulator of glucocorticoid receptor action and hormone-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; ANDROGEN RECEPTOR; THYROID-HORMONE; CELL-DEATH; PROTEIN; BAG-1; CLONING; FAMILY; IDENTIFICATION; OVEREXPRESSION	RAP46 was first identified by its ability to bind the glucocorticoid receptor. It has since been reported to bind several cellular proteins, including the anti-apoptotic protein Bcl-2, but the biological significance of these interactions is unknown. Here we show that RAP46 binds the hinge region of the glucocorticoid receptor and inhibits DNA binding and transactivation by the receptor. We further show that overexpression of RAP46 in mouse thymoma S49.1 cells inhibits glucocorticoid-induced apoptosis, Conversely, glucocorticoid-induced apoptosis and transactivation mere enhanced after treating S49.1 cells with the immunosuppressant rapamycin, which down-regulates cellular levels of BAG-1, the mouse homolog of RAP46, The effect of rapamycin can, however, be overcome by overexpression of RAP46. These results together identify RAP46 as a protein that controls glucocorticoid-induced apoptosis through its negative regulatory action on the transactivation property of the glucocorticoid receptor.	Forschungszentrum Karlsruhe, Inst Genet, D-76021 Karlsruhe, Germany; Univ Heidelberg, Inst Biol Chem, D-69120 Heidelberg, Germany	Helmholtz Association; Karlsruhe Institute of Technology; Ruprecht Karls University Heidelberg	Cato, ACB (corresponding author), Forschungszentrum Karlsruhe, Inst Genet, Postfach 3640, D-76021 Karlsruhe, Germany.	andrew.cato@igen.fzk.de	Kullmann, Michael Keith/AGY-4711-2022; Cato, Andrew C. B./H-2071-2013	Cato, Andrew C. B./0000-0001-8508-3834; Kullmann, Michael Keith/0000-0003-3567-3806				Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; Adachi M, 1996, BLOOD, V88, P4118, DOI 10.1182/blood.V88.11.4118.bloodjournal88114118; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; ANNWEILER A, 1991, NUCLEIC ACIDS RES, V19, P3750, DOI 10.1093/nar/19.13.3750; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; BURRIS TP, 1995, P NATL ACAD SCI USA, V92, P9525, DOI 10.1073/pnas.92.21.9525; CHEN DJ, 1995, NATURE, V377, P454; Clevenger CV, 1997, MOL ENDOCRINOL, V11, P608, DOI 10.1210/me.11.5.608; COLE TJ, 1995, GENE DEV, V9, P1608, DOI 10.1101/gad.9.13.1608; DIEHL EE, 1993, BIOCHEMISTRY-US, V32, P13510, DOI 10.1021/bi00212a016; FUJITA T, 1986, CELL, V46, P401, DOI 10.1016/0092-8674(86)90660-4; GAO XM, 1994, BIOCHEM BIOPH RES CO, V199, P734, DOI 10.1006/bbrc.1994.1290; GAST A, 1995, MOL CELL ENDOCRINOL, V111, P93, DOI 10.1016/0303-7207(95)03554-K; Heck S, 1997, EMBO J, V16, P4698, DOI 10.1093/emboj/16.15.4698; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; Henriksson A, 1997, MOL CELL BIOL, V17, P3065, DOI 10.1128/MCB.17.6.3065; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Ishizuka T, 1997, BIOCHEM BIOPH RES CO, V230, P386, DOI 10.1006/bbrc.1996.5967; Jeon SH, 1997, J EXP MED, V185, P1827, DOI 10.1084/jem.185.10.1827; KIM DW, 1990, GENE, V91, P217, DOI 10.1016/0378-1119(90)90091-5; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; McEwan IJ, 1997, BIOESSAYS, V19, P153, DOI 10.1002/bies.950190210; Miyashita T, 1997, BIOCHEM BIOPH RES CO, V233, P781, DOI 10.1006/bbrc.1997.6559; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NEBL G, 1994, J BIOL CHEM, V269, P7371; NEBL G, 1995, CELL MOL BIOL RES, V41, P85; NING YM, 1993, J BIOL CHEM, V268, P6073; Packham G, 1997, BIOCHEM J, V328, P807, DOI 10.1042/bj3280807; SANCHEZ ER, 1995, GLUCOCORTICOID RECEP, P105; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; Schneikert J, 1996, J BIOL CHEM, V271, P23907, DOI 10.1074/jbc.271.39.23907; SEOL WG, 1995, MOL ENDOCRINOL, V9, P72, DOI 10.1210/me.9.1.72; Soderstrom M, 1997, MOL ENDOCRINOL, V11, P682, DOI 10.1210/me.11.6.682; Takayama S, 1996, GENOMICS, V35, P494, DOI 10.1006/geno.1996.0389; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Wakui H, 1997, J BIOL CHEM, V272, P8153, DOI 10.1074/jbc.272.13.8153; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703; Zeiner M, 1997, EMBO J, V16, P5483, DOI 10.1093/emboj/16.18.5483; ZEINER M, 1995, P NATL ACAD SCI USA, V92, P11465, DOI 10.1073/pnas.92.25.11465	46	118	125	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14620	14625		10.1074/jbc.273.23.14620	http://dx.doi.org/10.1074/jbc.273.23.14620			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603979	hybrid			2022-12-27	WOS:000074021500081
J	Lee, HK; Lee, YK; Park, SH; Kim, YS; Park, SH; Lee, JW; Kwon, HB; Soh, J; Moore, DD; Choi, HS				Lee, HK; Lee, YK; Park, SH; Kim, YS; Park, SH; Lee, JW; Kwon, HB; Soh, J; Moore, DD; Choi, HS			Structure and expression of the orphan nuclear receptor SHP gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; SUPERFAMILY	To determine the organization of the orphan nuclear receptor SHP gene (Seol, W., Choi, H.-S., and Moore, D.D. (1996) Science 272, 1336-1339), genomic clones were isolated from human and mouse genomic Libraries. The SLIP gene was composed of two exons interrupted by a single intron spanning approximately 1.8 kilobases in human and 1.2 kilobases in mouse. Genomic Southern blot analysis and fluorescence in situ hybridization of human metaphase chromosomes indicated that the SRP gene is located at the human chromosome 1p36.1 sub-band. The 5'-flanking regions of human and mouse SHP genes were highly conserved, showing 77% homology in the resell of approximately 600 nucleotides upstream from the transcription start site. Primer extension analysis was carried out to determine the transcription start site of human SHP to 32 nucleotides downstream of a potential TATA box. The human SHP gene was specifically expressed En fetal liver, fetal adrenal gland, adult spleen, and adult small intestine, As expected from this expression pattern, the activity of the mouse SHP promoter measured by transient transfection was significantly higher in the adrenal-derived YI cells than HeLa cells.	Chonnam Natl Univ, Dept Biol, Kwangju 500757, South Korea; Chonnam Natl Univ, Coll Pharm, Kwangju 500757, South Korea; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Korea Univ, Coll Med, Dept Anat, Seoul 136750, South Korea; Seoul Natl Univ, Coll Med, Dept Pathol, Seoul 110799, South Korea; Chonnam Natl Univ, Hormone Res Ctr, Kwangju 500757, South Korea	Chonnam National University; Chonnam National University; Baylor College of Medicine; Korea University; Korea University Medicine (KU Medicine); Seoul National University (SNU); Chonnam National University	Choi, HS (corresponding author), Chonnam Natl Univ, Hormone Res Ctr, Kwangju 500757, South Korea.	hsc@chonnam.chonnam.ac.kr	Park, Seong Hoe/C-7353-2011		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046546] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46546] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BAES M, 1994, MOL CELL BIOL, V14, P1544, DOI 10.1128/MCB.14.3.1544; BALE SJ, 1991, NEW ENGL J MED, V324, P925; BALE SJ, 1989, NEW ENGL J MED, V320, P1367, DOI 10.1056/NEJM198905253202102; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; Choi HS, 1997, J BIOL CHEM, V272, P23565, DOI 10.1074/jbc.272.38.23565; CHOI HS, 1993, MOL ENDOCRINOL, V7, P1596, DOI 10.1210/me.7.12.1596; Enmark E, 1996, MOL ENDOCRINOL, V10, P1293, DOI 10.1210/me.10.11.1293; GENUARDI M, 1989, AM J HUM GENET, V45, P73; Guo WW, 1996, J CLIN ENDOCR METAB, V81, P2481, DOI 10.1210/jc.81.7.2481; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Ikeda Y, 1996, MOL ENDOCRINOL, V10, P1261, DOI 10.1210/me.10.10.1261; Ito M, 1997, MOL CELL BIOL, V17, P1476, DOI 10.1128/MCB.17.3.1476; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Masuda N, 1997, BBA-GENE STRUCT EXPR, V1350, P27, DOI 10.1016/S0167-4781(96)00196-0; Miyamoto K, 1997, MOL ENDOCRINOL, V11, P1165, DOI 10.1210/me.11.8.1165; MOLEY JF, 1992, CANCER RES, V52, P770; Park SH, 1997, MOL CELLS, V7, P200; SAKURAI A, 1990, MOL CELL ENDOCRINOL, V71, P83; SEGRAVES WA, 1990, GENE DEV, V4, P204, DOI 10.1101/gad.4.2.204; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; ZENNARO MC, 1995, J BIOL CHEM, V270, P21016, DOI 10.1074/jbc.270.36.21016	26	88	95	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14398	14402		10.1074/jbc.273.23.14398	http://dx.doi.org/10.1074/jbc.273.23.14398			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603951	hybrid			2022-12-27	WOS:000074021500053
J	Ruknudin, A; Schulze, DH; Sullivan, SK; Lederer, WJ; Welling, PA				Ruknudin, A; Schulze, DH; Sullivan, SK; Lederer, WJ; Welling, PA			Novel subunit composition of a renal epithelial K-ATP channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CORTICAL COLLECTING TUBULE; POTASSIUM-CHANNEL; SULFONYLUREA RECEPTOR; APICAL MEMBRANE; SODIUM-CHANNELS; CFTR; KATP; SECRETION; MECHANISM	Unique ATP-inhibitable K+ channels (K-ATP) in the kidney determine the rate of urinary K+ excretion and play an essential role in extracellular K+ balance. Here, we demonstrate that functionally similar low sulfonylurea affinity K+, channels are formed by two heterologous molecules, products of Kir1.1a and cystic fibrosis transmembrane conductance regulator (CFTR) genes. Go-injection of CFTR and Kir1.1a cRNA into Xenopus oocytes lead to the expression of K+ selective channels that retained the high open probability behavior of Kir1.1a but acquired sulfonylurea sensitivity and ATP-dependent gating properties. Similar to the K+, channels in the kidney but different from K+, channels in excitable tissues, the Kir1.1a/CFTR channel was inhibited by glibenclamide with micromolar affinity. Since the expression of Kir1.1a and CFTR overlap at sites in the kidney where the low sulfonylurea affinity K-ATP are expressed, our study offers evidence that these native K-ATP, channels are comprised of Kir1.1a and CFTR. The implication that Kir subunits can interact with ABC proteins beyond the subfamily of sulfonylurea receptors provides an intriguing explanation for functional diversity in K-ATP, channels.	Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Immunol Microbiol, Baltimore, MD 21201 USA; Univ Maryland, Inst Biotechnol, Dept Mol Biol & Biophys, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Welling, PA (corresponding author), Univ Maryland, Sch Med, Dept Physiol, 655 W Baltimore St, Baltimore, MD 21201 USA.		Lederer, William/B-1285-2010		NHLBI NIH HHS [HL36974, HL25675] Funding Source: Medline; NIDDK NIH HHS [DK48271] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036974, R01HL025675, R37HL036974] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK048271] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ASHCROFT F, 1981, ANN REV NEUROSCI, V11, P97; AUSTIN N, 1997, J AM SOC NEPHROL, V7, P1275; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0; CRAWFORD I, 1991, P NATL ACAD SCI USA, V88, P9262, DOI 10.1073/pnas.88.20.9262; DOUPNIK CA, 1995, CURR OPIN NEUROBIOL, V5, P268, DOI 10.1016/0959-4388(95)80038-7; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; FRINDT G, 1989, AM J PHYSIOL, V256, pF143, DOI 10.1152/ajprenal.1989.256.1.F143; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; HILLE B, 1992, IONIC CHANNELS EXCIT, P329; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; LEE WS, 1995, AM J PHYSIOL-RENAL, V268, pF1124, DOI 10.1152/ajprenal.1995.268.6.F1124; Macgregor Gordon G., 1996, Journal of the American Society of Nephrology, V7, P1285; McNicholas CM, 1996, AM J PHYSIOL-RENAL, V271, pF275, DOI 10.1152/ajprenal.1996.271.2.F275; MCNICHOLAS CM, 1994, P NATL ACAD SCI USA, V91, P8077, DOI 10.1073/pnas.91.17.8077; McNicholas CM, 1996, P NATL ACAD SCI USA, V93, P8083, DOI 10.1073/pnas.93.15.8083; METHFESSEL C, 1986, PFLUG ARCH EUR J PHY, V407, P577, DOI 10.1007/BF00582635; Morales MM, 1996, AM J PHYSIOL-RENAL, V270, pF1038, DOI 10.1152/ajprenal.1996.270.6.F1038; NICHOLS CG, 1991, J GEN PHYSIOL, V97, P1095, DOI 10.1085/jgp.97.5.1095; NICHOLS CG, 1991, BIOPHYS J, V60, P1164, DOI 10.1016/S0006-3495(91)82152-X; NICHOLS CG, 1996, SCIENCE, V272, P17852; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; Palmer LG, 1997, AM J PHYSIOL-RENAL, V273, pF404, DOI 10.1152/ajprenal.1997.273.3.F404; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SHEPPARD DN, 1992, J GEN PHYSIOL, V100, P573, DOI 10.1085/jgp.100.4.573; SMIT LS, 1993, P NATL ACAD SCI USA, V90, P9963, DOI 10.1073/pnas.90.21.9963; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; TSUCHIYA K, 1992, P NATL ACAD SCI USA, V89, P6418, DOI 10.1073/pnas.89.14.6418; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; WANG T, 1995, RENAL PHYSIOL BIOCH, V18, P169; WANG WH, 1991, J GEN PHYSIOL, V98, P35, DOI 10.1085/jgp.98.1.35; WANG WH, 1990, AM J PHYSIOL, V259, pF494, DOI 10.1152/ajprenal.1990.259.3.F494; WANG WH, 1992, ANNU REV PHYSIOL, V54, P81; WANG WH, 1995, KIDNEY INT, V48, P1024, DOI 10.1038/ki.1995.385; Welling Paul A., 1996, Journal of the American Society of Nephrology, V7, P1294; WRIGHT FS, 1993, KIDNEY PHYSL PATHOPH, P2249	40	72	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14165	14171		10.1074/jbc.273.23.14165	http://dx.doi.org/10.1074/jbc.273.23.14165			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603917	hybrid			2022-12-27	WOS:000074021500019
J	Wong, JM; Liang, VCT; Sachs, LM; Shi, YB				Wong, JM; Liang, VCT; Sachs, LM; Shi, YB			Transcription from the thyroid hormone-dependent promoter of the Xenopus laevis thyroid hormone receptor beta A gene requires a novel upstream element and the initiator, but not a TATA box	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; AMPHIBIAN METAMORPHOSIS; MOLECULAR MECHANISMS; EXPRESSION; ALPHA; SUPERFAMILY; REPRESSION; ACTIVATION; PROTEIN	The thyroid hormone receptor (TR) beta genes in Xenopus laevis are regulated by thyroid hormone in all organs of an animal during metamorphosis. This autoregulation appears to be critical for systematic transformations of different organs as a tadpole is transformed into a frog. To understand this autoregulation, we have previously identified a thyroid hormone response element in the hormone-dependent promoter of the X. laevis TR beta A gene. We report here the detailed characterization of the promoter. We have now mapped the transcription start site and demonstrated the existence of an initiator element at the start site critical for promoter function. More important, our deletion and mutational experiments revealed a novel upstream DNA element that is located 125 base pairs upstream of the start site and that is essential for active transcription from the promoter Promoter reconstitution experiments showed that this novel element does not function as an enhancer, but acts as a core promoter element, which, together with the initiator, directs accurate transcription from the promoter. Finally, we provide evidence for the existence of a protein(s) that specifically recognizes this element, Our studies thus demonstrate that the TR beta A promoter has a unique organization consisting of an initiator and a novel upstream promoter element. Such an organization may be important for the ubiquitous but tissue-dependent temporal regulation of the gene by thyroid hormone during amphibian metamorphosis.	NICHD, Mol Embryol Lab, NIH, Bethesda, MD 20892 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Baylor College of Medicine	Shi, YB (corresponding author), NICHD, Mol Embryol Lab, NIH, Bldg 18T,Rm 106, Bethesda, MD 20892 USA.	Shi@helix.nih.gov	Sachs, Laurent/AAE-1504-2020	Wong, Jiemin/0000-0002-5311-842X; Shi, Yun-Bo/0000-0002-6330-0639				ALMOUZNI G, 1993, GENE DEV, V7, P2033, DOI 10.1101/gad.7.10.2033; BROOKS AR, 1989, NUCLEIC ACIDS RES, V17, P9395, DOI 10.1093/nar/17.22.9395; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; Dodd M.H.I., 1976, P467; ELICEIRI BP, 1994, J BIOL CHEM, V269, P24459; Fairclough L, 1997, DEV GROWTH DIFFER, V39, P273; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Galton VA, 1983, MOL BASIS THYROID HO, P445; GILBERT LI, 1981, PROBLEM DEV BIOL; Gilbert LI, 1996, METAMORPHOSIS POST E; HELBING C, 1992, DEV GENET, V13, P289, DOI 10.1002/dvg.1020130406; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KANAMORI A, 1992, J BIOL CHEM, V267, P739; Kanamori A, 1996, GENES CELLS, V1, P429, DOI 10.1046/j.1365-2443.1996.d01-251.x; KAWAHARA A, 1991, DEVELOPMENT, V112, P933; Landsberger N, 1997, EMBO J, V16, P4361, DOI 10.1093/emboj/16.14.4361; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; MACHUCA I, 1995, MOL ENDOCRINOL, V9, P96, DOI 10.1210/me.9.1.96; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Nagasawa T, 1997, MOL CELL ENDOCRINOL, V130, P153, DOI 10.1016/S0303-7207(97)00085-3; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; RANJAN M, 1994, J BIOL CHEM, V269, P24699; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; Sambrook J., 2002, MOL CLONING LAB MANU; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHNEIDER MJ, 1991, MOL ENDOCRINOL, V5, P201, DOI 10.1210/mend-5-2-201; Shi YB, 1997, J BIOMED SCI, V4, P9, DOI 10.1007/BF02255588; SHI YB, 1994, FEBS LETT, V355, P61, DOI 10.1016/0014-5793(94)01173-7; SHI YB, 1992, J BIOL CHEM, V267, P733; Shi YB, 1996, BIOESSAYS, V18, P391, DOI 10.1002/bies.950180509; Shi YB, 1996, CURR TOP DEV BIOL, V32, P205, DOI 10.1016/S0070-2153(08)60429-9; SHI YB, 1994, TRENDS ENDOCRIN MET, V5, P14, DOI 10.1016/1043-2760(94)90116-3; Shi Yun-Bo, 1996, Journal of Biomedical Science, V3, P307, DOI 10.1007/BF02257960; SMALE S.T., 1994, TRANSCRIPTION MECHAN, P63; SUZUKI S, 1995, MOL ENDOCRINOL, V9, P1288, DOI 10.1210/me.9.10.1288; SUZUKI S, 1994, MOL ENDOCRINOL, V8, P305, DOI 10.1210/me.8.3.305; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; WANG Z, 1993, J BIOL CHEM, V268, P16270; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WONG JM, 1995, J BIOL CHEM, V270, P18479, DOI 10.1074/jbc.270.31.18479; WONG JM, 1995, GENE DEV, V9, P2696, DOI 10.1101/gad.9.21.2696; YAOITA Y, 1990, GENE DEV, V4, P1917, DOI 10.1101/gad.4.11.1917; YAOITA Y, 1990, P NATL ACAD SCI USA, V87, P7090, DOI 10.1073/pnas.87.18.7090; YEN PM, 1994, TRENDS ENDOCRIN MET, V5, P65, DOI 10.1016/1043-2760(94)90004-3; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	47	26	26	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14186	14193		10.1074/jbc.273.23.14186	http://dx.doi.org/10.1074/jbc.273.23.14186			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603920	hybrid			2022-12-27	WOS:000074021500022
J	Yang, DQ; Gong, XM; Yakhnin, A; Roche, TE				Yang, DQ; Gong, XM; Yakhnin, A; Roche, TE			Requirements for the adaptor protein role of dihydrolipoyl acetyltransferase in the up-regulated function of the pyruvate dehydrogenase kinase and pyruvate dehydrogenase phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNER LIPOYL DOMAIN; TRANSACETYLASE COMPONENT; BOVINE KIDNEY; MOLECULAR-CLONING; ACTIVATOR PROTEIN; COMPLEX; BINDING; HEART; PURIFICATION; MECHANISM	The dihydrolipoyl acetyltransferase (E2 component) is a 60-mer assembled via its COOH-terminal domain with exterior E1-binding domain and two lipoyl domains (L2 then L1) sequentially connected by mobile linker regions. E2 facilitates markedly enhanced function of the pyruvate dehydrogenase kinase (PDK) and pyruvate dehydrogenase phosphatase (PDP), Human E2 structures were prepared with only one lipogl domain (L1 or L2) or with alanines substituted at the sites of lipoylation (Lys-46 in L1 or Lys-173 in L2). The L2 domain and its lipoyl group were shown to be essential for markedly enhanced PDP function and were required for greatly up-regulated PDR function. The complete absence of the L1 domain reduced the enhancements of both of these activities but not the maximal effector-stimulated PDK activity through acetylation of L2. With nonlipoylated L2 present, lipoylated L1 supported a lesser enhancement in PDK function with significant stimulation upon acetylation of L1. Prevention of L1 lipoylation in K46AE2 removed this competitive LI pole and enhanced La-facilitated PDK activity beyond that of native E2 when PDK activity was measured in the absence or in the presence of stimulatory effectors, Thus, the E2-L2 domain has a paramount role in facilitating enhanced PDK and PDP function but inclusion of E2-L1 domain, even in a noninteracting (nonlipoylated) form, contributes to the marked elevation of these activities.	Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA	Kansas State University	Roche, TE (corresponding author), Kansas State Univ, Dept Biochem, 104 Willard Hall, Manhattan, KS 66506 USA.				NIDDK NIH HHS [DK18320] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018320, R55DK018320] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLEILE DM, 1981, J BIOL CHEM, V256, P514; CATE RL, 1978, J BIOL CHEM, V253, P496; CATE RL, 1979, J BIOL CHEM, V254, P1659; Chen GL, 1996, J BIOL CHEM, V271, P28064, DOI 10.1074/jbc.271.45.28064; DENTON RM, 1990, ANNU REV PHYSIOL, V52, P451, DOI 10.1146/annurev.ph.52.030190.002315; DENTON RM, 1972, BIOCHEM J, V128, P161, DOI 10.1042/bj1280161; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; KOROTCHKINA LG, 1995, J BIOL CHEM, V270, P14297, DOI 10.1074/jbc.270.24.14297; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI L, 1992, ARCH BIOCHEM BIOPHYS, V296, P497, DOI 10.1016/0003-9861(92)90603-T; LINN TC, 1972, ARCH BIOCHEM BIOPHYS, V148, P327, DOI 10.1016/0003-9861(72)90151-8; LIU SJ, 1995, J BIOL CHEM, V270, P793, DOI 10.1074/jbc.270.2.793; LIU SJ, 1995, ARCH BIOCHEM BIOPHYS, V316, P926, DOI 10.1006/abbi.1995.1124; McCartney RG, 1997, BIOCHEMISTRY-US, V36, P6819, DOI 10.1021/bi9630016; MISTRY SC, 1991, BIOCHEM J, V275, P775, DOI 10.1042/bj2750775; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; ONO K, 1993, J BIOL CHEM, V268, P26135; PERHAM RN, 1991, BIOCHEMISTRY-US, V30, P8501, DOI 10.1021/bi00099a001; PERHAM RN, 1996, ALPHA KETO ACID DEHY, P1; POPOV KM, 1992, J BIOL CHEM, V267, P13127; POPOV KM, 1993, J BIOL CHEM, V268, P26602; POPOV KM, 1994, J BIOL CHEM, V269, P29720; POWERSGREENWOOD SL, 1989, J BIOL CHEM, V264, P3655; PRIESTMAN DA, 1992, FEBS LETT, V308, P83, DOI 10.1016/0014-5793(92)81056-R; RADKE GA, 1993, BIOCHEM BIOPH RES CO, V190, P982, DOI 10.1006/bbrc.1993.1146; RAHMATULLAH M, 1990, J BIOL CHEM, V265, P14512; RAHMATULLAH M, 1985, J BIOL CHEM, V260, P146; RAHMATULLAH M, 1987, J BIOL CHEM, V262, P10265; RANDLE PJ, 1996, ALPHA KETO ACID DEHY, P151; Ravindran S, 1996, J BIOL CHEM, V271, P653, DOI 10.1074/jbc.271.2.653; ROCHE TE, 1976, BIOCHEM BIOPH RES CO, V72, P1375, DOI 10.1016/S0006-291X(76)80166-0; ROCHE TE, 1977, ARCH BIOCHEM BIOPHYS, V183, P664, DOI 10.1016/0003-9861(77)90400-3; ROCHE TE, 1996, ALPHA KETO ACID DEHY, P33; Rowles J, 1996, J BIOL CHEM, V271, P22376, DOI 10.1074/jbc.271.37.22376; SALE GJ, 1982, BIOCHEM J, V120, P535; Sanderson SJ, 1996, BIOCHEM J, V319, P109, DOI 10.1042/bj3190109; Wu PF, 1998, BIOCHEM J, V329, P197, DOI 10.1042/bj3290197; YANG D, 1996, J BIOL CHEM, V272, P6361; YEAMAN SJ, 1978, BIOCHEMISTRY-US, V17, P2364, DOI 10.1021/bi00605a017	39	34	36	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14130	14137		10.1074/jbc.273.23.14130	http://dx.doi.org/10.1074/jbc.273.23.14130			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603912	hybrid			2022-12-27	WOS:000074021500014
J	Eklund, EA; Jalava, A; Kakar, R				Eklund, EA; Jalava, A; Kakar, R			PU.1, interferon regulatory factor 1, and interferon consensus sequence-binding protein cooperate to increase gp91(phox) expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; TRANSCRIPTION FACTOR PU.1; CHAIN GENE-EXPRESSION; CYTOCHROME-B HEAVY; ENHANCER; GAMMA; GP91-PHOX; PROMOTER; MACROPHAGE; ACTIVATOR	gp91(phox) is a subunit of the phagocyte respiratory burst oxidase catalytic unit. Transcription of CYBB, the gene encoding gp91(phox), is restricted to terminally differentiated phagocytic cells. An element in the proximal CYBB promoter binds a protein complex, referred to as hematopoiesis-associated factor (HAF1), that is necessary for interferon-gamma (IFN gamma)-induced gp91(phox) expression. In these investigations, we determined that HAF1 was a multiprotein complex, cross-immunoreactive with the transcription factors PU.1, interferon regulatory factor 1 (IRF-1), and interferon consensus sequence-binding protein (ICSBP), In electrophoretic mobility shift assay, the HAF1 complex was reconstituted by either in vitro translated PU,1 with IRF-1 or PU.1 with ICSBP, but not by IRF-1 with ICSBP, HAF1a, a slower mobility complex with the same binding site specificity as HAF1, was also investigated. Similar to the HAF1 complex, the HAF1a complex was cross-immunoreactive with PU,1, IRF-1, and ICSBP, Unlike the HAF1 complex, reconstitution of the HAF1a complex required in vitro translated PU,1 with both IRF-1 and ICSBP, An artificial promoter construct containing the HAF1/HAF1a binding site was modestly activated in the myelomonocytic cell line U937 by co-transfection either with PU,1 and IRF-1 or with PU,1 and ICSBP, but it was strongly activated by co-transfection with PU,1, IRF-1, and ICSBP, This activation required serine 148-phosphorylated PU.1, These studies describe a novel mechanism for PU,1 transcriptional activation via interaction with both IRF-1 and ICSBP, a target gene for the interaction of IRF-1 with ICSBP, and a novel activation function for ICSBP as a component of a multiprotein complex.	Univ Alabama, Lurleen B Wallace Tumor Inst, Dept Hematol & Oncol, Birmingham, AL 35294 USA; Birmingham Vet Adm Hosp, Birmingham, AL 35294 USA; Univ Alabama, Ctr Comprehens Canc, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Eklund, EA (corresponding author), Univ Alabama, Lurleen B Wallace Tumor Inst, Dept Hematol & Oncol, WTI554,1824 6th Ave S, Birmingham, AL 35294 USA.				NHLBI NIH HHS [HL5400, KO8HL0313] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; BOLOVENTA C, 1994, P NATL ACAD SCI USA, V91, P5036; BORRAS FE, 1995, J BIOL CHEM, V270, P24385, DOI 10.1074/jbc.270.41.24385; Brass AL, 1996, GENE DEV, V10, P2335, DOI 10.1101/gad.10.18.2335; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; EISENBEIS CF, 1993, MOL CELL BIOL, V13, P6452, DOI 10.1128/MCB.13.10.6452; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; Eklund EA, 1997, J BIOL CHEM, V272, P9344; Eklund EA, 1996, J IMMUNOL, V157, P2418; EKLUND EA, 1995, J BIOL CHEM, V270, P8267, DOI 10.1074/jbc.270.14.8267; GEL GO, 1952, CANCER RES, V12, P264; KLEBANOFF SJ, 1975, SEMIN HEMATOL, V12, P117; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LARRICK JW, 1980, J IMMUNOL, V125, P6; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; Li SL, 1997, J BIOL CHEM, V272, P17802, DOI 10.1074/jbc.272.28.17802; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; NEWBURGER PE, 1988, P NATL ACAD SCI USA, V85, P5215, DOI 10.1073/pnas.85.14.5215; NEWBURGER PE, 1991, J BIOL CHEM, V266, P16171; NEWBURGER PE, 1994, J CLIN INVEST, V94, P1205, DOI 10.1172/JCI117437; ORKIN SH, 1989, ANNU REV IMMUNOL, V7, P277; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; POHL HL, 1993, J BIOL CHEM, V268, P5014; POLITIS AD, 1994, J IMMUNOL, V152, P2270; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; Pongubala JMR, 1997, P NATL ACAD SCI USA, V94, P127, DOI 10.1073/pnas.94.1.127; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; ROSMARIN AG, 1995, J BIOL CHEM, V270, P23627, DOI 10.1074/jbc.270.40.23627; Sambrook H., 1989, MOL CLONING LAB MANU; SCHOLER HR, 1989, EMBO J, V8, P2551, DOI 10.1002/j.1460-2075.1989.tb08393.x; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; SHARF R, 1995, J BIOL CHEM, V270, P13063, DOI 10.1074/jbc.270.22.13063; Sharf R, 1997, J BIOL CHEM, V272, P9785; SHIN MK, 1993, GENE DEV, V7, P2006, DOI 10.1101/gad.7.10.2006; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; TAKEBE Y, 1987, MOL CELL BIOL, V8, P2551; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TUCKER KA, 1987, BLOOD, V70, P372; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; WEISZ A, 1992, J BIOL CHEM, V267, P25589; ZHANG LQ, 1993, ONCOGENE, V8, P1621	45	144	152	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13957	13965		10.1074/jbc.273.22.13957	http://dx.doi.org/10.1074/jbc.273.22.13957			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593745	hybrid			2022-12-27	WOS:000073919100084
J	Lykidis, A; Murti, KG; Jackowski, S				Lykidis, A; Murti, KG; Jackowski, S			Cloning and characterization of a second human CTP : Phosphocholine cytidylyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER CTP; MEMBRANE-BINDING DOMAIN; PHOSPHATIDYLCHOLINE SYNTHESIS; SACCHAROMYCES-CEREVISIAE; PHOSPHORYLATION SITES; LIPID REGULATION; EXPRESSION; PROTEIN; GOLGI; GENE	CTP:phosphocholine cytidylyltransferase (CCT) is a key regulator of phosphatidylcholine biosynthesis, and only a single isoform of this enzyme, CCT alpha, is known. We identified and sequenced a human cDNA that encoded a distinct CCT isoform, called CCT beta, that is derived from a gene different from that encoding CCT alpha, CCT beta transcripts were detected in human adult and fetal tissues, and very high transcript levels were found in placenta and testis, CCT beta and CCT alpha proteins share highly related, but not identical, catalytic domains followed by three amphipathic helical repeats. Like CCT alpha, CCT beta required the presence of lipid regulators for maximum catalytic activity, The amino terminus of CCT beta bears no resemblance to the amino terminus of CCT alpha, and CCT beta protein was localized to the cytoplasm as detected by indirect immunofluorescent microscopy, Whereas CCT alpha activity is regulated by reversible phosphorylation, CCT beta lacks most of the corresponding carboxyl-terminal domain and contained only 3 potential phosphorylation sites of the 16 identified in CCT alpha. Transfection of COS-7 cells with a CCT beta expression construct led to the overexpression of CCT activity, the accumulation of cellular CDP-choline, and enhanced radiolabeling of phosphatidylcholine, CCT beta protein was posttranslationally modified in COS-7 cells, resulting in slower migration during polyacrylamide gel electrophoresis. Expression of CCT beta/CCT alpha chimeric proteins showed that the amino-terminal portion of CCT beta was required for posttranslational modification. These data demonstrate that a second, distinct CCT enzyme is expressed in human tissues and provides another mechanism by which cells regulate phosphatidylcholine production.	St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Virol & Mol Biol, Memphis, TN 38105 USA; Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA; Univ Tennessee, Dept Pathol, Memphis, TN 38163 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Jackowski, S (corresponding author), St Jude Childrens Res Hosp, Dept Biochem, 332 N Lauderdale St, Memphis, TN 38105 USA.	suzanne.jackowski@stjude.org	Jackowski, Suzanne/N-8168-2018	Jackowski, Suzanne/0000-0002-6855-1429	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045737] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM 45737] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arnold RS, 1996, BIOCHEMISTRY-US, V35, P9917, DOI 10.1021/bi960397c; Arnold RS, 1997, BIOCHEMISTRY-US, V36, P6149, DOI 10.1021/bi970023z; Boggs K, 1998, BBA-LIPID LIPID MET, V1389, P1, DOI 10.1016/S0005-2760(97)00145-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CRAIG L, 1994, J BIOL CHEM, V269, P3311; Dunne SJ, 1996, BIOCHEMISTRY-US, V35, P11975, DOI 10.1021/bi960821+; ESKO JD, 1981, J BIOL CHEM, V256, P7388; HIGGINS JA, 1987, J LIPID RES, V28, P268; HOUWELING M, 1994, J BIOL CHEM, V269, P7544; Houweling M, 1996, EUR J CELL BIOL, V69, P55; JACKOWSKI S, 1994, J BIOL CHEM, V269, P3858; Johnson JE, 1997, BBA-BIOMEMBRANES, V1324, P273, DOI 10.1016/S0005-2736(96)00233-7; JOHNSON JE, 1992, BIOCHEM J, V285, P815, DOI 10.1042/bj2850815; KALMAR GB, 1994, BBA-GENE STRUCT EXPR, V1219, P328, DOI 10.1016/0167-4781(94)90056-6; KALMAR GB, 1990, P NATL ACAD SCI USA, V87, P6029, DOI 10.1073/pnas.87.16.6029; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; Kobayashi M, 1997, J BIOL CHEM, V272, P16089, DOI 10.1074/jbc.272.26.16089; LUCHE MM, 1993, ARCH BIOCHEM BIOPHYS, V301, P114, DOI 10.1006/abbi.1993.1122; Lykidis A, 1997, J BIOL CHEM, V272, P33402, DOI 10.1074/jbc.272.52.33402; MACDONALD JIS, 1994, J BIOL CHEM, V269, P10529; MinSeok R, 1996, J BIOCHEM, V120, P1040; MURTI KG, 1992, EXP CELL RES, V202, P36, DOI 10.1016/0014-4827(92)90401-S; Nakashima A, 1997, J BIOL CHEM, V272, P9567; Park YS, 1997, J BIOL CHEM, V272, P15161, DOI 10.1074/jbc.272.24.15161; RUTHERFORD MS, 1993, GENOMICS, V18, P698, DOI 10.1016/S0888-7543(05)80377-5; SLOMIANY A, 1992, EXP CELL RES, V201, P321, DOI 10.1016/0014-4827(92)90280-L; SOHAL PS, 1990, J BIOL CHEM, V265, P11746; SWEITZER TD, 1994, ARCH BIOCHEM BIOPHYS, V311, P107, DOI 10.1006/abbi.1994.1215; Tang W, 1997, J BIOL CHEM, V272, P13146, DOI 10.1074/jbc.272.20.13146; TRONCHERE H, 1994, BBA-LIPID LIPID MET, V1212, P137, DOI 10.1016/0005-2760(94)90248-8; TSUKAGOSHI Y, 1987, EUR J BIOCHEM, V169, P477, DOI 10.1111/j.1432-1033.1987.tb13635.x; VANCE JE, 1988, J BIOL CHEM, V263, P5898; Veitch DP, 1996, BIOCHEMISTRY-US, V35, P10743, DOI 10.1021/bi960402c; WALKEY CJ, 1994, J BIOL CHEM, V269, P5742; WANG YL, 1995, J BIOL CHEM, V270, P17843, DOI 10.1074/jbc.270.30.17843; WANG YL, 1993, J BIOL CHEM, V268, P5899; WANG YL, 1995, J BIOL CHEM, V270, P354, DOI 10.1074/jbc.270.1.354; YANG W, 1995, J BIOL CHEM, V270, P23951, DOI 10.1074/jbc.270.41.23951; YANG W, 1995, J BIOL CHEM, V270, P16503, DOI 10.1074/jbc.270.28.16503	39	110	113	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					14022	14029		10.1074/jbc.273.22.14022	http://dx.doi.org/10.1074/jbc.273.22.14022			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593753	hybrid			2022-12-27	WOS:000073919100092
J	Rhee, SK; Quist, AP; Lal, R				Rhee, SK; Quist, AP; Lal, R			Amyloid beta protein-(1-42) forms calcium-permeable, Zn2+-sensitive channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATOMIC-FORCE MICROSCOPE; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; BILAYER-MEMBRANES; ZINC; PHOSPHORYLATION; PRESENILIN-1; INDUCTION; PEPTIDES; RELEASE	Amyloid beta protein (A beta P) forms senile plaques in the brain of the patients with Alzheimer's disease. The early-onset AD has been correlated with an increased level of 42-residue A beta P (A beta P1-42). However, very little is known about the role of A beta P1-42 in such pathology. We have examined the activity of A beta P1-42 reconstituted in phospholipid vesicles. Vesicles reconstituted with A beta P show strong immunofluorescence labeling with an antibody raised against an extracellular domain of A beta P suggesting the incorporation of A beta P peptide in the vesicular membrane. Vesicles reconstituted with A beta P showed a significant level of Ca-45(2+) uptake. The Ca-45(2+) uptake was inhibited by (i) a monoclonal antibody raised against the N-terminal region of A beta P, (ii) Tris, and (iii) Zn2+, However, reducing agents Trolox and dithiothreitol did not inhibit the Ca-45(2+) uptake, indicating that the oxidation of A beta P or its surrounding lipid molecules is not directly involved in the A beta P-mediated Ca2+ uptake. An atomic force microscope was used to image the structure and physical properties of these vesicles. Vesicles ranged from 0.5 to 1 mu m in diameter. The stiffness of the A beta P-containing vesicles was significantly higher in the presence of calcium. The stiffness change was prevented in the presence of zinc, Tris, and anti-A beta P antibody but not in the presence of Trolox and dithiothreitol. Thus the stiffness change is consistent with the vesicular uptake of Ca2+. These findings provide biochemical and structural evidence that A beta P1-42 forms calcium-permeable channels and thus may induce cellular toxicity by regulating the calcium homeostasis in Alzheimer's disease.	Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA; Yeungnam Univ, Dept Biochem, Kyongsan 712749, South Korea	University of California System; University of California Santa Barbara; Yeungnam University	Lal, R (corresponding author), Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA.	rlal@physics.ucsb.edu	Lal, Ratnesh/AAG-5424-2019; Quist, Arjan/F-7997-2011					ANHOLT R, 1982, J BIOL CHEM, V257, P7122; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; ARISPE N, 1993, P NATL ACAD SCI USA, V90, P10573, DOI 10.1073/pnas.90.22.10573; ARISPE N, 1993, P NATL ACAD SCI USA, V90, P567, DOI 10.1073/pnas.90.2.567; Arispe N, 1996, P NATL ACAD SCI USA, V93, P1710, DOI 10.1073/pnas.93.4.1710; ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; BENZI G, 1995, NEUROBIOL AGING, V16, P661, DOI 10.1016/0197-4580(95)00066-N; BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; BUSH AI, 1994, J BIOL CHEM, V269, P26618; CALINGASAN NY, 1995, BRAIN RES, V677, P50, DOI 10.1016/0006-8993(95)00136-E; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; DURELL SR, 1994, BIOPHYS J, V67, P2137, DOI 10.1016/S0006-3495(94)80717-9; ETCHEBERRIGARAY R, 1994, SCIENCE, V264, P276, DOI 10.1126/science.8146663; GANDY SE, 1993, ANN NY ACAD SCI, V695, P117, DOI 10.1111/j.1749-6632.1993.tb23038.x; GarzonRodriguez W, 1997, J BIOL CHEM, V272, P21037, DOI 10.1074/jbc.272.34.21037; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HOWELL GA, 1984, NATURE, V308, P736, DOI 10.1038/308736a0; ITO E, 1994, P NATL ACAD SCI USA, V91, P534, DOI 10.1073/pnas.91.2.534; Kawahara M, 1997, BIOPHYS J, V73, P67, DOI 10.1016/S0006-3495(97)78048-2; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; KOSIK K, 1992, NEUROBIOL AGING, V13, P535, DOI 10.1016/0197-4580(92)90052-Y; Lal R, 1997, INT J IMAG SYST TECH, V8, P293, DOI 10.1002/(SICI)1098-1098(1997)8:3<293::AID-IMA7>3.0.CO;2-5; LAL R, 1995, AM J PHYSIOL-CELL PH, V269, pC275, DOI 10.1152/ajpcell.1995.269.1.C275; Laney DE, 1997, BIOPHYS J, V72, P806, DOI 10.1016/S0006-3495(97)78714-9; Li JH, 1997, CELL, V90, P917, DOI 10.1016/S0092-8674(00)80356-6; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; MIRZABEKOV T, 1994, BIOCHEM BIOPH RES CO, V202, P1142, DOI 10.1006/bbrc.1994.2047; NAKADE S, 1994, J BIOL CHEM, V269, P6735; NASLUND J, 1995, NEURON, V15, P219, DOI 10.1016/0896-6273(95)90079-9; PIKE CJ, 1995, J NEUROCHEM, V64, P253, DOI 10.1046/j.1471-4159.1995.64010253.x; PRICE DL, 1995, CURR OPIN NEUROL, V8, P268, DOI 10.1097/00019052-199508000-00004; RADMACHER M, 1995, BIOPHYS J, V69, P264, DOI 10.1016/S0006-3495(95)79897-6; Rhee SK, 1996, BIOCHEMISTRY-US, V35, P9212, DOI 10.1021/bi960295m; Salinero O, 1997, J NEUROSCI RES, V47, P216; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Seilheimer B, 1997, J STRUCT BIOL, V119, P59, DOI 10.1006/jsbi.1997.3859; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1995, FASEB J, V9, P366, DOI 10.1096/fasebj.9.5.7896005; Waiter MF, 1997, BIOCHEM BIOPH RES CO, V233, P760, DOI 10.1006/bbrc.1997.6547; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; Young W C, 1989, ROARKS FORMULAS STRE; Zhu YJ, 1998, BIOPHYS J, V74, pA316	47	174	178	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13379	13382		10.1074/jbc.273.22.13379	http://dx.doi.org/10.1074/jbc.273.22.13379			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593665	hybrid			2022-12-27	WOS:000073919100004
J	Jin, P; Sun, Y; Grabowski, GA				Jin, P; Sun, Y; Grabowski, GA			Role of Sp proteins and ROR alpha in transcription regulation of murine prosaposin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROPERTIES; SULFATIDE ACTIVATOR; NEUROTROPHIC FACTOR; BETA-GLUCOSIDASE; MESSENGER-RNA; EXPRESSION; GENE; IDENTIFICATION; DISRUPTION; SEQUENCE	Prosaposin is the precursor of four low molecular weight sphingolipid-activating proteins (SAPs) or saposins. These four proteins function as intracellular activators of several lysosomal enzymes involved in the degradation of glycosphingolipids, and prosaposin itself has neurite outgrowth effects. Expression of prosaposin is regulated in a temporal and spatial manner with expression in specific brain neurons and visceral cell types. Here a major regulatory fragment was characterized within 310 bp 5' to the transcription start site. Using electrophoretic mobility shift assay (EMSA) and DNA footprinting, members of the Sp family (Sp1, Sp3, and Sp4), the orphan nuclear receptor (ROR alpha), and an unknown transcription factor (U; TGGGGGAG) were shown to bind to this region, To evaluate the role of such transcription factor binding sites for this locus, a series of mutant constructs was generated within this region, and their function was evaluated in cultured NS20Y neuroblastoma cells. A 3' Spl site, a 5' Sp1/U cluster and the ROR alpha binding sites were functional. The data are consistent with a model in which the factors that bind to the Sp1/U cluster and RORE site interact negatively to diminish promoter activity to a background level that is determined primarily by the 3' Sp1 site. These interactions depend on the tissue-specific repertoire of transcription factors leading to differential expression of this locus.	Childrens Hosp Res Fdn, Med Ctr, Div Human Genet, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	Grabowski, GA (corresponding author), Childrens Hosp Res Fdn, Med Ctr, Div Human Genet, 3333 Burnet Ave,PAV 3-52, Cincinnati, OH 45229 USA.	GRABG0@CHMCC.ORG	Jin, Peng/B-5977-2012	Jin, Peng/0000-0001-6137-6659				BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLLARD MW, 1988, BIOCHEMISTRY-US, V27, P4557, DOI 10.1021/bi00412a050; Du H, 1996, J LIPID RES, V37, P937; Fujita N, 1996, HUM MOL GENET, V5, P711, DOI 10.1093/hmg/5.6.711; GAVIELIRORMAN E, 1989, GENOMICS, V5, P486; GAVRIELIRORMAN E, 1992, GENOMICS, V13, P312; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; GIGUERE V, 1995, MOL CELL BIOL, V15, P2517; HadjSahraoui N, 1997, DEV BRAIN RES, V98, P1, DOI 10.1016/S0165-3806(96)00153-8; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; Hamilton BA, 1996, NATURE, V379, P736, DOI 10.1038/379736a0; HIRAIWA M, 1992, P NATL ACAD SCI USA, V89, P11254, DOI 10.1073/pnas.89.23.11254; HOLTSCHMIDT H, 1991, J BIOL CHEM, V266, P7556; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; Kotani Y, 1996, J NEUROCHEM, V66, P2019; Maxam A M, 1980, Methods Enzymol, V65, P499; MORRIS JF, 1994, MOL CELL BIOL, V14, P1786, DOI 10.1128/MCB.14.3.1786; NAKANO T, 1989, J BIOCHEM-TOKYO, V105, P152, DOI 10.1093/oxfordjournals.jbchem.a122629; OBRIEN JS, 1995, FASEB J, V9, P681, DOI 10.1096/fasebj.9.8.7768361; OBRIEN JS, 1988, SCIENCE, V241, P1098, DOI 10.1126/science.2842863; OBRIEN JS, 1994, P NATL ACAD SCI USA, V91, P9593, DOI 10.1073/pnas.91.20.9593; Ponce E, 1997, AM J HUM GENET, V61, pA180; Qi XY, 1996, J BIOL CHEM, V271, P6874, DOI 10.1074/jbc.271.12.6874; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SPRECHERLEVY H, 1993, CELL MOL BIOL, V39, P287; Sun Y, 1997, DNA CELL BIOL, V16, P23, DOI 10.1089/dna.1997.16.23; SUN Y, 1994, AM J PATHOL, V145, P1390; SUN Y, 1996, AM J HUM GENET, V59, P160; Supp DM, 1996, DEV BIOL, V176, P284, DOI 10.1006/dbio.1996.0134	31	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					13208	13216		10.1074/jbc.273.21.13208	http://dx.doi.org/10.1074/jbc.273.21.13208			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582364	hybrid			2022-12-27	WOS:000073768500075
J	Okamoto, T; Sekiyama, N; Otsu, M; Shimada, Y; Sato, A; Nakanishi, S; Jingami, H				Okamoto, T; Sekiyama, N; Otsu, M; Shimada, Y; Sato, A; Nakanishi, S; Jingami, H			Expression and purification of the extracellular ligand binding region of metabotropic glutamate receptor subtype 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUTROPIN CHORIOGONADOTROPIN RECEPTOR; HIGH-AFFINITY; PHENYLGLYCINE DERIVATIVES; MOLECULAR DIVERSITY; AGONIST; DOMAIN; ANTAGONISTS; ACTIVATION; PROTEINS; CELLS	Each metabotropic glutamate receptor possesses a large extracellular domain that consists of a sequence homologous to the bacterial periplasmic binding proteins and a cysteine-rich region, Previous experiments have proposed that the extracellular domain is responsible for ligand binding. However, it is currently unknown whether the extracellular ligand binding site can bind ligands without other domains of the receptor. We began by obtaining a sufficient amount of receptor protein on a baculovirus expression system. In addition to the transfer vector that encodes the entire coding region, transfer vectors that encode portions of the extracellular domain were designed. Here, we report a soluble metabotropic glutamate receptor that encodes only the extracellular domain and retains a ligand binding characteristic similar to that of the full-length receptor. The soluble receptor secreted into culture medium showed a dimerized form. Furthermore, we have succeeded in purifying it to homogeneity. Dose-response curves of agonists for the purified soluble receptor were examined. The effective concentration for half-maximal inhibition (IC50) of quisqualate for the soluble receptor was 3.8 x 10(-8) M, which was comparable to that for the full-length receptor. The rank order of inhibition of the agonists was quisqualate much greater than ibotenate greater than or equal to L-glutamate approximate to (1S,3R)-1-aminocyclopentane-1,3-dicarboxylic acid. These data demonstrate that a ligand binding event in metabotropic glutamate receptors can be dissociated from the membrane domain.	Biomol Engn Res Inst, Dept Biol Mol, Suita, Osaka 565, Japan; Kyoto Univ, Fac Med, Dept Sci Biol, Sakyo Ku, Kyoto 606, Japan	Kyoto University	Jingami, H (corresponding author), Kirin Brewery Co Ltd, Cent Labs Key Technol, Kanazawa Ku, Yokohama, Kanagawa 236, Japan.			Sato, Atsushi/0000-0003-1359-8905				ADAMS MD, 1989, J BIOL CHEM, V264, P15739; Annoura H, 1996, BIOORG MED CHEM LETT, V6, P763, DOI 10.1016/0960-894X(96)00104-7; ARAMORI I, 1992, NEURON, V8, P757, DOI 10.1016/0896-6273(92)90096-V; BASHIR ZI, 1993, NATURE, V363, P347, DOI 10.1038/363347a0; Bedingfield JS, 1995, BRIT J PHARMACOL, V116, P3323, DOI 10.1111/j.1476-5381.1995.tb15142.x; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; Brauner-Osborne H, 1996, J MED CHEM, V39, P3188, DOI 10.1021/jm9602569; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; COUGHLIN SR, 1994, CURR OPIN CELL BIOL, V6, P191, DOI 10.1016/0955-0674(94)90135-X; Fernandez LM, 1996, J BIOL CHEM, V271, P925, DOI 10.1074/jbc.271.2.925; HAYASHI Y, 1994, J NEUROSCI, V14, P3370; HAYASHI Y, 1993, NATURE, V366, P687, DOI 10.1038/366687a0; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; HERRERO I, 1992, NATURE, V360, P163, DOI 10.1038/360163a0; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; IKEDA SR, 1995, NEURON, V14, P1029, DOI 10.1016/0896-6273(95)90341-0; ITO I, 1992, NEUROREPORT, V3, P1013, DOI 10.1097/00001756-199211000-00017; JANE DE, 1993, NEUROPHARMACOLOGY, V32, P725, DOI 10.1016/0028-3908(93)90088-K; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; Kuusinen A, 1995, EMBO J, V14, P6327, DOI 10.1002/j.1460-2075.1995.tb00323.x; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; NAGAYAMA Y, 1991, P NATL ACAD SCI USA, V88, P902, DOI 10.1073/pnas.88.3.902; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NAKANISHI S, 1994, ANNU REV BIOPH BIOM, V23, P319, DOI 10.1146/annurev.bb.23.060194.001535; Neki A, 1996, NEUROSCI LETT, V202, P197, DOI 10.1016/0304-3940(95)12248-6; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; Ohashi H., 1997, Society for Neuroscience Abstracts, V23, P2023; PELLICCIARI R, 1995, J MED CHEM, V38, P3717, DOI 10.1021/jm00019a002; QUIOCHO FA, 1990, PHILOS T R SOC B, V326, P341, DOI 10.1098/rstb.1990.0016; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; Ryu KS, 1996, J BIOL CHEM, V271, P7301, DOI 10.1074/jbc.271.13.7301; SACK JS, 1989, J MOL BIOL, V206, P193, DOI 10.1016/0022-2836(89)90532-9; SCHOEPP DD, 1994, J NEUROCHEM, V63, P769; Sekiyama N, 1996, BRIT J PHARMACOL, V117, P1493, DOI 10.1111/j.1476-5381.1996.tb15312.x; Shigemoto R, 1997, J NEUROSCI, V17, P7503, DOI 10.1523/jneurosci.17-19-07503.1997; SHIGEMOTO R, 1994, NEURON, V12, P1245, DOI 10.1016/0896-6273(94)90441-3; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; TAKAHASHI K, 1993, J BIOL CHEM, V268, P19341; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; WATKINS JC, 1990, TRENDS PHARMACOL SCI, V11, P25, DOI 10.1016/0165-6147(90)90038-A; XIE YB, 1990, J BIOL CHEM, V265, P21411	44	138	143	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					13089	13096		10.1074/jbc.273.21.13089	http://dx.doi.org/10.1074/jbc.273.21.13089			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582347	hybrid			2022-12-27	WOS:000073768500058
J	Odermatt, A; Becker, S; Khanna, VK; Kurzydlowski, K; Leisner, E; Pette, D; MacLennan, DH				Odermatt, A; Becker, S; Khanna, VK; Kurzydlowski, K; Leisner, E; Pette, D; MacLennan, DH			Sarcolipin regulates the activity of SERCA1, the fast-twitch skeletal muscle sarcoplasmic reticulum Ca2+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLAMBAN GENE; MOLECULAR-CLONING; MESSENGER-RNAS; BRODYS DISEASE; CA-2+ ATPASE; CA-2+-ATPASE; PHOSPHORYLATION; EXPRESSION; PROTEINS; CA2+	The 31-amino acid proteolipid, sarcolipin (SLN), is associated with the fast-twitch skeletal muscle sarcoplasmic reticulum Ca2+-ATPase (SERCA1), Constructs of human and rabbit SLN and of rabbit SLN with the FLAG epitope at its N terminus (NF-SLN) or its C terminus (SLN-FC) were coexpressed with SERCA1 in HEK-293 T-cells, Immunohistochemistry was used to demonstrate colocalization of NF-SLN and SERCA1 in the endoplasmic reticulum membrane and to demonstrate the cytosolic orientation of the N terminus of SLN, Coexpression of native rabbit SLN or NF-SLN with SERCA1 decreased the apparent affinity of SERCA1 for Ca2+ but stimulated maximal Ca2+ uptake rates (V-max). The N terminus of SLN is not well conserved among species, and the addition of an N-terminal FLAG epitope did not alter SLN function. Anti-FLAG antibody reversed both the inhibition of Ca2+ uptake by NF-SLN at low Ca2+ concentrations and the stimulatory effect of NF-SLN on V-max. Addition of the FLAG epitope to the highly conserved C terminus decreased the apparent affinity of SERCA1 for Ca2+ relative to native SLN and decreased V-max significantly. Mutations in the C-terminal domain showed that this sequence is critical for SLN function. Mutational analysis of the transmembrane helix, together with the additive regulatory effects of coexpression of both SLN and phospholamban (PLN) with SERCA1, provided evidence for different mechanisms of interaction of SLN and PLN with SERCA molecules. Ca2+ uptake rates in sarcoplasmic reticulum vesicles, isolated from rabbit fast-twitch muscle (tibialis anterior) subjected to chronic low frequency stimulation, were reduced by approximately 40% in 3- and 4 day stimulated muscle, with a marginal increase in apparent affinity of SERCA1 for Ca2+. SERCA1 mRNA and protein levels were unaltered after stimulation. In contrast, SLN mRNA was decreased by 15%, and SLN protein was reduced by 40%. Reduced SLN expression could explain the decrease in SERCA1 activity observed in these muscles and might represent an early functional adaptation to chronic low frequency stimulation.	Univ Toronto, Banting & Best Dept Med Res, Charles H Best Inst, Toronto, ON M5G 1L6, Canada; Univ Konstanz, Fac Biol, D-78457 Konstanz, Germany	University of Toronto; University of Konstanz	MacLennan, DH (corresponding author), Univ Toronto, Banting & Best Dept Med Res, Charles H Best Inst, 112 Coll St, Toronto, ON M5G 1L6, Canada.	david.maclennan@utoronto.ca		Odermatt, Alex/0000-0002-6820-2712				BENDERS AAGM, 1994, J CLIN INVEST, V94, P741, DOI 10.1172/JCI117393; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; BRODY IA, 1969, NEW ENGL J MED, V281, P187, DOI 10.1056/NEJM196907242810403; CANTILINA T, 1993, J BIOL CHEM, V268, P17018; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE DM, 1990, J BIOL CHEM, V265, P17405; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; Cornea RL, 1997, BIOCHEMISTRY-US, V36, P2960, DOI 10.1021/bi961955q; DUX L, 1990, EUR J BIOCHEM, V192, P95, DOI 10.1111/j.1432-1033.1990.tb19200.x; FUJII J, 1988, FEBS LETT, V227, P51, DOI 10.1016/0014-5793(88)81412-1; GREEN HJ, 1992, PFLUG ARCH EUR J PHY, V420, P359, DOI 10.1007/BF00374471; Green HJ, 1997, EUR J APPL PHYSIOL O, V75, P418, DOI 10.1007/s004210050182; Hicks A, 1997, AM J PHYSIOL-CELL PH, V273, pC297, DOI 10.1152/ajpcell.1997.273.1.C297; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HU P, 1995, J BIOL CHEM, V270, P11619, DOI 10.1074/jbc.270.19.11619; KARPATI G, 1986, ANN NEUROL, V20, P38, DOI 10.1002/ana.410200108; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; Kimura Y, 1996, J BIOL CHEM, V271, P21726, DOI 10.1074/jbc.271.36.21726; Kimura Y, 1997, J BIOL CHEM, V272, P15061, DOI 10.1074/jbc.272.24.15061; KINGSTON RE, 1992, CURRENT PROTOCOLS MO; Klebl BM, 1998, FEBS LETT, V422, P381, DOI 10.1016/S0014-5793(98)00053-2; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LEBERER E, 1986, BIOCHEM J, V239, P295, DOI 10.1042/bj2390295; LEBERER E, 1989, EUR J BIOCHEM, V185, P51, DOI 10.1111/j.1432-1033.1989.tb15080.x; LEBERER E, 1987, EUR J BIOCHEM, V162, P555, DOI 10.1111/j.1432-1033.1987.tb10675.x; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; LYTTON J, 1988, J BIOL CHEM, V263, P15024; MacLennan D H, 1980, Ann N Y Acad Sci, V358, P138, DOI 10.1111/j.1749-6632.1980.tb15392.x; MACLENNAN DH, 1972, COLD SPRING HARB SYM, V37, P469; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MATSUSHITA S, 1992, BIOCHEM J, V285, P303, DOI 10.1042/bj2850303; MORRIS GL, 1991, J BIOL CHEM, V266, P11270; NAVARRE C, 1992, J BIOL CHEM, V267, P6425; NAVARRE C, 1994, J BIOL CHEM, V269, P21262; Odermatt A, 1997, GENOMICS, V45, P541, DOI 10.1006/geno.1997.4967; Odermatt A, 1996, NAT GENET, V14, P191, DOI 10.1038/ng1096-191; Odermatt A, 1996, J BIOL CHEM, V271, P14206, DOI 10.1074/jbc.271.24.14206; PETTE D, 1992, REV PHYSL BIOCH PHAR, V120, P116; RACKER E, 1975, J BIOL CHEM, V250, P7533; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIGRIST H, 1977, BIOCHEM BIOPH RES CO, V74, P178, DOI 10.1016/0006-291X(77)91391-2; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; Slack JP, 1997, J BIOL CHEM, V272, P18862, DOI 10.1074/jbc.272.30.18862; SRETER FA, 1987, AM J PHYSIOL, V253, pC296, DOI 10.1152/ajpcell.1987.253.2.C296; TOYOFUKU T, 1993, J BIOL CHEM, V268, P2809; WAWRZYNOW A, 1992, ARCH BIOCHEM BIOPHYS, V298, P620, DOI 10.1016/0003-9861(92)90457-8; WU KD, 1993, AM J PHYSIOL, V264, pC333, DOI 10.1152/ajpcell.1993.264.2.C333; ZHAN GKM, 1997, PFLUEGERS ARCH, V433, P766	49	191	195	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12360	12369		10.1074/jbc.273.20.12360	http://dx.doi.org/10.1074/jbc.273.20.12360			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575189	hybrid			2022-12-27	WOS:000073629800054
J	Nicholson, B; Sawamura, T; Masaki, T; MacLeod, CL				Nicholson, B; Sawamura, T; Masaki, T; MacLeod, CL			Increased Cat3-mediated cationic amino acid transport functionally compensates in Cat1 knockout cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECOTROPIC RETROVIRUS RECEPTOR; GENE-EXPRESSION; HIGH-AFFINITY; SYSTEM; IDENTIFICATION; DEPRIVATION; PROTEIN	Arginine transport is important for a number of biological processes in vertebrates, and its transport may be rate-limiting for the production of nitric oxide. The majority of L-Arg transport is mediated by System y(+), although several other carriers have been kinetically defined. System y(+) cationic amino acid transport is mediated by proteins encoded by a family of genes, Cat1, Cat2, and Cat3, High affinity L-arginine transport was investigated in embryonic fibroblast cells derived from Cat1 knockout mice that lack functional Cat1. Both wild type and knockout cells transport arginine with comparable K-m and V-max. However, the apparent affinity for lysine transport was 2.4 times lower in Cat1(-/-) cells when compared with wild type cells, a property characteristic of Cat3-mediated transport. Northern analysis-documented Cat2 mRNA increased 2-fold, whereas Cat3 mRNA levels increased 11-fold in Cat1(-/-) relative to Cat1(+/+) cells. The low affinity Cat2a mRNA was not detectably expressed in these cells. Even though Cat3 expression is normally limited to adult brain, there was a large increase in the amount of Cats protein present at the plasma membrane of Cat1(-/-) embryonic fibroblast cells. These results suggest that Cat3 compensates for the loss of functional Cat1 in cells derived from Cat1 knockout mice and mediates the majority of high affinity arginine transport.	Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Kyoto Univ, Fac Med, Dept Pharmacol, Kyoto 606, Japan	University of California System; University of California San Diego; University of California System; University of California San Diego; Kyoto University	MacLeod, CL (corresponding author), Univ Calif San Diego, Ctr Canc, 9500 Gilman Dr,0684, La Jolla, CA 92093 USA.		Sawamura, Tatsuya/E-7103-2010					ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; CHRISTENSEN HN, 1969, J BIOL CHEM, V244, P1497; CLOSS EI, 1993, J BIOL CHEM, V268, P7538; Closs EI, 1996, AMINO ACIDS, V11, P193, DOI 10.1007/BF00813860; Closs EI, 1997, BIOCHEMISTRY-US, V36, P6462, DOI 10.1021/bi962829p; DEVES R, 1992, J PHYSIOL-LONDON, V454, P491, DOI 10.1113/jphysiol.1992.sp019275; DURANTE W, 1995, AM J PHYSIOL-HEART C, V268, pH1158; Fink D, 1997, CANCER RES, V57, P1841; Hosokawa H, 1997, J BIOL CHEM, V272, P8717, DOI 10.1074/jbc.272.13.8717; ITO K, 1997, J BIOL CHEM, V272, P2670; Kakuda DK, 1993, TRANSGENE, V1, P91; Kanai Y, 1997, CURR OPIN CELL BIOL, V9, P565, DOI 10.1016/S0955-0674(97)80035-X; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; MacLeod CL, 1996, AMINO ACIDS, V11, P171, DOI 10.1007/BF00813859; MACLEOD CL, 1990, MOL CELL BIOL, V10, P3663, DOI 10.1128/MCB.10.7.3663; MacLeod CL, 1996, BIOCHEM SOC T, V24, P846, DOI 10.1042/bst0240846; Malandro MS, 1996, ANNU REV BIOCHEM, V65, P305; Nicholson B, 1996, J BIOL CHEM, V271, P12159, DOI 10.1074/jbc.271.21.12159; Palacin M, 1996, AMINO ACIDS, V11, P225, DOI 10.1007/BF00813862; Perkins CP, 1997, GENE DEV, V11, P914, DOI 10.1101/gad.11.7.914; PLAKIDOUDYMOCK S, 1993, BIOCHEM J, V295, P749, DOI 10.1042/bj2950749; VANWINKLE LJ, 1988, J BIOL CHEM, V263, P3150; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WHITE MF, 1982, J BIOL CHEM, V257, P4450; WOODARD MH, 1994, AM J PHYSIOL, V266, pE817, DOI 10.1152/ajpendo.1994.266.5.E817	25	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14663	14666		10.1074/jbc.273.24.14663	http://dx.doi.org/10.1074/jbc.273.24.14663			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614060	hybrid			2022-12-27	WOS:000074160400002
J	Zhao, YQ; Ratnayake-Lecamwasam, M; Parker, SK; Cocca, E; Camardella, L; di Prisco, G; Detrich, HW				Zhao, YQ; Ratnayake-Lecamwasam, M; Parker, SK; Cocca, E; Camardella, L; di Prisco, G; Detrich, HW			The major adult alpha-globin gene of Antarctic teleosts and its remnants in the hemoglobinless icefishes - Calibration of the mutational clock for nuclear genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENOL-CHLOROFORM EXTRACTION; SINGLE-STEP METHOD; RNA ISOLATION; DNA; EXPRESSION; EVOLUTION; SEQUENCES; PROMOTER; FISHES; ACID	The icefishes of the Southern Ocean (family Channichthyidae, suborder Notothenioidei) are unique among vertebrates in their inability to synthesize hemoglobin. We have shown previously (Cocca, E., Ratnayake-Lecamwasam, M., Parker, S. K., Camardella, L., Ciaramella, M., di Prisco, G., and Detrich, H. W., III (1995) Proc. Natl. Acad. Sci. U.S. A. 92, 1817-1821); that icefishes retain inactive genomic remnants of adult notothenioid alpha-globin genes but have lost the gene that encodes adult beta-globin, Here we demonstrate that loss of expression of the major adult alpha-globin, alpha 1, in two specie's of icefish (Chaenocephalus aceratus and Chionodraco rastrospinosus) results from truncation of the 5' end of the notothenioid alpha 1-globin gene. The wild-type, functional alpha 1-globin gene of the Antarctic yellowbelly rockcod, Notothenia coriiceps, contains three exons and two A + T-rich introns, and its expression may be controlled by two or three distinct promoters. Retained in both icefish genomes are a portion of intron 2, exon 3, and the 3'-untranslated region of the notothenioid alpha 1-globin gene. The residual, nonfunctional alpha-globin gene, no longer under positive selection pressure for expression, has apparently undergone random mutational drift at an estimated rate of 0.12-0.33%/million years. We propose that abrogation of hemoglobin synthesis in icefishes most likely resulted from a single mutational event in the ancestral channichthyid that deleted the entire beta-globin gene and the 5' end of the linked alpha 1-globin gene.	Northeastern Univ, Dept Biol, Boston, MA 02115 USA; CNR, Ist Biochim Prot & Enzimol, I-80125 Naples, Italy	Northeastern University; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica delle Proteine (IBP-CNR)	Detrich, HW (corresponding author), Northeastern Univ, Dept Biol, 414 Mugar Hall,360 Huntington Ave, Boston, MA 02115 USA.			Cocca, Ennio/0000-0003-2432-9663				Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; BARBER DL, 1981, J FISH BIOL, V19, P11, DOI 10.1111/j.1095-8649.1981.tb05807.x; BARGELLONI L, 1994, MOL BIOL EVOL, V11, P854; BERNARDI G, 1986, J MOL EVOL, V24, P1, DOI 10.1007/BF02099946; BERNARDI G, 1988, J MOL EVOL, V28, P7, DOI 10.1007/BF02143493; BERNARDI G, 1985, SCIENCE, V228, P953, DOI 10.1126/science.4001930; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; Chan FY, 1997, BLOOD, V89, P688, DOI 10.1182/blood.V89.2.688; Chen LB, 1997, P NATL ACAD SCI USA, V94, P3811, DOI 10.1073/pnas.94.8.3811; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COCCA E, 1995, P NATL ACAD SCI USA, V92, P1817, DOI 10.1073/pnas.92.6.1817; d'Avino R., 1991, P15; DAVINO R, 1989, EUR J BIOCHEM, V179, P699, DOI 10.1111/j.1432-1033.1989.tb14603.x; DAYHOFF MO, 1979, ATLAS PROTEIN SEQUEN; di Prisco G., 1991, P263; DIPRISCO G, 1992, EXPERIENTIA, V48, P473; DIPRISCO G, 1998, IN PRESS FISHES ANTA; Eastman J. T, 1993, ANTARCTIC FISH BIOL; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Hu ZZ, 1996, J BIOL CHEM, V271, P10242, DOI 10.1074/jbc.271.17.10242; HUREAU JC, 1977, ADAPTATIONS ANTARCTI, P459; KELLER EB, 1984, P NATL ACAD SCI-BIOL, V81, P7417, DOI 10.1073/pnas.81.23.7417; King SM, 1997, BIOCHEMISTRY-US, V36, P1306, DOI 10.1021/bi962229q; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LANFRANCHI G, 1994, DEV BIOL, V164, P402, DOI 10.1006/dbio.1994.1210; LIEBHABER SA, 1980, P NATL ACAD SCI-BIOL, V77, P7054, DOI 10.1073/pnas.77.12.7054; LOENEN WAM, 1983, GENE, V26, P171, DOI 10.1016/0378-1119(83)90187-7; MACDONALD JA, 1987, ADV MAR BIOL, V24, P321; MARTIN AP, 1993, P NATL ACAD SCI USA, V90, P4087, DOI 10.1073/pnas.90.9.4087; MARTIN AP, 1992, NATURE, V357, P153, DOI 10.1038/357153a0; McMorrow T, 1996, DNA CELL BIOL, V15, P407, DOI 10.1089/dna.1996.15.407; Miyata M, 1997, BBA-GENE STRUCT EXPR, V1354, P127, DOI 10.1016/S0167-4781(97)00111-5; MIYATA M, 1993, NIPPON SUISAN GAKK, V59, P1077, DOI 10.2331/suisan.59.1077; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PATIENT RK, 1980, CELL, V20, P565; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; RUUD JT, 1954, NATURE, V173, P848, DOI 10.1038/173848a0; Sambrook J., 2002, MOL CLONING LAB MANU; SAUGER F, 1977, P NATL ACAD SCI USA, V74, P5463; SMALL DJ, 1998, IN PRESS J MOL EVOL; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STRAUSS EC, 1992, P NATL ACAD SCI USA, V89, P5809, DOI 10.1073/pnas.89.13.5809; TRIEZENBERG SJ, 1995, CURRENT PROTOCOLS MO; WILBUR WJ, 1983, P NATL ACAD SCI-BIOL, V80, P726, DOI 10.1073/pnas.80.3.726	48	57	59	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14745	14752		10.1074/jbc.273.24.14745	http://dx.doi.org/10.1074/jbc.273.24.14745			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614073	hybrid			2022-12-27	WOS:000074160400015
J	Zhou, G; Lefebvre, V; Zhang, ZP; Eberspaecher, H; de Crombrugghe, B				Zhou, G; Lefebvre, V; Zhang, ZP; Eberspaecher, H; de Crombrugghe, B			Three high mobility group-like sequences within a 48-base pair enhancer of the Col2a1 gene are required for cartilage-specific expression in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTOSOMAL SEX REVERSAL; PRO-ALPHA-1(II) COLLAGEN GENE; SRY-RELATED GENE; CAMPOMELIC DYSPLASIA; TRANSGENIC MICE; BINDING-SITE; MOUSE; SOX9; DNA; MUTATIONS	To understand the molecular mechanisms by which mesenchymal cells differentiate into chondrocytes, we have used the gene for an early and abundant marker of chondrocytes, the mouse pro-alpha 1(II) collagen gene (Col2a1), to delineate a minimal sequence needed for chondrocyte-specific expression and to identify the DNA-binding proteins that mediate its activity, We show here that a 48-base pair (bp) Col2a1 intron 1 sequence specifically targets the activity of a heterologous promoter to chondrocytes in transgenic mice. Mutagenesis studies of this 48-bp element identified three separate sites (sites 1-3) that were essential for its chondrocyte-specific enhancer activity in both transgenic mice and transient transfections. Mutations in sites 1 and 2 also severely inhibited the chondrocyte-specific enhancer activity of a 468-bp Col2a1 intron 1 sequence in vivo, SOX9, an SRY-related high mobility group (HMG) domain transcription factor, was previously shown to bind site 3, to bend the 48-bp DNA at this site, and to strongly activate this 48-bp enhancer as well as larger Col2a1 enhancer elements. All three sites correspond to imperfect binding sites for HMG domain proteins and appear to be involved in the formation of a large chondrocyte-specific complex between the 48-bp element, Sox9, and other protein(s), Indeed, mutations in each of the three HMG-like sites of the 48-bp element, which abolished chondrocyte-specific expression of reporter genes in transgenic mice and in transiently transfected cells, inhibited formation of this complex, Overall our results suggest a model whereby both Sox9 and these other proteins bind to several HMG-like sites in the Col2a1 gene to cooperatively control its expression in cartilage.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	de Crombrugghe, B (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR042919, R01AR042909] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672] Funding Source: Medline; NIAMS NIH HHS [R01 AR42909, P01 AR42919-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P1604, DOI 10.1093/nar/23.9.1604; Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; Bridgewater LC, 1998, J BIOL CHEM, V273, P14998, DOI 10.1074/jbc.273.24.14998; CANCEDDA R, 1995, INT REV CYTOL, V159, P265, DOI 10.1016/S0074-7696(08)62109-9; CHEAH KSE, 1991, DEVELOPMENT, V111, P945; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHURCHILL MEA, 1995, EMBO J, V14, P1264, DOI 10.1002/j.1460-2075.1995.tb07110.x; CONNER F, 1994, NUCLEIC ACIDS RES, V22, P3339, DOI 10.1093/nar/22.16.3339; CONNOR F, 1995, NUCLEIC ACIDS RES, V23, P3365, DOI 10.1093/nar/23.17.3365; DAILEY L, 1994, MOL CELL BIOL, V14, P7758, DOI 10.1128/MCB.14.12.7758; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; French SW, 1996, MOL CELL BIOL, V16, P5393; GOODFELLOW PN, 1993, ANNU REV GENET, V27, P71, DOI 10.1146/annurev.ge.27.120193.000443; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; HARLEY VR, 1994, NUCLEIC ACIDS RES, V22, P1500, DOI 10.1093/nar/22.8.1500; HARLEY VR, 1992, SCIENCE, V255, P453, DOI 10.1126/science.1734522; HERR W, 1995, GENE DEV, V9, P1679, DOI 10.1101/gad.9.14.1679; HOSKING BM, 1995, NUCLEIC ACIDS RES, V23, P2626, DOI 10.1093/nar/23.14.2626; Kent J, 1996, DEVELOPMENT, V122, P2813; KWOK C, 1995, AM J HUM GENET, V57, P1028; LAUDET V, 1993, NUCLEIC ACIDS RES, V21, P2493, DOI 10.1093/nar/21.10.2493; Lefebvre V, 1996, MOL CELL BIOL, V16, P4512; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; LI SW, 1995, GENE DEV, V9, P2821, DOI 10.1101/gad.9.22.2821; MORAISDASILVA S, 1996, NAT GENET, V13, P62; MUKHOPADHYAY K, 1995, J BIOL CHEM, V270, P27711, DOI 10.1074/jbc.270.46.27711; Ng LJ, 1997, DEV BIOL, V183, P108, DOI 10.1006/dbio.1996.8487; Sudbeck P, 1996, NAT GENET, V13, P230, DOI 10.1038/ng0696-230; VANDEWETERING M, 1992, EMBO J, V11, P3039, DOI 10.1002/j.1460-2075.1992.tb05374.x; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; WEGNER M, 1990, BIOCHEM BIOPH RES CO, V166, P1110, DOI 10.1016/0006-291X(90)90981-R; Wirth J, 1996, HUM GENET, V97, P186, DOI 10.1007/BF02265263; WRIGHT E, 1995, NAT GENET, V9, P15, DOI 10.1038/ng0195-15; WRIGHT EM, 1993, NUCLEIC ACIDS RES, V21, P744, DOI 10.1093/nar/21.3.744; Zhao Q, 1997, DEV DYNAM, V209, P377, DOI 10.1002/(SICI)1097-0177(199708)209:4<377::AID-AJA5>3.0.CO;2-F; ZHOU G, 1995, J CELL SCI, V108, P3677	37	141	148	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14989	14997		10.1074/jbc.273.24.14989	http://dx.doi.org/10.1074/jbc.273.24.14989			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614106	hybrid			2022-12-27	WOS:000074160400048
J	Dikic, I; Dikic, I; Schlessinger, J				Dikic, I; Dikic, I; Schlessinger, J			Identification of a new Pyk2 isoform implicated in chemokine and antigen receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; FOCAL ADHESION KINASE; ACTIVATION; CELLS; MEGAKARYOCYTES; RAFTK; SRC	Pyk2 is a protein tyrosine kinase that links G-protein-coupled receptors, inflammatory cytokines, and extracellular stimuli that elevate intracellular calcium concentration with activation of the mitogen-activated protein kinase pathways and regulation of ion channel functions. Here we describe the identification, cloning, and characterization of a new isoform of Pyk2 (Pyk2-H) that is generated by alternative RNA splicing. Pyk2-H is mainly expressed in hematopoietic cells including T-cells, B-cells, and natural killer cells. Engagement of T-cell or B-cell antigen receptors leads to rapid tyrosine phosphorylation of Pyk2-H. Pyk2-H is also activated in response to the chemokines RANTES and macrophage inflammatory protein-1 beta in T cells. In addition, we show that glutathione S-transferase fusion proteins containing the carboxyl termini of Pyk2 and Pyk2-H bind to a different set of tyrosine-phosphorylated proteins in thymus lysates. Specific expression of Pyk2-H and its activation by antigens or chemokines in hematopoietic cells may contribute toward the generation of cell type-specific signals involved in host immune responses.	Ludwig Inst Canc Res, S-75124 Uppsala, Sweden; NYU, Med Ctr, Dept Pharmacol, New York, NY 10016 USA	Ludwig Institute for Cancer Research; New York University	Dikic, I (corresponding author), Ludwig Inst Canc Res, Box 595,Husargatan 3, S-75124 Uppsala, Sweden.	Ivan.Dikic@licr.uu.se	Dikic, Ivan/O-4650-2015	Dikic, Ivan/0000-0001-8156-9511				Astier A, 1997, J BIOL CHEM, V272, P228; Astier A, 1997, J BIOL CHEM, V272, P19719, DOI 10.1074/jbc.272.32.19719; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; BRUNSWICK M, 1988, J IMMUNOL, V140, P3364; DAVIDSON D, 1992, J EXP MED, V175, P1483, DOI 10.1084/jem.175.6.1483; DAVIDSON D, 1994, MOL CELL BIOL, V14, P4554, DOI 10.1128/MCB.14.7.4554; Davis CB, 1997, J EXP MED, V186, P1793, DOI 10.1084/jem.186.10.1793; Derkinderen P, 1996, SCIENCE, V273, P1719, DOI 10.1126/science.273.5282.1719; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Ganju RK, 1997, J EXP MED, V185, P1055, DOI 10.1084/jem.185.6.1055; GISMONDI A, 1997, J IMMUNOL, V159, P3364; KANNER SB, 1994, P NATL ACAD SCI USA, V91, P10484, DOI 10.1073/pnas.91.22.10484; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; Ma EA, 1997, EUR J IMMUNOL, V27, P329, DOI 10.1002/eji.1830270147; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; Neet K, 1996, GENES CELLS, V1, P147, DOI 10.1046/j.1365-2443.1996.d01-234.x; Qian DP, 1997, J EXP MED, V185, P1253, DOI 10.1084/jem.185.7.1253; RICHARDSON A, 1996, NATURE, V380, P588; Salgia R, 1996, J BIOL CHEM, V271, P31222, DOI 10.1074/jbc.271.49.31222; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993	26	114	115	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14301	14308		10.1074/jbc.273.23.14301	http://dx.doi.org/10.1074/jbc.273.23.14301			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603937	hybrid			2022-12-27	WOS:000074021500039
J	Lupu, VD; Kaznacheyeva, E; Krishna, UM; Falck, JR; Bezprozvanny, I				Lupu, VD; Kaznacheyeva, E; Krishna, UM; Falck, JR; Bezprozvanny, I			Functional coupling of phosphatidylinositol 4,5-bisphosphate to inositol 1,4,5-trisphosphate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; CEREBELLAR PURKINJE-CELLS; ENDOPLASMIC-RETICULUM; SMOOTH-MUSCLE; CA2+ RELEASE; SARCOPLASMIC-RETICULUM; PLASMALEMMAL-CAVEOLAE; MEMBRANE DOMAINS; TRISPHOSPHATE; CHANNELS	The inositol 1,4,5-trisphosphate receptor (InsP(3)R) plays a key role in intracellular Ca2+ signaling. InsP(3)R is activated by InsP(3) produced from phosphatidylinositol 4,5-bisphosphate (PIP2) by phospholipase C cleavage. Using planar lipid bilayer reconstitution technique, we demonstrate here that rat cerebellar InsP(3)R forms a stable inhibitory complex with endogenous PIP2. Disruption of InsP(3)R-PIP2 interaction by specific anti-PIP2 monoclonal antibody resulted in 3-4-fold increase in InsP(3)R activity and 10-fold shift in apparent affinity for InsP(3). Exogenously added PIP2 blocks InsP(3) binding to InsP(3)R and inhibits InsP(3)R activity. Similar results were obtained with a newly synthesized water soluble analog of PIP2, dioctanoyl-(4,5)PIP2, indicating that insertion of PIP2 into membrane is not required to exert its inhibitory effects on the InsP(3)R. We hypothesize that the functional link between InsP(3)R and PIP2 described in the present report provides a basis for a local, rapid, and efficient coupling between phospholipase C activation, PIP2 hydrolysis, and intracellular Ca2+ wave initiation in neuronal and non-neuronal cells.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Bezprozvanny, I (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5323 Harry Hines Blvd,K4112, Dallas, TX 75235 USA.	bezprozv@utsw.swmed.edu	Kaznacheyeva, Elena V/I-7260-2017	Kaznacheyeva, Elena V/0000-0003-1273-1188; Falck, John/0000-0002-9219-7845				ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; ANDERSON RGW, 1998, IN PRESS ANN REV BIO, V67; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1993, NEURON, V10, P1175, DOI 10.1016/0896-6273(93)90065-Y; BEZPROZVANNY I, 1994, J GEN PHYSIOL, V104, P821, DOI 10.1085/jgp.104.5.821; BEZPROZVANNY I, 1995, J MEMBRANE BIOL, V145, P205; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; CHADWICK CC, 1990, P NATL ACAD SCI USA, V87, P2132, DOI 10.1073/pnas.87.6.2132; CHU A, 1991, J BIOL CHEM, V266, P7699; CIFUENTES ME, 1994, J BIOL CHEM, V269, P1945; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FUJIMOTO T, 1995, J CELL SCI, V108, P7; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; FUKAMI K, 1988, P NATL ACAD SCI USA, V85, P9057, DOI 10.1073/pnas.85.23.9057; Furuichi Teiichi, 1994, Current Opinion in Neurobiology, V4, P294, DOI 10.1016/0959-4388(94)90089-2; Hilgemann DW, 1996, SCIENCE, V273, P956, DOI 10.1126/science.273.5277.956; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; PARADISO AM, 1995, NATURE, V377, P643, DOI 10.1038/377643a0; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; Reddy KK, 1997, BIOORG MED CHEM LETT, V7, P2115, DOI 10.1016/S0960-894X(97)00370-3; Ribeiro CMP, 1997, J BIOL CHEM, V272, P26555, DOI 10.1074/jbc.272.42.26555; RUSAKOV DA, 1993, J NEUROCYTOL, V22, P273, DOI 10.1007/BF01187126; SATOH T, 1990, J CELL BIOL, V111, P615, DOI 10.1083/jcb.111.2.615; TAYLOR CW, 1991, PHARMACOL THERAPEUT, V51, P97, DOI 10.1016/0163-7258(91)90043-L; VILLA A, 1993, J CELL BIOL, V121, P1041, DOI 10.1083/jcb.121.5.1041; WAKUI M, 1990, CELL, V63, P1025, DOI 10.1016/0092-8674(90)90505-9; Xu X, 1996, J BIOL CHEM, V271, P24684, DOI 10.1074/jbc.271.40.24684; YAMAMOTO A, 1991, CELL STRUCT FUNCT, V16, P419, DOI 10.1247/csf.16.419	34	63	63	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14067	14070		10.1074/jbc.273.23.14067	http://dx.doi.org/10.1074/jbc.273.23.14067			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603901	hybrid			2022-12-27	WOS:000074021500003
J	Pan, OH; Beck, K				Pan, OH; Beck, K			The C-terminal domain of matrilin-2 assembles into a three-stranded alpha-helical coiled coil	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARTILAGE MATRIX PROTEIN; STABILIZATION; STABILITY; SUBUNITS; BINDING; SYSTEM; CDNA; GENE	Matrilin-2 is a member of von Willebrand factor A containing extracellular matrix proteins in which the cDNA-derived sequence shows similar domain organization to cartilage matrix protein/matrilin-1, but information on the protein structure is limited. Here we studied the oligomerization potential of a synthetic peptide NH2-ENLILFQNVANEEVRKLTQRLEEMTQRMEALENRLKYR-COOH corresponding to the C-terminal sequence of mouse matrilin-2. The central portion of this sequence shows a periodicity of hydrophobic residues occupying positions a and d of a heptad pattern (abc-defg)(n), which is characteristic for alpha-helical coiled-coil proteins. Circular dichroism spectroscopy revealed a high Lu-helical content, and the shape of the spectra is indicative for a coiled-coil conformation. Chemical cross-linking and size exclusion chromatography suggest a homotrimeric configuration Thermal denaturation in benign buffer shows a single cooperative transition with Delta H-0 = -375 kJ/mol. Melting temperatures T-m, varied from 38 to 51 degrees C within a concentration range of 10 to 85 mu M, which is about 35 degrees C lower than determined for a peptide corresponding to the C-terminal domain of matrilin-1. The data suggest that despite the low sequence identity within this region, matrilin-2 will form a homotrimer as matrilin-1 does.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Biol Sci, Piscataway, NJ 08855 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick	Beck, K (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Lane, Piscataway, NJ 08854 USA.		Beck, Konrad/AAX-1351-2020	Beck, Konrad/0000-0001-5098-9484				ARGRAVES WS, 1987, P NATL ACAD SCI USA, V84, P464, DOI 10.1073/pnas.84.2.464; Aszodi A, 1996, EUR J BIOCHEM, V236, P970, DOI 10.1111/j.1432-1033.1996.00970.x; Beck K, 1996, J MOL BIOL, V256, P909, DOI 10.1006/jmbi.1996.0137; Beck K, 1997, EMBO J, V16, P3767, DOI 10.1093/emboj/16.13.3767; BECK K, 1998, IN PRESS J STRUCT BI; BECK K, 1992, PATTERNS PROTEIN SEQ, P229; Belluoccio D, 1997, FEBS LETT, V415, P212, DOI 10.1016/S0014-5793(97)01126-5; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; CHEN Q, 1995, MOL BIOL CELL, V6, P1743, DOI 10.1091/mbc.6.12.1743; COOPER TM, 1990, BIOPOLYMERS, V30, P657, DOI 10.1002/bip.360300703; DEWAK F, 1997, J BIOL CHEM, V272, P9268; ENGEL J, 1977, BIOPOLYMERS, V16, P601, DOI 10.1002/bip.1977.360160310; Gonzalez L, 1996, NAT STRUCT BIOL, V3, P1011, DOI 10.1038/nsb1296-1011; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HAUDENSCHILD DR, 1995, J BIOL CHEM, V270, P23150, DOI 10.1074/jbc.270.39.23150; HAUSER N, 1994, J BIOL CHEM, V269, P25747; JENKINS RN, 1990, J BIOL CHEM, V265, P19624; KISS I, 1989, J BIOL CHEM, V264, P8126; LAU SYM, 1984, J BIOL CHEM, V259, P3253; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PARTIS MD, 1983, J PROTEIN CHEM, V2, P263, DOI 10.1007/BF01025358; PAULSSON M, 1979, BIOCHEM J, V183, P539, DOI 10.1042/bj1830539; PAULSSON M, 1982, BIOCHEM J, V207, P207, DOI 10.1042/bj2070207; POTSCHKA M, 1987, ANAL BIOCHEM, V162, P47, DOI 10.1016/0003-2697(87)90009-1; PRIVALOV PL, 1982, ADV PROTEIN CHEM, V35, P1, DOI 10.1016/S0065-3233(08)60468-4; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; STECK G, 1980, ANAL BIOCHEM, V107, P21, DOI 10.1016/0003-2697(80)90486-8; Wagener R, 1997, FEBS LETT, V413, P129, DOI 10.1016/S0014-5793(97)00895-8; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3; Wiltscheck R, 1997, PROTEIN SCI, V6, P1734, DOI 10.1002/pro.5560060814; WINTERBOTTOM N, 1992, DEV DYNAM, V193, P266, DOI 10.1002/aja.1001930307; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; WOOLFSON DN, 1995, PROTEIN SCI, V4, P1596, DOI 10.1002/pro.5560040818; Zhou N.-E., 1993, PEPTIDES BIOL CHEM, P217; ZHOU NE, 1992, J BIOL CHEM, V267, P2664	37	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14205	14209		10.1074/jbc.273.23.14205	http://dx.doi.org/10.1074/jbc.273.23.14205			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603923	hybrid, Green Accepted			2022-12-27	WOS:000074021500025
J	Thai, MV; Guruswamy, S; Cao, KT; Pessin, JE; Olson, AL				Thai, MV; Guruswamy, S; Cao, KT; Pessin, JE; Olson, AL			Myocyte enhancer factor 2 (MEF2)-binding site is required for GLUT4 gene expression in transgenic mice - Regulation of MEF2 DNA binding activity in insulin-deficient diabetes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSIVE GLUCOSE-TRANSPORTER; SKELETAL-MUSCLE; MESSENGER-RNA; ADIPOSE-TISSUE; PRETRANSLATIONAL SUPPRESSION; OVEREXPRESSING GLUT4; METABOLIC-REGULATION; PLASMA-MEMBRANE; PROTEIN; RAT	We have previously demonstrated that important regulatory elements responsible for regulated expression of the human GLUT4 promoter are located between -1154 and -412 relative to transcription initiation (Olson, A. L., and Pessin, J. E. (1995) J. Biol. Chem. 270, 23491-23495), Through further analysis of this promoter regulatory region, we have identified a perfectly conserved myocyte enhancer factor 2 (MEF2)-binding domain (-CTAAAAATAG-) that is necessary, but not sufficient, to support tissue-specific expression of a chloramphenicol acetyltransferase reporter gene in transgenic mice. Biochemical analysis of this DNA element demonstrated the formation of a specific DNA-protein complex using nuclear extracts isolated from heart, hindquarter skeletal muscle, and adipose tissue but not from liver. DNA binding studies indicated that this element functionally interacted with the MEF2A and/or MEF2C MADS family of DNA binding transcription factors. MEF2 DNA binding activity was substantially reduced in nuclear extracts isolated from both heart and skeletal muscle of diabetic mice, which correlated with decreased transcription rate of the GLUT4 gene, MEF2 binding activity completely recovered to control levels following insulin treatment. Together these data demonstrated that MEF2 binding activity is necessary for regulation of the GLUT4 gene promoter in muscle and adipose tissue.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA; Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Iowa	Olson, AL (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, POB 26901,Rm 853-BMSB, Oklahoma City, OK 73190 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044612, R01DK042452, R01DK047894, R55DK047894] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44612, DK42452, DK47894] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERGER J, 1989, NATURE, V340, P70, DOI 10.1038/340070a0; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BOUREY RE, 1990, J CLIN INVEST, V86, P542, DOI 10.1172/JCI114742; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; CHARRON MJ, 1990, J BIOL CHEM, V265, P7994; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DODOU E, 1995, NUCLEIC ACIDS RES, V23, P4267, DOI 10.1093/nar/23.21.4267; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; GARVEY WT, 1991, J CLIN INVEST, V87, P1072, DOI 10.1172/JCI115068; GARVEY WT, 1989, SCIENCE, V245, P60, DOI 10.1126/science.2662408; GERRITS PM, 1993, J BIOL CHEM, V268, P640; GIBBS EM, 1995, J CLIN INVEST, V95, P1512, DOI 10.1172/JCI117823; GULVE EA, 1994, J BIOL CHEM, V269, P18366; HAN TH, 1995, MOL CELL BIOL, V15, P2907; HANSEN PA, 1995, J BIOL CHEM, V270, P1679; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; LEMARCHANDBRUSTEL Y, 1990, ENDOCRINOLOGY, V127, P2687; Leturque A, 1996, DIABETES, V45, P23, DOI 10.2337/diabetes.45.1.23; LIU ML, 1994, J BIOL CHEM, V269, P28514; LIU ML, 1992, J BIOL CHEM, V267, P11673; LIU ML, 1993, P NATL ACAD SCI USA, V90, P11346, DOI 10.1073/pnas.90.23.11346; Mao ZX, 1996, J BIOL CHEM, V271, P14371, DOI 10.1074/jbc.271.24.14371; MARSHALL BA, 1993, J BIOL CHEM, V268, P18442; Molkentin JD, 1996, MOL CELL BIOL, V16, P3814; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; OLSON AL, 1990, PEDIATR RES, V28, P183, DOI 10.1203/00006450-199009000-00001; OLSON AL, 1993, J BIOL CHEM, V268, P9839; OLSON AL, 1995, J BIOL CHEM, V270, P23491, DOI 10.1074/jbc.270.40.23491; Olson AL, 1996, ANNU REV NUTR, V16, P235, DOI 10.1146/annurev.nu.16.070196.001315; PELLEGRINI L, 1995, NATURE, V376, P490, DOI 10.1038/376490a0; REN JM, 1995, J CLIN INVEST, V95, P429, DOI 10.1172/JCI117673; REN JM, 1993, J BIOL CHEM, V268, P16113; SHEPHERD PR, 1993, J BIOL CHEM, V268, P22243; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; SIVITZ WI, 1990, MOL ENDOCRINOL, V4, P583, DOI 10.1210/mend-4-4-583; SIVITZ WI, 1989, NATURE, V340, P72, DOI 10.1038/340072a0; Stenbit AE, 1997, NAT MED, V3, P1096, DOI 10.1038/nm1097-1096; STEPHENS JM, 1995, ENDOCR REV, V16, P529, DOI 10.1210/er.16.4.529; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; Tozzo E, 1997, ENDOCRINOLOGY, V138, P1604, DOI 10.1210/en.138.4.1604	44	170	175	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14285	14292		10.1074/jbc.273.23.14285	http://dx.doi.org/10.1074/jbc.273.23.14285			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603935	hybrid			2022-12-27	WOS:000074021500037
J	Atsumi, G; Tajima, M; Hadano, A; Nakatani, Y; Murakami, M; Kudo, I				Atsumi, G; Tajima, M; Hadano, A; Nakatani, Y; Murakami, M; Kudo, I			Fas-induced arachidonic acid release is mediated by Ca2+-independent phospholipase A(2) but not cytosolic phospholipase A(2) which undergoes proteolytic inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; KAPPA-B ACTIVATION; CELL-DEATH; NUCLEAR-ENVELOPE; APOPTOSIS; TNF; RECEPTOR; PROTEIN; TRANSLOCATION; MOBILIZATION	Fas-mediated apoptosis of human leukemic U937 cells was accompanied by increased arachidonic acid (AA) and oleic acid release from membrane glycerophospholipids, indicating phospholipase A(2) (PLA(2)) activation. During apoptosis, type IV cytosolic PLA(2) (cPLA(2)), a PLA(2) isozyme with an apparent molecular mass of 110 kDa critical for stimulus-coupled AA release, was converted to a 78-kDa fragment with concomitant loss of catalytic activity. Cleavage of cPLA(2) correlated with increased caspase-3-like protease activity in apoptotic cells and was abrogated by a caspase-3 inhibitor. A mutant cPLA(2) protein in which Asp(522) was replaced by Asn, which aligns with the consensus sequence of the caspase-3 cleavage site (DXXD down arrow X), was resistant to apoptosis-associated proteolysis. Moreover, a COOH-terminal deletion mutant of cPLA(2) truncated at Asp(522) comigrated with the 78-kDa fragment and exhibited no enzymatic activity. Thus, caspase-3-mediated cPLA(2) cleavage eventually leads to destruction of a catalytic triad essential for cPLA, activity, thereby terminating its AA-releasing function. In contrast, the activity of type VI Ca2+-independent PLA(2) (iPLA(2)), a PLA(2) isozyme implicated in phospholipid remodeling, remained intact during apoptosis, Inhibitors of iPLA(2), but neither cPLA(2) nor secretory PLA(2) inhibitors, suppressed AA release markedly and, importantly, delayed cell death induced by Fas, Therefore, we conclude that iPLA(2)-mediated fatty acid release is facilitated in Fas-stimulated cells and plays a modifying although not essential role in the apoptotic cell death process.	Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Tokyo 142, Japan	Showa University	Kudo, I (corresponding author), Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, 1-5-8 Hatanodai, Tokyo 142, Japan.							ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; Atsumi G, 1997, BBA-LIPID LIPID MET, V1349, P43, DOI 10.1016/S0005-2760(97)00082-9; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; Balsinde J, 1997, J BIOL CHEM, V272, P29317, DOI 10.1074/jbc.272.46.29317; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; DOLE VP, 1960, J BIOL CHEM, V235, P2595; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Enari M, 1996, EUR J BIOCHEM, V236, P533, DOI 10.1111/j.1432-1033.1996.t01-1-00533.x; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; HAYAKAWA M, 1993, J BIOL CHEM, V268, P11290; Hernandez M, 1997, BIOCHEM J, V328, P263, DOI 10.1042/bj3280263; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Jayadev S, 1997, J BIOL CHEM, V272, P17196, DOI 10.1074/jbc.272.27.17196; KIZAKI H, 1989, J IMMUNOL, V143, P1790; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; Kuwata H, 1998, J BIOL CHEM, V273, P1733, DOI 10.1074/jbc.273.3.1733; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 1997, CELL, V7, P111; Martins LM, 1997, J BIOL CHEM, V272, P7421, DOI 10.1074/jbc.272.11.7421; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Murakami M, 1996, J BIOL CHEM, V271, P30041, DOI 10.1074/jbc.271.47.30041; Murakami M, 1997, J BIOL CHEM, V272, P19891, DOI 10.1074/jbc.272.32.19891; MURAKAMI M, 1998, IN PRESS J BIOL CHEM, V273; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Naraba H, 1998, J IMMUNOL, V160, P2974; Pickard RT, 1996, J BIOL CHEM, V271, P19225, DOI 10.1074/jbc.271.32.19225; Reddy ST, 1997, J BIOL CHEM, V272, P13591, DOI 10.1074/jbc.272.21.13591; ROSHAK A, 1994, J BIOL CHEM, V269, P25999; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sapirstein A, 1996, J BIOL CHEM, V271, P21505, DOI 10.1074/jbc.271.35.21505; SCHEVITZ RW, 1995, NAT STRUCT BIOL, V2, P458, DOI 10.1038/nsb0695-458; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; Surette ME, 1996, BIOCHEMISTRY-US, V35, P9187, DOI 10.1021/bi9530245; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; VoelkelJohnson C, 1996, J IMMUNOL, V156, P201; VOELKELJOHNSON C, 1995, J IMMUNOL, V154, P1707; Wang HC, 1996, FASEB J, V10, P1318, DOI 10.1096/fasebj.10.11.8836046; Wissing D, 1997, P NATL ACAD SCI USA, V94, P5073, DOI 10.1073/pnas.94.10.5073; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	55	193	197	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13870	13877		10.1074/jbc.273.22.13870	http://dx.doi.org/10.1074/jbc.273.22.13870			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593733	hybrid			2022-12-27	WOS:000073919100072
J	Li, JZ; Smithgall, TE				Li, JZ; Smithgall, TE			Fibroblast transformation by Fps/Fes tyrosine kinases requires Ras, Rac, and Cdc42 and induces extracellular signal-regulated and c-Jun N-terminal kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; FUJINAMI SARCOMA-VIRUS; LEUKEMIA-CELLS; MONOCYTIC DIFFERENTIATION; PROTOONCOGENE PRODUCT; HEMATOPOIETIC-CELLS; PROTEIN-KINASES; BCR; RHO; PHOSPHORYLATION	The small GTP-binding proteins Ras, Rac, and Cdc42 link protein-tyrosine kinases with mitogen-activated protein kinase (MAPK) signaling cascades. Ras controls the activation of extracellular signal-regulated kinases (ERKs), while Rac and Cdc42 regulate the c-Jun N-terminal kinases (JNKs), In this study, we investigated whether small G protein/MAPK cascades contribute to signal transduction by transforming variants of c-Fes, a nonreceptor tyrosine kinase implicated in cytokine signaling and myeloid differentiation. First, we investigated the effects of dominant-negative small Gr proteins on Rat-a fibroblast transformation by a retroviral homolog of c-Fes (v-Fps) and by c-Fes activated via N-terminal addition of the v-Src myristylation signal (Myr-Fes), We observed that dominant-negative Ras, Rac, and Cdc42 inhibited v-Fps-and Myr-Fes-induced growth of Rat-a cells in soft agar, indicating that activation of these small GTP-binding proteins is required for fibroblast transformation by Fps/Fes tyrosine kinases, To determine whether MAPK pathways are activated downstream of these small G; proteins, we measured ERK and JNK activity in the v-Fps-and Myr-Fes-transformed Rat-a cells. Both ERK and JNK activities were elevated in the transformed cells, suggesting that these pathways are involved in cellular transformation. Dominant-negative mutants of Ras (but not Rac or Cdc42) specifically inhibited ERK activation by v-Fps and Myr Fes, demonstrating that ERK activation occurs exclusively downstream of Ras, All three dominant-negative small Gr proteins inhibited JNK activation by v-Fps and Myr-Fes, indicating that JNK activation by these tyrosine kinases requires both Ras and Rho family GTPases, These data demonstrate that multiple small G protein/MAPK cascades are involved in downstream signal transduction by Fps/Fes tyrosine kinases.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Pharmacol, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Smithgall, TE (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc, 600 S 42nd St, Omaha, NE 68198 USA.				NATIONAL CANCER INSTITUTE [P30CA036727, R01CA058667] Funding Source: NIH RePORTER; NCI NIH HHS [CA58667, P30 CA36727] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Briggs SD, 1997, J BIOL CHEM, V272, P17899, DOI 10.1074/jbc.272.29.17899; Brizzi MF, 1996, J BIOL CHEM, V271, P3562; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CARMIER JF, 1986, CELL, V44, P159, DOI 10.1016/0092-8674(86)90494-0; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHUANG TH, 1995, P NATL ACAD SCI USA, V92, P10282, DOI 10.1073/pnas.92.22.10282; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2379, DOI 10.1073/pnas.82.8.2379; GREER P, 1994, MOL CELL BIOL, V14, P6755, DOI 10.1128/MCB.14.10.6755; Haigh J, 1996, CELL GROWTH DIFFER, V7, P931; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HANAFUSA T, 1980, P NATL ACAD SCI-BIOL, V77, P3009, DOI 10.1073/pnas.77.5.3009; HANAZONO Y, 1993, BLOOD, V81, P3193; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HANKS SK, 1996, BIOESSAYS, V19, P130; HJERMSTAD SJ, 1993, BIOCHEMISTRY-US, V32, P10519, DOI 10.1021/bi00090a031; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; IZUHARA K, 1994, J BIOL CHEM, V269, P18623; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; KATAGIRI K, 1994, BLOOD, V84, P1780; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KHARBANDA S, 1994, J BIOL CHEM, V269, P872; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Li JZ, 1996, J BIOL CHEM, V271, P32930, DOI 10.1074/jbc.271.51.32930; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; Maher J, 1996, LEUKEMIA, V10, P83; Manfredini R, 1997, BLOOD, V89, P135, DOI 10.1182/blood.V89.1.135.135_135_145; MARU Y, 1995, MOL CELL BIOL, V15, P835; MATSUDA T, 1995, J BIOL CHEM, V270, P11037, DOI 10.1074/jbc.270.19.11037; McCormick F, 1996, CURR OPIN BIOTECH, V7, P449, DOI 10.1016/S0958-1669(96)80123-6; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; Nagata Y, 1997, BLOOD, V89, P2664, DOI 10.1182/blood.V89.8.2664; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PaasinenSohns A, 1997, ONCOGENE, V15, P1953, DOI 10.1038/sj.onc.1201366; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rogers JA, 1996, J BIOL CHEM, V271, P17519, DOI 10.1074/jbc.271.29.17519; SAWYERS CL, 1992, CANCER SURV, V15, P37; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SHIBUYA M, 1982, CELL, V30, P787, DOI 10.1016/0092-8674(82)90283-5; SMITHGALL TE, 1988, J BIOL CHEM, V263, P15050; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; WESTWICK JK, 1995, METHOD ENZYMOL, V255, P342; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947; YU G, 1989, J BIOL CHEM, V264, P10276	65	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13828	13834		10.1074/jbc.273.22.13828	http://dx.doi.org/10.1074/jbc.273.22.13828			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593727	hybrid			2022-12-27	WOS:000073919100066
J	Neville, CM; Choe, YH; Lee, YS; Spinner, D; Tsay, HJ; Schmidt, J				Neville, CM; Choe, YH; Lee, YS; Spinner, D; Tsay, HJ; Schmidt, J			The E protein CTP4 and acetylcholine receptor expression in development and denervation supersensitivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEINS; DIRECT GENE-TRANSFER; DNA-BINDING; ELECTRICAL-ACTIVITY; SKELETAL-MUSCLE; TRANSCRIPTIONAL-ACTIVATION; MESSENGER-RNA; SUBUNIT GENE; MYOGENIN; MYOD	Motor activity blocks the extrasynaptic expression of many genes in skeletal muscle, including those encoding ion channels, receptors, and adhesion molecules. Denervation reinduces transcription throughout the multinucleated myofiber, restoring the developmental pattern of expression, especially of the genes coding for the acetylcholine receptor. A screen for trans-acting factors binding to the enhancer region of the cu-subunit gene of the acetylcholine receptor identified CTF4, a ubiquitously expressed and alternatively spliced chicken homologue of the human E protein transcription factor HTF4/HEB, Expression of the CTF4 locus closely parallels that of myogenin and acetylcholine receptor during development and maturation of skeletal muscle, but transcription is not similarly regulated by neuronal cues. Alternative splicing within the region encoding the transactivation domain generates two CTF4 isoforms with different tissue distributions, but similar binding affinities for the acetylcholine receptor cu-subunit enhancer and similar transcriptional potential when complexed to myogenin, Direct injection of a myogenin, but not a MyoD, antisense expression vector into denervated skeletal muscle caused a significant decrease in the transcriptional activation of a depolarization-sensitive reporter gene. Similarly, injection of a CTF4, but less so of an E12, antisense expression vector impaired the denervation response, further implicating the involvement of a myogenin/CTF4 heterodimer in the expression of AChR genes in vivo.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA 02129 USA; Samsung Biomed Res Inst, Seoul 135230, South Korea; Yang Ming Med Univ, Inst Neurosci, Taipei 112, Taiwan	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Harvard University; Massachusetts General Hospital; Sungkyunkwan University (SKKU); Samsung Medical Center; National Yang Ming Chiao Tung University	Schmidt, J (corresponding author), SUNY Stony Brook, Dept Biochem & Cellular Biol, Stony Brook, NY 11794 USA.	jschmidt@life.bio.sunysb.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS020233] Funding Source: NIH RePORTER; NINDS NIH HHS [NS20233] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BESSEREAU JL, 1994, P NATL ACAD SCI USA, V91, P1304, DOI 10.1073/pnas.91.4.1304; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BRUNETTI A, 1990, J BIOL CHEM, V265, P5960; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORNELIUSSEN B, 1991, J VIROL, V65, P6084, DOI 10.1128/JVI.65.11.6084-6093.1991; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUCLERT A, 1995, PHYSIOL REV, V75, P339, DOI 10.1152/physrev.1995.75.2.339; DUTTON EK, 1993, P NATL ACAD SCI USA, V90, P2040, DOI 10.1073/pnas.90.5.2040; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; GILMORE TD, 1996, EUKARYOTIC GENE TRAN, P102; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; Jennings C G, 1993, Curr Opin Neurobiol, V3, P75, DOI 10.1016/0959-4388(93)90038-Z; KLEIN ES, 1993, GENE DEV, V7, P55, DOI 10.1101/gad.7.1.55; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LIN HH, 1993, J BIOL CHEM, V268, P10214; LIN ZY, 1989, GENE DEV, V3, P986, DOI 10.1101/gad.3.7.986; MALIK S, 1995, EUR J BIOCHEM, V230, P88, DOI 10.1111/j.1432-1033.1995.tb20537.x; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MERLIE JP, 1994, J BIOL CHEM, V269, P2461; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; NEVILLE C, 1991, NEUROREPORT, V2, P655, DOI 10.1097/00001756-199111000-00005; NEVILLE C, 1996, EUKARYOTIC GENE TRAN, P192; NEVILLE CM, 1992, CELL MOL NEUROBIOL, V12, P511, DOI 10.1007/BF00711232; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; POCKETT S, 1981, DEV BRAIN RES, V1, P299, DOI 10.1016/0165-3806(81)90117-6; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; SALMINEN A, 1991, J CELL BIOL, V115, P905, DOI 10.1083/jcb.115.4.905; SANES J, 1992, CELL NEURON SZ, V72, P99; SHIEH BH, 1987, J CELL BIOL, V104, P1337, DOI 10.1083/jcb.104.5.1337; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; TSAY HJ, 1992, NUCLEIC ACIDS RES, V20, P2624, DOI 10.1093/nar/20.10.2624-b; TSAY HJ, 1992, NUCLEIC ACIDS RES, V20, P1805, DOI 10.1093/nar/20.7.1805; TSAY HJ, 1989, J CELL BIOL, V108, P1523, DOI 10.1083/jcb.108.4.1523; Walke W, 1996, J NEUROSCI, V16, P3641; WANG GK, 1976, BRAIN RES, V114, P524, DOI 10.1016/0006-8993(76)90976-8; WANG Y, 1988, NEURON, V1, P527, DOI 10.1016/0896-6273(88)90183-3; WEINTRAUB H, 1994, GENE DEV, V8, P2203, DOI 10.1101/gad.8.18.2203; WENTWORTH BM, 1991, P NATL ACAD SCI USA, V88, P1242, DOI 10.1073/pnas.88.4.1242; WITZEMANN V, 1991, FEBS LETT, V282, P259, DOI 10.1016/0014-5793(91)80490-T; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; WOLFF JA, 1991, BIOTECHNIQUES, V11, P474; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104; ZHANG Y, 1991, NUCLEIC ACIDS RES, V19, P4555, DOI 10.1093/nar/19.16.4555; Zhuang Y, 1996, MOL CELL BIOL, V16, P2898	48	9	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					14046	14052		10.1074/jbc.273.22.14046	http://dx.doi.org/10.1074/jbc.273.22.14046			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593756	hybrid			2022-12-27	WOS:000073919100095
J	Waterman, H; Sabanai, I; Geiger, B; Yarden, Y				Waterman, H; Sabanai, I; Geiger, B; Yarden, Y			Alternative intracellular routing of ErbB receptors may determine signaling potency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; LIGAND-INDUCED INTERNALIZATION; NEU DIFFERENTIATION FACTOR; TYROSINE KINASE-ACTIVITY; FACTOR EGF RECEPTOR; FACTOR-ALPHA; PHOSPHATIDYLINOSITOL 3-KINASE; MEDIATED ENDOCYTOSIS; POINT MUTATION; BINDING-SITE	The ErbB signaling module consists of four receptor tyrosine kinases and several dozen ligands that activate specific homo-and heterodimeric complexes of ErbB proteins. Combinatorial ligand/receptor/effector interactions allow large potential for signal diversification. Here we addressed the possibility that turn-off mechanisms enhance the diversification potential. Concentrating on ErbB-1 and two of its ligands, epidermal growth factor (EGF) and transforming growth factor alpha (TGF-alpha), and the Neu differentiation factor (NDF/neuregulin) and one of its receptors, ErbB-3, we show that ligand binding variably accelerates endocytosis of the respective ligand-receptor complex. However, unlike the EGF-activated ErbB-1, which is destined primarily to degradation in lysosomes, NDF and TGF-alpha direct their receptors to recycling, probably because these ligands dissociate from their receptors earlier along the endocytic pathway. In the case of NDF, structural, as well as biochemical, analyses imply that ligand degradation occurs at a relatively late endosomal stage. Attenuation of receptor down-regulation by this mechanism apparently confers to both NDF and TGF-alpha more potent and prolonged signaling activity. In conclusion, alternative endocytic trafficking of ligand-ErbB complexes may tune and diversify signal transduction by EGF family ligands.	Weizmann Inst Sci, Dept Biol Regulat, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Yarden, Y (corresponding author), Weizmann Inst Sci, Dept Biol Regulat, IL-76100 Rehovot, Israel.		YARDEN, YOSEF/K-1467-2012		NCI NIH HHS [CA72981] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072981, R37CA072981] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; BACUS SS, 1993, CANCER RES, V53, P5251; BARRANDON Y, 1987, CELL, V50, P1131, DOI 10.1016/0092-8674(87)90179-6; BASU SK, 1981, CELL, V24, P493, DOI 10.1016/0092-8674(81)90340-8; Baulida J, 1997, EXP CELL RES, V232, P167, DOI 10.1006/excr.1997.3515; Baulida J, 1996, J BIOL CHEM, V271, P5251; BENLEVY R, 1992, J BIOL CHEM, V267, P17304; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; CARDELLI JA, 1989, J BIOL CHEM, V264, P3454; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; CHANG CP, 1993, J BIOL CHEM, V268, P19312; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; Chen XM, 1996, J BIOL CHEM, V271, P7620, DOI 10.1074/jbc.271.13.7620; Cohen BD, 1996, J BIOL CHEM, V271, P30897, DOI 10.1074/jbc.271.48.30897; DAVIS CG, 1987, NATURE, V326, P760, DOI 10.1038/326760a0; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; EBNER R, 1991, CELL REGUL, V2, P599, DOI 10.1091/mbc.2.8.599; FAURE R, 1992, J BIOL CHEM, V267, P11215; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FRENCH AR, 1995, J BIOL CHEM, V270, P4334, DOI 10.1074/jbc.270.9.4334; GEUZE HJ, 1983, CELL, V32, P277, DOI 10.1016/0092-8674(83)90518-4; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HAIGLER HT, 1979, J CELL BIOL, V81, P382, DOI 10.1083/jcb.81.2.382; Hamel FG, 1997, MOL CELL ENDOCRINOL, V126, P185, DOI 10.1016/S0303-7207(96)03981-0; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; KADOWAKI H, 1990, J BIOL CHEM, V265, P21285; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Kornilova E, 1996, J BIOL CHEM, V271, P30340, DOI 10.1074/jbc.271.48.30340; KRAMER RH, 1994, J BIOL CHEM, V269, P8708; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Levkowitz G, 1996, ONCOGENE, V12, P1117; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MILLER K, 1986, J CELL BIOL, V102, P500, DOI 10.1083/jcb.102.2.500; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; Perrimon N, 1997, CELL, V89, P13, DOI 10.1016/S0092-8674(00)80177-4; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PRIGENT SA, 1992, ONCOGENE, V7, P1273; Reddy CC, 1996, NAT BIOTECHNOL, V14, P1696, DOI 10.1038/nbt1296-1696; RISE DJ, 1995, MOL CELL BIOL, V15, P5770; SCHREIBER AB, 1986, SCIENCE, V232, P1325; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; SORKIN A, 1992, J BIOL CHEM, V267, P8672; SORKIN A, 1993, ONCOGENE, V8, P3021; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; Sorkin A, 1996, J BIOL CHEM, V271, P13377, DOI 10.1074/jbc.271.23.13377; TOKUYASU KT, 1976, J CELL BIOL, V71, P894, DOI 10.1083/jcb.71.3.894; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Tzahar E, 1997, EMBO J, V16, P4938, DOI 10.1093/emboj/16.16.4938; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; YARDEN Y, 1981, BIOCHIM BIOPHYS ACTA, V674, P188, DOI 10.1016/0304-4165(81)90377-9; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; Yung Y, 1997, FEBS LETT, V408, P292, DOI 10.1016/S0014-5793(97)00442-0	62	165	171	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13819	13827		10.1074/jbc.273.22.13819	http://dx.doi.org/10.1074/jbc.273.22.13819			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593726	hybrid			2022-12-27	WOS:000073919100065
J	Bu, GJ; Sun, YL; Schwartz, AL; Holtzman, DM				Bu, GJ; Sun, YL; Schwartz, AL; Holtzman, DM			Nerve growth factor induces rapid increases in functional cell surface low density lipoprotein receptor-related protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPORADIC ALZHEIMERS-DISEASE; RAT HEPATOMA-CELLS; APOLIPOPROTEIN-E; ALPHA-2-MACROGLOBULIN RECEPTOR; NEURITE OUTGROWTH; 39-KDA PROTEIN; SUBCELLULAR TRAFFICKING; BINDING-PROTEIN; TYPE-4 ALLELE; IN-VITRO	The low density lipoprotein receptor-related protein (LRP) is a large endocytic receptor that binds multiple ligands and is highly expressed in neurons. Several LRP ligands, including apolipoprotein E/lipoproteins and amyloid precursor protein, have been shown to participate either in Alzheimer's disease pathogenesis or pathology. However, factors that regulate LRP expression in neurons are unknown. In the current study, we analyzed the effects of nerve growth factor (NGF) treatment on LRP expression, distribution, and function within neurons in two neuronal cell lines. Our results show that NGF induces a rapid increase of cell surface LRP expression in a central nervous system-derived neuronal cell line, GT1-1 Trk, which was seen within 10 min and reached a maximum at about 1 h of NGF treatment. This increase of cell surface LRP expression is concomitant with an increase in the endocytic activity of LRP as measured via ligand uptake and degradation assays. We also found that the cytoplasmic tail of LRP is phosphorylated and that NGF rapidly increases the amount of phosphorylation. Furthermore, we detected a significant increase of LRP expression at the messenger RNA level following 24 h of NGF treatment. Both rapid and long term induction of LRP expression were also detected in peripheral nervous system-derived PC12 cells following NGF treatment. Taken together, our results demonstrate that NGF regulates LRP expression in neuronal cells.	Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Bu, GJ (corresponding author), Washington Univ, Sch Med, Dept Pediat, CB 8116,1 Childrens Pl, St Louis, MO 63110 USA.	bu@kids.wustl.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059150] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013956, P50AG005681, R37AG013956] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL59150] Funding Source: Medline; NIA NIH HHS [AG13956, AG05681] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BELLOSTA S, 1995, J BIOL CHEM, V270, P27063, DOI 10.1074/jbc.270.45.27063; BOYLES JK, 1989, J CLIN INVEST, V83, P1015, DOI 10.1172/JCI113943; Breuer P, 1997, MOL BIOL CELL, V8, P567, DOI 10.1091/mbc.8.4.567; BU GJ, 1992, J BIOL CHEM, V267, P15595; BU GJ, 1994, J BIOL CHEM, V269, P18521; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Du YS, 1997, J NEUROCHEM, V69, P299; Dugan LL, 1997, P NATL ACAD SCI USA, V94, P4086, DOI 10.1073/pnas.94.8.4086; Fagan AM, 1996, J BIOL CHEM, V271, P30121, DOI 10.1074/jbc.271.47.30121; HALEGOUA S, 1991, CURR TOP MICROBIOL, V165, P119; HALES TG, 1994, NEUROENDOCRINOLOGY, V59, P297, DOI 10.1159/000126671; HANDLEYGEARHART PM, 1994, J BIOL CHEM, V269, P33171; Hardy MM, 1997, J BIOL CHEM, V272, P6812, DOI 10.1074/jbc.272.10.6812; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HIGAKI J, 1995, NEURON, V14, P651, DOI 10.1016/0896-6273(95)90322-4; Hollister RD, 1996, BRAIN RES, V728, P13; HOLTZMAN DM, 1995, P NATL ACAD SCI USA, V92, P9480, DOI 10.1073/pnas.92.21.9480; Howard GC, 1996, J CLIN INVEST, V97, P1193, DOI 10.1172/JCI118533; HUBBARD AL, 1972, J CELL BIOL, V55, P390, DOI 10.1083/jcb.55.2.390; IADONATO SP, 1993, BIOCHEM J, V296, P867, DOI 10.1042/bj2960867; Jordan J, 1998, J NEUROSCI, V18, P195; Kang DE, 1997, NEUROLOGY, V49, P56, DOI 10.1212/WNL.49.1.56; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; Knauer MF, 1996, BRAIN RES, V740, P6, DOI 10.1016/S0006-8993(96)00711-1; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; KUTT H, 1989, BIOCHIM BIOPHYS ACTA, V1009, P229, DOI 10.1016/0167-4781(89)90107-3; LADU MJ, 1994, J BIOL CHEM, V269, P23403; Lendon CL, 1997, NEUROSCI LETT, V222, P187, DOI 10.1016/S0304-3940(97)13381-X; LOHOF AM, 1993, NATURE, V363, P350, DOI 10.1038/363350a0; MASLIAH E, 1994, RES ADV ALZHEIMERS D, P405; MEDH JD, 1995, J BIOL CHEM, V270, P536, DOI 10.1074/jbc.270.2.536; MELLON PL, 1990, NEURON, V5, P1, DOI 10.1016/0896-6273(90)90028-E; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; Narita M, 1997, J NEUROCHEM, V68, P587; Narita M, 1997, J NEUROCHEM, V69, P1904; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; REBECK GW, 1993, NEURON, V11, P575; SATOH S, 1993, J BIOL CHEM, V268, P17820; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; SNIPS GJ, 1986, P NATL ACAD SCI USA, V83, P1130, DOI 10.1073/pnas.83.4.1130; STOORVOGEL W, 1991, J BIOL CHEM, V266, P5438; STRAUSS S, 1992, LAB INVEST, V66, P223; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; STRITTMATTER WJ, 1994, P NATL ACAD SCI USA, V91, P11183, DOI 10.1073/pnas.91.23.11183; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; VANGOOL D, 1993, NEUROBIOL AGING, V14, P233, DOI 10.1016/0197-4580(93)90006-W; WARSHAWSKY I, 1993, J BIOL CHEM, V268, P22046; WILEY HS, 1982, J BIOL CHEM, V257, P4222; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; Willnow TE, 1996, BIOCHEM J, V313, P71, DOI 10.1042/bj3130071; YANG J, 1993, J BIOL CHEM, V268, P4600; ZHOU J, 1994, P NATL ACAD SCI USA, V91, P3824, DOI 10.1073/pnas.91.9.3824	63	58	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					13359	13365		10.1074/jbc.273.21.13359	http://dx.doi.org/10.1074/jbc.273.21.13359			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582384	hybrid			2022-12-27	WOS:000073768500095
J	Kirsch, M; Lomonosova, EE; Korth, HG; Sustmann, R; de Groot, H				Kirsch, M; Lomonosova, EE; Korth, HG; Sustmann, R; de Groot, H			Hydrogen peroxide formation by reaction of peroxynitrite with HEPES and related tertiary amines - Implications for a general mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXYL RADICAL PRODUCTION; NITRIC-OXIDE; SUPEROXIDE-DISMUTASE; PULSE-RADIOLYSIS; HORSERADISH-PEROXIDASE; INCREASED CYTOTOXICITY; AQUEOUS-SOLUTION; CARBON-DIOXIDE; OXIDATION; IRON	Organic amine-based buffer compounds such as HEPES (Good's buffers) are commonly applied in experimental systems, including those where the biological effects of peroxynitrite are studied. In such studies 3-morpholinosydnonimine N-ethylcarbamide (SIN-1), a compound that simultaneously releases nitric oxide ((NO)-N-.) and superoxide (O-2(.)) is often used as a source for peroxynitrite. Whereas in mere phosphate buffer H2O2 formation from 1.5 mM SIN-1 was low (similar to 15 mu M), incubation of SIN-1 with Good's buffer compounds resulted in continuous H2O2 formation. After 2 h of incubation of 1.5 mM SIN-1 with 20 mM HEPES about 190 mu M H2O2 were formed. The same amount of H2O2 could be achieved from 1.5 mM SIN-1 by action of superoxide dismutase in the absence of HEPES. The increased H2O2 level, however, could not be related to a superoxide dismutase or to a NO scavenger activity of HEPES, On the other hand, SIN-1-mediated oxidation of both dihydrorhodamine 123 and deoxyribose as well as peroxynitrite-dependent nitration of p-hydroxyphenylacetic acid were strongly inhibited by 20 mM HEPES, Furthermore, the peroxynitrite scavenger tryptophan significantly reduced H2O2 formation from SIN-1-HEPES interactions. These observations suggest that peroxynitrite is the initiator for the enhanced formation of H2O2. Likewise, authentic peroxynitrite (1 mar) also induced the formation of both O-2(.) and H2O2 upon addition to HEPES (400 mM)-containing solutions in a pH (4.5-7.5)-dependent manner. In accordance with previous reports it was found that at pH greater than or equal to 5 oxygen is released in the decay of peroxynitrite, As a consequence, peroxynitrite(1 mM)-induced H,O, formation (similar to 80 mu M at pH 7.5) also occurred under hypoxic conditions. In the presence of bicarbonate/carbon dioxide (20 mM/5%) the production of H,O, from the reaction of HEPES with peroxynitrite was even further stimulated. Addition of SIN-1 or authentic peroxynitrite to solutions of Good's buffers resulted in the formation of piperazine-derived radical cations as detected by ESR spectroscopy. These findings suggest a mechanism for H2O2 formation in which peroxynitrite (or any strong oxidant derived from it) initially oxidizes the tertiary amine buffer compounds in a one-electron step. Subsequent deprotonation and reaction of the intermediate alpha-amino alkyl radicals with molecular oxygen leads to the formation of O-2(.), from which H2O2 is produced by dismutation, Hence, HEPES and similar organic buffers should be avoided in studies of oxidative compounds. Furthermore, this mechanism of H2O2 formation must be regarded to be a rather general one for biological systems where sufficiently strong oxidants may interact with various biologically relevant amino-type molecules, such as ATP, creatine, or nucleic acids.	Univ Essen Gesamthsch Klinikum, Inst Physiol Chem, D-45122 Essen, Germany; Univ Essen Gesamthsch, Inst Organ Chem, D-45117 Essen, Germany	University of Duisburg Essen; University of Duisburg Essen	de Groot, H (corresponding author), Univ Essen Gesamthsch Klinikum, Inst Physiol Chem, Hufelandstr 55, D-45122 Essen, Germany.							Alvarez B, 1996, CHEM RES TOXICOL, V9, P390, DOI 10.1021/tx950133b; ALVAREZ B, 1995, CHEM RES TOXICOL, V8, P859, DOI 10.1021/tx00048a006; ANTHOLINE WE, 1991, FREE RADICAL BIO MED, V10, P119, DOI 10.1016/0891-5849(91)90005-N; BARD AJ, 1976, ADV PHYSICAL ORGANIC, V13, P155; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1992, ARCH BIOCHEM BIOPHYS, V298, P438, DOI 10.1016/0003-9861(92)90432-V; CHOW YL, 1978, CHEM REV, V78, P243, DOI 10.1021/cr60313a003; Crow JP, 1997, NITRIC OXIDE-BIOL CH, V1, P145, DOI 10.1006/niox.1996.0113; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; DULING DR, 1994, J MAGN RESON SER B, V104, P105, DOI 10.1006/jmrb.1994.1062; Feelisch M., 1989, J CARDIOVASC PHARM, V14, P13; FLORIS R, 1993, EUR J BIOCHEM, V215, P767, DOI 10.1111/j.1432-1033.1993.tb18091.x; GERGEL D, 1995, J BIOL CHEM, V270, P20922, DOI 10.1074/jbc.270.36.20922; Good N E, 1972, Methods Enzymol, V24, P53; GOOD NE, 1966, BIOCHEMISTRY-US, V5, P467, DOI 10.1021/bi00866a011; GRADY JK, 1988, ANAL BIOCHEM, V173, P111, DOI 10.1016/0003-2697(88)90167-4; GRAF E, 1984, J BIOL CHEM, V259, P3620; HADDAD IY, 1994, AM J PHYSIOL, V267, pL242, DOI 10.1152/ajplung.1994.267.3.L242; HALLIWELL B, 1981, FEBS LETT, V128, P347, DOI 10.1016/0014-5793(81)80114-7; HAMADA T, 1994, EXPERIENTIA, V50, P49, DOI 10.1007/BF01992049; HAMMERICH O, 1984, ADV PHYS ORG CHEM, V20, P55, DOI 10.1016/S0065-3160(08)60148-3; HOGG N, 1992, BIOCHEM J, V281, P419, DOI 10.1042/bj2810419; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; Ingold KU, 1997, J AM CHEM SOC, V119, P12364, DOI 10.1021/ja972886l; IOANNIDIS I, 1993, BIOCHEM J, V296, P341, DOI 10.1042/bj2960341; Ioannidis I, 1996, BIOCHEM J, V318, P789, DOI 10.1042/bj3180789; Kelm M, 1997, J BIOL CHEM, V272, P9922; KING PA, 1992, J AM CHEM SOC, V114, P5430, DOI 10.1021/ja00039a068; KNIEP C, 1997, THESIS U ESSEN; KOBAYASHI K, 1995, J CHEM SOC DALTON, P2885, DOI 10.1039/dt9950002885; KOOY NW, 1994, FREE RADICAL BIO MED, V16, P149, DOI 10.1016/0891-5849(94)90138-4; Lemercier JN, 1997, ARCH BIOCHEM BIOPHYS, V345, P160, DOI 10.1006/abbi.1997.0240; LOMONOSOVA LL, 1998, IN PRESS FREE RADICA; LYMAR SV, 1995, J AM CHEM SOC, V117, P8867, DOI 10.1021/ja00139a027; Lymar SV, 1996, BIOCHEMISTRY-US, V35, P7855, DOI 10.1021/bi960331h; MASSEY V, 1959, BIOCHIM BIOPHYS ACTA, V34, P255, DOI 10.1016/0006-3002(59)90259-8; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MIEDEN OJ, 1989, J CHEM SOC PERK T 2, P2071, DOI 10.1039/p29890002071; MIEDEN OJ, 1993, J PHYS CHEM-US, V97, P3783, DOI 10.1021/j100117a026; NELSEN SF, 1990, LANDOLTBORNSTEIN NEW, V17, P122; NELSON SF, 1980, LANDOLTBORNSTEIN, V9, P22; NETA P, 1990, J PHYS CHEM REF DATA, V19, P413, DOI 10.1063/1.555854; PAOLETTI F, 1986, ANAL BIOCHEM, V154, P536, DOI 10.1016/0003-2697(86)90026-6; Pfeiffer S, 1997, J BIOL CHEM, V272, P3465, DOI 10.1074/jbc.272.6.3465; PRUTZ WA, 1990, Z NATURFORSCH C, V45, P1197; Prutz WA, 1996, ARCH BIOCHEM BIOPHYS, V332, P110, DOI 10.1006/abbi.1996.0322; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; RADI R, 1991, J BIOL CHEM, V266, P4244; Sampson JB, 1996, METHOD ENZYMOL, V269, P210; SIMPSON JA, 1988, BIOCHEM J, V254, P519, DOI 10.1042/bj2540519; UEDA J, 1994, ARCH BIOCHEM BIOPHYS, V315, P185, DOI 10.1006/abbi.1994.1488; Uppu RM, 1996, METHOD ENZYMOL, V269, P285; Uppu RM, 1996, ANAL BIOCHEM, V236, P242, DOI 10.1006/abio.1996.0162; VOLK T, 1995, BIOCHEM BIOPH RES CO, V213, P196, DOI 10.1006/bbrc.1995.2116; VONSONNTAG C, 1991, ANGEW CHEM INT EDIT, V30, P1229, DOI 10.1002/anie.199112291; WEISS RH, 1993, J BIOL CHEM, V268, P23049; WHITE CR, 1994, P NATL ACAD SCI USA, V91, P1044, DOI 10.1073/pnas.91.3.1044; YIM MB, 1990, P NATL ACAD SCI USA, V87, P5006, DOI 10.1073/pnas.87.13.5006	58	113	114	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					12716	12724		10.1074/jbc.273.21.12716	http://dx.doi.org/10.1074/jbc.273.21.12716			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582295	hybrid			2022-12-27	WOS:000073768500006
J	Valtavaara, M; Szpirer, C; Szpirer, J; Myllyla, R				Valtavaara, M; Szpirer, C; Szpirer, J; Myllyla, R			Primary structure, tissue distribution, and chromosomal localization of a novel isoform of lysyl hydroxylase (lysyl hydroxylase 3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNDROME TYPE-VI; HISTIDINE-RESIDUES; GENE PLOD; COLLAGENS; RAT; ASSIGNMENT; DISEASES; SEQUENCE; ENZYMES; CELLS	We report characterization of a novel isoform of lysyl hydroxylase (lysyl hydroxylase 3, LH3). The cDNA clones encode a polypeptide of 738 amino acids, including a signal peptide. The amino acid sequence has a high overall identity with LH1 and LH2, the isoforms characterized earlier. Conserved regions are present in the carboxyl-terminal portion of the isoforms and also in the central part of the molecules. Histidine and asparagine residues, which are conserved in the other isoforms and are known to be required for enzymatic activity, are also conserved in the novel isoform, The gene for LH3 (PLOD3) has been assigned to human chromosome 7q36 and rat chromosome 12. Gene expression of LH3 is highly regulated in adult human tissues, A strong hybridization signal, corresponding to an mRNA 2.75 kilobases in size, is obtained in heart, placenta and pancreas on multiple tissue RNA blots. Expression of the cDNA in vitro results in the synthesis of a protein that hydroxylates lysyl residues in collagenous sequences in a non-triple helical conformation.	Univ Oulu, Dept Biochem, FIN-90570 Oulu, Finland; Free Univ Brussels, Dept Biol Mol, B-1640 Rhode St Genese, Belgium	Finland National Institute for Health & Welfare; University of Oulu	Myllyla, R (corresponding author), Univ Oulu, Dept Biochem, FIN-90570 Oulu, Finland.	rmyllyla@koivu.oulu.fi						Ausubel FM., 1988, CURRENT PROTOCOLS MO; BARNES MJ, 1974, BIOCHEM J, V139, P461, DOI 10.1042/bj1390461; *GDB, 1997, GEN DAT BAS; HA VT, 1994, J CLIN INVEST, V93, P1716, DOI 10.1172/JCI117155; HAUTALA T, 1992, GENOMICS, V13, P62, DOI 10.1016/0888-7543(92)90202-4; HEIKKINEN J, 1994, GENOMICS, V24, P464, DOI 10.1006/geno.1994.1654; Heikkinen J, 1997, AM J HUM GENET, V60, P48; HYLAND J, 1992, NAT GENET, V2, P228, DOI 10.1038/ng1192-228; Kielty Cay M., 1993, P103; Kivirikko K. I., 1991, POST TRANSLATIONAL M, P1; KIVIRIKKO KI, 1993, ANN MED, V25, P113, DOI 10.3109/07853899309164153; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; MYLLYLA R, 1992, BIOCHEM J, V286, P923, DOI 10.1042/bj2860923; MYLLYLA R, 1988, BIOCHEM J, V253, P489, DOI 10.1042/bj2530489; Pajunen L, 1998, DNA CELL BIOL, V17, P117, DOI 10.1089/dna.1998.17.117; PINKEL D, 1988, P NATL ACAD SCI USA, V85, P9138, DOI 10.1073/pnas.85.23.9138; PINNELL SR, 1972, NEW ENGL J MED, V286, P1013, DOI 10.1056/NEJM197205112861901; Pirskanen A, 1996, J BIOL CHEM, V271, P9398, DOI 10.1074/jbc.271.16.9398; Pousi B, 1998, HUM MUTAT, V11, P55; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; *RATMAP, 1997, RAT GEN DAT BAS; Reichenberger E, 1996, SEMIN CELL DEV BIOL, V7, P631, DOI 10.1006/scdb.1996.0077; ROACH PL, 1995, NATURE, V375, P700, DOI 10.1038/375700a0; Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0; Stephanova E, 1996, CYTOGENET CELL GENET, V72, P83, DOI 10.1159/000134168; Szpirer C, 1996, FOLIA BIOL-PRAGUE, V42, P175; Szpirer C, 1997, MAMM GENOME, V8, P707, DOI 10.1007/s003359900549; Szpirer C, 1996, MAMM GENOME, V7, P701, DOI 10.1007/s003359900211; Valtavaara M, 1997, J BIOL CHEM, V272, P6831, DOI 10.1074/jbc.272.11.6831; VANROY N, 1993, GENOMICS, V18, P71, DOI 10.1006/geno.1993.1427; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; WatkinsChow DE, 1997, GENOMICS, V40, P114, DOI 10.1006/geno.1996.4532; Yeowell HN, 1997, P ASSOC AM PHYSICIAN, V109, P383; YEOWELL HN, 1994, J INVEST DERMATOL, V102, P382, DOI 10.1111/1523-1747.ep12371799	34	97	102	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					12881	12886		10.1074/jbc.273.21.12881	http://dx.doi.org/10.1074/jbc.273.21.12881			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582318	hybrid			2022-12-27	WOS:000073768500029
J	Gutknecht, R; Lanz, R; Erni, B				Gutknecht, R; Lanz, R; Erni, B			Mutational analysis of invariant arginines in the IIAB(Man) subunit of the Escherichia coli phosphotransferase system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTIDINE-CONTAINING PROTEIN; PHAGE-LAMBDA-DNA; MANNOSE TRANSPORTER; SUGAR-TRANSPORT; GLUCOSE-TRANSPORTER; IIA DOMAIN; PHOSPHORYLATION; PERMEASE; PHOSPHOENOLPYRUVATE; HPR	The mannose transporter of bacterial phosphotransferase system mediates uptake of mannose, glucose, and related hexoses by a mechanism that couples translocation with phosphorylation of the substrate. It consists of the transmembrane IICMan-IIDMan complex and the cytoplasmic IIAB(Man) subunit, IIAB(Man) has two flexibly linked domains, IIA(Man) and IIBMan, each containing a phosphorylation site (His-10 and His-175). Phosphoryl groups are transferred from the phosphoryl carrier protein phospho-HPr to His-10, hence to His-175 and finally to the 6' OH of the transported hexose, Phosphate-binding sites and phosphate-catalytic sites frequently contain arginines, which by their guanidino group can stabilize phosphate through hydrogen bonding and electrostatic interactions. IIBMan contains five arginines which are invariant in the homologous IIB subunits of Escherichia coli, Klebsiella pneumoniae and Bacillus subtilis, The IIA domains have no conserved arginines, The five arginines were replaced by Lys or Gin one at a time, and the mutants were analyzed for transport and phosphorylation activity. All five HB mutants can still be phosphorylated at His-175 by the IIA domain. R172Q is completely inactive with respect to glucose phosphotransferase (phosphoryltransfer from His-175 to the 6' OH of Glc) and hexose transport activity. R168Q has no hexose transport and strongly reduced phosphotransferase activity. R204K, has no transport but almost normal phosphotransferase activity, R304Q has only slightly reduced transport activity. R190K behaves like wild-type IIAB(Man). Arg-168, Arg-172, and Arg-304 are part of the hydrogen bonding network on the surface of HB, which contains the active site His-175 and the interface with the LIA domain (Schauder, S., Nunn, R.S., Lanz, R., Erni, B. and Schirmer, T. (1998) J. Mol. Biol, 276, 591-602) (Protein Data Bank accession code 1BLE), Arg-204 is at the putative interface between IIBMan and the IICMan-IIDMan complex.	Univ Bern, Dept Chem & Biochem, CH-3012 Bern, Switzerland	University of Bern	Erni, B (corresponding author), Univ Bern, Dept Chem & Biochem, Freiestr 3, CH-3012 Bern, Switzerland.	erni@ibc.unibe.ch						ANDERSON JW, 1993, J BIOL CHEM, V268, P12325; Bouma CL, 1996, J BIOL CHEM, V271, P33457, DOI 10.1074/jbc.271.52.33457; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; BUHR A, 1992, J BIOL CHEM, V267, P3847; BUHR A, 1994, J BIOL CHEM, V269, P23437; ELLIOTT J, 1978, MOL GEN GENET, V161, P1, DOI 10.1007/BF00266608; ERNI B, 1985, J BIOL CHEM, V260, P5495; ERNI B, 1989, J BIOL CHEM, V264, P18733; ERNI B, 1987, J BIOL CHEM, V262, P5238; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; Gschwind RM, 1997, FEBS LETT, V404, P45, DOI 10.1016/S0014-5793(97)00084-7; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huber F, 1996, EUR J BIOCHEM, V239, P810, DOI 10.1111/j.1432-1033.1996.0810u.x; HUBER F, 1996, THESIS U BERN; JOHNSON LN, 1993, ANNU REV BIOPH BIOM, V22, P199, DOI 10.1146/annurev.bb.22.060193.001215; Jones BE, 1997, PROTEIN SCI, V6, P2107; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lanz R, 1998, J BIOL CHEM, V273, P12239, DOI 10.1074/jbc.273.20.12239; Liao DI, 1996, STRUCTURE, V4, P861, DOI 10.1016/S0969-2126(96)00092-5; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; MAO QC, 1995, J BIOL CHEM, V270, P5258, DOI 10.1074/jbc.270.10.5258; Mukhija S, 1997, MOL MICROBIOL, V25, P1159, DOI 10.1046/j.1365-2958.1997.5501910.x; Nunn RS, 1996, J MOL BIOL, V259, P502, DOI 10.1006/jmbi.1996.0335; NUOFFER C, 1988, J BIOL CHEM, V263, P6647; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; Postma P.W., 1996, ESCHERICHIA COLI SAL, P1149; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; RAJAGOPAL P, 1994, BIOCHEMISTRY-US, V33, P15271, DOI 10.1021/bi00255a008; Reizer J, 1996, MICROBIOL-SGM, V142, P231, DOI 10.1099/13500872-142-2-231; ROOSSIEN FF, 1983, BIOCHIM BIOPHYS ACTA, V760, P185, DOI 10.1016/0304-4165(83)90141-1; Schauder S, 1998, J MOL BIOL, V276, P591, DOI 10.1006/jmbi.1997.1544; SEIP S, 1994, BIOCHEMISTRY-US, V33, P7174, DOI 10.1021/bi00189a021; STANSSENS P, 1989, NUCLEIC ACIDS RES, V17, P4441, DOI 10.1093/nar/17.12.4441; STOLZ B, 1993, J BIOL CHEM, V268, P27094; THOMPSON J, 1985, J BACTERIOL, V162, P224, DOI 10.1128/JB.162.1.224-234.1985; VANNULAND NAJ, 1995, J MOL BIOL, V246, P180, DOI 10.1006/jmbi.1994.0075; VERSTRAETE M, 1990, J MOL BIOL, V214, P657; Veyrat A, 1996, MICROBIOL-UK, V142, P3469, DOI 10.1099/13500872-142-12-3469; WEHMEIER UF, 1994, BBA-PROTEIN STRUCT M, V1208, P348, DOI 10.1016/0167-4838(94)90124-4	40	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12234	12238		10.1074/jbc.273.20.12234	http://dx.doi.org/10.1074/jbc.273.20.12234			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575172	hybrid			2022-12-27	WOS:000073629800037
J	Rohlfs, RJ; Bruner, E; Chiu, A; Gonzales, A; Gonzales, ML; Magde, D; Madge, MD; Vandegriff, KD; Winslow, RM				Rohlfs, RJ; Bruner, E; Chiu, A; Gonzales, A; Gonzales, ML; Magde, D; Madge, MD; Vandegriff, KD; Winslow, RM			Arterial blood pressure responses to cell-free hemoglobin solutions and the reaction with nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATION	Changes in mean arterial pressure were monitored in rats following 50% isovolemic exchange transfusion with solutions of chemically modified hemoglobins. Blood pressure responses fall into three categories: 1) an immediate and sustained increase, 2) an immediate yet transient increase, or 3) no significant change either during or subsequent to exchange transfusion. The reactivities of these hemoglobins with nitric monoxide ((.)NO) were measured to test the hypothesis that different blood pressure responses to these solutions result from differences in (.)NO scavenging reactions. All hemoglobins studied exhibited a value of 30 mu M(-1) s(-1) for both (.)NO bimolecular association rate constants and the rate constants for (.)NO-induced oxidation in vitro. Only the (.)NO dissociation rate constants and, thus, the equilibrium dissociation constants varied. Values of equilibrium dissociation constants ranged from 2 to 14 pM and varied inversely with vasopressor response. Hemoglobin solutions that exhibited either transient or no significant increase in blood pressure showed tighter (.)NO binding affinities than hemoglobin solutions that exhibited sustained increases. These results suggest that blood pressure increases observed upon exchange transfusion with cell-free hemoglobin solutions can not be the result of (.)NO scavenging reactions at the heme, but rather must be due to alternative physiologic mechanisms.	Univ Calif San Diego, Vet Affairs Med Ctr, Sch Med, Dept Med, San Diego, CA 92161 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Diego	Rohlfs, RJ (corresponding author), Univ Calif San Diego, Vet Affairs Med Ctr, Sch Med, Dept Med, 3350 La Jolla Village Dr,111-E, San Diego, CA 92161 USA.	rrohlfs@ucsd.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048018] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48018] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAINES AD, 1995, AM J PHYSIOL-RENAL, V269, pF628, DOI 10.1152/ajprenal.1995.269.5.F628; BALDWIN A, 1997, BLOOD SUBSTITUTES IN, P19; BOLAND EJ, 1987, J APPL PHYSIOL, V62, P791, DOI 10.1152/jappl.1987.62.2.791; BULL C, 1981, J BIOL CHEM, V256, P2673; CASSOLY R, 1975, J MOL BIOL, V91, P301, DOI 10.1016/0022-2836(75)90382-4; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; DOYLE MP, 1981, J INORG BIOCHEM, V14, P351, DOI 10.1016/S0162-0134(00)80291-3; Eich RF, 1996, BIOCHEMISTRY-US, V35, P6976, DOI 10.1021/bi960442g; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; Intaglietta M, 1996, CARDIOVASC RES, V32, P632; IWASHITA Y, 1995, ARTIFICIAL RED CELLS, P151; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; JOHNSON PC, 1995, BLOOD SUBSTITUTES, P175; KHARITONOV VG, 1994, J BIOL CHEM, V269, P5881; KLUGER R, 1992, BIOCHEMISTRY-US, V31, P7551, DOI 10.1021/bi00148a016; LEMON DD, 1996, ARTIF CELL BLOOD SUB, V24, P378; MCCARTHY M, 1997, THESIS U CALIFORNIA; Migita R, 1997, J APPL PHYSIOL, V82, P1995, DOI 10.1152/jappl.1997.82.6.1995; MONCADA S, 1991, PHARMACOL REV, V43, P109; MOORE EG, 1976, J BIOL CHEM, V251, P2788; Olson J S, 1981, Methods Enzymol, V76, P631; ROHLFS RJ, 1997, BLOOD SUBSTITUTES IN, P298; SAFFRAN WA, 1977, J BIOL CHEM, V252, P7955; SALHANY JM, 1975, BIOCHEMISTRY-US, V14, P2180, DOI 10.1021/bi00681a022; SHARMA VS, 1978, J BIOL CHEM, V253, P6467; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; TSAI AG, 1995, BLOOD SUBSTITUTES, P155; Tsai Amy G., 1996, P124; Vandegriff KD, 1997, BIOPHYS CHEM, V69, P23, DOI 10.1016/S0301-4622(97)00079-3; Vandegriff KD, 1998, ANAL BIOCHEM, V256, P107, DOI 10.1006/abio.1997.2487; VANDEGRIFF KD, 1995, BLOOD SUBSTITUTES, P143; WINSLOW RM, 1994, METHOD ENZYMOL, V231, P3; WINSLOW RM, 1992, HEMOGLOBIN BASED RED, P72; WINSLOW RM, 1997, BLOOD SUBSTITUTES IN, P167; ZALIPSKY S, 1991, ACS SYM SER, V469, P91	35	224	237	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12128	12134		10.1074/jbc.273.20.12128	http://dx.doi.org/10.1074/jbc.273.20.12128			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575158	hybrid			2022-12-27	WOS:000073629800023
J	Schwarz, SE; Rosa, JL; Scheffner, M				Schwarz, SE; Rosa, JL; Scheffner, M			Characterization of human hect domain family members and their interaction with UbcH5 and UbcH7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-CARRIER PROTEIN; PROTEOLYTIC PATHWAY; CONJUGATING ENZYMES; DEGRADATION; E6-AP; P53; E6; LIGASE; CLONING; GENE	The beet domain protein family was originally identified by sequence similarity of its members to the C-terminal region of E6-AP, an E3 ubiquitin-protein ligase. Since the C terminus of E6-AP mediates thioester complex formation with ubiquitin, a necessary intermediate step in E6-AP-dependent ubiquitination, it was proposed that members of the beet domain family in general have E3 activity. The beet domain is approximately 350 amino acids in length, and we show here that the beet domain of E6-AP is necessary and sufficient for ubiquitin thioester adduct formation. Furthermore, the human genome encodes at least 20 different beet domain proteins, and in further support of the hypothesis that beet domain proteins represent a family of E3s, several of these are shown to form thioester complexes with ubiquitin. In addition, some beet domain proteins interact preferentially with UbcH5, whereas others interact with UbcH7, indicating that human beet domain proteins can be grouped into at least two classes based on their E2 specificity. Since E3s are thought to play a major role in substrate recognition, the presence of a large family of E3s should contribute to ensure the specificity and selectivity of ubiquitin-dependent proteolytic pathways.	Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany; Univ Barcelona, Unitat Bioquim, Hospitalet 08907, Barcelona, Spain	Helmholtz Association; German Cancer Research Center (DKFZ); University of Barcelona	Scheffner, M (corresponding author), Deutsch Krebsforschungszentrum, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.	m.scheffner@dkfz-heidelberg.de	Scheffner, Martin/K-2940-2012; Rosa, Jose Luis/K-6685-2014	Scheffner, Martin/0000-0003-2229-0128; Rosa, Jose Luis/0000-0002-6161-5688				Albrecht U, 1997, NAT GENET, V17, P75, DOI 10.1038/ng0997-75; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BLUMENFELD N, 1994, J BIOL CHEM, V269, P9574; CIECHANOVER A, 1994, J BIOL CHEM, V269, P9582; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; GOSINK MM, 1995, P NATL ACAD SCI USA, V92, P9117, DOI 10.1073/pnas.92.20.9117; GU J, 1994, MOL BRAIN RES, V24, P77, DOI 10.1016/0169-328X(94)90120-1; Hatakeyama S, 1997, J BIOL CHEM, V272, P15085, DOI 10.1074/jbc.272.24.15085; HATFIELD PM, 1992, J BIOL CHEM, V267, P14799; HEIN C, 1995, MOL MICROBIOL, V18, P77, DOI 10.1111/j.1365-2958.1995.mmi_18010077.x; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Huibregtse JM, 1997, P NATL ACAD SCI USA, V94, P3656, DOI 10.1073/pnas.94.8.3656; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Kishino T, 1997, NAT GENET, V15, P70, DOI 10.1038/ng0197-70; Kumar S, 1997, J BIOL CHEM, V272, P13548, DOI 10.1074/jbc.272.21.13548; Matsuura T, 1997, NAT GENET, V15, P74, DOI 10.1038/ng0197-74; Nefsky B, 1996, EMBO J, V15, P1301, DOI 10.1002/j.1460-2075.1996.tb00472.x; Nuber U, 1996, J BIOL CHEM, V271, P2795, DOI 10.1074/jbc.271.5.2795; Pirozzi G, 1997, J BIOL CHEM, V272, P14611, DOI 10.1074/jbc.272.23.14611; Rosa JL, 1996, EMBO J, V15, P4262, DOI 10.1002/j.1460-2075.1996.tb00801.x; Rosa JL, 1996, EMBO J, V15, P5738; SCHEFFNER M, 1992, EMBO J, V11, P2425, DOI 10.1002/j.1460-2075.1992.tb05307.x; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SCHNEIDER R, 1990, EMBO J, V9, P1431, DOI 10.1002/j.1460-2075.1990.tb08259.x; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Smith SE, 1996, BIOL CHEM, V377, P437; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Yamamoto Y, 1997, GENOMICS, V41, P263, DOI 10.1006/geno.1997.4617	41	138	148	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12148	12154		10.1074/jbc.273.20.12148	http://dx.doi.org/10.1074/jbc.273.20.12148			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575161	Green Published, hybrid			2022-12-27	WOS:000073629800026
J	Yasuda, M; Theodorakis, P; Subramanian, T; Chinnadurai, G				Yasuda, M; Theodorakis, P; Subramanian, T; Chinnadurai, G			Adenovirus E1B-19K/BCL-2 interacting protein BNIP3 contains a BH3 domain and a mitochondrial targeting sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; E1B 19K; BCL-2 PROTEINS; BHRF1 PROTEIN; APOPTOSIS; BAX; HOMOLOG; PROLIFERATION; INHIBITION; INDUCTION	Adenovirus E1B-19K and BCL-2 anti-apoptosis proteins interact with certain BCL-2 family pro-apoptotic proteins. A conserved domain, BH3, present in these proteins is essential for their pro-apoptotic activity and for heterodimerization with anti-apoptosis proteins. Cellular protein BNIP3 (previously NIP3) interacts with E1B-19K, BCL-2, BCL-x(L), and EBV-BHRF1. BNIP3 contains a motif similar to the BH3 domain. Deletion of the BH3-like motif in BNIP3 abrogates its ability to heterodimerize with E1B-19K and BCL-x(L). Substitution of the BH3 domain of BNIP3 for the corresponding sequences of BAX functionally restores the pro-apoptotic and protein heterodimerization activities of BAX. BNIP3 exhibits a delayed cell death activity that is partially relieved by deletion of the BH3 domain. BNIP3 suppresses the anti-apoptosis activity of BCL-x(L) in a BH3-dependent manner. BNIP3 contains a C-terminal trans-membrane (TM) domain similar to other BCL-8 family proteins and BNIP1 (previously NIP1). The TM domains of BNIP3 and BNIP1 can functionally substitute for the TM domain of a BCL-2 family member EBV-BHRF1. The BNIP3 TM domain exclusively targets the heterologous green fluorescent protein (GFP) to mitochondria. These results suggest that BNIP3 is a member of the BH3-contaning BCL-2 family of pro-apoptotic proteins and functions in mitochondria.	St Louis Univ, Med Ctr, Inst Mol Virol, St Louis, MO 63110 USA	Saint Louis University	Chinnadurai, G (corresponding author), St Louis Univ, Med Ctr, Inst Mol Virol, 3681 Pk Ave, St Louis, MO 63110 USA.				NATIONAL CANCER INSTITUTE [R01CA033616] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA033616, CA-33616] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BOYD JM, 1995, ONCOGENE, V11, P1921; Chen G, 1996, J BIOL CHEM, V271, P24221, DOI 10.1074/jbc.271.39.24221; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHINNADURAI G, 1998, IN PRESS SEMIN VIROL; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Cosulich SC, 1997, CURR BIOL, V7, P913, DOI 10.1016/S0960-9822(06)00410-6; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Elangovan B, 1997, J BIOL CHEM, V272, P24494, DOI 10.1074/jbc.272.39.24494; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; Han J, 1996, MOL CELL BIOL, V16, P5857; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; Kelekar A, 1997, MOL CELL BIOL, V17, P7040, DOI 10.1128/MCB.17.12.7040; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Miller J.H., 1972, EXPT MOL GENETICS; Minn AJ, 1996, J BIOL CHEM, V271, P6306, DOI 10.1074/jbc.271.11.6306; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; Ottilie S, 1997, J BIOL CHEM, V272, P30866, DOI 10.1074/jbc.272.49.30866; Rao L, 1997, ONCOGENE, V15, P1587, DOI 10.1038/sj.onc.1201323; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Rose MD., 1990, METHODS YEAST GENETI; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Simonian PL, 1996, J BIOL CHEM, V271, P32073, DOI 10.1074/jbc.271.50.32073; Simonian PL, 1997, ONCOGENE, V15, P1871, DOI 10.1038/sj.onc.1201350; Subramanian T, 1995, ONCOGENE, V11, P2403; TARODI B, 1994, VIROLOGY, V201, P404, DOI 10.1006/viro.1994.1309; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; Theodorakis P, 1996, ONCOGENE, V12, P1707; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101	38	185	194	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12415	12421		10.1074/jbc.273.20.12415	http://dx.doi.org/10.1074/jbc.273.20.12415			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575197	hybrid			2022-12-27	WOS:000073629800062
J	Dai, Q; Choy, E; Chiu, V; Romano, J; Slivka, SR; Steitz, SA; Michaelis, S; Philips, MR				Dai, Q; Choy, E; Chiu, V; Romano, J; Slivka, SR; Steitz, SA; Michaelis, S; Philips, MR			Mammalian prenylcysteine carboxyl methyltransferase is in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; PLASMA-MEMBRANE; SACCHAROMYCES-CEREVISIAE; ISOPRENYLATED PEPTIDES; CYSTEINE RESIDUES; PROTEIN; METHYLATION; SEQUENCE; BINDING; YEAST	Prenylcysteine carboxyl methyltransferase (pcCMT) is the third of three enzymes that posttranslationally modify C-terminal CAAX motifs and thereby target CAAX proteins to the plasma membrane. Here we report the molecular characterization and subcellular localization of the first mammalian (human myeloid) pcCMT. The deduced amino acid sequence of mammalian pcCMT predicts a multiple membrane-spanning protein with homologies to the yeast pcCMT, STE14, and the mammalian band 3 anion transporter. The human gene complemented a ste14 mutant. pcCMT mRNAs were ubiquitously expressed in human tissues. An anti-pc-CMT antiserum detected a 33-kDa protein in myeloid cell membranes. Ectopically expressed recombinant pc-CMT had enzymatic activity identical to that observed in neutrophil membranes. Mammalian pcCMT was not expressed at the plasma membrane but rather restricted to the endoplasmic reticulum. Thus, the final enzyme in the sequence that modifies CAAX motifs is located in membranes topologically removed from the CAAX protein target membrane.	NYU, Sch Med, Dept Med, New York, NY 10016 USA; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; Johns Hopkins Univ, Sch Med, Dept Cell Biol & Anat, Baltimore, MD 21205 USA; Tanabe Res Labs USA Inc, San Diego, CA 92121 USA	New York University; New York University; Johns Hopkins University	Philips, MR (corresponding author), NYU, Sch Med, Dept Med, New York, NY 10016 USA.	mark.philips@mcccm.med.nyu.edu		Romano, Julia/0000-0001-8956-7377; Mark, Philips/0000-0002-1179-8156	NIAID NIH HHS [R01 AI036224, AI36224] Funding Source: Medline; NIGMS NIH HHS [GM55279, GM41223] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036224, R29AI036224] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041223] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; Boyartchuk VL, 1997, SCIENCE, V275, P1796, DOI 10.1126/science.275.5307.1796; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; FujimuraKamada K, 1997, J CELL BIOL, V136, P271, DOI 10.1083/jcb.136.2.271; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; HUZOORAKBAR W, 1993, P NATL ACAD SCI USA, V90, P868; Imai Y, 1997, MOL CELL BIOL, V17, P1543, DOI 10.1128/MCB.17.3.1543; INGROSSO D, 1989, J BIOL CHEM, V264, P20131; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KASINATHAN C, 1990, J BIOL CHEM, V265, P5139; LEE J, 1993, J BIOL CHEM, V268, P19192; MA YT, 1992, P NATL ACAD SCI USA, V89, P6275, DOI 10.1073/pnas.89.14.6275; MARCUS S, 1991, MOL CELL BIOL, V11, P3603, DOI 10.1128/MCB.11.7.3603; MICHAELIS S, 1988, MOL CELL BIOL, V8, P1309, DOI 10.1128/MCB.8.3.1309; Parish CA, 1996, BIOCHEMISTRY-US, V35, P8473, DOI 10.1021/bi960603g; PHILIPS MR, 1995, METHOD ENZYMOL, V256, P49; PHILIPS MR, 1991, J BIOL CHEM, V266, P1289; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; PILLINGER MH, 1994, J BIOL CHEM, V269, P1486; SAPPERSTEIN S, 1994, MOL CELL BIOL, V14, P1438, DOI 10.1128/MCB.14.2.1438; SCHENA M, 1991, METHOD ENZYMOL, V194, P389; SILVIUS JR, 1994, BIOCHEMISTRY-US, V33, P3014, DOI 10.1021/bi00176a034; STEPHENSON RC, 1992, J BIOL CHEM, V267, P13314; STOCK JB, 1991, ANNU REV BIOPHYS BIO, V20, P109, DOI 10.1146/annurev.bb.20.060191.000545; THISSEN JA, 1993, J BIOL CHEM, V268, P13780; VOLKER C, 1991, FEBS LETT, V295, P189, DOI 10.1016/0014-5793(91)81415-5; VOLKER C, 1991, J BIOL CHEM, V266, P21515; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x	33	236	244	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15030	15034		10.1074/jbc.273.24.15030	http://dx.doi.org/10.1074/jbc.273.24.15030			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614111	hybrid			2022-12-27	WOS:000074160400053
J	Morimoto, A; Tanaka, M; Takahashi, S; Ishimori, K; Hori, H; Morishima, I				Morimoto, A; Tanaka, M; Takahashi, S; Ishimori, K; Hori, H; Morishima, I			Detection of a tryptophan radical as an intermediate species in the reaction of horseradish peroxidase mutant (Phe-221 -> Trp) and hydrogen peroxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; ELECTRON-PARAMAGNETIC RESONANCE; NUCLEAR DOUBLE-RESONANCE; ENDOGENOUS CALCIUM-ION; COMPOUND-ES; ESCHERICHIA-COLI; DISTAL SITE; CRYSTAL-STRUCTURE; SODIUM-AZIDE; WILD-TYPE	The crucial reaction intermediate in the reaction of peroxidase with hydrogen peroxide (H2O2), compound I, contains a porphyrin pi-cation radical in horseradish peroxidase (HRP), which catalyzes oxidation of small organic and inorganic compounds, whereas cytochrome c peroxidase (CcP) has a radical center on the tryptophan residue (Trp-191) and oxidizes the redox partner, cytochrome c. To investigate the roles of the amino acid residue near the heme active center in discriminating the function of the peroxidases in these two enzymes, we prepared a CcP-like HRP mutant, F221W (Phe-221 --> Trp). Although the rapid spectral scanning and stopped-flow experiments confirmed that the F221W mutant reacts with H2O2 to form the porphyrin pi-cation radical at the same rate as for the wild-type enzyme, the characteristic spectral features of the porphyrin pi-cation radical disappeared rapidly, and were converted to the compound II-type spectrum. The EPR spectrum of the resultant species produced by reduction of the porphyrin pi-cation radical, however, was quite different from that of compound II in HRP, showing typical signals from a Trp radical as found for CcP. The sequential radical formation from the porphyrin ring to the Trp residue implies that the proximal Trp is a key residue in the process of the radical transfer from the porphyrin ring, which differentiates the function of peroxidases.	Kyoto Univ, Grad Sch Engn, Dept Mol Engn, Kyoto 6068501, Japan; Osaka Univ, Grad Sch Engn Sci, Div Biophys Engn, Osaka 5608531, Japan	Kyoto University; Osaka University	Morishima, I (corresponding author), Kyoto Univ, Grad Sch Engn, Dept Mol Engn, Kyoto 6068501, Japan.		Ishimori, Koichiro/S-1247-2016; Ishimori, Koichiro/AAQ-4434-2021; Tanaka, Motomasa/N-5064-2015	Ishimori, Koichiro/0000-0002-5868-0462; Ishimori, Koichiro/0000-0002-5868-0462; Tanaka, Motomasa/0000-0002-2994-7703				ADACHI S, 1991, BIOCHEM BIOPH RES CO, V180, P138, DOI 10.1016/S0006-291X(05)81266-5; ANTONINI E, 1971, HEMOGLOBIN MYOGLOBIN, P330; ATOR MA, 1987, J BIOL CHEM, V262, P1542; BLUMBERG WE, 1968, J BIOL CHEM, V243, P1854; Bonagura CA, 1996, BIOCHEMISTRY-US, V35, P6107, DOI 10.1021/bi960122x; COULSON AFW, 1971, J BIOL CHEM, V246, P917; DeGray JA, 1997, J BIOL CHEM, V272, P2359; DEPILLIS GD, 1990, ARCH BIOCHEM BIOPHYS, V280, P217, DOI 10.1016/0003-9861(90)90539-B; DOLPHIN D, 1971, P NATL ACAD SCI USA, V68, P614, DOI 10.1073/pnas.68.3.614; DUNFORD HB, 1976, COORDIN CHEM REV, V19, P187, DOI 10.1016/S0010-8545(00)80316-1; ERMAN JE, 1989, BIOCHEMISTRY-US, V28, P7992, DOI 10.1021/bi00446a004; FARHANGRAZI ZS, 1995, BIOCHEMISTRY-US, V34, P2866, DOI 10.1021/bi00009a017; FINZEL BC, 1984, J BIOL CHEM, V259, P3027; FISHEL LA, 1991, BIOCHEMISTRY-US, V30, P1986, DOI 10.1021/bi00221a036; Gajhede M, 1997, NAT STRUCT BIOL, V4, P1032, DOI 10.1038/nsb1297-1032; GAZARYAN IG, 1994, FEBS LETT, V354, P248, DOI 10.1016/0014-5793(94)01125-7; GOODIN DB, 1987, J BIOL CHEM, V262, P7719; Gunsalus I.C., 1974, MOL MECHANISMS OXYGE, P559; HARRIS RZ, 1991, J BIOL CHEM, V266, P8751; HASCHKE RH, 1978, BIOCHEM BIOPH RES CO, V80, P1039, DOI 10.1016/0006-291X(78)91350-5; HEWSON WD, 1979, J BIOL CHEM, V254, P3182; HOFFMAN BM, 1981, J BIOL CHEM, V256, P6556; HORI H, 1985, J BIOL CHEM, V260, P349; HOUSEMAN ALP, 1993, BIOCHEMISTRY-US, V32, P4430, DOI 10.1021/bi00067a036; KELMAN DJ, 1994, J BIOL CHEM, V269, P7458; LAMAR GN, 1980, J BIOL CHEM, V255, P6646; MAURO JM, 1988, BIOCHEMISTRY-US, V27, P6243, DOI 10.1021/bi00417a008; MILLER MA, 1995, BIOCHEMISTRY-US, V34, P12048, DOI 10.1021/bi00037a048; MILLER VP, 1992, J BIOL CHEM, V267, P8936; MORISHIMA I, 1986, J BIOL CHEM, V261, P9391; Musah RA, 1997, BIOCHEMISTRY-US, V36, P11665, DOI 10.1021/bi9708038; NAGANO S, 1995, BIOCHEM BIOPH RES CO, V207, P417, DOI 10.1006/bbrc.1995.1204; Nagano S, 1996, BIOCHEMISTRY-US, V35, P14251, DOI 10.1021/bi961740g; OGAWA S, 1979, BIOCHEM BIOPH RES CO, V90, P674, DOI 10.1016/0006-291X(79)91288-9; PATTERSON WR, 1994, J BIOL CHEM, V269, P17020; PAUL KG, 1953, ACTA CHEM SCAND, V7, P1284, DOI 10.3891/acta.chem.scand.07-1284; PELLETIER H, 1992, SCIENCE, V258, P1748, DOI 10.1126/science.1334573; PENNERHAHN JE, 1986, J AM CHEM SOC, V108, P7819, DOI 10.1021/ja00284a054; POULOS TL, 1980, J BIOL CHEM, V255, P8199; POULOS TL, 1980, J BIOL CHEM, V255, P322; RUPP H, 1979, BIOCHIM BIOPHYS ACTA, V548, P16, DOI 10.1016/0005-2728(79)90183-X; SAUNDERS BC, 1964, PEROXIDASE; SCHULZ CE, 1984, BIOCHEMISTRY-US, V23, P4743, DOI 10.1021/bi00315a033; SCHULZ CE, 1979, FEBS LETT, V23, P4743; SHIRO Y, 1986, J BIOL CHEM, V261, P9382; SIVARAJA M, 1989, SCIENCE, V245, P738, DOI 10.1126/science.2549632; SMITH AT, 1990, J BIOL CHEM, V265, P13335; Sutherland GRJ, 1997, BIOCHEMISTRY-US, V36, P3654, DOI 10.1021/bi962195m; Tanaka M, 1998, BIOCHEMISTRY-US, V37, P2629, DOI 10.1021/bi9725273; Tanaka M, 1997, BIOCHEMISTRY-US, V36, P9791, DOI 10.1021/bi9706172; Tanaka M, 1996, BIOCHEM BIOPH RES CO, V227, P393, DOI 10.1006/bbrc.1996.1518; Tanaka M, 1997, BIOCHEMISTRY-US, V36, P9889, DOI 10.1021/bi970906q; VEITCH NC, 1992, EUR J BIOCHEM, V207, P521, DOI 10.1111/j.1432-1033.1992.tb17078.x; Williams R.J.P., 1974, IRON BIOCH MED, P183; YAMADA H, 1975, ARCH BIOCHEM BIOPHYS, V169, P344, DOI 10.1016/0003-9861(75)90350-1; YAMAGUCHI K, 1993, J AM CHEM SOC, V115, P4058, DOI 10.1021/ja00063a026; YONETANI T, 1987, J BIOL CHEM, V262, P9547	57	41	41	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14753	14760		10.1074/jbc.273.24.14753	http://dx.doi.org/10.1074/jbc.273.24.14753			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614074	hybrid			2022-12-27	WOS:000074160400016
J	Papst, PJ; Sugiyama, H; Nagasawa, M; Lucas, JJ; Maller, JL; Terada, N				Papst, PJ; Sugiyama, H; Nagasawa, M; Lucas, JJ; Maller, JL; Terada, N			Cdc2-cyclin B phosphorylates p70 S6 kinase on Ser(411) at mitosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; CELL-CYCLE PROGRESSION; MOUSE 3T3 FIBROBLASTS; HUMAN T-CELLS; NUCLEAR LAMINA; MAP2 KINASE; CDC2 KINASE; RAPAMYCIN; P70(S6K); SITES	The carboxyl terminus of p70 S6 kinase (p70(s6k)) has a set of Ser and Thr residues (Ser(411), Ser(418), Ser(424), and Thr(421)) phosphorylated in vivo by an unidentified kinase(s). These Ser/Thr sites are immediately followed by proline, a motif that is commonly seen in the substrates of cyclin-dependent kinases (Cdk) and mitogen-activated protein kinases, A previous study has shown that Cdc2 (Cdk1) indeed phosphorylates these p70(s6k) Ser/Thr residues in vitro. Here, we demonstrate that Cdc2-cyclin B complex phosphorylates Ser(411) in the KIR (S) under bar PRR sequence, whereas other Cdk-cyclin complexes including those containing Cdk2, Cdk4, or Cdk6 do not. Additionally, Ser(411) phosphorylation in vivo was increased at mitosis in parallel with Cdc2 activation, and it was suppressed by a dominant negative form of Cdc2. These data indicate that p70(s6k) is a physiological substrate of Cdc2-cyclin B in mitosis. Since the activity of p70(s6k) is low during mitosis, Cdc2-cyclin B may play a role in inactivating p70(s6k) during mitosis, where protein synthesis is suppressed.	Natl Jewish Med & Res Ctr, Dept Pediat, Div Basic Sci, Denver, CO 80206 USA; Univ Colorado, Sch Med, Dept Pharmacol, Denver, CO 80262 USA; Univ Colorado, Sch Med, Howard Hughes Med Inst, Denver, CO 80262 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Terada, N (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Basic Sci, Denver, CO 80206 USA.	teradan@njc.org	Nagasawa, Masayuki/AAX-1734-2020; Nagasawa, Masayuki/CAI-8101-2022	Nagasawa, Masayuki/0000-0002-8085-4940; 	NCI NIH HHS [CA-64685] Funding Source: Medline; NIDDK NIH HHS [DK-28353] Funding Source: Medline; NIGMS NIH HHS [GM-26743] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA064685] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028353] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026743] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BANDI HR, 1993, J BIOL CHEM, V268, P4530; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; BLENIS J, 1991, CELL GROWTH DIFFER, V2, P279; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Edelmann HML, 1996, J BIOL CHEM, V271, P963, DOI 10.1074/jbc.271.2.963; FERRARI S, 1993, J BIOL CHEM, V268, P16091; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; Holmes JK, 1996, J BIOL CHEM, V271, P25240, DOI 10.1074/jbc.271.41.25240; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; KOZMA SC, 1993, J BIOL CHEM, V268, P7134; KUSUBATA M, 1992, J BIOL CHEM, V267, P20937; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LUCAS JJ, 1992, J IMMUNOL, V148, P1804; MARRACCINO RL, 1992, MOL BIOL CELL, V3, P389, DOI 10.1091/mbc.3.4.389; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PRESCOTT DM, 1962, EXP CELL RES, V26, P260, DOI 10.1016/0014-4827(62)90176-3; PRICE DJ, 1991, J BIOL CHEM, V266, P16281; Proud CG, 1996, TRENDS BIOCHEM SCI, V21, P181, DOI 10.1016/0968-0004(96)10016-5; REINHARD C, 1992, P NATL ACAD SCI USA, V89, P4052, DOI 10.1073/pnas.89.9.4052; SALB JM, 1965, P NATL ACAD SCI USA, V54, P1353, DOI 10.1073/pnas.54.5.1353; SRINIVASAN J, 1995, BIOCHEM J, V309, P927, DOI 10.1042/bj3090927; Sugiyama H, 1996, J IMMUNOL, V157, P656; SUSA M, 1989, CELL, V57, P817, DOI 10.1016/0092-8674(89)90796-4; TERADA N, 1991, J IMMUNOL, V147, P698; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; TERADA N, 1993, J BIOL CHEM, V268, P12062; TERADA N, 1995, J IMMUNOL, V155, P3418; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; WENG QP, 1995, MOL CELL BIOL, V15, P2333; ZHANG JW, 1994, ARCH BIOCHEM BIOPHYS, V315, P415, DOI 10.1006/abbi.1994.1519; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	45	48	49	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15077	15084		10.1074/jbc.273.24.15077	http://dx.doi.org/10.1074/jbc.273.24.15077			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614117	hybrid			2022-12-27	WOS:000074160400059
J	Takeshita, A; Imai, K; Kato, S; Kitano, S; Hanazawa, S				Takeshita, A; Imai, K; Kato, S; Kitano, S; Hanazawa, S			1 alpha,25-dehydroxyvitamin D-3 synergism toward transforming growth factor-beta 1-induced AP-1 transcriptional activity in mouse osteoblastic cells via its nuclear receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOATTRACTANT JE; RAT OSTEOSARCOMA CELLS; HUMAN OSTEOCALCIN GENE; I COLLAGEN-SYNTHESIS; OSTEO-SARCOMA CELLS; LACKING C-FOS; FACTOR-BETA; VITAMIN-D; MC3T3-E1 CELLS; RETINOIC-ACID	The present study demonstrates 1 alpha,25-dehydroxyvitamin D-3 (1 alpha-25-(OH)(2)D-3) synergism toward transforming growth factor (TGF)-beta 1-induced activation protein-1 (AP-1) activity in mouse osteoblastic MC3T3-E1 cells via the nuclear receptor of the vitamin. 1 alpha-25-(OH)(2)D-3 synergistically stimulated TGF-beta 1-induced expression of the c-jun gene in the cells but not that of the c-fos gene. We actually showed by a gel mobility shift assay 1 alpha-25(OH)(2)D-3 synergism of TGF-beta 1-induced AP-1 binding to the 12-(O-tetradecanoylphorbol-13-acetate response element (TRE), 1 alpha-25-(OH)(2)D-3 markedly stimulated the transient activity of TGF-beta 1-induced AP-1 in the cells transfected with a TRE-chloramphenicol acetyltransferase (CAT) reporter gene. Also, a synergistic increase in TGF-beta 1-induced CAT activity was observed in the cells cotransfected with an expression vector encoding vitamin D-3 receptor (VDR) and the reporter gene. However, the synergistic CAT activity was inhibited by pretreatment with VDR antisense oligonucleotides. In addition, in a Northern blot assay, we observed 1 alpha-25(OH)(2)D-3 synergism of TGF-beta 1-induced expression of the c-jun gene in the cells transfected with the VDR expression vector and also found that the synergistic action was clearly blocked by VDR antisense oligonucleotide pretreatment. The present study strongly suggests a novel positive regulation by 1 alpha-25-(OH)(2)D-3 of TGF-beta 1-induced AP-1 activity in osteoblasts via "genommc action.".	Meikai Univ, Sch Dent, Dept Oral Microbiol, Sakado, Saitama 35002, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 113, Japan	Meikai University; University of Tokyo	Hanazawa, S (corresponding author), Meikai Univ, Sch Dent, Dept Oral Microbiol, Sakado, Saitama 35002, Japan.							BONEWALD LF, 1992, J BIOL CHEM, V267, P8943; BOSKEY AL, 1992, CLIN ORTHOP RELAT R, P244; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNETTE E, 1992, NUCLEIC ACIDS RES, V20, P1151, DOI 10.1093/nar/20.5.1151; CENTRELLA M, 1987, J BIOL CHEM, V262, P2869; CHANG PL, 1989, CANCER RES, V264, P9682; Chen Y, 1996, J BIOL CHEM, V271, P31602, DOI 10.1074/jbc.271.49.31602; CHENU C, 1988, P NATL ACAD SCI USA, V85, P5683, DOI 10.1073/pnas.85.15.5683; CIVITELLI R, 1990, ENDOCRINOLOGY, V127, P2253, DOI 10.1210/endo-127-5-2253; CRAIG AM, 1991, GENE, V100, P163, DOI 10.1016/0378-1119(91)90362-F; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FARACHCARSON MC, 1991, ENDOCRINOLOGY, V129, P1876, DOI 10.1210/endo-129-4-1876; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; Felix R, 1996, EUR J ENDOCRINOL, V134, P143, DOI 10.1530/eje.0.1340143; FRANCESCHI RT, 1988, J BIOL CHEM, V263, P18938; FRANCESCHI RT, 1990, J BONE MINER RES, V5, P1157; Geilen CC, 1996, FEBS LETT, V378, P88, DOI 10.1016/0014-5793(95)01421-7; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; HANAZAWA S, 1994, J BIOL CHEM, V269, P21379; HANAZAWA S, 1993, J BIOL CHEM, V268, P9526; HAUSCHKA PV, 1988, CIBA F SYMP, V136, P207; HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292; INGRAM RT, 1994, DIFFERENTIATION, V55, P153, DOI 10.1046/j.1432-0436.1994.5520153.x; INOUE M, 1992, LIFE SCI, V51, P1105, DOI 10.1016/0024-3205(92)90511-M; JENNINGS JC, 1990, ENDOCRINOLOGY, V126, P1014, DOI 10.1210/endo-126-2-1014; KRUSE K, 1995, J PEDIATR-US, V126, P736, DOI 10.1016/S0022-3476(95)70401-9; KUROKI Y, 1994, CLIN EXP IMMUNOL, V95, P536; KUROKI Y, 1995, J CELL PHYSIOL, V164, P459, DOI 10.1002/jcp.1041640303; LIEBERHERR M, 1987, J BIOL CHEM, V262, P13168; Maniatis T, 1982, MOL CLONING LABORATO, P194; MIYAUCHI A, 1994, BIOCHEM BIOPH RES CO, V205, P1547, DOI 10.1006/bbrc.1994.2843; MURRAY IA, 1991, NUCLEIC ACIDS RES, V19, P6648; NODA M, 1987, J CELL PHYSIOL, V133, P426, DOI 10.1002/jcp.1041330303; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; OKADA S, 1994, MOL CELL BIOL, V14, P382, DOI 10.1128/MCB.14.1.382; OKANO T, 1989, J NUTR SCI VITAMINOL, V35, P529, DOI 10.3177/jnsv.35.529; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; OURSLER MJ, 1994, J BONE MINER RES, V9, P443; OWEN TA, 1990, P NATL ACAD SCI USA, V87, P9990, DOI 10.1073/pnas.87.24.9990; OZONO K, 1990, J BIOL CHEM, V265, P21881; OZONO K, 1991, J BONE MINER RES, V6, P1021; PRICE PA, 1980, J BIOL CHEM, V255, P1660; RAISZ LG, 1972, SCIENCE, V175, P768, DOI 10.1126/science.175.4023.768; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SLATER M, 1994, AM J PHYSIOL-ENDOC M, V267, pE990, DOI 10.1152/ajpendo.1994.267.6.E990; SONE T, 1989, J BIOL CHEM, V264, P20230; SREIN GS, 1993, ENDOCR REV, V14, P424; Staal A, 1996, ENDOCRINOLOGY, V137, P2001, DOI 10.1210/en.137.5.2001; STAAL A, 1994, BONE MINER, V26, P27, DOI 10.1016/S0169-6009(08)80160-2; TAKESHITA A, 1995, J IMMUNOL, V155, P419; TANAKA H, 1991, J BIOL CHEM, V266, P10888; Udagawa N, 1996, BONE, V18, P511, DOI 10.1016/8756-3282(96)00076-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VANLEEUWEN JPTM, 1992, J BIOL CHEM, V267, P12562; VERMA IM, 1990, CIBA F SYMP, V150, P128; WALI RK, 1990, J CLIN INVEST, V85, P1296, DOI 10.1172/JCI114567; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; YUKIHIRO S, 1994, J BIOL CHEM, V269, P23889	62	33	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14738	14744		10.1074/jbc.273.24.14738	http://dx.doi.org/10.1074/jbc.273.24.14738			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614072	hybrid			2022-12-27	WOS:000074160400014
J	Ballester, A; Velasco, A; Tobena, R; Alemany, S				Ballester, A; Velasco, A; Tobena, R; Alemany, S			Cot kinase activates tumor necrosis factor-alpha gene expression in a cyclosporin A-resistant manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIPHERAL-BLOOD LYMPHOCYTES; T-CELL ACTIVATION; HUMAN B-CELLS; PROTEIN-KINASE; TRANSCRIPTIONAL REGULATION; LYMPHOTOXIN PRODUCTION; PROMOTER REGION; NUCLEAR FACTOR; TNF-ALPHA; NF-AT	Cot kinase is a protein serine/threonine kinase, classified as a mitogen-activated protein kinase kinase kinase, implicated in T lymphocyte activation. Here we show that an increase in Cot kinase expression promotes tumor necrosis factor-alpha (TNF-alpha) production in Jurkat T cells stimulated by soluble anti-CD3 or by low concentrations of phorbol 12,13-dibutyrate (PDBu) and calcium ionophore. Overexpression of Cot kinase in Jurkat cells activates TNF-alpha gene expression. Cot kinase promotes TNF-alpha promoter activation to a similar extent as calcium ionophore and PDBu or soluble anti-CD28 and PDBu. Neither phorbol esters nor calcium ionophore can replace Cot kinase on TNF-alpha promoter driven transcription. Expression of a dominant negative form of Cot kinase inhibits TNF-alpha promoter activation induced by stimulation with either calcium ionophore and PDBu, soluble anti-CD28 and PDBu, or soluble anti-CDS and PDBu. TNF-alpha promoter-driven transcription by Cot kinase is partially mediated by MAPK/ERK kinase and is cyclosporin A-resistant. Cot kinase increases at least the AP-1 and AP-2 response elements. These data indicate that Cot kinase plays a critical role in TNF-alpha production.	Univ Autonoma Madrid, Inst Invest Biomed, CSIC, Fac Med, Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Alemany, S (corresponding author), Univ Autonoma Madrid, Inst Invest Biomed, CSIC, Fac Med, Arturo Duperier 4, Madrid, Spain.	Salemany@biomed.iib.uam.es	Alemany, Susana/J-6307-2014	Alemany, Susana/0000-0002-4089-7620; Ballester Jareno, Alicia/0000-0002-6474-7248				AOKI M, 1991, ONCOGENE, V6, P1515; AOKI M, 1993, J BIOL CHEM, V268, P22723; ARROYO AG, 1994, J CELL BIOL, V126, P1277, DOI 10.1083/jcb.126.5.1277; Ballester A, 1997, J IMMUNOL, V159, P1613; BAUMGARTNER RA, 1994, J IMMUNOL, V153, P2609; Ceci JD, 1997, GENE DEV, V11, P688, DOI 10.1101/gad.11.6.688; CHAN AML, 1993, ONCOGENE, V8, P1329; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; CORREALE J, 1995, J IMMUNOL, V154, P2959; CUTURI MC, 1987, J EXP MED, V165, P1581, DOI 10.1084/jem.165.6.1581; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DROUET C, 1991, J IMMUNOL, V147, P1694; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; Erny KM, 1996, ONCOGENE, V13, P2015; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; FERRERI NR, 1992, J BIOL CHEM, V267, P9443; FISCHER H, 1990, J IMMUNOL, V144, P4663; Ghosh P, 1996, J BIOL CHEM, V271, P7700, DOI 10.1074/jbc.271.13.7700; GOLDFELD AE, 1992, P NATL ACAD SCI USA, V89, P12198, DOI 10.1073/pnas.89.24.12198; GOLDFELD AE, 1989, P NATL ACAD SCI USA, V86, P1490, DOI 10.1073/pnas.86.5.1490; GOLDFELD AE, 1993, J EXP MED, V178, P1365, DOI 10.1084/jem.178.4.1365; GOLDFELD AE, 1991, J EXP MED, V174, P73, DOI 10.1084/jem.174.1.73; GOLDFELD AE, 1990, P NATL ACAD SCI USA, V87, P9769, DOI 10.1073/pnas.87.24.9769; GOLDFELD AE, 1996, CELL IMMUNOL, V103, P19; Hughes CB, 1996, PANCREAS, V13, P22, DOI 10.1097/00006676-199607000-00003; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; KRAMER B, 1994, BBA-GENE STRUCT EXPR, V1219, P413, DOI 10.1016/0167-4781(94)90066-3; LEITMAN DC, 1992, MOL CELL BIOL, V12, P1352, DOI 10.1128/MCB.12.3.1352; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; MAKRIS A, 1993, J VIROL, V67, P4283, DOI 10.1128/JVI.67.7.4283-4289.1993; MCCAFFREY PG, 1994, J BIOL CHEM, V269, P30445; MIYOSHI J, 1991, MOL CELL BIOL, V11, P4088, DOI 10.1128/MCB.11.8.4088; NEWELL CL, 1994, J LEUKOCYTE BIOL, V56, P27, DOI 10.1002/jlb.56.1.27; NORTHROP JP, 1992, J EXP MED, V175, P1235, DOI 10.1084/jem.175.5.1235; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; Ohtsuka T, 1996, BBA-MOL CELL RES, V1310, P223, DOI 10.1016/0167-4889(95)00172-7; PALIOGIANNI F, 1993, J CLIN INVEST, V91, P1481, DOI 10.1172/JCI116353; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; PATRIOTIS C, 1993, P NATL ACAD SCI USA, V90, P2251, DOI 10.1073/pnas.90.6.2251; RHOADES KL, 1992, J BIOL CHEM, V267, P22102; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; SANTIS AG, 1992, EUR J IMMUNOL, V22, P3155, DOI 10.1002/eji.1830221219; SANTIS AG, 1992, EUR J IMMUNOL, V22, P1253, DOI 10.1002/eji.1830220521; Souaze F, 1996, BIOTECHNIQUES, V21, P280; SPITS H, 1985, EUR J IMMUNOL, V15, P88, DOI 10.1002/eji.1830150117; STEFFAN NM, 1995, J IMMUNOL, V155, P4685; STEFFEN M, 1988, J IMMUNOL, V140, P2621; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; SUNG SSJ, 1988, J EXP MED, V167, P937, DOI 10.1084/jem.167.3.937; SUNG SSJ, 1991, J IMMUNOL, V147, P2047; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; Tsai EY, 1996, MOL CELL BIOL, V16, P5232; Tsai EY, 1996, MOL CELL BIOL, V16, P459; WARE CF, 1992, J IMMUNOL, V149, P3881; Zolotukhin S, 1996, J VIROL, V70, P4646, DOI 10.1128/JVI.70.7.4646-4654.1996	57	42	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14099	14106		10.1074/jbc.273.23.14099	http://dx.doi.org/10.1074/jbc.273.23.14099			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603908	hybrid			2022-12-27	WOS:000074021500010
J	Pedraza-Alva, G; Merida, LB; Burakoff, SJ; Rosenstein, Y				Pedraza-Alva, G; Merida, LB; Burakoff, SJ; Rosenstein, Y			T cell activation through the CD43 molecule leads to Vav tyrosine phosphorylation and mitogen-activated protein kinase pathway activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WISKOTT-ALDRICH SYNDROME; C-CBL PROTOONCOGENE; ANTIGEN RECEPTOR; LYMPHOBLASTOID-CELLS; SIGNAL-TRANSDUCTION; POSITIVE SELECTION; SHC PROTEINS; ZETA-CHAIN; GRB2; ASSOCIATION	CD43, the most abundant membrane protein of T lymphocytes, is able to initiate signals that lead to Ca2+ mobilization and interleukin-a production yet the molecular events involved in signal transduction pathway of the CD43 molecule are only beginning to be understood. We have shown recently that cross-linking CD43 on the cell surface of human T lymphocytes with the anti-CD43 monoclonal antibody L10 leads to CD43-Fyn kinase interactions and to Fyn phosphorylation on tyrosine residues. This interaction seems to be mediated by the SH3 domain of Fyn and a proline-rich sequence located in the cytoplasmic domain of CD43. Here we show that CD43-specific activation of human T lymphocytes induced tyrosine phosphorylation of the adaptor protein Shc and of the guanine exchange factor Vav, as well as the formation of a macromolecular complex that comprises She, GRB2, and Vav. CD43 Ligation resulted in enhanced formation of Vav-SLP-76 complexes and in the activation and nuclear translocation of ERK2. Crosslinking of the CD43 molecule in 3T3-CD43(+) cells induced luciferase activity from a construct under the control of the Fos serum responsive element, Altogether, these data suggest that the mitogen-activated protein kinase pathway is involved in CD43-dependent interleukin-2 gene expression.	Univ Nacl Autonoma Mexico, Inst Biotechnol, Cuernavaca 62250, Morelos, Mexico; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA	Universidad Nacional Autonoma de Mexico; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	Rosenstein, Y (corresponding author), Univ Nacl Autonoma Mexico, Inst Biotechnol, APDO Postal 510-3, Cuernavaca 62250, Morelos, Mexico.	yvonne@ibt.unam.mx						AXELSSON B, 1988, J IMMUNOL, V141, P2912; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; BAUM LG, 1995, J EXP MED, V181, P877, DOI 10.1084/jem.181.3.877; Brown TJ, 1996, J BIOL CHEM, V271, P27686, DOI 10.1074/jbc.271.44.27686; BUDAY L, 1994, J BIOL CHEM, V269, P9019; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; CYSTER JG, 1991, EMBO J, V10, P893, DOI 10.1002/j.1460-2075.1991.tb08022.x; DAMEN JE, 1993, BLOOD, V82, P2296; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; DRICKAMER K, 1994, J BIOL CHEM, V269, P20807; Ellies LG, 1996, BLOOD, V88, P1725, DOI 10.1182/blood.V88.5.1725.bloodjournal8851725; ERWIN RA, 1995, ENDOCRINOLOGY, V136, P3512, DOI 10.1210/en.136.8.3512; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; FUKUDA M, 1986, J BIOL CHEM, V261, P2796; Genot E, 1996, EMBO J, V15, P3923, DOI 10.1002/j.1460-2075.1996.tb00766.x; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Kishimoto H, 1996, J EXP MED, V184, P531, DOI 10.1084/jem.184.2.531; LI B, 1996, P NATL ACAD SCI USA, V94, P1001; Lin K, 1997, INT IMMUNOL, V9, P291, DOI 10.1093/intimm/9.2.291; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; MANJUNATH N, 1993, J IMMUNOL, V151, P1528; MANJUNATH N, 1995, NATURE, V377, P535, DOI 10.1038/377535a0; MCEVOY LM, J EXP MED, V1851, P97; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MENTZER SJ, 1987, J EXP MED, V165, P1383, DOI 10.1084/jem.165.5.1383; MUSEL MA, 1997, J IMMUNOL, V159, P1639; NEL AE, 1995, J BIOL CHEM, V270, P18428, DOI 10.1074/jbc.270.31.18428; Okumura K, 1997, ONCOGENE, V14, P713, DOI 10.1038/sj.onc.1200878; PADILLANORIEGA L, 1993, J CLIN MICROBIOL, V31, P622, DOI 10.1128/JCM.31.3.622-628.1993; PALLANT A, 1989, P NATL ACAD SCI USA, V86, P1328, DOI 10.1073/pnas.86.4.1328; PARK JK, 1991, NATURE, V350, P706, DOI 10.1038/350706a0; PEDRAZAALVA G, 1994, J BIOL CHEM, V269, P6978; PedrazaAlva G, 1996, J BIOL CHEM, V271, P27564, DOI 10.1074/jbc.271.44.27564; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PILLER F, 1988, J BIOL CHEM, V263, P15146; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; Raab M, 1997, IMMUNITY, V6, P155, DOI 10.1016/S1074-7613(00)80422-7; RAMOSMORALES F, 1994, ONCOGENE, V9, P1917; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; REMOLDODONNELL E, 1987, BLOOD, V70, P104; ROSENSTEIN Y, 1991, NATURE, V354, P233, DOI 10.1038/354233a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Rudd CE, 1996, IMMUNITY, V4, P527, DOI 10.1016/S1074-7613(00)80479-3; SANCHEZMATEOS P, 1995, BLOOD, V86, P2228, DOI 10.1182/blood.V86.6.2228.bloodjournal8662228; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; SHELLEY CS, 1989, P NATL ACAD SCI USA, V86, P2819, DOI 10.1073/pnas.86.8.2819; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; SILVERMAN LB, 1989, J IMMUNOL, V142, P4194; SMIT L, 1994, J BIOL CHEM, V269, P20209; Smit L, 1996, J BIOL CHEM, V271, P8564, DOI 10.1074/jbc.271.15.8564; Stockl J, 1996, J EXP MED, V184, P1769, DOI 10.1084/jem.184.5.1769; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; Teramoto H, 1997, J BIOL CHEM, V272, P10751; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Tuosto L, 1996, J EXP MED, V184, P1161, DOI 10.1084/jem.184.3.1161; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WHITEHURST CE, 1992, J IMMUNOL, V148, P3230; Wu J, 1997, J EXP MED, V185, P1877, DOI 10.1084/jem.185.10.1877; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0	64	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14218	14224		10.1074/jbc.273.23.14218	http://dx.doi.org/10.1074/jbc.273.23.14218			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603925	hybrid			2022-12-27	WOS:000074021500027
J	Giri, DK; Aggarwal, BB				Giri, DK; Aggarwal, BB			Constitutive activation of NF-kappa B causes resistance to apoptosis in human cutaneous T cell lymphoma HuT-78 cells - Autocrine role of tumor necrosis factor and reactive oxygen intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-ALPHA; TNF; PROTEIN; CYTOTOXICITY; EXPRESSION; DEGRADATION; INHIBITORS; BINDING; DEATH; GENE	Hom tumor cells develop resistance to apoptosis induced by cytokines and chemotherapeutic agents is incompletely understood. In the present report, we investigated apoptosis induction by tumor necrosis factor (TNF) in two human T cell lines, Jurkat and HuT-78. While TNF inhibited the growth of Jurkat cells and activated caspase-3, it had no effect on HuT-78 cells. It was further found that HuT-78 cells constitutively expressed the nuclear transcription factor NF-kappa B. TNF activated NF-kappa B in Jurkat cells but not in HuT-78 cells. HuT-78 cells were also resistant to NF-kappa B activation induced by phorbol ester, H2O2, ceramide, endotoxin, and interleukin-1. Despite the presence of preactivated NF-kappa B, HuT-78 cells also expressed high levels of I kappa B-alpha, the inhibitory subunit of NF-kappa B and, unlike Jurkat cells, were resistant to TNF-induced degradation of I kappa B-alpha. Its half-life in HuT-78 cells was 12 h as opposed to 45 min in Jurkat cells. Antibodies against TNF blocked the constitutive activation of NF-kappa B and proliferation of HuT-78 cells but had no significant effect on Jurkat cells, suggesting an autocrine role for TNF. The antioxidant pyrrolidine dithiocarbamate also suppressed constitutive NF-kappa B activation and it reversed the cell's sensitivity to TNF-induced cytotoxicity and activation of caspase-3, Overall, these results suggest that constitutive activation of NF-kappa B, TNF, and prooxidant pathway in certain T cell lymphomas causes resistance to apoptosis, and this can be reversed by antioxidants.	Univ Texas, MD Anderson Cancer Ctr, Dept Med Oncol, Cytokine Res Lab, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Med Oncol, Cytokine Res Lab, Houston, TX 77030 USA.		Aggarwal, Bharat B/G-3388-2013					BABOIR BM, 1988, OXYRADIALS MOL BIOL, P39; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldini N, 1997, NAT MED, V3, P378, DOI 10.1038/nm0497-378; BEG A, 1995, NATURE, V37, P167; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BELLAMY WT, 1994, ADV CLIN CHEM, V31, P1, DOI 10.1016/S0065-2423(08)60332-7; Boland MP, 1997, J BIOL CHEM, V272, P12952, DOI 10.1074/jbc.272.20.12952; BRACH MA, 1993, J BIOL CHEM, V268, P8466; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRINGMAN TS, 1987, HYBRIDOMA, V6, P489, DOI 10.1089/hyb.1987.6.489; Broxterman Henk J., 1995, Current Opinion in Oncology, V7, P532, DOI 10.1097/00001622-199511000-00011; CHATURVEDI MM, 1994, J BIOL CHEM, V269, P14575; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; CHU ZL, 1997, P NATL ACAD SCI USA, V94, P1005; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914; Goossens V, 1996, J BIOL CHEM, V271, P192, DOI 10.1074/jbc.271.1.192; HARRISON DJ, 1995, J PATHOL, V175, P7, DOI 10.1002/path.1711750103; HIMENO T, 1990, CANCER RES, V50, P4941; HUHTALA P, 1991, J BIOL CHEM, V266, P16485; Kochetkova M, 1997, J CLIN INVEST, V99, P3000, DOI 10.1172/JCI119495; Li JJ, 1997, CANCER RES, V57, P3569; MIYAMOTO S, 1994, MOL CELL BIOL, V14, P3276, DOI 10.1128/MCB.14.5.3276; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; OCONNELL MA, 1995, J BIOL CHEM, V270, P7399, DOI 10.1074/jbc.270.13.7399; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; PERERA CS, 1995, ARCH BIOCHEM BIOPHYS, V323, P471, DOI 10.1006/abbi.1995.0069; Perez C, 1997, J CELL SCI, V110, P337; Piret B, 1996, NUCLEIC ACIDS RES, V24, P4242, DOI 10.1093/nar/24.21.4242; Raziuddin A, 1997, J BIOL CHEM, V272, P15715, DOI 10.1074/jbc.272.25.15715; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; Roshak AK, 1996, J BIOL CHEM, V271, P31496, DOI 10.1074/jbc.271.49.31496; Sambrook J., 2002, MOL CLONING LAB MANU; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; ShattuckBrandt RL, 1997, CANCER RES, V57, P3032; Singh S, 1996, J BIOL CHEM, V271, P31049, DOI 10.1074/jbc.271.49.31049; SINGH S, 1995, J BIOL CHEM, V270, P10631, DOI 10.1074/jbc.270.18.10631; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WOLFE JT, 1994, FEBS LETT, V352, P58, DOI 10.1016/0014-5793(94)00920-1; ZIEGLERHEITBROCK HWL, 1993, J IMMUNOL, V151, P6986	44	266	283	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					14008	14014		10.1074/jbc.273.22.14008	http://dx.doi.org/10.1074/jbc.273.22.14008			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593751	hybrid			2022-12-27	WOS:000073919100090
J	Harvey, KF; Harvey, NL; Michael, JM; Parasivam, G; Waterhouse, N; Alnemri, ES; Watters, D; Kumar, S				Harvey, KF; Harvey, NL; Michael, JM; Parasivam, G; Waterhouse, N; Alnemri, ES; Watters, D; Kumar, S			Caspase-mediated cleavage of the ubiquitin-protein ligase Nedd4 during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ICE-LIKE PROTEASES; CELL-DEATH; LAMIN-A; C-MYC; EXPRESSION; SUBSTRATE; ENZYME; IDENTIFICATION; PROTEOLYSIS; INDUCTION	The onset of apoptosis is coupled to the proteolytic activation of a family of cysteine proteases, termed caspases, These proteases cleave their target proteins after an aspartate residue. Following caspase activation during apoptosis, a number of specific proteins have been shown to be cleaved. Here we show that Nedd4, a ubiquitin-protein ligase containing multiple WW domains and a calcium/lipid-binding domain, is also cleaved during apoptosis induced by a variety of stimuli including Fas-ligation, gamma-radiation, tumor necrosis factor-alpha, C-8 ceramide, and etoposide treatment. Extracts from apoptotic cells also generated cleavage patterns similar to that seen in vivo, and this cleavage was inhibited by an inhibitor of caspase-3-like proteases, In vitro, Nedd4 was cleaved by a number of caspases, including caspase-1, -3, -6, and -7. By site-directed mutagenesis, one of the in vitro caspase cleavage sites in mouse Nedd4 was mapped to a DQPD(237 down arrow) sequence, which is conserved between mouse, rat, and human proteins. This is the first report demonstrating that an enzyme of the ubiquitin pathway is cleaved by caspases during apoptosis.	Inst Med & Vet Sci, Hanson Ctr Canc Res, Adelaide, SA 5000, Australia; Univ Queensland, Royal Brisbane Hosp, Queensland Inst Med Res, Herston, Qld 4029, Australia; Thomas Jefferson Univ, Kimmel Canc Inst, Ctr Apoptosis Res, Philadelphia, PA 19107 USA	Institute Medical & Veterinary Science Australia; QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; University of Queensland; Jefferson University	Kumar, S (corresponding author), Inst Med & Vet Sci, Hanson Ctr Canc Res, POB 14,Rundle Mall,Frome Rd, Adelaide, SA 5000, Australia.	sharad.kumar@imvs.sa.gov.au	Alnemri, Emad S/B-4526-2010; Harvey, Kieran/AAD-5268-2022; Watters, Dianne J/E-6007-2010; Waterhouse, Nigel/I-9813-2016; Kumar, Sharad/AAX-7787-2020	Watters, Dianne J/0000-0002-2555-5825; Kumar, Sharad/0000-0001-7126-9814; Harvey, Natasha/0000-0001-9839-8966; Harvey, Kieran/0000-0001-7845-369X	NIA NIH HHS [AG13487] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG013487] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Beyaert R, 1997, J BIOL CHEM, V272, P11694, DOI 10.1074/jbc.272.18.11694; BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; Butt AJ, 1998, J BIOL CHEM, V273, P6763, DOI 10.1074/jbc.273.12.6763; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Crouch DH, 1996, ONCOGENE, V12, P2689; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Erhardt P, 1997, J BIOL CHEM, V272, P15049, DOI 10.1074/jbc.272.24.15049; Gavva NR, 1997, J BIOL CHEM, V272, P24105, DOI 10.1074/jbc.272.39.24105; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; Harvey NL, 1997, J BIOL CHEM, V272, P13134, DOI 10.1074/jbc.272.20.13134; Hatakeyama S, 1997, J BIOL CHEM, V272, P15085, DOI 10.1074/jbc.272.24.15085; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; KAUFMANN SH, 1989, CANCER RES, V49, P5870; Khanna KK, 1996, CELL DEATH DIFFER, V3, P315; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Kumar S, 1996, CELL DEATH DIFFER, V3, P255; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; KUMAR S, 1995, FEBS LETT, V375, P169, DOI 10.1016/0014-5793(95)01186-I; Kumar S, 1997, GENOMICS, V40, P435, DOI 10.1006/geno.1996.4582; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Plant PJ, 1997, J BIOL CHEM, V272, P32329, DOI 10.1074/jbc.272.51.32329; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Song QZ, 1997, BIOCHEM BIOPH RES CO, V233, P343, DOI 10.1006/bbrc.1997.6456; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; STAUB O, 1997, AM J PHYSIOL, V272, pC187; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Tan XQ, 1997, J BIOL CHEM, V272, P9613; TEWARI M, 1995, CELL, V81, P1; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; Waterhouse N, 1996, J BIOL CHEM, V271, P29335, DOI 10.1074/jbc.271.46.29335; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056	46	60	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13524	13530		10.1074/jbc.273.22.13524	http://dx.doi.org/10.1074/jbc.273.22.13524			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593687	hybrid			2022-12-27	WOS:000073919100026
J	Panzer, P; Preuss, U; Joberty, G; Naim, HY				Panzer, P; Preuss, U; Joberty, G; Naim, HY			Protein domains implicated in intracellular transport and sorting of lactase-phlorizin hydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; ADULT-TYPE HYPOLACTASIA; PHLORHIZIN HYDROLASE; INFLUENZA HEMAGGLUTININ; ENDOPLASMIC-RETICULUM; QUATERNARY STRUCTURE; SUCRASE-ISOMALTASE; AMINOPEPTIDASE-N; ENZYME; BIOSYNTHESIS	The roles of various domains of intestinal lactase-phlorizin hydrolase (pro-LPH) on its folding, dimerization, and polarized sorting are investigated in deletion mutants of the ectodomain fused or not fused with the membrane-anchoring and cytoplasmic domains (MACT), Deletion of 236 amino acids immediately upstream of MACT has no effect on the folding, dimerization, transport competence, or polarized sorting of the mutant LPH1646MACT, By contrast, LPH1646, an anchorless counterpart of LPH1646MACT, is not transported beyond the ER and persists as a mannose-rich monomer during its entire Life cycle. The further deletion of 87 amino acids generates a correctly folded but transport-incompetent monomeric LPH1559MACT mutant. The results strongly suggest that dimerization and transport of pro-LPH implicate a stretch of 87 amino acids in the ectodomain between LPH1646MACT and LPH1559MACT. In addition, dimerization of pro-LPH requires at least two further criteria: (i) a correctly folded ectodomain of pro-LPH and (ii) the presence of the transmembrane region. Neither of these requirements alone is sufficient for dimerization. Finally, the sorting of pro-LPH appears to be mediated by signals located between the cleavage site of pro-LPH and the LPH1646MACT mutant.	Hannover Sch Vet Med, Inst Physiol Chem, D-30559 Hannover, Germany; Univ Dusseldorf, Inst Microbiol, Prot Secret Grp, D-40225 Dusseldorf, Germany	University of Veterinary Medicine Hannover, Foundation; Heinrich Heine University Dusseldorf	Naim, HY (corresponding author), Hannover Sch Vet Med, Inst Physiol Chem, Bunteweg 17, D-30559 Hannover, Germany.	hnaim@biochemie.tiho-hannover.de						BOLL W, 1991, AM J HUM GENET, V48, P889; BORMANN BJ, 1989, J BIOL CHEM, V264, P4033; BOULAY F, 1988, J CELL BIOL, V106, P629, DOI 10.1083/jcb.106.3.629; CALLOWAY DH, 1966, NATURE, V212, P1238, DOI 10.1038/2121238a0; COLOMBO V, 1973, BIOCHIM BIOPHYS ACTA, V327, P412, DOI 10.1016/0005-2744(73)90425-7; DANIELSEN EM, 1984, BIOCHEM BIOPH RES CO, V122, P82; DOMS RW, 1986, J VIROL, V60, P833, DOI 10.1128/JVI.60.3.833-839.1986; DOYLE C, 1986, J CELL BIOL, V103, P1193, DOI 10.1083/jcb.103.4.1193; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HARVEY CB, 1995, GUT, V36, P28, DOI 10.1136/gut.36.1.28; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HOLZEL A, 1959, LANCET, V1, P1126; HUNZIKER W, 1986, CELL, V46, P227, DOI 10.1016/0092-8674(86)90739-7; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; Jacob R, 1996, EUR J BIOCHEM, V236, P789, DOI 10.1111/j.1432-1033.1996.t01-1-00789.x; Jacob R, 1997, EUR J CELL BIOL, V72, P54; JACOB R, 1994, J BIOL CHEM, V269, P2712; KRUSE TA, 1988, FEBS LETT, V240, P123, DOI 10.1016/0014-5793(88)80352-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVITT MD, 1970, GASTROENTEROLOGY, V59, P921; MAIURI L, 1991, GASTROENTEROLOGY, V100, P359, DOI 10.1016/0016-5085(91)90203-W; MANTEI N, 1988, EMBO J, V7, P2705, DOI 10.1002/j.1460-2075.1988.tb03124.x; NAIM HY, 1992, BIOCHEM J, V286, P451, DOI 10.1042/bj2860451; NAIM HY, 1987, BIOCHEM J, V241, P427, DOI 10.1042/bj2410427; NAIM HY, 1992, J BIOL CHEM, V267, P25494; NAIM HY, 1991, J BIOL CHEM, V266, P12313; Naim HY, 1996, EUR J CELL BIOL, V70, P198; OLSEN J, 1988, FEBS LETT, V238, P307, DOI 10.1016/0014-5793(88)80502-7; ROTUNDO RL, 1984, P NATL ACAD SCI-BIOL, V81, P479, DOI 10.1073/pnas.81.2.479; RUSSELL DW, 1984, CELL, V37, P577, DOI 10.1016/0092-8674(84)90388-X; SCHLEGEL.S, 1972, BIOCHIM BIOPHYS ACTA, V258, P506, DOI 10.1016/0005-2744(72)90242-2; SKLYANSKAYA EI, 1988, VIRUS RES, V10, P153, DOI 10.1016/0168-1702(88)90012-3; SKOVBJERG H, 1982, BIOCHIM BIOPHYS ACTA, V707, P89, DOI 10.1016/0167-4838(82)90400-9; SPORN LA, 1986, CELL, V46, P185, DOI 10.1016/0092-8674(86)90735-X; THOMSEN DR, 1984, P NATL ACAD SCI-BIOL, V81, P659, DOI 10.1073/pnas.81.3.659; VANDRIEL IR, 1987, J BIOL CHEM, V262, P16127; VOGEL LK, 1992, FEBS LETT, V308, P14, DOI 10.1016/0014-5793(92)81039-O; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WACKER H, 1992, J BIOL CHEM, V267, P18744; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529; WU GE, 1983, CELL, V33, P77, DOI 10.1016/0092-8674(83)90336-7; Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929	42	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13861	13869		10.1074/jbc.273.22.13861	http://dx.doi.org/10.1074/jbc.273.22.13861			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593732	hybrid			2022-12-27	WOS:000073919100071
J	Peng, JM; Marshall, NF; Price, DH				Peng, JM; Marshall, NF; Price, DH			Identification of a cyclin subunit required for the function of Drosophila P-TEFb	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; C-TERMINAL DOMAIN; TRANSCRIPTIONAL ELONGATION; PHOSPHORYLATION; PURIFICATION; COMPLEXES; KINASE; PREDICTION	P-TEFb is required for the transition from abortive elongation into productive elongation and is capable of phosphorylating the carboxyl-terminal domain (CTD) of the largest subunit of RNA polymerase II. We cloned a cDNA encoding the large subunit of Drosophila P-TEFb and found the predicted protein contained a cyclin motif, We now name the large subunit cyclin T and the previously cloned small subunit (Zhu, Y, R,, Peery, T,, Peng, J, M,, Ramanathan, Y,, Marshall, N,, Marshall, T,, Amendt, B,, Mathews, M. B,, and Price, D, H. (1997) Genes Dev, 11, 2622-2632) cyclin dependent kinase 9 (CDK9), Recombinant P-TEFb produced in baculovirus-transfected Sf9 cells exhibited 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole-sensitive kinase activity similar to native P-TEFb, K-c cell nuclear extract depleted of P-TEFb failed to generate long DRB-sensitive transcripts, but this activity was restored upon addition of either native or recombinant P-TEFb, Like other CDKs, CDK9 is essentially inactive in the absence of its cyclin partner. P-TEFb containing a CDK9 mutation that knocked out the kinase activity did not function in transcription. Deletion of the carboxyl-terminal domain of cyclin T in P-TEFb reduced both the kinase and transcription activity to about 10%, The CDK-activating kinase in TFIIH was unable to activate the CTD kinase activity of P-TEFb.	Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA	University of Iowa	Price, DH (corresponding author), Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA.	david-price@uiowa.edu	Peng, Junmin/N-2614-2018; Price, David H/F-6173-2010	Peng, Junmin/0000-0003-0472-7648; Price, David/0000-0002-5597-385X	NIGMS NIH HHS [GM35500] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035500] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKOULITCHEV S, 1995, NATURE, V377, P557, DOI 10.1038/377557a0; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Austin RJ, 1996, P NATL ACAD SCI USA, V93, P5788, DOI 10.1073/pnas.93.12.5788; Bazan JF, 1996, PROTEINS, V24, P1; DAHMUS ME, 1994, PROG NUCLEIC ACID RE, V48, P143, DOI 10.1016/S0079-6603(08)60855-7; DAHMUS ME, 1995, BBA-GENE STRUCT EXPR, V1261, P171, DOI 10.1016/0167-4781(94)00233-S; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Garriga J, 1996, BIOCHEM J, V319, P293, DOI 10.1042/bj3190293; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; KEPHART DD, 1992, MOL CELL BIOL, V12, P2067, DOI 10.1128/MCB.12.5.2067; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAHUE EE, 1991, GENE DEV, V5, P2166, DOI 10.1101/gad.5.12a.2166; LAYBOURN PJ, 1989, J BIOL CHEM, V264, P6693; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; Reines D, 1996, TRENDS BIOCHEM SCI, V21, P351, DOI 10.1016/0968-0004(96)10045-1; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; Xie Z, 1996, J BIOL CHEM, V271, P11043, DOI 10.1074/jbc.271.19.11043; YAMAGUCHI K, 1997, IN PRESS GENES CELLS; Yankulov KY, 1996, MOL CELL BIOL, V16, P3291; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	25	145	152	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13855	13860		10.1074/jbc.273.22.13855	http://dx.doi.org/10.1074/jbc.273.22.13855			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593731	hybrid			2022-12-27	WOS:000073919100070
J	Russo, D; Redman, C; Lee, S				Russo, D; Redman, C; Lee, S			Association of XK and Kell blood group proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIN-CONVERTING ENZYME; NEUTRAL ENDOPEPTIDASE-24.11; MCLEOD PHENOTYPE; GROUP SYSTEM; KX-ANTIGEN; RED-CELLS; MEMBRANE; EXPRESSION; GENE; CLONING	A disulfide bond links Kell and XK red cell membrane proteins. Kell, a type II membrane glycoprotein, carries over 20 blood group antigens, and XK, which spans the membrane 10 times, is lacking in rare individuals with the McLeod syndrome. Kell is classified in the neprilysin family of zinc endopeptidases, and XK has structural features that suggest it is a transport protein. Kell has 15 extracellular cysteines, and XK has one in its fifth extracellular loop. Five of the extracellular cysteine residues in Kell are not conserved in the other members of the neprilysin family, and based on the hypothesis that one of the nonconserved cysteines is linked to XK cysteines 72 and 319 were mutated to serine. The single extracellular cysteine 347 of XK was also mutated. Go-expression of combinations of wild-type and mutant proteins in transfected COS-l cells showed that Kell C72S did not form a Kell-XK complex with wild-type XK, while wild-type Kell. and Kell C319S did. XK C347S was also unable to form a complex with wild-type Kell, indicating that Kell cysteine 72 is linked to XK cysteine 347, Kell C72S was transported to the cell surface, indicating that linkage to XK is not required. In addition, chemical cross-linking of red cell membranes with dithiobispropionimidate indicated that glyceraldehyde-3-phosphate dehydrogenase is a near neighbor of Kell.	New York Blood Ctr, Lindsley F Kimball Res Inst, New York, NY 10021 USA	New York Blood Center	Redman, C (corresponding author), New York Blood Ctr, Lindsley F Kimball Res Inst, 310 E 67 St, New York, NY 10021 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054459] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54459] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERTELSON CJ, 1988, AM J HUM GENET, V42, P703; BRANCH DR, 1985, BRIT J HAEMATOL, V59, P505, DOI 10.1111/j.1365-2141.1985.tb07337.x; Carbonnet F, 1997, BRIT J HAEMATOL, V96, P857, DOI 10.1046/j.1365-2141.1997.d01-2110.x; FERNANDEZ J, 1994, TECHNIQUES PROTEIN C, V5, P215; HO MF, 1994, CELL, V77, P869, DOI 10.1016/0092-8674(94)90136-8; KHAMLICHI S, 1995, EUR J BIOCHEM, V228, P931, DOI 10.1111/j.1432-1033.1995.0931m.x; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LEE S, 1993, BLOOD, V81, P2804; Lee S, 1997, VOX SANG, V73, P1, DOI 10.1046/j.1423-0410.1997.7310001.x; LEE S, 1991, P NATL ACAD SCI USA, V88, P6353, DOI 10.1073/pnas.88.14.6353; LEE SH, 1995, BLOOD, V85, P912, DOI 10.1182/blood.V85.4.912.bloodjournal854912; LOW PS, 1986, BIOCHIM BIOPHYS ACTA, V864, P145, DOI 10.1016/0304-4157(86)90009-2; Marsh W L, 1987, Transfus Med Rev, V1, P4; MARSH WL, 1990, TRANSFUSION, V30, P158, DOI 10.1046/j.1537-2995.1990.30290162904.x; MARSH WL, 1981, VOX SANG, V40, P403, DOI 10.1111/j.1423-0410.1981.tb00728.x; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; REDMAN CM, 1988, BRIT J HAEMATOL, V68, P131, DOI 10.1111/j.1365-2141.1988.tb04191.x; REDMAN CM, 1993, SEMIN HEMATOL, V30, P209; REDMAN CM, 1984, TRANSFUSION, V24, P176, DOI 10.1046/j.1537-2995.1984.24284173356.x; REDMAN CM, 1986, J BIOL CHEM, V261, P951; REICHSTEIN E, 1974, J BIOL CHEM, V250, P6256; ROQUES BP, 1993, PHARMACOL REV, V45, P87; Rowe PSN, 1997, HUM MOL GENET, V6, P539, DOI 10.1093/hmg/6.4.539; RUSSO DCW, 1994, BLOOD, V84, P3518; Shimada K, 1996, BIOCHEM J, V315, P863, DOI 10.1042/bj3150863; SHIMADA K, 1994, J BIOL CHEM, V269, P18275; Turner AJ, 1997, FASEB J, V11, P355, DOI 10.1096/fasebj.11.5.9141502; VALDENAIRE O, 1995, J BIOL CHEM, V270, P29794; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1	29	97	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13950	13956		10.1074/jbc.273.22.13950	http://dx.doi.org/10.1074/jbc.273.22.13950			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593744	hybrid			2022-12-27	WOS:000073919100083
J	Tian, LJ; Knaus, HG; Shipston, MJ				Tian, LJ; Knaus, HG; Shipston, MJ			Glucocorticoid regulation of calcium-activated potassium channels mediated by serine/threonine protein phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+ CHANNEL; ADRENOCORTICOTROPIN SECRETION; CELLS; INHIBITION; KINASE; DEPHOSPHORYLATION; RECEPTORS; TISSUE; CAMP	Adrenal glucocorticoids exert powerful effects on cellular excitability in neuroendocrine cells and neurons, although the underlying mechanisms are poorly understood. In metabolically intact mouse anterior pituitary corticotrope (AtT20) cells glucocorticoid-induced proteins render large conductance calcium-activated potassium (BK) channels insensitive to inhibition by protein kinase A (PKA), In this study we have addressed whether this action of glucocorticoids is mediated via protein phosphatase activity at the level of single BK channels. In isolated inside-out patches from control AtT20 cells BK channels (125 pS) were inhibited by activation of closely associated PKA. Pretreatment (2 h) of cells with 1 mu M dexamethasone before patch excision did not modify the intrinsic properties or expression levels of BK channel alpha-subunits in AtT20 cells. However, PKA-mediated inhibition of BK channel activity in isolated patches from steroid-treated cells was severely blunted. This effect of steroid was not observed using adenosine 5'-O-(3-thiotriphosphate) as phosphate donor or on exposure of the intracellular face of the patch with 10 nM of the protein phosphatase inhibitors okadaic acid or calyculin A but was mimicked by application of protein phosphatase 2A (PP2A) to the intracellular face of patches from control cells. Glucocorticoids did not modify total PP2A activity in AtT20 cells, suggesting that modified PP2A-like phosphatase activity closely associated with BK channels is required for glucocorticoid action.	Univ Edinburgh, Sch Med, Dept Physiol, Membrane Biol Grp, Edinburgh EH8 9AG, Midlothian, Scotland; Inst Biochem Pharmakol, A-6020 Innsbruck, Austria	University of Edinburgh	Shipston, MJ (corresponding author), Univ Edinburgh, Sch Med, Dept Physiol, Membrane Biol Grp, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.		Shipston, Mike/C-7309-2013	Shipston, Mike/0000-0001-7544-582X				Antaraki A, 1997, BRIT J PHARMACOL, V121, P991, DOI 10.1038/sj.bjp.0701228; ANTONI FA, 1986, ENDOCR REV, V7, P351, DOI 10.1210/edrv-7-4-351; ATTALI B, 1995, P NATL ACAD SCI USA, V92, P6092, DOI 10.1073/pnas.92.13.6092; Baughman G, 1997, BIOCHEM BIOPH RES CO, V232, P437, DOI 10.1006/bbrc.1997.6307; CAMBILLAU C, 1995, ENDOCRINOLOGY, V136, P5476, DOI 10.1210/en.136.12.5476; Cohen PTW, 1997, TRENDS BIOCHEM SCI, V22, P245, DOI 10.1016/S0968-0004(97)01060-8; DAYANITHI G, 1989, ENDOCRINOLOGY, V125, P308, DOI 10.1210/endo-125-1-308; DEFRANCO DB, 1991, MOL ENDOCRINOL, V5, P1215, DOI 10.1210/mend-5-9-1215; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; JOELS M, 1989, SCIENCE, V245, P1502, DOI 10.1126/science.2781292; KERR DS, 1989, SCIENCE, V245, P1505, DOI 10.1126/science.2781293; KNAUS HG, 1995, J BIOL CHEM, V270, P22434, DOI 10.1074/jbc.270.38.22434; LEVITAN IB, 1994, ANNU REV PHYSIOL, V56, P193, DOI 10.1146/annurev.ph.56.030194.001205; LUINI A, 1985, P NATL ACAD SCI USA, V82, P8034, DOI 10.1073/pnas.82.23.8034; MIYAZAKI K, 1984, ENDOCRINOLOGY, V115, P1933, DOI 10.1210/endo-115-5-1933; PALIOGIANNI F, 1995, J IMMUNOL, V155, P1809; PEDARZANI P, 1993, NEURON, V11, P1023, DOI 10.1016/0896-6273(93)90216-E; Pompeo A, 1997, J STEROID BIOCHEM, V60, P51, DOI 10.1016/S0960-0760(96)00161-6; REINHART PH, 1995, J NEUROSCI, V15, P4572; Sansom SC, 1997, J BIOL CHEM, V272, P9902; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; Shipston MJ, 1996, J BIOL CHEM, V271, P9197, DOI 10.1074/jbc.271.16.9197; SHIPSTON MJ, 1995, TRENDS ENDOCRIN MET, V6, P261, DOI 10.1016/1043-2760(95)00149-2; Silverstein AM, 1997, J BIOL CHEM, V272, P16224, DOI 10.1074/jbc.272.26.16224; SINGER KL, 1994, J BIOL CHEM, V269, P16108; TAKIMOTO K, 1993, NEURON, V11, P359, DOI 10.1016/0896-6273(93)90191-S; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; WHITE RE, 1991, NATURE, V351, P570, DOI 10.1038/351570a0; WHITE RE, 1993, NATURE, V361, P263, DOI 10.1038/361263a0; WOODS MD, 1992, ENDOCRINOLOGY, V131, P2873, DOI 10.1210/en.131.6.2873	30	49	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13531	13536		10.1074/jbc.273.22.13531	http://dx.doi.org/10.1074/jbc.273.22.13531			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593688	hybrid			2022-12-27	WOS:000073919100027
J	Guan, ZH; Buckman, SY; Pentland, AP; Templeton, DJ; Morrison, AR				Guan, ZH; Buckman, SY; Pentland, AP; Templeton, DJ; Morrison, AR			Induction of cyclooxygenase-2 by the activated MEKK1 -> SEK1/MKK4 -> p38 mitogen-activated protein kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; C-JUN; INFLAMMATORY CYTOKINES; MOLECULAR-CLONING; GROWTH-FACTOR; PHOSPHORYLATION; STRESS; CASCADES	The mitogen-activated protein kinase (MAPK) cascade is believed to function as an important regulator of prostaglandin biosynthesis, Previously we reported that interleukin-1 beta induces activation of JNK/SAPK and p38 MAPK with concomitant up-regulation of cyclooxygenase (Cox)-2 expression and prostaglandin E-2 (PGE(2)) synthesis. Our experiments demonstrate that overexpression of Delta MEKK1 (a constitutively active truncation mutant of MEKK1 containing the C-terminal 324 amino acids) increases Cox-2 expression and PGE(2) production which is completely blocked by SC68376, a pharmacologic inhibitor of p38 MAPK. Delta MEKK1 overexpression results in activation of both c Jun N-terminal kinases/extracellular signal-regulated kinases (JNK/SAPK) and p38 MAPK. Furthermore, activation of Delta MEKK1 increases SEK1/MKK4 but not MKK3 or MKK6 activity. These findings suggest that MEKK1 --> SEK1/MKK4 may function as an upstream kinase capable of activating both p38 MAPK and JNK/SAPK with subsequent induction of Cox-2 expression and PGE(2) production. We also found that overexpression of the constitutively active form of SEK1 (SEK1-ED) increases both p38 MAPK and JNK/SAPK phosphorylation, and increases PGE(2) production and Cox-2 expression. By comparison, overexpression of the dominant negative form of SEK1 (SEK1-AL) decreases the phosphorylation of both p38 MAPK and JNK/SAPK and reduces Cox-2 expression. Together, this data suggests a potential role for the MEKK1 --> SEK1/MKK4 --> p38 MAPK -->--> Cox-2 cascade linking members of the MAPK pathway with prostaglandin biosynthesis.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol & Med, St Louis, MO 63110 USA; Univ Rochester, Sch Med, Dept Med, Rochester, NY 14642 USA; Case Western Reserve Univ, Sch Med, Inst Pathol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Cell Biol Program, Cleveland, OH 44106 USA	Washington University (WUSTL); University of Rochester; Case Western Reserve University; Case Western Reserve University	Morrison, AR (corresponding author), Barnes Jewish Hosp, Div Renal, 216 S Kingshighway,Box 8305, St Louis, MO 63110 USA.		Templeton, Dennis J/F-7695-2011		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038111, R01DK050606] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 38111, DK 50606] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; Deak JC, 1997, BIOCHEM J, V322, P185, DOI 10.1042/bj3220185; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEWITT D, 1995, CELL, V83, P345, DOI 10.1016/0092-8674(95)90109-4; Guan ZH, 1997, J BIOL CHEM, V272, P8083, DOI 10.1074/jbc.272.12.8083; GUAN ZH, 1996, AM J PHYSIOL-RENAL, V39, pF634; HABENICHT AJR, 1985, J CLIN INVEST, V75, P1381, DOI 10.1172/JCI111839; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Hazzalin CA, 1996, CURR BIOL, V6, P1028, DOI 10.1016/S0960-9822(02)00649-8; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MAIER JAM, 1990, J BIOL CHEM, V265, P10805; MARNETT LJ, 1992, CANCER RES, V52, P5575; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RAO CV, 1995, CANCER RES, V55, P1464; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; SMITH WL, 1994, ANN NY ACAD SCI, V744, P50, DOI 10.1111/j.1749-6632.1994.tb52723.x; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Wang XHS, 1996, J BIOL CHEM, V271, P31607; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XIE WL, 1992, DRUG DEVELOP RES, V25, P249, DOI 10.1002/ddr.430250402; Xie WL, 1996, J BIOL CHEM, V271, P31742, DOI 10.1074/jbc.271.49.31742; YAN MH, 1994, NATURE, V372, P798; YAN MH, 1994, J BIOL CHEM, V269, P19067	40	225	231	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					12901	12908		10.1074/jbc.273.21.12901	http://dx.doi.org/10.1074/jbc.273.21.12901			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582321	hybrid			2022-12-27	WOS:000073768500032
J	Joel, PB; Traish, AM; Lannigans, DA				Joel, PB; Traish, AM; Lannigans, DA			Estradiol-induced phosphorylation of serine 118 in the estrogen receptor is independent of p42/p44 mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; TRANSCRIPTIONAL ACTIVATION; DNA-BINDING; MAP KINASE; A/B REGION; INHIBITOR; DOMAIN; CELLS; SEQUENCE; REQUIRES	Phosphorylation of Ser(118) of human estrogen receptor alpha (ER) enhances ER-mediated transcription and is induced by hormone binding and by activation of the mitogen-activated protein kinase (MAPK) pathway, We discovered that phosphorylation of Ser(118) reduces the electrophoretic mobility of the ER, Using this mobility shift as an assay, we determined the in vivo stoichiometry and kinetics of Ser(118) phosphorylation in response to estradiol, ICI 182,780, epidermal growth factor (EGF), and phorbol 12-myristate 13-acetate (PMA). In human breast cancer MCF-7 cells, estradiol induced a steady state phosphorylation of Ser(118) within 20 min with a stoichiometry of 0.67 mol of phosphate/mol of ER. Estradiol did not activate p42/p44 MAPK, and basal p42/p44 MAPK activity was not sufficient to account for phosphorylation of Ser(118) in response to estradiol, In contrast, both EGF and PMA induced a rapid, transient phosphorylation of Ser(118) with a stoichiometry of similar to 0.25, and the onset of Ser(118) phosphorylation correlated with the onset of p42/p44 MAPK activation by these agents. Either the EGF- or PMA-induced Ser(118) phosphorylation could be inhibited without influencing estradiol-induced Ser(118) phosphorylation. The data suggest that a kinase other than p42/p44 MAPK is involved in the estradiol-induced Ser(118) phosphorylation. We propose that the hormone-induced change in ER conformation exposes Ser(118) for phosphorylation by a constitutively active kinase.	Univ Virginia, Hlth Sci Ctr, Ctr Cell Signaling, Charlottesville, VA 22908 USA; Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	University of Virginia; University of Virginia; Boston University	Lannigans, DA (corresponding author), Univ Virginia, Hlth Sci Ctr, Ctr Cell Signaling, 577, Charlottesville, VA 22908 USA.				NATIONAL CANCER INSTITUTE [R29CA055887] Funding Source: NIH RePORTER; NCI NIH HHS [R29CA-55887] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; ARNOLD SF, 1995, MOL ENDOCRINOL, V9, P24, DOI 10.1210/me.9.1.24; Barik S, 1993, Methods Mol Biol, V15, P277, DOI 10.1385/0-89603-244-2:277; BEEKMAN JM, 1993, MOL ENDOCRINOL, V7, P1266, DOI 10.1210/me.7.10.1266; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; CHO H, 1993, MOL ENDOCRINOL, V7, P441, DOI 10.1210/me.7.3.441; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DAUVOIS S, 1992, P NATL ACAD SCI USA, V89, P4037, DOI 10.1073/pnas.89.9.4037; DENTON RR, 1992, J BIOL CHEM, V267, P7263; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; GIBSON MK, 1991, ENDOCRINOLOGY, V129, P2000, DOI 10.1210/endo-129-4-2000; Grammer TC, 1997, ONCOGENE, V14, P1635, DOI 10.1038/sj.onc.1201000; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; IgnarTrowbridge DM, 1996, ENDOCRINOLOGY, V137, P1735, DOI 10.1210/en.137.5.1735; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; Joel PB, 1998, MOL CELL BIOL, V18, P1978, DOI 10.1128/MCB.18.4.1978; JOEL PB, 1995, MOL ENDOCRINOL, V9, P1041, DOI 10.1210/me.9.8.1041; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; LAHOOTI H, 1990, MOL CELL ENDOCRINOL, V74, P21, DOI 10.1016/0303-7207(90)90202-J; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Meijer L, 1996, TRENDS CELL BIOL, V6, P393, DOI 10.1016/0962-8924(96)10034-9; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; REESE JC, 1991, NUCLEIC ACIDS RES, V19, P6595, DOI 10.1093/nar/19.23.6595; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TRAIGH AM, 1994, 76TH ANN M END SOC A, P319; Traish AM, 1996, STEROIDS, V61, P549, DOI 10.1016/S0039-128X(96)00109-2; Trowbridge JM, 1997, P NATL ACAD SCI USA, V94, P10132, DOI 10.1073/pnas.94.19.10132; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; WASHBURN T, 1991, MOL ENDOCRINOL, V5, P235, DOI 10.1210/mend-5-2-235; Weigel NL, 1996, BIOCHEM J, V319, P657, DOI 10.1042/bj3190657	35	166	171	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					13317	13323		10.1074/jbc.273.21.13317	http://dx.doi.org/10.1074/jbc.273.21.13317			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582378	hybrid			2022-12-27	WOS:000073768500089
J	Seetharaman, J; Kanigsberg, A; Slaaby, R; Leffler, H; Barondes, SH; Rini, JM				Seetharaman, J; Kanigsberg, A; Slaaby, R; Leffler, H; Barondes, SH; Rini, JM			X-ray crystal structure of the human galectin-3 carbohydrate recognition domain at 2.1-angstrom resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALACTOSIDE-BINDING LECTINS; ENDOGENOUS LECTIN; RIBONUCLEOPROTEIN COMPLEX; ANIMAL LECTIN; PROTEIN; EXPRESSION; NUCLEAR; CELLS; IDENTIFICATION; NEUTROPHILS	Galectins are a family of lectins which share similar carbohydrate recognition domains (CRDs) and affinity for small beta-galactosides, but which show significant differences in binding specificity for more complex glycoconjugates. We report here the x-ray crystal structure of the human galectin-3 CRD, in complex with lactose and N-acetyllactosamine, at 2.1-Angstrom resolution. This structure represents the first example of a CRD determined from a galectin which does not show the canonical a-fold symmetric dimer organization. Comparison with the published structures of galectins-1 and -2 provides an explanation for the differences in carbohydrate-binding specificity shown by galectin-3, and for the fact that it fails to form dimers by analogous CRD-CRD interactions.	Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurobiol & Psychiat, San Francisco, CA 94143 USA	University of Toronto; University of Toronto; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Rini, JM (corresponding author), Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada.	james.rini@utoronto.ca	Leffler, Hakon/A-2416-2019	Leffler, Hakon/0000-0003-4482-8945				ABBOTT WM, 1988, BIOCHEM J, V252, P283, DOI 10.1042/bj2520283; Akahani S, 1997, TRENDS GLYCOSCI GLYC, V9, P69, DOI 10.4052/tigg.9.69; BAO Q, 1995, J CELL SCI, V108, P2791; BARONDES SH, 1994, CELL, V76, P597, DOI 10.1016/0092-8674(94)90498-7; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; BOURNE Y, 1994, NAT STRUCT BIOL, V1, P863, DOI 10.1038/nsb1294-863; BRUNGER AT, 1992, X PLOR V3 1 SYSTEM X; DAGHER SF, 1995, P NATL ACAD SCI USA, V92, P1213, DOI 10.1073/pnas.92.4.1213; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; EVANS SV, 1993, J MOL GRAPHICS, V11, P127; FOWLIS D, 1995, DEV DYNAM, V203, P241, DOI 10.1002/aja.1002030211; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; Goletz S, 1997, J CELL SCI, V110, P1585; HERRMANN J, 1993, J BIOL CHEM, V268, P26704; HSU DK, 1992, J BIOL CHEM, V267, P14167; HUGHES RC, 1994, GLYCOBIOLOGY, V4, P5, DOI 10.1093/glycob/4.1.5; IMBERTY A, 1991, GLYCOCONJUGATE J, V8, P456, DOI 10.1007/BF00769847; INOHARA H, 1995, CANCER RES, V55, P3267; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KNIBBS RN, 1993, J BIOL CHEM, V268, P14940; KUNDROT CE, 1987, ACTA CRYSTALLOGR B, V43, P544, DOI 10.1107/S0108768187097349; Kuwabara I, 1996, J IMMUNOL, V156, P3939; LAING JG, 1988, BIOCHEMISTRY-US, V27, P5329, DOI 10.1021/bi00414a057; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEFFLER H, 1986, J BIOL CHEM, V261, P119; Leffler H, 1997, TRENDS GLYCOSCI GLYC, V9, P9, DOI 10.4052/tigg.9.9; LIAO DI, 1994, P NATL ACAD SCI USA, V91, P1428, DOI 10.1073/pnas.91.4.1428; LINDSTEDT R, 1993, J BIOL CHEM, V268, P11750; LOBSANOV YD, 1993, J BIOL CHEM, V268, P27034; MASSA SM, 1993, BIOCHEMISTRY-US, V32, P260, DOI 10.1021/bi00052a033; MEHUL B, 1994, J BIOL CHEM, V269, P18250; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; QUIOCHO FA, 1988, CURR TOP MICROBIOL, V139, P135; QUN Z, 1993, ARCH BIOCHEM BIOPHYS, V300, P6, DOI 10.1006/abbi.1993.1002; RINI JM, 1995, ANNU REV BIOPH BIOM, V24, P551, DOI 10.1146/annurev.biophys.24.1.551; SATO S, 1992, J BIOL CHEM, V267, P6983; SATO S, 1994, EUR J IMMUNOL, V24, P216, DOI 10.1002/eji.1830240134; SPARROW CP, 1987, J BIOL CHEM, V262, P7383; WANG JL, 1992, BIOCHEM SOC T, V20, P269, DOI 10.1042/bst0200269; WANG L, 1995, BIOCHEM BIOPH RES CO, V217, P292, DOI 10.1006/bbrc.1995.2777; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3; YAMAOKA A, 1995, J IMMUNOL, V154, P3479; Yang RY, 1996, P NATL ACAD SCI USA, V93, P6737, DOI 10.1073/pnas.93.13.6737; ZUBERI RI, 1994, CELL IMMUNOL, V156, P1, DOI 10.1006/cimm.1994.1148	45	343	365	1	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					13047	13052		10.1074/jbc.273.21.13047	http://dx.doi.org/10.1074/jbc.273.21.13047			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582341	hybrid			2022-12-27	WOS:000073768500052
J	Zheng, LM; Cash, VL; Flint, DH; Dean, DR				Zheng, LM; Cash, VL; Flint, DH; Dean, DR			Assembly of iron-sulfur clusters - Identification of an iscSUA-hscBA-fdx gene cluster from Azotobacter vinelandii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROXY-ACID DEHYDRATASE; FE-S CLUSTER; ESCHERICHIA-COLI; SERINE ACETYLTRANSFERASE; NUCLEOTIDE-SEQUENCE; NITROGEN-FIXATION; NIFS GENE; CYSTEINE; DNA; PROTEIN	An enzyme having the same L-cysteine desulfurization activity previously described for the NifS protein was purified from a strain of Azotobacter vinelandii deleted for the nifS gene. This protein was designated IscS to indicate its proposed role in iron-sulfur cluster assembly. Like NifS, IscS is a pyridoxal-phosphate containing homodimer, Information gained from microsequencing of oligopeptides obtained by tryptic digestion of purified IscS was used to design a strategy for isolation and DNA sequence analysis of a 7,886-base pair & vinelandii genomic segment that includes the iscS gene. The iscS gene is contained within a gene cluster that includes homologs to nifU and another gene contained within the major nif cluster of A. vinelandii previously designated orf6. These genes have been designated iscU and iscA, respectively. Information available from complete genome sequences of Escherichia coli and Hemophilus influenzae reveals that they also encode iscSUA gene clusters. A wide conservation of iscSUA genes in nature and evidence that NifU and NifS participate in the mobilization of iron and sulfur for nitrogenase-specific iron-sulfur cluster formation suggest that the products of the iscSUA genes could play a general role in the formation or repair of iron-sulfur clusters. The proposal that IscS is involved in mobilization of sulfur for iron-sulfur cluster formation in A. vinelandii is supported by the presence of a cysE-like homolog in another gene cluster located immediately upstream from the one containing the iscSUA genes. O-Acetylserine synthase is the product of the cysE gene, and it catalyzes the rate-limiting step in cysteine biosynthesis, A similar cysE-like gene is also located within the nif gene cluster of A. vinelandii. The Likely role of such cysE-like gene products is to increase the cysteine pool needed for iron-sulfur cluster formation. Another feature of the iscSUA gene cluster region from it vinelandii is that E. coli genes previously designated as hscB, hscA, and fdx are located immediately downstream from, and are probably co-transcribed with, the iscSUA genes. The hscB, hscA, and fdx genes are also located adjacent to the iscSUA genes in both E. coli and H. influenzae. The E. coli hscA and hscB gene products have previously been shown to bear primary sequence identity when respectively compared with the dnaK and dnaJ gene products and have been proposed to be members of a heat-shock cognate molecular chaperone system of unknown function. The close proximity and apparent co expression of iscSUA and hscBA in A. vinelandii indicate that the proposed chaperone function of the hscBA gene products could be related to the maturation of iron-sulfur cluster-containing proteins. Attempts to place non polar insertion mutations within either A. vinelandii iscS or hscA revealed that such mutations could not be stably maintained in the absence of the corresponding wild-type allele, These results reveal a very strong selective pressure against the maintenance of A. vinelandii iscS or hscA knock-out mutations and suggest that such mutations are either lethal or highly deleterious, In contrast to iscS or hscA, a strain having a polar insertion mutation within the cysE-like gene was readily isolated and could be stably maintained. These results show that the cysE-like gene located upstream from iscS is not essential for cell growth and that the cysE-like gene and the iscSUA-hscBA-fdx genes are contained within separate transcription units.	Dupont Co, Cent Res & Dev, Expt Stn, Wilmington, DE 19880 USA; Virginia Tech, Dept Biochem, Blacksburg, VA 24061 USA	DuPont; Virginia Polytechnic Institute & State University	Flint, DH (corresponding author), Dupont Co, Cent Res & Dev, Expt Stn, Wilmington, DE 19880 USA.	flintdh@al.escax.umc.dupont.com; deandr@vt.edu						Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Chen SH, 1997, J BACTERIOL, V179, P7587, DOI 10.1128/jb.179.23.7587-7590.1997; DEAN DR, 1993, J BACTERIOL, V175, P6737, DOI 10.1128/jb.175.21.6737-6744.1993; DENK D, 1987, J GEN MICROBIOL, V133, P515; EVANS DJ, 1991, J BACTERIOL, V173, P5457, DOI 10.1128/jb.173.17.5457-5469.1991; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Flint DH, 1996, J BIOL CHEM, V271, P16068; Flint DH, 1996, J BIOL CHEM, V271, P16053, DOI 10.1074/jbc.271.27.16053; FU W, 1994, BIOCHEMISTRY-US, V33, P13445; Howard JB, 1996, CHEM REV, V96, P2965, DOI 10.1021/cr9500545; Hwang DM, 1996, J MOL EVOL, V43, P536, DOI 10.1007/PL00006114; JACOBSON MR, 1989, J BACTERIOL, V171, P1017, DOI 10.1128/jb.171.2.1017-1027.1989; JACOBSON MR, 1989, MOL GEN GENET, V219, P49, DOI 10.1007/BF00261156; KAWULA TH, 1994, J BACTERIOL, V176, P610, DOI 10.1128/jb.176.3.610-619.1994; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; KOLMAN C, 1993, J BACTERIOL, V175, P1433, DOI 10.1128/JB.175.5.1433-1442.1993; KREDICH NM, 1972, J BIOL CHEM, V247, P7157; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LELIVELT MJ, 1995, J BACTERIOL, V177, P4900, DOI 10.1128/jb.177.17.4900-4907.1995; Manna AC, 1997, MOL GEN GENET, V254, P207, DOI 10.1007/s004380050409; Mihara H, 1997, J BIOL CHEM, V272, P22417, DOI 10.1074/jbc.272.36.22417; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; PAGE WJ, 1979, J BACTERIOL, V139, P1058, DOI 10.1128/JB.139.3.1058-1061.1979; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAH VK, 1973, BIOCHIM BIOPHYS ACTA, V305, P445, DOI 10.1016/0005-2728(73)90190-4; STRANDBERG GW, 1968, CAN J MICROBIOL, V14, P25, DOI 10.1139/m68-005; TA DT, 1992, J BIOL CHEM, V267, P11120; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TOUKDARIAN A, 1990, J BACTERIOL, V172, P6529, DOI 10.1128/jb.172.11.6529-6539.1990; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; ZHENG LM, 1994, J BIOL CHEM, V269, P18723; ZHENG LM, 1994, BIOCHEMISTRY-US, V33, P4714, DOI 10.1021/bi00181a031	35	548	569	1	49	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					13264	13272		10.1074/jbc.273.21.13264	http://dx.doi.org/10.1074/jbc.273.21.13264			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582371	hybrid			2022-12-27	WOS:000073768500082
J	Jabbouri, S; Relic, B; Hanin, M; Kamalaprija, P; Burger, U; Prome, D; Prome, JC; Broughton, WJ				Jabbouri, S; Relic, B; Hanin, M; Kamalaprija, P; Burger, U; Prome, D; Prome, JC; Broughton, WJ			nolO and noeI (HsnIII) of Rhizobium sp. NGR234 are involved in 3-O-carbamoylation and 2-O-methylation of Nod factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGOSACCHARIDE NODULATION SIGNALS; INVITRO INSERTIONAL MUTAGENESIS; SYMBIOTIC HOST-SPECIFICITY; GRAM-NEGATIVE BACTERIA; AZORHIZOBIUM-CAULINODANS; STRAIN NGR234; VIGNA-UNGUICULATA; GENES; MELILOTI; PROTEIN	Loci unique to specific rhizobia direct the adjunction of special groups to the core lipo-oligosaccharide Nod factors, Host-Specificity of nodulation (Hsn) genes are thus essential for interaction with certain legumes. Rhizobium sp, NGR234, which can nodulate >110 genera of legumes, possesses three hsn loci and secretes a large family of Nod factors carrying specific substituents. Among them are 3-O (or 4-O)- and 8-O-carbamoyl groups, an N-methyl group, and a 2-O-methylfucose residue which may bear either 3-O-sulfate or 4-O (and 3-O)-acetyl substituents, The hsnIII locus comprises a nod box promoter followed by the genes nodABCIJnoLOnoeI, Complementation and mutation analyses show that the disruption of any one of nodIJ, nolO, or noeI has no effect on nodulation, Conjugation of nolO into Rhizobium fredii extends the host range of the recipient to the non-hosts Calopogonium caeruleum and Lablab purpureus, however. Chemical analyses of the Nod factors produced by the NodI, NolO, and NoeI mutants show that the nolO and noel gene products are required for 3 (or 4)-O-carbamoylation of the nonreducing terminus and for 2-O-methylation of the fucosyl group, respectively. Confirmation that NolO is a carbamoyltransferase was obtained from analysis of the Nod factors produced by R. fredii containing nolO; all are carbamoylated at O-3 (or O-4) on the nonreducing terminus. Since mutation of both nolO and nodU fails to completely abolish production of monocarbamoylated NodNGR factors, it is clear that a third carbamoyltransferase must exist. Nevertheless, the specificities of the two known enzymes are clearly different. NodU is only able to transfer carbamate to O-6 while NolO is specific for O-3 (or O-4) of NodNGR factors.	Univ Geneva, LBMPS, CH-1292 Chambesy, Geneva, Switzerland; Univ Geneva, Dept Chim Organ, CH-1211 Geneva 4, Switzerland; CNRS, Inst Pharmacol & Biol Struct, F-31077 Toulouse, France	University of Geneva; University of Geneva; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Broughton, WJ (corresponding author), Univ Geneva, LBMPS, 1 Ch Imperatrice, CH-1292 Chambesy, Geneva, Switzerland.		Jabbouri, Said/N-6672-2014	Jabbouri, Said/0000-0003-1354-494X				BROUGHTON WJ, 1986, J CELL BIOL, V102, P1173, DOI 10.1083/jcb.102.4.1173; BROUGHTON WJ, 1984, P NATL ACAD SCI-BIOL, V81, P3093, DOI 10.1073/pnas.81.10.3093; Denarie J, 1996, ANNU REV BIOCHEM, V65, P503, DOI 10.1146/annurev.bi.65.070196.002443; EVANS IJ, 1986, GENE, V43, P95, DOI 10.1016/0378-1119(86)90012-0; FELLAY R, 1987, GENE, V52, P147, DOI 10.1016/0378-1119(87)90041-2; FELLAY R, 1995, MOL MICROBIOL, V16, P657, DOI 10.1111/j.1365-2958.1995.tb02428.x; FernandezLopez M, 1996, MOL MICROBIOL, V20, P993, DOI 10.1111/j.1365-2958.1996.tb02540.x; FINAN TM, 1986, J BACTERIOL, V167, P66, DOI 10.1128/jb.167.1.66-72.1986; Freiberg C, 1997, NATURE, V387, P394, DOI 10.1038/387394a0; GEREMIA RA, 1994, P NATL ACAD SCI USA, V91, P2669, DOI 10.1073/pnas.91.7.2669; Hanin M, 1997, MOL MICROBIOL, V24, P1119, DOI 10.1046/j.1365-2958.1997.3981777.x; HANIN M, 1997, PLANT MICROBE INTERA, V2; HERON DS, 1989, MOL PLANT MICROBE IN, V1, P4; ISHHOROWICZ D, 1981, NUCLEIC ACIDS RES, V9, P2989, DOI 10.1093/nar/9.13.2989; JABBOURI S, 1995, J BIOL CHEM, V270, P22968, DOI 10.1074/jbc.270.39.22968; JOHN M, 1993, P NATL ACAD SCI USA, V90, P625, DOI 10.1073/pnas.90.2.625; JONES JDG, 1987, GENE, V61, P299, DOI 10.1016/0378-1119(87)90193-4; KRISHNAN HB, 1992, MOL MICROBIOL, V6, P3321, DOI 10.1111/j.1365-2958.1992.tb02200.x; LEROUGE P, 1990, NATURE, V344, P781, DOI 10.1038/344781a0; LEWIN A, 1987, PLANT MOL BIOL, V8, P447, DOI 10.1007/BF00017990; LEWIN A, 1990, MOL PLANT MICROBE IN, V3, P317, DOI 10.1094/MPMI-3-317; LOPEZLARA IM, 1995, MOL MICROBIOL, V15, P627, DOI 10.1111/j.1365-2958.1995.tb02372.x; LUKA S, 1993, J BIOL CHEM, V268, P27053; MERGAERT P, 1993, P NATL ACAD SCI USA, V90, P1551, DOI 10.1073/pnas.90.4.1551; Mergaert P, 1997, MOL MICROBIOL, V25, P811, DOI 10.1111/j.1365-2958.1997.mmi526.x; MESSING J, 1983, METHOD ENZYMOL, V101, P20; PANKHURST CE, 1983, MOL GENETICS BACTERI, P169; PERRET X, 1994, NUCLEIC ACIDS RES, V22, P1335, DOI 10.1093/nar/22.8.1335; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; PRICE NPJ, 1992, MOL MICROBIOL, V6, P3575, DOI 10.1111/j.1365-2958.1992.tb01793.x; QUANDT J, 1993, GENE, V127, P15, DOI 10.1016/0378-1119(93)90611-6; QuesadaVincens D, 1997, J BACTERIOL, V179, P5087, DOI 10.1128/jb.179.16.5087-5093.1997; RELIC B, 1993, MOL PLANT MICROBE IN, V6, P764, DOI 10.1094/MPMI-6-764; RELIC B, 1994, MOL MICROBIOL, V13, P171, DOI 10.1111/j.1365-2958.1994.tb00412.x; ROCHE P, 1991, CELL, V67, P1131, DOI 10.1016/0092-8674(91)90290-F; ROHRIG H, 1994, P NATL ACAD SCI USA, V91, P3122, DOI 10.1073/pnas.91.8.3122; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schultze M, 1996, CURR OPIN GENET DEV, V6, P631, DOI 10.1016/S0959-437X(96)80094-3; SIMON R, 1985, MOL GEN GENET, V96, P413; SPAINK HP, 1995, J BACTERIOL, V177, P6276, DOI 10.1128/jb.177.21.6276-6281.1995; STANLEY J, 1987, FEMS MICROBIOL LETT, V48, P25	42	47	50	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12047	12055		10.1074/jbc.273.20.12047	http://dx.doi.org/10.1074/jbc.273.20.12047			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575146	hybrid			2022-12-27	WOS:000073629800011
J	Thornton, C; Snowden, MA; Carling, D				Thornton, C; Snowden, MA; Carling, D			Identification of a novel AMP-activated protein kinase beta subunit isoform that is highly expressed in skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SUBUNIT; YEAST SNF1; SUBSTRATE-SPECIFICITY; TISSUE DISTRIBUTION; IN-VITRO; GENE; PURIFICATION; STRESS; DNA	The AMP-activated protein kinase (AMPK) is a member of a growing family of related kinases, including the SNF1 complex in yeast, which respond to nutritional stress. AMPK is a heterotrimeric complex of a catalytic subunit (alpha) and two regulatory subunits (beta and gamma), and proteins related to all three subunits have been identified in the SNF1 complex. We have used the two-hybrid system in order to identify proteins interacting with the catalytic subunit (alpha 2). Using this approach, we have isolated a novel AMPK beta isoform, which we designate AMPK beta 2. The N-terminal region of beta 2 differs significantly from that of the previously characterized isoform (beta 1), suggesting that this region could play a role in isoform-specific AMPK activity. Comparison of the C-terminal sequences of beta 1 and beta 2 with their related proteins in yeast identifies two highly conserved regions predicted to be involved in binding of the alpha and gamma subunits. The expression of beta 1 and beta 2 was examined in a number of tissues, revealing that the beta 1 isoform is highly expressed in liver with low expression in skeletal muscle, whereas the opposite pattern is observed for the beta 2 isoform. These results suggest that the beta isoforms have tissue-specific roles, which may involve altered responses to upstream signaling and/or downstream targeting of the AMPK complex.	Hammersmith Hosp, Imperial Coll, Sch Med, Cellular Stress Grp,MRC,Clin Sci Ctr, London W12 0NN, England; Glaxo Wellcome Res & Dev Ltd, Res Grp, Enzyme Pharmacol Unit, Stevenage SG1 2NY, Herts, England	Imperial College London; GlaxoSmithKline	Carling, D (corresponding author), Hammersmith Hosp, Imperial Coll, Sch Med, Cellular Stress Grp,MRC,Clin Sci Ctr, DuCane Rd, London W12 0NN, England.	dcarling@rpms.ac.uk	Thornton, Claire/AAF-7481-2019; Carling, David/F-1943-2014	Thornton, Claire/0000-0001-7676-3272; Carling, David/0000-0002-2316-1830				CARLING D, 1989, EUR J BIOCHEM, V186, P129, DOI 10.1111/j.1432-1033.1989.tb15186.x; CARLING D, 1994, J BIOL CHEM, V269, P11442; CELENZA JL, 1989, MOL CELL BIOL, V9, P5045, DOI 10.1128/MCB.9.11.5045; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CORTON JM, 1994, CURR BIOL, V4, P315, DOI 10.1016/S0960-9822(00)00070-1; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; DUGGAN MJ, 1990, J BIOL CHEM, V265, P3831; Dyck JRB, 1996, J BIOL CHEM, V271, P17798, DOI 10.1074/jbc.271.30.17798; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Gao G, 1996, J BIOL CHEM, V271, P8675, DOI 10.1074/jbc.271.15.8675; Hardie D. Grahame, 1994, Seminars in Cell Biology, V5, P409, DOI 10.1006/scel.1994.1048; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; HARDIE DG, 1994, CELL SIGNAL, V6, P813; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; Jiang R, 1996, GENE DEV, V10, P3105, DOI 10.1101/gad.10.24.3105; Jiang R, 1997, MOL CELL BIOL, V17, P2099, DOI 10.1128/MCB.17.4.2099; JOHNSON RD, 1994, ANNU REV BIOCHEM, V63, P869; Michell BJ, 1996, J BIOL CHEM, V271, P28445, DOI 10.1074/jbc.271.45.28445; MITCHELHILL KI, 1994, J BIOL CHEM, V269, P2361; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Stapleton D, 1996, J BIOL CHEM, V271, P611, DOI 10.1074/jbc.271.2.611; STAPLETON D, 1994, J BIOL CHEM, V269, P29343; Stapleton D, 1997, FEBS LETT, V409, P452, DOI 10.1016/S0014-5793(97)00569-3; Vavvas D, 1997, J BIOL CHEM, V272, P13255, DOI 10.1074/jbc.272.20.13255; VERHOEVEN AJM, 1995, EUR J BIOCHEM, V228, P236; Woods A, 1996, J BIOL CHEM, V271, P10282, DOI 10.1074/jbc.271.17.10282; Woods A, 1996, FEBS LETT, V397, P347, DOI 10.1016/S0014-5793(96)01209-4; WOODS A, 1994, J BIOL CHEM, V269, P19509; YANG XL, 1994, EMBO J, V13, P5878, DOI 10.1002/j.1460-2075.1994.tb06933.x	31	185	200	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12443	12450		10.1074/jbc.273.20.12443	http://dx.doi.org/10.1074/jbc.273.20.12443			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575201	hybrid			2022-12-27	WOS:000073629800066
J	Swope, MD; Sun, HW; Klockow, B; Blake, P; Lolis, E				Swope, MD; Sun, HW; Klockow, B; Blake, P; Lolis, E			Macrophage migration inhibitory factor interactions with glutathione and S-hexylglutathione	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR MIF; TRANSFERASE HOMOLOGS; PURIFICATION; CYTOKINE; PROTEINS; BINDING	Macrophage migration inhibitory factor (MIF) has been reported to interact with glutathione and S-hexylglutathione and to possess glutathione S-transferase activity. However, contrary to these reports, a recent NMR study concluded that MIF shows no affinity for glutathione. Re-examination of the glutathione-MIF interactions indicates that the reported increase in fluorescence upon addition of glutathione is because of pH-induced unfolding of the protein and not to any direct interactions. Circular dichroism shows that MIF remains folded from pH 4.5-7.5 but is 50% unfolded at pH 2.9 +/- 0.2. The reported increase in fluorescence can be achieved by acid titration. Under strongly buffered conditions, no fluorescence change is observed upon addition of glutathione. In contrast to the results with glutathione, MIF binds S-hexylglutathione with a K-d of 2.5 +/- 0.6 mM. Using NMR spectroscopy, a binding site which clusters around the N-terminal proline was identified. These data indicate that the binding site for S-hexylglutathione is the same as the catalytic site for the dopachrome tautomerase activity of MIF. Consequently, the binding of S-hexylglutathione as well as hexanethiol inhibits this catalytic activity.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA; Bayer Corp, Div Pharmaceut, Inst Chem, W Haven, CT 06516 USA	Yale University; Bayer AG	Lolis, E (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06510 USA.			Lolis, Elias/0000-0002-7902-7868				Bacher M, 1996, P NATL ACAD SCI USA, V93, P7849, DOI 10.1073/pnas.93.15.7849; BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; BERNHAGEN J, 1994, BIOCHEMISTRY-US, V33, P14144, DOI 10.1021/bi00251a025; Bernhagen J, 1996, J EXP MED, V183, P277, DOI 10.1084/jem.183.1.277; BLOCKI FA, 1993, PROTEIN SCI, V2, P2095, DOI 10.1002/pro.5560021210; BLOCKI FA, 1992, NATURE, V360, P269, DOI 10.1038/360269a0; BLOOM BR, 1966, SCIENCE, V153, P80, DOI 10.1126/science.153.3731.80; CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895; CALANDRA T, 1995, NATURE, V377, P68, DOI 10.1038/377068a0; DAVID JR, 1966, P NATL ACAD SCI USA, V56, P72, DOI 10.1073/pnas.56.1.72; Donnelly SC, 1997, NAT MED, V3, P320, DOI 10.1038/nm0397-320; DROGE W, 1994, FASEB J, V8, P1131; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; IRITA K, 1994, CIRC SHOCK, V42, P115; Meinhardt A, 1996, ENDOCRINOLOGY, V137, P5090, DOI 10.1210/en.137.11.5090; Mikulowska A, 1997, J IMMUNOL, V158, P5514; Muhlhahn P, 1996, PROTEIN SCI, V5, P2095; NISHIHIRA J, 1993, BIOCHEM MOL BIOL INT, V31, P841; PEARSON WR, 1994, PROTEIN SCI, V3, P525; RAIMBAULT C, 1995, EUR J BIOCHEM, V234, P570, DOI 10.1111/j.1432-1033.1995.570_b.x; Rosengren E, 1996, MOL MED, V2, P143, DOI 10.1007/BF03402210; Rosengren E, 1997, FEBS LETT, V417, P85, DOI 10.1016/S0014-5793(97)01261-1; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Sun HW, 1996, P NATL ACAD SCI USA, V93, P5191, DOI 10.1073/pnas.93.11.5191; Suzuki H, 1996, IMMUNOL LETT, V51, P141, DOI 10.1016/0165-2478(96)02543-6; SWOPE M, 1998, IN PRESS EMBO J; Waeber G, 1997, P NATL ACAD SCI USA, V94, P4782, DOI 10.1073/pnas.94.9.4782	27	24	24	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14877	14884		10.1074/jbc.273.24.14877	http://dx.doi.org/10.1074/jbc.273.24.14877			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614090	hybrid			2022-12-27	WOS:000074160400032
J	Cheng, HL; Feldman, EL				Cheng, HL; Feldman, EL			Bidirectional regulation of p38 kinase and c-Jun N-terminal protein kinase by insulin-like growth factor-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; CELL-DEATH; MAP KINASE; DIFFERENTIAL ACTIVATION; INFLAMMATORY CYTOKINES; TRANSCRIPTION FACTORS; SYMPATHETIC NEURONS; INDUCED APOPTOSIS; MAMMALIAN-CELLS; JNK ACTIVATION	We have previously shown that insulin-like growth factor I (IGF-I) activation of the IGF-I receptor rescues SH-SY5Y human neuroblastoma cells from high glucose-mediated programmed cell death (PCD). In the current study, we further explored the potential points in the cell death cascade where IGF-I receptor activation may afford neuroprotection. As an initial step, we examined the effects of the PCD stimulus, high glucose, on stress-activated protein kinases, specifically the two mitogen-activated protein kinases p38 kinase and c-Jun N-terminal kinase (JNK). High glucose treatment activated the tyrosine phosphorylation of both p38 kinase and JNK in a dose- and time-dependent fashion. We next examined the effects of IGF-I on JNF and p38 kinase under normoglycemic and hyperglycemic conditions. IGF-I activated p38 kinase alone and had additive effects on glucose-induced p38 kinase phosphorylation. In contrast, IGF-I inhibited glucose activation of JNK phosphorylation and JNK activity. IGF-I also inhibited the glucose-induced nuclear translocation of JNK, but did not effect glucose-induced translocation of p38 kinase. Finally, IGF-I inhibition of JNK phosphorylation was blocked by the mitogen-activated protein kinase/extracellular signal-regulated kinase inhibitor, PD98059, Collectively, these data imply cross-talk between the mitogen-activated protein kinase pathway and JNK and suggest that IGF-I activation of mitogen-activated protein kinases interferes with JNK activation and protects cells from PCD.	Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Feldman, EL (corresponding author), Univ Michigan, Dept Neurol, 200 Zina Pitcher Pl,4414 Kresge III, Ann Arbor, MI 48109 USA.			Feldman, Eva/0000-0002-9162-2694	NINDS NIH HHS [R01 NS36778, R29 NS32843] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS032843, R01NS036778] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; Chauhan D, 1997, ONCOGENE, V15, P837, DOI 10.1038/sj.onc.1201253; Chen D, 1996, J BIOL CHEM, V271, P6328, DOI 10.1074/jbc.271.11.6328; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; Crawley JB, 1997, J BIOL CHEM, V272, P15023, DOI 10.1074/jbc.272.23.15023; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P40; Deacon K, 1997, J BIOL CHEM, V272, P14489, DOI 10.1074/jbc.272.22.14489; DEMEYTS P, 1994, HORM RES, V42, P152, DOI 10.1159/000184188; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FANGER CR, 1997, CURR OPIN GENE DEV, V7, P67; FELDMAN EL, 1993, ANN NY ACAD SCI, V692, P262; Foltz IN, 1997, J BIOL CHEM, V272, P3296, DOI 10.1074/jbc.272.6.3296; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; Gandhi D, 1995, INT CONGR SER, V1084, P183; Geng Y, 1996, J CLIN INVEST, V98, P2425, DOI 10.1172/JCI119056; Graves JD, 1996, P NATL ACAD SCI USA, V93, P13814, DOI 10.1073/pnas.93.24.13814; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Heidenreich KA, 1996, J BIOL CHEM, V271, P9891, DOI 10.1074/jbc.271.17.9891; Herdegen T, 1997, TRENDS NEUROSCI, V20, P227, DOI 10.1016/S0166-2236(96)01000-4; HUOT J, 1995, EUR J BIOCHEM, V227, P416, DOI 10.1111/j.1432-1033.1995.tb20404.x; ISHII DN, 1994, PHARMACOL THERAPEUT, V62, P125, DOI 10.1016/0163-7258(94)90007-8; Jessell TM, 1996, CURR OPIN NEUROBIOL, V6, P1, DOI 10.1016/S0959-4388(96)80001-8; Kim B, 1997, J BIOL CHEM, V272, P21268, DOI 10.1074/jbc.272.34.21268; KOLBE M, 1990, CONNECT TISSUE RES, V25, P77, DOI 10.3109/03008209009009814; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1995, ANN NY ACAD SCI, V766, P303, DOI 10.1111/j.1749-6632.1995.tb26683.x; Landry J, 1995, BIOCHEM CELL BIOL, V73, P703, DOI 10.1139/o95-078; LAVENIUS E, 1994, GROWTH FACTORS, V10, P29, DOI 10.3109/08977199409019601; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Leventhal PS, 1997, TRENDS ENDOCRIN MET, V8, P1, DOI 10.1016/S1043-2760(96)00202-0; Leventhal PS, 1997, J BIOL CHEM, V272, P5214, DOI 10.1074/jbc.272.8.5214; Lim R, 1996, J BIOL CHEM, V271, P22953, DOI 10.1074/jbc.271.38.22953; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MARTIN DM, 1993, REGUL PEPTIDES, V48, P225, DOI 10.1016/0167-0115(93)90351-8; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; Matthews CC, 1997, NEUROSCIENCE, V79, P525, DOI 10.1016/S0306-4522(96)00611-2; MATTHEWS CC, 1996, J CELL PHYSL, V166, P323; McCormick SD, 1996, GEN COMP ENDOCR, V101, P3, DOI 10.1006/gcen.1996.0002; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Molnar A, 1997, J BIOL CHEM, V272, P13229, DOI 10.1074/jbc.272.20.13229; Pyne S, 1996, EUR J BIOCHEM, V237, P819, DOI 10.1111/j.1432-1033.1996.0819p.x; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RUKENSTEIN A, 1991, J NEUROSCI, V11, P2552; RUSSELL JW, 1996, ANN NEUROL, V40, P954; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SARA VR, 1990, PHYSIOL REV, V70, P591, DOI 10.1152/physrev.1990.70.3.591; SARA VR, 1986, P NATL ACAD SCI USA, V83, P4904, DOI 10.1073/pnas.83.13.4904; Singleton JR, 1996, CANCER RES, V56, P4522; Singleton JR, 1996, J BIOL CHEM, V271, P31791, DOI 10.1074/jbc.271.50.31791; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; SULLIVAN KA, 1994, ENDOCRINOLOGY, V135, P540, DOI 10.1210/en.135.2.540; Sutherland CL, 1996, J IMMUNOL, V157, P3381; Syu LJ, 1997, J CELL BIOCHEM, V67, P367, DOI 10.1002/(SICI)1097-4644(19971201)67:3<367::AID-JCB8>3.3.CO;2-N; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Virdee K, 1997, J NEUROCHEM, V69, P550; WAKIEWICZ AJ, 1997, EMBO J, V16, P1909; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; WOODGETT JR, 1995, CLIN EXP PHARMACOL P, V22, P281, DOI 10.1111/j.1440-1681.1995.tb01995.x; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN MH, 1994, NATURE, V372, P798; ZACKENFELS K, 1995, NEURON, V14, P731, DOI 10.1016/0896-6273(95)90217-1	73	98	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14560	14565		10.1074/jbc.273.23.14560	http://dx.doi.org/10.1074/jbc.273.23.14560			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603971	hybrid			2022-12-27	WOS:000074021500073
J	Chu, DM; Francis, SH; Thomas, JW; Maksymovitch, EA; Fosler, M; Corbin, JD				Chu, DM; Francis, SH; Thomas, JW; Maksymovitch, EA; Fosler, M; Corbin, JD			Activation by autophosphorylation or cGMP binding produces a similar apparent conformational change in cGMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE CARDIAC-MUSCLE; REGULATORY SUBUNIT; CYCLIC-AMP; CAMP; PHOSPHORYLATION; DOMAINS; HEART; PURIFICATION; INHIBITION; INCREASES	Binding of cyclic nucleotide to or autophosphorylation of cGMP-dependent protein kinase (PKG) activates this kinase, but the molecular mechanism of activation for either process is unknown. Activation of PKG by cGMP binding produces a conformational change in the enzyme (Chu, D.-M., Corbin, J. D., Grimes, K. A., and Francis, S. H. (1997) J. Biol. Chem. 272, 31922-31928; Zhao, J., Trewhella, J., Corbin, J., Francis, S., Mitchell, R., Brushia, R., and Walsh, D. (1997) J. Biol. Chem. 272, 39129-31936). In the present studies, activation of type Ip PKG by either autophosphorylation or cGMP-binding alone causes (i) an electronegative charge shift on ion exchange chromatography, (ii) a similar increase (similar to 3.5 Pi) in the Stokes radius as determined by gel filtration chromatography, and (iii) a similar decrease in the mobility of the enzyme on native gel electrophoresis. Consistent with these results, cGMP binding increases the rate of phosphoprotein phosphatase-l catalyzed dephosphorylation of PKG which is autophosphorylated only at Ser-63 (not activated); however, dephosphorylation of PKC: that is highly autophosphorylated (activated) is not stimulated by cGMP. The combined results suggest that activation of PKG by either autophosphorylation or cGMP binding alone produces a similar apparent elongation of the enzyme, implying that either process activates the enzyme by a similar molecular mechanism.	Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Vanderbilt University	Corbin, JD (corresponding author), Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, 221 Kirkland Hall, Nashville, TN 37232 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040029] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041269] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40029] Funding Source: Medline; NIGMS NIH HHS [GM41269] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN A, 1984, BIOCHIM BIOPHYS ACTA, V790, P219, DOI 10.1016/0167-4838(84)90025-6; CADENA DL, 1994, J BIOL CHEM, V269, P260; Chu DM, 1997, J BIOL CHEM, V272, P31922, DOI 10.1074/jbc.272.50.31922; COHN EJ, 1943, PROTEINS AMINO ACIDS, P424; COLBRAN RJ, 1989, J BIOL CHEM, V264, P4800; CORBIN JD, 1978, J BIOL CHEM, V253, P3997; CORBIN JD, 1988, METHOD ENZYMOL, V159, P74; ERLICHMAN J, 1974, J BIOL CHEM, V249, P5000; FLOCKHART DA, 1980, J BIOL CHEM, V255, P4435; FRANCIS SH, 1991, METHOD ENZYMOL, V200, P332; Francis SH, 1996, J BIOL CHEM, V271, P20748, DOI 10.1074/jbc.271.34.20748; Francis SH, 1998, METHODS, V14, P81, DOI 10.1006/meth.1997.0567; GAO ZH, 1992, BIOCHEMISTRY-US, V31, P6126, DOI 10.1021/bi00141a024; HOFMANN F, 1985, EUR J BIOCHEM, V147, P361, DOI 10.1111/j.1432-1033.1985.tb08758.x; HOFMANN F, 1983, EUR J BIOCHEM, V130, P599, DOI 10.1111/j.1432-1033.1983.tb07191.x; Johnson LN, 1997, ADV SEC MESS PHOSPH, V31, P11; LANDGRAF W, 1986, EUR J BIOCHEM, V154, P113, DOI 10.1111/j.1432-1033.1986.tb09365.x; Lin K, 1996, SCIENCE, V273, P1539, DOI 10.1126/science.273.5281.1539; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; PoteetSmith CE, 1997, J BIOL CHEM, V272, P379; RANGELALDAO R, 1976, J BIOL CHEM, V251, P3375; RANNELS SR, 1983, METHOD ENZYMOL, V99, P55; Rosen O M, 1975, Adv Cyclic Nucleotide Res, V5, P253; ROSSI S, 1992, CELL SIGNAL, V4, P443, DOI 10.1016/0898-6568(92)90038-A; SCOTT CW, 1985, J BIOL CHEM, V260, P2274; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Smith JA, 1996, J BIOL CHEM, V271, P20756, DOI 10.1074/jbc.271.34.20756; SMITH JA, 1993, MOL CELL BIOCHEM, V128, P51, DOI 10.1007/BF01076757; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; TAKIO K, 1982, P NATL ACAD SCI-BIOL, V79, P2544, DOI 10.1073/pnas.79.8.2544; VEREB G, 1989, INT J BIOCHEM, V21, P1137, DOI 10.1016/0020-711X(89)90056-6; WEBER IT, 1989, BIOCHEMISTRY-US, V28, P6122, DOI 10.1021/bi00440a059; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; WOLFE L, 1989, J BIOL CHEM, V264, P7734; Zhao JK, 1997, J BIOL CHEM, V272, P31929, DOI 10.1074/jbc.272.50.31929	35	44	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14649	14656		10.1074/jbc.273.23.14649	http://dx.doi.org/10.1074/jbc.273.23.14649			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603983	hybrid			2022-12-27	WOS:000074021500085
J	Liang, FQ; Gardner, DC				Liang, FQ; Gardner, DC			Autocrine/paracrine determinants of strain-activated brain natriuretic peptide gene expression in cultured cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEFT-VENTRICULAR HYPERTROPHY; RENIN-ANGIOTENSIN SYSTEM; GROWTH FACTOR-BETA(1) EXPRESSION; MESSENGER-RNA; RAT CARDIOMYOCYTES; CELL HYPERTROPHY; OVERLOAD; ENDOTHELIN-1; RECEPTOR; PROTEIN	The application of mechanical strain leads to activation of human brain natriuretic peptide gene promoter activity, a marker of hypertrophy, in cultured neonatal rat ventricular myocytes. We have used a combination of transient transfection analysis and reverse transcriptase-polymerase chain reaction to examine the role of locally produced factors in contributing to this activation. Conditioned media from strained, but not static, cultures led to a dose-dependent increase in human brain natriuretic peptide gene promoter activity. This increase was completely blocked by losartan or BQ-123, implying a role for angiotensin and endothelin as autocrine/paracrine mediators of the response to strain. Inclusion of the same antagonists in the cultures themselves led to only partial inhibition (similar to 60%), whereas inclusion of exogenous endothelin or angiotensin II resulted in amplification of the strain response. Angiotensin II and endothelin appear to be arrayed in series in the regulatory circuitry; the angiotensin response was blocked by BQ-123, whereas the endothelin response was unaffected by losartan. Mechanical strain was also shown to stimulate expression of the endogenous angiotensinogen, angiotensin-converting enzyme, and endothelin genes in this system. Collectively, these data indicate that locally generated angiotensin II and endothelin, acting in series, play an important autocrine/paracrine role in mediating strain-dependent activation of cardiac-specific gene expression.	Univ Calif San Francisco, Metab Res Unit, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Gardner, DC (corresponding author), Univ Calif San Francisco, Metab Res Unit, San Francisco, CA 94143 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035753] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 35753] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAKER KM, 1990, AM J PHYSIOL, V259, pH324, DOI 10.1152/ajpheart.1990.259.2.H324; BAKER KM, 1992, ANNU REV PHYSIOL, V54, P227, DOI 10.1146/annurev.physiol.54.1.227; BENES AJ, 1985, J CELL SCI, V75, P35; BOER PH, 1994, AM J PHYSIOL-HEART C, V267, pH1630, DOI 10.1152/ajpheart.1994.267.4.H1630; BRUCKSCHLEGEL G, 1995, HYPERTENSION, V25, P250, DOI 10.1161/01.HYP.25.2.250; Clavell AL, 1996, J CLIN INVEST, V97, P1286, DOI 10.1172/JCI118544; DESCHEPPER CF, 1990, HYPERTENSION, V16, P147, DOI 10.1161/01.HYP.16.2.147; DOSTAL DE, 1992, AM J HYPERTENS, V5, P276; EVERETT AD, 1994, HYPERTENSION, V23, P587, DOI 10.1161/01.HYP.23.5.587; FUJISAKI H, 1995, J CLIN INVEST, V96, P1059, DOI 10.1172/JCI118092; Harada M, 1997, CIRCULATION, V96, P3737; HASEGAWA K, 1993, CIRCULATION, V88, P372, DOI 10.1161/01.CIR.88.2.372; ITO H, 1993, J CLIN INVEST, V92, P398, DOI 10.1172/JCI116579; ITO H, 1994, CIRCULATION, V89, P2198, DOI 10.1161/01.CIR.89.5.2198; IWAI N, 1995, CIRCULATION, V92, P2690, DOI 10.1161/01.CIR.92.9.2690; KOMURO I, 1991, J BIOL CHEM, V266, P1265; KOVACICMILIVOJEVIC B, 1992, MOL CELL BIOL, V12, P292, DOI 10.1128/MCB.12.1.292; LaPointe MC, 1996, HYPERTENSION, V27, P715, DOI 10.1161/01.HYP.27.3.715; LEE AA, 1995, J MOL CELL CARDIOL, V27, P2347, DOI 10.1016/S0022-2828(95)91983-X; Lee YA, 1996, P NATL ACAD SCI USA, V93, P11035, DOI 10.1073/pnas.93.20.11035; LIANG F, 1928, J BIOL CHEM, P272; LINZ W, 1989, CLIN EXP HYPERTENS A, V11, P1325, DOI 10.3109/10641968909038172; MUKHERJEE DP, 1993, HYPERTENSION, V21, P142, DOI 10.1161/01.HYP.21.2.142; NAKAGAWA O, 1995, J CLIN INVEST, V96, P1280, DOI 10.1172/JCI118162; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; PAUL M, 1995, HYPERTENSION, V25, P683, DOI 10.1161/01.HYP.25.4.683; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; PFEFFER JM, 1982, P NATL ACAD SCI-BIOL, V79, P3310, DOI 10.1073/pnas.79.10.3310; RAMAN VK, 1995, AM J CARDIOL, V76, pD18, DOI 10.1016/S0002-9149(99)80487-1; ROBERTS AB, 1992, J CLIN INVEST, V90, P2056, DOI 10.1172/JCI116087; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; SADOSHIMA J, 1992, J BIOL CHEM, V267, P10551; Sakai S, 1996, NATURE, V384, P353, DOI 10.1038/384353a0; SCHUNKERT H, 1990, J CLIN INVEST, V86, P1913, DOI 10.1172/JCI114924; SHYU KG, 1995, BIOCHEM BIOPH RES CO, V211, P241, DOI 10.1006/bbrc.1995.1802; TAKAHASHI N, 1994, J CLIN INVEST, V94, P1470, DOI 10.1172/JCI117485; VONLUTTEROTTI N, 1994, CIRCULATION, V89, P458, DOI 10.1161/01.CIR.89.1.458; WEINER HL, 1989, P NATL ACAD SCI USA, V86, P2683, DOI 10.1073/pnas.86.8.2683; Wollert KC, 1996, J BIOL CHEM, V271, P9535, DOI 10.1074/jbc.271.16.9535; WOOZ GW, 1996, HYPERTENSION, V28, P635; Yamazaki T, 1996, J BIOL CHEM, V271, P3221, DOI 10.1074/jbc.271.6.3221; YAMAZAKI T, 1995, CIRC RES, V77, P258, DOI 10.1161/01.RES.77.2.258; YAMAZAKI T, 1995, J CLIN INVEST, V96, P438, DOI 10.1172/JCI118054	43	74	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14612	14619		10.1074/jbc.273.23.14612	http://dx.doi.org/10.1074/jbc.273.23.14612			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603978	hybrid			2022-12-27	WOS:000074021500080
J	Pancholi, V; Fischetti, VA				Pancholi, V; Fischetti, VA			alpha-enolase, a novel strong plasmin(ogen) binding protein on the surface of pathogenic streptococci	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A STREPTOCOCCI; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; PLASMINOGEN-BINDING; CANDIDA-ALBICANS; GLYCOLYTIC ENZYME; SEQUENCE-ANALYSIS; ESCHERICHIA-COLI; RECEPTOR; IDENTIFICATION; CLONING	The plasmin(ogen) binding property of group A streptococci is incriminated in tissue invasion processes. We have characterized a novel 45-kDa protein displaying strong plasmin(ogen) binding activity from the streptococcal surface. Based on its biochemical properties, we confirmed the identity of this protein as cu-enolase, a key glycolytic enzyme. Dose-dependent cy-enolase activity, immune electron microscopy of whole streptococci using specific antibodies, and the opsonic nature of polyclonal and monoclonal antibodies concluded the presence of this protein on the streptococcal surface. We, henceforth, termed the 45-kDa protein, SEN (streptococcal Surface enolase). SEN is found ubiquitously on the surface of most streptococcal groups and serotypes and showed significantly greater plasmin(ogen) binding affinity compared with previously reported streptococcal plasminogen binding proteins. Both the C-terminal lysine residue of SEN and a region N-terminal to it play a critical role in plasminogen binding. Results from competitive plasminogen binding inhibition assays and cross linking studies with intact streptococci indicate that SEN contributes significantly to the overall streptococcal ability to bind plasmin(ogen), Our findings, showing both the protected protease activity of SEN-bound plasmin and SEN-specific immune responses, provide evidence for an important role of SEN in the disease process and post-streptococcal autoimmune diseases.	Rockefeller Univ, Lab Bacterial Pathogenesis & Immunol, New York, NY 10021 USA	Rockefeller University	Pancholi, V (corresponding author), Rockefeller Univ, Lab Bacterial Pathogenesis & Immunol, 1230 York Ave, New York, NY 10021 USA.	panchov@rockvax.rockfeller.edu	Pancholi, Vijay/E-3810-2011		NIAID NIH HHS [AI11822] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI011822, R37AI011822] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALGIERY AG, 1992, BIOCHIM BIOPHYS ACTA, V1159, P134, DOI 10.1016/0167-4838(92)90017-8; Angiolella L, 1996, J INFECT DIS, V173, P684, DOI 10.1093/infdis/173.3.684; BERGE A, 1993, J BIOL CHEM, V268, P25417; BOTTALICO LA, 1993, ARTERIOSCLER THROMB, V13, P264, DOI 10.1161/01.ATV.13.2.264; Boyle MDP, 1997, THROMB HAEMOSTASIS, V77, P1; BROESEKER TA, 1988, MICROB PATHOGENESIS, V5, P19, DOI 10.1016/0882-4010(88)90077-0; Castellino F J, 1976, Methods Enzymol, V45, P244; CHATTOPADHYAY A, 1992, J BIOL CHEM, V267, P12323; CHRISTENSEN LR, 1945, J GEN PHYSIOL, V28, P363, DOI 10.1085/jgp.28.4.363; FISCHETTI VA, 1992, ZBL BAKT S, V22, P165; FISCHETTI VA, 1991, GENETICS MOL BIOL ST, P290; FLUIT AC, 1993, FEBS LETT, V316, P103, DOI 10.1016/0014-5793(93)81745-L; GALFRE G, 1977, NATURE, V266, P550, DOI 10.1038/266550a0; Gase K, 1996, EUR J BIOCHEM, V239, P42, DOI 10.1111/j.1432-1033.1996.0042u.x; HUANG TT, 1989, MOL MICROBIOL, V3, P197, DOI 10.1111/j.1365-2958.1989.tb01808.x; HUNTHER FJ, 1990, INFECT IMMUN, V58, P1043; JANKOVIC BD, 1985, J IMMUNOL, V135, P853; JONES JD, 1997, JAMA-J AM MED ASSOC, V105, P571; KEHOE MA, 1994, BACTERIAL CELL WALL, P217; KOHLER G, 1976, EUR J IMMUNOL, V6, P511, DOI 10.1002/eji.1830060713; LANCEFIELD RC, 1957, J EXP MED, V106, P525, DOI 10.1084/jem.106.4.525; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; LOPEZALEMANY R, 1994, THROMB RES, V75, P371, DOI 10.1016/0049-3848(94)90252-6; LOTTENBERG R, 1987, INFECT IMMUN, V55, P1914, DOI 10.1128/IAI.55.8.1914-1918.1987; LOTTENBERG R, 1992, J BACTERIOL, V174, P5204, DOI 10.1128/JB.174.16.5204-5210.1992; Lottenberg Richard, 1994, Trends in Microbiology, V2, P20, DOI 10.1016/0966-842X(94)90340-9; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; MUESCH A, 1990, TRENDS BIOCHEM SCI, V15, P86, DOI 10.1016/0968-0004(90)90186-F; NAKAJIMA K, 1994, J NEUROCHEM, V63, P2048; Pancholi V, 1997, J EXP MED, V186, P1633, DOI 10.1084/jem.186.10.1633; PANCHOLI V, 1993, P NATL ACAD SCI USA, V90, P8154, DOI 10.1073/pnas.90.17.8154; PANCHOLI V, 1989, J EXP MED, V170, P2119, DOI 10.1084/jem.170.6.2119; PANCHOLI V, 1988, J BACTERIOL, V170, P2618, DOI 10.1128/jb.170.6.2618-2624.1988; PANCHOLI V, 1992, J EXP MED, V176, P415, DOI 10.1084/jem.176.2.415; Peterson P, 1996, CLIN DIAGN LAB IMMUN, V3, P290, DOI 10.1128/CDLI.3.3.290-294.1996; PLOW EF, 1991, THROMB HAEMOSTASIS, V66, P32; PLOW EF, 1995, FASEB J, V9, P939, DOI 10.1096/fasebj.9.10.7615163; RATTNER JB, 1991, J IMMUNOL, V146, P2341; REDLITZ A, 1995, EUR J BIOCHEM, V227, P407, DOI 10.1111/j.1432-1033.1995.tb20403.x; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Sirover MA, 1996, LIFE SCI, V58, P2271, DOI 10.1016/0024-3205(96)00123-3; SPRING TG, 1971, J BIOL CHEM, V246, P6797; SUNDSTROM P, 1992, J BACTERIOL, V174, P6789, DOI 10.1128/JB.174.21.6789-6799.1992; SUNDSTROM P, 1994, J INFECT DIS, V169, P452, DOI 10.1093/infdis/169.2.452; TAKEI N, 1991, J NEUROCHEM, V57, P1178, DOI 10.1111/j.1471-4159.1991.tb08277.x; Tillett WS, 1933, J EXP MED, V58, P485, DOI 10.1084/jem.58.4.485; ULLBERG M, 1992, APMIS, V100, P21, DOI 10.1111/j.1699-0463.1992.tb00835.x; WALSH TJ, 1991, NEW ENGL J MED, V324, P1026, DOI 10.1056/NEJM199104113241504; WILLIAMS LA, 1985, EXP EYE RES, V40, P741, DOI 10.1016/0014-4835(85)90143-5; WIMAN B, 1981, METHOD ENZYMOL, V80, P395; Winram SB, 1995, DEV BIOL STAND, V85, P199; Winram SB, 1996, MICROBIOL-SGM, V142, P2311, DOI 10.1099/13500872-142-8-2311; WOLD F, 1957, J BIOL CHEM, V227, P301; Wold F., 1971, ENZYMES, P499	56	448	458	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14503	14515		10.1074/jbc.273.23.14503	http://dx.doi.org/10.1074/jbc.273.23.14503			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603964	hybrid			2022-12-27	WOS:000074021500066
J	Alconada, A; Bauer, U; Baudoux, L; Piette, J; Hoflack, B				Alconada, A; Bauer, U; Baudoux, L; Piette, J; Hoflack, B			Intracellular transport of the glycoproteins gE and gI of the varicella-zoster virus - gE accelerates the maturation of gI and determines its accumulation in the trans-Golgi network	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPES-SIMPLEX VIRUS; II PHOSPHORYLATION SITE; RAT VISUAL-SYSTEM; E DELETION MUTANT; SO-BENIGN VIRUS; CYTOPLASMIC DOMAIN; PSEUDORABIES VIRUS; BOVINE HERPESVIRUS-1; MANNOSE 6-PHOSPHATE; CELL-SURFACE	The varicella-zoster virus (VZV) is the etiological agent of two different human pathologies, chickenpox (varicella) and shingles (zoster), This alphaherpesvirus is believed to acquire its lipidic envelope in the trans-Golgi network (TGN), This is consistent with previous data showing that the most abundant VZV envelope glycoprotein gE accumulates at steady-state in this organelle when expressed from cloned cDNA. In the present study, we have investigated the intracellular trafficking of gI, another VZV envelope glycoprotein. In transfected cells, this protein shows a very slow biosynthetic transport to the cell surface where it accumulates. However, upon co-expression of gE, gI experiences a dramatic increase in its exit rate from the endoplasmic reticulum, it accumulates in a sialyltransferase-positive compartment, presumably the TGN, and cycles between this compartment and the cell surface. This differential behavior results from the ability of gE and gI to form a complex in the early stages of the biosynthetic pathway whose intracellular traffic is exclusively determined by the sorting information in the tail of gE, Thus, gI provides the first example of a molecule localized to the TGN by means of its association with another TGN protein. We also show that, during the early stages of VZV infection, both proteins are also found in the TGN of the host cell. This suggests the existence of an intermediate stage during VZV biogenesis in which the envelope glycoproteins, transiently arrested in the TGN, could promote the envelopment of newly synthesized nucleocapsids into this compartment and, therefore, the assembly of infective viruses.	Inst Pasteur, IFR3, Inst Biol, F-59021 Lille, France; Univ Liege, Inst Pathol, Lab Fundamental Virol, B-4000 Liege, Belgium	Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; University of Liege	Hoflack, B (corresponding author), Inst Pasteur, IFR3, Inst Biol, 1 Rue Prof Calmette, F-59021 Lille, France.	Bernard.Hoflack@pasteur-lille.fr	HOFLACK, Bernard/AAZ-6668-2020					Alconada A, 1996, EMBO J, V15, P6096, DOI 10.1002/j.1460-2075.1996.tb00998.x; BOS K, 1993, EMBO J, V12, P2219, DOI 10.1002/j.1460-2075.1993.tb05870.x; CARD JP, 1991, NEURON, V6, P957, DOI 10.1016/0896-6273(91)90236-S; CARD JP, 1992, J VIROL, V66, P3032, DOI 10.1128/JVI.66.5.3032-3041.1992; CHEN HJ, 1993, J BIOL CHEM, V268, P22338; CHEN SY, 1991, VIROLOGY, V183, P351, DOI 10.1016/0042-6822(91)90148-5; COOK ML, 1968, J VIROL, V2, P1458, DOI 10.1128/JVI.2.12.1458-1464.1968; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; DAVISON AJ, 1986, J VIROL, V57, P1195, DOI 10.1128/JVI.57.3.1195-1197.1986; Defechereux P, 1996, J GEN VIROL, V77, P1505, DOI 10.1099/0022-1317-77-7-1505; DEMIJNES JDF, 1996, J VIROL, V70, P5466; DEMIJNES JDF, 1997, J VIROL, V71, P8397; DINGWELL KS, 1994, J VIROL, V68, P834, DOI 10.1128/JVI.68.2.834-845.1994; DINGWELL KS, 1995, J VIROL, V69, P7087, DOI 10.1128/JVI.69.11.7087-7098.1995; EDSON CM, 1987, VIROLOGY, V161, P599, DOI 10.1016/0042-6822(87)90157-7; ENQUIST LW, 1994, J VIROL, V68, P5275, DOI 10.1128/JVI.68.8.5275-5279.1994; GABEL CA, 1989, J VIROL, V63, P4264, DOI 10.1128/JVI.63.10.4264-4276.1989; GERSHON A, 1973, J GEN VIROL, V18, P21, DOI 10.1099/0022-1317-18-1-21; GERSHON AA, 1994, J VIROL, V68, P6372, DOI 10.1128/JVI.68.10.6372-6390.1994; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; Harlow E., 1988, ANTIBODIES LAB MANUA; HOBMAN TC, 1995, MOL BIOL CELL, V6, P7, DOI 10.1091/mbc.6.1.7; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; JOHNSON DC, 1987, J VIROL, V61, P2208, DOI 10.1128/JVI.61.7.2208-2216.1987; JOHNSON DC, 1988, J VIROL, V62, P1347, DOI 10.1128/JVI.62.4.1347-1354.1988; JONES BG, 1995, EMBO J, V14, P5869, DOI 10.1002/j.1460-2075.1995.tb00275.x; JONES F, 1988, J VIROL, V62, P2701, DOI 10.1128/JVI.62.8.2701-2711.1988; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LITWIN V, 1992, J VIROL, V66, P3643, DOI 10.1128/JVI.66.6.3643-3651.1992; Mallory S, 1997, J VIROL, V71, P8279, DOI 10.1128/JVI.71.11.8279-8288.1997; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; MATSUOKA Y, 1991, CURR TOP MICROBIOL, V169, P161; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; MELIN L, 1995, VIRUS RES, V36, P49, DOI 10.1016/0168-1702(95)00006-C; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; METTENLEITER TC, 1987, J VIROL, V61, P2764, DOI 10.1128/JVI.61.9.2764-2769.1987; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; MONTALVO EA, 1985, J VIROL, V53, P761, DOI 10.1128/JVI.53.3.761-770.1985; MULDER WAM, 1994, J GEN VIROL, V75, P3095, DOI 10.1099/0022-1317-75-11-3095; NEIDHARDT H, 1987, J VIROL, V61, P600, DOI 10.1128/JVI.61.2.600-603.1987; PONNAMBALAM S, 1994, J CELL BIOL, V125, P253, DOI 10.1083/jcb.125.2.253; RABOUILLE C, 1995, J CELL SCI, V108, P1617; RAMBOURG A, 1990, EUR J CELL BIOL, V51, P189; REAVES B, 1994, FEBS LETT, V351, P448, DOI 10.1016/0014-5793(94)00813-2; RONNHOLM R, 1992, J VIROL, V66, P4525; SCHAFER W, 1995, EMBO J, V14, P2424, DOI 10.1002/j.1460-2075.1995.tb07240.x; Silberstein S, 1996, FASEB J, V10, P849, DOI 10.1096/fasebj.10.8.8666161; TAKAHASHI S, 1995, J BIOL CHEM, V270, P28397; VAFAI A, 1989, VIRUS RES, V13, P319, DOI 10.1016/0168-1702(89)90077-4; VAFAI A, 1988, J VIROL, V62, P2544, DOI 10.1128/JVI.62.8.2544-2551.1988; VANENGELENBURG FAC, 1994, J GEN VIROL, V75, P2311, DOI 10.1099/0022-1317-75-9-2311; VANENGELENBURG FAC, 1995, J GEN VIROL, V76, P2387, DOI 10.1099/0022-1317-76-9-2387; VOORHEES P, 1995, EMBO J, V14, P4961, DOI 10.1002/j.1460-2075.1995.tb00179.x; WELLER TH, 1983, NEW ENGL J MED, V309, P1362, DOI 10.1056/NEJM198312013092205; WHEALY ME, 1993, J VIROL, V67, P3786, DOI 10.1128/JVI.67.7.3786-3797.1993; Whitbeck JC, 1996, J VIROL, V70, P7878, DOI 10.1128/JVI.70.11.7878-7884.1996; WONG SH, 1993, J BIOL CHEM, V268, P22853; YAO ZB, 1993, J VIROL, V67, P305, DOI 10.1128/JVI.67.1.305-314.1993; Zhu Z, 1995, NEUROLOGY, V45, pS15, DOI 10.1212/WNL.45.12_Suppl_8.S15; Zhu ZL, 1996, J VIROL, V70, P6563, DOI 10.1128/JVI.70.10.6563-6575.1996; ZHU ZL, 1995, J VIROL, V69, P7951, DOI 10.1128/JVI.69.12.7951-7959.1995; ZHU ZL, 1995, P NATL ACAD SCI USA, V92, P3546, DOI 10.1073/pnas.92.8.3546; ZSAK L, 1992, J VIROL, V66, P2316, DOI 10.1128/JVI.66.4.2316-2325.1992; ZUCKERMANN FA, 1988, J VIROL, V62, P4622, DOI 10.1128/JVI.62.12.4622-4626.1988	66	38	39	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13430	13436		10.1074/jbc.273.22.13430	http://dx.doi.org/10.1074/jbc.273.22.13430			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593675	hybrid			2022-12-27	WOS:000073919100014
J	Schmidt, G; Selzer, J; Lerm, M; Aktories, K				Schmidt, G; Selzer, J; Lerm, M; Aktories, K			The Rho-deamidating cytotoxic necrotizing factor 1 from Escherichia coli possesses transglutaminase activity - Cysteine 866 and histidine 881 are essential for enzyme activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKING ENZYMES; ADP-RIBOSYLTRANSFERASE; DERMONECROTIC TOXIN; FACTOR-XIII; PROTEINS; ACTIN; PURIFICATION; BORDETELLA; INDUCTION; TISSUES	Recently, it has been reported that cytotoxic necrotizing factor 1 (CNF1) from Escherichia coli induces formation of stress fibers by deamidation of glutamine 63 of RhoA (Schmidt, G., Sehr, P., Wilm, M., Selzer, J., Mann, M., and Aktories, K. (1997) Nature 387, 725-729); Flatau, G., Lemichez, E., Gauthier, M., Chardin, P., Paris, S., Fiorentini, C., and Boquet, P. (1997) Nature 387, 729-733), By using mass spectrometric analysis, we show now that the toxin transfers ethylenediamine, putrescine, and dansylcadaverine specifically onto glutamine 63 of RhoA. RhoA was also a substrate for guinea pig liver transglutaminase, which modified not only glutamine 63, but also glutamine residues at positions 52 and 136. Treatment of the fully active N-terminal fragment of CNF1 (amino acid residues 709-1014) with iodoacetamide inhibited both deamidation and transglutamination activities, Moreover, exchange of cysteine 866 with serine blocked the enzyme activity of the N-terminal CNF1 fragment. In addition, we identified histidine 881 to be essential for the enzyme activity of CNF1. The data indicate that CNF1 shares a catalytic dyad of cysteine and histidine residues with eukaryotic transglutaminases and cysteine proteases.	Univ Freiburg, Inst Pharmakol & Toxikol, D-79104 Freiburg, Germany	University of Freiburg	Aktories, K (corresponding author), Univ Freiburg, Inst Pharmakol & Toxikol, Hermann Herder Str 5, D-79104 Freiburg, Germany.		Lerm, Maria/AAA-1780-2020; Lerm, Maria/AAM-8705-2020; Aktories, Klaus/CAJ-5682-2022	Lerm, Maria/0000-0002-5092-9892; Aktories, Klaus/0000-0002-5397-0436				AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; AKTORIES K, 1995, TRENDS CELL BIOL, V5, P441, DOI 10.1016/S0962-8924(00)89107-2; AKTORIES K, 1992, CURR TOP MICROBIOL, V175, P115; AKTORIES K, 1993, GTPASES BIOL, V1, P87; Babe LM, 1997, CELL, V91, P427, DOI 10.1016/S0092-8674(00)80426-2; FALZANO L, 1993, MOL MICROBIOL, V9, P1247, DOI 10.1111/j.1365-2958.1993.tb01254.x; FIORENTINI C, 1995, INFECT IMMUN, V63, P3936, DOI 10.1128/IAI.63.10.3936-3944.1995; Fischer D, 1996, PROTEIN SCI, V5, P947; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HETTASCH JM, 1994, J BIOL CHEM, V269, P28309; Horiguchi Y, 1997, P NATL ACAD SCI USA, V94, P11623, DOI 10.1073/pnas.94.21.11623; JUST I, 1992, J BIOL CHEM, V267, P10274; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; Lemichez E, 1997, MOL MICROBIOL, V24, P1061, DOI 10.1046/j.1365-2958.1997.4151781.x; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; NOBES C, 1994, CURR OPIN GENET DEV, V4, P77, DOI 10.1016/0959-437X(94)90094-9; OSWALD E, 1994, P NATL ACAD SCI USA, V91, P3814, DOI 10.1073/pnas.91.9.3814; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PEDERSEN LC, 1994, PROTEIN SCI, V3, P1131, DOI 10.1002/pro.5560030720; Pullinger GD, 1996, INFECT IMMUN, V64, P4163, DOI 10.1128/IAI.64.10.4163-4171.1996; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; Turk B, 1997, BIOL CHEM, V378, P141; WALKER KE, 1994, INFECT IMMUN, V62, P3817, DOI 10.1128/IAI.62.9.3817-3828.1994; Wei YY, 1997, NAT STRUCT BIOL, V4, P699, DOI 10.1038/nsb0997-699; YEE VC, 1994, P NATL ACAD SCI USA, V91, P7296, DOI 10.1073/pnas.91.15.7296	30	135	141	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13669	13674		10.1074/jbc.273.22.13669	http://dx.doi.org/10.1074/jbc.273.22.13669			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593707	hybrid			2022-12-27	WOS:000073919100046
J	Allard, JD; Herbst, R; Carroll, PM; Simon, MA				Allard, JD; Herbst, R; Carroll, PM; Simon, MA			Mutational analysis of the SRC homology 2 domain protein-tyrosine phosphatase corkscrew	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR-BETA; PHOSPHOTYROSINE PHOSPHATASE; SIGNAL-TRANSDUCTION; SH2 DOMAINS; SEVENLESS; SH-PTP2; DROSOPHILA; ACTIVATION; KINASE; RAS1	The SRC homology 2 (SH2) domain protein-tyrosine phosphatase, Corkscrew (CSW) is required for signaling by receptor tyrosine kinases, including the Sevenless receptor tyrosine kinase (SEV), which directs Drosophila R7 photoreceptor cell development, To investigate the role of the different domains of CSW, we constructed domain-specific csw mutations and assayed their effects on CSW function. Our results indicate that CSW SH2 domain function is essential, but either CSW SH2 domain can fulfill this requirement. We also found that CSW and activated SEV are associated in vivo in a manner that does not require either CSW SH2 domain function or tyrosine phosphorylation of SEV, In contrast, the interaction between CSW and Daughter of Sevenless, a CSW substrate, is dependent on SH2 domain function, These results suggest that the role of the CSW SH2 domains during SEV signaling is to bind Daughter of Sevenless rather than activated SEV, We also found that although CSW protein-tyrosine phosphatase activity is required for full CSW function, a catalytically inactive CSW is capable of providing partial function, In addition, we found that deletion of either the CSW protein-tyrosine phosphatase insert or the entire CSW carboxyl terminus, which includes a conserved DRK/GRB2 SH2 domain binding sequence, does not abolish CSW function.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	Stanford University	Simon, MA (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.	msimon@leland.stanford.edu			NATIONAL EYE INSTITUTE [R01EY009845] Funding Source: NIH RePORTER; NEI NIH HHS [1RO1EY9845] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Allard JD, 1996, DEVELOPMENT, V122, P1137; BASLER K, 1989, EMBO J, V8, P2381, DOI 10.1002/j.1460-2075.1989.tb08367.x; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; Cleghon V, 1996, GENE DEV, V10, P566, DOI 10.1101/gad.10.5.566; DECHERT U, 1994, J BIOL CHEM, V269, P5602; DECHERT U, 1995, EUR J BIOCHEM, V231, P673, DOI 10.1111/j.1432-1033.1995.0673d.x; Denu JM, 1996, CELL, V87, P361, DOI 10.1016/S0092-8674(00)81356-2; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; HAFEN E, 1993, DEVELOPMENT, P41; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; O'Reilly AM, 1998, MOL CELL BIOL, V18, P161, DOI 10.1128/MCB.18.1.161; Pei DH, 1996, P NATL ACAD SCI USA, V93, P1141, DOI 10.1073/pnas.93.3.1141; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; Perkins LA, 1996, DEV BIOL, V180, P63, DOI 10.1006/dbio.1996.0285; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; Pregel MJ, 1995, PROTEIN ENG, V8, P1309, DOI 10.1093/protein/8.12.1309; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; SCHAFFHAUSEN B, 1995, BBA-REV CANCER, V1242, P61, DOI 10.1016/0304-419X(95)00004-Y; SIMON MA, 1994, DEV BIOL, V166, P431, DOI 10.1006/dbio.1994.1327; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; Streuli M, 1996, CURR OPIN CELL BIOL, V8, P182, DOI 10.1016/S0955-0674(96)80064-0; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	34	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					13129	13135		10.1074/jbc.273.21.13129	http://dx.doi.org/10.1074/jbc.273.21.13129			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582352	hybrid			2022-12-27	WOS:000073768500063
J	Corydon, TJ; Bross, P; Jensen, TG; Corydon, MJ; Lund, TB; Jensen, UB; Kim, JJP; Gregersen, N; Bolund, L				Corydon, TJ; Bross, P; Jensen, TG; Corydon, MJ; Lund, TB; Jensen, UB; Kim, JJP; Gregersen, N; Bolund, L			Rapid degradation of short-chain acyl-CoA dehydrogenase variants with temperature-sensitive folding defects occurs after import into mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A DEHYDROGENASE; MOLECULAR HETEROGENEITY; BETA-OXIDATION; MCAD GENE; DEFICIENCY; MUTATION; FIBROBLASTS; PROTEIN; STABILITY; BACTERIAL	Most disease causing missense mutations in short-chain acyl-CoA dehydrogenase (SCAD) and medium-chain acyl-CoA dehydrogenase are thought to compromise the mitochondrial folding and/or stability of the mutant proteins. To address this question, me studied the biogenesis of SCAD proteins in COS-7 cells transfected with cDNA corresponding to two SCAD missense mutations, R22W (identified in a patient with SCAD deficiency) or R22C (homologous to a disease-associated R28C mutation in medium-chain acyl-CoA dehydrogenase deficiency). After cultivation at 37 degrees C the steady-state amounts of SCAD antigen and activity in extracts from cells transfected with mutant SCAD cDNAs were negligible compared with those of cells transfected with SCAD wild type cDNA, documenting the deleterious effect of the two mutations. Analysis of metabolically labeled and immunoprecipitated SCAD wild type and mutant proteins showed that the two mutant proteins were synthesized as the 44-kDa precursor form, imported into mitochondria and processed to the mature 41.7-kDa form in a normal fashion. However, the intramitochondrial level of matured mutant SCAD proteins decreased rapidly to very low levels, indicating a rapid degradation of the mutant proteins at 37 degrees C, A rapid initial elimination phase was also observed following cultivation at 26 degrees C; however, significantly higher amounts of metabolically labeled and immunoprecipitated mature mutant SCAD proteins remained detectable. This corresponds well with the appreciable steady-state levels of SCAD mutant enzyme activity observed at 26 degrees C, In addition, confocal laser scanning microscopy of immunostained cells showed that the SCAD mutant proteins were localized intramitochondrially. Together, these results show that newly synthesized SCAD R22W and R22C mutant proteins are imported and processed in the mitochondrial matrix, but that a fraction of the proteins is rapidly eliminated by a temperature-dependent degradation mechanism. Thermal stability profiles of wild type and mutant enzymes revealed no difference between the two mutants and the wild type protein. Furthermore, the turnover of the SCAD mutant enzymes in intact cells was comparable to that of the wild type, indicating that the rapid degradation of the mutant SCAD proteins is not due to lability of the correctly folded tetrameric structure but rather to elimination of partly folded or misfolded proteins along the folding pathway.	Aarhus Univ, Inst Human Genet, DK-8000 Aarhus C, Denmark; Aarhus Univ Hosp, Res Unit Mol Med, DK-8200 Aarhus, Denmark; Skejby Sygehus, Fac Hlth Sci, DK-8200 Aarhus N, Denmark; Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	Aarhus University; Aarhus University; Aarhus University; Medical College of Wisconsin	Corydon, TJ (corresponding author), Aarhus Univ, Inst Human Genet, Wilhelm Meyers Alle, DK-8000 Aarhus C, Denmark.		Bross, Peter/B-7219-2013; Jensen, Uffe Birk/E-6066-2017; Jensen, Uffe Birk/ABA-8306-2021	Bross, Peter/0000-0001-9526-8525; Jensen, Uffe Birk/0000-0002-6205-6355; Jensen, Uffe Birk/0000-0002-6205-6355; Corydon, Thomas Juhl/0000-0003-3588-6350				ANDRESEN BS, 1993, AM J HUM GENET, V53, P730; Andresen BS, 1997, HUM MOL GENET, V6, P695, DOI 10.1093/hmg/6.5.695; Andresen BS, 1996, J INHERIT METAB DIS, V19, P169, DOI 10.1007/BF01799421; Beinert H., 1963, ENZYMES, P447; BRACKETT JC, 1994, J CLIN INVEST, V94, P1477, DOI 10.1172/JCI117486; BROSS P, 1995, J BIOL CHEM, V270, P10284, DOI 10.1074/jbc.270.17.10284; BROSS P, 1993, BIOCHIM BIOPHYS ACTA, V1182, P264, DOI 10.1016/0925-4439(93)90068-C; COATES PM, 1992, PEDIATR RES, V31, P34, DOI 10.1203/00006450-199201000-00006; COOPER GM, 1982, SCIENCE, V217, P801, DOI 10.1126/science.6285471; Corydon MJ, 1997, MAMM GENOME, V8, P922, DOI 10.1007/s003359900612; Corydon MJ, 1996, PEDIATR RES, V39, P1059, DOI 10.1203/00006450-199606000-00021; Corydon TJ, 1998, BIOCHEM J, V331, P309, DOI 10.1042/bj3310309; DJORDJEVIC S, 1995, BIOCHEMISTRY-US, V34, P2163, DOI 10.1021/bi00007a009; Eaton S, 1996, BIOCHEM J, V320, P345, DOI 10.1042/bj3200345; Fenton WA, 1997, PROTEIN SCI, V6, P743; FENTON WA, 1987, P NATL ACAD SCI USA, V84, P1421, DOI 10.1073/pnas.84.5.1421; GORDON CL, 1994, GENETICS, V136, P427; Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Gregersen N, 1998, HUM MOL GENET, V7, P619, DOI 10.1093/hmg/7.4.619; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; IKEDA Y, 1985, P NATL ACAD SCI USA, V82, P7081, DOI 10.1073/pnas.82.20.7081; IKEDA Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P662, DOI 10.1016/0003-9861(87)90072-5; IKEDA Y, 1985, J BIOL CHEM, V260, P1311; JENSEN TG, 1992, BIOCHIM BIOPHYS ACTA, V1180, P65, DOI 10.1016/0925-4439(92)90028-L; JENSEN TG, 1995, HUM MUTAT, V6, P226, DOI 10.1002/humu.1380060305; KIM JJP, 1993, FLAVINS FLAVOPOROTEI, P273; KRISTENSEN MJ, 1994, HUM MOL GENET, V3, P1711, DOI 10.1093/hmg/3.9.1711-a; KRISTENSEN TJ, 1996, MOL CHAPERONES HEAT; Kunau WH, 1995, PROG LIPID RES, V34, P267, DOI 10.1016/0163-7827(95)00011-9; Langer T, 1996, EXPERIENTIA, V52, P1069, DOI 10.1007/BF01952104; LEHMAN TC, 1990, ANAL BIOCHEM, V186, P280, DOI 10.1016/0003-2697(90)90080-S; MITRAKI A, 1993, J BIOL CHEM, V268, P20071; NAITO E, 1990, J CLIN INVEST, V85, P1575, DOI 10.1172/JCI114607; NAITO E, 1989, J CLIN INVEST, V83, P1605, DOI 10.1172/JCI114058; NAITO E, 1989, J CLIN INVEST, V84, P1671, DOI 10.1172/JCI114346; SAIJO T, 1994, J BIOL CHEM, V269, P4401; Tanaka K., 1992, Human Mutation, V1, P271, DOI 10.1002/humu.1380010402; THORPE C, 1995, FASEB J, V9, P718, DOI 10.1096/fasebj.9.9.7601336	39	49	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					13065	13071		10.1074/jbc.273.21.13065	http://dx.doi.org/10.1074/jbc.273.21.13065			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582344	hybrid			2022-12-27	WOS:000073768500055
J	Donovan, FM; Cunningham, DD				Donovan, FM; Cunningham, DD			Signaling pathways involved in thrombin-induced cell protection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASES; RECEPTOR MESSENGER-RNA; NERVOUS-SYSTEM INJURY; HUMAN PLATELETS; GROWTH-FACTOR; CYTOSKELETAL REORGANIZATION; ALZHEIMERS-DISEASE; NEURITE OUTGROWTH; RAT ASTROBLASTS; PERTUSSIS TOXIN	This study examined the signal transduction pathways involved in thrombin-induced neuroprotection and compares these results with those of a similar study of thrombin-induced neuronal death. In thrombin-induced protection of astrocytes from hypoglycemia, pretreatment of astrocytes with tyrosine or serine/threonine kinase inhibitors, cytochalasin D, or exoenzyme C3, a potent inhibitor of the small GTPase RhoA, attenuated thrombin-induced protection. These same inhibitors were previously shown to block thrombin-induced cell death, implying a similarity in the cell death and cell-protective pathways. Biochemical assays determined that thrombin increased available RhoA activity, although more slowly and to a lesser extent than occurs in thrombin-induced cell death. A clear difference in these pathways was revealed when a time course study of thrombin-induced cell death indicated that unlike thrombin-induced protection, cells must be exposed to thrombin for >16 h to irreversibly enter the cell death pathway. Addition of lower doses of thrombin every 24 h also induced cell death. These studies indicate that exposure of cells to micromolar concentrations of thrombin alone does not induce cell death, but the continued exposure to thrombin is required. Thus the cell death and protective pathways may share initial signaling proteins, but differences in the amplitude as well as the duration of the signal may result in different final pathways.	Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92717 USA	University of California System; University of California Irvine	Cunningham, DD (corresponding author), Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92717 USA.	ddcunnin@uci.edu			NATIONAL INSTITUTE ON AGING [P01AG000538] Funding Source: NIH RePORTER; NIA NIH HHS [AG00096, AG00538] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AKIYAMA H, 1992, NEUROSCI LETT, V146, P152, DOI 10.1016/0304-3940(92)90065-F; Banno Y, 1996, J BIOL CHEM, V271, P14989, DOI 10.1074/jbc.271.25.14989; BRASS LF, 1994, J BIOL CHEM, V269, P2943; BRASS LF, 1994, SEMIN HEMATOL, V31, P251; Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604; CAVANAUGH KP, 1990, J NEUROCHEM, V54, P1735, DOI 10.1111/j.1471-4159.1990.tb01228.x; Chopp M, 1996, STROKE, V27, P363, DOI 10.1161/01.STR.27.3.363; COTMAN CW, 1995, MOL NEUROBIOL, V10, P19, DOI 10.1007/BF02740836; COUGHLIN SR, 1992, J CLIN INVEST, V89, P351, DOI 10.1172/JCI115592; Donovan FM, 1997, J NEUROSCI, V17, P5316; EHRENREICH H, 1993, BRAIN RES, V600, P201, DOI 10.1016/0006-8993(93)91374-2; EZUMI Y, 1995, J BIOL CHEM, V270, P11927, DOI 10.1074/jbc.270.20.11927; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GRABHAM P, 1995, J NEUROCHEM, V64, P583; Grand RJA, 1996, BIOCHEM J, V313, P353, DOI 10.1042/bj3130353; GRAND RJA, 1989, EMBO J, V8, P2209, DOI 10.1002/j.1460-2075.1989.tb08344.x; GURWITZ D, 1988, P NATL ACAD SCI USA, V85, P3440, DOI 10.1073/pnas.85.10.3440; GURWITZ D, 1990, J CELL PHYSIOL, V142, P155, DOI 10.1002/jcp.1041420119; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; HUANG CL, 1989, J BIOL CHEM, V264, P4391; ISHII K, 1993, J BIOL CHEM, V268, P9780; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; LI RY, 1994, CELL MOL BIOL, V40, P665; LORET C, 1989, J BIOL CHEM, V264, P8319; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MCGEER PL, 1994, TOHOKU J EXP MED, V174, P269, DOI 10.1620/tjem.174.269; NARUMIYA S, 1993, CELL SIGNAL, V5, P9, DOI 10.1016/0898-6568(93)90003-5; NELSON RB, 1990, DEV BRAIN RES, V54, P93, DOI 10.1016/0165-3806(90)90069-B; NEVEU I, 1993, J NEUROCHEM, V60, P858, DOI 10.1111/j.1471-4159.1993.tb03230.x; NICLOU S, 1994, CELL MOL BIOL, V40, P421; NISHINO A, 1993, J NEUROTRAUM, V10, P167, DOI 10.1089/neu.1993.10.167; Olsson Y, 1996, ACTA NEUROL SCAND, V94, P31, DOI 10.1111/j.1600-0404.1996.tb00370.x; PARIS S, 1986, EMBO J, V5, P55, DOI 10.1002/j.1460-2075.1986.tb04177.x; PERRAUD F, 1987, INT J DEV NEUROSCI, V5, P181, DOI 10.1016/0736-5748(87)90028-1; Pike CJ, 1996, J NEUROCHEM, V66, P1374; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SHUMAN MA, 1986, ANN NY ACAD SCI, V485, P228, DOI 10.1111/j.1749-6632.1986.tb34585.x; SMITHSWINTOSKY VL, 1995, J NEUROSCI, V15, P5840; SOIFER SJ, 1994, AM J PATHOL, V144, P60; VAUGHAN PJ, 1995, J NEUROSCI, V15, P5389; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Wallin A, 1993, J Geriatr Psychiatry Neurol, V6, P177; WEINSTEIN JR, 1995, J NEUROSCI, V15, P2906; WOOLKALIS MJ, 1995, J BIOL CHEM, V270, P9868, DOI 10.1074/jbc.270.17.9868	48	114	117	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					12746	12752		10.1074/jbc.273.21.12746	http://dx.doi.org/10.1074/jbc.273.21.12746			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582299	hybrid			2022-12-27	WOS:000073768500010
J	Fukumura, R; Araki, R; Fujimori, A; Mori, M; Saito, T; Watanabe, F; Sarashi, M; Itsukaichi, H; Eguchi-Kasai, K; Sato, K; Tatsumi, K; Abe, M				Fukumura, R; Araki, R; Fujimori, A; Mori, M; Saito, T; Watanabe, F; Sarashi, M; Itsukaichi, H; Eguchi-Kasai, K; Sato, K; Tatsumi, K; Abe, M			Murine cell line SX9 bearing a mutation in the dna-pkcs gene exhibits aberrant V(D)J recombination not only in the coding joint but also in the signal joint	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; SEVERE COMBINED IMMUNODEFICIENCY; COMBINED IMMUNE-DEFICIENCY; SCID MOUSE; DEFECT; MUTANTS; REPAIR; COMPLEMENTATION; KU80	We established the radiosensitive cell line SX9 from mammary carcinoma cell line FM3A. In SX9 cells a defect of DNA-dependent protein kinase (DNA-PK) activity was suggested. Additionally, a complementation test suggested that the SX9 cell line belongs to a x-ray cross-complementing group (XRCC) 7. Isolation and sequence analyses of DNA-dependent protein kinase catalytic subunit (dna-pkcs) cDNA in SX9 cells disclosed nucleotide "T" (9572) to "C" transition causing substitution of amino acid residue leucine (3191) to proline. Interestingly, the mutation occurs in one allele, and transcripts of the dna-pkcs expressed exclusively from mutated allele. V(D)J recombination assay using extrachromosomal vector revealed the defects of not only coding but also signal joint formation. The frequency of the signal joint decreased to approximately one-tenth and the fidelity drastically decreased to 12.2% as compared with the normal cell line. To confirm the responsibility of the dna-pkcs gene for abnormal V(D)J recombination in SX9, the full-length dna-pkcs gene was introduced into SX9. As a result, restoration of V(D)J recombination by wild type dna-pkcs cDNA was observed. SX9 is a novel dna-pkcs-deficient cell line.	Natl Inst Radiol Sci, Dept Biol & Oncol, Inage Ku, Chiba 2638555, Japan; Chiba Univ, Grad Sch Sci & Technol, Inage Ku, Chiba 263, Japan; Perkin Elmer Japan Co Ltd, Appl Biosyst Div, Chiba 279, Japan; Kinki Univ, Fac Biol Oriented Sci & Technol, Wakayama 64964, Japan	National Institutes for Quantum Science & Technology; Chiba University; Thermo Fisher Scientific; Applied Biosystems; Kindai University (Kinki University)	Abe, M (corresponding author), Natl Inst Radiol Sci, Dept Biol & Oncol, Inage Ku, Anagawa 4-9-1, Chiba 2638555, Japan.	abemasum@uexs7Z.nirs.go.jp	Fujimori, Atsushi/G-5099-2014	Fujimori, Atsushi/0000-0003-4876-0634; Abe, Masumi/0000-0003-1550-2006				ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; Araki R, 1997, P NATL ACAD SCI USA, V94, P2438, DOI 10.1073/pnas.94.6.2438; Blunt T, 1996, P NATL ACAD SCI USA, V93, P10285, DOI 10.1073/pnas.93.19.10285; CALDECOTT K, 1991, MUTAT RES, V255, P111, DOI 10.1016/0921-8777(91)90046-R; Critchlow SE, 1997, CURR BIOL, V7, P588, DOI 10.1016/S0960-9822(06)00258-2; Danska JS, 1996, MOL CELL BIOL, V16, P5507; EASTMAN QM, 1996, NATURE, V380, P86; Errami A, 1996, MOL CELL BIOL, V16, P1519; Fujimori A, 1997, GENOMICS, V45, P194, DOI 10.1006/geno.1997.4919; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; GUPTA RS, 1978, CELL, V14, P1007, DOI 10.1016/0092-8674(78)90354-9; Hamatani K, 1996, IMMUNOGENETICS, V45, P1, DOI 10.1007/s002510050159; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; ITOH M, 1993, RADIAT RES, V134, P364, DOI 10.2307/3578198; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; Li ZY, 1995, CELL, V83, P1079, DOI 10.1016/0092-8674(95)90135-3; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; Lin JYD, 1997, RADIAT RES, V147, P166, DOI 10.2307/3579417; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; Mizuta R, 1996, INT IMMUNOL, V8, P1467, DOI 10.1093/intimm/8.9.1467; Peterson SR, 1997, J BIOL CHEM, V272, P10227; Ramsden DA, 1997, NATURE, V388, P488, DOI 10.1038/41351; SATO K, 1986, JPN J CANCER RES, V77, P456; SATO K, 1995, J RADIAT RES, V36, P38, DOI 10.1269/jrr.36.38; Shin EK, 1997, J IMMUNOL, V158, P3565; Singleton BK, 1997, MOL CELL BIOL, V17, P1264, DOI 10.1128/MCB.17.3.1264; TACCIOLI GE, 1994, J BIOL CHEM, V269, P7439; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; Tambini CE, 1997, GENOMICS, V41, P84, DOI 10.1006/geno.1997.4636; Teo SH, 1997, EMBO J, V16, P4788, DOI 10.1093/emboj/16.15.4788; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; Weaver DT, 1997, NATURE, V388, P428, DOI 10.1038/41225; WILER R, 1995, P NATL ACAD SCI USA, V92, P11485, DOI 10.1073/pnas.92.25.11485; Wilson TE, 1997, NATURE, V388, P495, DOI 10.1038/41365; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	37	47	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					13058	13064		10.1074/jbc.273.21.13058	http://dx.doi.org/10.1074/jbc.273.21.13058			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582343	hybrid			2022-12-27	WOS:000073768500054
J	Lee, D; Oh, ES; Woods, A; Couchman, JR; Lee, W				Lee, D; Oh, ES; Woods, A; Couchman, JR; Lee, W			Solution structure of a syndecan-4 cytoplasmic domain and its interaction with phosphatidylinositol 4,5-bisphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; PROTEIN-KINASE-C; POTATO CARBOXYPEPTIDASE INHIBITOR; INTERPROTON DISTANCE DATA; FOCAL ADHESION FORMATION; 3-DIMENSIONAL STRUCTURES; PHOSPHOLIPASE-C; BINDING DOMAIN; FIBRONECTIN; GEOMETRY	Syndecan-4, a transmembrane heparan sulfate proteoglycan, is a coreceptor with integrins in cell adhesion. It has been suggested to form a ternary signaling complex with protein kinase C alpha and phosphatidylinositol 4,5-bisphosphate (PLP2). Syndecans each have a unique, central, and variable (V) region in their cytoplasmic domains, and that of syndecan-4 is critical to its interaction with protein kinase C and PIP2. Two oligopeptides corresponding to the variable region (4V) and whole domain (4L) of syndecan-4 cytoplasmic domain were synthesized for nuclear magnetic resonance (NMR) studies. Data from NMR and circular dichroism indicate that the cytoplasmic domain undergoes a conformational transition and forms a symmetric dimer in the presence of phospholipid activator PIP2. The solution conformations of both free and PIP2-complexed 4V have been determined by two-dimensional NMR spectroscopy and dynamical simulated annealing calculations. The 4V peptide in the presence of PIP2 formed a compact dimer with two twisted strands packed parallel to each other and the exposed surface of the dimer consisted of highly charged and polar residues. The overall three-dimensional structure in solution exhibits a twisted clamp shape having a cavity in the center of dimeric interface. In addition, it has been observed that the syndecan-4V strongly interacts not only with fatty acyl groups but also the anionic head group of PIP2. These findings reveal that PIP2 promotes oligomerization of syndecan-4 cytoplasmic domain for transmembrane signaling and cell-matrix adhesion.	Yonsei Univ, Coll Sci, Dept Biochem, Seodaemoon Gu, Seoul 120740, South Korea; Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama, Cell Adhes & Matrix Res Ctr, Birmingham, AL 35294 USA	Yonsei University; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Lee, W (corresponding author), Yonsei Univ, Coll Sci, Dept Biochem, Seodaemoon Gu, Seoul 120740, South Korea.	wlee@nestis.yonsei.ac.kr	Lee, Donghan/B-6893-2011	Lee, Donghan/0000-0002-6530-8060	NIGMS NIH HHS [GM50194] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASAOKA Y, 1992, TRENDS BIOCHEM SCI, V17, P414, DOI 10.1016/0968-0004(92)90011-W; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BEYTH RJ, 1984, EXP CELL RES, V155, P537, DOI 10.1016/0014-4827(84)90213-1; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Carey DJ, 1997, BIOCHEM J, V327, P1; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLORE GM, 1987, BIOCHEMISTRY-US, V26, P8012, DOI 10.1021/bi00398a069; DeCorte V, 1997, FEBS LETT, V401, P191, DOI 10.1016/S0014-5793(96)01471-8; DRISCOLL PC, 1989, BIOCHEMISTRY-US, V28, P2188, DOI 10.1021/bi00431a033; Flanagan LA, 1997, BIOPHYS J, V73, P1440, DOI 10.1016/S0006-3495(97)78176-1; Gironcel D, 1996, FEBS LETT, V389, P253, DOI 10.1016/0014-5793(96)00595-9; Hinchliffe KA, 1996, EMBO J, V15, P6516, DOI 10.1002/j.1460-2075.1996.tb01042.x; HUHTALA P, 1995, J CELL BIOL, V129, P867, DOI 10.1083/jcb.129.3.867; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MACURA S, 1980, MOL PHYS, V41, P95, DOI 10.1080/00268978000102601; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; NILGES M, 1988, FEBS LETT, V239, P129, DOI 10.1016/0014-5793(88)80559-3; NILGES M, 1993, PROTEINS, V17, P297, DOI 10.1002/prot.340170307; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Oh ES, 1997, J BIOL CHEM, V272, P11805, DOI 10.1074/jbc.272.18.11805; Oh ES, 1998, J BIOL CHEM, V273, P10624, DOI 10.1074/jbc.273.17.10624; Oh ES, 1997, J BIOL CHEM, V272, P8133, DOI 10.1074/jbc.272.13.8133; OTTING G, 1988, MAGN RESON, V66, P187; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; REID DG, 1987, J BIOL CHEM, V262, P7967; Ren XD, 1996, MOL BIOL CELL, V7, P435, DOI 10.1091/mbc.7.3.435; Sakisaka T, 1997, MOL CELL BIOL, V17, P3841, DOI 10.1128/MCB.17.7.3841; STERNWEIS PC, 1992, TRENDS BIOCHEM SCI, V17, P502, DOI 10.1016/0968-0004(92)90340-F; STREETER HB, 1987, J CELL BIOL, V105, P507, DOI 10.1083/jcb.105.1.507; Sun HQ, 1997, J CELL BIOL, V138, P811, DOI 10.1083/jcb.138.4.811; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; VANGEET AL, 1970, ANAL CHEM, V42, P679, DOI 10.1021/ac60288a022; WAGNER G, 1987, J MOL BIOL, V196, P611, DOI 10.1016/0022-2836(87)90037-4; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WOODS A, 1993, MOL BIOL CELL, V4, P605, DOI 10.1091/mbc.4.6.605; WOODS A, 1986, EMBO J, V5, P665, DOI 10.1002/j.1460-2075.1986.tb04265.x; WOODS A, 1992, ADV EXP MED BIOL, V313, P87; WOODS A, 1992, J CELL SCI, V101, P277; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; Wuthrich K, 1986, NMR PROTEINS NUCL AC; YANG JT, 1986, METHOD ENZYMOL, V130, P208	47	75	77	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					13022	13029		10.1074/jbc.273.21.13022	http://dx.doi.org/10.1074/jbc.273.21.13022			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582338	hybrid			2022-12-27	WOS:000073768500049
J	Lee, ZW; Kweon, SM; Kim, BC; Leem, SH; Shin, IC; Kim, JH; Ha, KS				Lee, ZW; Kweon, SM; Kim, BC; Leem, SH; Shin, IC; Kim, JH; Ha, KS			Phosphatidic acid-induced elevation of intracellular Ca2+ is mediated by RhoA and H2O2 in Rat-2 fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHOLIPASE-D; GROWTH-FACTOR; LYSOPHOSPHATIDIC ACID; SMOOTH-MUSCLE; INOSITOL TRISPHOSPHATE; ACTIN POLYMERIZATION; RESPIRATORY BURST; ACTIVATION; CALCIUM	We have investigated possible roles of RhoA and H2O2 in the elevation of intracellular Ca2+ ([Ca2+](i)) by phosphatidic acid (PA) in Rat-a fibroblasts. PA induced a transient elevation of [Ca2+](i) in the presence or absence of EGTA. Lysophosphatidic acid (LPA) also increased [Ca2+](i), but the sustained Ca2+ response was inhibited by EGTA LPA stimulated the production of inositol phosphates, but PA did not. In the presence of EGTA, preincubation with LPA completely blocked the subsequent elevation of [Ca2+](i) by PA but not vice versa. PA stimulated the translocation of RhoA to the particulate fraction as did LPA Scrape loading of C3 transferase inhibited the transient Ca2+ response to PA, but not to LPA, suggesting an essential role of RhoA in the elevation of [Ca2+](i) by PA. H2O2 also induced a transient increase of [Ca2+](i) as did PA. H2O2 scavengers, catalase and N-acetyl-L-cysteine, completely blocked the rise of [Ca2+](i) stimulated by PA, but not by LPA. Furthermore, preincubation with PA blocked the subsequent Ca2+ response to H2O2, and the incubation with H2O2 also blocked the PA-induced rise of [Ca2+](i). Thus, it was suggested that PA stimulated Ca2+ release from PA-sensitive, but not inositol 1,4,5-trisphosphate-sensitive, Ca2+ stores by the activation of RhoA and intracellular H2O2.	Korea Basic Sci Inst, Biomol Res Grp, Taejon 305333, South Korea; Hallym Univ, Inst Environm & Life Sci, Lab Mol & Cellular Genet, Chun Cheon 200702, Kangwon Do, South Korea; Hanyang Univ, Coll Med, Dept Biochem, Seoul 133701, South Korea; Dong A Univ, Dept Biol, Pusan 604714, South Korea	Korea Basic Science Institute (KBSI); Hallym University; Hanyang University; Dong A University	Ha, KS (corresponding author), Korea Basic Sci Inst, Biomol Res Grp, Taejon 305333, South Korea.		Kim, Jae-Hong/B-2530-2009	Kim, Jae-Hong/0000-0002-8019-0208; Ha, Kwon-Soo/0000-0002-4219-1787				Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; BELLAVITE P, 1988, J BIOL CHEM, V263, P8210; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOCCKINO SB, 1991, P NATL ACAD SCI USA, V88, P6210, DOI 10.1073/pnas.88.14.6210; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; Cross MJ, 1996, CURR BIOL, V6, P588, DOI 10.1016/S0960-9822(02)00545-6; DESAI NN, 1992, J BIOL CHEM, V267, P23122; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; EXTON JH, 1990, J BIOL CHEM, V265, P1; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; HA KS, 1994, BIOCHEM J, V303, P55, DOI 10.1042/bj3030055; HA KS, 1993, J BIOL CHEM, V268, P10534; HA KS, 1993, J CELL BIOL, V123, P1789, DOI 10.1083/jcb.123.6.1789; HIRATA K, 1992, J BIOL CHEM, V267, P8719; Hoyal CR, 1996, ARCH BIOCHEM BIOPHYS, V326, P166, DOI 10.1006/abbi.1996.0061; JONES GA, 1993, J BIOL CHEM, V268, P20845; Jung HI, 1997, MOL CELLS, V7, P431; Kato N, 1996, BIOCHEM BIOPH RES CO, V226, P580, DOI 10.1006/bbrc.1996.1397; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KNAUSS TC, 1990, J BIOL CHEM, V265, P14457; Leem SH, 1997, J BIOCHEM MOL BIOL, V30, P337; Malcolm KC, 1996, J BIOL CHEM, V271, P13135, DOI 10.1074/jbc.271.22.13135; MATTIE M, 1994, J BIOL CHEM, V269, P3181; MOOLENAAR WH, 1992, COLD SPRING HARB SYM, V57, P163, DOI 10.1101/SQB.1992.057.01.021; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; PUTNEY JW, 1980, NATURE, V284, P345, DOI 10.1038/284345a0; ROVERI A, 1992, ARCH BIOCHEM BIOPHYS, V297, P265, DOI 10.1016/0003-9861(92)90671-I; Sakano S, 1996, J BIOL CHEM, V271, P11148, DOI 10.1074/jbc.271.19.11148; SALMON DM, 1980, NATURE, V284, P344, DOI 10.1038/284344a0; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; THELEN M, 1993, PHYSIOL REV, V73, P797, DOI 10.1152/physrev.1993.73.4.797; Tokumura A, 1997, BBA-LIPID LIPID MET, V1344, P87, DOI 10.1016/S0005-2760(96)00130-0; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANCORVEN EJ, 1992, BIOCHEM J, V281, P163, DOI 10.1042/bj2810163; Volk T, 1997, MOL CELL BIOCHEM, V171, P11, DOI 10.1023/A:1006886215193; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645	39	57	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					12710	12715		10.1074/jbc.273.21.12710	http://dx.doi.org/10.1074/jbc.273.21.12710			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582294	hybrid			2022-12-27	WOS:000073768500005
J	Palma, M; Wade, D; Flock, M; Flock, JI				Palma, M; Wade, D; Flock, M; Flock, JI			Multiple binding sites in the interaction between an extracellular fibrinogen-binding protein from Staphylococcus aureus and fibrinogen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLUMPING FACTOR; PROCOAGULANT-BINDING; NUCLEOTIDE-SEQUENCE; STAPHYLOCOAGULASE; COAGULASE; DOMAIN; GENE; IDENTIFICATION; VIRULENCE; RECEPTOR	Efb (previously Fib) is a fibrinogen-binding protein secreted by Staphylococcus aureus. It has previously been shown that it plays a role in a wound infection model in the rat and that antibodies against Efb reduce the number of recovered bacteria from the mammary glands in a mouse mastitis model. Efb binds to the alpha-chain of fibrinogen and does not participate in bacterial adherence to fibrinogen. The binding of Efb to fibrinogen is divalent, with one binding site within the two repeat regions in Efb at the N terminus and one binding site at the C terminus. The divalent binding nature leads to precipitation of Efb-fibrinogen complex when the proteins are added to each other at a 1:1 molar ratio. The interaction between Efb and fibrinogen is strongly enhanced by Ca2+ or Zn2+ but not by Mg-2.	Huddinge Univ Hosp, Karolinska Inst, Dept Immunol Microbiol Pathol & Infect Dis, S-14186 Huddinge, Sweden; Huddinge Univ Hosp, Karolinska Inst, Dept Oral & Maxillofacial Surg, S-14186 Huddinge, Sweden	Karolinska Institutet; Karolinska Institutet	Flock, JI (corresponding author), Huddinge Univ Hosp, Karolinska Inst, Dept Immunol Microbiol Pathol & Infect Dis, F82, S-14186 Huddinge, Sweden.	jan-ingmar.flock@impi.ki.se	Palma, Marco/AAX-8408-2020; Wade, David/ABF-7688-2020	Palma, Marco/0000-0001-8910-994X; Wade, David/0000-0003-3343-510X				BODEN MK, 1992, MICROB PATHOGENESIS, V12, P289, DOI 10.1016/0882-4010(92)90047-R; BODEN MK, 1994, MOL MICROBIOL, V12, P599, DOI 10.1111/j.1365-2958.1994.tb01046.x; BODEN MK, 1989, INFECT IMMUN, V57, P2358; CHEUNG AI, 1995, INFECT IMMUN, V63, P1914, DOI 10.1128/IAI.63.5.1914-1920.1995; Furlan M, 1996, THROMB HAEMOSTASIS, V76, P377; HAWIGER J, 1982, BIOCHEMISTRY-US, V21, P1407, DOI 10.1021/bi00535a047; KAIDA S, 1987, J BIOCHEM, V102, P1177, DOI 10.1093/oxfordjournals.jbchem.a122156; KAWABATA S, 1986, J BIOL CHEM, V261, P1427; KAWABATA S, 1986, J BIOL CHEM, V261, P527; MAMO W, 1994, FEMS IMMUNOL MED MIC, V10, P47, DOI 10.1111/j.1574-695X.1994.tb00010.x; MCDEVITT D, 1992, INFECT IMMUN, V60, P1514, DOI 10.1128/IAI.60.4.1514-1523.1992; McDevitt D, 1997, EUR J BIOCHEM, V247, P416, DOI 10.1111/j.1432-1033.1997.00416.x; MCDEVITT D, 1995, MOL MICROBIOL, V16, P895, DOI 10.1111/j.1365-2958.1995.tb02316.x; MCDEVITT D, 1994, MOL MICROBIOL, V11, P237, DOI 10.1111/j.1365-2958.1994.tb00304.x; MOREILLON P, 1995, INFECT IMMUN, V63, P4738, DOI 10.1128/IAI.63.12.4738-4743.1995; Palma M, 1996, INFECT IMMUN, V64, P5284, DOI 10.1128/IAI.64.12.5284-5289.1996; PHONIMDAENG P, 1990, MOL MICROBIOL, V4, P393, DOI 10.1111/j.1365-2958.1990.tb00606.x; SCHNEEWIND O, 1993, EMBO J, V12, P4803, DOI 10.1002/j.1460-2075.1993.tb06169.x; WASTFELT MKB, 1995, J CLIN MICROBIOL, V33, P2347; Yee VC, 1997, STRUCTURE, V5, P125, DOI 10.1016/S0969-2126(97)00171-8	20	52	59	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					13177	13181		10.1074/jbc.273.21.13177	http://dx.doi.org/10.1074/jbc.273.21.13177			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582359	hybrid			2022-12-27	WOS:000073768500070
J	Fontaine, E; Eriksson, O; Ichas, F; Bernardi, P				Fontaine, E; Eriksson, O; Ichas, F; Bernardi, P			Regulation of the permeability transition pore in skeletal muscle mitochondria - Modulation by electron flow through the respiratory chain complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; CYCLOSPORINE-A; PYRIDINE-NUCLEOTIDES; HEART-MITOCHONDRIA; OXIDATIVE DAMAGE; MEMBRANE; HEPATOCYTES; REDUCTION; DEATH; STATE	We have investigated the regulation of the permeability transition pore (PTP), a cyclosporin A-sensitive channel, in rat skeletal muscle mitochondria. As is the case with mitochondria isolated from a variety of sources, skeletal muscle mitochondria can undergo a permeability transition following Ca2+ uptake in the presence of pi. We find that the PTP opening is dramatically affected by the substrates used for energization, in that much lower Ca2+ loads are required when electrons are provided to complex I rather than to complex II or IV. This increased sensitivity of PTP opening does not depend on differences in membrane potential, matrix pH, Ca2+ uptake, oxidation-reduction status of pyridine nucleotides, or production of H2O2, but is directly related to the rate of electron flow through complex I. Indeed, and with complex I substrates only, pore opening can be observed when depolarization is induced with uncoupler (increased electron flow) but not with cyanide (decreased electron flow). Consistent with pore regulation by electron flow, we find that PTP opening is inhibited by ubiquinone 0 at concentrations that partially inhibit respiration and do not depolarize the inner membrane. These data allow identification of a novel site of regulation of the PTP, suggest that complex I may be part of the pore complex, and open new perspectives for its pharmacological modulation in living cells.	Univ Grenoble 1, Lab Bioenerget Fondamentale & Appl, F-38041 Grenoble, France; Univ Padua, Sch Med, Dept Biomed Sci, Lab Biophys & Membrane Biol, I-35121 Padua, Italy; CNR, Unit Study Biomembranes, I-35121 Padua, Italy	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); University of Padua; Consiglio Nazionale delle Ricerche (CNR)	Bernardi, P (corresponding author), Dipartimento Sci Biomed Sperimentali, Viale Giuseppe Colombo 3, I-35121 Padua, Italy.		Ichas, François/ABD-8277-2020; Bernardi, Paolo/C-3656-2008; Fontaine, Eric/ABA-8853-2020	Ichas, François/0000-0001-8184-5248; Bernardi, Paolo/0000-0001-9187-3736; Fontaine, Eric/0000-0002-5204-9477	Telethon [847] Funding Source: Medline	Telethon(Fondazione Telethon)		ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; BERNARDI P, 1992, J BIOL CHEM, V267, P8834; Bernardi P, 1996, J BIOENERG BIOMEMBR, V28, P131, DOI 10.1007/BF02110643; CASTILHO RF, 1995, FREE RADICAL BIO MED, V18, P55, DOI 10.1016/0891-5849(94)00098-5; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; Decaudin D, 1997, CANCER RES, V57, P62; DEVRIES S, 1987, BIOCHIM BIOPHYS ACTA, V895, P205, DOI 10.1016/S0304-4173(87)80003-4; DIVIRGILIO F, 1982, J BIOL CHEM, V257, P4106; EMAUS RK, 1986, BIOCHIM BIOPHYS ACTA, V850, P436, DOI 10.1016/0005-2728(86)90112-X; Ernster L., 1967, METHOD ENZYMOL, V10, P86; Esposti MD, 1996, ARCH BIOCHEM BIOPHYS, V330, P395, DOI 10.1006/abbi.1996.0267; GAZZOTTI P, 1975, BIOCHEM BIOPH RES CO, V67, P634, DOI 10.1016/0006-291X(75)90859-1; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313, DOI 10.1152/ajpcell.1994.267.2.C313; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; IMBERTI R, 1993, J PHARMACOL EXP THER, V265, P392; Jung DW, 1997, J BIOL CHEM, V272, P21104, DOI 10.1074/jbc.272.34.21104; KOWALTOWSKI AJ, 1995, AM J PHYSIOL-CELL PH, V269, pC141, DOI 10.1152/ajpcell.1995.269.1.C141; LANDI L, 1984, J BIOENERG BIOMEMBR, V16, P153, DOI 10.1007/BF00743046; LAWFORD HG, 1972, BIOCHEM J, V130, P1029, DOI 10.1042/bj1301029; Madsen K, 1996, ANAL BIOCHEM, V237, P37, DOI 10.1006/abio.1996.0197; NICHOLLS DG, 1980, BIOCHEM J, V188, P113, DOI 10.1042/bj1880113; NICOLLI A, 1993, BIOCHEMISTRY-US, V32, P4461, DOI 10.1021/bi00067a039; Orrenius S, 1996, ADV NEUROL, V71, P137; PASTORINO JG, 1995, AM J PHYSIOL-CELL PH, V268, pC676, DOI 10.1152/ajpcell.1995.268.3.C676; PETRONILLI V, 1993, J BIOL CHEM, V268, P21939; PRPIC V, 1980, J BIOL CHEM, V255, P6193; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Scorrano L, 1997, J BIOL CHEM, V272, P12295, DOI 10.1074/jbc.272.19.12295; TAKEYAMA N, 1993, BIOCHEM J, V294, P719, DOI 10.1042/bj2940719; TISCHLER ME, 1977, ARCH BIOCHEM BIOPHYS, V184, P222, DOI 10.1016/0003-9861(77)90346-0; VINOGRADOV A, 1972, ARCH BIOCHEM BIOPHYS, V152, P646, DOI 10.1016/0003-9861(72)90261-5; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; ZORATTI M, 1985, FEBS LETT, V193, P276, DOI 10.1016/0014-5793(85)80168-X; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	36	280	293	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12662	12668		10.1074/jbc.273.20.12662	http://dx.doi.org/10.1074/jbc.273.20.12662			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575229	hybrid			2022-12-27	WOS:000073629800094
J	Lanz, R; Erni, B				Lanz, R; Erni, B			The glucose transporter of the Escherichia coli phosphotransferase system - Mutant analysis of the invariant arginines, histidines, and domain linker	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; MANNITOL PERMEASE; BACTERIAL PHOSPHOENOLPYRUVATE; MANNOSE TRANSPORTER; MEMBRANE TOPOLOGY; SUGAR-TRANSPORT; ENZYME-IIGLC; PHOSPHORYLATION; PROTEIN; SITE	The glucose transporter of the bacterial phosphotransferase system (PTS) consists of a hydrophilic (IIA(Glc)) and a transmembrane subunit (IICBGlc). IICBGlc has two domains (C and B), which are linked by a highly invariant sequence. Transport of glucose by IIC and phosphorylation by IIB are tightly coupled processes. Three motifs that are strongly conserved in 12 homologous PTS transporters, namely two invariant arginines (Arg-424 and Arg-426) adjacent to the phosphorylation site (Cys-421), the invariant interdomain sequence KTPGRED, and two conserved histidines (His-211 and His-212) in the IIC domain were mutated and the mutant proteins characterized in vivo and in vitro for transport and phosphorylation activity. Replacement of the strongly beta-turn favoring residues Thr and Gly of the linker by alpha-helix favoring Ala results in strong reduction of activity, whereas the substitutions of the other residues have only minor effects. The R424K and R426K mutants can be phosphorylated by IIA(Glc) but can no longer donate the phosphoryl group to glucose. The H211Q and H212Q mutants continue to phosphorylate glucose at a reduced rate but H212Q can no longer transport glucose. Mixtures of purified R424K/H212Q and R426K/H212Q have 10% of wild-type phosphorylation activity and when coexpressed in Escherichia coli support glucose transport.	Univ Bern, Dept Chem & Biochem, CH-3012 Bern, Switzerland	University of Bern	Erni, B (corresponding author), Univ Bern, Dept Chem & Biochem, Freiestr 3, CH-3012 Bern, Switzerland.	erni@ibc.unibe.ch						AB E, 1997, PROTEIN SCI, V6, P304; Boer H, 1996, BIOCHEMISTRY-US, V35, P12901, DOI 10.1021/bi9611016; Bouma CL, 1996, J BIOL CHEM, V271, P33457, DOI 10.1074/jbc.271.52.33457; BUHR A, 1993, J BIOL CHEM, V268, P11599; BUHR A, 1992, J BIOL CHEM, V267, P3847; BUHR A, 1994, J BIOL CHEM, V269, P23437; DORSCHUG M, 1984, EUR J BIOCHEM, V144, P113, DOI 10.1111/j.1432-1033.1984.tb08438.x; Eberstadt M, 1996, BIOCHEMISTRY-US, V35, P11286, DOI 10.1021/bi960492l; ERNI B, 1989, FEMS MICROBIOL LETT, V63, P13, DOI 10.1016/0168-6445(89)90004-1; ERNI B, 1986, J BIOL CHEM, V261, P6398; ERNI B, 1986, BIOCHEMISTRY-US, V25, P305, DOI 10.1021/bi00350a004; ERNI B, 1987, J BIOL CHEM, V262, P5238; Fauman EB, 1996, J BIOL CHEM, V271, P18780, DOI 10.1074/jbc.271.31.18780; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; Gemmecker G, 1997, BIOCHEMISTRY-US, V36, P7408, DOI 10.1021/bi963053v; GUTKNECHT R, 1998, IN PRESS J BIOL CHEM, V273; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUMMEL U, 1992, PROTEIN SCI, V1, P356; JOHNSON LN, 1993, ANNU REV BIOPH BIOM, V22, P199, DOI 10.1146/annurev.bb.22.060193.001215; KUNDIG W, 1971, J BIOL CHEM, V246, P1407; KUNDIG W, 1971, J BIOL CHEM, V246, P1392; LENGELER JW, 1994, BBA-BIOENERGETICS, V1188, P1, DOI 10.1016/0005-2728(94)90017-5; MAO QC, 1995, J BIOL CHEM, V270, P5258, DOI 10.1074/jbc.270.10.5258; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; MEINS M, 1993, J BIOL CHEM, V268, P11604; Nunn RS, 1996, J MOL BIOL, V259, P502, DOI 10.1006/jmbi.1996.0335; NUOFFER C, 1988, J BIOL CHEM, V263, P6647; PAS HH, 1988, BIOCHEMISTRY-US, V27, P5835, DOI 10.1021/bi00416a002; PAS HH, 1991, J BIOL CHEM, V266, P6690; PERHAM RN, 1991, BIOCHEMISTRY-US, V30, P8501, DOI 10.1021/bi00099a001; Postma P.W., 1996, ESCHERICHIA COLI SAL, P1149; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; Reizer J, 1996, MICROBIOL-SGM, V142, P231, DOI 10.1099/13500872-142-2-231; ROOSSIEN FF, 1983, BIOCHIM BIOPHYS ACTA, V760, P185, DOI 10.1016/0304-4165(83)90141-1; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Rost B, 1996, METHOD ENZYMOL, V266, P525; RUIJTER GJG, 1992, J BACTERIOL, V174, P2843, DOI 10.1128/JB.174.9.2843-2850.1992; SAIER MH, 1992, J BACTERIOL, V174, P1433, DOI 10.1128/jb.174.5.1433-1438.1992; SAIER MH, 1988, FASEB J, V2, P199, DOI 10.1096/fasebj.2.3.2832233; SaraceniRichards CA, 1997, J BACTERIOL, V179, P5171, DOI 10.1128/jb.179.16.5171-5177.1997; STANSSENS P, 1989, NUCLEIC ACIDS RES, V17, P4441, DOI 10.1093/nar/17.12.4441; STOLZ B, 1993, J BIOL CHEM, V268, P27094; SUGIYAMA JE, 1991, P NATL ACAD SCI USA, V88, P9603, DOI 10.1073/pnas.88.21.9603; VERSTRAETE IM, 1990, J MOL BIOL, V214, P657; Veyrat A, 1996, MICROBIOL-UK, V142, P3469, DOI 10.1099/13500872-142-12-3469; WAEBER U, 1993, FEBS LETT, V324, P109, DOI 10.1016/0014-5793(93)81542-8; WEHMEIER UF, 1994, BBA-PROTEIN STRUCT M, V1208, P348, DOI 10.1016/0167-4838(94)90124-4; WENG QP, 1992, J BIOL CHEM, V267, P19529; WENG QP, 1993, BIOCHEMISTRY-US, V32, P11211, DOI 10.1021/bi00092a034; WOOTTON JC, 1989, PROTEIN ENG, V2, P535, DOI 10.1093/protein/2.7.535; WU LF, 1990, J MOL BIOL, V213, P687, DOI 10.1016/S0022-2836(05)80256-6	51	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12239	12243		10.1074/jbc.273.20.12239	http://dx.doi.org/10.1074/jbc.273.20.12239			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575173	hybrid			2022-12-27	WOS:000073629800038
J	Lefebvre, P; Mouchon, A; Lefebvre, B; Formstecher, P				Lefebvre, P; Mouchon, A; Lefebvre, B; Formstecher, P			Binding of retinoic acid receptor heterodimers to DNA - A role for histones NH2 termini	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOCORTICOID RESPONSE ELEMENT; TRANSCRIPTION FACTOR-BINDING; NUCLEOSOMAL DNA; FACILITATED BINDING; TRANSLATIONAL POSITION; PROTEIN; ACETYLATION; ACTIVATION; CBP; COACTIVATOR	The retinoic acid signaling pathway is controlled essentially through two types of nuclear receptors, RARs and RXRs. Ligand dependent activation or repression of retinoid-regulated genes is dependent on the binding of retinoic acid receptor (RAR)/9-cis-retinoic acid receptor (RXR) heterodimers to retinoic acid response element (RARE). Although unliganded RXR/RAR heterodimers bind constitutively to DNA in vitro, a clear in vivo ligand-dependent occupancy of the RARE present in the RAR beta 2 gene promoter has been reported (Dey, A., Minucci, S., and Ozato, K. (1994) Mol. Cell. Biol. 14, 8191-8201). Nucleosomes are viewed as general repressors of the transcriptional machinery, in part by preventing the access of transcription factors to DNA. The ability of hRXR alpha/hRAR alpha heterodimers to bind to a nucleosomal template in vitro has therefore been examined. The assembly of a fragment from the RAR beta 2 gene promoter, which contains a canonical DR5 RARE, into a nucleosome core prevented hRXR alpha/hRAR alpha binding to this DNA, in conditions where a strong interaction is observed with a linear DNA template. However, histone tails removal by limited proteolysis and histone hyperacetylation yielded nucleosomal RAREs able to bind to hRXR alpha/hRAR alpha heterodimers. These data establish therefore the role of histones NH2 termini as a major impediment to retinoid receptors access to DNA, and identify histone hyperacetylation as a potential physiological regulator of retinoid-induced transcription.	Fac Med Henri Warembourg, Lab Biochim Struct, INSERM, U459, F-59045 Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille	Lefebvre, P (corresponding author), NICHHD, Lab Mol Growth Regulat, NIH, Bldg 6,Rm 2A11, Bethesda, MD 20892 USA.		Lefebvre, Philippe/F-2685-2010; , lefebvre/T-3005-2018	Lefebvre, Philippe/0000-0002-9366-5129; , lefebvre/0000-0003-4953-3185				ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; Ausubel FM., 2006, ENZYMATIC MANIPULATI; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BECKER PB, 1986, NATURE, V324, P686, DOI 10.1038/324686a0; Bhattacharyya N, 1997, MOL CELL BIOL, V17, P6481, DOI 10.1128/MCB.17.11.6481; Blomquist P, 1996, J BIOL CHEM, V271, P153, DOI 10.1074/jbc.271.1.153; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; Cote J, 1995, METH MOL G, P108, DOI [10.1016/S1067-2389(06)80009-9, DOI 10.1016/S1067-2389(06)80009-9]; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DEY A, 1994, MOL CELL BIOL, V14, P8191, DOI 10.1128/MCB.14.12.8191; Elgin SCR, 1996, CURR OPIN GENET DEV, V6, P193, DOI 10.1016/S0959-437X(96)80050-5; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GODDE JS, 1995, NUCLEIC ACIDS RES, V23, P4557, DOI 10.1093/nar/23.22.4557; Grunstein M, 1995, J CELL SCI, P29; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; HAGER GL, 1996, CHROMATIN STRUCTURE, P89; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; Lee JS, 1996, MOL CELL BIOL, V16, P4312; LEFEBVRE B, 1995, BIOTECHNIQUES, V19, P186; LEFEBVRE P, 1995, J BIOL CHEM, V270, P10806, DOI 10.1074/jbc.270.18.10806; LI BY, 1994, J BIOL CHEM, V269, P7756; LI Q, 1995, MOL CELL BIOL, V15, P4375; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Mangelsdorf David J., 1994, P319; Minucci S, 1997, P NATL ACAD SCI USA, V94, P11295, DOI 10.1073/pnas.94.21.11295; Minucci S, 1996, CURR OPIN GENET DEV, V6, P567, DOI 10.1016/S0959-437X(96)80085-2; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PANYIM S, 1969, ARCH BIOCHEM BIOPHYS, V130, P337, DOI 10.1016/0003-9861(69)90042-3; Rachez C, 1996, J BIOL CHEM, V271, P17996, DOI 10.1074/jbc.271.30.17996; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; SCHILD C, 1993, EMBO J, V12, P423, DOI 10.1002/j.1460-2075.1993.tb05674.x; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Sternglanz R, 1996, TRENDS BIOCHEM SCI, V21, P357, DOI 10.1016/S0968-0004(96)90120-6; TAHAYATO A, 1993, MOL ENDOCRINOL, V7, P1642, DOI 10.1210/me.7.12.1642; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VETTESEDADEY M, 1994, MOL CELL BIOL, V14, P970, DOI 10.1128/MCB.14.2.970; WALTER PP, 1995, MOL CELL BIOL, V15, P6178; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wilson CJ, 1996, CELL, V84, P235, DOI 10.1016/S0092-8674(00)80978-2; WONG JM, 1995, GENE DEV, V9, P2696, DOI 10.1101/gad.9.21.2696; Wong JM, 1997, EMBO J, V16, P7130, DOI 10.1093/emboj/16.23.7130; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009	63	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12288	12295		10.1074/jbc.273.20.12288	http://dx.doi.org/10.1074/jbc.273.20.12288			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575180	hybrid			2022-12-27	WOS:000073629800045
J	Noirot, P; Kolodner, RD				Noirot, P; Kolodner, RD			DNA strand invasion promoted by Escherichia coli RecT protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMOLOGOUS RECOMBINATION; GENETIC-RECOMBINATION; BREAK REPAIR; INTRAMOLECULAR RECOMBINATION; EXONUCLEASE; EXCHANGE; IDENTIFICATION; REPLICATION; MUTATIONS; BINDING	The RecT protein of Escherichia coli is a DNA-pairing protein required for the RecA-independent recombination events promoted by the RecE pathway. The RecT protein was found to bind to both single-stranded DNA (ssDNA) and double-stranded DNA (dsDNA) in the absence of Mg2+. In the presence of Mg2+, RecT binding to dsDNA was inhibited drastically, whereas binding to ssDNA was inhibited only to a small extent. RecT promoted the transfer of a single-stranded oligonucleotide into a supercoiled homologous duplex to form a D (displacement)-loop. D-loop formation occurred in the absence of Mg2+ and at 1 mM Mg2+ but was inhibited by increasing concentrations of Mg2+ and did not require a high energy cofactor. Strand transfer was mediated by a RecT-ssDNA nucleoprotein complex reacting with a naked duplex DNA and was prevented by the formation of RecT-dsDNA nucleoprotein complexes. Finally, RecT mediated the formation of joint molecules between a supercoiled DNA and a linear dsDNA substrate with homologous 3'-single-stranded tails. Together these results indicate that RecT is not a helix-destabilizing protein promoting a reannealing reaction but rather is a novel type of pairing protein capable of promoting recombination by a DNA strand invasion mechanism. These results are consistent with the observation that RecE (exonuclease VIII) and RecT can promote RecA-independent double-strand break repair in E. coli.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Human Canc Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	Kolodner, RD (corresponding author), INRA, CRJJ, F-78352 Jouy En Josas, France.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026017, R37GM026017] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26017] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASAI T, 1994, CELL, V78, P1051, DOI 10.1016/0092-8674(94)90279-8; BARBOUR SD, 1970, P NATL ACAD SCI USA, V67, P128, DOI 10.1073/pnas.67.1.128; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; CHEDIN F, 1994, MOL MICROBIOL, V12, P561, DOI 10.1111/j.1365-2958.1994.tb01042.x; CHEN JH, 1994, GENE DEV, V8, P1356, DOI 10.1101/gad.8.11.1356; CLARK AJ, 1993, J BACTERIOL, V175, P7673, DOI 10.1128/JB.175.23.7673-7682.1993; CLARK AJ, 1974, GENETICS, V78, P259; FISHEL RA, 1981, NATURE, V294, P184, DOI 10.1038/294184a0; FORMOSA T, 1986, CELL, V47, P793, DOI 10.1016/0092-8674(86)90522-2; HALL SD, 1994, P NATL ACAD SCI USA, V91, P3205, DOI 10.1073/pnas.91.8.3205; HALL SD, 1993, J BACTERIOL, V175, P277, DOI 10.1128/JB.175.1.277-287.1993; JOHNSON AW, 1991, J BIOL CHEM, V266, P14046; JOSEPH JW, 1983, J BIOL CHEM, V258, P418; KOBAYASHI I, 1988, GENETICS, V119, P751; Kogoma T, 1996, CELL, V85, P625, DOI 10.1016/S0092-8674(00)81229-5; KOLODNER R, 1994, MOL MICROBIOL, V11, P23, DOI 10.1111/j.1365-2958.1994.tb00286.x; Kong DC, 1996, EMBO J, V15, P2010, DOI 10.1002/j.1460-2075.1996.tb00552.x; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; KUSANO K, 1994, GENE, V138, P17; KUSHNER SR, 1971, P NATL ACAD SCI USA, V68, P824, DOI 10.1073/pnas.68.4.824; LABAN A, 1981, MOL GEN GENET, V184, P200, DOI 10.1007/BF00272905; LLOYD RG, 1985, J BACTERIOL, V164, P836, DOI 10.1128/JB.164.2.836-844.1985; LUISIDELUCA C, 1995, J BACTERIOL, V177, P566, DOI 10.1128/jb.177.3.566-572.1995; LUISIDELUCA C, 1992, J MOL BIOL, V227, P72, DOI 10.1016/0022-2836(92)90682-A; MCENTEE K, 1980, P NATL ACAD SCI-BIOL, V77, P857, DOI 10.1073/pnas.77.2.857; RESNICK MA, 1976, J THEOR BIOL, V59, P97, DOI 10.1016/S0022-5193(76)80025-2; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHIBATA T, 1979, P NATL ACAD SCI USA, V76, P1638, DOI 10.1073/pnas.76.4.1638; SMITH GR, 1989, CELL, V58, P807, DOI 10.1016/0092-8674(89)90929-X; SMITH GR, 1988, MICROBIOL REV, V52, P1; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; SYMINGTON LS, 1985, J MOL BIOL, V186, P515, DOI 10.1016/0022-2836(85)90126-3; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; TAKAHASHI NK, 1993, J BACTERIOL, V175, P5176, DOI 10.1128/JB.175.16.5176-5185.1993; Takahashi NK, 1997, GENETICS, V146, P9; TAYLOR AF, 1995, J BIOL CHEM, V270, P24459, DOI 10.1074/jbc.270.41.24459; TEMPLIN A, 1972, GENETICS, V72, P205; THRESHER RJ, 1988, J MOL BIOL, V201, P101, DOI 10.1016/0022-2836(88)90442-1; THRESHER RJ, 1995, J MOL BIOL, V254, P364, DOI 10.1006/jmbi.1995.0623; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; YOKOCHI T, 1995, GENETICS, V139, P5	41	67	86	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12274	12280		10.1074/jbc.273.20.12274	http://dx.doi.org/10.1074/jbc.273.20.12274			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575178	Green Published, hybrid			2022-12-27	WOS:000073629800043
J	Zhou, ZM; White, KA; Polissi, A; Georgopoulos, C; Raetz, CRH				Zhou, ZM; White, KA; Polissi, A; Georgopoulos, C; Raetz, CRH			Function of Escherichia coli MsbA, an essential ABC family transporter, in lipid A and phospholipid biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TEMPERATURE REQUIREMENT GENE; GRAM-NEGATIVE ENDOTOXIN; O-ANTIGEN SYNTHESIS; SALMONELLA-TYPHIMURIUM; HTRB GENE; NULL MUTATIONS; BACTERIAL-ENDOTOXINS; MULTICOPY SUPPRESSOR; OUTER-MEMBRANE; INNER MEMBRANE	The Escherichia coli msbA gene, first identified as a multicopy suppressor of htrB mutations, has been proposed to transport nascent core-lipid A molecules across the inner membrane (Polissi, k, and Georgopoulos, C. (1996) Mol. Microbiol. 20, 1221-1233), msbA is an essential E. coli gene with high sequence similarity to mammalian Mdr proteins and certain types of bacterial ABC transporters, htrB is required for growth above 32 degrees C and encodes the lauroyltransferase that acts after Kdo addition during lipid A biosynthesis (Clementz, T,, Bednarski, J., and Raetz, C. R. H. (1996) J. Biol. Chem. 271, 12095-12102). By using a quantitative new P-32(i) labeling technique, we demonstrate that hexa-acylated species of lipid A predominate in the outer membranes of wild type E. coli labeled for several generations at 42 degrees C. In contrast, in htrB mutants shifted to 42 degrees C for 3 h, tetraacylated lipid A species and glycerophospholipids accumulate in the inner membrane. Extra copies of the cloned msbA gene restore the ability of htrB mutants to grow at 42 degrees C, but they do not increase the extent of lipid A acylation. However, a significant fraction of the tetraacylated lipid A species that accumulate in htrB mutants are transported to the outer membrane in the presence of extra copies of msbA. E. coli strains in which msbA synthesis is selectively shut off at 42 degrees C accumulate hexa-acylated lipid A and glycerophospholipids in their inner membranes. Our results support the view that MsbA plays a role in lipid A and possibly glycerophospholipid transport. The tetra-acylated lipid A precursors that accumulate in htrB mutants may not be transported as efficiently by MsbA as are penta- or hexaacylated lipid A species.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Ctr Med Univ Geneva, Dept Biochim Med, CH-1211 Geneva 4, Switzerland	Duke University; University of Geneva	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, POB 3711, Durham, NC 27710 USA.			POLISSI, ALESSANDRA/0000-0003-0903-8024	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051310] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-51310] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ausubel FM, 1988, MOL REPROD DEV; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; BROZEK KA, 1987, J BIOL CHEM, V262, P5170; CAROFF M, 1988, CARBOHYD RES, V175, P273, DOI 10.1016/0008-6215(88)84149-1; Carty SM, 1997, FASEB J, V11, pA1423; CLEMENTZ T, 1991, J BIOL CHEM, V266, P9687; Clementz T, 1996, J BIOL CHEM, V271, P12095, DOI 10.1074/jbc.271.20.12095; Clementz T, 1997, J BIOL CHEM, V272, P10353; CLEMENTZ T, 1995, FASEB J, V9, pA1311; Dillon DA, 1996, J BIOL CHEM, V271, P30548, DOI 10.1074/jbc.271.48.30548; ELFERINK RPJO, 1995, J CLIN INVEST, V95, P31, DOI 10.1172/JCI117658; GALLOWAY SM, 1990, J BIOL CHEM, V265, P6394; Garrett TA, 1997, J BIOL CHEM, V272, P21855, DOI 10.1074/jbc.272.35.21855; Garrett TA, 1998, J BIOL CHEM, V273, P12457, DOI 10.1074/jbc.273.20.12457; GUYCAFFEY JK, 1992, J BACTERIOL, V174, P2460, DOI 10.1128/jb.174.8.2460-2465.1992; KARIBIAN D, 1993, J BACTERIOL, V175, P2988, DOI 10.1128/JB.175.10.2988-2993.1993; KAROW M, 1992, J BACTERIOL, V174, P702, DOI 10.1128/jb.174.3.702-710.1992; KAROW M, 1993, MOL MICROBIOL, V7, P69, DOI 10.1111/j.1365-2958.1993.tb01098.x; KAROW M, 1991, MOL MICROBIOL, V5, P2285, DOI 10.1111/j.1365-2958.1991.tb02159.x; KAROW M, 1991, J BACTERIOL, V173, P741, DOI 10.1128/jb.173.2.741-750.1991; KAROW M, 1992, J BACTERIOL, V174, P7407, DOI 10.1128/jb.174.22.7407-7418.1992; Liu D, 1996, J BACTERIOL, V178, P2102, DOI 10.1128/jb.178.7.2102-2107.1996; MARINO PA, 1991, J BACTERIOL, V173, P3128, DOI 10.1128/JB.173.10.3128-3133.1991; MARINO PA, 1985, J BIOL CHEM, V260, P4965; McDonald MK, 1997, J BACTERIOL, V179, P7638, DOI 10.1128/jb.179.24.7638-7643.1997; MCGRATH BC, 1991, J BACTERIOL, V173, P649, DOI 10.1128/jb.173.2.649-654.1991; MCGRATH BC, 1991, J BACTERIOL, V173, P3134, DOI 10.1128/JB.173.10.3134-3137.1991; Miller J. H., 1972, EXPT MOL GENETICS, P433; MORRISON DC, 1992, BACTERIAL ENDOTOXIC, V1; MULFORD CA, 1983, P NATL ACAD SCI-BIOL, V80, P1159, DOI 10.1073/pnas.80.5.1159; NISHIJIMA M, 1977, EUR J BIOCHEM, V73, P115, DOI 10.1111/j.1432-1033.1977.tb11297.x; Odegaard TJ, 1997, J BIOL CHEM, V272, P19688, DOI 10.1074/jbc.272.32.19688; Osborn M J, 1974, Methods Enzymol, V31, P642; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; Osborn MJ., 1979, BACTERIAL OUTER MEMB, P15; Polissi A, 1996, MOL MICROBIOL, V20, P1221, DOI 10.1111/j.1365-2958.1996.tb02642.x; Raetz C. R. H., 1996, ESCHERICHIA COLI SAL, V1, P1035; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; RAETZ CRH, 1990, J BIOL CHEM, V265, P1235; RAETZ CRH, 1979, J BACTERIOL, V137, P860, DOI 10.1128/JB.137.2.860-868.1979; RAY BL, 1984, J BIOL CHEM, V259, P4852; RAY BL, 1987, J BIOL CHEM, V262, P1122; REEVES PR, 1994, NEW COMPR BIOCH, V27, P281; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; SCHNAITMAN CA, 1993, MICROBIOL REV, V57, P655, DOI 10.1128/MMBR.57.3.655-682.1993; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; Somerville JE, 1996, J CLIN INVEST, V97, P359, DOI 10.1172/JCI118423; STRAIN SM, 1983, J BIOL CHEM, V258, P3466; Sunshine MG, 1997, J BACTERIOL, V179, P5521, DOI 10.1128/jb.179.17.5521-5533.1997; ZHOU ZH, UNPUB	53	277	287	2	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12466	12475		10.1074/jbc.273.20.12466	http://dx.doi.org/10.1074/jbc.273.20.12466			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575204	hybrid, Green Published			2022-12-27	WOS:000073629800069
J	Borg, JP; Yang, YN; De Taddeo-Borg, M; Margolis, B; Turner, RS				Borg, JP; Yang, YN; De Taddeo-Borg, M; Margolis, B; Turner, RS			The X11 alpha protein slows cellular amyloid precursor protein processing and reduces A beta 40 and A beta 42 secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; BETA-PROTEIN; CYTOPLASMIC DOMAIN; TRANSGENIC MICE; HUMAN NEURONS; IN-VIVO; PRESENILIN-1; DISTINCT; PATHWAY; CELLS	Constitutive amyloid precursor protein (APP) metabolism results in the generation of soluble APP (APPs) and A beta peptides, including A beta 40 and A beta 42-the major component of amyloid plaques in Alzheimer's disease brain. The phosphotyrosine binding (PTB) domain of X11 binds to a peptide containing a YENPTY motif found in the carboxyl terminus of APP. We have cloned the full-length X11 gene now referred to as X11 alpha. Coexpression of X11 alpha with APP results in comparatively greater levels of cellular APP and less APPs, A beta 40, and A beta 42 recovered in conditioned medium of transiently transfected HEK 293 cells. These effects are impaired by a single missense mutation of either APP (Y682G within the YENPTY motif) or X11 alpha (F608V within the PTB domain), which diminishes their interaction, thus demonstrating specificity. The inhibitory effect of X11 alpha on A beta 40 and A beta 42 secretion is amplified by coexpression with the Swedish mutation of APP (K595N/M596L), which promotes its amyloidogenic processing. Pulse-chase analysis demonstrates that X11 alpha prolongs the half-life of APP from similar to 2 h to similar to 4 h. The effects of X11 alpha on cellular APP and APPs recovery were confirmed in a 293 cell line stably transfected with APP. The specific binding of the PTB domain of X11 alpha to the YENPTY motif-containing peptide of APP appears to slow cellular APP processing and thus reduces recovery of its soluble fragments APPs, A beta 40, and A beta 42 in conditioned medium of transfected HEK 293 cells, X11 alpha may be involved in APP trafficking and metabolism in neurons and thus may be implicated in amyloidogenesis in normal aging and Alzheimer's disease brain.	Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Ann Arbor, MI 48105 USA; Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Vet Affairs Med Ctr, Dept Internal Med & Biol Chem, Ann Arbor, MI 48109 USA; Vet Affairs Med Ctr, Deptt Internal Med & Biol Chem, Ann Arbor, MI 48109 USA	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Howard Hughes Medical Institute; University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA)	Turner, RS (corresponding author), Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, 2214 Fuller Rd, Ann Arbor, MI 48105 USA.	raymondt@umich.edu	Turner, Raymond Scott/G-2263-2011; Borg, Jean-Paul/AAX-8096-2020	Turner, Raymond Scott/0000-0001-7534-2935; Borg, Jean-Paul/0000-0001-8418-3382	NIA NIH HHS [P50 AG08671, P50 AG008671] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P50AG008671] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Borg JP, 1998, CURR TOP MICROBIOL, V228, P23; Borg JP, 1996, MOL CELL BIOL, V16, P6229; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; Cataldo AM, 1997, J NEUROSCI, V17, P6142; Chien CT, 1998, MOL CELL BIOL, V18, P598, DOI 10.1128/MCB.18.1.598; Chyung ASC, 1997, J CELL BIOL, V138, P671, DOI 10.1083/jcb.138.3.671; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Cook DG, 1996, P NATL ACAD SCI USA, V93, P9223, DOI 10.1073/pnas.93.17.9223; COOK KG, 1997, NAT MED, V3, P1021; Ermekova KS, 1997, J BIOL CHEM, V272, P32869, DOI 10.1074/jbc.272.52.32869; ESSELMANI R, 1996, BIOCHEM BIOPH RES CO, V218, P89; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Guenette SY, 1996, P NATL ACAD SCI USA, V93, P10832, DOI 10.1073/pnas.93.20.10832; Guo M, 1996, NEURON, V17, P27, DOI 10.1016/S0896-6273(00)80278-0; HAASS C, 1993, J BIOL CHEM, V268, P3021; HAASS C, 1995, NAT MED, V1, P1291, DOI 10.1038/nm1295-1291; Hardy J, 1997, P NATL ACAD SCI USA, V94, P2095, DOI 10.1073/pnas.94.6.2095; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KOO EH, 1994, J BIOL CHEM, V269, P17386; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; MARTIN BL, 1995, J BIOL CHEM, V270, P26727, DOI 10.1074/jbc.270.45.26727; McLoughlin DM, 1996, FEBS LETT, V397, P197; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; SturchlerPierrat C, 1997, P NATL ACAD SCI USA, V94, P13287, DOI 10.1073/pnas.94.24.13287; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tienari PJ, 1997, P NATL ACAD SCI USA, V94, P4125, DOI 10.1073/pnas.94.8.4125; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Turner RS, 1996, J BIOL CHEM, V271, P8966, DOI 10.1074/jbc.271.15.8966; WERTKIN AM, 1993, P NATL ACAD SCI USA, V90, P9513, DOI 10.1073/pnas.90.20.9513; Xu HX, 1997, P NATL ACAD SCI USA, V94, P3748, DOI 10.1073/pnas.94.8.3748; Yaich L, 1998, J BIOL CHEM, V273, P10381, DOI 10.1074/jbc.273.17.10381; Zambrano N, 1997, J BIOL CHEM, V272, P6399, DOI 10.1074/jbc.272.10.6399; Zhang ZT, 1997, EMBO J, V16, P6141, DOI 10.1093/emboj/16.20.6141	40	184	190	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14761	14766		10.1074/jbc.273.24.14761	http://dx.doi.org/10.1074/jbc.273.24.14761			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614075	hybrid			2022-12-27	WOS:000074160400017
J	Brozinick, JT; Birnbaum, MJ				Brozinick, JT; Birnbaum, MJ			Insulin, but not contraction, activates Akt/PKB in isolated rat skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE GLUCOSE TRANSPORTERS; PROTEIN-KINASE-B; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSLOCATION; AKT; PHOSPHORYLATION; DISSOCIATION; STIMULATION; INCREASES; DISTINCT	Insulin and muscle contraction potently stimulate glucose uptake in mammalian skeletal muscle. Studies in muscle and adipose tissue have shown that insulin induces its receptor-dependent phosphorylation of insulin receptor substrates 1 and 2, which leads to activation of polyphosphatidylinositol (PI) 3'-kinase. In contrast, muscle contraction stimulates glucose transport via a mechanism that is independent of insulin, but the two pathways may converge downstream at the level of stimulation of GLUT4 translocation. In the present study, we have examined the role of Akt, an insulin-activated serine threonine kinase that has previously been shown to increase glucose transport in adipocytes. Either insulin or in vitro muscle contraction significantly elevated glucose transport in isolated rat epitrochlearis and soleus muscles. However, Akt kinase activity was significantly stimulated by insulin and not contraction. Moreover, wortmannin, an inhibitor of PI 3'-kinase, completely blocked the insulin-stimulated increase in Akt activity and glucose transport but did not alter either of these parameters in contracting muscles. The increases in Akt activity were paralleled by a decrease in the electrophoretic mobility of Akt, indicative of phosphorylation of Akt by an upstream kinase. These changes in Akt mobility appeared to be at least partially because of phosphorylation of Akt on serine 473. Mutative down-stream target of Akt, p70 S6 kinase, showed similar changes in mobility in response to insulin but not contraction. These data support the view that Akt is a downstream target of PI 3'-kinase and is involved in the signaling pathways involved in insulin but not contraction stimulation of glucose transport in skeletal muscle. These data provide further evidence that two distinct pathways exist for the stimulation of glucose transport in mammalian skeletal muscle.	Univ Penn, Sch Med, Howard Hughes Med Inst, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Cox Inst, Philadelphia, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania	Birnbaum, MJ (corresponding author), Univ Penn, Sch Med, Howard Hughes Med Inst, Dept Med, CRB 322,415 Curie Blvd, Philadelphia, PA 19104 USA.			Birnbaum, Morris/0000-0001-9972-8680	NIDDK NIH HHS [DK 39615] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039615] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BROZINICK JT, 1994, AM J PHYSIOL, V267, pR236, DOI 10.1152/ajpregu.1994.267.1.R236; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CARTEE GD, 1992, AM J PHYSIOL, V263, pR70, DOI 10.1152/ajpregu.1992.263.1.R70; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Chen D, 1997, J BIOL CHEM, V272, P27401, DOI 10.1074/jbc.272.43.27401; CODERRE L, 1995, J BIOL CHEM, V270, P27584, DOI 10.1074/jbc.270.46.27584; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; Cross DAE, 1997, FEBS LETT, V406, P211, DOI 10.1016/S0014-5793(97)00240-8; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DOUEN AG, 1990, J BIOL CHEM, V265, P13427; Etgen GJ, 1996, AM J PHYSIOL-ENDOC M, V271, pE294, DOI 10.1152/ajpendo.1996.271.2.E294; GOODYEAR LJ, 1995, J CLIN INVEST, V95, P2195, DOI 10.1172/JCI117909; GOODYEAR LJ, 1995, AM J PHYSIOL-ENDOC M, V268, pE987, DOI 10.1152/ajpendo.1995.268.5.E987; GOODYEAR LJ, 1990, AM J PHYSIOL, V258, pE667, DOI 10.1152/ajpendo.1990.258.4.E667; HANSEN PA, 1995, J BIOL CHEM, V270, P1679; Hemmings BA, 1997, SCIENCE, V277, P534, DOI 10.1126/science.277.5325.534; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; HENRIKSEN EJ, 1991, ACTA PHYSIOL SCAND, V143, P381, DOI 10.1111/j.1748-1716.1991.tb09249.x; HENRIKSEN EJ, 1989, AM J PHYSIOL, V256, pE662, DOI 10.1152/ajpendo.1989.256.5.E662; HENRIKSEN EJ, 1990, AM J PHYSIOL, V259, pE593, DOI 10.1152/ajpendo.1990.259.4.E593; HIRSHMAN MF, 1988, FEBS LETT, V238, P235, DOI 10.1016/0014-5793(88)80486-1; Holloszy JO, 1996, REV PHYSIOL BIOCH P, V128, P99; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; Krook A, 1997, DIABETES, V46, P2110, DOI 10.2337/diabetes.46.12.2110; LUND S, 1995, P NATL ACAD SCI USA, V92, P5817, DOI 10.1073/pnas.92.13.5817; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; NESHER R, 1985, AM J PHYSIOL, V249, pC226, DOI 10.1152/ajpcell.1985.249.3.C226; PLOUG T, 1984, AM J PHYSIOL, V247, pE726, DOI 10.1152/ajpendo.1984.247.6.E726; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; Sakaue H, 1997, MOL ENDOCRINOL, V11, P1552, DOI 10.1210/me.11.10.1552; Shepherd PR, 1997, DIABETOLOGIA, V40, P1172, DOI 10.1007/s001250050803; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; vanderKaay J, 1997, J BIOL CHEM, V272, P5477, DOI 10.1074/jbc.272.9.5477; WHITE MF, 1994, J BIOL CHEM, V269, P1; Wijkander J, 1997, J BIOL CHEM, V272, P21520, DOI 10.1074/jbc.272.34.21520; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107; Zhou Q, 1997, BIOCHEM BIOPH RES CO, V236, P647, DOI 10.1006/bbrc.1997.7028	39	123	125	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14679	14682		10.1074/jbc.273.24.14679	http://dx.doi.org/10.1074/jbc.273.24.14679			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614064	hybrid			2022-12-27	WOS:000074160400006
J	Henzinger, T; Reed, SI				Henzinger, T; Reed, SI			Cyclin D3 is rate-limiting for the G(1)/S phase transition in fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; RETINOBLASTOMA-PROTEIN; GENE-EXPRESSION; MAMMALIAN-CELLS; KINASE-ACTIVITY; D1; OVEREXPRESSION; ONCOGENESIS; PROGRESSION; INHIBITION	D-type cyclins are induced in response to mitogens and are believed to control progression through the G(1) phase of the cell cycle by activating their corresponding kinase partners (cyclin-dependent kinases). To investigate the function of individual D-type cyclins we have constructed rat fibroblast lines that allow controllable overexpression of a human cyclin D3 cDNA. Overexpression of cyclin D3 led to accelerated passage through G(1) in actively proliferating cells with no effect on the overall population doubling time. In cells re-entering the division cycle from a quiescent state, cyclin D3 caused an even more dramatic advancement of S phase entry. Accelerated progression through G(0)/G(1)-to-S correlated with premature phosphorylation of the pith tumor suppressor protein and its relatives, p107 and p130. We conclude that cyclin D3 can act as a rate-limiting G(1) cyclin and that this effect involves, in part, the premature phosphorylation of critical substrates.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Reed, SI (corresponding author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NIGMS NIH HHS [GM40006] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; JIANG W, 1993, ONCOGENE, V8, P3447; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; NEUMAN E, 1997, MOL CELL BIOL, V17, P538; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Reed SI, 1997, CANCER SURV, V29, P7; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WOLF DA, 1995, ONCOGENE, V10, P2067; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	27	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14958	14961		10.1074/jbc.273.24.14958	http://dx.doi.org/10.1074/jbc.273.24.14958			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614101	hybrid			2022-12-27	WOS:000074160400043
J	Previato, JO; Sola-Penna, M; Agrellos, OA; Jones, C; Oeltmann, T; Travassos, LR; Mendonca-Previato, L				Previato, JO; Sola-Penna, M; Agrellos, OA; Jones, C; Oeltmann, T; Travassos, LR; Mendonca-Previato, L			Biosynthesis of O-N-acetylglucosamine-linked glycans in Trypanosoma cruzi - Characterization of the novel uridine diphospho-N-acetylglucosamine : polypeptide-N-acetylglucosaminyltransferase- catalyzing formation of N-acetylglucosamine alpha 1 -> O-threonine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; SIALIC-ACID; CYTOPLASMIC PROTEINS; EPIMASTIGOTE FORMS; MAMMALIAN-CELLS; NUCLEAR-PORE; MUCIN GENES; GLYCOPROTEINS; GLYCOSYLATION; GLCNAC	In this study, we have characterized the activity of a uridine diphospho-N-acetylglucosamine:polypeptide-alpha-N-acetylglucosaminyltransferase (O-alpha-GlcNAc-transferase) from Trypanosoma cruzi. The activity is present in microsomal membranes and is responsible for the addition of O-linked alpha-N-acetylglucosamine to cell surface proteins. This preparation adds N-acetylglucosamine to a synthetic peptide KPPTTTTTTTTKPP containing the consensus threonine-rich dodecapeptide encoded by T. cruzi MUC gene (Di Noia, J. M., Sanchez D. O., and Frasch, A. C. C. (1995) J. Biol. Chem. 270, 24146-24149). Incorporation of N-[H-3]acetylglucosamine is linearly dependent on incubation time and concentration of enzyme and substrate. The transferase activity has an optimal pH of 7.5-8.5, requires Mn2+, is unaffected by tunicamycin or amphomycin, and is strongly inhibited by UDP, The optimized synthetic peptide acceptor for the cytosolic O-GlcNAc-transferase (YSDSPSTST) (Haltiwanger, R. S., Holt, G. D., and Hart, G. W. (1990) J. Biol. Chem. 265, 2563-2568) is not a substrate for this enzyme. The glycosylated KPPTTTTTTTTKPP product is susceptible to base-catalyzed beta-elimination, and the presence of N-acetylglucosamine beta-linked to threonine is supported by enzymatic digestion and nuclear magnetic resonance data. These results describe a unique biosynthetic pathway for T. cruzi surface mucin-like molecules, with potential chemotherapeutic implications.	Univ Fed Rio de Janeiro, Inst Microbiol, BR-21944970 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Fac Farm, BR-21944970 Rio De Janeiro, Brazil; Natl Inst Biol Stand & Controls, Mol Struct Lab, Potters Bar EN6 3QG, Herts, England; Vanderbilt Univ, Dept Mol Biol, Nashville, TN 37235 USA; Univ Fed Sao Paulo, Disciplina Biol Celular, BR-04023062 Sao Paulo, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; National Institute for Biological Standards & Control; Vanderbilt University; Universidade Federal de Sao Paulo (UNIFESP)	Mendonca-Previato, L (corresponding author), Univ Fed Rio de Janeiro, Inst Microbiol, CCS-Bloco I, BR-21944970 Rio De Janeiro, Brazil.		Travassos, Luiz R/J-3631-2012; Jones, Chris/AAF-4063-2021; Sola-Penna, Mauro/E-8221-2011; Travassos, Luiz/V-2467-2019	Jones, Chris/0000-0001-7109-492X; Sola-Penna, Mauro/0000-0001-9796-6829; Previato, Jose Osvaldo/0000-0002-9233-9954; Mendonca Previato, Lucia/0000-0003-3927-3244				ALMEIDA IC, 1994, BIOCHEM J, V304, P793, DOI 10.1042/bj3040793; BANERJEE DK, 1981, BIOCHEMISTRY-US, V20, P1561, DOI 10.1021/bi00509a024; BOCK K, 1983, ADV CARBOHYD CHEM BI, V41, P27, DOI 10.1016/S0065-2318(08)60055-4; BOCK K, 1974, J CHEM SOC PERK T 2, P293, DOI 10.1039/p29740000293; BRENER Z, 1973, ANNU REV MICROBIOL, V27, P347, DOI 10.1146/annurev.mi.27.100173.002023; BURLEIGH BA, 1995, ANNU REV MICROBIOL, V49, P175, DOI 10.1146/annurev.mi.49.100195.001135; Cazzulo JJ, 1997, BIOL CHEM, V378, P1; DABROWSKI J, 1994, 2 DIMENSIONAL NMR SP; DAVOUST D, 1985, CARBOHYD RES, V143, P233, DOI 10.1016/S0008-6215(00)90712-2; DIECKMANNSCHUPPERT A, 1993, EUR J BIOCHEM, V216, P779, DOI 10.1111/j.1432-1033.1993.tb18198.x; DiNoia JM, 1996, J BIOL CHEM, V271, P32078, DOI 10.1074/jbc.271.50.32078; DINOIA JM, 1995, J BIOL CHEM, V270, P24146, DOI 10.1074/jbc.270.41.24146; Dische Z., 1962, METHODS CARBOHYDRATE, V1, P507; Do KY, 1997, GLYCOBIOLOGY, V7, P183, DOI 10.1093/glycob/7.2.183; ERICSON MC, 1977, J BIOL CHEM, V252, P7431; GOLDSTEIN I. J., 1965, METHOD CARBOHYD CHEM, V5, P361; GOT R, 1967, BIOCHIM BIOPHYS ACTA, V136, P320, DOI 10.1016/0304-4165(67)90078-5; Gowda DC, 1997, J BIOL CHEM, V272, P6428, DOI 10.1074/jbc.272.10.6428; HALTIWANGER RS, 1990, J BIOL CHEM, V265, P2563; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; HANOVER JA, 1987, J BIOL CHEM, V262, P9887; Hart GW, 1996, GLYCOBIOLOGY, V6, P711, DOI 10.1093/glycob/6.7.711; HART GW, 1993, C MOSBACH, V44, P91; HOLT GD, 1987, J CELL BIOL, V104, P1157, DOI 10.1083/jcb.104.5.1157; Klich G, 1997, CARBOHYD RES, V299, P33, DOI 10.1016/S0008-6215(96)00337-0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu JY, 1996, CARBOHYD RES, V296, P1, DOI 10.1016/S0008-6215(96)00240-6; MENDONCAPREVIATO L, 1983, BIOCHEMISTRY-US, V22, P4980, DOI 10.1021/bi00290a016; ORTEGABARRIA E, 1990, MOL BIOCHEM PARASIT, V43, P151, DOI 10.1016/0166-6851(90)90141-8; Pao YL, 1996, BIOCHEM BIOPH RES CO, V219, P157, DOI 10.1006/bbrc.1996.0198; PAPANASTASIOU P, 1997, GLYCOCONJUGATE S1, V14, pS55; PREVIATO JO, 1985, MOL BIOCHEM PARASIT, V16, P85, DOI 10.1016/0166-6851(85)90051-9; PREVIATO JO, 1995, J BIOL CHEM, V270, P7241, DOI 10.1074/jbc.270.13.7241; PREVIATO JO, 1994, BIOCHEM J, V301, P151, DOI 10.1042/bj3010151; PREVIATO JO, 1990, J BIOL CHEM, V265, P2518; PREVIATO JO, 1991, MEM I O CRUZ S1, V86, P53; SAHA UK, 1997, CARBOHYD RES, V304, P233; Schachter H, 1992, GLYCOCONJUGATES COMP, P263; SCHENKMAN S, 1993, MOL BIOCHEM PARASIT, V59, P293, DOI 10.1016/0166-6851(93)90227-O; Seitz O, 1997, J AM CHEM SOC, V119, P8766, DOI 10.1021/ja971383c; SERRANO AA, 1995, J BIOL CHEM, V270, P27244, DOI 10.1074/jbc.270.45.27244; Tvaroska I, 1995, ADV CARBOHYD CHEM BI, V51, P15, DOI 10.1016/S0065-2318(08)60191-2; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; WIDER G, 1993, J MAGN RESON SER B, V102, P239, DOI 10.1006/jmrb.1993.1092; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; YEN PH, 1974, BIOCHEMISTRY-US, V13, P2420, DOI 10.1021/bi00708a029	46	66	67	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14982	14988		10.1074/jbc.273.24.14982	http://dx.doi.org/10.1074/jbc.273.24.14982			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614105	hybrid			2022-12-27	WOS:000074160400047
J	Roesler, WJ; Park, EA; McFie, PJ				Roesler, WJ; Park, EA; McFie, PJ			Characterization of CCAAT/enhancer-binding protein alpha as a cyclic AMP-responsive nuclear regulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; SERUM-ALBUMIN GENE; TRANSCRIPTION FACTORS; 3T3-L1 PREADIPOCYTES; CAMP RESPONSIVENESS; MAMMALIAN-CELLS; HEPATOMA-CELLS; C/EBP-ALPHA; ENHANCER; EXPRESSION	The alpha isoform of CCAAT/enhancer-binding protein (C/EBP alpha) is a transcription factor that regulates expression of genes linked to adipose differentiation and hepatic nutrient metabolism. Recently, our laboratory has characterized a role for C/EBP alpha in mediating hormonal responsiveness. For example, the cAMP responsiveness of the phosphoenolpyruvate carboxykinase gene promoter in liver requires synergism among the cAMP response element-binding protein (CREB), C/EBP alpha, and activator protein-1. in the present study, we show that C/EBP alpha can functionally substitute for CREB in this cAMP response unit, i.e. cAMP responsiveness can occur in the absence of CREB. This observation is physiologically relevant since both CREB and C/EBP alpha have been shown to hind with high affinity to the cAMP response element in this particular promoter. Structure/function analysis of C/EBP alpha identified specific mutations that differentially affected its constitutive and protein kinase A-inducible activities. This finding suggests that the mechanism whereby C/EBP alpha mediates constitutive transactivation is distinct from that whereby it mediates cAMP responsiveness. These delta support the hypothesis that C/EBP alpha plays a critical role in metabolism, in part by participating in the hormonal regulation of expression of metabolically important genes.	Univ Saskatchewan, Dept Biochem, Saskatoon, SK S7N 5E5, Canada; Univ Tennessee, Dept Pharmacol, Memphis, TN 38163 USA	University of Saskatchewan; University of Tennessee System; University of Tennessee Health Science Center	Roesler, WJ (corresponding author), Univ Saskatchewan, Dept Biochem, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046399] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 46399] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Croniger C, 1997, J BIOL CHEM, V272, P26306, DOI 10.1074/jbc.272.42.26306; DEGROOT RP, 1993, MOL ENDOCRINOL, V7, P145, DOI 10.1210/me.7.2.145; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Hanson R W, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P203; Harlow E, 1988, ANTIBODIES LABORATOR, P471; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; Lee YH, 1997, MOL CELL BIOL, V17, P6014, DOI 10.1128/MCB.17.10.6014; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; LIU JS, 1991, J BIOL CHEM, V266, P19095; MAHONEY CW, 1992, J BIOL CHEM, V267, P19396; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; MEISNER H, 1985, BIOCHEMISTRY-US, V24, P421, DOI 10.1021/bi00323a027; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; NERLOV C, 1995, EMBO J, V14, P4318, DOI 10.1002/j.1460-2075.1995.tb00106.x; NERLOV C, 1994, GENE DEV, V8, P350, DOI 10.1101/gad.8.3.350; NITSCH D, 1993, P NATL ACAD SCI USA, V90, P5479, DOI 10.1073/pnas.90.12.5479; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PARK EA, 1993, J BIOL CHEM, V268, P613; Park EA, 1997, BIOCHEM J, V322, P343, DOI 10.1042/bj3220343; PEI DQ, 1991, MOL CELL BIOL, V11, P1480, DOI 10.1128/MCB.11.3.1480; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; QUINN PG, 1993, J BIOL CHEM, V268, P16999; ROESLER WJ, 1995, J BIOL CHEM, V270, P8225, DOI 10.1074/jbc.270.14.8225; ROESLER WJ, 1993, J BIOL CHEM, V268, P3791; Roesler WJ, 1998, MOL CELL BIOCHEM, V178, P1, DOI 10.1023/A:1006886421795; Roesler WJ, 1996, J BIOL CHEM, V271, P8068, DOI 10.1074/jbc.271.14.8068; ROESLER WJ, 1994, J BIOL CHEM, V269, P14276; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; SHORT JM, 1986, J BIOL CHEM, V261, P9721; SUTHERLAND JA, 1992, GENE DEV, V6, P1810, DOI 10.1101/gad.6.9.1810; TRAUTWEIN C, 1994, J CLIN INVEST, V93, P2554, DOI 10.1172/JCI117266; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VANOOIJ C, 1992, MOL CELL BIOL, V12, P3023, DOI 10.1128/MCB.12.7.3023; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553	48	54	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14950	14957		10.1074/jbc.273.24.14950	http://dx.doi.org/10.1074/jbc.273.24.14950			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614100	hybrid			2022-12-27	WOS:000074160400042
J	Albrieux, M; Lee, HC; Villaz, M				Albrieux, M; Lee, HC; Villaz, M			Calcium signaling by cyclic ADP-ribose, NAADP, and inositol trisphosphate are involved in distinct functions in ascidian oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ RELEASE; CIONA-INTESTINALIS; CRYSTAL-STRUCTURE; SKELETAL-MUSCLE; EGG; FERTILIZATION; ACTIVATION; MEIOSIS; CONTRACTION; METABOLITE	ADP-ribosyl cyclase catalyzes the synthesis of two structurally and functionally different Ca2+ releasing molecules, cyclic ADP-ribose (cADPR) from beta-NAD and nicotinic acid-adenine dinucleotide phosphate (NAADP) from beta-NADP, Their Ca2+-mobilizing effects in ascidian oocytes were characterized ire connection with that induced by inositol 1,4,5-trisphosphate (InsP(3)). Fertilization of the oocyte is accompanied by a decrease in the oocyte Ca2+ current and an increase in membrane capacitance due to the addition of membrane to the cell surface, Both of these electrical changes could be induced by perfusion, through a patch pipette, of nanomolar concentrations of cADPR or its precursor, beta-NAD, into unfertilized oocytes. The changes induced by beta-NAD showed a distinctive delay consistent with its enzymatic conversion to cADPR. The cADPR-induced changes were inhibited by preloading the oocytes with a Ca2+ chelator, indicating the effects were due to Ca2+ release induced by cADPR. Consistently, ryanodine (at high concentration) or 8-amino-cADPR, a specific antagonist of cADPR, but not heparin, inhibited the cADPR induced changes. Both inhibitors likewise blocked the membrane insertion that normally occurred at fertilization consistent with it being mediated by a ryanodine receptor. The effects of NAADP were different from those of cADPR, Although NAADP induced a similar decrease in the Ca2+ current, no membrane insertion occurred. Moreover, pretreatment of the oocytes with NAADP inhibited the post-fertilization Ca2+ oscillation while cADPR did not. A similar Ca2+ oscillation could be artificially induced by perfusing into the oocytes a high concentration of InsP(3) and NAADP could likewise inhibit such an InsP(3)-induced oscillation. This work shows that three independent Ca2+ signaling pathways are present in the oocytes and that each is involved in mediating distinct changes associated with fertilization. The results are consistent with a hierarchical organization of Ca2+ stores in the oocyte.	DBMS, DSV, Lab Canaux Ion & Signalisat, F-38054 Grenoble, France; Univ Minnesota, Dept Physiol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Villaz, M (corresponding author), DBMS, DSV, Lab Canaux Ion & Signalisat, 17 Rue Martyrs, F-38054 Grenoble, France.		Lee, Hon Cheung/C-4329-2009; Albrieux, Mireille/H-3824-2017	Albrieux, Mireille/0000-0002-2817-2563	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017484] Funding Source: NIH RePORTER; NICHD NIH HHS [HD17484] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aarhus R, 1996, J BIOL CHEM, V271, P8513, DOI 10.1074/jbc.271.15.8513; AARHUS R, 1995, J BIOL CHEM, V270, P30827; Albrieux M, 1997, DEV BIOL, V189, P174, DOI 10.1006/dbio.1997.8674; Arnoult C, 1997, CELL CALCIUM, V21, P93, DOI 10.1016/S0143-4160(97)90033-6; ARNOULT C, 1994, DEV BIOL, V166, P1, DOI 10.1006/dbio.1994.1292; ARNOULT C, 1994, J MEMBRANE BIOL, V137, P127; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; COOMBS JL, 1992, DEV BIOL, V153, P272, DOI 10.1016/0012-1606(92)90112-T; CURRIE KPM, 1992, MOL BIOL CELL, V3, P1415, DOI 10.1091/mbc.3.12.1415; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; Genazzani AA, 1996, BIOCHEM J, V315, P721, DOI 10.1042/bj3150721; Genazzani AA, 1996, J BIOL CHEM, V271, P11599, DOI 10.1074/jbc.271.20.11599; Grumetto L, 1997, BIOCHEM BIOPH RES CO, V239, P723, DOI 10.1006/bbrc.1997.7537; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Guse AH, 1997, J BIOL CHEM, V272, P8546, DOI 10.1074/jbc.272.13.8546; HELLMICH MR, 1991, CELL REGUL, V2, P193, DOI 10.1091/mbc.2.3.193; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; Jacobson EL, 1997, ADV EXP MED BIOL, V419, P371; JOHNSON JD, 1976, NATURE, V262, P661, DOI 10.1038/262661a0; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1995, J BIOL CHEM, V270, P2152, DOI 10.1074/jbc.270.5.2152; LEE HC, 1994, NAT STRUCT BIOL, V1, P143, DOI 10.1038/nsb0394-143; Lee HC, 1997, PHYSIOL REV, V77, P1133, DOI 10.1152/physrev.1997.77.4.1133; LEE HC, 1989, J BIOL CHEM, V264, P1608; Lee HC, 1997, ADV EXP MED BIOL, V419, P411; Li PL, 1997, ADV EXP MED BIOL, V419, P437; MARTY I, 1994, P NATL ACAD SCI USA, V91, P2270, DOI 10.1073/pnas.91.6.2270; MCDOUGALL A, 1995, ZYGOTE, V3, P251, DOI 10.1017/S0967199400002641; MCDOUGALL A, 1995, CURR BIOL, V5, P318, DOI 10.1016/S0960-9822(95)00062-5; MOODY WJ, 1985, DEV BIOL, V112, P396, DOI 10.1016/0012-1606(85)90412-9; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; Prasad GS, 1996, NAT STRUCT BIOL, V3, P957, DOI 10.1038/nsb1196-957; Rakovic S, 1996, CURR BIOL, V6, P989, DOI 10.1016/S0960-9822(02)00643-7; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; RUSINKO N, 1989, J BIOL CHEM, V264, P11725; Russo GL, 1996, DEVELOPMENT, V122, P1995; SARDET C, 1989, DEVELOPMENT, V105, P237; SPEKSNIJDER JE, 1990, J CELL BIOL, V110, P1589, DOI 10.1083/jcb.110.5.1589; SPEKSNIJDER JE, 1989, DEV BIOL, V135, P182, DOI 10.1016/0012-1606(89)90168-1; STATES DJ, 1992, TRENDS BIOCHEM SCI, V17, P495, DOI 10.1016/0968-0004(92)90337-9; THORN P, 1994, EMBO J, V13, P2038, DOI 10.1002/j.1460-2075.1994.tb06478.x; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y	43	97	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14566	14574		10.1074/jbc.273.23.14566	http://dx.doi.org/10.1074/jbc.273.23.14566			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603972	hybrid			2022-12-27	WOS:000074021500074
J	Cunnick, JM; Dorsey, JF; Standley, T; Turkson, J; Kraker, AJ; Fry, DW; Jove, R; Wu, J				Cunnick, JM; Dorsey, JF; Standley, T; Turkson, J; Kraker, AJ; Fry, DW; Jove, R; Wu, J			Role of tyrosine kinase activity of epidermal growth factor receptor in the lysophosphatidic acid-stimulated mitogen-activated protein kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; SIGNAL-TRANSDUCTION; EGF RECEPTOR; MAP KINASE; PHOSPHATASE CATALYSIS; RAT-1 FIBROBLASTS; PHOSPHORYLATION; INTERMEDIATE; REQUIREMENT; COMPLEX	Recent evidence indicates that the epidermal growth factor (EGF) receptor mediates a branch of lysophosphatidic acid (LPA)-induced signal transduction pathways that activate mitogen-activated protein (MAP) kinase. However, it is unclear whether the intrinsic tyrosine kinase activity of EGF receptor is involved, We previously showed that reactive oxygen species (ROS) were involved in the LPA-stimulated MAP kinase pathway. Here, we identify tyrosine phosphorylation of EGF receptor as an LPA signaling step that requires ROS. To evaluate the role of the tyrosine kinase activity of EGF receptor in the LPA-stimulated MAP kinase pathway, we examined the effects of are EGF receptor-specific tyrosine kinase inhibitor, PD158780. PD158780 potently inhibited the LPA-stimulated MAP kinase kinase 1/2 (MKK1/2) activation and EGF receptor tyrosine phosphorylation in HeLa cells, while it had no detectable effect on c-Src kinase activity, PD158780 also inhibited LPA-induced MKK1/2 activation and DNA synthesis in NIH 3T3 cells. Furthermore, we compared LPA-stimulated MKK1/2 and MAP kinase activation, transcriptional activity of the c-fos promoter, and DNA synthesis in B82L cells, which lack endogenous EGF receptor, and B82L cells expressing kinase-defective or wild-type human EGF receptor. Results obtained from analysis of these cell Lines suggest that the EGF receptor tyrosine kinase contributes to the LPA-stimulated MAP kinase activation, c-fos transcription, and mitogenesis.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Med Microbiol & Immunol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Ann Arbor, MI 48105 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Pfizer	Wu, J (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, MDC 44,12902 Magnolia Dr, Tampa, FL 33612 USA.		Cunnick, Jess/F-1715-2018; Wu, Jie/R-2404-2019	Wu, Jie/0000-0002-2864-1606	NCI NIH HHS [CA55652] Funding Source: Medline; NIDA NIH HHS [T32 DA 07245] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055652] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [T32DA007245] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; BAE SY, 1997, J BIOL CHEM, V272, P217; BASUMODAK S, 1993, CANCER RES, V53, P4505; Boyer B, 1997, EMBO J, V16, P5904, DOI 10.1093/emboj/16.19.5904; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CHEN QL, 1995, J BIOL CHEM, V270, P28499, DOI 10.1074/jbc.270.48.28499; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; Chuprun JK, 1997, J BIOL CHEM, V272, P773, DOI 10.1074/jbc.272.2.773; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Denu JM, 1996, P NATL ACAD SCI USA, V93, P2493, DOI 10.1073/pnas.93.6.2493; Dixon JE, 1996, RECENT PROG HORM RES, V51, P405; Fry DW, 1997, BIOCHEM PHARMACOL, V54, P877, DOI 10.1016/S0006-2952(97)00242-6; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; GUAN KL, 1991, J BIOL CHEM, V266, P17026; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HARDWICK JS, 1995, P NATL ACAD SCI USA, V92, P4527, DOI 10.1073/pnas.92.10.4527; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HOWE LR, 1993, J BIOL CHEM, V268, P20717; JALINK K, 1993, CELL GROWTH DIFFER, V4, P247; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; Kranenburg O, 1997, EMBO J, V16, P3097, DOI 10.1093/emboj/16.11.3097; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LIN CR, 1986, CELL, V44, P839, DOI 10.1016/0092-8674(86)90006-1; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; Rewcastle GW, 1996, J MED CHEM, V39, P1823, DOI 10.1021/jm9508651; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; SAVILLE MK, 1994, BIOCHEM J, V301, P407, DOI 10.1042/bj3010407; Sekharam M, 1998, TOXICOL APPL PHARM, V149, P210, DOI 10.1006/taap.1997.8361; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; TOKUMURA A, 1994, AM J PHYSIOL, V267, pC204, DOI 10.1152/ajpcell.1994.267.1.C204; TONKS NK, 1988, J BIOL CHEM, V263, P6731; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; WASILENKO WJ, 1991, MOL CELL BIOL, V11, P309, DOI 10.1128/MCB.11.1.309; Weiss FU, 1997, CURR OPIN GENET DEV, V7, P80, DOI 10.1016/S0959-437X(97)80113-X; WRIGHT JD, 1995, J BIOL CHEM, V270, P12085, DOI 10.1074/jbc.270.20.12085; WU J, 1995, J BIOL CHEM, V270, P11484, DOI 10.1074/jbc.270.19.11484; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597; Yurchak LK, 1996, J BIOL CHEM, V271, P12549, DOI 10.1074/jbc.271.21.12549	48	140	145	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14468	14475		10.1074/jbc.273.23.14468	http://dx.doi.org/10.1074/jbc.273.23.14468			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603960	hybrid			2022-12-27	WOS:000074021500062
J	Izawa, M; Sasaki, N; Watahiki, M; Ohara, E; Yoneda, Y; Muramatsu, M; Okazaki, Y; Hayashizaki, Y				Izawa, M; Sasaki, N; Watahiki, M; Ohara, E; Yoneda, Y; Muramatsu, M; Okazaki, Y; Hayashizaki, Y			Recognition sites of 3 '-OH group by T7 RNA polymerase and its application to transcriptional sequencing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE; KLENOW FRAGMENT; BACTERIOPHAGE-T7; GENE; MUTANTS; ASP537; ASP812	When analyzing the elongation mechanisms in T7 RNA polymerase (T7 RNAP)by using site-directed mutagenesis and a protein expression system, we identified the recognition sites of the rNTP 3'-OH group in T7 RNAP. On the basis of three-dimensional crystal structure analysis, we selected sind analyzed six candidate sites interacting with the 3'-OH group of rNTP in T7 RNAP. We found that the Phe-644 and Phe-667 sites are responsible for the high selectivity of T7 RNAP for rNTPs. Also, we constructed the protein mutations of these residues, F644Y and F667Y, which display a >200-fold higher affinity than the wild type for 3'-dNTPs, These findings indicate that the phenylalaine residues of 644 and 667 specifically interact with the 3'-OH group. Thus, these mutants, F644Y and F667Y, with incorporation of 3'-dNTP terminators, which is similar to native rNTPs, can offer low backgrounds and equal intensities of the sequencing ladders in our method, called "transcriptional sequencing.".	RIKEN, Inst Phys & Chem Res, Tsukuba Life Sci Ctr, Genome Sci Lab, Tsukuba, Ibaraki 305, Japan; Nippon Gene Co Ltd, Res & Dev, Toyama 930, Japan; Japan Sci & Technol Corp, JST, CREST, Kawaguchi, Saitama 332, Japan	RIKEN; Japan Science & Technology Agency (JST)	Hayashizaki, Y (corresponding author), RIKEN, Inst Phys & Chem Res, Tsukuba Life Sci Ctr, Genome Sci Lab, Koyadai 3-1-1, Tsukuba, Ibaraki 305, Japan.		Sasaki, Nobuya/F-6579-2012					BEESE LS, 1993, BIOCHEMISTRY-US, V32, P14095, DOI 10.1021/bi00214a004; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BONNER G, 1994, J BIOL CHEM, V269, P25120; BONNER G, 1992, EMBO J, V11, P3767, DOI 10.1002/j.1460-2075.1992.tb05462.x; CHAMBERL.M, 1970, NATURE, V228, P227, DOI 10.1038/228227a0; CHAMBERL.M, 1973, J BIOL CHEM, V248, P2245; Gao GX, 1997, P NATL ACAD SCI USA, V94, P407, DOI 10.1073/pnas.94.2.407; Guajardo R, 1997, J MOL BIOL, V265, P8, DOI 10.1006/jmbi.1996.0707; HAYASHIZAKI Y, 1985, FEBS LETT, V188, P394, DOI 10.1016/0014-5793(85)80409-9; HIROTSUNE S, 1995, NAT GENET, V10, P77, DOI 10.1038/ng0595-77; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HUANG Y, 1997, BIOCHEMISTRY-US, V36, P8321; MOOKHTIAR KA, 1991, BIOCHEMISTRY-US, V30, P6305, DOI 10.1021/bi00239a032; OSUMIDAVIS PA, 1992, J MOL BIOL, V226, P37, DOI 10.1016/0022-2836(92)90122-Z; OSUMIDAVIS PA, 1994, J MOL BIOL, V237, P5, DOI 10.1006/jmbi.1994.1205; PATRA D, 1992, J MOL BIOL, V224, P307, DOI 10.1016/0022-2836(92)90996-W; Sasaki N, 1998, P NATL ACAD SCI USA, V95, P3455, DOI 10.1073/pnas.95.7.3455; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; Sousa R, 1996, TRENDS BIOCHEM SCI, V21, P186, DOI 10.1016/S0968-0004(96)10023-2; SOUSA R, 1995, EMBO J, V14, P4609, DOI 10.1002/j.1460-2075.1995.tb00140.x; TABOR S, 1995, P NATL ACAD SCI USA, V92, P6339, DOI 10.1073/pnas.92.14.6339; VALERIE M, 1996, NUCLEIC ACIDS RES, V24, P4845; VanderHorn PB, 1997, BIOTECHNIQUES, V22, P758, DOI 10.2144/97224pf02; Woody AYM, 1996, BIOCHEMISTRY-US, V35, P144, DOI 10.1021/bi952037f; ZAWADZKI V, 1991, NUCLEIC ACIDS RES, V19, P1948, DOI 10.1093/nar/19.8.1948	25	12	19	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14242	14246		10.1074/jbc.273.23.14242	http://dx.doi.org/10.1074/jbc.273.23.14242			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603929	hybrid			2022-12-27	WOS:000074021500031
J	Feyzi, E; Saldeen, T; Larsson, E; Lindahl, U; Salmivirta, M				Feyzi, E; Saldeen, T; Larsson, E; Lindahl, U; Salmivirta, M			Age-dependent modulation of heparan sulfate structure and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; LIPOPROTEIN-LIPASE; ALZHEIMERS-DISEASE; FINE-STRUCTURE; PDGF-AA; BINDING; PROTEOGLYCANS; SEQUENCES; DEPOLYMERIZATION; IDENTIFICATION	Heparan sulfate interacts with growth factors, matrix components, effecters and modulators of enzymatic catalysis as well as with microbial proteins via sulfated oligosaccharide domains. Although a number of such domains have been characterized, little is known about the regulation of their formation in vivo. Here we show that the structure of human aorta heparan sulfate is gradually modulated during aging in a manner that gives rise to markedly enhanced binding to isoforms of platelet-derived growth factor A and B chains containing polybasic cell retention sequences. By contrast, the binding to fibroblast growth factor 2 is affected to a much lesser extent. The enhanced binding of aorta heparan sulfate to platelet-derived growth factor is suggested to be due to an age-dependent increase of GlcN 6-O-sulfation, resulting in increased abundance of the trisulfated L-iduronic acid (2-OSO3)-GlcNSO(3)(6-OSO3) disaccharide unit. Such units have been shown to hallmark the platelet-derived growth factor A chain-binding site in heparan sulfate.	Univ Uppsala, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden; Univ Uppsala, Dept Surg, S-75123 Uppsala, Sweden; Univ Uppsala, Dept Genet & Pathol, S-75123 Uppsala, Sweden	Uppsala University; Uppsala University; Uppsala University	Feyzi, E (corresponding author), Univ Uppsala, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden.							BAIRD A, 1988, P NATL ACAD SCI USA, V85, P2324, DOI 10.1073/pnas.85.7.2324; BERRYMAN DE, 1995, J BIOL CHEM, V270, P24525, DOI 10.1074/jbc.270.41.24525; BIENKOWSKI MJ, 1985, J BIOL CHEM, V260, P356; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Feyzi E, 1997, J BIOL CHEM, V272, P24850, DOI 10.1074/jbc.272.40.24850; Feyzi E, 1997, J BIOL CHEM, V272, P5518, DOI 10.1074/jbc.272.9.5518; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; GUO Y, 1989, ANAL BIOCHEM, V176, P96, DOI 10.1016/0003-2697(89)90278-9; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; KATO M, 1994, J BIOL CHEM, V269, P18881; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Krettek A, 1997, ARTERIOSCL THROM VAS, V17, P2897, DOI 10.1161/01.ATV.17.11.2897; Lindahl B, 1996, J BIOL CHEM, V271, P16991, DOI 10.1074/jbc.271.29.16991; LINDAHL B, 1995, BIOCHEM J, V306, P177, DOI 10.1042/bj3060177; LORTAT-JACOB H, 1995, BIOCHEM J, V310, P497, DOI 10.1042/bj3100497; Lustig F, 1996, BIOCHEMISTRY-US, V35, P12077, DOI 10.1021/bi960118l; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; MACCARANA M, 1993, GLYCOBIOLOGY, V3, P271, DOI 10.1093/glycob/3.3.271; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; OSTMAN A, 1991, CELL REGUL, V2, P503, DOI 10.1091/mbc.2.7.503; OSTMAN A, 1992, J CELL BIOL, V118, P509, DOI 10.1083/jcb.118.3.509; PARTHASARATHY N, 1994, J BIOL CHEM, V269, P22391; RAINES EW, 1992, J CELL BIOL, V116, P533, DOI 10.1083/jcb.116.2.533; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; SANDERSON RD, 1994, J BIOL CHEM, V269, P13100; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292	32	125	127	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13395	13398		10.1074/jbc.273.22.13395	http://dx.doi.org/10.1074/jbc.273.22.13395			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593669	hybrid			2022-12-27	WOS:000073919100008
J	van Oosterwijk, MF; Filon, R; de Groot, AJL; van Zeeland, AA; Mullenders, LHF				van Oosterwijk, MF; Filon, R; de Groot, AJL; van Zeeland, AA; Mullenders, LHF			Lack of transcription-coupled repair of acetylaminofluorene DNA adducts in human fibroblasts contrasts their efficient inhibition of transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COCKAYNES-SYNDROME CELLS; COMPLEMENTATION GROUP-C; RNA-POLYMERASE-II; MALE B6C3F1 MICE; XERODERMA-PIGMENTOSUM; ESCHERICHIA-COLI; UVRABC NUCLEASE; ACTIVE GENES; STRAND; AMINOFLUORENE	The N-(deoxyguanosine-8-yl)-2-acetylaminofluorene (dG-C8-AAF) lesion is among the most helix distorting DNA lesions. In normal fibroblasts dG-C8-AAF is repaired rapidly in transcriptionally active genes, but without strand specificity, indicating that repair of dG-C8-AAF by global genome repair (GGR) overrules transcription-coupled repair (TCR), Yet, dG-C8-AAF is a very potent inhibitor of transcription. The target size of inhibition (45 kilobases) suggests that transcription inhibition by dG-C8-AAF is caused by blockage of initiation rather than elongation. Cockayne's syndrome (CS) cells appear to be extremely sensitive to the cytotoxic effects of dG-C8-AAF and are unable to recover inhibited RNA synthesis. However, CS cells exhibit no detectable defect in repair of dG-C8-AAF in active genes, indicating that impaired TCR is not the cause of the enhanced sensitivity of CS cells. These and data reported previously suggest that the degree of DNA helix distortion determines the rate of GGR as well as the extent of inhibition of transcription initiation. An interchange of the transcription/repair factor TFIIH from promoter sites to sites of damage might underlie inhibition of transcription initiation. This process is likely to occur more rapidly and efficiently in the case of strongly DNA helix distorting lesions, resulting in a very efficient GGR, a poor contribution of TCR to repair of lesions in active genes, and an efficient inhibition of transcription.	Leiden State Univ, Ctr Med Genet, Dept Radiat Genet & Chem Mutagenesis, NL-2333 AL Leiden, Netherlands; JA Cohen Inst, Interuniv Res Inst Radiopathol & Radiat Protect, NL-2333 AL Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC	Mullenders, LHF (corresponding author), Leiden State Univ, Ctr Med Genet, Dept Radiat Genet & Chem Mutagenesis, Wassenaarseweg 72, NL-2333 AL Leiden, Netherlands.							AMACHER DE, 1977, BIOCHEM BIOPH RES CO, V74, P285, DOI 10.1016/0006-291X(77)91406-1; Bol SAM, 1997, ANAL BIOCHEM, V251, P24, DOI 10.1006/abio.1997.2244; BURNOUF D, 1985, BIOCHIMIE, V67, P385, DOI 10.1016/S0300-9084(85)80085-7; CHEN YH, 1993, J BIOL CHEM, V268, P5849; CHEN YH, 1991, P NATL ACAD SCI USA, V88, P9583, DOI 10.1073/pnas.88.21.9583; CHRISTIANS FC, 1992, MUTAT RES, V274, P93, DOI 10.1016/0921-8777(92)90056-9; Delagoutte E, 1997, J MOL BIOL, V266, P703, DOI 10.1006/jmbi.1996.0830; Donahue BA, 1996, J BIOL CHEM, V271, P10588, DOI 10.1074/jbc.271.18.10588; EVANS FE, 1980, CARCINOGENESIS, V1, P955, DOI 10.1093/carcin/1.11.955; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUCHS RPP, 1976, BIOCHEMISTRY-US, V15, P3347, DOI 10.1021/bi00660a027; FUCHS RPP, 1974, BIOCHEMISTRY-US, V13, P4435, DOI 10.1021/bi00718a028; FUCHS RPP, 1984, EMBO J, V3, P757, DOI 10.1002/j.1460-2075.1984.tb01880.x; HEFLICH RH, 1994, MUTAT RES-REV GENET, V318, P73, DOI 10.1016/0165-1110(94)90025-6; KANTOR GJ, 1990, MUTAT RES, V235, P171, DOI 10.1016/0921-8777(90)90071-C; LAI CC, 1988, CARCINOGENESIS, V9, P1295, DOI 10.1093/carcin/9.7.1295; LAI CC, 1987, CARCINOGENESIS, V8, P471, DOI 10.1093/carcin/8.3.471; LATTIER DL, 1989, NUCLEIC ACIDS RES, V17, P1061, DOI 10.1093/nar/17.3.1061; LEADON SA, 1991, MUTAT RES, V255, P67, DOI 10.1016/0921-8777(91)90019-L; MA LB, 1995, BBA-REV CANCER, V1242, P137, DOI 10.1016/0304-419X(95)00008-4; MAYNE LV, 1982, CANCER RES, V42, P1473; MCGREGOR WG, 1995, J BIOL CHEM, V270, P27222, DOI 10.1074/jbc.270.45.27222; MOORE PD, 1982, P NATL ACAD SCI-BIOL, V79, P7166, DOI 10.1073/pnas.79.23.7166; PetitFrere C, 1996, MUTAT RES-FUND MOL M, V354, P87, DOI 10.1016/0027-5107(96)00042-5; PIERCE JR, 1989, BIOCHEMISTRY-US, V28, P5821, DOI 10.1021/bi00440a018; RUVEN HJT, 1994, MUTAT RES-DNA REPAIR, V315, P189, DOI 10.1016/0921-8777(94)90018-3; SEEBERG E, 1990, P NATL ACAD SCI USA, V87, P191, DOI 10.1073/pnas.87.1.191; TANG MS, 1989, J BIOL CHEM, V264, P14455; VANHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890, DOI 10.1093/nar/21.25.5890; VANHOFFEN A, 1994, EMBO J, V2, P360; VANHOUTE LPA, 1987, CARCINOGENESIS, V8, P759, DOI 10.1093/carcin/8.6.759; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; vanOosterwijk MF, 1996, MOL CELL BIOL, V16, P4436; vanOosterwijk MF, 1996, NUCLEIC ACIDS RES, V24, P4653, DOI 10.1093/nar/24.23.4653; VANZEELAND AA, 1982, MUTAT RES, V92, P379, DOI 10.1016/0027-5107(82)90237-8; VENEMA J, 1990, NUCLEIC ACIDS RES, V18, P443, DOI 10.1093/nar/18.3.443; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; VU VT, 1985, CARCINOGENESIS, V6, P45, DOI 10.1093/carcin/6.1.45	38	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13599	13604		10.1074/jbc.273.22.13599	http://dx.doi.org/10.1074/jbc.273.22.13599			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593697	hybrid			2022-12-27	WOS:000073919100036
J	Caulfield, JL; Wishnok, JS; Tannenbaum, SR				Caulfield, JL; Wishnok, JS; Tannenbaum, SR			Nitric oxide-induced deamination of cytosine and guanine in deoxynucleosides and oligonucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APURINIC APYRIMIDINIC SITES; DEOXYRIBONUCLEIC-ACID; ESCHERICHIA-COLI; SYNTHETIC POLYDEOXYRIBONUCLEOTIDES; POINT MUTATIONS; N-NITROSATION; HUMAN-CELLS; DNA; RESIDUES; GENE	The autoxidation of nitric oxide (NO.) forms the nitrosating agent N2O3, which can directly damage DNA by deamination of DNA bases following nitrosation of their primary amine functionalities. Within the G:C base pair, deamination results in the formation of xanthine and uracil, respectively. To determine the effect of DNA structure on the deamination of guanine and cytosine, the NO.-induced deamination rate constants for deoxynucleosides, single-and double-stranded oligonucleotides, and a G-quartet oligonucleotide were measured. Deamination rate constants were determined relative to morpholine using a Silastic membrane to deliver NO. at a rate of similar to 10-20 nmol/ml/min for 60 min, yielding a final concentration of similar to 600-1200 mu M NO3-. GC/MS analysis revealed formation of nanomolar levels of deamination products from millimolar concentrations of deoxynucleosides and oligomers. Deamination rate constants for cytosine and guanine in all types of DNA were lower than the morpholine nitrosation rate constant by a factor of similar to 10(3)-10(4). Xanthine was formed at twice the rate of uracil, and this may have important consequences for mechanisms of NO.-induced mutations. Single-stranded oligomers were 5 times more reactive than deoxynucleosides toward N2O3, Double-stranded oligomers were 10-fold less reactive than single-stranded oligomers, suggesting that Watson-Crick base pairing protects DNA from deamination. G-quartet structures were also protective, presumably because of hydrogen bonding. These results demonstrate that DNA structure is an important factor in determining the reactivity of DNA bases with NO .-derived species.	MIT, Dept Chem, Cambridge, MA 02139 USA; MIT, Div Toxicol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Tannenbaum, SR (corresponding author), MIT, Dept Chem, Room 56-731A, Cambridge, MA 02139 USA.		Wishnok, John S./A-3173-2009		NCI NIH HHS [CA26731, CA09112] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA026731] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BJURSELL G, 1979, NATURE, V280, P420, DOI 10.1038/280420a0; BOITEUX S, 1982, BIOCHEMISTRY-US, V21, P6746, DOI 10.1021/bi00269a020; CAREY FA, 1990, ADV ORGANIC CHEM A, P579; Caulfield JL, 1996, J BIOL CHEM, V271, P25859, DOI 10.1074/jbc.271.42.25859; COULONDRE C, 1978, NATURE, V274, P775, DOI 10.1038/274775a0; DOMENA JD, 1988, BIOCHEMISTRY-US, V27, P6742, DOI 10.1021/bi00418a015; DUKER NJ, 1986, CHEM-BIOL INTERACT, V60, P265, DOI 10.1016/0009-2797(86)90057-8; DUKER NJ, 1986, CHEM-BIOL INTERACT, V58, P241, DOI 10.1016/S0009-2797(86)80101-6; Duncan B. K., 1978, DNA REPAIR MECHANISM, V1978, P183; DUNCAN BK, 1980, NATURE, V287, P560, DOI 10.1038/287560a0; ERITJA R, 1994, NUCLEIC ACIDS RES, V24, P168; FIX DF, 1987, MOL GEN GENET, V209, P78, DOI 10.1007/BF00329839; FREDERICO LA, 1993, BIOCHEMISTRY-US, V32, P6523, DOI 10.1021/bi00077a005; FREDERICO LA, 1990, BIOCHEMISTRY-US, V29, P2532, DOI 10.1021/bi00462a015; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOULD ES, 1959, MECHANISM STRUCTURE, P452; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KAMIYA H, 1992, NUCLEOS NUCLEOT, V11, P247, DOI 10.1080/07328319208021700; KARRAN P, 1980, BIOCHEMISTRY-US, V19, P6005, DOI 10.1021/bi00567a010; Keshive M, 1996, CHEM RES TOXICOL, V9, P988, DOI 10.1021/tx960036y; LEU RW, 1991, J IMMUNOL, V147, P1816; LEWIS RS, 1995, J AM CHEM SOC, V117, P3933, DOI 10.1021/ja00119a006; LINDAHL T, 1974, P NATL ACAD SCI USA, V71, P3649, DOI 10.1073/pnas.71.9.3649; LINDAHL T, 1974, BIOCHEMISTRY-US, V13, P3405, DOI 10.1021/bi00713a035; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3610, DOI 10.1021/bi00769a018; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3618, DOI 10.1021/bi00769a019; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; MONCADA S, 1991, PHARMACOL REV, V43, P109; NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030, DOI 10.1073/pnas.89.7.3030; PATTINSON JK, 1990, BLOOD, V76, P2242; ROUTLEDGE MN, 1994, CHEM RES TOXICOL, V7, P628, DOI 10.1021/tx00041a007; SAGHER D, 1983, BIOCHEMISTRY-US, V22, P4518, DOI 10.1021/bi00288a026; SCHUSTER H, 1960, BIOCHEM BIOPH RES CO, V2, P320, DOI 10.1016/0006-291X(60)90025-5; SHAPIRO HS, 1966, BIOCHEMISTRY-US, V5, P3012, DOI 10.1021/bi00873a034; SHAPIRO R, 1972, BIOCHIM BIOPHYS ACTA, V281, P501, DOI 10.1016/0005-2787(72)90150-5; SHAPIRO R, 1966, BIOCHEMISTRY-US, V5, P2358, DOI 10.1021/bi00871a026; SHAPIRO R, 1968, BIOCHEMISTRY-US, V7, P448, DOI 10.1021/bi00841a057; SHAW BR, 1994, STRUCTURAL BIOLOGY: THE STATE OF THE ART, VOL 2, P367; SINGER B, 1983, MOL BIOL MUTAGENS CA, P19; SUGIMURA T, 1967, NATURE, V216, P943, DOI 10.1038/216943a0; TAMIR S, 1993, CHEM RES TOXICOL, V6, P895, DOI 10.1021/tx00036a021; WILLIAMSON JR, 1994, ANNU REV BIOPH BIOM, V23, P703, DOI 10.1146/annurev.bb.23.060194.003415; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501	45	153	156	3	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					12689	12695		10.1074/jbc.273.21.12689	http://dx.doi.org/10.1074/jbc.273.21.12689			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582291	hybrid			2022-12-27	WOS:000073768500002
J	Chang, JL; Jin, JP; Lollar, P; Bode, W; Brandstetter, H; Hamaguchi, N; Straight, DL; Stafford, DW				Chang, JL; Jin, JP; Lollar, P; Bode, W; Brandstetter, H; Hamaguchi, N; Straight, DL; Stafford, DW			Changing residue 338 in human factor IX from arginine to Alanine causes an increase in catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-IX; BLOOD-COAGULATION; FACTOR-VIIIA; FACTOR-X; HEMOPHILIA-B; FACTOR-XIA; SITE; ACTIVATION; THROMBIN; BINDING	This study was designed to identify functionally important factor IX (FIX) residues. Using recombinant techniques and cell culture, we produced a mutant FIX with arginine at 338 changed to alanine (R338A-FIX). This molecule had approximately 3 times greater clotting activity than that of wild type FIX (wt-FIX) in the activated partial thromboplastin assay. R338A-FIX reacted normally with a panel of three FIX specific monoclonal antibodies and migrated on sodium dodecyl sulfate-polyacrylamide gels indistinguishably from wt-FIX. Using functional assays, we determined that R338A-FIXa's K-d for factor VIIIa (FVIIIa) was similar to that of wt-FIXa. Our kinetic analysis, using factor X as substrate, indicated that the mutation's major effects were a S-fold increase in k(cat) and a 2-fold decrease in K-m both manifested only in the presence of FVIIIa, R338A-FIXa's increased catalytic efficiency did not result from ablation of a thrombin sensitive site, reported to occur at arginine 338, since in our assays the thrombin inhibitor, hirudin, had no effect on activity of either wt-FIXa or R338A-FIXa. R338A-FIXa and wt-FIXa had equal activity, with or without FVIIIa, toward the synthetic substrate, methylsulfonyl-D-cyclohexylglycyl-arginine-p-nitroanilide. Interestingly, R338A-FIXa had reduced affinity for heparin, Therefore, we propose that R338A-FIXa's increased activity is not due to an allosteric effect on the active site, but that the Arg-338 residue is part of an exosite that binds both factor X and the mucopolysaccharide, heparin.	Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Emory Univ, Dept Med, Div Hematol Oncol, Atlanta, GA 30322 USA; Max Planck Inst Biochem, D-82152 Martinsried, Germany	University of North Carolina; University of North Carolina Chapel Hill; Emory University; Max Planck Society	Stafford, DW (corresponding author), Univ N Carolina, Dept Biol, CB 3280, Chapel Hill, NC 27599 USA.		Brandstetter, Hans/E-6754-2011	Brandstetter, Hans/0000-0002-6089-3045	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038973] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 38973] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BAJAJ SP, 1983, BIOCHEMISTRY-US, V22, P4047, DOI 10.1021/bi00286a009; BARROW RT, 1994, J BIOL CHEM, V269, P26796; BODE W, 1992, PROTEIN SCI, V1, P426; BRANDSTETTER H, 1995, P NATL ACAD SCI USA, V92, P9796, DOI 10.1073/pnas.92.21.9796; CASTILLO MJ, 1983, BIOCHEMISTRY-US, V22, P1021, DOI 10.1021/bi00274a004; CHANG JY, 1995, THROMB HAEMOSTASIS, V73, P1202; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DUFFY EJ, 1992, J BIOL CHEM, V267, P17006; ENFIELD DL, 1984, BLOOD, V64, P821; Esmon CT, 1996, J BIOL CHEM, V271, P13882, DOI 10.1074/jbc.271.23.13882; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GRIFFITH MJ, 1985, J CLIN INVEST, V75, P4, DOI 10.1172/JCI111694; HAMAGUCHI N, 1991, J BIOL CHEM, V266, P15213; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; KISIEL W, 1985, BLOOD, V66, P1302; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larson PJ, 1996, J BIOL CHEM, V271, P3869; LAWSON JH, 1992, J BIOL CHEM, V267, P4834; LOZIER JN, 1990, BLOOD, V75, P1097; MUTUCUMARANA VP, 1992, J BIOL CHEM, V267, P17012; NESHEIM ME, 1981, J BIOL CHEM, V256, P9874; Segel I. H., 1993, ENZYME KINETICS BEHA, P100; SHEEHAN JP, 1994, P NATL ACAD SCI USA, V91, P5518, DOI 10.1073/pnas.91.12.5518; SPITZER SG, 1990, BIOCHEM J, V265, P219, DOI 10.1042/bj2650219; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VYSOTCHIN A, 1993, J BIOL CHEM, V268, P8436; WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775; YE J, 1991, J BIOL CHEM, V266, P23016	30	85	124	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12089	12094		10.1074/jbc.273.20.12089	http://dx.doi.org/10.1074/jbc.273.20.12089			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575152	hybrid, Green Published			2022-12-27	WOS:000073629800017
J	Crawford, MJ; Goldberg, DE				Crawford, MJ; Goldberg, DE			Role for the Salmonella flavohemoglobin in protection from nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE-STRESS-RESPONSE; ESCHERICHIA-COLI; GENE-EXPRESSION; SACCHAROMYCES-CEREVISIAE; ALCALIGENES-EUTROPHUS; BACTERIAL HEMOGLOBIN; S-NITROSOTHIOLS; NITROUS-OXIDE; OXYGEN; TYPHIMURIUM	Hemoglobin homologs are being identified in an expanding number of unicellular prokaryotic and eukaryotic organisms. Many of these hemoglobins are two domain proteins that possess a flavin-containing reductase in their C terminus. Determination of a function for these flavohemoglobins has been elusive. A Salmonella typhimurium strain harboring a deletion in the flavohemoglobin gene shows no difference in growth under oxidative stress conditions but displays an increased sensitivity to acidified nitrite and S-nitrosothiols, both of which produce nitric oxide. The effect is seen aerobically or anaerobically, indicating that oxygen is not required for flavohemoglobin function. These results suggest a role for the bacterial flavohemoglobins that is independent of oxygen metabolism and provide evidence for a bacterial route of protection from nitric oxide that is distinct from oxidative stress responses.	Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Microbiol, St Louis, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL)	Goldberg, DE (corresponding author), Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Med, POB 8230,660 S Euclid Ave, St Louis, MO 63110 USA.	goldberg@borcim.wustl.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007172] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARNELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279, DOI 10.1006/abbi.1995.1231; ARUTYUNYAN E G, 1981, Molekulyarnaya Biologiya (Moscow), V15, P27; BUNTON CA, 1955, NATURE, V175, P83, DOI 10.1038/175083b0; CASTRESANA J, 1994, EMBO J, V13, P2516, DOI 10.1002/j.1460-2075.1994.tb06541.x; CRAMM R, 1994, J BIOL CHEM, V269, P7349; CRAWFORD MJ, 1995, J BIOL CHEM, V270, P6991, DOI 10.1074/jbc.270.12.6991; Crow J P, 1995, Curr Top Microbiol Immunol, V196, P57; DEGROOTE MA, 1995, P NATL ACAD SCI USA, V92, P6399, DOI 10.1073/pnas.92.14.6399; DeGroote MA, 1996, SCIENCE, V272, P414, DOI 10.1126/science.272.5260.414; Dickerson R.E., 1983, HEMOGLOBIN STRUCTURE; DIKSHIT KL, 1990, NUCLEIC ACIDS RES, V18, P4149, DOI 10.1093/nar/18.14.4149; DIKSHIT RP, 1992, ARCH BIOCHEM BIOPHYS, V293, P241, DOI 10.1016/0003-9861(92)90391-9; Fang FC, 1997, J CLIN INVEST, V99, P2818, DOI 10.1172/JCI119473; FREELISCH M, 1989, J CARDIOVASC PHA S11, V17, P13; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; GILLESGONZALES MA, 1991, NATURE, V360, P170; Hardison RC, 1996, P NATL ACAD SCI USA, V93, P5675, DOI 10.1073/pnas.93.12.5675; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; Holmberg N, 1997, NAT BIOTECHNOL, V15, P244, DOI 10.1038/nbt0397-244; IOANNIDIS N, 1992, BIOCHEM J, V288, P649, DOI 10.1042/bj2880649; JI XB, 1988, BIOCHEM BIOPH RES CO, V157, P106, DOI 10.1016/S0006-291X(88)80018-4; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; KALDORF M, 1993, ARCH MICROBIOL, V160, P432, DOI 10.1007/BF00245303; KHOSLA C, 1988, NATURE, V331, P633, DOI 10.1038/331633a0; KHOSLA C, 1989, J BACTERIOL, V171, P5990; Konat Gregory W., 1994, P37; LaCelle M, 1996, J BACTERIOL, V178, P3803, DOI 10.1128/jb.178.13.3803-3808.1996; LANCASTER JR, 1994, P NATL ACAD SCI USA, V91, P8137, DOI 10.1073/pnas.91.17.8137; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; MembrilloHernandez J, 1997, J BACTERIOL, V179, P3164, DOI 10.1128/jb.179.10.3164-3170.1997; Moens L, 1996, MOL BIOL EVOL, V13, P324, DOI 10.1093/oxfordjournals.molbev.a025592; NUNOSHIBA T, 1993, P NATL ACAD SCI USA, V90, P9993, DOI 10.1073/pnas.90.21.9993; PARK JY, 1988, J PHYS CHEM-US, V92, P6294, DOI 10.1021/j100333a025; Poole RK, 1996, J BACTERIOL, V178, P5487, DOI 10.1128/jb.178.18.5487-5492.1996; POOLE RK, 1994, P ROY SOC B-BIOL SCI, V255, P251, DOI 10.1098/rspb.1994.0036; PROBST I, 1979, BIOCHIM BIOPHYS ACTA, V576, P471, DOI 10.1016/0005-2795(79)90422-7; RIGGS AF, 1991, AM ZOOL, V31, P535; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH MS, 1983, APPL ENVIRON MICROB, V45, P1545, DOI 10.1128/AEM.45.5.1545-1547.1983; SONCINI FC, 1995, J BACTERIOL, V177, P4364, DOI 10.1128/jb.177.15.4364-4371.1995; STAMLER JS, 1992, ANAL CHEM, V64, P779, DOI 10.1021/ac00031a014; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; Steiert J G, 1990, DNA Seq, V1, P107, DOI 10.3109/10425179009016038; STERNBERG NL, 1991, METHOD ENZYMOL, V204, P18; VASUDEVAN SG, 1991, MOL GEN GENET, V226, P49, DOI 10.1007/BF00273586; WATSON N, 1992, J BACTERIOL, V174, P530, DOI 10.1128/jb.174.2.530-540.1992; Zhao XJ, 1996, J BIOL CHEM, V271, P25131, DOI 10.1074/jbc.271.41.25131; ZHU H, 1992, P NATL ACAD SCI USA, V89, P5015, DOI 10.1073/pnas.89.11.5015	48	148	150	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12543	12547		10.1074/jbc.273.20.12543	http://dx.doi.org/10.1074/jbc.273.20.12543			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575213	hybrid			2022-12-27	WOS:000073629800078
J	Hubbard, SR; Mohammadi, M; Schlessinger, J				Hubbard, SR; Mohammadi, M; Schlessinger, J			Autoregulatory mechanisms in protein-tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							GROWTH-FACTOR RECEPTOR-3; HUMAN INSULIN-RECEPTOR; THANATOPHORIC DYSPLASIA; CRYSTAL-STRUCTURE; SRC FAMILY; AUTOPHOSPHORYLATION SITES; SIGNAL-TRANSDUCTION; CATALYTIC SUBUNIT; POINT MUTATION; DOMAIN		NYU Med Ctr, Dept Pharmacol, New York, NY 10016 USA; NYU Med Ctr, Skirball Inst Biomol Med, New York, NY 10016 USA	New York University; New York University	Schlessinger, J (corresponding author), NYU Med Ctr, Dept Pharmacol, New York, NY 10016 USA.		Mohammadi, Moosa/ABA-6745-2020; kasaei, fahime/T-7197-2018	Mohammadi, Moosa/0000-0003-2434-9437; 				ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; CAREY JO, 1995, DIABETES, V44, P682, DOI 10.2337/diabetes.44.6.682; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; Feng J, 1997, MOL CELL BIOL, V17, P2497, DOI 10.1128/MCB.17.5.2497; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; GOTOH N, 1992, BIOCHEM BIOPH RES CO, V186, P768, DOI 10.1016/0006-291X(92)90812-Y; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LONGATI P, 1994, ONCOGENE, V9, P49; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MITRA G, 1991, ONCOGENE, V6, P2237; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; POSNER BI, 1994, J BIOL CHEM, V269, P4596; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SUPERTIFURGA G, 1995, BIOESSAYS, V17, P321, DOI 10.1002/bies.950170408; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Webster MK, 1996, MOL CELL BIOL, V16, P4081; WEI L, 1995, J BIOL CHEM, V270, P8122, DOI 10.1074/jbc.270.14.8122; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	44	236	245	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					11987	11990		10.1074/jbc.273.20.11987	http://dx.doi.org/10.1074/jbc.273.20.11987			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575136	hybrid			2022-12-27	WOS:000073629800001
J	Masliah, E; Raber, J; Alford, M; Mallory, M; Mattson, MP; Yang, DS; Wong, DR; Mucke, L				Masliah, E; Raber, J; Alford, M; Mallory, M; Mattson, MP; Yang, DS; Wong, DR; Mucke, L			Amyloid protein precursor stimulates excitatory amino acid transport - Implications for roles in neuroprotection and pathogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY GLUTAMATE TRANSPORTER; CEREBRAL CORTICAL-NEURONS; CENTRAL-NERVOUS-SYSTEM; ALZHEIMERS-DISEASE; TRANSGENIC MICE; RAT-BRAIN; SECRETED FORMS; D-ASPARTATE; KINASE-C; BETA	Excitatory neurotransmitters such as glutamate are required for the normal functioning of the central nervous system but can trigger excitotoxic neuronal injury if allowed to accumulate to abnormally high levels. Their extracellular levels are controlled primarily by transmitter uptake into astrocytes. Here, we demonstrate that the amyloid protein precursor may participate in the regulation of this important process. The amyloid protein precursor has been well conserved through evolution, and a number of studies indicate that it may function as an endogenous excitoprotectant. However, the mechanisms underlying this neuroprotective capacity remain largely unknown. At moderate levels of expression, human amyloid protein precursors increased glutamate/aspartate uptake in brains of transgenic mice, with the 751-amino acid isoform showing greater potency than the 695-amino acid isoform. Cerebral glutamate/aspartate transporter protein levels were higher in transgenic mice than in non-transgenic controls, whereas transporter mRNA levels were unchanged. Amyloid protein precursor-dependent stimulation of aspartate uptake by cultured primary astrocytes was associated with increases in protein kinase A and C activity and could be blocked by inhibitors of these kinases. The stimulation of astroglial excitatory amino acid transport by amyloid protein precursors could protect the brain against excitotoxicity and may play an important role in neurotransmission.	Univ Calif San Francisco, Gladstone Inst Neurol Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94141 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; Univ Calif San Francisco, Program Neurosci, San Francisco, CA 94141 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Kentucky; University of Kentucky; University of California System; University of California San Francisco	Mucke, L (corresponding author), Univ Calif San Francisco, Gladstone Inst Neurol Dis, POB 419100, San Francisco, CA 94141 USA.	lennart_mucke@quickmail.ucsf.edu	Mattson, Mark P/F-6038-2012	Mucke, Lennart/0000-0001-6256-9559	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034602] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG011385, R01AG011385, R29AG010869] Funding Source: NIH RePORTER; NIA NIH HHS [AG11385, AG10869] Funding Source: Medline; NINDS NIH HHS [NS34602] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALFORD MF, 1994, J HISTOCHEM CYTOCHEM, V42, P283, DOI 10.1177/42.2.8288869; ARAKI W, 1991, BIOCHEM BIOPH RES CO, V181, P265, DOI 10.1016/S0006-291X(05)81412-3; ASKANAS V, 1992, NEUROSCI LETT, V143, P96, DOI 10.1016/0304-3940(92)90241-X; BALCAR VJ, 1992, LIFE SCI, V51, P1467, DOI 10.1016/0024-3205(92)90556-5; BARGER SW, 1995, J NEUROCHEM, V64, P2087; BRIDGES RJ, 1991, J MED CHEM, V34, P717, DOI 10.1021/jm00106a037; BUTT AM, 1994, J NEUROCYTOL, V23, P486, DOI 10.1007/BF01184072; Butterfield DA, 1997, CHEM RES TOXICOL, V10, P495, DOI 10.1021/tx960130e; CASADO M, 1993, J BIOL CHEM, V268, P27313; COWBURN R, 1988, NEUROSCI LETT, V86, P109, DOI 10.1016/0304-3940(88)90192-9; CROSS AJ, 1986, NEUROSCI LETT, V63, P121, DOI 10.1016/0304-3940(86)90047-9; DOSTMANN WRG, 1990, J BIOL CHEM, V265, P10484; FAGG GE, 1983, NEUROSCIENCE, V9, P701, DOI 10.1016/0306-4522(83)90263-4; Furukawa K, 1996, J NEUROCHEM, V67, P1882, DOI 10.1046/j.1471-4159.1996.67051882.x; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Gegelashvili G, 1997, MOL PHARMACOL, V52, P6, DOI 10.1124/mol.52.1.6; GREENAMYRE JT, 1994, NEUROLOGY, V44, P7; GUNDERSEN V, 1995, J NEUROSCI, V15, P4417; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; KANAI Y, 1993, FASEB J, V7, P1450, DOI 10.1096/fasebj.7.15.7903261; KANAI Y, 1994, J BIOL CHEM, V269, P20599; KANAI Y, 1993, TRENDS NEUROSCI, V16, P365, DOI 10.1016/0166-2236(93)90094-3; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; LeBlanc AC, 1996, J NEUROCHEM, V66, P2300; LeBlanc AC, 1997, J NEUROCHEM, V68, P1183; Lendon CL, 1997, JAMA-J AM MED ASSOC, V277, P825, DOI 10.1001/jama.277.10.825; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; LOFFLER J, 1992, J NEUROCHEM, V59, P1316, DOI 10.1111/j.1471-4159.1992.tb08443.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTINMORRIS LE, 1990, DEVELOPMENT, V110, P185; Masliah E, 1996, ANN NEUROL, V40, P759, DOI 10.1002/ana.410400512; MASLIAH E, 1992, BRAIN RES, V574, P312, DOI 10.1016/0006-8993(92)90831-S; Masliah E, 1997, NEUROSCIENCE, V78, P135, DOI 10.1016/S0306-4522(96)00553-2; MASLIAH E, 1992, BRAIN RES, V593, P323, DOI 10.1016/0006-8993(92)91329-D; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MOYA KL, 1994, DEV BIOL, V161, P597, DOI 10.1006/dbio.1994.1055; MUCKE L, 1995, J EXP MED, V181, P1551, DOI 10.1084/jem.181.4.1551; MUCKE L, 1994, BRAIN RES, V666, P151, DOI 10.1016/0006-8993(94)90767-6; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; NITSCH RM, 1993, P NATL ACAD SCI USA, V90, P5191, DOI 10.1073/pnas.90.11.5191; Olney J W, 1990, Can Dis Wkly Rep, V16 Suppl 1E, P47; Peters A, 1991, FINE STRUCTURE NERVO, V3; Pfrieger FW, 1996, CURR OPIN NEUROBIOL, V6, P615, DOI 10.1016/S0959-4388(96)80093-6; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; ROCH JM, 1994, P NATL ACAD SCI USA, V91, P7450, DOI 10.1073/pnas.91.16.7450; ROCKENSTEIN EM, 1995, J BIOL CHEM, V270, P28257; Rothstein JD, 1996, NEUROLOGY, V47, pS19, DOI 10.1212/WNL.47.4_Suppl_2.19S; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; ROTHSTEIN JD, 1993, P NATL ACAD SCI USA, V90, P6591, DOI 10.1073/pnas.90.14.6591; SCHUBERT W, 1991, BRAIN RES, V563, P184, DOI 10.1016/0006-8993(91)91532-6; SCOTT HL, 1995, J NEUROCHEM, V64, P2193, DOI 10.1046/j.1471-4159.1995.64052193.x; SELKOE DJ, 1994, J NEUROPATH EXP NEUR, V53, P438, DOI 10.1097/00005072-199409000-00003; SMITHSWINTOSKY VL, 1994, J NEUROCHEM, V63, P781, DOI 10.1046/j.1471-4159.1994.63020781.x; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; Torroja L, 1996, J NEUROSCI, V16, P4638; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; van Leeuwen FW, 1998, SCIENCE, V279, P242, DOI 10.1126/science.279.5348.242; WyssCoray T, 1996, J CLIN INVEST, V97, P789, DOI 10.1172/JCI118478; YAMAMOTO K, 1994, J NEUROBIOL, V25, P585, DOI 10.1002/neu.480250510	63	49	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12548	12554		10.1074/jbc.273.20.12548	http://dx.doi.org/10.1074/jbc.273.20.12548			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575214	hybrid			2022-12-27	WOS:000073629800079
J	Newitt, JA; Bernstein, HD				Newitt, JA; Bernstein, HD			A mutation in the Escherichia coli secY gene that produces distinct effects on inner membrane protein insertion and protein export	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; SIGNAL RECOGNITION PARTICLE; CYTOPLASMIC MEMBRANE; SECRETORY PROTEINS; CONDUCTING CHANNEL; 4.5S RNA; TRANSLOCATION; MUTANTS; OCCURS; RIBONUCLEOPROTEIN	E. coli strains that contain the secY40 mutation are cold-sensitive, but protein export defects have not been observed even at the nonpermissive temperature. Here we describe experiments designed to explain the conditional phenotype associated with this allele, We found that combining the secY40 mutation with defects in the signal recognition particle targeting pathway led to synthetic lethality. Since the signal recognition particle is required for the insertion of inner membrane proteins (IMPs) into the cytoplasmic membrane but not for protein export, this observation prompted us to examine the effect of the secY40 mutation on IMP biogenesis. The membrane insertion of all IMPs that we tested was impaired at both permissive and nonpermissive temperatures in secY40 cells grown in either rich or minimal medium. The magnitude of the insertion defects was greatest in cells grown at low temperature in rich medium, conditions in which the growth defect was most pronounced. Consistent with previous reports, we could not detect protein export defects in secY40 cells grown in minimal medium. Upon growth in rich medium, only slight protein export defects were observed. Taken together, these results suggest that the impairment of IMP insertion causes the cold sensitivity of secY40 strains. Furthermore, these results provide the first evidence that the protein export and membrane protein insertion functions of the translocon are genetically separable.	NIDDK, GBB, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Bernstein, HD (corresponding author), NIDDK, GBB, NIH, 10 Ctr Dr,MSC 1810, Bethesda, MD 20892 USA.							AKIYAMA Y, 1989, J BIOL CHEM, V264, P437; ANDERSSON H, 1993, EMBO J, V12, P683, DOI 10.1002/j.1460-2075.1993.tb05702.x; BABA T, 1990, J BACTERIOL, V172, P7005, DOI 10.1128/jb.172.12.7005-7010.1990; Bassilana M, 1996, EMBO J, V15, P5202, DOI 10.1002/j.1460-2075.1996.tb00905.x; BROWN S, 1984, J MOL BIOL, V178, P533, DOI 10.1016/0022-2836(84)90237-7; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; DANESE PN, 1995, J BACTERIOL, V177, P4969, DOI 10.1128/jb.177.17.4969-4973.1995; deGier JWL, 1996, FEBS LETT, V399, P307, DOI 10.1016/S0014-5793(96)01354-3; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; GEBERT JF, 1988, J BIOL CHEM, V263, P16652; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; GROSS L, 1992, J MOL BIOL, V228, P488, DOI 10.1016/0022-2836(92)90837-A; HARTMANN E, 1994, NATURE, V367, P654, DOI 10.1038/367654a0; HIGH S, 1993, J CELL BIOL, V121, P743, DOI 10.1083/jcb.121.4.743; INOUYE H, 1981, J BACTERIOL, V146, P668, DOI 10.1128/JB.146.2.668-675.1981; KUMAMOTO CA, 1985, J BACTERIOL, V163, P267, DOI 10.1128/JB.163.1.267-274.1985; Liao SR, 1997, CELL, V90, P31, DOI 10.1016/S0092-8674(00)80311-6; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Mothes W, 1997, CELL, V89, P523, DOI 10.1016/S0092-8674(00)80234-2; Newitt JA, 1997, EUR J BIOCHEM, V245, P720, DOI 10.1111/j.1432-1033.1997.00720.x; NILSSON I, 1994, J CELL BIOL, V126, P1127, DOI 10.1083/jcb.126.5.1127; OLIVER DB, 1982, CELL, V30, P311, DOI 10.1016/0092-8674(82)90037-X; PHILLIPS GJ, 1992, NATURE, V359, P744, DOI 10.1038/359744a0; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; RIBES V, 1990, CELL, V63, P591, DOI 10.1016/0092-8674(90)90454-M; RIGGS PD, 1988, GENETICS, V118, P571; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Sato K, 1997, J BIOL CHEM, V272, P20082, DOI 10.1074/jbc.272.32.20082; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; STOKER NG, 1982, GENE, V18, P335, DOI 10.1016/0378-1119(82)90172-X; TAURA T, 1994, MOL GEN GENET, V243, P261, DOI 10.1007/BF00301061; Traxler B, 1996, J BIOL CHEM, V271, P12394, DOI 10.1074/jbc.271.21.12394; TRAXLER B, 1992, J BIOL CHEM, V267, P5339; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0; WERNER PK, 1992, J BIOL CHEM, V267, P24523; WOLFE PB, 1985, J BIOL CHEM, V260, P1826	44	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12451	12456		10.1074/jbc.273.20.12451	http://dx.doi.org/10.1074/jbc.273.20.12451			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575202	hybrid			2022-12-27	WOS:000073629800067
J	Silverman, JA; Qi, HL; Riehl, A; Beckers, C; Nakaar, V; Joiner, KA				Silverman, JA; Qi, HL; Riehl, A; Beckers, C; Nakaar, V; Joiner, KA			Induced activation of the Toxoplasma gondii nucleoside triphosphate hydrolase leads to depletion of host cell ATP levels and rapid exit of intracellular parasites from infected cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARASITOPHOROUS VACUOLE MEMBRANE; PROTEINS	The nucleoside triphosphate hydrolase of Toxoplasma gondii is a potent apyrase. The protein is synthesized in large amounts and transported through the secretory pathway of the parasite and into the vacuolar space in an oxidized and thereby enzymatically inactive form. Complete activation of the purified enzyme is known to require dithiols (e.g. DTT); subcellular fractionation demonstrates that little if any (<5%) of the enzyme in the vacuolar space is active in the absence of DTT. Both native and epitope-tagged nucleoside triphosphate hydrolase (NTPase) were partially activated during immunoprecipitation, precluding precise assessment of enzyme activity in the vacuolar space but suggesting that protein-protein interactions may trigger activation. When infected cells were treated with DTT, the NTPase was activated in a dose-response fashion, as assessed by migration on SDS-polyacrylamide gel electrophoresis and by an increase in enzymatic activity. After activation, enzyme activity decreased with time in the presence of DTT; this inactivation was slowed by the presence of excess ATP. A rapid fall in host cell ATP was accompanied by an abrupt exit of parasites from cells. These results demonstrate that the oxidation/reduction status of the NTPase, the only parasite dense granule protein that contains disulfide bonds, is tightly controlled within the vacuolar space and may influence parasite exit from cells.	Yale Univ, Sch Med, Infect Dis Sect, New Haven, CT 06520 USA	Yale University	Joiner, KA (corresponding author), Yale Univ, Sch Med, Infect Dis Sect, LCI 808,333 Cedar St,POB 208022, New Haven, CT 06520 USA.		Joiner, Keith/AAH-1059-2021	Joiner, Keith/0000-0003-3062-823X				ACHBAROU A, 1991, PARASITOLOGY, V103, P321, DOI 10.1017/S0031182000059837; ASAI T, 1986, COMP BIOCHEM PHYS B, V85, P365, DOI 10.1016/0305-0491(86)90013-1; ASAI T, 1983, J BIOL CHEM, V258, P6816; ASAI T, 1995, J BIOL CHEM, V270, P11391, DOI 10.1074/jbc.270.19.11391; ASAI T, 1987, ZBL BAKT-INT J MED M, V264, P464; BEAMAN MH, 1995, PRINCIPLES PRACTICE, P2455; BECKERS CJM, 1994, J CELL BIOL, V127, P947, DOI 10.1083/jcb.127.4.947; BERMUDES D, 1994, J BIOL CHEM, V269, P29252; DUBREMETZ JF, 1995, MOL APPROACHES PARAS, P345; ENDO T, 1982, EXP PARASITOL, V53, P179, DOI 10.1016/0014-4894(82)90059-5; JOINER KA, 1990, SCIENCE, V249, P641, DOI 10.1126/science.2200126; Karsten V, 1997, METHODS, V13, P103, DOI 10.1006/meth.1997.0503; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NAKAAR V, 1998, IN PRESS MOL BIOCH P; PLESNER L, 1995, INT REV CYTOL, V158, P141; ROOS DS, 1994, METHOD CELL BIOL, V45, P27; SCHWAB JC, 1995, MOL BIOCHEM PARASIT, V70, P59, DOI 10.1016/0166-6851(95)00005-L; SCHWAB JC, 1994, P NATL ACAD SCI USA, V91, P509, DOI 10.1073/pnas.91.2.509; SCHWARTZMAN JD, 1982, EXP PARASITOL, V53, P77, DOI 10.1016/0014-4894(82)90094-7; Schwartzman Joseph D., 1992, V18, P333; SIBLEY LD, 1994, EXP PARASITOL, V79, P301, DOI 10.1006/expr.1994.1093; SILVERMAN JA, 1997, HOST RESPONSE INTRAC, P313; Stommel EW, 1997, EXP PARASITOL, V87, P88, DOI 10.1006/expr.1997.4187; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	24	64	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12352	12359		10.1074/jbc.273.20.12352	http://dx.doi.org/10.1074/jbc.273.20.12352			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575188	hybrid			2022-12-27	WOS:000073629800053
J	Wong, BC; Chiu, SK; Chow, SA				Wong, BC; Chiu, SK; Chow, SA			The role of negative superhelicity and length of homology in the formation of paranemic joints promoted by RecA protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; LINEAR DUPLEX DNA; ESCHERICHIA-COLI; NUCLEOPROTEIN NETWORKS; PLECTONEMIC JOINTS; BINDING PROTEIN; MOLECULES; RECOMBINATION; VISUALIZATION; FILAMENTS	Escherichia coli RecA protein pairs homologous DNA molecules to form paranemic joints when there is an absence of a free end in the region of homologous contact. Paranemic joints are a key intermediate in homologous recombination and are important in understanding the mechanism for a search of homology. The efficiency of paranemic joint formation depended on the length of homology and the topological forms of the duplex DNA. The presence of negative superhelicity increased the pairing efficiency and reduced the minimal length of homology required for paranemic joint formation. Negative superhelicity stimulated joint formation by favoring the initial unwinding of duplex DNA that occurred during the homology search and was not essential in the maintenance of the paired structure. Regardless of length of homology, formation of paranemic joints using circular duplex DNA required the presence of more than six negative supercoils. Above six negative turns, an increasing degree of negative superhelicity resulted in a linear increase in the pairing efficiency. These results support a model of two distinct kinds of DNA unwinding occurring in paranemic joint formation: an initial unwinding caused by heterologous contacts during synapsis and a later one during pairing of the homologous molecules.	Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; Univ Hong Kong, Dept Biochem, Hong Kong, Peoples R China	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Hong Kong	Chow, SA (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA.			Chiu, Sung Kay/0000-0002-9927-7346				BAASE WA, 1979, NUCLEIC ACIDS RES, V6, P797, DOI 10.1093/nar/6.2.797; BALIGA R, 1995, P NATL ACAD SCI USA, V92, P10393, DOI 10.1073/pnas.92.22.10393; BEATTIE KL, 1977, J MOL BIOL, V116, P783, DOI 10.1016/0022-2836(77)90271-6; BIANCHI M, 1983, CELL, V34, P931, DOI 10.1016/0092-8674(83)90550-0; BORTNER C, 1990, J MOL BIOL, V215, P623, DOI 10.1016/S0022-2836(05)80173-1; CHEN JH, 1994, GENE DEV, V8, P1356, DOI 10.1101/gad.8.11.1356; Chiu SK, 1997, P NATL ACAD SCI USA, V94, P6079, DOI 10.1073/pnas.94.12.6079; CHIU SK, 1990, J BIOL CHEM, V265, P21262; CHOW SA, 1985, P NATL ACAD SCI USA, V82, P5646, DOI 10.1073/pnas.82.17.5646; CHOW SA, 1988, J BIOL CHEM, V263, P200; CHOW SA, 1992, J MOL BIOL, V223, P79, DOI 10.1016/0022-2836(92)90717-X; CHRISTIANSEN G, 1986, P NATL ACAD SCI USA, V83, P2066, DOI 10.1073/pnas.83.7.2066; CONLEY EC, 1990, PROG CLIN BIOL RES, V340, P121; CONLEY EC, 1990, J BIOL CHEM, V265, P10156; COX MM, 1993, BIOESSAYS, V15, P617, DOI 10.1002/bies.950150908; CUNNINGHAM RP, 1981, CELL, V24, P213, DOI 10.1016/0092-8674(81)90517-1; DASGUPTA C, 1980, CELL, V22, P437, DOI 10.1016/0092-8674(80)90354-2; FLORY J, 1982, CELL, V28, P747, DOI 10.1016/0092-8674(82)90054-X; FLORY J, 1984, P NATL ACAD SCI-BIOL, V81, P7026, DOI 10.1073/pnas.81.22.7026; GONDA DK, 1986, J BIOL CHEM, V261, P3087; GONDA DK, 1983, CELL, V34, P647, DOI 10.1016/0092-8674(83)90397-5; GONDA DK, 1985, BIOCHEMISTRY-US, V24, P413, DOI 10.1021/bi00323a026; HSIEH P, 1990, GENE DEV, V4, P1951, DOI 10.1101/gad.4.11.1951; HSIEH P, 1992, P NATL ACAD SCI USA, V89, P6492, DOI 10.1073/pnas.89.14.6492; KOWALCZYKOWSKI SC, 1994, ANNU REV BIOCHEM, V63, P991, DOI 10.1146/annurev.biochem.63.1.991; KUHNLEIN U, 1976, P NATL ACAD SCI USA, V73, P1169, DOI 10.1073/pnas.73.4.1169; LINDSLEY JE, 1990, J BIOL CHEM, V265, P10164; PODYMINOGIN MA, 1995, BIOCHEMISTRY-US, V34, P13098, DOI 10.1021/bi00040a022; PUGH BF, 1989, J MOL BIOL, V205, P487, DOI 10.1016/0022-2836(89)90219-2; RADDING CM, 1993, CURR BIOL, V3, P358, DOI 10.1016/0960-9822(93)90200-8; RAMDAS J, 1989, J BIOL CHEM, V264, P17395; REDDY G, 1994, BIOCHEMISTRY-US, V33, P11486, DOI 10.1021/bi00204a010; RIDDLES PW, 1985, J BIOL CHEM, V260, P170; RIDDLES PW, 1985, J BIOL CHEM, V260, P165; ROULD E, 1992, J MOL BIOL, V226, P127, DOI 10.1016/0022-2836(92)90129-8; Sambrook J., 2002, MOL CLONING LAB MANU; SCHUTTE BC, 1988, BIOCHEMISTRY-US, V27, P7886, DOI 10.1021/bi00420a046; SHEN P, 1986, GENETICS, V112, P441; SINGER BS, 1982, CELL, V31, P25, DOI 10.1016/0092-8674(82)90401-9; SINGLETON CK, 1982, ANAL BIOCHEM, V122, P253, DOI 10.1016/0003-2697(82)90277-9; STASIAK A, 1982, NATURE, V299, P185, DOI 10.1038/299185a0; Thomas C A Jr, 1966, Prog Nucleic Acid Res Mol Biol, V5, P315, DOI 10.1016/S0079-6603(08)60237-8; TSANG SS, 1985, J MOL BIOL, V185, P295, DOI 10.1016/0022-2836(85)90405-X; UMLAUF SW, 1990, J BIOL CHEM, V265, P16898; WEINER BM, 1994, CELL, V77, P977, DOI 10.1016/0092-8674(94)90438-3; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; WILLIAMS R, 1988, J MOL BIOL, V187, P109; WU AM, 1993, P NATL ACAD SCI USA, V80, P1256; Zhou XH, 1997, BIOCHEMISTRY-US, V36, P4650, DOI 10.1021/bi9630063	49	19	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12120	12127		10.1074/jbc.273.20.12120	http://dx.doi.org/10.1074/jbc.273.20.12120			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575157	hybrid			2022-12-27	WOS:000073629800022
J	Priola, SA; Chesebro, B				Priola, SA; Chesebro, B			Abnormal properties of prion protein with insertional mutations in different cell types	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREUTZFELDT-JAKOB-DISEASE; SCRAPIE PRION; CULTURED-CELLS; BIOCHEMICAL-PROPERTIES; COPPER-BINDING; GENE; MUTANT; PRP; INFECTION; FORM	Inherited forms of the human transmissible spongiform encephalopathy Creutzfeldt-Jakob disease (CJD) have been associated with mutations in the normal soluble, protease-sensitive form of the host prion protein (PrP-sen). Normal PrP protein contains five copies of a repeating eight-amino acid region, and PrP molecules with six or more copies of this region are associated with disease in familial CJD. It has been hypothesized that these mutations might facilitate spontaneous formation of the abnormal, aggregated protease-resistant PrP isoform, PrP-res, associated with clinical CJD and other transmissible spongiform encephalopathies (TSE). In the present experiments, hamster PrP molecules with 5 (wild-type), 7, 9, or 11 copies of this repeat region were generated and expressed in mouse fibroblast cells or mouse neuroblastoma cells. In mouse fibroblast cells, mutant hamster PrP molecules expressing 7, 9, and 11 copies of the octapeptide repeat sequence showed altered cell surface expression, but both mutant and wild-type hamster PrP-sen molecules demonstrated abnormal properties of aggregation and increased protease resistance. By contrast in mouse neuroblastoma cells, hamster PrP-sen with 5, 9, and 11 octapeptide repeats were expressed normally on the cell surface, but only PrP-sen molecules with 9 or 11 copies of the repeat motif had abnormal properties of aggregation and increased protease resistance. Overall, regardless of cell type, hamster PrP molecules with greater than 7 octapeptide repeats were more aggregated and more protease-resistant than molecules with 7 repeats or less. However, these abnormal molecules were at least 1000-fold less protease-resistant than bona fide PrP-res derived from TSE-infected brain tissue, and they showed no increased ability to form PrP-res in a cell-free system.	NIAID, Persistent Viral Dis Lab, NIH, Rocky Mt Labs, Hamilton, MT 59840 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Priola, SA (corresponding author), NIAID, Persistent Viral Dis Lab, NIH, Rocky Mt Labs, Hamilton, MT 59840 USA.	spriola@nih.gov						BOLTON DC, 1984, BIOCHEMISTRY-US, V23, P5898, DOI 10.1021/bi00320a002; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; Capellari S, 1997, NEUROLOGY, V49, P133, DOI 10.1212/WNL.49.1.133; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CHESEBRO B, 1993, DEV BIOL STAND, V80, P131; Cochran EJ, 1996, NEUROLOGY, V47, P727, DOI 10.1212/WNL.47.3.727; Daude N, 1997, J BIOL CHEM, V272, P11604, DOI 10.1074/jbc.272.17.11604; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DebBurman SK, 1997, P NATL ACAD SCI USA, V94, P13938, DOI 10.1073/pnas.94.25.13938; GOLDFARB LG, 1993, NEUROLOGY, V43, P2392, DOI 10.1212/WNL.43.11.2392; GOLDFARB LG, 1991, P NATL ACAD SCI USA, V88, P10926, DOI 10.1073/pnas.88.23.10926; Goldfarb LG, 1996, TRANSMISSIBLE SUBACUTE SPONGIFORM ENCEPHALOPATHIES: PRION DISEASES, P425; HOPE J, 1986, EMBO J, V5, P2591, DOI 10.1002/j.1460-2075.1986.tb04539.x; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V207, P621, DOI 10.1006/bbrc.1995.1233; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V214, P993, DOI 10.1006/bbrc.1995.2384; IFIGLIA M, 1997, SCIENCE, V277, P1990; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Lehmann S, 1996, P NATL ACAD SCI USA, V93, P5610, DOI 10.1073/pnas.93.11.5610; LEHMANN S, 1995, J BIOL CHEM, V270, P24589, DOI 10.1074/jbc.270.41.24589; Lehmann S, 1996, J BIOL CHEM, V271, P1633, DOI 10.1074/jbc.271.3.1633; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MARCHUK D, 1984, CELL, V39, P491, DOI 10.1016/0092-8674(84)90456-2; MCKINLEY MP, 1983, CELL, V35, P57, DOI 10.1016/0092-8674(83)90207-6; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; OWEN F, 1990, MOL BRAIN RES, V7, P273, DOI 10.1016/0169-328X(90)90038-F; Petersen RB, 1996, J BIOL CHEM, V271, P12661, DOI 10.1074/jbc.271.21.12661; PIEZ KA, 1984, PROTEIN FOLDING PROB, P47; POCCHIARI M, 1994, MOL ASPECTS MED, V15, P195, DOI 10.1016/0098-2997(94)90042-6; POULTER M, 1992, BRAIN, V115, P675, DOI 10.1093/brain/115.3.675; PRIOLA SA, 1995, J BIOL CHEM, V270, P3299, DOI 10.1074/jbc.270.7.3299; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; RACE RE, 1988, J VIROL, V62, P2845, DOI 10.1128/JVI.62.8.2845-2849.1988; RACE RE, 1987, J GEN VIROL, V68, P1391, DOI 10.1099/0022-1317-68-5-1391; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Schirmer EC, 1997, P NATL ACAD SCI USA, V94, P13932, DOI 10.1073/pnas.94.25.13932; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; SUGIYAMA T, 1985, NUCLEIC ACIDS RES, V13, P8729, DOI 10.1093/nar/13.24.8729	40	76	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 8	1998	273	19					11980	11985		10.1074/jbc.273.19.11980	http://dx.doi.org/10.1074/jbc.273.19.11980			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZM408	9565627	hybrid			2022-12-27	WOS:000073536700081
J	Hara, K; Yonezawa, K; Weng, QP; Kozlowski, MT; Belham, C; Avruch, J				Hara, K; Yonezawa, K; Weng, QP; Kozlowski, MT; Belham, C; Avruch, J			Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE-CHAIN INITIATION; CAP-DEPENDENT TRANSLATION; ACTIVATED PROTEIN-KINASE; RAT SKELETAL-MUSCLE; HAMSTER OVARY CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; HEPATIC PROTEOLYSIS; PLASMA-MEMBRANE; FACTOR 4E; IN-VIVO	The present study identifies the operation of a signal tranduction pathway in mammalian cells that provides a checkpoint control, linking amino acid sufficiency to the control of peptide chain initiation. Withdrawal of amino acids from the nutrient medium of CHO-IR cells results in a rapid deactivation of p70 SG kinase and dephosphorylation of eIF-4E BP1, which become unresponsive to all agonises. Readdition of the amino acid mixture quickly restores the phosphorylation and responsiveness of p70 and eIF-4E BP1 to insulin. Increasing the ambient amino acids to twice that usually employed increases basal p70 activity to the maximal level otherwise attained in the presence of insulin and abrogates further stimulation by insulin, withdrawal of most individual amino acids also inhibits p70, although with differing potency. Amino acid withdrawal from CHO-IR cells does not significantly alter insulin stimulation of tyrosine phosphorylation, phosphotyrosine-associated phosphatidylinositol 3-kinase activity, c-Akt/protein kinase B activity, or mitogen-activated protein kinase activity. The selective inhibition of p70 and eIF-4E BP1 phosphorylation by amino acid withdrawal resembles the response to rapamycin, which prevents p70 reactivation by amino acids, indicating that mTOR is required for the response to amino acids. A p70 deletion mutant, p70 Delta 2-46/Delta CT104, that is resistant to inhibition by rapamycin (but sensitive to wortmannin) is also resistant to inhibition by amino acid withdrawal, indicating that amino acid sufficiency and mTOR signal to p70 through a common effector, which could be mTOR itself, or an mTOR-controlled downstream element, such as a protein phosphatase.	Massachusetts Gen Hosp, Med Serv, Boston, MA 02129 USA; Harvard Univ, Sch Med, Boston, MA 02129 USA; Kobe Univ, Biosignal Res Ctr, Kobe, Hyogo 657, Japan; Massachusetts Gen Hosp, Dept Mol Biol, Diabet Res Lab, Diabet Unit, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Kobe University; Harvard University; Massachusetts General Hospital	Avruch, J (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, Diabet Res Lab, Diabet Unit, 50 Blossom St, Boston, MA 02114 USA.	avruch@helix.mgh.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA073818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK017776, R01DK017776] Funding Source: NIH RePORTER; NCI NIH HHS [CA73818] Funding Source: Medline; NIDDK NIH HHS [DK17776] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abraham RT, 1996, CURR OPIN IMMUNOL, V8, P412, DOI 10.1016/S0952-7915(96)80132-4; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Arnez JG, 1997, TRENDS BIOCHEM SCI, V22, P211, DOI 10.1016/S0968-0004(97)01052-9; Azpiazu I, 1996, J BIOL CHEM, V271, P5033; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; CLEMENS MJ, 1987, J BIOL CHEM, V262, P767; Clemens MJ, 1996, TRANSLATIONAL CONTRO, P139; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; Diggle TA, 1996, BIOCHEM J, V316, P447, DOI 10.1042/bj3160447; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; Fadden P, 1997, J BIOL CHEM, V272, P10240; Feigenblum D, 1996, MOL CELL BIOL, V16, P5450; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; FLYNN A, 1995, J BIOL CHEM, V270, P21684, DOI 10.1074/jbc.270.37.21684; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; JOSHI B, 1995, J BIOL CHEM, V270, P14597, DOI 10.1074/jbc.270.24.14597; KADOWAKI M, 1992, J BIOL CHEM, V267, P22060; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; KELLY FJ, 1985, J BIOL CHEM, V260, P6677; KIMBALL SR, 1991, J BIOL CHEM, V266, P1969; KUNURAK I, 1996, SCIENCE, V273, P245; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; MIOTTO G, 1994, J BIOL CHEM, V269, P25348; MIOTTO G, 1992, J BIOL CHEM, V267, P22066; Morley SJ, 1997, J BIOL CHEM, V272, P17887, DOI 10.1074/jbc.272.28.17887; Moser BA, 1997, MOL CELL BIOL, V17, P5648, DOI 10.1128/MCB.17.9.5648; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; PAIN VM, 1994, BIOCHIMIE, V76, P718, DOI 10.1016/0300-9084(94)90076-0; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; POLLARD JW, 1989, EUR J BIOCHEM, V182, P1, DOI 10.1111/j.1432-1033.1989.tb14793.x; PREEDY VR, 1986, BIOSCIENCE REP, V6, P177, DOI 10.1007/BF01115004; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Proud CG, 1996, TRENDS BIOCHEM SCI, V21, P181, DOI 10.1016/0968-0004(96)10016-5; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; REDPATH NT, 1994, BBA-MOL CELL RES, V1220, P147, DOI 10.1016/0167-4889(94)90130-9; SCORSONE KA, 1987, J BIOL CHEM, V262, P14538; Svanberg E, 1997, AM J PHYSIOL-ENDOC M, V272, pE841, DOI 10.1152/ajpendo.1997.272.5.E841; SVANBERG E, 1996, ENDOCRINOL METAB, V33, pE614; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; WENG QP, 1995, MOL CELL BIOL, V15, P2333; WENG QP, IN PRESS J BIOL CHEM; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958	62	1071	1104	0	52	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14484	14494		10.1074/jbc.273.23.14484	http://dx.doi.org/10.1074/jbc.273.23.14484			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603962	hybrid, Green Published			2022-12-27	WOS:000074021500064
J	Zhu, ZY; Davidson, VL				Zhu, ZY; Davidson, VL			Redox properties of tryptophan tryptophylquinone enzymes - Correlation with structure and reactivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUINOPROTEIN METHYLAMINE DEHYDROGENASE; AROMATIC AMINE DEHYDROGENASE; ELECTRON-TRANSFER; PARACOCCUS-DENITRIFICANS; BACTERIUM W3A1; COFACTOR; AMICYANIN; COMPLEX; MODEL; INTERMEDIATE	The pH dependence of the redox potentials for the oxidized/reduced couples of methylamine dehydrogemase (MADH) and aromatic amine dehydrogenase (AADH) were determined. For each enzyme, a change of -30 mV/pH unit was observed, indicating that the two-electron transfer is linked to the transfer of a single proton. This result differs from what was obtained from redox studies of a tryptophan tryptophylquinone (TTQ) model compound for which the two-electron couple is linked to the transfer of two protons. This result also distinguishes the redox properties of the enzyme-bond TTQ from those of the membrane-bound quinone components of respiratory and photosynthetic electron transfer chains that transfer two protons per two electrons. This difference is attributed to the accessibility of TTG to solvent in the enzymes. One of the quinol hydroxyls is shielded from solvent and thus is not protonated. The unusual property of TTQ enzymes of stabilizing the an-ionic form of the reduced quinol is important for the reaction mechanism of MADH because it allows stabilization of physiologically important reaction intermediates. Examination of the extent to which disproportionation of the MADH and AADH semiquinones occurred as a function of BH revealed that the equilibrium concentration of semiquinone increased with pH. This indicates that the proton transfer is linked to the semiquinone/quinol couple. Therefore, the quinol is singly protonated, and the semiquinone is unprotonated and anionic. It was also shown that the oxidation-reduction midpoint potential for AADH is 20 mV less positive than that of MADH over the range of pH values that was studied and that the TTQ semiquinone of AADH was less stable than that of MADH. This may be explained by differences in the active site environments of the two enzymes, which modulate their respective redox properties.	Univ Mississippi, Med Ctr, Dept Biochem, Jackson, MS 39216 USA	University of Mississippi; University of Mississippi Medical Center	Davidson, VL (corresponding author), Univ Mississippi, Med Ctr, Dept Biochem, 2500 N State St, Jackson, MS 39216 USA.			Davidson, Victor/0000-0002-1966-7302	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041574, R01GM041574] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-41574] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anthony C, 1996, BIOCHEM J, V320, P697, DOI 10.1042/bj3200697; BAKER EN, 1988, J MOL BIOL, V203, P1071, DOI 10.1016/0022-2836(88)90129-5; BISHOP GR, 1995, BIOCHEMISTRY-US, V34, P12082, DOI 10.1021/bi00037a052; Bishop GR, 1996, BIOCHEMISTRY-US, V35, P8948, DOI 10.1021/bi960404x; Bishop GR, 1996, J AM CHEM SOC, V118, P12868, DOI 10.1021/ja9621859; Bishop GR, 1997, BIOCHEMISTRY-US, V36, P13586, DOI 10.1021/bi970586a; BROOKS HB, 1994, J AM CHEM SOC, V116, P11201, DOI 10.1021/ja00103a063; BURROWS AL, 1991, EUR J BIOCHEM, V199, P73, DOI 10.1111/j.1432-1033.1991.tb16093.x; CHEN L, 1988, J MOL BIOL, V276, P131; CHEN LY, 1991, FEBS LETT, V287, P163, DOI 10.1016/0014-5793(91)80041-Z; CHEN LY, 1994, SCIENCE, V264, P86, DOI 10.1126/science.8140419; DAVIDSON VL, 1990, METHOD ENZYMOL, V188, P241; DAVIDSON VL, 1989, BIOCHEM J, V261, P107, DOI 10.1042/bj2610107; DAVIDSON VL, 1992, BIOCHEMISTRY-US, V31, P1504, DOI 10.1021/bi00120a030; DAVIDSON VL, 1993, PRINCIPLES APPL QUIN, P73; Dutton P L, 1978, Methods Enzymol, V54, P411; EDWARDS SL, 1995, J BIOL CHEM, V270, P4293, DOI 10.1074/jbc.270.9.4293; GOVINDARAJ S, 1994, J BACTERIOL, V176, P2922, DOI 10.1128/JB.176.10.2922-2929.1994; HUSAIN M, 1986, J BIOL CHEM, V261, P8577; HUSAIN M, 1987, BIOCHEMISTRY-US, V26, P4139, DOI 10.1021/bi00387a059; HUSAIN M, 1985, J BIOL CHEM, V260, P4626; HYUN YL, 1995, BIOCHEMISTRY-US, V34, P816, DOI 10.1021/bi00003a015; ITOH S, 1995, J AM CHEM SOC, V117, P1485, DOI 10.1021/ja00110a004; IWAKI M, 1983, ARCH BIOCHEM BIOPHYS, V220, P253, DOI 10.1016/0003-9861(83)90408-3; KLINMAN JP, 1994, ANNU REV BIOCHEM, V63, P299, DOI 10.1146/annurev.bi.63.070194.001503; KUUSK V, 1994, J BIOL CHEM, V269, P26136; MCINTIRE WS, 1991, SCIENCE, V252, P817, DOI 10.1126/science.2028257; Merli A, 1996, J BIOL CHEM, V271, P9177, DOI 10.1074/jbc.271.16.9177; MURE M, 1993, J AM CHEM SOC, V115, P7117, DOI 10.1021/ja00069a008; OHNISHI T, 1980, J BIOL CHEM, V255, P3278; PRINCE RC, 1981, BIOCHIM BIOPHYS ACTA, V635, P132, DOI 10.1016/0005-2728(81)90014-1; ROSEN P, 1981, EUR J BIOCHEM, V120, P339, DOI 10.1111/j.1432-1033.1981.tb05709.x; SLEATH PR, 1985, J AM CHEM SOC, V107, P3328, DOI 10.1021/ja00297a044; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; WARNCKE K, 1995, J AM CHEM SOC, V117, P10063, DOI 10.1021/ja00145a018; WARNCKE K, 1993, J AM CHEM SOC, V115, P6464, DOI 10.1021/ja00067a093; Zhu ZY, 1998, BIOCHEM J, V329, P175, DOI 10.1042/bj3290175; Zhu ZY, 1998, BBA-BIOENERGETICS, V1364, P297, DOI 10.1016/S0005-2728(98)00035-8	38	26	26	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14254	14260		10.1074/jbc.273.23.14254	http://dx.doi.org/10.1074/jbc.273.23.14254			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603931	hybrid			2022-12-27	WOS:000074021500033
J	Corton, JC; Moreno, E; Johnston, SA				Corton, JC; Moreno, E; Johnston, SA			Alterations in the GAL4 DNA-binding domain can affect transcriptional activation independent of DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZN(2)CYS(6) BINUCLEAR CLUSTER; ZINC-FINGER REGION; GLUCOCORTICOID RECEPTOR; CRYSTAL-STRUCTURE; SPECIFICITY; MUTATIONS; PROTEINS; RECOGNITION; SEQUENCE; COMPLEX	The GAL4 protein belongs to a large class of fungal transcriptional activator proteins encoding within their DNA-binding domains (DBD) six cysteines that coordinate two atoms of zinc (the Zn(2)Cys(6) domain). In an effort to characterize the interactions between the Zn(2)Cys(6) class transcriptional activator proteins and their DNA-binding sites, we have replaced in the full-length GAL4 protein small regions of the Zn(2)Cys(6) domain with the analogous regions of another Zn(2)Cys(6) protein called PPR1 an activator of pyrimidine biosynthetic genes, Alterations between the first and third cysteines abolished binding to GAL4 (upstream activation sequence of GAL (UAS(G))) or PPR1 (upstream acitvation sequence of UAS) DNA-binding sites and severely reduced transcriptional activation in yeast. In contrast, alterations between the third and fourth cysteines had only minor effects on binding to UAS(G) but led to substantial decreases in activation in both yeast and a mammalian cell line. In the crystal structure of the GAL4 DBD-UAS(G) complex (Marmorstein, R., Carey, M., Ptashne, M., and Harrison, S, C. (1992) Nature 356, 408-414), this region is facing away from the DNA, making it likely that there exists within the GAL4 DBD an accessible domain important in activation.	Chem Ind Inst Toxicol, Res Triangle Pk, NC 27709 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Corton, JC (corresponding author), Chem Ind Inst Toxicol, 6 Davis Dr,POB 12137, Res Triangle Pk, NC 27709 USA.	corton@ciit.org						BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; COOK WJ, 1994, J BIOL CHEM, V269, P9374; CORTON JC, 1989, NATURE, V340, P724, DOI 10.1038/340724a0; Ding WV, 1997, MOL CELL BIOL, V17, P2538, DOI 10.1128/MCB.17.5.2538; DURRIN LK, 1991, CELL, V65, P1023, DOI 10.1016/0092-8674(91)90554-C; Ha N, 1996, NUCLEIC ACIDS RES, V24, P1453, DOI 10.1093/nar/24.8.1453; HIMMELFARB HJ, 1990, CELL, V63, P1299, DOI 10.1016/0092-8674(90)90425-E; HOCHSCHILD A, 1983, CELL, V32, P319, DOI 10.1016/0092-8674(83)90451-8; KAMMERER B, 1984, J MOL BIOL, V180, P239, DOI 10.1016/S0022-2836(84)80002-9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEFSTIN JA, 1994, GENE DEV, V8, P2842, DOI 10.1101/gad.8.23.2842; LEUTHER KK, 1993, CELL, V72, P575, DOI 10.1016/0092-8674(93)90076-3; Liang SD, 1996, MOL CELL BIOL, V16, P3773; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MANN RK, 1992, EMBO J, V11, P3297, DOI 10.1002/j.1460-2075.1992.tb05408.x; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MARMORSTEIN R, 1994, GENE DEV, V8, P2504, DOI 10.1101/gad.8.20.2504; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; PARRAGA G, 1988, SCIENCE, V241, P1489, DOI 10.1126/science.3047872; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; REECE RJ, 1993, SCIENCE, V261, P909, DOI 10.1126/science.8346441; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SALMERON JM, 1986, NUCLEIC ACIDS RES, V14, P7767, DOI 10.1093/nar/14.19.7767; Sambrook J., 2002, MOL CLONING LAB MANU; SCHENA M, 1989, GENE DEV, V3, P1590, DOI 10.1101/gad.3.10.1590; Schjerling P, 1996, NUCLEIC ACIDS RES, V24, P4599, DOI 10.1093/nar/24.23.4599; Swaminathan K, 1997, NAT STRUCT BIOL, V4, P751, DOI 10.1038/nsb0997-751; THUKRAL SK, 1992, MOL CELL BIOL, V12, P2784, DOI 10.1128/MCB.12.6.2784; VASHEE S, 1993, J BIOL CHEM, V268, P24699; WITTE MM, 1990, MOL CELL BIOL, V10, P5128, DOI 10.1128/MCB.10.10.5128; XU HE, 1994, J BIOL CHEM, V269, P21177; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	34	22	23	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13776	13780		10.1074/jbc.273.22.13776	http://dx.doi.org/10.1074/jbc.273.22.13776			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593720	hybrid			2022-12-27	WOS:000073919100059
J	Torti, SV; Torti, FM				Torti, SV; Torti, FM			Human H-kininogen is a ferritin-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-MOLECULAR-WEIGHT; PLASMA KALLIKREIN; HUMAN-SERUM; HUMAN-LIVER; CLEAVAGE; CELLS; RECEPTORS; SURFACE; PROLIFERATION; HEPATOCYTES	H-kininogen is a multifunctional protein: it inhibits cysteine proteases, plays a role in contact activation of the coagulation cascade, and is the precursor of the potent proinflammatory peptide bradykinin. In the experiments described here, we identify H-kininogen as a ferritin-binding protein. Ferritin is a cellular and serum protein that is elevated in acute and chronic inflammation and many cancers, Despite numerous reports of ferritin-binding protein(s) in human serum, the nature and function of these proteins remain unclear. As a first step in characterizing the interaction between ferritin and its binding protein(s), we devised a ligand blot assay and used it to guide purification of a ferritin binding protein from human serum. Edman degradation of the purified protein determined the sequence HNLGHGHK(H)ERDQGHG, a sequence with identity to residues 421-436 of human H kininogen. These results mere confirmed by demonstrating that commercially purified H-kininogen possessed ferritin binding activity and that ferritin binding could not be detected in plasma hom kininogen-deficient individuals. Ligand blot assays mapped the ferritin binding domain to the light chain of H-kininogen chain, and revealed that both H and L recombinant ferritins possess H-kininogen binding activity. The unexpected identification of H-kininogen as a ferritin-binding protein may link ferritin in the complex chain of interactions by which H-kininogen mediates its multiple effects in contact activation and inflammation.	Wake Forest Univ, Sch Med, Dept Biochem, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Canc Biol, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Internal Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Ctr Comprehens Canc, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest University; Wake Forest University; Wake Forest University	Torti, SV (corresponding author), Wake Forest Univ, Sch Med, Dept Biochem, Med Ctr Blvd, Winston Salem, NC 27157 USA.				NATIONAL CANCER INSTITUTE [P30CA012197] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR004869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042412, R37DK042412] Funding Source: NIH RePORTER; NCI NIH HHS [CA-12197] Funding Source: Medline; NCRR NIH HHS [RR-04869] Funding Source: Medline; NIDDK NIH HHS [DK 42412] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS PC, 1988, HEPATOLOGY, V8, P719, DOI 10.1002/hep.1840080402; BELLOTTI V, 1987, BRIT J HAEMATOL, V65, P489, DOI 10.1111/j.1365-2141.1987.tb04156.x; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; BOYD D, 1985, J BIOL CHEM, V260, P1755; BROXMEYER HE, 1992, J LAB CLIN MED, V120, P367; CHEN PCH, 1995, J BIOL CHEM, V270, P2874, DOI 10.1074/jbc.270.6.2874; COVELL AM, 1984, CLIN CHIM ACTA, V139, P75, DOI 10.1016/0009-8981(84)90194-3; DANIEL TO, 1983, J BIOL CHEM, V258, P4606; FARGION S, 1988, BLOOD, V71, P753; FARGION S, 1991, BLOOD, V78, P1056; FIGUEROA CD, 1992, RECENT PROGR KININS, V38, P617; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; HARRISON PM, 1991, ADV INORG CHEM, V36, P449; HASAN AAK, 1995, J BIOL CHEM, V270, P19256, DOI 10.1074/jbc.270.33.19256; HENDERSON LM, 1994, BLOOD, V84, P474; HERWALD H, 1995, J BIOL CHEM, V270, P14634; KARLSRUD TS, 1991, THROMB RES, V63, P641, DOI 10.1016/0049-3848(91)90090-J; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUZZAGO A, 1986, BIOCHIM BIOPHYS ACTA, V872, P61, DOI 10.1016/0167-4838(86)90147-0; MELONI FJ, 1992, BLOOD, V79, P1233; MORI K, 1981, J BIOCHEM-TOKYO, V89, P1465, DOI 10.1093/oxfordjournals.jbchem.a133339; MOSS D, 1992, J INORG BIOCHEM, V47, P219, DOI 10.1016/0162-0134(92)84067-W; NIITSU Y, 1988, BRIT J HAEMATOL, V68, P496, DOI 10.1111/j.1365-2141.1988.tb04244.x; OHISHI S, 1981, TOHOKU J EXP MED, V133, P67, DOI 10.1620/tjem.133.67; OSTERLOH K, 1989, BIOCHIM BIOPHYS ACTA, V1011, P40, DOI 10.1016/0167-4889(89)90075-X; PRICE WA, 1995, AM J RESP CELL MOL, V13, P466, DOI 10.1165/ajrcmb.13.4.7546777; ROGERS JT, 1990, J BIOL CHEM, V265, P14572; Rucker P, 1996, J BIOL CHEM, V271, P33352, DOI 10.1074/jbc.271.52.33352; SAITO H, 1975, J CLIN INVEST, V55, P1082, DOI 10.1172/JCI108009; SANTAMBROGIO P, 1989, BRIT J HAEMATOL, V71, P281, DOI 10.1111/j.1365-2141.1989.tb04268.x; SANTAMBROGIO P, 1987, BRIT J HAEMATOL, V65, P235, DOI 10.1111/j.1365-2141.1987.tb02271.x; SCHIFFMAN S, 1980, J BIOL CHEM, V255, P6433; SCHMAIER AH, 1988, J LAB CLIN MED, V112, P182; SIBILLE JC, 1988, HEPATOLOGY, V8, P296, DOI 10.1002/hep.1840080218; Stewart J M, 1993, Agents Actions Suppl, V42, P145; Stewart JM, 1997, CAN J PHYSIOL PHARM, V75, P719, DOI 10.1139/cjpp-75-6-719; TAKAGAKI Y, 1985, J BIOL CHEM, V260, P8601; TAKAGI A, 1986, BIOCHIM BIOPHYS ACTA, V884, P1, DOI 10.1016/0304-4165(86)90219-9; TAYEH MA, 1994, J BIOL CHEM, V269, P16318; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289; Torti S V, 1994, Adv Inorg Biochem, V10, P119; TORTI SV, 1988, J BIOL CHEM, V263, P12638; VANIWAARDEN F, 1988, J BIOL CHEM, V263, P4698; YAMADA H, 1974, BLOOD, V43, P875, DOI 10.1182/blood.V43.6.875.875	44	31	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13630	13635		10.1074/jbc.273.22.13630	http://dx.doi.org/10.1074/jbc.273.22.13630			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593701	hybrid			2022-12-27	WOS:000073919100040
J	Greulich, H; Erikson, RL				Greulich, H; Erikson, RL			An analysis of Mek1 signaling in cell proliferation and transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE KINASE; NIH 3T3 CELLS; TYROSINE THREONINE KINASE; PROTEIN-KINASE; GENE-PRODUCT; CONDITIONAL TRANSFORMATION; SERINE PHOSPHORYLATION; ESTROGEN-RECEPTOR; CYCLIN D1; ACTIVATION	The Mek1 dual specificity protein kinase phosphorylates and activates the mitogen-activated protein kinases Erk1 and Erk2 in response to mitogenic stimulation. The molecular events downstream of Mek and Erk necessary to promote cell cycle entry are largely undefined. In order to study signals emanating from Mek independent of upstream proteins capable of activating multiple sig naling pathways, we fused the hormone-binding domain of the estrogen receptor (ER) to the C terminus of constitutively activated Mek1 phosphorylation site mutants. Although 4-OH-tamoxifen stimulation of NIH-3T3 cells expressing constitutively activated Mek-ER resulted in only a small increase in specific activity of the fusion protein, a 5-10 fold increase in total cellular Mek activity was observed over a period of 1-2 days due to an accumulation of fusion protein. Induction of constitutively activated Mek-ER in NIH-3T3 cells resulted in accelerated S phase entry, proliferation in low serum, morphological transformation, and anchorage independent growth, Endogenous Erk1 and Erk2 were phosphorylated with kinetics similar to the elevation of Mek-ER activity. However, elevated Mek-ER activity attenuated subsequent stimulation of Erk1 and Erk2 by serum. 4-OH-tamoxifen stimulation of Mek-ER-expressing fibroblasts also resulted in up-regulation of cyclin D1 expression and down-regulation of p27(Kip1) expression, establishing a direct link between Mek1 and the cell cycle machinery.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Greulich, H (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, 16 Divin Ave, Cambridge, MA 02138 USA.				NCI NIH HHS [CA42580] Funding Source: Medline; NIGMS NIH HHS [F32 GM19098] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042580] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019098] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALESSANDRINI A, 1992, P NATL ACAD SCI USA, V89, P8200, DOI 10.1073/pnas.89.17.8200; Alessandrini A, 1996, J BIOL CHEM, V271, P31612, DOI 10.1074/jbc.271.49.31612; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ASHWORTH A, 1992, ONCOGENE, V7, P2555; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BROTT BK, 1993, CELL GROWTH DIFFER, V4, P921; BRUNET A, 1994, ONCOGENE, V9, P3379; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DANIELIAN PS, 1993, MOL ENDOCRINOL, V7, P232, DOI 10.1210/me.7.2.232; Greulich H, 1996, ONCOGENE, V12, P1689; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HUANG WD, 1995, MOL BIOL CELL, V6, P237, DOI 10.1091/mbc.6.3.237; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; HUANG WD, 1994, P NATL ACAD SCI USA, V91, P8960, DOI 10.1073/pnas.91.19.8960; JACKSON P, 1993, EMBO J, V12, P2809, DOI 10.1002/j.1460-2075.1993.tb05942.x; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; SAMUELS ML, 1994, MOL CELL BIOL, V14, P7855, DOI 10.1128/MCB.14.12.7855; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SASAOKA T, 1994, J BIOL CHEM, V269, P32621; SEGER R, 1994, J BIOL CHEM, V269, P25699; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Stofega MR, 1997, CELL GROWTH DIFFER, V8, P113; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TOYOSHIMA H, 1994, CELL, V78, P674; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; WU J, 1993, MOL CELL BIOL, V13, P453; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	48	70	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					13280	13288		10.1074/jbc.273.21.13280	http://dx.doi.org/10.1074/jbc.273.21.13280			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582373	hybrid, Green Published			2022-12-27	WOS:000073768500084
J	Trotter, PJ; Wu, WI; Pedretti, J; Yates, R; Voelker, DR				Trotter, PJ; Wu, WI; Pedretti, J; Yates, R; Voelker, DR			A genetic screen for aminophospholipid transport mutants identifies the phosphatidylinositol 4-kinase, Stt4p, as an essential component in phosphatidylserine metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; CA2+-ACTIVATED SECRETION; VACUOLAR PROTEIN; NULL ALLELE; KINASE; CLONING; DECARBOXYLASE; PATHWAY; DNA	In an effort to understand molecular mechanisms of intracellular lipid transport, we have focused upon specific events required for de novo aminophospholipid synthesis in the yeast Saccharomyces cerevisiae. A genetic system for examining the steps between phosphatidylserine (PtdSer) synthesis in the endoplasmic reticulum and its transport to and decarboxylation by PtdSer decarboxylase 2 in the Golgi/vacuole has been developed. We have isolated a mutant, denoted pstB1, that accumulates PtdSer and has diminished phosphatidylethanolamine formation despite normal PtdSer decarboxylase 2 activity. The lesion in PtdSer metabolism is consistent with a defect in interorganelle lipid transport. A genomic DNA clone that complements the mutation was isolated, and sequencing revealed that the clone contains the STT4 gene, encoding a phosphatidylinositol 4-kinase. The pstB1 mutant exhibits a defect in Stt4p-type phosphatidylinositol Li-kinase activity, and direct gene replacement indicates that STT4 is the defective gene in the mutant. Creation of an STT4 null allele (stt4 Delta::HIS3) demonstrates the gene is essential. These results provide evidence that implicates phosphoinositides in the regulation of intracellular aminophospholipid transport.	Natl Jewish Med & Res Ctr, Lord & Taylor Lab Lung Biochem, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Anna Perahia Adatto Clin Res Ctr, Denver, CO 80206 USA; Univ Texas, Div Nutr Sci, Austin, TX 78712 USA; Univ Texas, Inst Cellular & Mol Biol, Austin, TX 78712 USA	National Jewish Health; National Jewish Health; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Voelker, DR (corresponding author), Natl Jewish Med & Res Ctr, Dept Med, 1400 Jackson St, Denver, CO 80206 USA.	voelkerd@njc.org			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032453, R01GM032453, F32GM016701] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 32453, F32-GM 16701] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKINSON K, 1980, J BIOL CHEM, V255, P6653; ATTSCHUL SF, 1990, J MOL BIOL, V215, P403; CARDENAS ME, 1995, EMBO J, V14, P5892, DOI 10.1002/j.1460-2075.1995.tb00277.x; CARMAN GM, 1992, METHOD ENZYMOL, V209, P298; CLANCEY CJ, 1993, J BIOL CHEM, V268, P24580; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; Cutler NS, 1997, J BIOL CHEM, V272, P27671, DOI 10.1074/jbc.272.44.27671; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; FLANAGAN CA, 1992, J BIOL CHEM, V267, P24117; GAIGG B, 1995, BBA-BIOMEMBRANES, V1234, P214, DOI 10.1016/0005-2736(94)00287-Y; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; KANFER J, 1964, J BIOL CHEM, V239, P1720; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; KUCHLER K, 1986, J BACTERIOL, V165, P901, DOI 10.1128/jb.165.3.901-910.1986; MCKENZIE MA, 1982, J FOOD BIOCHEM, V6, P77, DOI 10.1111/j.1745-4514.1982.tb00297.x; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; OHTA A, 1981, J BIOL CHEM, V256, P2219; PALTAUF F, 1992, MOL CELLULAR BIOL YE, V2, P415; PHILIPPSEN P, 1991, METHOD ENZYMOL, V194, P169; PIKE LJ, 1992, ENDOCR REV, V13, P692, DOI 10.1210/er.13.4.692; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Singer S J, 1992, Trends Cell Biol, V2, P69, DOI 10.1016/0962-8924(92)90060-Z; STACK JH, 1994, J BIOL CHEM, V269, P31552; Stack JH, 1995, ANNU REV CELL DEV BI, V11, P1; STRATHERN JN, 1991, METHOD ENZYMOL, V194, P319; TROTTER PJ, 1995, J BIOL CHEM, V270, P6071, DOI 10.1074/jbc.270.11.6071; TROTTER PJ, 1995, J BIOL CHEM, V270, P6062, DOI 10.1074/jbc.270.11.6062; TROTTER PJ, 1993, J BIOL CHEM, V268, P21416; TROTTER PJ, 1994, BBA-LIPID LIPID MET, V1213, P241, DOI 10.1016/0005-2760(94)00073-5; VOELKER DR, 1996, BIOCH LIPIDS LIPOPRO, V31, P391; WALSH JP, 1991, P NATL ACAD SCI USA, V88, P9184, DOI 10.1073/pnas.88.20.9184; Wiedemann C, 1996, EMBO J, V15, P2094, DOI 10.1002/j.1460-2075.1996.tb00563.x; YOSHIDA S, 1992, MOL GEN GENET, V231, P337, DOI 10.1007/BF00292700; YOSHIDA S, 1994, MOL GEN GENET, V242, P631, DOI 10.1007/BF00283416; YOSHIDA S, 1994, J BIOL CHEM, V269, P1166	40	90	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					13189	13196		10.1074/jbc.273.21.13189	http://dx.doi.org/10.1074/jbc.273.21.13189			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582361	hybrid			2022-12-27	WOS:000073768500072
J	Arslan, T; Abraham, AT; Hecht, SM				Arslan, T; Abraham, AT; Hecht, SM			DNA duplexes containing 3 '-deoxynucleotides as substrates for DNA topoisomerase I cleavage and ligation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC TOPOISOMERASE; ABASIC SITE; SEQUENCE; ENZYME; INHIBITION	The DNA cleavage-ligation reaction of DNA topoisomerase I was investigated employing synthetic DNA substrates containing 3'-deoxyadenosine or 3'-deoxythymidine at specific sites and acceptor oligonucleotides of different lengths. The modified nucleotides were substituted systematically within the putative enzyme-binding domain and also next to the high efficiency cleavage site to determine the effect of single base changes on enzyme function. Depending on the site of substitution, the facility of the cleavage and ligation reactions were altered. The bases at positions -1 and -2 on the noncleaved strand were found to be important for determining the site of cleavage. Inclusion of 3'-deoxythymidine in the scissile strand at position -1 permitted the demonstration that topoisomerase I can cleave and form a 2' --> 5'-phosphodiester linkage. Partial duplexes doubly modified at positions -4 or -6 in the noncleaved strand and at positions +1 or -1 within scissile strand were not good substrates for topoisomerase I, showing that cleavage can depend importantly on binding interactions based on structural alterations at spatially separated sites. Substitution of a 3'-deoxynucleotide on the scissile strand at position -6 enhanced formation of the ligation product resulting from cleavage at site 1 and suppressed cleavage at site 2.	Univ Virginia, Dept Chem, Charlottesville, VA 22901 USA; Univ Virginia, Dept Biol, Charlottesville, VA 22901 USA	University of Virginia; University of Virginia	Hecht, SM (corresponding author), Univ Virginia, Dept Chem, Mccormick Rd, Charlottesville, VA 22901 USA.				NCI NIH HHS [CA-53913] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA053913] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arslan T, 1998, NUCLEOS NUCLEOT NUCL, V17, P515, DOI 10.1080/07328319808005195; BUSK H, 1987, NATURE, V327, P638, DOI 10.1038/327638a0; CARUTHERS MH, 1985, SCIENCE, V230, P281, DOI 10.1126/science.3863253; CHAMPOUX JJ, 1976, P NATL ACAD SCI USA, V73, P3488, DOI 10.1073/pnas.73.10.3488; CHAMPOUX JJ, 1981, J BIOL CHEM, V256, P4805; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; CHRISTIANSEN K, 1993, J BIOL CHEM, V268, P9690; CHRISTIANSEN K, 1987, J MOL BIOL, V193, P517, DOI 10.1016/0022-2836(87)90264-6; CHRISTIANSEN K, 1994, J BIOL CHEM, V269, P721; CHRISTIANSEN K, 1993, ALFRED BENZON SYMP S, V35, P361; DOUGHERTY JP, 1992, J AM CHEM SOC, V114, P6254, DOI 10.1021/ja00041a058; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; GOLJER I, 1992, BIOCHEMISTRY-US, V31, P11614, DOI 10.1021/bi00161a047; GUPTA M, 1995, BBA-GENE STRUCT EXPR, V1262, P1, DOI 10.1016/0167-4781(95)00029-G; HASHIMOTO H, 1992, J AM CHEM SOC, V114, P6255, DOI 10.1021/ja00041a059; HENNINGFELD KA, 1995, BIOCHEMISTRY-US, V34, P6120, DOI 10.1021/bi00018a015; Henningfeld KA, 1996, J AM CHEM SOC, V118, P11701, DOI 10.1021/ja961788h; KINGSBURY WD, 1991, J MED CHEM, V34, P98, DOI 10.1021/jm00105a017; KROGH S, 1991, NUCLEIC ACIDS RES, V19, P1235, DOI 10.1093/nar/19.6.1235; Maxam A M, 1980, Methods Enzymol, V65, P499; MCCOUBREY WK, 1986, J BIOL CHEM, V261, P5130; Pourquier P, 1997, J BIOL CHEM, V272, P7792, DOI 10.1074/jbc.272.12.7792; RIZZO CJ, 1992, TETRAHEDRON LETT, V33, P4129, DOI 10.1016/S0040-4039(00)74670-3; Sambrook J., 2002, MOL CLONING LAB MANU; SHIDA T, 1994, NUCLEOS NUCLEOT, V13, P1319, DOI 10.1080/15257779408012154; SHUMAN S, 1992, J BIOL CHEM, V267, P8620; STEVNSNER T, 1989, J BIOL CHEM, V264, P10110; SVEJSTRUP JQ, 1991, J MOL BIOL, V222, P669, DOI 10.1016/0022-2836(91)90503-X; SVEJSTRUP JQ, 1990, J BIOL CHEM, V265, P12529; VOSBERG HP, 1985, CURR TOP MICROBIOL, V114, P19; WANG LK, 1993, CHEM RES TOXICOL, V6, P813, DOI 10.1021/tx00036a010	31	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12383	12390		10.1074/jbc.273.20.12383	http://dx.doi.org/10.1074/jbc.273.20.12383			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575192	hybrid			2022-12-27	WOS:000073629800057
J	Garrett, TA; Que, NLS; Raetz, CRH				Garrett, TA; Que, NLS; Raetz, CRH			Accumulation of a lipid A precursor lacking the 4 '-phosphate following inactivation of the Escherichia coli lpxK gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE ENDOTOXIN; A DISACCHARIDE SYNTHASE; ACID-DEFICIENT MUTANT; 3-DEOXY-D-MANNO-OCTULOSONIC ACID; SALMONELLA-TYPHIMURIUM; RHIZOBIUM-LEGUMINOSARUM; BACTERIAL-ENDOTOXINS; ABC TRANSPORTER; MSBA GENE; BIOSYNTHESIS	The lpxK gene has been proposed to encode the lipid A 4'-kinase in Escherichia coli (Garrett, T, A., Kadrmas, J, L,, and Raetz, C, R, H. (1997) J, Biol, Chem, 272, 21855-21864), In cell extracts, the kinase phosphorylates the 4'-position of a tetraacyldisaccharide 1-phosphate precursor (DS-1-P) of lipid A, but the enzyme has not yet been purified because of instability. lpxK is co-transcribed with an essential upstream gene, msbA, with strong homology to mammalian Mdr proteins and ABC transporters, msbA may be involved in the transport of newly made lipid A from the inner surface of the inner membrane to the outer membrane. Insertion of an Omega-chloramphenicol cassette into msbA also halts transcription of lpxK, We have now constructed a strain in which only the lpxK gene is inactivated by inserting a kanamycin cassette into the chromosomal copy of lpxK, This mutation is complemented at 30 degrees C by a hybrid plasmid with a temperature-sensitive origin of replication carrying lpxK(+), When this strain (designated TG1/pTAG1) is grown at 44 degrees C, the plasmid bearing the lpxK(+) is lost, and the phenotype of an lpxK knock-out mutation is unmasked. The growth of TG1/pTAG1 was inhibited after several hours at 44 degrees C, consistent with lpxK being an essential gene. Furthermore, 4'-kinase activity in extracts made from these cells was barely detectable. In accordance with the proposed biosynthetic pathway for lipid A, DS-1-P (the 4'-kinase substrate) accumulated in TG1/pTAG1 cells grown at 44 degrees C, The DS-1-P from TG1/pTAG1 was isolated, and its structure was verified by H-1 NMR spectroscopy. DS-1-P had not been isolated previously from bacterial cells. Its accumulation in TG1/pTAG1 provides additional support for the pathway of lipid A biosynthesis in E. coli, Homologs of lpxK are present in the genomes of other Gram-negative bacteria.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	raetz@biochem.duke.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051310] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-51310] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1988, MOL REPROD DEV; BELUNIS CJ, 1995, J BIOL CHEM, V270, P27646, DOI 10.1074/jbc.270.46.27646; BELUNIS CJ, 1992, J BIOL CHEM, V267, P9988; BHAT UR, 1994, J BIOL CHEM, V269, P14402; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; BULAWA CE, 1984, J BIOL CHEM, V259, P4846; CLEMENTZ T, 1991, J BIOL CHEM, V266, P9687; CROWELL DN, 1986, J BACTERIOL, V168, P152, DOI 10.1128/jb.168.1.152-159.1986; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; GALLOWAY SM, 1990, J BIOL CHEM, V265, P6394; Garrett TA, 1997, J BIOL CHEM, V272, P21855, DOI 10.1074/jbc.272.35.21855; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HAMPTON RY, 1988, J BIOL CHEM, V263, P14802; JURGENS UJ, 1985, J BACTERIOL, V164, P384; Kaneko T, 1996, DNA Res, V3, P109; KAROW M, 1993, MOL MICROBIOL, V7, P69, DOI 10.1111/j.1365-2958.1993.tb01098.x; KELLY TM, 1993, J BIOL CHEM, V268, P19866; KUMADA H, 1995, J BACTERIOL, V177, P2098, DOI 10.1128/jb.177.8.2098-2106.1995; MDLULI KE, 1994, MICROBIOL-SGM, V140, P3309, DOI 10.1099/13500872-140-12-3309; Moran AP, 1997, J BACTERIOL, V179, P6453, DOI 10.1128/jb.179.20.6453-6463.1997; Nikaido H., 1996, ESCHERICHIA COLI SAL, P29; NISHIJIMA M, 1979, J BIOL CHEM, V254, P7837; Odegaard TJ, 1997, J BIOL CHEM, V272, P19688, DOI 10.1074/jbc.272.32.19688; Polissi A, 1996, MOL MICROBIOL, V20, P1221, DOI 10.1111/j.1365-2958.1996.tb02642.x; POOLE RK, 1994, FEMS MICROBIOL LETT, V117, P217, DOI 10.1111/j.1574-6968.1994.tb06768.x; PRICE NPJ, 1995, P NATL ACAD SCI USA, V92, P7352, DOI 10.1073/pnas.92.16.7352; RADIKA K, 1988, J BIOL CHEM, V263, P14859; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; RAETZ CRH, 1986, ANNU REV GENET, V20, P253, DOI 10.1146/annurev.ge.20.120186.001345; RAETZ CRH, 1985, J BIOL CHEM, V260, P6080; RAETZ CRH, 1996, ESCHERICHIA COLI SAL, P1035; RAY BL, 1984, J BIOL CHEM, V259, P4852; RAY BL, 1987, J BIOL CHEM, V262, P1122; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; RIETSCHEL ET, 1992, SCI AM, V267, P54, DOI 10.1038/scientificamerican0892-54; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; STRAIN SM, 1985, J BIOL CHEM, V260, P6089; TAKAYAMA K, 1983, J BIOL CHEM, V258, P7379; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; VAARA M, 1993, ANTIMICROB AGENTS CH, V37, P2255, DOI 10.1128/AAC.37.11.2255; Zhou ZM, 1998, J BIOL CHEM, V273, P12466, DOI 10.1074/jbc.273.20.12466	43	42	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12457	12465		10.1074/jbc.273.20.12457	http://dx.doi.org/10.1074/jbc.273.20.12457			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575203	hybrid			2022-12-27	WOS:000073629800068
J	Goessling, LS; Mascotti, DP; Thach, RE				Goessling, LS; Mascotti, DP; Thach, RE			Involvement of heme in the degradation of iron-regulatory protein 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING-PROTEIN; RECEPTOR MESSENGER-RNA; ERYTHROID 5-AMINOLEVULINATE SYNTHASE; FERRITIN REPRESSOR PROTEIN; 3' UNTRANSLATED REGION; RESPONSIVE ELEMENT; TRANSLATIONAL REGULATION; ACONITASE ACTIVITY; STABILITY; IDENTIFICATION	Iron-regulatory proteins (IRPs) recognize and bind to specific RNA structures called iron-responsive elements. Mediation of these binding interactions by iron and iron-containing compounds regulates several posttranscriptional events relevant to iron metabolism. There are two known IRPs, IRP1 and IRP2, both of which can respond to iron fluxes in the cell. There is ample evidence that IRP1 is converted by iron to cytoplasmic aconitase in vivo. It has also been shown that, under certain conditions, a significant fraction of IRP1 is degraded in cells exposed to iron or heme. Studies have shown that the degradation of IRP1 that is induced by iron can be inhibited by either desferrioxamine mesylate (an iron chelator) or succinyl acetone (an inhibitor of heme synthesis), whereas the degradation induced by heme cannot. This suggests that heme rather than iron is responsible for this degradation. Several laboratories have shown that IRP2 is also degraded in cells treated with iron salts. We now show evidence suggesting that this IRP2 degradation may be mediated by heme. Thus, in experiments analogous to those used previously to study IRP1, we find that IRP2 is degraded in rabbit fibroblast cells exposed to heme or iron salts. However, as shown earlier with IRP1, both desferrioxamine mesylate and succinyl acetone will inhibit the degradation of IRP2 induced by iron but not that induced by heme.	Washington Univ, Dept Biol, St Louis, MO 63130 USA; Richard Stockton Coll, Nat & Math Sci Div, Pomona, NJ 08240 USA	Washington University (WUSTL)	Thach, RE (corresponding author), Washington Univ, Dept Biol, Campus Box 1137, St Louis, MO 63130 USA.		Mascotti, David/G-3594-2012	Mascotti, David/0000-0003-1184-6784				BHASKER CR, 1993, J BIOL CHEM, V268, P12699; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; Butt J, 1996, P NATL ACAD SCI USA, V93, P4345, DOI 10.1073/pnas.93.9.4345; CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; COCCIA EM, 1994, J BIOL REG HOMEOS AG, V8, P81; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; DANDEKAR T, 1991, EMBO J, V10, P1903, DOI 10.1002/j.1460-2075.1991.tb07716.x; DRAPIER JC, 1993, EMBO J, V12, P3643, DOI 10.1002/j.1460-2075.1993.tb06038.x; GOESSLING LS, 1992, SCIENCE, V256, P670, DOI 10.1126/science.1316633; GOESSLING LS, 1994, J BIOL CHEM, V269, P4343; Gray NK, 1996, P NATL ACAD SCI USA, V93, P4925, DOI 10.1073/pnas.93.10.4925; GUO B, 1994, J BIOL CHEM, V269, P24252; GUO B, 1995, J BIOL CHEM, V270, P21645, DOI 10.1074/jbc.270.37.21645; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P7536, DOI 10.1073/pnas.89.16.7536; Henderson BR, 1996, BIOESSAYS, V18, P739, DOI 10.1002/bies.950180909; HENDERSON BR, 1993, J BIOL CHEM, V268, P27327; HENDERSON BR, 1994, J BIOL CHEM, V269, P17481; HENDERSON BR, 1995, J BIOL CHEM, V270, P20509, DOI 10.1074/jbc.270.35.20509; HIRLING H, 1994, EMBO J, V13, P453, DOI 10.1002/j.1460-2075.1994.tb06280.x; IWAI K, 1995, EMBO J, V14, P5350, DOI 10.1002/j.1460-2075.1995.tb00219.x; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; KIM HY, 1995, J BIOL CHEM, V270, P4983, DOI 10.1074/jbc.270.10.4983; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KOELLER DM, 1989, P NATL ACAD SCI USA, V86, P3574, DOI 10.1073/pnas.86.10.3574; Kohler SA, 1995, J BIOL CHEM, V270, P30781, DOI 10.1074/jbc.270.51.30781; LIN JJ, 1991, P NATL ACAD SCI USA, V88, P6068, DOI 10.1073/pnas.88.14.6068; Mascotti David P., 1998, P217; MASCOTTI DP, 1995, ANNU REV NUTR, V15, P239, DOI 10.1146/annurev.nu.15.070195.001323; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; MUNRO H, 1993, NUTR REV, V51, P65, DOI 10.1111/j.1753-4887.1993.tb03072.x; Phillips JD, 1996, BIOCHEMISTRY-US, V35, P15704, DOI 10.1021/bi960653l; SAMANIEGO F, 1994, J BIOL CHEM, V269, P30904; THEIL EC, 1993, BIOFACTORS, V4, P87; WEISS G, 1993, EMBO J, V12, P3651, DOI 10.1002/j.1460-2075.1993.tb06039.x	36	47	47	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12555	12557		10.1074/jbc.273.20.12555	http://dx.doi.org/10.1074/jbc.273.20.12555			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575215	hybrid			2022-12-27	WOS:000073629800080
J	Matsuda, S; Moriguchi, T; Koyasu, S; Nishida, E				Matsuda, S; Moriguchi, T; Koyasu, S; Nishida, E			T lymphocyte activation signals for interleukin-2 production involve activation of MKK6-p38 and MKK7-SAPK/JNK signaling pathways sensitive to cyclosporin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE CASCADES; TUMOR-NECROSIS-FACTOR; MAP KINASE; TRANSDUCTION PATHWAYS; REGULATED KINASES; MAJOR ACTIVATOR; OSMOTIC SHOCK; C-JUN; CELLS; STRESS	p38/CSBP, a subgroup member of mitogen-activated protein kinase (MAPK) superfamily molecules, is known to be activated by proinflammatory cytokines and environmental stresses. We report here that p38 is specifically activated by signals that lead to interleukin-a (IL-2) production in T lymphocytes. A p38 activator MKK6 was also markedly activated by the same stimulation. Pretreatment of cells with SB203580, a specific inhibitor of p38, as well as expression of a dominant-negative mutant of MKK6, suppressed the transcriptional activation of the IL-2 promoter. We also demonstrated that MKK7, a recently described MAPK kinase family member, plays a major role in the activation of stress-activated protein kinase (SAPK)/c-Jun NH2-terminal kinase (JNK) in T lymphocytes. Moreover, a dominant-negative mutant of MKK7 abrogated the transcriptional activation of the distal nuclear factor of activated T cells response element in the IL-2 promoter, Cyclosporin A, a potent immunosuppressant, inhibited activation of both p38 and SAPK/JNK pathways but not the MAPK/extracellular signal-regulated kinase (ERK) pathway. Our results indicate that both MKK6 to p38 and MKK7 to SAPK/JNK signaling pathways are activated in a cyclosporin A-sensitive manner and contribute to IL-2 gene expression in T lymphocytes.	Kyoto Univ, Grad Sch Sci, Dept Biophys, Sakyo Ku, Kyoto 60601, Japan; Keio Univ, Sch Med, Dept Immunol, Shinjuku Ku, Tokyo 160, Japan	Kyoto University; Keio University	Koyasu, S (corresponding author), Kyoto Univ, Grad Sch Sci, Dept Biophys, Sakyo Ku, Kyoto 60601, Japan.		Moriguchi, Tetsuo/D-7061-2012; Agena, Fabiana A/C-5819-2015; Koyasu, Shigeo/J-5583-2015	Moriguchi, Tetsuo/0000-0002-9598-4991; Agena, Fabiana A/0000-0002-4526-4857; Koyasu, Shigeo/0000-0001-9585-3038				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1996, EMBO J, V15, P4156, DOI 10.1002/j.1460-2075.1996.tb00790.x; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DeSilva DR, 1996, J EXP MED, V183, P2017, DOI 10.1084/jem.183.5.2017; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Fields PE, 1996, SCIENCE, V271, P1276, DOI 10.1126/science.271.5253.1276; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KOYASU S, 1987, J BIOL CHEM, V262, P4689; Lawler S, 1997, FEBS LETT, V414, P153, DOI 10.1016/S0014-5793(97)00990-3; Lee JC, 1996, J LEUKOCYTE BIOL, V59, P152, DOI 10.1002/jlb.59.2.152; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li W, 1996, SCIENCE, V271, P1272, DOI 10.1126/science.271.5253.1272; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Lu XH, 1997, J BIOL CHEM, V272, P24751, DOI 10.1074/jbc.272.40.24751; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; MCKEON F, 1991, CELL, V66, P823, DOI 10.1016/0092-8674(91)90426-Y; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; MORIGUCHI T, 1995, J BIOL CHEM, V270, P12969, DOI 10.1074/jbc.270.22.12969; Moriguchi T, 1996, J BIOL CHEM, V271, P26981, DOI 10.1074/jbc.271.43.26981; MORIGUCHI T, 1997, EMBO J, V16, P70415; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Nishina H, 1997, J EXP MED, V186, P941, DOI 10.1084/jem.186.6.941; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; RAO A, 1991, CRIT REV IMMUNOL, V10, P495; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; TOUNIER C, 1997, P NATL ACAD SCI USA, V94, P7337; Toyoshima F, 1997, J CELL BIOL, V139, P1005, DOI 10.1083/jcb.139.4.1005; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Whitehurst CE, 1996, J IMMUNOL, V156, P1020	56	169	177	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12378	12382		10.1074/jbc.273.20.12378	http://dx.doi.org/10.1074/jbc.273.20.12378			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575191	hybrid			2022-12-27	WOS:000073629800056
J	Pitcher, JA; Hall, RA; Daaka, Y; Zhang, J; Ferguson, SSG; Hester, S; Miller, S; Caron, MG; Lefkowitz, RJ; Barak, LS				Pitcher, JA; Hall, RA; Daaka, Y; Zhang, J; Ferguson, SSG; Hester, S; Miller, S; Caron, MG; Lefkowitz, RJ; Barak, LS			The G protein-coupled receptor kinase 2 is a microtubule-associated protein kinase that phosphorylates tubulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; MEMBRANES; ARRESTIN; MECHANISM; SUBUNITS; AGONIST; DESENSITIZATION; SEQUESTRATION; ACTIVATION; BINDING	The G protein-coupled receptor kinase 2 (GRK2) is a serine/threonine kinase that phosphorylates and desensitizes agonist-occupied G protein-coupled receptors (GPCRs). Here we demonstrate that GRK2 is a microtubule-associated protein and identify tubulin as a novel GRK2 substrate. GRK2 is associated with microtubules purified from bovine brain, forms a complex with tubulin in cell extracts, and colocalizes with tubulin in living cells. Furthermore, an endogenous tubulin kinase activity that copurifies with microtubules has properties similar to GRK2 and is inhibited by anti-GRK2 monoclonal antibodies. Indeed, GRK2 phosphorylates tubulin in vitro with kinetic parameters very similar to those for phosphorylation of the agonist-occupied beta(2)-adrenergic receptor, suggesting a functionally relevant role for this phosphorylation event. In a cellular environment, agonist occupancy of GPCRs, which leads to recruitment of GRK2 to the plasma membrane and its subsequent activation, promotes GRK2-tubulin complex formation and tubulin phosphorylation. These findings suggest a novel role for GRK2 as a GPCR signal transducer mediating the effects of GPCR activation on the cytoskeleton.	Duke Univ, Med Ctr, Howard Hughes Med Inst Labs, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med & Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Microbiol, Durham, NC 27710 USA	Duke University; Duke University; Duke University; Duke University	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst Labs, Box 3281, Durham, NC 27710 USA.		Lefkowitz, Robert/AAW-2649-2021; Pitcher, Julie/ABH-2078-2020	Hall, Randy/0000-0002-8318-8728	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003422, R37HL016037, R01HL016037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019576] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 03422, HL16037] Funding Source: Medline; NINDS NIH HHS [NS 19576] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; Barak LS, 1997, MOL PHARMACOL, V51, P177, DOI 10.1124/mol.51.2.177; BENOVIC JL, 1984, BIOCHEMISTRY-US, V23, P4510, DOI 10.1021/bi00315a002; CHAPLINE C, 1993, J BIOL CHEM, V268, P6858; CHERKSEY BD, 1980, P NATL ACAD SCI-BIOL, V77, P6401, DOI 10.1073/pnas.77.11.6401; CHERKSEY BD, 1985, J MEMBRANE BIOL, V84, P105, DOI 10.1007/BF01872208; CRUTE BE, 1992, J NEUROCHEM, V59, P2017; Daaka Y, 1997, P NATL ACAD SCI USA, V94, P2180, DOI 10.1073/pnas.94.6.2180; DebBurman SK, 1996, J BIOL CHEM, V271, P22552, DOI 10.1074/jbc.271.37.22552; DIAZNIDO J, 1990, J BIOL CHEM, V265, P13949; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; HAGA K, 1992, J BIOL CHEM, V267, P222; HAMMALVAREZ SF, 1994, P NATL ACAD SCI USA, V91, P7812, DOI 10.1073/pnas.91.16.7812; HARGREAVES AJ, 1986, NATURE, V323, P827, DOI 10.1038/323827a0; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HYATT SL, 1994, CELL GROWTH DIFFER, V5, P485; INGLESE J, 1993, J BIOL CHEM, V268, P23735; INGLESE J, 1995, PROTEIN KINASE FACTS, P98; Khan IA, 1996, BIOCHEMISTRY-US, V35, P3704, DOI 10.1021/bi951247p; KIM CM, 1993, J BIOL CHEM, V268, P15412; KIM CM, 1993, RECEPTOR, V3, P39; KOHTZ DS, 1989, J NEUROCHEM, V52, P285, DOI 10.1111/j.1471-4159.1989.tb10929.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEISER M, 1986, J BIOL CHEM, V261, P1904; LIAO L, 1994, BIOCHEMISTRY-US, V33, P1229, DOI 10.1021/bi00171a024; LIMAS CJ, 1983, BIOCHIM BIOPHYS ACTA, V735, P181, DOI 10.1016/0005-2736(83)90273-0; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; LUDUENA R F, 1992, Current Opinion in Cell Biology, V4, P53, DOI 10.1016/0955-0674(92)90058-K; MEISNER H, 1995, PROTEIN KINASE FACTS, P240; Menard L, 1996, BIOCHEMISTRY-US, V35, P4155, DOI 10.1021/bi952961+; MOCHLYROSEN D, 1995, BIOCHEM SOC T, V23, P596, DOI 10.1042/bst0230596; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; Oppermann M, 1996, P NATL ACAD SCI USA, V93, P7649, DOI 10.1073/pnas.93.15.7649; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; Sackett D L, 1995, Subcell Biochem, V24, P255; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SERRANO L, 1987, J CELL BIOL, V105, P1731, DOI 10.1083/jcb.105.4.1731; SIMON JR, 1991, MICRON MICROSC ACTA, V22, P405, DOI 10.1016/0739-6260(91)90058-8; SINGH TJ, 1984, BIOCHEM BIOPH RES CO, V121, P19, DOI 10.1016/0006-291X(84)90682-X; STRASSER RH, 1986, P NATL ACAD SCI USA, V83, P6362, DOI 10.1073/pnas.83.17.6362; VALETTE F, 1989, NUCLEIC ACIDS RES, V17, P723; VALLANO ML, 1986, ANN NY ACAD SCI, V466, P357, DOI 10.1111/j.1749-6632.1986.tb38406.x; VALLEE RB, 1982, J CELL BIOL, V92, P435, DOI 10.1083/jcb.92.2.435; VOTER WA, 1984, J BIOL CHEM, V259, P430; WASSARMAN PM, 1978, J CELL SCI, V29, P171	50	130	133	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12316	12324		10.1074/jbc.273.20.12316	http://dx.doi.org/10.1074/jbc.273.20.12316			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575184	hybrid			2022-12-27	WOS:000073629800049
J	Plaas, AHK; West, LA; Wong-Palms, S; Nelson, FRT				Plaas, AHK; West, LA; Wong-Palms, S; Nelson, FRT			Glycosaminoglycan sulfation in human osteoarthritis - Disease-related alterations at the non-reducing termini of chondroitin and dermatan sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SYNOVIAL-FLUID; ARTICULAR-CARTILAGE; INTERGLOBULAR DOMAIN; AGGRECAN FRAGMENTS; II COLLAGEN; JOINT FLUID; PROTEOGLYCANS; QUANTITATION; EXPRESSION; 6-SULFOTRANSFERASE	Chondroitin lyase products of aggrecan and small proteoglycans from normal and osteoarthritic cartilages were analyzed for chain internal Delta disaccharides and terminal mono-or disaccharides. Chondroitin and dermatan sulfate chains from arthritic cartilages were of essentially normal size and internal sulfation but had significantly altered sulfation of the terminal residues. Whereas in normal cartilage, similar to 60% of terminal GalNAc4S was 4,6-disulfated, it was reduced to similar to 30% in osteoarthritic cartilage. This is most likely due to a lower terminal GalNAc4,6S-disulfotransferase activity and reveals that metabolic changes in osteoarthritis can affect this distinct sulfation step during chondroitin and dermatan sulfate synthesis. GlcA beta 1,3GalNAc6S-, the mimotope for antibody 3B3(-), was present on similar to 8 and similar to 10% of chains from normal and osteoarthritic cartilages, respectively. 3B3(-) assayed by immunodot blot was within the normal range for most osteoarthritic samples, with only 5 of 24 displaying elevated reactivity. This resulted not from a higher content of mimotope, but possibly from other structural changes in the proteoglycan that increase mimotope reactivity. In summary, chemical determination of sulfation isomers at the non-reducing termini of chondroitin and dermatan sulfate provides a reliable assay for monitoring proteoglycan metabolism not only during normal growth of cartilage but also during remodeling of cartilage in osteoarthritis.	Shriners Hosp Crippled Children, Cell Biol Lab, Tampa Unit, Tampa, FL 33612 USA; Univ S Florida, Sch Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Henry Ford Hosp, Ctr Bone & Joint, Detroit, MI 48202 USA	State University System of Florida; University of South Florida; Henry Ford Health System; Henry Ford Hospital	Plaas, AHK (corresponding author), Shriners Hosp Crippled Children, Cell Biol Lab, Tampa Unit, 12502 N Pine Dr, Tampa, FL 33612 USA.	annaplaas@delphi.com						ADAMS ME, 1995, J RHEUMATOL, V22, P94; Aigner T, 1997, ANN RHEUM DIS, V56, P287, DOI 10.1136/ard.56.5.287; Bayliss MT, 1995, ACTA ORTHOP SCAND, V66, P22, DOI 10.3109/17453679509157642; Belcher C, 1997, ANN RHEUM DIS, V56, P299, DOI 10.1136/ard.56.5.299; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; Bjornsson S, 1995, ACTA ORTHOP SCAND, V66, P158; CARLSON CS, 1995, J ORTHOP RES, V13, P399, DOI 10.1002/jor.1100130314; CARNEY SL, 1985, J ORTHOPAED RES, V3, P140, DOI 10.1002/jor.1100030203; CATERSON B, 1990, J CELL SCI, V97, P411; Cheng F, 1996, J BIOL CHEM, V271, P28572, DOI 10.1074/jbc.271.45.28572; COUCHMAN JR, 1989, MATRICES CELL DIFFER, P31; COX MJ, 1985, BIOCHIM BIOPHYS ACTA, V840, P228, DOI 10.1016/0304-4165(85)90123-0; CsSzabo G, 1997, ARTHRITIS RHEUM, V40, P1037, DOI 10.1002/art.1780400607; CSSZABO G, 1995, ARTHRITIS RHEUM, V38, P660, DOI 10.1002/art.1780380514; Dourado GS, 1996, OSTEOARTHR CARTILAGE, V4, P187, DOI 10.1016/S1063-4584(96)80015-X; Eyre DR, 1975, ANN RHEUM DIS, V34, P138; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; FUKUTA M, 1995, J BIOL CHEM, V270, P18575, DOI 10.1074/jbc.270.31.18575; Hamai A, 1997, J BIOL CHEM, V272, P9123; HAZELL PK, 1995, ARTHRITIS RHEUM, V38, P953, DOI 10.1002/art.1780380711; HOLLANDER AP, 1994, J CLIN INVEST, V93, P1722, DOI 10.1172/JCI117156; Ilic MZ, 1995, ACTA ORTHOP SCAND, V66, P33, DOI 10.3109/17453679509157644; ILIC MZ, 1992, ARCH BIOCHEM BIOPHYS, V294, P115, DOI 10.1016/0003-9861(92)90144-L; LARK MW, 1995, J BIOL CHEM, V270, P2550, DOI 10.1074/jbc.270.6.2550; LOHMANDER LS, 1993, ARTHRITIS RHEUM, V36, P1214; Lohmander LS, 1997, J RHEUMATOL, V24, P782; MATYAS JR, 1995, ARTHRITIS RHEUM, V38, P420, DOI 10.1002/art.1780380320; MICHELLACCI YM, 1987, CONNECT TISSUE RES, V7, P29; MIDURA RJ, 1995, J BIOL CHEM, V270, P8009, DOI 10.1074/jbc.270.14.8009; MORALES TI, 1988, J BIOL CHEM, V263, P3632; NAKANISHI Y, 1981, J BIOL CHEM, V256, P5443; Plaas AHK, 1997, J BIOL CHEM, V272, P20603, DOI 10.1074/jbc.272.33.20603; Plaas AHK, 1996, GLYCOBIOLOGY, V6, P823, DOI 10.1093/glycob/6.8.823; POOLE AR, 1996, ARTHRITIS ALLIED CON, P279; RATCLIFFE A, 1993, ARTHRITIS RHEUM, V36, P543, DOI 10.1002/art.1780360416; RIZKALLA G, 1992, J CLIN INVEST, V90, P2268, DOI 10.1172/JCI116113; Sandy JD, 1995, ACTA ORTHOP SCAND, V66, P26, DOI 10.3109/17453679509157643; SANDY JD, 1984, ARTHRITIS RHEUM, V27, P388, DOI 10.1002/art.1780270405; SANDY JD, 1992, J CLIN INVEST, V89, P1512, DOI 10.1172/JCI115742; SANDY JD, 1986, J ORTHOPAED RES, V4, P263, DOI 10.1002/jor.1100040302; SANDY JD, 1996, ARTHRITIS ALLIED CON, P252; SHINMEI M, 1992, ARTHRITIS RHEUM, V35, P1304, DOI 10.1002/art.1780351110; SLATER RR, 1995, ARTHRITIS RHEUM-US, V38, P655, DOI 10.1002/art.1780380513; SWEET MBE, 1977, ANN RHEUM DIS, V36, P387, DOI 10.1136/ard.36.5.387; VASAN N, 1980, BIOCHEM J, V187, P781, DOI 10.1042/bj1870781; VILIM V, 1994, BIOCHEM J, V304, P887, DOI 10.1042/bj3040887; VISCO DM, 1993, ARTHRITIS RHEUM, V36, P1718, DOI 10.1002/art.1780361211	47	122	134	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12642	12649		10.1074/jbc.273.20.12642	http://dx.doi.org/10.1074/jbc.273.20.12642			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575226	hybrid			2022-12-27	WOS:000073629800091
J	Ott, M; Stockert, RJ; Ma, QZ; Gagandeep, S; Gupta, S				Ott, M; Stockert, RJ; Ma, QZ; Gagandeep, S; Gupta, S			Simultaneous up-regulation of viral receptor expression and DNA synthesis is required for increasing efficiency of retroviral hepatic gene transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID TRANSPORTER; ECOTROPIC MURINE RETROVIRUSES; CELL-SURFACE RECEPTOR; HEPATOCYTES IN-VIVO; APE LEUKEMIA-VIRUS; HOST RANGE; ENVELOPE PROTEINS; CULTURED-CELLS; LIVER; TRANSDUCTION	To understand the relative contribution of viral receptor expression and cell proliferation in retroviral gene transfer, we created human hepatocyte-derived HuH-7.MCAT-1 cell Lines. These cells constitutively express the murine ecotropic retroviral receptor MCAT-1 without changes in morphology or proliferation states. The MCAT-1 receptor is also a cationic amino acid transporter, and the HuH-7.MCAT-1.7 cells showed increased V-max of uptake and steady-state accumulation of the cationic amino acids L-arginine and L-lysine. In HuH-7.MCAT-1 cells, L-arginine uptake was significantly upregulated by norepinephrine and dexamethasone, and hepatocyte growth factor also increased L-arginine uptake along with cellular DNA synthesis. Gene transfer was also markedly increased in HuH-7.MCAT-1.7 cells incubated with an ecotropic LacZ retrovirus, and this further increased with hormones and hepatocyte growth factor. To define whether viral receptor up-regulation by itself increased gene transfer, cell cycling was inhibited by a recombinant adenovirus expressing the Mad transcription factor (AdMad), which is a dominant-negative c-Myc regulator. This restricted cells in G(0)/G(1), without attenuating MCAT-1 activity, as shown by flow cytometry and L-arginine uptake analysis, respectively. When asynchronously cycling HuH-7.MCAT-1.7 cells were first infected with the AdMad virus and then exposed to the ecotropic LacZ virus, gene transfer was virtually abolished. The data indicate that while upregulation of viral receptors can greatly enhance retrovirally mediated gene transfer, DNA synthesis remains an absolute requirement for hepatic gene therapy with this approach.	Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Div Gastroenterol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Gupta, S (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Med, 1300 Morris Pk Ave,Ullmann 625, Bronx, NY 10461 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046952] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK46952] Funding Source: Medline; PHS HHS [P30-41296] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALBRITTON LM, 1993, J VIROL, V67, P2091, DOI 10.1128/JVI.67.4.2091-2096.1993; ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; BATTINI JL, 1992, J VIROL, V66, P1468, DOI 10.1128/JVI.66.3.1468-1475.1992; BHANDARI B, 1991, MOL CELL ENDOCRINOL, V76, P71, DOI 10.1016/0303-7207(91)90261-P; BRANCHEREAU S, 1994, HUM GENE THER, V5, P803, DOI 10.1089/hum.1994.5.7-803; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CLOSS EI, 1993, J BIOL CHEM, V268, P20796; CLOSS EI, 1993, J VIROL, V67, P2097, DOI 10.1128/JVI.67.4.2097-2102.1993; CLOSS EI, 1993, J BIOL CHEM, V268, P7538; CROOKS GM, 1993, BLOOD, V82, P3290; ELFASSI E, 1987, VIROLOGY, V160, P259, DOI 10.1016/0042-6822(87)90069-9; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GAZZOLA GC, 1981, ANAL BIOCHEM, V115, P368, DOI 10.1016/0003-2697(81)90019-1; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; GUPTA S, 1992, HEPATOLOGY, V15, P485, DOI 10.1002/hep.1840150322; HEARD JM, 1991, J VIROL, V65, P4026, DOI 10.1128/JVI.65.8.4026-4032.1991; JOHANN SV, 1992, J VIROL, V66, P1635, DOI 10.1128/JVI.66.3.1635-1640.1992; KAVANAUGH MP, 1994, J BIOL CHEM, V269, P15445; KAVANAUGH MP, 1994, P NATL ACAD SCI USA, V91, P7071, DOI 10.1073/pnas.91.15.7071; KILBERG MS, 1993, ANNU REV NUTR, V13, P137, DOI 10.1146/annurev.nu.13.070193.001033; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; KIM JW, 1993, J BIOL CHEM, V268, P16316; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LIEBER A, 1995, HUM GENE THER, V6, P5, DOI 10.1089/hum.1995.6.1-5; LIEBER A, 1995, P NATL ACAD SCI USA, V92, P6210, DOI 10.1073/pnas.92.13.6210; LU B, 1995, HEPATOLOGY, V21, P752, DOI 10.1016/0270-9139(95)90529-4; MACLEOD CL, 1990, MOL CELL BIOL, V10, P3663, DOI 10.1128/MCB.10.7.3663; MALONE RW, 1994, J BIOL CHEM, V269, P29903; MILLER AD, 1993, METHOD ENZYMOL, V217, P581; MORGAN RA, 1993, J VIROL, V67, P4712, DOI 10.1128/JVI.67.8.4712-4721.1993; MORLING FJ, 1995, GENE THER, V2, P504; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; NUSSBAUM O, 1993, J VIROL, V67, P7402, DOI 10.1128/JVI.67.12.7402-7405.1993; PAGES JC, 1995, HUM GENE THER, V6, P21, DOI 10.1089/hum.1995.6.1-21; ROE TY, 1993, EMBO J, V12, P2099, DOI 10.1002/j.1460-2075.1993.tb05858.x; WANG H, 1992, J BIOL CHEM, V267, P23617; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WHITE MF, 1982, J BIOL CHEM, V257, P4450; WILSON CA, 1991, J VIROL, V65, P5975, DOI 10.1128/JVI.65.11.5975-5982.1991; Wilson JM, 1996, NEW ENGL J MED, V334, P1185, DOI 10.1056/NEJM199605023341809; WOODARD MH, 1994, AM J PHYSIOL, V266, pE817, DOI 10.1152/ajpendo.1994.266.5.E817; WU JY, 1994, J VIROL, V68, P1615, DOI 10.1128/JVI.68.3.1615-1623.1994; Wu ZD, 1996, MOL CELL BIOL, V16, P4128; YOSHIMOTO T, 1992, J VIROL, V66, P4377, DOI 10.1128/JVI.66.7.4377-4381.1992	44	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 8	1998	273	19					11954	11961		10.1074/jbc.273.19.11954	http://dx.doi.org/10.1074/jbc.273.19.11954			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZM408	9565624	hybrid			2022-12-27	WOS:000073536700078
J	Moinova, HR; Mulcahy, RT				Moinova, HR; Mulcahy, RT			An electrophile responsive element (EpRE) regulates p-naphthoflavone induction of the human gamma-glutamylcysteine synthetase regulatory subunit gene - Constitutive expression is mediated by an adjacent AP-1 site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL L2 CELLS; INDUCED OXIDATIVE STRESS; MESSENGER-RNA; BINDING-SITE; RAT-KIDNEY; TRANSCRIPTIONAL REGULATION; DETOXIFY CARCINOGENS; METHYL MERCURY; HEAVY SUBUNIT; GLUTATHIONE	Exposure of HepG2 cells to beta-naphthoflavone (beta-NF) results in time-and dose-dependent increase in the steady-state mRNA levels for both the catalytic (GCS(h)) and regulatory (GCS(1)) subunits of gamma-glutamylcysteine synthetase (GCS) which catalyzes the rate-limiting step in the de novo synthesis of the cellular antioxidant glutathione (GSH) (Mulcahy, R. T., Wartman, M. A., Bailey, H. B., and Gipp, J. J. (1997) J. Biol. Chem. 272, 7445-7454), Cloning and sequencing of the GCS, promoter region is reported. Regulatory sequences mediating basal and beta-NF induced expression of the GCS, gene were identified using a series of promoter/reporter fusion genes transfected into HepG2 cells. Sequences directing basal and beta-NF induced expression were localized between nucleotides -344 and -242 (numbered relative to the translation start site). Mutational analyses indicate that basal expression of the GCS, gene is directed by a consensus AP-1-binding site located 33 base pairs upstream of a consensus electrophile responsive element (EpRE) sequence; both cis-elements are capable of supporting beta-NF inducibility, Elimination of the inducible response requires simultaneous mutation of both sequences, however, in the presence of an intact EpRE the upstream AP-1 site is irrelevant to induction. Regulation of expression of both human GCS subunit genes in response to beta-NF is therefore mediated by cis-elements satisfying the consensus core EpRE motif.	Univ Wisconsin, Sch Med, Dept Human Oncol, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison	Mulcahy, RT (corresponding author), Univ Wisconsin, Sch Med, Dept Human Oncol, K4-316,600 Highland Ave, Madison, WI 53792 USA.				NCI NIH HHS [R01-CA57549] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057549] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; Blank V, 1997, TRENDS BIOCHEM SCI, V22, P437, DOI 10.1016/S0968-0004(97)01105-5; BORROZ KI, 1994, TOXICOL APPL PHARM, V126, P150, DOI 10.1006/taap.1994.1101; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHUNG AS, 1981, BIOCHEM PHARMACOL, V30, P3217, DOI 10.1016/0006-2952(81)90521-9; DANIEL V, 1993, CRIT REV BIOCHEM MOL, V28, P173, DOI 10.3109/10409239309086794; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; GIPP JJ, 1992, BIOCHEM BIOPH RES CO, V185, P29, DOI 10.1016/S0006-291X(05)80950-7; GIPP JJ, 1995, BIOCHEM BIOPH RES CO, V206, P584, DOI 10.1006/bbrc.1995.1083; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; HUANG CS, 1993, J BIOL CHEM, V268, P19675; Inamdar NM, 1996, BIOCHEM BIOPH RES CO, V221, P570, DOI 10.1006/bbrc.1996.0637; ITCH K, 1997, BIOCHEM BIOPH RES CO, V236, P313; JAISWAL AK, 1994, BIOCHEM PHARMACOL, V48, P439, DOI 10.1016/0006-2952(94)90272-0; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KERPPOLA TK, 1994, ONCOGENE, V9, P3149; LI Y, 1992, J BIOL CHEM, V267, P15097; LIU RM, 1994, CARCINOGENESIS, V15, P2347, DOI 10.1093/carcin/15.10.2347; Liu RM, 1996, AM J RESP CELL MOL, V14, P192, DOI 10.1165/ajrcmb.14.2.8630270; Liu RM, 1996, AM J RESP CELL MOL, V14, P186, DOI 10.1165/ajrcmb.14.2.8630269; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MEISTER A, 1995, METHOD ENZYMOL, V252, P26; MEISTER A, 1989, COENZYMES COFACTOR A, V3, P367; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; MULCAHY RT, 1995, BIOCHEM BIOPH RES CO, V209, P227, DOI 10.1006/bbrc.1995.1493; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; OBrien ML, 1996, EUR J CANCER, V32A, P967, DOI 10.1016/0959-8049(96)00051-2; PRESTERA T, 1993, P NATL ACAD SCI USA, V90, P2965, DOI 10.1073/pnas.90.7.2965; PRESTERA T, 1995, P NATL ACAD SCI USA, V92, P8965, DOI 10.1073/pnas.92.19.8965; REED DJ, 1990, ANNU REV PHARMACOL, V30, P603, DOI 10.1146/annurev.pa.30.040190.003131; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; SAKAI M, 1988, P NATL ACAD SCI USA, V85, P9456, DOI 10.1073/pnas.85.24.9456; Schroder CP, 1996, CANCER INVEST, V14, P158, DOI 10.3109/07357909609018891; SEELIG GF, 1984, J BIOL CHEM, V259, P9345; Sekhar KR, 1997, BIOCHEM BIOPH RES CO, V234, P588, DOI 10.1006/bbrc.1997.6697; SHI MM, 1994, J BIOL CHEM, V269, P26512; SHI MM, 1994, AM J PHYSIOL-LUNG C, V267, pL414, DOI 10.1152/ajplung.1994.267.4.L414; STEPHEN DWS, 1995, MOL MICROBIOL, V16, P415, DOI 10.1111/j.1365-2958.1995.tb02407.x; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; WOODS JS, 1995, BIOCHEM PHARMACOL, V50, P1719, DOI 10.1016/0006-2952(95)02075-6; WOODS JS, 1992, ARCH BIOCHEM BIOPHYS, V296, P350, DOI 10.1016/0003-9861(92)90583-I; WU AL, 1994, MOL CELL BIOL, V14, P5832, DOI 10.1128/MCB.14.9.5832; YAO KS, 1995, CANCER RES, V55, P4367	46	233	239	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14683	14689		10.1074/jbc.273.24.14683	http://dx.doi.org/10.1074/jbc.273.24.14683			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614065	hybrid			2022-12-27	WOS:000074160400007
J	Nagel, W; Zeitlmann, L; Schilcher, P; Geiger, C; Kolanus, J; Kolanus, W				Nagel, W; Zeitlmann, L; Schilcher, P; Geiger, C; Kolanus, J; Kolanus, W			Phosphoinositide 3-OH kinase activates the beta(2) integrin adhesion pathway and induces membrane recruitment of cytohesin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; BRUTONS TYROSINE KINASE; NUCLEOTIDE EXCHANGE FACTORS; ADRENERGIC-RECEPTOR KINASE; OUT SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAINS; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; CELL-ADHESION; LIGAND-BINDING	Signal transduction through phosphoinositide 3-OH kinase (PI 3-kinase) has been implicated in the regulation of lymphocyte adhesion mediated by integrin receptors, Cellular phosphorylation products of PI 3-kinases interact with a subset of pleckstrin homology (PH) domains, a module that has been shown to recruit proteins to cellular membranes. We have recently identified cytohesin-1, a cytoplasmic regulator of beta(2) integrin adhesion to intercellular adhesion molecule 1. We describe here that expression of a constitutively active PI 3-kinase is sufficient far the activation of Jurkat cell adhesion to intercellular adhesion molecule 1, and for enhanced membrane association of cytohesin-1. Up-regulation of cell adhesion by PI 3-kinase and membrane association of endogenous cytohesin-1 is abrogated by overexpression of the isolated cytohesin-1 PH domain, but not by a mutant of the PH domain which fails to associate with the plasma membrane. The PH domain of Bruton's tyrosine kinase (Btk), although strongly associated with the plasma membrane, had no effect on either membrane recruitment of cytohesin-1 or on induction of adhesion by PI 3-kinase. Having delineated the critical steps of the beta(2) integrin activation pathway by biochemical and functional analyses, we conclude that PI 3-kinase activates inside-out signaling of beta(2) integrins at least partially through cytohesin-1.	Univ Munchen, Genzentrum, Mol Biol Lab, D-81377 Munich, Germany	University of Munich	Kolanus, W (corresponding author), Univ Munchen, Genzentrum, Mol Biol Lab, Feodor Lynen Str 25, D-81377 Munich, Germany.	kolanus@lmb.uni-muenchen.de	Zeitlmann, Lutz/AAF-3586-2019					Auger KR, 1996, J BIOL CHEM, V271, P23452, DOI 10.1074/jbc.271.38.23452; Carr MW, 1996, IMMUNITY, V4, P179, DOI 10.1016/S1074-7613(00)80682-2; Chan ASH, 1997, J IMMUNOL, V159, P934; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; CHEN YP, 1994, J BIOL CHEM, V269, P18307; COPPOLINO M, 1995, J BIOL CHEM, V270, P23132, DOI 10.1074/jbc.270.39.23132; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; DIAMOND MS, 1994, CURR BIOL, V4, P506, DOI 10.1016/S0960-9822(00)00111-1; DOWNWARD J, 1994, NATURE, V371, P378, DOI 10.1038/371378a0; Driessens MHE, 1997, EXP CELL RES, V231, P242, DOI 10.1006/excr.1996.3463; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FILARDO EJ, 1994, J BIOL CHEM, V269, P4641; Frank S, 1998, J BIOL CHEM, V273, P23, DOI 10.1074/jbc.273.1.23; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Fukuda M, 1996, J BIOL CHEM, V271, P30303, DOI 10.1074/jbc.271.48.30303; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; KASSNER PD, 1993, J EXP MED, V178, P649, DOI 10.1084/jem.178.2.649; Klarlund JK, 1998, J BIOL CHEM, V273, P1859, DOI 10.1074/jbc.273.4.1859; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lemmon MA, 1997, TRENDS CELL BIOL, V7, P237, DOI 10.1016/S0962-8924(97)01065-9; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LEWIS JM, 1995, MOL BIOL CELL, V6, P151, DOI 10.1091/mbc.6.2.151; Li TJ, 1997, ONCOGENE, V15, P1375, DOI 10.1038/sj.onc.1201308; LI TJ, 1995, IMMUNITY, V2, P451, DOI 10.1016/1074-7613(95)90026-8; Ma AD, 1997, J CELL BIOL, V136, P1071, DOI 10.1083/jcb.136.5.1071; Meacci E, 1997, P NATL ACAD SCI USA, V94, P1745, DOI 10.1073/pnas.94.5.1745; Meller N, 1996, MOL CELL BIOL, V16, P5782; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; Nielsen M, 1996, J IMMUNOL, V157, P5350; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PASQUALINI R, 1994, J CELL BIOL, V125, P447, DOI 10.1083/jcb.125.2.447; Paterson HF, 1995, BIOCHEM J, V312, P661, DOI 10.1042/bj3120661; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PHILIPPOT J, 1983, BIOCHIM BIOPHYS ACTA, V734, P137, DOI 10.1016/0005-2736(83)90111-6; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; REIF K, 1996, CURR BIOL, V6, P145; RODRIGUEZ VP, 1996, EMBO J, V15, P2442; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; SHATTIL SJ, 1995, J CELL BIOL, V131, P807, DOI 10.1083/jcb.131.3.807; Shimizu Y, 1996, IMMUNOL TODAY, V17, P565, DOI 10.1016/S0167-5699(96)10061-X; Shimizu Y, 1995, J CELL BIOL, V131, P1867, DOI 10.1083/jcb.131.6.1867; Shpetner H, 1996, J CELL BIOL, V132, P595, DOI 10.1083/jcb.132.4.595; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Wang DS, 1995, BIOCHEM BIOPH RES CO, V217, P608, DOI 10.1006/bbrc.1995.2818; Ward SG, 1996, IMMUNOL TODAY, V17, P187, DOI 10.1016/0167-5699(96)80618-9; Weber C, 1996, J CELL BIOL, V134, P1063, DOI 10.1083/jcb.134.4.1063; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; YAGISAWA H, 1994, J BIOL CHEM, V269, P20179; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; Zauli G, 1997, BLOOD, V89, P883, DOI 10.1182/blood.V89.3.883; Zell T, 1996, J IMMUNOL, V156, P883; Zhang J, 1996, J BIOL CHEM, V271, P6265, DOI 10.1074/jbc.271.11.6265; Zheng Y, 1996, J BIOL CHEM, V271, P23815, DOI 10.1074/jbc.271.39.23815	73	125	129	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14853	14861		10.1074/jbc.273.24.14853	http://dx.doi.org/10.1074/jbc.273.24.14853			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614087	hybrid			2022-12-27	WOS:000074160400029
J	Saint, N; Lacapere, JJ; Gu, LQ; Ghazi, A; Martinac, B; Rigaud, JL				Saint, N; Lacapere, JJ; Gu, LQ; Ghazi, A; Martinac, B; Rigaud, JL			A hexameric transmembrane pore revealed by two-dimensional crystallization of the large mechanosensitive ion channel (MscL) of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-RECEPTOR; ELECTRON-DIFFRACTION; PATCH-CLAMP; PHOE PORIN; RESOLUTION	We have established a reconstitution method of the detergent-solubilized recombinant large mechanosensitive ion channel of Escherichia coli (MscL) that yielded two-dimensional crystals. For that purpose, we have developed a new protocol using Triton X-100 to solubilize and purify the MscL protein. This protocol not only allowed an increase in the protein yield but also made it possible to obtain a homogeneous delipidated and reproducible preparation of the purified protein. When examined by the patch-clamp method MscL channels were found to be fully functional, exhibiting characteristic conductance and activation by pressure. For electron crystallography the homogeneous Triton X-100-purified recombinant MscL was further reconstituted at low lipid-to-protein ratios using Bio-Beads SM2 to remove the detergent. Two-dimensional crystals, exhibiting a p6 plane group symmetry, have been produced and examined by negative stain electron microscopy. Image processing of selected micrographs yielded a projection map at 15-Angstrom resolution that provided the first explicit structural information about the molecular boundary and homohexameric organization of the MscL channels in the membrane bilayer.	Univ Western Australia, Dept Pharmacol, Nedlands, WA 6907, Australia; CEA, LRC, F-75231 Paris, France; Univ Paris 11, Lab Biomembranes, CNRS, ERS 571, F-91405 Orsay, France; Inst Curie, CNRS, UMR 168, F-75231 Paris 05, France	University of Western Australia; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; PSL Research University Paris; Sorbonne Universite; UNICANCER; Institut Curie	Rigaud, JL (corresponding author), Inst Curie, CNRS, UMR 168, 11 Rue Pierre & Marie Curie, F-75231 Paris 05, France.	rigaud@curie.fr	Martinac, Boris/A-7178-2018; Saint, Nathalie/S-5286-2016	Martinac, Boris/0000-0001-8422-7082; Saint, Nathalie/0000-0001-5219-9486				Blount P, 1996, P NATL ACAD SCI USA, V93, P11652, DOI 10.1073/pnas.93.21.11652; Blount P, 1996, EMBO J, V15, P4798, DOI 10.1002/j.1460-2075.1996.tb00860.x; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; Cruickshank CC, 1997, BIOPHYS J, V73, P1925, DOI 10.1016/S0006-3495(97)78223-7; DELCOUR AH, 1989, BIOPHYS J, V56, P631, DOI 10.1016/S0006-3495(89)82710-9; French RJ, 1996, NEURON, V16, P407, DOI 10.1016/S0896-6273(00)80058-6; GarciaAnoveros J, 1997, ANNU REV NEUROSCI, V20, P567, DOI 10.1146/annurev.neuro.20.1.567; GU L, 1998, IN PRESS BIOPHYS J; HAMILL OP, 1995, AM SCI, V83, P30; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hamill OP, 1996, PHARMACOL REV, V48, P231; HAMILL OP, 1994, TRENDS NEUROSCI, V17, P439, DOI 10.1016/0166-2236(94)90125-2; Hase CC, 1997, BIOCHEM BIOPH RES CO, V232, P777, DOI 10.1006/bbrc.1997.6370; Hase CC, 1997, J MEMBRANE BIOL, V157, P17, DOI 10.1007/s002329900212; JAP BK, 1988, J MOL BIOL, V199, P229, DOI 10.1016/0022-2836(88)90393-2; JAP BK, 1990, J STRUCT BIOL, V103, P57, DOI 10.1016/1047-8477(90)90086-R; MARTINAC B, 1993, CRC THERMODYNAMICS M, P327; MORRIS CE, 1990, J MEMBRANE BIOL, V113, P93, DOI 10.1007/BF01872883; Mosser G, 1997, J BIOL CHEM, V272, P20263, DOI 10.1074/jbc.272.32.20263; North RA, 1996, CURR OPIN CELL BIOL, V8, P474, DOI 10.1016/S0955-0674(96)80023-8; Rigaud JL, 1997, J STRUCT BIOL, V118, P226, DOI 10.1006/jsbi.1997.3848; SACHS F, 1988, CRIT REV BIOMED ENG, V16, P141; SACKIN H, 1995, ANNU REV PHYSIOL, V57, P333, DOI 10.1146/annurev.ph.57.030195.002001; SUKHAREV SI, 1994, NATURE, V368, P265, DOI 10.1038/368265a0; Sukharev SI, 1997, ANNU REV PHYSIOL, V59, P633, DOI 10.1146/annurev.physiol.59.1.633; Sukharev SI, 1996, SOC GEN PHY, V51, P133; TOYOSHIMA C, 1990, J CELL BIOL, V111, P2623, DOI 10.1083/jcb.111.6.2623; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; VALPUESTA JM, 1994, J MOL BIOL, V240, P281, DOI 10.1006/jmbi.1994.1445; Young HS, 1997, BIOPHYS J, V72, P2545, DOI 10.1016/S0006-3495(97)78898-2	31	45	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14667	14670		10.1074/jbc.273.24.14667	http://dx.doi.org/10.1074/jbc.273.24.14667			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614061	hybrid			2022-12-27	WOS:000074160400003
J	Wise, ML; Savage, TJ; Katahira, E; Croteau, R				Wise, ML; Savage, TJ; Katahira, E; Croteau, R			Monoterpene synthases from common sage (Salvia officinalis) - cDNA isolation, characterization, and functional expression of (+)-sabinene synthase, 1,8-cineole synthase, and (+)-bornyl diphosphate synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERANYL PYROPHOSPHATE; ENZYMATIC CYCLIZATION; BORNYL PYROPHOSPHATE; NERYL PYROPHOSPHATE; (-)-LINALYL PYROPHOSPHATE; (-)-BORNYL PYROPHOSPHATE; ISOLATED CHROMOPLASTS; PARTIAL-PURIFICATION; TERPENOID CYCLASE; OLEFIN FORMATION	Common sage (Salvia officinalis) produces an extremely broad range of cyclic monoterpenes bearing diverse carbon skeletons, including members of the p-menthane (1,8-cineole), pinane (alpha- and beta-pinene), thujane (isothujone), camphane (camphene), and bornane (camphor) families. An homology-based polymerase chain reaction cloning strategy was developed and used to isolate the cDNAs encoding three multiproduct monoterpene synthases from this species that were functionally expressed in Escherichia coli. The heterologously expressed synthases produce (+)-bornyl diphosphate, 1,8-cineole, and (+)-sabinene, respectively, as their major products from geranyl diphosphate. The bornyl diphosphate synthase also produces significant amounts of (+)-alpha-pinene, (+)-camphene, and (+/-)-limonene. The 1,8-cineole synthase produces significant amounts of (+)- and (-)-alpha-pinene, (+)- and (-)-beta-pinene, myrcene and (+)-sabinene, and the (+)-sabinene synthase produces significant quantities of gamma-terpinene and terpinolene. All three enzymes appear to be translated as preproteins bearing an amino-terminal plastid targeting sequence, consistent with the plastidial origin of monoterpenes in plants. Deduced sequence analysis and size exclusion chromatography indicate that the recombinant bornyl diphosphate synthase is a homodimer, whereas the other two recombinant enzymes are monomeric, consistent with the size and subunit architecture of their native enzyme counterparts. The distribution and stereochemistry of the products generated by the recombinant (+)-bornyl diphosphate synthase suggest that this enzyme might represent both (+)-bornyl diphosphate synthase and (+)-pinene synthase which were previously assumed to be distinct enzymes.	Washington State Univ, Inst Biol Chem, Pullman, WA 99164 USA; Washington State Univ, Dept Biochem & Biophys, Pullman, WA 99164 USA	Washington State University; Washington State University	Croteau, R (corresponding author), Washington State Univ, Inst Biol Chem, Pullman, WA 99164 USA.	croteau@mail.wsu.edu			NIGMS NIH HHS [GM-31354] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM031354, R01GM031354] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHBY MN, 1990, J BIOL CHEM, V265, P13157; Bohlmann J, 1997, J BIOL CHEM, V272, P21784, DOI 10.1074/jbc.272.35.21784; CANE DE, 1990, CHEM REV, V90, P1089, DOI 10.1021/cr00105a002; CANE DE, 1994, BIOCHEMISTRY-US, V33, P5846, DOI 10.1021/bi00185a024; CANE DE, 1982, J AM CHEM SOC, V104, P5831, DOI 10.1021/ja00385a067; CHEN AJ, 1994, PROTEIN SCI, V3, P600; Chen XY, 1995, ARCH BIOCHEM BIOPHYS, V324, P255, DOI 10.1006/abbi.1995.0038; COLBY SM, 1993, J BIOL CHEM, V268, P23016; COOPER TG, 1977, TOOLS BIOCH, P169; CROTEAU R, 1989, J BIOL CHEM, V264, P15309; CROTEAU R, 1977, ARCH BIOCHEM BIOPHYS, V184, P77, DOI 10.1016/0003-9861(77)90328-9; CROTEAU R, 1987, CHEM REV, V87, P929, DOI 10.1021/cr00081a004; CROTEAU R, 1976, ARCH BIOCHEM BIOPHYS, V176, P734, DOI 10.1016/0003-9861(76)90217-4; CROTEAU R, 1985, J BIOL CHEM, V260, P5956; CROTEAU R, 1979, ARCH BIOCHEM BIOPHYS, V198, P523, DOI 10.1016/0003-9861(79)90527-7; CROTEAU R, 1978, ARCH BIOCHEM BIOPHYS, V188, P182, DOI 10.1016/0003-9861(78)90371-5; CROTEAU R, 1994, ARCH BIOCHEM BIOPHYS, V309, P184, DOI 10.1006/abbi.1994.1101; CROTEAU R, 1986, J BIOL CHEM, V261, P3438; CROTEAU R, 1989, J BIOL CHEM, V264, P2075; CROTEAU R, 1988, J BIOL CHEM, V263, P10063; CROTEAU R, 1979, ARCH BIOCHEM BIOPHYS, V198, P512, DOI 10.1016/0003-9861(79)90526-5; CROTEAU R, 1977, ARCH BIOCHEM BIOPHYS, V179, P257, DOI 10.1016/0003-9861(77)90110-2; CROTEAU R, 1990, ARCH BIOCHEM BIOPHYS, V277, P374, DOI 10.1016/0003-9861(90)90593-N; CROTEAU R, 1985, METHOD ENZYMOL, V110, P383; CROTEAU R, 1992, RECENT DEV FLAVOR FR, P263; CROTEAU RB, 1985, BIOCHEMISTRY-US, V24, P7077, DOI 10.1021/bi00346a009; CROTEAU RB, 1987, BIOCHEMISTRY-US, V26, P5383, DOI 10.1021/bi00391a025; CROTEAU RB, 1992, ACS SYM SER, V490, P8; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; Dudareva N, 1996, PLANT CELL, V8, P1137, DOI 10.1105/tpc.8.7.1137; FACCHINI PJ, 1992, P NATL ACAD SCI USA, V89, P11088, DOI 10.1073/pnas.89.22.11088; GAMBLIEL H, 1984, J BIOL CHEM, V259, P740; GAMBLIEL H, 1982, J BIOL CHEM, V257, P2335; *GEN COMP GROUP, 1996, WISC PACK VERS 9 0; GLEIZES M, 1983, PLANTA, V159, P373, DOI 10.1007/BF00393177; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; KARP F, 1982, ARCH BIOCHEM BIOPHYS, V216, P616, DOI 10.1016/0003-9861(82)90251-X; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; Lewinsohn E., 1994, Plant Molecular Biology Reporter, V12, P20, DOI 10.1007/BF02668660; LEWINSOHN E, 1992, ARCH BIOCHEM BIOPHYS, V293, P167, DOI 10.1016/0003-9861(92)90380-F; MAU CJD, 1994, P NATL ACAD SCI USA, V91, P8497, DOI 10.1073/pnas.91.18.8497; MCCASKILL D, 1993, ANAL BIOCHEM, V215, P142, DOI 10.1006/abio.1993.1566; MCGEADY P, 1995, ARCH BIOCHEM BIOPHYS, V317, P149, DOI 10.1006/abbi.1995.1147; METTAL U, 1988, EUR J BIOCHEM, V170, P613, DOI 10.1111/j.1432-1033.1988.tb13741.x; PEREZ LM, 1990, PLANT PHYSIOL BIOCH, V28, P221; PORALLA K, 1994, TRENDS BIOCHEM SCI, V19, P157, DOI 10.1016/0968-0004(94)90276-3; Poulter C. D., 1981, BIOSYNTHESIS ISOPREN, V1, P161; PYUN HJ, 1994, ARCH BIOCHEM BIOPHYS, V308, P488, DOI 10.1006/abbi.1994.1069; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SATTERWHITE DM, 1988, J CHROMATOGR, V454, P61; SAVAGE TJ, 1995, ARCH BIOCHEM BIOPHYS, V320, P257, DOI 10.1016/0003-9861(95)90008-X; SAVAGE TJ, 1994, J BIOL CHEM, V269, P4012; SHI Z, 1994, P NATL ACAD SCI USA, V91, P7370, DOI 10.1073/pnas.91.15.7370; STEELE CL, 1995, P NATL ACAD SCI USA, V92, P4164, DOI 10.1073/pnas.92.10.4164; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TABOR S, 1991, CURRENT PROTOCOLS MO; TARSHIS LC, 1994, BIOCHEMISTRY-US, V33, P10871, DOI 10.1021/bi00202a004; Tarshis LC, 1996, P NATL ACAD SCI USA, V93, P15018, DOI 10.1073/pnas.93.26.15018; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WAGSCHAL K, 1991, TETRAHEDRON, V47, P5933, DOI 10.1016/S0040-4020(01)86486-3; WAGSCHAL KC, 1994, ARCH BIOCHEM BIOPHYS, V308, P477, DOI 10.1006/abbi.1994.1068; Wise ML, 1998, COMPREHENSIVE NATURA, V2; Yuba A, 1996, ARCH BIOCHEM BIOPHYS, V332, P280, DOI 10.1006/abbi.1996.0343; [No title captured]	64	201	220	3	41	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					14891	14899		10.1074/jbc.273.24.14891	http://dx.doi.org/10.1074/jbc.273.24.14891			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614092	hybrid			2022-12-27	WOS:000074160400034
J	Guy, HI; Schmidt, B; Herve, G; Evans, DR				Guy, HI; Schmidt, B; Herve, G; Evans, DR			Pressure-induced dissociation of carbamoyl-phosphate synthetase domains - The catalytically active form is dimeric	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIFUNCTIONAL PROTEIN CAD; INITIATES PYRIMIDINE BIOSYNTHESIS; CARBONIC-PHOSPHORIC ANHYDRIDE; ESCHERICHIA-COLI; ASPARTATE-TRANSCARBAMYLASE; REVERSIBLE DISSOCIATION; NUCLEOTIDE-SEQUENCE; MAMMALIAN-CELLS; SUBUNIT; GENE	Carbamoyl-phosphate synthetase consists of an amidotransferase domain or subunit (GLN) that hydpolyzes glutamine and transfers the ammonia to the synthetase component (CPS) where the biosynthetic reaction occurs. The CPS domain is composed of two homologous subdomains, CPS.A and CPS.B, that catalyze different ATP-dependent reactions involved in carbamoyl phosphate synthesis. When the individual CPS.A and CPS.B subdomains were individually cloned and expressed in Escherichia coli (Guy, H. I., and Evans, D. R., (1996) J. Biol, Chem. 271, 13762-13769), they were found to be functionally equivalent and could each independently catalyze carbamoyl phosphate synthesis, The proposal was advanced that, although the monomers could catalyze the individual partial reactions, overall synthesis of carbamoyl phosphate required a homodimer of CPS.A or CPS.B. To test this hypothesis, the GLN-CPS.B dimer was reversibly dissociated at 1500 bar in a high pressure cell. Dissociation was accompanied by a loss of both glutamine- and ammonia-dependent CPSase activity. Activity was recovered once the protein was returned to atmospheric pressure. If the sample was cross-linked before exposure to high pressure, there was no dissociation and no loss of biosynthetic activity. In contrast, the bicarbonate-dependent ATPase and the carbamoyl phosphate-dependent ATP synthetase activities were largely unaffected by pressure-induced dissociation. These experiments confirmed the hypothesis that the synthesis of carbamoyl phosphate requires the concerted action of the two active sites within the homodimer.	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA; Univ Paris 06, CNRS, UMR 7631, Paris, France	Wayne State University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Evans, DR (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA.	devans@cmb.biosci.wayne.edu			NIGMS NIH HHS [GM47399] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047399] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELAL AT, 1982, J BACTERIOL, V151, P1411, DOI 10.1128/JB.151.3.1411-1419.1982; ANDERSON PM, 1965, BIOCHEMISTRY-US, V4, P2803, DOI 10.1021/bi00888a034; ANDERSON PM, 1966, BIOCHEMISTRY-US, V5, P3157, DOI 10.1021/bi00874a012; ANDERSON PM, 1995, NITROGEN METABOLISM, P33; BAUR H, 1989, EUR J BIOCHEM, V179, P53, DOI 10.1111/j.1432-1033.1989.tb14520.x; BEIN K, 1991, J BIOL CHEM, V266, P3791; BISHOP SH, 1966, BIOCHIM BIOPHYS ACTA, V118, P211, DOI 10.1016/S0926-6593(66)80163-7; BOYER PD, 1989, FASEB J, V3, P2164, DOI 10.1096/fasebj.3.10.2526771; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLEMAN PF, 1977, J BIOL CHEM, V252, P6379; FAURE M, 1989, EUR J BIOCHEM, V179, P345, DOI 10.1111/j.1432-1033.1989.tb14560.x; FREUND JN, 1987, J MOL BIOL, V193, P1, DOI 10.1016/0022-2836(87)90621-8; GUILLOU F, 1992, BIOCHEMISTRY-US, V31, P1656, DOI 10.1021/bi00121a012; GUILLOU F, 1989, P NATL ACAD SCI USA, V86, P8304, DOI 10.1073/pnas.86.21.8304; Guy HI, 1997, J BIOL CHEM, V272, P29255, DOI 10.1074/jbc.272.46.29255; Guy HI, 1996, J BIOL CHEM, V271, P13762, DOI 10.1074/jbc.271.23.13762; GUY HI, 1994, J BIOL CHEM, V269, P7702; Hanahan D, 1985, DNA CLONING PRACTICA; HEREMANS K, 1982, ANNU REV BIOPHYS BIO, V11, P1, DOI 10.1146/annurev.bb.11.060182.000245; HOA GHB, 1990, ANAL BIOCHEM, V187, P258; HONG J, 1994, J MOL BIOL, V243, P131, DOI 10.1006/jmbi.1994.1638; HONG J, 1995, J BIOL CHEM, V270, P14130, DOI 10.1074/jbc.270.23.14130; JavidMajd F, 1996, BIOCHEMISTRY-US, V35, P14362, DOI 10.1021/bi961184q; KIM HS, 1992, J BIOL CHEM, V267, P7177; Kothe M, 1997, P NATL ACAD SCI USA, V94, P12348, DOI 10.1073/pnas.94.23.12348; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE L, 1985, P NATL ACAD SCI USA, V82, P6802, DOI 10.1073/pnas.82.20.6802; LEGRAIN C, 1995, MICROBIOL-SGM, V141, P1093, DOI 10.1099/13500872-141-5-1093; LUSTY CJ, 1993, BIOCHEMISTRY-US, V32, P1278, DOI 10.1021/bi00056a012; LUSTY CJ, 1983, J BIOL CHEM, V258, P4466; MALLY MI, 1981, P NATL ACAD SCI-BIOL, V78, P6647, DOI 10.1073/pnas.78.11.6647; Maniatis T., 1982, MOL CLONING; MEISTER A, 1989, ADV ENZYMOL RAMB, V62, P315; MILES BW, 1993, BIOCHEMISTRY-US, V32, P232, DOI 10.1021/bi00052a030; MORI M, 1975, BIOCHEMISTRY-US, V14, P2622, DOI 10.1021/bi00683a010; NOWLAN SF, 1985, J BIOL CHEM, V260, P4712; NYUNOYA H, 1985, P NATL ACAD SCI USA, V82, P2244, DOI 10.1073/pnas.82.8.2244; POST LE, 1990, J BIOL CHEM, V265, P7742; POWERS SG, 1976, P NATL ACAD SCI USA, V73, P3020, DOI 10.1073/pnas.73.9.3020; POWERS SG, 1978, J BIOL CHEM, V253, P1258; POWERS SG, 1978, J BIOL CHEM, V253, P800; PRESCOTT LM, 1969, ANAL BIOCHEM, V32, P408, DOI 10.1016/S0003-2697(69)80008-4; Purcarea C, 1996, EUR J BIOCHEM, V236, P189, DOI 10.1111/j.1432-1033.1996.00189.x; QUINN CL, 1991, J BIOL CHEM, V266, P9113; RAUN K, 1988, BIOCHEMISTRY-US, V27, P3295; RAUSHEL FM, 1979, BIOCHEMISTRY-US, V18, P3424, DOI 10.1021/bi00582a033; RAUSHEL FM, 1980, BIOCHEMISTRY-US, V19, P3170, DOI 10.1021/bi00555a009; RUBIO V, 1977, BIOCHEMISTRY-US, V16, P321, DOI 10.1021/bi00621a025; SCHADE BC, 1980, BIOCHEMISTRY-US, V19, P1121, DOI 10.1021/bi00547a013; SCHIMKE RT, 1966, J BIOL CHEM, V241, P2228; SEIFERT T, 1984, FEBS LETT, V173, P381, DOI 10.1016/0014-5793(84)80809-1; SHOAF WT, 1973, BIOCHEMISTRY-US, V12, P4039, DOI 10.1021/bi00745a004; SIMMER JP, 1990, J BIOL CHEM, V265, P10395; SOUCIET JL, 1989, GENE, V79, P59, DOI 10.1016/0378-1119(89)90092-9; Stapleton MA, 1996, BIOCHEMISTRY-US, V35, P14352, DOI 10.1021/bi961183y; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6305, DOI 10.1021/bi970503q; THORNE KJI, 1963, J BIOL CHEM, V238, P2992; TROTTA PP, 1971, P NATL ACAD SCI USA, V68, P2599, DOI 10.1073/pnas.68.10.2599; TROTTA PP, 1974, J BIOL CHEM, V249, P492; WEBER G, 1983, Q REV BIOPHYS, V16, P89, DOI 10.1017/S0033583500004935; WIMMER MJ, 1979, J BIOL CHEM, V254, P1854	61	10	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14172	14178		10.1074/jbc.273.23.14172	http://dx.doi.org/10.1074/jbc.273.23.14172			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603918	hybrid			2022-12-27	WOS:000074021500020
J	Stoffler, HE; Bahler, M				Stoffler, HE; Bahler, M			The ATPase activity of Myr3, a rat myosin I, is allosterically inhibited by its own tail domain and by Ca2+ binding to its light chain calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACANTHAMOEBA MYOSIN; ACTIN-BINDING; BRUSH-BORDER; UNCONVENTIONAL MYOSIN; MOTOR-ACTIVITY; SH3 DOMAIN; F-ACTIN; PURIFICATION; PROTEIN; IDENTIFICATION	We purified Myr3 (third unconventional myosin from rat), a mammalian "amoeboid" subclass myosin I, from rat liver. The heavy chain of purified Myr3 is associated with a single calmodulin light chain. Myr3 exhibits WEDTA-ATPase and Mg-ATPase activity, The Mg-ATPase activity is stimulated by increasing F-actin concentrations in a complex triphasic manner similar to the Mg-ATPase activity of myosin I molecules from protozoa, Although purified Myr3 was observed to cross-link actin filaments, it bound in an ATP regulated manner to F-actin, and no evidence for a nucleotide-independent high affinity actin binding site that could explain the triphasic activation pattern was obtained, Micromolar concentrations of free Ca2+ reversibly inhibit the Mg-ATPase activity of Myr3 by binding to its light chain calmodulin, which remains bound to the Myr3 heavy chain irrespective of the free Ca2+ concentration. Polyclonal antibodies and Fab fragments directed against the tail domain were found to stimulate the Mg-ATPase activity. A similar stimulation of the Myr3 Mg-ATPase activity is observed upon proteolytic removal of the very C-terminal SH3 domain. These results demonstrate that Myr3 is subject to negative regulation by free calcium and its own tail domain and possibly positive regulation by a tail-domain binding partner.	Ludwigs Maximillian Univ, Adolf Butenandt Inst, D-80336 Munchen, Germany	University of Munich	Bahler, M (corresponding author), Ludwigs Maximillian Univ, Adolf Butenandt Inst, Schillerstr 42, D-80336 Munchen, Germany.							ALBANESI JP, 1985, J BIOL CHEM, V260, P1174; BAHLER M, 1994, J CELL BIOL, V126, P375, DOI 10.1083/jcb.126.2.375; BARYLKO B, 1992, P NATL ACAD SCI USA, V89, P490, DOI 10.1073/pnas.89.2.490; BEMENT WM, 1994, J MOL BIOL, V243, P356, DOI 10.1006/jmbi.1994.1662; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; COLLINS JH, 1984, J BIOL CHEM, V259, P4128; COLLINS K, 1990, J CELL BIOL, V110, P1137, DOI 10.1083/jcb.110.4.1137; COLUCCIO LM, 1987, J CELL BIOL, V105, P325, DOI 10.1083/jcb.105.1.325; COLUCCIO LM, 1993, CELL MOTIL CYTOSKEL, V24, P189, DOI 10.1002/cm.970240306; CONZELMAN KA, 1987, J CELL BIOL, V105, P313, DOI 10.1083/jcb.105.1.313; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COTE GP, 1985, J BIOL CHEM, V260, P4543; DOBERSTEIN SK, 1992, J CELL BIOL, V117, P1241, DOI 10.1083/jcb.117.6.1241; GOODSON HV, 1995, CELL MOTIL CYTOSKEL, V30, P73, DOI 10.1002/cm.970300109; HALSALL DJ, 1990, FEBS LETT, V267, P126, DOI 10.1016/0014-5793(90)80305-3; JUNG G, 1994, FEBS LETT, V342, P197, DOI 10.1016/0014-5793(94)80500-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LYNCH TJ, 1989, J BIOL CHEM, V264, P19333; MARUTA H, 1978, J BIOL CHEM, V253, P6297; MCGOLDRICK CA, 1995, J CELL BIOL, V128, P577, DOI 10.1083/jcb.128.4.577; PANTALONI D, 1985, J BIOL CHEM, V260, P1180; PARDEE JD, 1982, METHOD CELL BIOL, V24, P271; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; POLLARD TD, 1973, J BIOL CHEM, V248, P4691; POLLARD TD, 1991, ANNU REV PHYSIOL, V53, P653, DOI 10.1146/annurev.ph.53.030191.003253; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; ROSENFELD SS, 1994, BIOCHEMISTRY-US, V33, P2322, DOI 10.1021/bi00174a045; RUPPERT C, 1993, J CELL BIOL, V120, P1393, DOI 10.1083/jcb.120.6.1393; STOFFLER HE, 1995, J CELL BIOL, V129, P819, DOI 10.1083/jcb.129.3.819; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALLIMANN T, 1981, BIOCHEMISTRY-US, V20, P1188, DOI 10.1021/bi00508a021; WILLIAMS R, 1994, CELL MOTIL CYTOSKEL, V27, P41, DOI 10.1002/cm.970270105; Zhu T, 1996, BIOCHEMISTRY-US, V35, P513, DOI 10.1021/bi952053c	34	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14605	14611		10.1074/jbc.273.23.14605	http://dx.doi.org/10.1074/jbc.273.23.14605			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603977	hybrid			2022-12-27	WOS:000074021500079
J	Yamaguchi, T; Pang, J; Reddy, KS; Surrey, S; Adachi, K				Yamaguchi, T; Pang, J; Reddy, KS; Surrey, S; Adachi, K			Role of beta 112 cys (G14) in homo- (beta(4)) and hetero- (alpha(2)beta(2)) tetramer hemoglobin formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HEMOGLOBINS; HUMAN APOHEMOGLOBIN; INTERFACE; KINETICS; OXYHEMOGLOBIN; ASSOCIATION; BINDING; GLOBIN; CHAINS	In order to assess the role of beta 112 Cys in homo-and hetero-tetrameric hemoglobin formation, we expressed four beta 112 variants (beta(112Cys-->Asp), beta(112Cys-->Ser), beta(112Cys-->Thr) and beta(112Cys-->Val)) and studied assembly with alpha chains in vitro, beta 112 Cys is normally present at beta(1) beta(2), and alpha(1) beta(1) interaction sites in homo-(beta(4)) and hetero-tetramers (alpha(2) beta(2)). beta(4) formation in vitro was influenced by the amino acid at beta 112, beta 112 Asp completely inhibited formation of homo-tetramers, whereas beta 112 Ser showed only slight inhibition. In contrast, beta 112 Thr or Val enhanced homotetramer formation compared with PA chains. Association constants for homo-tetramer formation increased in the order of beta(112Cys-->Ser), beta(A), beta(112Cys-->Thr), and beta(112Cys-->Val), whereas the value for beta(112Cys-->Asp) was Zero under the same conditions. These beta 112 changes also affected in vitro alpha(2) beta(2), hetero-tetramer formation. Order of alpha(2) beta(2) formation under limiting alpha-globin chain conditions showed Hb beta C112S > Hb A > Hb S = Hb beta C112T = Hb beta C112V * Hb beta C112D, Hb beta 112D can form tetrameric hemoglobin, but this beta 112 change promotes dissociation into alpha and beta chains instead of cup dimer formation upon dilution, These results indicate that amino acids at beta(1) alpha(1) interaction sites such as beta 112 on the G; helix play a key role in stable ap dimer formation. Our findings suggest, in addition to electrostatic interaction between alpha and beta chains, that dissociation of beta(4) homo-tetramers to monomers and hydrophobic interactions of the beta 112 amino acid with alpha chains governs stable alpha(1) beta(1) interactions, which then results in formation of functional hemoglobin tetramers, Information gained from these studies should increase our understanding of the mechanism of assembly of multi-subunit proteins.	Univ Penn, Div Hematol, Childrens Hosp Philadelphia, Sch Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Biophys, Philadelphia, PA 19104 USA; duPont Hosp Children, Dept Pediat, Wilmington, DE 19803 USA; duPont Hosp Children, Dept Res, Wilmington, DE 19803 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Pediat, Philadelphia, PA 19107 USA	University of Pennsylvania; Childrens Hospital of Philadelphia; University of Pennsylvania; Nemours Alfred I. duPont Hospital for Children; Nemours Alfred I. duPont Hospital for Children; Jefferson University	Adachi, K (corresponding author), Univ Penn, Div Hematol, Childrens Hosp Philadelphia, Sch Med, 34th St & Civ Ctr, Philadelphia, PA 19104 USA.	adachi@email.chop.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL020985, P60HL038632] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016691] Funding Source: NIH RePORTER; NHLBI NIH HHS [P60 HL38632, HL20985] Funding Source: Medline; NIDDK NIH HHS [DK 16691] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADACHI K, 1993, J BIOL CHEM, V268, P21650; Adachi K, 1998, BLOOD, V91, P1438, DOI 10.1182/blood.V91.4.1438; Ascoli F, 1981, Methods Enzymol, V76, P72; BAUDIN V, 1993, PROTEIN SCI, V2, P1320, DOI 10.1002/pro.5560020815; BENESCH RE, 1995, J BIOL CHEM, V270, P13785, DOI 10.1074/jbc.270.23.13785; BORGSTAHL GEO, 1994, J MOL BIOL, V236, P817, DOI 10.1006/jmbi.1994.1191; BUCCI E, 1965, J MOL BIOL, V12, P183, DOI 10.1016/S0022-2836(65)80292-3; BUNN HF, 1983, NATURE, V306, P498, DOI 10.1038/306498a0; BUNN HF, 1987, BLOOD, V69, P1; BUNN HF, 1986, HEMOGLOBIN MOL GENET, P168; CHIANCONE E, 1968, J BIOL CHEM, V243, P1212; Di Iorio E E, 1981, Methods Enzymol, V76, P57; FASMAN GD, 1966, J MOL BIOL, V19, P240, DOI 10.1016/S0022-2836(66)80002-5; FERMI G, 1981, ATLAS MOL STRUCTURE; FESTA RS, 1979, TRANSFUSION, V19, P107, DOI 10.1046/j.1537-2995.1979.19279160278.x; FRONTICELLI C, 1994, BIOPHYS CHEM, V51, P53, DOI 10.1016/0301-4622(94)00028-X; JOSHI AA, 1994, J BIOL CHEM, V269, P8549; KAWAMURA Y, 1983, J BIOCHEM-TOKYO, V93, P1159, DOI 10.1093/oxfordjournals.jbchem.a134241; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Manning LR, 1996, PROTEIN SCI, V5, P775; MCDONALD MJ, 1981, J BIOL CHEM, V256, P6487; MOULTON DP, 1994, BIOCHEM BIOPH RES CO, V199, P1278, DOI 10.1006/bbrc.1994.1369; MOULTON DP, 1994, BIOCHEM BIOPH RES CO, V204, P956, DOI 10.1006/bbrc.1994.2553; MRABET NT, 1986, J BIOL CHEM, V261, P5222; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PERUTZ MF, 1987, ACCOUNTS CHEM RES, V20, P309, DOI 10.1021/ar00141a001; PHILO JS, 1988, J BIOL CHEM, V263, P682; ROSE MY, 1983, J BIOL CHEM, V258, P4298; Shackleton CHL, 1994, MASS SPECTROMETRY CL, V2, P135; SHEN TJ, 1993, P NATL ACAD SCI USA, V90, P8108, DOI 10.1073/pnas.90.17.8108; VALDES R, 1978, P NATL ACAD SCI USA, V75, P311, DOI 10.1073/pnas.75.1.311; VALDES R, 1977, J BIOL CHEM, V252, P74; WHITE SP, 1994, HEMOGLOBIN, V18, P413, DOI 10.3109/03630269409045773; Yamaguchi T, 1996, J BIOL CHEM, V271, P26677, DOI 10.1074/jbc.271.43.26677	34	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14179	14185		10.1074/jbc.273.23.14179	http://dx.doi.org/10.1074/jbc.273.23.14179			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603919	hybrid			2022-12-27	WOS:000074021500021
J	Pedram, A; Razandi, M; Hu, RM; Levin, ER				Pedram, A; Razandi, M; Hu, RM; Levin, ER			Astrocyte progression from G(1) to S phase of the cell cycle depends upon multiple protein interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; NATRIURETIC-PEPTIDE; MICE LACKING; TGF-BETA; POTENTIAL MEDIATOR; KINASE INHIBITOR; P27(KIP1); PROLIFERATION; G1; ARREST	The proliferation of cultured astrocytes is positively and negatively regulated, respectively, by the endogenous neuropeptides, endothelin-3 (ET-3) and atrial natriuretic peptide (ANP), Here, we determined the important steps for the modulation by ET and ANP of G(1) to S phase cell cycle progression. ET-3 stimulated an increased number of fetal rat diencephalic astrocytes to progress through G(1)/S, and this was blocked significantly by ANP, ET augmented the gene expression and/or protein production of D-type, A and E cyclins, whereas ANP inhibited these events significantly, ET also stimulated the activation of the cyclin-dependent kinases Cdk2, Cdk4, and Cdk6, directed against the retinoblastoma protein pRb, and this was inhibited by as much as 80% by ANP, As an additional mechanism of cell cycle restraint, ANP stimulated the production of multiple cyclin-dependent kinase inhibitory (CKI) proteins, including p16, p27, and p57, This was critical because antisense oligonucleotides to each CKI reversed ANP-induced inhibition of ET-stimulated DNA synthesis by as much as 85%, CKI antisense oligonucleotides also reversed the ANP inhibition of Cdk phosphorylation of pRb, In turn, ET inhibited ANP-stimulated production of the CKIs, thereby promoting cell cycle progression. Specific and changing associations of the CKI with Cdk2 and Cdk4 were stimulated by ANP and inhibited by ET, Our findings identify several mechanisms by which endogenous modulators of astrocyte proliferation can control the G(1)-S progression and indicate that multiple CKIs are necessary to restrain cell cycle progression in these cells.	Long Beach VA Med Ctr, Med Serv 111I, Div Endocrinol, Long Beach, CA 90822 USA; Univ Calif Irvine, Dept Med, Irvine, CA 92717 USA; Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92717 USA	University of California System; University of California Irvine; University of California System; University of California Irvine	Levin, ER (corresponding author), Long Beach VA Med Ctr, Med Serv 111I, Div Endocrinol, 5901 E 7th St, Long Beach, CA 90822 USA.		Levin, Ellis/J-5402-2013		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050161] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030521] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-50161] Funding Source: Medline; NINDS NIH HHS [NS-30521] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		APPEL RG, 1992, AM J PHYSIOL, V262, pF911, DOI 10.1152/ajprenal.1992.262.6.F911; Biesiada E, 1996, J BIOL CHEM, V271, P18576, DOI 10.1074/jbc.271.31.18576; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; GUPTA S, 1994, FEBS LETT, V353, P281, DOI 10.1016/0014-5793(94)01052-8; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HERMAN WH, 1995, J BIOL CHEM, V270, P11654, DOI 10.1074/jbc.270.19.11654; HU RM, 1994, J CLIN INVEST, V93, P1820, DOI 10.1172/JCI117167; Hunt T, 1991, Semin Cell Biol, V2, P213; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; LEVIN ER, 1991, AM J PHYSIOL, V261, pR453, DOI 10.1152/ajpregu.1991.261.2.R453; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; Lukas J, 1996, MOL CELL BIOL, V16, P6917; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NAZARIO B, 1995, J CLIN INVEST, V95, P1151, DOI 10.1172/JCI117763; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; Pines J, 1991, Trends Cell Biol, V1, P117, DOI 10.1016/0962-8924(91)90116-Q; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; PORTER JG, 1992, AM J PHYSIOL, V263, pC1001, DOI 10.1152/ajpcell.1992.263.5.C1001; Prins BA, 1996, J BIOL CHEM, V271, P14156, DOI 10.1074/jbc.271.24.14156; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; RUBANYI GM, 1994, PHARMACOL REV, V46, P328; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SERRANO S, 1997, CELL, V88, P593; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WU LT, 1994, ONCOGENE, V9, P2089; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; Yan YX, 1997, J BIOL CHEM, V272, P33181, DOI 10.1074/jbc.272.52.33181; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0	48	44	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13966	13972		10.1074/jbc.273.22.13966	http://dx.doi.org/10.1074/jbc.273.22.13966			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593746	hybrid			2022-12-27	WOS:000073919100085
J	Dyck, C; Maxwell, K; Buchko, J; Trac, M; Omelchenko, A; Hnatowich, M; Hryshko, LV				Dyck, C; Maxwell, K; Buchko, J; Trac, M; Omelchenko, A; Hnatowich, M; Hryshko, LV			Structure-function analysis of CALX1.1, a Na+-Ca-2 exchanger from Drosophila - Mutagenesis of ionic regulatory sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CALCIUM EXCHANGE; CA2+-BINDING DOMAIN; DYNAMIC PROPERTIES; STEADY-STATE; CLONING; CA2+; IDENTIFICATION; INACTIVATION; EXPRESSION; ISOFORMS	Cytoplasmic Na+ and Ca2+ regulate the activity of Na+-Ca2+ exchange proteins, in addition to serving as the transported ions, and protein regions involved in these processes have been identified for the canine cardiac Na+-Ca2+ exchanger, NCX1.1. Although protein regions associated with Na-i(+)- and Ca-i(2+)-dependent regulation are highly conserved among cloned Na+-Ca2+ exchangers, it is unknown whether or not the structure-function relationships characteristic of NCX1.1 apply to any other exchangers. Therefore, we studied structure-function relationships in a Na+-Ca2+ exchanger from Drosophila, CALX1.1, which is unique among characterized members of this family of proteins in that mu M levels of Ca-i(2+) inhibit exchange current. Wild-type and mutant CALX1.1 exchangers were expressed in Xenopus oocytes and characterized electrophysiologically using the giant excised patch technique, Mutations within the putative regulatory Ca-i(2+) binding site of CALX1.1, like corresponding alterations in NCX1.1, led to reduced ability (i,e. D516V and D5501) or inability (i.e. G555P) of Ca-i(2+) to inhibit Na+-Ca2+ exchange activity. Similarly, mutations within the putative XIP region of CALX1.1, as in NCX1.1, led to two distinct phenotypes: acceleration (i.e. K306Q) and elimination (i.e. Delta 310-313) of Na-i(+)-dependent inactivation. These results indicate that the respective regulatory roles of the Ca-i(2+) binding site and XIP region are conserved between CALX1.1 and NCX1.1, despite opposite responses to Ca-i(2+), We extended these findings using chimeric constructs of CALX1.1 and NCX1.1 to determine whether or not functional interconversion of Ca-i(2+) regulatory phenotypes was feasible. With one chimera (i,e. CALX:NCX:CALX), substitution of a 193-amino acid segment, from the large intracellular loop of NCX1.1, for the corresponding 177-amino acid segment of CALX1.1 led to an exchanger that was stimulated by Ca-i(2+). This result indicates that the regulatory Ca-i(2+) binding site of NCX1.1 retains function in a CALX1.1 parent transporter and that the substituted segment contains some of the amino acid sequence(s) required for transduction of the Ca-i(2+) binding signal.	Univ Manitoba, Fac Med, Inst Cardiovasc Sci, St Boniface Gen Hosp,Dept Physiol,Res Ctr, Winnipeg, MB R2H 2A6, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba	Hryshko, LV (corresponding author), Univ Manitoba, Fac Med, Inst Cardiovasc Sci, St Boniface Gen Hosp,Dept Physiol,Res Ctr, 351 Tache Ave, Winnipeg, MB R2H 2A6, Canada.	lhryshko@sbrc.umanitoba.ca		Hryshko, Larry/0000-0003-1079-8549				BAKER PF, 1976, J PHYSL, V259, P104; Barnes KV, 1997, J BIOL CHEM, V272, P11510, DOI 10.1074/jbc.272.17.11550; BERS DM, 1994, METHOD CELL BIOL, V40, P3; DIPOLO R, 1979, J GEN PHYSIOL, V73, P91, DOI 10.1085/jgp.73.1.91; Doering AE, 1998, J BIOL CHEM, V273, P778, DOI 10.1074/jbc.273.2.778; GABELLINI N, 1995, J BIOL CHEM, V270, P6917, DOI 10.1074/jbc.270.12.6917; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P905, DOI 10.1085/jgp.100.6.905; HILGEMANN DW, 1990, NATURE, V344, P242, DOI 10.1038/344242a0; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P933, DOI 10.1085/jgp.100.6.933; Hryshko LV, 1996, J GEN PHYSIOL, V108, P67, DOI 10.1085/jgp.108.1.67; HRYSHKO LV, 1996, PATHOPHYSIOLOGY HEAR, P331; KIMURA J, 1986, NATURE, V319, P596, DOI 10.1038/319596a0; KOFUJI P, 1994, J BIOL CHEM, V269, P5145; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LEE SL, 1994, J BIOL CHEM, V269, P14849; LEVITSKY DO, 1994, J BIOL CHEM, V269, P22847; LI ZP, 1991, J BIOL CHEM, V266, P1014; LI ZP, 1994, J BIOL CHEM, V269, P17434; MATSUOKA S, 1994, J PHYSIOL-LONDON, V476, P443, DOI 10.1113/jphysiol.1994.sp020146; MATSUOKA S, 1995, J GEN PHYSIOL, V105, P403, DOI 10.1085/jgp.105.3.403; Matsuoka S, 1997, J GEN PHYSIOL, V109, P273, DOI 10.1085/jgp.109.2.273; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, P3870, DOI 10.1073/pnas.90.9.3870; Nicholas SB, 1998, AM J PHYSIOL-HEART C, V274, pH217, DOI 10.1152/ajpheart.1998.274.1.H217; Nicoll DA, 1996, J BIOL CHEM, V271, P13385, DOI 10.1074/jbc.271.23.13385; Nicoll DA, 1996, J BIOL CHEM, V271, P24914, DOI 10.1074/jbc.271.40.24914; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; OMELCHENKO A, 1998, IN PESS J GEN PHYSL, V3; Philipson KD, 1996, ANN NY ACAD SCI, V779, P20, DOI 10.1111/j.1749-6632.1996.tb44766.x; Quednau BD, 1997, AM J PHYSIOL-CELL PH, V272, pC1250, DOI 10.1152/ajpcell.1997.272.4.C1250; Reeves JP, 1996, ANN NY ACAD SCI, V779, P73, DOI 10.1111/j.1749-6632.1996.tb44771.x; Ruknudin A, 1997, AM J PHYSIOL-CELL PH, V273, pC257, DOI 10.1152/ajpcell.1997.273.1.C257; Schwarz EM, 1997, P NATL ACAD SCI USA, V94, P10249, DOI 10.1073/pnas.94.19.10249; Trac M, 1997, J GEN PHYSIOL, V109, P361, DOI 10.1085/jgp.109.3.361	33	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					12981	12987		10.1074/jbc.273.21.12981	http://dx.doi.org/10.1074/jbc.273.21.12981			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582332	hybrid			2022-12-27	WOS:000073768500043
J	Gerber, HP; Dixit, V; Ferrara, N				Gerber, HP; Dixit, V; Ferrara, N			Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; SIGNAL-TRANSDUCTION; RECEPTOR; SURVIVAL; CLONING; BINDING; DEATH; FLT-1; PCR; GAP	We examined the role of vascular endothelial growth factor (VEGF) in preventing apoptosis in primary human umbilical vein endothelial (HUVE) cells. VEGF was capable of preventing serum starvation-induced apoptosis at concentrations between 10 and 100 ng/ml. The addition of VEGF to serum-starved HUVE cells led to a 5.2-fold induction of Bcl-2 after 36 h and to a transient, 2.4-fold induction of A1 after a 7-h incubation, as quantitated by real time reverse transcriptase-polymerase chain reaction analysis. Western blot analysis demonstrated a 2-3-fold induction of Bcl-2 protein after 18-36 h of exposure to VEGF and a transient induction of A1 after 7 h of VEGF stimulation. Moreover, overexpression of Bcl-2 by means of transient biolistic transfection experiments of HUVE cells was sufficient to prevent endothelial cells from apoptotic cell death in the absence of VEGF. These findings indicate that Bcl-2 plays an important role in mediating the survival activity of VEGF on endothelial cells.	Genentech Inc, Dept Cardiovasc Res, S San Francisco, CA 94080 USA; Genentech Inc, Dept Mol Oncol, S San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech	Ferrara, N (corresponding author), Genentech Inc, Dept Cardiovasc Res, 1 DNA Way, S San Francisco, CA 94080 USA.							Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; Benjamin LE, 1997, P NATL ACAD SCI USA, V94, P8761, DOI 10.1073/pnas.94.16.8761; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CUNNINGHAM SA, 1995, J BIOL CHEM, V270, P20254, DOI 10.1074/jbc.270.35.20254; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; Ferrara N, 1998, NAT MED, V4, P336, DOI 10.1038/nm0398-336; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659; Giardino I, 1996, J CLIN INVEST, V97, P1422, DOI 10.1172/JCI118563; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Haendeler J, 1996, EUR J PHARMACOL, V317, P407, DOI 10.1016/S0014-2999(96)00759-5; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Karsan A, 1996, J BIOL CHEM, V271, P27201, DOI 10.1074/jbc.271.44.27201; Karsan A, 1996, BLOOD, V87, P3089, DOI 10.1182/blood.V87.8.3089.bloodjournal8783089; KONDO S, 1994, EXP CELL RES, V213, P428, DOI 10.1006/excr.1994.1219; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Li YG, 1997, BIOTECHNIQUES, V23, P1026, DOI 10.2144/97236bm12; Merenmies J, 1997, CELL GROWTH DIFFER, V8, P3; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; Morris CB, 1996, AM J PATHOL, V148, P1055; PARK JE, 1994, J BIOL CHEM, V269, P25646; RODGER FE, 1995, HUM REPROD, V10, P1566, DOI 10.1093/HUMREP/10.6.1566; SEETHARAM L, 1995, ONCOGENE, V10, P135; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; TERMAN BI, 1991, ONCOGENE, V6, P1677; TSUKADA T, 1995, BIOCHEM BIOPH RES CO, V210, P1076, DOI 10.1006/bbrc.1995.1766; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Yuan F, 1996, P NATL ACAD SCI USA, V93, P14765, DOI 10.1073/pnas.93.25.14765; Yue TL, 1997, MOL PHARMACOL, V51, P951, DOI 10.1124/mol.51.6.951	36	758	802	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					13313	13316		10.1074/jbc.273.21.13313	http://dx.doi.org/10.1074/jbc.273.21.13313			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582377	hybrid			2022-12-27	WOS:000073768500088
J	Hamberg, M; Su, C; Oliw, E				Hamberg, M; Su, C; Oliw, E			Manganese lipoxygenase - Discovery of a bis-allylic hydroperoxide as product and intermediate in a lipoxygenase reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALGA LITHOTHAMNION-CORALLIOIDES; LINOLEIC-ACID; SOYBEAN LIPOXYGENASE; FATTY-ACIDS; ARACHIDONIC-ACID; BIOSYNTHESIS; MECHANISM; OXYGENATION; OXIDATION; ABSTRACTION	Linoleic acid was incubated with manganese lipoxygenase (Mn-LO) from the fungus Gaumannomyces graminis. The product consisted of (13R)-hydroperoxy-(9Z,11E)-octadecadienoic acid ((13R)-HPOD) and a new hydroperoxide, (11S)-hydroperoxy-(9Z,12Z)-octadecadienoic acid ((11S)-HPOD). Incubation of (11R)-[H-2]- and (11S)-[H-2]linoleic acids with Mn-LO led to the formation of hydroperoxides that largely retained and lost, respectively, the deuterium label. Conversion of the (11S)-deuteriolinoleic acid was accompanied by a primary isotope effect, which manifested itself in a strongly reduced rate of formation of hydroperoxides and in a time dependent accumulation of deuterium in the unconverted substrate. These experiments indicated that the initial step catalyzed by Mn-LO consisted of abstraction of the pro-S hydrogen of linoleic acid to produce a linoleoyl radical. (11S)-HPOD was converted into (13R)-HPOD upon incubation with Mn-LO. The mechanism of this enzyme-catalyzed hydroperoxide rearrangement was studied in experiments carried out with O-18(2) gas or O-18(2)-labeled hydroperoxides, Incubation of [11-O-18(2)](11S)-HPOD with Mn-LO led to the formation of (13R)-HPOD, which retained 39-44% of the O-18 label, whereas (11S)-HPOD incubated with Mn-LO under O-18(2) produced (13R)-HPOD, which had incorporated 57% of O-18. Furthermore, analysis of the isotope content of (11S)-HPOD remaining unconverted in such incubations demonstrated that [11-O-18(2)](11S)-HPOD suffered a time-dependent loss of O-18 when exposed to Mn-LO, whereas (11S)-HPOD incorporated O-18 when incubated with Mn-LO under O-18(2). On the basis of these experiments, it was proposed that the conversion of (11S)-HPOD into (13R)-HPOD occurred in a non-concerted way by deoxygenation into a linoleoyl radical. Subsequent reoxygenation of this intermediate by dioxygen attack at C-13 produced (13R)-HPOD, whereas attack at C-ll regenerated (11S)-HPOD, The hydroperoxide rearrangement occurred by oxygen rebound, although, as demonstrated by the O-18 experiments, the oxygen molecule released from (11S)-HPOD exchanged with surrounding molecular oxygen prior to its reincorporation.	Karolinska Inst, Dept Med Biochem & Biophys, Div Physiol Chem 2, S-17177 Stockholm, Sweden; Uppsala Univ, Uppsala Biomed Ctr, Dept Pharmaceut Biosci, Div Biochem Pharmacol, S-75124 Uppsala, Sweden	Karolinska Institutet; Uppsala University	Hamberg, M (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Div Physiol Chem 2, S-17177 Stockholm, Sweden.	mats.hamberg@mbb.ki.se		Oliw, Ernst/0000-0002-7986-8130; Hamberg, Mats/0000-0002-8910-7810				Brash AR, 1996, J BIOL CHEM, V271, P20949, DOI 10.1074/jbc.271.34.20949; BRASH AR, 1986, BIOCHIM BIOPHYS ACTA, V875, P256, DOI 10.1016/0005-2760(86)90175-X; BRODOWSKY ID, 1992, J BIOL CHEM, V267, P14738; CHAN HWS, 1979, CHEM PHYS LIPIDS, V24, P245, DOI 10.1016/0009-3084(79)90030-6; COREY EJ, 1987, J AM CHEM SOC, V109, P8107, DOI 10.1021/ja00260a038; COREY EJ, 1983, J AM CHEM SOC, V105, P4093, DOI 10.1021/ja00350a059; DEGROOT JJM, 1975, BIOCHIM BIOPHYS ACTA, V377, P71, DOI 10.1016/0005-2744(75)90287-9; EGMOND MR, 1972, BIOCHEM BIOPH RES CO, V48, P1055, DOI 10.1016/0006-291X(72)90815-7; EGMOND MR, 1973, BIOCHEM BIOPH RES CO, V54, P1178, DOI 10.1016/0006-291X(73)90816-4; FAHLSTADIUS P, 1990, J CHEM SOC PERK T 1, P2027, DOI 10.1039/p19900002027; GARDNER HW, 1991, BIOCHIM BIOPHYS ACTA, V1084, P221, DOI 10.1016/0005-2760(91)90063-N; GLICKMAN MH, 1994, J AM CHEM SOC, V116, P793, DOI 10.1021/ja00081a060; Hamberg M, 1997, ARCH BIOCHEM BIOPHYS, V344, P194, DOI 10.1006/abbi.1997.0194; HAMBERG M, 1968, EUR J BIOCHEM, V6, P135, DOI 10.1111/j.1432-1033.1968.tb00430.x; HAMBERG M, 1967, J BIOL CHEM, V242, P5329; HAMBERG M, 1980, BIOCHEM BIOPH RES CO, V95, P1090, DOI 10.1016/0006-291X(80)91584-3; HAMBERG M, 1967, J BIOL CHEM, V242, P5336; HAMBERG M, 1971, ANAL BIOCHEM, V43, P515, DOI 10.1016/0003-2697(71)90282-X; HAMBERG M, 1993, J CHEM SOC PERK T 1, P3065, DOI 10.1039/p19930003065; HAMBERG M, 1993, ARCH BIOCHEM BIOPHYS, V305, P115, DOI 10.1006/abbi.1993.1400; HAMBERG M, 1986, BIOCHIM BIOPHYS ACTA, V877, P447, DOI 10.1016/0005-2760(86)90211-0; Hamberg M, 1998, ARCH BIOCHEM BIOPHYS, V349, P376, DOI 10.1006/abbi.1997.0443; HAMBERG M, 1984, BIOCHIM BIOPHYS ACTA, V793, P129, DOI 10.1016/0005-2760(84)90062-6; HAMBERG M, 1973, LIPIDS, V8, P737, DOI 10.1007/BF02531842; HAMBERG M, 1992, LIPIDS, V27, P487, DOI 10.1007/BF02536128; HAWKINS DJ, 1987, J BIOL CHEM, V262, P7629; HERMAN RP, 1987, PROSTAGLANDINS, V34, P129; HUGHES MA, 1991, BIOCHIM BIOPHYS ACTA, V1081, P347, DOI 10.1016/0005-2760(91)90292-P; HWANG CC, 1994, J AM CHEM SOC, V116, P795, DOI 10.1021/ja00081a061; LUND E, 1992, J BIOL CHEM, V267, P12462; MATTHEW JA, 1977, LIPIDS, V12, P324, DOI 10.1007/BF02533358; Nieuwenhuizen WF, 1997, BIOCHEMISTRY-US, V36, P4480, DOI 10.1021/bi962956l; PORTER NA, 1981, J AM CHEM SOC, V103, P6447, DOI 10.1021/ja00411a032; PORTER NA, 1995, LIPIDS, V30, P277, DOI 10.1007/BF02536034; RAO SI, 1994, J BIOL CHEM, V269, P7210; Su C, 1998, J BIOL CHEM, V273, P13072, DOI 10.1074/jbc.273.21.13072; YAMAMOTO S, 1992, BIOCHIM BIOPHYS ACTA, V1128, P117, DOI 10.1016/0005-2760(92)90297-9	37	116	118	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					13080	13088		10.1074/jbc.273.21.13080	http://dx.doi.org/10.1074/jbc.273.21.13080			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582346	hybrid			2022-12-27	WOS:000073768500057
J	O'Connor, MB; O'Connor, CM				O'Connor, MB; O'Connor, CM			Complex interactions of the protein L-isoaspartyl methyltransferase and calmodulin revealed with the yeast two-hybrid system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL METHYLTRANSFERASE; BINDING DOMAIN; SPONTANEOUS DEGRADATION; O-METHYLTRANSFERASE; ASPARTYL RESIDUES; DAMAGED PROTEINS; XENOPUS OOCYTES; METHYLATION; PEPTIDES; REPAIR	The widely distributed protein-L-isoaspartyl, D-aspartyl carboxylmethyltransferase (EC 2.1.1.77) is hypothesized to play a role in the repair or metabolism of deamidated and isomerized proteins that are spontaneously generated during the aging of proteins in cells. The yeast two-hybrid system was used to identify proteins that potentially interact with the methyltransferase in a cellular processing pathway. Two cDNAs, both encoding calmodulin, were isolated from a human fetal brain cDNA Library using the human methyltransferase as the bait. Enzymatic assays with purified components revealed a complex set of interactions between the methyltransferase and calmodulin, Calmodulin weakly stimulated protein carboxylmethyltransferase activity in vitro at concentrations of the two proteins reflecting their representation in mammalian brain. Calmodulin stimulation of methyltransferase was observed in both the presence and absence of calcium, although the effect was greater in the presence of calcium. Native calmodulin was not a substrate for the carboxylmethyltransferase, but deamidated variants of calmodulin act as substrates for the methyltransferase, with calculated K-m values of 3.6 and 8.6 mu M for calcium-liganded and unliganded calmodulin, respectively. Both the effector and substrate interactions of calmodulin with the protein isoaspartyl methyltransferase likely contributed to the positive results obtained with the two-hybrid system.	Boston Coll, Dept Biol, Chestnut Hill, MA 02167 USA	Boston College	O'Connor, CM (corresponding author), Boston Coll, Dept Biol, Chestnut Hill, MA 02167 USA.	clare.oconnor@bc.edu	O'Connor, Michael B/C-9977-2014; O'Connor, Clare/A-1679-2010	O'Connor, Michael B/0000-0002-3067-5506; O'Connor, Clare/0000-0002-7201-647X	NIA NIH HHS [AG08109] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG008109] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AELST LV, 1993, P NATL ACAD SCI USA, V90, P6213; ALEXANDER KA, 1988, J BIOL CHEM, V263, P7544; ASWAD DW, 1987, TRENDS BIOCHEM SCI, V12, P155, DOI 10.1016/0968-0004(87)90073-9; ASWAD DW, 1983, J NEUROCHEM, V41, P1702, DOI 10.1111/j.1471-4159.1983.tb00883.x; AUSEMBEL FM, 1996, CURRENT PROTOCOLS MO; BRENNAN TV, 1994, J BIOL CHEM, V269, P24586; BRUNAUER LS, 1986, BIOCHEM J, V236, P811, DOI 10.1042/bj2360811; Chao S, 1996, MOL BRAIN RES, V40, P195, DOI 10.1016/0169-328X(96)00049-6; CLARKE S, 1985, ANNU REV BIOCHEM, V54, P479, DOI 10.1146/annurev.bi.54.070185.002403; CONZELMAN KA, 1987, J CELL BIOL, V105, P313, DOI 10.1083/jcb.105.1.313; DESROSIERS RR, 1990, J BIOL CHEM, V265, P21368; DIDONATO A, 1993, J BIOL CHEM, V268, P4745; DILIBERTO EJ, 1976, J NEUROCHEM, V26, P1159, DOI 10.1111/j.1471-4159.1976.tb07001.x; ENYEDI A, 1987, J BIOL CHEM, V262, P6425; FINLEY RL, 1996, DNA CLONING EXPRESSI, P169; GALLETTI P, 1988, BIOCHEMISTRY-US, V27, P1752, DOI 10.1021/bi00405a055; GEIGER T, 1987, J BIOL CHEM, V262, P785; GEORGENASCIMENTO C, 1990, BIOCHEMISTRY-US, V29, P9584, DOI 10.1021/bi00493a012; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GOLEMIS EA, 1992, MOL CELL BIOL, V12, P3006, DOI 10.1128/MCB.12.7.3006; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HOWE CL, 1983, J CELL BIOL, V97, P974, DOI 10.1083/jcb.97.4.974; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; JOHNSON BA, 1991, BIOCHEM INT, V24, P841; JOHNSON BA, 1987, J BIOL CHEM, V262, P12283; JOHNSON BA, 1987, J BIOL CHEM, V262, P5622; JOHNSON BA, 1989, ARCH BIOCHEM BIOPHYS, V268, P276, DOI 10.1016/0003-9861(89)90589-4; JOHNSON BA, 1985, J BIOL CHEM, V260, P913; JOHNSON BA, 1989, J BIOL CHEM, V264, P14262; Kagan RM, 1997, COMP BIOCHEM PHYS B, V117, P379, DOI 10.1016/S0305-0491(96)00333-1; KEMP BE, 1987, J BIOL CHEM, V262, P2542; Kim E, 1997, P NATL ACAD SCI USA, V94, P6132, DOI 10.1073/pnas.94.12.6132; LI B, 1993, FASEB J, V7, P957, DOI 10.1096/fasebj.7.10.8344494; LI C, 1992, J BACTERIOL, V174, P355, DOI 10.1128/jb.174.2.355-361.1992; LOWENSON JD, 1991, J BIOL CHEM, V266, P19396; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MACLAREN DC, 1995, PROTEIN EXPRES PURIF, V6, P99, DOI 10.1006/prep.1995.1013; MCFADDEN PN, 1987, P NATL ACAD SCI USA, V84, P2595, DOI 10.1073/pnas.84.9.2595; NAIRN AC, 1994, SEMIN CANCER BIOL, V5, P295; OCONNOR CM, 1985, BIOCHEM BIOPH RES CO, V132, P1144, DOI 10.1016/0006-291X(85)91926-6; OTA IM, 1990, ARCH BIOCHEM BIOPHYS, V279, P320, DOI 10.1016/0003-9861(90)90498-N; OTA IM, 1989, J BIOL CHEM, V264, P54; OTA IM, 1989, BIOCHEMISTRY-US, V28, P4020, DOI 10.1021/bi00435a058; PARANANDI MV, 1995, BIOCHEM BIOPH RES CO, V212, P442, DOI 10.1006/bbrc.1995.1989; POTTER SM, 1993, PROTEIN SCI, V2, P1648, DOI 10.1002/pro.5560021011; PUTKEY JA, 1985, J BIOL CHEM, V260, P4704; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; ROMANIK EA, 1989, J BIOL CHEM, V264, P14050; RUNTE L, 1982, FEBS LETT, V147, P125, DOI 10.1016/0014-5793(82)81025-9; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHMIDT HHHW, 1992, CELL CALCIUM, V13, P427, DOI 10.1016/0143-4160(92)90055-W; STEPHENSON RC, 1989, J BIOL CHEM, V264, P6164; Szymanska G, 1997, ANAL BIOCHEM, V252, P96, DOI 10.1006/abio.1997.2319; VINCENT PL, 1987, J NEUROCHEM, V49, P1613, DOI 10.1111/j.1471-4159.1987.tb01035.x; Wolff D J, 1979, Adv Cyclic Nucleotide Res, V11, P27; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	56	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					12909	12913		10.1074/jbc.273.21.12909	http://dx.doi.org/10.1074/jbc.273.21.12909			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582322	hybrid			2022-12-27	WOS:000073768500033
J	Puertollano, R; Alonso, MA				Puertollano, R; Alonso, MA			A short peptide motif at the carboxyl terminus is required for incorporation of the integral membrane MAL protein to glycolipid-enriched membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; EPITHELIAL-CELLS; ENDOPLASMIC-RETICULUM; TRANSPORT VESICLES; TRANSMEMBRANE PROTEINS; TYROSINE KINASES; PLASMA-MEMBRANE; GOLGI-APPARATUS; GENE FAMILY; MDCK CELLS	The MAL (VIP17, MVP17) proteolipid, an integral membrane protein with specific residence in glycolipid-enriched membrane (GEM) microdomains, has been recently proposed as a component of the protein machinery for GEM vesiculation. In this work, me have searched the COOH terminus of MAL for sorting determinants responsible for targeting to GEMs. This has allowed the identification of the sequence Leu-Ile-Arg-Trp (LIRW) as necessary for the access of MAL to GEMs. This motif requires at least one additional amino acid at its COOH end for full effectiveness. The arginine within the LIRW motif is the most crucial residue for targeting to GEMs, tryptophan replacement affects targeting to a lesser extent, and the leucine-isoleucine pair tolerates substitution by valine, but not by alanine, without effect on targeting. Pulse-chase experiments indicate that the LIRW tetrapeptide is required for access to GEMs early after MAL biosynthesis, Interestingly, the loss of the capacity of the MAL protein to be incorporated into GEMs correlated with the loss of its response to brefeldin A treatment. This is the first identification of a juxtamembrane peptide motif required for incorporation of an integral membrane protein into GEMs.	Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Alonso, MA (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.		Alonso, Miguel A/J-3945-2016	Alonso, Miguel A/0000-0002-7001-8826				ALONSO MA, 1987, P NATL ACAD SCI USA, V84, P1997, DOI 10.1073/pnas.84.7.1997; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; BROWN D, 1993, CURR OPIN IMMUNOL, V5, P349, DOI 10.1016/0952-7915(93)90052-T; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CINEK T, 1992, J IMMUNOL, V149, P2262; Deber CM, 1996, NAT STRUCT BIOL, V3, P815, DOI 10.1038/nsb1096-815; DEBRABANDER MJ, 1976, CANCER RES, V36, P905; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; FIEDLER K, 1993, BIOCHEMISTRY-US, V32, P6365, DOI 10.1021/bi00076a009; FIEDLER K, 1995, J CELL BIOL, V128, P1043, DOI 10.1083/jcb.128.6.1043; HOPKINS CR, 1983, CELL, V35, P321, DOI 10.1016/0092-8674(83)90235-0; ITIN C, 1995, EMBO J, V14, P2250, DOI 10.1002/j.1460-2075.1995.tb07219.x; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KIM T, 1995, J NEUROSCI RES, V42, P413, DOI 10.1002/jnr.490420316; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; LETOURNEUR F, 1993, CELL, V9, P129; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Machamer CE, 1993, CURR OPIN CELL BIOL, V5, P606, DOI 10.1016/0955-0674(93)90129-E; MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; Martin-Belmonte F, 1998, ENDOCRINOLOGY, V139, P2077, DOI 10.1210/en.139.4.2077; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; Millan J, 1997, BIOCHEM J, V321, P247, DOI 10.1042/bj3210247; Millan J, 1997, BIOCHEM BIOPH RES CO, V233, P707, DOI 10.1006/bbrc.1997.6530; MUNRO S, 1995, EMBO J, V14, P4695, DOI 10.1002/j.1460-2075.1995.tb00151.x; NILSSON T, 1994, EMBO J, V13, P562, DOI 10.1002/j.1460-2075.1994.tb06294.x; NILSSON T, 1994, CURR OPIN CELL BIOL, V6, P517, DOI 10.1016/0955-0674(94)90070-1; Puertollano R, 1997, J BIOL CHEM, V272, P18311, DOI 10.1074/jbc.272.29.18311; RANCANO C, 1994, J BIOL CHEM, V269, P8159; REITHMEIER RAF, 1995, CURR OPIN STRUC BIOL, V5, P491, DOI 10.1016/0959-440X(95)80034-4; RODGERS W, 1994, MOL CELL BIOL, V14, P5384, DOI 10.1128/MCB.14.8.5384; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Sambrook J., 2002, MOL CLONING LAB MANU; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SANDOVAL IV, 1994, J BIOL CHEM, V269, P6622; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SCHAERENWIEMERS N, 1995, J NEUROSCI, V15, P5753; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; SCHLESINGER MJ, 1981, ANNU REV BIOCHEM, V50, P193, DOI 10.1146/annurev.bi.50.070181.001205; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; SHIN J, 1991, P NATL ACAD SCI USA, V88, P1918, DOI 10.1073/pnas.88.5.1918; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; Song KS, 1997, J BIOL CHEM, V272, P4398, DOI 10.1074/jbc.272.7.4398; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; Tugores A, 1997, DNA CELL BIOL, V16, P245, DOI 10.1089/dna.1997.16.245; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987; WEISZ OA, 1993, J CELL BIOL, V122, P1185, DOI 10.1083/jcb.122.6.1185; Zacchetti D, 1995, FEBS LETT, V377, P465, DOI 10.1016/0014-5793(95)01396-2	57	26	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					12740	12745		10.1074/jbc.273.21.12740	http://dx.doi.org/10.1074/jbc.273.21.12740			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582298	hybrid			2022-12-27	WOS:000073768500009
J	Ritter, SJ; Davies, PJA				Ritter, SJ; Davies, PJA			Identification of a transforming growth factor-beta 1/bone morphogenetic protein 4 (TGF-beta 1/BMP4) response element within the mouse tissue transglutaminase gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; BOVINE ENDOTHELIAL-CELLS; CROSS-LINKING ENZYMES; FACTOR-BETA; BINDING SEQUENCE; EXPRESSION; APOPTOSIS; ACTIVATION; INDUCTION; GROWTH-FACTOR-BETA-1	Tissue transglutaminase is a calcium-dependent, protein cross-linking enzyme that is highly expressed in cells undergoing apoptosis, The expression of tissue transglutaminase is regulated by a variety of molecules including retinoids, interleukin-6, and transforming growth factor-beta 1 (TGF-beta 1). Retinoid and interleukin-6 inductions of tissue transglutaminase expression are mediated by specific cis-regulatory elements located within the first 4.0 kilobase pairs of the promoter of the gene. The present studies were designed to identify the molecular mechanisms mediating the regulation of tissue transglutaminase gene expression by TGF-beta family members. Transient transfection of Mv1Lu cells with transglutaminase promoter constructs demonstrated that 0.2 nar TGF-beta 1 maximally induced the activation of the promoter through a 10-base pair TGF-beta 1 response element (TRE; GAGTTGGTGC) located 868 base pairs upstream of the transcription start site. This same element mediated an inhibitory activity of TGF-beta 1 on the transglutaminase promoter in MC3T3 El cells. The TRE through which TGF-beta 1-regulated the activity of the transglutaminase promoter was necessary and sufficient for bone morphogenetic protein 2-(BMP) and BMP4-dependent inhibition of the tissue transglutaminase promoter. The TGF-beta 1, BMP2, and BMP4 regulation of the transglutaminase promoter activity was similar to the responses we observed for the endogenous transglutaminase activity of Mv1Lu and MC3T3 El cells. For BMP2 and BMP4, this regulation was paralleled by a decrease in tissue transglutaminase mRNA in MC3T3 El cells. The results of these experiments suggest that TGF-beta 1, BMP2, and BMP4 regulation of mouse tissue transglutaminase gene expression requires a composite TRE located in the 5'-flanking DNA.	Univ Texas, Sch Med, Dept Integrat Biol Pharmacol & Physiol, Houston, TX 77030 USA	University of Texas System	Davies, PJA (corresponding author), Univ Texas, Sch Med, Dept Integrat Biol Pharmacol & Physiol, POB 20708, Houston, TX 77030 USA.	pdavies@farmr1.med.uth.tmc.edu						AESCHLIMANN D, 1995, J CELL BIOL, V129, P881, DOI 10.1083/jcb.129.3.881; AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; Borge L, 1996, BBA-MOL CELL RES, V1312, P117, DOI 10.1016/0167-4889(96)00028-6; BOWNESS JM, 1988, BIOCHIM BIOPHYS ACTA, V967, P234; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; CONKLING PR, 1989, THROMB RES, V55, P57, DOI 10.1016/0049-3848(89)90456-8; CONNOR AM, 1989, BIOCHIM BIOPHYS ACTA, V1009, P75, DOI 10.1016/0167-4781(89)90081-X; DARGENIO G, 1992, SCAND J GASTROENTERO, V27, P111, DOI 10.3109/00365529209165428; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DAVIES PJA, 1985, J BIOL CHEM, V260, P5166; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Fesus L, 1996, EXPERIENTIA, V52, P942, DOI 10.1007/BF01920102; FESUS L, 1989, FEBS LETT, V245, P150, DOI 10.1016/0014-5793(89)80210-8; FESUS L, 1991, EUR J CELL BIOL, V56, P170; FESUS L, 1987, FEBS LETT, V224, P104, DOI 10.1016/0014-5793(87)80430-1; FUKUDA K, 1994, J CELL BIOCHEM, V54, P67, DOI 10.1002/jcb.240540108; GEORGE MD, 1990, J BIOL CHEM, V265, P11098; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HIRAKI Y, 1991, J BONE MINER RES, V6, P1373; JONES CM, 1991, DEVELOPMENT, V111, P531; Kaufmann E, 1996, EMBO J, V15, P6739, DOI 10.1002/j.1460-2075.1996.tb01063.x; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KOJIMA S, 1993, J CELL BIOL, V121, P439, DOI 10.1083/jcb.121.2.439; KOJIMA S, 1995, J CELL PHYSIOL, V163, P210, DOI 10.1002/jcp.1041630124; KUNCIO GS, 1997, IN PRESS AM J PHYSL; KYPRIANOU N, 1989, MOL ENDOCRINOL, V3, P1515, DOI 10.1210/mend-3-10-1515; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LORAND L, 1972, ANAL BIOCHEM, V50, P623, DOI 10.1016/0003-2697(72)90074-7; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; Nagy L, 1996, J BIOL CHEM, V271, P4355; NAGY L, 1997, IN PRESS CELL DEATH; Nakao A, 1997, J BIOL CHEM, V272, P2896, DOI 10.1074/jbc.272.5.2896; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; OBERHAMMER F, 1993, HEPATOLOGY, V18, P1238; Oberhammer F, 1996, MICROSC RES TECHNIQ, V34, P247, DOI 10.1002/(SICI)1097-0029(19960615)34:3<247::AID-JEMT7>3.0.CO;2-M; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PIACENTINI M, 1991, EUR J CELL BIOL, V54, P246; PRINCE CW, 1991, BIOCHEM BIOPH RES CO, V177, P1205, DOI 10.1016/0006-291X(91)90669-X; RICCIO A, 1992, MOL CELL BIOL, V12, P1846, DOI 10.1128/MCB.12.4.1846; RICCIO A, 1985, NUCLEIC ACIDS RES, V13, P2759, DOI 10.1093/nar/13.8.2759; SCHULTEHERMANN R, 1993, ENVIRON HEALTH PERSP, V101, P87, DOI 10.2307/3431847; STEVENSON BJ, 1986, NUCLEIC ACIDS RES, V14, P8307, DOI 10.1093/nar/14.21.8307; SUTO N, 1993, J BIOL CHEM, V268, P7469; TENNISWOOD MP, 1992, CANCER METAST REV, V11, P197, DOI 10.1007/BF00048064; VERMA AK, 1992, J NUTR, V122, P2144, DOI 10.1093/jn/122.11.2144; Yokouchi Y, 1996, DEVELOPMENT, V122, P3725; Zou HY, 1996, SCIENCE, V272, P738, DOI 10.1126/science.272.5262.738; ZSCHMAR M, 1997, NATURE, V389, P618	53	79	79	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					12798	12806		10.1074/jbc.273.21.12798	http://dx.doi.org/10.1074/jbc.273.21.12798			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582307	hybrid			2022-12-27	WOS:000073768500018
J	Gu, PD; Ishii, Y; Spencer, TA; Shechter, I				Gu, PD; Ishii, Y; Spencer, TA; Shechter, I			Function-structure studies and identification of three enzyme domains involved in the catalytic activity in rat hepatic squalene synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FARNESYL-DIPHOSPHATE SYNTHASE; SITE-DIRECTED MUTAGENESIS; MOLECULAR-CLONING; CAROTENOID BIOSYNTHESIS; PRESQUALENE PYROPHOSPHATE; SACCHAROMYCES-CEREVISIAE; OXIDOSQUALENE CYCLASE; CONSERVED ASPARTATE; SYNTHETASE; EXPRESSION	Rat hepatic squalene synthase (RSS, EC 2.5.1.21) contains three conserved sections, A, B, and C, that were proposed to be involved in catalysis (McKenzie, T. L., Jiang, G., Straubhaar, J. R., Conrad, D., and Shechter, I. (1992) J. Biol. Chem. 267, 21368-21374). Here we use the high expression vector pTrxRSS and site-directed mutagenesis to determine the specific residues in these sections that are essential for the two reactions catalyzed by RSS. Section C mutants F288Y, F288L, F286Y, F286W, F286L, Q293N, and Q2833 accumulate presqualene diphosphate (PSPP) from trans-farnesyl diphosphate (FPP) with reduced production of squalene. F288L, which retains approximately 50% first step activity, displays only residual activity (0.2%) in the production of squalene from either FPP or PSPP. Substitution of either Phe(288) or Phe(286) with charged residues completely abolishes the enzyme activity. Thus, F288W, F288D, F288R, F286D, and F286R cannot produce squalene from either FPP or PSPP. All single residue mutants in Section A, except Tyr(171), retain most of the RSS activity, with no detectable accumulation of PSPP in an assay mixture complete with NADPH. P171F, Y171S, and Y171W are all inactive. Section B, which binds the diphosphate moieties of the allylic diphosphate subtrates, contains four negatively charged residues: Glu(222), Glu(226), Asp(219), and Asp(223). The two Glu residues can be replaced with neutral or with positively charged residues without significantly affecting enzyme activity. However, replacement of either Asp residues with Asn eliminates all but a residual level of activity, and substitution with Glu abolishes all activity. These results indicate that 1) Section C, in particular Phe(288), may be involved in the second step of catalysis, 2) Tyr(171) of Section A is essential for catalysis, most likely for the first reaction, 3) the two Asp residues in Section B are essential for the activity and most likely bind the substrate via magnesium salt bridges. Based on these results, a mechanism for the first reaction is proposed.	Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Biochem & Mol Biol, Bethesda, MD 20814 USA; Dartmouth Coll, Dept Chem, Hanover, NH 03755 USA	Uniformed Services University of the Health Sciences - USA; Dartmouth College	Shechter, I (corresponding author), Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Biochem & Mol Biol, Bethesda, MD 20814 USA.	shaike@usuhsb.usuhs.mil	Gu, Peng/GPW-7040-2022		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050628] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50628] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABE I, 1995, P NATL ACAD SCI USA, V92, P9274, DOI 10.1073/pnas.92.20.9274; ALTMAN LJ, 1978, J AM CHEM SOC, V100, P6174, DOI 10.1021/ja00487a037; ARMSTRONG GA, 1990, P NATL ACAD SCI USA, V87, P9975, DOI 10.1073/pnas.87.24.9975; ASHBY MN, 1992, J BIOL CHEM, V267, P4128; BARTLEY GE, 1992, J BIOL CHEM, V267, P5036; BEYTIA E, 1973, J BIOL CHEM, V248, P1856; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUNTEL CJ, 1992, J AM CHEM SOC, V114, P9711, DOI 10.1021/ja00050a090; COHEN T, 1974, J AM CHEM SOC, V96, P5627, DOI 10.1021/ja00824a082; DAVISSON VJ, 1988, BIOORG CHEM, V16, P111, DOI 10.1016/0045-2068(88)90001-6; DEWAR MJS, 1987, TETRAHEDRON, V43, P2661, DOI 10.1016/S0040-4020(01)86871-X; DOGBO O, 1988, P NATL ACAD SCI USA, V85, P7054, DOI 10.1073/pnas.85.19.7054; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; FEGUEUR M, 1991, CURR GENET, V20, P365, DOI 10.1007/BF00317063; Guan GM, 1997, J BIOL CHEM, V272, P10295; Hanley KM, 1996, PLANT MOL BIOL, V30, P1139, DOI 10.1007/BF00019548; INOUE T, 1995, BBA-GENE STRUCT EXPR, V1260, P49, DOI 10.1016/0167-4781(94)00178-6; JENNINGS SM, 1991, P NATL ACAD SCI USA, V88, P6038, DOI 10.1073/pnas.88.14.6038; Jenson C, 1997, J AM CHEM SOC, V119, P10846, DOI 10.1021/ja9714245; JIANG GJ, 1993, J BIOL CHEM, V268, P12818; JOLY A, 1993, J BIOL CHEM, V268, P26983; JULIA MY, 1991, CHEM SOC REV, V20, P129, DOI 10.1039/cs9912000129; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lesburg CA, 1997, SCIENCE, V277, P1820, DOI 10.1126/science.277.5333.1820; Ma JC, 1997, CHEM REV, V97, P1303, DOI 10.1021/cr9603744; MARRERO PF, 1992, J BIOL CHEM, V267, P21873; MASH EA, 1981, J AM CHEM SOC, V103, P3927, DOI 10.1021/ja00403a055; MCKENZIE TL, 1992, J BIOL CHEM, V267, P21368; MISAWA N, 1990, J BACTERIOL, V172, P6704, DOI 10.1128/jb.172.12.6704-6712.1990; NAKASHIMA T, 1995, P NATL ACAD SCI USA, V92, P2328, DOI 10.1073/pnas.92.6.2328; POPJAK G, 1979, MOL CELL BIOCHEM, V27, P97; POPJAK G, 1966, BIOCHEM J, V101, P553, DOI 10.1042/bj1010553; PORALLA K, 1994, BIOORG MED CHEM LETT, V4, P285, DOI 10.1016/S0960-894X(01)80130-X; Poulter C. D., 1981, BIOSYNTHESIS ISOPREN, V1, P161; POULTER CD, 1990, ACCOUNTS CHEM RES, V23, P70, DOI 10.1021/ar00171a003; RILLING HC, 1985, BIOCHEM SOC T, V13, P997, DOI 10.1042/bst0130997; RILLING HC, 1971, J AM CHEM SOC, V93, P1783; RILLING HC, 1966, J BIOL CHEM, V241, P3233; ROBINSON GW, 1993, MOL CELL BIOL, V13, P2706, DOI 10.1128/MCB.13.5.2706; SASIAK K, 1988, ARCH BIOCHEM BIOPHYS, V260, P622, DOI 10.1016/0003-9861(88)90490-0; SHECHTER I, 1992, J BIOL CHEM, V267, P8628; SHI Z, 1994, P NATL ACAD SCI USA, V91, P7370, DOI 10.1073/pnas.91.15.7370; SONG LS, 1994, P NATL ACAD SCI USA, V91, P3044, DOI 10.1073/pnas.91.8.3044; STAMELLOS KD, 1993, J BIOL CHEM, V268, P12825; Starks CM, 1997, SCIENCE, V277, P1815, DOI 10.1126/science.277.5333.1815; SUMMERS C, 1993, GENE, V136, P185, DOI 10.1016/0378-1119(93)90462-C; VAN TAMELEN EE, 1971, J AM CHEM SOC, V93, P1780, DOI 10.1021/ja00736a036; Wendt KU, 1997, SCIENCE, V277, P1811, DOI 10.1126/science.277.5333.1811; ZHANG DL, 1993, ANAL BIOCHEM, V213, P356, DOI 10.1006/abio.1993.1432	49	71	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12515	12525		10.1074/jbc.273.20.12515	http://dx.doi.org/10.1074/jbc.273.20.12515			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575210	hybrid			2022-12-27	WOS:000073629800075
J	Lagree, V; Pellerin, I; Hubert, JF; Tacnet, F; Le Caherec, F; Roudier, N; Thomas, D; Gouranton, J; Deschamps, S				Lagree, V; Pellerin, I; Hubert, JF; Tacnet, F; Le Caherec, F; Roudier, N; Thomas, D; Gouranton, J; Deschamps, S			A yeast recombinant aquaporin mutant that is not expressed or mistargeted in Xenopus oocyte can be functionally analyzed in reconstituted proteoliposomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; WATER CHANNEL; MOLECULAR-CLONING; SACCHAROMYCES-CEREVISIAE; MEMBRANE-PROTEIN; PLASMA-MEMBRANE; MESSENGER-RNA; KIDNEY; MERCURY; FAMILY	We have recently identified AQPcic (for aquaporin cicadella), an insect aquaporin found in the digestive tract of homopteran insects and involved in the elimination of water ingested in excess with the dietary sap (Le Caherec, F,, Deschamps, S,, Delamarche, C,, Pellerin, I., Bonnec, G,, Guillam, M, T,, Gouranton, J,, Thomas, D,, and Hubert, J, F, (1996) fur. J, Biochem, 241, 707-715), Like many other aquaporins, AQPcic is inhibited by mercury reagents. In this study, we have demonstrated that residue Cys(82) is essential for mercury inhibition. Another mutant version of AQPcic (AQP-C134S), expression of which in Xenopus laevis failed to produce an active molecule, was successfully expressed in Saccharomyces cerevisiae, Using stopped-flow analysis of reconstituted proteoliposomes, we demonstrated that the biological activity and Hg sensitivity of yeast-expressed wild type and mutant type AQPcic was readily assessed. Therefore, we propose that the yeast system is a valid alternative to Xenopus oocytes for studying particular mutants of aquaporin.	Univ Rennes 1, UPRES A CNRS, F-35042 Rennes, France; CEA Saclay, Serv Biol Cellulaire, Dept Biol Cellulaire & Mol, F-91191 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); Universite de Rennes; CEA; UDICE-French Research Universities; Universite Paris Saclay	Deschamps, S (corresponding author), Univ Rennes 1, UPRES A CNRS, F-35042 Rennes, France.		THOMAS, Danniel/AAJ-5033-2020; TACNET, Frédérique/B-3074-2009	THOMAS, Danniel/0000-0002-9650-0434; 				Bai LQ, 1996, J BIOL CHEM, V271, P5171; BEURON F, 1995, J BIOL CHEM, V270, P17414, DOI 10.1074/jbc.270.29.17414; CALAMITA G, 1995, J BIOL CHEM, V270, P29063, DOI 10.1074/jbc.270.49.29063; CENTENO F, 1994, FEBS LETT, V354, P117, DOI 10.1016/0014-5793(94)01104-4; CHEN DC, 1992, CURR GENET, V21, P83, DOI 10.1007/BF00318659; DANIELS MJ, 1994, PLANT PHYSIOL, V106, P1325, DOI 10.1104/pp.106.4.1325; Daniels MJ, 1996, PLANT CELL, V8, P587, DOI 10.1105/tpc.8.4.587; DENKER BM, 1988, J BIOL CHEM, V263, P15634; FELDHEIM D, 1993, MOL BIOL CELL, V4, P931, DOI 10.1091/mbc.4.9.931; FELDHEIM D, 1994, J CELL BIOL, V126, P935, DOI 10.1083/jcb.126.4.935; FINKELSTEIN A, 1987, WATER MOVEMENT LIPID, P1; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; GOLDIN AL, 1991, METHOD CELL BIOL, V36, P487; GOURANTON J, 1968, J MICROSC-PARIS, V7, P559; GUILLAM MT, 1992, EXP CELL RES, V200, P301, DOI 10.1016/0014-4827(92)90176-9; HANN BC, 1992, NATURE, V356, P532, DOI 10.1038/356532a0; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HASEGAWA H, 1994, J BIOL CHEM, V269, P5497; Ishibashi K, 1997, J BIOL CHEM, V272, P20782, DOI 10.1074/jbc.272.33.20782; Ishibashi K, 1997, BIOCHEM BIOPH RES CO, V237, P714, DOI 10.1006/bbrc.1997.7219; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; JUNG JS, 1994, J BIOL CHEM, V269, P14648; JUNG JS, 1994, P NATL ACAD SCI USA, V91, P13052, DOI 10.1073/pnas.91.26.13052; KNEPPER MA, 1994, P NATL ACAD SCI USA, V91, P6255, DOI 10.1073/pnas.91.14.6255; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LeCaherec F, 1996, J CELL SCI, V109, P1285; LeCaherec F, 1996, EUR J BIOCHEM, V241, P707, DOI 10.1111/j.1432-1033.1996.00707.x; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MAUREL C, 1995, EMBO J, V14, P3028, DOI 10.1002/j.1460-2075.1995.tb07305.x; MAUREL C, 1993, EMBO J, V12, P2241, DOI 10.1002/j.1460-2075.1993.tb05877.x; Mulders SM, 1997, AM J PHYSIOL-RENAL, V273, pF451, DOI 10.1152/ajprenal.1997.273.3.F451; Mulders SM, 1997, J AM SOC NEPHROL, V8, P242; OGG SC, 1992, MOL BIOL CELL, V3, P895, DOI 10.1091/mbc.3.8.895; POMPON D, 1988, EUR J BIOCHEM, V177, P285, DOI 10.1111/j.1432-1033.1988.tb14375.x; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1993, J BIOL CHEM, V268, P17; RAINA S, 1995, J BIOL CHEM, V270, P1908, DOI 10.1074/jbc.270.4.1908; Shi LB, 1996, BIOCHEMISTRY-US, V35, P538, DOI 10.1021/bi9520038; SIGEL E, 1990, J MEMBRANE BIOL, V117, P201, DOI 10.1007/BF01868451; SMITH BL, 1991, J BIOL CHEM, V266, P6407; Tsiuriupa G P, 1994, Mol Biol (Mosk), V28, P725; Urban P, 1997, J BIOL CHEM, V272, P19176, DOI 10.1074/jbc.272.31.19176; VERKMAN AS, 1995, KIDNEY INT, V48, P1069, DOI 10.1038/ki.1995.390; ZADUNAISKY JA, 1963, NATURE, V200, P365, DOI 10.1038/200365a0; ZHANG R, 1990, J BIOL CHEM, V265, P15375	45	22	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12422	12426		10.1074/jbc.273.20.12422	http://dx.doi.org/10.1074/jbc.273.20.12422			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575198	hybrid			2022-12-27	WOS:000073629800063
J	Pelegrin, M; Devedjian, JC; Costa, C; Visa, J; Solanes, G; Pujol, A; Asins, G; Valera, A; Bosch, F				Pelegrin, M; Devedjian, JC; Costa, C; Visa, J; Solanes, G; Pujol, A; Asins, G; Valera, A; Bosch, F			Evidence from transgenic mice that interferon-beta may be involved in the onset of diabetes mellitus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; RAT PANCREATIC-ISLETS; GENE-EXPRESSION; GLUCOSE-TOLERANCE; ALPHA-INTERFERON; ALFA THERAPY; IFN-GAMMA; INSULIN; CELLS; MOUSE	A number of cytokines have been shown to alter the function of pancreatic beta-cells and thus might be involved in the development of type 1 diabetes. Interferon-beta (IFN-beta) expression is induced in epithelial cells by several viruses, and it has been detected in islets of type 1 diabetic patients. Here we show that treatment of isolated mouse islets with this cytokine was able to alter insulin secretion in vitro. To study whether IFN-beta alters beta-cell function in vivo and leads to diabetes, we have developed transgenic mice (C57BL6/SJL) expressing IFN-beta in beta-cells. These mice showed functional alterations in islets and impaired glucose-stimulated insulin secretion. Transgenic animals presented mild hyperglycemia, hypoinsulinemia, hypertriglyceridemia, and altered glucose tolerance test, all features of a prediabetic state. However, they developed overt diabetes, with lymphocytic infiltration of the islets, when treated with low doses of streptozotocin, which did not induce diabetes in control mice. In addition, about 9% of the transgenic mice obtained from the N3 back-cross to outbred albino CD-1 mice spontaneously developed severe hyperglycemia and hypoinsulinemia and showed mononuclear infiltration of the islets. These results suggest that IFN-beta may be involved in the onset of type 1 diabetes when combined with either an additional factor or a susceptible genetic background.	Univ Autonoma Barcelona, Fac Vet, Dept Bioquim & Biol Mol, Bellaterra 08193, Spain	Autonomous University of Barcelona	Bosch, F (corresponding author), Univ Autonoma Barcelona, Fac Vet, Dept Bioquim & Biol Mol, Bellaterra 08193, Spain.	fatima.bosch@blues.uab.es	Pujol, Anna/J-7939-2017; Costa, Cristina/AAP-4005-2020	Pujol, Anna/0000-0002-3484-598X; Costa, Cristina/0000-0002-1837-4268; BOSCH, FATIMA/0000-0002-7705-5515; Pelegrin, Mireia/0000-0002-0117-2010				ABDI EA, 1986, SCAND J HAEMATOL, V36, P515; BEER SF, 1990, DIABETOLOGIA, V33, P497, DOI 10.1007/BF00405112; BERNTON EW, 1987, SCIENCE, V238, P519, DOI 10.1126/science.2821620; BOLAFFI JL, 1994, ENDOCRINOLOGY, V134, P537, DOI 10.1210/en.134.2.537; BURMAN P, 1986, J CLIN ENDOCR METAB, V63, P1086, DOI 10.1210/jcem-63-5-1086; CALKINS JH, 1988, ENDOCRINOLOGY, V123, P1605, DOI 10.1210/endo-123-3-1605; CAMPBELL IL, 1988, J IMMUNOL, V141, P2325; CASTANO L, 1990, ANNU REV IMMUNOL, V8, P647, DOI 10.1146/annurev.iy.08.040190.003243; CHEN XZ, 1988, J VIROL, V62, P3883, DOI 10.1128/JVI.62.10.3883-3887.1988; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANDOYDRON F, 1991, NUCLEIC ACIDS RES, V19, P4925, DOI 10.1093/nar/19.18.4925; DAVID R, 1994, DIABETES, V43, P843; DERYNCK R, 1980, NATURE, V287, P193, DOI 10.1038/287193a0; DOCHERTY K, 1994, FASEB J, V8, P20, DOI 10.1096/fasebj.8.1.8299887; DYRBERG T, 1990, CURR TOP MICROBIOL, V156, P1; EIZIRIK DL, 1991, ENDOCRINOLOGY, V128, P1611, DOI 10.1210/endo-128-3-1611; EIZIRIK DL, 1989, ENDOCRINOLOGY, V125, P752, DOI 10.1210/endo-125-2-752; FABRIS P, 1992, LANCET, V340, P548, DOI 10.1016/0140-6736(92)91744-S; FOULIS AK, 1987, LANCET, V2, P1423; GILLESPIE G, 1981, TEX REP BIOL MED, V41, P37; GUERCI AP, 1994, LANCET, V343, P1167, DOI 10.1016/S0140-6736(94)90276-3; HOGAN B, 1986, MANIPULATING MOUSE E, P497; HOOD L, 1983, ANNU REV IMMUNOL, V1, P529, DOI 10.1146/annurev.iy.01.040183.002525; HUANG XJ, 1994, IMMUNITY, V1, P469, DOI 10.1016/1074-7613(94)90089-2; HUGHES SJ, 1992, NUTRIENT REGULATION, P271; IWAKURA Y, 1988, EMBO J, V7, P3757, DOI 10.1002/j.1460-2075.1988.tb03259.x; JIANG Z, 1991, J IMMUNOL, V146, P2990; KOIVISTO VA, 1989, DIABETES, V38, P641, DOI 10.2337/diabetes.38.5.641; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; LIKE AA, 1976, SCIENCE, V193, P415, DOI 10.1126/science.180605; LONERGAN M, 1993, MOL CELL BIOL, V13, P6629, DOI 10.1128/MCB.13.11.6629; MCCALLAGH KG, 1983, J INTERFERON RES, V3, P97; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; OFFERMANN MK, 1989, MOL CELL BIOL, V9, P1969, DOI 10.1128/MCB.9.5.1969; PUJOLBORRELL R, 1986, CLIN EXP IMMUNOL, V65, P128; RABINOVITCH A, 1995, J IMMUNOL, V154, P4874; RHODES CJ, 1985, BIOCHEM J, V228, P87, DOI 10.1042/bj2280087; RONNBLOM LE, 1991, ANN INTERN MED, V115, P178, DOI 10.7326/0003-4819-115-3-178; SARVETNICK N, 1988, CELL, V52, P773, DOI 10.1016/0092-8674(88)90414-X; SARVETNICK N, 1990, NATURE, V346, P844, DOI 10.1038/346844a0; SEN GC, 1992, J BIOL CHEM, V267, P5017; SHIMIZU F, 1985, ENDOCRINOLOGY, V117, P2081, DOI 10.1210/endo-117-5-2081; SJOHOLM A, 1992, AM J PHYSIOL, V263, pC114, DOI 10.1152/ajpcell.1992.263.1.C114; SOMOZA N, 1994, J IMMUNOL, V153, P1360; SPANGELO BL, 1989, ENDOCRINOLOGY, V125, P575, DOI 10.1210/endo-125-1-575; SRIKANTA S, 1983, ANN INTERN MED, V99, P320, DOI 10.7326/0003-4819-99-3-320; STEWART TA, 1993, SCIENCE, V260, P1942, DOI 10.1126/science.8100367; Tisch R, 1996, CELL, V85, P291, DOI 10.1016/S0092-8674(00)81106-X; WAGURI M, 1994, DIABETES RES CLIN PR, V23, P26; WILKINSON MF, 1986, METHOD ENZYMOL, V119, P96; WINSTON SE, 1991, CURRENT PROTOCOLS IM; WITT PL, 1993, J IMMUNOTHER, V13, P191, DOI 10.1097/00002371-199304000-00006; ZINN K, 1982, P NATL ACAD SCI-BIOL, V79, P4897, DOI 10.1073/pnas.79.16.4897; ZUZINO SJ, 1994, AM J PATHOL, V145, P661	55	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12332	12340		10.1074/jbc.273.20.12332	http://dx.doi.org/10.1074/jbc.273.20.12332			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575186	hybrid			2022-12-27	WOS:000073629800051
J	Hirsh, AJ; Cheeseman, CI				Hirsh, AJ; Cheeseman, CI			Cholecystokinin decreases intestinal hexose absorption by a parallel reduction in SGLT1 abundance in the brush-border membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORT; EXPRESSION; FRUCTOSE; PROTEIN; COTRANSPORTER; INSULIN; CLONING; HUMANS	The dual lumenaly and vascularly perfused small intestine was used to determine the mechanism by which cholecystokinin octapeptide (CCK-8) decreases the rate of glucose absorption. With CCK-8 in the vascular perfusate the rate of 3-O-methyl-D-glucose absorption decreased, whereas the rate of D-fructose absorption was unaffected. The substrate pool size within the tissue during steady-state transport, in the presence and absence of CCK-8, was estimated by compartmental analysis of the 3-O-methyl-D-glucose washout into the vascular bed. When CCK-8 was included in the vascular perfusate, the absorptive cell pool size decreased when compared with untreated tissue. Both the steady-state hexose absorption data and the washout studies indicated that the locus of action of CCK-8 was the SGLT1 transporter located in the brush-border membrane. The SGLT1 protein abundance in isolated brush-border membranes, as quantified by Western blotting, showed a decrease that paralleled the decrease in the steady-state transport rate induced by CCK-8, These results indicate that CCK-8 diminishes the rate of intestinal hexose absorption by decreasing SGLT1 protein abundance in the brush-border membrane of the rat jejunum and therefore provides evidence for acute enteric hormonal regulation of the rate of glucose absorption across the small intestine.	Univ Alberta, Dept Physiol, Membrane Transport Grp, Edmonton, AB T6G 2H7, Canada	University of Alberta	Cheeseman, CI (corresponding author), Univ Alberta, Dept Physiol, Membrane Transport Grp, 7-55 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.							BISMUT H, 1993, EUR J BIOCHEM, V213, P721, DOI 10.1111/j.1432-1033.1993.tb17812.x; BOYD CAR, 1979, J PHYSIOL-LONDON, V287, P371, DOI 10.1113/jphysiol.1979.sp012665; BOYD CAR, 1978, J PHYSIOL-LONDON, V274, P17, DOI 10.1113/jphysiol.1978.sp012131; CHEESEMAN CI, 1993, GASTROENTEROLOGY, V105, P1050, DOI 10.1016/0016-5085(93)90948-C; Cheeseman CI, 1996, AM J PHYSIOL-GASTR L, V271, pG477, DOI 10.1152/ajpgi.1996.271.3.G477; Cheeseman CI, 1997, AM J PHYSIOL-REG I, V273, pR1965, DOI 10.1152/ajpregu.1997.273.6.R1965; CHEESEMAN CI, 1981, J PHYSIOL-LONDON, V317, P91, DOI 10.1113/jphysiol.1981.sp013815; CRANE RK, 1962, FED PROC, V21, P891; DAVIDSON NO, 1992, AM J PHYSIOL, V262, pC795, DOI 10.1152/ajpcell.1992.262.3.C795; DEBAS HT, 1975, GASTROENTEROLOGY, V68, P1211; DEBNAM ES, 1995, PFLUG ARCH EUR J PHY, V430, P151, DOI 10.1007/BF00374645; DEBNAM ES, 1975, J PHYSIOL-LONDON, V252, P681, DOI 10.1113/jphysiol.1975.sp011165; HARDIN JA, 1993, AM J PHYSIOL, V264, pG312, DOI 10.1152/ajpgi.1993.264.2.G312; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; Hirsch JR, 1996, J BIOL CHEM, V271, P14740, DOI 10.1074/jbc.271.25.14740; Hirsh AJ, 1997, GASTROENTEROLOGY, V113, P205, DOI 10.1016/S0016-5085(97)70096-9; Hirsh AJ, 1996, AM J PHYSIOL-GASTR L, V271, pG755, DOI 10.1152/ajpgi.1996.271.5.G755; HOLLOWAY PAH, 1984, BIOCHEM J, V222, P57, DOI 10.1042/bj2220057; HOPFER U, 1975, P NATL ACAD SCI USA, V72, P2027, DOI 10.1073/pnas.72.6.2027; Ishikawa Y, 1997, BBA-MOL CELL RES, V1357, P306, DOI 10.1016/S0167-4889(97)00043-8; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; LIDDLE RA, 1986, J CLIN INVEST, V77, P992, DOI 10.1172/JCI112401; LIDDLE RA, 1988, J CLIN INVEST, V81, P1675, DOI 10.1172/JCI113505; PENNINGTON AM, 1994, J PHYSIOL-LONDON, V478, P187, DOI 10.1113/jphysiol.1994.sp020241; VEYHL M, 1993, J BIOL CHEM, V268, P25041	25	47	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1998	273	23					14545	14549		10.1074/jbc.273.23.14545	http://dx.doi.org/10.1074/jbc.273.23.14545			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZR856	9603969	hybrid			2022-12-27	WOS:000074021500071
J	Ilg, T; Craik, D; Currie, G; Multhaup, G; Bacic, A				Ilg, T; Craik, D; Currie, G; Multhaup, G; Bacic, A			Stage-specific proteophosphoglycan from Leishmania mexicana amastigotes - Structural characterization of novel mono-, di-, and triphosphorylated phosphodiester-linked oligosaccharides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETED ACID-PHOSPHATASE; PROTEIN-KINASE-C; GLYCOSYLATED PHOSPHATIDYLINOSITOLS; SURFACE LIPOPHOSPHOGLYCAN; MONOCLONAL-ANTIBODIES; MAJOR PROMASTIGOTES; DONOVANI; BIOSYNTHESIS; EXPRESSION; PURIFICATION	Intracellular amastigotes of the protozoan parasite Leishmania mexicana secrete a macromolecular proteophosphoglycan (aPPG) into the phagolysosome of their host cell, the mammalian macrophage. The structures of aPPG glycans were analyzed by a combination of high pH anion exchange high pressure liquid chromatography, gas chromatography-mass spectrometry, enzymatic digestions, electrospray-mass spectrometry as well as H-1 and P-31 NMR spectroscopy. Some glycans are identical to oligosaccharides known from Leishmania mexicana promastigote lipophosphoglycan and secreted acid phosphatase, However, the majority of the aPPG glycans represent amastigote stage-specific and novel structures. These include neutral glycans ([Glc beta(1-3)](1-2)Gal beta 1-4Man, Gal beta 1-3Gal beta 1-4Man, Gal beta 1-3Glc beta 1-3Gal beta 1-4Man), several monophosphorylated glycans containing the conserved phosphodisaccharide backbone (R-3-[PO4-6-Gal]beta 1-4Man) but carrying stage-specific modifications (R = Gal beta 1-, [Glc beta 1-3](1-2)Glc beta 1-), and monophosphorylated aPPG tri- and tetrasaccharides that are uniquely phosphorylated on the terminal hexose (PO4-6-Glc beta 1-3Gal beta 1-4Man, PO4-6-Glc beta 1-3Glc beta 1-3Gal beta 1-4Man, PO4-6-Gal beta 1-3Glc beta 1-3Gal beta 1-4Man), In addition aPPG contains highly unusual di- and triphosphorylated glycans whose major species are PO4-6-Glc beta 1-3Glc beta 1-3[PO4-6-Gal]beta 1-4Man, PO4-6-Gal beta 1-3Glc beta 1-3 [PO4-6-Gal]beta 1-4Man, PO4-6-GaL beta 1-3Glc beta 1-3Glc beta 1-3[PO4-6-Gal]beta 1-4Man, PO4-6-Glc beta 1-3[PO4-6-Glc]beta 1-3[PO4-6-Gal]beta 1-4Man, PO4-6Gal beta 1-3[PO4-6-Glc]beta 1-3Glc beta 1-3[PO4-6-Gal]beta 1-4Man, and PO4-6-Glc beta 1-3[PO4-6-Glc]beta 1-3Glc beta 1-3[PO4-6-Gal]beta 1-4Man. These glycans are linked together by the conserved phosphodiester R-Man alpha 1-PO4-6-Gal-R or the novel phosphodiester R-Man alpha 1-PO4-6-Glc-R and are connected to Ser(P) of the protein backbone most likely via the linkage R-Man alpha 1-PO4-Ser. The variety of stage-specific glycan structures in Leishmania mexicana aPPG suggests the presence of developmentally regulated amastigote glycosyltransferases which may be potential anti-parasite drug targets.	Univ Melbourne, Sch Bot, Plant Cell Biol Res Ctr, Parkville, Vic 3052, Australia; Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia; Univ Queensland, Ctr Drug Design & Dev, Brisbane, Qld 4072, Australia; Ctr Mol Biol, Heidelberg, Germany	University of Melbourne; Royal Melbourne Hospital; Walter & Eliza Hall Institute; University of Queensland	Ilg, T (corresponding author), Max Planck Inst Biol, Abt Membranbiochem, Corrensstr 38, D-72076 Tubingen, Germany.	thomas.ilg@tuebingen.mpg.de	Craik, David/B-1695-2010	Craik, David/0000-0003-0007-6796; Bacic, Tony/0000-0001-7483-8605				ANTOINE JC, 1990, INFECT IMMUN, V58, P779, DOI 10.1128/IAI.58.3.779-787.1990; BAHR V, 1993, MOL BIOCHEM PARASIT, V58, P107, DOI 10.1016/0166-6851(93)90095-F; BALLOU CE, 1990, METHOD ENZYMOL, V185, P440; BALSAMO J, 1986, BIOCHEMISTRY-US, V25, P5402, DOI 10.1021/bi00367a009; BATES PA, 1994, PARASITOLOGY, V108, P1, DOI 10.1017/S0031182000078458; BATES PA, 1990, MOL BIOCHEM PARASIT, V39, P247, DOI 10.1016/0166-6851(90)90063-R; Brown GM, 1996, EUR J BIOCHEM, V242, P410, DOI 10.1111/j.1432-1033.1996.0410r.x; CARVER MA, 1992, ARCH BIOCHEM BIOPHYS, V295, P309, DOI 10.1016/0003-9861(92)90523-Y; CARVER MA, 1991, J BIOL CHEM, V266, P10974; DESCOTEAUX A, 1993, PARASITOL TODAY, V9, P468, DOI 10.1016/0169-4758(93)90105-O; DESCOTEAUX A, 1995, SCIENCE, V269, P1869, DOI 10.1126/science.7569927; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FOX A, 1989, ANAL CARBOHYDRATES G; Giorgione JR, 1996, P NATL ACAD SCI USA, V93, P11634, DOI 10.1073/pnas.93.21.11634; GLASER TA, 1991, MOL BIOCHEM PARASIT, V45, P337, DOI 10.1016/0166-6851(91)90102-C; GUSTAFSON GL, 1984, METHOD ENZYMOL, V107, P172; HAYES BK, 1993, J BIOL CHEM, V268, P16170; Haynes PA, 1996, GLYCOBIOLOGY, V6, P869, DOI 10.1093/glycob/6.8.869; HERNANDEZ LM, 1989, J BIOL CHEM, V264, P13648; Ho JL, 1996, J IMMUNOL, V157, P3013; HUANG CC, 1993, J BIOL CHEM, V268, P24060; ILG T, 1993, EUR J BIOCHEM, V217, P603, DOI 10.1111/j.1432-1033.1993.tb18283.x; ILG T, 1991, J CELL SCI, V99, P175; ILG T, 1995, EUR J CELL BIOL, V66, P205; ILG T, 1994, J BIOL CHEM, V269, P24073; ILG T, 1992, J BIOL CHEM, V267, P6834; Ilg T, 1996, J BIOL CHEM, V271, P21583, DOI 10.1074/jbc.271.35.21583; ILG T, 1994, PARASITOLOGY, V108, pS63, DOI 10.1017/S0031182000075739; ILG T, 1993, FEBS LETT, V327, P103, DOI 10.1016/0014-5793(93)81049-6; JAFFE CL, 1990, MOL BIOCHEM PARASIT, V41, P233, DOI 10.1016/0166-6851(90)90186-P; KELLEHER M, 1995, INFECT IMMUN, V63, P43, DOI 10.1128/IAI.63.1.43-50.1995; KELLEHER M, 1992, P NATL ACAD SCI USA, V89, P6, DOI 10.1073/pnas.89.1.6; LIS H, 1993, EUR J BIOCHEM, V218, P1, DOI 10.1111/j.1432-1033.1993.tb18347.x; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MCCONVILLE MJ, 1995, BIOCHEM J, V310, P807, DOI 10.1042/bj3100807; MCCONVILLE MJ, 1991, J BIOL CHEM, V266, P15170; MCCONVILLE MJ, 1992, EMBO J, V11, P3593, DOI 10.1002/j.1460-2075.1992.tb05443.x; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P19611; McNeely TB, 1996, ARCH BIOCHEM BIOPHYS, V334, P1, DOI 10.1006/abbi.1996.0422; MEDINAACOSTA E, 1989, MOL BIOCHEM PARASIT, V37, P263, DOI 10.1016/0166-6851(89)90158-8; MEDINAACOSTA E, 1993, MOL BIOCHEM PARASIT, V57, P31, DOI 10.1016/0166-6851(93)90241-O; MENZ B, 1991, MOL BIOCHEM PARASIT, V47, P101, DOI 10.1016/0166-6851(91)90152-V; MOODY SF, 1993, J BIOL CHEM, V268, P18457; NG K, 1994, GLYCOBIOLOGY, V4, P845, DOI 10.1093/glycob/4.6.845; Ng K, 1996, BIOCHEM J, V317, P247, DOI 10.1042/bj3170247; PETERS C, 1995, J CELL SCI, V108, P3715; Peters C, 1997, EUR J IMMUNOL, V27, P2666, DOI 10.1002/eji.1830271028; Peters C, 1997, INFECT IMMUN, V65, P783, DOI 10.1128/IAI.65.2.783-786.1997; PIMENTA PFP, 1992, SCIENCE, V256, P1812, DOI 10.1126/science.1615326; PIMENTA PFP, 1991, EXP PARASITOL, V72, P191, DOI 10.1016/0014-4894(91)90137-L; PIMENTA PFP, 1994, P NATL ACAD SCI USA, V91, P9155, DOI 10.1073/pnas.91.19.9155; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; PROUDFOOT L, 1995, BIOCHEM J, V308, P45, DOI 10.1042/bj3080045; Proudfoot L, 1996, P NATL ACAD SCI USA, V93, P10984, DOI 10.1073/pnas.93.20.10984; PUPKIS MF, 1986, EXP PARASITOL, V62, P29, DOI 10.1016/0014-4894(86)90005-6; PUPKIS MF, 1986, COMP BIOCHEM PHYS B, V83, P629, DOI 10.1016/0305-0491(86)90308-1; SACKS DL, 1994, PARASITOLOGY, V108, pS55, DOI 10.1017/S0031182000075727; SACKS DL, 1995, J EXP MED, V181, P685, DOI 10.1084/jem.181.2.685; SACKS DL, 1989, EXP PARASITOL, V69, P100, DOI 10.1016/0014-4894(89)90176-8; SHIBATA N, 1995, J BIOL CHEM, V270, P1113, DOI 10.1074/jbc.270.3.1113; STIERHOF YD, 1994, J CELL BIOL, V125, P321, DOI 10.1083/jcb.125.2.321; TURCO SJ, 1991, MOL BIOCHEM PARASIT, V45, P91, DOI 10.1016/0166-6851(91)90030-A; TURCO SJ, 1984, J BIOL CHEM, V259, P3883; TURCO SJ, 1992, ANNU REV MICROBIOL, V46, P65, DOI 10.1146/annurev.mi.46.100192.000433; VARKI A, 1980, J BIOL CHEM, V255, P847	65	41	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13509	13523		10.1074/jbc.273.22.13509	http://dx.doi.org/10.1074/jbc.273.22.13509			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593686	hybrid			2022-12-27	WOS:000073919100025
J	Maehama, T; Dixon, JE				Maehama, T; Dixon, JE			The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALING SYSTEM; PROTEINS	Phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P-3) is a key molecule involved in cell growth signaling. We demonstrated that overexpression of PTEN, a putative tumor suppressor, reduced insulin-induced PtdIns(3,4,5)P-3 production in human 293 cells without effecting insulin-induced phosphoinositide S-kinase activation. Further, transfection of the catalytically inactive mutant of PTEN (C124S) caused PtdIns(3,4,5)P-3 accumulation in the absence of insulin stimulation. Purified recombinant PTEN catalyzed dephosphorylation of PtdIns(3,4,5)P-3, specifically at position 3 on the inositol ring. PTEN also exhibited 3-phosphatase activity toward inositol 1,3,4,5-tetrakisphosphate, Our results raise the possibility that PTEN acts in vivo as a phosphoinositide 3-phosphatase by regulating PtdIns(3,4,5)P-3 levels. As expected, the C124S mutant of PTEN was incapable of catalyzing dephosphorylation of PtdIns(3,4,5)P-3 consistent with the mechanism observed in protein-tyrosine phosphatase-catalyzed reactions.	Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Maehama, T (corresponding author), Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA.		Maehama, Tomohiko/HGB-4896-2022; Maehama, Tomohiko/AAX-8926-2020	Maehama, Tomohiko/0000-0002-9685-2317; 				CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Guilherme A, 1996, J BIOL CHEM, V271, P29533, DOI 10.1074/jbc.271.47.29533; Kurosu H, 1997, J BIOL CHEM, V272, P24252, DOI 10.1074/jbc.272.39.24252; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li LW, 1997, J BIOL CHEM, V272, P29403, DOI 10.1074/jbc.272.47.29403; Lohse DL, 1997, BIOCHEMISTRY-US, V36, P4568, DOI 10.1021/bi963094r; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Okada T, 1996, BIOCHEM J, V317, P475, DOI 10.1042/bj3170475; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; Scharenberg AM, 1996, CELL, V87, P961, DOI 10.1016/S0092-8674(00)81790-0; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; Takagi T, 1997, CELL, V89, P867, DOI 10.1016/S0092-8674(00)80272-X; Woscholski R, 1997, TRENDS BIOCHEM SCI, V22, P427, DOI 10.1016/S0968-0004(97)01120-1	20	2433	2523	2	88	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 29	1998	273	22					13375	13378		10.1074/jbc.273.22.13375	http://dx.doi.org/10.1074/jbc.273.22.13375			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZQ947	9593664	hybrid			2022-12-27	WOS:000073919100003
J	Ananvoranich, S; Perreault, JP				Ananvoranich, S; Perreault, JP			Substrate specificity of delta ribozyme cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENOMIC HDV RIBOZYME; VIRUS-RNA; SELF-CLEAVAGE; MUTAGENESIS ANALYSIS; CATALYTIC RNA; HEPATITIS; SEQUENCE	The specificity of delta ribozyme cleavage was investigated using a trans-acting antigenomic delta ribozyme. Under single turnover conditions, the wild type ribozyme cleaved the Il-mer ribonucleotide substrate with a rate constant of 0.34 min(-1), an apparent K-m of 17.9 nM and an apparent second-order rate constant of 1.89 x 10(7) min(-1) M-1. The substrate specificity of the delta ribozyme was thoroughly investigated using a collection of substrates that varied in either the length or the nucleotide sequence of their P1 stems. We observed that not only is the base pairing of the substrate and the ribozyme important to cleavage activity, but also both the identity and the combination of the nucleotide sequence in the substrates are essential for cleavage activity. We show that the nucleotides in the middle of the P1 stem are essential for substrate binding and subsequent steps in the cleavage pathway. The introduction of any mismatches at these positions resulted in a complete lack of cleavage by the wild type ribozyme. Our findings suggest that factors more complex than simple base pairing interactions, such as tertiary structure interactions, could play an important role in the substrate specificity of delta ribozyme cleavage.	Univ Sherbrooke, Fac Med, Dept Biochim, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Perreault, JP (corresponding author), Univ Sherbrooke, Fac Med, Dept Biochim, Sherbrooke, PQ J1H 5N4, Canada.				Canadian Institutes of Health Research [12673] Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		Amiri KMA, 1996, J MOL BIOL, V261, P125, DOI 10.1006/jmbi.1996.0446; BEEN MD, 1994, TRENDS BIOCHEM SCI, V19, P251, DOI 10.1016/0968-0004(94)90151-1; Been MD, 1995, RNA, V1, P1061; BEEN MD, 1992, BIOCHEMISTRY-US, V31, P11843, DOI 10.1021/bi00162a024; BRANCH AD, 1991, P NATL ACAD SCI USA, V88, P10163, DOI 10.1073/pnas.88.22.10163; Chartrand P, 1997, BIOCHEMISTRY-US, V36, P3145, DOI 10.1021/bi962219p; Esteban JA, 1997, J BIOL CHEM, V272, P13629, DOI 10.1074/jbc.272.21.13629; Fauzi H, 1997, NUCLEIC ACIDS RES, V25, P3124, DOI 10.1093/nar/25.15.3124; FEDOR MJ, 1992, BIOCHEMISTRY-US, V31, P12042, DOI 10.1021/bi00163a012; FERSHT AR, 1988, BIOCHEMISTRY-US, V27, P1577, DOI 10.1021/bi00405a027; Hertel KJ, 1996, EMBO J, V15, P3751, DOI 10.1002/j.1460-2075.1996.tb00745.x; Hertel KJ, 1997, P NATL ACAD SCI USA, V94, P8497, DOI 10.1073/pnas.94.16.8497; Kawakami J, 1996, FEBS LETT, V394, P132, DOI 10.1016/0014-5793(96)00941-6; KUMAR PKR, 1993, FASEB J, V7, P124, DOI 10.1096/fasebj.7.1.8422958; LAZINSKI DW, 1995, RNA, V1, P225; MAKINO S, 1987, NATURE, V329, P343, DOI 10.1038/329343a0; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; Nishikawa F, 1997, NUCLEIC ACIDS RES, V25, P1605, DOI 10.1093/nar/25.8.1605; PERROTTA AT, 1992, BIOCHEMISTRY-US, V31, P16, DOI 10.1021/bi00116a004; PERROTTA AT, 1991, NATURE, V350, P434, DOI 10.1038/350434a0; Serra MJ, 1995, METHOD ENZYMOL, V259, P242; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; WU HN, 1992, NUCLEIC ACIDS RES, V20, P5937, DOI 10.1093/nar/20.22.5937; WU HN, 1992, J MOL BIOL, V223, P233, DOI 10.1016/0022-2836(92)90728-3; WU HN, 1989, P NATL ACAD SCI USA, V86, P1831, DOI 10.1073/pnas.86.6.1831; WU HN, 1993, NUCLEIC ACIDS RES, V21, P4193, DOI 10.1093/nar/21.18.4193	26	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					13182	13188		10.1074/jbc.273.21.13182	http://dx.doi.org/10.1074/jbc.273.21.13182			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582360	Green Accepted, hybrid			2022-12-27	WOS:000073768500071
J	Hadac, EM; Pinon, DI; Ji, ZS; Holicky, EL; Henne, RM; Lybrand, TP; Miller, LJ				Hadac, EM; Pinon, DI; Ji, ZS; Holicky, EL; Henne, RM; Lybrand, TP; Miller, LJ			Direct identification of a second distinct site of contact between cholecystokinin and its receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROKININ-1 RECEPTOR; BINDING-SITE; SHORT PROBES; PROTEIN; PEPTIDE; PANCREOZYMIN; ANALOGS	We have developed a biologically active analogue of cholecystokinin (CCK) that incorporates a photolabile benzoylphenylalanine (Bpa) moiety in the middle of its pharmacophoric domain, which efficiently establishes a covalent bond with an interacting domain of the CCK receptor, This probe incorporated L-Bpa in the position of Gly(29) of the well characterized, radioiodinatable CCK analogue, D-Tyr-Gly-[(Nle(28,31))CCK-26-33]. It was a potent pancreatic secretagogue (EC50 = 28 +/- 6 nM) that was equally efficacious with natural CCK, and bound to the CCK receptor with moderate affinity (IC50 = 450 +/- 126 nM). This was adequate to allow specific covalent labeling of the receptor. The labeled domain was within the cyanogen bromide fragment of the receptor including the top of TM6 (the sixth transmembrane domain), the third extracellular loop, and TM7 (the seventh transmembrane domain), as proven by direct Edman degradation sequencing, When this fragment was modified by the replacement of Val(342) with Met to generate an additional site of cyanogen bromide cleavage, the labeled fragment was reduced in apparent size consistent with its representing the carboxyl-terminal portion of this fragment. Radiochemical sequencing of that fragment demonstrated covalent attachment of the probe to His(347) and Leu(348) in this domain, This represents the second experimentally demonstrated contact between a CCH analogue and this receptor, complementing the labeling of the domain just above TM1 (the first transmembrane domain) by a photolabile residue at the carboxyl terminus of CCK (Ji, Z. S., Hadac, E. M., Henne, R. M., Patel, S. A., Lybrand, T. P., and Miller, L. J. (1997) J. Biol. Chem, 272, 24393-24401). Both contacts are consistent with the conformational model of CCB. binding proposed on the basis of the initial contact.	Mayo Clin & Mayo Fdn, Ctr Basic Res Digest Dis, Rochester, MN 55905 USA; Univ Washington, Dept Bioengn, Seattle, WA 98195 USA	Mayo Clinic; University of Washington; University of Washington Seattle	Miller, LJ (corresponding author), Mayo Clin & Mayo Fdn, Ctr Basic Res Digest Dis, Guggenheim 17, Rochester, MN 55905 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032878, R37DK032878] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033290] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK32878] Funding Source: Medline; NINDS NIH HHS [NS33290] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CESKA M, 1969, CLIN CHIM ACTA, V26, P437, DOI 10.1016/0009-8981(69)90071-0; COUGHLIN SR, 1994, CURR OPIN CELL BIOL, V6, P191, DOI 10.1016/0955-0674(94)90135-X; Hadac EM, 1996, PANCREAS, V13, P130, DOI 10.1097/00006676-199608000-00003; HUANG RRC, 1994, MOL PHARMACOL, V45, P690; HUANG RRC, 1994, BIOCHEMISTRY-US, V33, P3007, DOI 10.1021/bi00176a033; Ji ZS, 1997, J BIOL CHEM, V272, P24393, DOI 10.1074/jbc.272.39.24393; KAUER JC, 1986, J BIOL CHEM, V261, P695; Klueppelberg U G, 1990, Receptor, V1, P1; KLUEPPELBERG UG, 1989, BIOCHEMISTRY-US, V28, P3463, DOI 10.1021/bi00434a047; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUTZ MP, 1993, J BIOL CHEM, V268, P11119; MILLER LJ, 1992, BIOCHEM BIOPH RES CO, V183, P396, DOI 10.1016/0006-291X(92)90494-6; MILLER LJ, 1992, YALE J BIOL MED, V65, P441; MILLER WT, 1988, P NATL ACAD SCI USA, V85, P5429, DOI 10.1073/pnas.85.15.5429; ONDETTI MA, 1970, AM J DIG DIS, V15, P149, DOI 10.1007/BF02235646; PEARSON RK, 1987, J BIOL CHEM, V262, P13850; PEARSON RK, 1987, J BIOL CHEM, V262, P869; PEARSON RK, 1986, GASTROENTEROLOGY, V90, P1985, DOI 10.1016/0016-5085(86)90271-4; POWERS SP, 1988, INT J PEPT PROT RES, V31, P429; POWERS SP, 1988, J BIOL CHEM, V263, P5295; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; SERVANT G, 1993, MOL PHARMACOL, V43, P677; SHOELSON SE, 1993, J BIOL CHEM, V268, P4085; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; Wong SS., 1991, CHEM PROTEIN CONJUGA, P7; YANAIHARA C, 1985, BIOMED RES-TOKYO, V6, P111; ZHOU W, 1994, MOL PHARMACOL, V45, P165	28	79	79	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					12988	12993		10.1074/jbc.273.21.12988	http://dx.doi.org/10.1074/jbc.273.21.12988			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582333	hybrid			2022-12-27	WOS:000073768500044
J	Richards, OC; Ehrenfeld, E				Richards, OC; Ehrenfeld, E			Effects of poliovirus 3AB protein on 3D polymerase-catalyzed reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENOME-LINKED PROTEIN; DEPENDENT RNA-POLYMERASE; NEGATIVE-STRAND RNA; ESCHERICHIA-COLI; VIRAL POLYPEPTIDE; POLYURIDYLIC ACID; VPG; PRECURSOR; IDENTIFICATION; INVITRO	Poliovirus RNA replication requires the activities of a viral RNA-dependent RNA polymerase, 3D(pol), in conjunction with several additional viral and likely cellular proteins. The importance of both the 3A and 3B coding regions has been documented previously by genetic tests, and their biochemical activities have been the subject of several recent investigations. In this study, we examined the previously reported stimulation of 3D-catalyzed RNA synthesis by 3AB, We show that 3AB does not stimulate RNA synthesis on templates that are stably base paired to a primer, indicating that 3AB does not stabilize or otherwise activate 3D(pol) for chain elongation. Similarly, it does not alter the kinetic parameters or binding affinities of 3D for substrates. In the absence of a primer, or in the presence of a primer that does not form a stable hybrid with the template, 3AB increases the utilization of 3'-hydroxyl termini as sites for chain elongation by 3D, and thereby stimulates RNA synthesis, 3AB may interact with and stabilize these sites and/or may recruit 3D(pol) to the site, resulting in stimulation of the initiation of elongation events. We propose that this activity is required for stabilizing weak interactions that occur during nucleotidyl-protein-primed initiation events in the viral RNA replication complex.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA	University of California System; University of California Irvine	Ehrenfeld, E (corresponding author), NIH, Ctr Sci Review, 6701 Rockledge Dr,Bldg 2,Rm 3109,MSC 7776, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017386, R37AI017386] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 17386] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDINO R, 1990, CELL, V63, P369, DOI 10.1016/0092-8674(90)90170-J; BARON MH, 1982, CELL, V28, P395, DOI 10.1016/0092-8674(82)90357-9; BERNSTEIN HD, 1988, J VIROL, V62, P2922, DOI 10.1128/JVI.62.8.2922-2928.1988; FLANEGAN JB, 1979, J VIROL, V29, P352, DOI 10.1128/JVI.29.1.352-360.1979; GIACHETTI C, 1991, J VIROL, V65, P2647, DOI 10.1128/JVI.65.5.2647-2654.1991; Hansen JL, 1997, STRUCTURE, V5, P1109, DOI 10.1016/S0969-2126(97)00261-X; HARRIS KS, 1994, J BIOL CHEM, V269, P27004; Hope DA, 1997, J VIROL, V71, P9490, DOI 10.1128/JVI.71.12.9490-9498.1997; KITAMURA N, 1981, NATURE, V291, P547, DOI 10.1038/291547a0; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LAMA J, 1994, J BIOL CHEM, V269, P66; LAMA J, 1992, BIOCHEM BIOPH RES CO, V188, P972, DOI 10.1016/0006-291X(92)91327-M; LAMA J, 1995, J BIOL CHEM, V270, P14430, DOI 10.1074/jbc.270.24.14430; LARSEN GR, 1980, NUCLEIC ACIDS RES, V8, P1217, DOI 10.1093/nar/8.6.1217; LUNDQUIST RE, 1974, P NATL ACAD SCI USA, V71, P4773, DOI 10.1073/pnas.71.12.4773; MARCOS JF, 1994, BIOTECHNIQUES, V16, P212; MOLLA A, 1994, J BIOL CHEM, V269, P27015; MORROW CD, 1984, VIRUS RES, V1, P89, DOI 10.1016/0168-1702(84)90066-2; NEUFELD KL, 1991, J BIOL CHEM, V266, P24212; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; PATA JD, 1995, RNA, V1, P466; PAUL AV, 1994, J BIOL CHEM, V269, P29173; PETTERSSON RF, 1978, J VIROL, V27, P357, DOI 10.1128/JVI.27.2.357-365.1978; PLOTCH SJ, 1995, J VIROL, V69, P7169, DOI 10.1128/JVI.69.11.7169-7179.1995; PLOTCH SJ, 1989, J VIROL, V63, P216, DOI 10.1128/JVI.63.1.216-225.1989; REUER Q, 1990, J VIROL, V64, P2967, DOI 10.1128/JVI.64.6.2967-2975.1990; RICHARDS OC, 1992, J BIOL CHEM, V267, P17141; RICHARDS OC, 1987, VIROLOGY, V161, P348, DOI 10.1016/0042-6822(87)90127-9; ROEHL HH, 1995, J VIROL, V69, P2954, DOI 10.1128/JVI.69.5.2954-2961.1995; SEMLER BL, 1982, CELL, V28, P405, DOI 10.1016/0092-8674(82)90358-0; TAKEGAMI T, 1983, VIROLOGY, V128, P33, DOI 10.1016/0042-6822(83)90316-1; Towner JS, 1996, J BIOL CHEM, V271, P26810, DOI 10.1074/jbc.271.43.26810; TOYODA H, 1987, J VIROL, V61, P2816, DOI 10.1128/JVI.61.9.2816-2822.1987; TUSCHALL DM, 1982, J VIROL, V44, P209, DOI 10.1128/JVI.44.1.209-216.1982; VANDYKE TA, 1980, J VIROL, V35, P732, DOI 10.1128/JVI.35.3.732-740.1980; WU M, 1978, NUCLEIC ACIDS RES, V5, P4711, DOI 10.1093/nar/5.12.4711; XIANG WK, 1995, J VIROL, V69, P3658, DOI 10.1128/JVI.69.6.3658-3667.1995	37	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					12832	12840		10.1074/jbc.273.21.12832	http://dx.doi.org/10.1074/jbc.273.21.12832			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582311	hybrid			2022-12-27	WOS:000073768500022
J	Santoro, MF; Annand, RR; Robertson, MM; Peng, YW; Brady, MJ; Mankovich, JA; Hackett, MC; Ghayur, T; Walter, G; Wong, WW; Giegel, DA				Santoro, MF; Annand, RR; Robertson, MM; Peng, YW; Brady, MJ; Mankovich, JA; Hackett, MC; Ghayur, T; Walter, G; Wong, WW; Giegel, DA			Regulation of protein phosphatase 2A activity by caspase-3 during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; SMALL NUCLEAR RIBONUCLEOPROTEIN; CELL-DEATH; A-SUBUNIT; POLY(ADP-RIBOSE) POLYMERASE; ICE/CED-3 PROTEASE; MAMMALIAN HOMOLOG; TUMOR-ANTIGENS; MAP KINASE; CLEAVAGE	Although the available evidence suggests that whereas the caspase family plays a major role in apoptosis, they are not the sole stimulators of death. A random yeast two-hybrid screen of a lymphocyte cDNA library (using caspase-3 as the bait) found an interaction between caspase-3 and the regulatory subunit A alpha of protein phosphatase 2A. This protein was found to be a substrate for caspase-3, but not caspase-1, and could compete effectively against either a protein or synthetic peptide substrate. In Jurkat cells induced to undergo apoptosis with anti-Fas antibody, protein phosphatase 2A (PP2A) activity increased 4.5-fold after 6 h. By 12 h, the regulatory A alpha subunit could no longer be detected in cell lysates, There was no change in the amount of the catalytic subunit, The effects on PP2A could be prevented by the caspase family inhibitors acetyl-Asp-Glu-Val-Asp (DEVD) aldehyde or Ac-DEVD fluoromethyl ketone. The mitogen-activated protein (MAP) kinase pathway is regulated by PP2A. At 12 h after the addition of anti-Fas antibody, a decrease in the amount of the phosphorylated forms of MAP kinase was observed. Again, this loss of activated MAP kinase could be prevented by the addition of DEVD-cho or DEVD-fmk, These data are consistent with a pathway whereby induction of apoptosis activates caspase-3, This enzyme then cleaves the regulatory A alpha subunit of PP2A, increasing its activity. These data show that the activated PP2A will then effect a change in the phosphorylation state of the cell. These data provide a link between the caspases and signal transduction pathways.	Warner Lambert Parke Davis, Parke Davis Pharmaceut Res Div, Dept Biochem, Ann Arbor, MI 48105 USA; Warner Lambert Parke Davis, Parke Davis Pharmaceut Res Div, Dept Cell Biol, Ann Arbor, MI 48105 USA; BASF Biores Corp, Dept Immunol, Worcester, MA 01605 USA; BASF Biores Corp, Dept Biochem, Worcester, MA 01605 USA; Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA	Pfizer; Pfizer; BASF; BASF; University of California System; University of California San Diego	Giegel, DA (corresponding author), Warner Lambert Parke Davis, Parke Davis Pharmaceut Res Div, Dept Biochem, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.	Giegeld@aa.wl.com						AGOSTINIS P, 1992, EUR J BIOCHEM, V205, P241, DOI 10.1111/j.1432-1033.1992.tb16774.x; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; An B, 1996, FEBS LETT, V399, P158, DOI 10.1016/S0014-5793(96)01311-7; An B, 1996, CANCER RES, V56, P438; BEGUM N, 1993, ENDOCRINOLOGY, V133, P2085, DOI 10.1210/en.133.5.2085; BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; Cain K, 1996, BIOCHEM J, V314, P27, DOI 10.1042/bj3140027; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; CEGIELSKA A, 1994, MOL CELL BIOL, V14, P4616, DOI 10.1128/MCB.14.7.4616; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; COHEN P, 1988, METHOD ENZYMOL, V159, P390; DOU QP, 1995, P NATL ACAD SCI USA, V92, P9019, DOI 10.1073/pnas.92.20.9019; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FERRIGNO P, 1993, MOL BIOL CELL, V4, P669, DOI 10.1091/mbc.4.7.669; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fraser A, 1996, CURR OPIN NEUROBIOL, V6, P71, DOI 10.1016/S0959-4388(96)80011-0; Gamen S, 1996, FEBS LETT, V390, P233, DOI 10.1016/0014-5793(96)00666-7; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; GJERTSEN BT, 1995, BBA-MOL CELL RES, V1269, P187, DOI 10.1016/0167-4889(95)00117-B; Han ZY, 1996, J BIOL CHEM, V271, P25035, DOI 10.1074/jbc.271.40.25035; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KAMIBAYASHI C, 1994, J BIOL CHEM, V269, P20139; KAMIBAYASHI C, 1992, J BIOL CHEM, V267, P21864; Kremmer E, 1997, MOL CELL BIOL, V17, P1692, DOI 10.1128/MCB.17.3.1692; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Margolin N, 1997, J BIOL CHEM, V272, P7223, DOI 10.1074/jbc.272.11.7223; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Martins LM, 1997, J BIOL CHEM, V272, P7421, DOI 10.1074/jbc.272.11.7421; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Morana SJ, 1996, J BIOL CHEM, V271, P18263, DOI 10.1074/jbc.271.30.18263; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; NEWTON RC, 1986, J LEUKOCYTE BIOL, V39, P299, DOI 10.1002/jlb.39.3.299; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; Quintaje SB, 1996, BIOCHEM BIOPH RES CO, V221, P539, DOI 10.1006/bbrc.1996.0632; Rosen A, 1997, J CELL BIOCHEM, V64, P50, DOI 10.1002/(SICI)1097-4644(199701)64:1<50::AID-JCB8>3.0.CO;2-Z; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; RUEDIGER R, 1994, J VIROL, V68, P123, DOI 10.1128/JVI.68.1.123-129.1994; RUEDIGER R, 1992, MOL CELL BIOL, V12, P4872, DOI 10.1128/MCB.12.11.4872; Schwartz LM, 1996, TRENDS NEUROSCI, V19, P555, DOI 10.1016/S0166-2236(96)10067-9; SOLA MM, 1991, BIOCHIM BIOPHYS ACTA, V1094, P211, DOI 10.1016/0167-4889(91)90011-L; SONG QZ, 1993, BIOCHEM BIOPH RES CO, V190, P47, DOI 10.1006/bbrc.1993.1009; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; TAKAI A, 1992, BIOCHEM J, V287, P101, DOI 10.1042/bj2870101; Talanian RV, 1997, J BIOL CHEM, V272, P9677; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P18738, DOI 10.1074/jbc.270.32.18738; THORNBERRY NA, 1994, METHOD ENZYMOL, V244, P615; Turowski P, 1997, EUR J BIOCHEM, V248, P200, DOI 10.1111/j.1432-1033.1997.t01-1-00200.x; Vasilakos JP, 1997, APOPTOSIS, V2, P289, DOI 10.1023/A:1026489104188; VASILAKOS JP, 1995, J IMMUNOL, V155, P3433; WALTER G, 1989, P NATL ACAD SCI USA, V86, P8669, DOI 10.1073/pnas.86.22.8669; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; Wolf CM, 1997, EXP CELL RES, V230, P22, DOI 10.1006/excr.1996.3401; Zhang C, 1997, J BIOL CHEM, V272, P13397, DOI 10.1074/jbc.272.20.13397	63	137	141	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 22	1998	273	21					13119	13128		10.1074/jbc.273.21.13119	http://dx.doi.org/10.1074/jbc.273.21.13119			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZP588	9582351	hybrid			2022-12-27	WOS:000073768500062
J	Ala, PJ; DeLoskey, RJ; Huston, EE; Jadhav, PK; Lam, PYS; Eyermann, CJ; Hodge, CN; Schadt, MC; Lewandowski, FA; Weber, PC; McCabe, DD; Duke, JL; Chang, CH				Ala, PJ; DeLoskey, RJ; Huston, EE; Jadhav, PK; Lam, PYS; Eyermann, CJ; Hodge, CN; Schadt, MC; Lewandowski, FA; Weber, PC; McCabe, DD; Duke, JL; Chang, CH			Molecular recognition of cyclic urea HIV-1 protease inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS PROTEASE; CRYSTAL-STRUCTURE; INCREASED RESISTANCE; TYPE-1 PROTEASE; RATIONAL DESIGN; VARIANTS; RESOLUTION; SELECTION; ABT-538; POTENCY	As long as the threat of human immunodeficiency virus (HIV) protease drug resistance still exists, there will be a need for more potent antiretroviral agents. We have therefore determined the crystal structures of HIV-1 protease in complex with six cyclic urea inhibitors: XK216, XK263, DMP323, DMP450, XV638, and SD146, in an attempt to identify 1) the key interactions responsible for their high potency and 2) new interactions that might improve their therapeutic benefit. The structures reveal that the preorganized, C-2 symmetric scaffolds of the inhibitors are anchored in the active site of the protease by six hydrogen bonds and that their P1 and P2 substituents participate in extensive van der Waals interactions and hydrogen bonds. Because all of our inhibitors possess benzyl groups at P1 and P1', their relative binding affinities are modulated by the extent of their P2 interactions, e.g. XK216, the least potent inhibitor (K-i (inhibition constant) = 4.70 nM), possesses the smallest P2 and the lowest number of P2-S2 interactions; whereas SD146, the most potent inhibitor (K-i = 0.02 nM), contains a benzimidazolylbenzamide at P2 and participates in fourteen hydrogen bonds and similar to 200 van der Waals interactions. This analysis identifies the strongest interactions between the protease and the inhibitors, suggests ways to improve potency by building into the S2 subsite, and reveals how conformational changes and unique features of the viral protease increase the binding affinity of HIV protease inhibitors.	Dupont Merck Pharmaceut Co, Expt Stn, Wilmington, DE 19880 USA	DuPont	Chang, CH (corresponding author), Dupont Merck Pharmaceut Co, Expt Stn, POB 80228, Wilmington, DE 19880 USA.							Ala PJ, 1997, BIOCHEMISTRY-US, V36, P1573, DOI 10.1021/bi962234u; Backbro K, 1997, J MED CHEM, V40, P898, DOI 10.1021/jm960588d; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1996, XPLOR VERSION 3 851; CHEN ZG, 1994, J BIOL CHEM, V269, P26344; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; Darke P L, 1994, Adv Pharmacol, V25, P399, DOI 10.1016/S1054-3589(08)60438-X; DeLucca GV, 1997, DRUG DISCOV TODAY, V2, P6, DOI 10.1016/S1359-6446(96)10048-9; DREYER GB, 1993, BIOCHEMISTRY-US, V32, P937, DOI 10.1021/bi00054a027; ELFARRASH MA, 1994, J VIROL, V68, P233, DOI 10.1128/JVI.68.1.233-239.1994; ERICKSON J, 1990, SCIENCE, V249, P527, DOI 10.1126/science.2200122; ERICKSONVIITANEN S, 1994, ANTIMICROB AGENTS CH, V38, P1628, DOI 10.1128/AAC.38.7.1628; FITZGERALD PMD, 1991, ANNU REV BIOPHYS BIO, V20, P299, DOI 10.1146/annurev.biophys.20.1.299; GENG XD, 1992, J CHROMATOGR, V599, P185, DOI 10.1016/0021-9673(92)85472-6; GRZESIEK S, 1994, J AM CHEM SOC, V116, P1581, DOI 10.1021/ja00083a058; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; HENDERSON LE, 1988, J VIROL, V62, P2587, DOI 10.1128/JVI.62.8.2587-2595.1988; HO DD, 1994, J VIROL, V68, P2016, DOI 10.1128/JVI.68.3.2016-2020.1994; Hodge CN, 1996, CHEM BIOL, V3, P301, DOI 10.1016/S1074-5521(96)90110-6; Hulten J, 1997, J MED CHEM, V40, P885, DOI 10.1021/jm960728j; Jadhav PK, 1997, J MED CHEM, V40, P181, DOI 10.1021/jm960586t; KAPLAN AH, 1994, P NATL ACAD SCI USA, V91, P5597, DOI 10.1073/pnas.91.12.5597; KEMPF DJ, 1995, P NATL ACAD SCI USA, V92, P2484, DOI 10.1073/pnas.92.7.2484; KORANT B, 1992, BIOL CHEM H-S, V373, P517, DOI 10.1515/bchm3.1992.373.2.517; Lam PYS, 1996, J MED CHEM, V39, P3514, DOI 10.1021/jm9602571; LAM PYS, 1994, SCIENCE, V263, P380, DOI 10.1126/science.8278812; LAM PYS, 1997, Patent No. 5610294; LOEB DD, 1989, J VIROL, V63, P111, DOI 10.1128/JVI.63.1.111-121.1989; LOEB DD, 1989, NATURE, V340, P397, DOI 10.1038/340397a0; MARKOWITZ M, 1995, J VIROL, V69, P701, DOI 10.1128/JVI.69.2.701-706.1995; MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029; NICHOLSON LK, 1995, NAT STRUCT BIOL, V2, P274, DOI 10.1038/nsb0495-274; ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354; Sham HL, 1996, J MED CHEM, V39, P392, DOI 10.1021/jm9507183; WLODAWER A, 1993, ANNU REV BIOCHEM, V62, P543, DOI 10.1146/annurev.bi.62.070193.002551	35	50	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12325	12331		10.1074/jbc.273.20.12325	http://dx.doi.org/10.1074/jbc.273.20.12325			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575185	hybrid			2022-12-27	WOS:000073629800050
J	Olivera, A; Kohama, T; Tu, ZX; Milstien, S; Spiegel, S				Olivera, A; Kohama, T; Tu, ZX; Milstien, S; Spiegel, S			Purification and characterization of rat kidney sphingosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE 3-KINASE; CELLULAR PROLIFERATION; ACID SPHINGOMYELINASE; SIGNAL-TRANSDUCTION; LIPID 2ND-MESSENGERS; CALCIUM MOBILIZATION; INDUCED APOPTOSIS; PHOSPHOLIPASE-D; 2ND MESSENGER; SMOOTH-MUSCLE	Sphingosine kinase catalyzes the formation of the bioactive sphingolipid metabolite sphingosine l-phosphate, which plays important roles in numerous physiological processes, including growth, survival, and motility. We have purified rat kidney sphingosine kinase 6 x 10(5)-fold to apparent homogeneity. The purification procedure involved ammonium sulfate precipitation followed by chromatography on an anion exchange column. Partially purified sphingosine kinase was found to be stabilized by the presence of high salt, and thus, a scheme was developed to purify sphingosine kinase using sequential dye-ligand chromatography steps (since the enzyme bound to these matrices even in the presence of salt) followed by EAH-Sepharose chromatography. This 385-fold purified sphingosine kinase bound tightly to cahmodulin-Sepharose and could be eluted in high yield with EGTA in the presence of 1 M Nacl. After concentration, the calmodulin eluate was further purified by successive high pressure Liquid chromatography separations on hydroxylapatite, Mono Q, and Superdex 75 gel filtration columns. Purified sphingosine kinase has an apparent molecular mass of similar to 49 kDa under denaturing conditions on SDS-polyacrylamide gel, which is similar to the molecular mass determined by gel filtration, suggesting that the active form is a monomer. Sphingosine kinase shows substrate specificity for D-erythro-sphingosine and does not catalyze the phosphorylation of phosphatidylinositol, diacylglycerol, ceramide, DL-threo-dihydrosphingosine, or N,N-dimethylsphingosine. However, the latter two sphingolipids were potent competitive inhibitors. With sphingosine as substrate, the enzyme had a broad pH optimum of 6.6-7.5 and showed Michaelis-Menten kinetics, with K-m values of 5 and 93 mu M for sphingosine and ATP, respectively. This study provides the basis for molecular characterization of a key enzyme in sphingolipid signaling.	Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20007 USA; NIMH, Lab Cellular & Mol Regulat, Bethesda, MD 20892 USA	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Spiegel, S (corresponding author), Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, 353 Basic Sci Bldg,3900 Reservoir Rd NW, Washington, DC 20007 USA.	spiegel@biochem1.basic-sci.georgetown.edu		Kohama, Takafumi/0000-0002-6822-8170	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043880, R37GM043880] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43880] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERNARDO K, 1995, J BIOL CHEM, V270, P11098, DOI 10.1074/jbc.270.19.11098; BORNFELDT KE, 1995, J CELL BIOL, V130, P193, DOI 10.1083/jcb.130.1.193; BUEHRER BM, 1992, J BIOL CHEM, V267, P3154; CAO ZM, 1995, NEUROCHEM RES, V20, P643, DOI 10.1007/BF01705530; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; Choi OH, 1996, NATURE, V380, P634; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DESAI NN, 1992, J BIOL CHEM, V267, P23122; Edsall LC, 1997, J NEUROSCI, V17, P6952; FLANAGAN CA, 1992, J BIOL CHEM, V267, P24117; GOODEMOTE KA, 1995, J BIOL CHEM, V270, P10272, DOI 10.1074/jbc.270.17.10272; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; JOHANSON RA, 1988, J BIOL CHEM, V263, P7465; KEENAN RW, 1972, BIOCHIM BIOPHYS ACTA, V270, P383, DOI 10.1016/0005-2760(72)90201-9; KEENAN RW, 1969, BIOCHIM BIOPHYS ACTA, V176, P348, DOI 10.1016/0005-2760(69)90193-3; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; Kozikowski AP, 1996, TETRAHEDRON LETT, V37, P3279, DOI 10.1016/0040-4039(96)00575-8; KUSWIKRABIEGA G, 1987, J BIOL CHEM, V262, P1505; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN A, 1993, ARCH BIOCHEM BIOPHYS, V303, P412, DOI 10.1006/abbi.1993.1303; LOUIE DD, 1976, J BIOL CHEM, V251, P4557; MANDALA S, 1997, P NATL ACAD SCI USA, V95, P150; MATTIE M, 1994, J BIOL CHEM, V269, P3181; MAZUREK N, 1994, BIOCHEM BIOPH RES CO, V198, P1, DOI 10.1006/bbrc.1994.1001; OKAMURA S, 1994, J BIOL CHEM, V269, P31207; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; OLIVERA A, 1994, J BIOL CHEM, V269, P17924; OLIVERA A, 1994, ANAL BIOCHEM, V223, P306, DOI 10.1006/abio.1994.1589; Olivera A, 1996, J CELL BIOCHEM, V60, P529, DOI 10.1002/(SICI)1097-4644(19960315)60:4<529::AID-JCB9>3.0.CO;2-U; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; Portilla D, 1996, J BIOL CHEM, V271, P15451, DOI 10.1074/jbc.271.26.15451; Pyne S, 1996, EUR J BIOCHEM, V237, P819, DOI 10.1111/j.1432-1033.1996.0819p.x; QUINTERN LE, 1987, BIOCHIM BIOPHYS ACTA, V922, P323, DOI 10.1016/0005-2760(87)90055-5; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SPIEGEL S, 1995, J MEMBRANE BIOL, V146, P225; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; STOFFEL W, 1973, H-S Z PHYSIOL CHEM, V354, P562, DOI 10.1515/bchm2.1973.354.1.562; STOFFEL W, 1968, H-S Z PHYSIOL CHEM, V349, P1149, DOI 10.1515/bchm2.1968.349.2.1149; STOFFEL W, 1970, H-S Z PHYSIOL CHEM, V351, P1041, DOI 10.1515/bchm2.1970.351.2.1041; TAKAZAWA K, 1990, BIOCHEM J, V268, P213, DOI 10.1042/bj2680213; VANVELDHOVEN PP, 1991, J BIOL CHEM, V266, P12502; VANVELDHOVEN PP, 1994, BIOCHEM J, V299, P597, DOI 10.1042/bj2990597; VANVELDHOVEN PP, 1994, FEBS LETT, V350, P91, DOI 10.1016/0014-5793(94)00739-X; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang F, 1996, GLYCOCONJUGATE J, V13, P937, DOI 10.1007/BF01053189; WU J, 1995, J BIOL CHEM, V270, P11484, DOI 10.1074/jbc.270.19.11484; YAMANAKA T, 1982, J NEUROCHEM, V38, P1753, DOI 10.1111/j.1471-4159.1982.tb06659.x; Yatomi Y, 1997, FEBS LETT, V404, P173, DOI 10.1016/S0014-5793(97)00121-X; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155	51	195	207	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12576	12583		10.1074/jbc.273.20.12576	http://dx.doi.org/10.1074/jbc.273.20.12576			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575218	hybrid			2022-12-27	WOS:000073629800083
J	Sugimoto, H; Odani, S; Yamashita, S				Sugimoto, H; Odani, S; Yamashita, S			Cloning and expression of cDNA encoding rat liver 60-kDa lysophospholipase containing an asparaginase-like region and ankyrin repeat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL PROTEIN LYSOPHOSPHOLIPASE; ACTIVATING-FACTOR ACETYLHYDROLASE; HUMAN ERYTHROCYTE ANKYRIN; ESCHERICHIA-COLI K-12; AMINO-ACID-SEQUENCE; CYTOSOLIC PHOSPHOLIPASE-A(2); SACCHAROMYCES-CEREVISIAE; GLUTAMINASE-ASPARAGINASE; ERWINIA-CHRYSANTHEMI; NUCLEOTIDE-SEQUENCE	Mammalian tissues contain small form and large form lysophospholipases. Here we report the cloning, sequence, and expression of cDNA encoding the latter form of lysophospholipase using antibody raised against the enzyme purified from rat liver supernatant (Sugimoto, H., and Yamashita, S. (1994) J. Biol. Chem. 269, 6252-6258). The 2,539-base pair cDNA encoded 564 amino acid residues with a calculated M-r of 60,794. The amino-terminal two-thirds of the deduced amino acid sequence significantly resembled Escherichia coli asparaginase I with the putative asparaginase catalytic triad Thr-Asp-Lys and was followed by leucine zipper motif. The carboxyl-terminal region carried ankyrin repeat. When the cDNA was transfected into HEK293 cells, not only lysophospholipase activity but also asparaginase and platelet-activating factor acetylhydrolase activities were expressed. Reverse transcription-polymerase chain reaction revealed that the transcript occurred at high levels in liver and kidney but was hardly detectable in lung and heart from which large form lysophospholipases had been purified, suggesting the presence of multiple forms of large form lysophospholipase in mammalian tissues.	Gunma Univ, Sch Med, Dept Biochem, Maebashi, Gumma 3718511, Japan; Niigata Univ, Dept Biol, Niigata 9502181, Japan	Gunma University; Niigata University	Yamashita, S (corresponding author), Gunma Univ, Sch Med, Dept Biochem, Maebashi, Gumma 3718511, Japan.	sayamash@sb.gunma-u.ac.jp						AARSMAN AJ, 1991, EUR J BIOCHEM, V200, P187, DOI 10.1111/j.1432-1033.1991.tb21066.x; ACKERMAN SJ, 1993, J IMMUNOL, V150, P456; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARTON GJ, 1987, J MOL BIOL, V198, P327, DOI 10.1016/0022-2836(87)90316-0; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BONTHRON DT, 1990, GENE, V91, P101, DOI 10.1016/0378-1119(90)90168-Q; BRUMLEY G, 1977, J LIPID RES, V18, P523; DECARVALHO MS, 1993, ARCH BIOCHEM BIOPHYS, V306, P534, DOI 10.1006/abbi.1993.1549; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; DEJONG JGN, 1974, BIOCHIM BIOPHYS ACTA, V369, P50, DOI 10.1016/0005-2760(74)90191-X; DENHARDT DT, 1966, BIOCHEM BIOPH RES CO, V23, P641, DOI 10.1016/0006-291X(66)90447-5; DUAN RD, 1993, BIOCHIM BIOPHYS ACTA, V1167, P326, DOI 10.1016/0005-2760(93)90236-3; FUJIMORI Y, 1993, EUR J BIOCHEM, V218, P629, DOI 10.1111/j.1432-1033.1993.tb18416.x; GARSETTI D, 1992, BIOCHEM J, V288, P831, DOI 10.1042/bj2880831; GARSETTI DE, 1993, J LIPID MEDIATOR, V6, P223; GARSETTI DE, 1992, BIOCHIM BIOPHYS ACTA, V1165, P229, DOI 10.1016/0005-2760(92)90191-W; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; GROSS RW, 1983, J BIOL CHEM, V258, P5221; GROSS RW, 1983, J BIOL CHEM, V258, P5165; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; Haystead CMM, 1995, FEBS LETT, V377, P123, DOI 10.1016/0014-5793(95)01318-0; HONG KH, 1991, AGR BIOL CHEM TOKYO, V55, P2839, DOI 10.1080/00021369.1991.10871052; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; JERLSTROM PG, 1989, GENE, V78, P37, DOI 10.1016/0378-1119(89)90312-0; KIM KW, 1988, J BIOL CHEM, V263, P11948; KORDELI E, 1995, J BIOL CHEM, V270, P2352, DOI 10.1074/jbc.270.5.2352; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KYGER EM, 1989, BIOCHEM BIOPH RES CO, V164, P1302, DOI 10.1016/0006-291X(89)91811-1; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERT S, 1990, P NATL ACAD SCI USA, V87, P1730, DOI 10.1073/pnas.87.5.1730; LARDELLI M, 1994, MECH DEVELOP, V46, P123, DOI 10.1016/0925-4773(94)90081-7; LIN YN, 1979, ARCH BIOCHEM BIOPHYS, V193, P213, DOI 10.1016/0003-9861(79)90025-0; Lubkowski J, 1996, EUR J BIOCHEM, V241, P201, DOI 10.1111/j.1432-1033.1996.0201t.x; LUBKOWSKI J, 1994, BIOCHEMISTRY-US, V33, P10257, DOI 10.1021/bi00200a005; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MASAI I, 1993, P NATL ACAD SCI USA, V90, P11157, DOI 10.1073/pnas.90.23.11157; MINTON NP, 1986, GENE, V46, P25, DOI 10.1016/0378-1119(86)90163-0; MIYAMOTO M, 1994, EMBO J, V13, P1873, DOI 10.1002/j.1460-2075.1994.tb06456.x; Odani S, 1996, EUR J BIOCHEM, V241, P77, DOI 10.1111/j.1432-1033.1996.0077t.x; Pete MJ, 1996, J BIOL CHEM, V271, P18114, DOI 10.1074/jbc.271.30.18114; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RAY P, 1995, J BIOL CHEM, V270, P10680, DOI 10.1074/jbc.270.18.10680; REYNOLDS LJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P272, DOI 10.1016/0005-2760(93)90229-3; SALVI S, 1994, MOL GEN GENET, V243, P124, DOI 10.1007/BF00283885; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SHIMIZU H, 1994, J BIOL CHEM, V269, P30407; SINCLAIR K, 1994, GENE, V144, P37, DOI 10.1016/0378-1119(94)90200-3; SPRING KJ, 1986, J BACTERIOL, V166, P135, DOI 10.1128/jb.166.1.135-142.1986; STAFFORINI DM, 1990, METHOD ENZYMOL, V187, P344; Sugimoto H, 1996, J BIOL CHEM, V271, P7705, DOI 10.1074/jbc.271.13.7705; SUGIMOTO H, 1994, J BIOL CHEM, V269, P6252; SUN DX, 1991, J BACTERIOL, V173, P3831, DOI 10.1128/JB.173.12.3831-3845.1991; SUNAGA H, 1995, BIOCHEM J, V308, P551, DOI 10.1042/bj3080551; SWAIN AL, 1993, P NATL ACAD SCI USA, V90, P1474, DOI 10.1073/pnas.90.4.1474; TAKEISHI K, 1982, J BIOCHEM-TOKYO, V92, P1173, DOI 10.1093/oxfordjournals.jbchem.a134033; TANAKA S, 1988, J BIOL CHEM, V263, P8583; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; TSE WT, 1991, GENOMICS, V10, P858, DOI 10.1016/0888-7543(91)90173-C; VANDENBOSCH H, 1975, BIOCHIM BIOPHYS ACTA, V398, P244, DOI 10.1016/0005-2760(75)90140-X; VANDIJL JM, 1991, FEMS MICROBIOL LETT, V81, P345, DOI 10.1111/j.1574-6968.1991.tb04784.x; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; WAITE M, 1991, BIOCH LIPIDS LIPOPRO, P269; Wang AJ, 1997, J BIOL CHEM, V272, P22030, DOI 10.1074/jbc.272.35.22030; Wang AJ, 1997, J BIOL CHEM, V272, P12723, DOI 10.1074/jbc.272.19.12723; WELLER PF, 1984, J BIOL CHEM, V259, P5100; Wolf MJ, 1996, J BIOL CHEM, V271, P30879, DOI 10.1074/jbc.271.48.30879; ZHANG Y, 1988, J BIOL CHEM, V263, P9965	71	37	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1998	273	20					12536	12542		10.1074/jbc.273.20.12536	http://dx.doi.org/10.1074/jbc.273.20.12536			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZN277	9575212	hybrid			2022-12-27	WOS:000073629800077
J	Obungu, VH; Wang, YD; Beattie, DS				Obungu, VH; Wang, YD; Beattie, DS			The role of charged amino acids in the alpha 1-beta 4 loop of the iron-sulfur protein of the cytochrome bc(1) complex of yeast mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MUTATIONAL ANALYSIS; MEMBRANE; LACKING; IMPORT; RIP1; GENE	Previous experiments using deletion mutants of the iron-sulfur protein had indicated that amino acid residues 138-153 might be involved in the assembly of this protein into the cytochrome bc(1) complex. To determine which specific residues might be involved in the assembly process, charged amino acids located in the alpha 1-beta 4 loop of the iron-sulfur protein were mutated to uncharged residues and tryptophan 152 to phenylalanine. The mutant genes were used to transform yeast cells (JPJ1) lacking the iron-sulfur protein gene. Mutants R146I and W152F had almost undetectable growth in medium containing glycerol/ethanol, whereas mutants D143A, K148I, and D149A grew more slowly than the wild type. Activity of the cytochrome bc(1) complex was decreased 50, 90, 67, 89, and 90% in mutants D143A, R146I, K148I, D149A, and W152F, respectively, but unchanged in mutants D139A, Q141I, D145L, and V147S, In all of these mutants except W152F, the cytochrome c(1) content, determined by immunoblotting, was comparable with that of wild-type cells. However, immunoblotting revealed that the content of the iron-sulfur protein was decreased proportionately in the five mutants with lowered enzymatic activity and growth suggesting that these amino acids are critical for maintaining the stability of the iron-sulfur protein. The efficiency of assembly in vitro compared with the wild type determined by selective immunoprecipitation was unchanged in the mutants with the exception of R146I, D149A, and W152F where decreases of 80, 60, and 60%, respectively, were observed suggesting that these amino acids are critical for the proper assembly of the iron-sulfur protein into the bc(1) complex.	W Virginia Univ, Dept Biochem, Sch Med, Morgantown, WV 26506 USA	West Virginia University	Beattie, DS (corresponding author), W Virginia Univ, Dept Biochem, Sch Med, POB 9142, Morgantown, WV 26506 USA.		Wang, Yudong/ABG-1086-2021	Wang, Yudong/0000-0003-3224-4555	NIGMS NIH HHS [GM 38433] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038433] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKMANN JD, 1987, J BIOL CHEM, V262, P8901; BRANDT U, 1994, CRIT REV BIOCHEM MOL, V29, P165, DOI 10.3109/10409239409086800; CRIVELLONE MD, 1988, J BIOL CHEM, V263, P14323; diRago JP, 1996, J BIOL CHEM, V271, P15341, DOI 10.1074/jbc.271.26.15341; DUNN B, 1984, CELL, V39, P191, DOI 10.1016/0092-8674(84)90205-8; FU W, 1991, J BIOL CHEM, V266, P16212; FU W, 1990, J BIOL CHEM, V265, P16541; GRAHAM LA, 1993, J BIOENERG BIOMEMBR, V25, P245, DOI 10.1007/BF00762586; GRAHAM LA, 1991, J BIOL CHEM, V266, P22485; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Iwata S, 1996, STRUCTURE, V4, P567, DOI 10.1016/S0969-2126(96)00062-7; JAPA S, 1989, ARCH BIOCHEM BIOPHYS, V268, P716, DOI 10.1016/0003-9861(89)90340-8; Liebl U, 1997, BIOCHEMISTRY-US, V36, P11675, DOI 10.1021/bi970776l; OBUNGU V, 1997, BIOCHIM BIOPHYS ACTA, V1231, P229; Ramabadran RS, 1997, J BIOENERG BIOMEMBR, V29, P45, DOI 10.1023/A:1022459722020; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1981, SCIENCE, V214, P1205, DOI 10.1126/science.7302589; SEN K, 1985, ARCH BIOCHEM BIOPHYS, V242, P393, DOI 10.1016/0003-9861(85)90223-1; SIDHU A, 1983, J BIOL CHEM, V258, P2308; SIDHU A, 1983, J BIOL CHEM, V258, P649; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60	22	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 8	1998	273	19					11917	11922		10.1074/jbc.273.19.11917	http://dx.doi.org/10.1074/jbc.273.19.11917			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZM408	9565619	hybrid			2022-12-27	WOS:000073536700073
